,nct_id,primaryOutcomes,secondaryOutcomes,otherOutcomes,startDate,status,study_type,phases
0,NCT03646721,Adverse event,HbA1c,Assessment of key metabolite(s) of DA-1241,2018-08-29,COMPLETED,INTERVENTIONAL,['PHASE1']
1,NCT00115570,Change in total glycated hemoglobin measured as HbA1c equivalents (GHb )from baseline to endpoint,Change from Baseline in basal insulin dose,,2005-04,COMPLETED,INTERVENTIONAL,['PHASE3']
2,NCT02275845,incidence of gestational diabetes mellitus in both groups,Neonatal outcomes,,2014-09,UNKNOWN,INTERVENTIONAL,['PHASE3']
3,NCT02331147,proportion of ulcers completely healed by the allogenic dermal graft protocol of care to the standard protocol of care in the management of indolent diabetic ulcers at 6 weeks,Mean time to healing,,2014-12,COMPLETED,INTERVENTIONAL,['NA']
4,NCT02682121,The primary outcome will be gene expression levels of mitofusin 2 and uncoupling protein 2,,,2012-04,COMPLETED,INTERVENTIONAL,['PHASE1']
5,NCT03747978,24-hour blood pressure,night blood pressure dip,,2016-10-01,COMPLETED,INTERVENTIONAL,['PHASE4']
6,NCT03386097,Cholesterol level in skin biopsies,,,2018-01-10,COMPLETED,OBSERVATIONAL,['NA']
7,NCT00295633,Change From Baseline in Hemoglobin A1c (A1C) at Week 24,Changes From Baseline in Postprandial Glucose (PPG) Area Under the Curve (AUC) Response to an Oral Glucose Tolerance Test (OGTT) at Week 24,,2006-03,COMPLETED,INTERVENTIONAL,['PHASE3']
8,NCT06281301,Number of participants that showed Macrosomia knowledge greater than 50 percent as assessed by the score on a survey,,,2024-01-30,RECRUITING,INTERVENTIONAL,['NA']
9,NCT00004266,,,,1993-08,COMPLETED,INTERVENTIONAL,['PHASE3']
10,NCT01271231,Glycated hemoglobin,Probing depth,,2010-04,COMPLETED,INTERVENTIONAL,['NA']
11,NCT04729985,Emergency room visit and rehospitalization,Patient satisfaction,,2021-06-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
12,NCT03176472,Change in Mean Average Pain Intensity (NRS),Change in Non-pain Neuropathic Signs (UENS),,2020-12-07,COMPLETED,INTERVENTIONAL,['PHASE2']
13,NCT05755555,HbA1C(%),,,2022-08-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
14,NCT01140542,Mean change in HbA1c [percent] from baseline to the last study visit (Vlast),"Time to event (study withdrawal, time to study withdrawal due to an adverse event (AE) and time to lack of efficacy (LOE)",,2006-08,COMPLETED,INTERVENTIONAL,['PHASE2']
15,NCT02148861,Number of treatment emergent adverse events,area under the glucose infusion rate - time curve at steady-state,,2014-05-26,COMPLETED,INTERVENTIONAL,['PHASE1']
16,NCT00948168,Improvement in HbA1c,"Non-invasive modeling of glucose homeostasis determinants, including insulin sensitivity",,2008-07,COMPLETED,INTERVENTIONAL,['PHASE4']
17,NCT01001104,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 12 Weeks,Percentage of Participants With Self-Reported Hypoglycemic Episodes During the 12-week Treatment Period,,2009-10,COMPLETED,INTERVENTIONAL,['PHASE2']
18,NCT02157480,Mean CGM glucose from a 6-day CGM recording,HbA1c,cardiometabolic stress test,2014-09,COMPLETED,INTERVENTIONAL,['NA']
19,NCT03660384,BCVA,,,2018-09-04,COMPLETED,INTERVENTIONAL,['NA']
20,NCT04841720,Tmax,AE/serious AE,,2021-04-01,UNKNOWN,INTERVENTIONAL,['PHASE1']
21,NCT00527254,HBA1c Glycosylated hemoglobin,"Blood glucose, Total Cholesterol, HDL Cholesterol,LDL Cholesterol, Triglycerides, BMI, systolic and diastolic blood pressure and system adherence",,2003-10,COMPLETED,INTERVENTIONAL,['NA']
22,NCT04734158,corneal epithelial thickness,,,2019-08-12,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
23,NCT03378635,Time to Plasma Glucose Recovery,Time to First Rescue Infusion of IV Glucose,,2017-12-07,COMPLETED,INTERVENTIONAL,['PHASE3']
24,NCT03662997,% of Participants With No Strike-through After 7 Days Wear Time at Day 7 and 21,Mean Difference in Score in SF12 Health-Related Quality-of-Life Questionnaire,,2019-03-19,COMPLETED,INTERVENTIONAL,['NA']
25,NCT03205436,Time to initial closure of diabetic foot ulcer,Mean cost to heal,,2017-05-01,COMPLETED,INTERVENTIONAL,['NA']
26,NCT02158078,Change in glycosylated hemoglobin A1C (HbA1c) (obtained from venous blood) from baseline at Week 12,Change in measures of PROs from baseline at Week 12,,2014-06,TERMINATED,OBSERVATIONAL,['NA']
27,NCT03580330,Mean HbA1c,,,2014-04-17,COMPLETED,INTERVENTIONAL,['NA']
28,NCT00526513,Glycosylated Haemoglobin (HbA1c),Control of Post-Prandial Glycemia (PPBG),,2007-07,COMPLETED,INTERVENTIONAL,['PHASE4']
29,NCT01307904,Dates Glycemic Index,,,2010-03,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
30,NCT04742023,Average Daily Glucose,Total Insulin Use,,2020-04-21,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
31,NCT05919667,Change in blood glucose level,Change in plasma amino acid concentrations,,2022-02-28,COMPLETED,INTERVENTIONAL,['NA']
32,NCT03878706,Comparison of Global Longitudinal Strain (GLS) difference among treatment groups.,Comparison of liver steatosis level between treatment groups,,2017-11-03,RECRUITING,OBSERVATIONAL,['NA']
33,NCT01053728,- Pharmacodynamics (Glucose infusion rate) time-action profile,- anti-insulin antibody production,,2010-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
34,NCT00657800,Quality of Life (QoL),Emergency Room visits; admissions,,2007-12,COMPLETED,INTERVENTIONAL,['NA']
35,NCT02802644,Neointimal coverage assessed by optical coherence tomography,Biomarkers,,2016-06,UNKNOWN,INTERVENTIONAL,['PHASE4']
36,NCT04659330,glucose variability,Insulin dose in patients with and without lipohypertrophy,,2018-06-01,COMPLETED,INTERVENTIONAL,['NA']
37,NCT01051674,Weight,Hemoglobin A1c,,2010-01,COMPLETED,INTERVENTIONAL,['PHASE4']
38,NCT00721084,Total energy expenditure,Physical activity related energy expenditure,,2008-07,COMPLETED,OBSERVATIONAL,['NA']
39,NCT04442334,Detailed Characterisation of the NAFLD Patient Phenotype,Health Related Quality of Life: NASH-CHECK,,2015-05-01,RECRUITING,OBSERVATIONAL,['NA']
40,NCT03544541,Carotid Intima-Media Thickness,,,2018-01-05,COMPLETED,OBSERVATIONAL,['NA']
41,NCT03219411,Fasting plasma glucose at 12 weeks,Area under the curve-glucose during OGTT (oral glucose tolerance test),,2017-08-28,COMPLETED,INTERVENTIONAL,['PHASE2']
42,NCT05668325,Home Based Mini Trampoline Exercise Tracking Form,,,2021-03-01,COMPLETED,INTERVENTIONAL,['NA']
43,NCT01027871,Fasting Blood Glucose (FBG) Level at Week 12 Endpoint as Measured by the 8-Point Self-Monitored Blood Glucose (SMBG) Profiles,Glycemic Variability in Fasting Blood Glucose at Baseline and Week 12 - Subgroup Analysis of LY2605541 Dosing Algorithms,,2010-01,COMPLETED,INTERVENTIONAL,['PHASE2']
44,NCT00734383,"Perioperative Plasma 15 f2t isoprostane, a biologically active marker of oxidative stress","Perioperative (includes coronary sinus levels) plasma antioxidant concentration; ET-1, TNF alpha, Troponin I, peroxynitrite; gene and protein expression of eNOS and iNOS; hemodynamics",,2005-04,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
45,NCT00456300,"Mean Plasma Glucose Area Under the Curve (AUC) for Blood Glucose Concentration in the Exenatide 1.25 mcg or Exenatide 2.5 mcg Treated Groups Along With Insulin, Compared to Insulin Alone",,,2007-03,COMPLETED,INTERVENTIONAL,['PHASE2']
46,NCT05746975,Peripheral DR lesions characterization,Correlate and analysed DR findings in each imaging technique with disease severity,,2023-04-03,RECRUITING,OBSERVATIONAL,['NA']
47,NCT00607139,Glucose level at which counter-regulatory hormone response is achieved,Accuracy of the Guardian-RT continuous glucose monitoring device,,2006-12,COMPLETED,OBSERVATIONAL,['NA']
48,NCT02225379,Positive Predictive Value of the hypo-Sense,,,2014-09,COMPLETED,INTERVENTIONAL,['NA']
49,NCT01044017,Effect on postprandial plasma glucose concentration,"Safety and tolerability: AEs, laboratory parameters",,2009-12,COMPLETED,INTERVENTIONAL,['PHASE1']
50,NCT00240019,The amount of protein in the urine after 8 weeks of treatment.,The estimated glomerular filtration rate after 8 weeks of treatment.,,2003-12,COMPLETED,INTERVENTIONAL,['NA']
51,NCT02589730,change in glycated hemoglobin levels,change in scores measured by MKT,change in scores measured by self anxiety scale,2015-10,UNKNOWN,INTERVENTIONAL,['NA']
52,NCT04014023,Change from baseline in HbA1c,"The proportion of patients who achieve HbA1c < 7.0%, HbA1c < 6.5% and HbA1c reduction >0.5% from baseline",,2019-07-10,UNKNOWN,INTERVENTIONAL,['PHASE2']
53,NCT00566319,2-hour glucose,"Pedometer counts, Fasting glucose, total cholesterol, HDL-cholesterol, LDL- cholesterol, TNFα, IL-6, CRP, systolic and diastolic blood pressure, body mass, waist circumference, BMI, physical activity, psychological determinants",,2006-10,COMPLETED,INTERVENTIONAL,['NA']
54,NCT04181307,Number of Participants Who Are CW-Compliant and CW-Noncompliant,Number of Total Prescription Encounters,,2020-12-01,COMPLETED,INTERVENTIONAL,['NA']
55,NCT00769275,"Overall cardiac event rate (cardiac death, myocardial infarction) was 3.0%, not different in screened and not screened cohort",,,2000-08,COMPLETED,OBSERVATIONAL,['NA']
56,NCT00733577,"Safety measures including: AEs daily; laboratory testing: day -1,2,5,7 and follow up; ECG: day -1, 2, 5, 6, 7 and follow-up; vital signs: daily; PK parameters day -1,5, and 6.",Subject reports of hunger and craving as reported on the Hunger and Craving questionnaire,,2008-08-11,COMPLETED,INTERVENTIONAL,['PHASE1']
57,NCT01479933,Insulin sensitivity,Adipose tissue gene expression,,2011-09,COMPLETED,INTERVENTIONAL,['NA']
58,NCT06073756,Neutrophil-to-lymphocyte ratio and platelets to lymphocytes ratio,HbA1c with good glycemic control and have HBA1C lower than 7and poor glycemic control and have HBA1C higher than 7with prescence or abscence of vascular complications,,2023-12,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
59,NCT00361153,"To evaluate the effect of 8 weeks treatment with WelChol on insulin sensitivity,as measured by the hyperinsulinemic-euglycemic clamp method, i.e., placebo-corrected change from baseline in M-value.","To evaluate the effect of treatment with WelChol on HbA1C, insulin, fasting plasma glucose, and fructosamine.",,2006-05,COMPLETED,INTERVENTIONAL,['PHASE2']
60,NCT02653599,Change in HbA1c from baseline at 12 weeks,Pulse,Change in glucagon-like peptide-1 levels from baseline at 12 weeks,2015-12,COMPLETED,INTERVENTIONAL,['PHASE2']
61,NCT01103284,Change From Baseline in Glucagon-Stimulated C-Peptide AUC at 24 Months,Mean Number of Days With at Least One Hypoglycemic Event,Percentage of Subjects Requiring a Daily Insulin Dose ≤ 0.5 IU/kg at End of Study,2010-04,COMPLETED,INTERVENTIONAL,['PHASE3']
62,NCT02340260,Glycosylated hemoglobin (HbA1c),,,2013-08,COMPLETED,INTERVENTIONAL,['NA']
63,NCT03291834,Occurence of hypoglycemia or hyperglycemia,Measures taken to prevent hypoglycemia or hyperglycemia,,2017-08-15,COMPLETED,OBSERVATIONAL,['NA']
64,NCT03714646,Plasma acetate concentrations (microM),"Breath H2 using (Bedfont EC60 Gastrolyzer, Rochester, UK)",,2018-09-05,COMPLETED,INTERVENTIONAL,['NA']
65,NCT00166803,"Vulnerable plaque analyses by PET: Define plaque location and activity at baseline, and compare with the follow-up scans site by site.","2.Biomarkers:hs-CRP, MMP-1, MCP-1.",,2005-06,SUSPENDED,INTERVENTIONAL,['NA']
66,NCT03722225,"The percentage of the glucose values spent in target range, defined as 72-180 mg/dl.",,,2016-01-20,COMPLETED,INTERVENTIONAL,['NA']
67,NCT02862431,Number of Participants With Adverse Events as a Measure of Safety and Tolerability,Change From Baseline for Glucagon,,2016-07-12,TERMINATED,INTERVENTIONAL,['PHASE1']
68,NCT04124354,Change in Shannon Index (Alpha-Diversity) as Reflected in Change in Operational Taxonomic Units,Change in Body Fat Percentage,,2020-02-10,TERMINATED,INTERVENTIONAL,['NA']
69,NCT03574935,Wound healing rate,,,2018-07-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
70,NCT00553020,To assess the duration of the metabolic effect of a sc injected single dose of either insulin glargine (LantusT) or NPH-insulin (ProtaphanT) on blood glucose control in patients with type 2 diabetes,"To evaluate the effect of insulin glargine (LantusT) and NPH-insulin (ProtaphanT) on suppression of endogenous glucose production, endogenous insulin secretion, and lipolysis",,2004-04,COMPLETED,INTERVENTIONAL,['PHASE4']
71,NCT01642394,Change in Glycated hemoglobin,Change in the diet composition,,2011-10-01,COMPLETED,INTERVENTIONAL,['NA']
72,NCT01789190,We aimed to study the influence of regular physical activity on the prolongation of the honeymoon period in type 1 diabetic patients by determining circulating parameters.,To study the influence of regular physical activity on the control of the inflammation process associated to type 1 diabetes.,,2011-01,TERMINATED,OBSERVATIONAL,['NA']
73,NCT02512068,Number of Participants Who Had One or More TEAE Occurred After 1st Dose of Trelagliptin 25 mg Tablet,Number of Participants With Markedly Abnormal Values of Clinical Laboratory Parameters Before the Start of Study Drug Administration in Treatment Period II,,2015-08-07,COMPLETED,INTERVENTIONAL,['PHASE3']
74,NCT00069615,Feasibility of collecting data from home computers,,,2003-02,COMPLETED,INTERVENTIONAL,['PHASE4']
75,NCT01029288,"Decisional quality (knowledge, decisional conflict, and satisfaction)",Patient medication adherence,,2010-04,COMPLETED,INTERVENTIONAL,['NA']
76,NCT02471404,Change in Haemoglobin A1c (HbA1c) From Baseline to Week 52,Number of Patients Rescued,,2015-09-21,COMPLETED,INTERVENTIONAL,['PHASE4']
77,NCT02518022,• Number of hypoglycaemic events <70 mg/dl per arm from begin of consumption until lunch next day (12:00 am),• Max. alcohol in expiratory breath,,2015-09,WITHDRAWN,INTERVENTIONAL,['NA']
78,NCT03117543,Percentage of hOGTT venous plasma equivalent glucose (hOGTT-VPEqG) results within ±10% of paired venous plasma glucose measured on a YSI analyser (VPG-YSI) (reference standard).,Specificity of HbA1c for screening for GDM versus gold standard of 75g OGTT and VPG-YSI measurement (IADPSG 2010 criteria).,Serum insulin concentration at 60 min after 75g oral glucose in pregnant women of Black (Black African and Black Caribbean) compared to White European ethnicity.,2016-03,UNKNOWN,OBSERVATIONAL,['NA']
79,NCT06282055,Identify different trajectories of insulin sensitivity throughout the menstrual cycle,Correlations between insulin sensitivity trajectories and confounders,,2024-03-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
80,NCT01676116,"Change in Glycosylated Haemoglobin (HbA1c) From Baseline (Randomisation, Visit 2)",Change From Baseline in Patient Reported Outcomes (PROs) Based on Diabetes Treatment Satisfaction Questionnaire (DTSQ).,,2012-08-29,COMPLETED,INTERVENTIONAL,['PHASE3']
81,NCT02631148,Change in Systemic Renin-aldosterone-angiotensin System (RAAS) Activity,Change in Central Blood Pressure,,2016-01,TERMINATED,INTERVENTIONAL,['PHASE2']
82,NCT04144920,Glucose variability (mean amplitude glycemic excursions),Physical and Emotional feeling states,,2018-08-01,COMPLETED,INTERVENTIONAL,['NA']
83,NCT01883804,The Change From Baseline of DQ8 Antigen Presentation by Peripheral Blood Mononuclear Cells After 6 Weeks of Methyldopa Treatment.,The Change in Insulin Use From Baseline to Study Completion.,,2013-06,COMPLETED,INTERVENTIONAL,['NA']
84,NCT01059812,Change in HbA1c (Glycosylated Haemoglobin) After 26 Weeks of Treatment,Change in Body Weight,,2010-02-01,COMPLETED,INTERVENTIONAL,['PHASE3']
85,NCT00512538,Time to complete wound healing (full epithelialization with no drainage),Incidence of complete healing,,2000-10,TERMINATED,INTERVENTIONAL,['PHASE3']
86,NCT00119041,A1c,Patient Satisfaction,,2005-09,COMPLETED,INTERVENTIONAL,['NA']
87,NCT01754337,Percentage of time of plasma glucose levels spent in target range.,Percentage of overnight time of plasma glucose levels spent in the high range,,2012-12,COMPLETED,INTERVENTIONAL,['PHASE2']
88,NCT02115711,Absolute reduction in average number of cigarettes/bidis smoked per day amongst smokers,"Absolute mean reduction in weight and waist circumference, for those who are overweight or have increased waist size at baseline, at the end of 2 years.",,2014-04,COMPLETED,INTERVENTIONAL,['NA']
89,NCT00213109,,,,na,COMPLETED,INTERVENTIONAL,['PHASE3']
90,NCT02812030,Change in Best-Corrected Visual Acuity (BCVA),Non-ocular adverse events,,2016-09,WITHDRAWN,OBSERVATIONAL,['NA']
91,NCT01889706,Body fat content and anthropometric parameters,Insulin requirement,Assessment of skin AGE,2009-01,UNKNOWN,OBSERVATIONAL,['NA']
92,NCT01741467,Differences in blood glucose,Changes in medication use,,2012-05,COMPLETED,INTERVENTIONAL,['NA']
93,NCT06280729,Primary Endpoint,Exploratory Objectives,,2024-03-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
94,NCT01354262,Change in serum levels of Hemoglobin A1c.,,,2011-03,COMPLETED,INTERVENTIONAL,['PHASE2']
95,NCT05616026,Change in HbA1c,Appointment Adherence,,2023-02-07,RECRUITING,INTERVENTIONAL,['NA']
96,NCT05922280,Douleur Neuropathique 4 Questionnaire DN4,,,2023-02-15,COMPLETED,INTERVENTIONAL,['NA']
97,NCT01742208,Percent Change From Baseline in Total Daily Bolus Amount of Exogenous Insulin Required Calculated Over Days 3 to 27 (Treatment Outpatient Period),Change From Day 1 in 3-hour Urinary Glucose Excretion Following a Mixed Meal Tolerance Test (MMTT) to Day 29: Expansion Groups,,2013-02,COMPLETED,INTERVENTIONAL,['PHASE2']
98,NCT05124457,Prolonged neonatal hypoglycemia,5 Minute APGAR,,2022-02-01,RECRUITING,INTERVENTIONAL,['PHASE2']
99,NCT05110092,blood sugar control-HbA1c,,,2016-12-14,UNKNOWN,INTERVENTIONAL,['NA']
100,NCT00666718,Change From Baseline in Hemoglobin A1c (HbA1c) to Week 24,Number of Injections of Insulin at Week 24,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE3']
101,NCT02579148,Improvements in IIEF scores,Safety and Tolerability assessed by Adverse Events,,2015-09,WITHDRAWN,INTERVENTIONAL,['PHASE1']
102,NCT00707031,Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24,Percentage of Patients Requiring Rescue Therapy During Main 24-Week Period,Quality of Life: Change From Baseline in Patient's Satisfaction to Treatment (PAGI-QOL) at Week 24,2008-06,COMPLETED,INTERVENTIONAL,['PHASE3']
103,NCT03939000,International normalized ratio,,,2016-03,COMPLETED,OBSERVATIONAL,['NA']
104,NCT06234332,Numbers and morbidity of participants with adverse pregnancy outcomes,Incidence of depression in adolescents,,2024-02-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
105,NCT05762471,"Incidence, severity and relationship of AE/SAE, vital signs, laboratory measures and ECG to assess safety and tolerability of multiple oral doses of GSBR-1290 in HOV and T2DM",Identification of GSBR-1290 metabolites following oral administration of multiple doses in plasma,,2023-01-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
106,NCT00877929,Change From Baseline in Trough Seated Systolic Blood Pressure to Week 8,Change From Baseline in Urine Albumin:Creatinine Ratio (UACR),,2009-02,COMPLETED,INTERVENTIONAL,['PHASE3']
107,NCT03685253,Thigh Intraepidermal Nerve Fiber Density,Distal lower limb intraepidermal nerve fiber density,Cardiac Autonomic Neuropathy,2019-01-24,SUSPENDED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
108,NCT02180334,Area under the curve (AUC) of plasma total GLP-1 levels,Area under the curve (AUC) of plasma active GLP-1 levels,The time to peak concentration of plasma paracetamol,2014-07,COMPLETED,INTERVENTIONAL,['PHASE4']
109,NCT05013229,Change in HbA1c,Weekly insulin dose (total),,2021-11-30,COMPLETED,INTERVENTIONAL,['PHASE3']
110,NCT05118061,Analytical verification of StatStrip glucose/ketone meter system - ketone comparison,,,2022-05-25,COMPLETED,OBSERVATIONAL,['NA']
111,NCT03800875,Total percentage of time (22:00-22:00) that the glucose concentration remained within 3.9 and 10.0 mmol/L,Mean glucose level,,2019-02-08,COMPLETED,INTERVENTIONAL,['PHASE2']
112,NCT05416580,Change in inflammation marker level: high sensitivity CRP,Change in body weight,,2022-09-12,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE3']
113,NCT05414409,Changes in the gut microbial metabolites in obese youth with type 1 in response to metformin,Changes in measures of beta cell function using a timed mixed meal tolerance test,,2022-09-30,RECRUITING,INTERVENTIONAL,['PHASE2']
114,NCT03526536,Change in blood glucose level,,,2018-05-01,TERMINATED,INTERVENTIONAL,['PHASE4']
115,NCT02739906,BG1h,Local tolerability (Number of injection site reactions),,2016-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
116,NCT00171717,% of patients whose diabetes resolves 6 months after the conversion (fasting glucose < 1.26 g/L without hypoglycemic treatment).,Incidence of acute and chronic rejection treated at 6 months and at 1 year.,,2004-02,COMPLETED,INTERVENTIONAL,['PHASE4']
117,NCT05849714,"proportion of patients with glycaemia level within target from arrival to departure from the endoscopy unit, i.e. between 4 - 10 mmol/L. (Part 2 of study)","Proportion of participants who experienced: episode of hypoglycemia <3 and < 4 mmol/L, episode of hyperglycemia >10, > 15 and >20 mmol/L, episode of ketoacidosis. (Part 2 of study)",,2023-09-01,RECRUITING,INTERVENTIONAL,['NA']
118,NCT00862875,Changes in total fat mass (in kg),"Epicardial fat, trunk fat, total fat free mass, weight & waist circumference, HbA1c, fasting glucose, RMR, TEF,PAEE & TEE, energy intake.",,2009-03,COMPLETED,INTERVENTIONAL,['PHASE4']
119,NCT00715221,"Physiological measurement; Differences in tissue insulin-stimulated glucose uptake used by PET imaging among normal weight, obese and patients with type 2 diabetes",,,2007-07,COMPLETED,OBSERVATIONAL,['NA']
120,NCT02492763,Change From Baseline in Heart Rate at Week 12,Change From Baseline in Diastolic Blood Pressure (DBP) at Week 12,,2015-07-27,TERMINATED,INTERVENTIONAL,['PHASE2']
121,NCT02002221,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 12 Weeks Between Treatment Groups,"Number of Participants With Adverse Events, Serious Adverse Events and Death",,2013-12,COMPLETED,INTERVENTIONAL,['PHASE4']
122,NCT02585778,Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (AEs),Absolute Change From Baseline in Number of Glucose-Lowering Treatments at Weeks 12 and 24 - On-Treatment Analysis,,2015-10-23,COMPLETED,INTERVENTIONAL,['PHASE3']
123,NCT00659477,The change in blood glucose variability,Comparison of dose of insulins NPH vs Lantus,,2008-03,COMPLETED,INTERVENTIONAL,['PHASE4']
124,NCT03785236,Hepatic uptake of 68Ga-NODAGA-exendin-4,Islet graft function,,2016-06-06,TERMINATED,OBSERVATIONAL,['NA']
125,NCT01213784,Left ventricular function,Muscle strength and mass,,2010-09,COMPLETED,INTERVENTIONAL,['PHASE2']
126,NCT05317585,Large for Gestational Age Infant,Maternal Patient Satisfaction Survey with Glucose Monitoring,,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
127,NCT02747680,Brain activation during hypoglycemia (low blood sugar) using functional MRI,,,2004-01,COMPLETED,INTERVENTIONAL,['NA']
128,NCT02693392,Glycosylated hemoglobin (HbA1c),Post-prandial Blood Glucose,,2016-01-17,COMPLETED,INTERVENTIONAL,['NA']
129,NCT02804620,Change in HbA1c%,ApoB,Weight,2014-10,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
130,NCT05313529,Change of cognitive function,Change of general cognitive function,,2022-10-08,RECRUITING,INTERVENTIONAL,['NA']
131,NCT05125185,Change of VCAM-1,,,2021-08-01,COMPLETED,INTERVENTIONAL,['NA']
132,NCT03568630,"Result of MMTT which may indicate type 3c diabetes, which may be a risk factor for pancreas cancer.",,,2018-07-26,RECRUITING,OBSERVATIONAL,['NA']
133,NCT03700528,Committed Action Questionnaire (CAQ-8),Work and Social Adjustment Scale (WSAS),,2018-10-01,UNKNOWN,INTERVENTIONAL,['NA']
134,NCT01030601,Central Retinal Thickness,Best corrected visual acuity and incidence of laser treatments,,2010-01,COMPLETED,INTERVENTIONAL,['PHASE2']
135,NCT02729441,24 Hour Ambulatory Blood Pressure Monitoring,,,2010-04,COMPLETED,INTERVENTIONAL,['PHASE3']
136,NCT06063759,Accuracy of the Vital USA VitalDetectTM for assessment of microcirculation (in AU),,,2023-09-25,SUSPENDED,INTERVENTIONAL,['NA']
137,NCT01730534,Subjects Included in the Composite Endpoint of CV Death or Hospitalization Due to Heart Failure.,Subjects Included in the Endpoint of All-cause Mortality.,,2013-04-25,COMPLETED,INTERVENTIONAL,['PHASE3']
138,NCT02848833,Percentage of Participants With Adverse Events Leading to Discontinuation of the Drug,Number of Participants Per Final Effectiveness Assessment Category at Last Visit,,2016-08-10,COMPLETED,OBSERVATIONAL,['NA']
139,NCT01032395,Differences in the Seroconversion Rates or Significant Increase by Visit (Vaccine With Adjuvant - Vaccine Without Adjuvant),,,2010-03,COMPLETED,INTERVENTIONAL,['PHASE3']
140,NCT04728620,User Experience,Order Completion,,2021-05-06,COMPLETED,INTERVENTIONAL,['NA']
141,NCT05395442,Collection of Post-Test Data,,,2022-06-03,COMPLETED,INTERVENTIONAL,['NA']
142,NCT00993473,"Event Rate of ""All Hypoglycemia"" Defined as the Total Number of Episodes Divided by the Total Duration of the On-treatment Period in Years (Events Per Patient-year)",Average Daily Blood Glucose (BG) Based on CGMS Values: End of Treatment and Change From Baseline to End of Treatment,Nocturnal Blood Glucose Variability Based on All On-treatment CGMS Values,2009-10,COMPLETED,INTERVENTIONAL,['PHASE3']
143,NCT01633762,changes in postprandial GLP-1 secretion,changes in metabolomic profile,,2012-04,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
144,NCT04306848,Blood glucose profile,participant survey,,2021-01-01,WITHDRAWN,INTERVENTIONAL,['NA']
145,NCT02829593,Change in Euglycemic GABA level in hypothalamus using MRI,,,2019-10-31,COMPLETED,INTERVENTIONAL,['NA']
146,NCT04615910,Pancreatic 68Ga-exendin uptake,relative 68Ga-exendin uptake,,2021-07-01,RECRUITING,INTERVENTIONAL,['PHASE2']
147,NCT05391984,SPADI for pain and disability,,,2022-06-07,RECRUITING,INTERVENTIONAL,['NA']
148,NCT00851201,"BMI percentile for age and sex, biomarkers e.g, glucose, insulin, lipids","dietary intake, and physical activity measures",,2009-08,COMPLETED,INTERVENTIONAL,['NA']
149,NCT01606904,change in weight,change in incretins,,2012-05,COMPLETED,INTERVENTIONAL,['NA']
150,NCT03449199,Changes in Log-transformed Urinary Albumin-to-creatinine Ratio (UACR) at Week 12,Changes in Exploratory Renal Biomarkers (Creatinine-Corrected N-acetyl-beta-D-glucosaminidase),,2018-04-10,COMPLETED,INTERVENTIONAL,['PHASE2']
151,NCT02834715,Glycaemic profile in response to mixed meal test,Liver enzymes,,2016-03,COMPLETED,INTERVENTIONAL,['NA']
152,NCT03937453,Early Stage Pancreatic Cancer or Precursor Lesions,Relative Risk of Pancreatic Cancer Among Individuals with Detiorating diabetes,,2018-01-19,RECRUITING,OBSERVATIONAL,['NA']
153,NCT04974333,HbA1C,Waist circumference,,2021-10-04,UNKNOWN,INTERVENTIONAL,['NA']
154,NCT04316429,Change in Endothelial Function (EF) Assessment:,Change in Physical Activity,,2020-06-09,COMPLETED,INTERVENTIONAL,['NA']
155,NCT00203632,The primary end-point of the study is the percent change in forearm blood flow to acetylcholine in patients randomized to rosiglitazone compared with placebo.,"Secondary end-points include (i) the percent change in forearm blood flow to verapamil and the absolute change to both acetylcholine and verapamil and (ii) the relationship between HOMA-IR, CRP and endothelial function.",,2003-09,TERMINATED,INTERVENTIONAL,['PHASE3']
156,NCT03552991,Quantitative insulin sensitivity check index (QUICKI),Lipopolysaccharide (LPS),,2014-02,COMPLETED,INTERVENTIONAL,['PHASE4']
157,NCT04152915,"Cmax,sema,1mg: Maximum observed semaglutide concentration after one dose of s.c. semaglutide 1 mg administration following a 6-week dose escalation period","t½,sema,1mg: terminal elimination half-life of semaglutide after one dose of s.c. semaglutide 1 mg administration following a 6-week dose escalation period",,2019-11-25,COMPLETED,INTERVENTIONAL,['PHASE1']
158,NCT03174522,Complete healing of all ischemic ulcers on the index leg.,,,2017-04-25,TERMINATED,INTERVENTIONAL,['PHASE3']
159,NCT02627287,Injection success (full dose delivered s.c.) (yes/no),"Grading of bleeding, redness, bruising and swelling at the site of injection",,2015-12-01,COMPLETED,INTERVENTIONAL,['PHASE1']
160,NCT02542774,First occurrence of cardiovascular disease,All cause mortality,,2015-08,UNKNOWN,OBSERVATIONAL,['NA']
161,NCT03205865,Diagnosis of Type 1 Diabetes,Detection of Islet Autoantibodies,Detection of Transglutaminase Antibodies,1993-12-06,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
162,NCT03985098,Adherence Measure,,,2019-05-29,COMPLETED,INTERVENTIONAL,['NA']
163,NCT05653050,Time in target glucose range,"Total, basal, and bolus insulin dose",Human Factor assessment,2023-02-20,RECRUITING,INTERVENTIONAL,['NA']
164,NCT02594033,Maximum concentration of insulin aspart measured in serum,,,2015-10-27,COMPLETED,INTERVENTIONAL,['PHASE1']
165,NCT01705899,Change in measured creatinine clearance,Change in glycemic lability score,,2006-11,SUSPENDED,INTERVENTIONAL,['PHASE1']
166,NCT01980264,To noninvasively provide real-time imaging of cutaneous histopathology and molecular changes.,To provide a diagnostic tool for diseases.,,2009-08-05,RECRUITING,INTERVENTIONAL,['NA']
167,NCT03635671,Perfusion density,Retinal layer thickness,,2018-09-01,TERMINATED,OBSERVATIONAL,['NA']
168,NCT00696995,"The number of serious adverse drug reactions, including major hypoglycaemic events",Fasting plasma glucose at visits,,2007-01,COMPLETED,OBSERVATIONAL,['NA']
169,NCT02482610,Vascular Endothelial Function,Oxidative Stress Biomarker (Malondialdehyde; MDA),,2016-06,COMPLETED,INTERVENTIONAL,['NA']
170,NCT01401751,To evaluate the performance of the System while the subject is under close medical supervision in the Clinical Research Center (CRC) setting.,Safety Evaluation,,2011-07-01,COMPLETED,INTERVENTIONAL,['NA']
171,NCT05194592,Change (%) in LV mass index,Change (%) in mean 24hr ambulatory systolic and diastolic blood pressure,,2022-01-07,RECRUITING,INTERVENTIONAL,['PHASE4']
172,NCT00738088,HbA1c reduction,insulin secretory response to glucose and tolbutamide,,2007-06,TERMINATED,INTERVENTIONAL,['PHASE4']
173,NCT05941468,Plaque Control Record (PCR),Oral Health Related Quality of Life(OHRQoL),,2023-03-28,RECRUITING,INTERVENTIONAL,['NA']
174,NCT04072523,Prevalence of Left Ventricular dysfunction,Correlation of Left ventricular dysfunction and heart failure,,2019-12-03,COMPLETED,OBSERVATIONAL,['NA']
175,NCT03085251,System accuracy criteria,,,2017-03-16,COMPLETED,INTERVENTIONAL,['NA']
176,NCT02093702,Mean Change in Diastolic Blood Pressure,Mean Change in Adherence to the Canadian Diabetes Association's Clinical Practice Guidelines Resistance Exercise Recommendations,,2014-04,COMPLETED,INTERVENTIONAL,['NA']
177,NCT03237455,Inflammatory changes in the spine and/or sacroiliac joints,,,2018-08-01,RECRUITING,INTERVENTIONAL,['NA']
178,NCT06056167,The percentage of blood glucose readings at the target glycemic control 140- 180 mg/dL (7.8 -10 mmol/L).,Intensive care unit (ICU) length of stay,,2023-05-17,RECRUITING,INTERVENTIONAL,['NA']
179,NCT06111664,"Prevalence of hypophosphatemia, DPi and SSL at the population level.",,,2023-05-01,RECRUITING,OBSERVATIONAL,['NA']
180,NCT01809431,weight (body mass index),breastfeeding,,2012-05,COMPLETED,INTERVENTIONAL,['NA']
181,NCT00427401,The primary end point is glucose lowering (24 hour mean glucose concentration).,Fasting blood glucose,,2007-02,TERMINATED,INTERVENTIONAL,['PHASE2']
182,NCT02368704,Show an increase in markers of ER stress in fasting patients with type 2 diabetes,Lipolysis on insulin,,2012-11,UNKNOWN,OBSERVATIONAL,['NA']
183,NCT04275479,Share data with the current SBDS Registry,,,2020-01-10,RECRUITING,OBSERVATIONAL,['NA']
184,NCT05764850,Cluster analysis to decipher underlying mechanisms of type 1 diabetes,,,2023-02-01,RECRUITING,OBSERVATIONAL,['NA']
185,NCT00911625,Average Blood Glucose Over 6 Days,The Number of Participants Who Experience at Least One Blood Glucose Level Below 70 Milligrams Per Deciliter,,2009-01-21,COMPLETED,INTERVENTIONAL,['PHASE4']
186,NCT00425269,"Plasma Glucose, 2-h, Post-test","Intake of Fish, Post Test",,2006-04,COMPLETED,INTERVENTIONAL,['NA']
187,NCT01089205,,,,na,COMPLETED,INTERVENTIONAL,['PHASE1']
188,NCT00059254,Oxygen consumption,excess Post exercise oxygen consumption (EPOC),,2000-09,COMPLETED,INTERVENTIONAL,['NA']
189,NCT05618756,Postprandial Triglyceridaemia,Postprandial Insulinaemia,,2021-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
190,NCT05629806,Blood glucose fluctuation,,,2022-04-10,RECRUITING,INTERVENTIONAL,['PHASE3']
191,NCT03736668,Measurement of left ventricular ejection fraction,Comparing the volume of the left atrium in Simpson biplane and in 3D,,2018-05-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
192,NCT04291703,Progression to Stage 3 T1D,,,2023-01-01,RECRUITING,INTERVENTIONAL,['PHASE2']
193,NCT02470403,"Part 2: Number of Patients With Any Adverse Events, Serious Adverse Events and Death",The Apparent Volume of Distribution of LIK066 During the Terminal Elimination Phase Following Extra Vascular Administration (Vz/F) in Part 2 of the Study,,2015-06-05,COMPLETED,INTERVENTIONAL,['PHASE2']
194,NCT05166122,Referral adherence,Assess AI performance,,2022-01-01,RECRUITING,INTERVENTIONAL,['NA']
195,NCT01881958,efficacy will be measured by comparing Hemoglobin A1c,Safety will be evaluated calculating number of Adverse Events.,,2015-01,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
196,NCT02121717,Change in HbA1c from baseline after 24 weeks of treatment,Percentage of patients who use rescue therapy,,2014-06,COMPLETED,INTERVENTIONAL,['PHASE3']
197,NCT00226330,Body weight,Patient reported outcomes using the Medical Outcomes Study Short Form-36 (SF-36),,2005-03,TERMINATED,INTERVENTIONAL,['PHASE3']
198,NCT05299177,"% time spent in target glucose range measured by continuous glucose monitoring (3.9-10mmol/L, 70-180mg/dL)",Change in weight (kg),Productivity lost,2022-04-01,RECRUITING,INTERVENTIONAL,['NA']
199,NCT04587336,"Aim1: Differences in Diabetes Distress Scale score by HbA1c level (HbA1c < 9 and HbA1c 9) and by medication regimen (no insulin, insulin).",,,2020-08-24,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
200,NCT00704652,Morphologic changes in the retina detected by HD-OCT following darbepoetin alpha therapy compared to control patients,"Changes in blood count, chemistry, Astrup and blood clotting following darbepoetin alpha therapy compared to control patients.",,2008-05,TERMINATED,OBSERVATIONAL,['NA']
201,NCT03406897,MMTT (Mixed Meal Tolerance Test),Incidence of Adverse Events (AE),,2018-07-23,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
202,NCT05755360,Absolute change in glycated haemoglobin (HbA1c) (millimoles per mole [mmol/mol]),Absolute change in diabetes distress survey (DDS) scores (points),,2023-02-21,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
203,NCT02068638,Amount of exogenous glucose required to maintain glycemia within a range between 7-10mM,Heart rate variability,,2014-02,COMPLETED,INTERVENTIONAL,['NA']
204,NCT06081231,proportion of time spent in the target glucose range,concentration of HbA1c,,2021-06-01,RECRUITING,OBSERVATIONAL,['NA']
205,NCT05036343,Glucose,Change in Self-Efficacy for Managing Chronic Conditions - Managing Medications and Treatment Score,,2021-09-14,COMPLETED,INTERVENTIONAL,['NA']
206,NCT04117763,Arrhythmogenic burden,,,2019-10-04,RECRUITING,INTERVENTIONAL,['PHASE4']
207,NCT04029103,self-efficacy,,,2017-06-01,COMPLETED,INTERVENTIONAL,['NA']
208,NCT00001985,,,,2000-01,COMPLETED,OBSERVATIONAL,['NA']
209,NCT02449850,Food allergy to any intervention allergen,Rhinitis/Allergic rhinitis,Any other allergic disease,2014-12-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
210,NCT03307850,"Impact of Stress and Exercise on CGM Glucose Levels, determining how these factors affect time within target glucose range 70-180 mg/dl",CGM Glucose Levels greater than 180 mg/dl,,2017-11-01,COMPLETED,INTERVENTIONAL,['NA']
211,NCT05611944,SSI rate,patient satisfaction,,2017-04-01,COMPLETED,INTERVENTIONAL,['NA']
212,NCT01217073,Percentage of Participants Who Discontinued From Study Drug Due to an Adverse Event During the 66-week Extension Period,Change From Baseline in FPG Levels at Week 78,,2010-10-08,COMPLETED,INTERVENTIONAL,['PHASE2']
213,NCT00001368,,,,1993-10,COMPLETED,INTERVENTIONAL,['PHASE1']
214,NCT05941286,"Time in range (3.9~10.0mmol/L, %)",Glycemia risk index (GRI),,2024-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
215,NCT00168857,Change from baseline after one year of treatment in proteinuria (ratio of protein to creatinine as measure in spot urine sample).,Change from baseline after one year of treatment in the following: glomerular filtration rate; serum creatinine; macroalbuminuria; sodium excretion; high sensitive C-reactive protein; serum aldosterone; and other renal and cardiovascular measures.,,2003-07-09,COMPLETED,INTERVENTIONAL,['PHASE4']
216,NCT01667185,System Performance Effectiveness,System Performance at Alternate Wear Site,,2012-07,COMPLETED,OBSERVATIONAL,['NA']
217,NCT02332434,"production and clearance rates of intestinal and hepatic TRL, in 2 groups of obese patients (15 patients per surgery procedure), before and 6 months after the surgery.",,,2015-03,UNKNOWN,INTERVENTIONAL,['NA']
218,NCT03617393,Survival at 1 Year,Humoral Immunoserologic Indexes,,2017-07-10,UNKNOWN,OBSERVATIONAL,['NA']
219,NCT01039896,"Css,max and AUCinf","AUCtau, AUCt, Tmax",,2009-06,COMPLETED,INTERVENTIONAL,['PHASE1']
220,NCT00042042,,,,na,UNKNOWN,INTERVENTIONAL,['NA']
221,NCT02130284,Rescue Events During In-clinic Procedues,,Device Metric/Performance - All Device Deficiencies,2014-10,COMPLETED,INTERVENTIONAL,['NA']
222,NCT04104711,Costs via frequency of complication-related hospital admissions,,Sociodemographic and disease-related characteristics of patients with diabetes,2015-01-01,COMPLETED,INTERVENTIONAL,['NA']
223,NCT05766774,Change in fasted plasma Eh[CySS] from baseline,Change in fasted plasma Eh[GSSG],,2023-06-28,RECRUITING,INTERVENTIONAL,['NA']
224,NCT03253562,benefit of improving the condition of elevated blood pressure in patients through neovascularization,comparing the anti-hyperglycemic effect of each drug for diabetic hypertensive patients,,2017-02-01,COMPLETED,INTERVENTIONAL,['PHASE4']
225,NCT02607007,Subjective Appetite,Food Intake,,2015-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
226,NCT05394532,HbA1c,self management,,2020-10-02,COMPLETED,INTERVENTIONAL,['NA']
227,NCT05556161,HbA1c change,Social support,,2021-04-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
228,NCT04115917,Discomfort During Scleral Depression with Schocket Depressor and Cotton Tipped Applicator,Retinal pathology,,2018-01-01,COMPLETED,INTERVENTIONAL,['NA']
229,NCT04356898,Area under the curve (AUC); ((mmol/L)*h),High blood glucose index (HBGI),,2018-04-15,COMPLETED,OBSERVATIONAL,['NA']
230,NCT02827708,Change in HbA1c,Change in Urinalysis,,2016-09-20,COMPLETED,INTERVENTIONAL,['PHASE3']
231,NCT03805191,The extent of change in MAGE,The control rate of HbA1c,Gene polymorphism,2019-01-01,UNKNOWN,OBSERVATIONAL,['NA']
232,NCT05532553,Assessment of carotid atherosclerosis,,,2022-09-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
233,NCT00361907,Primary: Assessment of effect of Pulsatile Intravenous Insulin therapy on circulating blood markers for diabetic patients.,,,2005-02,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
234,NCT00668785,Mean Change From Pre-PRP Best Corrected Visual Acuity (BCVA) at 3 Months as Expressed as an Early Treatment Diabetic Retinopathy Study (ETDRS) Score (Number of Letters Correctly Read.),Percentage of Patients That Maintain Pre-PRP Visual Acuity at the 3 Month Time Point,,2007-03,TERMINATED,INTERVENTIONAL,['PHASE2']
235,NCT01603940,Endothelial Function,Vascular Stiffness by Augmentation Index,,2012-05,COMPLETED,INTERVENTIONAL,['PHASE4']
236,NCT04284033,"Number of infusion set failures due to ""unexplained hyperglycemia""",Duration of infusion set wear,,2017-02-14,WITHDRAWN,INTERVENTIONAL,['NA']
237,NCT01938521,Fasting and postprandial Clock Genes expression in peripheral blood cells (PBC),Fasting HbA1c,"fasting and postprandial glucose, Insulin, GLP-1, asymmetric dimethylarginine (ADMA),and lipid plasma levels",2013-09,COMPLETED,INTERVENTIONAL,['NA']
238,NCT03214367,Change From Baseline in Hemoglobin A1c (HbA1c) Efficacy Estimand at Week 26,Change From Baseline in HbA1c at Week 52,,2017-07-17,COMPLETED,INTERVENTIONAL,['PHASE3']
239,NCT03672422,Length of time from progression from Acute Recurrent Pancreatitis to Chronic Pancreatitis,Number of subjects with abnormal oral glucose tolerance test (OGTT),,2017-06-30,COMPLETED,OBSERVATIONAL,['NA']
240,NCT03244579,Fasting blood glucose,Shoulder dystocia,,2017-08-20,UNKNOWN,INTERVENTIONAL,['NA']
241,NCT06295913,LDL-ox as marker of oxidative status,Aspartate aminotransferase (transaminase AST),,2024-03,RECRUITING,INTERVENTIONAL,['NA']
242,NCT02735044,Change From Baseline in HbA1c to Month 6,Percentage of Participants With Any Hyperglycemia With Ketosis at Month 12,,2016-04-14,COMPLETED,INTERVENTIONAL,['PHASE3']
243,NCT00442325,Proportion of subjects achieving a LDL-C target of < 100 mg/dL (2.6 mmol/L) after 12 weeks.,"The mean percent change in LDL-C, high density lipoprotein cholesterol (HDL-C),TC/HDL-C ratio, non HDL-C (in subjects with triglycerides [TG] ≥200 mg/dL or 2.3 mmol/L), TC and TG from baseline to 6 and 12 weeks of treatment. Change from baseline in apol",,2003-01,COMPLETED,INTERVENTIONAL,['PHASE4']
244,NCT04552600,To evaluate safety of Nuvastatic - Letter Score,To evaluate short-term visual outcomes on DRSS,,2019-09-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
245,NCT04670198,Glycated haemoglobin (HbA1c),Acceptability of Intervention Measure (AIM),,2021-06-01,COMPLETED,INTERVENTIONAL,['NA']
246,NCT02035644,change in HbA1c levels,blood pressures,,2014-02,UNKNOWN,INTERVENTIONAL,['PHASE4']
247,NCT00862602,Glucose tolerance,Insulin,,2009-07,COMPLETED,INTERVENTIONAL,['NA']
248,NCT00831779,Adjusted Mean Percent Change From Baseline in Insulin Sensitivity at Week 12 (Last Observation Carried Forward [LOCF]),Adjusted Mean Change From Baseline in Insulin Secretion at Week 12 (Last Observation Carried Forward [LOCF]),,2009-04,COMPLETED,INTERVENTIONAL,['PHASE2']
249,NCT01462864,we aim for a 2000 steps increase in Number of steps per day,Brief Illness Perception,,2011-09,COMPLETED,INTERVENTIONAL,['NA']
250,NCT00623610,Evidence of clinically relevant beta cell function.,,,2000-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
251,NCT01302639,postprandial fat oxidation,,,2011-02,COMPLETED,INTERVENTIONAL,['NA']
252,NCT03423589,Alterations in Plasma-Induced Transcriptional Analysis,Intestinal Microbiota,,2018-04-23,COMPLETED,INTERVENTIONAL,['NA']
253,NCT04867629,Proteomic biomarkers,Oxidative stress biomarkers,,2015-07,COMPLETED,INTERVENTIONAL,['NA']
254,NCT00171496,Incidence of biopsy-proven acute rejection (BPAR) or graft loss or death within the first 6 months post-transplantation.,"incidence of BPAR or graft loss or death within the first 3 months post-transplantation, as well as the incidence of each individual event within 3 and 6 months post-transplantation.",,2003-10,COMPLETED,INTERVENTIONAL,['PHASE4']
255,NCT06330194,Percent time in sensor glucose target range (3.9-10.0 mmol/L),Frailty,,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
256,NCT00453817,"Semi-quantitative assessment of intrahepatic MRI signal on T2*-weighted sequences, at 6 days, 6 weeks, 6 months and 1 year after transplantation","Islet graft function assessed by exogenous insulin requirements, HbA1c, mean amplitude of glucose excursions (MAGE) and fasting C-peptide.",,2005-06,TERMINATED,INTERVENTIONAL,['PHASE1']
257,NCT03913793,Six minute walk test distance,,,2016-03-01,COMPLETED,INTERVENTIONAL,['NA']
258,NCT01665989,Change in weight (percent weight loss from baseline to 6 months),Cost effectiveness and savings,,2012-08,COMPLETED,INTERVENTIONAL,['NA']
259,NCT04305587,Number of Participants With Abnormal Electrocardiogram (ECG),Renal Clearance (CLr) for PF-07081532,,2020-03-16,COMPLETED,INTERVENTIONAL,['PHASE1']
260,NCT06152042,To assess the effect on endogenous insulin secretion,Incidence of adverse events,,2023-12-28,RECRUITING,INTERVENTIONAL,['PHASE2']
261,NCT00982358,The primary objective of the study was to evaluate the anti-inflammatory effect of VAL by analyzing the reduction of the inflammatory markers interleukin-6 (IL-6) and tumor necrosis factor alpha (TNFα) in serum after 16 weeks of treatment.,"To explore the effect of 160/320 mg valsartan on coronary perfusion, in the group of patients with angiographically documented CAD",,2004-07,COMPLETED,INTERVENTIONAL,['PHASE4']
262,NCT01644201,HbA1c,,,2012-10,TERMINATED,INTERVENTIONAL,['PHASE3']
263,NCT06186245,Length of stay in the medical intensive care unit (in days).,mortality,,2023-12-27,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
264,NCT00606034,Improvement in Glycemic Control as Assessed by Change in Hemoglobin A1c (HbA1c),Patient Satisfaction With Insulin Delivery Method Via Insulin Delivery Rating System Questionnaire (IDRSQ),,2007-12,COMPLETED,INTERVENTIONAL,['PHASE4']
265,NCT06226727,Cmax,,,2024-02-14,COMPLETED,INTERVENTIONAL,['PHASE1']
266,NCT01951183,Change from baseline in HbA1c,Safety: Incidence of adverse events,,2013-12,WITHDRAWN,INTERVENTIONAL,['PHASE2']
267,NCT01344668,Improvement in A1C at 12 months,,,2011-05,COMPLETED,INTERVENTIONAL,['NA']
268,NCT00095056,Safety and Tolerability of Sitagliptin After 12 Weeks of Treatment,Safety and Tolerability of Sitagliptin Over 54 Weeks,,2004-10,COMPLETED,INTERVENTIONAL,['PHASE3']
269,NCT01095822,How therapy with valsartan (160mg/daily) in combination with aliskiren (150-300mg/daily) affects platelet/coagulation/fibrinolytic biomarkers in recently diagnosed hypertensive patients with type 2 diabetes mellitus.,"Whether combination therapy is superior over monotherapy with aliskiren with regard to the improvement of hemostatic biomarkers (platelet aggregation, expression of GP IIb/IIIa, and plasma levels of antithrombin-III).",,2010-03,UNKNOWN,INTERVENTIONAL,['PHASE4']
270,NCT06157684,Infant birthweight percentile,need for insulin or metformin during pregnancy,feasibility and acceptability,2022-10-01,RECRUITING,INTERVENTIONAL,['NA']
271,NCT04190199,Nutritype signature of T2DM risks in women post-GDM,Smoking habit and exposure,,2020-05,UNKNOWN,OBSERVATIONAL,['NA']
272,NCT03920683,Toe-brachial index,Coronary angiography,,2019-07-08,COMPLETED,OBSERVATIONAL,['NA']
273,NCT03497390,Change in glycemic control,Change in waist-hip ratio [WHR],mortality,2012-07,COMPLETED,INTERVENTIONAL,['NA']
274,NCT02990299,Hemoglobin A1c,Diabetes Self-efficacy,Health Coach Satisfaction,2017-03-24,COMPLETED,INTERVENTIONAL,['NA']
275,NCT03546062,Myocyte Lipid Accumulation as Oil Red-O Positive Biopsie,,,2010-01-01,COMPLETED,OBSERVATIONAL,['NA']
276,NCT05586594,To see how many patient with diabetes diagnosed at early age with features not suggestive of type 1 or type 2 are found to have MODY monogenic diabetes (commonest subtypes) among young Emirati patients,To find out the antibodies present in young patient with diabetes and if they are helpful in ruling out monogenic diabetes,,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
277,NCT05056376,Achievement of CDC's benchmark for type 2 diabetes risk reduction as a binary outcome (yes/no),Correlation between self-reported and measured physical activity,,2021-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
278,NCT01490151,Safety and Feasibility of TTR Closed-loop Control System as Measure by the Count of Successful Hospital Admissions,,,2011-12,COMPLETED,INTERVENTIONAL,['NA']
279,NCT01802541,insulin resistance,,,na,COMPLETED,INTERVENTIONAL,['NA']
280,NCT04603885,BDNF DNA demethylation in percentage,Processing speed,,2020-10-27,UNKNOWN,INTERVENTIONAL,['NA']
281,NCT01916694,Glycosylated haemogloblin,Neonatal hypoglycaemia,Economic evaluation,2013-09,COMPLETED,INTERVENTIONAL,['NA']
282,NCT01853332,Social Adjustment Scale,Health Risk Factors,,2009-01,COMPLETED,OBSERVATIONAL,['NA']
283,NCT02777060,Change in Balance,Change in average of longest walking bout,,2014-09,UNKNOWN,INTERVENTIONAL,['NA']
284,NCT00254124,"- prespecified per protocol analysis: same outcomes as above, looking at patients who were >=80% compliant with the intervention",- change in blood pressure,,2004-04,COMPLETED,INTERVENTIONAL,['NA']
285,NCT04943692,Change in HbA1c,Incidence of adverse events,,2021-08,SUSPENDED,INTERVENTIONAL,['PHASE3']
286,NCT00821379,,,,2008-04,COMPLETED,OBSERVATIONAL,['NA']
287,NCT00596973,Treatment sucess based on patients' glycemic control,,,2008-01,WITHDRAWN,INTERVENTIONAL,['PHASE4']
288,NCT05237271,CPV-measured cost difference,CPV-measured Assessment of use case types,,2022-03-15,COMPLETED,INTERVENTIONAL,['NA']
289,NCT02262832,Serum hemoglobin A1C,Bone mineral density &amp; metabolism,,2014-10-09,RECRUITING,INTERVENTIONAL,['PHASE3']
290,NCT05065892,Neutralizing antibody level,Adverse events following vaccination,,2021-10,UNKNOWN,INTERVENTIONAL,['PHASE4']
291,NCT04919499,Part B: Number of subjects with drug related Adverse Events (AEs) from drug administration until end of study (EOS),Part B: Number of subjects with any ocular Adverse Events (AEs) (eye disorders) from drug administration until end of study (EOS),,2021-07-30,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
292,NCT00798915,"The effects of GIP, xenin-25, or a combination of GIP plus xenin-25 on insulin secretion and blood glucose levels",The effects of xenin-25 on GIP action in persons with type 2 diabetes,,2008-12,COMPLETED,INTERVENTIONAL,['PHASE1']
293,NCT02020616,Change From Baseline in Hemoglobin A1c (HbA1c) at 12-Week Endpoint,"Pharmacokinetics: Area Under the Concentration Versus Time Curve During One Dosing Interval at Steady State (AUC [τ,ss]) of LY3053102",,2013-12,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
294,NCT02796248,Presence of stigma,Well-Being Index,,2016-05,COMPLETED,OBSERVATIONAL,['NA']
295,NCT06110728,Number of missed behavioral health visits,,Changes in weight,2023-11,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
296,NCT00229268,,,,2005-09,COMPLETED,OBSERVATIONAL,['NA']
297,NCT06180655,Study Feasibility: Intervention safety,Objective measures using an Oura Ring: Heart Rate Variability,,2024-01-31,RECRUITING,INTERVENTIONAL,['NA']
298,NCT01046994,Diabetes control as defined by FSG and HbA1c,Assessment of patient BMI,,2009-07,UNKNOWN,INTERVENTIONAL,['PHASE3']
299,NCT01997424,Steatosis,Steatosis (serum),,2013-05,COMPLETED,INTERVENTIONAL,['NA']
300,NCT02987751,Changes in HbA1c,Number of participants treated related to adverse events,,2016-12-29,COMPLETED,INTERVENTIONAL,['PHASE4']
301,NCT01399385,"To develop, implement, and optimize new non-invasive methods for characterization of the micro-environment in the thoracic and abdominal area utilizing specialized techniques",,,2011-07-06,RECRUITING,INTERVENTIONAL,['NA']
302,NCT00809705,"Tmax, log (AUC), log(Cmax)of paracetamol",Multiple dose pharmacokinetics of Taspoglutide,,2008-12,COMPLETED,INTERVENTIONAL,['PHASE3']
303,NCT03566511,Change in Arterial Spin Labeling (ASL) signal measured using 3T MRI from 2 hours post dosing to 4 hours post dosing,,,2018-06-12,SUSPENDED,INTERVENTIONAL,['PHASE2']
304,NCT06201806,Glycemic Responses (GR),Assessment of Appetite:,,2019-01-02,COMPLETED,INTERVENTIONAL,['NA']
305,NCT04893148,Changes in glycated hemoglobin (HbA1c),Changes in weight,,2020-05-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4']
306,NCT05152121,AUC,hypoglycemia epizode,,2017-07-01,COMPLETED,INTERVENTIONAL,['NA']
307,NCT00970567,"glucose metabolism, time course of positive ketone bodies",,,2007-11,COMPLETED,INTERVENTIONAL,['NA']
308,NCT01572389,Change in Patient Health Questionnaires-9 During Intervention,,,2012-11-01,COMPLETED,INTERVENTIONAL,['NA']
309,NCT04416841,Global cognition-Montreal Cognitive Assessment at 36 Weeks,"Quality of life-Medical Outcomes Study 36-item Short-Form Health Survey at 24, 36 weeks",functional Magnetic Resonance Imaging (fMRI),2020-06-03,COMPLETED,INTERVENTIONAL,['NA']
310,NCT03186560,Microcirculatory flux in the lower limb of the different subgroups with geko device on.,Adverse Events,,2018-02-12,TERMINATED,INTERVENTIONAL,['NA']
311,NCT05233592,Total Daily Insulin Resistance (TDIR),Change in Time in Hyperglycemia,Post-hoc t-test,2022-03-08,COMPLETED,OBSERVATIONAL,['NA']
312,NCT03859856,ovarian volume,,,2018-11-25,COMPLETED,OBSERVATIONAL,['NA']
313,NCT01565733,Frequency of severe hypoglycaemic episodes,Average plasma glucose level at bedtime and at night,,2007-01,COMPLETED,OBSERVATIONAL,['NA']
314,NCT06283576,Cancer detection,Overall survival,,2024-03-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
315,NCT02177643,Hepatic Function Panel,,,2013-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
316,NCT04014582,Change in diabetes self-care,Change in diabetes specific self-efficacy,Daily self-efficacy,2019-07-20,COMPLETED,INTERVENTIONAL,['NA']
317,NCT05599477,Reduction in HbA1c,Costs and cost-effectiveness.,,2022-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
318,NCT05859165,24h AUC of Nutren Diabetes group with Fresubin Diabetes group,Albumin,,2023-02-01,RECRUITING,INTERVENTIONAL,['NA']
319,NCT04569994,Number of treatment-emergent adverse events (AEs),Maximum observed serum NNC0363-0845 concentration after a single dose,,2020-09-30,COMPLETED,INTERVENTIONAL,['PHASE1']
320,NCT02833389,Percentage of Participants with Adverse Events,Serum Concentration of UTTR1147A,,2016-11-14,COMPLETED,INTERVENTIONAL,['PHASE1']
321,NCT01497561,Area under the glucose infusion rate curve,Terminal half-life,,2003-03,COMPLETED,INTERVENTIONAL,['PHASE1']
322,NCT04809311,Patient with at least 70% unblinded FGM (flash glucose monitoring) data,Coefficient of variation (CV),,2024-03-18,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
323,NCT01824264,Change from baseline in glycated hemoglobin (HbA1c) after 12 weeks,Change from baseline in renal threshold for glucose excretion,,2015-11,WITHDRAWN,INTERVENTIONAL,['PHASE2']
324,NCT00315939,Frequency of Severe Hypoglycemia,,,2006-01,COMPLETED,INTERVENTIONAL,['NA']
325,NCT00117026,Lower-limb nerve conduction velocity,"Serum advanced glycation end products (AGEs) and markers of inflammation (CRP, IL-6, VCAM-1)",,2005-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
326,NCT01175629,Determine the prevalence of lifetime and current psychiatric conditions including PTSD in Vietnam Era Twin Registry members who served during the Vietnam Era.,Characterize the level of current disability in Vietnam Era Twin Registry members who served during the Vietnam Era.,,2010-01,COMPLETED,OBSERVATIONAL,['NA']
327,NCT03184662,Renal Function Decline,Safety of HIPA performed by e-coaching in the context of COVID infection,,2018-02-12,UNKNOWN,INTERVENTIONAL,['NA']
328,NCT05121844,Change in weight,Time in range,,2021-11-02,RECRUITING,INTERVENTIONAL,['NA']
329,NCT00198510,Resolution of Vitreous Hemorrhage,Visual Acuity,,1998-11,COMPLETED,INTERVENTIONAL,['PHASE3']
330,NCT01950676,Change in glycemic control (HbA1c) between the intervention and the control group,Treatment satisfaction as measured by DTSCs and DTSQc,,2013-03,COMPLETED,INTERVENTIONAL,['NA']
331,NCT00541775,Hemoglobin A1C (A1C) at Week 18,2-hour Post-meal Glucose (PMG) at Week 18,,2006-06,COMPLETED,INTERVENTIONAL,['PHASE3']
332,NCT03782636,Differences in slopes of DBS (Dried Blood Spot) C-peptide over the 6 month-treatment period between the active and placebo groups.,Change in HbA1c and daily insulin requirements during the trial period.,,2019-01-28,UNKNOWN,INTERVENTIONAL,['PHASE2']
333,NCT00649246,autoantibodies against the pancreas and type 1 diabetes,Risk factors for type 1 diabetes,,1997-07,COMPLETED,OBSERVATIONAL,['NA']
334,NCT01580475,"Changes from baseline in glycemic control measurements (follow-up for 21 months) at training (9 months), detraining (3 months) and retraining (9 months)",Measurement of muscular strength in patients with type 2 diabetes,,2008-09,COMPLETED,INTERVENTIONAL,['NA']
335,NCT00845559,Whether treatment with exenatide attenuates post-prandial glycemic excursions as assessed by oral glucose tolerance testing (OGTT) and continuous monitoring system (CGMS) technology.,Change in body mass index (BMI).,,2008-08,WITHDRAWN,INTERVENTIONAL,['PHASE4']
336,NCT02094846,Glycated hemoglobin,Physical activity,,2012-10,COMPLETED,INTERVENTIONAL,['NA']
337,NCT05609279,Proportion of enrolled participants providing serum samples for metabolomic analysis,,,2021-02-18,RECRUITING,OBSERVATIONAL,['NA']
338,NCT01735643,HbA1c,weight,,2011-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
339,NCT03036800,Weight loss of ≥15% at 52 weeks,Patient quality of life,Waist circumference,2017-11-28,UNKNOWN,INTERVENTIONAL,['PHASE4']
340,NCT00602953,Disposition Index (DI),,,2007-09,COMPLETED,OBSERVATIONAL,['NA']
341,NCT05104944,Quality of life and resource data collection - patient diary.,Progression of foot deformity as documented by measuring radiological foot alignment angles.,Economic Evaluation - Reported through a patient diary,2017-11-20,COMPLETED,INTERVENTIONAL,['NA']
342,NCT02291250,Plasma Glucose Area Under the Curve,Plasma Insulin Area Under the Curve,,2014-11,UNKNOWN,INTERVENTIONAL,['NA']
343,NCT01496365,Mean Change From Baseline to Week 5 in Average Daily Pain Score (ADPS) Following Treatment With DS-5565 Compared to Pregabalin and Placebo,Drug-related Treatment-Emergent Adverse Events (n ≥2 Participants in Any Treatment Group) Following Treatment With DS-5565 Compared to Pregabalin and Placebo,,2011-11-28,COMPLETED,INTERVENTIONAL,['PHASE2']
344,NCT00863954,Reduction in blood glucose and A1c levels at endpoint compared to start,,,2009-01,COMPLETED,INTERVENTIONAL,['PHASE1']
345,NCT04045184,Compare hemoglobin A1c levels between groups with high versus low dietary fiber intake,,,2018-10-20,RECRUITING,OBSERVATIONAL,['NA']
346,NCT05186389,Metagenomic analysis,Clinical associations with metagenomic analysis,,2022-01-26,UNKNOWN,OBSERVATIONAL,['NA']
347,NCT00134524,Subject tolerance to the MME procedure,"Quality of Life assessments at baseline, post-procedure and 6 month follow-up",,2005-07,UNKNOWN,INTERVENTIONAL,['PHASE3']
348,NCT02098733,Number of Participants With Adverse Drug Reactions,Fasting Insulin Level,,2011-06,COMPLETED,OBSERVATIONAL,['NA']
349,NCT00974090,Change From Baseline in HbA1c at Week 12,Change From Baseline in 2-hour Postprandial Plasma Glucose at Week 12,,2009-09,COMPLETED,INTERVENTIONAL,['PHASE3']
350,NCT02967406,Dementia,Blood lipids,Cognitive function,2016-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
351,NCT01594060,,,,2012-06,COMPLETED,INTERVENTIONAL,['PHASE4']
352,NCT05610722,HbA1c,Percentage of sensor readings below 54 mg/dl,"The time required to review insulin and glucose data, make and send recommendations",2022-11-06,RECRUITING,INTERVENTIONAL,['NA']
353,NCT00157586,"The rate of decline of glomerular filtration rate (GFR).GFR is measured at baseline,and at 6,12,18,24,30 and 36 months after randomization",Major cardiovascular events,,2002-02,COMPLETED,INTERVENTIONAL,['PHASE3']
354,NCT05740514,"The effect of T1D on skeletal muscle health, quantified by physiological parameters (detailed in description)","The effect of a detraining period on skeletal muscle health compared to baseline, quantified by physiological parameters (detailed in description)",,2023-10-01,RECRUITING,INTERVENTIONAL,['NA']
355,NCT06074601,Clinical validation of cell-free RNA-based biomarkers of adverse pregnancy outcomes,Discovery of multi-omic biomarkers of adverse pregnancy outcomes,,2021-08-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
356,NCT01349114,Change in Flow-mediated Dilation,Mean Central Aortic Pressure at 3 Months,,2011-06,TERMINATED,INTERVENTIONAL,['PHASE4']
357,NCT03475108,Hemoglobin A1c,Quality of life (primary care giver),,2018-04-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
358,NCT02993614,CVD REAL1 Incidence of hospitalization for heart failure. / CVD REAL 2 All-cause mortality,"CVD REAL1 All-cause mortality; CVD REAL 2: Hospitalization for heart failure (HHF), stroke, myocardial infarction (MI) and including composite endpoints",,2017-11-30,COMPLETED,OBSERVATIONAL,['NA']
359,NCT05852054,Primary care visit (PCV) completion,Dysglycemia and hypertension cases detected,,2023-11-01,RECRUITING,INTERVENTIONAL,['PHASE3']
360,NCT00263419,Progression of albuminuria,Cardiovascular risk factors,,2005-01,UNKNOWN,INTERVENTIONAL,['NA']
361,NCT02767336,Marketing Claims Evaluation questionnaire.,,,2016-04,COMPLETED,INTERVENTIONAL,['NA']
362,NCT05166447,Major adverse cardiovascular events (MACE) (Register data),Chronic Kidney Disease (CKD) Stage 3/4/5 (Blood samples),,2021-09-13,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
363,NCT01399346,"tmax(ins), time to maximum observed serum insulin aspart concentration","t10%max(ins), time to reach 10% of maximum observed serum insulin aspart concentration",,2011-04,COMPLETED,INTERVENTIONAL,['PHASE1']
364,NCT04993482,Change in 24-hour movement composition from baseline over one year and two-year follow-up,Change in Advanced Glycation Endproducts from baseline to one and two-year follow-up,Explanatory variables: physical environmental factors,2021-08-29,RECRUITING,OBSERVATIONAL,['NA']
365,NCT03330548,Change in Low-density lipoprotein (LDL),Change in Hemoglobin A1C (HgbA1c),,2015-07-09,COMPLETED,INTERVENTIONAL,['NA']
366,NCT05814393,HbA1c (24 Weeks) lowering effect,HbA1c lowering effect,,2023-01-03,RECRUITING,INTERVENTIONAL,['PHASE3']
367,NCT00438321,Insulin sensitivity,Intramyocellular fat,,2006-09,TERMINATED,INTERVENTIONAL,['PHASE1']
368,NCT04387422,Glucose kinetics during hyperglycemic clamps before and after induction of IAH,Antecedent physical activity - sleep quality,,2020-08-12,RECRUITING,INTERVENTIONAL,['NA']
369,NCT04978376,Body weight,HbA1c,,2021-09-01,COMPLETED,INTERVENTIONAL,['NA']
370,NCT04195191,Adherence to treatment,Satisfaction with the service,,2019-01-18,UNKNOWN,INTERVENTIONAL,['NA']
371,NCT03389607,SCUBE-1,total antioxidant capacity,,2018-01-08,COMPLETED,OBSERVATIONAL,['NA']
372,NCT01885208,Change From Baseline in HbA1c (Glycosylated Haemoglobin),Subjects Who Achieve HbA1c Equal to or Below 6.5% (48 mmol/Mol) American Association of Clinical Endocrinologists (AACE) Target: (Yes/no),,2013-12-02,COMPLETED,INTERVENTIONAL,['PHASE3']
373,NCT03959514,Area under the glucose infusion rate-time curve of insulin aspart,Area under the serum insulin aspart concentration-time curve from 0-60 minutes,,2019-04-12,COMPLETED,INTERVENTIONAL,['PHASE1']
374,NCT03844126,Transition preparedness,,,2018-04-13,COMPLETED,INTERVENTIONAL,['NA']
375,NCT00044395,Reduction in neuropathic symptoms,"Vibration sensation;Neurological signs;Electrophysiology of peroneal, tibial and sural nerves;Relief of symptoms as measured by VAS;Composite scores of nerve function;Clinical global impression of change",,2002-07,COMPLETED,INTERVENTIONAL,['PHASE3']
376,NCT02465021,Food intake,Blood insulin,Food Recall,2015-03,COMPLETED,INTERVENTIONAL,['NA']
377,NCT02939118,Incidence of adverse events reported during the study.,,,2016-11-07,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
378,NCT03713996,Change in Insomnia Severity Index,Change in Random Glucose Level,,2019-01-16,COMPLETED,INTERVENTIONAL,['NA']
379,NCT00279084,Decrease in Cockcroft's creatinine clearance between inclusion and end of two years follow-up period.,Quality of life: SF 36 auto-questionnaire,,2004-01,UNKNOWN,INTERVENTIONAL,['NA']
380,NCT02048904,Change in Microalbuminuria Level,,,2014-01,TERMINATED,INTERVENTIONAL,['PHASE4']
381,NCT04769765,"Number of patients on the basic diabetic program, included in the study, who have completed at least three of the four scheduled follow-up visits.",Logistic feasability of managing these patients (who have had at least one unscheduled hospitalization during the year) by tele-expertise. Number of follow-up visits per patient per center.,Complications,2022-05-04,RECRUITING,INTERVENTIONAL,['NA']
382,NCT04244110,Usability of the Diacare platform,,,2020-01-17,COMPLETED,OBSERVATIONAL,['NA']
383,NCT03555994,To assess the effect of MEDI0382 on hepatic glycogen levels versus placebo after 28 days (Part A) and 35 days (Part B) of treatment,Measures of safety and tolerability of daily SC doses of MEDI0382 titrated up to a dose level of 300μg (Parts A and B) by assessment of changes in haematology and clinical chemistry parameters,,2018-05-31,COMPLETED,INTERVENTIONAL,['PHASE2']
384,NCT05958602,Change in HbA1C of Participants,App Engagement,,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
385,NCT01175486,Diabetic nephropathy,Diabetic nephropathy,,2010-07,UNKNOWN,INTERVENTIONAL,['PHASE4']
386,NCT04674384,Occurrence of Serious Adverse Events (SAEs) deemed potentially related to the dietary programmes.,Percentage of contacts with Dietitian conducted face to face after baseline (for ILED and CLED),,2022-01-19,RECRUITING,INTERVENTIONAL,['NA']
387,NCT02488278,Operating the GlucoMe device: obtaining a glucose reading and recording the results,Documenting specific user errors and inefficiencies related to the use of the device and application,,2015-07,WITHDRAWN,INTERVENTIONAL,['NA']
388,NCT05989256,Inpatient hypoglycemia event rates,Number of Inpatient hospitalizations with a hyperglycemic event,,2024-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
389,NCT05046158,Incidence of wound closure,Clinician Acceptability,,2021-08-16,RECRUITING,INTERVENTIONAL,['NA']
390,NCT04828512,Survival,major complications of cirrhosis,,2007-01-02,UNKNOWN,OBSERVATIONAL,['NA']
391,NCT01000545,macroalbuminuria and serum creatinine,adverse events,,2009-11,UNKNOWN,INTERVENTIONAL,['PHASE3']
392,NCT01330121,Adherence with discharge diabetes medications up to 120 days following pharmacist counseling during hospital stay about diabetes self management,Change in lipids after 90 days,,2010-09,COMPLETED,INTERVENTIONAL,['NA']
393,NCT01214590,Diabetic neuropathic pain,Nerve conduction velocity,,2011-03,UNKNOWN,INTERVENTIONAL,['NA']
394,NCT06016478,Change in total peripheral resistance during acute hyperglycemia,Change in 24-hour ambulatory blood pressure monitoring,,2023-05-01,RECRUITING,INTERVENTIONAL,['NA']
395,NCT05478252,Change in Glycated Haemoglobin (HbA1c),Anti-semaglutide Antibodies Level (Measured as Titre),,2022-08-03,COMPLETED,INTERVENTIONAL,['PHASE3']
396,NCT05647798,Initial neonatal glucose post delivery,Mother's childbirth experience score,Intrapartum insulin dose (total),2023-05-22,RECRUITING,INTERVENTIONAL,['NA']
397,NCT02500303,Further surgery,Co-morbidities,,2014-03,UNKNOWN,OBSERVATIONAL,['NA']
398,NCT04071977,Changes in concentration of total antioxidant capacity (TAC) after intervention from baseline.,"Correlate the levels of total antioxidant capacity (TAC) in systemic samples, aqueous humor and vitreous humor with the glycosylated hemoglobin value of patients with proliferative diabetic retinopathy.",,2020-03-25,COMPLETED,INTERVENTIONAL,['PHASE2']
399,NCT01928329,Change From Baseline in HbA1c Levels,Major Hypoglycemic Event Rate Off Drug,,2013-09,COMPLETED,INTERVENTIONAL,['PHASE2']
400,NCT02407132,"Glycemic Control, Measured by Change in Adjusted Mean HbA1c (%) From Baseline to Immediate Post-intervention, 6 Months Post-intervention, and 12 Months Post-intervention.","Change in Mean Triglycerides From Baseline to Immediate Post-intervention, 6 Months Post-intervention, and 12 Months Post-intervention",,2015-06,COMPLETED,INTERVENTIONAL,['NA']
401,NCT01690091,insulin sensitivity,heart function,,2012-11,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
402,NCT02811575,Number of lymphocyte TCD4 Th17 in colon sample,Bacteria production,,2016-12,COMPLETED,OBSERVATIONAL,['NA']
403,NCT03770728,Change From Baseline to Week 30 in HbA1c,Number of Hypoglycemic Events (Documented Symptomatic Hypoglycemia <3.0 mmol/L [<54 mg/dL] and Severe Hypoglycemia) Per Participant-Year,,2019-08-01,TERMINATED,INTERVENTIONAL,['PHASE3']
404,NCT01399645,To determine liver fat fraction evolution induced by liraglutide and insulin,,,2011-05,COMPLETED,INTERVENTIONAL,['PHASE2']
405,NCT02053103,Change from baseline in Weighted Mean Daily Glucose (WMDG) when compared to placebo,Change from baseline in very low density lipoprotein (VLDL),,2014-03,TERMINATED,INTERVENTIONAL,['PHASE2']
406,NCT04794283,neonatal hypoglycemia on day 0 of life will be meassured,Hyperbilirubinemia during the first week of life will be meassured,,2021-03-01,UNKNOWN,OBSERVATIONAL,['NA']
407,NCT00339703,,,,2004-11,COMPLETED,OBSERVATIONAL,['NA']
408,NCT02900417,The changes of the composition of gut microbiota before and after the use of sitagliptin,"Changes of fasting plasma glucose levels, lipids levels and insulin sensitivity",,2016-09,UNKNOWN,INTERVENTIONAL,['NA']
409,NCT02709031,Time to potassium rescue,Average levels of magnesium in patients on cicletanine with and without magnesium,,2022-06,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
410,NCT03228420,Composite of Safety and Effectiveness,Hemoglobin A1c,,2017-07-20,UNKNOWN,INTERVENTIONAL,['NA']
411,NCT06129994,Ecological Momentary Assessment (EMA) methods for measuring depression,Hemoglobin A1c,,2023-11-07,RECRUITING,OBSERVATIONAL,['NA']
412,NCT03077386,Acute care utilization,Acute care costs,,2018-05-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
413,NCT00235196,Clinical effectiveness of CAM in DFU by comparing the reduction in wound area between 2 treatment groups.,Wound characteristics,,2004-07,COMPLETED,INTERVENTIONAL,['PHASE4']
414,NCT02162901,Body weight,,,2014-03-13,COMPLETED,INTERVENTIONAL,['NA']
415,NCT00684528,The efficacy and safety of Metformin VS Metformin + Janufer in the community setting,,,2008-06,UNKNOWN,INTERVENTIONAL,['PHASE3']
416,NCT04994327,Glycemic control,Compliance,,2021-05-07,COMPLETED,INTERVENTIONAL,['NA']
417,NCT00225264,Absolute change from Baseline in carotid intima-media thickness.,"Incidence of cardiovascular events as a composite of cardiovascular mortality, nonfatal MI, nonfatal stroke, coronary revascularization, carotid endarterectomy/stenting, hospitalization for unstable angina and hospitalization for CHF",,2003-10,COMPLETED,INTERVENTIONAL,['PHASE3']
418,NCT00239538,Changes from baseline in the mean SBP and DBP as measured by ambulatory blood pressure monitoring (ABPM),Metabolic and inflammatory marker changes from baseline,,2003-01,COMPLETED,INTERVENTIONAL,['PHASE4']
419,NCT01089790,"To demonstrate safety and tolerability of dutogliptin as assessed by vital signs, adverse event reporting, routine clinical laboratory assessments, and ECG",To demonstrate maintenance or lowering of HbA1c and fasting plasma glucose.,,2010-03,TERMINATED,INTERVENTIONAL,['PHASE3']
420,NCT04938557,The time spent with glucose levels between 3.5-7.8 mmol/L based on CGM measures (Time In Range TIR 3.5-7.8mmol/L),Hospital length of stay (infant).,,2019-09-26,COMPLETED,INTERVENTIONAL,['NA']
421,NCT00823992,Absolute change from baseline in HbA1c,"Safety:Adverse events,clinical laboratory tests, vital signs,physical examination, ECG, anti-taspoglutide antibodies\n",,2009-01,COMPLETED,INTERVENTIONAL,['PHASE3']
422,NCT04071535,Assessment of small fiber neuropathy in Chinese patients with diabetes by calculating intraepidermal nerve fiber density (IENFD) via skin biopsy,Evaluation of diagnostic sensitivity and specificity of sudoscan in Chinese diabetic patients with small fiber neuropathy compared with intraepidermal nerve fiber density (IENFD),,2015-12-01,UNKNOWN,OBSERVATIONAL,['NA']
423,NCT02214654,circulation endothelial cell,,,2014-08,UNKNOWN,OBSERVATIONAL,['NA']
424,NCT04547023,Number of Participants With a Positive Gestational Diabetes Mellitus (GDM) Screen (>= 140 mg/dL) on the 1 Hour 50-g Oral Glucose Tolerance Test (OGTT),Number of Neonates Exclusively Breastfeeding at Time of Hospital Discharge,,2020-11-02,COMPLETED,INTERVENTIONAL,['NA']
425,NCT06178250,Ductus venosus volume in ultrasound,,,2021-09-22,COMPLETED,INTERVENTIONAL,['NA']
426,NCT05405244,Change in Voxel-wise Blood Oxygen Level-Dependent (BOLD) Brain Activation in Response to Milkshake Anticipation and Receipt vs. Water,Change in Voxel-wise Blood Oxygen Level-Dependent (BOLD) Brain Activation in Response to Milkshake Anticipation and Receipt vs. Water by TaqIA Allele Status (A1 vs. A2/A2),,2017-09-19,COMPLETED,INTERVENTIONAL,['PHASE3']
427,NCT04034511,Change in hemoglobin A1c,Change in Hemoglobin A1c,,2020-01-21,COMPLETED,INTERVENTIONAL,['NA']
428,NCT03118713,The percentage of change of Urine Albumin-to-Creatinine Ratio (UACR),Change from baseline in Quality of Life as measured through Audit of Diabetes-Dependent Quality of Life-19 (ADDQoL-19) questionnaire,,2017-04-25,TERMINATED,INTERVENTIONAL,['PHASE4']
429,NCT04094662,Average Daily Pain Score (ADPS),Five Level EuroQol-5D (EQ-5D) version,Actigraphy signal collected from a wrist-worn medical-grade sensor,2019-09-18,COMPLETED,INTERVENTIONAL,['PHASE3']
430,NCT03939793,Adherence Rate,,Change in Glycosylated Hemoglobin,2019-05-15,COMPLETED,INTERVENTIONAL,['NA']
431,NCT03960463,Change in tissue oxygenation from baseline to 4 weeks,Presence of scar tissue,,2017-05-18,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
432,NCT01493115,Glucose infusion rate,"Safety-related parameters including electrocardiogram, vital signs and laboratory tests",,2011-11,COMPLETED,INTERVENTIONAL,['PHASE1']
433,NCT00276471,Ability to communicate between patient wand and the device.,Improvement in co-morbid parameters,,2005-12,COMPLETED,INTERVENTIONAL,['PHASE1']
434,NCT05783700,BIOIMPEDANCEMETRY,Resting heart rate,,2023-10-02,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
435,NCT06000722,Delphi Round 2,,,2023-12-05,RECRUITING,OBSERVATIONAL,['NA']
436,NCT00927394,Change From Baseline in Mean 24-hour Ambulatory Systolic Blood Pressure (MASBP) at Week 8,"Number of Patients With Adverse Events, Serious Adverse Events and Death",,2009-05,COMPLETED,INTERVENTIONAL,['PHASE4']
437,NCT00446381,"Levels of intravitreal VEGF, TGFbeta, ET-1, PDGF, IGF-1,angiopoietin, HIF 1 alpha, HIF 1 beta pre and post injection of intravitreal Macugen.",Effect on concomitant diabetic macular edema post injection of intravitreal Macugen,,2006-10,COMPLETED,INTERVENTIONAL,['NA']
438,NCT03299010,Factors that have sufficient power to classify Chinese DM patients in primary care into risk group in terms of total CVD and all-cause mortality,,,2017-07-01,COMPLETED,OBSERVATIONAL,['NA']
439,NCT01240759,Change from Baseline to Week 12 in Hemoglobin A1c (HbA1c),Safety assessments,,2010-10,COMPLETED,INTERVENTIONAL,['PHASE2']
440,NCT05105620,Fréchet inception distance (FID) score.,,,2018-08-01,COMPLETED,OBSERVATIONAL,['NA']
441,NCT02467881,Actigraph Accelerometry,EQ-5D Quality of Life Survey,,2015-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
442,NCT00344136,,,,2000-09,COMPLETED,OBSERVATIONAL,['NA']
443,NCT06330948,Hematology Test,,,2024-03,RECRUITING,INTERVENTIONAL,['NA']
444,NCT04869605,"the role of 1,5 anhydroglucitol and 1,5 anhydroglucitol / HbA1c ratio as a potential biomarker for islet β-cell function and insulin resistance among patients with type 2 diabetes",,,2021-05-06,UNKNOWN,OBSERVATIONAL,['NA']
445,NCT02240420,Behavior change,Weight loss,,2014-12,COMPLETED,INTERVENTIONAL,['NA']
446,NCT04032197,Change in maximum target-to-background ratio (TBR) for 18F-fluorodeoxyglucose (FDG) in the carotid arteries,Change in average fibrous cap thickness (FCT) of the atherosclerotic plaque in the most diseased carotid artery,,2019-08-12,COMPLETED,INTERVENTIONAL,['PHASE1']
447,NCT01407640,Validation of cutaneous insulin tests,Immunogenetic of patients with IA (Insulin Allergy),,2012-02-06,COMPLETED,INTERVENTIONAL,['NA']
448,NCT05842993,Change in glycosylated hemoglobin (HbA1c),Safety measurement,,2023-05-01,RECRUITING,INTERVENTIONAL,['NA']
449,NCT04460573,Adherence to offloading,Physical Activity,,2021-10-19,RECRUITING,INTERVENTIONAL,['PHASE2']
450,NCT03342495,Health services utilization,Variation in SF-12 Scores,Youth/Caregiver Satisfaction,2018-02-06,COMPLETED,INTERVENTIONAL,['NA']
451,NCT00468676,"Glycated Hemoglobin (HbA1c) at Baseline, 6 Months and 12 Months",Health Care Costs,,2007-05,COMPLETED,INTERVENTIONAL,['NA']
452,NCT04933851,Diabetes Distress Scale,Diabetes Support and Isolation Questionnaire,Body Mass Index (BMI),2021-10-25,RECRUITING,INTERVENTIONAL,['PHASE2']
453,NCT04442529,Perceived stress,Mothers and Babies Skill Utilization,,2021-05-01,UNKNOWN,INTERVENTIONAL,['NA']
454,NCT03484741,Adverse events,Blood insulin level,,2017-04-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
455,NCT03638362,TCJ and hsCRP,fasting triglycerides,,2009-08-21,COMPLETED,INTERVENTIONAL,['NA']
456,NCT03959501,Change in serum ketone levels after treatment,Change in homeostasis model assessment 2 steady-state beta-cell function,,2017-08-16,COMPLETED,INTERVENTIONAL,['PHASE4']
457,NCT04351880,Anxiety and Depression measured through the Hospital Anxiety and Depression Scale,Re-hospitalization and Emergency Department Visits,,2020-04-16,COMPLETED,INTERVENTIONAL,['NA']
458,NCT06152887,Change in numeric rating scale (NRS) scores in pain diary,Quantitative sensory testing,,2023-08-01,RECRUITING,INTERVENTIONAL,['NA']
459,NCT06184568,Proportion of subjects who achieve composite endpoint of HbA1c <7.0% and ≥10% weight loss,"Percent Change from Baseline in Triglycerides, Total Cholesterol, LDL-c, HDL-c, non-HDL-c",,2024-02-29,RECRUITING,INTERVENTIONAL,['PHASE3']
460,NCT00575159,Mean of Derived Plasma Glucose Parameters,"The Metabolite to Parent AUC Ratio, AUCmetabolite/AUCparent Ratio for GSK279782 Over Period",,2008-03-31,COMPLETED,INTERVENTIONAL,['PHASE2']
461,NCT03940482,Change in glycaemic control of patients as measured by >= 5% reduction in glycosylated haemoglobin (HbA1C) over a 12 week period.,Change in a levels of ketonemia (Serum Beta-Hydroxybutyrate 0.5-3.0 mmol/L) over a 12 week period.,,2019-01-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
462,NCT03428945,Change from Treatment Assignment Glucose Tolerance to Abnormal Glucose Tolerance or Diabetes,,,2018-08-15,TERMINATED,INTERVENTIONAL,['PHASE2']
463,NCT02357043,Accuracy - Blood Glucose Level Obtained by Layperson With the Dario Meter Compared to Blood Glucose Level on Yellow Springs Instrument Obtained by Nurse/Technician,,,2014-12,COMPLETED,INTERVENTIONAL,['NA']
464,NCT00438126,increased self-reported leisure physical activity,resting blood pressure,,2002-01,COMPLETED,INTERVENTIONAL,['NA']
465,NCT00237588,Insulin sensitivity assessed with hyperinsulinaemic isoglycaemic glucose clamp(GDR),Microalbuminuria,,2004-12,COMPLETED,INTERVENTIONAL,['PHASE4']
466,NCT00198926,caloric compensation,,,2000-05,COMPLETED,INTERVENTIONAL,['NA']
467,NCT02597127,Percentage Change in LDL-C From Baseline to Day 180,Percentage Change in Other Lipids and Inflammatory Markers From Baseline to Day 180,,2016-01,COMPLETED,INTERVENTIONAL,['PHASE2']
468,NCT00671008,Glycaemic control as measured by HbA1c,Change in body weight,,2007-12,COMPLETED,OBSERVATIONAL,['NA']
469,NCT05702463,"Among initial ASA non-responder participants, define the proportion of participants that remain ASA non-responders with different formulations and dosing regimens of ASA.","Platelet response levels to various agonists not directly related to the pharmacological target of ASA, including ADP, collagen, epinephrine and thrombin receptor-activating peptide (TRAP).",,2023-06-13,RECRUITING,INTERVENTIONAL,['PHASE1']
470,NCT02135549,Postprandial serum glucose area under the curve in mg*hr/dL over four hours,Peak blood serum excursion at 2 hours from baseline in mg/dL,,2014-05,COMPLETED,INTERVENTIONAL,['NA']
471,NCT00520962,,,,1997-06,COMPLETED,OBSERVATIONAL,['NA']
472,NCT02354235,Change From Baseline in Percentage of Glycated Hemoglobin (HbA1c),Change From Baseline in 2-hour Postprandial Plasma Glucose Level,,2015-01,COMPLETED,INTERVENTIONAL,['PHASE3']
473,NCT01002235,Dose limiting toxicity,Pain Levels,,2010-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
474,NCT03804658,Glucose variability,Health Literacy,,2019-01-13,RECRUITING,OBSERVATIONAL,['NA']
475,NCT01861756,"Overall Decisional Comfort (0-100, 100=no Conflict)",Glycemic Control (HbA1c),,2013-05,COMPLETED,INTERVENTIONAL,['NA']
476,NCT05530356,Spatial Metabolomics,Age-corrected composite fluid cognition score,,2022-09-30,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
477,NCT04303364,Assess the uniqueness of diabetic cardiomyopathy (DCM) relative to other forms of cardiomyopathy,Explore the pathophysiological and potentially causal pathways characterizing diabetic cardiomyopathy,,2020-10-02,RECRUITING,OBSERVATIONAL,['NA']
478,NCT01870713,"different proteins detected between obese persons, type 2 diabetes patients prior to surgery, 10 days after surgery and 3 months after surgery.",evaluating the change in glucose between the baseline evaluation and the follow-up evaluation.,,2010-10,UNKNOWN,OBSERVATIONAL,['NA']
479,NCT01762085,occurrence of plantar foot ulceration wound,Visual Analog Pain Score,Incidence of falls during the study,2013-06,UNKNOWN,INTERVENTIONAL,['NA']
480,NCT01753934,Memory score on ImPACT testing,White matter volume on MRI using diffusion tensor imaging,,2011-05,COMPLETED,OBSERVATIONAL,['NA']
481,NCT01487382,Hypoglycaemic events,Adverse events,,2002-04,COMPLETED,OBSERVATIONAL,['NA']
482,NCT01698112,Fasting fructosamine,adiponectin,,2006-07,COMPLETED,INTERVENTIONAL,['NA']
483,NCT02327429,Change in Cholesterol Intake (3-day Food Record),Change in Fasting High-density Lipoprotein Cholesterol,,2015-02,COMPLETED,INTERVENTIONAL,['NA']
484,NCT01075282,Change From Baseline to 52 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c),"Number of Participants With LY2189265 Antibodies at 26, 52, 78 Weeks and 4 Weeks After Last Dose of Study Drug (83 Weeks Maximum)",,2010-02,COMPLETED,INTERVENTIONAL,['PHASE3']
485,NCT01351701,Risk factors associated with different grades of severity of DFI,Percentage sensitivity to different empiric antibiotics,,2011-06,UNKNOWN,OBSERVATIONAL,['NA']
486,NCT03867942,Gemigliptin Cmax,,,2019-03-21,UNKNOWN,INTERVENTIONAL,['PHASE1']
487,NCT04957173,The primary outcome of this study will be weight loss in the participants.,,,2021-10-14,WITHDRAWN,INTERVENTIONAL,['NA']
488,NCT05437848,Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs,Change in coefficient of variation as measured by CGM over 7 days,,2022-02-25,COMPLETED,INTERVENTIONAL,['PHASE1']
489,NCT00818142,Adherence to insulin regimen.,,,2008-01,COMPLETED,OBSERVATIONAL,['NA']
490,NCT02130687,Norepinephrine (NE) Concentrations,24hr Urinary Testing for Sodium,"Aldosterone, Angiotensin II, and Plasma Renin Activity (PRA)",2014-06,COMPLETED,INTERVENTIONAL,['NA']
491,NCT03959306,Effect on Markers of Endothelial Dysfunction(The change in the level of soluble intercellular adhesion molecule ( ICAM) in serum using ELISA kit),Effect on Quality of Life ( Using Diabetes-39 questionnaire ),,2019-04-24,UNKNOWN,INTERVENTIONAL,['PHASE2']
492,NCT05487352,gestational diabetes mellitus,"neonatal weight, height and head circumference",,2021-05-30,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
493,NCT00541710,homeostasis model assessment for insulin resistance (HOMA-IR),Adverse events,,2007-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
494,NCT01196546,HbA1c reduction,"To evaluate the effect of combination therapy of vildagliptin (50 mg) plus metformin (500 or 1000 mg) twice daily on FPG and BMI, safety and tolerability profiles",,2010-03,COMPLETED,INTERVENTIONAL,['PHASE4']
495,NCT04831216,"Hemoglobin A1c (HbA1c), %",,,2021-08-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
496,NCT04600128,Change in blood glucose levels,,Insulin,2019-11-18,COMPLETED,INTERVENTIONAL,['NA']
497,NCT05873322,The extent of beta cell function at week 22/23/28,,,2022-08-30,RECRUITING,OBSERVATIONAL,['NA']
498,NCT01395290,nasal staphylococcus colonisation,,,2011-04,COMPLETED,INTERVENTIONAL,['PHASE3']
499,NCT00935441,Glycemic control (HbA1c),Systolic blood pressure control in patients with elevated blood pressure at baseline,,2009-06,COMPLETED,INTERVENTIONAL,['NA']
500,NCT03269799,sulcus bleeding index,,,2017-08-30,UNKNOWN,INTERVENTIONAL,['PHASE2']
501,NCT04790604,Acute care service use,Medication adherence,,2021-01-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
502,NCT01093651,Plasma HIV Viremia (Viral Load),Self-reported Symptoms,,2010-06,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
503,NCT01412710,Blood Lipid,Glycemic Control,,2011-07,COMPLETED,INTERVENTIONAL,['NA']
504,NCT05131139,Safety Objective: To demonstrate safety of the Eversense 524 CGM System and ROME CGM System.,,,2021-10-20,RECRUITING,INTERVENTIONAL,['NA']
505,NCT02276742,Urinary sodium will be determined from a time 24-hour urine sample,,,2014-10,COMPLETED,INTERVENTIONAL,['NA']
506,NCT06081413,improvement in obesity-related diseases,,,2022-06-01,COMPLETED,OBSERVATIONAL,['NA']
507,NCT03403699,Differentiate iPSCs into CD34+ cells and mesoderm,,,2018-01-11,RECRUITING,OBSERVATIONAL,['NA']
508,NCT04219787,Primary endpoint,Secondary endpoints,,2020-06-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
509,NCT01350102,Hgb A1c Level,Wound Area Measurements,,2012-02,TERMINATED,INTERVENTIONAL,['PHASE4']
510,NCT04790006,Safety and tolerability assessed by incidence and severity of adverse events,Apparent clearance (CL/F),,2021-04,UNKNOWN,INTERVENTIONAL,['PHASE1']
511,NCT01802034,Change in disease progression,,,2013-02,RECRUITING,OBSERVATIONAL,['NA']
512,NCT02457130,Platelet reactivity,,,2015-04,UNKNOWN,INTERVENTIONAL,['PHASE4']
513,NCT06067399,To assess the correlation between RDW and HbA1C levels in patients with T2DM before and after glycemic control.,To determine if changes in RDW levels correlate with the presence of other comorbidities and complications.,,2024-04-01,RECRUITING,OBSERVATIONAL,['NA']
514,NCT02064647,Time spent with postprandial glucose level in target range,Frequency & duration of postprandial hypoglycemia,Satisfaction/ease of use of Trend Arrow Adjustment Tool,2014-07,COMPLETED,INTERVENTIONAL,['NA']
515,NCT01494987,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24,Change From Baseline in 2-hour Postprandial Serum Glucose at Week 24,,2012-01,COMPLETED,INTERVENTIONAL,['PHASE3']
516,NCT02477865,HbA1c,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,,2014-03-23,UNKNOWN,INTERVENTIONAL,['PHASE3']
517,NCT00840307,Pancreatic and Liver Triglyceride (Fat) Content,,,2008-08,COMPLETED,OBSERVATIONAL,['NA']
518,NCT02383238,Microcirculation,Macrovascular circulation,,2014-03,COMPLETED,INTERVENTIONAL,['PHASE3']
519,NCT01060059,Percentage of Patients Who Achieved Glycemic Target of HbA1c ≤ 7.0% With Minimal Weight Gain (≤ 1 Kg) at Month 12.,"Factors of Higher Creatinine, Higher Fasting High Density Lipoprotein (HDL) Cholesterol, Higher Fasting Cholesterol, and Higher Fasting Triglycerides Which Were Associated With Treatment Choice at Baseline",,2010-04,COMPLETED,OBSERVATIONAL,['NA']
520,NCT00737269,,,,2008-06,COMPLETED,OBSERVATIONAL,['NA']
521,NCT03418415,Changes in glucose metabolism from baseline to 6 months,Changes in renal function up to 2 years,,2018-01-18,UNKNOWN,INTERVENTIONAL,['NA']
522,NCT03633266,Mean change from baseline in best-corrected visual acuity (BCVA),chang from baseline in retinal neovascularization,,2018-09-01,UNKNOWN,INTERVENTIONAL,['NA']
523,NCT03126786,Mean Change From Baseline in Best Corrected Visual Acuity Letter Score,Mean Change From Baseline in Central Subfield Thickness,,2017-07-11,COMPLETED,INTERVENTIONAL,['PHASE2']
524,NCT02634229,Identification of novel predisposition gene,Correlation between genotype and HbA1c,,2012-09,COMPLETED,OBSERVATIONAL,['NA']
525,NCT00707993,Change From Baseline in Glycosylated Hemoglobin at Week 52.,Incidence of Glycosylated Hemoglobin Decrease From Baseline.,,2008-06,COMPLETED,INTERVENTIONAL,['PHASE3']
526,NCT03785522,Change in HbA1c (mmol/mol),"Reason(s) for discontinuing treatment with Tresiba® during the treatment period, if applicable",,2018-12-23,COMPLETED,OBSERVATIONAL,['NA']
527,NCT03150030,Part 2: Difference in MAGE,Part 2: Correlation between plasma glucose variation and risk of clinical relevant arrhythmias,,2017-02-01,COMPLETED,OBSERVATIONAL,['NA']
528,NCT04362540,The primary outcome measure for the study will be the mean difference in values of the HOMA-IR (as a surrogate for insulin resistance) in those with NAFLD vs. those without NAFLD 6-12 weeks post partum,MRI scan to confirm the presence of NAFLD at 6-12 weeks post partum.,,2019-05-05,RECRUITING,OBSERVATIONAL,['NA']
529,NCT05346250,Incidence of type 2 diabetes,Serum lipid change,,2011-07-01,COMPLETED,OBSERVATIONAL,['NA']
530,NCT04147637,Percentage time in range 4-10mmol/L,Change in dose of insulin,,2020-10-14,WITHDRAWN,INTERVENTIONAL,['NA']
531,NCT05666596,Body mass index(kg/m2),,,2021-01-07,COMPLETED,OBSERVATIONAL,['NA']
532,NCT05207774,obesity,omental and subcutaneous fat inflammation,,2020-01-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
533,NCT01710553,"Cmax, Tmax, AUC0-t, AUC0-∞, AUC%_Extrap, Kel and t1/2",Safety profile,,2012-07,COMPLETED,INTERVENTIONAL,['PHASE2']
534,NCT03842813,The primary endpoint is Target Lesion Failure (TLF) rate at 1 year,Stent thrombosis at 1 year in the sub-group of patients with a short planned dual-therapy,,2019-04-09,UNKNOWN,OBSERVATIONAL,['NA']
535,NCT03437421,Change in longitudinal strain,,,2018-02-04,COMPLETED,INTERVENTIONAL,['NA']
536,NCT06221969,Relative change in body weight,"Number of severe hypoglycaemic episodes (level 3): hypoglycaemia associated with severe cognitive impairment requiring external assistance for recovery, with no specific glucose threshold",,2024-01-16,RECRUITING,INTERVENTIONAL,['PHASE3']
537,NCT03838900,Measure of Loop Safety by Self-Report of Hospitalization Events,Measure of Loop Safety by Self-Report of Hospitalization Events,Loop Follow-Up General Data Collection,2019-01-17,COMPLETED,OBSERVATIONAL,['NA']
538,NCT01907399,quantification of Treg,,,2010-09,COMPLETED,INTERVENTIONAL,['NA']
539,NCT00354341,Change From Baseline in Left Ventricle Mass Index (LVMI) at Month 15,Percentage of Participants With Stable Hb Levels Between 13 to 15 g/dL,,2002-09,COMPLETED,INTERVENTIONAL,['PHASE3']
540,NCT05909046,Rate of postpartum diabetes mellitus screening,Prediabetes or type 2 diabetes,,2023-07-24,RECRUITING,INTERVENTIONAL,['NA']
541,NCT03081598,"To evaluate the efficacy of PBI-4050 400 mg, 800 mg, and 1200 mg",To evaluate the effect of PBI-4050 on frequency of hypoglycaemia events,,2017-05-29,TERMINATED,INTERVENTIONAL,['PHASE2']
542,NCT04219215,Change in rate of glucose disappearance,,,2020-02-01,COMPLETED,INTERVENTIONAL,['NA']
543,NCT02453685,Change in HbA1c (Glycosylated Haemoglobin),Total Daily Insulin Dose,,2015-08-31,COMPLETED,INTERVENTIONAL,['PHASE4']
544,NCT03049605,Motor and sensory conduction velocity of the lower limb nerves,,,2014-01-25,COMPLETED,INTERVENTIONAL,['PHASE2']
545,NCT04661358,Worsening of diabetic retinopathy,Visual acuity loss from any cause,,2021-03-05,RECRUITING,INTERVENTIONAL,['PHASE3']
546,NCT01754181,Time spent in glucose reference intervals,"Measuring glucose sensor 2h, 3h and 4h post-prandial and AUC, in every situation tested to evaluate the efficacy and safety (time spent in hypoglycemia)","Comparison of glucose sensor 2h, 3h and 4h post-prandial and AUC in conditions identical meals for each trigger level (50 or 75%). Measuring AUC during and 2 hours after physical activity, then to lunch time, during dinner and throughout the night.",2013-03,COMPLETED,INTERVENTIONAL,['PHASE3']
547,NCT01492465,Subject incidence of anti-AMG 876 antibodies.,Pharmacodynamic parameters:,,2011-11,TERMINATED,INTERVENTIONAL,['PHASE1']
548,NCT01368978,Efficacy,,,2009-12,COMPLETED,INTERVENTIONAL,['PHASE3']
549,NCT00223574,glycated hemoglobin,diet satisfactio,,2002-01,COMPLETED,INTERVENTIONAL,['NA']
550,NCT04222894,Plasma Lipids,Food Acceptability: The Food Acceptability Questionnaire,,2020-06-26,COMPLETED,INTERVENTIONAL,['NA']
551,NCT06197360,Hypoglycemia fear worry,The self-management attitude scale for diabetes patients,,2021-08-01,COMPLETED,INTERVENTIONAL,['NA']
552,NCT05831644,Pharmacodynamic effect,,,2023-04-25,COMPLETED,INTERVENTIONAL,['PHASE1']
553,NCT03260881,EAT inflammation,EAT GLP-1R,,2018-09-01,RECRUITING,INTERVENTIONAL,['PHASE4']
554,NCT01474603,body weight change from baseline (non-diabetic patients),change from baseline of inflammatory and metabolic parameters,,2011-11,COMPLETED,OBSERVATIONAL,['NA']
555,NCT02916251,PD endpoint: Plasma glucose profiles above baseline: tmax,Safety endpoints: Antidrug antibodies incidences,,2016-12-01,COMPLETED,INTERVENTIONAL,['PHASE2']
556,NCT06017089,Primary Safety Endpoint (Hypoglycemia),Basal Insulin,,2023-11-10,RECRUITING,INTERVENTIONAL,['NA']
557,NCT03349840,Comparison of the glycemic control of insulin glargine U100 with insulin degludec in patients with type 2 diabetes from baseline to end of Ramadan.,Incidence of Treatment-Emergent Adverse Events,,2018-01-07,TERMINATED,INTERVENTIONAL,['PHASE4']
558,NCT04259112,Serum cystatin C (CysC) level,Renal tissue oxygen saturation,,2020-10-01,UNKNOWN,INTERVENTIONAL,['NA']
559,NCT00656851,Myocardial Fatty Acid Esterification,Fasting Glucose Insulin and HOMA,,2005-09,COMPLETED,INTERVENTIONAL,['NA']
560,NCT05937373,Disparities in Continuous Glucose Monitoring (CGM) accuracy - serum and arterial glucose values,Disparities in Continuous Glucose Monitoring (CGM) accuracy - interference amount,,2023-08-04,RECRUITING,INTERVENTIONAL,['NA']
561,NCT02213549,Change in 2h glucose concentration after the oral glucose tolerance test (OGTT) from baseline,Change in serum triglyceride from baseline,,2014-07,COMPLETED,INTERVENTIONAL,['NA']
562,NCT02359617,Mean absolute relative difference between sensor readings and capillary glucose readings,,,2013-02,COMPLETED,INTERVENTIONAL,['NA']
563,NCT01459601,FBS (fasting blood sugar),HbA1C,,2012-01,UNKNOWN,INTERVENTIONAL,['NA']
564,NCT00120328,"To determine the effect of each dose of avosentan on time to doubling of serum creatinine, end stage renal disease (ESRD) or death when administered on top of standard treatment in subjects with type 2 diabetes mellitus and diabetic nephropathy.",unstable angina,,2005-07,TERMINATED,INTERVENTIONAL,['PHASE3']
565,NCT04236609,Rate of Target lesion failure TLF,Bleeding,Target vessel revascularization (TVR),2020-06-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
566,NCT00307749,Nerve Conduction Studies,Clinical Global Impression,,2006-03,COMPLETED,INTERVENTIONAL,['PHASE2']
567,NCT01541215,Change in HbA1c (Glycosylated Haemoglobin),Change From Week 52 in Bone Age Assessment (X-ray of Left Hand and Wrist)- Week 156,,2012-11-13,COMPLETED,INTERVENTIONAL,['PHASE3']
568,NCT05943886,AUC,Assessment of the incidence of anti drug antibodies (ADA) developed against HEC88473 after dosing,,2021-08-11,COMPLETED,INTERVENTIONAL,['PHASE1']
569,NCT01876563,erytrocyte thioredoxin reductase,GENE EXPRESSION OF TBP-2,,2012-08,UNKNOWN,INTERVENTIONAL,['PHASE4']
570,NCT04791267,Acute care service use,Medication adherence,,2021-04-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
571,NCT05645653,Medication Adherence,Treatment burden,,2022-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
572,NCT04409171,incidence & risk factors of worsened DM,characteristics of new-onset and worsened DM,,2015-09-01,COMPLETED,OBSERVATIONAL,['NA']
573,NCT03745157,Change in local laboratory measured glycosylated haemoglobin (HbA1c),Change in selected patient reported outcomes: Diabetes Therapy Related Quality of Life (DTR-QoL),,2018-11-21,COMPLETED,OBSERVATIONAL,['NA']
574,NCT03093298,Altered gene expression in the endocrine secretome following Roux-en-Y gastric bypass surgery,,,2014-12-12,COMPLETED,INTERVENTIONAL,['NA']
575,NCT00252876,"Adverse events, laboratory variables, physical examination, cardiac evaluation, hypoglycemic events, electrocardiogram, vital signs (blood pressure and pulse), body weight","Central obesity (waist circumference, hip circumference, waist/hip ratio)",,2005-03,TERMINATED,INTERVENTIONAL,['PHASE3']
576,NCT03085771,Endothelial precursor cell account (EPC),,,2017-01-01,RECRUITING,INTERVENTIONAL,['PHASE2']
577,NCT01129258,PD Endpoint: glucose excursion (change from Day -1 baseline) in response to a liquid meal test (MMTT) on Days 1 and 14.,"Lactate (change from Day -1 baseline), at times specified in the SOA.",,2010-06,COMPLETED,INTERVENTIONAL,['PHASE1']
578,NCT01457911,Absolute change in HbA1c,"Hematology, Serum chemistry and lipids",,2011-10,COMPLETED,INTERVENTIONAL,['PHASE3']
579,NCT02513641,Insulin Sensitivity,2-hour Insulin Area-under-the-curve Via Oral Glucose Tolerance Test,,2015-12,COMPLETED,INTERVENTIONAL,['NA']
580,NCT05918068,Glycated Hemoglobin (HbAlc),"Indoleamine 2,3 dioxygenase (IDO)",,2022-11-01,COMPLETED,INTERVENTIONAL,['NA']
581,NCT01547156,Change in Hba1c(for diabetes patients),Change in FÍNSIK scores,,2011-05,COMPLETED,INTERVENTIONAL,['NA']
582,NCT01201278,"Insulin tolerability, PK, and PD",,,na,UNKNOWN,INTERVENTIONAL,['PHASE1']
583,NCT06141278,Change of SBP at baseline and at 12 month,Treatment rate at baseline and at 12 month,,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
584,NCT04779164,Femoral cartilage thickness,radiographic knee osteoarthritis,,2020-09-04,COMPLETED,INTERVENTIONAL,['NA']
585,NCT04814147,Weight loss (kg) at 12 months of sleeve gastrectomy,Pre and post-operative hip circumference,,2021-03-13,RECRUITING,OBSERVATIONAL,['NA']
586,NCT00762736,Change from Baseline in glycosylated hemoglobin.,Change from Baseline in matrix metalloproteinase-9.,,2004-07,COMPLETED,INTERVENTIONAL,['PHASE2']
587,NCT05699759,Adverse Events,Mean change in best-corrected visual acuity (BCVA) at other study timepoints,,2023-02-28,RECRUITING,INTERVENTIONAL,['PHASE1']
588,NCT03955107,time in range at Week 8 after enrollment,adverse pregnancy outcomes,,2019-04-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
589,NCT02185755,HbA1c Levels before and after intervention,HbA1c levels remain at 8% or higher,,2014-08,COMPLETED,INTERVENTIONAL,['NA']
590,NCT01186562,Insulin Independence,Acute C-peptide Response (ACR) to Glucose,,2010-08,COMPLETED,INTERVENTIONAL,['PHASE4']
591,NCT01345500,Total weight loss,Biochemical/social outcomes,,2012-02,COMPLETED,INTERVENTIONAL,['NA']
592,NCT02786979,Number of participants with abnormal laboratory values and/or adverse events related to treatment,Change from baseline in value of TNF-α,,2010-07,TERMINATED,INTERVENTIONAL,['PHASE4']
593,NCT03070106,Number of subjects in each study arm discontinuing insulin use with Hemoglobin A1c <7%,Change in the subject's score on the Medical Symptom Questionnaire (MSQ) in each study arm,,2017-03-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
594,NCT04227431,Change in glycosylated haemoglobin (HbA1c),"Reason(s) for starting Tresiba®, at time of switch/add-on, if available",,2020-01-17,COMPLETED,OBSERVATIONAL,['NA']
595,NCT00094991,The change from baseline in insulin medicated glucose disposal after 16 weeks of treatment with Muraglitazar,,,2004-05,COMPLETED,INTERVENTIONAL,['PHASE3']
596,NCT02161094,Change in HbA1c,Score on the Diabetes Quality Of Life,,2013-04,UNKNOWN,INTERVENTIONAL,['NA']
597,NCT05303857,Central (aortic) pulse pressure assessed by Sphygmocor XCEL,Renal perfusion of both kidneys assessed by Arterial Spin Labeling MRI,,2022-03-03,RECRUITING,INTERVENTIONAL,['PHASE4']
598,NCT04652999,Patient satisfaction with the relaxation intervention,Heart rate,Clinical Data,2019-03-19,COMPLETED,INTERVENTIONAL,['NA']
599,NCT01299246,Number of the residents in detecting the early neurovasculopathy,,,2009-11,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
600,NCT02160275,Mean sensor glucose concentration,Time that the control algorithm is inactive,Glucagon use,2014-06,COMPLETED,INTERVENTIONAL,['NA']
601,NCT05735340,A1C,,,2023-04-15,RECRUITING,INTERVENTIONAL,['NA']
602,NCT03975556,Change in levels of metabolic risk factors,Changes in diet satisfaction: diet satisfaction scale,,2019-07-01,COMPLETED,INTERVENTIONAL,['NA']
603,NCT03347890,Change of Bold Oxygenation Level Dependent (BOLD) signal (%) in brain regions involved in the reward system,BOLD in brain regions involved in the reward system,,2018-03-05,COMPLETED,INTERVENTIONAL,['PHASE4']
604,NCT02040337,Sensitivity and specificity of T cell repertoire analysis to classify Type I Diabetes,,,2014-04,COMPLETED,OBSERVATIONAL,['NA']
605,NCT04003194,Change in Glucose,Change in Hemoglobin A1c,,2009-03-01,COMPLETED,INTERVENTIONAL,['NA']
606,NCT03242005,Compare Pro-set® vs. Quick-set® for non-inferiority for set insertion failures (set removal) due to either occlusion alerts or hyperglycemia,Compare Pro-set® vs. Quick- set® for duration of wear,,2017-09,WITHDRAWN,INTERVENTIONAL,['NA']
607,NCT00238550,"Improvement in pain symptoms, including pain perception and sleep quality, utilising daily diaries and validated pain questionnaires during 12 week treatment period and after 3 month cessation of treatment",MR spectroscopy of the chemical constituents in the deep nuclei of the brain will be analysed before and after 12 week treatment period.,,2003-10,COMPLETED,INTERVENTIONAL,['PHASE2']
608,NCT03087266,Levels C-Reactive Protein,Endothelial Function,,2016-06-01,COMPLETED,INTERVENTIONAL,['NA']
609,NCT02071979,Wound Size,Wound recurrence,,2014-04,TERMINATED,INTERVENTIONAL,['NA']
610,NCT00440284,glycosylated hemoglobin (GHb),"mild and severe hypoglycemia, insulin dosage, blood pressure and body-mass-index (BMI).",,2004-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
611,NCT00916604,"Safety by assessment of adverse events, BP, pulse rate, plasma glucose, safety laboratory variables and ECG","Pharmacodynamic variables (P-Glucose, S-Insulin and S-C-peptide).",,2009-05,COMPLETED,INTERVENTIONAL,['PHASE1']
612,NCT02215408,The mean percent of applicable Guideline Advantage standards of care that are met at 12 months,The percent of intervention group patients who rate the intervention as helpful (versus not helpful),,2015-01-20,COMPLETED,INTERVENTIONAL,['NA']
613,NCT05482789,Area Under the Plasma Concentration Versus Time Curve (AUC) of glucose,Area Under the Plasma Concentration Versus Time Curve (AUC) of exenatide,,2023-04-12,RECRUITING,INTERVENTIONAL,['PHASE4']
614,NCT04080518,To demonstrate that SGLT-2 inhibition induces urea-dominated renal water conservation within the renal concentration mechanism. ( Change from baseline in urinary osmolyte concentration,Analysis of glycogen and fat content in skeletal muscle and liver,,2019-11-11,COMPLETED,INTERVENTIONAL,['PHASE4']
615,NCT04024631,Glucose response to an oral glucose load,Disposition index,,2019-06-17,RECRUITING,INTERVENTIONAL,['NA']
616,NCT00946426,Insulin sensitivity,Hepatic glucose output,,2009-07,WITHDRAWN,OBSERVATIONAL,['NA']
617,NCT05815342,Change in HbA1c,Coefficient of variation,,2023-04-11,COMPLETED,INTERVENTIONAL,['NA']
618,NCT02019082,The plasma level of VEGF(pg/ml) and NO (microM),Wound surface area(cm2),,2011-03,COMPLETED,INTERVENTIONAL,['NA']
619,NCT03769701,Proportion of women who achieve glycemic control.,,,2018-12-07,UNKNOWN,INTERVENTIONAL,['NA']
620,NCT03978286,Effect of antidepressant treatment (sertraline versus vortioxetine) in triglycerides control in depressed type 2 diabetic patients.,Effect of antidepressant treatment (sertraline versus vortioxetine) in anthropometric variables in depressed type 2 diabetic patients.,,2016-06-30,COMPLETED,INTERVENTIONAL,['PHASE4']
621,NCT04590703,Evaluation of incidence of adverse events,,,2020-06-24,COMPLETED,OBSERVATIONAL,['NA']
622,NCT05235425,Change in HbA1c,Change in HbA1c,,2022-03-20,RECRUITING,INTERVENTIONAL,['NA']
623,NCT00236210,The percentage of patients who attained a significant reduction in their global cardiovascular risk at 6 and 12 months. This was determined a priori by the investigators to be an increase in the ACTION Score of 5 or more.,"Secondary outcomes were change in the average ACTION Score, change in individual risk domains as measured by the ACTION Score, patient satisfaction, and quality of life, all after 6 months and 12 months, comparing intervention versus control.",,2004-08,COMPLETED,INTERVENTIONAL,['NA']
624,NCT00355680,Regression of new vessels,Bruch's membrane rupture,,2005-12,COMPLETED,INTERVENTIONAL,['PHASE3']
625,NCT00467675,,,,2006-04,COMPLETED,OBSERVATIONAL,['NA']
626,NCT04535960,Proximal tubular natriuresis,"Urinary EGF,FGF2,Eotaxin,TGFa,G-CSF,Flt-3L,GM-CSF,Fractalkine,IFNa2,IFNy,GRO,IL10,MCP-3,IL-12P40,MDC,IL-12P70,PDGF-AA,IL-13,PDGF-BB,IL-15,sCD40L,IL-17A,IL-1RA,IL1a,IL9,IL1B,IL2,IL3,IL4,IL5,IL6,IL7,IL8,IL10,MCP-1,MIP-1a,MIP-1B,RANTES,TNFalpha,TNFB,VEGF",,2019-01-24,RECRUITING,INTERVENTIONAL,['PHASE2']
627,NCT03683368,Time to infusion set failure due to an occlusion,Glucose variability,,2018-10-09,COMPLETED,INTERVENTIONAL,['NA']
628,NCT01339520,Change in total score,HbA1c,,2008-11,COMPLETED,INTERVENTIONAL,['NA']
629,NCT01728740,AUC(0-tn) of metformin,,,2012-09,COMPLETED,INTERVENTIONAL,['PHASE1']
630,NCT02093676,change in self monitoring of blood glucose,change in parental monitoring,,2014-07-30,COMPLETED,INTERVENTIONAL,['NA']
631,NCT03358797,Change in physical activity engagement,Change in Self-Rated health,,2016-12-29,RECRUITING,INTERVENTIONAL,['NA']
632,NCT05333055,Aqueous Humor Levels of Angiopoietin-2,Aqueous Humor Levels of Additional Disease State Biomarkers,Correlation of Biomarkers,2022-04-11,UNKNOWN,OBSERVATIONAL,['NA']
633,NCT02708758,incidence of large for gestational age,incidence of cesarean section,,2016-03,UNKNOWN,INTERVENTIONAL,['NA']
634,NCT04361552,30-day mortality rate,Length of hospital stay,,2020-04-07,WITHDRAWN,INTERVENTIONAL,['PHASE3']
635,NCT04281784,Proportion of Patients With EHR Documentation of Goals of Care Discussions,All-cause Mortality at 1 Year (Safety Outcome),,2020-04-23,COMPLETED,INTERVENTIONAL,['NA']
636,NCT00553475,Change From Baseline at Week 13 in Mean Weekly Pain Scores,Patient Global Impression of Change,,2007-10,COMPLETED,INTERVENTIONAL,['PHASE3']
637,NCT01405547,Infant growth,Getational hyperglycemia and insulinemia (insulin resistance/sensitivity),,2009-03,COMPLETED,OBSERVATIONAL,['NA']
638,NCT04327713,Total cardiovascular disease (CVD) incidence,Arrhythmia incidence,,2020-03-28,UNKNOWN,OBSERVATIONAL,['NA']
639,NCT02213003,procedural complications,,,2014-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
640,NCT01186107,Angiographic in-segment late loss,target-vessel revascularization,,2010-08,COMPLETED,INTERVENTIONAL,['PHASE4']
641,NCT04030013,Evaluate the effect of diabetes education given to renal transplant recipients with new onset diabetes after transplantation .,comparison of type of diabetes education,,2015-05,COMPLETED,INTERVENTIONAL,['NA']
642,NCT05114590,Change from baseline to week 16 in the percentage of Time in Range (TIR),Number of participants with adverse events,,2022-01-27,COMPLETED,INTERVENTIONAL,['PHASE4']
643,NCT02617732,Change from baseline in mean amplitude of glycemic excursions (MAGE) and mean of daily differences (MODD) at 12 weeks.,Renal Function Examination,,2016-01,UNKNOWN,INTERVENTIONAL,['NA']
644,NCT00700817,Mean Change in Glycosylated Haemoglobin A1c (HbA1c) From Week 52 to Week 78,"Hypoglycaamic Episodes, Weeks 52-78",,2008-06,COMPLETED,INTERVENTIONAL,['PHASE3']
645,NCT01606930,Adherence to anti-hypertensive drug treatment at three months,Systolic and Diastolic Blood Pressure at three months,,2010-11,COMPLETED,INTERVENTIONAL,['NA']
646,NCT02484209,Difference in hypoglycaemia occurrence (mild-moderate category) between treatment arms,Duration of Hypoglycaemia,,2016-02,WITHDRAWN,INTERVENTIONAL,['PHASE3']
647,NCT01435603,Percent Change in Body Weight,Percent Change in Physical Activity,,2011-08,COMPLETED,INTERVENTIONAL,['NA']
648,NCT01954147,HbA1C,Fasting Blood Glucose,,2013-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
649,NCT01554293,"Pharmacokinetics Variables (Cmax, tmax, AUC, t1/2, kel, CL/F & Vz/F)",Exploratory markers (plasma DPP-IV activity and GLP-1 levels),,2012-07,UNKNOWN,INTERVENTIONAL,['PHASE1']
650,NCT00820378,,,,2009-01,UNKNOWN,OBSERVATIONAL,['NA']
651,NCT02390167,Percent of Self-Test Fingerstick Blood Glucose (BG) Results (From Subjects WITH Diabetes) Within +/- 15mg/dL (<100mg/dL) and Within +/- 15% (>=100 mg/dL) of Laboratory Glucose Method,Percent of Self-Test Alternate Site Palm Blood Glucose (BG) Results (From Subjects WITH and WITHOUT Diabetes) Within +/- 15 mg/dL (<75 mg/dL) and Within +/- 15% (>= 75 mg/dL) of Laboratory Glucose Method,,2015-03,COMPLETED,INTERVENTIONAL,['NA']
652,NCT02406443,Percent Change in Fractional Excretion of Sodium (FENA),Change in Effective Renal Plasma Flow (ERPF),,2015-03,COMPLETED,INTERVENTIONAL,['PHASE4']
653,NCT01121029,C-peptide levels before and after the hematopoietic stem cell transplantation,Serum levels of Hb A1C before and after the hematopoietic stem cell transplantation,,2010-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
654,NCT04101604,Peripheral blood mononuclear cell (PBMC) signatures,PBMC cell types frequencies,,2019-09-26,UNKNOWN,OBSERVATIONAL,['NA']
655,NCT02733302,IPAQ-SF questionnaire for measure of Physical Activity,,,2016-04-04,UNKNOWN,INTERVENTIONAL,['NA']
656,NCT03819127,Evaluation of cognitive decline,Rate of Glycated hemoglobin (%),,2015-01,COMPLETED,INTERVENTIONAL,['PHASE4']
657,NCT04646941,the new onset and types of tumor in T2DM patients,,,2020-06-10,RECRUITING,OBSERVATIONAL,['NA']
658,NCT05663554,Change in HbA1c% at 12 months,Change in weight bias at 12 months,,2023-01-15,WITHDRAWN,INTERVENTIONAL,['NA']
659,NCT02099981,The vascular response to flicker,Contrast sensitivity,,2016-07,COMPLETED,INTERVENTIONAL,['PHASE1']
660,NCT01348568,change in serum lipids,cancer cell proliferation (in vitro),,2011-03,COMPLETED,INTERVENTIONAL,['PHASE2']
661,NCT04916093,Changes in HbA1c (%),Changes in Renal function tests,,2019-12-20,COMPLETED,INTERVENTIONAL,['PHASE4']
662,NCT06242106,Perceived stress scale:,,,2023-03-15,RECRUITING,INTERVENTIONAL,['NA']
663,NCT02715258,Change in HbA1c From Baseline at Week 24,Change in Body Weight From Baseline at Week 24 in Subjects With a BMI ≥ 25 Kg/m2,Proportion of Subjects Who Achieve an HbA1c < 7%,2016-03,COMPLETED,INTERVENTIONAL,['PHASE3']
664,NCT01293396,Area Over Basal for Postprandial Triglycerides,Area Over Basal for Postprandial C-peptide,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE4']
665,NCT03805412,Percent Body Fat Change at 14 Weeks,MAGE Mean Amplitude of Glycemic Excursion,,2019-01-10,COMPLETED,INTERVENTIONAL,['NA']
666,NCT05760118,Revised Osteoporosis Knowledge Test,Osteoporosis Health Belief Scale,,2023-07-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
667,NCT05463705,"Rate of prescriptions for SGLT-2i or GLP-1RA among eligible patients in each arm, compared across study arms","Change in Hemoglobin A1c (A1c) over the 6-month intervention period among eligible patients, compared across study arms",,2023-05-04,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
668,NCT02607566,Feasibility as measured by study completion,Diabetes Self-Care,,2015-09,COMPLETED,INTERVENTIONAL,['NA']
669,NCT01297062,"Comparison of LS Mean Changes From Baseline in QTcP Intervals Between Exenatide and Placebo on Day 3 Averaged Over 1300h, 1400h, 1500h (Target Steady State Exenatide Concentration of 500 pg/mL)","Plasma Exenatide Concentrations at Steady State on Day 1, 2 and 3",,2011-02,COMPLETED,INTERVENTIONAL,['PHASE1']
670,NCT01296412,Change From Baseline in Hemoglobin A1c (A1C),Percentage of Participants Reaching A1C Goal of <6.5%,,2011-03-11,COMPLETED,INTERVENTIONAL,['PHASE3']
671,NCT02917902,Change in HbA1c (measured as part of routine care),"Change in Body Mass Index, measured in kg/m^2, weight in kilograms, height in meters",,2015-01,COMPLETED,INTERVENTIONAL,['NA']
672,NCT02444156,Change in Cardiac function,Change in Sample size in a full-scale trial,,2015-06,COMPLETED,INTERVENTIONAL,['NA']
673,NCT02015429,Blood glucose,Subjective appetite,Palatability of treatments,2007-12,COMPLETED,INTERVENTIONAL,['NA']
674,NCT00587132,Number of Subjects With Evidence of Pancreatic Tumor or Any Secondary Findings of Pancreatic Tumor as Shown by CT.,,,2006-11,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
675,NCT03653013,Improved Glycemic Control measured by assessment of glycemic control (HgbA1C),,,2019-07-16,COMPLETED,INTERVENTIONAL,['NA']
676,NCT06192251,Participant Feedback,Participant Feedback,,2023-11-06,RECRUITING,OBSERVATIONAL,['NA']
677,NCT03267576,Change From Baseline in Glycemic Coefficient of Variation (CV) in Treatment Period 2,Change From Baseline in Percentage of 2 Consecutive Glucose Readings With < 70 mg/dL,,2017-10-27,COMPLETED,INTERVENTIONAL,['PHASE4']
678,NCT00195884,hemoglobin A1c (HbA1c),quality of life (QOL),,1999-09,COMPLETED,INTERVENTIONAL,['NA']
679,NCT04473326,Medication Adherence,Glycemic Control,,2021-02-04,COMPLETED,INTERVENTIONAL,['NA']
680,NCT01252524,Change in Hemoglobin A1c from baseline,Adverse outcomes,,2010-10,COMPLETED,INTERVENTIONAL,['NA']
681,NCT02269735,Number of participants who discontinued study drug due to an adverse event,Number of participants with anti-drug antibody (ADA) formation,,2014-11-26,COMPLETED,INTERVENTIONAL,['PHASE1']
682,NCT03124134,Safety and Tolerability,Post prandial insulin,,2017-04-18,COMPLETED,INTERVENTIONAL,['NA']
683,NCT00846716,Onset and progression of diabetic nephropathy,Progression of diabetes mellitus change from the baseline in HbA1c change from the baseline in albumine/creatinine ratio change from the baseline in cystatin C onset and progression of diabetic retinopathy safety assessment,,2008-03,UNKNOWN,INTERVENTIONAL,['NA']
684,NCT01794052,Change in compliance to therapy and follow-up rate among people with hypertension and/or diabetes.,,,2012-12,COMPLETED,INTERVENTIONAL,['NA']
685,NCT01059799,Change in Glycosylated Haemoglobin (HbA1c),Mean of 9-point Self Measured Plasma Glucose Profile (SMPG),,2010-02-01,COMPLETED,INTERVENTIONAL,['PHASE3']
686,NCT02597101,Insulin Sensitivity at 6 Months From Baseline,Change From Baseline in the Serum Levels of Inflammatory Markers,,2015-11,COMPLETED,INTERVENTIONAL,['PHASE2']
687,NCT01505036,"Rate of patients who attain,Hemoglobin A1C ≤ 7.0% and Blood pressure ≤ 130/80 and LDL-Cholesterol ≤ 100 or LDL-Cholesterol ≤ 70, all at 12 months.",Changes in Blood Pressure,,2010-12,COMPLETED,INTERVENTIONAL,['NA']
688,NCT06160817,Healing time,Clinical characteristics of the ulcer: Local Clinical Signs of Infection,SINBAD classification of diabetic foot ulcers,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
689,NCT01860599,"Measures of Endothelial Function by studying number, function and gene expression of endothelial progenitor cells (identified as CD34+ cells)",Measures of Vacular Reactivity,Measures of Insulin Sensitivity by measuring inflammatory molecules as a surrogate of insulin resistance,2010-03,COMPLETED,INTERVENTIONAL,['NA']
690,NCT01215968,Time Required for 50% of Radioactivity To Be Emptied From the Stomach by Scintigraphy,Number of Participants With Clinically Significant Effects,,2010-09,COMPLETED,INTERVENTIONAL,['PHASE1']
691,NCT04615351,Prediabetes or Diabetes,Prediabetes or diabetes at 15 months postpartum,,2020-11-15,UNKNOWN,INTERVENTIONAL,['PHASE3']
692,NCT00556244,Snellen BCVA and epiretinal membrane formation measured with OCT,central macular thickness measured bt OCT,,2007-04,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
693,NCT03437551,prevalence (percentages) of the stages of diabetic retinopathy (DR),mean NEI-VFQ 25 score,,2012-09,COMPLETED,OBSERVATIONAL,['NA']
694,NCT04907838,Leg blood flow,,,2018-05-01,UNKNOWN,INTERVENTIONAL,['NA']
695,NCT02777073,Difference in Ketone Bodies Formation After Single Dose of Liraglutide and Dapagliflozin,Change in Ghrelin Concentrations,,2016-03-01,COMPLETED,INTERVENTIONAL,['NA']
696,NCT03186300,"Change in the percentage of time spent in hypoglycaemia (glucose level below 3, 9 mmol/L or 70 mg/dl)",Evaluation of usability and the treatment satisfaction of PEPPER system by using non-validated questionnaires.,,2017-09-01,COMPLETED,INTERVENTIONAL,['NA']
697,NCT00855374,,,,2008-06,COMPLETED,OBSERVATIONAL,['NA']
698,NCT01484457,Restoration of Euglycemia,Average percent-of-time-in-range (80 - 180 mg/dL),,2008-07,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
699,NCT03828890,Family Physicians Screening for Diabetic Retinopathy - Number of photographs that are interpreted accurately by the family physicians when compared to the retinal specialist,Screening Impact - Percentage increase in the screening rates for Diabetic Retinopathy using retinal imaging.,Patient Satisfaction,2019-06-12,COMPLETED,INTERVENTIONAL,['NA']
700,NCT04805853,the change level of cardiac extracellular volume (ECV),Changes in score of Patient Health Questionnaire-9(PHQ-9),,2020-02-20,UNKNOWN,OBSERVATIONAL,['NA']
701,NCT01524809,Area under the serum insulin curve 6-14 hours after dinner at day 15,Adverse events,,2001-01,COMPLETED,INTERVENTIONAL,['PHASE1']
702,NCT05031000,Analysis of system accuracy based on DIN EN ISO 15197,,,2021-09-03,COMPLETED,INTERVENTIONAL,['NA']
703,NCT03997773,Change in quality of life,Change in moderate to vigorous physical activity patterns,Changes in health literacy,2019-05-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
704,NCT01468181,Percentage of Participants With Hypoglycemic Episodes,Change From Baseline in Updated Homeostasis Model Assessment (HOMA2),,2011-11,COMPLETED,INTERVENTIONAL,['PHASE3']
705,NCT06293742,Midazolam PK parameters: Cmax,ECC5004 PK parameters: Ctau,,2024-02-09,RECRUITING,INTERVENTIONAL,['PHASE1']
706,NCT03804892,IMTG utilisation during exercise,,,2019-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
707,NCT02964715,Change in serum FGF 21,Change in MRI features of NASH,,2016-11,UNKNOWN,INTERVENTIONAL,['PHASE4']
708,NCT00806975,"HbA1c change rate from the start to 12 and 24 weeks are investigated and compared. Furthermore, using a questionnaire sheet ""IDSQ-J"" related to the insulin infusion device, the patient's usability and satisfaction with KwikPen® or FlexPen® are performed.","As the secondary endpoints, the incidence of hypoglycemia, changes in body weight (BMI) and blood pressure, and the dose of insulin are investigated and compared before and after the changeover.",,2009-01,UNKNOWN,INTERVENTIONAL,['NA']
709,NCT04140201,The 80 participants will be evaluated through reduction of macular edema,The 80 participants will be evaluated through reduction of cardiovascular risk,,2020-02,UNKNOWN,INTERVENTIONAL,['PHASE4']
710,NCT04304729,Vascular structure (Pulse-wave velocity),Hypertension,,2017-01-12,SUSPENDED,OBSERVATIONAL,['NA']
711,NCT05202002,"Rate of type II Diabetes Mellitus (DM) diagnosis, as diagnosed by the 75gm oral glucose tolerance test (OGTT)",Rate of exclusive breastfeeding,,2021-03-01,UNKNOWN,INTERVENTIONAL,['NA']
712,NCT00340613,Hemoglobin A1c,Urine microalbumin,,2006-06,COMPLETED,INTERVENTIONAL,['PHASE4']
713,NCT03236116,Homa-Percent Beta,Compliance,,2017-08-01,COMPLETED,INTERVENTIONAL,['NA']
714,NCT02485132,Total incidence rate of hypoglycemia episode,,,2016-03,TERMINATED,OBSERVATIONAL,['NA']
715,NCT00433069,Early virological response,Improvement (vs. baseline) of glucose tolerance parameters after 12 and 48 weeks of therapy and after 24 weeks of follow-up,,2007-01,COMPLETED,INTERVENTIONAL,['PHASE2']
716,NCT03962686,methylase status,,,2015-01-01,COMPLETED,OBSERVATIONAL,['NA']
717,NCT01566110,Metabolic Control,Continuous Glucose Monitoring,,2012-03,COMPLETED,INTERVENTIONAL,['NA']
718,NCT05478291,Effects of vitamin D supplementation on physiology of atherosclerosis,,,2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
719,NCT02876393,Presence of DMO evaluated from the optical coherence tomography (OCT) images,,,2014-11,COMPLETED,OBSERVATIONAL,['NA']
720,NCT05004428,Percentage of Type 2 Diabetes Mellitus (T2DM) patients with Chronic Kidney Disease (CKD) in database.,Annual average costs among patients,,2021-08-14,COMPLETED,OBSERVATIONAL,['NA']
721,NCT00264927,Serum sodium,"Safety: Physical examination, vital signs, adverse events, ECG, hematology, serum chemistry",,2004-05,COMPLETED,INTERVENTIONAL,['PHASE3']
722,NCT04924777,HbA1c Levels,,,2021-04-01,COMPLETED,INTERVENTIONAL,['NA']
723,NCT04537923,"Change From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses of Tirzepatide 5 mg, 10 mg and 15 mg)",Change From Baseline in 36-Item SF-36 Mental Component Summary (MCS) Score,,2020-10-19,COMPLETED,INTERVENTIONAL,['PHASE3']
724,NCT03212950,Time within range 3.9 - 10 mmol/l (70 - 180 mg/dl),,,2017-07-10,COMPLETED,INTERVENTIONAL,['NA']
725,NCT05692388,Self-Care Behavior,,,2023-01-23,RECRUITING,OBSERVATIONAL,['NA']
726,NCT00224237,,,,2005-12,COMPLETED,OBSERVATIONAL,['NA']
727,NCT01191320,Change in HbA1C,,,2010-10,COMPLETED,INTERVENTIONAL,['PHASE2']
728,NCT03019510,fasting glucose level,beta cell function,,2016-10,COMPLETED,INTERVENTIONAL,['NA']
729,NCT03848793,HbA1c,Change in Body Weight,,2019-03-06,COMPLETED,INTERVENTIONAL,['PHASE2']
730,NCT01475734,Glucagon Concentration (Nanomoles Per Liter [Nmol/L]) During the Hypoglycemic Periods of the Glucose Clamp Procedure,Number of Participants With Any Treatment-emergent Serious Adverse Event (SAE) and Treatment-emergent Non-serious Adverse Event (AE) During the Clamp Period,,2011-12,COMPLETED,INTERVENTIONAL,['PHASE2']
731,NCT00974740,C-peptide after a liquid mixed meal stimulation,plasma CRP,,2004-03,TERMINATED,INTERVENTIONAL,['PHASE1']
732,NCT03470961,Incidence and severity of adverse event,,,2018-03-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
733,NCT05101473,4x10-meter fast-paced walk test,,,2021-09-01,COMPLETED,INTERVENTIONAL,['NA']
734,NCT03072901,Evaluation of Effectiveness of the EndoBarrier GI Liner upon weight loss,,,2010-12,TERMINATED,OBSERVATIONAL,['NA']
735,NCT02655770,Change in diastolic properties as assessed by CMR.,Echocardiographic indices of diastolic dysfunction,,2016-02,COMPLETED,INTERVENTIONAL,['PHASE4']
736,NCT04764968,Difference in percentage of time in range between the two study periods,Percentage of participants with treatment-induced or treatment-boosted anti-dasiglucagon antibodies,Number of device failures/malfunctions,2021-04-27,COMPLETED,INTERVENTIONAL,['PHASE2']
737,NCT04547790,Change in HbA1c,Change in weight,,2020-12-23,COMPLETED,INTERVENTIONAL,['NA']
738,NCT01010100,The principal objective was to determine if the administration of small doses of Acarbose could prevent or delay the appearance of Type 2 DM in a population of subjects with impaired glucose homeostasis.,Delay in the conversion to diabetes mellitus,,2000-08,COMPLETED,INTERVENTIONAL,['PHASE3']
739,NCT04060056,Adverse birth outcomes,Number of participants developing type 2 diabetes,,2019-08-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
740,NCT04765982,Incidence of developing pre diabetes in patient with post operative stress hyperglycemia,other morbidity measures,,2021-12-01,RECRUITING,INTERVENTIONAL,['NA']
741,NCT03667300,UACR percent change at Week 24,eGFR change at Week 12,,2017-03-16,COMPLETED,INTERVENTIONAL,['PHASE2']
742,NCT02542722,Incidence of type 2 diabetes in subjects at risk,,,2009-01,COMPLETED,INTERVENTIONAL,['NA']
743,NCT01819493,Body Mass Index,Blood Pressure,,2013-03,COMPLETED,INTERVENTIONAL,['NA']
744,NCT05024656,Incidence of complete wound closure,,,2021-09,WITHDRAWN,INTERVENTIONAL,['NA']
745,NCT00406133,Time With Glucose Level <=70 mg/dL (for the Cohort With Baseline HbA1c <7.0%),Total Costs: Direct and Indirect Costs,26-week A1c Level <7.0% (for Cohort With Baseline HbA1c <7.0%),2006-12,COMPLETED,INTERVENTIONAL,['PHASE3']
746,NCT00976495,Adjusted Percent Change From Baseline in Glomerular Filtration Rate (GFR) at Week 12 (Modified Last Observation Carried Forward [MLOCF]),Adjusted Mean Change From Baseline in Nighttime (0100 to 0600 Hours) Ambulatory Systolic Blood Pressure (ASBP) at Week 12 (Last Observation Carried Forward [LOCF]),,2009-10,COMPLETED,INTERVENTIONAL,['PHASE2']
747,NCT01733524,Glycemic control,Self Management of Diabetes in Adolescents,Health care burden,2012-10,COMPLETED,INTERVENTIONAL,['NA']
748,NCT01214824,Change in HbA1C From Baseline to 6 Months,Proportion of Time in Hypoglycaemia (<3.9mmol/L)-Unmasked,,2010-11,COMPLETED,INTERVENTIONAL,['NA']
749,NCT00448487,"same as in ICARE: composite major CVD outcomes (non fatal MI, Stroke and CVD death)",,,2005-04,COMPLETED,OBSERVATIONAL,['NA']
750,NCT00589680,Hospital length of stay,Time to correction of glucose level and anion gap,,2007-12,COMPLETED,OBSERVATIONAL,['NA']
751,NCT00434538,Percentage of subjects with closed ulcers at week 12,Reduction of incidence of clinical signs of infection.,,2007-02,TERMINATED,INTERVENTIONAL,['PHASE3']
752,NCT03001999,Feasibility of study procedures,Changes in SDSCA Scores,Hemoglobin A1c,2017-01,COMPLETED,INTERVENTIONAL,['NA']
753,NCT03352596,insulin,Blood pressure,,2017-01-01,UNKNOWN,INTERVENTIONAL,['NA']
754,NCT01237301,Percentage Change in Hemoglobin A1c,Change From Baseline in CGM Glucose Variability,,2010-10,COMPLETED,INTERVENTIONAL,['NA']
755,NCT00933101,Determine the impact of glycemic control on vascular oxidative stress/inflammation in adolescents with Type 1 diabetes mellitus,To determine the impact of glycemic control and vascular oxidative stress/inflammation on vascular health in adolescents with T1DM,,2010-01,COMPLETED,OBSERVATIONAL,['NA']
756,NCT01809093,Level of thrombospondin (TSP1) and pigment epithelium derived factor (PEDF) in the vitreous and plasma,,,2010-03,COMPLETED,OBSERVATIONAL,['NA']
757,NCT00785577,Change From Baseline in Weekly Mean 24-hour Average Pain Severity (APS) Score at 5 Weeks,Number of Participants With Neurological Treatment Emergent Adverse Events (TEAEs),,2008-11,COMPLETED,INTERVENTIONAL,['PHASE2']
758,NCT01486966,Change From Baseline in Mean 8-point Plasma Glucose (PG) After Two Weeks of Treatment,Incidence of Hypoglycaemic Episodes,,2011-11,TERMINATED,INTERVENTIONAL,['PHASE4']
759,NCT01299844,Hemoglobin A1c,Diabetes Knowledge Test Score,,2006-12,COMPLETED,INTERVENTIONAL,['NA']
760,NCT05999773,SGLT-2 inhibitors related adverse events,Adverse events classification,,2023-07-15,RECRUITING,OBSERVATIONAL,['NA']
761,NCT05803772,Change from baseline in AUC0-2h values of Oral Glucose Tolerance Test (OGTT) as measured in blood samples,Number of Participants Reported with At least One Treatment Emergent Adverse Event (TEAE),Change from baseline in AUC0-2h of OGTT as measured by Flash Glucose Monitoring (FGM),2023-04-01,RECRUITING,INTERVENTIONAL,['PHASE2']
762,NCT01486290,Hemoglobin A1c,Economic impact,,2007-07,COMPLETED,INTERVENTIONAL,['NA']
763,NCT02401243,Percentage of patients reaching fasting SMPG ≤5.6 mmol/L without nocturnal (midnight to 6:00 am) hypoglycemia (confirmed or symptomatic or severe),Percentage of patients with adverse events,,2015-03,COMPLETED,INTERVENTIONAL,['PHASE3']
764,NCT00532610,Continuous holter monitor & ECG each treatment period:,"12-lead ECGs, vital signs, adverse events, and clinical laboratory tests.",,2007-09,COMPLETED,INTERVENTIONAL,['PHASE1']
765,NCT02624908,Self monitoring and continuous monitoring blood glucose levels,,,2016-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4']
766,NCT04977427,Intraocular Inflammation,Macular Edema,,2021-07,UNKNOWN,INTERVENTIONAL,['PHASE4']
767,NCT01408095,Change from baseline to 12 week endpoint in glycosylated fraction of hemoglobin A (HbA1c),"Pharmacokinetics: Area under the curve of concentration-time curve for one dosing interval at steady state (AUC0-tau, ss) of LY2608204",,2011-09,WITHDRAWN,INTERVENTIONAL,['PHASE2']
768,NCT05123248,Gestational Diabetes Mellitus (GDM),Plasma glucose measures from OGTT,"Applicability, acceptability, compliance of the unblinded CGM device use in a GDM pregnancy",2018-10-16,RECRUITING,INTERVENTIONAL,['NA']
769,NCT04444570,Rate and type of complications,Cardiovascular events and/or surgical site or implants complications,,2021-12-01,UNKNOWN,OBSERVATIONAL,['NA']
770,NCT05245825,Hemoglobin A1C,Stool classification,,2021-11-20,RECRUITING,INTERVENTIONAL,['NA']
771,NCT02355197,neonatal outcome assessed by neonatal ICU admission,oxidative stress parameters: non enzymatic and enzymatic oxidative stress parameters in neonatal blood in women with GDM named malondialdahyde and superoxide dismutase,,2013-01,COMPLETED,INTERVENTIONAL,['PHASE4']
772,NCT01938807,Diabetes Management,Hemoglobin A1c,Satisfaction and usability of the mobile application,2013-10,COMPLETED,INTERVENTIONAL,['NA']
773,NCT02899949,change in HbA1c value,Evidence of urinary tract infection (UTI) documented,,2016-10,COMPLETED,OBSERVATIONAL,['NA']
774,NCT01555788,Percentage of time spent with blood glucose between 3.9 and 8.0 mmol/L (79 - 144 mg/dl),Percentage of time spent in hyperglycemia,,2012-02,COMPLETED,INTERVENTIONAL,['NA']
775,NCT04464772,System Performance,,,2020-07-10,COMPLETED,OBSERVATIONAL,['NA']
776,NCT05566847,HbA1c<9%,Hypoglycemia events post-intervention start,,2022-09-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
777,NCT00304538,"1) Evaluate the safety and tolerability of VLD-glucagon in doses of 2, 4 and 8 ng/kg/minute when infused overnight 2) Evaluate the PK profile in plasma of VLD-glucagon 3) Evaluate the pharmacodynamic activity of these doses by measuring glucose levels",Compare the number of times and amount of time subjects have glucose levels < 70 mg/dL when treated with VLD-glucagon vs. the control infusion,,2006-03,COMPLETED,INTERVENTIONAL,['PHASE1']
778,NCT06334484,change in time spent in tighter glucose range after 24 months of hybrid closed loop system,,,2024-03-26,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
779,NCT00535886,"The primary outcome measure will be the ratio of total to high density lipoprotein (HDL) cholesterol. Blood draws will take place at screening, three weeks, and five weeks.","Related secondary outcome measures include concentrations of low density lipoprotein (LDL) cholesterol, HDL cholesterol, triglyceride (TG) and Lp(a) measured at screening, three weeks, and five weeks.",,2005-11,COMPLETED,INTERVENTIONAL,['NA']
780,NCT00816010,"Composite endpoint of death and/or CVD related hospitalisations (acute myocardial infarction, revascularisation procedures, heart failure or unstable angina or arrhythmia requiring hospital admissions, lower extremity amputation and stroke) by 24 months.","Number of hospital admissions, total number of days of hospitalization",,2008-07,TERMINATED,INTERVENTIONAL,['NA']
781,NCT01473576,Muscle protein fractional synthetic rate,Plasma nitrate,,2011-08,COMPLETED,INTERVENTIONAL,['NA']
782,NCT01992133,Change in glucose metabolism as assessed by change in Insulin sensitivity index as calculated by HOMA -IR28,Change in plasma 25-OH- Vitamin D level pre and post replacement,,2011-06,COMPLETED,INTERVENTIONAL,['NA']
783,NCT00790088,Percentage of Patients Achieving HbA1c < 7.5%,Diabetes Treatment Satisfaction Questionnaire Status Version (DTSQs),,2009-02,COMPLETED,OBSERVATIONAL,['NA']
784,NCT00412906,"Gene expression evaluated by measuring mRNA via RT-PCR. Plasma cytokine content, PLasma PAI-1 content, endotoxemia score","Mean Arterial Pressure, heart rate, Temperature,",,2006-11,COMPLETED,INTERVENTIONAL,['NA']
785,NCT03195400,Hepatic glucose fluxes,,,2017-03-01,COMPLETED,OBSERVATIONAL,['NA']
786,NCT03689738,Change in the Matsuda insulin sensitivity index (MISI),Change in the total AUC for breath hydrogen,,2018-09-24,COMPLETED,INTERVENTIONAL,['NA']
787,NCT04071808,Blood norepinephrine content,,,2019-10-01,COMPLETED,OBSERVATIONAL,['NA']
788,NCT01272973,Frequency of adverse events (AEs),Terminal phase elimination half-life,,2011-01,COMPLETED,INTERVENTIONAL,['PHASE1']
789,NCT03106246,Determine whether these EVs contain islet-specific antigens,Mutivariate analysis will be performed with patient parameters and EV parameters,,2016-12,UNKNOWN,OBSERVATIONAL,['NA']
790,NCT01397279,M Value in hyperinsulinemic euglycemic clamp,Insulin-suppressed endogenous glucose production (liver insulin sensitivity),,2011-07,COMPLETED,INTERVENTIONAL,['NA']
791,NCT02377076,HbA1c,,,2014-09,COMPLETED,INTERVENTIONAL,['NA']
792,NCT06273020,Blood-Brain-Barrier Permeability after 10-14days of cerebrolysin in patients with AIS of the middle cerebral artery,"Comparison of cognitive impairment, using Montreal Cognitive Assessment in patients with and withouth cerebrolysin",,2022-11-17,RECRUITING,INTERVENTIONAL,['PHASE4']
793,NCT02682680,Proportion of subjects who achieve target HbA1c and LDL cholesterol,Absolute change in creatine kinase (CK),Mean dose of colesevelam,2016-01-11,COMPLETED,INTERVENTIONAL,['PHASE4']
794,NCT01252810,Comparison of Overall Image Quality Between Ioforminol and Iopamidol-enhanced Images as Determined by an Independent Reader.,Assessing the Incidence of Renal Biomarker-based Contrast-induced Acute Kidney Injury (CI-AKI) in Subjects Post Administration of Ioforminol or Iopamidol Injections,,2010-11,COMPLETED,INTERVENTIONAL,['PHASE2']
795,NCT03729479,Systolic blood pressure,Weight loss,,2018-11-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
796,NCT02556398,area under the curve (AUC) above target (> 180 mg/dL),,,2015-09,COMPLETED,INTERVENTIONAL,['NA']
797,NCT00806520,,,,2008-04,COMPLETED,OBSERVATIONAL,['NA']
798,NCT05351190,A1c,Quality of Life - GMSS T2DM Version,,2022-05-15,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
799,NCT02157155,Insulin signaling expressed as a CHANGE in phosphorylation of intracellular target proteins and CHANGE in mRNA expression of target genes in muscle- and fat-tissue.,Cytokines and stress hormones,,2014-06,COMPLETED,INTERVENTIONAL,['NA']
800,NCT01589757,SUB-STUDY (n=75): Oxygen Radical Absorbance Capacity (ORAC) (Antioxidant Capacity) of transitional and mature breast milk.,MAIN STUDY: Change in behaviour from baseline (pre-class) to 6-8 weeks after delivery.,,2011-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
801,NCT05118945,Time in glucose range 70 - 180mg/dl (%),mean daily insulin amount before study start,,2021-03-03,COMPLETED,OBSERVATIONAL,['NA']
802,NCT05866536,Change in HbA1c values,Change in insulin usage,Exploratory: Change in hypoglycemia,2023-05-04,RECRUITING,INTERVENTIONAL,['PHASE2']
803,NCT05646017,Change in Time in range,Change in Hypoglycemia frequency,Change in Percentage of patients attaining the the International Consensus on Time in Range (ICTR) goals,2022-12-15,COMPLETED,OBSERVATIONAL,['NA']
804,NCT03863535,Change in best-corrected visual acuity (BCVA),Foveal avascular zone,,2019-01-18,UNKNOWN,INTERVENTIONAL,['NA']
805,NCT02347020,Food Intake,Cardio-metabolic risk profile,,2014-10,COMPLETED,INTERVENTIONAL,['NA']
806,NCT06268977,Effect of adding SGLTi on BMI,,,2024-03-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
807,NCT01786564,Oral Disposition Index,,,2011-12-06,COMPLETED,OBSERVATIONAL,['NA']
808,NCT04863872,Self-reported severe hypoglycemia,,,2022-01-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
809,NCT04204733,Moderate to vigorous physical activity (subjective),,,2020-01-06,COMPLETED,INTERVENTIONAL,['NA']
810,NCT04131582,Change from basal fasting and post2h OGTT glucose levels at 6 and 12 months,Change from basal Weight at 6 and 12 months,,2019-09-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
811,NCT03859934,Change of insulin signalling,Change of assessment of resting energy expenditure (REE),,2019-09-26,COMPLETED,INTERVENTIONAL,['PHASE1']
812,NCT03929601,C-Peptide Response to 2-hr MMTT at 24 months post-randomization,Analysis of changes in immune responses to known diabetes antigens and a neoantigen over time by treatment group,,2023-10-30,RECRUITING,INTERVENTIONAL,['PHASE2']
813,NCT03643692,Time in Range (%),,,2019-02-26,COMPLETED,INTERVENTIONAL,['NA']
814,NCT01673204,Changes in renal function with proteinuria,changes in sTNFR and TNF-related proteins,,2012-10,UNKNOWN,INTERVENTIONAL,['PHASE4']
815,NCT01358929,Safety: Incidence of adverse events,Change in meal tolerance test,,2011-04,COMPLETED,INTERVENTIONAL,['PHASE1']
816,NCT01479062,Change from baseline in diabetes risk markers,Change from baseline in physical activity and dietary factors,,2014-02,COMPLETED,INTERVENTIONAL,['NA']
817,NCT06187493,prevention of the development of DKD and alter its natural progression.,,,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
818,NCT00645528,Barriers to Insulin Treatment Total Sum Score Visit 2 (Week 2),Number of Patients Experiencing a Severe Hypoglycemic Event,,2008-04,COMPLETED,INTERVENTIONAL,['NA']
819,NCT04607915,Feasibility - Delivery of Intervention (Coach strategies),Virtual Care Team experience and satisfaction via semi-structured interview,Exploratory Outcome - Diabetes self-management,2021-05-04,COMPLETED,INTERVENTIONAL,['NA']
820,NCT04663659,length of stay in intensive care,,,2020-03-15,COMPLETED,OBSERVATIONAL,['NA']
821,NCT01025973,Foetal HbA1c,Foetal acetylated Hb,,2009-10,COMPLETED,OBSERVATIONAL,['NA']
822,NCT02886013,Prevalence of the FTO rs9939609 and PPARy rs1801282 polymorphisms.,,,2013-01,COMPLETED,OBSERVATIONAL,['NA']
823,NCT00184626,HbA1c,Fasting plasma glucose value,,2004-09-10,COMPLETED,INTERVENTIONAL,['PHASE4']
824,NCT00476710,Bile Acid Pool Size and Kinetic Parameters,Resting Metabolic Rate,,2007-05,COMPLETED,OBSERVATIONAL,['NA']
825,NCT01667614,Urinary albumin excretion,Serum potassium concentrations,,2010-05,COMPLETED,INTERVENTIONAL,['PHASE2']
826,NCT03751007,Incidence of Treatment-emergent Adverse Events (TEAE),C-peptide Area Under the Concentration-time Curve (AUC) Calculated From a 2 Hour Mixed Meal Tolerance Test (MMTT) at 12 Months,Incidence of Treatment Emergent Adverse Events up to 12 Months,2018-10-24,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
827,NCT01248286,Homeostatic model assessment (HOMA) index.,Sirtuin 1,,2010-11,COMPLETED,INTERVENTIONAL,['NA']
828,NCT04191902,differences in glycemic control,,,2021-01-05,UNKNOWN,OBSERVATIONAL,['NA']
829,NCT04306406,A high-sensitivity C-reactive protein (hs-CRP) measured in milligrams per liter,"3,4-Dihydroxyphenylacetic acid (DOPAC) measured in nanograms per milliliter",,2015-01-07,COMPLETED,INTERVENTIONAL,['NA']
830,NCT01872611,Percentage of Participants Who Develop Macular Edema Within 90 Days Following Cataract Surgery (Day 0),Percentage of Participants With With a > 10-letter Loss in BCVA From Day 7 to Any Visit,,2013-06,COMPLETED,INTERVENTIONAL,['PHASE3']
831,NCT00338949,Change in Visceral Fat Mass From Baseline to Week 26,,,2006-06,COMPLETED,INTERVENTIONAL,['PHASE4']
832,NCT01931982,Change in coronary flow reserve (CFR),Change in Endothelial function:,Change in waist circumference,2013-05,COMPLETED,INTERVENTIONAL,['PHASE4']
833,NCT02813668,Number of Participants Reaching Two or More Cardiometabolic Risk Goals,Number of Patients With Prediabetes or Newly Detected Diabetes That Achieve Normoglycemia Rates,,2017-05-02,COMPLETED,INTERVENTIONAL,['NA']
834,NCT02418884,the Density Score of Coronary Artery Calcification in CAD patients with Diabetes Mellitus,the volume score of CAC in CAD patients with diabetes mellitus,,2015-04,UNKNOWN,INTERVENTIONAL,['PHASE4']
835,NCT03939065,Differences in CGM percent time over 140 mg/dl,Statstrip glucose,beta-cell function,2020-06-12,TERMINATED,INTERVENTIONAL,['NA']
836,NCT05654831,"Number of participants with adverse events, with abnormal laboratory test results, abnormal ECGs, abnormal vital signs, and abnormal physical examinations",Pharmacodynamic Parameters: Fasting plasma insulin homeostatic model assessment,,2022-12-01,RECRUITING,INTERVENTIONAL,['PHASE1']
837,NCT01295775,Hard exudates,Intraretinal microvascular abnormalities (IRMA),,2009-02,COMPLETED,INTERVENTIONAL,['PHASE2']
838,NCT00898950,"Change in markers of oxidative stress, endothelial function, glycaemic control, and insulin resistance",Change in inflammatory markers,,2004-08,COMPLETED,INTERVENTIONAL,['NA']
839,NCT03832790,BMI,,,2019-12-04,COMPLETED,OBSERVATIONAL,['NA']
840,NCT02094534,"Change From Baseline in Total, Basal, and Bolus Exogenous Insulin Requirements","Mean Nighttime, Daytime, and Fasting Glucose Levels",,2014-03,COMPLETED,INTERVENTIONAL,['PHASE2']
841,NCT02718950,Evaluate the effect of liraglutide administration on brown adipose tissue (BAT) activation in humans,Evaluate the effect of liraglutide administration on body composition in humans,,2016-06,UNKNOWN,INTERVENTIONAL,['PHASE3']
842,NCT00542633,change in HbA1c,,,2006-12,COMPLETED,INTERVENTIONAL,['PHASE3']
843,NCT00846144,Identify humans with marginal Cu status that may benefit from copper supplementation and normalize their GSIS.,,,2009-09,UNKNOWN,INTERVENTIONAL,['NA']
844,NCT01531517,Healing of the Ulcer,local reaction that may be due to study drug,,2011-07,TERMINATED,INTERVENTIONAL,['PHASE3']
845,NCT02877186,Taxa abundance before and after one-week of three times daily diet soda consumption,,,2015-02,COMPLETED,INTERVENTIONAL,['NA']
846,NCT02060240,Insulin mediated skeletal muslce blood flow and capillary recruitment,Quantification of endothelial derived Vasodilators,"Correalte changes in fitness to vasodilators, blood flow, and insulin sensitivity",2014-02,COMPLETED,INTERVENTIONAL,['NA']
847,NCT00004983,,,,1999-09,COMPLETED,INTERVENTIONAL,['NA']
848,NCT00101712,Change from baseline in HbA1c at 52 weeks,Coefficient of failure for HbA1c between 24 weeks and 52 weeks,,2004-10,COMPLETED,INTERVENTIONAL,['PHASE3']
849,NCT05134129,Differential lipid compounds,,,2021-04-25,RECRUITING,OBSERVATIONAL,['NA']
850,NCT05294653,Occurrence of Atherosclerotic Cardiovascular Disease(ASCVD) high risk rating,Occurrence of subclinical ASCVD(coronary artery calcium),Occurrence of rheumatic diseases,2022-06-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
851,NCT04599920,Changes in the intake of nutrients and nutritional status of participants as a measure of diet modification.,Changes in the concentrations of N-nitroso compounds in feces.,,2020-09-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
852,NCT05152589,Hearing Loss,diabetic mother,,2022-01-01,UNKNOWN,OBSERVATIONAL,['NA']
853,NCT02621008,blood pressure,stress mindset scale,,2015-11,UNKNOWN,INTERVENTIONAL,['NA']
854,NCT02972996,Blood Pressure,Hemoglobin A1C,,2017-01-19,COMPLETED,INTERVENTIONAL,['NA']
855,NCT02456428,Hospitalization for incident heart failure,,,2014-03,COMPLETED,OBSERVATIONAL,['NA']
856,NCT01683409,Change From Baseline in Urinary Albumin/Creatinine Ratio (UACR) at Week 24,"Pharmacokinetics (PK): Area Under the Concentration-Time Curve at Steady State (AUC,ss)",,2012-08,COMPLETED,INTERVENTIONAL,['PHASE2']
857,NCT02575937,Change in Glycosylated hemoglobin (HbA1c),Food Frequency Questionnaire（FFQ）,,2016-05,UNKNOWN,INTERVENTIONAL,['NA']
858,NCT02102958,Frequency of foot examination at home,New foot problems discovered at home,Total new foot problems,2011-07,COMPLETED,INTERVENTIONAL,['NA']
859,NCT01334684,Fasting glucose change after metformin treatment in respect to mRNA and miRNA expression profiles in white blood cells,Change in fasting insulin levels after metformin treatment in respect to mRNA and miRNA expression profiles in white blood cells,,2011-05,UNKNOWN,INTERVENTIONAL,['NA']
860,NCT05902546,Insulin Resistance (Homa-IR),,,2023-01-07,COMPLETED,INTERVENTIONAL,['NA']
861,NCT02344329,Time to closure of a Diabetic Foot Ulcer using Human Amnion Allograft and Total Contact Casting vs Standard Wound Care and Total Contact Casting.,,,2014-08,UNKNOWN,INTERVENTIONAL,['PHASE4']
862,NCT02783469,Neuropathic Pain,,,2004-10,COMPLETED,OBSERVATIONAL,['NA']
863,NCT06061991,GDM diagnosis,Stillbirth,,2024-01-30,RECRUITING,INTERVENTIONAL,['NA']
864,NCT00454662,"Composite of following events: Sudden death, Cerebrovascular events, Coronary events, Renal dysfunction","All deaths, Death from cardiovascular events, Glucose metabolism, Incidence of primary outcomes events, New onset of atrial fibrillation, Safety, Withdrawal rate",,2007-04,COMPLETED,INTERVENTIONAL,['PHASE4']
865,NCT03462589,Number of participants with treatment-related adverse events as assessed by CTCAE v4.03,C-peptide secretion following single dose of SY-008,,2018-08-02,COMPLETED,INTERVENTIONAL,['PHASE1']
866,NCT02235519,Blood pressure,Renal function improvement.,,2014-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
867,NCT01514838,Change in HbA1c from baseline to end of treatment,"Safety assessed by the incidence of adverse events, vital signs safety labo-tests and 12-lead ECG",,2012-04-23,TERMINATED,INTERVENTIONAL,['PHASE3']
868,NCT06256523,Changes from baseline in hemoglobin A1c (HbA1c) at the end of the study,HbA1c control rate (proportions of subjects with HbA1c < 6.5 % and HbA1c < 7.0 %),,2022-06-29,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
869,NCT00978744,Gaps in care; compliance with quality measures,Costs of care,,2008-12,UNKNOWN,OBSERVATIONAL,['NA']
870,NCT04754581,Individual steps of muscle glucose uptake (post-exercise),,,2021-03-30,RECRUITING,INTERVENTIONAL,['NA']
871,NCT02039934,Improvement of Insulin sensitivity by high intensity interval training,,,2014-07,COMPLETED,INTERVENTIONAL,['NA']
872,NCT03519217,Evaluate possible risk factors among diabetic infants,Detection of gene mutation responsible for infantile diabetes through gene sequencing,,2020-06-05,UNKNOWN,OBSERVATIONAL,['NA']
873,NCT05633810,"First event of the composite of cardiovascular death, resuscitated cardiac arrest, non-fatal myocardial infarction, non-fatal stroke, or urgent hospitalization for angina requiring coronary revascularization.",MoCA Scores Assessed Over Time,,2022-12-21,RECRUITING,INTERVENTIONAL,['PHASE3']
874,NCT00480779,Change in Weight,Change in Triglycerides,,2007-06,COMPLETED,INTERVENTIONAL,['NA']
875,NCT00770679,Change in Endothelial Function as Measured on MRI in the Legs,,,2008-06,TERMINATED,INTERVENTIONAL,['NA']
876,NCT05255497,The effect of biodex balance training on motor nerves,,,2017-09-02,COMPLETED,INTERVENTIONAL,['NA']
877,NCT04964388,Trabecular bone score,Sclerostin and Bone formation markers,,2021-11-09,RECRUITING,INTERVENTIONAL,['PHASE2']
878,NCT01662193,change in adipocytokines from baseline at 8 weeks,change in blood pressure from baseline at 8 weeks,,2012-02,UNKNOWN,INTERVENTIONAL,['NA']
879,NCT03968055,Contacts with the care provider,Hemoglobin A1c,,2019-03-25,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
880,NCT05415826,CRT,Intraretinal hemorrhage,,2022-06-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
881,NCT01171248,Ambulatory blood pressure (AMBP),Diabetic late complications,,2009-09,COMPLETED,OBSERVATIONAL,['NA']
882,NCT01804049,Change in Total Lean Mass From Baseline,Change in Muscle Characteristics,,2014-04-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
883,NCT01131650,Prevalence of diabetic retinopathy,associated risk factors of diabetic retinopathy,,2009-03,COMPLETED,OBSERVATIONAL,['NA']
884,NCT01619332,Area under the effect curve (AUC0-4h) over the 4-hour post-dose period to measure glucose response following a standard mixed meal test,Change from baseine in Gastric inhibit polypeptide (GIP) (Part III),,2012-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
885,NCT02769884,CGM percent time < 60 mg/dl,% of subjects with mean CGM <169 (eHbA1C < 7.5%),Safety Criteria 4: No seizures or loss of consciousness while system is on and functional,2016-07,COMPLETED,INTERVENTIONAL,['PHASE2']
886,NCT01872299,"Prevalence, incidence, persistence and phenotype of obesity, cachexia and type 2 diabetes in patients with chronic heart failure.","Changes of metabolic status in patients with heart failure and type 2 diabetes, obesity and cachexia",,2010-03,COMPLETED,OBSERVATIONAL,['NA']
887,NCT02473991,Placental Thickness at 3rd Trimester,,,2015-03,COMPLETED,OBSERVATIONAL,['NA']
888,NCT03816761,Time in Low Interstitial Glucose (Defined as Below 54 mg/dL [3 mmol/L]) From Initiation of Treatment (Day 1) to End of Treatment (Day 7) (Percentage) - Median,Total Insulin Dose Per Day,,2019-02-25,COMPLETED,INTERVENTIONAL,['PHASE2']
889,NCT03700801,HbA1c,Rate of hypoglycemia,,2018-10-01,COMPLETED,INTERVENTIONAL,['PHASE4']
890,NCT06250049,Number of individuals with diabetes who have received individual education related to diabetic foot care.,"Number of diabetic individuals referred to podiatry, vascular surgery, and traumatology and orthopedics.",,2023-03-01,COMPLETED,INTERVENTIONAL,['NA']
891,NCT03030729,"Comparison between retinal measurements, done by the RTOCT device and a commercial OCT",,,2017-03-14,COMPLETED,OBSERVATIONAL,['NA']
892,NCT02354222,Change From Baseline in Percentage of Glycated Hemoglobin (HbA1c),Change From Baseline in 2-hour Postprandial Plasma Glucose Level,,2015-01,COMPLETED,INTERVENTIONAL,['PHASE3']
893,NCT04924673,HbA1c,Stress,,2020-06-17,COMPLETED,OBSERVATIONAL,['NA']
894,NCT02536820,glycosylated hemoglobin (HbAc1 %),Follow-up lost,,2015-09,UNKNOWN,INTERVENTIONAL,['PHASE3']
895,NCT04516018,area under the curve (AUC) of the glucose tolerance test,skeletal muscle GLUT4 translocation,Shivering activity,2020-09-01,COMPLETED,INTERVENTIONAL,['NA']
896,NCT03481361,The relationship between OSA and cardiac autonomic neuropathy (CAN) in patients with T1D.,The potential mechanisms for the relationship between OSA and diabetic-related complications,,2018-02-14,COMPLETED,OBSERVATIONAL,['NA']
897,NCT01253733,Health related self-efficacy,Quality of Life,,2009-10,COMPLETED,INTERVENTIONAL,['NA']
898,NCT05979779,"Percent change from baseline in liver fat, as assessed by magnetic resonance imaging liver proton density fat fraction (MRI-Liver PDFF) at 6 months (26 weeks)",Change from baseline in HbA1c at 6 months (26 weeks).,,2023-09-05,RECRUITING,INTERVENTIONAL,['PHASE2']
899,NCT06081387,Vitamin D,Food consumption and adherence to the Mediterranean diet,,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
900,NCT04631289,Incidence of AKI,,,2020-08-01,COMPLETED,OBSERVATIONAL,['NA']
901,NCT05180721,Change in A1C value,Health care engagement - negative,,2022-10-03,RECRUITING,INTERVENTIONAL,['NA']
902,NCT01633177,Incident type 2 diabetes,HbA1c levels,,2010-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
903,NCT01925248,Blood Glucose Level,Change in Urine glucose level,,2013-07,COMPLETED,INTERVENTIONAL,['NA']
904,NCT00657930,Efficacy (HbA1c),Insulin dose change,,2008-03,COMPLETED,OBSERVATIONAL,['NA']
905,NCT00623194,Insulin Detemir-insulin Aspart Cross-reacting Antibodies,Vital Signs: Pulse,,2008-02,COMPLETED,INTERVENTIONAL,['PHASE3']
906,NCT01903356,Incidence Rate of Adverse Events (AE),Change From Baseline in Fasting Plasma Glucose (FPG) After 24 Weeks of Treatment.,,2013-07-11,COMPLETED,OBSERVATIONAL,['NA']
907,NCT02721888,Effects of liraglutide on High Density Lipoprotein (HDL) apolipoprotein A1 (apoA1) fractional catabolic rate,Modification of visceral fat by Magnetic Resonance Imaging (MRI),,2012-07-10,TERMINATED,INTERVENTIONAL,['PHASE4']
908,NCT03394456,Glycemic control,longitudinal outcomes,Access to care,2018-01-13,COMPLETED,INTERVENTIONAL,['NA']
909,NCT06163482,Concentration of Glucose,Concentration of fatty acids,,2023-03-28,RECRUITING,OBSERVATIONAL,['NA']
910,NCT00206362,,,,2004-07,COMPLETED,OBSERVATIONAL,['NA']
911,NCT03881254,Percentage of index ulcers healed at 12 weeks,"Changes in peripheral neuropathy using Semmes Weinstein Monofilament ""10""point discrimination test",Visible Graft Take at each visit,2019-04-02,COMPLETED,INTERVENTIONAL,['NA']
912,NCT00417989,Change in A1c From Baseline to 52 Weeks,Quality of Life - Insulin Delivery System Rating Questionnaire (IDSRQ) for Subject Satisfaction With Type of Insulin Therapy,,2007-01,COMPLETED,INTERVENTIONAL,['NA']
913,NCT05367024,Change in glycated haemoglobin (HbA1c) after broccoli and courgette soup interventions,Treatment effects on whole blood gene expression from RNAseq,,2021-09-27,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
914,NCT00357890,Beta Cell Function,Percent Body Fat,,2005-12,COMPLETED,INTERVENTIONAL,['NA']
915,NCT00928057,Percent (%) Absolute Change in Fructosamine,Relative Injection Pain Score Assessed by Subject,"Reported Injection Site Leakage Events, by Pen Needle Type and Droplet Size",2009-06,COMPLETED,INTERVENTIONAL,['NA']
916,NCT02449603,Change of mean amplitude of glycemic excursions,Number of participants with clinical hypoglycemia,,2015-11,COMPLETED,INTERVENTIONAL,['PHASE4']
917,NCT00870818,"The Number of Participants Who Experience an Adverse Event, Serious Adverse Event or Adverse Event of Special Interest.",Human Anti-human Antibody (HAHA) Levels,,2009-02,TERMINATED,INTERVENTIONAL,['NA']
918,NCT02077803,Plasma concentration of metformin following the single dose of drug administration,Number of participants with adverse events as a measure of safety and tolerability,,2014-03,COMPLETED,INTERVENTIONAL,['PHASE1']
919,NCT03870971,measurement performance,,,2019-02-04,COMPLETED,INTERVENTIONAL,['NA']
920,NCT05990205,Change in weigth loss,Change in HbA1c,,2018-04-17,RECRUITING,INTERVENTIONAL,['PHASE2']
921,NCT01945060,Low Blood Glucose Index (LBGI),,,2013-09,COMPLETED,INTERVENTIONAL,['NA']
922,NCT03194100,serum METRNL concentration,,,2014-01-01,COMPLETED,OBSERVATIONAL,['NA']
923,NCT00111228,Hemoglobin A1c (HbA1c) - Change From Baseline to End of 3 Month Study Period,"Average Blood Glucose - Change From Baseline to End of 3 Month Study Period, Calculated as Average Blood Glucose at 3 Month - Average Blood Glucose at Baseline",,2004-10,COMPLETED,INTERVENTIONAL,['NA']
924,NCT05504785,Observe correlation of glucose control and post-operative adverse clinical events,Compare the CGM and Accu-Chek time-match glucose measurements,,2020-08-01,TERMINATED,INTERVENTIONAL,['NA']
925,NCT06285396,Motility index,Integrated area under response curve (AUC),,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
926,NCT06034574,%MARD lab phase,%MARD home phase,,2023-12,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
927,NCT01360697,Percentage of patients who attain 2 or more of the 'ABC'targets,Default rates at the end of the study,,2011-05,UNKNOWN,INTERVENTIONAL,['NA']
928,NCT05322369,: Prevalence of Periodontitis in diabetics of Egyptian outpatients of faculty of dentistry cairo university.,,,2022-05,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
929,NCT00595374,HbA1c,Incidence of hypoglycaemic episodes,,2003-12-02,COMPLETED,INTERVENTIONAL,['PHASE3']
930,NCT00678886,Change From Baseline in 2-hour Mixed Meal Stimulated C-peptide Area Under Curve [AUC] (Normalized for 120-minute Time Interval) at Month 12,"Percent Change From Baseline in CD3/TCR Modulation on CD4+ T Cells and CD8+ T Cells at Day 1, Day 4, Day 8",,2008-07-29,COMPLETED,INTERVENTIONAL,['PHASE3']
931,NCT05084079,The time to glycemic goal,Change of insulin dosage,,2021-11,UNKNOWN,INTERVENTIONAL,['PHASE4']
932,NCT05307120,Acceptability,Health-related quality of life,Health literacy,2022-01-13,RECRUITING,INTERVENTIONAL,['NA']
933,NCT05073237,change in beta cell function,change in serum lipidomics,,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
934,NCT03039569,Eat >= 5 Servings Fruit and Vegetables,Degree of Concern of CVD Event in Lifetime,,2017-02-28,COMPLETED,INTERVENTIONAL,['NA']
935,NCT00351676,"Improvement in proportion of quality indicators achieved, for target diseases as a most responsible or primary diagnosis, between groups.",Qualitative evaluation of the impact of the intervention via interviews with the participating pharmacists and physicians.,,2006-02,COMPLETED,INTERVENTIONAL,['PHASE4']
936,NCT03630263,Metabolic fuel utilization,Self reported satiety scores,,2019-05-01,COMPLETED,INTERVENTIONAL,['NA']
937,NCT01435642,Mean HbA1c (glycosylated haemoglobin),To quantify quality of life,,2011-09,COMPLETED,OBSERVATIONAL,['NA']
938,NCT00336349,VAS of pain,blood flow of feet,,2006-06,COMPLETED,INTERVENTIONAL,['NA']
939,NCT01825382,Patient Reported Outcomes as it relates to hypoglycemia fear and quality of life.,Improvement in glucose control and indices off glucose variability from SMBG and CGM data.,,2012-12,COMPLETED,INTERVENTIONAL,['PHASE4']
940,NCT03573102,decrease in proteinuria,,,2018-06-20,UNKNOWN,INTERVENTIONAL,['PHASE4']
941,NCT01551381,Platelet aggregation,Renal function,,2012-01,TERMINATED,INTERVENTIONAL,['PHASE2']
942,NCT01154933,Fasting Insulin,Intranuclear NFκB Binding Activity,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE2']
943,NCT03658655,Total daily insulin,HbAlc,,2018-06-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
944,NCT00634673,postprandial serum fatty acids,serum endothelin serum fibrinogen,,2006-06,COMPLETED,INTERVENTIONAL,['NA']
945,NCT03979352,Percentage of time spent in sensor glucose target range defined as between 3.9 and 7.8 mmol/L on 4- weeks automated AP on empagliflozin when compared to 4-weeks conventional pump therapy with placebo,Number of technical adverse events,,2019-08-01,COMPLETED,INTERVENTIONAL,['PHASE3']
946,NCT03955952,Composite of All-Cause Mortality and Cardiovascular Outcomes,Incidence of Atrial Fibrillation,Percentage Change in Triglycerides,2019-06-05,COMPLETED,OBSERVATIONAL,['NA']
947,NCT01284634,Percent Change From Baseline To The End Of Treatment (EOT) In Mean Liver Triglyceride Levels,Change From Baseline To The EOT In Mean Serum Triglyceride Levels,,2011-05-03,COMPLETED,INTERVENTIONAL,['PHASE2']
948,NCT05199636,Blood pressure,HbA1C,,2022-01-20,COMPLETED,INTERVENTIONAL,['NA']
949,NCT01300273,"monitor podocyte loss by detecting nephrin, podocin, and synaptopodin mRNA in urine particulates with quantitative reverse transcriptase-PCR.",,,2011-02,UNKNOWN,INTERVENTIONAL,['PHASE4']
950,NCT01056887,,,,2008-03,COMPLETED,OBSERVATIONAL,['NA']
951,NCT02711124,The level of preoperative HbA1c that will be a predictor of the higher prevalence of platelet resistance to the aspirin,"The level of HbA1c, that will represent the reliable predictor of platelet hyperreactivity and MAACE",,2014-02,UNKNOWN,OBSERVATIONAL,['NA']
952,NCT02610530,Reduction in glycated hemoglobin (HbA1c),Weight Control,,2015-12,UNKNOWN,OBSERVATIONAL,['NA']
953,NCT01968044,HbA1c change,Albuminuria,,2013-10,COMPLETED,INTERVENTIONAL,['PHASE3']
954,NCT02758522,Glycemic control,Differences in hospital stay days,,2013-10,COMPLETED,INTERVENTIONAL,['PHASE4']
955,NCT03530644,Performance evaluation,Safety by paucity of adverse events,,2018-08-28,COMPLETED,INTERVENTIONAL,['NA']
956,NCT00474630,Co-primary: Body Weight- Proportion of Subjects With ≥5% Decrease,Change in Food Craving Inventory Carbohydrates Subscale Score,,2007-05,COMPLETED,INTERVENTIONAL,['PHASE3']
957,NCT00980746,"Change From Baseline to Endpoint in Mean Pain, Scored Daily on a on an 11-point (0-10) Numeric Rating Pain Scale (NRPS), Where 0 = no Pain and 10 = Worst Possible Pain",,,2007-11,COMPLETED,INTERVENTIONAL,['PHASE2']
958,NCT01113658,Frequency of complaints about device use and operation,,,2010-03,WITHDRAWN,INTERVENTIONAL,['NA']
959,NCT02183415,Number of patients with abnormal changes in clinical laboratory parameters,Plasma glucose levels,,2005-08,COMPLETED,INTERVENTIONAL,['PHASE1']
960,NCT06182852,HbA1c,Body fat,,2024-01-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
961,NCT05754190,[General Study] Acute-Chronic Pain Transition Probability,[Sub-study] Treatment outcome prediction in chronic low back pain and failed back surgery syndrome patients,,2023-06-20,RECRUITING,OBSERVATIONAL,['NA']
962,NCT05283538,Statin prescription indication based on the patient's LDL cholesterol value and the LDL cholesterol target determined according to the cardiovascular risk level according to the ESC/ESA 2019 recommendations,,,2022-03-28,RECRUITING,INTERVENTIONAL,['NA']
963,NCT02678676,Percentage of Participants With First Occurrence of Macro-vascular Event or Death,Incidences With Malignancies,,2004-11,COMPLETED,OBSERVATIONAL,['NA']
964,NCT03377699,Last Planned Glycosylated Haemoglobin (HbA1c) Prior to Delivery,Neonatal Hypoglycaemic Episodes Defined as Plasma Glucose Below or Equal to 1.7 mmol/L (31 mg/dL) or Below or Equal to 2.5 mmol/L (45 mg/dl) (Yes/no),,2017-11-22,COMPLETED,INTERVENTIONAL,['PHASE3']
965,NCT00470262,Insulin Sensitivity,IMCL,,2007-01,COMPLETED,INTERVENTIONAL,['NA']
966,NCT05540249,Peri-operative Change from baseline HOMA-IR,High-sensitivity C-reactive protein (hs-CRP),Mechanical ventilation time,2022-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
967,NCT05901831,Change in Urinary albumin-to-creatinine ratio (UACR),Number of participants with Hyperkalaemia,,2024-02-26,RECRUITING,INTERVENTIONAL,['PHASE3']
968,NCT03662334,Part 3: Time to Achieve Plasma Glucose >90 mg/dL After Release of Hypoglycemic CSII Clamp,Part 3: Insulin Analog Serum Concentration as a Function of Time Following Termination of Insulin Infusion,,2013-10-03,COMPLETED,INTERVENTIONAL,['PHASE4']
969,NCT02227303,Weekly changes over 8 weeks as compared to baseline in quality of life as measured by the PROMIS® Global Health questionnaire (global physical health and global mental health subscale scores and social and overall health scores).,,Changes from baseline to 4 and 8 weeks in compliance with exercise goals as measured by active minutes (provided by the Fitbit Flex; requires subject input of data).,2014-08,COMPLETED,INTERVENTIONAL,['NA']
970,NCT01220804,Optical reflectivity as measured by optical coherence tomography,,,2010-11,COMPLETED,OBSERVATIONAL,['NA']
971,NCT04377321,colchicine for treatment of type diabetes patients,,,2019-10-10,COMPLETED,OBSERVATIONAL,['NA']
972,NCT03752567,Percent of Participants With Adherence to the PDTA,Economic Impact,,2018-11-01,COMPLETED,OBSERVATIONAL,['NA']
973,NCT04293731,insulin sensitivity (%S),cytokines levels,,2018-11-01,COMPLETED,INTERVENTIONAL,['NA']
974,NCT05987410,Six Minute Walking Test (6MWT) distance in meters,Peak Oxygen Uptake (VO2),,2023-12-01,RECRUITING,INTERVENTIONAL,['NA']
975,NCT00806858,"The change in subjects' satisfaction with insulin therapy, measured by change from visit 1 to visit 2 in subject treatment satisfaction scores on the DTSQ (Diabetes Treatment Satisfaction Questionnaire)",Number of clinical technical complaints,,2008-11,COMPLETED,OBSERVATIONAL,['NA']
976,NCT00703755,"The percentage of normalized patients at V4 (fasting glucose < 6.1 mmol/L, TG < 1.69 mmol/L and HDL-C >= 1.03 mmol/L in males and >= 1.29 mmol/L in females)",Blood pressure.,,2003-03,COMPLETED,INTERVENTIONAL,['PHASE2']
977,NCT00575471,Change in HbA1c from baseline for rivoglitazone compared to placebo,Change in Fasting Plasma Glucose from baseline for rivoglitazone HCl compared to placebo,,2007-07,COMPLETED,INTERVENTIONAL,['PHASE2']
978,NCT02001051,Count of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0),Correlation Between Dermal Thickness and Patients With Subclinical Hypercortisolism,,2013-11-27,TERMINATED,INTERVENTIONAL,['PHASE2']
979,NCT02309502,"prevention on the developing of proliferative diabetic retinopathy (assessed with slitlamp, color fundus, and fluorangiography)",Pain assessment (questionnaire),,2012-10,WITHDRAWN,INTERVENTIONAL,['NA']
980,NCT01181674,Normoglycemia on Therapy,Number of Participants With Severe Hypoglycemic Episodes,,2011-01,COMPLETED,INTERVENTIONAL,['PHASE4']
981,NCT03165084,HbA1c,eHealth literacy,,2017-05-05,UNKNOWN,INTERVENTIONAL,['NA']
982,NCT04655690,Number of adverse events (AEs),"t½, NNC0471-0119: Terminal half-life for NNC0471-0119",,2020-11-09,COMPLETED,INTERVENTIONAL,['PHASE1']
983,NCT02565940,dermal sample,,,2014-12,UNKNOWN,OBSERVATIONAL,['NA']
984,NCT04009980,Changes of Retinal sensitivity and contrast sensitivity function after topical citicoline use in patients with diabetic retinopathy,Morphological retinal changes after topical citicoline use in patients with diabetic retinopathy,,2015-09-23,COMPLETED,INTERVENTIONAL,['NA']
985,NCT06236750,Safety Endpoint: Incidence of Adverse Events,,Safety Endpoint: Incidence of Device Deficiencies,2023-08-04,RECRUITING,INTERVENTIONAL,['NA']
986,NCT05754775,Remission,Weight loss,,2023-06-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
987,NCT05153070,Treg variation,incidence of adverse events at month 24,,2022-09-21,RECRUITING,INTERVENTIONAL,['PHASE2']
988,NCT02332824,Change From End of Pre-treatment Period (Week 0) in Log-transformed Urine Albumin/Creatinine Ratio (UACR) at the End of Treatment Period (Week 12),Progression Rate From Early-Stage Nephropathy (Stage 2) to Overt Nephropathy (Stage 3) During the Treatment Period (Week 12),Number of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE),2014-10-16,COMPLETED,INTERVENTIONAL,['PHASE2']
989,NCT00968006,Change in circulating CD34+KDR+ endothelial progenitor cells,Change in SDF-1alpha concentrations,,2009-10,COMPLETED,INTERVENTIONAL,['PHASE4']
990,NCT03630458,Glycemic response,Appetitive response,,2018-06-11,COMPLETED,INTERVENTIONAL,['NA']
991,NCT01574508,Glycated albumin levels,Number of participants with adverse events,,2011-12,UNKNOWN,INTERVENTIONAL,['PHASE4']
992,NCT02247596,Change from baseline in Resting Energy Expenditure via indirect calorimetry at 2 weeks,Change from baseline in Glycated hemoglobin at 2 weeks,,2009-07,COMPLETED,INTERVENTIONAL,['PHASE2']
993,NCT02548299,Investigator-Designed Cooking Skills Questionnaire - Change from Baseline to 6 months,"Dietary Fiber, Fruit and Vegetable Consumption Questionnaire - Change from Baseline to 6 months",,2015-05,COMPLETED,INTERVENTIONAL,['NA']
994,NCT02858830,Lower body muscle strength measured by knee extension,,,2016-08,COMPLETED,INTERVENTIONAL,['NA']
995,NCT02824874,"Css,max of Lobeglitazone","swing[(Css,max-Css,min)/Css,min] of Lobeglitazone",,2016-04,COMPLETED,INTERVENTIONAL,['PHASE1']
996,NCT00666094,HbA1C,"body composition, C-peptid, BP, Cholesterol (LDL, HDL), Triglycerides",,2008-08,COMPLETED,INTERVENTIONAL,['NA']
997,NCT03388697,Gestational Diabetes,NICU admission,,2017-12-15,COMPLETED,OBSERVATIONAL,['NA']
998,NCT04304261,Changes of cognitive function assessed by cognitive function scale after 12 weeks,,,2020-04-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
999,NCT05326958,average weighted corneal nerve fiber thickness (CNFTh),,,2016-07,COMPLETED,INTERVENTIONAL,['NA']
1000,NCT01025934,,,,na,COMPLETED,INTERVENTIONAL,['PHASE4']
1001,NCT02122926,Cardiac medication adherence,Hospital Readmissions,,2011-12,COMPLETED,INTERVENTIONAL,['NA']
1002,NCT05507892,Kidney Transcript Changes,Renal Plasma Flow (RPF),,2022-10-10,RECRUITING,INTERVENTIONAL,['PHASE2']
1003,NCT05240274,Diagnosis of post-transplant diabetes,diagnosis of PTDM in OGTT screen fails,,2019-01-25,COMPLETED,INTERVENTIONAL,['PHASE2']
1004,NCT02169167,Wound healing,Eradication of bacteria,Wound healing and infection,2014-06,COMPLETED,INTERVENTIONAL,['NA']
1005,NCT01631929,Time to Achieve Patient Stabilization,,,2012-08,TERMINATED,INTERVENTIONAL,['NA']
1006,NCT00721617,Change in Diastolic Blood Pressure From Baseline to 8 Hours,C-peptides Levels for Intralipid/Dextrose Infusion,,2009-04,COMPLETED,INTERVENTIONAL,['NA']
1007,NCT00736879,Adjusted Mean Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24 Last Observation Carried Forward (LOCF) - All Randomized Participants,Number of Participants With Marked Laboratory Abnormalities in 24 Week Double Blind Treatment Period - Treated Participants,,2008-09-22,COMPLETED,INTERVENTIONAL,['PHASE3']
1008,NCT05260281,does AI augment diagnostic performance of resident,does physical consultation augment diagnostic performance of AI,,2022-03-01,UNKNOWN,OBSERVATIONAL,['NA']
1009,NCT04285151,Visual acuity improvement,,,2015-01,COMPLETED,INTERVENTIONAL,['NA']
1010,NCT02470260,Cognition,Depressive symptoms,,2012-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
1011,NCT01947075,"Proportion of patients with each disease among all febrile patients, overall and stratified by HIV status","Proportion of febrile patients with acute respiratory infection infected with a certain respiratory pathogen, compared to the proportion of healthy controls infected with the same pathogen.",Strength of association between each febrile disease and diabetes mellitus and between acute respiratory infections and indoor air pollution,2013-07,COMPLETED,OBSERVATIONAL,['NA']
1012,NCT03998436,"Proportion of Subjects Achieving Target Ulcer Closure Within 12-week Treatment Phase, as Assessed by Blinded Investigator","Proportion of Subjects Achieving Target Ulcer Closure Till End of Study, as Assessed by the Blinded Investigator.",Proportion of Subjects With Treatment Emergent Adverse Events (TEAEs),2018-12-26,COMPLETED,INTERVENTIONAL,['PHASE3']
1013,NCT03815006,HbA1c Level at 24 Weeks,Glucose Monitoring Satisfaction Survey Score,,2020-01-09,COMPLETED,INTERVENTIONAL,['NA']
1014,NCT05562063,Changes in Left Ventricular mass in CMRI,Changes in The Kansas City Cardiomyopathy Questionnaire (KCCQ),,2022-10-26,RECRUITING,INTERVENTIONAL,['PHASE4']
1015,NCT04255433,"Time to First Occurrence of Death from Cardiovascular (CV) Causes, Myocardial Infarction (MI), or Stroke (MACE-3)",Cumulative Number of Primary Composite Events of CV Death and Total (First and Recurrent) MI and/or Stroke,,2020-05-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
1016,NCT04545567,Percentage of Time From Dinner Time Until Midnight With Blood Glucose in Range 70-180 mg/dL in the Unannounced Meal,Units of Insulin Injected Outside of the Study Dinner Sessions,,2020-12-16,COMPLETED,INTERVENTIONAL,['NA']
1017,NCT03196895,change in medication,change in psychological functioning (attitude towards glucose monitoring questionnaire),,2017-06-28,COMPLETED,INTERVENTIONAL,['NA']
1018,NCT00883558,Postprandial Glucose Excursion,Number of Participants With Hypoglycemic Events,,2009-05,COMPLETED,INTERVENTIONAL,['PHASE2']
1019,NCT04481737,Change in average fidelity scores,Change from baseline level of cardiovascular disease risk to 3-months and 6-month follow-up,Change from baseline patient satisfaction to 3-months and 6-month follow-up,2021-02-01,COMPLETED,INTERVENTIONAL,['NA']
1020,NCT04658264,Reduction in 2 hours post meal blood sugar,,,2021-01-15,UNKNOWN,INTERVENTIONAL,['PHASE1']
1021,NCT03394859,Impact of return of clinically actionable results on patient treatment,,,2015-09-01,COMPLETED,OBSERVATIONAL,['NA']
1022,NCT05578352,Insulin autoimmune antibody,T cell,,2022-08-05,RECRUITING,INTERVENTIONAL,['NA']
1023,NCT03942081,Foot Ulcer Size,Quality of Photos: 1 - 5 scale,,2017-09-05,RECRUITING,INTERVENTIONAL,['NA']
1024,NCT03510000,Comparison of mean glucose levels between AP with empagliflozin with simple meal announcement strategy and AP without empagliflozin with carb-counting.,Morning capillary ketone concentration,,2018-05-15,COMPLETED,INTERVENTIONAL,['NA']
1025,NCT00563875,Platelet aggregation,,,2007-11,COMPLETED,INTERVENTIONAL,['NA']
1026,NCT02922296,Metabolic status of adult SCD subjects,Genetic and genomic predictors in SCD subjects,,2015-05-01,RECRUITING,OBSERVATIONAL,['NA']
1027,NCT01125215,"Pain relief from pain score reduction, using visual analog scale (VAS)",,,2009-09,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
1028,NCT05159570,Differences in lipolysis rate,Changes in signaling in muscle and adipose tissue,,2023-02-01,COMPLETED,INTERVENTIONAL,['NA']
1029,NCT06161701,Incidence of steroid diabetes in nephrotic patients after glucocorticoid use,"Cumulative use time of glucocorticoid, cumulative dose of glucocorticoid and drugs that may affect blood glucose in combination with steroid diabetes",,2024-01-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
1030,NCT01363791,Non-Alcoholic Fatty Liver (NAFL) Analysis,,,2009-05,UNKNOWN,OBSERVATIONAL,['NA']
1031,NCT01402362,Percent of patients with Diabetes Mellitus or impaired glucose tolerance,Prevalence of hypertension and hyperlipidemia,,2011-09,UNKNOWN,OBSERVATIONAL,['NA']
1032,NCT01708694,Insulin Sensitivity and Secretion,Hunger,,2012-08,COMPLETED,INTERVENTIONAL,['NA']
1033,NCT01268267,Numbers of Fingerstick Blood Glucose (BG) Results Within +/- 5 to 20mg/dL (<75 mg/dL) or Within +/- 5% to 20% (>=75 mg/dL) of Laboratory Glucose Method,Numbers of Forearm Blood Glucose (BG) Results Within +/- 5 to 20 mg/dL (<75 mg/dL) or Within +/- 5% to 20% (>=75 mg/dL) of Laboratory Glucose Method,,2010-12,COMPLETED,INTERVENTIONAL,['NA']
1034,NCT04653545,What is the prevalence of glucose intolerance (diabetes and IGT) in patients presenting to an acute medical emergency department?,Diabetes control in those with known diabetes,,2022-02-01,RECRUITING,OBSERVATIONAL,['NA']
1035,NCT02384265,Change from Baseline in Hemoglobin A1c at 12-months,Change from Baseline in Systolic and Diastolic Blood Pressure at 12-months,,2012-06-21,COMPLETED,INTERVENTIONAL,['NA']
1036,NCT05172401,Frequency of adverse device effects and frequency of serious adverse device effects,,,2022-09-15,WITHDRAWN,INTERVENTIONAL,['NA']
1037,NCT01804478,Muscle Blood Flow,Skin Blood Flow,,2005-05,COMPLETED,INTERVENTIONAL,['NA']
1038,NCT05560412,Change in GLP-1 AUC,Insulin Levels,Blood Pressure,2023-01-10,COMPLETED,INTERVENTIONAL,['NA']
1039,NCT00327015,"Change From Baseline in A1C at Week 24, Saxagliptin Plus Metformin Versus Metformin Monotherapy","Percentage of Participants Requiring Rescue or Discontinuation at Week 24, Saxagliptin Plus Metformin Versus Metformin Monotherapy",,2006-05,COMPLETED,INTERVENTIONAL,['PHASE3']
1040,NCT03820635,correlation coefficient between serum level of osteoponton and the rate of different aspects of vascular affection as discussed previously,,,2019-03-01,UNKNOWN,OBSERVATIONAL,['NA']
1041,NCT02920801,flow-mediated dilation,renal function test,,2014-12,COMPLETED,INTERVENTIONAL,['PHASE4']
1042,NCT03170544,GIRmax After a Single Dose Administration of Subcutaneous MK-1092 or Glargine to Adult Participants With Type 1 Diabetes Mellitus (T1DM) (Part 3),Time to Reach a 50% Decrease In Plasma Insulin Glargine Concentration (t1/2) Part 4,,2017-08-16,COMPLETED,INTERVENTIONAL,['PHASE1']
1043,NCT05074849,A Change in Adherence to prescribed footwear is being assessed,A change in Perception of Benefits is being assessed,A change in Acceptability and Ease of Use is being assessed,2024-10-20,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1044,NCT04499287,postprandial insulinemia,postprandial oxidative stress,,2014-09-17,COMPLETED,INTERVENTIONAL,['NA']
1045,NCT03678831,Expression levels in femoral spinal adipocytes of mRNAs of 18 genes compared to those of adipocytes isolated from the subcutaneous adipose tissue in the same patient,the intra patients difference of the expression level of medullary adipocytes mRNA compared to that of subcutaneous adipocytes according to presence or absence of metabolic syndrome,,2020-06-30,RECRUITING,OBSERVATIONAL,['NA']
1046,NCT02207712,The number of intravitreal injections of ranibizumab required by each study eye at 48 weeks,Adverse events rates,Changes in sleep pattern.,2014-11,TERMINATED,INTERVENTIONAL,['NA']
1047,NCT02288273,Change in 24-hour Mean Weighted Glucose,Change in HbA1c From Baseline to Day 22 and Baseline to Day 70,,2014-12,COMPLETED,INTERVENTIONAL,['PHASE4']
1048,NCT03724526,"Combined changes in HbA1C, SBP and LDL-cholesterol levels, simultaneous modeled using a scaled marginal model.",Change in ACC/AHA Risk Score of CVD,,2018-11-01,COMPLETED,INTERVENTIONAL,['NA']
1049,NCT00553592,Pain and Safety,"Clinical Global Impression of Improvement, McGill Pain Questionnaire, Amount of Rescue Medication Used for Pain, Quality of Life Survey (SF-36), Patient Global Impression of Change",,2007-09,UNKNOWN,INTERVENTIONAL,['PHASE2']
1050,NCT01176201,"Metabolic profiling and identification of 14C-labeled parent compound and metabolites of SLV337 in plasma, urine and feces (Part 2)","Safety and tolerability assessments including adverse events, clinical laboratory tests, ECG and vital signs (Part 1 and Part 2)",,2010-07,COMPLETED,INTERVENTIONAL,['PHASE1']
1051,NCT00547274,,,,2003-07,TERMINATED,INTERVENTIONAL,['PHASE3']
1052,NCT01999361,allosensitization after complete islet graft loss,,,2009-01,RECRUITING,INTERVENTIONAL,['NA']
1053,NCT01128894,Mean Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 32,Mean Change From Baseline in Body Weight at Week 32,,2010-05,COMPLETED,INTERVENTIONAL,['PHASE3']
1054,NCT01381926,Determine Changes in Bone Turnover Markers by Tartrate-Resistant Acid Phosphatase 5b (TRACP5b) During the Treatment With a GLP-1 Receptor Agonist (Exenatide) Compared to Placebo in Patients With T2DM.,,,2011-02,TERMINATED,INTERVENTIONAL,['PHASE4']
1055,NCT03434288,Time for identification of bacteria responsible for foot osteomyelitis,Time for identification of sensitivity/resistance to antibiotics of the bacteria responsible for foot osteomyelitis,,2018-02-08,COMPLETED,OBSERVATIONAL,['NA']
1056,NCT02388815,Point Accuracy,,,2015-03,COMPLETED,INTERVENTIONAL,['NA']
1057,NCT04307875,Prevalence of hypertension,CAPS-5,,2021-10-01,UNKNOWN,OBSERVATIONAL,['NA']
1058,NCT03840850,"Feasibility of implementing the intervention in primary care: Binary outcome (feasible / not feasible), as judged by the investigators",Change in self-management behaviour,Rate of missing data,2017-09-15,COMPLETED,INTERVENTIONAL,['NA']
1059,NCT01128374,HbA1c percentage,gene polymorphisms,,2010-06,COMPLETED,INTERVENTIONAL,['NA']
1060,NCT01813708,disease control,Self-Efficacy,,2004-11,COMPLETED,INTERVENTIONAL,['NA']
1061,NCT04939038,Number of patients with delayed diabetic foot ulcer healing,Number of patients with all-cause death,Number of serious adverse events,2022-01-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
1062,NCT03354286,Time spent in blood glucose range,Health care utilization,,2017-11-07,COMPLETED,INTERVENTIONAL,['NA']
1063,NCT05378282,Differential Expression in blood and urine of diabetic patiens with and without diabetic nephropathy assesed by RNA seq,"Molecular data, Whole messenger RNA sequencing",,2021-09-03,COMPLETED,OBSERVATIONAL,['NA']
1064,NCT00298740,Glucose Control as Assessed by Mean Glucose Levels,,,2003-02,COMPLETED,INTERVENTIONAL,['NA']
1065,NCT03676465,Family Communication Inventory Questionnaire,Change of Insulin Parameters,,2019-01-18,COMPLETED,INTERVENTIONAL,['NA']
1066,NCT05297045,Change in HbA1c from baseline to end of treatment in the modified intent-to-treat population,"Proportion of patients who report AEs of Special Interest (AESI) including GI intolerability, hypoglycemia, drug hypersensitivity reactions, acute pancreatitis, thyroid C-cell hyperplasia and C-cell neoplasms, and cardiovascular (CV) events",,2022-03-29,TERMINATED,INTERVENTIONAL,['PHASE2']
1067,NCT01026688,Patient is receiving a statin,Change in treatment recommended following an LDL-cholesterol level above 2.0 mmol/L,,2010-06,COMPLETED,INTERVENTIONAL,['NA']
1068,NCT05560568,Sleep efficiency,,,2023-01-20,RECRUITING,OBSERVATIONAL,['NA']
1069,NCT02792400,Difference in postprandial glucose excursions,Resting energy expenditure,,2016-05,COMPLETED,INTERVENTIONAL,['NA']
1070,NCT00970528,Glycosylated hemoglobin (HbA1c),High Sensitivity C-reactive protein (hs-CRP),,2009-11,COMPLETED,INTERVENTIONAL,['PHASE4']
1071,NCT01868698,Doppler ultrasound,,,2009-01,COMPLETED,INTERVENTIONAL,['NA']
1072,NCT02310724,cardiovascular risk lipid values,healthcare usage,,2014-03-01,COMPLETED,OBSERVATIONAL,['NA']
1073,NCT00579813,Changes in Fat Inflammation Following Pioglitazone,,,2005-04,COMPLETED,INTERVENTIONAL,['PHASE4']
1074,NCT01709929,Incidence of serious adverse drug reactions (SADRs) including major hypoglycaemic events,Treatment satisfaction as assessed by Insulin Treatment Satisfaction Questionnaire (ITSQ-22),,2005-10,COMPLETED,INTERVENTIONAL,['PHASE3']
1075,NCT02358408,Evaluation of System Accuracy according to ISO 15197 (see description),,,2015-01,COMPLETED,INTERVENTIONAL,['NA']
1076,NCT05523362,Change in glucose variability as measured by continuous glucose monitor,Glucose Monitoring Satisfaction Survey,,2022-01-15,COMPLETED,INTERVENTIONAL,['NA']
1077,NCT04227379,HbA1c percent time in control,blood pressure control,,2023-01-30,RECRUITING,INTERVENTIONAL,['NA']
1078,NCT05324488,Biomarker identification,Biomarker validation,,2015-10-21,RECRUITING,OBSERVATIONAL,['NA']
1079,NCT00753142,First-Phase Insulin Release (FPIR),Number of Participants With Beta-cell Failure,,2004-03,COMPLETED,INTERVENTIONAL,['NA']
1080,NCT01336751,Change from baseline in hemoglobin A1c (HbA1c) levels at week 24,Number and severity of hypoglycemic events and time of occurrence of hypoglycemic events,,2001-07,COMPLETED,INTERVENTIONAL,['PHASE3']
1081,NCT00798486,Number of A1C Results Either Equal To Or Within +/- 13.5% of the Laboratory Method (ACCURACY),Number of Participants Who Provided These Ratings For Overall Testing Experience With A1C Test Kit,,2008-11,COMPLETED,INTERVENTIONAL,['NA']
1082,NCT04412746,Diabetes-related factors risk,,,2020-04-01,UNKNOWN,OBSERVATIONAL,['NA']
1083,NCT02909725,Change in Time Spent Sedentary,Maternal Insulin Resistance,Maternal Body Weight Change,2016-02,UNKNOWN,INTERVENTIONAL,['NA']
1084,NCT00598013,Insulin Resistance and Insulin Secretion,carotid intima-media thickness,,2004-11,COMPLETED,INTERVENTIONAL,['NA']
1085,NCT02664233,Change in weight measures from baseline to 3 months,Usability of the connected interface technology as indicated by a System Usability Scale,,2015-06,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
1086,NCT03200795,Cholesterol level Change is being assessed,Quality of life Change is being assessed,,2018-03-15,UNKNOWN,INTERVENTIONAL,['NA']
1087,NCT04283942,Change of liver fat content in %,Change of lipid profile: free fatty acid,Change of brain functional MRI,2020-07-30,COMPLETED,INTERVENTIONAL,['NA']
1088,NCT00214825,Coronary microvascular function assessed by myocardial perfusion reserve measured by MRI,Proteinuria,,2003-08,COMPLETED,INTERVENTIONAL,['NA']
1089,NCT02390050,Change in HbA1c After 12 Weeks of Treatment,Change in HbA1c Over Time,,2015-05-12,COMPLETED,INTERVENTIONAL,['PHASE2']
1090,NCT05041816,Changes in NIS,,,2021-09-01,WITHDRAWN,INTERVENTIONAL,['NA']
1091,NCT02585622,Number and severity of all pre-specified infusion-associated events and the overall number and frequency of adverse events.,Cost-effectiveness of cell therapy,,2017-12-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1092,NCT04721509,change in HbA1c of experimental group,No change in HbA1c of control group,,2021-02,UNKNOWN,INTERVENTIONAL,['NA']
1093,NCT03111004,Change in length of the hospital stay,Carer perception of service utility according to eCCIS (selected questions),,2014-09-01,COMPLETED,OBSERVATIONAL,['NA']
1094,NCT05870293,Diabetes potentiation scale,,,2023-05-01,COMPLETED,INTERVENTIONAL,['NA']
1095,NCT00918801,,,,2007-04,COMPLETED,OBSERVATIONAL,['NA']
1096,NCT01766245,"Cmax, the maximum plasma semaglutide concentration",Hypoglycaemic episodes,,2012-12,COMPLETED,INTERVENTIONAL,['PHASE1']
1097,NCT03798080,Change in HbA1c,Immunogenicity (antibody variables),,2019-02-19,COMPLETED,INTERVENTIONAL,['PHASE3']
1098,NCT05884814,Change in interstitial glucose time in range,Change in interstitial glucose time in hyperglycaemia,,2023-07-01,RECRUITING,INTERVENTIONAL,['NA']
1099,NCT06097065,Number and types of proteins/peptides differential characteristic peaks,ROC curve and area under curve AUC of clinical predictive diagnostic model,,2022-05-20,RECRUITING,OBSERVATIONAL,['NA']
1100,NCT05565716,Feasibility: Acceptability of SMART-HABITS-4-Health,Reach,,2023-08-21,RECRUITING,INTERVENTIONAL,['NA']
1101,NCT00529399,The Primary Outcome is the Area Under the Stimulated C-peptide Curve (AUC) at the One Year Visit,,,2009-02,COMPLETED,INTERVENTIONAL,['PHASE2']
1102,NCT01210001,HbA1c Change From Baseline for Pio and Met Background Medication Patients,Body Weight Change From Baseline,Hypoglycaemic Events,2010-09,COMPLETED,INTERVENTIONAL,['PHASE3']
1103,NCT00039013,Change in HbA1c (glycosylated hemoglobin) from baseline to study termination (Week 30),Change in body weight from Baseline to each intermediate visit and Week 30,,2002-03,COMPLETED,INTERVENTIONAL,['PHASE3']
1104,NCT04962139,The proportion of subjects with complete closure of Target Ulcer,The proportion of patients with Target Ulcer recurrence,,2021-08-10,RECRUITING,INTERVENTIONAL,['PHASE3']
1105,NCT04369001,Change of Depression Scores,Change of Diabetes Quality of Life,,2020-12,WITHDRAWN,INTERVENTIONAL,['NA']
1106,NCT02997319,Disposition index,Plasma Melatonin,Depression,2017-02-24,COMPLETED,OBSERVATIONAL,['NA']
1107,NCT04503239,Collect Device Data - Activity Tracker,Collect Current Subject Lifestyle and Treatment Regimen,,2020-07-22,UNKNOWN,OBSERVATIONAL,['NA']
1108,NCT05704075,Wound Size,Identification of regulatory cytokines for peripheral blood mesenchymal stem cells (PB-MSCs) mobilization,,2023-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1109,NCT05659147,Frequency of genetic mutations in patients progressing to diabetes vs. those not,,,2023-01-18,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE4']
1110,NCT02099513,"Perception of perceived usefulness, attitudes, and experiences",,,2014-03,COMPLETED,INTERVENTIONAL,['NA']
1111,NCT00814190,The primary endpoint is the A1c level or the change in A1c level.,"The secondary endpoints include severe hypoglycemia defined as requiring external aid, hospital admissions for any CVD related intervention, and adverse events such as unplanned hospitalizations for any cause that last more than 24 hours.",,2009-01,COMPLETED,INTERVENTIONAL,['NA']
1112,NCT01468376,Glucose and insulin response to the Oral Glucose Tolerance Test after administration of GLU-xx formulations,Safety and tolerability of GLU-xx formulations,,2011-02,TERMINATED,INTERVENTIONAL,['PHASE1']
1113,NCT01488383,change in capillary blood glucose levels,"Adverse reactions of treatments (nausea, diarrhea, vomiting, allergic signs)",,2013-09,WITHDRAWN,INTERVENTIONAL,['NA']
1114,NCT03857191,Difference in OSA risk before and after nutritional and psychocomportemental rehabilitation,To assess the effect of Weight loss on OSA,,2019-03-22,COMPLETED,OBSERVATIONAL,['NA']
1115,NCT01580904,Fasting Glycemia,LDL Cholesterol,,2009-09,COMPLETED,INTERVENTIONAL,['NA']
1116,NCT00160160,Blood pressure reduction,Comparison of responder rates,,2004-10,COMPLETED,INTERVENTIONAL,['NA']
1117,NCT01646320,Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24,Percentage of Subjects Achieving a Therapeutic Glycemic Response (Hemoglobin A1c [HbA1C]) <7.0% at Week 24 (Last Observation Carried Forward [LOCF]),,2012-09,COMPLETED,INTERVENTIONAL,['PHASE3']
1118,NCT03387683,Adjusted Mean Change From Baseline in Global Longitudinal Strain of the Left Ventricle (GLSLV) at End of Treatment.,Adjusted Mean Change From Baseline in Myocardial Efficiency at End of Treatment.,,2018-02-28,COMPLETED,INTERVENTIONAL,['PHASE4']
1119,NCT01606475,,,,na,AVAILABLE,EXPANDED_ACCESS,['NA']
1120,NCT04045938,HbA1c,Inflammation - C-reactive protein (CRP),,2019-08-01,UNKNOWN,OBSERVATIONAL,['NA']
1121,NCT03683784,Prevalence of diabetes in Fayoum,,,2017-01-01,COMPLETED,OBSERVATIONAL,['NA']
1122,NCT02279524,Change From Baseline in Mean Liver Fat,Change From Baseline to Week 52/Termination in ALT,Change From Baseline to Termination/Early Termination in HbA1C,2015-04-29,COMPLETED,INTERVENTIONAL,['PHASE2']
1123,NCT05183191,Diagnostic accuracy of the hypoglycemia warning system using in-vehicle data to detect hypoglycemia (blood glucose <3.9mmol/L) quantified as the area under the receiver operator characteristics curve (AUC ROC).,Technology acceptance of the hypoglycemia warning system,,2021-11-29,COMPLETED,INTERVENTIONAL,['NA']
1124,NCT01195259,Time to first occurrence of a serious adverse event of malignancy (excluding non-melanomatous skin cancers),,,2009-10,COMPLETED,OBSERVATIONAL,['NA']
1125,NCT04373265,Dose-limiting Toxicity (DLT),Plasma Concentrations of Relacorilant in Combination with Pembrolizumab in Patients with Advanced ACC and Glucocorticoid Excess,,2020-09-30,COMPLETED,INTERVENTIONAL,['PHASE1']
1126,NCT03527368,Weight Change,Glycated albumin,,2018-09-24,COMPLETED,INTERVENTIONAL,['NA']
1127,NCT00044746,,,,2000-10,COMPLETED,INTERVENTIONAL,['PHASE4']
1128,NCT01498939,Area under the insulin detemir concentration curve,Adverse events,,2007-08,COMPLETED,INTERVENTIONAL,['PHASE1']
1129,NCT04916457,The incidence of developing into diabetic foot among the groups,,,2020-12-18,RECRUITING,OBSERVATIONAL,['NA']
1130,NCT02947568,Association of genetical factors with NFS and HSI,Association of pathological tyrosine isoforms with hepatic setatosis indices,,2016-03,UNKNOWN,OBSERVATIONAL,['NA']
1131,NCT04801199,Change in HbA1c level,Frequency of adverse events,,2020-01-26,COMPLETED,INTERVENTIONAL,['PHASE3']
1132,NCT01374594,GLP-1 secretion,,,2011-06,COMPLETED,OBSERVATIONAL,['NA']
1133,NCT01220089,weight change,cost effectiveness,,2010-10,COMPLETED,INTERVENTIONAL,['NA']
1134,NCT01828931,HbA1c levels,,,2012-12,COMPLETED,INTERVENTIONAL,['NA']
1135,NCT01544309,Change in HbA1c Level,"Change From Baseline in 1,5-AG Level",,2012-03,COMPLETED,INTERVENTIONAL,['NA']
1136,NCT01867502,Change in Glycemic variability,"Change in Hemodynamic response to exercise: Cardiac output (Q), Stroke Volume (SV) and blood pressure (BP)",Change in Oxidative stress (F2 isoprostane 8-iso prostaglandin F2α);,2014-04,UNKNOWN,INTERVENTIONAL,['PHASE4']
1137,NCT03641170,Blood glucose,,,2018-04-03,COMPLETED,INTERVENTIONAL,['NA']
1138,NCT01977833,"Postprandial GLP-1 plasma levels, after breakfast,lunch and dinner meal test","Postprandial Plasma Glucose levels after breakfast, lunch and dinner meal challenge","Postprandial Insulin plasma levels, after breakfast,lunch and dinner meal test",2013-10,UNKNOWN,INTERVENTIONAL,['NA']
1139,NCT01257776,"Major adverse event (death, target limb amputation)",University of Texas Classification at target limb,,2010-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1140,NCT02097615,Unlike the ultimate determinations for the initial surface of the ulcer obtained in square millimeters.,,,2014-05,COMPLETED,INTERVENTIONAL,['PHASE4']
1141,NCT06128265,Change in glucose homeostasis measured by Continuous Glucose Monitor (CGM),"Weight in kg, measured from screening through study completion.",,2024-01-03,RECRUITING,INTERVENTIONAL,['NA']
1142,NCT05477017,Variation in HbA1c values (% -point),Evaluation of the main side effects and the withdrawal rate,,2022-09,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
1143,NCT00252525,The primary outcome measures are cardiovascular morbidity and mortality.,,,2007-06,COMPLETED,OBSERVATIONAL,['NA']
1144,NCT01934660,Our primary outcome of interest is vascular inflammation measured by standard uptake values from PET/CT and PET/MRI imaging with FDG,"As a tertiary analysis, we will add novel biomarkers to the above models including HDL efflux, HOMA-IR and inflammatory mediators to understand the association of each biomarker on vascular disease markers",,2013-12-02,COMPLETED,OBSERVATIONAL,['NA']
1145,NCT02510521,insulin sensitivity measured by the reference euglycemic hyperinsulinemic clamp technique,,,2012-02,COMPLETED,INTERVENTIONAL,['NA']
1146,NCT00462436,Primary Outcome: Reduction of total and LDL cholesterol,"Improved markers of glycemic control - fructosamine, HOMA",,2007-02,COMPLETED,INTERVENTIONAL,['PHASE2']
1147,NCT01307371,Number of patient death during the follow up period,six-min walk distance (6MWD),,2007-03,UNKNOWN,OBSERVATIONAL,['NA']
1148,NCT06333665,Disease-free survival,perioperative 90-day mortality,,2024-02-20,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
1149,NCT01895179,Change in Glucose Tolerance,Change in Inflammation and Metabolic Markers,,2013-07,COMPLETED,INTERVENTIONAL,['NA']
1150,NCT04810026,Change in mean glucose time in range from baseline at Week 16,Change in self-reported blood pressure,Change from baseline in abbreviated Medical Outcomes Study Sleep Scale,2021-05-03,COMPLETED,INTERVENTIONAL,['NA']
1151,NCT00723411,Meal stimulated C-peptide (area under the curve),Insulin Dose,,2008-07,TERMINATED,INTERVENTIONAL,['PHASE3']
1152,NCT01854593,Reoperation,Silicon Oil Tamponade,,2012-05,COMPLETED,INTERVENTIONAL,['PHASE4']
1153,NCT05687474,Feasibility - reliability,To improve the detection technique for disease related mutations that are not detected in classical screening by improving the classification of unspecified variants.,,2022-09-01,RECRUITING,OBSERVATIONAL,['NA']
1154,NCT00845897,Plantar Flexor Muscle Strength,Barefoot Plantar Pressure,,2005-03,COMPLETED,INTERVENTIONAL,['NA']
1155,NCT00842556,Exposure to the investigational drug will be measured to compare with and without the co-administration of other drugs,To assess the safety and tolerability in healthy subjects,,2009-03,COMPLETED,INTERVENTIONAL,['PHASE1']
1156,NCT01766570,Change in cardiometabolic statute from baseline to the end of intervention.,Change in anthropometric measurements from baseline to the end of the intervention.,,2012-03,COMPLETED,INTERVENTIONAL,['NA']
1157,NCT05346978,Lipid profile,Atherogenic Coefficient (AC),,2018-06-01,COMPLETED,INTERVENTIONAL,['NA']
1158,NCT05476861,Insulin omission,Waist circumference,,2022-11-01,COMPLETED,OBSERVATIONAL,['NA']
1159,NCT04531176,Change in A1C,Mean total cost of care,,2020-09-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4']
1160,NCT03212755,The number of patients with high level of immunoglobulin in serum,,,2017-08,UNKNOWN,INTERVENTIONAL,['NA']
1161,NCT00760110,Death,Macrovascular complications,,1997-11,COMPLETED,OBSERVATIONAL,['NA']
1162,NCT03369067,Percent time spent in glycemic zone (70-180mg/dl),,,2017-12-18,COMPLETED,INTERVENTIONAL,['NA']
1163,NCT01787617,Change in insulin response to an oral glucose tolerance test over 5 months.,Quality of Life Measures,,2012-12,UNKNOWN,INTERVENTIONAL,['NA']
1164,NCT04625595,Change in total daily insulin use,Cytokine level from in vitro presentation of antigen by HLA-DQ8,,2020-11-09,COMPLETED,INTERVENTIONAL,['PHASE1']
1165,NCT03747471,Change from baseline Diabetes distress (DD) 3 months:,Change from baseline HbA1C at 3 months:,,2019-01-01,COMPLETED,INTERVENTIONAL,['NA']
1166,NCT02990832,Infection assessed as per Infectious Disease Society of America (IDSA) guidelines,Safety and complications (incidence of adverse events),,2017-01,WITHDRAWN,INTERVENTIONAL,['NA']
1167,NCT02745015,Metabolic,Periodontal 3,,2014-12,COMPLETED,INTERVENTIONAL,['NA']
1168,NCT04124848,To determine the severity of obstructive sleep apnea,Body composition,,2019-10-25,RECRUITING,OBSERVATIONAL,['NA']
1169,NCT05585983,Change in fasting residual β cell (C-peptide) function.,Variation of blood glucose.,Treatment-emergent events of diabetic ketoacidosis (safety outcome),2022-12-14,RECRUITING,INTERVENTIONAL,['PHASE4']
1170,NCT01342497,Rate of healing of diabetic foot ulcers (% reduction in area from baseline),Safety and tolerability of BBR-012 as assessed by reported adverse events and safety laboratory parameters,,2011-07,UNKNOWN,INTERVENTIONAL,['PHASE2']
1171,NCT01028287,Percentage of patients achieving less than 300 mg protein per 24 hours after 6 months of Acthar Gel.,Percentage of patients achieving greater than 50% reduction in urinary proteinuria after 6 months of Acthar Gel.,,2009-05,COMPLETED,INTERVENTIONAL,['PHASE4']
1172,NCT04960514,Referrals,,,2021-11-22,RECRUITING,OBSERVATIONAL,['NA']
1173,NCT03335371,Sentinel - Time to Maximum Concentration (Tmax),Change From Baseline in Basal Insulin Use,,2017-10-25,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1174,NCT00353587,Evaluate safety of MBX-102 with particular emphasis on endpoints of weight gain and edema,,,2006-05,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
1175,NCT02422446,Change From Baseline in Endothelial Function at 12 Weeks Using Reactive Hyperemia Index (RHI),"Change in Endothelin-1 (ET-1), High-sensitive C-reactive Protein (hsCRP), and Oxidized LDL Between Baseline and 12 Weeks",,2015-04,TERMINATED,INTERVENTIONAL,['PHASE3']
1176,NCT01244646,Impact of Weight on Quality of Life (IWQOL-Lite) questionnaire,"Investigator-asked Symptoms of Hypoglycemia, hypoglycemic events, weight, compliance",,2010-12,TERMINATED,OBSERVATIONAL,['NA']
1177,NCT03527277,Endogenous glucose production,non-high density lipoprotein cholesterol (non-HDL-C),Eating motivation,2018-06-01,COMPLETED,INTERVENTIONAL,['NA']
1178,NCT05744232,Global score of disordered eating psychopathology,Weight,Safety/ New cases needing referral to specialist services,2023-03-01,RECRUITING,INTERVENTIONAL,['NA']
1179,NCT02318108,Hemoglobin A1c,,,2012-07,UNKNOWN,INTERVENTIONAL,['NA']
1180,NCT03159494,Blood pressure,Physical acitity,,2014-02-14,COMPLETED,INTERVENTIONAL,['NA']
1181,NCT00849017,Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 52,Albiglutide Plasma Concentration at Weeks 8 and 24,,2009-01,COMPLETED,INTERVENTIONAL,['PHASE3']
1182,NCT00006305,Number of Participants With All-Cause Mortality,"Number of Participants With Death, Myocardial Infarction, or Stroke",,2000-09,COMPLETED,INTERVENTIONAL,['PHASE3']
1183,NCT04889157,Maximum observed plasma concentration,Number of participants with laboratory abnormalities,,2021-07-07,COMPLETED,INTERVENTIONAL,['PHASE1']
1184,NCT00950040,Percentage heavy drinking days,HbA1c levels,,2009-07,COMPLETED,INTERVENTIONAL,['NA']
1185,NCT03436498,Infusion set occlusions,Number of patients with hypoglycemic events,,2018-05-10,COMPLETED,INTERVENTIONAL,['PHASE1']
1186,NCT01072565,Evaluate the efficacy of SMBG for clinical decisions related to the management of type 2 diabetes.,Determine the incremental benefit of CGM for clinical decision-making.,,2010-02,COMPLETED,INTERVENTIONAL,['NA']
1187,NCT06277466,Correlation between T2DM susceptibility gene expression and clinicopathological features,Baseline LDL-C of controls with different genotypes,,2024-01-01,RECRUITING,INTERVENTIONAL,['NA']
1188,NCT03938740,Basal/bolus ratios during the last 2 weeks of the treatment period,,,2019-03-18,COMPLETED,INTERVENTIONAL,['PHASE2']
1189,NCT01755572,Change in plasma ANP level at 21 Days,Office-measured heart rate;Treatment difference for liraglutide compared to crossover with placebo,Change in HDL,2013-01,COMPLETED,INTERVENTIONAL,['PHASE4']
1190,NCT04579900,Microbial signature,,,2021-02-01,RECRUITING,INTERVENTIONAL,['NA']
1191,NCT03695731,brown adipose tissue activation,Energy expenditure,,2018-10-15,UNKNOWN,INTERVENTIONAL,['NA']
1192,NCT03043859,Change in Hb A1C,Changes in BMI(kg/m^2),,2017-05-09,COMPLETED,INTERVENTIONAL,['NA']
1193,NCT05637749,Flow Short Scale (FSS) scores,,,2023-02-01,COMPLETED,INTERVENTIONAL,['NA']
1194,NCT01480297,Intra-epidermal Nerve Fiber Density (IENFD) Fibers Per mm,,,2011-11,COMPLETED,INTERVENTIONAL,['PHASE2']
1195,NCT01230632,intravenous glucose tolerance test (IVGTT),insulin sensitivity,,2010-09,COMPLETED,INTERVENTIONAL,['NA']
1196,NCT05929066,Change from Baseline in Apnea-Hypopnea Index (AHI) Events Per Hour for GSA1 Subset,Percentage of Participants with AHI <5 or with AHI 5-14 with Epworth Sleepiness Scale (ESS) ≤10 for GSA1 Subset,,2023-07-10,RECRUITING,INTERVENTIONAL,['PHASE3']
1197,NCT01217905,Investigate the safety and tolerability of AZD7687 following administration of single and multiple doses,Evaluate the pharmacokinetics (PK) (plasma and urine) of AZD7687 and it´s glucuronic acid metabolite (AZ13128940) after single and multiple doses,,2010-11,COMPLETED,INTERVENTIONAL,['PHASE1']
1198,NCT05806502,Endothelium-dependant increase in forearm blood flow,,,2018-11-01,RECRUITING,INTERVENTIONAL,['NA']
1199,NCT03571139,Detecting changes in the retinal vascular plexuses and choriocapillaris after cataract surgery in type 2 diabetes mellitus patients with and without diabetic retinopathy using OCT angiography.,,,2018-06-01,UNKNOWN,OBSERVATIONAL,['NA']
1200,NCT01752985,Percent Change From Baseline in Urinary Albumin-to-Creatinine Ratio (UACR) Across 12 Weeks of Treatment With BMS-813160,Dose-Response Relationship Using Change in Baseline Urinary Albumin-to-Creatinine Ratio (UACR) Across 12 Weeks of Treatment,,2013-03-18,TERMINATED,INTERVENTIONAL,['PHASE2']
1201,NCT00915707,Disposition Index reflecting Diabetes Risk as a result of decreased sleep duration and/or quality.,,,2007-01,COMPLETED,INTERVENTIONAL,['NA']
1202,NCT03288740,Area under the semaglutide plasma concentration time curve at steady state (semaglutide 1.0 mg),Incidence of anti-semaglutide antibodies (positive/negative) at follow-up,,2017-09-21,COMPLETED,INTERVENTIONAL,['PHASE1']
1203,NCT02065791,"Primary Composite Endpoint of Doubling of Serum Creatinine (DoSC), End-stage Kidney Disease (ESKD), and Renal or Cardiovascular (CV) Death",CV Composite Endpoint,,2014-02-17,COMPLETED,INTERVENTIONAL,['PHASE3']
1204,NCT03786133,Total bacterial load,Genotypes of Porphyromonas gingivalis and Aggregatibacter actinomycetemcomitans,,2016-06-10,COMPLETED,OBSERVATIONAL,['NA']
1205,NCT01829464,Change From Baseline in HbA1c at Week 24,Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24,,2013-05,TERMINATED,INTERVENTIONAL,['PHASE3']
1206,NCT04769141,Medication dosing optimization,(CURATE.AI) pilot deployment using prospective data,,2021-08,UNKNOWN,OBSERVATIONAL,['NA']
1207,NCT02846233,Change in A1c at the End of Study Period,Changes in Treatment Satisfaction Scores (DM-SAT Total Score),,2016-08,COMPLETED,INTERVENTIONAL,['NA']
1208,NCT00157924,LDL-C lowering efficacy,Safety,,2005-11,COMPLETED,INTERVENTIONAL,['PHASE4']
1209,NCT03296800,AUC0-inf (Area Under the Plasma Concentration-time Curve From Time 0 to Infinity),Urinary Glucose Excretion 0-48 hr,,2017-09-27,COMPLETED,INTERVENTIONAL,['PHASE1']
1210,NCT01035320,"Compare the effects of simvastatin + ezetimibe with those of simvastatin alone, on thrombogenic mechanisms, in patients with diabetes mellitus type 2.",Compare effects of simvastatin alone with those of placebo on thrombogenic mechanisms. Compare the effects of simvast. + ezetim. with those of simvast. alone on inflammatory variables. Assess how the treatment effect relate to renal function.,,2006-01,COMPLETED,INTERVENTIONAL,['PHASE4']
1211,NCT00621608,"Freedom from having, or meeting the criteria for, a major amputation (below knee amputation, or metatarsal level) up to 12 weeks after randomization.",Cost effectiveness of HBOT: calculate the incremental cost per amputation avoided and the incremental cost per quality-adjusted life-year (QALY) gained,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE4']
1212,NCT03057158,"Proportions of differentially methylated CpG sites between cohorts, from Illumina EPIC chip",Gene expression (from PCR),,2017-05-01,COMPLETED,OBSERVATIONAL,['NA']
1213,NCT05488002,Cholesterol LDL-cholesterol Triglycerides Cholesterol LDL-cholesterol Triglycerides,Medication adherance,,2022-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1214,NCT01273584,Birth Weight centile (z-score),2nd trimester miscarriages,,2010-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
1215,NCT01029704,Pharmacokinetics of EGT0001442 (AUC 0-t and 0-24) at 4 Dose Levels at Week 4,Change in FPG Following Cessation of Treatment,,2009-12,COMPLETED,INTERVENTIONAL,['PHASE2']
1216,NCT04257370,Wound healing at Week 16,Percentage of ulcers healed 50% or more at 12 weeks,,2020-07-09,COMPLETED,INTERVENTIONAL,['NA']
1217,NCT00394524,Mean Blood Glucose (BG) in mg/dl Among Glucommander Group Compared to Standard Insulin Infusion,Mean Hospital Length of Stay in Days Among the Glucommander Group Compared to Standard Insulin Infusion,,2006-06,COMPLETED,INTERVENTIONAL,['NA']
1218,NCT01313975,Incidence of sodium-fluid disturbances,Associated changes in natriuretic peptide levels,,2011-01,COMPLETED,OBSERVATIONAL,['NA']
1219,NCT04798937,Transition Readiness Assessment Questionnaire (TRAQ) scores,Hemoglobin glycated values,,2020-01-01,COMPLETED,INTERVENTIONAL,['NA']
1220,NCT00200018,Mean excess weight loss and percent excess weight loss,Diabetes status and use of diabetes medication,,2005-06,COMPLETED,INTERVENTIONAL,['NA']
1221,NCT01791907,HbA1c,Health economics,,2013-02,COMPLETED,INTERVENTIONAL,['NA']
1222,NCT04380584,prediction of diabetic nephropathy,,,2019-11-30,COMPLETED,OBSERVATIONAL,['NA']
1223,NCT03916211,amputation rate,Wong-Baker Faces Pain Rating Scale,,2019-04-20,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
1224,NCT00300287,Change from baseline in HbA1c at 108 weeks,Change from baseline in body weight at week 108,,2006-02-20,COMPLETED,INTERVENTIONAL,['PHASE3']
1225,NCT04690270,Insulin secretion,,,2021-01-04,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
1226,NCT06154915,Determine the functional contribution of macrophages to diabetic chronic foot ulcers,,,2022-09-09,RECRUITING,OBSERVATIONAL,['NA']
1227,NCT02718547,Change of at least 50 micron in Macular edema,,,2017-03-26,UNKNOWN,INTERVENTIONAL,['NA']
1228,NCT04027062,"Percent of change of knowledge, attitude and practice of primary healthcare physicians",,,2019-08-01,UNKNOWN,INTERVENTIONAL,['NA']
1229,NCT04807374,Change in CGM Time in Range (TIR),Semi-structured interviews with youth and parents exploring the overall experience and barriers to expanding access to hybrid closed loop technology,,2021-06-01,COMPLETED,INTERVENTIONAL,['NA']
1230,NCT02024750,"Change in Parent Quality of Life (QOL) for Usual Care and Tailored Resources (Intervention) Arms, During and Post-Intervention","Change In Parent Fear of Hypoglycemia (FOH) for Usual Care and Tailored Resources (Intervention) Arms, During and Post-Intervention",,2014-09,COMPLETED,INTERVENTIONAL,['NA']
1231,NCT00356109,To test that preprandial AIR Insulin is non-inferior to preprandial injectable insulin (insulin lispro) with respect to mean change in HbA1c from baseline to endpoint.,To assess rate and incidence of hypoglycemia,,2006-08,COMPLETED,INTERVENTIONAL,['PHASE3']
1232,NCT06004219,Diabetes Distress Screening Scale (DDS17),,,2023-11-21,RECRUITING,INTERVENTIONAL,['NA']
1233,NCT01827826,Program feasibility: Attendance,Physical activity level,,2010-07,COMPLETED,INTERVENTIONAL,['NA']
1234,NCT04949958,Body fat percentage,,,2022-04-15,COMPLETED,INTERVENTIONAL,['NA']
1235,NCT02501616,Reactive hyperemic index to measure endothelial function,Urine β2 microglobulin,,2014-12,UNKNOWN,INTERVENTIONAL,['PHASE4']
1236,NCT02318693,Change From Baseline in Mean Amplitude of Glycemic Excursions (MAGE) at Day 13,"Change From Baseline in Percentage of Hypoglycemic Values (Glucose Sensor Readings: < 70, <60, <50 mg/dL)",,2015-02-04,COMPLETED,INTERVENTIONAL,['PHASE4']
1237,NCT03049709,agreement of diastolic central blood pressure measurements,,,2015-05-01,COMPLETED,OBSERVATIONAL,['NA']
1238,NCT01279161,Identification of the effect of the FTO gene polymorphism on the development of overweight/obesity in insulin treated children,• Comparison of frequency distribution of FTO gene polymorphism involved in the pathogenesis of obesity in children with diabetes versus children without diabetes.,,2010-12,COMPLETED,OBSERVATIONAL,['NA']
1239,NCT00388518,Absolute change from baseline in Hemoglobin A1c (HbA1c),"Adverse Events (AEs), laboratory parameters.",,2006-11,COMPLETED,INTERVENTIONAL,['PHASE2']
1240,NCT04098549,Positive incremental area under the glucose curve (PI-AUC) (using the plasma glucose concentration before glucagon administration as basal level),Number of subjects experiencing vomiting,,2019-09-12,COMPLETED,INTERVENTIONAL,['NA']
1241,NCT01814995,percentage change in weight in participant,Change in mindful eating,,2012-01,COMPLETED,INTERVENTIONAL,['NA']
1242,NCT02122250,user engagement,Diabetes and Physical activity knowledge,Single item: whether you would recommend the website to others,2014-10,COMPLETED,INTERVENTIONAL,['NA']
1243,NCT04988204,Number of participants in the program at the end of the study,Bilirubin level,,2018-10-03,COMPLETED,INTERVENTIONAL,['NA']
1244,NCT04075513,Percentage of Time of Glucose Concentration Within the Target Range of Greater Than or Equal to (>=) 70 to Less Than or Equal to (<=) 180 Milligrams Per Deciliter: Non-inferiority Analysis,Number of Hypoglycemic Events Per Participant Year During the On-treatment Period,,2019-10-09,COMPLETED,INTERVENTIONAL,['PHASE4']
1245,NCT04101396,Clinical characteristics of participants,Participants' satisfaction,,2019-10-25,COMPLETED,INTERVENTIONAL,['NA']
1246,NCT01219959,Change From the Baseline Value in HbA1c at Month 3 and 6,Change From Baseline of Left Ventricular (LV) Ejection Fraction as Determined by MRI at Month 6,,2010-10,COMPLETED,INTERVENTIONAL,['PHASE3']
1247,NCT00348179,Vascular abnormalities as measured by the SyphmgnoCor equipment,,,2004-04,COMPLETED,INTERVENTIONAL,['NA']
1248,NCT03707379,HbA1c,LDL-C,,2016-03-01,RECRUITING,OBSERVATIONAL,['NA']
1249,NCT00786019,"Ejection Fraction: Percentage of Blood Leaving the Heart Before and After Exercise at Baseline, After a Vitamin C Infusion, and After Exercise Training",,,2008-05,COMPLETED,INTERVENTIONAL,['NA']
1250,NCT00494715,Progression to ESRD (i.e. need for renal replacement therapy by chronic dialysis or renal transplantation),"Doubling of serum creatinine (versus baseline), Rate of GFR decline, Incidence of fatal and non-fatal cardiovascular events (stroke, acute myocardial infarction, sudden death), Albumin to creatinine ratio and 24-hour urinary protein excretion.",,2007-05,COMPLETED,INTERVENTIONAL,['PHASE3']
1251,NCT02932475,Number of Participants With Composite Adverse Neonatal Outcome,Neonatal Safety Based on Treatment Emergent Adverse Events,,2017-05-25,TERMINATED,INTERVENTIONAL,['PHASE3']
1252,NCT03843840,Test retest reliability,,,2019-02-15,COMPLETED,OBSERVATIONAL,['NA']
1253,NCT00607503,Safety of bedtime administration of the epinephrine simulating β2 adrenergic agonist terbutaline to reduce the incidence of nocturnal hypoglycemia without compromising glycemic control in youth with type 1 diabetes (T1D).,,,2008-02,COMPLETED,INTERVENTIONAL,['PHASE1']
1254,NCT03491930,Change in weight,"Change in quality of life by ""SF-12v2"" questionnaire",,2018-06,WITHDRAWN,INTERVENTIONAL,['NA']
1255,NCT01585948,The incidence and extent of coronary artery disease between diabetics and non-diabetic patients.,TCF7L2 gene polymorphims and the incidence and extent of coronary artery disease.,,2009-11,COMPLETED,OBSERVATIONAL,['NA']
1256,NCT02003872,Excess weight loss,liver fat infiltration,,2015-01,TERMINATED,INTERVENTIONAL,['NA']
1257,NCT04068272,Epitheliopathy,Anterior segment inflammation,,2019-09-07,COMPLETED,INTERVENTIONAL,['PHASE1']
1258,NCT02156349,The mean HbA1c change by means of Generalized Estimating Equations (GEE) methods,Effects of integrated Personalized Diabetes Management (PDM) by means of Generalized Estimating Equations [GEE] methods,,2014-05-14,COMPLETED,INTERVENTIONAL,['NA']
1259,NCT03253328,Stump Healing using the Bates-Jensen Wound Assessment Tool,Determine effect size to power a larger trial,Stump Healing,2016-12-15,SUSPENDED,INTERVENTIONAL,['NA']
1260,NCT04959071,Comparison of mean healing time of wounds in diabetic foot ulcers among Vac and conventional dressings,,,2020-02-28,COMPLETED,INTERVENTIONAL,['NA']
1261,NCT00786721,Near Infrared Spectroscopy to assess muscle mitochondrial OXPHOS function.,,,2006-11,COMPLETED,OBSERVATIONAL,['NA']
1262,NCT01329822,Fetuin-A,cardiovascular risk factors,,2010-03,COMPLETED,INTERVENTIONAL,['NA']
1263,NCT04132401,Area under the receiver operating characteristic curve of the algorithm,,,2021-05-01,COMPLETED,INTERVENTIONAL,['NA']
1264,NCT03049631,Changes in gut microbiome composition as measured by 16S rRNA gene sequencing in 12-week intervention of active treatment vs Experimental,Changes in blood pressure in 12-week intervention of active treatment vs Experimental,Changes in plasma HDL cholesterol in 12-week intervention of active treatment vs Experimental,2017-05-18,COMPLETED,INTERVENTIONAL,['NA']
1265,NCT00390273,Lactate production following exogenous lactate overload,Parameters modelizing elimination of lactate following muscular exercise test (bi-exponential model).,,2006-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1266,NCT06154746,aeffect of risk factors in progression of diabetic retinopathy.,,,2024-06,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
1267,NCT01957696,Surgical complications,Non-surgical complications,"Scheduled, conventional, percutaneous, ultrasound-guided pancreas graft biopsies at 6 weeks and 12 months post-Tx [Amendment 2; Approved by Regional Ethics Commitee]",2013-09,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
1268,NCT05629221,Haemoglobin glycated (Hb1Ac) mean changes,Time spent for telemedicine visits,,2022-12-30,RECRUITING,INTERVENTIONAL,['NA']
1269,NCT00522327,Adherence with care,care parameters,,2004-11,COMPLETED,INTERVENTIONAL,['NA']
1270,NCT00965991,Number of Participants Assessed for Glucose Control,Failure Rate of the Drug to Control Blood Glucose,,2003-07,COMPLETED,INTERVENTIONAL,['NA']
1271,NCT02520258,Blood glucose,C-peptide,Interval changes in frequency distribution of microbes found in stool samples (Phase II - cohort 1),2015-08,COMPLETED,INTERVENTIONAL,['NA']
1272,NCT01677299,Within Treatment Comparison Based on Ratios of AUCs of PYY,,,2012-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1273,NCT03131232,The effect of empagliflozine on glucose metabolism,- echocardiographic parameters (if collected) with determination of the systolic and diastolic left ventricular function,,2015-12-10,UNKNOWN,OBSERVATIONAL,['NA']
1274,NCT01560546,Lean body mass,Sexual function,,2012-03,COMPLETED,INTERVENTIONAL,['PHASE4']
1275,NCT02577900,Number of Participants With Complete Healing of Ulcer During the Observation Period,the Change in Concentration of Interleukin-1 Alpha (IL-1α) Level Inside Wound Fluid at Week 1 and Week 4,,2013-02,COMPLETED,INTERVENTIONAL,['NA']
1276,NCT00313001,Superiority as assessed by HbA1c reduction,Patient satisfaction,,2006-04,COMPLETED,INTERVENTIONAL,['PHASE3']
1277,NCT03765112,Perfusion density,Change in perfusion density in patients with moderate or severe non proliferative diabetic retinopathy (DR) or low risk proliferative DR over the follow up of one year,,2018-09-20,UNKNOWN,INTERVENTIONAL,['NA']
1278,NCT01392677,Adjusted Mean Change From Baseline in HbA1c Levels,Adjusted Mean Change From Baseline in Seated Systolic Blood Pressure,,2011-10,COMPLETED,INTERVENTIONAL,['PHASE3']
1279,NCT02824003,Change in fasting hepatic lipid content,"Safety and Tolerability will be assessed by determining the incidence, severity, dose relationship of adverse effects, and changes in laboratory evaluations",,2016-04,COMPLETED,INTERVENTIONAL,['PHASE2']
1280,NCT05367622,Medication compliance,Diabetes health literacy assessment scale,,2022-12-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
1281,NCT00904020,"Average daily pain intensity (Brief Pain Inventory [BPI] Questions 3, 4, 5, and 6)",QoL: Patient Global Assessment of Patch Satisfaction,,2002-06,COMPLETED,INTERVENTIONAL,['PHASE4']
1282,NCT04241575,Action on suspected advanced liver fibrosis,Confirmed diagnosis of advanced liver fibrosis,,2020-05-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
1283,NCT06112925,"Change in percentage of of glycemic control, blood pressure control and medication adherence among adult patients comorbid with diabetes mellitus and hypertension at outpatient clinics in Southwest Ethiopia",,,2022-03-27,COMPLETED,INTERVENTIONAL,['NA']
1284,NCT02987348,Changes from baseline in composite outcomes of HbA1c<=7.0% and weight reduction,Health care utilization,,2015-06-30,COMPLETED,OBSERVATIONAL,['NA']
1285,NCT00279201,ADDENDUM: 24-Week Endpoint HbA1c,ADDENDUM: HbA1c at Specified Visits and Endpoint,,2005-12,COMPLETED,INTERVENTIONAL,['PHASE4']
1286,NCT02474823,Result of ESAP testing,Result of PSG testing,,2015-07,COMPLETED,INTERVENTIONAL,['NA']
1287,NCT01050868,To compare the difference between the self-monitoring blood glucose (SMBG) value achieved at 6 hours after meals with induced post-prandial hyperglycemia and the mean target value of 110 mg/dL. Target post-prandial range is 80-140 mg/dL.,"To compare the absolute relative difference (RAD, multiplied by 100) between the SMBG value and the target value between the calculators",,2009-06,COMPLETED,INTERVENTIONAL,['NA']
1288,NCT04084418,Daily blood glucose standard deviation,Effects on physical activity (steps/day),,2019-10-15,TERMINATED,INTERVENTIONAL,['NA']
1289,NCT01100125,The change of HbA1C,the change of insulin dose,,2010-04,COMPLETED,INTERVENTIONAL,['PHASE4']
1290,NCT02351232,Change in HbA1c,Change in anxiety and depression as measured by Hospital Anxiety and Depression Scale,,2015-02,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
1291,NCT00781547,Glucose tolerance,Progress of atherosclerosis (IMT),,1999-01,COMPLETED,INTERVENTIONAL,['PHASE3']
1292,NCT04869761,Adverse events and/or serious adverse events,,,2021-10-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
1293,NCT02989961,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]) as a result of the injection,Assess the efficacy of autologous Resticutis injection by clinical examination,,2013-11-15,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1294,NCT05354245,Peripheral insulin sensitivity,Stool consistency,,2022-09-08,RECRUITING,INTERVENTIONAL,['NA']
1295,NCT01676272,"Proposal for a multi center site randomized, prospective controlled head-to-head clinical trial comparing a bioengineered skin substitute to a human skin allograft.",,,2012-07,COMPLETED,OBSERVATIONAL,['NA']
1296,NCT00533559,"we will measure insulin secretion, calculate disposition index and insulin clearance during a hyperglycemic clamp. We will also measure insulin sensitivity during a euglycemic hyperinsulinemic clamp","During the hyperglycemic clamp we will also measure Free Fatty Acid, C-peptide and triyglycerides. During the euglycemic hyperinsulinemic clamp we will determine the insulin sensitivity index and the disposition index.",,2007-09,COMPLETED,INTERVENTIONAL,['PHASE4']
1297,NCT02290067,User performance of blood glucose monitoring systems indicated by patient [questionnaire],,,2014-10,COMPLETED,INTERVENTIONAL,['NA']
1298,NCT02826759,"serum concentration of sphingosine-1-phosphate, micromol per liter","serum concentration of ceramide, micromol per liter",,2016-07,UNKNOWN,OBSERVATIONAL,['NA']
1299,NCT03337828,Homeostatic model assessment (HOMA) index change after each alcohol-free beer phase.,Micriobota change after each alcohol-free beer phase.,,2017-03-01,UNKNOWN,INTERVENTIONAL,['NA']
1300,NCT03776227,AUC 0-72h (area under the curve),Area under the curve (AUC),,2019-01-25,COMPLETED,INTERVENTIONAL,['PHASE1']
1301,NCT05227105,Objective accelerometry,Objective accelerometry,,2023-05-23,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
1302,NCT02994966,Foot ulcer recurrence,Determinants of ulcer formation,,2016-11,COMPLETED,INTERVENTIONAL,['NA']
1303,NCT04263311,Change in BP control,Barriers and Facilitators to Implementation Adoption and Implications for Scalability,,2020-07-20,COMPLETED,INTERVENTIONAL,['NA']
1304,NCT03199716,Daily frequency of blood glucose monitoring (BGM),HbA1c levels,Responsibility for diabetes care,2014-09,COMPLETED,INTERVENTIONAL,['NA']
1305,NCT01115621,Effect of dietary intervention on the development of islet autoantibodies,Effect of dietary intervention on the development of Type 1 diabetes.,,2001-02,UNKNOWN,INTERVENTIONAL,['NA']
1306,NCT05947370,Differences of blood glucose levels between BBR and placebo treatment groups during the glucose tolerance test.,Differences of serum calcium levels between BBR and placebo treatment groups during the glucose tolerance test.,Differences of QT-interval duration between BBR and placebo treatment groups during the glucose tolerance test.,2022-10-12,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
1307,NCT02851745,Increase in LV systolic function,Changes in diastolic LV function,,2015-07,COMPLETED,INTERVENTIONAL,['PHASE3']
1308,NCT00337038,endothelial function,blood pressure and glycemic control,,2006-06,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
1309,NCT03660553,Hemoglobin A1c (HbA1c),Incidence of Severe Hypoglycemia,,2018-10-10,TERMINATED,INTERVENTIONAL,['PHASE4']
1310,NCT00150085,"Proportion of patients who no longer require a hypoglycemic agent, or who move from insulin to an oral agent, or who no longer meet the American Diabetes Association criteria, or a relative improvement in mean glycosylated hemoglobin at 12 and 26 weeks","Safety assessed by death, graft loss, biopsy supported clinically manifested acute rejection, change in kidney function, change in liver function, serious adverse events and adverse events at 12 and 26 weeks",,2004-02,TERMINATED,INTERVENTIONAL,['PHASE4']
1311,NCT00094263,,,,2004-09,COMPLETED,OBSERVATIONAL,['NA']
1312,NCT01779609,Flow mediated dilation,Maximal Oxygen Uptake,,2010-04,COMPLETED,INTERVENTIONAL,['PHASE4']
1313,NCT06007014,HbA1C,Fasting C-Peptide,,2023-10-31,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1314,NCT03393715,24-hour blood pressure profile,Night time blood pressure dip,,2016-02,COMPLETED,INTERVENTIONAL,['PHASE4']
1315,NCT03037918,Whole body insulin sensitivity index,Microbiome analysis,,2017-02-03,COMPLETED,INTERVENTIONAL,['NA']
1316,NCT02157298,Adjusted Mean Change in HbA1c Levels,Proportion of Participants With Mean Daily Insulin Dose Reduction of Greater Than or Equal 10%,,2014-06,COMPLETED,INTERVENTIONAL,['PHASE4']
1317,NCT03481530,Hypoglycemia rate,Comparison hypoglycemia rate,,2018-10-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
1318,NCT01904422,Glycated hemoglobin (HbA1c),Tumor Necrosis Factor (TNF),clinical attachment level (CAL),2013-03,COMPLETED,INTERVENTIONAL,['NA']
1319,NCT00149331,Preference for Insulin therapy,Satisfaction with the education session,,2005-07,COMPLETED,INTERVENTIONAL,['PHASE4']
1320,NCT00475371,Determine the safety and tolerability of ascending doses of MKC253 Inhalation Powder,Pharmacokinetic (PK) parameters of plasma GLP-1,,2007-04,COMPLETED,INTERVENTIONAL,['PHASE1']
1321,NCT04682067,Number of participants with >80% completion of daily ecological momentary assessments (EMA) completed,Number of participants with biochemically verified abstinence at 4 weeks post quit,,2021-01-08,COMPLETED,INTERVENTIONAL,['NA']
1322,NCT02436551,prevalence of gestational diabetes,,,2015-09,COMPLETED,OBSERVATIONAL,['NA']
1323,NCT02974413,Glycemic control,Weight,,2016-03,UNKNOWN,INTERVENTIONAL,['NA']
1324,NCT00825695,functional transcranial doppler measures,,,2009-01,COMPLETED,INTERVENTIONAL,['NA']
1325,NCT06195566,"Validation of the Mission T2D (MT2D) algorithm outputs, that predicts the real time risk for developing pre-diabetes.",,,2024-01-29,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
1326,NCT01676233,Change in 24-hour blood glucose profile measured by continuous glucose monitoring,Change in HbA1c from baseline to each treatment end by treatment,,2012-09,COMPLETED,INTERVENTIONAL,['PHASE1']
1327,NCT03437798,Correlation of CDC-AAP periodontal condition questions vs. periodontal disease diagnosis,,,2018-01-30,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
1328,NCT01234597,Changes in Hemoglobin A1c (HbA1c) level,Changes in insulin glulisine dose,,2012-12,COMPLETED,INTERVENTIONAL,['PHASE4']
1329,NCT06046560,Proportion of patients with prescriptions of SGLT2i or GLP1-RA at any time,Short-form Patient Activation Measure (PAM),Change in laboratory measured HbA1c,2021-03-22,COMPLETED,INTERVENTIONAL,['PHASE4']
1330,NCT05066152,HOMA-IR,Dietary cholesterol,,2016-02-01,COMPLETED,INTERVENTIONAL,['NA']
1331,NCT03587623,Serum Copeptin concentration,,,2018-07-04,COMPLETED,OBSERVATIONAL,['NA']
1332,NCT02974309,HbA1c,Sleep Duration,Cortisol,2017-09-15,RECRUITING,INTERVENTIONAL,['NA']
1333,NCT01562782,Fold Change in Plasma Very Low Density Lipoprotein (VLDL) Triglyceride Palmitate,Peak Glucose in 2 Study Groups,,2012-04-02,COMPLETED,INTERVENTIONAL,['NA']
1334,NCT03605329,study of heart rate variability (HRV),monitoring of blood pressure,,2018-09-05,TERMINATED,INTERVENTIONAL,['NA']
1335,NCT01647542,Change From Baseline in HbA1c at Week 24,Change From Baseline in 2-hour Postprandial Glucose (PPG) Following Oral Glucose Tolerance Test (OGTT) at Week 24,,2012-10,TERMINATED,INTERVENTIONAL,['PHASE3']
1336,NCT00191282,Number of Participants Who Experienced a Primary Combined Outcome,Number of Episodes of Self-Reported Hypoglycemia Reported by Participants With Self-Reported Hypoglycemia During Month 18,Summary of Reasons for Deaths,2002-10,COMPLETED,INTERVENTIONAL,['PHASE4']
1337,NCT02551835,HbA1c,Two-hour glucose,,2015-04,UNKNOWN,OBSERVATIONAL,['NA']
1338,NCT05909800,Differences in AUC in C-peptide stimulation test,Genetical analysis,,2022-09-29,RECRUITING,INTERVENTIONAL,['PHASE2']
1339,NCT02559479,Change in insulin resistance (HOMA index).,"Change in lipid profile (total cholesterol, LDL cholesterol, HDL cholesterol, non HDL cholesterol, triglycerides and apolipoproteins).",,2015-09,UNKNOWN,INTERVENTIONAL,['NA']
1340,NCT03652480,Glycemia,Subjective Outcomes Determination (SOD) score,,2013-03,COMPLETED,OBSERVATIONAL,['NA']
1341,NCT00005419,,,,1992-03,COMPLETED,OBSERVATIONAL,['NA']
1342,NCT01565564,The Rate of Macrosomia.,The Rate of Pregnancy-induced Hypertension.,,2010-09,COMPLETED,INTERVENTIONAL,['NA']
1343,NCT04799938,Level of Growth Diferantiation Factor-15,Level of VO2max,,2021-04-15,RECRUITING,INTERVENTIONAL,['NA']
1344,NCT01714986,"Intervention with Affect School with Script Analysis and Basic Basal Awareness Therapy in patients with diabetes, psychological symptoms and high HbA1c",Self-image,,2009-03,WITHDRAWN,INTERVENTIONAL,['NA']
1345,NCT05298735,Pancreatic calcium-handling: Rate of change of pancreatic T1 values with manganese-enhanced magnetic resonance imaging,,,2021-03-01,COMPLETED,OBSERVATIONAL,['NA']
1346,NCT06116149,Difference in mean 12-month weight reduction (primary health-related outcome),Difference in proportion of participants meeting intervention goals at 12 months,Sustainability (Participants): comparison of the proportion of participants maintaining DPP goals at six months after their participation in the DPP has ended,2023-12-12,RECRUITING,INTERVENTIONAL,['NA']
1347,NCT04688359,Measurements behind the Icelandic heart association risk calculator,Hip-to-Waist ratio,LDL cholesterol changes from start point to endpoint in both groups,2021-11-01,COMPLETED,INTERVENTIONAL,['NA']
1348,NCT00067626,Homeostasis Model Assessment for Insulin Resistance (HOMA-IR),endothelial function measures as percent flow-mediated dilitation (FMD).,,2005-04,COMPLETED,INTERVENTIONAL,['PHASE2']
1349,NCT00832182,Number of hypoglycemic episodes and adverse events,9-point blood glucose profile,,1999-12-22,COMPLETED,INTERVENTIONAL,['PHASE3']
1350,NCT02107326,Effect of Webdia Software use on HbA1C,Effect of Webdia Software use on the incidence of hypoglycaemic events,,2014-05,COMPLETED,INTERVENTIONAL,['NA']
1351,NCT05742230,Change From Baseline in Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score (KCCQ-CSS) at Week 12,"Change From Baseline in blood pressure at Week 4, 12",Occurrence of major renal events,2023-04-15,RECRUITING,INTERVENTIONAL,['NA']
1352,NCT02252224,The number and incidence rate of adverse events and serious adverse event including unexpected adverse drug reactions,Changes in 2-hr PPG before and after administration of Forxiga,,2014-09-23,COMPLETED,OBSERVATIONAL,['NA']
1353,NCT05179668,Δ Left ventricular mass indexed to body surface area,Δ Body weight [kg],,2022-10-01,RECRUITING,INTERVENTIONAL,['PHASE2']
1354,NCT00953914,autonomic modulation assessed by heart rate variability,,,2005-03,COMPLETED,INTERVENTIONAL,['NA']
1355,NCT04653454,CGM accuracy - mean absolute relative difference (MARD),Readmission rate at 30 days,,2021-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
1356,NCT02710448,"the percentage of patients in stage 1 of chronic kidney disease (CKD) each category of renal function whose rate of erythrocyte metformin remain within the therapeutic range, at each stage of treatment.","the percentage of patients in stages 3-5 of CKD each stage renal disease with a blood erythrocyte remaining within the therapeutic range or higher, and but without significative hyperlactatemia (≥ 2.5 mmol / l) in the latter case.",,2012-06,COMPLETED,INTERVENTIONAL,['PHASE2']
1357,NCT01060670,Incidence of Complete Wound Closure,Change in Short Form Health Survey (SF-36) Quality of Life Metrics,,2010-04,COMPLETED,INTERVENTIONAL,['NA']
1358,NCT00006162,,,,1994-10,COMPLETED,INTERVENTIONAL,['NA']
1359,NCT03304626,Number of Participants With Acute Cellular Rejection Between Study and Control Groups,Number of Participants With Adverse Events,,2017-06-27,COMPLETED,INTERVENTIONAL,['PHASE2']
1360,NCT00159731,Adverse events,,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE4']
1361,NCT02366351,The number of volunteers with adverse events as a measure of safety and tolerability,Proportion of Participants Achieving Glycemic Response Defined as HbA1c <7%,,2015-02,UNKNOWN,INTERVENTIONAL,['PHASE1']
1362,NCT04571723,Change in Health Mindset,waist circumference,,2021-10-01,COMPLETED,INTERVENTIONAL,['NA']
1363,NCT01088594,Time-course absolute urinary sodium excretion calculated on the Day 1 of each study period,Creatinine clearance calculated on Day 1 of each study period,,2010-02,COMPLETED,INTERVENTIONAL,['PHASE1']
1364,NCT03570138,Prevalence of cardiac arrythmic events during a 14 days Continuous ECG Monitoring,Prevalence of ventricular extrasystoles,,2018-06-29,UNKNOWN,INTERVENTIONAL,['NA']
1365,NCT00620282,Change in Acetylcholine (ACh)-Mediated Forearm Blood Flow (FBF),Number of Hypoglycaemic Episodes,,2008-02,COMPLETED,INTERVENTIONAL,['PHASE3']
1366,NCT00073255,,,,2003-06,COMPLETED,INTERVENTIONAL,['PHASE1']
1367,NCT02624583,Changes in platelet reactivity between the three time points,Changes in the lipid profile between the three time points,,2010-06,COMPLETED,OBSERVATIONAL,['NA']
1368,NCT05925946,Reversal of diabetes,Insulin Resistance,,2023-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1369,NCT00791453,Hgb A1C and BMI measurements will improve,,,2008-04,COMPLETED,OBSERVATIONAL,['NA']
1370,NCT01079364,Self Measured Blood Glucose (SMBG),Adverse Events (excluding hypoglycemic events),,2010-01,TERMINATED,INTERVENTIONAL,['PHASE4']
1371,NCT03947073,Total number of women who failed management with diet alone,Total number of neonates with a preterm birth,,2019-06-12,COMPLETED,INTERVENTIONAL,['NA']
1372,NCT05348122,Changes in glycosylated hemoglobin (HbA1c) from baseline to week 17,The occurrence of TG103 anti-drug antibodies (ADA) and neutralizing antibody (Nab).,,2022-06-15,UNKNOWN,INTERVENTIONAL,['PHASE2']
1373,NCT00486291,Change From Baseline in HbA1c at Week 28.,Absolute Weight Change (kg) From Baseline to Week 28,,2007-06,COMPLETED,INTERVENTIONAL,['PHASE2']
1374,NCT03864744,Change in hepatic lipid content (steatosis) after total pancreatektomy or pancreaticoduodenectomy,Changes in NAFLD/NASH biomarkers,,2019-01-30,UNKNOWN,OBSERVATIONAL,['NA']
1375,NCT02986984,Rapid progression of kidney function loss,Serious Adverse Events,,2016-12,RECRUITING,OBSERVATIONAL,['NA']
1376,NCT05561855,The change of HbA1c from baseline,The change in depression severity from baseline,,2022-10-07,COMPLETED,INTERVENTIONAL,['NA']
1377,NCT01486862,Percentage of subjects achieving HbA1c (glycosylated haemoglobin A1c) below 7.0%,Adverse events,,2005-10,COMPLETED,INTERVENTIONAL,['PHASE4']
1378,NCT02773095,Price of Novartis Access medicines and equivalents at alternative for-profit drug sellers,,,2016-06,COMPLETED,INTERVENTIONAL,['NA']
1379,NCT04292509,blood ketones > 0.6mmol/l.,severe hypoglycemic episodes,,2020-02-15,COMPLETED,INTERVENTIONAL,['NA']
1380,NCT02634216,Effect of Capros on Blood Glycemic Index,,,2015-01,COMPLETED,INTERVENTIONAL,['NA']
1381,NCT00567112,Half Life (t½) for OCT (Fasted) and DFC (Fasted),t1/2 for OCT (Fasted) and OCT (After Meal),,2007-11,COMPLETED,INTERVENTIONAL,['PHASE1']
1382,NCT05632029,Malondialdehyde,Glutathione,,2022-10-20,RECRUITING,INTERVENTIONAL,['NA']
1383,NCT02000024,Changes in weight,Changes in HDL-cholesterol,,2011-12,COMPLETED,INTERVENTIONAL,['NA']
1384,NCT02961595,Appearance of type 1 diabetes associated auto-antibodies in serum,Presence of enterovirus RNA in stools,,1999-10,COMPLETED,INTERVENTIONAL,['PHASE1']
1385,NCT03670641,Change in Baseline A1C and A1C Measured at 3 Month Intervals up to 12 Months,Number of Participants Achieving Euglycemic Glucose Targets Within a 4 Week Period,,2019-03-26,COMPLETED,INTERVENTIONAL,['PHASE4']
1386,NCT05966727,Measurement of serum persistent organic pollutants (POPs) concentrations by mass spectrometry.,Measurement of serum POPs concentrations by mass spectrometry after bariatric surgery,,2024-03-31,RECRUITING,INTERVENTIONAL,['NA']
1387,NCT04450693,Complete wound healing,Patient-reported mobility,,2020-11-20,RECRUITING,INTERVENTIONAL,['PHASE3']
1388,NCT03376789,Change in HbA1c,Change in 8-point SMBG,,2017-11-29,COMPLETED,INTERVENTIONAL,['PHASE3']
1389,NCT01356849,Change from baseline to Week 12 in Urinary Albumin to Creatinine Ratio (UACR),Differences in change from baseline to each post baseline measure for each of the Kidney Disease Quality of Life (KDQOL) Kidney Disease Targeted Scales,,2011-04,COMPLETED,INTERVENTIONAL,['PHASE2']
1390,NCT01314222,The primary endpoint of this study is the average pain score for BMS-954561 vs. placebo.,"Evaluate the tolerability and safety of BMS-954561 in patients with DPNP as measured by the frequency and severity of adverse events, frequency of severe adverse events, and discontinuations due to adverse events.",,2011-03,COMPLETED,INTERVENTIONAL,['PHASE2']
1391,NCT02246582,Enlite 3 Sensor Accuracy Mean Absolute Relative Difference (MARD),Retrospective Analysis (MARD for the GSR With Minimum and 1 Additional Calibration),,2014-09,COMPLETED,INTERVENTIONAL,['NA']
1392,NCT00504673,Body weight loss,Incidence of hypoglycaemia,,2005-04,COMPLETED,INTERVENTIONAL,['PHASE3']
1393,NCT06084052,Device questionnaire,Reduction in CO2 comparing carbon dioxide emitted due to ulcer treatment vs carbon dioxide emitted due to device manufacture,,2023-08-01,RECRUITING,INTERVENTIONAL,['NA']
1394,NCT05756712,The Change of Blood Glucose Level in mmol/L based on OGTT (Oral Glucose Tolerance Test) after Intervention,The Change of Fast Blood Glucose Level in mmol/L based on OGTT (Oral Glucose Tolerance Test) after Intervention,,2023-03-06,COMPLETED,INTERVENTIONAL,['NA']
1395,NCT05733455,Fasting serum C-peptide,Fasting serum low-density lipoprotein (LDL) cholesterol levels,,2023-05-09,COMPLETED,INTERVENTIONAL,['PHASE1']
1396,NCT05660928,Composite outcome of proportion of patients with controlled disease,Number of glycohemoglobin measurements,Program adherence,2022-12-21,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
1397,NCT04784130,Clinical Outcomes-A1c,Behavioral outcome - medication adherence; questions,,2019-10-01,COMPLETED,INTERVENTIONAL,['NA']
1398,NCT01729078,Changes in liver fat content after 12 weeks of intervention,Change in glucose metabolism after 12 weeks of intervention,,2012-10,COMPLETED,INTERVENTIONAL,['NA']
1399,NCT01873066,The proportion of time spent in the target glucose range from 3.9 to 10.0 mmol/l based on CGM,"The proportion of time with glucose levels in significant hyperglycaemia, as based on CGM (glucose levels > 16.7 mmol/l)",Utility evaluation,2014-08-28,COMPLETED,INTERVENTIONAL,['NA']
1400,NCT04950634,To assess the role of sex on the progression of subclinical atherosclerosis in patients with T1D.,To identify novel circulating markers of subclinical atherosclerosis,,2018-09-01,RECRUITING,OBSERVATIONAL,['NA']
1401,NCT06077162,Hemoglobin A1c,Dietary intake - 24 hour recall,,2023-09-01,RECRUITING,INTERVENTIONAL,['NA']
1402,NCT03686657,Change from baseline in acute insulin response to glucose (AIRg) for treatment naive patients,Change from baseline in Adiponectin,,2023-10-10,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1403,NCT00542009,Body weight,"Change in following parameters: Post-prandial and fasting glucose, and insulin",,2007-12,COMPLETED,INTERVENTIONAL,['PHASE2']
1404,NCT05747118,Adherence,Change in triglycerides,,2022-08-15,COMPLETED,OBSERVATIONAL,['NA']
1405,NCT01814748,Percentage of Participants Who Discontinued Study Drug Due to an AE,Percentage of Participants Who Required Glycemic Rescue by Week 24,,2013-05-03,COMPLETED,INTERVENTIONAL,['PHASE3']
1406,NCT01868542,Change in Glycosylated Haemoglobin A1c (HbA1c) From Baseline.,Incidence of Adverse Events,,2013-06,COMPLETED,INTERVENTIONAL,['PHASE4']
1407,NCT05531838,Incidence of diabetes,HbA1c increased by 0.5%,,2022-10-17,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1408,NCT03820752,"Proportion of adult chronically ill patients correctly vaccinated diphtheria, tetanus, pneumococci, hepatitis B and influenza according to Belgian recommended vaccination schedule","Proportion of adult patients with antibodies against diphtheria, tetanus and pertussis.",,2014-10,COMPLETED,OBSERVATIONAL,['NA']
1409,NCT02805283,Condition-specific treatment satisfaction,Self-reported body weight,,2016-06-22,COMPLETED,OBSERVATIONAL,['NA']
1410,NCT00069836,Change from baseline in HbA1c,"Insulin dose, FPG,glycaemic responders, beta-cell function, hypoglycaemia, treatment satisfaction",,2003-10,COMPLETED,INTERVENTIONAL,['PHASE3']
1411,NCT00843232,"Distinctive curves of glucose, C peptide, insulin, glucagon, GLP-1, GIP and ghrelin during a standardized mixed meal tolerance test, in T2DM subjects after sixty-five years old in comparison with middle-age T2DM subjects",Distinctive DPP-IV activity as measured by spectrophotometer in T2DM subjects after sixty-five years old in comparison with middle-age T2DM subjects.,,2009-07,COMPLETED,OBSERVATIONAL,['NA']
1412,NCT00556114,Medical exam tool,,,2007-01,COMPLETED,OBSERVATIONAL,['NA']
1413,NCT05318183,Change in fasting plasma glucose,Intestinal whole wheat phytochemical: phenolic compounds,Gut microbiota relative abundance,2022-01-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
1414,NCT05971940,Change from Baseline in Hemoglobin A1c (HbA1c),Change from Baseline in Short Form 36 Version 2 (SF-36v2) Acute Form Domain Scores,,2023-08-09,RECRUITING,INTERVENTIONAL,['PHASE3']
1415,NCT00494988,Remission rate,HbA1c,,2004-12,COMPLETED,INTERVENTIONAL,['PHASE4']
1416,NCT03512184,Determine if Liver Fat via Fibroscan Controlled Attentuation Pattern score has decreased as a result of YMCA program,"Measuring the effectiveness of the YMCA Program, as per metabolic blood work that's analyzed",,2018-01-03,COMPLETED,INTERVENTIONAL,['NA']
1417,NCT04643873,Muscle mass amounts in the trunk and extremities,6 minutes walk test,,2020-01-06,UNKNOWN,INTERVENTIONAL,['NA']
1418,NCT00743756,Weight Loss in the elderly african american population,Endothelial Function (assessed by pulse-wave analysis); sympathetic activity; insulin sensitivity,,2006-04,TERMINATED,INTERVENTIONAL,['NA']
1419,NCT01086137,Salivary Biomarker Levels,,,2010-03,COMPLETED,OBSERVATIONAL,['NA']
1420,NCT05788341,Positive Islet Autoantibodies,,,2023-05-30,RECRUITING,OBSERVATIONAL,['NA']
1421,NCT00701090,Change From Baseline in HbA1c at Week 30,Percent of Patients With A1C <6.5% at Week 30,,2008-05,COMPLETED,INTERVENTIONAL,['PHASE3']
1422,NCT02713841,Bioavailability,,,2013-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1423,NCT04763525,Glycosylated haemoglobin,Intracellular water,,2018-10-04,COMPLETED,INTERVENTIONAL,['NA']
1424,NCT01257087,Percentage of Patients With Type 2 Diabetes Mellitus Who Achieve Fasting Blood Glucose of Less Than 5.6 mmol/l and/or HbA1c of Less Than 6%,Number of Participants With Microvascular Events,,2010-12,COMPLETED,INTERVENTIONAL,['NA']
1425,NCT06124547,Area under the plasma concentration versus time curve (AUC) 0-inf (Metformin only),Number of participants with adverse events (AEs),,2023-01-16,COMPLETED,INTERVENTIONAL,['PHASE1']
1426,NCT02810691,Plasma glucose area under the curve,Post-meal peak plasma glucose,,2016-07,COMPLETED,INTERVENTIONAL,['NA']
1427,NCT01788930,Response to antiplatelet therapy,Effects of CPAP treatment for severe obstructive sleep apnea on aspirin efficacity in type-2 diabetic patients,,2013-02,TERMINATED,INTERVENTIONAL,['NA']
1428,NCT00634842,Percentage of Participants Achieving Glycosylated Haemoglobin A1c (HbA1c) Less Than 7%,"Incidence of Hypoglycaemic Episodes (All, Major, Minor and Symptoms Only)",,2008-02,COMPLETED,INTERVENTIONAL,['PHASE4']
1429,NCT00972283,Rate of Treatment Emergent Adverse Events (AEs),Main Trial (Secondary Endpoint): Rate of Nocturnal Confirmed Hypoglycaemic Episodes,,2009-09-01,COMPLETED,INTERVENTIONAL,['PHASE3']
1430,NCT01983215,number of patients with infections,infection rates,,2013-04,UNKNOWN,INTERVENTIONAL,['NA']
1431,NCT00821977,Measure: To evaluate the efficacy of vildagliptin as monotherapy in patients with T2DM by assessing changes in HbA1c from baseline to 24 weeks.,Measure: To evaluate the body weight change from baseline with vildagliptin compared to placebo after 24 weeks of treatment as monotherapy in patients with T2DM,,2008-11,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
1432,NCT00502515,Rate of epidermal nerve fiber regeneration,"Safety: physical examination, clinical laboratories, adverse event reporting",,2007-07,COMPLETED,INTERVENTIONAL,['PHASE2']
1433,NCT03155867,Area under the blood glucose curve (AUC 0-240),AUC (0-30min) for insulin,,2017-04-05,COMPLETED,INTERVENTIONAL,['NA']
1434,NCT02530866,Change in baseline maternal glycemia at 32-36 weeks gestation,Lipid profile measurements,,2015-11,COMPLETED,INTERVENTIONAL,['NA']
1435,NCT00089557,,,,na,TERMINATED,INTERVENTIONAL,['PHASE2']
1436,NCT00103935,"Assess the safety, tolerability, and pharmacokinetics of exenatide long-acting release (LAR) administered weekly by subcutaneous (SC) injection in subjects with type 2 diabetes (T2DM)",Change in seven-point glucose concentrations from Baseline to Week 14 and Week 15,,2005-02,COMPLETED,INTERVENTIONAL,['PHASE2']
1437,NCT01057693,Change From Single-Blind Baseline in Mean Pain Score at Week 19 During Double-Blind Phase,Patient Global Evaluation of Study Medication (GESM) (Double-Blind Phase),,2010-03-31,COMPLETED,INTERVENTIONAL,['PHASE3']
1438,NCT04724967,Number of Participants at Each Dry Skin Scale,,,2021-03-12,COMPLETED,INTERVENTIONAL,['PHASE4']
1439,NCT01564719,Metabolic Syndrome,Stress,,2010-10,COMPLETED,INTERVENTIONAL,['NA']
1440,NCT04375020,gaba improve c peptide levels,,,2019-11-01,COMPLETED,OBSERVATIONAL,['NA']
1441,NCT01173926,Area under the glucose infusion rate curve,Area under the serum insulin aspart concentration-time curve,,2010-07,COMPLETED,INTERVENTIONAL,['PHASE1']
1442,NCT01841398,Effectiveness of a 12 Month Culturally-Specific Multi-media Intervention on Heart Health Risk,Change in Hypertension Status,,2012-06,UNKNOWN,INTERVENTIONAL,['NA']
1443,NCT00215735,,,,2004-06,TERMINATED,INTERVENTIONAL,['NA']
1444,NCT00490893,Hormone response to hypoglycemia (glucagon) Symptom response to hypoglycemia,"Hormone response (epinephrine, growth hormone, cortisol) to hypoglycemia",,2006-03,TERMINATED,INTERVENTIONAL,['PHASE4']
1445,NCT05893927,"""Self-Efficacy for Diabetes Scale""",Blood pressure,,2024-02-15,RECRUITING,INTERVENTIONAL,['NA']
1446,NCT03620357,HbA1c,,,2018-09-05,COMPLETED,INTERVENTIONAL,['NA']
1447,NCT06079008,The proportion of cardiac valve calcification between survival group and mortality group,,,2016-06-01,COMPLETED,OBSERVATIONAL,['NA']
1448,NCT01948037,Change from the intensity of numbness and cold feeling at 4 weeks. Change from the improvement of the pain index at 4 weeks.,Change from ankle-brachial index at 4 weeks,Change from flow velocity values at 4 weeks,2012-01,UNKNOWN,INTERVENTIONAL,['NA']
1449,NCT03530579,Change in hip-to-waist ratio measurements,,,2014-02-13,COMPLETED,INTERVENTIONAL,['NA']
1450,NCT04323462,Wound Healing,time to ulcer healing,amputation,2021-10-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
1451,NCT01588743,AUC75-120 of Glucose Infusion Rate (GIR),AUC0-10 of Acute Insulin Response (AIR) during IVGTT,,2008-10,UNKNOWN,INTERVENTIONAL,['NA']
1452,NCT02276950,All-cause mortality,Composite,,2011-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
1453,NCT00308451,Primary(baseline versus final): AUCg as recorded from a 2-hour OGTT with 75 g glucose beverage; fructosamine; fasting plasma glucose.,"Secondary (baseline versus final): Lipid panels (Total-C, HDL, LDL, VLDL), lipid ratios , apolipoprotein A and B.",,2003-11,COMPLETED,INTERVENTIONAL,['NA']
1454,NCT00241904,HbA1c,Patients' Satisfaction With Care and Health Care Utilization,,2006-05,COMPLETED,INTERVENTIONAL,['PHASE4']
1455,NCT05103306,Changes in HbA1c From Baseline to months 36,Percentage of patients with at least 1 episode of genitourinary tract infections,,2017-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
1456,NCT05023798,Exploratory Usability Objective,,,2021-09-15,UNKNOWN,OBSERVATIONAL,['NA']
1457,NCT01970241,Mean POC Glucose Level Between Groups,Episodes of Hypoglycemia Between NPH and Control Groups,Correlation of C-peptide With Length of Stay,2014-07,COMPLETED,INTERVENTIONAL,['PHASE4']
1458,NCT01394510,Fasting Urine F2 Alpha Isoprostane Levels,Oral Disposition Index,,2011-06,COMPLETED,INTERVENTIONAL,['NA']
1459,NCT04117022,Full-field flicker ERG (ffERG) Measurements: magnitude (microvolts) and the phase (milliseconds) and the area ratio for magnitude and the area ratio for Phase,Optical coherence tomography angiography (OCTA): radial macular and optic nerve capillary density (number/square millimeter),,2019-09-01,UNKNOWN,INTERVENTIONAL,['NA']
1460,NCT03719911,Change in Hemoglobin A1c,,,2018-08-05,COMPLETED,INTERVENTIONAL,['NA']
1461,NCT03495349,"Occurrence of adverse effects in patients treated by antibiotherapy for diabetic foot infection, assessed by clinical or biological methods",,,2018-06-05,COMPLETED,OBSERVATIONAL,['NA']
1462,NCT02256332,Post prandial blood glucose positive incremental area under the curve,Post prandial insulin area under the curve,Intestinal discomfort,2015-01,COMPLETED,INTERVENTIONAL,['NA']
1463,NCT00657943,Carotid intima media thickness,adverse events,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE4']
1464,NCT03445702,Lactate to pyruvate ratio,Genomic testing,,2018-10-15,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
1465,NCT06200532,Ease of use scores,,,2024-01-31,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1466,NCT00442884,change of glucose measurements after stress test in the fasting and fed state,,,2006-02,COMPLETED,INTERVENTIONAL,['NA']
1467,NCT03739034,high density lipoprotein cholesterol,full plate,,2018-06-28,COMPLETED,INTERVENTIONAL,['NA']
1468,NCT01117831,Lipids goal achievement,Achievement of National Clinical Practice Recommendations among Puerto Rican Population with Diabetes Mellitus,Achievement of National Clinical Practice Recommendations among Puerto Rican Population with Diabetes Mellitus,2010-03,COMPLETED,OBSERVATIONAL,['NA']
1469,NCT00633997,"Skin concentration of vildagliptin and its two metabolites, LAY151 and LAF237-O-Glucuronide, compared to the plasma concentration on Day 10","10 day's treatment with vildagliptin 50 mg orally twice daily on hematology, blood chemistry and physical exams in healthy volunteers and patients with type 2 diabetes",,2008-02,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1470,NCT01482247,Functional transcranial doppler measures,Finger Blood Flow - Plethysmography (PAT),,2012-04,COMPLETED,INTERVENTIONAL,['PHASE2']
1471,NCT05365438,Volume of carotid artery plaque,Changes of gut microbiota,,2022-10-01,RECRUITING,INTERVENTIONAL,['PHASE4']
1472,NCT02931773,Sympathetic hyperactivity in recently diagnosed DM2 patients,,,2016-08,UNKNOWN,OBSERVATIONAL,['NA']
1473,NCT04269668,Percentage of time of glucose sensor readings below 54 mg/dl,incidence of DKA,INSPIRE questionnaire measures,2020-07-19,COMPLETED,INTERVENTIONAL,['NA']
1474,NCT04529889,Change of obesity status during childhood and adolescence,Change of type 2 diabetes during childhood and adolescence,,2012-02-01,RECRUITING,OBSERVATIONAL,['NA']
1475,NCT02061124,Incremental and total area under the Concentration-Time Curve (AUC 0-240 min),Incremental and total area under the Concentration-Time Curve (AUC 0-240 min),Visual analog scale score,2014-02,COMPLETED,INTERVENTIONAL,['NA']
1476,NCT06152536,Physiopathology of glucose after two different meals,Physiopathology of insulin after two different meals,,2022-06-09,RECRUITING,INTERVENTIONAL,['NA']
1477,NCT04391088,number of diabetic patients up to date with their mandatory and recommended vaccinations,number of patients vaccinated during hospitalization,,2019-05-01,COMPLETED,OBSERVATIONAL,['NA']
1478,NCT05407831,HOMA Index and Beta cell function,MODY probability >25%,,2022-03-15,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
1479,NCT01358981,Number of Participants With Clinically Significant Adverse Effects,C-Peptide Area Under the Effective Concentration Curve (AUEC),,2011-05-24,COMPLETED,INTERVENTIONAL,['PHASE1']
1480,NCT05019508,We will assess the predictive ability of fetal Cardiac Function Parameter for diagnosis of Gestational Diabetes Mellitus by oral glucose tolerance tests,Secondary neonatal outcomes,,2021-08-13,UNKNOWN,OBSERVATIONAL,['NA']
1481,NCT01236365,Hs-CRP Levels Assessed at Randomization and 6 Months,Descending Aortic Strain,,2010-10,COMPLETED,INTERVENTIONAL,['PHASE3']
1482,NCT03622359,Lower extremity perfusion,Limb salvage,,2017-02-17,RECRUITING,INTERVENTIONAL,['NA']
1483,NCT00286494,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26.,Change From Baseline in Body Weight (Week 26).,,2006-02,COMPLETED,INTERVENTIONAL,['PHASE3']
1484,NCT03743779,weight,adherence,,2018-09-09,COMPLETED,OBSERVATIONAL,['NA']
1485,NCT01092806,The primary objective is to compare insulin secretion (Secr2.phase) between the two different formulations of Tac.,insulin sensitivity,,2009-10,COMPLETED,INTERVENTIONAL,['PHASE4']
1486,NCT06322212,Assess anxiety in T2DM adults with thiamine treatment.,,,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1487,NCT06123871,Statistical analysis and target gene prediction of misexpressed mirnas and enrichment pathway analysis,,,2020-06-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
1488,NCT02432586,Change in Hemoglobin A1c one month pre-camp to one month post-camp Session 2,Change in Behavioral Pediatrics Feeding Assessment one month pre-camp to one month post-camp Session 2,,2014-07,COMPLETED,INTERVENTIONAL,['NA']
1489,NCT05543720,Death and/or all-cause unplanned readmission,Days alive and out-of-hospital,,2022-10-17,RECRUITING,INTERVENTIONAL,['NA']
1490,NCT05873049,Artificial dermis (AD) or split-thickness skin graft (STSG) take rate,Vancouver scar score on 180 days,,2022-02-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
1491,NCT02324842,Fasting Plasma Glucose (FPG) at 4 Months,Body Mass Index (BMI) at 4 Months,Change in 24-hour Blood Pressure at Study End Compared to Baseline.,2014-11,COMPLETED,INTERVENTIONAL,['NA']
1492,NCT03830216,CGM time in range,Change in patient reported outcomes - HCS,Number of insulin dose administrations,2019-05-30,TERMINATED,INTERVENTIONAL,['NA']
1493,NCT04789993,Type of additional autoimmune diseases at type 1 diabetes diagnosis,Occurence of specific treatment onset in patients followed for type 1 diabetes with thyroid dysfunction due to Hashimoto,,2021-03-15,UNKNOWN,OBSERVATIONAL,['NA']
1494,NCT03279627,"Patient understanding of discharge instructions for home diabetes therapy according to presence or absence of hypoglycemia (defined as BG < 70 mg/dl), hyperglycemia (defined as BG > 250 mg/dl), or BG 70-250 mg/dl at time of hospital discharge",Association between patient understanding of home diabetes therapy and frequency of ER visits and hospital readmissions at 30- and 90-day following the index hospitalization,,2017-08-28,COMPLETED,OBSERVATIONAL,['NA']
1495,NCT00705861,"Erectile Function domain score (sum of Question 1,2,3,4,5 and 15) of the International Index of Erectile Function (IIEF) Questionnaire","the score from : 1) IIEF Q3 & Q4, 2) other domains of IIEF, 3) Sexual Encounter Profile(SEP)Q2 and Q3, 4) Life Satisfaction Checklist, 5) Global Efficacy Assessment Question(GEAQ)",,2007-11,COMPLETED,INTERVENTIONAL,['PHASE3']
1496,NCT02752412,Change from baseline in HbA1c,Measurement of anti-insulin antibodies from baseline,,2016-05-17,COMPLETED,INTERVENTIONAL,['PHASE3']
1497,NCT01867970,Physical activity,Physical activity in daily life,Health status,2013-04,COMPLETED,INTERVENTIONAL,['NA']
1498,NCT05602532,TyG index in type 2diaberes Mellitus,,,2022-11-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
1499,NCT00433823,,,,2007-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
1500,NCT01538485,Increase of regulatory FOXP3+ T cells,serum calcium level,,2012-01,COMPLETED,INTERVENTIONAL,['PHASE4']
1501,NCT05435677,"Dose-normalised AUCSema,0-tz: Area under the plasma semaglutide concentration-time curve after a single dose divided by dose",Adverse events,,2022-06-22,COMPLETED,INTERVENTIONAL,['PHASE1']
1502,NCT03761251,Hemoglobin A1c,,,2018-10-31,COMPLETED,INTERVENTIONAL,['NA']
1503,NCT01664676,Glomerular Filtration Rate (51Cr-EDTA plasma clearance),Plasma concentrations of various hormones,,2012-12,COMPLETED,INTERVENTIONAL,['PHASE4']
1504,NCT02064348,"QTcI, (Individual heart rate corrected QT (Interval in the ECG: from the start of the QRS complex to the end) interval) based on ECG recordings obtained at 11 time points","QTcI, based on ECG (electrocardiogram) recordings obtained at 2 out of 8 time points",,2014-02-26,COMPLETED,INTERVENTIONAL,['PHASE1']
1505,NCT01557296,Metabolic Control - HbA1c,"gastrointestinal symptoms - Questionnaire: Patient Assessment of upper Gastrointestinal Disorders Symptoms, Gastrointestinal Symptom Rating Scale",,2007-09,COMPLETED,INTERVENTIONAL,['PHASE2']
1506,NCT00285909,PPAR-gamma activated gene expression,Postprandial changes of HPA-axis activity,,2006-03,COMPLETED,INTERVENTIONAL,['NA']
1507,NCT05099367,Exploring PGI2 pathway in skin microvascular reactivity,role of PGI2 pathway on cell migration in vitro,,2021-10-01,RECRUITING,INTERVENTIONAL,['NA']
1508,NCT04509362,TIR (70-180 mg/dl,Diabetic Ketoacidosis,,2020-10-01,COMPLETED,OBSERVATIONAL,['NA']
1509,NCT01787396,HbA1c,,,2013-04,COMPLETED,INTERVENTIONAL,['PHASE3']
1510,NCT00478595,Relative change from baseline in in body weight,Safety: overview of adverse events,,2007-04,TERMINATED,INTERVENTIONAL,['PHASE3']
1511,NCT03034798,Blood glucose concentrations,Participants estimated blood glucose concentration,,2015-01-14,COMPLETED,OBSERVATIONAL,['NA']
1512,NCT02841553,Changes in C-peptide levels in participants,Changes in best-corrected visual acuity in participants measured by Snellen optotype,,2011-07,RECRUITING,OBSERVATIONAL,['NA']
1513,NCT02807974,Change from baseline in sitting systolic and diastolic blood pressure,Time course of urine-albumin-to-creatinine ratio,,2016-06,COMPLETED,INTERVENTIONAL,['PHASE3']
1514,NCT03211195,Assessment of PK parameter: AUC,Treatment emergent adverse events (TEAE),,2017-06-29,COMPLETED,INTERVENTIONAL,['PHASE1']
1515,NCT03278587,Cataract surgical rate,Number of cases of ocular disease detected,,2018-05-31,COMPLETED,INTERVENTIONAL,['NA']
1516,NCT03678896,Change from baseline in hemoglobin A1c levels at 6 months,Change from baseline in self-reported health,,2017-01-05,COMPLETED,INTERVENTIONAL,['NA']
1517,NCT03467503,Maternal inflammation,Maternal dietary intakes,Maternal metabolomics,2018-05-01,COMPLETED,INTERVENTIONAL,['NA']
1518,NCT06336239,The prevalence of albuminuria,Evaluate the management of patients with type 2 diabetes mellitus and cardiovascular disease across different levels of cardiology departments in hospitals.,Exploratory Objective,2023-12-21,RECRUITING,OBSERVATIONAL,['NA']
1519,NCT02556918,Number of Patients With Persistent Hyperglycemia,Number of Subjects Returning to the ER Within 30 Days,,2016-01,COMPLETED,INTERVENTIONAL,['PHASE4']
1520,NCT00202618,A 50% reduction in UAE from the baseline,A change in high sensitivity C-reactive protein (hsCRP) from the baseline to the end of the intervention period,,2003-12,UNKNOWN,INTERVENTIONAL,['PHASE4']
1521,NCT00615368,Cognitive function,Hypoglycemic hormonal response,,2008-05,COMPLETED,INTERVENTIONAL,['NA']
1522,NCT00797615,The primary outcome measure will be the between-group differences in BMI and body fat.,Secondary outcomes will include dietary intake and physical activity.,,2008-11,COMPLETED,INTERVENTIONAL,['NA']
1523,NCT05576298,Area under the glucose infusion rate curve from administration to end of clamp from time zero to 24 hours,Maximum glucose infusion rate,,2021-10-08,COMPLETED,INTERVENTIONAL,['PHASE1']
1524,NCT01421966,Proportion of patients with complete healing/closure of their target ulcer at any time during the 16-week double-blind core treatment period with sustained complete closure for 4 additional weeks of follow-up.,Proportion of patients whose Target Ulcer completely closed during the core double blind treatment phase and remained closed at the FU12 follow-up visit.,,2011-08,COMPLETED,INTERVENTIONAL,['PHASE3']
1525,NCT00592332,Catecholamine levels,,,2005-06,COMPLETED,INTERVENTIONAL,['NA']
1526,NCT06165159,The primary outcome corresponds to the score obtained after completing the study questionnaire. The questionnaire is completed at the participation agreement.,,,2024-01-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
1527,NCT01690208,Glycemic control as measured by HbA1c compared to baseline,Control of BMI and other obesity indices compared to baseline,,2012-05,UNKNOWN,INTERVENTIONAL,['NA']
1528,NCT04306289,Changes in Pain severity,Changes in Neuropathic Pain Symptom,,2020-06-01,UNKNOWN,INTERVENTIONAL,['NA']
1529,NCT06203002,Change from Baseline to Week 8 in Average Daily Pain Score (ADPS),Change from Baseline to Week 8 in Total Neuropathic Pain Symptom Inventory (NPSI) Score,,2023-11-29,RECRUITING,INTERVENTIONAL,['PHASE2']
1530,NCT02709915,Insulin Dose,Clock Gene mRNA expression,Body Weight,2016-11,COMPLETED,INTERVENTIONAL,['NA']
1531,NCT00635492,Estimates of Probability to Remain on Initial Injectable Treatment at 12 and 24 Months.,Percentage of Patients Hospitalized Between Baseline and 24 Months,,2008-01,COMPLETED,OBSERVATIONAL,['NA']
1532,NCT03755752,Endothelial cell density,Mean corneal thickness,,2018-01-01,COMPLETED,INTERVENTIONAL,['NA']
1533,NCT01610518,postprandial blood glucose,,,2011-02,COMPLETED,INTERVENTIONAL,['NA']
1534,NCT03169413,Human Leucocytic antigen typing and mutation of adenosine triphosphate sensitive potassium channel gene in diabetic patients diagnosed under the age of one year.,dentification of possible demographic and environmental risk factors associated with increased risk of diabetes in diabetic patient under the age of one year.,,2018-01,UNKNOWN,OBSERVATIONAL,['NA']
1535,NCT00129233,"Composite cardiovascular events including fatal or non-fatal myocardial infarction, fatal or non-fatal stroke, admission due to heart failure, coronary intervention and sudden cardiac death",renal function,,2004-10,COMPLETED,INTERVENTIONAL,['PHASE4']
1536,NCT05683392,Number of other serious device-related adverse events,Number of interventions for study meal challenges,,2023-02-01,COMPLETED,INTERVENTIONAL,['NA']
1537,NCT01268813,Development of Diabetes or complication,,,2011-02,UNKNOWN,INTERVENTIONAL,['PHASE1']
1538,NCT04654676,"Changes in mean amplitude of glycemic excursions in mmol/L, Standard deviation of the mean glucose levels in mmol/L, M value in mmol/L, Mean absolute glucose in mmol/L, Continuous overlapping net glycemic action in mmol/L, Lability index in mmol/L","Area under curve above 10.0mmol/day, area under curve below 3.9mmol/day",,2018-09-15,COMPLETED,INTERVENTIONAL,['PHASE4']
1539,NCT03039933,Decrease in scores on the Hypoglycemia Fear Survey,,,2016-08,COMPLETED,INTERVENTIONAL,['NA']
1540,NCT03508739,Intact glucagon like peptide-1 (GLP-1) levels after the mixed meal,"Neprilysin enzyme (drug) activity at baseline, during sacubitril/valsartan, and during valsartan",,2018-06-01,SUSPENDED,INTERVENTIONAL,['PHASE3']
1541,NCT05368220,Impact on clinical decision-making and clinical trajectories,,,2022-05-06,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
1542,NCT00925080,"IVBG System accuracy will primarily be assessed relative to ISO 15197 criteria (i.e., within ±15 mg/dL at YSI glucose levels < 75 mg/dL, and within ±20% at YSI glucose levels >75 mg/dL).",,,2009-06,COMPLETED,OBSERVATIONAL,['NA']
1543,NCT05072353,Healing,amount of adipose stem cells used for grafting,,2021-12,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1544,NCT00706693,To determine if sucrose and fructose are equally effective as glucose in the treatment of spontaneous hypoglycemia in children with type 1 diabetes.,To determine preferred mode of treatment for hypoglycemia after completing the study.,,2003-08,COMPLETED,INTERVENTIONAL,['NA']
1545,NCT02444910,Change from baseline of the 2 hour oral glucose tolerance test (OGTT) at day 28.,Change in Insulin Sensitivity Based on Euglycemic Clamp Study,,2015-04,COMPLETED,INTERVENTIONAL,['PHASE2']
1546,NCT02998944,Obesty,,,2011-01,COMPLETED,OBSERVATIONAL,['NA']
1547,NCT05002933,Mean change in HbA1c from baseline to week 24,Mean change in body weight from baseline to Week 12 and Week 24,,2021-05-20,COMPLETED,INTERVENTIONAL,['PHASE4']
1548,NCT03323294,Fatty Acid Oxidation in Type 2 Diabetes with metformin,,,2017-10-18,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
1549,NCT01454284,Hemoglobin A1c (HbA1c),Rapid Assessment of Physical Activity (RAPA),,2012-01,COMPLETED,INTERVENTIONAL,['PHASE3']
1550,NCT00732511,"Effect of Coreg CR compared to Toprol XL on endothelial function, vascular compliance, and parameters of oxidative stress from time of randomization to study drug termination",,,2008-04,UNKNOWN,INTERVENTIONAL,['PHASE4']
1551,NCT05087225,measurement of blood glucose one month after first or second shot of mRNA based covid-19 vaccines,enhancements of hypoglycemic effects of metformin and insulin by PEG,,2021-11-11,UNKNOWN,OBSERVATIONAL,['NA']
1552,NCT06248775,Acceptability of the VITAAAL intervention,Morning void urine,,2023-11-16,RECRUITING,INTERVENTIONAL,['NA']
1553,NCT03815487,Reduction of Sensor Glucose,,,2018-11-19,COMPLETED,INTERVENTIONAL,['NA']
1554,NCT05893797,Difference in the Average Number of Missed Bolus Doses (MBDs),Change from Baseline (Run in Week 0) in Health Care Provider (HCP) Questionnaires,,2023-10-05,RECRUITING,INTERVENTIONAL,['NA']
1555,NCT00138541,Change from baseline in HbA1c at 52 weeks,Change from baseline in HOMA IR at 52 weeks,,2004-10,COMPLETED,INTERVENTIONAL,['PHASE3']
1556,NCT05081011,Attitudes Toward Medication Adherence,Glycemic Improvement,,2021-03-24,COMPLETED,INTERVENTIONAL,['NA']
1557,NCT01149421,Change From Baseline to 16 Weeks in Mean 24-hour Systolic Blood Pressure (SBP),Measurement of LY2189265 Drug Concentration for Pharmacokinetics - Area Under the Concentration Time Curve (AUC),,2010-06,COMPLETED,INTERVENTIONAL,['PHASE2']
1558,NCT01392560,Change in Glomerular Filtration Rate (GFR) After 8 Weeks of Treatment With Empagliflozin Under Controlled Conditions of Euglycaemia and Hyperglycaemia,,,2011-06,COMPLETED,INTERVENTIONAL,['PHASE2']
1559,NCT01803828,Change from Baseline in Left Ventricular torsion (°) at 5 months,Effects of PDE5i on Body composition,,2014-05,COMPLETED,INTERVENTIONAL,['PHASE4']
1560,NCT01811849,Time to 1/2 maximal insulin concentration,AUC 0-30 and AUC 0-60,,2012-08,COMPLETED,INTERVENTIONAL,['PHASE1']
1561,NCT00736515,"Decreasing value of FPG and HbA1c, dosage of insulin and control rate of FPG",Weight change,,2008-10,COMPLETED,INTERVENTIONAL,['PHASE4']
1562,NCT05139784,To define the frequency and phenotype of autoimmune T lymphocytes reactive to islet antigens in the different study groups.,To define the differences between lymphocytes in the blood and those in pancreatic lymph nodes.,,2022-10-24,RECRUITING,OBSERVATIONAL,['NA']
1563,NCT03560271,Change in Glycosylated Hemoglobin (HbA1c) from Baseline at Week 24,Proportion of subjects with decrease in HbA1c of ≥ 1.0% from Baseline at Week 24,,2018-06-18,COMPLETED,INTERVENTIONAL,['PHASE2']
1564,NCT04163757,type 2 diabetes,,,2019-01-20,COMPLETED,INTERVENTIONAL,['NA']
1565,NCT03761134,Change in hemoglobin A1c (HbA1c),Adverse events,,2018-11-30,TERMINATED,INTERVENTIONAL,['PHASE3']
1566,NCT03654313,Number of subjects with adverse events and serious adverse events as a measure of safety and tolerability of MEDI6570,Immunogenicity rate,,2018-09-28,COMPLETED,INTERVENTIONAL,['PHASE1']
1567,NCT05882071,"Proportion of patients with a history of cardio-vascular events including heart failure hospitalizations and lower limb amputation, renal events, ketoacidosis, Fournier's gangrene over the two years before the index date (initiation of SGLT2i)",Time from drug initiation to death all cause,,2023-11-15,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
1568,NCT00960882,DMMET-01 Plasmatic concentration,glycated hemoglobin,,2007-06,COMPLETED,INTERVENTIONAL,['PHASE1']
1569,NCT02549495,Systolic blood pressure,Disease control,,2013-03,COMPLETED,OBSERVATIONAL,['NA']
1570,NCT01334229,Measurement of Apolipoprotein B48 and Apolipoprotein B100 Production Rates With Stable Isotope During Postprandial Period,Measurement of Apolipoprotein B48 and Apolipoprotein B100 Fractional Catabolic Rates With Stable Isotope During Postprandial Period,,2011-04,COMPLETED,INTERVENTIONAL,['PHASE3']
1571,NCT00476931,"Total Neuropathy Score (TNS),Evoked nerve conduction velocity (NCV), Quantitative Sensory Testing (QST), %of subjects with conversion of unmeasurable to measurable NCV and NIS-LL",Safety,,2007-05,COMPLETED,INTERVENTIONAL,['PHASE2']
1572,NCT04257877,"Targeted proteomic analysis in children with DT1 (levels of certain plasma proteomics such as sorbitol, fructose, myo-inositol, scyllo-inositol, serine, lysine, tertadecanoic, palmitic, stearic, eicosanoic fatty acids)",Electrophysiological study,,2018-11-20,RECRUITING,OBSERVATIONAL,['NA']
1573,NCT01365091,"AUC From Time 0 Extrapolated to Infinite Time (AUC[0-inf]) for Metformin, Saxagliptin, and 5-Hydroxy (5-OH) Saxagliptin as a Fixed-dose Combination (FDC) and as Individual Tablets",Number of Participants With Death as Outcome and Serious Adverse Events (SAEs),,2011-06,COMPLETED,INTERVENTIONAL,['PHASE1']
1574,NCT03730610,Effects of exercise training - brain inflammation,Effects of exercise training - ectopic fat,,2019-01-30,COMPLETED,INTERVENTIONAL,['NA']
1575,NCT04641312,Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-inf]) of LY3457263,,2020-11-25,COMPLETED,INTERVENTIONAL,['PHASE1']
1576,NCT05053828,"Calculate MedWise Risk Score (TM) of <10, 11-14, 15-19, 20-30, >30 for T2D patients to examine patient risk for adverse drug events.",,,2021-09-20,COMPLETED,OBSERVATIONAL,['NA']
1577,NCT00782366,"Assess accessibility and feasibility, including positive and negative aspects of integrating predictive genomics at the clinic focusing on patients' and physicians' attitudes",Assess effects of predictive genomics on self-reported health behavior and on physician-patient interaction,,2008-03,COMPLETED,OBSERVATIONAL,['NA']
1578,NCT01316484,"Qualitative, Content Analysis of Cognitive Debriefing Data",,,2011-03,COMPLETED,OBSERVATIONAL,['NA']
1579,NCT04691219,Effect on glycated hemoglobin (A1C) (efficacy),Self-reported adverse events (safety),,2019-05-26,COMPLETED,INTERVENTIONAL,['NA']
1580,NCT01025557,Food intake,Blood glucose,,2009-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1581,NCT06120881,Feasibility of Higher Metformin Dose measured with the Feasibility of Intervention Measure (FIM),Co-efficient of variation of glucose,,2024-04-01,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
1582,NCT02421393,Effect of intervention on bone quality (trabecular bone score),Effect of intervention on fracture incidence (history or medical records and vertebral morphometry),Effect of intervention on coronary heart disease 10-year risk,2018-10-01,COMPLETED,INTERVENTIONAL,['NA']
1583,NCT02750111,Blood Glucose,,,2016-05,UNKNOWN,OBSERVATIONAL,['NA']
1584,NCT00989079,Apparent volume of distribution (Vz/F),Urinary recovery of Ertugliflozin,,2009-10-16,COMPLETED,INTERVENTIONAL,['PHASE1']
1585,NCT05774015,Fasting Blood Glucose (FBG),Serum creatinine,,2023-09-25,RECRUITING,INTERVENTIONAL,['NA']
1586,NCT01038895,Antiproteinuric effect as well as antihypertensive effect of aliskiren 300 mg / daily versus ramipril 10 mg daily in hypertensive patients with type 2 diabetes and microalbuminuria.,"Average night, systolic and diastolic blood pressure",,2009-11,UNKNOWN,INTERVENTIONAL,['PHASE4']
1587,NCT01095653,Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF]),Percentage of Participants Achieving a Therapeutic Glycemic Response (Hemoglobin A1c [HbA1C]) <7.0% at Week 24 (Last Observation Carried Forward [LOCF]),,2010-06,COMPLETED,INTERVENTIONAL,['PHASE3']
1588,NCT03970031,"Change in the weighted average of standardized AST, CK-18, and HbA1c values (standard deviations) from baseline to Week 26","Time to first event of death or adjudicated non-fatal MI or USA hospitalization, adjudicated hospital admission for HF, adjudicated nonfatal ischemic stroke, or liver event in all randomized subjects.",,2022-06,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
1589,NCT00442988,,,,2000-10,COMPLETED,OBSERVATIONAL,['NA']
1590,NCT01472432,Capillary Density,iNOS,,2011-05,COMPLETED,INTERVENTIONAL,['PHASE4']
1591,NCT02613897,Change in Endogenous Glucose Production (EGP),Change in Free Fatty Acids (FFA),,2016-01,COMPLETED,INTERVENTIONAL,['NA']
1592,NCT04634500,Change from baseline in HbA1c,,,2020-11-18,COMPLETED,INTERVENTIONAL,['PHASE3']
1593,NCT02672280,Percentage of wound closure as determined,Percentage area of re-grafting as determined,,2016-05,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1594,NCT01887431,Change in Glycosylated Hemoglobin (Hba1c),Patients' satisfaction,,2013-10,COMPLETED,INTERVENTIONAL,['NA']
1595,NCT01408888,Pharmacokinetics: Maximum Observed Drug Concentration (Cmax) of Sitagliptin,Pharmacokinetics: Time of Maximum Observed Drug Concentration (Tmax) of LY2189265,,2011-08,COMPLETED,INTERVENTIONAL,['PHASE1']
1596,NCT03312439,Non-communicable disease assessed by the Swedish national patient register,,,2012-06-01,UNKNOWN,INTERVENTIONAL,['NA']
1597,NCT03029351,change from baseline in albuminuria levels,Change in Nrf-2/keap-1,,2017-01-10,TERMINATED,INTERVENTIONAL,['PHASE4']
1598,NCT01650129,Glycosylated haemoglobin A1c (HbA1c),Insulin doses,,2000-12-13,COMPLETED,INTERVENTIONAL,['PHASE3']
1599,NCT05057065,Efficacy of NAs therapy,Incidence of liver fibrosis and cirrhosis,,2021-09-15,UNKNOWN,OBSERVATIONAL,['NA']
1600,NCT01439672,Insulin Sensitivity,,,2010-08,COMPLETED,INTERVENTIONAL,['NA']
1601,NCT04105348,effect of IBD on DM,,,2019-10-01,UNKNOWN,OBSERVATIONAL,['NA']
1602,NCT02523222,Treatment failure of at-risk infants,,,2016-07,COMPLETED,INTERVENTIONAL,['NA']
1603,NCT02589639,Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) After 16 Weeks of Treatment.,Percentage of Patients With Investigator Defined Drug-Related Adverse Events (AEs),,2015-10-28,COMPLETED,INTERVENTIONAL,['PHASE4']
1604,NCT01251510,GLP-1 secretion,,,2010-10,COMPLETED,OBSERVATIONAL,['NA']
1605,NCT03485092,left ventricular global longitudinal strain (GLS),Intensification of diuretic therapy,DNA and epigenetics,2018-03-16,COMPLETED,INTERVENTIONAL,['PHASE4']
1606,NCT04053712,Number of carbohydrate interventions to treat hypoglycemia,Mean Borg scale level during exercise (RANGE:0-10),,2019-07-16,COMPLETED,INTERVENTIONAL,['PHASE4']
1607,NCT00823940,"Pharmacokinetic parameters: AUC, Cmax, Tmax, t1/2, tlag, Cl/F, and V/F","Pharmacodynamic parameters may include change from baseline in glucose, insulin, C-peptide and AUC following administration of IV glucagon in a standardized GC test with and without prior administration of GSK1362885",,2009-01-13,COMPLETED,INTERVENTIONAL,['PHASE1']
1608,NCT05546138,Progression and regression of neuropathy,Correlation between central and peripheral measurements,fMRI as a marker for progression of neuropathy,2023-10-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
1609,NCT00308386,"% of patients at goal for all three parameters (HbA1C <7, BP <130/80, LDL <100)",Physician satisfaction - survey filled out by physician,,2006-08-10,COMPLETED,INTERVENTIONAL,['PHASE3']
1610,NCT04894903,Number of Diabetes Care Gaps at 12 months,Reported Services Completed Outside Vanderbilt System,,2022-04-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
1611,NCT04831697,Change in Glycemic Control from Baseline to 6 months,Change in Health Related Quality of Life from Baseline to 6 months,,2021-12-14,RECRUITING,INTERVENTIONAL,['NA']
1612,NCT01888796,Change in left ventricular diastolic function,Change in serum NT-pro BNP levels,,2013-09,TERMINATED,INTERVENTIONAL,['PHASE3']
1613,NCT04383015,Time in glucose target range during exercise intervention,Recovery Interstitial Glucose,,2018-10-31,COMPLETED,INTERVENTIONAL,['NA']
1614,NCT01427699,Safety and Tolerability,Preliminary Efficacy,,2011-06-30,COMPLETED,INTERVENTIONAL,['PHASE2']
1615,NCT05443334,Change in HbA1c,"DTSQs, change in absolute treatment satisfaction",,2020-11-10,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
1616,NCT02500186,Change in blood glucose level using CGM,Adverse events,,2015-05,COMPLETED,INTERVENTIONAL,['NA']
1617,NCT04001231,Ctrough,The presence and titer of anti-exenatide antibodies,HbA1c,2020-06-30,WITHDRAWN,INTERVENTIONAL,['PHASE1']
1618,NCT04556760,Change in glucose AUC(0-4) versus baseline compared to prednisolone following a standardised MMTT,Safety and tolerability of AZD9567 by assessing the number of participants with adverse events,,2020-11-26,COMPLETED,INTERVENTIONAL,['PHASE2']
1619,NCT03350191,Glucagon receptor occupancy,Change lipid biomarkers,,2017-12-20,COMPLETED,INTERVENTIONAL,['PHASE1']
1620,NCT03968354,Measure of RANKL mRNA expression in the liver,NF-kB pathway in hepatocytes and Kupffer cells,,2020-02,UNKNOWN,OBSERVATIONAL,['NA']
1621,NCT00784966,The functional capability of the islet allograft to normalize glucose metabolism in the absence of insulin therapy.,Reduction in insulin requirements in those patients who do not achieve insulin independence with improved metabolic control.,,2011-08,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1622,NCT04055480,Time spent in the target glucose range from 3.9 to 10.0 mmol/l based on subcutaneous glucose monitoring (CGM).,"Total, basal and bolus insulin dose",Utility evaluation is the frequency and duration of use of the closed-loop system at home.,2019-08-10,COMPLETED,INTERVENTIONAL,['NA']
1623,NCT02130180,Mean Optic Nerve Sheath Diameter,,,2014-04,UNKNOWN,OBSERVATIONAL,['NA']
1624,NCT01403831,Hemoglobin A1C at 6 months,Diabetes knowledge,,2011-07,COMPLETED,INTERVENTIONAL,['NA']
1625,NCT02745613,Insulin sensitivity,Myokine concentrations,,2016-04,COMPLETED,INTERVENTIONAL,['NA']
1626,NCT01801631,Change in Diabetes related distress,Change in Biomedical variables,Change in Spousal support,2011-10,COMPLETED,INTERVENTIONAL,['NA']
1627,NCT01326598,The primary objective is to compare change of average glycemic control as measured by A1C from baseline to the end of V-Go use for the whole cohort as well as each of the five categories of baseline treatment.,To describe changes in participants' weight from the beginning to the end of the study.,,2012-01,COMPLETED,OBSERVATIONAL,['NA']
1628,NCT01115205,Change in haemoglobin A1c (HbA1c) levels,Compliance with walking sessions,,2006-03,COMPLETED,INTERVENTIONAL,['NA']
1629,NCT03294915,Insulin sensitivity,Glycemic control,,2018-10,UNKNOWN,INTERVENTIONAL,['NA']
1630,NCT03213093,the rate of incidence of diabetic foot ulcer,Neurovascular response to pressure,,2017-12-01,RECRUITING,INTERVENTIONAL,['NA']
1631,NCT03848533,Nuclear anomalies frequency,Serum Lactate,Treatment attachment,2019-08-22,UNKNOWN,INTERVENTIONAL,['PHASE2']
1632,NCT01959984,The c-peptide level.,"The plasma glucose, insulin, c-peptide and relevant incretin hormones level during ""75g Oral Glucose Tolerance Test"", ""100g Standard Noodles Tolerance Test"" and ""100g Steamed Bread Tolerance Test"".",Safety,2013-01,UNKNOWN,INTERVENTIONAL,['NA']
1633,NCT00576277,Pharmacodynamic profile,Correlation between plasma concentrations of AV411 and pain intensity assessments,,2006-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1634,NCT02510664,Acceptability: Number of Participants That Felt the Intervention Was Well-Received,"Provider-family Relationship, Provider-report",,2014-07,COMPLETED,INTERVENTIONAL,['NA']
1635,NCT01289587,Aerobic fitness,Adherence/Attendance: Number of physical activity sessions attended,,2011-02,COMPLETED,INTERVENTIONAL,['NA']
1636,NCT03603990,Visual acuity,,,2018-09-01,WITHDRAWN,INTERVENTIONAL,['NA']
1637,NCT01374854,c-peptide area under the curve during OGTT,insulin area under the curve during OGTT,,2009-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1638,NCT04428606,Blood glucose effects of dietary supplement: Metabolic Rheostat vs. Butyrate Ultra,Impact of Metabolic Rheostat and Butyrate Ultra on food addiction and cravings,,2021-04-01,COMPLETED,INTERVENTIONAL,['NA']
1639,NCT01271517,HbA1c,IGF-I,,2005-09,UNKNOWN,INTERVENTIONAL,['PHASE4']
1640,NCT02314533,urinary albumin to creatinine ratio (mg/g),,,2014-12,UNKNOWN,INTERVENTIONAL,['PHASE4']
1641,NCT00208221,Microalbuminuria,systolic blood pressure,,2006-08,TERMINATED,INTERVENTIONAL,['PHASE3']
1642,NCT06084468,Incidence of heart failure,Number of Participants with admission with stroke,,2023-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
1643,NCT01165190,,,,2008-05,UNKNOWN,OBSERVATIONAL,['NA']
1644,NCT00643110,Completion of 6 subjects.,,,2008-04,WITHDRAWN,INTERVENTIONAL,['NA']
1645,NCT02029924,Area under the curve (AUC),"Safety and Tolerability: adverse events, local tolerability, vital signs variation, ECG, laboratory safety parameters",,2013-12,COMPLETED,INTERVENTIONAL,['PHASE1']
1646,NCT04285983,Percentage of Participants who had One or More Adverse Reactions,,,2020-03-01,COMPLETED,OBSERVATIONAL,['NA']
1647,NCT05574231,Effect on medical diseases,,,2022-11,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
1648,NCT03190798,Change in Pulmonary capillary wedge pressure (PCWP),Change in Pulmonary capillary wedge pressure (PCWP),,2017-09-01,WITHDRAWN,INTERVENTIONAL,['PHASE4']
1649,NCT00790205,Percentage of Participants With First Confirmed CV Event of Major Adverse Cardiovascular Event (MACE) Plus (Intent to Treat Population),Percentage of Participants With Initiation of Co-interventional Agent (Intent to Treat Population),,2008-12-10,COMPLETED,INTERVENTIONAL,['PHASE3']
1650,NCT02926079,Metabolic flexibility - Mother,Oxygen consumption rates in umbilical cord mesenchymal stem cells,,2017-05-23,COMPLETED,OBSERVATIONAL,['NA']
1651,NCT03742440,Number of Participants With Complete Closure of the Index Ulcer,Total Adverse Events,,2018-11-20,COMPLETED,INTERVENTIONAL,['PHASE4']
1652,NCT03593746,Glycemic control,Other Biochemical Analyzes,,2020-08-01,RECRUITING,INTERVENTIONAL,['NA']
1653,NCT02466217,Immune cells phenotyping expressed as the each cell type % within total PBMCs,Characterization specific and common variations in immune cells frequencies between patients - between Disease cohorts,,2015-07-29,COMPLETED,OBSERVATIONAL,['NA']
1654,NCT01083212,PK of AZD1656 when administered with placebo or following repeated dosing of gemfibrozil by assessment of AUC and Cmax.,"Safety of AZD1656 when administered with placebo or following repeated dosing of gemfibrozil by assessment of electrocardiogram, weight, pulse, blood pressure, laboratory variables including 24-h plasma glucose, physical examination and adverse events",,2010-03,COMPLETED,INTERVENTIONAL,['PHASE1']
1655,NCT02252965,Overall Gastrointestinal (GI) Tolerability Assessed as Percentage of Subjects With Gastrointestinal Adverse Events During Treatment Period,Percentage of Subjects Who Are Compliant to Treatment,,2014-12,COMPLETED,INTERVENTIONAL,['PHASE4']
1656,NCT00252018,Improvement of endothelial function as measured by FMD,,,2006-01,COMPLETED,INTERVENTIONAL,['NA']
1657,NCT02621489,The degree of non-covered stent struts by Bydureon add on to Insulin over that of Insulin as analyzed by optical coherence tomography (OCT).,"Gene expression (Affymetrix) e.g., transcription factors of sirtuins (SIRT) and nitric oxide synthase (NOS)",,2015-12,COMPLETED,INTERVENTIONAL,['PHASE4']
1658,NCT06288269,1 year survival death,,,2023-11-01,COMPLETED,OBSERVATIONAL,['NA']
1659,NCT02150109,Number of Self-Test Fingerstick Blood Glucose (BG) Results Within +/- 15 mg/dL (<100 mg/dL) and Within +/- 15% (>=100 mg/dL) of Laboratory Glucose Method,Number of Subject Responses That Either 'Strongly Agree' or 'Agree' or Are 'Neutral' With Questionnaire Statements,,2014-06,COMPLETED,INTERVENTIONAL,['NA']
1660,NCT06277258,Number of Participants with adequate glycaemic control,Maternal satisfaction,,2023-01-31,RECRUITING,INTERVENTIONAL,['NA']
1661,NCT01604213,Reduction in serum levels of Interleukin 6 (IL-6),Improvement in other markers of athero-thrombosis and inflammation:,,2012-09,COMPLETED,INTERVENTIONAL,['PHASE4']
1662,NCT06069518,Average glucose concentration detected in 24-hour periods.,Magnitude and duration of periods1s of hiccups (<70 mg/dl) and hyperglycemia (>180 mg/dl) recorded in 24-hour periods.,,2023-11-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
1663,NCT01856790,Peak Post-prandial Venous Glucose Levels,the Incremental Meal-related Glucose Area Under Curve (AUC),Mean Nocturnal Glucose Levels,2013-02,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
1664,NCT06132204,PK parameters of HRS-7535: AUC0-inf,Adverse events,,2023-11,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
1665,NCT00945711,define general characteristics of the diabetes and eating disorder population,,,2010-03,COMPLETED,OBSERVATIONAL,['NA']
1666,NCT01294436,Mean Change in Seated Systolic Blood Pressure,,Mean Change in Body Weight,2011-02,COMPLETED,INTERVENTIONAL,['PHASE3']
1667,NCT03607604,Urinary C-peptide Creatinine Ratio (UCPCR),Prevalence of MODY,,2015-04-01,UNKNOWN,OBSERVATIONAL,['NA']
1668,NCT04932928,Change in HbA1c,Change in the Korean Version of Revised Summary of Diabetes Self-Care Activities Questionnaire (SDSCA-K) survey score,Change in CGM glucose variability,2021-03-23,RECRUITING,INTERVENTIONAL,['NA']
1669,NCT05620576,Change from Baseline in Average Pain Intensity as Measured by the Numeric Rating Scale (NRS),Change from Baseline on the EuroQol-5D 5 Level Questionnaire (EQ-5D-5L),,2022-11-14,COMPLETED,INTERVENTIONAL,['PHASE2']
1670,NCT04646473,HbA1c,Problem solving,,2021-04-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
1671,NCT00145288,,,,2003-10,UNKNOWN,OBSERVATIONAL,['NA']
1672,NCT02573662,Change in insulin sensitivity,Change in insulin sensitivity,,2015-04,UNKNOWN,OBSERVATIONAL,['NA']
1673,NCT03726008,Changes of biological indicator,Basic information of maternal,,2018-01-22,TERMINATED,INTERVENTIONAL,['NA']
1674,NCT01339208,Change in HbA1c % from baseline,Patient satisfaction,,2011-06,COMPLETED,INTERVENTIONAL,['NA']
1675,NCT00767741,Insulin blood level with and with out the intervention,,,2010-11,COMPLETED,INTERVENTIONAL,['NA']
1676,NCT00844194,Change of Brief Pain Inventory (BPI) Average Interference Score From Baseline to Week 12,Change of Pulse Rate From Baseline at Week 12,,2009-02,COMPLETED,INTERVENTIONAL,['PHASE4']
1677,NCT05917132,Fasting and postprandial lipid metabolite production in response to dietary lipid intervention in abdominal obesity and type 2 diabetes,Gut microbiota in response to a 2 day dietary lipid intervention in abdominal obesity and type 2 diabetes,,2023-06-12,RECRUITING,INTERVENTIONAL,['NA']
1678,NCT01671345,Patients Active Participatory Communication Behaviors,Hemoglobin A1c,,2013-11-27,COMPLETED,INTERVENTIONAL,['NA']
1679,NCT00927524,Insulin levels,,,2005-04,COMPLETED,INTERVENTIONAL,['NA']
1680,NCT02179281,Significant between-group difference in number of hypoglycemic events,,,2014-10,COMPLETED,INTERVENTIONAL,['NA']
1681,NCT05759637,Hidden Hypercortisolism prevalence in a sample of Obese patients,,,2022-05-06,RECRUITING,OBSERVATIONAL,['NA']
1682,NCT02917928,Change in Oral Glucose Tolerance Test,Change in general cognitive function,Change in body composition,2016-10,RECRUITING,INTERVENTIONAL,['PHASE2']
1683,NCT02650726,anti-inflammatory ability of HDL,endothelium-dependent flow-mediated dilatation (FMD),,2014-11,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
1684,NCT03525769,Death,Hepatocellular carcinom,Chronic kidney disease,2018-05-05,RECRUITING,OBSERVATIONAL,['NA']
1685,NCT03109951,Abnormal Glucose Levels After Colonoscopic Preparation,Number of Participants With Self-treatment and Relief of Hypoglycemic Symptoms,,2017-03-25,COMPLETED,INTERVENTIONAL,['NA']
1686,NCT02040025,Change from baseline in TCOM (Transcutaneous oximetry measurement) values,Change from baseline in hemoglobin A1C laboratory values,,2014-04,TERMINATED,OBSERVATIONAL,['NA']
1687,NCT06054841,Two hour glucose tolerance test,Primary care,,2023-05-22,RECRUITING,INTERVENTIONAL,['NA']
1688,NCT04932356,HbA1c Result,patient motivation,,2021-05-10,RECRUITING,INTERVENTIONAL,['NA']
1689,NCT00951119,The effect of the breathing device on SBP is the main study parameter,Secondary endpoints include diastolic blood pressure (DBP) and quality of life.,,2009-09,COMPLETED,INTERVENTIONAL,['PHASE3']
1690,NCT00241605,Change from baseline in HbA1c at week 48.,Change from baseline in FPG at week 48. Time to glycemic control. Change from baseline in C-peptide and insulin at week 48.,,2003-06-25,COMPLETED,INTERVENTIONAL,['PHASE4']
1691,NCT00749190,Change From Baseline in HbA1c After 12 Weeks of Treatment,Trough Concentrations of Empagliflozin in Plasma,,2008-08,COMPLETED,INTERVENTIONAL,['PHASE2']
1692,NCT03700645,hs-CRP,Diastolic function,,2018-12-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
1693,NCT02000700,Plasma concentrations of canagliflozin following multiple oral doses of canagliflozin,Number of participants with adverse events as a measure of safety and tolerability,,2014-03,COMPLETED,INTERVENTIONAL,['PHASE1']
1694,NCT05441072,Ptosis,,,2022-12-19,RECRUITING,OBSERVATIONAL,['NA']
1695,NCT05354518,Simulation Design Scale,Semi-Structured Focus Group Training Activity Evaluation Form,,2022-04-19,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1696,NCT00557518,Change from baseline in albumin excretion rate (µg/min),"Albumin:creatinine ratio(mg/g), plasma renin level, collagen markers, AGE related markers, 24 hour blood pressure determinations",,2007-11,TERMINATED,INTERVENTIONAL,['PHASE2']
1697,NCT03217409,Low density lipoprotein cholesterol (LDL-C) (%),Fibroblast Growth Factor 21,,2017-08-10,COMPLETED,INTERVENTIONAL,['PHASE4']
1698,NCT01967992,Hemoglobin A1c,Hemoglobin A1c,Body weight,2013-10,COMPLETED,INTERVENTIONAL,['PHASE2']
1699,NCT02134132,ABI,Quality of life,,2012-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1700,NCT02435693,Fasting blood glucose measurements recorded (mg/dl).Postprandial blood glucose Recorded: Fasting blood glucose measurements recorded (mg/dl).Postprandial bloodglucoseRecorded,Quality of Life score,,2012-07,COMPLETED,INTERVENTIONAL,['NA']
1701,NCT00694070,Number of Participants That Could Answer at Least 85% of the Comprehension Questions Correctly (Comprehension of the Program Reports),,,2008-07,COMPLETED,OBSERVATIONAL,['NA']
1702,NCT05263310,Any incidence of hypoglycemia,Medication-Related Outcome: Aggregate measure of diabetes medication deprescribing,,2022-04-25,RECRUITING,INTERVENTIONAL,['NA']
1703,NCT00198913,weight,psychometrics,,2002-06,COMPLETED,INTERVENTIONAL,['NA']
1704,NCT04514523,Acceptability - Clinicians,Feasibility 3,,2020-04-28,COMPLETED,INTERVENTIONAL,['NA']
1705,NCT02131948,Endogenous glucose production,,,2013-11,COMPLETED,INTERVENTIONAL,['PHASE1']
1706,NCT00001963,,,,1999-12,COMPLETED,INTERVENTIONAL,['PHASE1']
1707,NCT01997762,Change in beta cell function,Change in insulin sensitivity,change in plasma levels of resveratrol and resveratrol metabolites,2014-05,UNKNOWN,INTERVENTIONAL,['PHASE4']
1708,NCT01088165,The influence of adalimumab treatment in comparison to treatment with fumaric acid esters on the functional integrity of the endothelium will be monitored by flow mediated dilatation (FMD),Influence of adalimumab in comparison to fumaric acid esters on biochemical cardiovascular and metabolic risk factors,,2010-05,UNKNOWN,INTERVENTIONAL,['PHASE4']
1709,NCT00338104,Percentage of Blood Glucose Values Between 80 - 140,Percentage of Glucose Levels > 180 mg/dL,,2004-07,COMPLETED,INTERVENTIONAL,['PHASE4']
1710,NCT03687840,Step Length,Symmetry Index,,2017-02-14,COMPLETED,INTERVENTIONAL,['NA']
1711,NCT01156974,change in number of care goals met,Kinds of patients who benefit from working with a care guide,,2010-07,COMPLETED,INTERVENTIONAL,['PHASE2']
1712,NCT04657367,Plasma microRNAs,,,2020-02-03,RECRUITING,OBSERVATIONAL,['NA']
1713,NCT00979394,Evaluate characteristics or co morbidities being existent for patient with T2D at GP,,,2009-10,TERMINATED,OBSERVATIONAL,['NA']
1714,NCT05396079,Assessment of Flow-Mediated Dilatation,,,2023-03-28,COMPLETED,INTERVENTIONAL,['NA']
1715,NCT00841919,Pre and post- prandial glucose levels,High excursions of blood sugars (>300 mg/dl).,,2006-12,COMPLETED,INTERVENTIONAL,['PHASE4']
1716,NCT02355145,Change in the frequency of usage by physicians of the main criteria for selecting the add-on therapy in patients with inadequately metformin-controlled type 2 diabetes,Number of years until starting the add-on therapies after diagnosis,,2015-04-02,COMPLETED,OBSERVATIONAL,['NA']
1717,NCT02984514,Activity of brown adipose tissue in correlation to exogenous insulin needs using the tracer 18F-deoxy glucose in positron emission tomography measurements,Glucose uptake in muscle in correlation to exogenous insulin needs; assessment using the tracer 18F deoxy glucose in positron emission tomography measurements.,,2015-10,COMPLETED,INTERVENTIONAL,['NA']
1718,NCT00111631,Absolute change from baseline in HbAlc\n,"AEs, vital signs, laboratory tests, body weight, waist/hip ratio, ECG\n",,2005-05,COMPLETED,INTERVENTIONAL,['PHASE2']
1719,NCT05526157,Descriptive summary of patient comedications,Descriptive summary of temporal changes in the baseline characteristics of medication-specific cohorts,,2022-10-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
1720,NCT03960255,Proportion (%) of patients with complete wound healing at 24 weeks,Proportion of patients who Die,,2021-02-20,RECRUITING,OBSERVATIONAL,['NA']
1721,NCT00102388,Change from baseline in HbA1c at 104 weeks,Patients with reduction in HbA1x >/= 0.5% after 104 weeks,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE3']
1722,NCT00707668,The incidence of diabetes,Insulin sensitivity and resistance of Korean subjects,,2007-05,UNKNOWN,OBSERVATIONAL,['NA']
1723,NCT04847219,TIme in range,calorie intake,,2019-10-09,COMPLETED,INTERVENTIONAL,['NA']
1724,NCT02304718,the risk of gestational diabetes mellitus,pregnancy outcome,,2014-12,COMPLETED,INTERVENTIONAL,['NA']
1725,NCT02457858,"Islet yield using BMX-010, compared to current standard islet isolation data",AE/SAE morbidity within 1 month post-transplant,,2014-08,COMPLETED,INTERVENTIONAL,['PHASE1']
1726,NCT01538589,Adverse events,Total dose of insulin infused subcutaneously,,2003-12,COMPLETED,OBSERVATIONAL,['NA']
1727,NCT01715818,"Time to first occurrence of any component of the composite event (cardiovascular death, non-fatal myocardial infarction (MI), non-fatal stroke) as adjudicated by the Clinical Events Committee (CEC)","Time to first occurrence of a composite with components as adjudicated by the CEC: all-cause mortality, non-fatal MI and non-fatal stroke (in each of the subgroups with or without evidence of T2D at baseline)",,2012-12,COMPLETED,INTERVENTIONAL,['PHASE3']
1728,NCT05887895,Area under the Glucose Infusion Rate (GIR) - time curve (Only for HR20014 and INS062）,Incidence and severity of adverse events (AEs),,2023-05-23,COMPLETED,INTERVENTIONAL,['PHASE1']
1729,NCT03187145,Number of patients with full stomach,the mean gastric emptying time of clear liquid and light meal,Correlation of diabetes mellitus complications with delayed stomach empty,2017-06-15,UNKNOWN,OBSERVATIONAL,['NA']
1730,NCT01269034,The Role of Exenatide as Compared to Insulin Monotherapy in Reducing Postprandial Hyperglycemia.,"Postprandial Glucose Excursions, Glucagon Concentrations and Gastric Emptying in Normal Healthy Controls.",,2010-12,COMPLETED,INTERVENTIONAL,['PHASE4']
1731,NCT05655117,The detection rate of macular oedema in the intervention group vs. control group.,The screening rate for macular odema,,2023-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1732,NCT05975528,Changes of Cellular senescence markers,Changes of body composition using Inbody (cm2),,2023-08,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
1733,NCT04949568,Glucose Variability data from continuous glucose monitor (CGM) will be downloaded directly from participants provided (blinded) FreeStyle Libre Pro,"Diabetes Distress Scale (DDS) (17-item), using Numerical Rating Scale: 0-6",,2023-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1734,NCT02150707,Monocyte:chemoattractant protein 1 (MCP-1):creatinine ratio,Albumin:creatinine ratio,,2014-05,COMPLETED,OBSERVATIONAL,['NA']
1735,NCT05422092,The activity of CEPT in pmol/mL/min,The activity of CEPT in pmol/mL/min,,2022-09-20,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1736,NCT04534894,fluorescence characteristics of NAD(P)H in venous blood by FLIM can assist early diagnosis of diabetic cardiomyopathy,,,2020-10-01,UNKNOWN,OBSERVATIONAL,['NA']
1737,NCT02638246,Percentage of days conducted at least 4 tests per day.,Feasibility,,2011-04,COMPLETED,INTERVENTIONAL,['NA']
1738,NCT05473325,Signal to Noise,,,2023-01-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
1739,NCT04266171,Change in HbA1c from baseline,Compliance/Satisfaction Questionnaire,,2020-01-16,UNKNOWN,INTERVENTIONAL,['NA']
1740,NCT00634608,health information experiences of the patient,clinician feedback on the health information prescription process,,2008-02,COMPLETED,INTERVENTIONAL,['NA']
1741,NCT04853810,Percentage of skin intolerance to adhesives in diabetic patients,Evolution of lesions,,2021-05-17,COMPLETED,OBSERVATIONAL,['NA']
1742,NCT05058690,Number of participants identified with pre-diabetes/type 2 diabetes mellitus when fasting blood sample test results are compared against FatHealth algorithm results,Number of participants identified with pre-diabetes/type 2 diabetes mellitus when oral glucose tolerance test results are compared against FatHealth algorithm results,,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1743,NCT05624762,pain score,Neuropathy Deficit Score (NDS),The sensory nerve conduction velocity (SNCS),2022-07-07,RECRUITING,INTERVENTIONAL,['NA']
1744,NCT05000762,Platelet aggregation,,,2021-06-01,WITHDRAWN,OBSERVATIONAL,['NA']
1745,NCT04765631,"The main outcome is the comparison of total volumetric bone mineral density (vBMD) at the tibia and distal radius, in type 2 diabetics compared to non-diabetic subjects.",,,2020-01-01,COMPLETED,OBSERVATIONAL,['NA']
1746,NCT01454401,Ulcer Healing Within 20 Weeks,Ulcer Healing Within 12 Weeks.,,2010-10,COMPLETED,INTERVENTIONAL,['NA']
1747,NCT03907618,HbA1c,,,2018-07-01,COMPLETED,OBSERVATIONAL,['NA']
1748,NCT02603510,Frequency of infusion set occlusions,Number of adverse events,,2015-11,COMPLETED,INTERVENTIONAL,['PHASE1']
1749,NCT02307110,prevalence (percentages) of the stages of diabetic retinopathy (DR),mean NEI-VFQ 25 score,,2010-08,COMPLETED,INTERVENTIONAL,['NA']
1750,NCT02275091,small LDL particles,,,2014-10,UNKNOWN,OBSERVATIONAL,['NA']
1751,NCT04149054,Sallis Self Efficacy for Physical Activity Scale,Body weight,,2014-07-22,COMPLETED,INTERVENTIONAL,['PHASE1']
1752,NCT02360774,Change in Body Weight,Change in Glycemic Control,,2015-02,COMPLETED,INTERVENTIONAL,['PHASE4']
1753,NCT00082407,Change in Glcosylated Hemoglobin (HbA1c),Change in Rate of Hypoglycemic Events,,2003-11,COMPLETED,INTERVENTIONAL,['PHASE3']
1754,NCT03362554,Change in insulin sensitivity,Body mass,,2018-02-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
1755,NCT05813652,"Medications (appropriateness, comprehensiveness)",,,2022-10-05,RECRUITING,OBSERVATIONAL,['NA']
1756,NCT00490672,Proportion of patients able to reach treatment goals.,The safety of the drug product used in the study will be assessed using the procedure for adverse drug reactions reporting for marketed medicinal products regulated by the Malaysian regulatory authority.,,2007-08,COMPLETED,INTERVENTIONAL,['PHASE4']
1757,NCT04952948,Change in blood pressure in type-2 diabetes,,,2016-08-23,COMPLETED,INTERVENTIONAL,['NA']
1758,NCT03816488,Feasibility: recruitment rate (total number per month),Number of participants with inflammation,,2023-12-01,WITHDRAWN,INTERVENTIONAL,['PHASE1']
1759,NCT02312843,Change in cognitive performance from baseline following 6 month of high or low intensity exercise regimen,Change from baseline in blood sugar concentration and cerebrospinal fluid glucose measures during an oral glucose tolerance test following 6 months of high or low intensity exercise,Change from baseline in brain network connectivity using brain imaging,2013-03,COMPLETED,INTERVENTIONAL,['NA']
1760,NCT00417729,Oxidative stress,Adiponectin,,2007-01,COMPLETED,INTERVENTIONAL,['PHASE4']
1761,NCT03390179,glucose concentration,glucose concentraion,,2017-09-04,COMPLETED,OBSERVATIONAL,['NA']
1762,NCT00548197,Best Corrected Visual Acuity,Anatomic Status of the Retina,,2007-02,COMPLETED,INTERVENTIONAL,['PHASE1']
1763,NCT01341795,differences of sitagliptin and metformin trough concentration according to genetic variations of transporters,differences of HbA1c change according to genetic variations of transporters,,2011-07,UNKNOWN,OBSERVATIONAL,['NA']
1764,NCT03232294,The relationship between fetal abdominal wall thickness and macrosomia,,,2016-04-01,COMPLETED,OBSERVATIONAL,['NA']
1765,NCT05163912,Acceptability,,,2022-01-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
1766,NCT01443143,Percent of time in euglycemic range,Percent of time in hyperglycemic range,,2010-12,UNKNOWN,INTERVENTIONAL,['NA']
1767,NCT03638102,Sleep duration,Depressive symptoms,,2019-02-01,COMPLETED,INTERVENTIONAL,['NA']
1768,NCT03147677,Changes in 24h urinary protein quantity by comparing visits at week 20 with the baseline,Changes in urinary albumin / creatinine (UACR) of morning urine by comparing visits at week 20 with the baseline,Incidence of all adverse events (AEs) and serious adverse events (SAEs),2016-07-28,COMPLETED,INTERVENTIONAL,['PHASE4']
1769,NCT00754689,Change from baseline in A1C,Percent change from baseline in HDL-C,,2008-09,WITHDRAWN,INTERVENTIONAL,['PHASE3']
1770,NCT03374462,Improvement in A1C Levels,Acceptability of home-based telemedicine,,2017-11-27,COMPLETED,INTERVENTIONAL,['NA']
1771,NCT01319357,effect of saxagliptin compared to placebo on endothelial and vascular function of the retinal circulation,,,2010-10,COMPLETED,INTERVENTIONAL,['PHASE3']
1772,NCT01581736,insulin sensitivity,acetylation of mitochondrial adenine nucleotide translocase,,2012-04,TERMINATED,INTERVENTIONAL,['PHASE1']
1773,NCT00469339,"Examine whether a family-centered feedback approach, as compared to an individual-focused approach, encourages communications regarding family risk and the development of strategies to adopt health promoting behaviors within the household.",,,2007-04-27,COMPLETED,OBSERVATIONAL,['NA']
1774,NCT03614039,liver stiffness (LS),cytokines levels,,2015-09-15,COMPLETED,INTERVENTIONAL,['NA']
1775,NCT05608265,Successful performance of the real-time eye tracking function by post-image processing,Image Quality as assessed by user assessment of image quality parameters,,2022-08-31,COMPLETED,INTERVENTIONAL,['NA']
1776,NCT00872846,Evaluation of the of device and/or procedure related adverse events,Significant decrease in the HbA1c values from baseline,,2009-02,COMPLETED,INTERVENTIONAL,['PHASE1']
1777,NCT00567489,Change From the Baseline Value in HbA1c at Month 3 and 6,Change From Baseline of Left Ventricular (LV) Ejection Fraction as Determined by MRI at Month 6,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE4']
1778,NCT02628301,Microvascular Insulin Sensitivity,Whole Body Insulin Sensitivity,,2015-04,COMPLETED,INTERVENTIONAL,['NA']
1779,NCT01517568,"Total recovery of tritium, [3H]-liraglutide and metabolites in urine and faeces",Adverse events,,2006-11,COMPLETED,INTERVENTIONAL,['PHASE1']
1780,NCT03709966,Physical activity measurements,Motivation and auto-regulation of physical activity,Cardiometabolic measurement: Low-density lipoprotein cholesterol (LDL),2017-12-07,COMPLETED,INTERVENTIONAL,['NA']
1781,NCT04591925,Days of successful insulin delivery through the SteadiSet™ insulin infusion device versus a commercially available insulin infusion set,,,2021-02-05,TERMINATED,INTERVENTIONAL,['NA']
1782,NCT01360567,Percent change of HOMA insulin resistance and TG,Percent change of HbA1C and Cholesterol,,2011-05,COMPLETED,INTERVENTIONAL,['PHASE3']
1783,NCT02180646,Plasma Glucose Level Post-meal (AUC [0-4]),Post-meal Level of Glucose-dependent Insulinotropic Peptide (GIP) (AUC),Post-meal Glucagon-like Peptide-1 (GLP-1) Level (AUC ),2011-12,COMPLETED,INTERVENTIONAL,['NA']
1784,NCT00518102,"The number of reported cases of cancers of all kinds, grouped by organ site in patients who have used REGRANEX (becaplermin) and patients who have not used not used REGRANEX (becaplermin).",The number of reported deaths from cancer in patients who have used REGRANEX (becaplermin) and patients who have not used not used REGRANEX (becaplermin).,,2003-01,COMPLETED,OBSERVATIONAL,['NA']
1785,NCT04016012,Change in Blood glucose levels,Change of Body Mass Index (BMI),,2023-04-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1786,NCT01954472,Feasibility measured by recruitment and retention rates,Exercise history,,na,WITHDRAWN,INTERVENTIONAL,['NA']
1787,NCT02461394,Acceptance criteria defined by ISO 15197:2013 (see description),,,2015-05,COMPLETED,INTERVENTIONAL,['NA']
1788,NCT04622371,SF-36,,,2020-01-10,COMPLETED,INTERVENTIONAL,['NA']
1789,NCT00662857,Relative Bioavailability of 30 U of TI (TI Inhalation Powder B) Versus 10 U of sc Insulin Lispro,,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE2']
1790,NCT00349427,glycemic control at treatment 24-week measured by HbA1c (Glycosylated hemoglobin),"glycemic control at treatment 24-week measured by fasting plasma glucose and daily insulin dose, proportion of subjects who reduce total daily insulin dose after treatment of 8, 16, and 24 weeks",,2005-10,COMPLETED,INTERVENTIONAL,['PHASE3']
1791,NCT05022615,"Number of Ungradable ETDRS Images within the 7 standard fields of Clarus, Optos, and Standard 7 Field imaging",Reason Image Quality is compromised per image grader,,2021-09-29,COMPLETED,OBSERVATIONAL,['NA']
1792,NCT02481466,Change from baseline of the maximum vessel wall volume of the carotid arteries by MRI at year 1 and 3,Atrial Fibrillation and heart failure,Cognitive Assessment,2016-11-25,COMPLETED,INTERVENTIONAL,['NA']
1793,NCT04784975,High-resolution peripheral quantitative computed tomography (HRpQCT) strength of cortical and trabecular bone.,Glycemia,,2021-04-23,COMPLETED,OBSERVATIONAL,['NA']
1794,NCT03804879,Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs),Change From Baseline in Waist-to-hip Ratio,,2018-12-17,COMPLETED,INTERVENTIONAL,['PHASE2']
1795,NCT03914404,Changes of Total Symptom Score(TSS),Changes of EuroQol-5 Dimensions(EQ 5D),,2016-01-26,COMPLETED,INTERVENTIONAL,['PHASE4']
1796,NCT05472441,Change in Hemoglobin A1c,Change in food security assessed using the 18-item U.S. Household Food Security Survey Module,,2023-02-06,RECRUITING,INTERVENTIONAL,['NA']
1797,NCT02320526,Glycemic control,"Rate of dissappearance during a 2-step (pancreatic + hyperinsulinemic) hyperglycemic clamp, as a measure of glucose effectiveness + insulin sensitivity",Resting energy expenditure and respiratory exchange rate,2014-11,COMPLETED,INTERVENTIONAL,['NA']
1798,NCT02516657,Mean weekly blood glucose,Total Daily insulin dose,Amylase level,2012-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
1799,NCT04943926,Diabetes remission,Changes in quality of life,Changes in appetite/satiety and ketones from baseline,2022-01-04,RECRUITING,INTERVENTIONAL,['NA']
1800,NCT03086330,Change in HbA1c,Change in Fundoscopy,,2017-03-15,COMPLETED,INTERVENTIONAL,['PHASE3']
1801,NCT03929679,Change in Glycated Haemoglobin A1c (HbA1c),Patient completed the study under treatment with semaglutide (yes/no),,2019-05-28,COMPLETED,OBSERVATIONAL,['NA']
1802,NCT01892917,Target Lesion Failure (TLF),Clinical Procedural Success,,2012-09,TERMINATED,OBSERVATIONAL,['NA']
1803,NCT00913367,Mean change in HbA1c from baseline to the last visit,Adverse events,,2009-05,COMPLETED,INTERVENTIONAL,['PHASE4']
1804,NCT04289948,Work Package 3,Work Package 3: Impact on the bacterial microbiome of systemically chosen antibiotics and of anti-staphylococcal phage gel.,,2019-03-01,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1805,NCT01240252,Proportion of insulin resistant patients with elevated serine/threonine phosphorylation of IRS-1 in muscle.,Quantitative assay of the ability of insulin to clear glucose from the blood in insulin resistant patients.,,2012-03,COMPLETED,INTERVENTIONAL,['PHASE1']
1806,NCT05291351,Change in postprandial glycemic response,Treatment palatability,,2022-04-01,RECRUITING,INTERVENTIONAL,['NA']
1807,NCT01394887,presence of inflammation,presence of type 2 diabetes,,2002-07,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
1808,NCT02049814,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12,Change From Baseline in Body Weight Over Time,,2014-05-09,COMPLETED,INTERVENTIONAL,['PHASE4']
1809,NCT04692415,Changes from baseline in arterial stiffness after treatment,Changes from baseline in CRP,,2018-12-15,COMPLETED,INTERVENTIONAL,['PHASE4']
1810,NCT06151964,Drug accumulation ratio for Cmax of AZD9550 following repeat weekly SC doses,Effect of AZD9550 on amino acid levels in blood versus placebo,,2023-09-29,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1811,NCT02520921,"first main vascular event occurring within the 18 months after randomization among the following: Death (any), Myocardial infarction, Stroke, Urgent coronary revascularization and/or stent thrombosis, Acute arterial thrombotic event","Death, myocardial infarction, stroke, urgent revascularization, stent thrombosis, acute arterial thrombotic event and major bleeding analyzed specifically and separately",,2016-06-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4']
1812,NCT01740817,Muscle Insulin Sensitivity-M Value,Extracellular Signal-regulated Kinase (ERK) Phosphorylation in Muscle,,2008-01,COMPLETED,INTERVENTIONAL,['NA']
1813,NCT00598793,HbA1c,Insulin dose,,2002-11,COMPLETED,INTERVENTIONAL,['PHASE3']
1814,NCT01213940,Change in Late Outgrowth Endothelial Progenitor Cells,,,2010-09,COMPLETED,INTERVENTIONAL,['NA']
1815,NCT05251116,System Performance,,,2021-12-11,COMPLETED,INTERVENTIONAL,['NA']
1816,NCT01824043,Gain in visual acuity and transparence of vitreous in treated eyes.,,Serum glucose levels will be compared with the visual outcomes,2013-03,UNKNOWN,INTERVENTIONAL,['PHASE4']
1817,NCT06096506,Change in Hemoglobin A1c (HbA1c),Change in Diabetes Management by the Nourishing the Community Through Culinary Medicine survey (NCCM),,2023-11-08,RECRUITING,INTERVENTIONAL,['NA']
1818,NCT03260673,Comparison of the corneal endothelial cell density before-after cataract surgery,Comparison of the central corneal thickness(CCT) before-after cataract surgery,,2015-09-01,COMPLETED,OBSERVATIONAL,['NA']
1819,NCT01271062,Acute insulin response (AIR) to glucose during IVGTT will be used as a primary variable characterizing the beta cell function,• Plasma concentrations and adipose tissue expression of selected adipokines and inflammatory cytokines characterizing the adipoinsular axis,,2009-10,COMPLETED,INTERVENTIONAL,['NA']
1820,NCT02985502,Quality of Life Questionnaire,,,2016-12,UNKNOWN,OBSERVATIONAL,['NA']
1821,NCT05018026,Sugar Levels,Overall Diet Quality,,2021-09-01,COMPLETED,INTERVENTIONAL,['NA']
1822,NCT00930956,Blood glucose,,,2006-05,COMPLETED,INTERVENTIONAL,['NA']
1823,NCT04616066,The effect of phytoestrogens on HbA1C and fasting blood glucose in patients with type 2 diabetes,Determine whether date phytoestrogens affect insulin resistance,,2021-10-10,COMPLETED,INTERVENTIONAL,['NA']
1824,NCT01212133,The number of serious adverse drug reactions (SADRs) during the study period,Frequency of hypoglycaemic episodes,,2010-11,COMPLETED,OBSERVATIONAL,['NA']
1825,NCT00604396,HbA1c,Insulin antibodies,,2003-03,COMPLETED,INTERVENTIONAL,['PHASE3']
1826,NCT02722499,HbA1c,Resource Utilization and Cost,,2016-03,COMPLETED,INTERVENTIONAL,['NA']
1827,NCT06074965,Event rate of lipohypertrophy (LH),Cohort analysis by duration of diabetes,,2022-10-05,COMPLETED,INTERVENTIONAL,['NA']
1828,NCT01331681,Change From Baseline in BCVA (Best Corrected Visual Acuity) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 52 - Last Observation Carried Forward (LOCF),Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Distance Activities Subscale at Week 52 - LOCF,,2011-05-09,COMPLETED,INTERVENTIONAL,['PHASE3']
1829,NCT04219800,Sitting time,Musculoskeletal problems,General self-efficacy,2020-12-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
1830,NCT01219400,Glucagon response to hypoglycemia,Catecholamine response to hypoglycemia,,2012-01,COMPLETED,INTERVENTIONAL,['PHASE4']
1831,NCT04134650,Change from basal fasting and 2 hours glucose levels during the oral glucose tolerance test at 12 months,Change from basal insulin sensitivity at 12 months,,2019-09-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
1832,NCT01794364,Apparent Volume of Distribution (Vz/F),,,2013-01,COMPLETED,INTERVENTIONAL,['PHASE1']
1833,NCT03599401,Change in Glycosylated Hemoglobin levels,Change in Clinical attachment level,,2016-10-15,COMPLETED,INTERVENTIONAL,['NA']
1834,NCT03849612,Continuous Glucose Monitor (CGM) Measured Percentage of Time <70 mg/dL,,,2019-02-21,COMPLETED,INTERVENTIONAL,['NA']
1835,NCT02098447,change in local blood perfusion index (BPI) related to physiological state (diabetics/healthy),Adverse effects of stimulation,,2014-02,COMPLETED,INTERVENTIONAL,['NA']
1836,NCT02129946,Fasting and postprandial insulin,Satiety-producing effect,3-Day food records,2014-01,COMPLETED,INTERVENTIONAL,['NA']
1837,NCT06151821,Diabetes distress scale,Number of hypoglycemic and hyperglycemic episodes,,2023-08-01,COMPLETED,INTERVENTIONAL,['NA']
1838,NCT00006160,,,,na,COMPLETED,INTERVENTIONAL,['NA']
1839,NCT02912728,Time in glucose range 70-180,Satisfaction Questionnaire,,2017-01-30,COMPLETED,INTERVENTIONAL,['NA']
1840,NCT01956305,determine glycemic response,To assess the effects of repeated doses of DS-7309 on glucagon levels in T2DM subjects,,2013-09,COMPLETED,INTERVENTIONAL,['PHASE1']
1841,NCT01819272,Change in Fasting Plasma Glucose (mg/dL) at 4 Weeks,Change in HbA1c (%) at 12 Weeks,,2013-04,COMPLETED,INTERVENTIONAL,['PHASE2']
1842,NCT06257966,HbA1c,blood pressure,,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
1843,NCT03243058,C-peptide response,C-peptide response,HbA1c level,2023-06,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1844,NCT02218268,Determine the Difference Between Acute Effect of a Mixed Meal on Radial Artery Stiffness in Subjects With Type I Diabetes Mellitus Who do and Who do Not Take an Additional Bolus of Insulin.,,,2014-10,COMPLETED,OBSERVATIONAL,['NA']
1845,NCT00991380,Physical Activity,,,2009-10,COMPLETED,INTERVENTIONAL,['NA']
1846,NCT02486341,Intraday glycemic variability measured by the average of MAGE index (Mean amplitude of glycemic excursions) everyday of exploitable recording by the participant.,Fragility level (Rockwood criteria),,2016-03-31,COMPLETED,INTERVENTIONAL,['NA']
1847,NCT01765946,Longevity gene expression,Monocyte polarization status,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE4']
1848,NCT00489242,"To assess the difference in CFV/CFR (coronary flow velocity/coronary flow reserve) in diabetic versus non-diabetic patients and to correlate CK-MB, TnI and HsCRP release after otherwise successful coronary stenting.","Correlation of CK-MB, Troponin-I and HsCRP release with CFR<2.0, FFR<0.8 in diabetic vs non-diabetic group. Evaluation of 30-day Major Adverse Cardiac Events (MACE) defined as death, MI, or urgent revascularization.",,2003-08,COMPLETED,INTERVENTIONAL,['NA']
1849,NCT05258630,Retention in assessments,Diabetes medication adherence,,2022-02-23,COMPLETED,INTERVENTIONAL,['PHASE2']
1850,NCT03583268,Percent time spent </= 3.9 mmol/L as measured by continuous glucose monitor,Continuous overall net glycemic action (CONGA-mmol/L) as measured by continuous glucose monitor,Muscle mass as assessed by DEXA,2013-05,COMPLETED,INTERVENTIONAL,['NA']
1851,NCT05768945,Time to dementia onset,Time to Alzheimer's disease onset,,2022-11-30,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
1852,NCT02333864,Accuracy Verification of the POGO® BGMS: Minimum outcome of 95% of results within 20% of reference measurement.,,,2014-12,COMPLETED,OBSERVATIONAL,['NA']
1853,NCT00653510,Metabolic changes,Left ventricular function,,2008-03,COMPLETED,INTERVENTIONAL,['NA']
1854,NCT00950677,Glucose,exenatide concentrations,,2009-07,COMPLETED,INTERVENTIONAL,['PHASE4']
1855,NCT01824862,foveal sensitivity,Retinal thickness,,2013-01,COMPLETED,OBSERVATIONAL,['NA']
1856,NCT00359879,Change in HbA1c (glycosylated hemoglobin) from Baseline to Week 12,Changes in self-monitored blood glucose (SMBG) profile from Baseline through Week 12,,2006-09,COMPLETED,INTERVENTIONAL,['PHASE3']
1857,NCT02261545,Serum Fasting Blood Sugar(FBS),Serum HDL cholesterol,,2014-09,UNKNOWN,INTERVENTIONAL,['PHASE4']
1858,NCT00228891,Measure the stabilization or reduction of the decline of diabetic neuropathy by pt questionnaires and diagnostic tests,,,2004-02,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
1859,NCT05434754,To test the effect of a text message-based T1D transition intervention compared to control at 12 months in the Self-Efficacy for Diabetes management scale. A higher score indicates better self-efficacy.,Evaluate the impact of this text message-based intervention costs compared to usual care costs,Evaluation of intervention fidelity,2022-01-16,RECRUITING,INTERVENTIONAL,['NA']
1860,NCT01781533,the percentage of glucose values obtained every 15 min in predefined glucose ranges,Accuracy of the glucose monitoring unit,,2013-01,COMPLETED,INTERVENTIONAL,['NA']
1861,NCT04142229,Time in target glucose range,Socially evaluated cold-pressor test (SECPT),Questionnaire Score,2019-10-25,COMPLETED,INTERVENTIONAL,['NA']
1862,NCT00546325,"Change in physical examinations, vital signs, laboratory parameters, adverse events","Change in adiponectin, fasting insulin, Blood Pressure, concomitant medications, health resource use, CRP (C Reactive Protein), ALT (Alanine Aminotransferase), albumin/creatinine ratio",,2007-10,COMPLETED,INTERVENTIONAL,['PHASE3']
1863,NCT01991548,User Acceptance of the New MiniMed 640G Insulin Pump and Guardian Link Transmitter,,,2013-11,COMPLETED,INTERVENTIONAL,['NA']
1864,NCT03283566,Quotient of Stimulated C-peptide/Glucose Level Normalized for IEQ/Kg Infused in Response to MMTT,Ratio of C-peptide AUC to Glucose AUC in Response to MMTT Adjusted for Infused Islet Cell Mass,,2017-10-03,COMPLETED,INTERVENTIONAL,['PHASE2']
1865,NCT05352022,Glycemic control (HbA1c),Quality of life as measured by the Short Form Health Survey (SF-12),,2022-05-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
1866,NCT05870280,The hypoglycemıc attıtudes and behavıor,The risk perception,,2023-08-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1867,NCT01295385,"To quantify the myocardial blood flow at rest and after ""cold pressor test"" in a population of healthy volunteers",To estimate the metabolic and structural abnormalities in this population,,2011-02,UNKNOWN,INTERVENTIONAL,['NA']
1868,NCT05375695,"Participants' experiences, needs and barriers",Sexual functioning,,2022-04-01,COMPLETED,INTERVENTIONAL,['NA']
1869,NCT05408416,central retinal thickness,reoperation,,2021-09-01,COMPLETED,INTERVENTIONAL,['NA']
1870,NCT01052272,Peak Early Filling Rate Normalized to EDV,,,2005-07,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
1871,NCT02928939,Patients with diabetes mellitus and systemic corticosteroids,,,2016-10,COMPLETED,OBSERVATIONAL,['NA']
1872,NCT04076384,Patient Activation Measure (PAM-13),The Finnish Diabetes Risc Calculator (FINDRISC),,2019-08-19,COMPLETED,INTERVENTIONAL,['NA']
1873,NCT00703599,Lowering of insulin-dependence and anti-hyperglycemic medication dosages,"No detrimental change seen in kidney function tests, liver function tests and other haematological parameters.",,2007-11,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1874,NCT04025320,Pain Quality Assessment Scale,Sensory organization test (SOT),,2019-09-27,COMPLETED,INTERVENTIONAL,['NA']
1875,NCT06205030,HOMA-estimated insulin resistance,Inflammatory biomarkers,lipid profile,2024-06-14,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
1876,NCT00917930,"to evaluate the effective prevalence of glucose metabolism alterations in patients with chronic ischemic heart disease and stable chronic heart failure, without previous diagnosis of diabetes mellitus",to evaluate the potential beneficial effect of physical training on the glycometabolic state,,2006-01,COMPLETED,OBSERVATIONAL,['NA']
1877,NCT06229236,Percent of participants whose Diabetes Technology Utilization Score (DTUS) increases (based on review of last 14 days of CGM and insulin pump data),HbA1c change,Provider reported Feasibility of Intervention Measure (FIM),2024-02-13,RECRUITING,INTERVENTIONAL,['NA']
1878,NCT04795271,Change in the maximum plantar pressure (kPa),,,2020-11-12,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
1879,NCT02747108,Weight Change From Baseline to 12 Months,Change in Mental Health,,2015-12-02,COMPLETED,INTERVENTIONAL,['NA']
1880,NCT03582956,Peripheral Sensitivity to High Dose Insulin,,,2019-01-01,TERMINATED,INTERVENTIONAL,['NA']
1881,NCT00491465,fructosamine,3 days CGMS & SBGM profile,,2007-07,UNKNOWN,INTERVENTIONAL,['NA']
1882,NCT05268705,The primary endpoint is the difference between study arms in difference from start to end plasma glucose concentration during 45 min fasted cycling (assessed by YSI (Yellow Spring Instruments 2900 STAT Plus)).,Change in plasma glucose from injection of glucagon to peak plasma glucose assessed by YSI during observation phase 3,,2022-02-03,COMPLETED,INTERVENTIONAL,['NA']
1883,NCT03999125,Best Corrected Visual Acuity,Injection Count,,2019-06-25,UNKNOWN,INTERVENTIONAL,['PHASE4']
1884,NCT03439592,cardiac deaths,,,2016-01-01,UNKNOWN,OBSERVATIONAL,['NA']
1885,NCT05356884,Change in Adult Waist Circumference (WC) 6 - 12 months,Change in Adolescent Waist Circumference (WC) 6 - 12 months,,2022-07-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
1886,NCT04273412,incidence of gestational diabetes mellitus,feto-maternal,,2018-10-13,COMPLETED,INTERVENTIONAL,['NA']
1887,NCT04028427,Change in Diabetes Self-Management Questionnaire,Change in HbA1c level,,2019-10-14,COMPLETED,INTERVENTIONAL,['NA']
1888,NCT04053504,Monthly Intervention Calls Completed by Parent Leaders,Change in Degree of Impact of diabetes on the family system,,2019-05-04,COMPLETED,INTERVENTIONAL,['NA']
1889,NCT04648618,Cytokines,,,2018-01-01,UNKNOWN,OBSERVATIONAL,['NA']
1890,NCT03569501,neonatal leptin,maternal fasting plasma glucose concentration,,2017-08-01,UNKNOWN,INTERVENTIONAL,['NA']
1891,NCT02401880,• Change in glucagon release (AUC0-180 min) during Liquid Meal Test (LMT) from V3 to V4 between the two treatment groups (Linagliptin vs. placebo),• Change in glucagon release (AUC0-180 min) during LMT from V2 to V3 during treatment with Empagliflozin (V2 vs. V3),,2015-05,COMPLETED,INTERVENTIONAL,['PHASE4']
1892,NCT05483140,Program Effectiveness,Medication Usage use,Quality of Life (QOL) SF-12,2022-10-26,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
1893,NCT04569721,Number of Procedure Related Complications,Change in Fasting C-peptide Levels,,2021-02-19,WITHDRAWN,INTERVENTIONAL,['NA']
1894,NCT02795052,Change in Neurologic Function,,,2016-06,RECRUITING,INTERVENTIONAL,['NA']
1895,NCT02532088,Blood Glucose Level,Beta Cell Function,,2020-05,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1896,NCT00561132,Changes on insulin sensitivity assessed with a euglycemic-hyperinsulinemic clamp technique,Changes on anthropometrical measures,,2003-11,COMPLETED,INTERVENTIONAL,['PHASE3']
1897,NCT02162550,Change in carotid plaque volume,Change in carotid plaque composition,,2014-06,UNKNOWN,INTERVENTIONAL,['PHASE4']
1898,NCT03369899,System Related adverse device effects,,,2017-12-11,COMPLETED,OBSERVATIONAL,['NA']
1899,NCT00998335,Hepatic Steatosis,Percent Change From Baseline in Vascular Inflammatory Markers,,2007-06,COMPLETED,INTERVENTIONAL,['PHASE4']
1900,NCT04184622,Percentage of Participants Who Achieve ≥5% Body Weight Reduction,Pharmacokinetics (PK): Steady State Area Under the Concentration Time Curve (AUC) of Tirzepatide,,2019-12-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
1901,NCT01841073,Glycaemic Control,Food Intake in Gram at 9 Weeks,Percentage Change in Body Weight,2011-03,COMPLETED,INTERVENTIONAL,['NA']
1902,NCT02229487,GLP-1 Levels in Response to Oral Glucose Tolerance Test,,,2014-10,COMPLETED,INTERVENTIONAL,['NA']
1903,NCT00882336,"Gender, age, patients with diabetes and/or hypertension (%), smoker status, family medical history.","Biomarkers: Apo-A1, Apo-B, Hs-CRP, Creatinine, albuminuria, uric acid, glomerular filtration rate.",,2009-05,COMPLETED,OBSERVATIONAL,['NA']
1904,NCT00497536,CV SSPIasp,"• Δ SSPIAsp (S.C. /I.V.) • AUC IAsp • Tmax IAsp • Cmax IAsp - Bioequivalence of Iasp under SS (GIR, S-FFA, S-glycerol)",,2007-07,COMPLETED,INTERVENTIONAL,['PHASE4']
1905,NCT03027219,Flow change,,,2017-01-31,COMPLETED,OBSERVATIONAL,['NA']
1906,NCT06298799,Genetic variants and miRNA expressions associated with changes in BMI.,Genetic variants and miRNA expressions associated with changes in A1c.,Demographic parameters that affect GLP1 AG therapy.,2023-10-01,RECRUITING,INTERVENTIONAL,['NA']
1907,NCT01145534,blood glucose,Salivary glucose level,,2009-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1908,NCT00094757,Change From Baseline in A1C at Week 18,Change From Baseline in FPG at Week 54,,2004-10-06,COMPLETED,INTERVENTIONAL,['PHASE3']
1909,NCT03555565,Percentage of Participants Who Had One or More Adverse Events,Change From Baseline in Fasting Insulin Level,,2017-02-28,COMPLETED,OBSERVATIONAL,['NA']
1910,NCT01021826,Occurrence (and severity) of hyperglycemia following primary hip or knee replacement,Prevalence of glucose metabolism disorders and metabolic syndrome,,2009-12,COMPLETED,OBSERVATIONAL,['NA']
1911,NCT05824572,Patient Activation Measure-Short Form,Patient Satisfaction Questionnaire-18,,2023-09-01,RECRUITING,INTERVENTIONAL,['NA']
1912,NCT02344641,The change in plasma NT-proBNP level after using exenatide for 4 weeks,,,2015-01,UNKNOWN,INTERVENTIONAL,['NA']
1913,NCT05260814,changes in HbA1c,cytokine changes,,2022-03,UNKNOWN,INTERVENTIONAL,['NA']
1914,NCT05553145,Prevalence of autoimmune antibodies in patients with Type 2 Diabetes,Prevalence of autoimmune antibodies in patients with T2D managed by primary care,,2022-09-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
1915,NCT00641550,"Maternal outcome: preterm labor, weight gain, preeclampsia, gestational diabetes Perinatal outcome: birthweight, Apgar scores, body composition, admission at neonatal intensive care unit","Doppler flow velocimetry indexes: pulsatility, resistance and A/B relation (uterine arteries, fetal middle cerebral artery and umbilical arteries)",,2008-04,UNKNOWN,INTERVENTIONAL,['NA']
1916,NCT03810846,Rate of Enjoyment,Medication,,2018-09-17,COMPLETED,INTERVENTIONAL,['NA']
1917,NCT00156897,Absolute weight loss compared to baseline,Changes in other safety parameters,,2004-12,COMPLETED,INTERVENTIONAL,['PHASE2']
1918,NCT04723550,Glucose control (HbA1c levels),Change in biological parameter: e-GFR,Cost effectiveness,2021-01-05,UNKNOWN,INTERVENTIONAL,['NA']
1919,NCT02933164,CGM Relative Difference to Laboratory Reference reported as MARD,,,2016-10,UNKNOWN,INTERVENTIONAL,['NA']
1920,NCT00365781,"Evaluate and examine the effect of treatment on laboratory results, vital signs, and adverse events.",,,2006-08,COMPLETED,INTERVENTIONAL,['PHASE1']
1921,NCT05038761,Mean absolute relative difference (MARD%),AE with special concern: erythema/edema under the adhesive patch or at the insertion site,,2021-10-08,COMPLETED,OBSERVATIONAL,['NA']
1922,NCT04194450,Plasma Glucose,Monocyte Histone Acetylation,,2020-01-15,COMPLETED,INTERVENTIONAL,['NA']
1923,NCT02769728,Changes in insulin sensitivity,Changes in beta-cell function,,2016-02,COMPLETED,INTERVENTIONAL,['NA']
1924,NCT04970940,"Css,max of AJU-A51R1 and AJU-A51R2",,,2020-07-02,COMPLETED,INTERVENTIONAL,['PHASE1']
1925,NCT02354911,Change from baseline in the mean 2-hour area under the curve (AUC) for plasma c-peptide at 12 and 24 months,Change from baseline in Total Daily Insulin Dose,,2015-10,WITHDRAWN,INTERVENTIONAL,['PHASE2']
1926,NCT00813995,Change From Baseline in Hemoglobin A1c (A1C) at Week 24,Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24,,2008-12-09,COMPLETED,INTERVENTIONAL,['PHASE3']
1927,NCT01901757,"Metformin, rosuvastatin Cmax, AUClast","Metformin, rosuvastatin Vd/F",,2013-06,COMPLETED,INTERVENTIONAL,['PHASE1']
1928,NCT00578604,diffuse near infrared spectroscopy measurements,,,2007-09,COMPLETED,OBSERVATIONAL,['NA']
1929,NCT02561078,Change From Baseline in Hemoglobin A1c (HbA1c),Change From Baseline in Body Weight,,2015-10-20,COMPLETED,INTERVENTIONAL,['PHASE3']
1930,NCT01346046,Continuing validation of SCOUT DS algorithm,,,2011-05,COMPLETED,OBSERVATIONAL,['NA']
1931,NCT00908271,Absolute oral bioavailability,Electrocardiograms (ECGs),,2009-07,COMPLETED,INTERVENTIONAL,['PHASE1']
1932,NCT00339313,,,,2000-01-12,COMPLETED,OBSERVATIONAL,['NA']
1933,NCT00812591,Ratio between the plasma glucose level and the glucose concentration at the subcutaneous insulin delivery site,,,2006-05,COMPLETED,INTERVENTIONAL,['NA']
1934,NCT01099618,Length of Remission,,,2010-03,COMPLETED,INTERVENTIONAL,['PHASE4']
1935,NCT05383859,Change in Physical activity recommendations (mean),Change in HbA1c (Mean percentage),,2022-05-01,COMPLETED,INTERVENTIONAL,['NA']
1936,NCT00419497,area under the curve for insulin (AUC Insulin0-120) at the oral glucose tolerance test,120-min plasma insulin,,2003-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
1937,NCT02366598,Blood pressure,Energy/fatigue,,2015-05,COMPLETED,INTERVENTIONAL,['NA']
1938,NCT00425178,Pharmacokinetics,Wound improvement,,2005-09-02,COMPLETED,INTERVENTIONAL,['PHASE1']
1939,NCT04765358,Time in Range (TIR),,,2020-08-24,UNKNOWN,INTERVENTIONAL,['NA']
1940,NCT05095259,Glycogen concentration,Hypoglycemia awareness status,,2019-12-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
1941,NCT04170543,Urine albumin:creatinine ratio (UACR),Safety and tolerability by clinical laboratory evaluations,Safety and tolerability by assessment of vital signs,2019-11-18,COMPLETED,INTERVENTIONAL,['PHASE2']
1942,NCT00099619,Change in HbA1c (glycosylated hemoglobin) from the baseline of the first period (16-weeks of exenatide or insulin) to the end of each 16-week period.,Change in patient-reported outcomes from Baseline to the end of each 16-week period,,2004-09,COMPLETED,INTERVENTIONAL,['PHASE3']
1943,NCT05696964,Changes in perceptions of the patient-clinician relationship by patients of participating residents.,"Changes in the ""spirit of motivational interviewing"" rating given to the resident by the facilitator in role plays in motivational interviewing practice.",,2024-02-01,WITHDRAWN,INTERVENTIONAL,['NA']
1944,NCT02393573,Change in fasting blood glucose,length of hospital stay,,2015-11,TERMINATED,INTERVENTIONAL,['NA']
1945,NCT04040426,Percentage of index ulcers healed at 12 weeks,"Changes in peripheral neuropathy using Semmes Weinstein Monofilament ""10""point",,2019-08-06,COMPLETED,INTERVENTIONAL,['NA']
1946,NCT04256486,"Glycemic Control, Measured by Change in Adjusted Mean HbA1c(%) From Baseline at various time points",,,2022-04-21,RECRUITING,INTERVENTIONAL,['NA']
1947,NCT05770687,Major adverse cardiac and cerebrovascular events,Changes in echocardiograhic parameters,,2020-08-01,RECRUITING,OBSERVATIONAL,['NA']
1948,NCT03567408,activated clotting time(ACT),30-day bleeding events,,2018-09-15,UNKNOWN,INTERVENTIONAL,['PHASE2']
1949,NCT00001223,To develop a database and collection of samples obtained from patients with CF during their clinical care to allow for future research,,,1988-01-01,RECRUITING,OBSERVATIONAL,['NA']
1950,NCT05140798,Change in resting metabolic rate,Change in serum cortisol,,2016-04-25,UNKNOWN,OBSERVATIONAL,['NA']
1951,NCT04906213,Number of Genital infections,Changes in Hemoglobin A1C as measured by blood work,Adverse events will be collected form the medical record and patient report,2022-07-25,RECRUITING,INTERVENTIONAL,['PHASE2']
1952,NCT01137058,Target goal of HbA1c (< 7.0%) without hypoglycemia,Body mass index (BMI) changes,,2009-06,COMPLETED,INTERVENTIONAL,['NA']
1953,NCT04345120,GIP concentration changes before and after meal.,"Stable Valley concentration (ctrough, SS).",,2020-06-15,COMPLETED,INTERVENTIONAL,['PHASE1']
1954,NCT01767441,change in glucose response (pAUC) to mixed meal test between baseline and 1 month after undergoing bariatric surgery or being put on low calorie diet,changes in active GLP1 systemic bioavailability during a mixed meal test between baseline and 1 or 12 months after undergoing bariatric surgery or being put on low calorie diet.,change in HbA1c between baseline and 1 or 12 months after undergoing bariatric surgery or being put on low calorie diet.,2013-02,COMPLETED,OBSERVATIONAL,['NA']
1955,NCT02236793,Incidence of complete wound closure.,Treatment emergent adverse events.,,2014-12,COMPLETED,INTERVENTIONAL,['PHASE3']
1956,NCT00157508,Cardiac and renal hemodynamics after 4 weeks of treatment,,,2003-03,TERMINATED,INTERVENTIONAL,['PHASE2']
1957,NCT05477433,Measures frequency of psychiatric problems with diabetes mellitus type 1,,,2022-08-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
1958,NCT03805633,Change in glucose during oral glucose tolerance test (oGTT),Hemoglobin A1c (HbA1c),,2018-02-02,WITHDRAWN,OBSERVATIONAL,['NA']
1959,NCT01741103,change from baseline in mean glucose concentrations,Change in NFkappaB following meal challenge.,,2011-06,WITHDRAWN,INTERVENTIONAL,['NA']
1960,NCT01046721,superior mesenteric (SMA) blood flow,Peripheral resistance,,2009-09,COMPLETED,INTERVENTIONAL,['NA']
1961,NCT05115188,Glucose values in the oral glucose tolerance test,Participant preference - qualitative measurement,,2022-10-01,RECRUITING,INTERVENTIONAL,['PHASE2']
1962,NCT04507685,Change in Matsuda index for whole body insulin sensitivity,Change in Faecal characteristics- including short chain fatty acids (SCFAs).,Change in dietary intake (diet checklists),2020-10-19,COMPLETED,INTERVENTIONAL,['NA']
1963,NCT03472846,detection of microRNA concentration in serum,microRNAs and changes in bone metabolism under treatment,,2017-03-01,COMPLETED,INTERVENTIONAL,['PHASE4']
1964,NCT05229718,"Change in diabetes-related distress, measured by Problem Areas in Diabetes (PAID)","Change in alcohol use, measured by Alcohol Use Disorders Identification Test Consumption (AUDIT-C)",,2021-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
1965,NCT02852980,Glycemia realized after childbirth,Percentage of women who have pursued the dietary and hygiene rules,,2015-07,COMPLETED,OBSERVATIONAL,['NA']
1966,NCT06155539,Differential metabolites,,,2024-01-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
1967,NCT05185518,glucose sensing accuracy,user satisfaction,,2025-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1968,NCT03002675,The effect of exenatide on BAT activity and energy expenditure in healthy young South Asian compared to white Caucasian men,Visualisation of BAT as measured with MRI scan compared to FDG-PET CT,,2016-08,UNKNOWN,INTERVENTIONAL,['PHASE4']
1969,NCT01114763,,,,2003-06,COMPLETED,OBSERVATIONAL,['NA']
1970,NCT00205335,Hemoglobin A1C,Satisfaction with care,,2004-01,COMPLETED,INTERVENTIONAL,['NA']
1971,NCT00971659,the unadjusted 6-hour postprandial blood glucose excursion (AUCBG0-6h) following ingestion of a standardized breakfast,"mean daily blood glucose (BG) from 7-point 24h BG profiles, fasting BG, self-measured 7-point BG profiles, percentage of subjects achieving ADA HbA1c treatment goals, fasting lipid profiles, HOMA-IR index, hypoglycemic episodes",,2008-01,COMPLETED,INTERVENTIONAL,['PHASE1']
1972,NCT01888315,Safety and efficacy of renal denervation,Safety and efficacy of renal denervation,,2011-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1973,NCT05741125,Acceptability (Satisfaction): The Percentage of Participants Who Were Satisfied with the Delivery and Content of the Intervention,Changes in Binge Eating Episodes,,2024-01-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1974,NCT01771250,VLDL-TG Clearance Rate,,,2013-10,COMPLETED,INTERVENTIONAL,['PHASE1']
1975,NCT02868931,Changes in Glycemic Control Measured by A1c,Severe hypoglycaemia,,2016-04-01,COMPLETED,INTERVENTIONAL,['NA']
1976,NCT01809327,Change in Glycated Hemoglobin (HbA1c) From Baseline at Week 26,Number of Participants With Treatment Emergent Adverse Events (AEs),,2013-06-04,COMPLETED,INTERVENTIONAL,['PHASE3']
1977,NCT02758483,Compare the intraday and interday glucose variability effect of sucrose-free with a sucrose-free diet for patients with type 1 diabetes.,"Compare the interday glycemic variability effect of sucrose-free diet and sucrose-added diet, through MODD index, in patients with type 1 diabetes",,2017-03-23,COMPLETED,INTERVENTIONAL,['NA']
1978,NCT03577119,Changes in insulin sensitivity and β-cell function: OGTT,Changes to Colonic microbiota structure: relative abundance,,2018-06-01,COMPLETED,INTERVENTIONAL,['NA']
1979,NCT01486771,Establish efficacy of intravitreal pegaptanib sodium injections in causing regression of high risk proliferative diabetic retinopathy as compared to panretinal photocoagulation,Establish the efficacy of intravitreal pegaptanib injections in preventing the loss of best corrected visual acuity,,2007-11,UNKNOWN,INTERVENTIONAL,['PHASE4']
1980,NCT01977495,Enrollment and participation rates,Uptake of Device Usage,Change in Hemoglobin A1c,2013-12,COMPLETED,INTERVENTIONAL,['NA']
1981,NCT00141232,Prop of pats. who achieve measured triglycerides <1.5 mmol/L (<200 mg/dl),Prop of pats who achieve triglycerides <1.5 mmol/L (<200 mg/dl) at 52 weeks.,,2004-11,COMPLETED,INTERVENTIONAL,['PHASE4']
1982,NCT04424238,glycemic qualification rate,pregnancy outcome,,2016-03-15,UNKNOWN,INTERVENTIONAL,['NA']
1983,NCT05967260,Probability of overnight hypoglycemia,Change in weight,,2023-09-01,RECRUITING,INTERVENTIONAL,['NA']
1984,NCT01817777,Change From Baseline in HbA1c Values at Week 28,Number of Participants Withdrawn From the Study Due to the Following Reasons: Withdrawal of Informed Consent; Lost to Follow-up,,2013-05,TERMINATED,INTERVENTIONAL,['PHASE4']
1985,NCT03908762,Change in A1C,Rate of Hypoglycemia,,2019-01-01,UNKNOWN,INTERVENTIONAL,['NA']
1986,NCT01621178,Change From Baseline in Hemoglobin A1c (HbA1c),Participants With Events of Allergic/Hypersensitivity Reactions,,2012-07,COMPLETED,INTERVENTIONAL,['PHASE3']
1987,NCT01389362,Resolution/progression of foot ulcer based on PEDIS,Hospital admission/attendance/stay,,2009-05,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
1988,NCT06049420,physical activity,Self-efficacy,,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1989,NCT03078764,Diabetes related distress,Fasting blood glucose,Self-efficacy (for nurse),2017-06-09,COMPLETED,INTERVENTIONAL,['NA']
1990,NCT04200391,"Glucagon treatment success, defined as an increase in glucose level to ≥ 70 mg/dL or an Increase of ≥ 20 mg/dL from glucose nadir within 30 minutes after receiving 1 mg glucagon IM",Plasma glucose levels following glucagon administration,,2020-01-03,RECRUITING,INTERVENTIONAL,['NA']
1991,NCT03681691,Change in Uptake of Glucose and Ketone Bodies in Whole Brain and Alzheimer's Disease-related Regions of Interest.,Change in Short-term Memory and Executive Function Composite Scores.,Number of Microbleeds,2019-05-13,COMPLETED,INTERVENTIONAL,['PHASE1']
1992,NCT05349591,Adverse Events,Stimulated C-peptide level,,2022-08-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
1993,NCT02332005,change from baseline in peroneal motor nerve conduction velocity,change from baseline in VPT conduction velocity measurement,,2014-11,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
1994,NCT01731080,calcification score,site of calcification,,2012-01,UNKNOWN,OBSERVATIONAL,['NA']
1995,NCT04082390,Change in Fasting Blood Glucose (FBG) at approximately 4 weeks of the GFL System Diet with Release supplement versus GFL System Diet with placebo supplement,Change from baseline in Heart Rate between the 2 groups,,2019-10-01,UNKNOWN,INTERVENTIONAL,['NA']
1996,NCT00941369,"Health Assessment, Patient treatment satisfaction and Quality-of-Life",Hypoglycemia assessment,,2009-06,COMPLETED,INTERVENTIONAL,['PHASE4']
1997,NCT04120077,glycosylated hemoglobin (HbA1c) percentage,Color Contrast Threshold Sensitivity (minimal percentage contrast detection for each pre-specified wavelength),Macular pigment optical density (MPOD) in relative density units,2020-01-01,UNKNOWN,INTERVENTIONAL,['NA']
1998,NCT00810420,,,,2007-02,COMPLETED,OBSERVATIONAL,['NA']
1999,NCT00521937,Complete wound closure at week 12,Time to complete wound healing,,2009-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
2000,NCT03847116,Light-to-moderate alcohol consumption (LMAC) and risk of prevalent type 2 diabetes mellitus (T2DM),LMAC and incident risk of T2DM,,2009-01-01,COMPLETED,OBSERVATIONAL,['NA']
2001,NCT03804411,Body mass index,Molecular-genetic markers of endothelial damage,,2017-08-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
2002,NCT03989908,Change in insulin response,Change in satiety rating,,2019-01-13,COMPLETED,INTERVENTIONAL,['NA']
2003,NCT01613716,Visual Acuity,,,2012-07,COMPLETED,INTERVENTIONAL,['PHASE4']
2004,NCT03203811,AUC,Insulin,,2017-02-17,COMPLETED,INTERVENTIONAL,['PHASE1']
2005,NCT04496154,Fasting WAT IL-1β secretion,Insulin sensitivity and secretion,Post-hoc analysis of WAT receptors for apoB-lipoproteins and fatty acids,2013-09-05,COMPLETED,INTERVENTIONAL,['NA']
2006,NCT01579136,change in blood pressure over time,,,2011-12,TERMINATED,INTERVENTIONAL,['NA']
2007,NCT00627445,Change in Glycosylated Haemoglobin A1c (HbA1c),Number of Nocturnal Hypoglycaemic Episodes,,2008-02,COMPLETED,INTERVENTIONAL,['PHASE3']
2008,NCT04664205,Change in Fat Metabolism,Change in Continuous Glucose (Area Under the Curve),,2021-02-01,COMPLETED,INTERVENTIONAL,['NA']
2009,NCT00600262,,,,2005-12,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2010,NCT05285449,High-sensitivity C-reactive protein,,,2022-02-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2011,NCT01424046,HbA1c,Microalbuminuria,,2011-05,COMPLETED,INTERVENTIONAL,['NA']
2012,NCT05790317,"Presence of post-operative nausea, vomiting and retching",,,2022-02-14,COMPLETED,INTERVENTIONAL,['NA']
2013,NCT00335101,Quality of diagnostic information,Diabetes mellitus,,2006-06,WITHDRAWN,INTERVENTIONAL,['PHASE4']
2014,NCT05073068,Nocturnal respiratory exchange ratio,Blood glucose levels following the exercise intervention measured continuously using a continuous glucose monitor device,Feet sensitivity based on a clinical foot assessment,2022-01-25,RECRUITING,INTERVENTIONAL,['NA']
2015,NCT00629434,A1c,Diabetes Treatment Satisfaction Questionnaire,,2001-06,TERMINATED,INTERVENTIONAL,['NA']
2016,NCT00793754,Thrombin generation,C-reactive protein,,2009-03,COMPLETED,INTERVENTIONAL,['PHASE4']
2017,NCT06054126,Cardiac function evaluated by echocardiography,Cardiovascular events,,2010-01-01,RECRUITING,OBSERVATIONAL,['NA']
2018,NCT03309254,Glycemic response,Respiratory quotient and fat oxidation,,2016-01-18,COMPLETED,INTERVENTIONAL,['NA']
2019,NCT01122316,Health-Related Quality of Life (HRQoL),Creatinine Level as a Measure of Renal Function,,2009-09,COMPLETED,INTERVENTIONAL,['NA']
2020,NCT01984762,Rate of resolution of type 2 diabetes,postoperative complications,Glycemic control mechanisms,2012-09,RECRUITING,INTERVENTIONAL,['NA']
2021,NCT00148538,HbA1c at the end of the 6-month exercise period,quality of life,,2005-07,COMPLETED,INTERVENTIONAL,['PHASE3']
2022,NCT01886170,For Phase II of the Study: Change in Hemoglobin A1C,For Phase II of the Study: Understanding of diabetes control,,2013-10,COMPLETED,INTERVENTIONAL,['NA']
2023,NCT01611883,Change in Glycated Hemoglobin (HbA1c) From Baseline,Percent Change in Non-HDL-cholesterol From Baseline,,2012-07-02,COMPLETED,INTERVENTIONAL,['PHASE4']
2024,NCT01975935,Difference in Hemoglobin A1c Values,Change in Weight,,2014-01,COMPLETED,INTERVENTIONAL,['PHASE2']
2025,NCT02529449,Safety assessed by Adverse events,,,2015-09-01,COMPLETED,INTERVENTIONAL,['PHASE2']
2026,NCT00289354,Pharmacoeconomic outcomes (as deduced by changes in HbA1c),"ANCOVAs: Treatment outcomes based on treatment group compared to gender, ethnicity, age, co-morbidities, Rx medications, glycemic states at entrance, lipid status at entrance.",,2003-03,COMPLETED,INTERVENTIONAL,['NA']
2027,NCT01499095,Change in HbA1c From Baseline to Month 6 Endpoint,Percentage of Participants With Hypoglycemia (All and Nocturnal) Events From Baseline to Month 12,Change in HbA1c From Month 6 to Month 9,2011-12,COMPLETED,INTERVENTIONAL,['PHASE3']
2028,NCT05031429,"Safety, as indicated by hypoglycemia","Impact on activities of daily living, as indicated by Munich Chronotype Questionnaire (MCTQ)",,2022-01-01,COMPLETED,INTERVENTIONAL,['NA']
2029,NCT00141453,Renal Composite Outcomes,Reciprocal (1/Serum Creatinine) of Serum Creatinine,,2003-04,COMPLETED,INTERVENTIONAL,['PHASE3']
2030,NCT05497960,Program satisfaction,Perceived Stress Scale Center for Epidemiologic Studies Depression Scale (CES-D),,2022-09-01,COMPLETED,INTERVENTIONAL,['NA']
2031,NCT01620476,Area under the plasma liraglutide curve,Adverse events,,2003-09,COMPLETED,INTERVENTIONAL,['PHASE1']
2032,NCT01213888,To evaluate the effect of a copper chelator in suppressing post-PRP macular edema in eyes with retinal neovascularization.,,,2010-11,TERMINATED,INTERVENTIONAL,['NA']
2033,NCT00738153,"The incidence of serious adverse drug reactions, including major hypoglycaemic events",Sub -group analysis of hypo risk,,2008-06,COMPLETED,OBSERVATIONAL,['NA']
2034,NCT00786136,An absolute increase in SCr >=0.5mg/dL（>=44.2μmmol/L）or a >= 25% increase in SCr from baseline to 72h after the procedure,"The composite of hospitalization for aggravated renal function, acute renal failure, dialysis or hemofiltration, aggravated at least 1 class of heart function, acute left ventricular failure or death from all causes.",,2008-12,COMPLETED,INTERVENTIONAL,['PHASE4']
2035,NCT01864239,Self-reported medication adherence,Serum Cholesterol Levels,,2012-11,COMPLETED,INTERVENTIONAL,['NA']
2036,NCT01792986,Difference in Mean Glucose Level Between Baseline and the End of the Sixth Week.,Difference in Red Blood Cell Count Between Baseline and the End of the Sixth Week.,,2013-02,COMPLETED,INTERVENTIONAL,['NA']
2037,NCT05632055,miRNA profile,FGF21 profile,,2000-08-26,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
2038,NCT01346085,The Proportion of Insulin Free Patients 3 Years After the Last Islet Infusion,Any Adverse Event Throughout Follow-up,,2006-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2039,NCT05747664,AUClast of DWP16001,,,2023-02-28,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
2040,NCT05765292,C-peptide,cytokines levels,,2021-03-01,COMPLETED,INTERVENTIONAL,['NA']
2041,NCT04968171,Partial clinical remission time,Albumine to creatynine ratio ACR [mg/g],,2020-01-01,RECRUITING,OBSERVATIONAL,['NA']
2042,NCT03130244,Mean change in HbA1c,Mean change in diabetes medication,,2019-09-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2043,NCT03544892,Time in Range,Diet Quality,,2018-05-01,TERMINATED,INTERVENTIONAL,['NA']
2044,NCT01409408,Renin activity and concentration,Correlation of drug effects and left ventricular mass and function (systolic and diastolic),,2011-04,WITHDRAWN,INTERVENTIONAL,['PHASE4']
2045,NCT00901992,A1c values,weight (Body mass index),,2009-05,COMPLETED,INTERVENTIONAL,['NA']
2046,NCT02879422,Proliferative retinopathy diabetic,,,2013-10-16,COMPLETED,INTERVENTIONAL,['NA']
2047,NCT00556465,Proteinuria,"blood pressure,serum creatinine,GFR,c-reactive protein,",,2007-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2048,NCT01979471,The difference in change in estimated cardiovascular risk between advanced care and usual care groups,"Achievement of individual and the ""triple target""",,2014-01,COMPLETED,INTERVENTIONAL,['NA']
2049,NCT05287737,Pancreatic islet function,Histological examination pancreas,,2022-06-21,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
2050,NCT01542450,The ratio of area under the glucose infusion rate curve (AUCGIR) 0-5 hours to AUCGIR 0-24 hours,Adverse events,,2002-08,COMPLETED,INTERVENTIONAL,['PHASE1']
2051,NCT02445170,Health-related quality of life measured by the HRQoL score,The 15D health-related quality of life instrument,,2015-07,WITHDRAWN,OBSERVATIONAL,['NA']
2052,NCT02566330,Excess Weight (%),C-peptide (nmol/L),,2015-10,COMPLETED,OBSERVATIONAL,['NA']
2053,NCT01940770,Adverse event incidence,Mean change of lipid metabolism,,2013-10-18,COMPLETED,OBSERVATIONAL,['NA']
2054,NCT04091516,Weight loss,Body Composition,,2019-08-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2055,NCT02315287,Change of HbA1c,microalbumin to creatinine ratio,Body weight,2014-09,UNKNOWN,INTERVENTIONAL,['PHASE4']
2056,NCT03016910,Changes in plaque morphology stratified by cardiovascular risk factors.,Impact of asymtomatic CAD in diabetes on future events.,,2016-03,UNKNOWN,OBSERVATIONAL,['NA']
2057,NCT03471104,Change in Diabetes Distress Scale (DDS),Change in Glycosylated hemoglobin A1c (HbA1c),,2018-01-15,WITHDRAWN,INTERVENTIONAL,['NA']
2058,NCT02218099,"Part 2: Safety and tolerability of ASP8232 measured by nature, frequency and severity of AEs, vital signs, safety laboratory tests, routine ECG",Part 2: 24-hour urinary albumin excretion rate (UAER),,2013-09-16,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2059,NCT00390520,Glucagon counterregulatory response to hypoglycemia of the last 30 min of the 2.5 mM hypoglycemic clamp after 4 weeks treatment,"Safety based primarily on frequency of adverse events, number of notable abnormal laboratory values, and frequency and severity of hypoglycemic events",,2006-09,COMPLETED,INTERVENTIONAL,['PHASE3']
2060,NCT05019274,Hemoglobin A1c,Food security score,,2021-08-09,COMPLETED,INTERVENTIONAL,['NA']
2061,NCT04182646,Change in NAFLD activity Score,Changes in Glycemic control,,2020-01-08,UNKNOWN,INTERVENTIONAL,['NA']
2062,NCT01629199,"At 12 weeks, wound closure rate of diabetic foot ulcers",average size reduction of diabetic ulcer,,2010-10,COMPLETED,INTERVENTIONAL,['PHASE3']
2063,NCT01877200,Proportion of patients having HbA1c ((Glycosylated Haemoglobin) as measured during survey) less than 7%,Proportion of patients having diabetic eye complications,,2013-06,COMPLETED,OBSERVATIONAL,['NA']
2064,NCT01054092,HbA1c,"Safety assessed by adverse events, vital signs laboratory tests and 12-lead ECGs",,2010-01-14,COMPLETED,INTERVENTIONAL,['PHASE3']
2065,NCT02600377,HbA1c,Diastolic blood pressure,,2015-11,UNKNOWN,OBSERVATIONAL,['NA']
2066,NCT04538352,Change in HbA1C ≤ 7.5%,Total daily insulin dose,,2021-01-18,COMPLETED,INTERVENTIONAL,['PHASE4']
2067,NCT00708604,Percent of subjects who have achieved insulin sufficiency post transplant.,HgAlc</= 6.5%,,2005-08,COMPLETED,INTERVENTIONAL,['PHASE1']
2068,NCT00871936,Reduction in HbA1c,Adverse Events,,2009-04,COMPLETED,INTERVENTIONAL,['PHASE2']
2069,NCT03571100,Patient Comfort,Patient Comfort,,2018-05-07,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
2070,NCT01789788,Safety: Incidence of adverse events,Pharmacodynamics of RO681135: Blood analysis,,2013-03,COMPLETED,INTERVENTIONAL,['PHASE1']
2071,NCT03743285,Continuous Glucose Monitor (CGM) Measured Percentage of Time <70 mg/dL,,,2018-11-14,COMPLETED,INTERVENTIONAL,['NA']
2072,NCT05649891,Degree of indication of interventions performed thanks to Do-Confirm Emergency Manual use,Structured interviews,,2023-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2073,NCT03121196,Epices score distribution,Adverse perinatal outcomes,,2017-05,UNKNOWN,OBSERVATIONAL,['NA']
2074,NCT03847194,Diabetes Distress,Adherence,,2020-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2075,NCT00404599,Reduction in oxLDL levels,Reduction in plasma endothelial function parameters such as soluble Vascular Adhesion Molecule (sVCAM) and von Willebrand factor,,2007-02,UNKNOWN,INTERVENTIONAL,['PHASE4']
2076,NCT06139913,Estradiol blood test,,,2023-03-15,COMPLETED,INTERVENTIONAL,['NA']
2077,NCT01379729,Primary outcome measurement is a parameter of functional beta cell mass at 6 months PT. Functional beta-cell mass will be calculated using the AUC/min between 150 and 160 min during hyperglycemic clamp at 180 mg/dl.,Changes from Baseline,,2011-05,UNKNOWN,INTERVENTIONAL,['PHASE2']
2078,NCT02670928,Number of Patients With Clinically Significant Weight Reduction (>5%) Compared to Baseline at Month 12,Percentage Hange From Baseline in Body Mass Index (BMI) at Month 12,,2015-07-20,COMPLETED,INTERVENTIONAL,['PHASE4']
2079,NCT06283797,Glycated hemoglobin (HbA1c) level,Number of needed interventions by the parents/guardians or care providers,"Severity of treatment-emergent SUSARs, SAEs, ARs and AEs",2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2080,NCT03410277,Neurochemical response to HG before and after induction of IAH,Antecedent physical activity,,2018-05-24,RECRUITING,INTERVENTIONAL,['NA']
2081,NCT04854083,HbA1c,"Change in the oxygen uptake and perfusion in subcutaneous and intra-abdominal adipose tissue, brown adipose tissue, skeletal muscle, gut and liver",,2022-02-17,RECRUITING,INTERVENTIONAL,['PHASE4']
2082,NCT03643783,Change in T2DM parameters and sPRR after surgery,,,2018-09-11,COMPLETED,OBSERVATIONAL,['NA']
2083,NCT01440517,Evidence of Active Myocardial Angiogenesis/Remodeling,Uptake of 99mTc-maraciclatide Agent in Diabetic Subjects With Heart Failure With Preserved Left Ventricular Fraction and Subjects With Diabetes Mellitus and Asymptomatic Diastolic Dysfunction,,2011-08,TERMINATED,INTERVENTIONAL,['PHASE2']
2084,NCT03314272,Percentage of patients who had hypoglycemic events,,,2018-05-16,COMPLETED,INTERVENTIONAL,['NA']
2085,NCT00237640,"- Primary outcomes include HbA1c, glucose, total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides levels.",,,2005-03,COMPLETED,INTERVENTIONAL,['PHASE2']
2086,NCT01504724,Central macular thickness,Retinal nerve fiber layer thickness,,2011-08,COMPLETED,INTERVENTIONAL,['PHASE4']
2087,NCT04411277,Primary outcome is time in range (TIR),-Glucose Variability,,2020-08-05,COMPLETED,OBSERVATIONAL,['NA']
2088,NCT02629263,HbA1c (%),HOMA-IR (mU/mmol/l),,2015-09,COMPLETED,OBSERVATIONAL,['NA']
2089,NCT04689971,Improvement in Brief Pain inventory at week 8,,,2020-11-03,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2090,NCT01029795,Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at 12 Weeks,Mean Total Daily Dose of LY2599506 During the 12-week Treatment Period,,2010-02,TERMINATED,INTERVENTIONAL,['PHASE2']
2091,NCT01754792,To assess hidrocarbonated metabolism parameters before and after pinitol/placebo administration,To evaluate oxidative stress on mitochondrial function before and after pinitol/placebo administration,,2012-01,COMPLETED,INTERVENTIONAL,['NA']
2092,NCT02035995,Retinal evaluation,,,2013-01,COMPLETED,OBSERVATIONAL,['NA']
2093,NCT01295073,Change in retinal thickness measurements by Optical Coherence Tomography (OCT) from screening to Day 28 between subjects undergoing surgery with and without Trientine use.,Secondary analyses will involve evaluations of the change in visual acuity and fundus photography results from screening to Day 28.,,na,WITHDRAWN,INTERVENTIONAL,['PHASE2']
2094,NCT02982330,Incremental area under the glucose curve (continuous glucose monitor),Mean Blod Glucose (continuous glucose monitor),Satiety VAS 100,2016-11,COMPLETED,INTERVENTIONAL,['NA']
2095,NCT00382239,Change in HbA1c (glycosylated hemoglobin) from Baseline to Week 12,"Changes in body weight, waist size and waist/hip ratio from Baseline to Week 12",,2006-09,COMPLETED,INTERVENTIONAL,['PHASE2']
2096,NCT01531933,Change in 15-minute post prandial insulin level,Adverse events,,2011-11,COMPLETED,INTERVENTIONAL,['PHASE3']
2097,NCT05088993,Change from baseline postural stability at 3 months,Change from baseline functional capacity at 3 months,,2021-02-15,COMPLETED,INTERVENTIONAL,['NA']
2098,NCT02957838,Changes in Mitochondrial Function,diabetic late complications,,2016-11,COMPLETED,INTERVENTIONAL,['NA']
2099,NCT00260156,Change from baseline in hyperglycemia and arginine-stimulated first phase insulin secretion at 52 weeks,Beta-cell function parameter derived from standard meal challenge,,2005-11,COMPLETED,INTERVENTIONAL,['PHASE3']
2100,NCT04470310,HbA1c,The change in lipid profile from baseline at week 12 and 24,,2015-12-31,UNKNOWN,INTERVENTIONAL,['PHASE4']
2101,NCT03609463,Feasibility (Acceptability of Intervention),% Weight Change,Change in Health-Related Quality of Life,2018-03-27,COMPLETED,INTERVENTIONAL,['NA']
2102,NCT05177107,Percent area reduction of study ulcer through Week 13,Microbiological eradication of the target pathogen,Treatment-emergent AEs due to phage therapy,2021-11-24,RECRUITING,INTERVENTIONAL,['PHASE2']
2103,NCT05580536,Understanding Health Implications of Genomics at 6 months,Change in Baseline Glycosylated Hemoglobin A1C (HbA1c) at 6 months,,2023-02-17,RECRUITING,INTERVENTIONAL,['NA']
2104,NCT02925299,The primary outcome is the centralised measurement of glycated haemoglobin (HbA1c) at 6 months.,"HbA1c <7.0%, HbA1c <7.5%, Relative reduction ≥10% from baseline. o Absolute reduction ≥0.5% from baseline o Absolute reduction ≥1% from baseline o Absolute reduction ≥1% from baseline or HbA1c <7.0%",Health Economic Evaluation,2017-05-12,COMPLETED,INTERVENTIONAL,['NA']
2105,NCT02159014,Activity adherence rates,10 year risk of developing diabetes mellitus,Life quality,2014-08,COMPLETED,INTERVENTIONAL,['NA']
2106,NCT00318214,"Changes in electrocardiograms (ECGs), vital signs, and clinical laboratory values.",Time to closure and percent reduction in surface area of the target ulcer.,,2006-06,TERMINATED,INTERVENTIONAL,['PHASE2']
2107,NCT00562952,Reduction in cardiac events,Reduction in NT-proBNP,,2007-11,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2108,NCT00904761,exercise capacity,,,2001-10,COMPLETED,INTERVENTIONAL,['NA']
2109,NCT01964833,Change in the clinical attachment level at 180 days.,Cytokines in the crevicular fluid,,2013-10,COMPLETED,INTERVENTIONAL,['NA']
2110,NCT04232293,eLift and FibroMeter sensitivity for the diagnosis of advanced hepatic fibrosis,Complication of diabetes,,2021-06-25,RECRUITING,INTERVENTIONAL,['NA']
2111,NCT00315627,Measurement of Glycemic Control by HbA1c and Prevention of Severe Hypoglycemia,Restoration of Hypoglycemia Awareness 1 Year After Transplantation,,2005-07,COMPLETED,INTERVENTIONAL,['PHASE2']
2112,NCT01849289,Change From Baseline in HbA1c (%) (Analysed by Central Laboratory),Number of Treatment Emergent AEs (Adverse Events),,2013-06-02,COMPLETED,INTERVENTIONAL,['PHASE3']
2113,NCT00703482,Evolution of the E'/E septal ratio,Evolution of the PV doppler parameters,,2003-05,COMPLETED,INTERVENTIONAL,['PHASE2']
2114,NCT05203653,percent time spent in hyperglycemia,capillary glucose,,2022-03-01,COMPLETED,INTERVENTIONAL,['NA']
2115,NCT04721145,Change in Personal CGM Use,Using Personal CGM,,2021-01-25,COMPLETED,INTERVENTIONAL,['NA']
2116,NCT03562208,C Peptide,A1C,,2018-01-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2117,NCT04446754,Diet intake,Lean mass,,2019-04-10,COMPLETED,OBSERVATIONAL,['NA']
2118,NCT00387452,Time and frequency domain measures of heart rate variability,Linear transfer-function analysis of cerebral autoregulation during upright tilt,,2006-02,COMPLETED,INTERVENTIONAL,['NA']
2119,NCT05628597,Glycated hemoglobin,Compliance,,2021-11-23,COMPLETED,INTERVENTIONAL,['NA']
2120,NCT00577174,Examine the relationship between mitochondrial function and insulin resistance in obese and non-obese children,"Evaluate the relationship of obesity, timing of puberty and related changes in hormone levels to mitochondrial function and the development of insulin resistance and/or impaired glucose tolerance in longitudinal analyses",,2007-06,UNKNOWN,OBSERVATIONAL,['NA']
2121,NCT04034524,"Time until first composite CV event (myocardial infarction, stroke)",Time until first episode of acute cholecystitis,Change from baseline HbA1c,2019-05-01,UNKNOWN,OBSERVATIONAL,['NA']
2122,NCT05160142,% Change in Hemoglobin A1c,Change in primary caregiver self-efficacy for healthy meal planning and eating score,,2019-09-05,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
2123,NCT03603704,Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,Pharmacodynamics (PD): Change from Baseline in Fasting Plasma Glucose,,2018-08-17,COMPLETED,INTERVENTIONAL,['PHASE1']
2124,NCT04579016,Weight loss,"Questionnaire data pertaining to physical activity, General Health and Well Being, Motivation to change and Risk Perception Survey for Developing Diabetes",,2020-01-13,UNKNOWN,INTERVENTIONAL,['NA']
2125,NCT04334213,"AUCtau,ss of CKD-501, D745, D150","Fluctuation of CKD-501, D745, D150",,2020-05-07,COMPLETED,INTERVENTIONAL,['PHASE1']
2126,NCT05653518,Glucose Time-in-Range,Insulin sensitivity,Human CD14+CD16- monocytes,2023-09-09,RECRUITING,INTERVENTIONAL,['NA']
2127,NCT02835014,Number of patients with a positive depression screening,Improvement in Diabetes Control defined by HbA1C equal or lower than 8.5%,,2017-04-26,COMPLETED,OBSERVATIONAL,['NA']
2128,NCT03310944,Assessment of PK Parameter: Maximum plasma concentration (Cmax),Adverse Events,,2017-10-18,COMPLETED,INTERVENTIONAL,['PHASE1']
2129,NCT00190970,The objectives of this study is to evaluate the effect of ruboxistaurin on subjects with diabetic peripheral polyneuropathy,Ruboxistaurin will improve quantitative sensory testing and increase nerve fiber density in subjects with diabetic peripheral polyneuropathy.,,2004-10,COMPLETED,INTERVENTIONAL,['PHASE2']
2130,NCT03356262,Body mass index (BMI),Dyslipidemia,,2005-07-25,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
2131,NCT03714451,Change in glycemic variability,Change in glucose levels,Eating behavior,2018-11-01,COMPLETED,INTERVENTIONAL,['NA']
2132,NCT01969747,"Change From Baseline in 24 h UGE (g/24 h) After Seven Days of Treatment With Empagliflozin 2.5 mg, 10 mg, or 25 mg, or Placebo",,,2013-11,COMPLETED,INTERVENTIONAL,['PHASE2']
2133,NCT06301191,Comparison of liver stiffness difference among treatment groups,,,2022-03-01,RECRUITING,OBSERVATIONAL,['NA']
2134,NCT04499638,How is the influence of T2DM on complications related to peripheral vascular catheters in hospitalized patients,,,2020-01-01,UNKNOWN,OBSERVATIONAL,['NA']
2135,NCT03692208,Documentation of Diabetes Goal,Patient Ability to Reach Personalized Goals,Health Care Utilization,2018-10-29,COMPLETED,INTERVENTIONAL,['NA']
2136,NCT00362518,The goal is to determine the effects of the vitamin C and vitamin E on surrogate markers of atherosclerosis following an atherogenic meal in type 2 diabetes,To determine changes in surrogate markers of atherosclerosis in type 2 diabetes,,2004-07,COMPLETED,INTERVENTIONAL,['PHASE3']
2137,NCT03055169,value of the odds ratio associated with the relationship between a polymorphism TCF7L2 gene and the occurrence of hyperglycemia,Insulin Resistance (HOMA),Number of patients with genotype TCF7L2 by PCR,2012-04,COMPLETED,OBSERVATIONAL,['NA']
2138,NCT00287183,Primary endpoint of efficacy will be assessed by comparing the treatment groups based on the change in urinary albumin-creatinine ratio (UACR),To evaluate the effect of treatment with TTP488 on UACR,,2006-02,COMPLETED,INTERVENTIONAL,['PHASE2']
2139,NCT05814107,Incidence of Treatment-Emergent Adverse Events in CT-996 participants,Effect of a High-Fat Meal on Plasma Concentration of CT-996,,2023-05-09,RECRUITING,INTERVENTIONAL,['PHASE1']
2140,NCT01633710,Presence or absence of peripheral arterial disease,,,2009-05,TERMINATED,OBSERVATIONAL,['NA']
2141,NCT00943059,lipid accumulation in ectopic tissue (cardiac and skeletal muscle),oxidative stress markers,,2010-03,COMPLETED,INTERVENTIONAL,['NA']
2142,NCT05249062,Participants' engagement with the SHAPES app during the pilot,Exploration of user engagement behaviors,Economic impact of the intervention,2023-02-09,COMPLETED,INTERVENTIONAL,['NA']
2143,NCT00559286,Changes in Elongation-Index (EI) Method: To determine the elongation index (EI) we use the Laser assisted optical rotational cell analyzer (Lorrca).,Decrease of RBC aggregation (using Laser assisted optical rotational cell analyzer (Lorrca),,2007-12,TERMINATED,INTERVENTIONAL,['PHASE4']
2144,NCT01509755,HbA1c (glycosylated haemoglobin),Adverse events,,2000-10,COMPLETED,INTERVENTIONAL,['PHASE2']
2145,NCT05081037,Body fat mass at the end of the 6 month intervention period,"Change in fasting lipid profile from baseline, 6 months, 12 months, 24 months and 36 months",Change in quality of life from baseline at 36 months (34-38 months),2021-09-06,RECRUITING,INTERVENTIONAL,['NA']
2146,NCT02892604,Percent time of active insulin closed-loop delivery,Percent time with blood glucose in target range,,2015-11-24,TERMINATED,INTERVENTIONAL,['NA']
2147,NCT03224533,Diabetes Outcome- Combined Definition,Sex Interaction,,2015-06-01,COMPLETED,OBSERVATIONAL,['NA']
2148,NCT03156478,Change in body weight,Usage of the Internet intervention,,2017-04-10,RECRUITING,INTERVENTIONAL,['NA']
2149,NCT01178476,The frequency of severe hypoglycaemia event,"The frequency of clinical hypoglycaemia (sensation of hypoglycaemia and BG<3.5mmol/l), biochemical hypoglycaemia (BG<3.5mmol/l), and nocturnal hypoglycaemia (waking up with a sensation of hypoglycaemia and BG<3.5mmol/l)",,2009-11,WITHDRAWN,INTERVENTIONAL,['NA']
2150,NCT00419484,,,,2004-03,COMPLETED,OBSERVATIONAL,['NA']
2151,NCT01074762,Stroke,Amputation,,1989-03,COMPLETED,INTERVENTIONAL,['NA']
2152,NCT04686552,insulin,lipids,,2018-01-01,COMPLETED,INTERVENTIONAL,['NA']
2153,NCT02807155,Number of Routine Diabetes Clinic Visits,Arizona Integrative Outcomes Scale,,2009-10,COMPLETED,INTERVENTIONAL,['NA']
2154,NCT02815748,The area under the plasma concentration-time curve (AUC) of SP2086 acid,The number of volunteers with adverse events as a measure of safety and tolerability,,2015-08,COMPLETED,INTERVENTIONAL,['PHASE1']
2155,NCT01342614,Blood pressure measurement,,,2006-05,COMPLETED,INTERVENTIONAL,['NA']
2156,NCT00935766,Change in Pulse Wave Velocity in Active vs. Placebo-treated Patients.,Change in hsCRP,,2009-09,TERMINATED,INTERVENTIONAL,['PHASE3']
2157,NCT03867851,Other AEs/SAEs after islet transplantation,Change in C-peptide / (glucose x creatinine) ratio (CPGCR),,2021-02-08,RECRUITING,INTERVENTIONAL,['PHASE2']
2158,NCT01046110,Change in Glycosylated Haemoglobin (HbA1c),Change in Fasting Plasma Glucose (FPG),,2010-01,COMPLETED,INTERVENTIONAL,['PHASE3']
2159,NCT02067923,Mixed Meal Tolerance Test (MMTT) C-peptide levels,Safety experience,,2014-02,COMPLETED,OBSERVATIONAL,['NA']
2160,NCT05088265,System Usability Scale,,,2021-10-26,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
2161,NCT04560998,Change in maximum walking distance on a constant load treadmill test,Change in Short Form 36 (SF-36) physical functioning domain,,2020-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
2162,NCT05092620,Biospecimens collected,,,2021-05-01,RECRUITING,OBSERVATIONAL,['NA']
2163,NCT02585427,Triglycerides response of different treatments,Gastric inhibitory polypeptide response of different treatments,,2014-11,COMPLETED,INTERVENTIONAL,['NA']
2164,NCT03094819,Qualified eye examination rate,Participant perceptions,,2016-03-17,UNKNOWN,INTERVENTIONAL,['NA']
2165,NCT03957603,Change in Fasting insulin concentration from Baseline at 2 months,The incidence of macrosomia infants,,2019-05-16,COMPLETED,INTERVENTIONAL,['NA']
2166,NCT05535478,Change in proportion of long term care facility (LTCF) residents with Alzheimer's disease adn related dementias (ADRD) and diabetes with high risk medications (HRM) use,Feasibility of the STRIDE Educational Program,,2023-01-31,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
2167,NCT02738086,Study-Related Adverse Events,"Late Life Function and Disability Scale, Limitation",,2016-07-01,COMPLETED,INTERVENTIONAL,['NA']
2168,NCT05165706,Change from baseline in plasma inflammatory cytokine levels in serum samples as measured by Luminex immunoassay,,,2019-01-31,RECRUITING,INTERVENTIONAL,['NA']
2169,NCT05628584,Differences in postprandial glycemia,Gastrointestinal symptoms,,2022-11-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2170,NCT05461560,Changes in maximal incremental capillary blood glucose level (iCmax) between baseline and endpoint within the intervention group vs. control.,Changes in area under the curve of incremental capillary blood glucose levels (iAUC) in the intervention group vs. control,,2021-12-05,RECRUITING,INTERVENTIONAL,['NA']
2171,NCT03602989,Sensitivity and specificity,,,2018-07-05,UNKNOWN,OBSERVATIONAL,['NA']
2172,NCT00895921,Change in Glucose Disposition,Akathisia,,2008-11,COMPLETED,INTERVENTIONAL,['PHASE4']
2173,NCT01440530,Diabetes Knowledge,Diabetes Self Care,,2010-02,COMPLETED,INTERVENTIONAL,['NA']
2174,NCT03934970,Comparison of diagnostic accuracy of Diffusion tensor imaging of peripheral nerves in comparison to Diabetic Neuropathy Examination in diabetic patients.,Identifying cut-off value for abnormal diffusion tensor apparent diffusion coefficient in diabetic neuropathy.,,2015-04-30,COMPLETED,OBSERVATIONAL,['NA']
2175,NCT04820348,Adherence to wearing continuous glucose monitoring (CGM) devices to measure glucose levels.,Feasibility of assessing the comorbidity of depressive/anxiety symptoms and type 2 diabetes and the impact of depression and anxiety on diet-medication adherence and lifestyle choices.,,2021-04-09,COMPLETED,OBSERVATIONAL,['NA']
2176,NCT01175928,Nerve Conduction Studies,Quality of life questionnaires,,2010-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2177,NCT05170867,HbA1c,Proportion of subjects losing more than 50% of baseline excess weight,,2022-01-14,RECRUITING,INTERVENTIONAL,['NA']
2178,NCT01087866,Percentage of fetal macrosomy,,,2005-06,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2179,NCT03259984,DNA methylation of genes in insulin resistance,mRNA expression of genes,,2016-11,COMPLETED,OBSERVATIONAL,['NA']
2180,NCT02835287,Incidence of composite major cardiovascular disease events,Cost-effectiveness,,2016-10-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2181,NCT00856011,"Nerve morphology (Fascicular area, myelinated nerve fiber density, endoneurial capillary density and subperineurial space",,,2003-12,COMPLETED,OBSERVATIONAL,['NA']
2182,NCT05504226,Changes from baseline HbA1c at week 24,Changes from baseline in BMI at week 24,,2022-10,RECRUITING,INTERVENTIONAL,['PHASE3']
2183,NCT05913193,Nutritional status risk by MUST,Global Leadership Initiative on Malnutrition (GLIM) Diagnosis of Malnutrition,Calf Circumference,2023-12-15,RECRUITING,OBSERVATIONAL,['NA']
2184,NCT01256892,,,,na,COMPLETED,INTERVENTIONAL,['NA']
2185,NCT03551535,Adherence rate,Neonatal hypoglycemia rates,,2018-11-01,WITHDRAWN,INTERVENTIONAL,['NA']
2186,NCT00656422,To describe changes in hepatic fat content between groups.,To evaluate safety between groups.,,2007-11,TERMINATED,INTERVENTIONAL,['PHASE3']
2187,NCT03794934,Percentage of time in target range 70-180 mg/dL,Percentage of time in target range 70-180 mg/dL,,2019-02-26,UNKNOWN,INTERVENTIONAL,['NA']
2188,NCT01764919,Assess the Sensitivity and Specificity of [124I]FIAU PET-CT Scanning in Detecting Osteomyelitis as Determined by Bone Biopsy in Patients With Diabetic Foot Infection.,Assess Any Additional Information That [124I]FIAU PET-CT Scanning Provides Compared to MRI,"Explore the Performance of [124I]FIAU PET-CT Compared to MRI in Detecting Osteomyelitis by Chronic Kidney Disease (CKD) Stage (Stage 1+2, Stage 3, and Stage 4+5).",2013-04,TERMINATED,INTERVENTIONAL,['PHASE2']
2189,NCT00321542,Death or acute myocardial infarction,"Composite of the primary outcome and the onset of new symptoms of coronary artery disease with proven myocardial ischemia (supported by treadmill, nuclear scan or stress echo findings) or the need for a revascularization procedure.",,2006-09,UNKNOWN,OBSERVATIONAL,['NA']
2190,NCT03270436,Change in Mean Body Weight (kg),Change in Proportion of Participants Engaging in Sufficient Levels of Physical Activity,Change in Perceived Family Support for Exercise and Dietary Habits,2018-01-08,COMPLETED,INTERVENTIONAL,['NA']
2191,NCT05440968,"Attendance of patients with knowledge of their risk for diabetes type 2 to a confirmatory test, oral glucose tolerance test",Describe the causes of non-performance of the confirmatory test throughout a brief questionnaire,,2022-06-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2192,NCT02282475,Assess visceral adipose fat and intrahepatic lipid stores change during pregnancy,Compare glucose tolerance in pregnant women with gestational diabetes to those with normal glucose tolerance,,2014-11-30,COMPLETED,OBSERVATIONAL,['NA']
2193,NCT00021580,,,,na,UNKNOWN,INTERVENTIONAL,['PHASE1']
2194,NCT00042601,Change in food intake of participants on Pramlintide,Effect of pramlintide on postprandial metabolic and hormonal responses,,2002-07,COMPLETED,INTERVENTIONAL,['PHASE2']
2195,NCT04883086,The extent of root dental caries,Measuring the vitamin D levels,,2020-12-15,COMPLETED,OBSERVATIONAL,['NA']
2196,NCT00699179,Change in HbA1c from baseline,Number of adverse drug reactions (ADR),,2008-06,COMPLETED,OBSERVATIONAL,['NA']
2197,NCT04066959,Hemoglobin A1c,Blood glucose testing,,2020-11-16,RECRUITING,INTERVENTIONAL,['NA']
2198,NCT05798637,Rate of platelet activation,Rate of platelet heterogeneity,,2020-02-10,RECRUITING,OBSERVATIONAL,['NA']
2199,NCT00755547,Insulin sensitivity measured from Bergman's frequently sampled intravenous glucose tolerance test,1H-Magnetic resonance spectroscopy-derived measure of lipid content in liver and muscle tissue,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE4']
2200,NCT03533478,Macular retinal thickness,Visual acuity,,2015-03-01,COMPLETED,INTERVENTIONAL,['PHASE2']
2201,NCT03449784,number with dyslipidemia,number of patient not achieving LDL-C target according to cardiovascular risk,,2012-05-01,RECRUITING,OBSERVATIONAL,['NA']
2202,NCT00132288,"Change in physical activity of those allocated to the intervention group compared to ""wait-listed"" controls as measured by the Seattle-Rapid Assessment of Physical Activity questionnaire",Determinants of choice in favor of study participation,,2005-05,COMPLETED,INTERVENTIONAL,['NA']
2203,NCT01511900,Frequency and severity of adverse events,Changes from baseline in vital signs,,2011-12,COMPLETED,INTERVENTIONAL,['PHASE1']
2204,NCT01525784,to examine prospectively frequency of hypoglycemia,To examine prosectively the effect of rt-cgms on glycemic control,,2012-02,UNKNOWN,OBSERVATIONAL,['NA']
2205,NCT01662999,AUC(INF) of Saxagliptin From a Single Dose of 5 mg Saxagliptin Versus AUC(INF) of Saxagliptin When Co-administered With 10 mg Dapagliflozin - PK Evaluable Population,Number of Participants With Change From Baseline in ECG Interval - Safety Population,,2012-08,COMPLETED,INTERVENTIONAL,['PHASE1']
2206,NCT03764280,Percentage of time of sensor glucose levels spent in target range (defined to be between 3.9 mmol/L and 10.0 mmol/L).,Number of participants experiencing hypoglycemia requiring oral treatment during,,2018-07-02,COMPLETED,INTERVENTIONAL,['NA']
2207,NCT02014220,blood glucose,food intake,satiety,na,COMPLETED,INTERVENTIONAL,['NA']
2208,NCT02531386,System accuracy criteria (see description),,,2015-08,COMPLETED,INTERVENTIONAL,['NA']
2209,NCT02754817,Change in HbA1c (Hemoglobin A1c),Percentage of responders for HbA1c below 7 percent (53 mmol/mol) with no hypoglycaemic episodes,,2016-04-26,COMPLETED,OBSERVATIONAL,['NA']
2210,NCT02056431,Change in Patient Quality of Life at Baseline and 8 Months,Number of Participants With Minimally Effective Dose in 12 Months,,2014-10,COMPLETED,INTERVENTIONAL,['NA']
2211,NCT01512654,Percentage of total time spent by patients in safe range (70-180mg/dL),Score of patient survey regarding the acceptability of DIAdvisor-2 system,,2008-09,COMPLETED,INTERVENTIONAL,['NA']
2212,NCT01852136,Overall Pen Needle Preference,Pen user group subset comparisons,,2012-09,COMPLETED,OBSERVATIONAL,['NA']
2213,NCT01900470,Change in standardized score,Patient Activation,Medical Adherence,2013-07,COMPLETED,INTERVENTIONAL,['NA']
2214,NCT02496221,Maximum Change From Baseline in Common Bile Duct Diameter During CCK Infusion,Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick,,2015-06-11,COMPLETED,INTERVENTIONAL,['PHASE4']
2215,NCT03007329,change in hepatic lipid content measured with magnetic resonance spectroscopy in %,change in glomerular filtration rate,change in cholesterol,2017-03-08,COMPLETED,INTERVENTIONAL,['PHASE4']
2216,NCT05887180,"Rate of adverse cardiovascular and cerebrovascular events (MACCE ""Plus"" events)",Incremental cost-utility relation (societal perspective),,2022-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2217,NCT01230034,Size of the reduction of urinary albumin in 24 hours to the various controls,"1. Size of the reduction of mean 24-hour average daytime and nighttime average. 2. Size of the reduction of central blood pressure. 3. Magnitude of changes in plasma concentrations of angiotensin II, bradykinin and BNP after 24 weeks of treatment.",,2010-10,UNKNOWN,INTERVENTIONAL,['PHASE3']
2218,NCT05898750,Blood glucose level,Insulin level,,2023-04-22,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
2219,NCT04504968,Difference in physical function,Health-related quality of life,,2022-02-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2220,NCT04131049,Postprandial glucose response by continous glucose monitoring,,,2019-06-24,COMPLETED,INTERVENTIONAL,['NA']
2221,NCT04030364,Program retention,Hypothetical program cost per patient,,2019-09,UNKNOWN,INTERVENTIONAL,['NA']
2222,NCT04051632,Successful implementation of hybrid closed loop technology,Assess impact of hybrid closed loop technology on glycemic control by analysis of sensor glucose data.,,2018-06-13,COMPLETED,OBSERVATIONAL,['NA']
2223,NCT00169832,Change in plaque volume in one SVG (by IVUS),14 Fluid retention,,2003-06,COMPLETED,INTERVENTIONAL,['PHASE3']
2224,NCT04208620,Clinical laboratory evaluations,Proportion of subjects achieving > 5% body weight loss,,2020-01-21,COMPLETED,INTERVENTIONAL,['PHASE1']
2225,NCT01614782,Number of participants who discontinued from study drug due to an adverse event,Apparent terminal half-life (apparent t1/2) following once daily administration of MK-5823,,2012-06,TERMINATED,INTERVENTIONAL,['PHASE1']
2226,NCT02058641,Macrophage cell count and surface expression of markers of M1 and M2 polarization in blister fluid,Time to healing of cantharidin-induced blisters,,2014-02-26,COMPLETED,INTERVENTIONAL,['PHASE1']
2227,NCT01866748,Part B: Number of treatment emergent adverse events (TEAEs),Part B: Change in body weight from baseline,,2013-05,COMPLETED,INTERVENTIONAL,['PHASE1']
2228,NCT05719675,Health-related quality of life,,,2023-03-01,COMPLETED,INTERVENTIONAL,['NA']
2229,NCT06158503,Bone remodeling improvement,HbA1c change,,2024-01-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
2230,NCT03078231,Number of subjects whose EyeArt results match the reading center grading for identifying referable diabetic eye disease (moderate NPDR or higher on the ICDR scale or surrogate markers for CSME).,,,2017-02-17,COMPLETED,OBSERVATIONAL,['NA']
2231,NCT03136484,Change in HbA1c,Change in CoEQ: Individual Items,,2017-03-15,COMPLETED,INTERVENTIONAL,['PHASE3']
2232,NCT01498367,HbA1c levels,Economic Evaluation (Cost-Effective Analysis- Cost Utility Analysis),,2011-03,COMPLETED,INTERVENTIONAL,['NA']
2233,NCT03487887,Glycemic variability,Hypogliaemia,,2018-03-19,COMPLETED,OBSERVATIONAL,['NA']
2234,NCT04537624,Change in Glycated haemoglobin (HbA1c ),HbA1c reduction >=1%-points and body weight reduction of >=3% (Yes/No),,2020-08-24,COMPLETED,OBSERVATIONAL,['NA']
2235,NCT00364312,Quality of life,Self-efficacy,,2004-05,UNKNOWN,INTERVENTIONAL,['NA']
2236,NCT04897802,Change in oxytocin concentration (pg/mL),Alexithymia assessment,,2021-09-13,RECRUITING,INTERVENTIONAL,['PHASE4']
2237,NCT04624516,The time of plantar foot diabetic ulcer recurrence incidence,callus,,2019-09-04,COMPLETED,INTERVENTIONAL,['NA']
2238,NCT03677609,Patient adherence: Vaccine and screening recommendations,Physician mindset: Mindset Beliefs Survey,,2018-01-04,COMPLETED,INTERVENTIONAL,['NA']
2239,NCT05985135,Protein synthesis,,,2024-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2240,NCT01022177,retinal perfusion by HRF/OBF/RVA,,,2009-10,UNKNOWN,INTERVENTIONAL,['PHASE2']
2241,NCT04849845,Post-prandial Glucose Excursion,"Change in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Between Two Points, Baseline and 120 Minutes Post-Afrezza Dose",,2021-04-09,COMPLETED,INTERVENTIONAL,['PHASE4']
2242,NCT04364087,the prevalence of diabetes and prediabetes in infertile women with PCOS,Factors associated with diabetes and prediabetes,,2020-06-01,COMPLETED,OBSERVATIONAL,['NA']
2243,NCT00701831,Time to dose titration,Physician Satisfaction Questionnaire,,2008-05,COMPLETED,INTERVENTIONAL,['PHASE4']
2244,NCT03651531,Hgb A1c,Incidence neonatal hypoglycemia,,2018-01-03,TERMINATED,INTERVENTIONAL,['PHASE3']
2245,NCT01392573,Change From Baseline in HbA1c (Glycosylated Haemoglobin),Change in Body Weight,,2011-11-28,COMPLETED,INTERVENTIONAL,['PHASE3']
2246,NCT04107259,IRAPe,,,2019-01-19,COMPLETED,OBSERVATIONAL,['NA']
2247,NCT00167830,Improvement in fitness measures,Improved family cohesiveness,,2003-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2248,NCT00820573,Average of Plasma Glucose During Mixed Meal Tolerance Test (MTT) Compared to Baseline Plasma Glucose to Post Therapy (6-weeks).,Changes in Plasma Glucose Post-MTT After Each Six Weeks of Therapy Compared to Baseline,,2009-10,COMPLETED,INTERVENTIONAL,['PHASE4']
2249,NCT00631488,Change From Baseline (BL) to Week 4 in 24-hour Weighted Mean Glucose (WMG) Levels,Change From BL to Week 4 in the 2-Hour Active GLP-1 Total AUC,,2008-02,COMPLETED,INTERVENTIONAL,['PHASE2']
2250,NCT02400515,Glucose levels,Low Density Level (LDL) Cholesterol levels,Hospital Anxiety and Depression scale (HADS),2007-08,COMPLETED,INTERVENTIONAL,['NA']
2251,NCT05026424,Post-prandial glycemic markers,Insulinogenic index,,2021-08-02,COMPLETED,INTERVENTIONAL,['NA']
2252,NCT02330484,Hypoglycemic Medication adherence rates using electronically monitored adherence (MEMS cap) data,MEMS cap data compared to PHQ-9 and AIS assessment,,2014-03,UNKNOWN,INTERVENTIONAL,['NA']
2253,NCT01228032,Quality of healthcare services received,,,2010-04,COMPLETED,INTERVENTIONAL,['PHASE3']
2254,NCT00700830,Assessment the incidence of the Serious Adverse Events including the major Hypoglycaemia.,Weight,,2008-01,COMPLETED,OBSERVATIONAL,['NA']
2255,NCT00417131,,,,2006-10,COMPLETED,OBSERVATIONAL,['NA']
2256,NCT00286637,Number of Participants who Show Evidence of Glaucoma Progression,,,1995-01,COMPLETED,OBSERVATIONAL,['NA']
2257,NCT04028960,Percentage of Time With Dangerous Hypoglycemia,Glucose Management Indicator (GMI),,2019-10-23,TERMINATED,INTERVENTIONAL,['PHASE2']
2258,NCT04863235,Changes in self-compassion from pre-intervention to 12 week follow-up (20 weeks),Personal Growth Initiative as a potential mediator,,2021-03-01,UNKNOWN,INTERVENTIONAL,['NA']
2259,NCT00873561,To assess the effect of repeated administrations of NBI-6024 on endogenous insulin production as measured by C-peptide levels in adult and adolescent patients with new onset type 1 diabetes mellitus,"To examine the effects of repeated administrations of NBI-6024 on insulin usage, glycemic control, and immune function (immunodynamics and pharmacodynamics) To examine the safety and tolerability of repeated administrations of NBI-6024",,2001-12,COMPLETED,INTERVENTIONAL,['PHASE1']
2260,NCT00454623,,,,2006-03,UNKNOWN,INTERVENTIONAL,['NA']
2261,NCT04569409,Proportions of subjects who achieved complete wound closure,Change rates in wound size and depth compared to baseline groups,,2020-07-14,RECRUITING,INTERVENTIONAL,['PHASE3']
2262,NCT01585506,Frequency and level of difficulty in introducing changes in compliance with the guidelines for biphasic insulin analogue use in subjects previously treated with biphasic human insulins,"Correlations between the difficulty in introducing changes in compliance with the guidelines for biphasic insulin analogue use in subjects previously treated with biphasic human insulins, and psychosocial factors",,2010-09-20,COMPLETED,OBSERVATIONAL,['NA']
2263,NCT00819325,"The primary IVUS endpoint of the study was the change in three-dimensional neointimal plaque volume within the stented segment at follow-up, compared to baseline.","The secondary IVUS endpoint was the change in the two-dimensional NIA within the stent, using the cross-sectional slice showing the smallest LA on follow-up and comparing it to the corresponding baseline slice.",,2002-08,COMPLETED,INTERVENTIONAL,['PHASE4']
2264,NCT02325206,reduction of intravenous insulin dose,urinary glucose excretion,,2014-12,COMPLETED,INTERVENTIONAL,['PHASE1']
2265,NCT01774149,Change in the Frequency of Hyper- and Hypo-glycemic Events From Baseline to Week 8-12.,Change in HbA1c,Empowerment,2013-03,COMPLETED,INTERVENTIONAL,['NA']
2266,NCT00410800,,,,1996-08-19,COMPLETED,OBSERVATIONAL,['NA']
2267,NCT04132739,Changes in strength,,,2019-03-01,TERMINATED,INTERVENTIONAL,['NA']
2268,NCT00984737,To determine the prevalence of newly diagnosed hyperglycemia in coronary ICU.,"To search for the cases with stress hyperglycemia and inquire its relationship with disease severity and functional outcomes, such as longevity of ICU stay.",,2007-05,COMPLETED,INTERVENTIONAL,['NA']
2269,NCT03257449,Body fat percentage change,,,2016-03,UNKNOWN,OBSERVATIONAL,['NA']
2270,NCT01071785,"Changes on the components of metabolic syndrome (according to IDF and WHO criteria): blood pressure, waist, body mass index (BMI), triglycerides, high-density lipoprotein (HDL) cholesterol, glucose values (HBA1c) and urinary albumin excretion.",changes on serum fatty acids and serum cholesterol,,2007-06,COMPLETED,INTERVENTIONAL,['NA']
2271,NCT00755404,To assess the efficacy of L-Carnitine containing PD solution on insulin sensitivity evaluated by measuring insulin requirement,To assess the efficacy of L-Carnitine containing PD solution on hematological parameters (hemoglobin and EPO requirements),,2007-06,WITHDRAWN,INTERVENTIONAL,['PHASE2']
2272,NCT03205904,glycemic improvement after nutritional orientation in patients with cystic fibrosis in the pre-diabetic phase,To evaluate anthropometric data of the patients before and after the intervention.,,2016-12-12,COMPLETED,INTERVENTIONAL,['NA']
2273,NCT02589314,Evidence of alteration on pro and anti-inflammatory cytokines by CBA,,,2015-11,TERMINATED,OBSERVATIONAL,['NA']
2274,NCT03437694,Hypertension,,,2018-08-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2275,NCT00069784,"Composite of the First Occurrence of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), Nonfatal Stroke, Revascularization Procedure or Hospitalization for Heart Failure (HF)",Incidence of Development of Type 2 Diabetes Mellitus in Participants With IGT and/or IFG,Number of Patients With First Occurrence of Any Type of Cancer,2003-08,COMPLETED,INTERVENTIONAL,['PHASE3']
2276,NCT03015480,Change in 24-hour urine sodium,Change in Net Endogenous Acid Production (NEAP),,2017-02-13,COMPLETED,INTERVENTIONAL,['NA']
2277,NCT02438397,MAGE: mean amplitude of glycemic excursion/MODD: mean of daily differences,,,2014-12,UNKNOWN,INTERVENTIONAL,['PHASE4']
2278,NCT00396357,Change from baseline in hemoglobin A 1 c (HbA1c) after 24 weeks of treatment,Change from baseline in fasting plasma glucose after 24 weeks,,2006-10,COMPLETED,INTERVENTIONAL,['PHASE3']
2279,NCT02069197,Change of body mass index from baseline in 9 months period,To evaluate safety of ketogenic diet as a treatment of obesity.,,2014-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
2280,NCT00277732,The difference between the study groups in the change of blood glucose and HbA1c,Frequency of eye and foot examination,,2006-01,COMPLETED,INTERVENTIONAL,['NA']
2281,NCT01056315,Average Pain Intensity,Assessment of Rescue Medication Usage During the 4-week Titration.,,2009-11,TERMINATED,INTERVENTIONAL,['PHASE2']
2282,NCT06290349,Change from the baseline in HbA1c (%) after 24 weeks,Change from the baseline in weight after 24 weeks,,2024-02-28,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
2283,NCT05610865,Interview and visual inspection of ulcers recovery rate,Percentages (%) of wound closure rate (with respect to time) will be assessed.,,2020-11-20,RECRUITING,INTERVENTIONAL,['PHASE1']
2284,NCT02506452,Wound closure observed at up to 12 weeks following baseline visit defined as 100% re-epithelialization without drainage confirmed at 2 weeks following initial observation of closure.,,,2015-06,UNKNOWN,INTERVENTIONAL,['NA']
2285,NCT03169205,Maternal outcome,fetal outcome,,2017-05-01,UNKNOWN,OBSERVATIONAL,['NA']
2286,NCT02535715,Hepatic Glucose Production (Co-primary Outcome),Plasma Free Fatty Acid Concentrations,,2015-01,COMPLETED,INTERVENTIONAL,['PHASE2']
2287,NCT05985291,Average change from baseline to 3 months in treatment responder rates,Average change from baseline to 6 months in treatment responder rates assessed by Visual Analog Scale (0-10 cm),Assessment of subject outcomes satisfaction as measured through Patient Global Impression of Change (PGIC) (1-7 where higher scores mean better outcome) at 3 months and 6 months.,2023-07-03,RECRUITING,OBSERVATIONAL,['NA']
2288,NCT00604656,Insulin aspart antibodies,HbA1c,,2003-05-05,COMPLETED,INTERVENTIONAL,['PHASE3']
2289,NCT01368536,Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) After 12 Weeks of Treatment Ending With the Combination of Valturna and Amlodipine Versus Valturna Alone,"Number of Patients With Adverse Events, Serious Adverse Events and Death to Assess Safety and Tolerability of Treatment With Valturna and Chlorthalidone or Valturna and Amlodipine Versus Valturna Alone",,2011-05,TERMINATED,INTERVENTIONAL,['PHASE4']
2290,NCT00787215,Glucose intolerance status by OGTT,Glucose intolerance status predicted by Chinese University Diabetes Risk Score validated by OGTTT,,2008-11,UNKNOWN,OBSERVATIONAL,['NA']
2291,NCT05281562,Effect of supplemental immunonutrition on wound healing in patients with diabetic foot ulcers as assessed by the Pressure Ulcer Scale for Healing (PUSH) Tool 3.0.,"Long term effect of supplemental immunonutrition on wound healing in patients with diabetic foot ulcers on rates of ulcer recurrence, infection, surgical intervention, and amputation.",,2022-07-01,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2292,NCT01045707,Extension Trial (Primary Endpoint): Rate of Treatment Emergent Adverse Events (AEs),Main Trial (Secondary Endpoint): Mean of 9-point Self Measured Plasma Glucose Profile (SMPG) at Week 26,,2010-01,COMPLETED,INTERVENTIONAL,['PHASE3']
2293,NCT04980014,Percentage of Participants With Abnormal Laboratory Findings Reported as AEs,Change From Baseline in Diastolic Blood Pressure,,2015-10-02,COMPLETED,OBSERVATIONAL,['NA']
2294,NCT01967901,Quality of life,Kidney function,,2014-03,COMPLETED,INTERVENTIONAL,['NA']
2295,NCT00563433,Reduction in clinical signs and symptoms of infection,Wound depth.,,1994-08,COMPLETED,INTERVENTIONAL,['PHASE3']
2296,NCT02548273,CHANGE FROM BASELINE IN CENTRAL CORNEAL THICKNESS AT 3 MONTHS,,,2013-01,COMPLETED,OBSERVATIONAL,['NA']
2297,NCT05078255,Mean glucose levels (assessed by blinded continuous glucose monitoring (CGM)),,,2022-01-27,RECRUITING,INTERVENTIONAL,['NA']
2298,NCT04503564,Rate of Infusion Set Survival at End of Day 7,,,2019-11-13,COMPLETED,INTERVENTIONAL,['NA']
2299,NCT00607737,laser doppler blood flow,insulin detemir specific antibodies,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE4']
2300,NCT00944450,Peak Plasma Concentration (Cmax) Following Single Dose Administration of the Anhydrous and Monohydrate Forms of MK0431 (Sitagliptin),,,2004-08,COMPLETED,INTERVENTIONAL,['PHASE1']
2301,NCT00229918,Central macular thickness,Increased intraocular pressure,,2005-09,UNKNOWN,INTERVENTIONAL,['PHASE2']
2302,NCT00934336,"Assay of isoprostane-F2, an indicator of lipid peroxidase derivative production, in the 24 hour urine",,,2008-11,COMPLETED,INTERVENTIONAL,['NA']
2303,NCT04426474,Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug,PD: Change from Baseline to Week 12 in Fasting Insulin,,2020-10-08,COMPLETED,INTERVENTIONAL,['PHASE1']
2304,NCT04907708,Mean morphometric diffusion capacity for oxygen (MMDC) in placental tissues,Percentage of immuno-antigens present in placental tissue,,2018-01-01,COMPLETED,INTERVENTIONAL,['NA']
2305,NCT04657016,Percentage of Participants with ≥5% Body Weight Reduction,Change from Baseline in Waist Circumference,,2021-03-29,COMPLETED,INTERVENTIONAL,['PHASE3']
2306,NCT06053359,Semi-structured and Open-Ended Interview Questions,Social Determinants of Health Questionnaire,,2024-04,WITHDRAWN,OBSERVATIONAL,['NA']
2307,NCT03674281,Percentage of Time of Blood Glucose in Range 70-180 mg/dL,Sleep Patterns,,2018-09-24,COMPLETED,INTERVENTIONAL,['NA']
2308,NCT01956162,"Evaluate the efficiency of ""Orthèse Diabète"" compared to ""conventional"" removable devices, in terms of the proportion of diabetic patients whose principal ulcer will heal completely.",Patients satisfaction with the prescribed device,,2013-10,COMPLETED,INTERVENTIONAL,['NA']
2309,NCT03569735,Cognitive disorder (occurrence of cognitive disorder),Usual gait speed,,2018-05-26,RECRUITING,OBSERVATIONAL,['NA']
2310,NCT00778804,Framingham 10-year risk index,"Blood pressure, cholesterol, 6 minute walk test, glucose and A1c, CVD knowledge and risk perception",,2004-07,COMPLETED,INTERVENTIONAL,['NA']
2311,NCT04828785,Hemoglobin A1c at Month 6,Frequency of self-reported severe hypoglycemia at Month 12,Stress Score at 12 months,2021-07-02,RECRUITING,INTERVENTIONAL,['NA']
2312,NCT03952143,Change From Baseline in Hemoglobin A1c (HbA1c),Percentage of Participants With HbA1c <7% and ≤6.5%,,2019-05-27,COMPLETED,INTERVENTIONAL,['PHASE3']
2313,NCT00403481,Change From Baseline to Week 12 in Systolic BP (SBP) as Measured by 24-hour ABPM.,Change in Ambulatory BP (Diastolic) From Baseline to Week 12 During the Last (Week 12 ) 4 and 6 Hours of the Last 24-hour Dosing Period.,,2006-11,COMPLETED,INTERVENTIONAL,['PHASE4']
2314,NCT02844907,AIM3: To determine the fasting GLP-1 effect.,,,2018-07-01,COMPLETED,INTERVENTIONAL,['PHASE4']
2315,NCT05155917,the rates of hypoglycemia,ICU Mortality rate,,2022-03-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
2316,NCT04735640,Change in fasting plasma glucose,Maintenance of acquired dietary and physical activity changes,,2021-04-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2317,NCT00516464,"To evaluate the effect of ranibizumab on vitrectomy complications such as recurrent vitreous hemorrhage, postoperative retinal detachment rates, and development of intraoperative retinal breaks.",,,2007-08,UNKNOWN,INTERVENTIONAL,['PHASE3']
2318,NCT01951547,Effect of periodontal intervention on probing attachment levels of diabetics with periodontal disease,Effect Of periodontal intervention on hs-CRP levels in diabetics with periodontal disease,,2010-01,COMPLETED,INTERVENTIONAL,['NA']
2319,NCT03829800,Change from baseline Subjective appetite at 180 minutes,HbA1c,,2016-09-01,COMPLETED,INTERVENTIONAL,['NA']
2320,NCT00328393,Median of systolic 24-hour ambulatory blood pressure,Median of 24-hour diastolic ambulatory blood pressure,,2007-03,COMPLETED,INTERVENTIONAL,['PHASE3']
2321,NCT01860547,Serum Alanine aminotransferase (ALAT),Body composition,"Subclasses of serum lipoproteins, serum fatty acids and lipid classes of serum",2008-06,COMPLETED,INTERVENTIONAL,['NA']
2322,NCT02372253,Functional Beta Cell Mass,Hypoglycemic Events,Beta Cell Markers,2015-02,COMPLETED,INTERVENTIONAL,['PHASE2']
2323,NCT05670366,Database which contains food intake data (type of food) retrieved from the diary app.,,,2022-09-26,RECRUITING,INTERVENTIONAL,['NA']
2324,NCT02386020,Change in Clinical attachment level,Change in Probing depth,,2014-06,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2325,NCT05505994,Change from baseline in HbA1c,,,2022-09,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
2326,NCT05703386,Progression of cerebral small vessel disease,,,2022-11-08,RECRUITING,OBSERVATIONAL,['NA']
2327,NCT03785951,Change in fasting and day long insulin levels,Change in body composition,Metabonomics,2018-12,UNKNOWN,INTERVENTIONAL,['NA']
2328,NCT04125784,Changes from baseline in diabetes mellitus type II prevalence,Changes from baseline in therapeutic regimes within those patients who were identified as having diabetes mellitus type 2 in the first study in 2014,,2021-08-01,COMPLETED,OBSERVATIONAL,['NA']
2329,NCT00806585,Change From Baseline in Sitting Systolic Blood Pressure (SiSBP) at Week 12,Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24,,2008-12,TERMINATED,INTERVENTIONAL,['PHASE2']
2330,NCT02355717,Bone strength-strain index,Serum C-terminal telopeptide of type 1 collagen (CTX),,2014-12,UNKNOWN,OBSERVATIONAL,['NA']
2331,NCT02361138,Plasma glucose concentration of SHR3824.,Serum creatinine,,2013-12,COMPLETED,INTERVENTIONAL,['PHASE1']
2332,NCT05529108,Change in bile acid concentration,Change in dietary,,2022-10-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2333,NCT00876213,,,,2007-03,COMPLETED,OBSERVATIONAL,['NA']
2334,NCT02306681,The percentage of patients who experience at least 1 hypoglycaemic episode,DSQOLS (Diabetes-Specific Quality-of-Life Scale) scores,,2014-10-30,COMPLETED,OBSERVATIONAL,['NA']
2335,NCT02994277,System connectivity,Meal composition's effect in the efficacy of the system to control glycaemia,,2016-11,COMPLETED,INTERVENTIONAL,['NA']
2336,NCT00210847,Change in the average of daily pain score recorded in the IVR system from baseline to the patient's final week of treatment with study medication.,"Efficacy measured by Brief Pain Inventory, Visual Analogue Scale, Short-Form McGill Pain Questionnaire, Profile of Mood States, SF-36 Health Survey, Physician and Subject Global Impression of Change, average daily sleep interference",,2003-12,COMPLETED,INTERVENTIONAL,['PHASE3']
2337,NCT05213988,Glucose tolerance,,,2018-07-30,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
2338,NCT04265261,Percentage of Participants with Adverse Events (AEs),Change from Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye,,2020-06-05,COMPLETED,INTERVENTIONAL,['PHASE2']
2339,NCT04155060,The primary outcome was 28-day mortality,,,2017-04-01,COMPLETED,OBSERVATIONAL,['NA']
2340,NCT00700154,Plasma glucose levels,laboratories for inflammation and oxidative stress,,2011-11,TERMINATED,INTERVENTIONAL,['NA']
2341,NCT01914302,Blood Volumes measured in microliters,Pain rating measure on a 0-20 Gracely Scale,,2013-07,COMPLETED,OBSERVATIONAL,['NA']
2342,NCT03377946,Changes of gut microbiota composition,"Composite changes of weight, waist circumference and BMI",Changes of Intestinal endocrine function,2017-12-21,UNKNOWN,INTERVENTIONAL,['NA']
2343,NCT04905459,Specificity of ARDA mtmDR for detection of mtmDR in UWF images,,,2021-09-30,COMPLETED,OBSERVATIONAL,['NA']
2344,NCT03848767,Continuous Glucose Monitor (CGM) Measured Percentage of Time <70 mg/dL,,,2019-02-20,COMPLETED,INTERVENTIONAL,['NA']
2345,NCT06216340,Weight change,Incident diabetes,Changes of C-reactive protein,2024-02-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
2346,NCT00539396,Change in blood glucose following a standard meal,Mean change from baseline HbA1c,,2005-03,COMPLETED,INTERVENTIONAL,['PHASE2']
2347,NCT03795662,Number of participants who develop diabetes,Number of participants who are readmitted,HbA1c to assess the average blood glucose levels 3 months before admission,2019-01-07,RECRUITING,OBSERVATIONAL,['NA']
2348,NCT02290184,Feasibility for Participant Enrollment and Retention,Change in Waist Circumference,,2014-11-01,COMPLETED,INTERVENTIONAL,['NA']
2349,NCT01488916,incremental areas under the curves of plasma glucose after meal challenge,"Meal-related glycemic excursion indexes (∆G, ∆T, BR)from the meal test",,2011-08,UNKNOWN,OBSERVATIONAL,['NA']
2350,NCT02366572,Subjective Appetite,Energy/fatigue,,2016-03,COMPLETED,INTERVENTIONAL,['NA']
2351,NCT02375828,Acceptability of an oral solution of glibenclamide (Hedonic visual scale),No alteration in metabolic control of the disease,,2015-03-20,COMPLETED,INTERVENTIONAL,['PHASE3']
2352,NCT02333539,Frequency of Insulin Pump Adherence Behaviors,Change in Glycemic Control (A1C),,2012-09,COMPLETED,INTERVENTIONAL,['NA']
2353,NCT04020822,Accuracy of Sensor Glucose Before and After Acetaminophen Administration,,,2019-07-29,COMPLETED,INTERVENTIONAL,['NA']
2354,NCT02705430,HbA1c < 7%,Lipid membrane fatty acid composition analysis,,2018-06-20,UNKNOWN,INTERVENTIONAL,['NA']
2355,NCT01418716,Quality of the cardiovascular preventive care,Use of public programs,,2011-04,COMPLETED,INTERVENTIONAL,['NA']
2356,NCT03741153,the percentage of diabetic patients with pseudo-exfoliation syndrome,,,2019-01,UNKNOWN,OBSERVATIONAL,['NA']
2357,NCT03325569,The main outcome was difference in fasting and after load GLP1 levels between two groups,"The secondary outcome was to evaluate the between group difference in beta cell function, and visceral adipose tissue.",,2017-02-13,COMPLETED,INTERVENTIONAL,['NA']
2358,NCT01030744,Self-Monitoring of Blood Glucose,,,2015-12,WITHDRAWN,OBSERVATIONAL,['NA']
2359,NCT03426709,Diabetes control measured by VR d= Hb glucosidal,System Usability Scale (SUS),,2018-11-26,COMPLETED,INTERVENTIONAL,['NA']
2360,NCT05945576,The morphometric characteristics of IDs in pediatric and adult's patients.,Analyse of (epi)genetic mutations transmission in proband and relatives.,"Description of different scientific rational for transferring a therapeutic approach (clinical guidelines) from an ID to another (identification of common phenotype, i.e. metabolic profile).",2017-03-10,RECRUITING,OBSERVATIONAL,['NA']
2361,NCT05544435,Summary of diabetes self-care activities scale (SDSCA),Metabolic variable values,,2019-09-25,COMPLETED,INTERVENTIONAL,['NA']
2362,NCT00698230,Change from Baseline to Week 12 in hemoglobin A1c (HbA1c),Change from Baseline to Week 12 in fasting plasma glucose (FPG).,,2008-05,COMPLETED,INTERVENTIONAL,['PHASE2']
2363,NCT01377935,Hospital admission for acute kidney injury,Hospitalizations for acute kidney injury and/or death due to acute kidney injury,,2009-08,COMPLETED,OBSERVATIONAL,['NA']
2364,NCT00179777,Number of Participants With Type 1 Diabetes Mellitus,Number of Participants With Diabetes Associated Autoantibodies,,2002-05-06,COMPLETED,INTERVENTIONAL,['NA']
2365,NCT03748433,Time Spent in Hypoglycaemia,,,2019-01-03,TERMINATED,INTERVENTIONAL,['NA']
2366,NCT03539627,Systolic blood pressure,Dynamics of renal function (proteinuria detecton),,2018-11-07,COMPLETED,OBSERVATIONAL,['NA']
2367,NCT06198543,differential proteins of exosomes,,,2024-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
2368,NCT01495013,Non inferiority of glimepiride/atorvastatin compared with glimepiride + atorvastatin taken as separate tablets in reducing LDL levels,,,2011-12,COMPLETED,INTERVENTIONAL,['PHASE3']
2369,NCT01475552,"Peak cardiac enzyme level (CK-MB,troponin-I)",The rate of periprocedural myocardial infarction,,2010-09,COMPLETED,INTERVENTIONAL,['PHASE4']
2370,NCT05266742,Patient Identification Form,,,2019-12-15,COMPLETED,INTERVENTIONAL,['NA']
2371,NCT00185159,Time to the first occurrence of microalbuminuria defined as excretion of greater than 35 mg albumin/g urine creatinine for women and greater than 25 mg albumin/g urine creatinine for men in morning spot urine,Safety and tolerability,,2004-10,COMPLETED,INTERVENTIONAL,['PHASE3']
2372,NCT00411333,Change in retinal vascular density from baseline on fluorescein angiography,Safety,,2006-07,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
2373,NCT01687582,Improvement of PASI score,Evolution of BMI,,2012-01,COMPLETED,INTERVENTIONAL,['NA']
2374,NCT00592735,weight loss,,,2007-05,COMPLETED,OBSERVATIONAL,['NA']
2375,NCT00283218,"• Cmaxglu: Peak plasma glucose following test meal (breakfast). A comparison will be made between BIAsp 50 vs BIAsp 70, BIAsp 30 vs BIAsp 70, BIAsp 30 vs BIAsp 50 and IAsp vs BIAsp 30, 50 and 70.","AUCins: The area under insulin aspart concentration (0-12, 0-6, 6-12, 0-4, 4-8, 8-12 hours after test meal) after a single injection of one of the four insulin aspart preparation: IAsp (NovoRapid®), Biphasic insulin aspart 30, 50 and 70.",,2006-01,COMPLETED,INTERVENTIONAL,['NA']
2376,NCT05580978,Change in percentage of CGM glucose readings > 120 mg/dL,Motivation and Attitudes Toward Changing Health,,2022-11-01,RECRUITING,INTERVENTIONAL,['NA']
2377,NCT05416060,Change from Baseline in Baseline Glycosylated Hemoglobin A1C (HbA1c) at 6 months,Change from Baseline Diabetes Treatment Satisfaction Questionnaire (DTSQ) at 6 months,,2023-03-23,RECRUITING,INTERVENTIONAL,['NA']
2378,NCT05588258,Assessment of the skin quality of participants' feet before and after the cream application intervention using a validated questionnaire.,,,2021-11-02,COMPLETED,INTERVENTIONAL,['NA']
2379,NCT03987802,Adverse Events (AEs),Change in HbA1c,,2021-01-20,COMPLETED,OBSERVATIONAL,['NA']
2380,NCT01455922,Change in HbA1c,,,2013-02,WITHDRAWN,INTERVENTIONAL,['PHASE3']
2381,NCT01614379,,,,2012-06,WITHDRAWN,OBSERVATIONAL,['NA']
2382,NCT02891928,Anteroposterior displacement amount of the center of pressure with regard to the center of mass.,,,2014-12,COMPLETED,INTERVENTIONAL,['PHASE4']
2383,NCT00824616,Number of Participants Who Experienced One or More Episodes of Hypoglycemia (Symptomatic or Asymptomatic),,,2009-01,COMPLETED,INTERVENTIONAL,['PHASE2']
2384,NCT04971317,Health Perceptions of SSBs Post-Intervention or Post-Control,,,2018-09-05,COMPLETED,INTERVENTIONAL,['NA']
2385,NCT06109311,"Orforglipron Dose 1, 2: Change from Baseline in Hemoglobin A1c (HbA1c)",Change from Baseline in Short Form 36-Version 2 (SF-36v2) Acute Form Domain and Summary Scores,,2023-11-10,RECRUITING,INTERVENTIONAL,['PHASE3']
2386,NCT01831336,Target Lesion Failure (TLF),Target Lesion Failure (TLF),,2013-02,COMPLETED,OBSERVATIONAL,['NA']
2387,NCT04109508,"AUC0-24h,sema,SS; area under the semaglutide plasma concentration-time curve during a dosing interval at steady state","t½,sema,SS; terminal half-life of semaglutide at steady state",,2019-10-02,COMPLETED,INTERVENTIONAL,['PHASE1']
2388,NCT05615740,Vascular density in central and peripheral retina - healthy subjects,Vascular density in central and peripheral retina - diabetic patients,,2022-05-02,RECRUITING,INTERVENTIONAL,['NA']
2389,NCT05591664,eicosapentaenoic acid,,,2022-10-17,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
2390,NCT05984459,Diabetes remission,Decreases in poglycemic drug treatments,,2023-01-30,COMPLETED,OBSERVATIONAL,['NA']
2391,NCT04802044,Correlation of HbA1c with Clinical Disease Severity,Proportion of Long COVID Syndrome,,2020-12-08,UNKNOWN,OBSERVATIONAL,['NA']
2392,NCT06044532,Change of skin hydration on the dorsum of the forearm after two and a half hours of wearing the sham device.,Change of skin blood flux induced by oral glycemia tolerance test,,2023-03-01,COMPLETED,INTERVENTIONAL,['NA']
2393,NCT00746460,Feasibility of using health care providers other than physicians within a GMF to conduct a CV risk assessment and intervention on primary prevention patients,Satisfaction of the patient,,2008-06,COMPLETED,INTERVENTIONAL,['NA']
2394,NCT03399994,In-stent neointimal volume,Procedural success,,2018-05-21,COMPLETED,INTERVENTIONAL,['NA']
2395,NCT01180712,Oral Glucose Tolerance Test,Fasting blood glucose/insulin,,2010-06,COMPLETED,INTERVENTIONAL,['NA']
2396,NCT05508425,Abdominal bloating after glucose solution administration,,,2021-11-01,COMPLETED,INTERVENTIONAL,['NA']
2397,NCT00037297,,,,2001-07,COMPLETED,OBSERVATIONAL,['NA']
2398,NCT02568384,"Percent of Responses From Persons Who Performed Each ""Software Operations"" Task and Rated Each Statement as Strongly Agree, Agree, or Neither Agree Nor Disagree.",Percent of Responses From Persons With Diabetes That Either 'Strongly Agree' or 'Agree' or Are 'Neither Agree Nor Disagree' With Questionnaire Statements Regarding Clarity and Utility of User Instructions For Onyx Glucose Meter and App System,Average Change in Total Daily Insulin Dose From Study Start to End of Study,2015-10,COMPLETED,INTERVENTIONAL,['NA']
2399,NCT03001323,Reduction in frequency of diabetic ketoacidosis,Basal insulin requirements,,2017-01,TERMINATED,INTERVENTIONAL,['NA']
2400,NCT03672656,Pain assessed by NRS,Satisfaction assessed by the VAS,,2008-01-01,COMPLETED,INTERVENTIONAL,['NA']
2401,NCT00309465,Primary: Preoperative Fasting Blood Sugar Upon Arrival at the Hospital Prior to Surgery,,,2005-10,COMPLETED,INTERVENTIONAL,['PHASE4']
2402,NCT01607931,Incretin effect,,,2013-01,COMPLETED,INTERVENTIONAL,['NA']
2403,NCT04618458,Parent BMI,Child stress,Child tanner stage,2020-12-01,COMPLETED,INTERVENTIONAL,['NA']
2404,NCT01848795,Glycated hemoglobin,,,2013-05,UNKNOWN,INTERVENTIONAL,['PHASE4']
2405,NCT00663884,Change of HbA1c before and after administration of test drug,"Change of CRP, 8-OHdG and Nitrotyrosine before and after administration of test drug",,2008-02,COMPLETED,INTERVENTIONAL,['PHASE4']
2406,NCT04897113,Dynamics summary for improvement of aging biomarkers' values assessed by a patient's biochemical blood count,"scales of the ""Health-Promoting Lifestyle Profile""",,2021-05-12,UNKNOWN,INTERVENTIONAL,['NA']
2407,NCT04847999,Blood glucose incremental area under the curve,Blood glucose total area under the curve,Taste Questionnaire,2020-11-20,COMPLETED,INTERVENTIONAL,['NA']
2408,NCT05160272,Circulating C-peptide by iAUC of C-peptide during an IVGTT,Ctrough-ss (Day 28) and the change from baseline to Day 28,,2022-01-07,RECRUITING,INTERVENTIONAL,['PHASE2']
2409,NCT00013598,,,,2001-03,COMPLETED,INTERVENTIONAL,['PHASE2']
2410,NCT05524259,The incidence of PCOS patients in the two study arm that give birth before 37 completed weeks of gestational age.,"The incidence of neonatal outcomes in the two study arms (e.g. incidence of neonatal intensive care unit (NICU) admissions, incidence of Neonatal hypoglycaemia).",Cost-effectiveness of myo-inositol supplementation using Health Technology Assessment (HTA) analyses.,2019-06-21,RECRUITING,INTERVENTIONAL,['NA']
2411,NCT02501538,Tissue Perfusion as Measured by TCPO2,Percent Wound Area Reduction,,2015-06,COMPLETED,INTERVENTIONAL,['NA']
2412,NCT02452632,Change from baseline in HbA1c at the end of treatment,Percentage of subjects achieving the target HbA1c(<6.5% and <7.0%) at each visit,,2015-06-22,COMPLETED,INTERVENTIONAL,['PHASE3']
2413,NCT02638805,Number (percentage) and severity of treatment-emergent adverse events (TEAEs) of nausea and/or vomiting,Change in body weight,Change from baseline in cholesterol,2015-12,COMPLETED,INTERVENTIONAL,['PHASE3']
2414,NCT05620251,humoral immune response after second vaccine dose,Adverse events,,2021-09-03,COMPLETED,OBSERVATIONAL,['NA']
2415,NCT03902925,Pain score,Surgical complications,Anesthetic medications,2019-01-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2416,NCT00650897,Depressive symptoms,Diabetes self-care,,2008-04,UNKNOWN,INTERVENTIONAL,['PHASE4']
2417,NCT02578498,Peak glucose value,Plasma glucose variation,,2015-10,COMPLETED,INTERVENTIONAL,['PHASE4']
2418,NCT05539963,Number of participants with no clinical need for further additional surgical procedure or debridement to treat infection at the index site,Number of systemic antibiotic free days since trial surgery,,2023-01-23,RECRUITING,INTERVENTIONAL,['PHASE2']
2419,NCT04427488,Circadian Rhythm Evaluation with Morningness Eveningness Questionnaire,Ferrans&Powers Quality of Life,,2020-06-15,COMPLETED,INTERVENTIONAL,['NA']
2420,NCT00211510,Change in A1c From Baseline to 26 Weeks,Problem Areas in Diabetes (PAID) Questionnaire Assessed and Compared Between Groups,,2005-06,COMPLETED,INTERVENTIONAL,['NA']
2421,NCT01699100,plantar pressure of region of interest,Plantar pressure of non-region of interest,plantar pressure of midfoot area,2011-09,COMPLETED,INTERVENTIONAL,['NA']
2422,NCT02532855,Percentage of Participants Who Discontinued Study Drug Due to an AE,Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24,,2015-10-20,COMPLETED,INTERVENTIONAL,['PHASE3']
2423,NCT01186952,Total fat mass,visceral fat thickness,,2010-09,COMPLETED,INTERVENTIONAL,['NA']
2424,NCT04198948,Gliclazide AUC,Insulin,,2019-03-04,COMPLETED,INTERVENTIONAL,['PHASE1']
2425,NCT05351879,"Number of Clinically Significant Abnormal Results From Laboratory measurements (hematology, clinical chemistry) and Urine analysis.",Change in time in hyperglycemic range > 10 mmol/L,,2022-05-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2426,NCT02728687,BPI pain interference improvement 3 months,incidence of side effects,,2017-03-15,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2427,NCT06296251,Body fat mass,AST,,2024-03-25,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2428,NCT03555656,Incidence of foot ulcers,incidence of foot ulcers,,2018-03-01,TERMINATED,INTERVENTIONAL,['NA']
2429,NCT05971524,Glycemic control,Triglycerides,,2023-05-04,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2430,NCT04555421,Fat percentage,Blood tests changes - glycemic control,,2020-10,UNKNOWN,INTERVENTIONAL,['NA']
2431,NCT01564797,Effect of the intervention on physical activity levels in diabetics and pre-diabetic participants,Effect of the intervention on changes in knowledge and attitudes about diabetes,,2008-07,COMPLETED,INTERVENTIONAL,['NA']
2432,NCT02916680,Absence of ophthalmic complications,Change in total number of hypoglycemic events,,2016-03,RECRUITING,INTERVENTIONAL,['NA']
2433,NCT03297294,Change in Weekly Mean 24-hour Average Pain Score Using the 11 Point Numerical Rating Scale (NRS) From Baseline to Week 12,Treatment Emergent Adverse Events During Urgent Safety Measure (USM) Follow-Up,,2018-03-14,TERMINATED,INTERVENTIONAL,['PHASE2']
2434,NCT03025451,Weight,Fasting Glucose,,2011-05,COMPLETED,INTERVENTIONAL,['NA']
2435,NCT00065312,,,,na,COMPLETED,INTERVENTIONAL,['PHASE2']
2436,NCT05662189,pancreatic beta cell function (BCF),,,2022-03-15,RECRUITING,INTERVENTIONAL,['NA']
2437,NCT01593059,Target Lesion Failure (TLF),Clinical Procedural Success,,2012-08,TERMINATED,OBSERVATIONAL,['NA']
2438,NCT01302756,Gestational diabetes,Gestational hypertension,,2012-04,WITHDRAWN,INTERVENTIONAL,['NA']
2439,NCT01098253,Hemoglobin A1C,Nine Item Patient Health Questionnaire (PHQ-9),,2009-01,COMPLETED,INTERVENTIONAL,['NA']
2440,NCT01223456,Clinical Response determined by cure rate,,,2010-10,TERMINATED,OBSERVATIONAL,['NA']
2441,NCT03032354,"Area under the curve (AUC) during fasting and at 30,60,90,120 min following the start of the meal",Fasting c- peptide concentrations in ng/ml,,2017-07-15,UNKNOWN,INTERVENTIONAL,['PHASE4']
2442,NCT01331343,Difference in Change in A1c (%) between continuous use of CGM and control,Difference in change in A1c (%) between biweekly use of CGM and continuous use of CGM,,2004-06,COMPLETED,INTERVENTIONAL,['PHASE4']
2443,NCT03680079,HbA1c,Depression screening,,2018-09-01,COMPLETED,INTERVENTIONAL,['NA']
2444,NCT02754739,Insulin resistance assessed by HOMA-IR (homeostatic model assessment index for insulin resistance),"Biomarkers predicting cardiovascular diseases, assessed by plasminogen activator inhibitor-1 (PAI-1) (ng/mL)",,2014-04-15,COMPLETED,INTERVENTIONAL,['PHASE4']
2445,NCT01575080,Number of Self-Test Fingerstick Blood Glucose Results Within +/- 15mg/dL (<100mg/dL) or Within +/- 15% (>=100mg/dL) of Laboratory Glucose Method,Number of Subject Responses That 'Agree' or 'Strongly Agree' With Questionnaire Statements,,2012-04,COMPLETED,INTERVENTIONAL,['NA']
2446,NCT05412264,Increased pedometer steps,Waist circumference,Questionnaire,2014-01,TERMINATED,INTERVENTIONAL,['NA']
2447,NCT01663207,,,,2012-05,COMPLETED,OBSERVATIONAL,['NA']
2448,NCT02593032,Percent of Participants With Adherence at Month 6,,,2015-02,COMPLETED,INTERVENTIONAL,['NA']
2449,NCT04579406,adverse cardiovascular events,"NPY, CGRP, SP and TRPV1",,2020-10-15,RECRUITING,OBSERVATIONAL,['NA']
2450,NCT02619877,Proportion of re-epithelialization,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,,2015-10,COMPLETED,INTERVENTIONAL,['PHASE2']
2451,NCT00270608,,,,2007-03,UNKNOWN,OBSERVATIONAL,['NA']
2452,NCT06028139,HbA1c,Healthcare cost as measured by WPAI,,2023-11,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2453,NCT03821753,Macular capillary density in the external deep capillary network,Oxidative stress markers,,2019-01-07,UNKNOWN,OBSERVATIONAL,['NA']
2454,NCT00803777,Number of Duplicate Subject BGM Results Within +/- 15mg/dL or +/- 20% of Healthcare Professional Capillary Results,Average Within Replicate Coefficient of Variation CV (Precision),,2008-12,COMPLETED,INTERVENTIONAL,['NA']
2455,NCT01642355,Reduction of Non-HDL cholesterol,Cardiovascular events,,2012-06,COMPLETED,INTERVENTIONAL,['NA']
2456,NCT04325126,serum RBP4 level,,,2020-04-01,RECRUITING,OBSERVATIONAL,['NA']
2457,NCT06190405,Large-for-gestational age,Rate of hypertensive disorders of pregnancy,,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2458,NCT01617304,change in AGE levels in skin from baseline to 4 weeks,change in HbA1c from baseline to 4 weeks,,2011-12,COMPLETED,INTERVENTIONAL,['NA']
2459,NCT00506272,average blood glucose,,,2007-12,UNKNOWN,INTERVENTIONAL,['NA']
2460,NCT01498159,Hemoglobin A1c,LDL Cholesterol,,2011-12,COMPLETED,INTERVENTIONAL,['NA']
2461,NCT00903500,Dexa scan,"Questionnaires on psycho-social determinants of physical activity, on environmental determinants of physical activity and a motivational questionnaire",,2007-07,COMPLETED,INTERVENTIONAL,['NA']
2462,NCT03437109,The prevalence of hypogonadism in patients with T2DM,,,2017-12-06,COMPLETED,OBSERVATIONAL,['NA']
2463,NCT00839150,,,,2005-05,COMPLETED,OBSERVATIONAL,['NA']
2464,NCT02411032,Medication refills,LDL cholesterol,,2015-04,COMPLETED,INTERVENTIONAL,['NA']
2465,NCT01987674,HbA1c,Postprandial glycemia,Homeostasis model assessment of insulin resistance (HOMA-IR),2014-01,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2466,NCT00782717,Percent of Patients Who Developed Macular Edema (ME) Within 90 Days Following Cataract Surgery,Percent of Patients With a Decrease of More Than 5 Letters in Best-corrected Visual Acuity (BCVA).,,2008-11,COMPLETED,INTERVENTIONAL,['PHASE2']
2467,NCT00997763,Angiographic in-segment late loss at angiography,Angiographic pattern of restenosis,,2008-07,COMPLETED,INTERVENTIONAL,['PHASE4']
2468,NCT04484480,Medial-Lateral Stability Index,,,2020-01-01,COMPLETED,INTERVENTIONAL,['NA']
2469,NCT03331432,Glucose tolerance,,,2015-10-28,COMPLETED,INTERVENTIONAL,['NA']
2470,NCT00864838,Intraocular pressure (mmHg),,,2008-06,COMPLETED,INTERVENTIONAL,['PHASE2']
2471,NCT02136758,Body Mass Index,Blood Lipids,Exercise Capacity,2009-04,TERMINATED,INTERVENTIONAL,['NA']
2472,NCT02015806,Optimal medication adherence to all cardiovascular or non-depression chronic disease medications,Optimal adherence to cardiovascular medications among subjects who are suboptimally adherent to these medications at time of randomization,,2014-03,COMPLETED,INTERVENTIONAL,['NA']
2473,NCT02684565,Change in glucose tolerance and body composition that Are Related to Low protein BCAA Treatment,Change in glucose tolerance and body composition that Are Related to High Protein BCAA treament,,2016-10,COMPLETED,INTERVENTIONAL,['NA']
2474,NCT00306696,Changes in Haematocrit following 7 days diuretic adminstration.,"Total body fluid & extracellular fluid, body weight, haematocrit & haemoglobin.",,2002-10,COMPLETED,INTERVENTIONAL,['PHASE4']
2475,NCT01684709,12-month glycemic control,Secondary effects upon adjustment to diabetes,,2012-12,COMPLETED,INTERVENTIONAL,['NA']
2476,NCT03809793,Insulin Sensitivity,Change in intramuscular DAGs,,2020-01-06,COMPLETED,INTERVENTIONAL,['NA']
2477,NCT02322762,Anti-diabetic treatments prescribed by physicians in a real-world setting.,Use of Healthcare resources.,,2014-12-30,COMPLETED,OBSERVATIONAL,['NA']
2478,NCT01588470,Myocardial Glucose Uptake,Change in Hemoglobin A1c,,2006-06,COMPLETED,INTERVENTIONAL,['PHASE4']
2479,NCT03588104,Change in glycemic control,Patient Assessment of Chronic Illness Care (PACIC),,2018-12-03,COMPLETED,INTERVENTIONAL,['NA']
2480,NCT01155284,2 Hour C-peptide AUC in Response to MMTT,2 Hour C-peptide AUC in Response to MMTT,,2010-08,COMPLETED,INTERVENTIONAL,['PHASE2']
2481,NCT03654521,Fetal interventricular septum thickness,,,2018-08-01,UNKNOWN,INTERVENTIONAL,['NA']
2482,NCT02399657,The ratio of eyes showing reduced hard exudates in macula (1500 micrometer from foveal center),Number of eyes having increased intraocular pressure,,2015-02,UNKNOWN,INTERVENTIONAL,['PHASE4']
2483,NCT01042769,"Effect on cardiovascular death, non-fatal myocardial infarction and non-fatal stroke",Tolerability and long-term safety profile,,2010-02,COMPLETED,INTERVENTIONAL,['PHASE3']
2484,NCT00701454,"prevalence of diabetes, hypertension and hyperlipidemia",,,2005-09,COMPLETED,OBSERVATIONAL,['NA']
2485,NCT01415115,SCOUT Comparison,Hypertension,,2007-03,COMPLETED,OBSERVATIONAL,['NA']
2486,NCT01241448,Change From Baseline to 24 Week Endpoint in Hemoglobin A1c (HbA1c),The 30-Day Adjusted Rate of Hypoglycemic Episodes,,2011-01,COMPLETED,INTERVENTIONAL,['PHASE2']
2487,NCT02768480,Glycemic Control,Death,Blood Pressure,2015-06,COMPLETED,INTERVENTIONAL,['NA']
2488,NCT03891927,change of fasting glucose after intervention by extra virgin olive oil,"change at Lipid profile (cholesterol, TG, LDL, HDL) after intervention .",,2019-05-01,UNKNOWN,INTERVENTIONAL,['NA']
2489,NCT04011683,"Incidence of cardiac arrhythmias during hypoglycaemia, euglycaemia, hyperglycaemia.",Mean amplitude of glycaemic excursions (MAGE) and cardiac arrhythmia.,,2018-12-01,COMPLETED,OBSERVATIONAL,['NA']
2490,NCT01562561,HbA1c (glycosylated haemoglobin),Adverse events,,2001-06-01,COMPLETED,INTERVENTIONAL,['PHASE3']
2491,NCT01667900,Pharmacokinetics: Half-life of Dulaglutide,Part B - Pharmacodynamics: Area Under the Plasma Glucose Time Curve From Time Zero to 4 Hours Postmeal (gAUC[0-4]),,2012-08,COMPLETED,INTERVENTIONAL,['PHASE1']
2492,NCT00837408,Type 2 Diabetes,,,2009-02-03,COMPLETED,OBSERVATIONAL,['NA']
2493,NCT00114998,,,,2005-06,COMPLETED,OBSERVATIONAL,['NA']
2494,NCT05046886,Mean Amplitude of Glycemic Excursion (MAGE),HbA1c Levels,,2021-12-14,RECRUITING,INTERVENTIONAL,['NA']
2495,NCT03179280,post-prandial euglycaemia (PPG),,,2011-03,COMPLETED,INTERVENTIONAL,['NA']
2496,NCT03453281,Central macular thickness,Uncorrected visual acuity (number of letters),,2017-10-10,COMPLETED,INTERVENTIONAL,['PHASE4']
2497,NCT01040962,,,,2008-08,COMPLETED,OBSERVATIONAL,['NA']
2498,NCT03368586,FGM accuracy,Sensor related-issues,,2016-07-02,COMPLETED,OBSERVATIONAL,['NA']
2499,NCT06118671,Change of HbA1c,Change of LDL-c,,2023-11-07,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2500,NCT00446810,Endothelial function (flow mediated dilatation - ultrasound- and reactive hyperemia- laser doppler-),Parameters of autonomic neuropathy,,2007-09,UNKNOWN,INTERVENTIONAL,['PHASE4']
2501,NCT02564913,nailfold videocapillaroscopy,,,2011-12,COMPLETED,OBSERVATIONAL,['NA']
2502,NCT04888780,Quality Criteria for Consumer Health Information (DISCERN) Website Evaluation Scale,,,2017-01-01,COMPLETED,INTERVENTIONAL,['NA']
2503,NCT01400659,CGM-Glucose Area Under the Curve,frequency of adverse events (incl. SAE),,2009-03,COMPLETED,INTERVENTIONAL,['PHASE4']
2504,NCT04547244,CRTd responders rate,,,2015-01-01,COMPLETED,OBSERVATIONAL,['NA']
2505,NCT02010242,Albuminuria,Glucose metabolism,Neuropathic pain,2013-10,COMPLETED,INTERVENTIONAL,['PHASE2']
2506,NCT05199454,Brachial artery flow-mediated dilation (percent vasodilation) in 60 obese diabetic subjects,Glycosphingolipid content (ng/ml) in adiposomes from 60 obese diabetic subjects,,2022-05-16,RECRUITING,INTERVENTIONAL,['NA']
2507,NCT06018324,DTSQc,Treatment costs,,2023-09,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
2508,NCT04754919,"The rates of diabetes related hospital episodes, including Diabetic Ketoacidosis, between the 2 study groups before and after transition",To compare the proportion of young people in the study groups who fail to attend at least one out-patient adult diabetes appointment during the first year after transition,,2018-12-01,UNKNOWN,INTERVENTIONAL,['NA']
2509,NCT00261352,The change in HDL-C from baseline to the end of the randomized treatment period.,"Safety and tolerability of tesaglitazar by assessment of adverse events, laboratory values, electrocardiogram, pulse, blood pressure, hypoglycemic events, body weight, cardiac evaluation, and physical examination",,2005-03,TERMINATED,INTERVENTIONAL,['PHASE3']
2510,NCT01633021,Social &amp; relational factors from family network data,Cognitive network utility evaluation,,2012-07-05,COMPLETED,OBSERVATIONAL,['NA']
2511,NCT02879409,Determination of the variability of HbA1c (by measurement of standard deviation of HbA1c) between the 2 diabetes treatment thresholds,Comparison of HbA1c (percent) for each subject at baseline and following sample storage of 2 years to assess HbA1c measurement stability.,,2016-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2512,NCT02918591,Change of Soluble Klotho,Change of HbA1c,,2017-11,UNKNOWN,INTERVENTIONAL,['NA']
2513,NCT02445079,Baseline prevalence and incident change in carotid intima media thickness,Baseline prevalence and incident change in chronic obstructive pulmonary disease,,2013-12,COMPLETED,OBSERVATIONAL,['NA']
2514,NCT05315908,Timeliness of Testing,Number of Household Members Referred for Testing,,2020-11-01,TERMINATED,INTERVENTIONAL,['NA']
2515,NCT00288977,independence from insulin injections with adequate control of blood glucose in subjects with Type 1 diabetes at one year post final transplant,,,2000-09,COMPLETED,INTERVENTIONAL,['NA']
2516,NCT05336019,Retention rate,Glycated Hemoglobin A1c (HbA1c),,2022-10-01,COMPLETED,INTERVENTIONAL,['NA']
2517,NCT00305604,Change From Baseline in HbA1c (Hemoglobin A1c) at Week 24,Rapidity of Onset of Action as Determined by Home Glucose Monitoring After 1 Week,,2006-03-08,COMPLETED,INTERVENTIONAL,['PHASE3']
2518,NCT04634591,Changes in GI hormones concentrations during the mixed meal tolerance test (MMTT),Adipose tissue methylome,,2015-09-10,RECRUITING,OBSERVATIONAL,['NA']
2519,NCT04216849,UACR,eGFR,,2020-07-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2520,NCT03919877,Classification of metabolic subphenotype,Change in area under the curve (AUC) of blood glucose level,,2018-05-24,RECRUITING,INTERVENTIONAL,['NA']
2521,NCT01174381,Proportion of participants who change their lifestyle characteristics related to NCDs,Proportion of participants with decrease in Body Mass Index following lifestyle modification programme,,2010-08,COMPLETED,INTERVENTIONAL,['NA']
2522,NCT02945332,Miles walked,Waist circumference change,Food consumption change,2016-10,COMPLETED,INTERVENTIONAL,['NA']
2523,NCT02224742,Healing,,,2013-08,COMPLETED,INTERVENTIONAL,['PHASE4']
2524,NCT00922194,Change in Glycosylated Haemoglobin (A1C) From Baseline at 12 Months or More,,,2006-02,COMPLETED,INTERVENTIONAL,['NA']
2525,NCT04049149,Incidence of any diabetes-related micro/macrovascular endpoints (Part 3 of study),Changes in patient's Depression Anxiety Stress (Part 3 of study),,2020-01-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2526,NCT03072407,"the number of AEs and the finding from the physical examination, the abnormal lab results",Disposition Index,,2015-11-24,COMPLETED,INTERVENTIONAL,['PHASE1']
2527,NCT00878891,Percent of time in normoglycemia (0.8 - 1.10 g/L),Adverse events due to the device,,2009-04,TERMINATED,INTERVENTIONAL,['NA']
2528,NCT01461330,Change from Baseline in Blood Pressure at 4 weeks,Change from Baseline in glucose control at 4 weeks,,2011-02,TERMINATED,INTERVENTIONAL,['NA']
2529,NCT01037842,the change in HbA1c from randomization to endpoint,the proportion of subjects with HbA1c <7% after 16 weeks of treatment and the change in FPG and 2-hr postprandial glucose (PPG) from baseline,,2006-08,COMPLETED,INTERVENTIONAL,['PHASE3']
2530,NCT03802487,Pharmacokinetic (PK) parameter: Absolute Bioavailability (F),Safety: Adverse events,,2019-01-14,COMPLETED,INTERVENTIONAL,['PHASE1']
2531,NCT01591681,Hypoglycemia Outcome: Percentage of Nights With Sensor Glucose Value </=60 mg/dl,Percent of Nights With Sensor Glucose >250 mg/dL,,2012-11,COMPLETED,INTERVENTIONAL,['PHASE2']
2532,NCT05409391,mean daily blood glucose concentration,glycemic variability,,2022-06-15,COMPLETED,INTERVENTIONAL,['NA']
2533,NCT03765359,Changes in the insulin need during pregnancy,Inflammatory markers,,2019-08-05,COMPLETED,INTERVENTIONAL,['PHASE4']
2534,NCT04677127,Glycemic Control Change,Self-Efficacy Questionnaire,,2019-06-17,COMPLETED,INTERVENTIONAL,['NA']
2535,NCT05954819,Change of Diabetes Self-Management,,,2023-07-28,COMPLETED,INTERVENTIONAL,['NA']
2536,NCT02838784,Ulcer recurrence,Number of grafts and graft size(s),Health economic outcomes,2016-09,UNKNOWN,INTERVENTIONAL,['NA']
2537,NCT04597957,Change in weight (pounds) in intervention and control group.,Number of visits to Clinic based farmers market (the mercardo) per participant in Fresh Rx program.,,2018-07-12,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
2538,NCT03486223,Insulin Sensitivity,Renal Plasma Flow (RPF),Soluble Epoxide Hydrolase Activity in Tissue,2018-05-17,COMPLETED,INTERVENTIONAL,['PHASE2']
2539,NCT03982238,total testosterone levels,free testosterone,,2019-06-15,COMPLETED,INTERVENTIONAL,['PHASE4']
2540,NCT01814137,Change From Baseline in HbA1c (Glycosylated Haemoglobin),Change From Baseline in Fasting Plasma Glucose (FPG),,2013-03,COMPLETED,INTERVENTIONAL,['PHASE3']
2541,NCT04606576,Mean change from baseline in A1C,Mean change in fasting glucose,,2020-12-15,TERMINATED,INTERVENTIONAL,['PHASE3']
2542,NCT01240070,Cardiovascular events,cardiovascular risk factors changes,,2002-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
2543,NCT01223651,Accuracy of continuous glucose monitoring system (CGMS).,The effect of altitude on the recognition of hypoglycaemic symptoms.,,2012-01,TERMINATED,INTERVENTIONAL,['NA']
2544,NCT00653185,Change from baseline in glycosylated hemoglobin,Body weight,,2007-05,COMPLETED,INTERVENTIONAL,['PHASE2']
2545,NCT04417218,Change in Plasma 2-AAA Concentration From Baseline,,,2020-08-17,COMPLETED,INTERVENTIONAL,['NA']
2546,NCT01066130,"Psychosocial well-being as measured by interview with a medical social worker, Hospital Anxiety and Depression Scale, General Coping Questionnaire, Social Situation Questionnaire, and self-reported satisfaction with psychosocial treatment","Medical parameters that show whether the patient has reached treatment goals for his or her disease; for example, glycated hemoglobin (HbA1c) for diabetes and the Disease Activity Score (DAS) for rheumatoid arthritis",,2001-01,COMPLETED,INTERVENTIONAL,['NA']
2547,NCT03636243,Reactive Hyperemia Index (RHI),study of the peri-aortic and peri-brachial adipose tissue (TAPV),,2019-10-15,RECRUITING,INTERVENTIONAL,['NA']
2548,NCT05559515,A1C,return to normoglycemia,,2023-02-01,RECRUITING,INTERVENTIONAL,['NA']
2549,NCT00390637,For adults: body weight loss maintenance,For Children: Change in BMI-Z-score,For adults: Identify traits gene - diet interactions that determine responses to the dietary intervention.,2006-01,COMPLETED,INTERVENTIONAL,['PHASE4']
2550,NCT02790957,Wound healing rate,Incidence of adverse events and reactions,,2016-06,TERMINATED,INTERVENTIONAL,['PHASE2']
2551,NCT03694145,Proportion of patients accurately diagnosed with retinopathy,,,2018-10-25,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
2552,NCT00622271,"Enroll patients and their families into either a treatment group or a wait list control (WLC) group to determine the impact of a peer and family-based group intervention on improving adjustment, coping, and functioning among adolescents with diabetes.",Diabetes-related medical improvements from baseline to post-treatment and maintained at 4 months and 6 months post-treatment.,,2008-02,COMPLETED,INTERVENTIONAL,['NA']
2553,NCT02173067,varition in blood glucose levels during oral surgery with local anaesthesia (lidocaina and lidocaine with epinephrine),Hemodynamic effects during the surgery with local anesthetia (lidocaine and lidocaine with epinephrine),Anxiety levels during the oral surgery with local anesthesia (lidocaine and lidocaine and epinephrine),2009-09,COMPLETED,OBSERVATIONAL,['NA']
2554,NCT00277277,Body weight at 8 weeks; Body Mass Index at 8 weeks; Diabetes outcomes at 8 weeks,Hip/waist circumference at 8 weeks; Energy and nutrient intake at 8 weeks; Physical activity at 8 weeks,,2004-08,COMPLETED,INTERVENTIONAL,['NA']
2555,NCT02339311,Patient Activation,Diabetes associated health indicators,,2012-06,TERMINATED,OBSERVATIONAL,['NA']
2556,NCT02799563,Test 1 scores,Scores on Standardized exams,,2014-07,COMPLETED,INTERVENTIONAL,['NA']
2557,NCT00551954,forearm blood flow assessed by forearm occlusion plethysmography after a mixed meal,"forearm blood flow assessed by forearm occlusion plethysmography in the fasting state, plasma glucose excursion in response to the mixed meal, insulin levels in response to the mixed meal, triglyceride levels in response to the mixed meal",,2006-07,COMPLETED,INTERVENTIONAL,['PHASE3']
2558,NCT03670602,Change From Baseline in Glycemic Control,Changes in Working Memory,Changes in Relative Reinforcing Efficacy of Unhealthy Food,2019-01-17,COMPLETED,INTERVENTIONAL,['NA']
2559,NCT05081921,Change in the International Knee Documentation Committee (IKDC 2000),Change in ultrasonographic findings in knee joint,,2022-01-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2560,NCT02111226,Blood Pressure,Blood Pressure,,2012-01,UNKNOWN,INTERVENTIONAL,['NA']
2561,NCT00363987,changes in urine protein and GFR,plasma lipids,,2006-05,COMPLETED,INTERVENTIONAL,['PHASE4']
2562,NCT06041399,the presence of diabetic peripheral neuropathy,,,2012-02-01,RECRUITING,INTERVENTIONAL,['PHASE4']
2563,NCT00629304,Comparison of HbA1c mean between the 3 groups,"Effective number of patients carrying on the use of the system in routine care, at their own expense and in agreement with their physician",,2007-09,COMPLETED,INTERVENTIONAL,['PHASE3']
2564,NCT00717288,Patients With Morning (AM) Glucose Between 80-130 mg/dl on Day 2 and 3,Reversion to Intravenous Insulin for Failure of Glycemic Control,,2008-07,COMPLETED,INTERVENTIONAL,['PHASE4']
2565,NCT04604548,Treatment Emergent Adverse Events (TEAE),Heart rate (bpm),,2021-08-09,COMPLETED,INTERVENTIONAL,['PHASE2']
2566,NCT05972954,Number of Treatment Emergent Adverse Events (TEAE),Pharmacokinetics: Cmax [ng/ml],,2023-05-22,RECRUITING,INTERVENTIONAL,['PHASE2']
2567,NCT03826381,Prevalence of NAFLD and actual estimate of liver signal measured by MR spectroscopy,"NAFLD, as measured by MR spectroscopy, and its association with glucose profiles in relation to impaired renal function",,2019-05-06,COMPLETED,OBSERVATIONAL,['NA']
2568,NCT06334302,Delta postprandial glucose level,Labeled Magnitude Scale (gLMS),,2024-03-25,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2569,NCT03490942,Plasma Epinephrine,,,2018-03-15,TERMINATED,INTERVENTIONAL,['PHASE2']
2570,NCT00842972,,,,na,COMPLETED,OBSERVATIONAL,['NA']
2571,NCT00854503,Glucose tolerance assessed by HbA1c and fasting glucose,insulin-resistance assessed by clamp. Endothelial function assessed by FMD %. Inflammatory status assessed by biochemical markers.,,2008-09,COMPLETED,INTERVENTIONAL,['PHASE3']
2572,NCT01354015,Change in HbA1c,Change in HbA1c Over 3 Months,,2011-05,COMPLETED,INTERVENTIONAL,['NA']
2573,NCT01101568,AUC(0-inf) and Cmax of simvastatin/simvastatin acid alone and in the presence of GSK1292263,"PK parameter values: AUC(0-24h), Cmax, tmax and t1/2 for GSK1292263 and assessment of steady-state",,2010-04-14,COMPLETED,INTERVENTIONAL,['PHASE1']
2574,NCT00353600,,,,1994-08-19,COMPLETED,OBSERVATIONAL,['NA']
2575,NCT02101151,glycemic control,Obesity Parameter,,2012-06,COMPLETED,INTERVENTIONAL,['NA']
2576,NCT04588259,Change From Baseline in HbA1c (Millimoles Per Mole [mmol/Mol]),Number of Treatment Emergent Hypoglycaemic Episodes Classified Both According to the ADA Definition and NN Definition: Hypoglycaemic Episodes From 2 Hours (Exclusive) to 4 Hours (Inclusive) After Start of Meal,,2020-10-09,COMPLETED,INTERVENTIONAL,['PHASE3']
2577,NCT02973477,Changes in Measure of Heart Rate Variability Using Dapagliflozin vs Active Comparator Glimepiride.,Change in B-type Natriuretic Peptide With Each Intervention as a Measure of Left Ventricular Function,Glucose Variability,2017-01-12,COMPLETED,INTERVENTIONAL,['PHASE4']
2578,NCT06064058,HBA1C,,,2023-01-30,COMPLETED,INTERVENTIONAL,['NA']
2579,NCT05762432,Reduction in Wound Area,Dressing Changes,,2024-02-26,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2580,NCT01122979,Proportion of patients that reach the target of HbA1c ≤7% without confirmed nocturnal hypoglycaemia in each treatment group and the respective CI 90%.,Creatinine clearance variation,,2010-07,COMPLETED,INTERVENTIONAL,['PHASE4']
2581,NCT04100278,LDL-c change,DASS-C21scale score change,Diabetes complications,2020-01-01,UNKNOWN,INTERVENTIONAL,['NA']
2582,NCT03528707,liver stiffness (LS),cytokines levels,,2015-04-14,COMPLETED,INTERVENTIONAL,['NA']
2583,NCT02812238,Mean IL-1 Beta Release From Peripheral Blood Mononuclear Cells During Refeeding After 24 Hour Fast,,,2016-06-23,COMPLETED,INTERVENTIONAL,['NA']
2584,NCT06236334,Diabetes risk based on HbA1c level (mmol/mol),"Habitual food intake (frequencies, number and grams)",,2024-02,RECRUITING,INTERVENTIONAL,['NA']
2585,NCT00067678,,,,2001-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2586,NCT00732524,The primary outcome was the patients' ability to avoid repeat ED visits or hospitalization in either of the discharge regimens.,The secondary outcomes included the number of subjects who reached a fasting or pre-meal BG goal of 80 to 130 mg/dl and assessment of the beta cell function at the beginning and end of the study as measured by C-peptide levels during OGTT testing.,,2004-09,COMPLETED,INTERVENTIONAL,['PHASE4']
2587,NCT02467478,Urinary Function Marker in CKD,Resting Metabolic Rate (RMR),,2015-04,COMPLETED,INTERVENTIONAL,['PHASE4']
2588,NCT00367445,Variability of blood glucose over a period of 72 hours,Insulin pharmacokinetics,,2006-09,COMPLETED,INTERVENTIONAL,['PHASE4']
2589,NCT01809288,"Determine if there are differences in African, African-American and white women in the relationship between triglyceride levels, (a frequently used screening test for diabetes and heart disease) glucose tolerance status and insulin resistance.",Determine if there are race or ethnic differences in the pancreatic secretion of insulin relative to the degree of insulin resistance.,,2013-09-26,COMPLETED,OBSERVATIONAL,['NA']
2590,NCT01147718,The pharmacokinetic parameters of digoxin with and without albiglutide,Safety of digoxin with and without albiglutide,,2010-06-11,COMPLETED,INTERVENTIONAL,['PHASE1']
2591,NCT00486629,Excessive weight gain during pregnancy,"macrosomia, requirement of delivery procedures",,2004-07,RECRUITING,INTERVENTIONAL,['NA']
2592,NCT05276401,To Assess the Number of Participants With Treatment-related Adverse Events After Nu-3 Gel Use on cDFU as Assessed by CTCAE v4.0,,,2022-03-11,TERMINATED,INTERVENTIONAL,['PHASE2']
2593,NCT03104933,Levels o Copeptin as predictor of vasopressor requirements (measured by index inotropic and vasopressor dependency ratio) and fluid requirement,Levels of proADM and Copeptin as predictors of lactate clearance,,2016-07-01,COMPLETED,OBSERVATIONAL,['NA']
2594,NCT01754662,"Insulin resistance, lipid profile",Endothelial function,,2011-10,COMPLETED,INTERVENTIONAL,['NA']
2595,NCT04880291,Safety and tolerability following single ascending doses of GFB-024,Characterize the incidence and persistence of immunogenicity of GFB-024 following repeated doses,,2021-05-05,COMPLETED,INTERVENTIONAL,['PHASE1']
2596,NCT00690638,To demonstrate changes in HbA1c,,,2008-07,COMPLETED,INTERVENTIONAL,['PHASE3']
2597,NCT00214786,Achievement of Insulin Independence at 12-month Post Transplant,The Quality of Life of the Recipients Measured With the RAND 36-item Short Form Health Survey,,2005-04,COMPLETED,INTERVENTIONAL,['PHASE1']
2598,NCT00044148,,,,2002-07-16,COMPLETED,INTERVENTIONAL,['PHASE2']
2599,NCT00468117,Proportion of patients w/HbA1c </= to 6.5% and an absence of severe hypoglycemic events or a reduction in HbA1c of at least 1 point and an absence of severe hypoglycemic events,"Reduction in insulin requirements, HbA1c, MAGE, LI, HYPO score, fasting glucose, beta score, serum creatinine, c-peptide levels, MMTT, Clarke Survey, FSIGT, CGMS, number of hypoglycemic events, renal impact, cardiovascular impact, and quality of life",,2007-01,COMPLETED,INTERVENTIONAL,['PHASE3']
2600,NCT02808182,whole-body organ-specific DFA partitioning,Lipoprotein lipase activity,,2017-01-17,COMPLETED,INTERVENTIONAL,['NA']
2601,NCT05210504,Change in level of 2-AAA in urine,,,2022-03-09,COMPLETED,INTERVENTIONAL,['PHASE1']
2602,NCT03689374,Change From Baseline in Glycated Haemoglobin (HbA1c),Change From Baseline to Week 52 in Diabetes Quality of Life Clinical Trial Questionnaire (DQLCTQ-R): Scores From the 8 Domains,,2018-10-01,COMPLETED,INTERVENTIONAL,['PHASE3']
2603,NCT04159922,Score of the Bortner self-questionnaire,,,2019-12-03,COMPLETED,OBSERVATIONAL,['NA']
2604,NCT01242137,HbA1c,,,2009-10,UNKNOWN,OBSERVATIONAL,['NA']
2605,NCT04233138,Users' satisfaction of the SUPPORT platform,Knowledge about diabetes self-management,,2020-02-05,UNKNOWN,INTERVENTIONAL,['NA']
2606,NCT06134986,Change in percent body weight,Change in ketones,,2023-11-20,RECRUITING,INTERVENTIONAL,['NA']
2607,NCT04335565,Postprandial glucose levels,Subjective feelings of satiety,,2020-03-03,WITHDRAWN,INTERVENTIONAL,['NA']
2608,NCT03169530,Cardiovascular Disease or Death,Diabetes,Pre-Diabetes,2018-02-05,TERMINATED,INTERVENTIONAL,['NA']
2609,NCT01751360,Blood Glucose,,,2013-04-01,COMPLETED,INTERVENTIONAL,['PHASE3']
2610,NCT03509441,Assessing level of edema via T2 mapping,Urine test for creatinine levels,,2015-01-15,COMPLETED,OBSERVATIONAL,['NA']
2611,NCT04460092,Pain when insulin injection,,,2020-05-25,UNKNOWN,INTERVENTIONAL,['NA']
2612,NCT01232946,Myocardial Fatty Acid Esterification Rate,,,2012-01,COMPLETED,INTERVENTIONAL,['NA']
2613,NCT01094418,Nerve conduction parameters,Clinical neuropathic scoring system,,2009-06,COMPLETED,OBSERVATIONAL,['NA']
2614,NCT04023539,Glycated hemoglobin,Blood pressure,,2019-09-04,COMPLETED,INTERVENTIONAL,['NA']
2615,NCT00668954,Percent change of oxidant stress and lipid oxidation,High Sensitivity C-reactive protein HsCRP,,2008-04,COMPLETED,INTERVENTIONAL,['NA']
2616,NCT03328845,Oxidative stress markers with the new slow insulin analogues,Diabetes treatment satisfaction questionnaire (DTSQ).,,2017-01-20,COMPLETED,INTERVENTIONAL,['PHASE4']
2617,NCT04297592,Periprosthetic joint infections,Wound complication,,2020-06-11,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE4']
2618,NCT03550963,between-group difference in glucose control,between-group difference in undesirable clinical outcome,,2018-06-23,UNKNOWN,INTERVENTIONAL,['NA']
2619,NCT04983979,Proportion of patients on Maximum dose (300mg) Irbesartan therapy at 12 weeks compared to placebo,Change in GFR at the end of study from baseline,,2022-06-17,TERMINATED,INTERVENTIONAL,['PHASE2']
2620,NCT05610046,Glycaemic response (Matsuda index),Gutt insulin sensitivity index,,2023-01-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2621,NCT06106035,HbA1c,Food Cost,,2024-02-13,RECRUITING,INTERVENTIONAL,['NA']
2622,NCT06252038,Weight change across 12 months,CDC-NDPP Physical Activity Goal,,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2623,NCT03522870,Glycosylated Hemoglobin A1c,EQ-5D-5L,,2018-05-01,COMPLETED,INTERVENTIONAL,['NA']
2624,NCT06140485,Comparing the mean change in HbA1c levels between the experimental arm and the active-control arm,Comparing the mean change in weight between the experimental arm and the active-control arm,,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
2625,NCT00881543,"secretion of glucose, insulin, glucagon, C-peptide and lipid profile after isocaloric diets",Washout of dipeptidyl peptidase IV inhibitors after one month without the drug,,2009-06,COMPLETED,INTERVENTIONAL,['NA']
2626,NCT00875459,The frequency of occurrence of hypoglycemia measured quarterly over one year.,"Changes in total daily:prandial insulin dose, insulin dose, body weight, insulin antibody titers, the effects of insulin antibodies on glycemic control, individual and group mean %HbA1c measured quarterly and over one year.",,2007-04,COMPLETED,INTERVENTIONAL,['PHASE3']
2627,NCT00603499,Reduction in the systolic and diastolic blood pressures,Average increase of serum magnesium levels Changes in lipid profile,,2006-07,COMPLETED,INTERVENTIONAL,['PHASE4']
2628,NCT02256293,Acceptability,Diabetes self-management,,2015-01,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2629,NCT03985306,Qualitative assessment of the inforatio technique,,,2019-03-20,COMPLETED,INTERVENTIONAL,['NA']
2630,NCT05757713,"Treatment-emergent adverse events (TEAEs), adverse events of special interest (AESIs), TEAEs leading to withdrawal, and serious adverse events (SAEs)",CD3 receptor occupancy,,2023-07-25,RECRUITING,INTERVENTIONAL,['PHASE4']
2631,NCT01982565,Measure the efficacy of the NOx generating dressing,Measure the rate of repeat ulcers and breakdown in healing.,,2013-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2632,NCT01114438,Change From Baseline in SF 36v2 Quality of Life Assessment,,,2010-10,COMPLETED,INTERVENTIONAL,['NA']
2633,NCT05256875,Measurement of the agreement between the prevalence rates of non-adherence obtained by LC-MS/MS and the prevalence as diagnosed by (Medication Possession Ratio) MPR ≤0.80,Determination of significant predictors of non-adherence as diagnosed by urine LC-MS/MS,,2022-08-30,RECRUITING,OBSERVATIONAL,['NA']
2634,NCT06265181,Type 2 Diabetes Self-Management Scale,Introductory Features Form,,2024-03-27,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2635,NCT02347553,To measure changes in electrolyte levels and QT interval on electrocardiography between hypoglycaemic and euglycaemic states,,,2014-08,COMPLETED,OBSERVATIONAL,['NA']
2636,NCT05581043,Blood glucose following the OGTT,"Plasma concentrations of 3-OHB, insulin, C-peptide, glucagon like peptide-1 (GLP-1), cholecystokinin (CCK), acetaminophen, free fatty acids along others.",,2023-01-12,COMPLETED,INTERVENTIONAL,['NA']
2637,NCT00707434,Mean Relative Difference in Patient Glucose Monitoring: Continuous Glucose Monitoring (CGM) Device as Compared With Point of Care (POC) Glucose Testing,,,2008-06,TERMINATED,INTERVENTIONAL,['NA']
2638,NCT06232421,Number of patients with trophic ulcers cured,percentage reduction in the non-epithelialized area of the wound surface in relation to the initial one,,2024-02-08,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2639,NCT00318656,Episodes of Hyperglycaemia (>126 mg/dL) at Baseline Compared to After 12 Weeks on Treatment,"Glycaemia According to CGMS (MAGE), mg/dL",,2005-11,COMPLETED,INTERVENTIONAL,['PHASE4']
2640,NCT02730949,efficacy of DCI oral supplementation on metabolic control,Insulin Requirement (I.R.) IU/kg,,2014-03,COMPLETED,INTERVENTIONAL,['PHASE3']
2641,NCT00381134,Change in 24 hour urine albumin to creatinine ratio after 12 months of treatment,plasma aldosterone level,,2003-07,COMPLETED,INTERVENTIONAL,['PHASE2']
2642,NCT01756196,episodes of systemic reactions after spinal steroid injection,,,2011-10,COMPLETED,OBSERVATIONAL,['NA']
2643,NCT04537520,Wound area,,,2020-07-02,COMPLETED,INTERVENTIONAL,['NA']
2644,NCT00747383,Comparison of GLP-1 response at baseline and after 3 months treatment of both groups.,,,2008-09,COMPLETED,INTERVENTIONAL,['NA']
2645,NCT04089462,Percentage of time spent in the hypoglycemic range (CGM <3.9 mmol/l),Question about patient preference regarding the two study arms,,2019-09-30,COMPLETED,INTERVENTIONAL,['NA']
2646,NCT06218992,MMP-9,Thermal imaging: Ocular surface temperature (OST),,2023-12-30,RECRUITING,OBSERVATIONAL,['NA']
2647,NCT04738799,"Change in time in range, under controlled conditions","Change in satiety, as measured by Visual Analog Scale (VAS)",,2021-04-29,COMPLETED,INTERVENTIONAL,['NA']
2648,NCT00385697,Mean HbA1c Change From Baseline in Segment 1,Mean HbA1c Change From Baseline in Segment 1,,2006-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2649,NCT02057861,reversal of diabetic patients,hemodynamic changes,,2013-01,COMPLETED,OBSERVATIONAL,['NA']
2650,NCT03721874,Change in nightly substrate oxidation measured as respiration quotient (RQ) during the sleeping period,Change in systolic and diastolic blood pressure,,2019-04-30,COMPLETED,INTERVENTIONAL,['PHASE4']
2651,NCT04945070,HbA1C,Treatment Satisfaction,hsCRP,2021-07,UNKNOWN,INTERVENTIONAL,['PHASE4']
2652,NCT02007577,Quantification of Insulin Action With the Insulin Suppression Test (IST),Quantification of Insulin Clearance With the Graded Glucose Infusion Test (GGIT),,2010-07,COMPLETED,INTERVENTIONAL,['NA']
2653,NCT00000112,,,,na,UNKNOWN,OBSERVATIONAL,['NA']
2654,NCT05950282,"Assessment of Fasting Insulin levels and HOMA-IR (Homeostatic Model Assessment for Insulin Resistance) scores among different groups stratified by age, sex, race/ethnicity, BMI, and PCOS (Polycystic Ovary Syndrome) diagnosis.","Identify any significant interactions or relationships between the primary outcomes (Fasting Insulin and HOMA-IR) and the demographic and clinical factors, including age, sex, race/ethnicity, BMI, and PCOS diagnosis.",,2023-10,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
2655,NCT02481596,Adherence to Diet - Problem Eating Behavior,Diabetes Self-efficacy,,2016-05-23,COMPLETED,INTERVENTIONAL,['NA']
2656,NCT04228484,Change in [plasma C-peptide] / [plasma glucose] after near-normalisation of plasma glucose,,,2020-01-07,COMPLETED,INTERVENTIONAL,['NA']
2657,NCT00414986,HEDIS-like measures of acute phase management of depression,Patient report (by survey) of their primary care experience,,2005-09,COMPLETED,INTERVENTIONAL,['NA']
2658,NCT01850810,Hunger,Prospective Consumption,,2013-05,COMPLETED,INTERVENTIONAL,['NA']
2659,NCT01617031,Intensity of platelet agregation following exposure to 0.5 mg/ml arachidonic acid,Closure time after exposure of total blood to Collagen-epinephrine,,2010-09,COMPLETED,OBSERVATIONAL,['NA']
2660,NCT00288678,"Through the health manager's coordination and consultation, diabetic patients will have better glycemic control for fasting plasma glucose, HbA1c, and blood cholesterol level.","Patients in the intervention group will have better health status such as lower hospitalization rate, shorter length of stay in hospitals, and fewer diabetic complications.",,2003-07,COMPLETED,INTERVENTIONAL,['PHASE3']
2661,NCT00888836,"To assess the efficacy of bariatric surgery in inducing partial or total remission of type 2 diabetes mellitus, as compared to standard medical anti-diabetic care (STC).","Secondary endpoints include percentage change of fasting plasma glucose levels, glycated hemoglobin, weight, waist circumference, blood pressure, cholesterol, HDL-cholesterol and triglycerides, hard cardiovascular risk and quality of life.",,2009-04,COMPLETED,INTERVENTIONAL,['NA']
2662,NCT06137469,Pharmacokinetics parameters of acetaminophen after a single dose of 1.0 g was measured after administration of the standardized meal.：(AUC0-300min),Immunogenicity indicators: anti-Noiiglutide antibodies,,2023-12-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
2663,NCT03254368,"Safety and tolerability as assessed by change in medication use, vital signs, physical examination findings, mental well-being questionnaires, laboratory evaluations, and electrocardiogram results",Change in patient reported outcomes measures,,2017-09-12,COMPLETED,INTERVENTIONAL,['PHASE2']
2664,NCT00380445,To explore whether vildagliptin augments insulin mediated inhibition of adipose tissue lipid mobilization following a mixed meal in patients with type 2 diabetes,To measure the effects of vildagliptin on tissue carbohydrate metabolism (skeletal muscle),,2006-01,COMPLETED,INTERVENTIONAL,['PHASE3']
2665,NCT03416127,Glycosylated Hemoglobin (A1C),Diastolic Blood Pressure,,2018-01-30,COMPLETED,INTERVENTIONAL,['PHASE2']
2666,NCT00730392,The primary end points of this study are percent change from baseline for HbA1c and C-peptide area under the curve (AUC).,"Secondary end points are insulin dose and number of insulin injection discontinued, if any",,2002-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2667,NCT03640221,Muscle sympathetic nerve activity (bursts/minute),Arterial baroreflex gain.,,2018-09-01,WITHDRAWN,INTERVENTIONAL,['PHASE4']
2668,NCT00104182,HbA1C,Blood glucose,,2005-02,COMPLETED,INTERVENTIONAL,['PHASE3']
2669,NCT01980524,MYCL,Ejection Fraction,Stroke Volume,2013-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2670,NCT05187806,Comparison of the pretest-posttest Diabetes Self-management Instrument-35 scores,Comparison of the pretest-posttest HbA1c values,,2017-02-07,COMPLETED,INTERVENTIONAL,['NA']
2671,NCT00350103,Change in Average Daily Pain Score From Baseline Week to the Last 4 Weeks of the Maintenance Phase,Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale Scores at Visit 8,,2006-06-30,COMPLETED,INTERVENTIONAL,['PHASE3']
2672,NCT04673656,Changes in HOMA-IR,Changes in fasting insulin,,2021-04-18,COMPLETED,INTERVENTIONAL,['NA']
2673,NCT05334173,Excess Weight Loss (%EWL),Remission or improvement of Obstructive Sleep Apnea Syndrome,Quality of life after surgery,2019-01-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2674,NCT06310148,The cost-effectiveness for delivering the CDCC Pilot Scheme on the incremental cost-effectiveness ratio,Amount of direct medical costs between two groups,,2024-01-18,RECRUITING,INTERVENTIONAL,['NA']
2675,NCT00287404,,,,2005-10,COMPLETED,OBSERVATIONAL,['NA']
2676,NCT05594706,"Correlation of 1,5-anhydroglucitol levels in patients with longstanding disease with indirect markers of beta-cell function and mass",,,2023-01-27,RECRUITING,OBSERVATIONAL,['NA']
2677,NCT01102959,Number the answers correct or incorrect on carbohydrate counting in portions of real food,,,2010-03,UNKNOWN,INTERVENTIONAL,['NA']
2678,NCT01425866,Mean change in glycated haemoglobin (GlyHb),Change in blood pressure,,2011-10,COMPLETED,INTERVENTIONAL,['NA']
2679,NCT01665352,Change from baseline in HbA1c (%) as compared to placebo,Subject achievement of body weight loss ≥ 2%,,2012-08,COMPLETED,INTERVENTIONAL,['PHASE2']
2680,NCT00387101,To determine the efficacy and safety of Dermal-LSR plus Standard of Care (SOC) for the treatment of chronic diabetic foot ulcers in comparison to treatment with SOC alone.,,,2006-02,TERMINATED,INTERVENTIONAL,['PHASE3']
2681,NCT01083108,The primary outcome of the study is the change in total body insulin sensitivity due to RYGBP alone using the euglycemic hyperinsulinemic clamp technique.,"The secondary outcomes are changes in insulin sensitivity, insulin secretion, and gut hormones due to caloric restriction alone, caloric restriction plus RYGBP, and RYGBP alone.",,2011-03-31,TERMINATED,INTERVENTIONAL,['PHASE2']
2682,NCT02568280,Mean change in plasma glucose concentration,Area under the serum insulin aspart concentration-time curve,,2015-10-06,COMPLETED,INTERVENTIONAL,['PHASE1']
2683,NCT02012972,NCDs and NCD risk factors in the study population by time on ART,Changes in NCD risks or prevalence,,2014-01,COMPLETED,OBSERVATIONAL,['NA']
2684,NCT02715791,Diabetes self-efficacy,Physical Activity,,2016-02,COMPLETED,INTERVENTIONAL,['NA']
2685,NCT00424411,Primary outcome is 24 week change in baseline in HbA1c.,Patient satisfaction and preference.,,1999-09,COMPLETED,INTERVENTIONAL,['PHASE3']
2686,NCT00309231,Efficacy,,,na,WITHDRAWN,OBSERVATIONAL,['NA']
2687,NCT00157729,"Determine the efficacy of MC-1 and of the combination of MC-1/ACE inhibitor on metabolic function as measured by insulinemia, fasting serum glucose, glycated hemoglobin, and triglycerides.",mean changes in creatinine,,2004-08,COMPLETED,INTERVENTIONAL,['PHASE2']
2688,NCT01473147,Mean amplitude of glycaemic excursions (MAGE),homeostasis model assessment(HOMA),,2011-10,COMPLETED,INTERVENTIONAL,['NA']
2689,NCT05810545,Maternal health - Gestational diabetes mellus,,,2012-01-01,COMPLETED,OBSERVATIONAL,['NA']
2690,NCT01741181,Endothelial function as assessed by the reactive hyperemia index and endothelial progenitor cells,No. of circulating endothelial cells and endothelial microparticles,,2012-09,COMPLETED,INTERVENTIONAL,['PHASE4']
2691,NCT03078491,Change in duration of hypoglycemia,Barriers and facilitators of CGM use,,2017-03-30,COMPLETED,INTERVENTIONAL,['NA']
2692,NCT00717158,Health Care utilization and costs using claims data,Change in quality of life,,2001-05,COMPLETED,INTERVENTIONAL,['NA']
2693,NCT05333393,Blood Glucose Levels,Regulating the Nutrition of Children according to their blood sugar level,,2023-05-01,RECRUITING,INTERVENTIONAL,['NA']
2694,NCT01643967,Evaluate the efficacy and safety of ozone released by the device Philozon Medplus in the treatment of patients with diabetic foot.,Evaluate the release of ozone in the environment by equipment MEdplus after insufflation rectal in patients with diabetic foot.,,2012-06,UNKNOWN,INTERVENTIONAL,['PHASE3']
2695,NCT00207233,Change in expression of selected adipocyte metabolic genes,,,2004-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2696,NCT04237129,GIRmax,Safety and local tolerability,,2019-08-27,COMPLETED,INTERVENTIONAL,['PHASE1']
2697,NCT02672748,Adult BMI change,child BMI z-score change,,2015-11,COMPLETED,INTERVENTIONAL,['NA']
2698,NCT00482976,"Improvement in selective measurements of oxidative stress, endothelial activity and vascular abnormalities which will correlate with PKC activity in the peripheral monocytes.",Safety of ruboxistaurin,,2003-12,COMPLETED,INTERVENTIONAL,['PHASE2']
2699,NCT02181842,Blood Glucose-Related Laboratory Parameters (HbA1c Values) at Each Time Point,Number of Participants Who Experience at Least One Adverse Drug Reactions (ADRs),,2009-01-26,COMPLETED,OBSERVATIONAL,['NA']
2700,NCT04926298,Time spent in hyper and hypoglycemia during Marathon,Time spent in hyper and hypoglycemia during PR1 and PR2,,2020-08-15,UNKNOWN,OBSERVATIONAL,['NA']
2701,NCT03562767,Percentage of Participants That Are Enrolled and Attend the Study the Study Sessions Compared to Enrolled,Change in Diabetes Health Belief Scale,,2018-12-05,TERMINATED,INTERVENTIONAL,['NA']
2702,NCT04005287,"Incidence and Treatment-Emergent Adverse Events as assessed by a dermal assessment (Draize score (scale 0.0 - 4.0) score of skin erythema, edema, pruritus and dryness score) of the dosing area",Norfolk Quality of Life Measure (QOL) Patient Questionnaire,Patients' Global Impression of Change,2019-10-15,COMPLETED,INTERVENTIONAL,['PHASE2']
2703,NCT01106677,Change in HbA1c From Baseline to Week 26,Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 52,,2010-05,COMPLETED,INTERVENTIONAL,['PHASE3']
2704,NCT01542489,Change in HbA1c (glycosylated haemoglobin),Number of adverse events,,2006-10,COMPLETED,OBSERVATIONAL,['NA']
2705,NCT01449019,The incretin effect,Plasma concentrations of Glucose-dependent insulinotropic polpypeptide (GIP),,2006-12,COMPLETED,INTERVENTIONAL,['PHASE1']
2706,NCT02073188,Proportion of participants performing at least 30% of the recommended Self-Monitoring Blood Glucose tests after 6 months from randomization,Type of overall contacts between centers and participants,,2012-06,COMPLETED,INTERVENTIONAL,['PHASE3']
2707,NCT01923389,Number of Participants With Positive Anti-PF-05231023 Antibodies and Neutralizing Antibodies.,Observed Accumulation Ratio (Rac) for Cmax and AUCtau of PF-05231023 (C-terminus and N-terminus PF-05231023 and Total CVX-2000 Antibody Scaffold),,2013-09,TERMINATED,INTERVENTIONAL,['PHASE1']
2708,NCT04768673,AUClast,CL/F,,2021-03-26,COMPLETED,INTERVENTIONAL,['PHASE1']
2709,NCT05377385,Usability of and problems encountered with the Omnipod Dash insulin administration system,Metabolic control of type 1 diabetes mellitus,,2022-04-13,COMPLETED,OBSERVATIONAL,['NA']
2710,NCT03528720,The earliest and most frequently occurring fundus quadrant of diabetic retinopathy in fundus fluorescein angiography.,,,2017-06-13,COMPLETED,OBSERVATIONAL,['NA']
2711,NCT02308254,Blood Pressure,Blood glucose concentration,Stroke volume,2013-11,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2712,NCT02308800,"Compare clinical outcomes (time to wound healing, number of surgeries) with Negative Pressure Wound Therapy with irrigation and Negative Pressure Wound Therapy without irrigation.",Compare quantitative cultures (bacterial load as measured by qPCR) and number of clinical infections in patients treated with NPWT with irrigation compared to conventional NPWT.,Compare responses to the HR-QOL questionnaires of patients treated with NPWT with irrigation compared to conventional NPWT.,2015-01,WITHDRAWN,INTERVENTIONAL,['NA']
2713,NCT02325622,Association between mean plasma glucose concentration and glycated hemoglobin in cirrhosis,,,2013-12,UNKNOWN,OBSERVATIONAL,['NA']
2714,NCT02614170,Measure C-peptide and Insulin in Healthy Individuals,,,2015-03,COMPLETED,OBSERVATIONAL,['NA']
2715,NCT03185741,Medication Adherence: Pill Count,Treatment Knowledge,,2018-01-05,COMPLETED,INTERVENTIONAL,['NA']
2716,NCT06028503,Reduction in Hemoglobin A1C,Health literacy,,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2717,NCT04725630,Blood glucose levels via hemoglobin A1C,Diabetes Competing Demands scores,Proportion of energy from ultra-processed foods,2021-05-29,RECRUITING,INTERVENTIONAL,['NA']
2718,NCT06068205,"In 48 subjects with type 1 diabetes with and without microvascular complications, the average stiffness of red blood cells, measured using atomic force microscope and quantified using Young's modulus, will be measured.",,,2023-09-29,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
2719,NCT01755494,Area under plasma concentration time curve (AUC) for metformin during treatment with fixed dose combination tablet of metformin plus saxagliptin compared with individual metformin XR and saxaglitpin tablets,"Safety and tolerability assessment based on medical review of AE reports:physical examination, ECG, heart rate, blood pressure, lab test",,2013-02,COMPLETED,INTERVENTIONAL,['PHASE1']
2720,NCT00521820,Progression of Congestive Heart Failure.,All cause mortality.,,2000-06,TERMINATED,INTERVENTIONAL,['PHASE3']
2721,NCT05847075,Plasma HSP72,Inflammatory/anti-inflammatory markers,,2023-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2722,NCT04595370,Percent change from baseline in UACR at 12 weeks,Percent change from baseline in UACR at 12 weeks to assess dose-response relationship,Change from baseline in eGFR over time,2021-01-26,COMPLETED,INTERVENTIONAL,['PHASE2']
2723,NCT05050266,Engagement in virtual care for preventive services,Participation and engagement: ROSE,,2021-10-21,RECRUITING,INTERVENTIONAL,['NA']
2724,NCT06190808,Mean Absolute Relative Difference (MARD).,Adverse event nature and frequency,,2024-01-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2725,NCT02727608,Increased survival of ICC´s transplanted as measured by peak c-peptide,Bleeding,Effect of eculizumab on IBMIR,2016-05-15,COMPLETED,INTERVENTIONAL,['PHASE2']
2726,NCT01518166,Area under the curve of digoxin,Adverse events,,2006-05,COMPLETED,INTERVENTIONAL,['PHASE1']
2727,NCT00713011,Change in Proteinuria,Change in index of glycemia (HbA1c),,2008-11,WITHDRAWN,INTERVENTIONAL,['PHASE3']
2728,NCT01509001,glucose control,haemodynamic improvement,,2011-01,COMPLETED,INTERVENTIONAL,['PHASE4']
2729,NCT05524987,Effectiveness outcome: Systolic Blood Pressure,Effectiveness outcome: HbA1c,Implementation outcome: Sustainability,2023-03-20,RECRUITING,INTERVENTIONAL,['NA']
2730,NCT02463500,Adverse Events,,,2015-01,COMPLETED,OBSERVATIONAL,['NA']
2731,NCT06272565,Untargeted metabolomics for metabolic profile using UHPLC/MS,Central subfield thickness,,2024-03-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
2732,NCT05413746,Changes in wound size,Time to removal of non-viable tissue from wound bed,,2018-02-05,COMPLETED,INTERVENTIONAL,['NA']
2733,NCT05961163,"Composite index of nausea, vomiting, tiredness/fatigue, vertigo, circulation problems/syncopes, muscle cramps, headache, extrasystoles, palpitations, edemas, shortness of breath, depressive mood, anxiety, mental confusion","Reasons for drop out (eg, bad health condition, hospital admission, death)",,2023-07-24,TERMINATED,OBSERVATIONAL,['NA']
2734,NCT01130558,Mean blood Glucose,rate of use of sliding scale insulin,,2009-03,COMPLETED,INTERVENTIONAL,['NA']
2735,NCT00731432,The primary endpoint of the study will be the comparison between THPP and PP in reducing the gingival index (GI) at the site of patch placement,Beta-glucuronidase enzyme found in gingival crevicular fluid (GCF) of the tested sites. The GCF will be collected from the second most posterior tooth in all four quadrants.,,2008-08,SUSPENDED,INTERVENTIONAL,['PHASE2']
2736,NCT04542148,Time In Range,Umbilical cord blood surfactant protein D (SP-D),,2022-02-10,RECRUITING,INTERVENTIONAL,['PHASE2']
2737,NCT00373269,FVIIa,TF-PCA,,2001-10,COMPLETED,OBSERVATIONAL,['NA']
2738,NCT04536285,Prognosis of pediatric and adolescent patients with type 1 diabetes hospitalized with COVID -19.,Presentation of diabetes and its acute complications among pediatric and adolescent patients with type 1 diabetes during COVID-19 Pandemic in Egypt,,2020-05-01,COMPLETED,OBSERVATIONAL,['NA']
2739,NCT02212665,Changes in insulin sensitivity,Patient-reported outcome measure,,2014-01,COMPLETED,INTERVENTIONAL,['NA']
2740,NCT02556554,Change(s) in Behavior and/or Concerns of Diabetics.,Evaluation of Maternal and Fetal Outcomes.,,2015-08,COMPLETED,INTERVENTIONAL,['NA']
2741,NCT00295555,Normalization of high blood pressure,,,2004-01,COMPLETED,INTERVENTIONAL,['PHASE4']
2742,NCT03436693,The proportion of subjects with a decline in estimated glomerular filtration rate (eGFR) from baseline at Week 104,Change from baseline in urine albumin-to-creatinine ratio (UACR) at each assessment time point,,2018-02-15,COMPLETED,INTERVENTIONAL,['PHASE3']
2743,NCT05631054,Best corrected visual acuity at the last follow-up,The occurrence of vitrectomy for the fellow eye,,2022-11-10,RECRUITING,OBSERVATIONAL,['NA']
2744,NCT05230589,Change in Glycated haemoglobin (HbA1c ),"DTSQs, (Diabetes Treatment Satisfaction Questionnaire, status) change in absolute treatment satisfaction",,2022-01-11,RECRUITING,OBSERVATIONAL,['NA']
2745,NCT00325962,To compare oral 6R-BH4 to placebo with respect to change from baseline in arterial systolic blood pressure after 8 weeks of treatment in subjects with poorly controlled hypertension.,To assess the safety of oral dosing of 6R-BH4 in subjects with poorly controlled hypertension,,2006-05,COMPLETED,INTERVENTIONAL,['PHASE2']
2746,NCT01789021,Differences in accuracy between blood glucose monitoring systems across the overall tested glucose range by comparing the mean absolute value of relative (percent) difference (MARD) between the meter value and the reference value,,,2013-02,COMPLETED,INTERVENTIONAL,['NA']
2747,NCT03928340,2 hours post prandial blood sugar measurement.,neonatal Intensive care admission,,2019-04-29,COMPLETED,INTERVENTIONAL,['PHASE4']
2748,NCT04186377,Change of ulcer surface area,Incidence of amputations,,2020-05-15,TERMINATED,INTERVENTIONAL,['PHASE2']
2749,NCT03654989,"Comparison of wound closure between the 3 groups: iontophoresis of treprostinil, iontophoresis of placebo, and standard of care, over12 weeks.",Evaluation of safety via the appearance of the wound,,2020-01-28,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2750,NCT01206647,percentage of patients with stable HbA1c,impact of the switch on:,,2010-02,UNKNOWN,INTERVENTIONAL,['PHASE4']
2751,NCT05441267,Time to the first occurrence of a Major Adverse Cardiovascular Events (MACE+),Time to the first occurrence of a Major Adverse Cardiovascular Events (MACE),,2023-03-13,RECRUITING,INTERVENTIONAL,['PHASE4']
2752,NCT03580967,Change in depressive symptoms measured by Hamilton Depression Rating Scale (HAM-D),,,2019-07-01,WITHDRAWN,INTERVENTIONAL,['PHASE4']
2753,NCT05204134,Severe Hypoglycemic Events,Patient Reported Outcomes,,2022-03-24,COMPLETED,INTERVENTIONAL,['NA']
2754,NCT02207777,Changes in hepatic insulin sensitivity,Changes in fat free mass,,2014-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2755,NCT06037538,Analysis of system accuracy based on DIN EN ISO 15197,,,2023-04-19,COMPLETED,INTERVENTIONAL,['NA']
2756,NCT00343603,,,,2004-10,COMPLETED,OBSERVATIONAL,['NA']
2757,NCT00517465,Glucose AUC,Pharmacokinetic parameters,,2007-09,COMPLETED,INTERVENTIONAL,['PHASE1']
2758,NCT02977442,Effects of exercise on mitochondrial dynamics,Insulin sensitivity,,2016-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2759,NCT01852968,alterations in hippocampal glucose transport kinetics,alterations in hippocampal neurochemistry,,2013-05,COMPLETED,OBSERVATIONAL,['NA']
2760,NCT03992248,Hepatic glycogen,Insulin sensitivity,,2019-01-31,COMPLETED,INTERVENTIONAL,['NA']
2761,NCT01580917,Latency time after occlusive loading,Response time to Maximum Flow,,2007-11,COMPLETED,OBSERVATIONAL,['NA']
2762,NCT01074801,The primary outcome measure is time spent with plasma glucose concentration in the target range (3.9-10.0 mmol/L) between 24:00 on Day 1 to 08:00 on Day 3.,Secondary outcomes will include: (i) Total and basal insulin delivery between 24:00 on Day 1 and 08:00 on Day 3 (36 hours) (ii) CGM glucose levels between 24:00 on Day 1 and 08:00 on Day 3 (36 hours),,2010-03,COMPLETED,INTERVENTIONAL,['PHASE2']
2763,NCT00636766,Ultrasound and immunohistochemical parameters of plaque stability; novel cardiovascular risk factors,Long-term cardiovascular outcomes,,2005-09,COMPLETED,INTERVENTIONAL,['NA']
2764,NCT03813316,The percentage of participants achieving an A1C value of ≤ 7% at 24 weeks,The percentage of participants on antihypertensive therapy at Week 24.,,2019-05-01,WITHDRAWN,INTERVENTIONAL,['PHASE4']
2765,NCT01398423,Safety,Efficacy,,2011-06,COMPLETED,INTERVENTIONAL,['PHASE2']
2766,NCT05126251,The scores of short form health survey (SF-36),,,2021-12-13,UNKNOWN,INTERVENTIONAL,['PHASE2']
2767,NCT00439101,To determine if daily administration of megestrol acetate (MA) for 3 months compared to placebo prevents weight loss or improves weight gain in children with cancer-associated anorexia-cachexia.,To evaluate toxicities associated with MA in pediatric oncology subjects.,,2007-04,COMPLETED,INTERVENTIONAL,['NA']
2768,NCT01650324,Number of Participants With Adverse Events as a Measure of Safety and Tolerability,Change of Dipeptidyl Peptidase 4 (DPP4) Activities Between 48 Hrs Post Dose and 0 hr Predose,,2012-07,COMPLETED,INTERVENTIONAL,['PHASE1']
2769,NCT00837759,Change in C-peptide,Change in ZnT8 Autoantibody Titer,,2009-02,TERMINATED,INTERVENTIONAL,['PHASE2']
2770,NCT01689051,Femoral artery blood flow,Leg glucose uptake,,2012-03,COMPLETED,INTERVENTIONAL,['NA']
2771,NCT02108353,Efficacy (AUC),Efficacy AUC insulin 12 weeks,,2015-01,COMPLETED,INTERVENTIONAL,['PHASE3']
2772,NCT01228240,,,,2008-12,COMPLETED,INTERVENTIONAL,['PHASE4']
2773,NCT01086150,Pain Scores From Composite Visual Analog Scale,"Keratinocyte Immunoreactivity of Nav1.6, Nav1.7, CGRP",,2009-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2774,NCT03165240,Percentage of patients with drug related Adverse Events (AEs),Change from baseline in log transformed Urine Albumin-to-Creatinine Ratio (UACR) measured in daytime (10-hour) urine,,2017-10-05,COMPLETED,INTERVENTIONAL,['PHASE1']
2775,NCT01556529,"HbA1c, incidence of typical diabetes complications",quantitative diabetes typical complication risk profile,,2007-06,COMPLETED,INTERVENTIONAL,['NA']
2776,NCT03718715,change from baseline in the fecal microbiota composition by detecting bacteria families with help of relative abundance (%) and diversity metrics,correlation between microbiota and beneficial glucose lowering response,,2019-02-20,UNKNOWN,OBSERVATIONAL,['NA']
2777,NCT06027151,PERIODONTAL POCKET DEPTH (PPD),RECESIION OF GINGIVAL MARGIN:,,2022-10-06,COMPLETED,INTERVENTIONAL,['NA']
2778,NCT03887416,Changes in nighttime blood pressure,Changes in HBA1C,,2019-04-12,UNKNOWN,INTERVENTIONAL,['PHASE4']
2779,NCT06217887,Change of olfactory brain activation by fMRI,Change of metabolism,,2020-05-10,RECRUITING,INTERVENTIONAL,['NA']
2780,NCT00949169,We compared prevalence of large artery stenosis according to carotid IMT group and evaluated whether maximal IMT ≥ 1.0 mm could predict for significant CAD by MDCT.,We performed invasive coronary angiography in some patients (N=14) and analyzed association for degrees of CAD between two angiographic methods.,,2006-04,COMPLETED,OBSERVATIONAL,['NA']
2781,NCT05924516,Use of coping strategies,Usability,Energy level,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2782,NCT04438018,HbA1c,Marker of inflammation #4: interleukin-1 receptor antagonist (IL-1Ra),Fear of diabetes complications,2020-07-01,COMPLETED,OBSERVATIONAL,['NA']
2783,NCT02109978,Response to diabetes therapy and rate of diabetes progression,Collection of samples for analysis of potential biomarkers,,2013-04,COMPLETED,OBSERVATIONAL,['NA']
2784,NCT00280085,Pancreatic perfusion,,,2005-12,TERMINATED,INTERVENTIONAL,['NA']
2785,NCT01874431,Ratio of UACR at Day 90 to UACR at Baseline,Change From Baseline to Day 90 in EQ-5D Scores (EQ5D - Visual Analog Scale),,2013-06-12,COMPLETED,INTERVENTIONAL,['PHASE2']
2786,NCT04800536,QTc interval,Plasma glucose decline rate and symptomatic response,,2021-06-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2787,NCT02612844,The number of treatment emergent adverse events,The maximum glucose infusion rate,,2015-11,COMPLETED,INTERVENTIONAL,['PHASE1']
2788,NCT01953224,Change in Physical Activity From Baseline to 12 Weeks,Change in Motivation From Baseline to 12 Weeks,Number of Participants With Adverse Events,2014-09,COMPLETED,INTERVENTIONAL,['NA']
2789,NCT00479791,"Insulin, and glucose",Triglycerides,,1997-04,COMPLETED,INTERVENTIONAL,['NA']
2790,NCT05198895,Accuracy of the Glyconics-SX System in detection of DM status based on dichotomised outcomes as per the chemometric model (HbA1c measurements as internal control),"Analysis of safety outcomes (AEs, SAEs), including any safety outcomes listed in the comments, such as potential, suspected de novo diabetes diagnosis cases based on HbA1c readings",,2022-08-01,COMPLETED,INTERVENTIONAL,['NA']
2791,NCT00361738,Change in Mean Plasma Glucose (MPG) from baseline to week 4.,"Glucose parameters (change from baseline to week 4 in fasting and post prandial plasma glucose) ; Change in HbA1c and fructosamine ; Safety: physical examination, adverse events, ECG, laboratory tests",,2006-07,COMPLETED,INTERVENTIONAL,['PHASE2']
2792,NCT00988689,Appetite,Palatability of treatments,,2008-06,COMPLETED,INTERVENTIONAL,['NA']
2793,NCT00973492,"MAGE, ADRR, Lability Index and LBGI computed with the blood glucose measurement or CGMS",anti-insulin antibodies by ELISA,,2007-09,UNKNOWN,OBSERVATIONAL,['NA']
2794,NCT02682940,"Aggregate reduction in the rate of mild hypoglycemia (biochemical and logged) as measured by meter or logged home blood glucose values <56 mg/dL at 3 months, compared to the monthly rate of hypoglycemia in the baseline period.",Improvement in self-reported psychosocial self-efficacy as compared to baseline measured using the Diabetes Empowerment Scale Short Form (DES-SF).,"Average ratings of ""acceptable"" or better from self-reported survey clinician feedback on the utility of Vigilant in managing patients.",2016-05,TERMINATED,INTERVENTIONAL,['NA']
2795,NCT03542240,Change in intestinal barrier function,,,2018-09-19,COMPLETED,INTERVENTIONAL,['NA']
2796,NCT05662826,Satisfaction,System usability,,2023-01-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2797,NCT01610934,Fasting Plasma Glucose,Plasma concentrations of incretin hormones,,2012-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2798,NCT00622284,HbA1c Change From Baseline at Week 104,Change in Baseline Lipid Parameter Triglyceride at Week 104,,2008-02,COMPLETED,INTERVENTIONAL,['PHASE3']
2799,NCT01863810,Numerical pain rating scale (NRS),Adverse events,,2013-08,UNKNOWN,INTERVENTIONAL,['PHASE3']
2800,NCT02956655,The remission rate of diabetes,Uric acid (mmol/l),,2016-07,UNKNOWN,INTERVENTIONAL,['NA']
2801,NCT02621476,Percent of Participants Using Mail Order Pharmacy (MOP) After Intervention,,,2017-02-01,COMPLETED,INTERVENTIONAL,['NA']
2802,NCT00566813,Number of Participants With HbA1c Less Than or Equal to 6.5 & Free of Severe Hypoglycemic Events,,,2004-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2803,NCT01046435,"Serum levels of C-reactive protein, fibrinogen,erythrosedimentation rate and white blood cell count","Clinical periodontal parameters: probing depth, bleeding on probing, clinical attachment level",,2007-03,COMPLETED,INTERVENTIONAL,['NA']
2804,NCT03961542,blood glucose measurements after with or without chewing,,,2017-12-22,COMPLETED,INTERVENTIONAL,['NA']
2805,NCT01855243,Mean BG After First Day of Hospitalization,Mortality Rate,,2010-03,COMPLETED,INTERVENTIONAL,['NA']
2806,NCT02791490,Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event,Percentage of Participants Receiving Glycemic Rescue Therapy,,2016-06-16,COMPLETED,INTERVENTIONAL,['PHASE3']
2807,NCT02402504,Subjective Appetite,Physical Comfort,,2015-03,COMPLETED,INTERVENTIONAL,['NA']
2808,NCT01052597,to determine the effectiveness of curcumin on reduction of atherosclerotic events and risks in Type 2 diabetic patients,"To examine the effectiveness of curcumin on the reduction of blood sugar, glycosylated hemoglobin (HBA1c), lipid profile, and insulin resistance",,2009-07,UNKNOWN,INTERVENTIONAL,['PHASE4']
2809,NCT04562467,Change in the frequency of ALDHhiSSClowCD133+ cells in individuals treated with IPE compared to SOC for 3 months,,Changes in the concentration of serum inflammatory markers from baseline to the 3-month visit in individuals treated with IPE compared to SOC,2020-09-24,COMPLETED,INTERVENTIONAL,['PHASE4']
2810,NCT03437720,Resolution of Non-alcoholic steatohepatitis (NASH),Assessment of PK parameter: Ctrough,,2019-05-23,WITHDRAWN,INTERVENTIONAL,['PHASE2']
2811,NCT03935919,Sensor accuracy in the perioperative period,Standard deviation of sensor glucose levels in the postoperative period,,2019-08-13,COMPLETED,OBSERVATIONAL,['NA']
2812,NCT05881616,Content of serum metabolomics,,,2023-07-18,RECRUITING,OBSERVATIONAL,['NA']
2813,NCT05813912,Change in glycated haemoglobin (HbA1c),Relative change in weekly insulin icodec dose,,2023-09-22,RECRUITING,INTERVENTIONAL,['PHASE3']
2814,NCT01971047,BG concentration differences at 1 and 2 hours post intervention and post operatively,Number of perioperative complications,,2013-10,WITHDRAWN,INTERVENTIONAL,['PHASE4']
2815,NCT02222909,Change in Emergency Department Visits + Hospital Days,,,2014-04,COMPLETED,INTERVENTIONAL,['NA']
2816,NCT05423938,Postprandial glycemic response,Postprandial insulin response,,2019-11-04,COMPLETED,INTERVENTIONAL,['NA']
2817,NCT01346072,Body Weight,,,2011-04,COMPLETED,INTERVENTIONAL,['PHASE4']
2818,NCT03250403,pain,Conduction velocity,,2017-04-01,COMPLETED,INTERVENTIONAL,['NA']
2819,NCT06202079,Change in HbA1c,Change in ADA and Nab of GZR4,,2023-08-29,RECRUITING,INTERVENTIONAL,['PHASE2']
2820,NCT03639545,Arterial function,Glycemic control,,2018-03-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
2821,NCT01486914,Area under the Curve (AUC) (insulin aspart),Adverse events,,2003-01-19,COMPLETED,INTERVENTIONAL,['PHASE1']
2822,NCT00013741,,,,na,COMPLETED,INTERVENTIONAL,['NA']
2823,NCT06144554,Glucose Outcomes during the 4-hour post-bolus period using the SmartBolus Calculator: o Percentage of time < 54 mg/dL o Percentage of time in range 70-180 mg/dL,,,2023-09-25,RECRUITING,OBSERVATIONAL,['NA']
2824,NCT03579420,Treatment success at 6 months,Waist circumference,,2018-03-01,UNKNOWN,INTERVENTIONAL,['NA']
2825,NCT00412126,Volume of intimal hyperplasia in the stented segment by IVUS at 6 months following PCI,"Late loss in minimal luminal diameter of stented site in coronary vessel evaluated by QCA at 6 months post-PCIb) Rate of clinical events at one year (hospital admission for unstable angina, CHF, MI, stroke, revascularization, and death)",,2002-07,COMPLETED,INTERVENTIONAL,['NA']
2826,NCT00793273,Change in FPG (fasting plasma glucose) of treatment,Insulin dose and concomitant oral antidiabetic medication time period between diagnosis of type 2 diabetes and insulin initiation,,2008-11,COMPLETED,OBSERVATIONAL,['NA']
2827,NCT04401904,AGE-RAGE Measurement in Plasma,6 Minute Walking Distance,,2020-06-25,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2828,NCT00258115,glycemia,,,2003-12,COMPLETED,INTERVENTIONAL,['PHASE2']
2829,NCT00993070,"Pain relief from pain score reduction, using visual analog scale (VAS)","Overall clinical improvement, measured by Clinician Global Impression of Change(CGIC)",,2009-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2830,NCT06198725,The 2h C-peptide level of the MMTT test,Triglyceride,,2024-01-08,RECRUITING,INTERVENTIONAL,['NA']
2831,NCT05673837,volumetric Bone material density (vBMD),Trabecular area,Other structural and remodelling measures from bone histomorphometry,2021-12-10,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
2832,NCT04413357,Area under the blood glucose curve,Insulinogenic index,,2020-05-18,COMPLETED,INTERVENTIONAL,['NA']
2833,NCT03092752,Percentage of Comorbidities by OAD Classes.,Number of Prescriptions of OAD by Each Renal Impairment (RI) Stages,,2017-03-01,COMPLETED,OBSERVATIONAL,['NA']
2834,NCT02984813,Flavoprotein fluorescence index,Humphrey visual field testing (24-2),,2016-04-15,TERMINATED,INTERVENTIONAL,['PHASE1']
2835,NCT00099866,Change from baseline in HbA1c at 52 weeks,Change from baseline in HOMA B at 52 weeks,,2004-01,COMPLETED,INTERVENTIONAL,['PHASE3']
2836,NCT05609266,Incident type 2 diabetes,,,1990-01,COMPLETED,OBSERVATIONAL,['NA']
2837,NCT03193125,Liver mitochondrial fatty acid processing,,,2017-05-15,COMPLETED,INTERVENTIONAL,['NA']
2838,NCT05881837,Percentage change in body weight,Change from baseline in glycosylated haemoglobin (HbA1c) after 32 weeks of treatment,,2023-06-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
2839,NCT00131287,Percent reduction of glycated hemoglobin (HAb1C) and insulin resistance(HOMA-IR),"Glucose, cholesterol, triglyceride, leptin, adiponectin comparisons",,2005-07,COMPLETED,INTERVENTIONAL,['PHASE3']
2840,NCT02728414,change from baseline in glycosylated hemoglobin change at 3 months,change from baseline in c peptide at 3 months,,2015-10,UNKNOWN,INTERVENTIONAL,['NA']
2841,NCT01538576,HbA1c (glycosylated haemoglobin),Adverse Events,,2003-12,COMPLETED,OBSERVATIONAL,['NA']
2842,NCT02426099,Efficacy (Blood pressure reduction),Creatinine (Change in serum creatinine),,2011-10,COMPLETED,INTERVENTIONAL,['PHASE4']
2843,NCT05157815,Change in plasma HbA1c concentration,Change in Fasting Insulin (mIU/L).,Change in TNF alpha,2021-10-04,UNKNOWN,INTERVENTIONAL,['NA']
2844,NCT02676648,HbA1c,Body Weight Percent Lost,,2016-02,COMPLETED,INTERVENTIONAL,['NA']
2845,NCT00732121,Change from baseline in the integrated response to the mixed meal test of markers of bone turnover following 8 weeks of treatment with sitagliptin vs. placebo.,Change in insulin secretion during the mixed meal test.,,2008-08,UNKNOWN,INTERVENTIONAL,['PHASE4']
2846,NCT01043770,The proportion of people in the intervention and control groups with prevalent metabolic syndrome according to the IDF criteria.,Changes in general self-efficacy as measured by GSE,,2009-08,COMPLETED,INTERVENTIONAL,['NA']
2847,NCT05946148,>30% Liver Fat Fraction reduction,Shearwave Elastography (SWE),,2018-06-01,COMPLETED,OBSERVATIONAL,['NA']
2848,NCT00790348,,,,2008-07,UNKNOWN,OBSERVATIONAL,['NA']
2849,NCT04480801,Percentage of patients developing a foot ulcer,Change in foot care practices,,2020-09-15,COMPLETED,INTERVENTIONAL,['NA']
2850,NCT05407662,Baseline all-cause healthcare costs by place of service,"sMRA continuing user questions - Treatment Satisfaction Questionnaire for Medication version 1.4 (TSQM v1.4) - validated PROM the evaluates patients' perception of sMRA treatment effectiveness, convenience, and overall satisfaction",,2022-11-02,COMPLETED,OBSERVATIONAL,['NA']
2851,NCT06284785,Difference in kidney oxygenation before and after bariatric surgery,"Difference in kidney oxygenation between obese, hyperfiltering men and women with T2D versus non-diabetic lean controls",,2023-08-01,RECRUITING,OBSERVATIONAL,['NA']
2852,NCT04791358,Referrals,,,2021-11-01,UNKNOWN,OBSERVATIONAL,['NA']
2853,NCT04874922,metabolic control variables evaluation form (fourth),Pregnancy Outcomes Evaluation Form for Mother and Baby,,2021-05-15,COMPLETED,INTERVENTIONAL,['NA']
2854,NCT05695170,Study protocol feasibility,Partner support.,,2022-12-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2855,NCT02590094,Visual Acuity,Time,,2015-10,COMPLETED,INTERVENTIONAL,['NA']
2856,NCT03726983,Newborn baby weight,Change of Health Promotion Scale,,2017-01-05,COMPLETED,INTERVENTIONAL,['NA']
2857,NCT05164523,BDNF concentrations,,,2021-03-01,COMPLETED,OBSERVATIONAL,['NA']
2858,NCT06146699,prevalence of diabetic retinopathy,,,2023-12,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
2859,NCT03202095,Change from Baseline in Hamilton Depression Rating Scale,,,2017-08-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
2860,NCT00143520,Change in HbA1c,"FPG, Lipids, hsCRP, Adiponectin",,2004-12,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2861,NCT06325670,Number of binge eating episodes,HbA1c,Blood Pressure,2024-02-23,RECRUITING,INTERVENTIONAL,['NA']
2862,NCT04509856,Diabetes knowledge level (DKL),Blood pressure,,2019-04-01,COMPLETED,INTERVENTIONAL,['NA']
2863,NCT01345734,Incidence of serious adverse drug reactions (SADRs),"Change in HbA1c (glycosylated haemoglobin)""",,2011-09-01,COMPLETED,OBSERVATIONAL,['NA']
2864,NCT05948969,New prescription of a SGLT2i and/or GLP-1RA,,,2023-09-01,RECRUITING,INTERVENTIONAL,['NA']
2865,NCT02107976,Whether acute changes in glycemia and/or red blood cell ascorbate (vitamin C) modify RBC deformability.,Whether RBC vitamin C concentrations can be increased by vitamin Csupplementation over several weeks in diabetic subjects.,,2019-06-14,RECRUITING,INTERVENTIONAL,['PHASE1']
2866,NCT02487537,"change in combined levels of glucose and insulin, expressed in calculated indices for insulin sensitivity",,,2015-03,COMPLETED,INTERVENTIONAL,['NA']
2867,NCT00764244,Percentage of patients with visual gain ≥ 3 ETDRS lines at 2 years,Evolution of visual field in each group,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE3']
2868,NCT04302974,"Incremental cost-effectiveness ratio per DM/HT-related complication or all-cause death avoided, and per QALY gained by RAMP or PSCC",,,2019-08-01,RECRUITING,OBSERVATIONAL,['NA']
2869,NCT03228706,"Change of medication adherence at baseline, and at 3, 6 and 12 months after intervention.","Change of intention to adhere at baseline, and at 3, 6 and 12 months after intervention.",Sustainability of the Program,2017-08-01,COMPLETED,INTERVENTIONAL,['NA']
2870,NCT03623607,Patient acceptance of diabetes self-management education delivered via an e-learning platform.,To conduct iterative rapid-cycle usability testing of the enhanced Diabetes To Go program content and processes and establish a Diabetes To Go program toolkit for widespread implementation,Implementation effectiveness evaluation,2016-04-01,COMPLETED,OBSERVATIONAL,['NA']
2871,NCT01748305,Need for medication for diabetes,Mode of delivery,,2012-12,TERMINATED,INTERVENTIONAL,['NA']
2872,NCT00441129,Difference in HbA1C From Baseline and 6 Months,Change From Baseline in Total Daily Dose (TDD),,2006-06,COMPLETED,INTERVENTIONAL,['NA']
2873,NCT01298154,Food Intake,Blood Glucose,,2009-07,COMPLETED,INTERVENTIONAL,['PHASE1']
2874,NCT02816099,Comparaison of linear correlation coefficients between plasma concentrations of apoC1 and CETP activity,,,2014-11-20,COMPLETED,INTERVENTIONAL,['NA']
2875,NCT05876273,Percent of Time-in-Range (TIR) on NAP versus UMPC.,Participant Feedback,,2023-05-30,COMPLETED,INTERVENTIONAL,['NA']
2876,NCT05355090,Change in HbA1c,Change in body weight,,2022-04-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2877,NCT00308646,,,,2004-10,TERMINATED,OBSERVATIONAL,['NA']
2878,NCT01507597,Plasma Glucose response to the GLP-1 infusion / glucose clamp,Food Intake,,2011-12,COMPLETED,INTERVENTIONAL,['NA']
2879,NCT03421262,Large for gestational age,Medical cost,,2017-06-01,UNKNOWN,INTERVENTIONAL,['NA']
2880,NCT04313998,Early Child Development,,,2016-06,UNKNOWN,OBSERVATIONAL,['NA']
2881,NCT01688986,,,,2012-08-25,COMPLETED,OBSERVATIONAL,['NA']
2882,NCT01956851,correlation of kisspeptin levels with GLP 1,,,2013-09,COMPLETED,OBSERVATIONAL,['NA']
2883,NCT01511042,Frequency of Intermediate Phenotypes in Subjects with Diabetes Mellitus versus Hypertension,Frequency of salt sensitive subtype in Diabetics versus hypertensives,,1999-12,TERMINATED,OBSERVATIONAL,['NA']
2884,NCT00630617,Body Mass Index,Knowledge and attitudes,,2004-07,COMPLETED,INTERVENTIONAL,['NA']
2885,NCT01505426,Change in HbA1c from baseline to end of treatment,"Safety assessed by the incidence of adverse events, vital signs safety labo-tests and 12-lead ECG",,2011-11-28,COMPLETED,INTERVENTIONAL,['PHASE3']
2886,NCT03101930,Change in Plasminogen Activator Inhibitor-1,Fasting Insulin,Change in Weight,2017-05-01,COMPLETED,INTERVENTIONAL,['PHASE4']
2887,NCT01858506,Change in lifestyle knowledge,Weight and waist circumference,Medical regimen for diabetes management,2014-08,COMPLETED,INTERVENTIONAL,['NA']
2888,NCT05066516,AUC,Vd,,2020-06-25,COMPLETED,INTERVENTIONAL,['PHASE1']
2889,NCT05044130,VLDL-triglyceride uptake in adipose tissue - Measurement of fatty acid concentration and specific activity in adipose tissue biopsies,Insulin sensitivity,,2021-09-14,COMPLETED,INTERVENTIONAL,['NA']
2890,NCT00759889,To analyze and image wounds using microscopy and molecular techniques,,,2007-03,COMPLETED,OBSERVATIONAL,['NA']
2891,NCT03774069,Percentage of readings below 54 mg/dl (3.3 mmol/l),Number of physician override Advisor recommendation,,2020-12-01,WITHDRAWN,INTERVENTIONAL,['NA']
2892,NCT00456027,"The development over time of safety variables, i.e. injection site discomfort, vital signs, laboratory values and AEs/SAEs as well as development of diabetes status, i.e. HbA1c, C-peptide, blood glucose and insulin requirement.",,,2004-12,COMPLETED,INTERVENTIONAL,['PHASE2']
2893,NCT06299800,Glycated assessment at first visit,"Tumour characterization in the considered population, detected at the first clinical visit",,2024-02-04,RECRUITING,OBSERVATIONAL,['NA']
2894,NCT02842359,Change from baseline in flow mediated dilatation,Rate of change from baseline in T-cell induced inflammatory factors,,2016-08-23,COMPLETED,INTERVENTIONAL,['PHASE4']
2895,NCT06319703,Change in Hemoglobin A1C (HbA1c) Test Scores,International Physical Activity Questionnaire (IPAQ) Short-Version Score,,2024-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2896,NCT02974504,HbA1c,HbA1c response rate,,2016-09,COMPLETED,INTERVENTIONAL,['PHASE4']
2897,NCT04984226,FACIT-F Fatigue (PRO),PROMIS Fatigue (PRO),Inflammatory cytokines. TNF-alpha and IL-6,2023-09-08,RECRUITING,INTERVENTIONAL,['PHASE2']
2898,NCT06331338,glycemic control (HbA1c),Diabetes Self-Care Behavior Scale,,2024-02-14,RECRUITING,INTERVENTIONAL,['NA']
2899,NCT05209061,Evaluation of metabolic profile,Appendix biofilm,,2023-02-01,RECRUITING,OBSERVATIONAL,['NA']
2900,NCT01421355,Change in Brachial Artery Diameter,,,2012-05,COMPLETED,INTERVENTIONAL,['PHASE1']
2901,NCT06092515,Red blood cell membrane fatty acids concentrations,Anemia,,2023-01-01,RECRUITING,INTERVENTIONAL,['NA']
2902,NCT06231225,Post-COVID-19 Functional Status scale,Dyspnoea-12 (D-12) scale,,2024-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2903,NCT00298428,Primary biological end-point: To compare SIPA levels in DM vs. MS vs. no DM/MS patients,,,2006-05,COMPLETED,INTERVENTIONAL,['NA']
2904,NCT02147522,Response Rate - 50 Percent or Greater Reduction in Patient Health Survey-9 (PHQ-9) Score Since Baseline,Change From Baseline in MOS Short-Form Health Survey Physical Component Summary (PCS),Change From Baseline in Self-Efficacy for Managing Chronic Disease (SEMCD) Score,2013-10,COMPLETED,INTERVENTIONAL,['NA']
2905,NCT04329871,Glycemic control while using the Medtronic MiniMed 670g system,Efficacy of Quality of Life and satisfaction while using the MiniMed 670g system,,2020-03-24,UNKNOWN,OBSERVATIONAL,['NA']
2906,NCT00874809,What are the mean number of changes in the basal infusion rate(change is defined as any alternation in the basal rate >0.1 U/hr) and what are the mean differences and mean duration (hrs) of these changes.,What mathematical formulas describe the relationship between the dosing factors and do they significantly differ from those previously established by King and Armstrong,,2009-03,COMPLETED,INTERVENTIONAL,['NA']
2907,NCT02416765,Mean glucose levels as measured by the glucose sensor.,Total carbohydrate intake,,2015-05,COMPLETED,INTERVENTIONAL,['PHASE2']
2908,NCT05928260,HbA1c,Quality of Life,,2023-08-10,RECRUITING,INTERVENTIONAL,['NA']
2909,NCT06032325,biomarkers,,,2024-01-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
2910,NCT00254800,Assessment of Pharmacokinetics profile of exenatide measured by AUC and Cmax,"Safety and Tolerability assessment by Adverse events, clinical laboratory evaluations, vital signs, ECG blood glucose, body weight, physical examination and exenatide antibodies.",,2005-11,COMPLETED,INTERVENTIONAL,['PHASE1']
2911,NCT01579981,Beta cell glucose sensitivity,Ad libitum food intake,,2012-04,COMPLETED,INTERVENTIONAL,['NA']
2912,NCT03862690,Change in glycosylated haemoglobin A1c (HbA1c),Change in health-related quality of life (EQ-5D),,2020-05-28,WITHDRAWN,OBSERVATIONAL,['NA']
2913,NCT00117793,Limb Pistoning,Frustration (PEQ Scale),,2005-08,COMPLETED,INTERVENTIONAL,['NA']
2914,NCT02477761,Plasma glucose concentration,Plasma glucose-dependent insulinotropic polypeptide concentration,,2015-06,UNKNOWN,INTERVENTIONAL,['NA']
2915,NCT04846673,visual analogue scale (VAS),"3 level version of Euro-Qol-5 dimensions, EQ-5D-3L",,2021-05-14,UNKNOWN,INTERVENTIONAL,['PHASE4']
2916,NCT02537587,Incremental area under the blood glucose response curve,Insulinogenic index,,2014-01,COMPLETED,INTERVENTIONAL,['NA']
2917,NCT02258698,Number of adverse outcomes in relation to Insulin resistance measured as HOMA (homeostasis model assessment),Number of adverse outcomes in relation to Insulin resistance measured as irisin,,2013-05,COMPLETED,OBSERVATIONAL,['NA']
2918,NCT03825562,Glycemic control,Psychological flexibility assessed by CAMM,,2015-10,COMPLETED,INTERVENTIONAL,['NA']
2919,NCT06186102,"Change in Physical performance, peak oxygen consumption (VO2max)",Days alive and out of hospital,Skeletal muscle satellite cell (MuSC) proliferation assays,2024-01-01,RECRUITING,INTERVENTIONAL,['PHASE2']
2920,NCT02643225,The Number of Participants Who Were Diagnosed With Fetal Macrosomia (Birth Weight),Interventricular Septum Thickness,,2015-04,COMPLETED,OBSERVATIONAL,['NA']
2921,NCT01264497,Change from baseline in relative insulin response,Number of subjects with a change in the control of diabetes,,2002-02,COMPLETED,INTERVENTIONAL,['PHASE2']
2922,NCT03481335,HbA1c,Cost-utility,,2018-06-01,COMPLETED,INTERVENTIONAL,['NA']
2923,NCT02609815,gut microbiota composition change from baseline,HbA1c change,PYY,2015-11-01,COMPLETED,INTERVENTIONAL,['NA']
2924,NCT00569426,Overall needle preference,Handling and acceptance of needles,,2005-04,COMPLETED,INTERVENTIONAL,['PHASE4']
2925,NCT04744714,Neonatal outcomes,annual follow-up results,,2021-02-01,RECRUITING,OBSERVATIONAL,['NA']
2926,NCT01330251,Changes in fecal microbiota,,,2011-01,COMPLETED,OBSERVATIONAL,['NA']
2927,NCT01458210,Pharmacokinetics: Time of Maximum Observed Drug Concentration (Tmax) of Ortho-Cyclen - Ethinyl Estradiol (EE),,,2011-10,COMPLETED,INTERVENTIONAL,['PHASE1']
2928,NCT02464033,Number of Patients With an Infection Reported as Adverse Event Related to Study Treatment,GAD65-induced MCP-1 Secretion,,2015-05,COMPLETED,INTERVENTIONAL,['PHASE2']
2929,NCT00035906,,,,2001-10,COMPLETED,INTERVENTIONAL,['PHASE2']
2930,NCT00971503,Significant increase in C-peptide levels after transplant in 70% of the patient.,Normalization of the hemoglobin A1C after transplant in 70% of the patients. Normalization of blood glucose levels.,,2011-02,WITHDRAWN,INTERVENTIONAL,['PHASE2']
2931,NCT02051647,Change in copeptin levels upon examination stress comparing copeptin levels prior and after examination,Correlation to cortisol as the classical stress marker,,2014-01,COMPLETED,OBSERVATIONAL,['NA']
2932,NCT01212120,Presence/absence of the same S. aureus genetic profile in the nose and on the foot lesion.,,,2010-09,COMPLETED,OBSERVATIONAL,['NA']
2933,NCT01053195,Incidence of type 2 diabetes,Cost-effectiveness of the lifestyle intervention,,2005-12,COMPLETED,INTERVENTIONAL,['NA']
2934,NCT03862716,Proportion of participants achieving drug-free diabetes remission,Proportion of participants achieving drug-free diabetes regression,"the change in time range over 2 weeks (defined as 4-8 mmol/l), based on up to 2 weeks of Abbott Freestyle Libre ProTM sensor wear",2019-04-23,COMPLETED,INTERVENTIONAL,['PHASE3']
2935,NCT00300911,"Plasma Brain Natriuretic Peptide levels, echocardiographic measurements were made before the treatment and repeated after three months and six months of the treatment",,,2005-12,COMPLETED,INTERVENTIONAL,['PHASE4']
2936,NCT05079399,Epigenetic changes in circulating angiogenic cells with different severities of diabetic retinopathy,Change in retinal thickness in optical coherence tomography angiography (OCT-A),,2022-01-01,RECRUITING,OBSERVATIONAL,['NA']
2937,NCT01588587,Frequency of cancers,Receptor for AGE concentration,,2012-10,UNKNOWN,OBSERVATIONAL,['NA']
2938,NCT03508934,Decrease in hypoglycemia during the hospitalization,,,2018-07-01,RECRUITING,INTERVENTIONAL,['NA']
2939,NCT03362398,Human plasma concentration of 12 participants will be measured after 1.5 h,,,2017-11-20,COMPLETED,INTERVENTIONAL,['NA']
2940,NCT02637973,Change in liver fat content,,,2015-12,COMPLETED,INTERVENTIONAL,['PHASE4']
2941,NCT01824355,Percent of Self Test Fingerstick Blood Glucose Results Within ±15 mg/dL (< 75 mg/dL) and Within ±20% (≥ 75 mg/dL) of the Laboratory Glucose Method,Number of Subject Responses That 'Strongly Agree' or 'Agree' or Are 'Neutral' With Questionnaire Statements,,2013-03,COMPLETED,INTERVENTIONAL,['NA']
2942,NCT01277913,Mean isometric hand grip force,"% patients with vitamin D hypervitaminosis (>200 ng/ml (500 nmol/L) and or hypercalcemia (>2.7 mmol/l) assessed at summer,spring, autumn, and winter",,2011-01,COMPLETED,INTERVENTIONAL,['PHASE4']
2943,NCT01505673,Glycemic Control Measured by HbA1c,Quality of Life Survey (QoL) - Willingness to Continue Insulin Treatment,,2012-01,COMPLETED,INTERVENTIONAL,['PHASE4']
2944,NCT00993187,Number of Participants Who Discontinued Study Drug Due to an Adverse Event,Percentage of Participants With HbA1C < 7.0% at Week 30,,2010-05-04,COMPLETED,INTERVENTIONAL,['PHASE4']
2945,NCT00338702,Time to definitive closure,,,2008-03,WITHDRAWN,INTERVENTIONAL,['PHASE4']
2946,NCT01145742,Blood pressure,LDL Cholesterol,,2006-11,COMPLETED,INTERVENTIONAL,['NA']
2947,NCT00286741,Systolic Blood Pressure,"Cost-effectiveness, Proportion of Patients With LDL < 100, Health Services Utilization, Quality of Life (as Measured by DQoL), Patient Empowerment (as Measured by DES).",,2006-06,COMPLETED,INTERVENTIONAL,['PHASE3']
2948,NCT02746861,Average reduction in HbA1c from baseline,,,2016-04,UNKNOWN,INTERVENTIONAL,['NA']
2949,NCT00166036,Change in Plasma Thiobarbituric Acid Reactive Substance (TBARS) Levels,Change in Flow-mediated Dilatation (FMD),,2004-09,COMPLETED,INTERVENTIONAL,['PHASE2']
2950,NCT00308347,"Combined endpoint of doubling of serum creatinine, ESRD or death.",Secondary parameters: number of cardiovascular events and changes in proteinuria. Tertiary parameters: quality of life and healthcare resource utilization.,,1996-05,COMPLETED,INTERVENTIONAL,['PHASE3']
2951,NCT05344690,Association of EPO gene polymorphism and the risk of confirmed diabetic retinopathy diagnosis,The association of confounding factors on the incidence of diabetic retinopathy,,2022-05-20,COMPLETED,OBSERVATIONAL,['NA']
2952,NCT03902288,Cortisol hormone measurement,Serum total antioxidant activity measurement,,2012-10,COMPLETED,INTERVENTIONAL,['NA']
2953,NCT00940173,"To establish preliminary evidence of the efficacy of DIABECELL(R), as measured by a reduction in serial HbA1C levels",To determine whether DIABECELL(R) causes an improvement in quality-of-life,,2009-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2954,NCT03526289,food intake,bone turnover markers,,2017-11-08,COMPLETED,INTERVENTIONAL,['NA']
2955,NCT03382015,Average Daily Glucose Levels,Triglycerides,,2018-01-09,COMPLETED,INTERVENTIONAL,['NA']
2956,NCT00528918,Hypoglycemic events,,,2007-06,COMPLETED,INTERVENTIONAL,['NA']
2957,NCT01944124,Systolic Blood Pressure,,,2009-11,COMPLETED,INTERVENTIONAL,['NA']
2958,NCT01537705,VAS,Routine Blood Panel,,2012-03,UNKNOWN,INTERVENTIONAL,['PHASE2']
2959,NCT01194830,Change From Baseline in HbA1c (Glycosylated Hemoglobin) After 24 Weeks,Change From Baseline in 2-hour Post-prandial Glucose (PPG) After 24 Weeks,,2010-09,COMPLETED,INTERVENTIONAL,['PHASE3']
2960,NCT03876015,Change in HbA1c,Patient completed the study under treatment with semaglutide (yes/no),,2019-05-01,COMPLETED,OBSERVATIONAL,['NA']
2961,NCT03921242,Heterogeneity of Treatment Effect Via Pre-specified Sub-Group Analyses,Difference in Laboratory-Measured eGFR (mL/min),,2019-08-01,COMPLETED,OBSERVATIONAL,['NA']
2962,NCT02895672,A1C,,,2016-08,COMPLETED,OBSERVATIONAL,['NA']
2963,NCT01371266,"Area under the curve glucose, response for OGTT. Glucose-120 min OGTT-AUC",Serum Lipids,,2011-06,COMPLETED,INTERVENTIONAL,['NA']
2964,NCT00315614,A Reduction or Absence of Rejection Episodes,Number of Subjects With Reduction of Severe Hypoglycemia and Improvement in Hypoglycemia Awareness,,2000-12,TERMINATED,INTERVENTIONAL,['PHASE2']
2965,NCT00001870,,,,1999-01,COMPLETED,INTERVENTIONAL,['PHASE2']
2966,NCT00673231,Adjusted Mean Change in HbA1c Levels,Adjusted Mean Change in Fasting Plasma Glucose (FPG),Proportion of Participants With Lack of Glycemic Control,2008-04,COMPLETED,INTERVENTIONAL,['PHASE3']
2967,NCT00829387,Numeric Rating Scale (NRS) Pain Intensity,Beck Depression Inventory (BDI),,2010-03,COMPLETED,INTERVENTIONAL,['NA']
2968,NCT00135057,Compare the change in glycemic control (as measured by A1c) from baseline to endpoint of fixed dose bolus regimen vs. variable bolus regimen based on carbohydrate count,,,2004-04,COMPLETED,INTERVENTIONAL,['PHASE3']
2969,NCT02404896,,,,na,AVAILABLE,EXPANDED_ACCESS,['NA']
2970,NCT03138746,insulin sensitivity,change in inflammatory cytokines,,2018-08-13,COMPLETED,OBSERVATIONAL,['NA']
2971,NCT00127296,Combined measure of accuracy and precision between target and measured amounts of insulin dispensed (mean square percent difference),Precision (coefficient of variation),,2005-07,COMPLETED,INTERVENTIONAL,['PHASE1']
2972,NCT04625452,Loss-to-follow-up at 24 weeks,"Change of TTT sub-scales means from 12 to 24 weeks in the ""Theoretical Model of Change"" scores",Means change from baseline to 24 weeks in the level of triglycerides (TGC) (mg/dl).,2020-08-13,UNKNOWN,INTERVENTIONAL,['NA']
2973,NCT03864991,Changes in HbA1c,Episodes of acute complications,,2018-10-29,UNKNOWN,INTERVENTIONAL,['NA']
2974,NCT01326026,Change in Glycosylated Haemoglobin (HbA1c),Rate of Nocturnal Confirmed Hypoglycaemic Episodes,,2011-03,COMPLETED,INTERVENTIONAL,['PHASE3']
2975,NCT06281899,Time to the First Occurrence of Any of the Components of the Composite: ≥30% Sustained Decline in eGFR or Reaching ESRD or CV Death or Renal Death,Changes in the quality of life,Compliance to carbohydrate intake,2022-01-01,RECRUITING,INTERVENTIONAL,['PHASE4']
2976,NCT00703417,,,,2006-05,COMPLETED,OBSERVATIONAL,['NA']
2977,NCT02053051,Post-prandial hypoglycaemia,Number achieving target HbA1c ( ≤ 53 mmol/mol ),Acceptability questionnaire (non-validated),2013-11-12,COMPLETED,INTERVENTIONAL,['NA']
2978,NCT00320502,Safety,Myocardial ischemia by 24-hour continuous 12-lead ECG,,2006-05,COMPLETED,INTERVENTIONAL,['PHASE2']
2979,NCT05577728,Long-term glycemic control defined as proportion of patients who will achieve an HbA1c of less than 7.0% (53.0 mmol/mol),Number of hypoglycemic episodes leading to an inpatient admission or emergency room encounter.,,2021-07-01,COMPLETED,OBSERVATIONAL,['NA']
2980,NCT01254084,"Fating plasma glucose, Steady state plasma glucose in Somatostatin-Insulin-Glucose Infusion Test","Body weight (BMI, hip-waist ratio)",,2010-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2981,NCT03717207,syncope recurrence,,,2010-01-01,COMPLETED,OBSERVATIONAL,['NA']
2982,NCT04504370,Change in HbA1c,Change in Body Mass Index,,2020-04-27,COMPLETED,INTERVENTIONAL,['PHASE3']
2983,NCT03252080,ADDQoL score at endpoint,HbA1c at endpoint,,2017-08,UNKNOWN,INTERVENTIONAL,['NA']
2984,NCT01995539,Change From Baseline in A1C at 3 Months,Number of Serious Adverse Device Effects (SADE).,,2012-12,COMPLETED,INTERVENTIONAL,['NA']
2985,NCT01627977,Visibility of the membrane after injection of the dye,Usefulness of the dye,,2012-10,COMPLETED,INTERVENTIONAL,['PHASE3']
2986,NCT03241303,Plasma glucose,,,2017-08-01,COMPLETED,INTERVENTIONAL,['NA']
2987,NCT03834610,"Improvement in Penile Doppler parameters after treatment including peak systolic velocity in (cm/sec), end diastolic volume in (cm/sec) and resistive index (RI) that = (peak systolic velocity - end diastolic velocity ) / peak systolic velocity.",,,2017-10-01,COMPLETED,INTERVENTIONAL,['NA']
2988,NCT03878745,BD Nano™ PRO Pen Needle Compared to Terumo Nanopass® (Injection Pain),BD Nano™ PRO vs Terumo Nanopass® (Leakage),Compare BD Nano™ PRO vs Terumo Nanopass® (Needle Breaking),2019-02-11,COMPLETED,INTERVENTIONAL,['NA']
2989,NCT00377858,Hemoglobin A1c (HbA1c) at 36 Week Endpoint,Change From Baseline in Absolute Body Weight at 36 Week Endpoint,,2006-08,COMPLETED,INTERVENTIONAL,['PHASE4']
2990,NCT05124405,To evaluate the feasibility of the ( PA) Physical Activity intervention.,,,2018-05-24,SUSPENDED,INTERVENTIONAL,['NA']
2991,NCT04225455,To compare the data generated from the continuous glucose monitoring system (CGMS) Dexcom G6® with their routine self-glucose monitoring in pilots with class 1 and class 2 certificates,Previous 6 months logged data,,2019-12-05,RECRUITING,OBSERVATIONAL,['NA']
2992,NCT02355288,"Successfully enrolled, eligible and consenting patients within the first year of enrollment.",Quality of Life (QOL),,2018-10-01,WITHDRAWN,INTERVENTIONAL,['NA']
2993,NCT00579228,Carotid intima media measurement change,,,2007-04-25,COMPLETED,OBSERVATIONAL,['NA']
2994,NCT01095068,,,,2010-03,TERMINATED,INTERVENTIONAL,['NA']
2995,NCT01993511,Change in beta-cell function after RYGB.,Change in insulin sensitivity after RYGB.,Change in insulin clearance after RYGB.,2010-06,UNKNOWN,OBSERVATIONAL,['NA']
2996,NCT00913497,Difference in the Two Hour and Four Hour Post Prandial Blood Glucose Levels Following Administration of Insulin Glulisine Versus Insulin Aspart at the End of the Twenty Study Days,Occurrence of Hypoglycemia;,,2009-06,COMPLETED,INTERVENTIONAL,['PHASE4']
2997,NCT05444842,healing rate,,,2022-07-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2998,NCT06292962,Neuropathic pain scores,Quality of life score,,2023-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2999,NCT03199261,Bioequivalency between the 2 formulations of rE-4,,,2016-12-23,COMPLETED,INTERVENTIONAL,['PHASE1']
3000,NCT00362960,proteinuria (total urinary protein excretion) from baseline.,Evaluate safety and tolerability of all treatments.,,2003-05,COMPLETED,INTERVENTIONAL,['PHASE3']
3001,NCT03011177,HbA1c,,,2017-01,COMPLETED,INTERVENTIONAL,['PHASE4']
3002,NCT03475069,Quality of life,Body mass index,,2013-10-20,COMPLETED,INTERVENTIONAL,['NA']
3003,NCT03660631,Effect of physician/pharmacist collaboration on implementation fidelity,Development of payment contracts,,2018-09-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
3004,NCT05261906,Change in HbA1c from Baseline,Change in rapid insulin use from Baseline,Participant Feedback,2022-09-26,RECRUITING,INTERVENTIONAL,['NA']
3005,NCT00571935,HbA1c,Quality of Life (QoL),,2003-08,COMPLETED,INTERVENTIONAL,['PHASE4']
3006,NCT00911404,Need of insulin treatment for GDM,Fetal morbidity,,2009-01,COMPLETED,INTERVENTIONAL,['NA']
3007,NCT06071208,prevention of diabetic complications,,,2023-10-14,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
3008,NCT01030978,"2-hour plasma glucose, category of glucose tolerance (IGT, NGT, T2DM)",Family assessment device (FAD) score,,2009-09,COMPLETED,INTERVENTIONAL,['NA']
3009,NCT03899402,Change in HbA1c following dapagliflozin,Diabetic ketoacidosis assessment,,2019-05-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
3010,NCT06021145,Percentage of time of glucose levels spent in the target range (empagliflozin vs placebo),Fasting ketone levels,,2024-03,RECRUITING,INTERVENTIONAL,['PHASE4']
3011,NCT00819455,Progression to diabetes,Acceptability of text messaging as tool to prevent diabetes.,,2009-03,COMPLETED,INTERVENTIONAL,['NA']
3012,NCT00905255,"Overview of Adverse Event Profile (Treatment Emergent Adverse Events) of the One-Step and Two-Step Titration Arms Assessed Through Adverse Events Collection and Vital Signs, Electrocardiogram (ECG) and Laboratory Monitoring",Change From Baseline in Fasting Plasma Glucose (FPG) for All Patients at Week 52 and 76,Number of Patients With Symptomatic Hypoglycemia and Severe Symptomatic Hypoglycemia for All Patients During On-Treatment Period,2009-05,COMPLETED,INTERVENTIONAL,['PHASE3']
3013,NCT00593424,Paired t-test or Wilcoxon signed rank test will be used to evaluate the change in fasting triglycerides with the diets.,Post-prandial lipids will be evaluated by t-test or Wilcoxon signed rank test for AUC of triglyceride and remnant lipoprotein measured by immunoseparation.,,2002-08,COMPLETED,INTERVENTIONAL,['NA']
3014,NCT05968222,Five times Sit To Stand (5STS),,,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
3015,NCT03313297,Skin 11β-HSD1 activity,Skin RNA-seq gene expression profiling,,2018-04-10,COMPLETED,INTERVENTIONAL,['PHASE2']
3016,NCT00013299,,,,2000-10,COMPLETED,INTERVENTIONAL,['PHASE2']
3017,NCT00465881,,,,2006-01,COMPLETED,OBSERVATIONAL,['NA']
3018,NCT03755934,Change in the weekly average of the average daily pain scores,To characterise the dose-response relationship of MEDI7352 on chronic pain in subjects with PDN,,2018-11-19,COMPLETED,INTERVENTIONAL,['PHASE2']
3019,NCT04749030,Number of adverse events of severity grade 2 or more assessed by CTCAE v5.0 during the first week after first intervention (FMT or placebo).,Blood samples.,,2021-06-15,COMPLETED,INTERVENTIONAL,['NA']
3020,NCT05996380,Safety endpoints: Number of Adverse Events,,,2023-06-09,RECRUITING,INTERVENTIONAL,['PHASE1']
3021,NCT03134170,Hemoglobin A1C,Preventative care,,2015-08-01,UNKNOWN,INTERVENTIONAL,['NA']
3022,NCT02964572,changes in the secretion of IL-1 beta from peripheral blood mononuclear cells,"Changes in protein expression pattern (western blot, relative to control) of IL-1beta, TNF-alpha, and NLRP3 in peripheral blood mononuclear cells, before and after the administration of empagliflozin or glimepiride",,2016-11,COMPLETED,INTERVENTIONAL,['NA']
3023,NCT05767177,Glucemia following a Mixed Meal Test:,Enteroscopy: mucosal glucose-transport capacity,"Glucemia, insulinemia and GLPi-emia following the Mixed Meal Test",2023-06-01,RECRUITING,INTERVENTIONAL,['NA']
3024,NCT04132908,blood samples,,,2016-10-01,COMPLETED,INTERVENTIONAL,['NA']
3025,NCT02671656,Uricemia,"Haematocrit, glucose and lipid levels, medications",,2016-03,WITHDRAWN,OBSERVATIONAL,['NA']
3026,NCT00320970,Urinary carboxymethyllysine,,,2002-08,COMPLETED,INTERVENTIONAL,['NA']
3027,NCT05176795,Gut microbiota composition,Fecal contamination with nanoparticles,,2022-03-16,RECRUITING,OBSERVATIONAL,['NA']
3028,NCT04533659,Glycemic control,In-home self-monitoring of blood glucose,,2020-08-01,RECRUITING,INTERVENTIONAL,['NA']
3029,NCT06322940,Change in whole-body insulin sensitivity,Change in lipid profile,Change in total energy intake,2024-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
3030,NCT01932944,Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System compared to venous and capillary glucose,,,2013-08,COMPLETED,OBSERVATIONAL,['NA']
3031,NCT01352663,Change in HbAlc from baseline till the end of treatment period.,Percentage change in immunogenic response.,,na,WITHDRAWN,INTERVENTIONAL,['PHASE3']
3032,NCT01589835,HbA1c Progression to diabetes,,,2012-07,COMPLETED,INTERVENTIONAL,['PHASE2']
3033,NCT00297583,serum insulin concentrations,Adverse events and hypoglycemic episodes collection,,2004-04,COMPLETED,INTERVENTIONAL,['PHASE1']
3034,NCT00021944,,,,2001-04,COMPLETED,OBSERVATIONAL,['NA']
3035,NCT04284943,The success rate of biochemical improvement of diabetes as measured by HbA1c < 6.5%,The success rate of biochemical improvement of diabetes as measured by HbA1c < 6.5%,,2020-12-01,RECRUITING,INTERVENTIONAL,['NA']
3036,NCT05114018,Insulin sensitivity by Matsuda Index,Adverse events,,2020-06-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
3037,NCT00135070,Glucose control,Length of stay,,2005-07,TERMINATED,INTERVENTIONAL,['PHASE4']
3038,NCT06131372,Change in urinary albumin-to-creatinine ratio (UACR),"Number of severe hypoglycaemic episodes (level 3): hypoglycaemia associated with severe cognitive impairment requiring external assistance for recovery, with no specific glucose threshold",,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
3039,NCT06120556,"Difference in HbA1c change from baseline (%) among SIDD, SIRD, MARD, MOD subtypes","Difference in percentage of patients reaching HbA1c below 7% among SIDD, SIRD, MARD, MOD subtypes",,2023-06-10,COMPLETED,OBSERVATIONAL,['NA']
3040,NCT01566981,Change From Baseline in HbA1C at 1 Year.,Change of the Following Parameter : HbA1C,,2012-03,COMPLETED,INTERVENTIONAL,['NA']
3041,NCT00820703,To evaluate the safety and clinical effect of Nexagon® administered topically to diabetic foot ulcers.,To pilot the collection of data that may be considered useful in planning future studies of Nexagon® administered topically to diabetic foot ulcers.,,2009-04,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3042,NCT01333592,Incidences of Adverse Events,Change From Baseline in HbA1c at 52 Weeks,,na,COMPLETED,INTERVENTIONAL,['PHASE3']
3043,NCT02439879,Total Symptoms Score,,,2009-12,COMPLETED,INTERVENTIONAL,['PHASE4']
3044,NCT03951168,Diabetes Specific Quality of Life,HDL-C,,2019-07-01,COMPLETED,INTERVENTIONAL,['NA']
3045,NCT03919656,Metabolomics changes in urine,Changes in albuminuria,,2019-05,UNKNOWN,INTERVENTIONAL,['PHASE4']
3046,NCT02467790,Pharmacokinetic index,Incidence of adverse events and serious adverse events,,2015-02,UNKNOWN,INTERVENTIONAL,['PHASE1']
3047,NCT01469065,Change From Baseline (Day -1) in Mean Daily Glucose at Day 14,Change From Baseline in Fasting Lipid Parameters at Day 14 and 16,,2011-12,COMPLETED,INTERVENTIONAL,['PHASE1']
3048,NCT01880372,Decreased progression of diabetic retinopathy.,Changes in the plasma level of glutathione as measured by ELISA technique,Changes in visual acuity as measured by electronic visual testing algorithm,2013-09,TERMINATED,INTERVENTIONAL,['NA']
3049,NCT05849428,Time-matched CGM-derived blood glucose differences between left arm and right arm in patients with Type 1 or Type 2 Diabetes below target range (<70 mg/dL).,Time-matched CGM-derived blood glucose differences between left arm and right arm in patients above target range (>180 mg/dL).,,2023-05,RECRUITING,INTERVENTIONAL,['NA']
3050,NCT00402194,Insulin-stimulated Leg Glucose Uptake,,,2005-06,COMPLETED,INTERVENTIONAL,['NA']
3051,NCT05090488,Change from baseline HbA1C at 3 months and 6 months,Change from baseline quality of life,,2020-12-14,UNKNOWN,INTERVENTIONAL,['NA']
3052,NCT02843724,Clinically meaningful reduction of HbA1c above and beyond that of control arm,Adverse Events,,2016-07,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3053,NCT03690180,Decrease in serum magnesium,,,2018-01-01,COMPLETED,OBSERVATIONAL,['NA']
3054,NCT00548639,Morisky medication adherence scale,,,2007-08,COMPLETED,INTERVENTIONAL,['NA']
3055,NCT05422053,Other serious adverse events,Glucose < 70 mg/dL,CGM Metrics by Time of Day,2022-06-29,COMPLETED,INTERVENTIONAL,['NA']
3056,NCT04491253,Self-management: diabetes,Social support,,2021-09-13,COMPLETED,INTERVENTIONAL,['NA']
3057,NCT01222078,Proportion of Anti-otelixizumab Neutralizing Antibodies,Terminal Phase Half-life (Thalf) of Otelixizumab,,2010-11-22,TERMINATED,INTERVENTIONAL,['PHASE2']
3058,NCT05054842,Changes in HbA1c relative to baseline,Evaluate the concentration of the main metabolite of SP2086 in Type 2 diabetes,,2021-12-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
3059,NCT00388986,AUC0-tau of glyburide,"AEs, laboratory parameters.",,2006-10,COMPLETED,INTERVENTIONAL,['PHASE1']
3060,NCT03207269,Fasting Plasma glucose,Fasting continuous glucose monitoring glucose,,2017-07-20,COMPLETED,INTERVENTIONAL,['NA']
3061,NCT05992350,Minutes of Sleep per Day,Change in how parents feel about episodes of hypoglycemia in their children,,2024-01-16,RECRUITING,OBSERVATIONAL,['NA']
3062,NCT05566977,Efficacy of the adoptive T regs transfer,Prevention or stop progression to organ failure,,2022-12,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
3063,NCT04572009,percentage of time in glycemic target,changes in activity over time,,2021-01-12,COMPLETED,INTERVENTIONAL,['NA']
3064,NCT03362762,"Characteristic of type 2 diabetes patients, treated with insulin in Guadeloupe",Describe the relation between the rate of HbAC and the plan of insulinothérapie,,2013-12-16,COMPLETED,OBSERVATIONAL,['NA']
3065,NCT01113515,Safety outcome,Efficacy outcome,Pharmacokinetics,2014-02,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3066,NCT01713465,Frequency of participants with increase in treatment adherence scores,Frequency of participants with increase in Satisfaction to Medical Care,,2012-03,UNKNOWN,INTERVENTIONAL,['NA']
3067,NCT05636007,nocturnal hypoglycemia,,,2022-12-01,RECRUITING,OBSERVATIONAL,['NA']
3068,NCT03481283,Blood vessel wall amylin deposition vs severity of peripheral neuropathy,Heat thermode test vs RBC amylin and blood vessel wall amylin deposition,,2018-02-05,RECRUITING,OBSERVATIONAL,['NA']
3069,NCT03739268,plasma glucose,Appetite measured by visual analog scale,,2018-09-01,COMPLETED,INTERVENTIONAL,['NA']
3070,NCT06295900,Patient Introduction Form,Patient Follow-up Form,Visual Comparison Sleep Scale,2024-01-05,RECRUITING,INTERVENTIONAL,['NA']
3071,NCT01018017,Mean clinical chemistry parameters including serum creatinine,"Muscle histology and biomarkers of oxidative capacity-succinate dehydrogenase content Complex I, Complex II/III, complex IV.",,2010-03-03,COMPLETED,INTERVENTIONAL,['PHASE2']
3072,NCT02227875,Change in HbA1c From Baseline to 24 Weeks,Change in Cross-Reactive Insulin Antibody Percent Binding for Lantus Assay Over Time,,2014-08,COMPLETED,INTERVENTIONAL,['PHASE3']
3073,NCT00888732,"Cmaxglu: Peak plasma glucose following test meal (breakfast). A comparison will be made between fast-acting human insulin vs. IAsp, BIAsp 50 and BIAsp 70, IAsp vs BIAsp 50 and BIAsp 70, BIAsp 50 vs. BIAsp 70.","Serum GH, total IGF-I, IGF-I bioactivity, IGFBP-1, IGFBP-2, binary complex of IGF-I, IGFBP-3 and the acid-labile subunit (ALS)",,2009-06,COMPLETED,INTERVENTIONAL,['PHASE3']
3074,NCT04260100,Dietary Behaviour,Fasting Blood Glucose,,2020-02-17,COMPLETED,INTERVENTIONAL,['NA']
3075,NCT01726413,Mean 24-hour average pain intensity (API) score.,Clinician Global Impression of Change,,2012-11,COMPLETED,INTERVENTIONAL,['PHASE2']
3076,NCT06041412,the presence of DPN,,,2012-02-01,RECRUITING,OBSERVATIONAL,['NA']
3077,NCT01871428,Change in HbA1c,Safety: Incidence of adverse events,,2013-06,COMPLETED,INTERVENTIONAL,['PHASE3']
3078,NCT05203042,Timed Get Up and Go Test-Motor and Cognitive Task:,Biochemical Analysis,,2022-01-15,UNKNOWN,OBSERVATIONAL,['NA']
3079,NCT02081586,Computer System Usability Questionnaire (CSUQ),Body Mass Index Change,,2013-05,COMPLETED,INTERVENTIONAL,['NA']
3080,NCT05175677,Impact on diabetes control in the study population,Lifestyle modification for diabetic patients,,2022-03-10,COMPLETED,OBSERVATIONAL,['NA']
3081,NCT00069628,HbA1c value obtained 6 months after randomization,Diabetes Self Management Profile at 6 months,,2003-07,COMPLETED,INTERVENTIONAL,['PHASE4']
3082,NCT04369703,Assess relative change,,,2020-01-28,COMPLETED,OBSERVATIONAL,['NA']
3083,NCT01630512,change in severity of depressive symptoms,intersession changes in mood,,2011-05,COMPLETED,INTERVENTIONAL,['NA']
3084,NCT02030600,Number of Treatment Emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During the Maintenance Period,FPG (Fasting Plasma Glucose),,2014-01-06,COMPLETED,INTERVENTIONAL,['PHASE3']
3085,NCT00771576,Pancreas [11C] DTBZ binding,,,2006-09,COMPLETED,OBSERVATIONAL,['NA']
3086,NCT00155922,,,,2003-11,UNKNOWN,OBSERVATIONAL,['NA']
3087,NCT03534193,Effectiveness of tablet education in newly diagnosed type 1 diabetes,Improved subject compliance with glucose monitoring,,2017-04-17,SUSPENDED,INTERVENTIONAL,['NA']
3088,NCT02175121,Number of Participants With Electrocardiogram (ECG) Data Meeting Criteria of Potential Clinical Concern,Apparent Clearance (CL/F),,2014-08,COMPLETED,INTERVENTIONAL,['PHASE2']
3089,NCT01821846,The incidence of SADRs (Serious Adverse Drug Reactions),Number of SAEs/ ADRs (Serious Adverse Events/Adverse Drug Reactions),,2013-11-20,COMPLETED,OBSERVATIONAL,['NA']
3090,NCT05723445,Change in percent time in target range 70-180 mg/dL,Change in intestinal fatty acid binding protein (I-FABP),,2023-09-01,RECRUITING,INTERVENTIONAL,['NA']
3091,NCT02521675,percentage of time spent over 24 hours in hyperglycemia (> 180 mg / dL) (> 10 mmol / L),"Comparison between number of hypoglycemic events predicted by the prediction function ""DIABRASPORT"" and number of hypoglycemic events actually occurred.",,2016-01,COMPLETED,INTERVENTIONAL,['NA']
3092,NCT05824286,Change in measured HbA1c from baseline to 24 weeks,The rate of severe hypoglycemic events and confirmed hypoglycemic events during the 24 weeks of the study,,2023-01-04,RECRUITING,INTERVENTIONAL,['NA']
3093,NCT01228500,Time to healing,,,2008-01,WITHDRAWN,INTERVENTIONAL,['NA']
3094,NCT05838222,Feasibility measure,Hypertension,,2023-05-08,COMPLETED,INTERVENTIONAL,['NA']
3095,NCT02649465,The improvement in histologic features of NAFLD,Epigenomic changes from baseline in genes of the liver and blood cells,,2015-11-11,COMPLETED,INTERVENTIONAL,['PHASE4']
3096,NCT01303900,Cardiovascular disease risk factors,Association between clotting factor concentrate administration and cardiovascular events,,2009-01,UNKNOWN,OBSERVATIONAL,['NA']
3097,NCT01968265,The effect of ISIS-GCCRRx on serum fructosamine,The tolerability of ISIS-GCCRRx,,2013-10,COMPLETED,INTERVENTIONAL,['PHASE2']
3098,NCT01760707,Exercise capacity,maximal oxygen pulse,,2002-11,COMPLETED,INTERVENTIONAL,['NA']
3099,NCT04822480,Medical expenditures,Coping self-efficacy,Implementation,2020-02-01,RECRUITING,OBSERVATIONAL,['NA']
3100,NCT00108927,,,,2003-12,COMPLETED,OBSERVATIONAL,['NA']
3101,NCT01099137,The change of HbA1c,HbA1c < 7.0% without hypoglycemia,,2010-01,COMPLETED,INTERVENTIONAL,['PHASE4']
3102,NCT02661906,Improvement in quality of life,Improvement in lipid profile,,2016-08,COMPLETED,INTERVENTIONAL,['NA']
3103,NCT03161652,Vasoinhibin vitreous levels,Blood pressure,,2017-05-24,RECRUITING,INTERVENTIONAL,['PHASE2']
3104,NCT02290925,Glycosylated Haemoglobin,Renal Adverse Effects - 2,,2014-05,COMPLETED,INTERVENTIONAL,['PHASE3']
3105,NCT01686945,Number of treatment emergent adverse events (TEAEs) recorded,Change from baseline in glycosylated haemoglobin type A1c (HbA1c),,2012-09-19,COMPLETED,INTERVENTIONAL,['PHASE1']
3106,NCT01189422,Dose regimen,,,2010-08,TERMINATED,INTERVENTIONAL,['PHASE1']
3107,NCT02060357,Endothelial stent coverage,MACE,,2011-11,COMPLETED,INTERVENTIONAL,['NA']
3108,NCT01697657,Incidence of total self-recorded hypoglycaemic episodes,Incidence of adverse events,,2001-09,COMPLETED,INTERVENTIONAL,['PHASE3']
3109,NCT05316662,Change in HbA1c,"DTSQs, change in absolute treatment satisfaction",,2022-04-06,RECRUITING,OBSERVATIONAL,['NA']
3110,NCT02558270,Change in endogenous glucose production,Changes in hormones involved in hypoglycemia counter regulation,,2016-06,UNKNOWN,INTERVENTIONAL,['PHASE2']
3111,NCT05394727,Change from baseline in Plasma insulin concentrations to week 4,,,2021-04-01,RECRUITING,INTERVENTIONAL,['NA']
3112,NCT03851666,Effect of the treatment on reduction of the HbA1c level (%),Effect of the treatment on evolution of the subject weight,,2018-08-09,COMPLETED,INTERVENTIONAL,['NA']
3113,NCT03549559,11C-Martinostat Binding,,,2018-09-07,UNKNOWN,INTERVENTIONAL,['NA']
3114,NCT05924724,Treatment Satisfaction,Activity in the last 7 days,,2023-06-01,RECRUITING,INTERVENTIONAL,['NA']
3115,NCT01961401,insulin sensitivity,,,2013-01,TERMINATED,INTERVENTIONAL,['NA']
3116,NCT02011178,Glomerular filtration rate,Lipids,Quality of life score,2014-03,WITHDRAWN,INTERVENTIONAL,['NA']
3117,NCT01467141,Change in HbA1c (glycosylated haemoglobin A1c),Incidence of Adverse Events (AEs),,2002-06-19,COMPLETED,INTERVENTIONAL,['PHASE4']
3118,NCT01475786,The Primary Study Endpoint Was the Change in Average 24-hour Pain Score From Baseline to the 6-month Follow-up.,,,2012-08,COMPLETED,INTERVENTIONAL,['PHASE2']
3119,NCT04240574,Subjects Feedback,,,2020-01-24,TERMINATED,INTERVENTIONAL,['NA']
3120,NCT04825795,Prevalence of obstructive coronary disease,Change in coronary calcium score,,2010-01-01,COMPLETED,OBSERVATIONAL,['NA']
3121,NCT02426073,"Inflammatory markers (TNF-α, interleukin-1, interleukin-2, interleukin-6, RANKL, Myostatin and GDF11)",,,2017-01,COMPLETED,OBSERVATIONAL,['NA']
3122,NCT05442398,HbA1c,,,2022-07-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
3123,NCT04161651,changes in quality of life evaluated questionnaires (DTSQ),Any adverse event related to study device,,2019-11,UNKNOWN,INTERVENTIONAL,['NA']
3124,NCT02227212,Ease-of-use / ease of learning questionnaire,Number of participants with site injection site reactions / hypersensitivity reactions,,2014-08,COMPLETED,INTERVENTIONAL,['PHASE3']
3125,NCT02756832,Change From Baseline in Glycosylated Hemoglobin (HbA1c) Level at Month 6,Percentage of Participants Who Used Healthcare Resources,,2016-09-20,COMPLETED,OBSERVATIONAL,['NA']
3126,NCT03774394,Platelet Reactivity Index (PRI) Assessed by VASP. The Cutoff for High Platelet Reactivity is >50%,Clopidogrel Active Metabolite Concentration,Platelet Reactivity Index (PRI) Assessed by VASP. The Cutoff for High Platelet Reactivity is >50%,2019-08-22,COMPLETED,INTERVENTIONAL,['PHASE4']
3127,NCT00394030,Pharmacokinetic measurements for different injection sites after one dose.,Pharmacodynamic measurements at three different times after one dose.,,2006-10-16,COMPLETED,INTERVENTIONAL,['PHASE1']
3128,NCT01582308,Percent Inhibition of Dipeptidyl Peptidase IV (DPP-4) Activity at Trough,Pharmacokinetic Analysis: Time to the Peak Plasma Drug Concentration (Tmax),,2012-06-21,COMPLETED,INTERVENTIONAL,['PHASE1']
3129,NCT01964950,Number of Participants Reporting One or More Serious Adverse Drug Reaction,Change From Baseline in Fasting Insulin Level,,2011-07,COMPLETED,OBSERVATIONAL,['NA']
3130,NCT00031213,,,,2001-09,COMPLETED,OBSERVATIONAL,['NA']
3131,NCT01582282,Triglyceride Change From Baseline,,,1988-05,TERMINATED,INTERVENTIONAL,['PHASE4']
3132,NCT03235440,Change in Body Weight,Body Image Assessment of Children (BIA-C):,,2017-06-19,COMPLETED,INTERVENTIONAL,['NA']
3133,NCT00099515,Hypothesis that std training for HIIP system is noninferior to intensive training by 1.2 mmol/L with respect to overall 2-hr postprandial glucose excursion of (SMBG) in type 2 diabetes patients that have been on preprandial trmt with HIIP,Compare the test meal blood glucose profiles of preprandial HIIP administration with standard training and with intensive training,,2004-11,COMPLETED,INTERVENTIONAL,['PHASE2']
3134,NCT06287840,Bone Strength (Failure load),Alkaline phosphatase,,2024-04-01,RECRUITING,OBSERVATIONAL,['NA']
3135,NCT00184561,Change in HbA1c,after 24 weeks of treatment.,,2005-07,COMPLETED,INTERVENTIONAL,['PHASE4']
3136,NCT01609088,Brachial artery flow mediated dilation,C-reactive protein,,2012-05,COMPLETED,INTERVENTIONAL,['NA']
3137,NCT00519480,"Home diary of blood sugar results, adverse events and drug dosing.",fluid intake & output,,2007-09-11,COMPLETED,INTERVENTIONAL,['PHASE1']
3138,NCT00990184,Acute Insulin Response (AIRg) to Intravenous Glucose,Glucose Disappearance Rate,,2009-09,COMPLETED,INTERVENTIONAL,['PHASE3']
3139,NCT00488930,"Measure changes in dendritic cells at baseline, 6 months and 1 year following weight loss",,,2007-06,TERMINATED,OBSERVATIONAL,['NA']
3140,NCT03999853,Insulin sensitivity,Glucose Variability and Triglycerides,,2022-07-28,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3141,NCT04975464,COVID 19 survey,,,2011-11-15,UNKNOWN,OBSERVATIONAL,['NA']
3142,NCT04567563,Change in ulcer area and overall healing rate,tissue perfusion,,2020-11,UNKNOWN,INTERVENTIONAL,['NA']
3143,NCT00569595,"Serum glycosylated hemoglobin, heart rate recovery step test","Total Cholesterol, BMI, waist circumference, healthy eating, physical activity, perceived health status, patient satisfaction, mood",,2008-11,COMPLETED,INTERVENTIONAL,['PHASE3']
3144,NCT05579977,"Placebo-adjusted, percent change from baseline in body weight at Week 32 in Obesity",Assessment of mental health as determined by Columbia-Suicide Severity Rating Scale (C-SSRS) in Obesity,,2022-10-27,TERMINATED,INTERVENTIONAL,['PHASE2']
3145,NCT04757285,determine stress hormones in serum cortisol and copeptin,correlation of psychological stress with stress hormone copeptin,,2020-05-10,COMPLETED,OBSERVATIONAL,['NA']
3146,NCT00873925,C-Peptide following the 1 year mixed meal tolerance test,Peripheral Blood T-cell assays,,2009-03,COMPLETED,INTERVENTIONAL,['PHASE1']
3147,NCT03623139,Change in mean amplitude of glycaemic excursions (MAGE),Change in intake of dietary fibre,Change in urinary biomarkers of carbohydrate intake,2018-09-28,COMPLETED,INTERVENTIONAL,['NA']
3148,NCT01563887,The change in the number of hypoglycemia-related driving mishaps,,,2012-02,COMPLETED,INTERVENTIONAL,['NA']
3149,NCT01698385,Change from Baseline in oral glucose tolerance test at variable time frames,Change from Baseline in weight at variable time frames,,2008-02,COMPLETED,INTERVENTIONAL,['NA']
3150,NCT06036004,Change in EmBody/EmFace to assess recognition of facial and body expressions,Change in Beck's Depression Inventory II (BDI-II) to assess depression,Change in Close third-person assessment,2024-01-08,RECRUITING,INTERVENTIONAL,['PHASE2']
3151,NCT03486964,Post-prandial plasma glucose,Cardiovascular death,,2018-03-27,COMPLETED,OBSERVATIONAL,['NA']
3152,NCT04664036,Association of NAFLD with microvascular and macrovascular complications in type 1 diabetes mellitus: odds ratio to develop in NAFLD and diabetes compared to diabetes without NAFLD in subjects with no prior complications,Natural history of NAFLD in type 1 diabetes,,2018-09-17,RECRUITING,OBSERVATIONAL,['NA']
3153,NCT05577650,Prevalence of chronic kidney disease,,,2023-01-09,COMPLETED,OBSERVATIONAL,['NA']
3154,NCT00726505,The change in urinary glucose excretion dynamics,Glucose effects on tubular markers,,2009-06,TERMINATED,INTERVENTIONAL,['PHASE1']
3155,NCT01002352,Improvement of comorbidities,"Mortality, weight loss, surgical complications",,2007-06,UNKNOWN,OBSERVATIONAL,['NA']
3156,NCT02307279,Co-Primary Outcome: Percentage of Subjects Who Achieve Body Weight Loss ≥ 5%,Change in Hemoglobin HbA1c in Subjects With Type 2 Diabetes at Baseline,Assess Safety and Tolerability of Administration of Gelesis100,2014-11,COMPLETED,INTERVENTIONAL,['NA']
3157,NCT04275141,In vivo kinetics of lactate,DNA Banking,,2022-01-17,RECRUITING,INTERVENTIONAL,['NA']
3158,NCT04016155,Difference in time in hypoglycaemia,Fear of hypoglycaemia,,2019-07-17,UNKNOWN,INTERVENTIONAL,['NA']
3159,NCT03066284,Impact of IPT on QoL of children and adolescents from their perspective and their parents' perspective,,,2016-03-14,UNKNOWN,OBSERVATIONAL,['NA']
3160,NCT02555332,75g oral glucose tolerance test (OGTT) positive or not,,,2012-12,COMPLETED,OBSERVATIONAL,['NA']
3161,NCT06005051,Changes in postprandial metabolites response as measured by micro-sampling,Changes in personal metabolic states through the day as measured in micro-sampling by Olink proteomics,,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
3162,NCT04370171,Comparison of metabolic control (HbA1C) between diabetic patients followed by teleconsultation and patients with a conventional follow-up during Covid-19 infection.,"Number of conventional hospitalizations, in intensive care and deaths.",,2020-05-04,COMPLETED,OBSERVATIONAL,['NA']
3163,NCT06190717,Primary Effectiveness Endpoint,Freedom from Events through 30 and 90 Days,Intervention to Assist Maturation Rate,2024-02-21,RECRUITING,INTERVENTIONAL,['NA']
3164,NCT01759953,Knowledge on insulin therapy for diabetes,Attitudes regarding diabetes/insulin,Reasons for not finishing the game,2014-07,COMPLETED,INTERVENTIONAL,['NA']
3165,NCT03562078,Hemoglobin,high frequency (HF),,2017-05-22,UNKNOWN,INTERVENTIONAL,['NA']
3166,NCT04090242,Change in Attitude Toward Diabetes - Diabetes Empowerment Scale (DES) From Baseline to End of Study,Patient Satisfaction at Study End,Number of Hours of Patient Engagement With App,2019-09-06,TERMINATED,INTERVENTIONAL,['NA']
3167,NCT05266404,Volume of distribution (apparent) following extravascular administration (based on terminal phase) (Vz/F),Number of subjects with adverse events (AEs),,2022-03-21,COMPLETED,INTERVENTIONAL,['PHASE1']
3168,NCT02691247,Change From Baseline in 4-hour Mixed Meal Tolerance Test (MMTT)-Stimulated C-peptide Area Under the Curve (AUC) at Week 52,Change From Baseline in Mean Daily Dose of Insulin,,2016-02,COMPLETED,INTERVENTIONAL,['PHASE2']
3169,NCT02107469,Improvement of NTSS-6 SCORE in per cent from baseline,Assessment of compliance regarding medication and dietary recommendations (score).,Patient Diary,2014-06,COMPLETED,INTERVENTIONAL,['NA']
3170,NCT02684929,Change in glucose disposal,Change in gene expression in adipose tissue,,2013-04,COMPLETED,INTERVENTIONAL,['NA']
3171,NCT02249910,Area under the digoxin plasma concentration-time curve,Number of hypoglycaemic episodes,,2014-09-18,COMPLETED,INTERVENTIONAL,['PHASE1']
3172,NCT01509742,Area under the Curve (AUC) glucagon,Adverse events,,2001-04,COMPLETED,INTERVENTIONAL,['PHASE1']
3173,NCT04407234,PK: Maximum Observed Drug Concentration (Cmax) of Acetaminophen,PK: Cmax of Acetaminophen at Steady State For T2DM,,2020-09-15,COMPLETED,INTERVENTIONAL,['PHASE1']
3174,NCT04061200,Albuminuria,Inflammatory and endothelial biomarkers,,2019-11-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
3175,NCT03566810,Maximum Observed Plasma Concentration (Cmax) of Metformin,Number of Participants With Clinically Significant Abnormalities in 12-lead Electrocardiogram (ECG) Findings,,2018-10-11,COMPLETED,INTERVENTIONAL,['PHASE1']
3176,NCT00000620,First Occurrence of Major Cardiovascular Event (MCE) in the Lipid Trial.,First Occurrence of MCE or Revascularization or Hospitalization for Congestive Heart Failure (CHF) in Lipid Trial.,,1999-09,COMPLETED,INTERVENTIONAL,['PHASE3']
3177,NCT04696653,Change in self-efficacy as assessed by an adapted version of Compeau & Higgins' task-focused self-efficacy scale,Change in the percent of individuals diagnosed with dyslipidemia who received lifestyle counseling,,2021-02-24,COMPLETED,INTERVENTIONAL,['NA']
3178,NCT04229628,Proportion of community diabetes mellitus patients receiving treatment as Chinese guideline recommended,,,2020-01-01,UNKNOWN,OBSERVATIONAL,['NA']
3179,NCT01293773,Target lesion failure,Effect of dual antiplatelet therapy on outcome,,2010-10,WITHDRAWN,INTERVENTIONAL,['PHASE4']
3180,NCT02848547,Incidence of type 2 diabetes among participants enrolled in the diabetes prevention programme.,Long-term impact of healthy lifestyle through mobile phone based text messaging,,2016-01,COMPLETED,OBSERVATIONAL,['NA']
3181,NCT01536626,HbA1c (glycosylated haemoglobin),Quality of Life (QoL) using the World Health Organization Wellbeing Index (WHO-5),,2006-06-09,COMPLETED,OBSERVATIONAL,['NA']
3182,NCT02383537,miRNA profiling,,,2017-04,UNKNOWN,OBSERVATIONAL,['NA']
3183,NCT04306939,Common disease mechanisms and repurposing of medications.,Patient Reported Global Health Assessment,,2014-11-01,SUSPENDED,OBSERVATIONAL,['NA']
3184,NCT04440319,Statistical analyses for HbA1c and Fasting blood glucose,Statistical analyses for Waist Circumference,,2020-07-01,COMPLETED,INTERVENTIONAL,['NA']
3185,NCT01944618,Incidence rates of spontaneously reported hypoglycaemia in patients with Type 2 diabetes who are treated with Forxiga in routine Australian clinical practice,Subgroup analyses may be conducted for selected safety parameters,,2013-10,TERMINATED,OBSERVATIONAL,['NA']
3186,NCT03102892,Salivary glucose - collection of stimulated saliva in 10 minutes and measured with a colorimetric kit,Capillary glycemia measured by a glucometer,,2017-04-24,TERMINATED,INTERVENTIONAL,['NA']
3187,NCT00134277,Primary patency after 6 months,Proving the superiority or non-superiority of one treatment procedure to another treatment procedure,,2004-09,COMPLETED,INTERVENTIONAL,['NA']
3188,NCT05696366,Change in HbA1c,Change in subject self reported ambulatory insulin dosing,,2023-02,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3189,NCT00127192,Change From Baseline in HbA1c at Week 12,Change From Baseline in Fasting Plasma Glucose at Week 12,,2005-07,COMPLETED,INTERVENTIONAL,['PHASE2']
3190,NCT05368454,Change in HbA1c,Change in diabetes distress,,2022-05-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
3191,NCT04388059,glycemic control in morbid obese diabetic adolescents.,weight loss in morbid obese diabetic adolescents.,,2014-12,COMPLETED,OBSERVATIONAL,['NA']
3192,NCT01756105,Efficacy of metformin in treatment of gestational diabetes based on capillary glycaemia with an objective of less than 6 measures out of range,,,2012-06,TERMINATED,INTERVENTIONAL,['PHASE2']
3193,NCT00674518,Improve physical activity and dietary behaviors among sedentary patients,"Improve biomarkers of obesity including glucose, lipid levels, CRP, leptin and insulin.",,2005-01,COMPLETED,INTERVENTIONAL,['NA']
3194,NCT00063232,Change in the Histological NASH Activity Index at 48 Weeks Compared With Baseline (Number of Participants in Each Change Category),"Change in Insulin Sensitivity (Glucose Tolerance, Homeostatic Model Assessment of Insulin Resistence (HOMA-IR)) From Baseline",,2003-06,COMPLETED,INTERVENTIONAL,['PHASE2']
3195,NCT01405261,Overview of Treatment Emergent Adverse Events (AEs),The time to maximum concentration (tmax) of NNC 0113-0987 in plasma,,2011-08,COMPLETED,INTERVENTIONAL,['PHASE1']
3196,NCT02817217,The area under the plasma concentration-time curve (AUC) of Valsartan,The number of volunteers with adverse events as a measure of safety and tolerability,,2016-03,UNKNOWN,INTERVENTIONAL,['PHASE1']
3197,NCT03758430,Change from Baseline to Week 16 in Hemoglobin A1c (HbA1c),Change from Baseline to Week 16 in Post-Prandial Glucose Concentrations Following Commonly Eaten Meals,,2019-02-06,COMPLETED,OBSERVATIONAL,['NA']
3198,NCT01873859,Change of Baseline Creatinine 48 hr After Recieving Contrast Media in the Presence or Absence of Metformin Use.,,,2013-05,COMPLETED,INTERVENTIONAL,['NA']
3199,NCT05477628,zBMI,Dietary Quality,,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
3200,NCT05514184,Dietary adherence to PLAFOND vs. standard-of-care renal diet assessed by diet diaries,Glycemic status by continuous glucose monitoring (GCM),,2023-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
3201,NCT01004848,Change in Weight From Baseline to 6 Months,Knowledge & Attitudes About Diabetes Risk,,2009-03,COMPLETED,INTERVENTIONAL,['NA']
3202,NCT02626832,AVP response to plasma osmolality as measured by slopes between the two variables,,,2010-02,COMPLETED,INTERVENTIONAL,['NA']
3203,NCT01656915,Cytokines,,,2012-06,COMPLETED,OBSERVATIONAL,['NA']
3204,NCT02987738,Time in Range 70-180%,Reduction of Insulin dose,,2017-02-09,COMPLETED,INTERVENTIONAL,['PHASE1']
3205,NCT03278158,"Safety and tolerability of single ascending oral doses of XEN-D0501, (1, 2, 4 and 8 mg) versus placebo in type 2 diabetic patients in treatment with metformin (Incidence of adverse events in type 2 diabetic patients)",,,2017-09-18,COMPLETED,INTERVENTIONAL,['PHASE2']
3206,NCT00689377,"Prevalence of lower extremities peripheral arterial disease (PAD), in subjects with a moderate CVD risk, with no overt cardiovascular diseases nor diabetes mellitus","Determinants (i.e., subject and physician characteristics) for PAD underdiagnosis in the selected population",,2007-05,COMPLETED,OBSERVATIONAL,['NA']
3207,NCT03965000,Changes in the gene expression,,,2019-01-24,UNKNOWN,OBSERVATIONAL,['NA']
3208,NCT01727349,Measure of risk of developing type 2 diabetes in at-risk families,,,2011-12-14,COMPLETED,INTERVENTIONAL,['NA']
3209,NCT04563598,Total earnings from employment and/or self-employment by study year (all study participants),Ever received Supplemental Security Income (SSI) benefits at age 65 since randomization (all study participants),Ever retired during first 10 years after randomization (all study participants),2016-12-19,COMPLETED,OBSERVATIONAL,['NA']
3210,NCT00797134,Retinal thickness.,Choroidal Thickness,,2008-11,COMPLETED,OBSERVATIONAL,['NA']
3211,NCT02740283,Rate of GDM diagnosed in 18-20 gestational week.,,,2016-05,UNKNOWN,INTERVENTIONAL,['NA']
3212,NCT04521634,Stroke Primary outcome - MRS,,,2020-09-30,COMPLETED,OBSERVATIONAL,['NA']
3213,NCT03023293,postpartum glucose metabolism,,,2017-03-10,UNKNOWN,OBSERVATIONAL,['NA']
3214,NCT04002557,Young people's beliefs about good health as assessed by interview with open questions,,,2019-05-31,COMPLETED,OBSERVATIONAL,['NA']
3215,NCT04253431,Volume (uL) of blood in the capillary tube,The intensity of pain perceived by the patient assessed with the use of the VAS (Visual Analog Scale).,,2013-08,COMPLETED,INTERVENTIONAL,['NA']
3216,NCT06323538,Incidence of diabetes type 2,Intake of medication,Microbiome,2024-04-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
3217,NCT01344928,,,,na,UNKNOWN,INTERVENTIONAL,['NA']
3218,NCT02775266,Serum Resistin Levels and HBAIC Levels,Clinical Attachment levels,,2016-02,COMPLETED,INTERVENTIONAL,['NA']
3219,NCT02470637,Assessment of PD parameter: Area under the glucose infusion rate curve within 24 hours after administration of the investigational medicinal product or until administration of rescue insulin (GIR-AUC0-end),Number of patients with adverse events,,2015-06,COMPLETED,INTERVENTIONAL,['PHASE1']
3220,NCT01538290,,,,2011-11,COMPLETED,OBSERVATIONAL,['NA']
3221,NCT00966368,Maximum observed Insulin Degludec concentration after single dose,Terminal half-life for Insulin Degludec,,2009-08,COMPLETED,INTERVENTIONAL,['PHASE1']
3222,NCT00791479,Change From Baseline in Glycosylated Hemoglobin (HbA1c),Collection and Evaluation of Plasma Levels (Pharmacokinetics [PK]) of LY2189265,,2008-12,COMPLETED,INTERVENTIONAL,['PHASE2']
3223,NCT04112069,Percentage of Time With CGM Glucose Values <54 mg/dl,,Number of Episodes of Diabetic Ketoacidosis (DKA),2018-07-09,COMPLETED,INTERVENTIONAL,['NA']
3224,NCT05349955,Primary Outcome of Phase 2: Composite of 3P MACE and hospitalization for heart failure.,Secondary Outcome of Phase 2: All-cause death,The time rate of glycemic target range,2022-11-21,RECRUITING,INTERVENTIONAL,['NA']
3225,NCT05422352,Nerve Growth Factor,,,2021-01-14,COMPLETED,INTERVENTIONAL,['NA']
3226,NCT01574157,Change in Urinary Transforming Growth Factor Beta 1 (TGF-b1),Change in Estimated Glomerular Filtration (eGFR),,2012-11-05,COMPLETED,INTERVENTIONAL,['NA']
3227,NCT03305367,Gastrointestinal tolerability,,,2017-02-06,COMPLETED,INTERVENTIONAL,['NA']
3228,NCT00810173,,,,2008-01,COMPLETED,INTERVENTIONAL,['NA']
3229,NCT01481116,Change From Baseline in HbA1c at Weeks 78 and 104,"Change From Baseline in Fasting Plasma Glucose at Weeks 26, 52, 78 and 104",,2012-01,TERMINATED,INTERVENTIONAL,['PHASE3']
3230,NCT01521598,Relief of diabetic neuropathy pain,Average daily pain score,,2012-01,COMPLETED,INTERVENTIONAL,['PHASE2']
3231,NCT02177786,Change in eGFR From Baseline at Week 48,Percentage of Participants Achieving at Least a 30% Reduction From Baseline in Albuminuria (As Measured by Urine Albumin to Creatinine Ratio) at Week 48,,2014-06,COMPLETED,INTERVENTIONAL,['PHASE2']
3232,NCT02733211,Percentage of glucose sensor readings within 70 to 180 mg/dl (3.9 to 10 mmol/l) during the night (23:00-7:00 h),Percentage of sensor glucose readings >300 mg/dl,,2019-03,WITHDRAWN,INTERVENTIONAL,['NA']
3233,NCT05015946,Health related quality of life (HRQoL),Aerobic intensity and movement patterns,,2021-09-01,COMPLETED,INTERVENTIONAL,['NA']
3234,NCT02224365,Blood Pressure,Body Composition,,2014-08,COMPLETED,INTERVENTIONAL,['PHASE2']
3235,NCT03906513,changes in the characteristics of the subbasal corneal plexus at confocal,- changes in clinical signs and symptoms of ocular surface damage,,2017-05-03,COMPLETED,INTERVENTIONAL,['NA']
3236,NCT03193944,Achieving 25 (OH) D upper than insufficient serum 25(OH) D level >30 ng/l.,Improved blood pressure,,2017-02-10,COMPLETED,INTERVENTIONAL,['PHASE2']
3237,NCT04573920,Change in proteinuria for FSGS patients at 1.5 mg dose,,,2021-02-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
3238,NCT05055219,Progression of glucose tolerance,,,2015-06,COMPLETED,OBSERVATIONAL,['NA']
3239,NCT05829239,Change in insulin sensitivity,Change in intrahepatic triglyceride content,Change in the transcriptome in adipose tissue,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
3240,NCT03952728,Medicare Part D Prescription Drug Fill Count,Medicare Skilled Nursing Facility payments,Medicare Imaging + Test payments,2016-12-19,COMPLETED,OBSERVATIONAL,['NA']
3241,NCT05368142,Wound healing rate up to 30 days,Pathogenic bacteria positive rate,,2022-05-20,UNKNOWN,INTERVENTIONAL,['PHASE4']
3242,NCT00238836,,,,na,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
3243,NCT05315973,Accuracy: glucose readings in mg/dL,"Acceptability: questionnaire ratings on a scale of 1-5, with 5 being the highest",,2022-06-01,WITHDRAWN,INTERVENTIONAL,['NA']
3244,NCT00957060,Fasting and postprandial glucose,,,2009-07,COMPLETED,INTERVENTIONAL,['PHASE4']
3245,NCT00700362,Plasma glucose level.,laboratories for inflammation and oxidative stress.,,2011-12,WITHDRAWN,OBSERVATIONAL,['NA']
3246,NCT03660293,"The cardiac changes induced by Simvastatin, captopril and L-Carnitine in type 1 diabetic children and adolescents.",Identification of risk factors for developing diabetic cardiac insult.,,2017-04-01,COMPLETED,INTERVENTIONAL,['NA']
3247,NCT00104572,Effect of Testosterone Gel vs. Anastrozole on Bone Mineral Density,Effect of Testosterone Gel vs. Anastrozole on Prostate Volume/Prostate Specific Antigen Levels/Urinary Function,,2004-03,COMPLETED,INTERVENTIONAL,['PHASE2']
3248,NCT04833569,Crestal bone loss,Interleukin-6,,2020-09-20,COMPLETED,INTERVENTIONAL,['PHASE1']
3249,NCT04845412,Rate of Hearing loss,,,2019-06-01,COMPLETED,OBSERVATIONAL,['NA']
3250,NCT05593575,Percentage change from baseline in UACR,The change trend of eGFR,,2023-03-22,RECRUITING,INTERVENTIONAL,['PHASE2']
3251,NCT00781950,"Number of Participants With All-cause Mortality, Cardiovascular Mortality, Stroke, and Myocardial Infarctions","Effects on Exercise Performance, Blood Pressure and Circulating Lipid Levels.",,2008-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
3252,NCT00552370,"To compare the frequency of severe hypoglycemia events for 5 dosing algorithms of Lantus®, each of varying intensity and defined by their end-of-study target for self monitored blood glucose (SMBG).",To compare the number of subjects whose final A1c is <7.0% at the end of the study for the 5 dosing algorithms.,,2003-03,COMPLETED,INTERVENTIONAL,['PHASE4']
3253,NCT03625648,Time to ESRD or death,Rate of change in eGFR per year during the study period,,2019-11-18,RECRUITING,INTERVENTIONAL,['PHASE4']
3254,NCT04834245,the percentage of a reduction rate of the diabetic foot ulcer after intervention,,,2019-01-03,COMPLETED,INTERVENTIONAL,['NA']
3255,NCT01760356,Change in the Percentage of expression of IL-2 in CD4 and CD8 subsets of T lymphocytes.,Post transplant surgical complications,,2011-05-01,TERMINATED,OBSERVATIONAL,['NA']
3256,NCT03023228,Assessment of change in Diabetes knowledge as measured by an 11-item diabetes knowledge survey,Medication adherence (Modified Morisky Medication Adherence Scale 4-item),,2010-05,COMPLETED,INTERVENTIONAL,['NA']
3257,NCT04558775,Proportion of participants who have DFU wound recurrence by 16 weeks after complete wound healing,Clinician assessment of DFU wound recurrence,,2020-06-17,COMPLETED,OBSERVATIONAL,['NA']
3258,NCT03407196,Change in HbA1c(%),Discontinuation rates of dapagliflozin in the first 6 months of treatment,,2017-05-24,COMPLETED,OBSERVATIONAL,['NA']
3259,NCT05158244,"Number of participants with clinically significant, abnormal 12-lead ECG parameters",Plasma Decay Half-Life (t1/2) of PF-07081532,,2021-12-22,COMPLETED,INTERVENTIONAL,['PHASE1']
3260,NCT03313024,T cell population content at the time of preeclampsia diagnosis compared to controls and verified by flow cytometry,,,2017-09-26,RECRUITING,OBSERVATIONAL,['NA']
3261,NCT03426085,Sudomotor Function,Inflammatory Markers Tumor Necrosis factor α (TNF α),,2016-05,UNKNOWN,INTERVENTIONAL,['PHASE2']
3262,NCT04621656,Assessment of percent of total time monitored that blood glucose is in range 70-180 mg/dL,Assessment of change in sleep quality and pattern as measured by heart rate monitor coupled to participant logs.,,2017-11-01,UNKNOWN,OBSERVATIONAL,['NA']
3263,NCT03516994,Proportion of Whites who complete advance care planning,Patient Quality of Life,,2018-08-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
3264,NCT01467063,Insulin Sensitivity,Glucagon-like Peptide 1 (GLP-1),,2011-10,COMPLETED,INTERVENTIONAL,['NA']
3265,NCT06253429,Changes in urinary albumin excretion rate,,,2023-01-01,RECRUITING,INTERVENTIONAL,['PHASE3']
3266,NCT04431947,Duration of Sleep,Impact of Sleep on Glycemic Variability,,2020-03-13,COMPLETED,OBSERVATIONAL,['NA']
3267,NCT01989988,Remission of diabetes,weight loss and improvement in quality of life,,2013-01,UNKNOWN,INTERVENTIONAL,['NA']
3268,NCT01277900,Gastric Bypass in the Treatment of Type 2 Diabetes in Patients with a BMI of 25 to 35 kg/m2,,,2011-01,UNKNOWN,OBSERVATIONAL,['NA']
3269,NCT04334499,Quantitation of mitochondrial DNA in vitreous humor and serum samples,Evaluation of mtDNA quantitation versus ocular comorbidities as described in electronic medical record.,,2020-02-21,WITHDRAWN,OBSERVATIONAL,['NA']
3270,NCT01304615,consumption of Self-made Meals,Percent Body fat,,2011-02,COMPLETED,INTERVENTIONAL,['NA']
3271,NCT04219124,Plasma concentration of 3-hydroxybutyrate,Plasma acylcarnitines measured by targeted metabolomics,,2018-09-20,COMPLETED,INTERVENTIONAL,['PHASE4']
3272,NCT00099944,Change from baseline in HbA1c after 24 weeks,Change from baseline in HbA1c at 24 weeks for patients with high baseline HbA1c vs. low baseline HbA1c,,2004-05,COMPLETED,INTERVENTIONAL,['PHASE3']
3273,NCT04076007,24 hour Ambulatory Blood Pressure monitoring after 2 weeks placebo juice,Insulin sensitivity,,2009-12,COMPLETED,INTERVENTIONAL,['NA']
3274,NCT01973413,Percent Time Near Normoglycemia,Glycemic Events,,2013-07,COMPLETED,INTERVENTIONAL,['NA']
3275,NCT02671331,Excess weight loss (EWL),Protein malnutrition,,2016-01,TERMINATED,OBSERVATIONAL,['NA']
3276,NCT00309712,percent of patients achieving study goal oftriglycerides <200 mg/dL,"Percent of patients achieving all study goals: LDL-C < 100 mg/dL, HDL-C:40 mg/dL, Triglycerides <200 mg/dL and the Percent of patients achieving non-HDL cholesterol <130 mg/dL",,2002-08,COMPLETED,INTERVENTIONAL,['NA']
3277,NCT00470795,GCSI score,SF-12 Health Survey Questionnaire; C-13 acetate breath test,,2009-06,SUSPENDED,INTERVENTIONAL,['PHASE3']
3278,NCT04402710,"Acceptability as assessed by semi-structured exit interviews with participants which will include questions related to their thoughts and feelings about the study and whether they believed the study was acceptable (e.g. content, timing).",Change in Cognitive Emotion Regulation strategies from baseline to 6 weeks (intervention end),,2020-09-01,COMPLETED,INTERVENTIONAL,['NA']
3279,NCT01168765,Biomarkers,Quality adjusted life years,,2010-06,COMPLETED,INTERVENTIONAL,['NA']
3280,NCT01089829,"The primary outcome of the study is to identify the neurovascular risk factors for foot ulceration as renal function declines, and to develop a suitable foot protection programme for CKD patients.",The secondary outcome measure is to identify whether dialysis modality choice influence foot ulcer development and should this be used to inform patient choice of dialysis.,,2010-04,UNKNOWN,OBSERVATIONAL,['NA']
3281,NCT01939470,Change from Baseline in Bone Mineral Density at Year 1 and Year 2,Change from Baseline in C-reactive Protein at Year 1 and Year 2,,2007-10,COMPLETED,OBSERVATIONAL,['NA']
3282,NCT01047735,Feasibility of performing a randomized trial comparing two major types of bariatric surgery versus a lifestyle weight loss intervention (LWLI) induced by diet and increased physical activity in moderately obese patients with T2DM.,Preliminary information regarding the effectiveness of two dominant bariatric surgery procedures versus an intensive lifestyle intervention to induce weight loss with diet and increased physical activity.,,2009-09-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
3283,NCT04648137,area under the concentration time curve in oxytocin level,Level of general physical & mental health using the short form health survey (SF-36),,2021-02-05,COMPLETED,INTERVENTIONAL,['NA']
3284,NCT03630445,"Appetite ratings (Visual Analog Scale, VAS)",Breath hydrogen (fermentability),,2015-06-02,COMPLETED,INTERVENTIONAL,['NA']
3285,NCT03666065,maximum insulin concentration,Time to GIR Max,,2020-01-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
3286,NCT01728883,Test efficacy of the test algorithm improvements,Assess patient satisfaction with the test,,2013-04,COMPLETED,OBSERVATIONAL,['NA']
3287,NCT01236794,Insulin Sensitivity,QOL,,2010-05,COMPLETED,INTERVENTIONAL,['NA']
3288,NCT03463564,Change in glucose variability,Diabetes treatment satisfaction,,2016-01,RECRUITING,INTERVENTIONAL,['PHASE4']
3289,NCT05961878,Handgrip test,Dietary lifestyle,health-related quality of life,2023-07-31,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
3290,NCT02680457,Glycemic Variability: Mean Amplitude of Glucose Excursion (MAGE),Glycemic Variability: Area Under the Curve of Glucose,,2013-11,COMPLETED,INTERVENTIONAL,['PHASE4']
3291,NCT00720317,"We aim to screen African-American diabetic patients with retinopathy to ascertain whether sickle trait is present, and if so whether there is increased severity of diabetic retinopathy in the group with sickle trait.",,,2008-05,COMPLETED,OBSERVATIONAL,['NA']
3292,NCT05458167,Time-in-range of Hedia Diabetes Assistant bolus calculator with physical activity module,Time-below-range of Hedia Diabetes Assistant bolus calculator with physical activity module,Usability of Hedia Diabetes Assistant bolus calculator with physical activity module,2023-04-03,RECRUITING,INTERVENTIONAL,['NA']
3293,NCT00770926,Body weight,diet,,2006-09,COMPLETED,INTERVENTIONAL,['NA']
3294,NCT01769378,Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at 24 Weeks,Change From Baseline in Amylase,,2013-01,COMPLETED,INTERVENTIONAL,['PHASE3']
3295,NCT01946997,Normative retinal thickness data for comparison,,,2006-07,COMPLETED,OBSERVATIONAL,['NA']
3296,NCT01982435,Number of Participants With Severe Non-ocular Adverse Event,Number of Participants With Nonperfusion,,2014-06-24,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3297,NCT04039945,presence of multiple islet autoantibodies,,,2015-02,RECRUITING,OBSERVATIONAL,['NA']
3298,NCT04342624,Mircobiome effects of cinnamon through stool sample collection,,,2021-04-14,COMPLETED,INTERVENTIONAL,['NA']
3299,NCT05072587,Serum 7-Ketocholesterol (7-KC),World Health Organization (WHO-5) Index of Well Being,,2021-07-01,UNKNOWN,INTERVENTIONAL,['NA']
3300,NCT02910076,glucose level,,,2016-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3301,NCT01790945,% change in Diabetic Retinopahy/Diabetic Macular Edema diagnosis with pre-screening system compared to post-screening system,Change in HgA1C from Primary Care Physician referral to post retinal specialist visit,Time from PCP referral for patient to see an ophthalmologist and appointment with retinal specialist,2013-02,UNKNOWN,OBSERVATIONAL,['NA']
3302,NCT01608620,Coronary heart disease (CHD) analysis,,,2012-05,UNKNOWN,OBSERVATIONAL,['NA']
3303,NCT01589718,Tractional Retinal Detachment Repair,Visual Acuity,,2012-04,WITHDRAWN,INTERVENTIONAL,['PHASE3']
3304,NCT04992312,Number of Participants with One or More Treatment-Emergent Adverse Event(s) (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,Pharmacokinetics (PK): AUC of Nasal Glucagon,,2022-03-24,COMPLETED,INTERVENTIONAL,['PHASE1']
3305,NCT01375270,Insulin Secretion,"Plasma Cytokines (IL-6, TNF, IL-1beta, IL-1ra)",,2011-04,COMPLETED,INTERVENTIONAL,['NA']
3306,NCT02956642,Change in HbA1c Levels,Change in fasting lipid panel.,,2018-11-14,COMPLETED,INTERVENTIONAL,['NA']
3307,NCT00770952,Change from Baseline in Homeostatic Model Assessment - Beta cell.,Change from Baseline in Total Cholesterol,,2006-12,COMPLETED,INTERVENTIONAL,['PHASE3']
3308,NCT00013910,,,,na,COMPLETED,INTERVENTIONAL,['PHASE1']
3309,NCT06203106,Biobank,,,2022-11-10,RECRUITING,OBSERVATIONAL,['NA']
3310,NCT01047865,"Retrospective and prospective analysis of pancreas transplant recipients to determine frequency, and time course of autoantibody recurrence of disease. Prospective follow up to: monitor autoantibody levels, monitor and phenotype autoreactive T",Monitor autoantibody levels as well as phenotype autoreactive T cells in peripheral blood.,,2005-05,RECRUITING,OBSERVATIONAL,['NA']
3311,NCT03845114,Decrease in plasma glucose levels during exercise,Amount of carbohydrates needed to treat a hypoglycemic event,,2019-06-30,RECRUITING,INTERVENTIONAL,['NA']
3312,NCT01451398,Change From Baseline to Week 24 in HbA1c,Change in Body Weight From Baseline to Week 24,,2011-11,COMPLETED,INTERVENTIONAL,['PHASE3']
3313,NCT02353923,Change in Electronic-ETDRS (Early Treatment Diabetic Retinopathy Study) visual acuity testing,Change in Blood levels of circulating endothelial progenitor cells (EPC),,2014-09,UNKNOWN,INTERVENTIONAL,['NA']
3314,NCT00467285,Changes in BMD 0.33 Radius,Changes in CTx at Follow up,,2006-10,COMPLETED,OBSERVATIONAL,['NA']
3315,NCT01546844,"Change in Hemoglobin A1c - In control, over time.",Disease Management,,2012-03,UNKNOWN,INTERVENTIONAL,['NA']
3316,NCT01794650,24 hour blood glucose area under the curve,Ketogenesis,,2013-03,COMPLETED,INTERVENTIONAL,['NA']
3317,NCT00498537,reduction in proteinuria,Changes in GFR and incidence of hyperkalemia,,2003-01,COMPLETED,INTERVENTIONAL,['NA']
3318,NCT01147250,"Time to First Occurence of Primary CV Event: CV Death, Non-Fatal MI, Non-Fatal Stroke or Hospitalization for Unstable Angina",Percent Change From Baseline in the Urinary Albumin/Creatinine Ratio (UACR) at Week 108,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE3']
3319,NCT01241253,Net blood glucose changes over time,,,2009-11,COMPLETED,INTERVENTIONAL,['PHASE2']
3320,NCT00958997,PET-determined pancreatic islet beta-cell mass,Insulin secretion response following an acute arginine-stimulus test,,2009-08,COMPLETED,OBSERVATIONAL,['NA']
3321,NCT01967849,Glucose Tolerance,Insulin resistance,Gene Expression,1999-09,RECRUITING,INTERVENTIONAL,['NA']
3322,NCT02962492,Change in Beta-hydroxybutyrate Levels in Blood,Change in Total Insulin Dose,,2016-11-01,COMPLETED,INTERVENTIONAL,['NA']
3323,NCT00613782,Insulin Resistance,Bone microarchitecture,,2009-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
3324,NCT01820377,Waist Circumference,Parent Lifestyle Behaviours Questionnaire,Social Determinants of Health,2010-10,COMPLETED,INTERVENTIONAL,['NA']
3325,NCT04620967,Time in range,Ketoacidosis,,2021-02-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
3326,NCT02858843,Change in units of insulin used over a period of 6 months to 1 year.,Pulmonary function test (PFT) forced expiratory volume at one second (FEV1) measurements,,2016-08-01,TERMINATED,INTERVENTIONAL,['NA']
3327,NCT04642755,"Prevalence of malnutrition, DM and helminth infections in LTBI individuals and their effects on biosignatures",,,2021-04-19,RECRUITING,OBSERVATIONAL,['NA']
3328,NCT04810507,Effect of Improving Glycemic Variability,Average nighttime (18:00~07:59) blood glucose change after 12 weeks compared to baseline,,2018-11-09,COMPLETED,INTERVENTIONAL,['PHASE4']
3329,NCT00499824,Change in HbA1c from baseline in subjects with baseline HbA1c >/=6.5%,"HbA1c, FPG, BP, lipids; hypoglycemic events; health care use; number of GP HbA1c measurements; number of treatment escalations; adverse events; barriers to guideline implementation; determine if study patients are representative of GP's diabetic practice",,2007-01,COMPLETED,INTERVENTIONAL,['NA']
3330,NCT00916513,"Diabetes-related QoL and treatment satisfaction questionnaires: DTSQ, ADDQoL, HFSws and EQ5D","Health-economic variables: Use of healthcare resources Days off work (for either hypoglycaemias, acute or chronic complications)",,2009-05,COMPLETED,OBSERVATIONAL,['NA']
3331,NCT02321904,The utility of corneal confocal microscopy to assess diabetic neuropathy in children.,Corneal nerve branching density (CBD) by CCM,,2008-06,COMPLETED,OBSERVATIONAL,['NA']
3332,NCT03679273,PEDIS score,,,2018-10-01,UNKNOWN,INTERVENTIONAL,['NA']
3333,NCT04038528,glycated hemoglobin (GlyH) level,Hyperglycemic events,,2018-03-01,UNKNOWN,OBSERVATIONAL,['NA']
3334,NCT05679115,Change of long-term blood glucose concentration measured as glycated hemoglobin at 1 year,,,2023-01-10,RECRUITING,INTERVENTIONAL,['NA']
3335,NCT03332472,HbA1c,Standard deviation,,2013-12,COMPLETED,INTERVENTIONAL,['NA']
3336,NCT01965665,Change in Sepsis Rate,,,2013-10,COMPLETED,INTERVENTIONAL,['NA']
3337,NCT05330247,Change in glycated hemoglobin (HbA1c) after 12 months on the CRHP diet compared with the CD diet,Change in hepatic fat content after 12 months on the CRHP diet compared with the CD diet,Change in Health Literacy after follow-up at 24 months on the CRHP diet compared with the CD diet,2022-09-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
3338,NCT04643899,Carbohydrate balance,MES sessions check,,2021-03-29,COMPLETED,INTERVENTIONAL,['NA']
3339,NCT04970810,A1c,Diabetes Self-Efficacy,,2021-07-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
3340,NCT03429088,Feasibility of identifying and recruiting sufficient number of participants into a telephone-based physical activity intervention.,Physical Activity Self-Regulation,,2015-06-01,COMPLETED,INTERVENTIONAL,['NA']
3341,NCT03272074,"Fasting blood glucose, insulin resistance, and insulin sensitivity",Lipid panel,ABCA1 Protein,2015-09-11,COMPLETED,INTERVENTIONAL,['NA']
3342,NCT06117436,Wound Healing size,Treatment-related side effects.,,2023-10-19,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
3343,NCT02445833,Changes in blood pressure levels at 6 and 12 months,Satisfaction with treatment,,2014-09,COMPLETED,INTERVENTIONAL,['NA']
3344,NCT04838405,Incidence of Treatment-Emergent Adverse Events as assessed by self-report,Change in mean insulin levels,,2021-04-01,RECRUITING,INTERVENTIONAL,['PHASE1']
3345,NCT04210089,Complete Healing Rates,Patient Complications,,2020-10-13,RECRUITING,INTERVENTIONAL,['NA']
3346,NCT00515801,plasma glucagon concentrations during insulin induced hypoglycemia with and without glibenclamide pretreatment,cognitive function during insulin induced hypoglycemia with and without glibenclamide pretreatment,,2007-06,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
3347,NCT02029833,Abdominal imaging of visceral and subcutaneous abdominal fat,Lipopolysaccharide (LPS),,2013-03,COMPLETED,INTERVENTIONAL,['NA']
3348,NCT00458029,Fasting insulin (mU/mL),"Decisions, policies, and activities at the school, local, state, or federal level that influence the school environment for nutrition and physical activity",,2006-08,COMPLETED,INTERVENTIONAL,['NA']
3349,NCT03352674,Incidence of immune response,Adverse events,,2016-09,COMPLETED,INTERVENTIONAL,['PHASE2']
3350,NCT00610038,assess continuously the capillary glycaemia for three consecutive days and evaluate the insulin secretion under insulin and sulfonylureas,To assess the kinetics of glibenclamide in children,,2006-07,COMPLETED,INTERVENTIONAL,['PHASE2']
3351,NCT00608101,catecholamines,,,2010-09,WITHDRAWN,INTERVENTIONAL,['NA']
3352,NCT05930561,Annualized number of aflibercept injections in the study eye,Percentage of subjects with a ≥2 and ≥3-Step Diabetic Retinopathy Severity (DRS) improvement from baseline on the ETDRS-DRSS,"Incidence and severity of treatment-emergent adverse events and serious adverse events, including clinically significant changes in safety parameters",2023-08-09,RECRUITING,INTERVENTIONAL,['PHASE2']
3353,NCT05607979,Primary Endpoint,Change in Pain Scores over time (60 days),,2022-12-15,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
3354,NCT05904769,Blood glucose level,,,2023-05-31,RECRUITING,INTERVENTIONAL,['NA']
3355,NCT01811485,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 14 Weeks Between Treatment Groups,"Number of Patients With Adverse Events (Including Hypoglycemia), Serious Adverse Events and Death",,2013-05,COMPLETED,INTERVENTIONAL,['PHASE3']
3356,NCT05301413,DPP Class Attendance,Office/clinic visits,,2022-07-20,RECRUITING,INTERVENTIONAL,['PHASE2']
3357,NCT02261831,rDNA comparison between cases and controls,,,2014-02,COMPLETED,INTERVENTIONAL,['NA']
3358,NCT02432391,Change from baseline glycosylated hemoglobin at 6 months,,,2013-05,COMPLETED,INTERVENTIONAL,['NA']
3359,NCT03839641,Overnight Respiratory Exchange Ratio,Slope of Respiratory Exchange Ratio,,2019-01-14,COMPLETED,INTERVENTIONAL,['NA']
3360,NCT00374361,,,,2003-07,COMPLETED,OBSERVATIONAL,['NA']
3361,NCT02949037,Patient Activation Measure (PAM),Summary of Diabetes Self-Care Activities (SDSCA),,2017-07-01,COMPLETED,INTERVENTIONAL,['NA']
3362,NCT05576025,24-hour area under the curve (AUC) for glucose,,Sedentary time,2022-11-23,RECRUITING,INTERVENTIONAL,['NA']
3363,NCT00313742,The difference between plasma glucose concentrations immediately pre-exercise and the minimum plasma glucose concentrations (nadir) in the period 0-150 min following exercise,Incidence of adverse events during the trial,,2006-04,COMPLETED,INTERVENTIONAL,['PHASE4']
3364,NCT00134147,Glycosylated hemoglobin,Safety based on adverse events reported and laboratory tests,,2005-04,COMPLETED,INTERVENTIONAL,['PHASE3']
3365,NCT01219582,Change in Hemoglobin A1c (HbA1c) levels,Percentage of patients with satisfaction of treatment,,2010-10,COMPLETED,OBSERVATIONAL,['NA']
3366,NCT00516204,Cholesterol levels,,,2007-07,COMPLETED,OBSERVATIONAL,['NA']
3367,NCT01152957,Glycemic Control,Cholesterol,,2010-07,COMPLETED,INTERVENTIONAL,['NA']
3368,NCT03531905,Percent Change From Baseline to Week 12/End of Study (EOS) in Low-density Lipoprotein Cholesterol (LDL-C),Percent Change From Baseline to Week 12 in HbA1c,Number of Participants With Any Treatment-emergent Adverse Event (TEAE),2018-05-09,COMPLETED,INTERVENTIONAL,['PHASE2']
3369,NCT01678469,link between plasma concentrations and dietary intakes of lipophilic micronutrients and risk of developing a Gestational diabetes mellitus,,,2011-11-28,COMPLETED,INTERVENTIONAL,['NA']
3370,NCT03947879,Change in hemoglobin A1c,Change in waist circumference,,2019-05,UNKNOWN,INTERVENTIONAL,['PHASE1']
3371,NCT02122666,Sarcoplasmic Reticulum Composition,Lean and Fat Body Mass,,2014-03,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
3372,NCT01937598,Incremental Area Under the Plasma Glucose (BG) Concentration-time Profile (AUC),AUC Active GIP,,2013-08,COMPLETED,INTERVENTIONAL,['PHASE3']
3373,NCT05366868,Time from study drug initiation (Week 0) to detection of two consecutive HbA1c levels of 7.0% or higher by laboratory tests after Week 16.,Time from Week 0 to detection of two consecutive HbA1c levels of 7.0% or higher by laboratory tests after Week 16 by patient characteristics,,2022-05-26,RECRUITING,INTERVENTIONAL,['PHASE4']
3374,NCT00286598,Change in weight-bearing physical activity (steps/day),Foot-related self-care,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE1']
3375,NCT05933174,Proportion of patients who had a conversation with their primary care provider about SU use and alternatives for their diabetes management,Diabetes Distress Scale,,2023-10-01,RECRUITING,INTERVENTIONAL,['NA']
3376,NCT00725127,"To evaluate the effects of awakening vs. bedtime 100 mg/day ASA administration in subjects with impaired fasting glucose or type 2 diabetes on primary prevention of cardiovascular, cerebrovascular and renal fatal, and non-fatal events.","To evaluate, for all previous objectives, potential differences in the benefits of low-dose ASA for primary prevention between subjects with and without metabolic syndrome.",,2008-10,RECRUITING,INTERVENTIONAL,['PHASE4']
3377,NCT01519466,Time in Target Blood Glucose Range,Change in Diabetes Treatment Satisfaction Questionnaire (DTSQc) Scores From Day 1 to Day 60.,,2012-01,COMPLETED,INTERVENTIONAL,['NA']
3378,NCT00782496,Average Number of Weekly Post-Prandial Blood Glucose Tests Performed by Subjects Using Either Basic or Advanced Meter Features,Percent of Level 2 Participants Who Rated Helpfulness of Advanced Meter Features as 1 or 2,,2008-11,COMPLETED,INTERVENTIONAL,['NA']
3379,NCT03387657,Assessment of PK parameter: AUCtau,Assessment of PK parameter: tmax,,2018-01-03,COMPLETED,INTERVENTIONAL,['PHASE1']
3380,NCT00005474,,,,1996-09,COMPLETED,OBSERVATIONAL,['NA']
3381,NCT04104321,Double Blind Part: To evaluate the effect of Aramchol compared to placebo on composite long-term outcome,,,2019-09-23,SUSPENDED,INTERVENTIONAL,['PHASE3']
3382,NCT01593371,Serum concentrations of leptin,,,2011-07,COMPLETED,INTERVENTIONAL,['NA']
3383,NCT04405895,Change in Clock Genes mRNA,Change in Overall Glycemia,,2020-05-31,UNKNOWN,INTERVENTIONAL,['NA']
3384,NCT02192255,120 day medication adherence,"Composite Control Level of Blood pressure, A1c and/or LDL",,2012-01,COMPLETED,INTERVENTIONAL,['NA']
3385,NCT04385888,Glycemic Variability,Inflammatory cytokines (e.g. IL-6),,2020-10-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
3386,NCT02201199,Area under the serum insulin glargine (INS) concentration curve over the first 12 hours after dosing,"Safety and tolerability (Number of patients with adverse events, clinically significant changes in vital signs, laboratory parameters)",,2014-08,COMPLETED,INTERVENTIONAL,['PHASE1']
3387,NCT06268743,Gut microbiome diversity through 16S ribosomal RNA genes,,,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
3388,NCT05701813,"Efficacy on insulin-resistance, measured with the HOMA-IR index","Improvements in triglycerides, total cholesterol and HDL cholesterol.",Effect on BMI (Body Mass Index),2023-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
3389,NCT04762251,HbA1c,Adherence,,2021-02-17,RECRUITING,INTERVENTIONAL,['NA']
3390,NCT03356340,End-stage Renal Disease,,,1993-04-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
3391,NCT04583800,Heart failure (≥ stade B).,Major cardio-neuro-vascular events,,2021-06-22,RECRUITING,OBSERVATIONAL,['NA']
3392,NCT04668651,Antral content,Perioperative respiratory complications,,2021-01-12,COMPLETED,OBSERVATIONAL,['NA']
3393,NCT04886388,The difference in the mean change from baseline in HbA1c at Day 90 between Intervention and Standard of Care groups,The difference in the mean change from baseline in HbA1c at Day 180 between Intervention and Standard of Care groups,,2021-04-22,COMPLETED,INTERVENTIONAL,['PHASE3']
3394,NCT02334241,Favourable healing outcome (FHO),Number of local cares requiring instrumental debridement (surgical or sharp debridement).,,2014-10,COMPLETED,INTERVENTIONAL,['NA']
3395,NCT01774565,Time spent in target glucose range (5.6-10.0mmol/l),"Pre-breakfast, pre-lunch, pre-dinner, and evening capillary glucose values",Total and endogenous insulin exposure within 1 hour postprandial period (Phase 4 only),2016-08,COMPLETED,INTERVENTIONAL,['NA']
3396,NCT01768559,Change in Body Weight From Baseline to Week 26,"Percentage of Participants Who Reached the Target of HbA1c <7%, Had no Weight Gain at Week 26, and Did Not Experience Documented (Plasma Glucose <60 mg/dL) Symptomatic Hypoglycemia During 26-Week Treatment Period",,2013-01,COMPLETED,INTERVENTIONAL,['PHASE3']
3397,NCT03597412,Change from baseline to week 24 in LDL-C level,Occurrence of MACCE (Major Adverse Cardiovascular and Cerebrovascular Event),,2018-10-17,COMPLETED,INTERVENTIONAL,['PHASE4']
3398,NCT01681147,Barriers Associated With Poorer Adherence to Diabetes Screening Guidelines and Weight Loss Goals,Exercise Frequency in Women With Gestational Diabetes Post-Partum,,2012-06,COMPLETED,INTERVENTIONAL,['NA']
3399,NCT00287807,"Glycemic control; HbA1c at baseline, 3 months, 6 months, 9 months and 1 year (endpoint)",bodyweight; Bodymass index at baseline and endpoint,,2006-02,COMPLETED,INTERVENTIONAL,['PHASE3']
3400,NCT05468632,Change in glycated haemoglobin (HbA1c),Having at least 1 severe hypoglycaemic episode,,2022-07-05,COMPLETED,OBSERVATIONAL,['NA']
3401,NCT00677664,Retinal function,Nerve fiber layer thickness,,2006-07,UNKNOWN,INTERVENTIONAL,['PHASE4']
3402,NCT00765063,Number of Trivial Hemorrhages,36-Item Short-Form Health Survey (SF-36) Score,,2008-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
3403,NCT02105792,Response to diabetes therapy,Collection of samples for analysis of potential biomarkers,,2013-03,COMPLETED,OBSERVATIONAL,['NA']
3404,NCT02117063,Change in mean score for the PACES scale after 6-months of intervention,Changes in anthropometric and biochemical indices of metabolism and possible PCOS,,2012-04,RECRUITING,INTERVENTIONAL,['NA']
3405,NCT02572856,Feasibility of Instrument: Count of CGM Instrument Issues,,,2018-08-01,COMPLETED,INTERVENTIONAL,['NA']
3406,NCT01932476,Change in Markers of Autoimmunity,Gastrointestinal Symptoms,,2013-08,COMPLETED,INTERVENTIONAL,['NA']
3407,NCT06071975,"Change in pain level on the Numeric Rating Scale (NRS, 0-10) between baseline and at treatment week 14 (end of first treatment phase) in comparison of study arm 1 (verum) and study arm 2 (placebo)","Number of patients with rescue medication over the course of the clinical trial and within periods: until treatment week ≤5, ≤11, ≤14, ≤18, ≤22, ≤26, ≤30, ≤34, ≤43, ≤47, ≤52",Number and severity of adverse events (AE),2023-11-02,RECRUITING,INTERVENTIONAL,['PHASE3']
3408,NCT05524792,Other Diabetes mellitus,Taste disorders,,2018-01-01,COMPLETED,OBSERVATIONAL,['NA']
3409,NCT02528396,AUClispro 0-30min (timepoint 0 = time of dosing),Local tolerability injection site reactions,,2015-08,COMPLETED,INTERVENTIONAL,['PHASE1']
3410,NCT04238949,Hemoglobin A1c,Healthcare costs,,2019-12-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
3411,NCT03021811,Rate of complete wound closure,Impact of treatment on Health-related Quality of Life (CWIS questionnaire),,2015-10,COMPLETED,INTERVENTIONAL,['NA']
3412,NCT02509858,area under the glucose uptake versus time curve-AUC,Number of participants with adverse events,,2009-02,COMPLETED,INTERVENTIONAL,['NA']
3413,NCT03426956,Difference in GLP-1 secretion (evaluated by iAUC).,Difference in bile acid responses (evaluated by iAUC) between the two test days.,,2018-02-08,UNKNOWN,INTERVENTIONAL,['NA']
3414,NCT05622981,Change from baseline body mass index (BMI) percentile at 24 weeks,Adherence to follow-up scheduling,,2023-03-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
3415,NCT01529541,The Change in HbA1c from baseline to week24.,change from baseline to week 24 in HOMA-IR,,2011-05,COMPLETED,INTERVENTIONAL,['PHASE3']
3416,NCT04060693,Measurement accuracy of IMD,Safety evaluation: paucity of adverse events,,2019-12-10,WITHDRAWN,INTERVENTIONAL,['NA']
3417,NCT03027960,urine sodium concentrations via ion selective electrodes,blood volume,,2017-06-27,COMPLETED,INTERVENTIONAL,['PHASE1']
3418,NCT01582451,Change From Baseline to 26-week Endpoint in Hemoglobin A1c (HbA1c),Number of Participants With Change in Anti-LY2605541 Antibodies,,2012-05,COMPLETED,INTERVENTIONAL,['PHASE3']
3419,NCT01350284,The effect of 3grams cinnamon on gastric emptying half time,Food intake,,2009-06,COMPLETED,INTERVENTIONAL,['NA']
3420,NCT03358745,Area under the curve of postprandial glycemia,"Area under the curve (AUC) of postprandial Glucagon-like peptide (GLP-1), Peptide YY (PYY) and glucose-dependent insulinotropic polypeptide (GIP)",,2016-06-01,COMPLETED,INTERVENTIONAL,['NA']
3421,NCT01451372,Daily Usage of Blood Glucose Test (BG Testing),Frequency of Sensor Usage Per Month,,2011-06,COMPLETED,OBSERVATIONAL,['NA']
3422,NCT05039957,Complication rate,,,2021-09-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
3423,NCT04758884,"To compare changes in HbA1c at 6 months in a group of patients with T1D in the reference area of the ""Hospital Comarcal de l´Alt Penedès"" followed by telemedicine versus to the usual management in consultation.",Differences in terms of number of unplanned contacts with the specialist in a group of patients with T1D followed by telemedicine versus to the usual management in consultation.,,2021-01-01,UNKNOWN,INTERVENTIONAL,['NA']
3424,NCT05147116,Mean AUC (Area Under the Curve) Plasma [Glucose],Sleep efficiency (time in bed + time asleep),,2022-02-17,COMPLETED,INTERVENTIONAL,['NA']
3425,NCT03267758,change in baseline flow mediated dilation (FMD) at 6 weeks,,,2018-05-15,RECRUITING,INTERVENTIONAL,['NA']
3426,NCT02686177,Difference of ANGPTL4 concentration at 4 weeks of treatment from baseline in Liraglutide and control group,Difference of Circulating soluble adhesion molecules as endothelial activation markers: ICAM-1 and VCAM-1 concentration at 4 weeks of treatment from baseline (Liraglutide versus control group),,2016-05-18,COMPLETED,INTERVENTIONAL,['PHASE4']
3427,NCT00558571,"Clinical Relevant Abnormalities for Vital Signs, Blood Chemistry, Haematology, Urinanalysis and ECG",HbA1c,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE1']
3428,NCT01999452,Change of HbA1c,,,2015-10,WITHDRAWN,INTERVENTIONAL,['NA']
3429,NCT03115099,Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,Pharmacokinetics: Maximum Concentration (Cmax) of LY3325656,,2017-05-31,COMPLETED,INTERVENTIONAL,['PHASE1']
3430,NCT00690326,incremental physical activity,glycosylated hemoglobin,,2006-05,COMPLETED,INTERVENTIONAL,['NA']
3431,NCT05324189,Specificity of identification of referable and non-referable Diabetic,The accuracy of identification of referable and non-referable DR for early diagnosis of DR,,2022-04-18,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
3432,NCT00230464,Rate of appearance of endogenous glucose,Rate of appearance of oral glucose,,2004-11,COMPLETED,INTERVENTIONAL,['PHASE3']
3433,NCT01441518,Perinatal mortality and morbidity rates,Costs,,2010-05,COMPLETED,INTERVENTIONAL,['PHASE2']
3434,NCT01487629,Central subfield macular thickness (CSFT) change,Best-corrected visual acuity change,,2010-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
3435,NCT02601729,Evolution over time of HbA1c,Quality of life measured by the Diabetes Quality of Life for Youth for children,,2014-09,COMPLETED,OBSERVATIONAL,['NA']
3436,NCT01653119,A composite of cardiovascular mortality or a clinical diagnosis of a non-fatal ACS,A composite of cardiovascular mortality or a clinical diagnosis of a non-fatal ACS,The proportion of any AST or ALT >3 x ULN or CK >5 x ULN,2012-04,UNKNOWN,INTERVENTIONAL,['NA']
3437,NCT00105352,"Co-efficient of reproducibility of the MMTT, and the GST, provided from the duplicate tests within the same individuals",,,2004-11,COMPLETED,INTERVENTIONAL,['NA']
3438,NCT00018486,,,,1999-04,COMPLETED,OBSERVATIONAL,['NA']
3439,NCT00032734,serum sodium concentration,safety assessment,,2001-06,COMPLETED,INTERVENTIONAL,['PHASE2']
3440,NCT01798030,Vitamin D,,PTH,2009-11,UNKNOWN,OBSERVATIONAL,['NA']
3441,NCT01011387,Mean Change in Wound Area.,,,2010-01,COMPLETED,INTERVENTIONAL,['NA']
3442,NCT01307995,,,,2007-04,COMPLETED,OBSERVATIONAL,['NA']
3443,NCT03064906,Percentage of time in hyperglycemic range(defined as ≥ 250 mg/dL),Effect of changing setpoints,,2017-03-18,COMPLETED,INTERVENTIONAL,['NA']
3444,NCT05829642,Number of Participants with hospital readmission,Number of hypertension patients (all risk levels) with drug prescription appropriate,,2020-11-24,COMPLETED,OBSERVATIONAL,['NA']
3445,NCT02070510,Area under the lisinopril concentration-time curve,Maximum observed lisinopril plasma concentration,,2014-02-27,COMPLETED,INTERVENTIONAL,['PHASE1']
3446,NCT01644500,Change From Baseline in HbA1c at 26 Weeks,Visual Analog Scale (VAS) Score at 26 Weeks,,2012-07,COMPLETED,INTERVENTIONAL,['PHASE3']
3447,NCT03180710,Cmax_total,Number of hypoglycaemic events in each treatment arm,,2017-06-06,COMPLETED,INTERVENTIONAL,['PHASE1']
3448,NCT03794752,Response Speed to Visual-motor Skills to Identify Shapes and Objects With the Head-mounted Electronic Visual Enhancement Device,,,2015-02,TERMINATED,INTERVENTIONAL,['NA']
3449,NCT05769712,Elasticity of the supraspinatus tendon,Thickness of the supraspinatus tendon,Blood flow within the supraspinatus tendon,2021-03-01,RECRUITING,OBSERVATIONAL,['NA']
3450,NCT04008147,insulin,alpha glycoprotein,,2019-07-03,RECRUITING,INTERVENTIONAL,['NA']
3451,NCT01930097,The positive incremental area under the curve of postprandial glucose excursions,Incremental area under the curve of the 4-hr postprandial glucose excursions but the reference glucose is set to 5.0 mmol/L if premeal glucose is less than 5.0 mmol/L.,,2013-08,COMPLETED,INTERVENTIONAL,['PHASE2']
3452,NCT04421053,The incidence rate of infant outcomes,the value of gestational weight gain during third trimester,,2020-03-24,UNKNOWN,OBSERVATIONAL,['NA']
3453,NCT03498001,Change from Baseline Concentration of intramyocardial triglycerides at 6 months,,,2018-04-16,COMPLETED,INTERVENTIONAL,['NA']
3454,NCT03278236,Change in glycaemia,Change in food intake,,2017-09-21,TERMINATED,INTERVENTIONAL,['NA']
3455,NCT05733962,Percentage of time spent in 70 - 180 mg/dL glycemic range,Scoring of Diabetes Treatment Satisfaction (DTSQs) Questionnaire,,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
3456,NCT02106104,"Changes from baseline following 8-week treatment with linagliptin vs glimepiride on fasting and postprandial renal hemodynamics, measured as GFR / ERPF (determined by inulin/para-aminohippuric-acid clearance)",Blood Pressure and Heart Rate,DPP4- and ACE activity,2014-03,COMPLETED,INTERVENTIONAL,['PHASE4']
3457,NCT00550095,Change in Albumin Creatinine Ratio (ACR) from baseline over a period of 24 weeks.,Percent reduction of (BP) at 24 weeks compared to baseline level. Percent of patients whose BP is controlled at 24 weeks (< 130/80),,2007-06,COMPLETED,INTERVENTIONAL,['PHASE4']
3458,NCT01940003,Glycemic control,Birth injury,,2016-09,COMPLETED,INTERVENTIONAL,['NA']
3459,NCT01073020,Fasting Plasma Glucose <126 mg/dL and HbA1c < 6.5% at Three Years of Follow-up.,Cardiovascular Risk,,2010-01,COMPLETED,INTERVENTIONAL,['NA']
3460,NCT05822232,Efficacy endpoint,,,2022-08-17,RECRUITING,INTERVENTIONAL,['NA']
3461,NCT01531855,24 hour blood glucose area under the curve,Ketogenesis,,2012-02,COMPLETED,INTERVENTIONAL,['NA']
3462,NCT03545841,Maximal aerobic capacity,Vascular stiffness,,2015-03-09,COMPLETED,INTERVENTIONAL,['NA']
3463,NCT03951805,Percentage of Time in Target Range (TIR) 3.9-10.0 Millimoles Per Liter (mmol/L) (70-180 Milligrams Per Deciliter (mg/dL) Measured Using CGM (Continuous Glucose Monitoring),"Number of Hypoglycaemic Alert Episodes (Level 1) (Greater Than or Equal to 3.0 and Below 3.9 mmol/L (Greater Than or Equal to 54 and Below 70 mg/dL), Confirmed by Blood Glucose (BG) Meter)",,2019-05-09,COMPLETED,INTERVENTIONAL,['PHASE2']
3464,NCT00217061,Adherence to the decision to use or not to use statins,Trust in clinician,,2005-04,COMPLETED,INTERVENTIONAL,['PHASE3']
3465,NCT05322213,Change in Vascular Endothelial Function,,,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
3466,NCT02501876,The rate of conversion to Alzheimer's disease (AD),The presence of common alleles for Alzheimer's disease (AD) and Diabetes mellitus type 2,,2015-05,COMPLETED,OBSERVATIONAL,['NA']
3467,NCT01085292,Safety and tolerability of multiple intravenous doses of NOX-E36 in healthy subjects and patients with type II diabetes mellitus,Multiple dose pharmacokinetics and pharmacodynamics of NOX-E36 in healthy subjects and patients with type II diabetes mellitus,,2010-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3468,NCT03861039,Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,Number of Participants With Anti-Tirzepatide Antibodies,,2019-03-30,COMPLETED,INTERVENTIONAL,['PHASE3']
3469,NCT00234871,Changes in urinary albumin:creatinine ratio,"Changes in blood pressure (BP), BP control, ABPM, proteinuria, GFR lipid parameters, glycemic control, quality of life, CRP, oxidative stress markers, clinical safety labs and adverse events.",,2004-01,COMPLETED,INTERVENTIONAL,['PHASE4']
3470,NCT00566865,pharmacodynamics of mitiglinide,safety and tolerance of mitiglinide when co-administered with 600 mg gemfibrozil,,2007-11,COMPLETED,INTERVENTIONAL,['PHASE1']
3471,NCT00261417,"Dose-response relationship of tesaglitazar in subjects with type 2 diabetes by the assessment of the effects of each of four doses of tesaglitazar (0.25, 0.5, 0.75 and 1 mg) to placebo with respect to fasting plasma glucose",Assess the safety and tolerability of tesaglitazar compared to placebo,,2004-05,TERMINATED,INTERVENTIONAL,['PHASE2']
3472,NCT00368095,,,,2006-08,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
3473,NCT00606138,Number of Participants With Occurrence of Adverse Events,"Occurrence Rate of Proliferative Diabetic Complications Including Vitreous Hemorrhage, Iris Neovascularization, and Tractional Retinal Detachment",,2008-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3474,NCT04482283,Proportion of patients diagnosed with symptomatic HF,,,2020-07-20,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
3475,NCT01329016,Study drug dosage in pregnancy,Determine GLY and MET PK parameters,,2011-07,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3476,NCT02657876,Number of participants with adverse events through study completion,,,2018-01-31,COMPLETED,INTERVENTIONAL,['PHASE1']
3477,NCT05535985,Incidence of postoperative delirium,Expression of peroxisome proliferators-activated receptor-γcoactivator-1α (PGC-1α),Mini-mental state examination (MMSE) score,2023-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
3478,NCT06256614,"The Blood glucose of Time in Range (TIR, %) of type 1 diabetes mellitus.","The incidence of treatment-related adverse events (AE) assessed by CTCAE, Version 5.0",,2024-03-01,RECRUITING,OBSERVATIONAL,['NA']
3479,NCT02610036,presence of microangiopathy,,,2012-03,COMPLETED,OBSERVATIONAL,['NA']
3480,NCT00558909,Global tolerability - number of patients by category,PTF (peak trough fluctuation).,,2007-06,COMPLETED,INTERVENTIONAL,['PHASE1']
3481,NCT02668250,Incidence of a composite of mortality or major postoperative morbidity.,,,2017-02-03,COMPLETED,INTERVENTIONAL,['NA']
3482,NCT02751398,subclinical diastolic dysfunction assessed by supine bicycle diastolic stress echocardiography,the impact of dapagliflozin on resting diastolic function,,2016-08-18,COMPLETED,INTERVENTIONAL,['PHASE4']
3483,NCT03255902,Effect of Intervention on Evening Glucose Control.,Difference Between Child's Pre-intervention and 3 Month Hemoglobin A1c Value,,2016-05-24,COMPLETED,INTERVENTIONAL,['NA']
3484,NCT02672059,Diagnosis of neuropathy,Synovium tissue collection for RNA,,2011-02,UNKNOWN,OBSERVATIONAL,['NA']
3485,NCT01945840,Weight loss,Glycaemia,,2013-10,RECRUITING,INTERVENTIONAL,['NA']
3486,NCT01069549,,,,2009-11,COMPLETED,OBSERVATIONAL,['NA']
3487,NCT00993603,To estimate the correlation between weight loss over 8 months achieved through a programme of intensive lifestyle management and changes in GLP-1 production over the same period in obese without presence of diabetes but with family history of diabetes.,"The secondary aim is to examine the changes in weight, cardiovascular risk factors and hormonal regulators of food intake and blood glucose metabolism.",,2010-09,COMPLETED,INTERVENTIONAL,['NA']
3488,NCT00861341,Percent Platelet Aggregation Induced by Collagen,,,2008-12,COMPLETED,INTERVENTIONAL,['PHASE2']
3489,NCT02316522,DNA methylation,Micro-RNAs,,2014-10-23,COMPLETED,OBSERVATIONAL,['NA']
3490,NCT03906383,Diameter change of retinal vessels,,,2017-11-21,COMPLETED,INTERVENTIONAL,['NA']
3491,NCT03239366,Change in HbA1c levels from baseline,Evaluation of the safety profile of 2 capsules of Bio-K+50B® (dosage of 100 billions bacterias),,2017-09-06,UNKNOWN,INTERVENTIONAL,['PHASE2']
3492,NCT00938405,To demonstrate a 10% LDL reduction in type 1 diabetic subjects with initial LDL > 100 after twelve weeks in the colesevelam group.,"In addition change in insulin dose at one, two and three months from baseline will be evaluated.",,2009-07,COMPLETED,INTERVENTIONAL,['NA']
3493,NCT00704314,insulin sensitivity,ectopic lipid deposition in liver and muscle,,2002-10,COMPLETED,INTERVENTIONAL,['NA']
3494,NCT04314427,Glucose control,Changes in glycemic control,,2012-09,COMPLETED,OBSERVATIONAL,['NA']
3495,NCT02459496,change in blood glucose profile in the mixed-meal tolerance test (MMTT) - combined parameter,"change in parameters of autonomic neuropathy - measures of cardio-autonomic neuropathy (SANN, MSDD)",,2013-09,UNKNOWN,INTERVENTIONAL,['NA']
3496,NCT01800734,1. Composite plasma glucose and hormone responses to a mixed meal 2. Glucose control coefficients,Composite plasma free fatty and amino acid responses to a mixed meal,,2012-10,UNKNOWN,INTERVENTIONAL,['PHASE4']
3497,NCT04099550,Weight (Kg) change,lipid profile,,2019-12-06,UNKNOWN,INTERVENTIONAL,['NA']
3498,NCT06222476,renal magnetic resonance imaging(MRI),HOMA2-IS,,2024-02-20,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
3499,NCT02783066,Gait Speed Difference Between Pulseflow Offflaoding and Standard Offloading,Peak Forefoot Pressure,,2016-01,COMPLETED,INTERVENTIONAL,['PHASE2']
3500,NCT01230749,Change From Baseline (Day -1) to Day 28 in Twenty-Four-Hour Weighted Average Glucose (24-Hour WAG),Change From Baseline to Day 29 in Body Weight,,2010-12,COMPLETED,INTERVENTIONAL,['PHASE2']
3501,NCT02352480,Time to heal,W-QOL (Quality of life with chronic wounds) score,,2015-01,UNKNOWN,INTERVENTIONAL,['NA']
3502,NCT05234944,Acceptability,Glycemic Outcome - Time in Range,,2022-12-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
3503,NCT02510612,sedation level,noradrenaline measured by Biochemical test,,2015-08,UNKNOWN,INTERVENTIONAL,['PHASE4']
3504,NCT02312375,Insulinogenic index,"Urinary albumin creatinine ratio, urinary protein creatinine ratio",,2015-03,COMPLETED,INTERVENTIONAL,['NA']
3505,NCT03557151,Glycosylated Hemoglobin (HbA1c),Diabetes Self Management Profile - Parent Proxy Report,Type 1 Diabetes and Life (T1DAL) Scale - Caregiver Report,2018-07-13,COMPLETED,INTERVENTIONAL,['NA']
3506,NCT06052371,Performance evaluation: blood glucose monitoring system accuracy: BGMS vs reference instrument,,,2023-10-16,TERMINATED,OBSERVATIONAL,['NA']
3507,NCT01787916,Assessment of Changes in Glycemic Control by HbA1c.,Assessment of Changes on Adipose Tissue,,2013-04,COMPLETED,INTERVENTIONAL,['PHASE4']
3508,NCT01152242,"Part II: The within-subject coefficient of variation in time-action profile of glargine for AUC-GIR (AUC of glucose infusion rate), GIRmax (maximum level of glucose infusion rate), over the duration of action of glargine",Part II: The within-subject standard deviation in duration of action of glargine (the difference between onset of action and end of action),,2010-08,COMPLETED,INTERVENTIONAL,['PHASE1']
3509,NCT00044694,Change in HbA1c (glycosylated hemoglobin) from Baseline to Day 28,Change in serum fructosamine from Baseline (Day 1) to Day 14 and to Day 28,,2002-08,COMPLETED,INTERVENTIONAL,['PHASE2']
3510,NCT02077686,Change from baseline in diabetes-specific empowerment on the adapted Diabetes Empowerment Scale at the 2-week and 6-month follow-up,Change from baseline in depressive symptoms on the CES-D at the 2-week and 6-month follow-up,,2014-02,COMPLETED,INTERVENTIONAL,['NA']
3511,NCT01371747,Least Squares Mean Change in Serum Potassium From Baseline to Week 4 or Time of First Titration for Each Individual Starting Dose Group,Proportions of Participants Achieving Serum Potassium Levels Within 3.8 to 5.0 mEq/L at Week 52 for Each Individual Starting Dose Group,,2011-06,COMPLETED,INTERVENTIONAL,['PHASE2']
3512,NCT02110979,Knowledge score,Decisional conflict,,2014-04,COMPLETED,INTERVENTIONAL,['NA']
3513,NCT02671864,Prevalence of Severe DR at V1 (inclusion),Concentrations of blood circulating EPCs and PBMCs,,2016-04-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
3514,NCT00000462,,,,1987-04,COMPLETED,INTERVENTIONAL,['PHASE3']
3515,NCT04239521,Study 4: The incidence of a composite of viral infections in adult patients with Alopecia Areata,Study 4: The incidence of herpes simplex infection in adult patients with Alopecia Areata,,2020-10-01,COMPLETED,OBSERVATIONAL,['NA']
3516,NCT05044442,Severe hypoglycaemia (using continuous glucose monitoring),area under the curve of episodes of hypoglycaemia and hyperglycaemia,,2018-10-01,COMPLETED,INTERVENTIONAL,['NA']
3517,NCT06064786,GCF levels of fetuin A and hsCRP evaluation in all groups,,,2023-08-01,COMPLETED,OBSERVATIONAL,['NA']
3518,NCT01239550,Low dose basal insulin detemir will potentiate weight loss in obese patients with type 2 diabetes mellitus undergoing a hypocaloric diet intervention by improving dopamine signaling,Neuropsychiatric functions,,2011-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
3519,NCT04790175,Safety Information (Non-serious Adverse Events),,,2021-03-29,RECRUITING,OBSERVATIONAL,['NA']
3520,NCT05990517,C-peptide change,Quality of life score,,2023-02-22,RECRUITING,INTERVENTIONAL,['PHASE2']
3521,NCT04774822,To determine the sensitivity and specificity of RETINA-AI Galaxy to detect vision-threatening diabetic retinopathy in the primary care setting,,,2021-03-25,COMPLETED,OBSERVATIONAL,['NA']
3522,NCT05922033,Fasting glycemic control,Diabetes Distress Screening (DDS) Scale,,2023-10-19,RECRUITING,INTERVENTIONAL,['PHASE4']
3523,NCT01556152,Mean 24-hour average pain intensity (API) score,"Pharmacokinetics: Cmax, Tmax, AUC 0-tau, AUC0-24",,na,WITHDRAWN,INTERVENTIONAL,['PHASE2']
3524,NCT00313547,Heart rate variability,Impact of selected pharmacogenetic polymorphisms,,2006-04,TERMINATED,INTERVENTIONAL,['PHASE4']
3525,NCT04766450,Concentration of Glutathione peroxidase,,Toronto clinical scoring system,2021-12-01,RECRUITING,INTERVENTIONAL,['PHASE4']
3526,NCT01939834,Time in range overnight,Time within target range,,2013-12,TERMINATED,INTERVENTIONAL,['NA']
3527,NCT04414579,Time to stabilization of rising blood sugar by CGM after correction bolus,Treatment related impact measures between arms,,2019-03-27,UNKNOWN,INTERVENTIONAL,['PHASE4']
3528,NCT01499472,healed ulcer,,,2012-01,UNKNOWN,INTERVENTIONAL,['NA']
3529,NCT04524949,Change in stimulated C-peptide response during the first two hours of a mixed meal tolerance test (MMTT) from baseline to 48 weeks between IMCY-0098 and placebo groups,To evaluate the safety features of IMCY-0098 on lymphocytes ratio,,2020-12-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
3530,NCT05509881,Percent (%) of time in target glucose range (70-180 mg/dl),Hypoglycemia Fear,Participant feedback on continuous glucose monitoring training sessions,2023-12-12,RECRUITING,INTERVENTIONAL,['NA']
3531,NCT04272099,"Glycemic control, health related quality of life and clinical phenotypes of PG1","Psychometric evaluation of the health literacy, health-related quality of life, self-esteem and self-efficacy questionnaires in PG1",,2017-06-20,RECRUITING,OBSERVATIONAL,['NA']
3532,NCT04634890,Total cholesterol,Subcutaneous adipose tissue transcriptome,,2016-08-11,UNKNOWN,INTERVENTIONAL,['NA']
3533,NCT03841591,Rate of maternal weight gain per week,Incidence of macrosomia,,2018-02-01,COMPLETED,INTERVENTIONAL,['PHASE3']
3534,NCT05123157,Mortality among patients with diabetic foot,,,2020-09-01,COMPLETED,OBSERVATIONAL,['NA']
3535,NCT02688075,Change From Baseline in Mean Glycosylated Hemoglobin (HbA1c) at 6 and 12 Months,Number of Participants with Adverse Events (AEs) and Serious AEs,,2015-11-13,COMPLETED,OBSERVATIONAL,['NA']
3536,NCT01728714,"Number of people with type 2 diabetes treated with oral antidiabetics assessed as compliant with treatment after 1 year educational programme on diabetes, compared with normal clinical practice.","Measure level of satisfaction of the patient with treatment and medical care following 1 year educational programme on diabetes, compared with normal clinical practice.",,2014-05-19,COMPLETED,OBSERVATIONAL,['NA']
3537,NCT01173991,Glycated haemoglobin (HbA1c),Hypoglycemia (capillary glucose<50 mg/dl),,2008-10,COMPLETED,INTERVENTIONAL,['PHASE3']
3538,NCT00652288,Maximum Glucose Infusion Rate (GIR) to maintain euglycemia,Time to Maximum Glucose Infusion Rate,,2007-04,COMPLETED,INTERVENTIONAL,['PHASE1']
3539,NCT02798393,Decrease in Pain (MPI Pain Scale),Improvement in Sensation,Safety Assessment (incidence of treatment related AEs at each follow up visit),2016-06,TERMINATED,INTERVENTIONAL,['NA']
3540,NCT02538055,Quality of Life (SF12),Diet - eating unhealthy foods because of pain in the past 7 days,,2011-09,COMPLETED,INTERVENTIONAL,['NA']
3541,NCT00678704,The Erectile Function (EF) domain score of IIEF calculated as the sum of scores from Questions 1 to 5 and 15,Safety data,,2004-01,COMPLETED,INTERVENTIONAL,['PHASE3']
3542,NCT04031300,Safety evaluation: paucity of adverse events,Device usability,,2019-06-01,WITHDRAWN,INTERVENTIONAL,['NA']
3543,NCT01411865,Death or non-fatal myocardial infarction,Prescription for nitrate,,2011-08,COMPLETED,INTERVENTIONAL,['NA']
3544,NCT02891382,Change in Glycated Hemoglobin,Change in Weight,,2016-07,COMPLETED,INTERVENTIONAL,['NA']
3545,NCT04094064,Mean Absolute Relative Difference (MARD) Between Continuous Glucose Monitor (CGM) Value and Venous Blood Glucose (vBGM),,,2020-02-19,COMPLETED,INTERVENTIONAL,['NA']
3546,NCT02931656,Change from Glycemic level,Change from Fetal heart rate,,2016-03,COMPLETED,INTERVENTIONAL,['NA']
3547,NCT01265017,stimulated C-peptide response,Insulin requirement,,2012-07,WITHDRAWN,INTERVENTIONAL,['PHASE1']
3548,NCT00885352,Change From Baseline in Hemoglobin A1c (A1C) at Week 26,Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26,,2009-04-15,COMPLETED,INTERVENTIONAL,['PHASE3']
3549,NCT05541458,Body Weight - 12 month,,,2022-09-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
3550,NCT02193984,Changes in HbA1c levels.,Changes in distress.,,2009-02,UNKNOWN,INTERVENTIONAL,['NA']
3551,NCT02607865,Change in HbA1c: Week 26,Change in CoEQ: Scores From the 4 Domains and the 19 Items,,2016-02-15,COMPLETED,INTERVENTIONAL,['PHASE3']
3552,NCT00961480,The area under the plasma concentration-time curve (AUC) after administration of sitagliptin/metformin (50/500; 50/850; 50/1000 mg/mg) FDC tablet and co-administration of corresponding doses of sitagliptin and metformin as individual tablets.,"Peak plasma concentration (Cmax) for metformin after administration of sitagliptin/metformin (50/500; 50/850, 50/1000 mg/mg) FDC tablet and co-administration of corresponding doses of sitagliptin and metformin as individual tablets.",,2007-10,COMPLETED,INTERVENTIONAL,['PHASE1']
3553,NCT00145379,HbA1c after the two intervention periods,"Insulin need, hypoglycaemia frequence, body weight, lipid profile, blood pressure after the two intervention periods",,2003-03,COMPLETED,INTERVENTIONAL,['PHASE4']
3554,NCT06043245,Type 2 Diabetes (T2D) remission.,Epicardial fat,,2023-06-21,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
3555,NCT04594603,To record the vascular changes that may be present in the macular after uncomplicated phacoemulsification surgery by using OCTA,,,2021-04-13,RECRUITING,OBSERVATIONAL,['NA']
3556,NCT00784511,2-hr post load glucose,,,2008-07,COMPLETED,INTERVENTIONAL,['PHASE2']
3557,NCT05219942,Total crystalline insulin consumption,,,2020-12-01,RECRUITING,INTERVENTIONAL,['NA']
3558,NCT02451137,Percentage of Participants With Individualized Glycated Hemoglobin Target Attainment Per Healthcare Effectiveness Data and Information Set (HEDIS) Criteria Without Documented Symptomatic(Blood Glucose <=70 mg/dL [<=3.9 mmol/L]) and/or Severe Hypoglycemia,"Percentage of Participants With at Least One Treatment-Emergent Hypoglycemia Event (Any Time of the Day, Nocturnal) Per Type of Hypoglycaemia During the Month 6 and Month 12 on Treatment Period",,2015-06-16,COMPLETED,INTERVENTIONAL,['PHASE4']
3559,NCT02475109,Number of Patients with Adverse Events,Time to first rescue treatment,,2015-08,COMPLETED,INTERVENTIONAL,['PHASE1']
3560,NCT03526445,Hepatic lipid metabolism,Changes in appetite sensation,,2018-05-01,COMPLETED,INTERVENTIONAL,['NA']
3561,NCT00784745,Incremental GLP-1 response during the mixed meal test. Assessed as AUC during the 4 hour test.,,,2008-11,COMPLETED,INTERVENTIONAL,['NA']
3562,NCT04618354,Bone mineral density,LH,,2019-01-01,COMPLETED,OBSERVATIONAL,['NA']
3563,NCT03557658,Urinary Glucose Excretion 0-48 Hours,,,2018-07-26,COMPLETED,INTERVENTIONAL,['PHASE1']
3564,NCT04302012,Agreement between multiple EyeArt operations,,,2019-12-18,COMPLETED,OBSERVATIONAL,['NA']
3565,NCT00580710,Brain response to blood glucose levels,,,2001-08,COMPLETED,OBSERVATIONAL,['NA']
3566,NCT06040567,Inflammatory Neuropathy Cause and Treatment (INCAT),Physical Activity Scale (PAS2),,2023-09-23,RECRUITING,OBSERVATIONAL,['NA']
3567,NCT00823225,Major amputation free survival,"Total survival, major amputation rate, rate of complete ulcer healing, rate of adverse events",,2008-06,TERMINATED,INTERVENTIONAL,['PHASE3']
3568,NCT04529317,Blood glucose fluctuations,Nutrient intake recorded,Serum albumin in g/dL,2016-05,COMPLETED,INTERVENTIONAL,['NA']
3569,NCT04303611,Weight Loss,,,2018-08-13,COMPLETED,OBSERVATIONAL,['NA']
3570,NCT03956914,Changes of blood glucose,Waist-hip ratio (WHR),,2016-06-02,COMPLETED,INTERVENTIONAL,['NA']
3571,NCT00400231,triglyceride levels,"HDL-C, Resistin, insulin resistance",,2005-08,COMPLETED,INTERVENTIONAL,['PHASE2']
3572,NCT00917449,To evaluate the efficacy of long term (18 months) L-Arginine therapy in preventing or delaying clinical onset of type 2 diabetes mellitus in subjects with impaired glucose tolerance (IGT) and Metabolic Syndrome.,Define if the treatment with L-arginine can ameliorate insulin sensitivity and endothelial dysfunction and find new risk profiles and candidate genes able to characterize the sub-group of patients at higher risk to develop type 2 diabetes mellitus.,,2005-12,COMPLETED,INTERVENTIONAL,['PHASE3']
3573,NCT01889784,Change in muscle oxygen uptake after phototherapy and placebo phototherapy with light emitting diode (LED) - 300J,Change in baroreflex sensitivity after phototherapy and placebo phototherapy with light emitting diode (LED) - 300J,Change in heart rate after phototherapy and placebo phototherapy with light emitting diode (LED) - 300J,2013-08,UNKNOWN,INTERVENTIONAL,['NA']
3574,NCT05687812,Plasma c-peptide levels changes,Appetite regulation,,2022-01-01,COMPLETED,INTERVENTIONAL,['NA']
3575,NCT00175266,,,,na,COMPLETED,INTERVENTIONAL,['PHASE2']
3576,NCT02504086,Change in diabetes self-management behaviours as measured by Summary of Diabetes Self Care Activities (SDSCA; Toobert et al 2000),"Perceived usefulness and perceived ease of use of online support as measured by the Unified Theory of the Acceptance and Use of Technology (UTAUT) for telehealth (Kohnke et al., 2014 based on Venkatesh et al., 2003)",,2015-08,TERMINATED,INTERVENTIONAL,['NA']
3577,NCT00173641,,,,2005-09,UNKNOWN,OBSERVATIONAL,['NA']
3578,NCT03191227,Metabolic syndrome,Anxiety,,2010-04,COMPLETED,OBSERVATIONAL,['NA']
3579,NCT02692040,Number of Participants With Treatment-Emergent Adverse Events (TEAEs) [Safety and Tolerability],Body Weight (Percentage Change From Baseline),,2015-01,COMPLETED,INTERVENTIONAL,['PHASE1']
3580,NCT05294822,Changes in HbA1c values,Changes in glucagon,,2019-09-30,UNKNOWN,INTERVENTIONAL,['NA']
3581,NCT02963441,Sufficient vs. Insufficient Image Quality Output From IDx-DR,,,2017-01,COMPLETED,OBSERVATIONAL,['NA']
3582,NCT00980187,"Better metabolic effects of indapamide SR 1.5 mg+quinapril by comparison with hydrochlorothiazide 25 mg+quinapril, in patients with hypertension and type 2 diabetes mellitus.","Better safety of indapamide SR 1.5 mg+quinapril by comparison with hydrochlorothiazide 25 mg+quinapril, in patients with hypertension and type 2 diabetes mellitus",,2008-03,COMPLETED,INTERVENTIONAL,['PHASE4']
3583,NCT03911843,Number of Participants With Insulin Demand Adjusted for HbA1c %(IDAA1c) <9,,,2017-01-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
3584,NCT04496817,Change in Retina Function,,,2022-07-11,RECRUITING,INTERVENTIONAL,['NA']
3585,NCT04040777,Mortality rate,,,2015-06,RECRUITING,OBSERVATIONAL,['NA']
3586,NCT05688332,Change in mean Glycated Hemoglobin (HbA1c) levels,Drug related AEs,,2023-08,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
3587,NCT01648244,Change in A1c,Demographic variables,,2012-03,COMPLETED,INTERVENTIONAL,['NA']
3588,NCT02330276,Change From Baseline in Circulating Urinary Concentrations of Intact Epicatechin and Epi Metabolites,Change From Baseline in Circulating C-Peptide Concentrations (ng/mL*24hr),,2014-09,COMPLETED,INTERVENTIONAL,['PHASE1']
3589,NCT05145998,Change in baseline blood glucose over 3 hours (glycemic response),Change in satiety sensation,,2018-05-23,COMPLETED,INTERVENTIONAL,['NA']
3590,NCT00201292,,,,2005-03,UNKNOWN,OBSERVATIONAL,['NA']
3591,NCT06126354,Relative change in serum C-peptide,Plasma glucose kinetics: endogenous glucose production,Serum cortisol level,2023-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
3592,NCT05363761,Device success,Hypertension Control:,,2022-04-19,RECRUITING,INTERVENTIONAL,['PHASE1']
3593,NCT00964574,Mean change in Glycosylated haemoglobin (HbA1c),Mean change of Fasting Blood Glucose and Post Prandial Glycemia,,2009-07,COMPLETED,INTERVENTIONAL,['PHASE4']
3594,NCT05446337,Facilitators and Barriers,Value-Based Healthcare,,2022-07-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
3595,NCT03909269,HbA1c evaluated by the total mean glucose from continuous glucose monitoring,Hypoglycaemic events,,2018-04-01,COMPLETED,OBSERVATIONAL,['NA']
3596,NCT03928249,Fasting glycemia,Rate of change in anthropometric parameters,,2019-12-01,COMPLETED,INTERVENTIONAL,['NA']
3597,NCT04012983,measurement of the level of FGF21 (pg/ml) in gingival crevicular fluid of healthy controls,measurement of the level of chemerin (ng/ml) in gingival crevicular fluid of healthy controls,,2018-03-01,COMPLETED,OBSERVATIONAL,['NA']
3598,NCT04422821,Mean glycemia results (fasting and 1-h postprandial glucose concentrations),Neonatal glycemia,,2020-09-01,COMPLETED,INTERVENTIONAL,['NA']
3599,NCT01390636,Variation in Glycemic Profiles of ED-DMT1 and ED/only,Impact of Dietary Intake on Glucose Profiles of ED-DMT1 and ED/only,,2011-07,TERMINATED,OBSERVATIONAL,['NA']
3600,NCT06094920,Treatment adherence,(Additive) treatment effects finerenone on fasting plasma glucose,,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
3601,NCT00331162,Acute Rejection,Health Status and Quality of Life,,2005-02,COMPLETED,INTERVENTIONAL,['PHASE4']
3602,NCT00738114,assess impact of hyperglycemia and diabetes during the periop period on clinical outcome(mortality and morbidity)in patients undergoing general and non-cardiac surgery.,determine the scope of clinical inertia in patients with diabetes and untreated hyperglycemia in patients undergoing non-cardiac surgery,,2008-08,COMPLETED,OBSERVATIONAL,['NA']
3603,NCT04892771,Number of wound,Adequate footwear,,2021-05-20,COMPLETED,OBSERVATIONAL,['NA']
3604,NCT01980914,Number of Participants With Hypoglycemia (Blood Sugar Level <70 mg/dl,Alteration in Cardiac Rhythm,,2015-03,COMPLETED,INTERVENTIONAL,['NA']
3605,NCT00949091,TAK-875 M-I renal clearance CLr,Absolute change from baseline to Day 14 in insulinogenic index,,2009-01,COMPLETED,INTERVENTIONAL,['PHASE1']
3606,NCT04042441,Change in local laboratory measured glycosylated haemoglobin (HbA1c),Time period from initiation to discontinuation of treatment with Ryzodeg®,,2019-07-29,COMPLETED,OBSERVATIONAL,['NA']
3607,NCT01413542,"The Effect of Enalaprilat (ACE Inhibition), Sitagliptin (DPP4 Inhibition), or the Combination on the Vasodilator Response (Forearm Blood Flow) to Substance P (SP) and Bradykinin (Group 1) or Glucagon Like Peptide-1 and Brain Naturetic Peptide (Group 2).",Effect of Treatment (DPP4 Inhibition vs. Placebo) on Venous GLP-1 Levels in Response to Arterial GLP-1 Infusion,,2011-11,COMPLETED,INTERVENTIONAL,['NA']
3608,NCT03646799,AUClast of Metformin,CL/F of Metformin,,2018-08-30,UNKNOWN,INTERVENTIONAL,['PHASE1']
3609,NCT01729130,Change in body fat distribution,,,2009-09,COMPLETED,OBSERVATIONAL,['NA']
3610,NCT04298970,iAUC,,,2020-03-03,COMPLETED,INTERVENTIONAL,['NA']
3611,NCT00791895,Percentage of subjects achieving HbA1c below 6.5%,,,2003-06-26,COMPLETED,INTERVENTIONAL,['PHASE4']
3612,NCT05141968,"Percent of HbA1c in children with T1DM for both intervention, and control groups.","Concentration of Vitamin D for both intervention, and control groups",,2017-10-01,COMPLETED,INTERVENTIONAL,['NA']
3613,NCT00263965,Whole-body insulin sensitivity by assessing the M value during high (80 mU/m2/min) insulin level euglycemic hyperinsulinemic clamp.,Safety and tolerability of tesaglitazar in patients with type 2 diabetes.,,2005-08,TERMINATED,INTERVENTIONAL,['PHASE2']
3614,NCT01925443,Muscle function,Quality of life,,2015-12,SUSPENDED,INTERVENTIONAL,['NA']
3615,NCT02147314,Accuracy of the Yofimeter as compared to the YSI 2300 Stat Plus Glucose Analyzer,Evaluate the usability of instructional materials.,,2014-06,COMPLETED,OBSERVATIONAL,['NA']
3616,NCT01039532,Glycaemic control,Weight gain Hypoglycaemic episodes Adverse effects Cost effectiveness,,2008-07,COMPLETED,OBSERVATIONAL,['NA']
3617,NCT03888872,Measuring Nerve Conduction Velocity,,,2019-03-12,COMPLETED,INTERVENTIONAL,['NA']
3618,NCT00940472,"Metabolic Control (Fasting glucose, postprandial glucose, HbA1C)",Adverse Events,,2009-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
3619,NCT00233142,hemoglobin A1C (indicator of blood glucose),quality of life,,2005-09,COMPLETED,INTERVENTIONAL,['PHASE2']
3620,NCT04330079,Percent change in global myocardial perfusion reserve (MPR) index,"Change in blood pressure(systolic, diastolic both )",,2020-05-21,TERMINATED,INTERVENTIONAL,['PHASE4']
3621,NCT00289497,Intervention of device use decreases foot ulcers.,Comparison of foot ulceration from enhanced device group as opposed to control group.,,2000-06,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
3622,NCT04254653,Evaluate diabetes nutrition education program impact on self efficacy for healthful eating,,,2020-02-20,UNKNOWN,INTERVENTIONAL,['NA']
3623,NCT01767688,Area Under the Plasma Concentration Versus Time Curve (AUC) From Hour 0 to Infinity (AUC0-∞),Number of Participants Discontinued From Study Due to AEs,,2013-01-16,COMPLETED,INTERVENTIONAL,['PHASE1']
3624,NCT02765204,Change in plasma glucagon levels from baseline to 7 hours after single-dose administration of drug.,,,2016-03,COMPLETED,INTERVENTIONAL,['PHASE4']
3625,NCT02099929,ODILE minimal model analysis,Glucose metabolism,,2012-06,COMPLETED,INTERVENTIONAL,['NA']
3626,NCT04392284,Treatment credibility,Changes in lipids,,2021-04-19,COMPLETED,INTERVENTIONAL,['NA']
3627,NCT00595504,Change in Abdominal Fat (DEXA).,,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE4']
3628,NCT05481034,Percentage of time with sensor glucose measurements between 3.9 and 10.0 mmol/L,Proportion of participants with sensor glucose in the target range (3.9 - 10.0 mmol/L for >70% of the time.,Nature and severity of adverse events,2023-01-11,COMPLETED,INTERVENTIONAL,['NA']
3629,NCT00191581,"The primary objective of this study is to compare the 2-hour PPBG excursion following a standard test meal in IDDM patients treated BID with human insulin mix 50/50, vs the 2-hour PPBG excursion in patients treated BID with insulin lispro mix 50/50",Effects on fasting blood glucose values obtained throughout the study;,,2005-03,COMPLETED,INTERVENTIONAL,['PHASE3']
3630,NCT00249314,,,,2005-11,UNKNOWN,OBSERVATIONAL,['NA']
3631,NCT04342455,"diagnosis accuracy (including sensitivity,specificity of the low-dose radiation and contrast agent exposure protocol for coronary CTA)",kidney function,,2018-10-07,UNKNOWN,INTERVENTIONAL,['NA']
3632,NCT01546558,"Area under the plasma concentration vs time curve over the dosing interval, at steady state (AUCtau) of metformin","Area under the plasma concentration versus time curve over the dosing interval, at steady state (AUCtau) of ranolazine and metabolites",,2012-02,COMPLETED,INTERVENTIONAL,['PHASE1']
3633,NCT02980276,Insulin Initiation/Fasting Glucose,Gestational weight gain,Cost effectiveness and budget impact of metformin treatment in addition to standard care,2017-06-06,COMPLETED,INTERVENTIONAL,['PHASE3']
3634,NCT00815828,To compare the frequency of women who use insulin in the group who participate in the exercise program with the group that don't do the exercises,To verify the impact of the exercise program on the adequacy of capillary glycemic control of the pregnant women,,2006-10,COMPLETED,INTERVENTIONAL,['NA']
3635,NCT05197114,Feasibility and acceptability of the virtual summerlunch+At Home program,Changes in glycemic control as measured through HbA1C levels,,2022-01-25,UNKNOWN,INTERVENTIONAL,['NA']
3636,NCT02240381,Expression of Helios or glycoprotein A repetitions predominant in alpha4beta7+Foxp3+ Tregs versus alpha4beta7+Foxp3- conventional T cells,Post-HCT donor derived Th1 and Treg subsets,,2014-11-20,TERMINATED,INTERVENTIONAL,['NA']
3637,NCT00472888,,,,2005-11,COMPLETED,OBSERVATIONAL,['NA']
3638,NCT04854187,Absolute change in fasting blood glucose for people with diabetes using air purifier and facemask,,,2021-03-25,RECRUITING,INTERVENTIONAL,['NA']
3639,NCT01636258,"Effect of ""FRESH"" Program on Weight Loss",Sleep,,2012-05,COMPLETED,INTERVENTIONAL,['NA']
3640,NCT00097292,Development of type 1 diabetes,Metabolic and Autoantibody Assessments,,2004-02,RECRUITING,OBSERVATIONAL,['NA']
3641,NCT00430040,Brachial artery vascular reactivity at 6 months,"Oxidative stress in Mononuclear cells, serum and plasma at six months",,2007-02,TERMINATED,INTERVENTIONAL,['PHASE4']
3642,NCT00681278,Attainment rate to the target blood pressure.,Change in DBP/SBP value during the follow-up period will be addressed. Change in the DBP/SBP value will be investigated according to the risk factors and concurrent disease.,,2008-04,COMPLETED,OBSERVATIONAL,['NA']
3643,NCT02886884,Number of Treatment Emergent Serious Adverse Events (TE-SAEs),Tumor Necrosis Factor (TNF) Alpha Levels,,2017-10-20,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3644,NCT04671043,Hypoglycaemia,Area under the glucose curve post exercise,,2022-02-04,COMPLETED,INTERVENTIONAL,['NA']
3645,NCT01398826,,,,2011-05,UNKNOWN,OBSERVATIONAL,['NA']
3646,NCT04754334,Mean change in A1C,The mean change in fasting plasma glucose,,2021-03-16,TERMINATED,INTERVENTIONAL,['PHASE3']
3647,NCT04164602,incidence of pancreatic ductal adenocarcinoma in patients with new-onset diabetes,Cost-benefit analysis,,2019-10-09,RECRUITING,OBSERVATIONAL,['NA']
3648,NCT01718925,Fatigue,,,2012-10,COMPLETED,OBSERVATIONAL,['NA']
3649,NCT01460459,HbA1c,quality of life,,2011-05,UNKNOWN,INTERVENTIONAL,['NA']
3650,NCT03830879,Fetal outcomes.,Neurodevelopment.,,2018-03-06,RECRUITING,OBSERVATIONAL,['NA']
3651,NCT01379170,Thyroid hormone-induced change in whole body insulin sensitivity (change in insulin-stimulated glucose disposal) and muscle mitochondrial function,Thyroid hormone-induced change of lipid content in skeletal muscle and liver and brown adipose tissue activity,,2011-06,UNKNOWN,INTERVENTIONAL,['PHASE4']
3652,NCT05726461,Time in range(TIR),Frequency of serious adverse events about device,,2023-02-11,RECRUITING,INTERVENTIONAL,['NA']
3653,NCT00830076,Incremental Post-prandial 4-hour Weighted Mean Active Glucagon-like Peptide-1 (GLP-1) Plasma Concentrations,Incremental Post-prandial 4-hour Weighted Mean Plasma Glucose Concentrations,,2008-12-02,COMPLETED,INTERVENTIONAL,['PHASE1']
3654,NCT02588950,Part B: Pharmacodynamics: Maximum Glucose Infusion Rate (Rmax) of U-500R,Part B: Pharmacodynamics: Time to Rmax (tRmax) of U-500R,,2016-01-12,TERMINATED,INTERVENTIONAL,['PHASE1']
3655,NCT01074268,Extension Trial (Primary Endpoint): Rate of Treatment Emergent Adverse Events (AEs),Extension Trial (Secondary Endpoint): Rate of Nocturnal Confirmed Hypoglycaemic Episodes,,2010-02,COMPLETED,INTERVENTIONAL,['PHASE3']
3656,NCT02874963,Biochemical parameter: high sensitive C-Reactive Protein - hs-CRP (mean value in mg/L),"Mean probing depth (PD) (mean in mm, as a measure of periodontal parameter)",,2015-11,UNKNOWN,INTERVENTIONAL,['NA']
3657,NCT06154135,Time in range,Reasons to stop using the DBLG-1 device,Patients who stop using the DBLG-1 system,2022-12-30,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
3658,NCT00666458,Hemoglobin A1c (HbA1c) Change From Baseline to Week 18,Fasting Plasma Glucose Change From Baseline to Week 18 (mmol/L),,2008-04,COMPLETED,INTERVENTIONAL,['PHASE3']
3659,NCT00608049,"Systolic blood pressure (SBP), Low Density Lipoproteins (LDL) cholesterol, High Density Lipoproteins (HDL) cholesterol, triglycerides, and insulin sensitivity",Overall CVD risk using risk equations,,2008-02,COMPLETED,INTERVENTIONAL,['NA']
3660,NCT02009527,Change in endothelial function,,,2012-01,COMPLETED,INTERVENTIONAL,['PHASE1']
3661,NCT01343589,fatty acid composition in plasma,phytanic acid,,2010-01,COMPLETED,INTERVENTIONAL,['NA']
3662,NCT02845791,The primary endpoint is to detect a change in objectively measured MVPA of 10 minutes per day within the intervention group at 6 months.,Blood Pressure (Parent(s)/guardian(s)),,2016-07,COMPLETED,INTERVENTIONAL,['NA']
3663,NCT03264976,exosomal miRNAs in serum samples,,,2018-07-01,UNKNOWN,OBSERVATIONAL,['NA']
3664,NCT02788903,Number of Participants Diagnosed With COVID-19 Who Were Hospitalized,"Number of Patients With a COVID-19 Diagnosis and ICU Use, Ventilator Use, or Death",,2016-03,COMPLETED,OBSERVATIONAL,['NA']
3665,NCT01918865,Change in plasma HbA1c levels at Week 27 compared to Baseline as a measure of efficacy,"Change in FPG, weekly average SMPG, seven-point glucose profile, lipid profile, body weight, & BMI at Week 27 compared to Baseline as a measure of efficacy",,2013-08,COMPLETED,INTERVENTIONAL,['PHASE2']
3666,NCT01760746,The primary outcome will be the change in global levels of intraocular inflammatory cytokines in the aqueous humour of patients with Proliferative Diabetic Retinopathy.,Secondary outcome measure considers intraoperative complications during vitrectomy.,,2012-07,COMPLETED,OBSERVATIONAL,['NA']
3667,NCT01181986,Reactive Hyperemia Index (RHI),Plasma Glucose,,2010-08,COMPLETED,INTERVENTIONAL,['PHASE4']
3668,NCT06035874,The change in liver fat content,Change between groups in HDL levels,,2023-10-15,RECRUITING,INTERVENTIONAL,['NA']
3669,NCT02925559,Glycemic Variability,Hypoglycemia,,2016-10,COMPLETED,INTERVENTIONAL,['PHASE4']
3670,NCT01316367,HbA1c level,Body Mass Index (BMI),,2003-02,COMPLETED,INTERVENTIONAL,['PHASE4']
3671,NCT05597293,Number of participants with a change in HbA1c of 5.5 mmol/mol or more,Change in the Diabetes Quality of Life (DQOL) score,,2023-02-27,RECRUITING,INTERVENTIONAL,['NA']
3672,NCT00958269,"Safety and tolerability of dutogliptin as assessed by analysis of AEs/SAEs, laboratory data, vital signs, and ECGs",Per cent ex vivo DPP4 inhibition after drug dosing,,2009-08,TERMINATED,INTERVENTIONAL,['PHASE3']
3673,NCT00113620,Pain rating scale obtained from patient diaries,Additional diary rating scales and scores obtained from clinic visits,,2005-07,COMPLETED,INTERVENTIONAL,['PHASE3']
3674,NCT01928199,2-hour Oral Glucose Tolerance Test-derived Blood Sugar,6 Month OGTT Result (Completion of Washout From Study Drug),"Hemoglobin A1c, 6 Month",2013-09,COMPLETED,INTERVENTIONAL,['PHASE4']
3675,NCT03244800,Cohort 1: Percent Change From Baseline in Body Weight to Day 50,Cohort 1 and Cohort 2: Number of Participants With Positive Anti-drug Antibodies (ADA) to MEDI0382,,2017-09-04,COMPLETED,INTERVENTIONAL,['PHASE2']
3676,NCT04409587,Percent time in euglycemia (BG 70 to 180 mg/dl) by CGM,Total daily insulin dosage,,2018-04-12,COMPLETED,INTERVENTIONAL,['PHASE4']
3677,NCT02683746,Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 26,Trough Plasma Concentration of Albiglutide Over Time,,2016-03-16,COMPLETED,INTERVENTIONAL,['PHASE3']
3678,NCT00839774,Postprandial dietary fatty acid oxidation,,,2007-02,COMPLETED,INTERVENTIONAL,['PHASE2']
3679,NCT01713530,Change From Baseline in HbA1c (%),Incidence of Treatment Emergent Adverse Events (TEAE),,2013-02-21,COMPLETED,INTERVENTIONAL,['PHASE3']
3680,NCT02912455,Change at Six Months Versus Baseline in Hemoglobin A1c Value (%),Change in Leg Bone Mineral Density,,2017-01-05,TERMINATED,INTERVENTIONAL,['PHASE4']
3681,NCT02920385,Area under the semaglutide plasma concentration-time curve during a dosing interval (0-24 hours) at steady state,Maximum observed SNAC plasma concentration during a dosing interval (0-24 hours) at steady state,,2016-10-10,COMPLETED,INTERVENTIONAL,['PHASE1']
3682,NCT01924637,Mean change in plasma glucose concentration,Area under the serum insulin aspart concentration-time curve,,2013-08,COMPLETED,INTERVENTIONAL,['PHASE1']
3683,NCT02629406,Endothelial precursor cell account (EPC),,,2015-11,COMPLETED,OBSERVATIONAL,['NA']
3684,NCT00273286,treatment adherence,quality of life,,2006-01,COMPLETED,INTERVENTIONAL,['PHASE2']
3685,NCT04283201,New type 2 diabetes cases,,,2020-02-20,COMPLETED,INTERVENTIONAL,['PHASE2']
3686,NCT02866734,"The overall, & at different fee level, uptake (as a percentage of participants) of screening from those at-risk patients who attend private GP's","Prevalence of DR (overall, and for sight-threatening diabetic retinopathy) among diabetic patients in private primary care",,2016-09-01,COMPLETED,INTERVENTIONAL,['NA']
3687,NCT00502359,,,,2005-04,COMPLETED,OBSERVATIONAL,['NA']
3688,NCT02168816,Number of Participants With Bone Infection,Number of Participants With Ulcer Resolution,,2014-03-19,TERMINATED,INTERVENTIONAL,['PHASE2']
3689,NCT03235050,Percent Change in Body Weight,Immunogenicity Endpoint: Median Titer of the Anti-Drug Antibodies (ADA) to MEDI0382 in the Positive Participants,,2017-08-02,COMPLETED,INTERVENTIONAL,['PHASE2']
3690,NCT02457975,Visual Acuity as assessed by the Early Treatment of Diabetic Retinopathy Study (EDTRS) Classification,Spectral Density-Optical Coherence Tomography (SD-OCT),,2015-06,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
3691,NCT04769167,Maternal Immune Response,,,2021-02-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
3692,NCT01851694,Second-phase insulin response during GPA test,Change in insulin secretion among CF groups,,2013-05,RECRUITING,INTERVENTIONAL,['NA']
3693,NCT00713440,"Incretin effect before and after dysregulation of glucose homeostasis using high calorie diet, physical inactivity and administration of adrenocortical steroids.",GLP-1 and GIP response curves,,2008-07,COMPLETED,INTERVENTIONAL,['NA']
3694,NCT01100892,"Change in lung function (FEV1, FVC)","Change in effort-dependent lung function: MIP, MEP, SnIP",,2010-12,COMPLETED,INTERVENTIONAL,['PHASE3']
3695,NCT00950898,plasma glucose levels,plasma insulin,,2006-11,COMPLETED,INTERVENTIONAL,['NA']
3696,NCT05228340,Ulcer recurrence,Incremental cost-effectiveness in QALY's of flexor tenotomy after 2 years,,2022-03-15,RECRUITING,INTERVENTIONAL,['NA']
3697,NCT04193566,Change in Renal oxygenation,Change in baroreflex sensitivity,,2020-02-01,COMPLETED,INTERVENTIONAL,['PHASE4']
3698,NCT02201550,Change in number of specific immune cells in blood detected by flow cytometry,,,2013-02,COMPLETED,OBSERVATIONAL,['NA']
3699,NCT05941000,Change in Diabetes Distress,Change in Health-Related Problem-Solving,,2024-03-06,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
3700,NCT01640834,Pharmacodynamics: Change From Baseline to Day 2 in 24-hour Insulin Dose,Pharmacodynamics: Area Under the Glucose Concentration Curve After a Single Dose of Glucagon on Day 3,,2012-07,COMPLETED,INTERVENTIONAL,['PHASE1']
3701,NCT02017171,iGFR at the End of the Wash-out Period,Fatal or Non-fatal Cardiovascular Events,,2014-02,COMPLETED,INTERVENTIONAL,['PHASE3']
3702,NCT02553408,Patient and Care provider satisfaction structured interview guide,,,2015-09,COMPLETED,INTERVENTIONAL,['NA']
3703,NCT01084850,Corneal endothelium cell number,Corneal endothelium morphology,,2009-06,UNKNOWN,OBSERVATIONAL,['NA']
3704,NCT03885869,The Evaluation of Dual Task Performance,,,2019-03-25,COMPLETED,OBSERVATIONAL,['NA']
3705,NCT01101503,The metabolic memory effect of endothelium-dependent arterial dilation,,,2010-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
3706,NCT03560505,Common fibular nerve fascicle properties,,,2018-05-16,COMPLETED,OBSERVATIONAL,['NA']
3707,NCT04978974,Effects of stress management program as assessed using Coping Strategies Questionnaire,Effects of stress management program as assessed using Baseline,,2019-05-03,COMPLETED,INTERVENTIONAL,['NA']
3708,NCT01275235,Risk of type 2 diabetes mellitus (T2DM),,,2012-12,TERMINATED,OBSERVATIONAL,['NA']
3709,NCT02610738,Participant feedback on teaching,Change in perceived stress - parent participants,,2015-01,COMPLETED,INTERVENTIONAL,['NA']
3710,NCT00320853,"OGIS Index, Total Insulin Secretion",ApoB,,2006-04,COMPLETED,INTERVENTIONAL,['NA']
3711,NCT03094767,Change from baseline of Glycated Hemoglobin at 3 months,Change from baseline of the distance traveled at 3 months.,,2016-10,UNKNOWN,INTERVENTIONAL,['NA']
3712,NCT02255266,Frequency of patients achieving HbA1c reduction of at least 1%-point,Changes in blood pressure and lipid profile,,2015-03-26,COMPLETED,OBSERVATIONAL,['NA']
3713,NCT00775736,"The number of serious adverse drug reactions, including major hypoglycaemic episodes, reported during the study period.",Weight changes,,2008-10,COMPLETED,OBSERVATIONAL,['NA']
3714,NCT03159299,Change in Hemoglobin A1C From Baseline,Change in Diabetes Self-Efficacy From Baseline,Fidelity of Yo Puedo Sessions,2017-05-08,COMPLETED,INTERVENTIONAL,['NA']
3715,NCT01512797,Change in Area Under the Curve (AUC) Glucose Levels After Mixed Meal Test,Active GLP-1,,2012-07,COMPLETED,INTERVENTIONAL,['NA']
3716,NCT03700580,100% epithelization,80% epithelization,,2012-08-15,COMPLETED,INTERVENTIONAL,['PHASE2']
3717,NCT01919385,Evaluate the performance of the System while the subject is under close medical supervision in the Clinical Research Center (CRC) setting,Capturing the number of Adverse Events as a measure of assessing subject safety,,2013-07,COMPLETED,INTERVENTIONAL,['PHASE1']
3718,NCT04124302,Postprandial glycemia,Hypoglycemia Episodes,,2019-11,UNKNOWN,INTERVENTIONAL,['PHASE4']
3719,NCT03401697,Number of Type 2 Diabetes patients that initiate HCV treatment,HCV cure rate,,2018-01-23,COMPLETED,OBSERVATIONAL,['NA']
3720,NCT02384447,ultrasonographic appearance,,,2014-06,WITHDRAWN,OBSERVATIONAL,['NA']
3721,NCT04052815,Change from Baseline Glycated hemoglobin at 12 months,Dietary assessment of fat consumption,Rosenberg self-esteem,2020-01-01,UNKNOWN,INTERVENTIONAL,['NA']
3722,NCT05493345,Feasibility and fidelity,Loneliness,,2022-08-05,RECRUITING,OBSERVATIONAL,['NA']
3723,NCT00596323,,,,2007-06,COMPLETED,OBSERVATIONAL,['NA']
3724,NCT05564481,glycemic variability,Diabetes self-management,,2022-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
3725,NCT01520428,HbA1C,HbA1c,,2010-06,UNKNOWN,INTERVENTIONAL,['NA']
3726,NCT03406585,Efficacy; comparison of the intervention versus placebo at day 372 versus start of treatment,"Numbers of patients with peak C-peptide >0.20 nmol/l, in response to the MMTT, at day 372",,2017-11-28,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3727,NCT02763943,Patient reported survey results regarding psychosocial status from baseline to end of study,,,2016-04-01,COMPLETED,INTERVENTIONAL,['NA']
3728,NCT01140438,insulin secretion,glycemic control,,2009-03,COMPLETED,INTERVENTIONAL,['NA']
3729,NCT00389350,HbA1c,,,2005-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
3730,NCT01705210,Functional and structural connectivity relationships of multiple brain regions and biomarkers of brain alterations,Cardiovascular risk factors,,2012-05,COMPLETED,OBSERVATIONAL,['NA']
3731,NCT05584085,Change from baseline HbA1c at 3 months post-intervention,Psychological flexibility,,2022-10-15,RECRUITING,INTERVENTIONAL,['NA']
3732,NCT05087758,Wound Healing,Incidence of Treatment Emergent Adverse Events,,2022-03-01,RECRUITING,INTERVENTIONAL,['NA']
3733,NCT02798757,Composite outcome measure. % change to the concentrations of specific metabolites.,,,2016-06,COMPLETED,INTERVENTIONAL,['PHASE4']
3734,NCT04475861,PEDIS,,,2018-10-31,WITHDRAWN,INTERVENTIONAL,['NA']
3735,NCT00451321,Number of Participants With Positive Epstein Barr Virus (EBV) Viral Load,Change From Baseline in Percent Glycosylated Hemoglobin (HbA1c),,2006-07-31,TERMINATED,INTERVENTIONAL,['PHASE2']
3736,NCT05994755,"association between hypoglycemia, glycemic variability and cardiac arrhythmias","association between hypoglycemia, glycemic variability and heart failure",,2023-10-30,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
3737,NCT02045199,Complete healing of target fissure on the heel,,,2014-02,COMPLETED,INTERVENTIONAL,['NA']
3738,NCT01677611,Skeletal muscle sirtuin 1 (SIRT1) expression,Liver function,,2008-12,COMPLETED,INTERVENTIONAL,['PHASE1']
3739,NCT05895552,Count of reported adverse events,,,2023-08-21,RECRUITING,INTERVENTIONAL,['PHASE2']
3740,NCT04062773,HbA1c,Inflammatory markers,,2019-07-10,UNKNOWN,INTERVENTIONAL,['NA']
3741,NCT03437330,Change in skeletal muscle H202 concentration between baseline and end of treatment (EoT),Change in plasma FFA levels,,2021-10-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4']
3742,NCT02508844,Change in glucose levels (Oral glucose tolerance test),Change in HbA1c,,2015-04,COMPLETED,INTERVENTIONAL,['PHASE4']
3743,NCT04306770,Diabetic control,Incidence of vascular complications,,2020-01-20,UNKNOWN,INTERVENTIONAL,['NA']
3744,NCT01106157,Change in Metabolic Function Baseline to 12 Months.,Change in White Blood Count (WBC) From Baseline to 12 Months,,2010-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3745,NCT05820477,Change in Self-Management (Person with Diabetes),Diabetes Distress (Person with Diabetes),Change in emotional support (support person),2023-04-25,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
3746,NCT01225653,The diameter of retinal arterioles,The severity of diabetic retinopathy,,2010-11,COMPLETED,INTERVENTIONAL,['PHASE4']
3747,NCT01144078,Feasibility of these exercise interventions in people with type 2 diabetes,Exercise Self-efficacy,,2010-06,COMPLETED,INTERVENTIONAL,['NA']
3748,NCT04063930,Urinary albumin creatinine ratio (UACR),Urinary potassium,Safety outcome - Electrocardiogram,2019-10,UNKNOWN,INTERVENTIONAL,['PHASE4']
3749,NCT05965869,Evaluate the integration of the intervention,Provide acceptability data of the intervention,,2023-08-01,RECRUITING,INTERVENTIONAL,['NA']
3750,NCT05290207,endocrine hormone changes,,,2022-01-06,COMPLETED,OBSERVATIONAL,['NA']
3751,NCT03988764,Proportion of patients carrying mutations in previously unstudied genes that meet statistical criteria of pathogenicity for monogenic diabetes.,Risk-prediction score for monogenic diabetes mutation in antibody negative T1D patients,,2019-09-24,RECRUITING,OBSERVATIONAL,['NA']
3752,NCT05197101,vaginal birth rate,,,2022-01-17,UNKNOWN,INTERVENTIONAL,['NA']
3753,NCT01498185,Mean Change From Baseline in 7-Point Glucose Monitoring (7-PGM) at Day 7,Pharmacokinetic Parameters on Day 7 - Ratio of Metabolite (RM) to Parent AUC[TAU],,2012-02,COMPLETED,INTERVENTIONAL,['PHASE2']
3754,NCT00486681,compare glycemic control of patients hospitalized in 3 departments,mean of % of glycemia for patients in warning phase with or without diabetologist intervention,,2007-01,COMPLETED,OBSERVATIONAL,['NA']
3755,NCT04706481,"To discover the pathological mechanism of different acute and chronic diseases such as cancer, stroke, heart disease, dementia & diabetes",,,2020-01-01,RECRUITING,OBSERVATIONAL,['NA']
3756,NCT03050619,Baseline Characteristics of Adults (as Measured by Concomitant Medications) With a Recorded Diagnosis of T2DM Starting Index Prescriptions in the UK,Baseline Characteristics (as Measured by Concomitant Medications) of Patients Starting Index Prescriptions Off-label,,2016-09-10,COMPLETED,OBSERVATIONAL,['NA']
3757,NCT00331487,Change in fasting triglyceride level,Apolipoprotein C-III.,,2000-09,COMPLETED,INTERVENTIONAL,['PHASE3']
3758,NCT03522597,Breastmilk and infant microbiomes,Hormones and cytokines in infant serum,,2018-06-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
3759,NCT00460018,Postpartum weight retention,breastfeeding duration,,2005-09,COMPLETED,INTERVENTIONAL,['PHASE2']
3760,NCT05358080,Proportion of subjects maintained or improved in DRSS level,Proportion of subjects with CSME,,2022-05-27,RECRUITING,INTERVENTIONAL,['PHASE4']
3761,NCT04804774,HbA1c,,,2021-03-23,COMPLETED,INTERVENTIONAL,['NA']
3762,NCT05256043,Length of hospital Stay,,,2011-01-01,COMPLETED,OBSERVATIONAL,['NA']
3763,NCT04724330,Total gestational weight gain,Proportion of low birth weight infants,,2021-03-15,RECRUITING,INTERVENTIONAL,['NA']
3764,NCT01864460,Autonomic Function: heart rate variability,balance,Sweat gland nerve fiber density,2013-11-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
3765,NCT04143412,Urinary albumin/creatinin ratio (UACR),Serum K,,2019-02-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
3766,NCT02981966,Endogenous Glucose Production Measurement,Renal Glucose Production Measurement of Change,,2019-05-23,COMPLETED,INTERVENTIONAL,['PHASE4']
3767,NCT01055080,Beta-cell autoantibodies,,,2002-05,COMPLETED,INTERVENTIONAL,['NA']
3768,NCT01435616,Change From Baseline to 52 Week Endpoint in Hemoglobin A1c (HbA1c),Percentage of Participants With Equal or Above 2- and 3-fold ULN for Alanine Transaminase/Serum Glutamic Pyruvic Transaminase (ALT/SGPT) and Aspartate Transaminase/Serum Glutamic Oxaloacetic Transaminase (AST/SGOT),,2011-11,COMPLETED,INTERVENTIONAL,['PHASE3']
3769,NCT00651105,GLP-1 and non GLP-1 effects of LAF237 on glucagon secretion in patients with Type-2 diabetes and matching healthy subjects,"Effects of LAF237 on prandial glucose profiles, prandial insulin, and gastric-emptying in patients with Type-2 diabetes and in matching healthy subjects.",,2008-02,COMPLETED,INTERVENTIONAL,['PHASE3']
3770,NCT00780650,Change in level of catecholamines in blood from baseline,,,2009-05,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
3771,NCT04092569,"Change from Baseline Blood Glycosylated haemoglobin, HbA1c at 9 months",The Chinese version of the Diabetes Empowerment Scale Questionnaire - Short Form,,2019-09-10,UNKNOWN,INTERVENTIONAL,['NA']
3772,NCT01702298,Number of Participants Who Discontinued Study Drug Due to an Adverse Event,Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C),,2012-12-07,COMPLETED,INTERVENTIONAL,['PHASE3']
3773,NCT05935410,Glycemic Control (Hemoglobin A1C [HbA1C]),,,2023-08-01,RECRUITING,INTERVENTIONAL,['NA']
3774,NCT05368402,"The proportion of responders at week 27/28 (visit 4), with responders defined as ""patients with an HbA1c reduction from baseline of ≥0.50% (absolute difference) without episodes of severe hypoglycemia",Incidence of Treatment Emergent Adverse Events (TEAEs) recorded from the beginning of study treatment to up to the end of study participation,,2022-07-27,TERMINATED,INTERVENTIONAL,['PHASE2']
3775,NCT06291129,Bleeding on probing,,,2022-10-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
3776,NCT03223389,Within group difference in cholecystokinin (CCK) secretion (evaluated by AUC above basal).,Between group comparison of differences in CCK secretion (evaluated by AUC above basal).,,2017-08-07,UNKNOWN,INTERVENTIONAL,['NA']
3777,NCT03005288,Change From Baseline in Total Body Fat Mass by Dual Energy X-ray Absorptiometry (DXA) at Week 48,Immunogenicity Assessed by the Number of Participants Developing Anti-BYM338 Antibodies During the Trial,,2017-02-01,COMPLETED,INTERVENTIONAL,['PHASE2']
3778,NCT04489966,Abdominal fat Abdominal fat,The 10-year risk assessment table for Ischemic cardiovascular disease,,2018-12-01,COMPLETED,INTERVENTIONAL,['NA']
3779,NCT04516200,sway index of sensory integration test,risk of fall index,,2020-08,UNKNOWN,INTERVENTIONAL,['NA']
3780,NCT05168657,"Percentage of individuals with mean CGM glucose <183 mg/dL (corresponding to an estimated HbA1c of <8.0%) on days 3-14, by group.","Percentage of individuals with mean CGM glucose <154 mg/dL (corresponding to an estimated HbA1c of <7.0%) on days 3-14, by group.",,2022-03-31,COMPLETED,INTERVENTIONAL,['NA']
3781,NCT02571738,"Complete closure of the index wound, defined as 100% re-epithelialization as determined by the Investigator, by the End of Single-Blind Treatment Visit with follow-up confirmation of continued closure at 2 consecutive study visits 2 weeks apart","Percentage of patients who achieve complete wound closure, defined as 100% re-epithelialization as determined by the Investigator, who participate in the Open-Label Treatment Phase","Change in Quality of Life from Baseline, as determined by the Cardiff Wound Impact Schedule (CWIS)",2015-10,TERMINATED,INTERVENTIONAL,['PHASE3']
3782,NCT01337362,EEG,Cognitive function,,2011-05,COMPLETED,INTERVENTIONAL,['NA']
3783,NCT03819335,Empowerment,Satisfaction with the app,,2019-04-09,COMPLETED,INTERVENTIONAL,['NA']
3784,NCT02447172,Percent of Patients With a Clinical Outcome of Clinical Cure (Resolution of All Clinical Signs and Symptoms of Infection),Percent of Subjects That Had an Amputation Associated With the Target Ulcer,,2015-06,COMPLETED,INTERVENTIONAL,['PHASE3']
3785,NCT04667728,Change From Baseline in HbA1c at 3 Months,,Change From Baseline in daily fat intake at 3 Months,2017-05-30,COMPLETED,INTERVENTIONAL,['NA']
3786,NCT01199783,Clinical Response of the Infection at Test-of-cure (TOC) at Day 14 Post Therapy,Rate of Amputations Due to Infection,,2011-07,TERMINATED,INTERVENTIONAL,['PHASE3']
3787,NCT00001612,,,,1997-05,COMPLETED,OBSERVATIONAL,['NA']
3788,NCT00727220,Change in HgBA1c,,,1999-11,COMPLETED,OBSERVATIONAL,['NA']
3789,NCT02246959,Change in LDL cholesterol from baseline to 12 months,Statin Adherence,,2015-02,COMPLETED,INTERVENTIONAL,['NA']
3790,NCT01625598,Sensitivity of detecting moderate non proliferative diabetic retinopathy or more severe DR and/or significant macular edema on a person-specific basis.,Specificity on an eye-specific basis [Clinical examination only],,2012-04,COMPLETED,OBSERVATIONAL,['NA']
3791,NCT05948592,3. Percentage of patients that achieve a 50% reduction in wound surface area by week 4,4. Percentage of patients with target strain not-susceptible to TP-102 for TP-102 versus Placebo at EOT;,,2023-11-08,RECRUITING,INTERVENTIONAL,['PHASE2']
3792,NCT03369821,"Measure beta cell function in EET1D compared to T1D, NDM and non-diabetic controls.",Association of maternal and paternal non-inherited HLA alleles with EET1D,,2017-09-01,RECRUITING,OBSERVATIONAL,['NA']
3793,NCT01966432,Treatment for Drug Use or Alcohol,,,2013-08,COMPLETED,INTERVENTIONAL,['NA']
3794,NCT04603508,Percent change from baseline of LDL-c levels.,Incidence and severity of adverse events recorded during the study.,,2023-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
3795,NCT01030861,Rate of New Diabetes Per Year,Number of Participants With Adverse Events,,2010-08,COMPLETED,INTERVENTIONAL,['PHASE2']
3796,NCT01086111,insulin sensitivity and beta cell function,changes in plasma levels of gut hormones and inflammation markers,,2010-02,COMPLETED,OBSERVATIONAL,['NA']
3797,NCT05211479,Evaluation of the anxiety level of adolescents with type 1 diabetes,,,2021-12-20,COMPLETED,INTERVENTIONAL,['NA']
3798,NCT01194479,Norepinephrine (pg/mL),Blood Glucose Levels (Average),,2010-08,COMPLETED,INTERVENTIONAL,['NA']
3799,NCT04915066,Permanent discontinuation of insulin pump use.,type of diabete,,2021-06-29,COMPLETED,OBSERVATIONAL,['NA']
3800,NCT00762671,Endothelium-dependent and endothelium-independent vasodilation of peripheral resistance and conduit vessels will be studied in diabetic (type 1 and 2) and healthy subjects two weeks following randomization to the ebselen or placebo.,,,1999-05,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
3801,NCT04784637,Number of SAE or ADE Related to the Use of ATM / WST and BAM Modules.,INSPIRE Questionnaire,,2021-07-23,COMPLETED,INTERVENTIONAL,['NA']
3802,NCT02460081,Transcutaneous oxygen measurement (TCOM),Patient Global Impression of Change in Neuropathy (PGICN),,2015-06,WITHDRAWN,INTERVENTIONAL,['PHASE2']
3803,NCT02450500,Participants acceptability of intervention by focus group,"Health status, well being, food intake and exercise levels by questionnaires",,2015-03,COMPLETED,INTERVENTIONAL,['NA']
3804,NCT04454827,Fear of Hypoglycemia,HbA1c,,2019-04-01,COMPLETED,OBSERVATIONAL,['NA']
3805,NCT01158131,Postpartum weight loss,,,2009-11,COMPLETED,INTERVENTIONAL,['PHASE2']
3806,NCT05855863,Cognitive function testing,Attention assessment,Concentration of irisin,2023-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
3807,NCT03896360,Proportion of participants achieving a normal 2-hour glucose (less than 140mg/dl) and/ or greater than or equal to 15% improvement in 2-hour glucose,,,2019-02-28,COMPLETED,INTERVENTIONAL,['NA']
3808,NCT04195243,Flow Mediated Dilation,Blood pressure,,2019-12-02,UNKNOWN,INTERVENTIONAL,['PHASE3']
3809,NCT04712916,Change in value of blood pressure readings,,,2017-06-10,COMPLETED,INTERVENTIONAL,['NA']
3810,NCT01418456,Time to healing of foot ulceration in each group,• Percentage of patients in each group that are healed at 20 weeks.,,2011-08,UNKNOWN,INTERVENTIONAL,['PHASE4']
3811,NCT05740254,Mean change in weight in excess of the 95th percentile at week 24 compared to baseline,Mean change in systolic and diastolic blood pressure at week 24 compared to baseline,,2023-03-27,RECRUITING,INTERVENTIONAL,['NA']
3812,NCT00432809,Success Rate of Biochemical Resolution of Diabetes at 12 Months as Measured by HbA1c ≤ 6% With no Diabetes Medications,Cardiovascular Medications - Anticoagulants,,2007-02,COMPLETED,INTERVENTIONAL,['NA']
3813,NCT01123239,Hemoglobin A1c,Health-related quality of life,,2006-01,COMPLETED,INTERVENTIONAL,['NA']
3814,NCT06246578,Difference between paired Dexcom and Libre glucose values,,,2024-01-19,RECRUITING,INTERVENTIONAL,['NA']
3815,NCT04279444,Insulin resistance (HOMA-IR),"Triglyceride, glucose, and insulin AUCs",,2020-06-16,COMPLETED,INTERVENTIONAL,['NA']
3816,NCT04186702,central subfield thickness (CST),patient compliant-complications,,2014-09-10,COMPLETED,INTERVENTIONAL,['NA']
3817,NCT03092310,Percent time within the target glucose range of 70-180 mg/dl overall as assessed by continuous glucose monitoring (CGM).,Failure analysis of the devices/connectivity issues that may occur (# disconnects and device restarts).,,2017-03-20,COMPLETED,INTERVENTIONAL,['NA']
3818,NCT01580462,,,,2012-04,UNKNOWN,OBSERVATIONAL,['NA']
3819,NCT03514238,Insulin Sensitivity,,,2017-09-01,COMPLETED,INTERVENTIONAL,['NA']
3820,NCT01106287,Number of Participants Who Discontinued Study Drug Due to an Adverse Event,,,2009-10,COMPLETED,INTERVENTIONAL,['PHASE1']
3821,NCT06003751,Systemic Adverse events,,,2023-08-05,RECRUITING,INTERVENTIONAL,['PHASE2']
3822,NCT00151021,Step-count bout ratio = 7 day average of steps taken during 10 minute bouts in one day divided by total steps taken during the same day,,,2005-06,COMPLETED,INTERVENTIONAL,['NA']
3823,NCT05279911,Osteoprotegrin (OPG) level,,,2021-03-03,COMPLETED,INTERVENTIONAL,['NA']
3824,NCT02134860,Insulin resistance,,,2014-06,COMPLETED,INTERVENTIONAL,['NA']
3825,NCT01682902,Mean change in plasma glucose concentration,Number of episodes of infusion set occlusions,,2012-09,COMPLETED,INTERVENTIONAL,['PHASE1']
3826,NCT03192228,Success rate of the therapeutic education program,Long term success rate of the therapeutic education program,,2011-07,COMPLETED,OBSERVATIONAL,['NA']
3827,NCT01519102,Incremental area under the curve of plasma glucose concentration as compared to pre-meal glucose value of the postprandial glucose excursions,Percentage of postprandial time of plasma glucose concentrations spent in the low range (below 4.0mmol/l),,2012-01,COMPLETED,INTERVENTIONAL,['PHASE2']
3828,NCT02750267,Percent of Sensor Glucose Readings Between 70-180 mg/dL,End of Night Blood Glucose,,2016-05,COMPLETED,INTERVENTIONAL,['NA']
3829,NCT02561377,glycemic control,Incidence rate of diabetes,,2015-09,UNKNOWN,INTERVENTIONAL,['NA']
3830,NCT00829699,Percent change in flow mediated dilation of brachial artery,Change in Lipid measures,,2009-07,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
3831,NCT04369833,Number of Participants With Insulin Resistance,,,2020-05-11,COMPLETED,OBSERVATIONAL,['NA']
3832,NCT02985866,Time Above 180 mg/dL,Coefficient of Variation,,2017-10-27,COMPLETED,INTERVENTIONAL,['NA']
3833,NCT01297387,,,,2009-01,COMPLETED,OBSERVATIONAL,['NA']
3834,NCT03816293,Surgical Site Infection Rate per 100 surgeries,Dehiscence incidence and rate per 100 surgeries,,2019-05-01,COMPLETED,INTERVENTIONAL,['NA']
3835,NCT04540536,Change in hemoglobin A1c after three-month follow-up visit after remote continuous glucose monitoring monitoring and secure text messaging.,,Average time spent by medical provider per participant per day.,2021-11-01,RECRUITING,INTERVENTIONAL,['NA']
3836,NCT06336512,Estimation of Gestational DM,,,2023-01-15,COMPLETED,INTERVENTIONAL,['NA']
3837,NCT05409027,Pharmacokinetics (Cmax),Urinary HSD-1 Ratio,,2021-08-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
3838,NCT02333851,Differences in mean daily blood glucose concentration,Total daily Insulin use in International Units per Kg of weight,,2013-06,TERMINATED,INTERVENTIONAL,['PHASE4']
3839,NCT03281616,Body weight reduction,Blood HbA1c,,2014-06-01,COMPLETED,INTERVENTIONAL,['NA']
3840,NCT04127448,Change in Verbal fluency test (VFT) from baseline to 6th week,Change in Random Blood sugar (RBS) from baseline to 6th week,Change in respiratory rate in breaths/min from baseline to 6th week.,2017-03-01,COMPLETED,INTERVENTIONAL,['NA']
3841,NCT03495362,Changes in islet function,Changes in hepatorenal function,,2018-03-13,UNKNOWN,INTERVENTIONAL,['NA']
3842,NCT03199053,Change from baseline in HbA1c at Week 26,"Percentage of subjects with baseline HbA1c ≥ 7%, who achieve an HbA1c level < 7.0% at Week 26",Percentage of subjects with baseline HbA1c ≥ 7% who achieve an HbA1c level < 7.0% at Week 52,2017-10-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
3843,NCT03102476,"Onset of action, time from trial product administration until the blood glucose concentration has decreased at least 0.3 mmol/L (5 mg/dL) from the baseline",Time to maximum glucose infusion rate curve,,2016-06,COMPLETED,INTERVENTIONAL,['NA']
3844,NCT05428943,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,Serum samples collected to determine glucose levels (mmol/L) pre and post mixed meal tolerance test,,2022-09-27,RECRUITING,INTERVENTIONAL,['PHASE1']
3845,NCT05669547,Time in Range (TIR) at 12 months (measured with an independent FSL Pro IQ sensor),Percentage of time glucose control algorithm active DHFCL outcomes,Reasons for discontinuation of the DHFCL treatment.,2023-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
3846,NCT00408993,Change From Baseline to 12 Week Endpoint in Brief Pain Inventory 24-hour Average Pain Score,Statistically Significant Change From Baseline to 12 Week Endpoint in Laboratory Measures - Uric Acid,,2006-12,COMPLETED,INTERVENTIONAL,['PHASE3']
3847,NCT03061266,Glycated hemoglobin (HbA1c),quality of life using questionnaire,,2016-03-09,UNKNOWN,INTERVENTIONAL,['NA']
3848,NCT01282957,Rate of use of the three home-based technologies,"Usability and functionality of the study's online web portal, Way to Health, and wifi-enabled home health monitoring devices",,2011-02,COMPLETED,INTERVENTIONAL,['NA']
3849,NCT06059404,Mini Nutritional Assessment-Short Form,Falls efficacy scale,,2023-09-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
3850,NCT05284344,Gastric-half emptying time of the 75 g glucose drink,Heart rate,,2021-01-24,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
3851,NCT06223204,Change of the electrical impedance tomography (EIT) signal of the thoracic region across the glycemic trajectory.,"Performance of the machine learning model to predict glucose values from the above-mentioned signals (EIT, symptoms, voice, physiological signals) using the Clarke Error Grid.",,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
3852,NCT03477786,development of microalbuminuria,development of cardiovascular events,,2013-10-28,UNKNOWN,INTERVENTIONAL,['NA']
3853,NCT01272583,Glucagon Response to Acute Hypoglycaemia,Symptomatic Hormone Responses to Acute Hypoglycaemia.,,2011-03,COMPLETED,INTERVENTIONAL,['NA']
3854,NCT06115460,Percentage of Time in range,Level of Stromal cell-derived factor-1 (SDF-1),,2022-03-01,COMPLETED,INTERVENTIONAL,['PHASE3']
3855,NCT01607450,Myocardial Glucose Uptake.,GLP-1 Concentrations,,2010-05,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
3856,NCT01201928,"Comparison of change from baseline to final treatment visit in pulmonary function (FEV1 FVC, TLC and DLco) between treatment Groups (TI vs comparator arms) using ANCOVA models.",,,2010-10,TERMINATED,OBSERVATIONAL,['NA']
3857,NCT00738660,Reduction in albumin excretion rate,"24 hr ambulatory BP reduction,nocturnal BP reduction, proportion of dippers",,2007-02,COMPLETED,INTERVENTIONAL,['PHASE3']
3858,NCT05039645,Patient Adherence,DFU Incidence rates and severities,,2022-03-31,COMPLETED,INTERVENTIONAL,['NA']
3859,NCT03411395,Blood glucose response,Capillary blood glucose response,,2016-10-13,COMPLETED,INTERVENTIONAL,['NA']
3860,NCT02074683,Durability of Relief and reduction of foot pressure,Assessment of pain and skin lesions,,2013-11,COMPLETED,INTERVENTIONAL,['NA']
3861,NCT01695629,changes between control and diabetic patients,,,2011-01,COMPLETED,OBSERVATIONAL,['NA']
3862,NCT00535535,"A comparison of the iAUC in VLDL TG palmitate 4 hours after F:G1:1, 1g/kg, vs. 1) fructose 0.5g/kg, and 2) F:G:1:1, 2g/kg.",Linear regression analysis of the relationship between the iAUC in VLDL TG palmitate after oral fructose and markers of carbohydrate and lipid flux,,2007-08,COMPLETED,INTERVENTIONAL,['PHASE1']
3863,NCT03342274,Weight loss,Triglycerides,,2018-02-16,COMPLETED,INTERVENTIONAL,['NA']
3864,NCT05548218,Change in A1C level,,,2022-08-15,RECRUITING,INTERVENTIONAL,['NA']
3865,NCT02491814,Subjective Appetite,Food Intake,,2015-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3866,NCT02027103,Serum concentrations of osteoprotegrin,,,2012-01,COMPLETED,INTERVENTIONAL,['NA']
3867,NCT05560386,Body Mass Index (BMI),Emotional Eating Score,,2020-08-01,COMPLETED,INTERVENTIONAL,['NA']
3868,NCT04665102,Validation of Image classification by transfer learning algorithm,,,2021-02-01,UNKNOWN,OBSERVATIONAL,['NA']
3869,NCT00771901,Body Composition,VLDL-triglyceride (TG) Concentration,,2008-02,COMPLETED,INTERVENTIONAL,['NA']
3870,NCT05694741,"Adverse Events (AEs), and Serious Adverse Events (SAEs)",Maximum observed concentration (Cmax),,2022-12-20,TERMINATED,INTERVENTIONAL,['PHASE1']
3871,NCT02891954,Urinary glucose excretion (during the time interval 24-48 hours after first administration of canagliflozin),Serum uric acid,,2016-09,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE1']
3872,NCT01511198,Body weight,Adverse events,,2001-02,COMPLETED,INTERVENTIONAL,['PHASE2']
3873,NCT03302377,Feasibility of recruitment,Physical activity change,,2017-10-03,COMPLETED,INTERVENTIONAL,['NA']
3874,NCT01026194,Change From Baseline in HbA1c at Week 12,Change From Baseline in 2-hour Postprandial Plasma Glucose at Week 12,,2009-12,COMPLETED,INTERVENTIONAL,['PHASE3']
3875,NCT01493388,Percentage of adolescents between 13 and 15 years with HbA1c less than 7.5%,Type and dose of insulin treatment,,2012-03,COMPLETED,OBSERVATIONAL,['NA']
3876,NCT00918151,"Percentage of diabetic patients having dyslipidemia and hypertension, cardiovascular complications, peripheral vascular disease, diabetic nephropathy and diabetic eye complications, respectively","Minimum duration of diabetes associated with 10% incidence of diabetic complications (CVD, nephropathy and retinopathy)",,2009-05,COMPLETED,OBSERVATIONAL,['NA']
3877,NCT02168491,Change in HbA1c From Baseline to End,Change in Body Weight From Baseline to End of Study,,2014-11,COMPLETED,INTERVENTIONAL,['PHASE3']
3878,NCT04564911,Change from baseline HbA1c at week 24,Number of individuals requiring medication up-titration from baseline to week 24,,2020-12-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
3879,NCT06334172,Insulin secretion - c-peptide,Procollagen type I N-terminal propeptide (P1NP),,2024-01-01,RECRUITING,INTERVENTIONAL,['NA']
3880,NCT00450489,,,,2008-06,WITHDRAWN,OBSERVATIONAL,['NA']
3881,NCT06146036,Incremental Area Under the Curve (AUC),Blood pressure,,2024-01-20,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
3882,NCT04172337,Change in average calories per serving purchased per shopping trip,Calories per dollar spent per shopping trip,,2019-01-01,COMPLETED,INTERVENTIONAL,['NA']
3883,NCT01235039,Serum insulin concentration,Glucose infusion rate,,2009-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3884,NCT06066528,Achievement of body weight reduction ≥5% (yes/no) from baseline to Week 76,Absolute change from baseline to Week 76 in aspartate aminotransferase (AST) (U/L),,2023-11-15,RECRUITING,INTERVENTIONAL,['PHASE3']
3885,NCT00357370,Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 12 (Last Observation Carried Forward [LOCF]) - Cohort 2,"Adjusted Mean Total Daily Dose of Insulin (TDDI) Change From Baseline at Week 12 (LOCF), Including Data After Up-titration of Insulin) - Cohort 2",,2006-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
3886,NCT00912002,Mean Percent of Dose Recovered in Urine and Feces Following a Single Oral Dose of [^14C]MK-0941 (160 µCi).,Number of Participants Who Discontinued the Study Due to An Adverse Event,,2008-10,COMPLETED,INTERVENTIONAL,['PHASE1']
3887,NCT01092663,Postprandial Glucose (AUC),Postprandial Glucagon (AUC),,2010-03,COMPLETED,INTERVENTIONAL,['NA']
3888,NCT02932514,Usability of the Eversense CGM System over 180 days will be evaluated through Study Questionnaires.,,,2016-10,UNKNOWN,INTERVENTIONAL,['NA']
3889,NCT00439985,quality of life,parent-child collaboration,,2006-09,TERMINATED,INTERVENTIONAL,['NA']
3890,NCT05505669,Changes in frequency of circulating biomarkers that correlate with beta cell death from type 1 diabetes patients compared to other cohorts,,,2022-03-29,RECRUITING,OBSERVATIONAL,['NA']
3891,NCT00789295,Postprandial response triglyceride of chylomicrons and large VLDL,Lipolytic activities,,2004-03,COMPLETED,INTERVENTIONAL,['NA']
3892,NCT04702672,Postprandial glycemic response,Visual analogue scale (VAS),,2023-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
3893,NCT00795600,Absolute Change in Trunk Fat Mass,Number of Non-serious Adverse Events,,2009-04,COMPLETED,INTERVENTIONAL,['PHASE4']
3894,NCT01193218,Change From Baseline in HbA1c After 12 Weeks of Treatment.,Change From Baseline in FPG,Confirmed Hypoglycaemic Adverse Events,2010-09,COMPLETED,INTERVENTIONAL,['PHASE2']
3895,NCT01142908,Framingham Risk Percent (Estimate of 10 Year Risk of Cardiovascular Disease in Percent),HBA1C in Diabetic Patients,,2011-11-01,COMPLETED,INTERVENTIONAL,['NA']
3896,NCT03164538,Number of PP-MI Sessions Completed by Participants,Change in Diabetes Self-Care,Change in Hemoglobin A1c,2017-07-25,COMPLETED,INTERVENTIONAL,['NA']
3897,NCT04100551,relationship between renal function and podological grade,factors associated with the occurrence of complications and comorbidities,,2019-10-01,COMPLETED,OBSERVATIONAL,['NA']
3898,NCT03398577,Percent reduction in interleukin (IL)-1β levels,Percent change in Adiponectin levels,,2018-02-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
3899,NCT02384226,Engagement with the Application,Acceptability of the Application,,2015-09,COMPLETED,OBSERVATIONAL,['NA']
3900,NCT01937858,Correlation,,,2012-07,TERMINATED,OBSERVATIONAL,['NA']
3901,NCT03596983,Protocol adherence rates measured by the percentage of participants completing greater than or equal to 4 daily sleep diary entries per week for 80% or more of the intervention period.,,,2019-04-10,COMPLETED,INTERVENTIONAL,['NA']
3902,NCT04663282,Change in HbA1c,Serum INS068 concentration,,2021-02-04,COMPLETED,INTERVENTIONAL,['PHASE2']
3903,NCT06177691,C-peptide,Hospitalizations,,2021-05-07,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
3904,NCT05023538,Global longitudinal strain (%),"Calf muscle oxygen saturation (haemoglobin variables: ΔHHb, ΔtHb, ΔHbO2 and ΔTSI%)",,2022-03-01,RECRUITING,INTERVENTIONAL,['NA']
3905,NCT00577148,Mean change per year in Non-Alcoholic Fatty Liver Disease [NAFLD] Activity Score (NAS),Change from baseline in serum hyaluronate and hepatic transaminases (AST/ALT),,2008-02,TERMINATED,INTERVENTIONAL,['PHASE3']
3906,NCT00488423,To assess the effect of gastric by-pass surgery to decrease lipotoxicity.,To examine the effect of roux-en-Y compared to gastric banding on pancreatic B cell recovery or insulin secretion in response to oral and IV glucose.,,2006-11,COMPLETED,INTERVENTIONAL,['PHASE1']
3907,NCT02272348,To assess the impact of therapeutic education by functional insulin therapy in patients with type 1 diabetes on their ability to disease self-management.,"To assess the validity, the concordance and the sensitivity to change of EAD questionnaire (specific for self-management of diabetes) in comparison with CIDS test",,2015-02-10,TERMINATED,INTERVENTIONAL,['NA']
3908,NCT01709305,Change From Phase 2 Baseline to Week 44 in Hemoglobin A1c (HbA1c) Levels (Phase 2),Percentage of Participants With a GI AE of Abdominal Pain (Phase 2),,2012-11-08,COMPLETED,INTERVENTIONAL,['PHASE4']
3909,NCT06115616,g of glucose,,,2024-02-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
3910,NCT00639613,,,,2008-03,COMPLETED,OBSERVATIONAL,['NA']
3911,NCT02222623,Mean daily blood glucose,Hospital mortality,Length of hospital stay,2015-04,WITHDRAWN,INTERVENTIONAL,['NA']
3912,NCT05559892,Quality of Life as measured by SF-12,Self-Care,,2022-11-01,RECRUITING,INTERVENTIONAL,['NA']
3913,NCT00707616,Disposition Index,,,2006-03,COMPLETED,OBSERVATIONAL,['NA']
3914,NCT05955339,Quality of Life - Physical functioning,Visit communication style and shared decision-making,Caregiver engagement in clinic visit [Caregiver outcome],2024-01-24,RECRUITING,INTERVENTIONAL,['NA']
3915,NCT00224224,"To identify the differences between primary care and traditional medicine residents in clinical performance, continuity of care and utilization of resources.",,,1995-01,COMPLETED,OBSERVATIONAL,['NA']
3916,NCT02227485,Modified Gingival Index,Satisfaction of Patients,,2014-07,COMPLETED,INTERVENTIONAL,['NA']
3917,NCT00932048,Vascular inflammation analyzed by PET: Define attenuation of plaque inflammation (plaque SUV or TBR) at 12 weeks,Change in carotid plaque thickness by ultrasound,,2011-08,WITHDRAWN,INTERVENTIONAL,['NA']
3918,NCT00434811,Proportion of participants with a HbA1c less than 7.0% AND free of severe hypoglycemic events,"Acute insulin response to glucose insulin sensitivity, and disposition index derived from the FSIGT test",,2006-10,COMPLETED,INTERVENTIONAL,['PHASE3']
3919,NCT02344992,Area under the blood glucose time curve: AUCbg(0-2h),"Safety and tolerability: adverse events, local tolerability, vital signs variation, ECG, laboratory safety parameters",,2015-01,COMPLETED,INTERVENTIONAL,['PHASE1']
3920,NCT03335930,exercise-induced glucose response,trend of post-exercise blood glucose,,2009-03-01,COMPLETED,INTERVENTIONAL,['NA']
3921,NCT02171351,Sympathetic nerve reactivity in response to a single session of neuromuscular electrostimulation,sympathetic nerve reactivity in response to a single session of voluntary muscular contractions,comparison of sympathetic nerve reactivity between the different groups and procedures,2020-08-01,WITHDRAWN,INTERVENTIONAL,['NA']
3922,NCT02276144,Compare prevalence of obstetric complications between non-alcoholic fatty liver and normal pregnant women,,,2014-11,UNKNOWN,OBSERVATIONAL,['NA']
3923,NCT03221452,Change in Diabetes Self-Care Activities,Center for Epidemiologic Studies Depression Scale,,2016-09-02,UNKNOWN,INTERVENTIONAL,['NA']
3924,NCT01831765,Change From Baseline in HbA1c (Glycosylated Haemoglobin),Change in PPG (Postprandial Glucose),,2013-08-26,COMPLETED,INTERVENTIONAL,['PHASE3']
3925,NCT00793884,Social and Demographic Characteristics,Change in Diastolic Blood Pressure,,2008-10,SUSPENDED,OBSERVATIONAL,['NA']
3926,NCT00628212,Change From Baseline in HbA1c at Week 12,Change From Baseline in the Areas Under the Curve From 0 to 2 h (AUC0-2h) for Postprandial Plasma Glucose at Week 12,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE2']
3927,NCT05492630,AUC0-∞,,,2021-05-24,COMPLETED,INTERVENTIONAL,['PHASE1']
3928,NCT05514925,Intraoperative bleeding,Visual acuity,,2017-11-21,RECRUITING,INTERVENTIONAL,['PHASE4']
3929,NCT02084004,Change in HbA1c from baseline to week 12,Adverse effects,,2015-11,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
3930,NCT01544881,"PK measures for RAA (8U) as measured by area under the concentration-time curve (AUC 0-360) - timepoints 0, 5, 10, 15, 20, 30, 40, 50, 60, 75, 90, 105, 120, 150, 180, 210, 240, 270, 300 and 360 minutes post-RAA dosing","Area under serum glucose infusion rate (GIR AUC 0-360) for RAA (8U) as measured by: GIR AUC 0-360 timepoints: 0, 5, 10, 15, 20, 30, 40, 50, 60, 75, 90, 105, 120, 150, 180, 210, 240, 270, 300 and 360 minutes post-RAA dosing",,2012-03,COMPLETED,INTERVENTIONAL,['PHASE1']
3931,NCT00347698,Score on a patient satisfaction scale at six months and one year,Complications associated to each treatment,,2006-03,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
3932,NCT00533442,Event-Specific Survival Comparisons,"Overall Pancreas Transplant Function at 12, 36, and 60 Months Post-transplant.",,2000-09,COMPLETED,INTERVENTIONAL,['PHASE2']
3933,NCT03550976,Incidence of gestational diabetes,,,2018-10-01,UNKNOWN,INTERVENTIONAL,['NA']
3934,NCT06070103,"Depression ,Anxiety and stress disorders among diabetic patients in Assuit University Hospitals.",,,2024-04-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
3935,NCT04455867,Neuropsychological function,Cognitive Status,,2017-12-21,RECRUITING,OBSERVATIONAL,['NA']
3936,NCT00800410,Hemoglobin A1c,Diabetes specific emotional distress,,2004-09,COMPLETED,INTERVENTIONAL,['PHASE2']
3937,NCT02893891,SF-36 Questionnaire evaluation,Effectiveness evaluation,,2012-03,COMPLETED,INTERVENTIONAL,['NA']
3938,NCT01943045,Fasting Plasma Glucose,Lipids,,2013-09,COMPLETED,INTERVENTIONAL,['PHASE2']
3939,NCT02372578,Change from Baseline in mean 24-hour average pain intensity as reported on the NPRS,Clinical Global Impression of Change (CGIC),,2015-05-27,TERMINATED,INTERVENTIONAL,['PHASE2']
3940,NCT00139659,Change From Baseline in Post-Bronchodilator Carbon Monoxide Diffusing Capacity (DLco),Severe Hypoglycemic Event Rates,,2003-01,COMPLETED,INTERVENTIONAL,['PHASE3']
3941,NCT00685594,development of diabetes type 2,change in telomer length,Oral glucose tolerance response to vitamin D supplementation in relation to polymorphisms in the vitamin D system,2008-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
3942,NCT03728647,nursing hours,insulin performance rate,,2013-08-16,COMPLETED,INTERVENTIONAL,['NA']
3943,NCT01699074,Effect of KWG on vascular and glycemic measures,Effect of KWG on vascular and glycemic measures,KWG and satiety,2013-05,COMPLETED,INTERVENTIONAL,['PHASE1']
3944,NCT00330733,Change in Systemic Glucose Disposal- Glucose Infusion Rates,Plasma Adiponectin,,2007-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
3945,NCT03280524,Quality of Life Questionnaire SF-36,,Stanford Health Assessment Questionnaire,2016-01,COMPLETED,INTERVENTIONAL,['NA']
3946,NCT03720197,Number of non-severe hypoglycemic episodes,Number of steps,,2019-02-20,RECRUITING,OBSERVATIONAL,['NA']
3947,NCT05604352,Assessing the safety of the DiaSole insole,acceptability of DiaSole to health care professionals (HCPs),,2023-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
3948,NCT04083820,Change in Glycated Haemoglobin A1c (HbA1c),Patient completed the study under treatment with semaglutide (yes/no),,2019-09-16,COMPLETED,OBSERVATIONAL,['NA']
3949,NCT01884363,Change in reactive hyperemia index occurring between baseline and 12 weeks (end of intervention),Change in blood levels of hormones produced by fat cells between baseline and 12 weeks (end of intervention),Change in heart rate variability between baseline and 12 weeks post-intervention,2013-06,COMPLETED,INTERVENTIONAL,['NA']
3950,NCT02346344,"Repeatability of the meal tolerance test and the arginine stimulation test, as indicated by the ICC (intraclass correlation coefficient)",,,2014-04,COMPLETED,OBSERVATIONAL,['NA']
3951,NCT02749942,Peripheral tissue oxygen oxygenation of dorsal part of foot,Cardiovascular Autonomic neuropathy; Heart rate variability,"Assessment of quality of life and empowerment, 4",2016-05-11,COMPLETED,INTERVENTIONAL,['NA']
3952,NCT05048719,Change From Baseline in HbA1c in LY3502970 as Compared to Placebo,Pharmacokinetics (PK): Steady State Area Under the Concentration Curve (AUC) of LY3502970,,2021-09-15,COMPLETED,INTERVENTIONAL,['PHASE2']
3953,NCT03119584,Improvement in frequency of bowel movements,,,2015-09-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4']
3954,NCT00944060,body weight,"dietary fat intake, fruit and vegetable intake, physical activity, stress, affects",,na,COMPLETED,INTERVENTIONAL,['PHASE3']
3955,NCT00918138,Change From Baseline in 24-Hour Mean Weighted Glucose (MWG) at Week 4,"Change From Baseline Fasting Plasma Glucose (FPG) at Week 4, Obtained Immediately Before the Morning Meal",Participants With Reported Hypoglycemic Adverse Events During Treatment Period,2009-08,COMPLETED,INTERVENTIONAL,['PHASE3']
3956,NCT00194558,Hemoglobin A1c,Satisfaction with care,,2005-02,COMPLETED,INTERVENTIONAL,['NA']
3957,NCT05918484,Specificity,Percentage of iCGM in MODY patients,,2023-07-01,RECRUITING,OBSERVATIONAL,['NA']
3958,NCT00689546,Duration of icteric hepatitis.,Mortality,,2007-02,UNKNOWN,OBSERVATIONAL,['NA']
3959,NCT01061060,Symptomatic improvement by Total Symptom Score (TSS),Change in mean rate of blood flow in the toes,,2010-01,COMPLETED,INTERVENTIONAL,['PHASE4']
3960,NCT01935466,Bladder cancer rate,,,2013-07,COMPLETED,OBSERVATIONAL,['NA']
3961,NCT00865033,Bioequivalence according to US FDA guidelines,,,2005-11,COMPLETED,INTERVENTIONAL,['PHASE1']
3962,NCT00806169,Best Corrected Visual Acuity,,,2006-04,COMPLETED,INTERVENTIONAL,['PHASE3']
3963,NCT01998269,Measure of Medication Self-Management (MeDS),,,2013-11,COMPLETED,OBSERVATIONAL,['NA']
3964,NCT01810822,Albumin to Creatinine Ratio,,,1994-05,COMPLETED,OBSERVATIONAL,['NA']
3965,NCT00588380,Insulin Secretion at 150-180 Minutes.,Insulin Secretion at 210-240 Minutes,,2007-11,COMPLETED,INTERVENTIONAL,['NA']
3966,NCT00655798,inflammation parameters,glucose and fat response,,2006-12,COMPLETED,INTERVENTIONAL,['NA']
3967,NCT00535483,,,,2007-08,COMPLETED,OBSERVATIONAL,['NA']
3968,NCT05630508,User friendliness,physical performance assessments - endurance,,2022-10-01,RECRUITING,INTERVENTIONAL,['NA']
3969,NCT01397513,Fibrin network permeability,Platelet microparticles,,2006-03,COMPLETED,INTERVENTIONAL,['PHASE4']
3970,NCT02608853,Incidence of all malignant neoplasms,Incidence of acute pancreatitis,,2015-01,COMPLETED,OBSERVATIONAL,['NA']
3971,NCT01769404,Concentration of Epinephrine,Concentration of Norepinephrine,,2013-02,COMPLETED,INTERVENTIONAL,['PHASE1']
3972,NCT01114061,show no increase in hypoglycemia events when the InsuPatch device is used compared to the number of hypoglycemia events when the InsuPatch device is not used.,,,na,SUSPENDED,INTERVENTIONAL,['NA']
3973,NCT04521452,Change in aortic valve calcium volume at week 96 from baseline,Time of major cardiovascular event,,2020-09,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
3974,NCT02202876,Acute oxidation,,,2014-11,COMPLETED,INTERVENTIONAL,['NA']
3975,NCT02287883,PHQ-4,,,2015-04,COMPLETED,OBSERVATIONAL,['NA']
3976,NCT02664207,Post-operative complications,,,2016-01-26,RECRUITING,INTERVENTIONAL,['NA']
3977,NCT05404061,Prospective assessment of gut hormone response pre and post-surgery: Change in Peak plasma level of gut hormones after meal ingestion.,Change in Genetic factors,,2018-08-01,RECRUITING,INTERVENTIONAL,['NA']
3978,NCT00407381,Mean Change in Best Corrected Visual Acuity (BCVA) at Month 6,,,2006-12,COMPLETED,INTERVENTIONAL,['PHASE2']
3979,NCT00132418,"Incidence of medically important infections, defined as infections that result in hospitalization or treatment with intravenous antibiotics","Infections associated with antimicrobial use; physical examination, vital signs, clinical laboratory assessments; symptom assessment, withdrawals, deaths, and serious adverse events",,2000-04,COMPLETED,INTERVENTIONAL,['PHASE4']
3980,NCT02252757,Measuring Cardiac Output for wireless transmission as per discharge guideline,,,2014-09,COMPLETED,OBSERVATIONAL,['NA']
3981,NCT03380403,Infection control,Osteomyelitis evaluation,,2010-01-01,COMPLETED,INTERVENTIONAL,['NA']
3982,NCT05394844,A1C,Self-Efficacy for Diabetes,,2022-11-11,RECRUITING,INTERVENTIONAL,['NA']
3983,NCT00223340,Document changes made to study procedures to better implement this study's interventions that are designed to reduce risks of heart disease and stroke,Assessment of Chronic Illness Care (ACIC) Surveys,,2005-03,COMPLETED,INTERVENTIONAL,['NA']
3984,NCT05489172,Sallis Self Efficacy for Physical Activity,Weight loss,HbA1C level,2020-02-01,COMPLETED,INTERVENTIONAL,['NA']
3985,NCT00954967,Smoking abstinence: Self reported abstinence (6 or more months without smoking) confirmed by an expired air carbon monoxide concentration of 6 parts per millions or less,Total time (minutes) spent in the intensive smoking cessation intervention,,2009-09,COMPLETED,INTERVENTIONAL,['NA']
3986,NCT00690768,amount of intraoperative intra-ocular bleeding,,,2008-03,COMPLETED,INTERVENTIONAL,['PHASE2']
3987,NCT05219526,Measurement performance: System accuracy,,,2022-01-03,COMPLETED,INTERVENTIONAL,['NA']
3988,NCT05353114,The primary outcome measure was the requirement of Therapeutic Footwear change after prescription because ill fitting.,Number of participants with an ulcer occurrence event,,2022-06-15,COMPLETED,INTERVENTIONAL,['NA']
3989,NCT00198497,Vitreous hemorrhage resolution,Visual Acuity,,1999-06,COMPLETED,INTERVENTIONAL,['PHASE3']
3990,NCT00343980,Treatment difference in HbA1c,Hypoglycaemia,,2006-10-10,TERMINATED,INTERVENTIONAL,['PHASE3']
3991,NCT04885712,Changes in HbA1c,,,2021-05-28,COMPLETED,INTERVENTIONAL,['PHASE3']
3992,NCT00570102,Positivity for two or more diabetes-associated autoantibodies and/or clinical type 1 diabetes,,,1995-02,COMPLETED,INTERVENTIONAL,['PHASE2']
3993,NCT00865124,Change in Coronary Flow Reserve From Baseline to 6 Months,Change in Renal Plasma Flow,,2008-09,COMPLETED,INTERVENTIONAL,['NA']
3994,NCT05286853,Primary Composite Endpoint,Second Secondary Endpoint: Time to End Stage Renal Disease,,2024-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
3995,NCT01179945,Blood glucose area under the curve (AUC),Metabolite Profiles,,2010-08,COMPLETED,INTERVENTIONAL,['NA']
3996,NCT05472883,Correlation between plasma levels of 9 target molecules and diabetes remission,The expression level of genes encoding 9 biomarkers in the adipocyte and the muscle cell,,2023-02-27,RECRUITING,INTERVENTIONAL,['NA']
3997,NCT03085524,Restenosis,,,2017-08-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
3998,NCT05929196,Blood sample relative permittivity,Mathematical model of blood glucose dependence on blood dielectric parameters,,2023-07-12,COMPLETED,INTERVENTIONAL,['NA']
3999,NCT03192605,Glucose (mmol/L),,,2017-05-15,COMPLETED,INTERVENTIONAL,['NA']
4000,NCT03567824,Change in Serum Magnesium Concentration,Change in HbA1c,,2026-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
4001,NCT04518813,Safety evaluation of the Investigational Medical Device by reporting of adverse events,Device function,,2020-09-24,COMPLETED,INTERVENTIONAL,['NA']
4002,NCT02429297,Change from baseline on self-care behaviors and health at 16 weeks (questionnaire),"Evaluate program feasibility (questionnaire, satisfaction, and usage rates)",,2014-06,COMPLETED,INTERVENTIONAL,['NA']
4003,NCT00892372,,,,2009-04,COMPLETED,OBSERVATIONAL,['NA']
4004,NCT02579837,Proportion of participants with Actionable Eye Disease (AED),Proportion of participants with Diabetic Maculopathy (DME),,2016-03,COMPLETED,INTERVENTIONAL,['NA']
4005,NCT01594333,Number of Subjects With Major Adverse Cardiovascular Event or Hospitalization for Unstable Angina That Led to Urgent Coronary Revascularization,Number of Subjects With New Onset Type 2 Diabetes,Number of Subjects With Atrial Fibrillation,2013-04,COMPLETED,INTERVENTIONAL,['PHASE3']
4006,NCT05444595,Body weight,Program acceptability from community health workers and study participants,,2023-07,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
4007,NCT01832181,Adiposity in the offspring,adipocytokine profile in the offspring,,2013-04,COMPLETED,OBSERVATIONAL,['NA']
4008,NCT05763069,Feasibility of Home monitoring of high-risk pregnancies,Placenta-associated biomarkers: improving CTG prediction of adverse outcomes?,,2022-11-21,RECRUITING,OBSERVATIONAL,['NA']
4009,NCT00668590,Hemoglobin A1c,Diabetes self-care behaviors,,2008-08,COMPLETED,INTERVENTIONAL,['NA']
4010,NCT05166200,Glucose positive area under the curve (AUC),Glucose Concentrations,Sensory Questionnaire,2022-03-11,COMPLETED,INTERVENTIONAL,['NA']
4011,NCT00661063,pain evaluation by visual analogue scale,pain evaluation by amount of rescue medication required,,2008-04,UNKNOWN,INTERVENTIONAL,['PHASE3']
4012,NCT06251466,Admission to the neonatal intensive care (NIC) in pregnancies with gestational diabetes mellitus in which telemonitoring was added to the standard care of gestational diabetes mellitus compared to the standard care without telemonitoring.,Reaction time from measuring abnormal glucose values to performing an intervention in pregnancies in which telemonitoring was added to the standard care of gestational diabetes mellitus compared to the standard care alone.,Satisfaction and usability of the modified care process through the administration of patient and staff questionnaires compared to the conventional follow-up approach.,2023-12-18,RECRUITING,INTERVENTIONAL,['NA']
4013,NCT03390231,Changes of inflammation-related markers in diabetic patients after Stem Cell Educator therapy,Metabolic control in fasting C-peptide levels,,2017-11-27,UNKNOWN,INTERVENTIONAL,['PHASE2']
4014,NCT03201406,Mortality,,,2017-06-20,UNKNOWN,OBSERVATIONAL,['NA']
4015,NCT03920085,Clinical Evaluation of Blood Glucose result (mg/dl) from LifeScan Blood Glucose Monitoring Systems by comparison of a blood glucose result (mg/dl) obtained from a reference instrument (YSI2900) to demonstrate accuracy (%).,,,2019-01-08,COMPLETED,INTERVENTIONAL,['NA']
4016,NCT01648218,Blood glucose - inpatient,Mortality,,2012-08,TERMINATED,INTERVENTIONAL,['PHASE4']
4017,NCT05380596,Adherence to treatment - Brief Medication Questionnaire (BMQ),Quality of life measured by DQOL-Brazil;,,2022-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
4018,NCT00790153,Pharmacodynamic variables,"Safety Variables (AEs, BP, pulse, electrocardiogram (ECG), hypoglycaemic symptoms and laboratory variables)",,2008-11,COMPLETED,INTERVENTIONAL,['PHASE1']
4019,NCT02498054,Success rate to categorize blood glucose values into accepted ranges.,Actual time taken to categorize blood glucose values into accepted ranges on the questionnaire provided.,,2015-07,COMPLETED,INTERVENTIONAL,['NA']
4020,NCT05869344,Glucose postprandial levels,,,2018-10-15,COMPLETED,INTERVENTIONAL,['NA']
4021,NCT05711602,Mini Nutritional Assessment (MNA),,,2023-01-09,COMPLETED,INTERVENTIONAL,['NA']
4022,NCT03798054,Change in HbA1c,Immunogenicity (antibody variables),,2019-02-15,COMPLETED,INTERVENTIONAL,['PHASE3']
4023,NCT05709847,Verbal memory,Processing Speed,,2023-01-01,RECRUITING,INTERVENTIONAL,['NA']
4024,NCT00921960,Prevalence and severity of LVD,,,2005-01,COMPLETED,INTERVENTIONAL,['NA']
4025,NCT00412269,,,,1998-02,COMPLETED,OBSERVATIONAL,['NA']
4026,NCT05139472,Peak Pulmonary Capillary Wedge Pressure (PCWP),6 minute walk time,,2021-11-09,COMPLETED,INTERVENTIONAL,['PHASE3']
4027,NCT02841969,Rate of complete wound healing,,,2017-02-28,SUSPENDED,INTERVENTIONAL,['NA']
4028,NCT00370565,"HbA1c is measured at Weeks -4, -1, 0, 6, and 12 of comparative treatment. The baseline value is the mean of the Week -1 and Week 0 values.","A patient satisfaction and preference questionnaire will be administered at screening, at baseline, during active therapy, and at the end of the study.",,1999-06,COMPLETED,INTERVENTIONAL,['PHASE3']
4029,NCT03021837,The length of time that maternal glucose levels remain elevated after steroid administration.,,,2012-08-24,COMPLETED,OBSERVATIONAL,['NA']
4030,NCT00561158,"Fat intake (measured by Food Frequency Questionnaire) including: percent calories from fat, percent calories from saturated fat.",Cultural relevancy,,1994-06,COMPLETED,INTERVENTIONAL,['PHASE2']
4031,NCT06188234,Change in HbA1c at 6 months of prescribing Tenero Tablet/Tenero Emextended Release Tablet compared to baseline,,,2022-12-27,RECRUITING,OBSERVATIONAL,['NA']
4032,NCT01904383,Percentage of Participants With Drug Related Adverse Events,The Mean Change From Baseline to Last Observation of the Treatment Period in Haemoglobin A1c (HbA1c),,2013-07-01,COMPLETED,OBSERVATIONAL,['NA']
4033,NCT00312156,HbA1c,Hypoglycaemia,,2002-08,COMPLETED,INTERVENTIONAL,['PHASE3']
4034,NCT03016832,ACR,High sensitivity C,,2017-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
4035,NCT03280758,Lipid profiles,Functional performance,,2017-10-01,UNKNOWN,INTERVENTIONAL,['NA']
4036,NCT00496405,Retinal thickness,Best corrected visual acuity,,2007-04,COMPLETED,INTERVENTIONAL,['PHASE4']
4037,NCT00541879,Diabetes knowledge and prevention behaviors in elementary school children,"Parental diabetes knowledge, self-reported physical activity",,2001-08,COMPLETED,INTERVENTIONAL,['NA']
4038,NCT01820169,Improvement in HbA1c in 6 months,5. Doctor's opinion for Accu-Chek 360° View.,,2013-04,TERMINATED,INTERVENTIONAL,['NA']
4039,NCT04004273,Change in liver saturated lipid index (%) determined by proton magnetic resonance spectroscopy (1H-MRS) using a 3T MRI scanner,Change in macronutrient intake,,2018-10-30,COMPLETED,INTERVENTIONAL,['NA']
4040,NCT01303042,pre- and postprandial glucose levels in SMBG,Total score of Questionnaire on QOL,,2011-02,UNKNOWN,INTERVENTIONAL,['NA']
4041,NCT00360815,,,,1983-08,COMPLETED,INTERVENTIONAL,['NA']
4042,NCT05666895,"Measure of inflammatory markers like (platelets-lymphocyte ratio, red blood cell distribution width) changes in DKA patients and affection of these changes on inflammation development and prognosis of DKA","Hematological parameters (RBC, Hct , Hb MCV, PLT ,WBC) which are used as an alternative approach to estimate the extent of dehydration in DKA patients",,2023-01-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
4043,NCT00709514,The incidence of complete ulcer closure,The time of healing rate and change in ulcer area,,2008-12,COMPLETED,INTERVENTIONAL,['PHASE2']
4044,NCT05777330,Progression to persistent dysglycemia and stage 3 type 1 diabetes,,,2023-08-09,RECRUITING,INTERVENTIONAL,['NA']
4045,NCT00306072,The primary variable to be measured was positive AUC (0-180 minutes) for plasma glucose.,· Positive AUC 0-180 (0 to 120) minutes for serum insulin,,2005-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4046,NCT00219440,glucose,blood pressure,,2003-02,COMPLETED,INTERVENTIONAL,['PHASE4']
4047,NCT01062048,Mean change in 2hr-postprandial glucose (PPG),,,2008-10,COMPLETED,OBSERVATIONAL,['NA']
4048,NCT05566912,Completing the surveys,,,2021-10-15,COMPLETED,OBSERVATIONAL,['NA']
4049,NCT01929863,Mean Change From Baseline in Overall Gastrointestinal Symptom Rating Scale (GSRS) Scores,Median Time to Observed Peak Plasma Concentration (Tmax) When Co-dosed With GSK2330672 or Placebo on Day 7,,2013-08-01,COMPLETED,INTERVENTIONAL,['PHASE2']
4050,NCT00675220,Safety profile of Insulin Aspart among Filipino patients,,,2007-06,COMPLETED,OBSERVATIONAL,['NA']
4051,NCT02041377,Number of Self-Test Fingerstick Blood Glucose (BG) Results Within +/- 15 mg/dL (<100 mg/dL) and Within +/- 15% (>=100 mg/dL) of Laboratory Glucose Method,Number of Subject Responses That Strongly Agree or Agree or Are Neutral With Questionnaire Statements,,2014-01,COMPLETED,INTERVENTIONAL,['NA']
4052,NCT01110577,Intra-class correlation coefficient (ICC) for repeated hepatic fat fraction (HFF) measurements from the LIPOQuant method,ICC for repeated HFF measurements from the 3-point Dixon method,,2010-05,COMPLETED,OBSERVATIONAL,['NA']
4053,NCT02060266,"Concentration of the major metabolites of [3H]-semaglutide in plasma, urine, and faeces",Maximum observed semaglutide plasma concentration,,2014-02-04,COMPLETED,INTERVENTIONAL,['PHASE1']
4054,NCT00977808,Occurrence of Hypoglycemic Episodes,,,2008-05,COMPLETED,INTERVENTIONAL,['NA']
4055,NCT05609747,high sensitivity C- reactive protein- hsCRP.,Clinical and Radiographic success,,2021-12-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4056,NCT05963152,Chronic change in Colour Trails Test score,12 week acute change in Colour Trails Test score,,2023-07-20,RECRUITING,INTERVENTIONAL,['NA']
4057,NCT01162694,The primary endpoint is the A1c level or the change in A1c level,A secondary endpoint includes adverse events such as unplanned hospitalizations for any cause that last more than 24 hours,,2010-07,SUSPENDED,INTERVENTIONAL,['NA']
4058,NCT04203147,LDL-Cholesterol,Self-Care Behaviors,Resource Utilization and Cost,2020-01-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4059,NCT02959762,Change in beta-cell function,Change in endothelial function (flow-mediated dilation),,2016-10,UNKNOWN,INTERVENTIONAL,['NA']
4060,NCT00136773,Change from baseline in the urine albumin/creatinine ratio after 52 weeks,Change from baseline in a marker of heart failure after 52 weeks,,2003-04,COMPLETED,INTERVENTIONAL,['PHASE4']
4061,NCT04476472,Time in Range 70-180 mg/dL,Body Mass Index (BMI) (kg/m^2),,2020-09-08,COMPLETED,INTERVENTIONAL,['NA']
4062,NCT02649010,Enlite 3 Sensor inserted at Arm accuracy using a real time device: (640G pump) with the minimum calibration requirements (every 12 hours after the second calibration) will be evaluated.,,,2016-01,WITHDRAWN,INTERVENTIONAL,['NA']
4063,NCT01107431,Fasting Blood Glucose,Fasting Blood Insulin Levels,,2008-12,COMPLETED,INTERVENTIONAL,['NA']
4064,NCT01008163,"Change from baseline in the fasting plasma glucose and postprandial glucose [after 2 hours, oral glucose tolerance test (OGTT) (75 g)] and HbA1c",Lipid profile,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE2']
4065,NCT02925156,Difference in body weight index (BMI) between high and low activity energy expenditure (AEE) groups.,,,2008-07,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
4066,NCT03766724,"Cmax,ss",,,2018-11-22,COMPLETED,INTERVENTIONAL,['PHASE1']
4067,NCT00649909,The outcome measure is the laboratory Aspirin Resistance.,"To determine the incidence of laboratory aspirin resistance in type 2 DM in stable out-patients in the diabetic clinic, and possibly related factors.",,2008-11,COMPLETED,OBSERVATIONAL,['NA']
4068,NCT04759495,Changes in glycated haemoglobin (HbA1c),"Incidence of skin reaction, infection or hematoma at the site of insertion of the sensor",,2019-06-01,UNKNOWN,INTERVENTIONAL,['NA']
4069,NCT05737654,Change in quality of life,,,2023-10-01,RECRUITING,INTERVENTIONAL,['NA']
4070,NCT01444248,compliance of patients treated with once-daily or twice-daily,other adverse events,,2010-08,COMPLETED,INTERVENTIONAL,['PHASE4']
4071,NCT00661362,Absolute Change From Baseline to Week 24 in Glycosylated Haemoglobin A1c (HbA1c),Proportion of Patients Achieving a Therapeutic Glycemic Response,,2008-06,COMPLETED,INTERVENTIONAL,['PHASE3']
4072,NCT05467345,Number of results from the Contour Next and Contour Plus Elite BGMSs reference values within ±20% of reference values,,,2022-08-24,COMPLETED,OBSERVATIONAL,['NA']
4073,NCT01508065,Accuracy of the Glucometer CGM-305 blood glucose readings as evaluated by Clark error grid with measurements of venous blood as the comparing value,The safety of the Glucometer CGM-305 in evaluating blood glucose levels,,2012-09,UNKNOWN,OBSERVATIONAL,['NA']
4074,NCT06032429,the self-management level assessed by the self-developed scale,the self-care level assessed by the self-developed scale,,2019-02-01,COMPLETED,INTERVENTIONAL,['NA']
4075,NCT01664624,Change From Baseline in Postprandial Area Under the Curve From Time 0 to 8 Hours (AUC[0-8]) for Active Glucagon-like Peptide-1,Change From Baseline to Day 11 in 24-hour Average Plasma Glucose,,2012-07,COMPLETED,INTERVENTIONAL,['PHASE1']
4076,NCT00525577,Change from baseline in HbA1c to the 6-month time point is identical in the study groups (placebo and AGI-1067 treatment groups),• Change of HbA1c from baseline throughout the study • Change of FPG from baseline throughout the study•,,2007-08,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
4077,NCT03063229,Total metabolic Rate (TMR),,,2016-06,TERMINATED,INTERVENTIONAL,['NA']
4078,NCT05322746,Short Form McGill Pain Questionnaire,,,2022-04-28,COMPLETED,INTERVENTIONAL,['NA']
4079,NCT02821117,Change in Time in Range,,,2016-06-30,COMPLETED,INTERVENTIONAL,['NA']
4080,NCT00727857,Percent Change From Baseline in Glycosylated Hemoglobin,Change From Baseline in Small Very Low Density Lipoprotein (V1+V2) Concentration,,2007-06,COMPLETED,INTERVENTIONAL,['PHASE3']
4081,NCT05200390,Change in percent time in range of 70-180mg/dL (%TIR),Percentage of patients at goal % CV,,2022-01-24,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
4082,NCT00824499,HBA1C,Influenza Vaccination Prescriptions,,2004-02,UNKNOWN,INTERVENTIONAL,['NA']
4083,NCT04129190,Oral Glucose Tolerance,,,2019-10-15,UNKNOWN,INTERVENTIONAL,['PHASE2']
4084,NCT00566124,"Area under GIR-curve, maximal glucose infusion rate, time to maximal glucose infusion rate.",,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE4']
4085,NCT02305355,The mean percent change of Triglyceride(TG),The mean percent change of apolipoprotein B,,2009-02,COMPLETED,INTERVENTIONAL,['PHASE4']
4086,NCT00521027,"Reduction in the average skin-to-skin time of the first surgical debridement with VERSAJET™, compared to conventional debridement techniques.","Difference in outcomes of the procedure, according to the debridement technique in terms of; time to wound closure, number of subsequent debridements, number of serious adverse events",,2006-04,COMPLETED,INTERVENTIONAL,['PHASE4']
4087,NCT01856595,Changes From Baseline for Mean Daily Glucose (mg/dL) on Day 28 (AUC Approach),Percent Change From Baseline in Lipid Parameters (mg/dL) by Treatment Group on Days 14 and 28 - Part B,,2013-05-13,COMPLETED,INTERVENTIONAL,['PHASE1']
4088,NCT05340868,Body composition - change in body weight (kg),Body composition - change in lean body mass content (kg),,2022-09-01,RECRUITING,INTERVENTIONAL,['NA']
4089,NCT03398538,Percentage of index ulcers healed at 12 weeks,Difference in cellulitis and/or infection at 12 weeks,,2017-12-26,COMPLETED,INTERVENTIONAL,['NA']
4090,NCT01176253,Use the assays to detect beta cell destruction throughout the early time-course of type 1 diabetes mellitus,,,2009-07,COMPLETED,OBSERVATIONAL,['NA']
4091,NCT03030209,Number of participants with new-onset diabetes mellitus as defined by American Diabetes Association,Number of participants with new-onset exocrine insufficiency,,2004-01-01,COMPLETED,OBSERVATIONAL,['NA']
4092,NCT00394875,lipid profile,health care consumption and costs,,2002-03,COMPLETED,INTERVENTIONAL,['NA']
4093,NCT06324669,Rate of endogenous glucose production,Energy expenditure,,2024-03-16,RECRUITING,INTERVENTIONAL,['NA']
4094,NCT02216201,Identification of participants with abnormal SUDOSCAN electrochemical skin conductance scores,,,2014-12,WITHDRAWN,OBSERVATIONAL,['NA']
4095,NCT00230087,(2) HOMA model- determined by the OGTT method,"Change in serum levels of proinflammatory cytokines (ie IL-6, TnF-αR2)",,2005-09,COMPLETED,INTERVENTIONAL,['PHASE2']
4096,NCT05761743,Assess glycemic control after parathyroidectomy in patients with primary hyperparathyroidism and concomitant type 2 diabetes mellitus,Assess the changes in skeletal profile after parathyroidectomy in patients with primary hyperparathyroidism and concomitant type 2 diabetes mellitus,,2023-02-27,RECRUITING,OBSERVATIONAL,['NA']
4097,NCT01201785,Collagen Induced Aggregation,,,2009-01,COMPLETED,INTERVENTIONAL,['PHASE4']
4098,NCT02706119,Hypoglycemia symptoms,Blood glucose coefficient of variation (CV),Adverse events,2016-07-01,COMPLETED,INTERVENTIONAL,['PHASE4']
4099,NCT01107886,"Participants With Any Event From the Composite of Cardiovascular Death (CV Death), Non-fatal Myocardial Infarction (MI), or Non-fatal Ischaemic Stroke",Participants With Event of Death,,2010-05,COMPLETED,INTERVENTIONAL,['PHASE4']
4100,NCT04803708,3. Incidence and severity of treatment-emergent SAEs and relationship to IP from first administration until EOS.,"Changes in wound/ulcer healing from to baseline in terms of wound complete closure and partial closure (25%, 50% and 75%) at EOT.",,2021-03-22,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4101,NCT05034380,Change from baseline in skeletal muscle whole genome nucleosome maps,Cholesterol,,2014-09-14,COMPLETED,INTERVENTIONAL,['NA']
4102,NCT00411970,Subjective postoperative recovery,Intra- and postoperative complications,,2004-09,COMPLETED,INTERVENTIONAL,['PHASE4']
4103,NCT03899623,"The diagnostic sensitivity, specificity and ROC curve of the artificial intelligence（AI） system compared with reference standard (ophthalmologist).",,,2018-04-23,UNKNOWN,OBSERVATIONAL,['NA']
4104,NCT05838287,Change in Diastolic function,PCr:ATP ratio,,2023-07-10,RECRUITING,INTERVENTIONAL,['PHASE4']
4105,NCT00462631,Late lumen loss at 9 months,Target vessel failure,,2007-05,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
4106,NCT04959799,Retrospective description of the setting of dalbavancin treatment in diabetic patients.,Incidence of Adverse Events,,2022-01-02,COMPLETED,OBSERVATIONAL,['NA']
4107,NCT00523393,Change of number of circulating EPC 4 weeks after start of therapy compared to baseline as detected by FACS analysis,Markers of inflammation and vascular risk in diabetes,,2007-08,UNKNOWN,INTERVENTIONAL,['PHASE4']
4108,NCT01093833,Blood Glucose,,,2009-01,COMPLETED,INTERVENTIONAL,['PHASE1']
4109,NCT03872089,Correlation with podologic grade,,,2019-04-08,TERMINATED,INTERVENTIONAL,['NA']
4110,NCT03534921,Healthcare interventions - referrals,,,2018-04-01,COMPLETED,OBSERVATIONAL,['NA']
4111,NCT00807976,Prevalence of orthostatic hypotension,"Adverse events, Score risk profile questionnaire, Heart rate, Gender, Body mass index, Medication, Smoking, History of cardiovascular disease, Family history of cardiovascular disease, Duration of diabetes mellitus, Glycosylated haemoglobin, Insulin use",,2009-01,COMPLETED,OBSERVATIONAL,['NA']
4112,NCT04597229,Change of fasting serum insulin,,,2020-09-28,COMPLETED,INTERVENTIONAL,['NA']
4113,NCT01940835,Mean Interleukin 15 (IL-15) Expression,,,2013-09,COMPLETED,OBSERVATIONAL,['NA']
4114,NCT05363774,Number of treatment emergent adverse events (TEAE) in T2D QW cohort,"Cmax,NNC0519-0130,SS: Maximum plasma concentration of NNC0519-0130 after the last dose in each treatment period in the MAD QW s.c. cohort",,2022-04-20,RECRUITING,INTERVENTIONAL,['PHASE1']
4115,NCT06220968,Cavernosal blood glutathione level,,,2024-03,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
4116,NCT05616351,Compliance with the hospital in-house guidelines for diabetic foot infections with regard to antibiotic treatment,Relapse of diabetic foot infections (number),,2022-10-12,COMPLETED,OBSERVATIONAL,['NA']
4117,NCT05426096,Hyperglycemia (glucose >180 mmol/dL),Glucose at first PACU measurement,Incidence of surgical site infection,2022-10-05,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
4118,NCT01521910,Rate of decline of GFR,,,1995-04,COMPLETED,INTERVENTIONAL,['NA']
4119,NCT01849965,The proportion of subjects with a target ulcer which achieves complete wound closure by 10 weeks (confirmed 2 weeks later) after initiation of treatment.,The proportion of subjects with a target ulcer which achieves complete wound closure by 10 weeks (confirmed two weeks later) after initiation of treatment.,Incidence of and time to target ulcer recurrence after confirmed complete wound closure has been established.,2013-04,TERMINATED,INTERVENTIONAL,['PHASE3']
4120,NCT02861157,STARx Transition Readiness Questionnaire,Quality of Life,,2015-07-01,COMPLETED,INTERVENTIONAL,['PHASE2']
4121,NCT05061030,Efficacy measured as change in C-peptide Area under the curve to a mixed mealtolerance test.,Change in peak C-peptide,Peripheral blood mononuclear cells,2022-01-14,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4122,NCT05886088,Glycated hemoglobin (HbA1c),Blood pressure,,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
4123,NCT04754464,BFM,HOMA-IR,WHtR,2020-05-13,COMPLETED,INTERVENTIONAL,['NA']
4124,NCT01127659,Insulin Sensitivity,Body Composition,,2010-05,COMPLETED,INTERVENTIONAL,['PHASE4']
4125,NCT05065879,Neutralizing antibody level,Adverse events following vaccination,,2021-10-05,COMPLETED,INTERVENTIONAL,['PHASE4']
4126,NCT01869959,Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,Change From Baseline to Day 28 in The Patient Health Questionnaire (PHQ-9) Score,,2009-04,COMPLETED,INTERVENTIONAL,['PHASE1']
4127,NCT03441919,"Arterial wall inflammation, measured by 18F-FDG-PET/CT","Arterial wall inflammation, measured by 18F-FDG-PET/CT",,2018-01-18,COMPLETED,OBSERVATIONAL,['NA']
4128,NCT03189225,"Venous blood collected for impact assessment of Biochemistry parameters on 3 LifeScan Blood Glucose Monitoring Systems (OneTouch Ultra 2, OneTouch Verio, OneTouch SelectPlus).",,,2016-08-01,COMPLETED,INTERVENTIONAL,['NA']
4129,NCT05811078,Implementation of trainings containing peer interactive group support to adolescents and application of scales,Evaluation of Data,,2023-04-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
4130,NCT06333132,Number of participants with incretin effect's restoration after achieving weightloss-induced diabetes remission,Rate of sustained weightloss-induced diabetes remission assessed by 2 consecutive HbA1c <48mmol/mol within 6 months,,2024-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
4131,NCT03565458,"Peak Plasma Concentration (Cmax) of gemigliptin, dapagliflozin, empagliflozin",metabolic ratio of gemigliptin,,2018-04-05,UNKNOWN,INTERVENTIONAL,['PHASE1']
4132,NCT00728156,To compare the effect of Clopidogrel in reduction of thrombogenicity in patients with T2DM and CAD with placebo,To characterise features in T2DM patients responsible for increased thrombogenicity,,2009-08,COMPLETED,INTERVENTIONAL,['PHASE4']
4133,NCT03044860,Evaluation of differences in enteroendocrine cells (density and mRNA expression) along the intestinal tract of healthy individuals compared with type 2 diabetes patients.,,,2011-03,COMPLETED,INTERVENTIONAL,['NA']
4134,NCT05135195,Average time it takes to understand how to interact with the system and run the simulation of the bus ride,,,2021-10-24,COMPLETED,INTERVENTIONAL,['NA']
4135,NCT01870934,Comparison of 3D image and normal assessment of wounds,Comparison of 3D and 2D image assessment of wounds,,2013-01,UNKNOWN,OBSERVATIONAL,['NA']
4136,NCT00771680,Serious adverse drug reactions including major hypoglycaemic events,Quality of Life (QoL) as assessed by patient questionnaire,,2008-10,COMPLETED,OBSERVATIONAL,['NA']
4137,NCT00375960,11 point numerical pain rating scale (NPRS) daily diary,daily sleep interference score,,2006-06,COMPLETED,INTERVENTIONAL,['PHASE2']
4138,NCT05337098,24-hour glycemic control,Monocyte chemoattractant protein-1,,2023-01-16,RECRUITING,INTERVENTIONAL,['NA']
4139,NCT00772356,Comparison of glucose infusion rate necessary to keep blood glucose constant,Serum insulin and free fatty acid levels,,2008-01,COMPLETED,INTERVENTIONAL,['NA']
4140,NCT01955746,Type 1 diabetes gene,,,2013-09,COMPLETED,OBSERVATIONAL,['NA']
4141,NCT01908894,Speed of absorption (TINS-50%-early) of BIOD-123 and BIOD-125 versus Humalog.,,,2012-02,COMPLETED,INTERVENTIONAL,['PHASE1']
4142,NCT02436369,Change from baseline in values of HbA1c at 8 week,"Change from baseline in values of Lipid profile (Total cholesterol, triglyceride, LDL-C, HDL-C) at 8 week",,2014-09,COMPLETED,INTERVENTIONAL,['NA']
4143,NCT00326326,HDL-C Safety and Efficacy,,,2006-07,COMPLETED,INTERVENTIONAL,['PHASE2']
4144,NCT00468351,"Central Macular Thickness, Best Corrected Visual Acuity",Intraocular pressure; lens status,,2006-04,UNKNOWN,INTERVENTIONAL,['PHASE1']
4145,NCT01103609,To evaluate the pharmacokinetics of warfarin after a single dose when administered alone and in combination with AZD1656 at steady state by assessment of AUC and Cmax of both enantiomers of warfarin (S- and R-warfarin).,"To describe the pharmacokinetics of AZD1656 and its metabolite during concomitant warfarin administration by assessment of AUC0-24, Cmax, Ctrough, tmax, t1/2 and CL/F (AZD1656 only).",,2010-04,COMPLETED,INTERVENTIONAL,['PHASE1']
4146,NCT04084171,Primary Outcome,CGM Consensus Goal,,2019-09-26,COMPLETED,INTERVENTIONAL,['NA']
4147,NCT04051359,The rate of treatment failure defined as patients needing additional hypoglycemic therapy by long-insulin acting analogue detemir evaluated by capillary glucose levels,,,2019-08-15,UNKNOWN,INTERVENTIONAL,['NA']
4148,NCT01062269,Patient Acceptability of Orange-flavored Generic Questran (Cholestyramine) vs. Tang (a Commercial Powdered Orange Drink) Via 2 Versions of a Bile Acid Sequestrant Acceptability (BASA) Scale.,Weighted vs. Unweighted BASA Scale,,2010-01,COMPLETED,INTERVENTIONAL,['PHASE4']
4149,NCT02666924,Glycemic control,Albuminuria screen,Diabetes self knowledge assessment,2017-10-31,COMPLETED,INTERVENTIONAL,['NA']
4150,NCT03132571,BMI,Waist Circumference (Inches),,2017-06-01,TERMINATED,INTERVENTIONAL,['PHASE2']
4151,NCT02482662,proportion of OGTTs falsely negative,preference of participants regarding the two tests (OGTT vs. SMBG),,2014-11,COMPLETED,OBSERVATIONAL,['NA']
4152,NCT01352390,Number of Participants that schedule an appointment for receipt of a Pap smear.,Number of Participants that schedule an appointment for receipt of a Fasting plasma glucose test,,2011-05,COMPLETED,INTERVENTIONAL,['NA']
4153,NCT01423877,Insulin Resistance,Vitals status,,2011-08,COMPLETED,OBSERVATIONAL,['NA']
4154,NCT00566566,,,,2008-01,UNKNOWN,OBSERVATIONAL,['NA']
4155,NCT01105858,Diabetes,,,2010-11-16,RECRUITING,OBSERVATIONAL,['NA']
4156,NCT03863054,Percentage change in ulcer size,Pain at wound site,,2018-08-17,COMPLETED,OBSERVATIONAL,['NA']
4157,NCT00790517,Cholesterol levels,Health/functional status,,2009-06,COMPLETED,INTERVENTIONAL,['PHASE2']
4158,NCT05407207,Change in fear of falling,Change in depression,,2018-06-01,UNKNOWN,INTERVENTIONAL,['NA']
4159,NCT00548522,The documentation of Cpeptide in women with type 1 diabetes who are pregnant,,,2007-08,TERMINATED,OBSERVATIONAL,['NA']
4160,NCT00968786,"blood pressure, blood glucose, body weight and visceral fat levels.",albuminuria,,2008-08,UNKNOWN,INTERVENTIONAL,['NA']
4161,NCT04190368,Number of Standard Care cohort participants completing appointments,PROMIS - Informational Support,Provider/Facilitator Session Feedback Form:,2021-09-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4162,NCT02835859,Measure in glucose concentrations,,,2014-08,COMPLETED,INTERVENTIONAL,['NA']
4163,NCT04150315,Major adverse coronary or cerebral event,,,2018-06-01,UNKNOWN,OBSERVATIONAL,['NA']
4164,NCT05736484,Change in mean daily step count from baseline to the end of the 26 week intervention period.,Participants' acute care utilization throughout the entire study (Baseline to end of study [52 weeks]).,,2023-09-19,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
4165,NCT04014660,Autoimmunity,,,2019-10-01,RECRUITING,INTERVENTIONAL,['NA']
4166,NCT02737722,"Number of Participants With Normal and Abnormal Cultures at Visits 2, 3, 4, and 5",Mean Change From Baseline in the Percentage of Area Reduction for Ulcers in the Per-Protocol Population,,2016-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4167,NCT00464061,Efficacy (sub-study): change from baseline for glycemic measure HbA1c,Safety: adverse events and laboratory abnormalities,,2007-04,TERMINATED,INTERVENTIONAL,['PHASE3']
4168,NCT02819011,Center of Mass (COM) Sway Change Baseline to 6 Months,Stride Length,,2016-05,COMPLETED,INTERVENTIONAL,['PHASE2']
4169,NCT01421225,Nocturnal Glycemic Control,Pre-lunch Blood Glucose Level,,2011-08,COMPLETED,INTERVENTIONAL,['NA']
4170,NCT03006666,Patient Activation Measure (PAM) scores,,,2017-07-13,COMPLETED,INTERVENTIONAL,['NA']
4171,NCT00902616,Improvement in microcirculation,Effect of L-arginine on clinical parameters of neuropathy,,2003-06,COMPLETED,INTERVENTIONAL,['PHASE4']
4172,NCT03882970,Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg),Rate of Hypoglycemia With Blood Glucose <54 Milligram/Deciliter (mg/dL) [<3.0 (Millimole/Liter (mmol/L))] or Severe Hypoglycemia,,2019-04-01,COMPLETED,INTERVENTIONAL,['PHASE3']
4173,NCT02135952,Changes in number of sites with probing depth (PD) ≥5 mm post-treatment,Occurrence of adverse events,,2011-09,UNKNOWN,INTERVENTIONAL,['PHASE4']
4174,NCT05492916,Percentage Change in Body Weight,Change in San Francisco Chinese Food Security Module Score,,2023-06-27,RECRUITING,INTERVENTIONAL,['NA']
4175,NCT04454957,Healthcare expenditures,Patient Health Questionnaire,,2020-08-24,RECRUITING,INTERVENTIONAL,['NA']
4176,NCT03486535,Sensory block duration,Rescue analgesic consumption,,2018-02-20,COMPLETED,OBSERVATIONAL,['NA']
4177,NCT00760526,Number of Participants With a Decrease >=0.5% HbA1c With no Severe Hypoglycemic Events,Parental Quality of Life Measures: CGM Satisfaction Scale,,2010-09,COMPLETED,INTERVENTIONAL,['PHASE3']
4178,NCT01709123,Blood Glucose Levels,Blood Levels of Cytokines/Inflammatory Biomarkers,,2007-08,COMPLETED,INTERVENTIONAL,['NA']
4179,NCT01654172,Change in Fasting Brain Blood Flow,Change in diabetes control,,2006-09,COMPLETED,INTERVENTIONAL,['NA']
4180,NCT05222373,Change from Baseline HbA1c to 6 months,Change from Baseline Quality of Life to 6 months,Intervention Implementation Adaptability,2023-12-07,RECRUITING,INTERVENTIONAL,['NA']
4181,NCT02293135,Peripheral microcirculation measured using Laser Doppler flowmetry,Reactive Hyperemia Index (RHI),,2014-11,UNKNOWN,INTERVENTIONAL,['NA']
4182,NCT01316107,change from baseline in hemoglobin A1c (HbA1c),"Safety as reflected by adverse events, routine safety laboratories, vital signs, physical examinations and 12-lead electrocardiograms (ECGs)",,2011-01-15,COMPLETED,INTERVENTIONAL,['PHASE3']
4183,NCT00229112,Clinical Cure/Improvement at discontinuation of IV antibiotic therapy.,Clinical Cure: 1. Day 5 of IV antibiotic therapy; 2.10 days after completion of all antibiotic therapy.,,2001-04,COMPLETED,INTERVENTIONAL,['PHASE3']
4184,NCT01751399,Pharmacokinetics: Maximum Concentration (Cmax) of LY2605541,,,2012-12,COMPLETED,INTERVENTIONAL,['PHASE1']
4185,NCT02365129,Change from Baseline in BAT mass and activity evaluated with Positron emission tomography/computed tomography (PET/CT),Change from Baseline in Basal Heart Rate Variability: with a heart rate monitor,,2015-02,UNKNOWN,INTERVENTIONAL,['NA']
4186,NCT05201846,Time in range,Perceived stress scale of parents,,2022-01-18,UNKNOWN,INTERVENTIONAL,['NA']
4187,NCT01018602,development of type 2 diabetes mellitus by criteria of ADA 1997,,,2008-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
4188,NCT05304975,Generation of variability data on the primary outcome measure (cognition) from baseline to 6 months on which to base a formal power calculation for a large-scale trial,,,2021-11-01,COMPLETED,INTERVENTIONAL,['NA']
4189,NCT01654380,Part B: Glycodynamics: Maximum Rate of Glucose Disposal,,,2012-07,COMPLETED,INTERVENTIONAL,['PHASE1']
4190,NCT02907684,Liver fat %,Plasma leptin,4 day food diaries,2017-03-29,COMPLETED,INTERVENTIONAL,['NA']
4191,NCT01715012,Safety,Scarring of skin graft donor site,,2012-10,TERMINATED,INTERVENTIONAL,['PHASE2']
4192,NCT01919489,Glycemic Control at Hospital Discharge and 6 Months Follow up,Self-measured Blood Glucose (SMBG) 7-point Profiles at 26 Weeks Follow up,,2014-03,COMPLETED,INTERVENTIONAL,['PHASE4']
4193,NCT03067662,Change in fasting plasma glucose levels (mg/dL),Length (cm) of child 3 months after delivery,,2012-09-27,UNKNOWN,INTERVENTIONAL,['NA']
4194,NCT05616273,A description of the strength and reproducibility of the relationship of post-Mixed Meal and Arginine stimulated glucagon with hypoglycaemia.,Home finger prick blood spot C-peptide measurement is a practical alternative to MMTT,,2023-03-23,RECRUITING,OBSERVATIONAL,['NA']
4195,NCT00998699,Change in beta-cell function as measured by change in C-peptide level during thd MMTT (Mixed meal tolerance test) at Day 112 compared to baseline (Day 0 pre-dose),Measurement of serum concentrations of XOMA 052,,2010-02,COMPLETED,INTERVENTIONAL,['PHASE2']
4196,NCT01744132,All Aims: DFE follow-up adherence rate,Aim 3: Rates of ocular disease,,2012-10,COMPLETED,INTERVENTIONAL,['NA']
4197,NCT02949193,HbA1c,HbA1c response rate,,2013-05,COMPLETED,INTERVENTIONAL,['PHASE3']
4198,NCT03650088,Change in Weight,Change in Diabetes-related Quality of Life: The Diabetes Obstacles Questionnaire (DOQ-30),,2019-10-20,COMPLETED,INTERVENTIONAL,['NA']
4199,NCT01494935,Insulin Sensitivity,ceramides and diacylglycerol,,2011-04,COMPLETED,INTERVENTIONAL,['NA']
4200,NCT06319300,time in target range (3.9-10.0 mmol/L ),Other/Serious Adverse Events,,2024-03-20,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
4201,NCT00603031,phase insulin response and phase insulin response measured as incremental area under the curve from 0-10 minutes and incremental area under the curve from 10-45 minutes respectively after iv glucose,maximal insulin response defined as mean insulin at time 47 and 49 minutes (2 and 4 minutes after infusion of L-Arginine),,2008-01,COMPLETED,INTERVENTIONAL,['NA']
4202,NCT05850611,Wound Size,Neutrophils count at baseline and after the intervention,,2023-04-30,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
4203,NCT06099509,Completion of 75-gram oral glucose tolerance test,,Patient satisfaction,2023-11-02,RECRUITING,INTERVENTIONAL,['NA']
4204,NCT00704223,number of major and minor hypoglycaemic events and adverse events,FBG,,2008-05,COMPLETED,OBSERVATIONAL,['NA']
4205,NCT00441077,Intentions to seek information about family history.,,,2007-02-19,COMPLETED,INTERVENTIONAL,['NA']
4206,NCT00824148,Level of HbA1c concentration,Number of hypoglycemic events,,2009-01,COMPLETED,INTERVENTIONAL,['NA']
4207,NCT02244814,Neonatal adiposity,Placental fatty acid transporter protein-2 expression,Infant Adiposity,2015-07,COMPLETED,INTERVENTIONAL,['NA']
4208,NCT01214239,HbA1c Change From Baseline at Week 24,Number With HbA1c at Least Lowering 0.5%,,2010-10,COMPLETED,INTERVENTIONAL,['PHASE3']
4209,NCT00116922,Development of diabetes based on 1 positive OGTT or 2 fasting glucose levels,"Lipids, CBC, CRP, homocysteine, adiponectin, insulin, proinsulin, and routine biochemistry will be done annually",,2004-06,COMPLETED,INTERVENTIONAL,['PHASE3']
4210,NCT01922791,Prevalence of allergy in child,Physical activity by questionnaires and activity monitor,"Body composition, growth, development and metabolic markers of the child",2013-10,COMPLETED,INTERVENTIONAL,['NA']
4211,NCT03922750,Percentage of Time in Target Range 3.9-10.0 mmol/L (70-180 Milligrams Per Deciliter (mg/dL)) Measured Using CGM (Continuous Glucose Monitoring),"Number of Hypoglycaemic Alert Episodes(Level 1) (Greater Than or Equal to 3.0 and Below 3.9 mmol/L (Greater Than or Equal to 54 and Below 70 mg/dL), Confirmed by BG Meter)",,2019-05-09,COMPLETED,INTERVENTIONAL,['PHASE2']
4212,NCT05457933,Noninferiority in mean differences between groups in their daily blood glucose concentrations,Diuretics Use,,2022-07-29,COMPLETED,INTERVENTIONAL,['PHASE4']
4213,NCT01829256,Change in kidney function as measured by estimated glomerular filtration rate based on cystatin C(eGFRcys),"Change in blood pressure, glucose/HbA1c and urine albumin",,2014-05,COMPLETED,INTERVENTIONAL,['NA']
4214,NCT03758742,"Mean 24-hour glucose levels, peak glucose levels, and mean amplitude of glycemic excursions (MAGE), as measured using continuous glucose monitoring",Dosage of cardiovascular medications used,Intervention satisfaction and feedback,2019-09-10,COMPLETED,INTERVENTIONAL,['NA']
4215,NCT05165628,"Incidence of changes from baseline in haematology, biochemistry, and urinalysis parameters.",Duration of clinic/home care visits across groups,,2022-01-04,RECRUITING,INTERVENTIONAL,['PHASE1']
4216,NCT01718522,Number (n) of Excursions <70 mg/dl Per Sensor Day at Baseline and 3 Months,Interstitial Sensor Glucose Excursions After Meals (Amplitude of Excursions) at Baseline and 3 Months,,2012-02,COMPLETED,OBSERVATIONAL,['NA']
4217,NCT03416270,Proximal sodium reabsorption (FENa),Urinary adenosine,,2018-06-28,COMPLETED,INTERVENTIONAL,['PHASE2']
4218,NCT02287285,Beta Cell Sensitivity (BCS),Maximal Beta Cell Function,,2014-10,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
4219,NCT02969863,Percentage of Time Spent With Dexcom CGMG < 60 mg/dl,,,2017-04-01,COMPLETED,INTERVENTIONAL,['NA']
4220,NCT05006872,Mean adherence to antidiabetic drugs (%),Self-efficacy to manage Diabetes (DSES-S),International Physical Activity Questionnaire (IPAQ),2021-10-06,UNKNOWN,INTERVENTIONAL,['NA']
4221,NCT03863431,Whole-body insulin sensitivity index,Subjective appetite ratings,,2019-05-22,UNKNOWN,INTERVENTIONAL,['NA']
4222,NCT04088461,Pancreatic beta cell function,,,2016-09,COMPLETED,INTERVENTIONAL,['PHASE4']
4223,NCT01429506,weight loss,glycemic control,,2011-01,COMPLETED,INTERVENTIONAL,['NA']
4224,NCT00722631,Effect of treatment on the nominal change in FDG uptake of atherosclerotic plaque from baseline after 4 months of treatment as measured by FDG-PET/CT imaging.,All cardiovascular events and all cause death for 5 years,,2007-05,COMPLETED,INTERVENTIONAL,['NA']
4225,NCT03999268,Change from baseline in psychological insulin resistance at 6 months,Provider Satisfaction,Provider usability,2019-11-25,COMPLETED,INTERVENTIONAL,['NA']
4226,NCT04436900,Angiography with fluorescein,,,2018-04-10,COMPLETED,INTERVENTIONAL,['NA']
4227,NCT00563225,"To evaluate safety & efficacy of Insulin glargine ( injection at bedtime, once a day) on the changes of HbA1c.","To evaluate the efficacy of Insulin glargine (injection at bedtime, once a day) on the changes of FPG.",,2002-10,COMPLETED,INTERVENTIONAL,['PHASE3']
4228,NCT01868555,Adverse events (AEs),Area under the serum insulin aspart concentration curve,,2007-12,COMPLETED,INTERVENTIONAL,['PHASE1']
4229,NCT05491005,HbA1c,Diabetes complications follow-up,proBNP,2022-08-31,RECRUITING,INTERVENTIONAL,['NA']
4230,NCT01837121,Not-attended rate,Satisfaction with care,,2015-01,COMPLETED,INTERVENTIONAL,['NA']
4231,NCT05762107,Incidence of nocturnal hypoglycemia,Incidence of hypoglycemia,Mean glucose concentration,2023-07-28,RECRUITING,INTERVENTIONAL,['PHASE2']
4232,NCT00177398,Time to mean 24 hour plasma glucose < 180 mg/dl,Outpatient glycemic control and self management practices,,2005-02,COMPLETED,INTERVENTIONAL,['PHASE4']
4233,NCT05577286,balance,,,2023-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
4234,NCT04786262,Proportion of Participants Free of Severe Hypoglycemic Events With Either a Glycosylated Hemoglobin (HbA1c) <7.0% or a ≥ 1% Reduction in HbA1c From Baseline,Changes in Stimulated C-peptide,,2021-03-29,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4235,NCT00434616,"Major amputation of the index limb or persisting, unchanged critical limb ischemia",survival without amputation,,2007-04,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
4236,NCT06287645,Finding inter-rater agreement among the graders,,,2022-05-12,RECRUITING,OBSERVATIONAL,['NA']
4237,NCT04589689,Adolescent quality of life,Hemoglobin A1c (HbA1c),,2020-12-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4238,NCT04977635,"Change in patient-reported outcomes between baseline and 2 year timepoint as measured by WHO-5, PAID-20 and WHOQOL surveys",,,2016-06-08,COMPLETED,OBSERVATIONAL,['NA']
4239,NCT02489968,Change in Glycated Haemoglobin A1c (HbA1c) (%) From Baseline After 24 Weeks of Treatment,,,2015-05-12,COMPLETED,INTERVENTIONAL,['PHASE3']
4240,NCT02068872,Safety of Sleeve Gastrectomy,Weight Loss,,2014-02,COMPLETED,INTERVENTIONAL,['PHASE1']
4241,NCT01249677,Improvements in first and second phase insulin secretion,,,2009-01,COMPLETED,INTERVENTIONAL,['PHASE4']
4242,NCT00308308,Compare the Mean Change From Baseline to Week 52 in HbA1c,Severe Hypoglycemia Event Rate,,2006-02,COMPLETED,INTERVENTIONAL,['PHASE3']
4243,NCT00182286,,,,1999-09,COMPLETED,OBSERVATIONAL,['NA']
4244,NCT06254339,Dyslipidemia,The China-PAR project model,,2011-01-01,COMPLETED,OBSERVATIONAL,['NA']
4245,NCT03308773,Time to development of type 2 diabetes,,,2009-01-05,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
4246,NCT02051959,Reduced phantom limb pain,Effects of treatment on the electrical activity of the brain,,2015-05,SUSPENDED,INTERVENTIONAL,['NA']
4247,NCT01242826,Area under the serum insulin aspart concentration-time curve from 0 to 24hours,Number of hypoglycaemic events,,2011-02,COMPLETED,INTERVENTIONAL,['PHASE1']
4248,NCT02597049,Change From Baseline in the HbA1c at 24 Weeks (Efficacy Estimand),Number of Participants With Adjudicated Cardiovascular (CV) Events,,2015-11,COMPLETED,INTERVENTIONAL,['PHASE3']
4249,NCT05624853,Change from baseline to week 8 in Visual Analogue Scale(VAS),Number and proportion of subjects with adverse event,,2020-05-12,COMPLETED,INTERVENTIONAL,['PHASE4']
4250,NCT01043029,Renal function: estimated glomerular filtration rate,Effect on blood hemoglobin,,2010-05,COMPLETED,INTERVENTIONAL,['PHASE2']
4251,NCT02920918,Change From Baseline Ventilatory Efficiency at 12 Weeks,,,2016-10,COMPLETED,INTERVENTIONAL,['PHASE4']
4252,NCT05915884,Change in triglyceride index,,,2023-06-10,RECRUITING,OBSERVATIONAL,['NA']
4253,NCT03222180,Glycated hemoglobin (Hemoglobin A1c),Website utilization,,2018-02-15,COMPLETED,INTERVENTIONAL,['NA']
4254,NCT03883412,Microvascular Blood Volume - change from baseline,Insulin Sensitivity-Change from baseline,,2019-02-28,RECRUITING,INTERVENTIONAL,['PHASE4']
4255,NCT05751720,Change in Liver fat quantification,Glycaemic control,,2023-10-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4256,NCT00423215,Measure of Glycolysated Haemoglobin (HbA1c) level reduction,Patient's satisfaction,,2006-03,COMPLETED,OBSERVATIONAL,['NA']
4257,NCT03965975,Accuracy to compared device,,,2019-06-10,UNKNOWN,INTERVENTIONAL,['NA']
4258,NCT03221127,Death,Infectious disease,,1984-03-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
4259,NCT02695433,Changes in insulin sensitivity as measured by the Matsuda composite index of insulin sensitivity (MISI) in 12-week intervention of active treatment vs control treatment.,Changes in plasma HDL cholesterol in 12-week intervention of active treatment vs control treatment.,Changes in blood MCP-1 in 12-week intervention of active treatment vs control treatment.,2016-03-01,COMPLETED,INTERVENTIONAL,['NA']
4260,NCT01894568,Change From Baseline to Week 26 in Hemoglobin A1c (HbA1c),Percentage of Participants With Total and Nocturnal Hypoglycemic Events (HE),,2013-07,COMPLETED,INTERVENTIONAL,['PHASE3']
4261,NCT02544347,omentin levels,clinical attachment level,,2014-07,COMPLETED,INTERVENTIONAL,['NA']
4262,NCT02924207,change in hemoglobin A1c from baseline,actual cost and change in frequency of drug side effects,,2016-09,COMPLETED,INTERVENTIONAL,['NA']
4263,NCT03018938,Change From Baseline to Week 24 in Hemoglobin A1c (HbA1c),Change From Baseline to Week 48 in Self-Efficacy About Insulin Therapy Questionnaire (SEITQ) Score,,2017-02-06,COMPLETED,INTERVENTIONAL,['PHASE4']
4264,NCT03167996,Initial User Assessment,,,2016-06-23,COMPLETED,INTERVENTIONAL,['NA']
4265,NCT05904743,Change in HbA1c,CGM-measured hypoglycemia events (both a safety and efficacy endpoint),Patient-reported outcome (PRO) questionnaires,2023-07-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4']
4266,NCT00355537,"The effect of testosterone replacement on arterial stiffness measured by ultrasound derived index B of the femoral artery in men with a combination of DM, PVD and hypogonadism.","The effect of testosterone on markers of vascular risk; blood pressure, serum-lipid levels, weight, waist circumference, body fat percentage, urinary micro-albumin concentration and C reactive protein levels.",,2006-02,COMPLETED,INTERVENTIONAL,['PHASE4']
4267,NCT04992299,Recruitment Feasibility: Percentage of Eligible Adolescents who Enroll,Assessment Feasibility: Percentage Accuracy of Protocols,,2022-05-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4268,NCT01480791,The primary endpoint is baseline-adjusted change in media/lumen ratio in patients who were randomized to aliskiren (group 1) comparatively to those randomized to hydrochlorothiazide (group 2),Flow-mediated dilation in hypertensive diabetic patients randomized to aliskiren vs. hydrochlorothiazide,,2012-01,WITHDRAWN,INTERVENTIONAL,['PHASE2']
4269,NCT03638778,"AUC0-24h,sema,day10, area under the semaglutide plasma concentration time curve from 0 to 24 hours after the 10th dosing",Number of treatment emergent adverse events,,2018-08-17,COMPLETED,INTERVENTIONAL,['PHASE1']
4270,NCT04286529,C-Peptide Level,PROMIS 10 Questionnaire,,2020-10-01,TERMINATED,INTERVENTIONAL,['PHASE1']
4271,NCT00858273,Glutathione Concentration,Plasma Protein Bound 3-nitrotyrosine,,2008-03,COMPLETED,INTERVENTIONAL,['NA']
4272,NCT03869281,Fracture incidence,,,2019-12-07,COMPLETED,OBSERVATIONAL,['NA']
4273,NCT04031222,Inflammatory markers,,,2017-05-19,COMPLETED,OBSERVATIONAL,['NA']
4274,NCT03753568,Adherence to the medication,Variation of daily pill taking times,,2019-03-20,UNKNOWN,INTERVENTIONAL,['NA']
4275,NCT02464462,Serum calcidiol,Glycated Hemoglobin,,2010-05,COMPLETED,INTERVENTIONAL,['PHASE1']
4276,NCT05222477,"Sleep quality (0 is best, 3 is worst)",Abdominal and pelvic floor muscle electrical activity,,2021-11-15,COMPLETED,INTERVENTIONAL,['NA']
4277,NCT03761797,Number of Participants With Adverse Drug Reactions (ADRs),,,2019-01-15,COMPLETED,OBSERVATIONAL,['NA']
4278,NCT06206005,Crestal bone loss around implants,Probing depth,,2023-12-04,RECRUITING,OBSERVATIONAL,['NA']
4279,NCT01465672,"diagnostic accuracy, i.e. difference of copeptin levels between patients without and patients with postoperative DI, of copeptin in the diagnosis of water disturbance in neurosurgical patients",,,2011-10,COMPLETED,OBSERVATIONAL,['NA']
4280,NCT05492305,subjective effect of GLP1 receptor agonist on mental health,mean change in eating disorder examination questionnaire (EDE-Q) score with GLP1 receptor agonist over 12-16 weeks,,2022-09,RECRUITING,OBSERVATIONAL,['NA']
4281,NCT03427931,Percentage Time in Range 70-180 mg/dL by CGM,Percentage Time in Range <70 mg/dL by CGM,,2018-02-01,COMPLETED,INTERVENTIONAL,['NA']
4282,NCT01340924,Glucose tolerance assessed using a 75g-Oral Glucose Tolerance Test (OGTT) in mothers,Physical activity,,2009-09,UNKNOWN,OBSERVATIONAL,['NA']
4283,NCT05091736,Analysis of system accuracy based on DIN EN ISO 15197,,,2021-10-18,COMPLETED,INTERVENTIONAL,['NA']
4284,NCT05154045,Glucose positive area under the curve (AUC),Glucose Concentrations,Sensory Questionnaire,2022-04-09,COMPLETED,INTERVENTIONAL,['NA']
4285,NCT00800176,Absolute Change in HbA1c,Percentage of Participants With at Least One Adverse Event,,2009-01-22,COMPLETED,INTERVENTIONAL,['PHASE2']
4286,NCT04429737,Assessment of the change in Albumin (g/L) relative to baseline,,,2017-03-01,UNKNOWN,INTERVENTIONAL,['NA']
4287,NCT05684341,Change from baseline in HbA1c at Week 24,Number of participants with adverse events during the 24-week study period,,2023-02-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4288,NCT05571306,Changes in Diabetes Distress levels,Changes in Blood lipds,Changes in Resilience measured using the Conner-Davidson Resilience Scale,2022-01-01,RECRUITING,INTERVENTIONAL,['NA']
4289,NCT04217291,Changes in Glycosylated Hemoglobin A1c (HbA1c),Changes in abdominal weight relative to baseline at 8 and 16 weeks.,,2019-12-10,COMPLETED,INTERVENTIONAL,['PHASE2']
4290,NCT01726621,User Acceptance of the New MiniMed 620G and 640G Insulin Pumps and Guardian Link Transmitter,,,2013-03,COMPLETED,INTERVENTIONAL,['NA']
4291,NCT04073641,"Diabetes membership survey of health, access to care, support and services",,,2019-04-11,COMPLETED,OBSERVATIONAL,['NA']
4292,NCT02194517,HbA1c (glycated hemoglobin),Glucose Area Under the Curve (AUC),Treatment satisfaction,2013-04,COMPLETED,INTERVENTIONAL,['NA']
4293,NCT02208115,Acute subjective appetite responses,,,2013-11,COMPLETED,INTERVENTIONAL,['NA']
4294,NCT02216552,Efficacy Outcome,Efficacy Outcome,,2015-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
4295,NCT06297980,Glucose standard deviation,Glucose standard deviation,,2024-03-15,RECRUITING,INTERVENTIONAL,['NA']
4296,NCT05523375,Body weight (Percent Change),Perceived Stress Scale-4 Questionnaire,,2022-08-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4297,NCT05214209,Acceptability of mobile app assessed by a semi-structured interview,Change in waist-to-hip ratio,,2022-03-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4298,NCT02718638,Changes in cytokines plasma levels,,,2013-01,COMPLETED,INTERVENTIONAL,['NA']
4299,NCT06039293,Number of Steps,General Quality of Life,Aerobic Capacity,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
4300,NCT05181254,Proportion of patients who change their risk profile,Blood pressure,,2020-01-01,RECRUITING,INTERVENTIONAL,['NA']
4301,NCT01001689,Maternal body composition,Proportion of newborns with birth weight over the 90th percentile for gestational age,,2009-09,COMPLETED,INTERVENTIONAL,['NA']
4302,NCT01161043,Glucose Sensor Accuracy When Compared to SMBG: Proportion of Glucose Sensor Readings That Met Accuracy Criteria [Time Frame: Days One Through Six of Sensor Use],Device Related Moderate or Device Related Severe Adverse Events,,2010-07,COMPLETED,INTERVENTIONAL,['NA']
4303,NCT04857996,Ocular and systemic safety and tolerability of a single IVT injection of UBX1325 evaluated by incidence of treatment emergent adverse events (TEAEs),Proportion of patients without macular fluid as assessed by SD-OCT,,2021-06-25,COMPLETED,INTERVENTIONAL,['PHASE2']
4304,NCT03945968,incidence of postoperative complications,mortality after abdominal surgery,,2019-07-01,RECRUITING,OBSERVATIONAL,['NA']
4305,NCT00399997,Patient-reported health related quality of life at 4 and 10 months,Patient-reported compliance with national guidelines for physical activity at 4 and 10 months,,2005-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
4306,NCT03430284,Control rate of diabetes and diabetic vascular complications,Stage of diabetic retinopathy evaluated by fundus photograph,,2018-04-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
4307,NCT02627898,"Change from Baseline in Aortic Pulse Wave Velocity measured in meters / second, at 12 weeks",Change from Baseline in central systolic blood pressure measured in mm / Hg at 12 weeks,Change from Baseline in Body and visceral fat measured in centimeters ^ 2 at 12 weeks,2016-01,COMPLETED,INTERVENTIONAL,['PHASE2']
4308,NCT00561171,ABPM,sitting PB,,2007-11,COMPLETED,INTERVENTIONAL,['PHASE2']
4309,NCT01051245,"Combined outcome assessing adequate control of hypertension, LDL-cholesterol and glycated hemoglobin",Quality of care process measures,,2010-03,COMPLETED,INTERVENTIONAL,['NA']
4310,NCT05484427,metabolic control (HbA1c concentrations) at Month 9,Patient´s satisfaction of regular and telemedicine (email) visits.,,2021-04-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4311,NCT03479788,REM OSA,,,2018-06-04,COMPLETED,OBSERVATIONAL,['NA']
4312,NCT02662842,Comparative Infusion Set Wear Comfort,Overall Infusion Set Preference,,2016-01,COMPLETED,OBSERVATIONAL,['NA']
4313,NCT04660006,Change from baseline of retinal thickness up to 3 months post-cataract surgery.,Development of new cystoid macular edema,,2019-05-27,UNKNOWN,OBSERVATIONAL,['NA']
4314,NCT05202470,The Problem Areas in Diabetes Scale (PADS),,,2022-01-06,COMPLETED,INTERVENTIONAL,['NA']
4315,NCT02647346,Occurrence of Plantar Diabetic Foot Ulcer,Device-related Injuries,,2013-11,COMPLETED,INTERVENTIONAL,['NA']
4316,NCT02460783,Mean Change in Neuron-Derived Extracellular Vesicle (NDEV) P-pan-Tyrosine-IRS-1 (pY-IRS-1),Mean Change in Total Sedentary Bouts,,2015-06-22,COMPLETED,INTERVENTIONAL,['NA']
4317,NCT00944619,Percentage of plasma glucose values in target (3.9-8.0 mmol/L),Percentage of plasma glucose and CGM values below 3.0 mmol/L,,2009-09,COMPLETED,INTERVENTIONAL,['NA']
4318,NCT05944718,Impact of continuous and intermittent CGM use on blood glucose levels in comparison to standard of care in people living with type 1 diabetes,5. Cost of continuous and intermittent CGM use from a user and provider perspective,,2023-09-11,RECRUITING,INTERVENTIONAL,['NA']
4319,NCT05716308,Criteria for visual acuity changes,,,2019-06-01,COMPLETED,INTERVENTIONAL,['NA']
4320,NCT01620125,HOMA index,Changes in diabetes medication and hypoglycemia events,,2012-05,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
4321,NCT00975533,"composite quantitative score calculate from the results of glycemic control, weight response and degree of hypoglycemia",differences in insulin requirement,,2009-10,UNKNOWN,INTERVENTIONAL,['PHASE3']
4322,NCT01260857,Report of Adverse Events occurence (Safety),% of patients reaching BP goal of <140/90 mmHg and <130/80 mmHg for DM and proteinuric patients,,2013-03,WITHDRAWN,OBSERVATIONAL,['NA']
4323,NCT01941719,Patient Interpretation of Neuropathy (PIN) Questionnaire,Foot Complications,,2008-05-02,COMPLETED,INTERVENTIONAL,['NA']
4324,NCT05500937,Changes of HbA1c,Rate of MACE,,2021-03-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
4325,NCT01391585,response rate to home monitoring prompts,response to barrier questions for non-adherence,,2011-06,COMPLETED,INTERVENTIONAL,['NA']
4326,NCT02805543,The correlation between the bilateral retrobulbar RI and bilateral kidney RI in 34 patients,,,2016-02,COMPLETED,OBSERVATIONAL,['NA']
4327,NCT00891683,To evaluate the potential efficacy of AEG33773 in reducing chronic pain due to DPN,To explore AEG33773-dependent pharmacodynamic (PD) effects in blood of patients,,2009-03,COMPLETED,INTERVENTIONAL,['PHASE2']
4328,NCT04047537,Hemoglobin A1c,Change from baseline in Laboratory Complete Blood count Values,,2019-08-06,TERMINATED,INTERVENTIONAL,['NA']
4329,NCT03751501,Change in Visual Acuity (Letters),Number of AEs/SAEs,,2018-11-22,UNKNOWN,INTERVENTIONAL,['NA']
4330,NCT00654381,Examination of Long-term Safety of Linagliptin (52-week Treatment),Change From Baseline in Fasting Plasma Glucose (FPG) at Week 52,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE3']
4331,NCT00734448,Insulin sensitivity index (HOMA-IR) and continuous glucose monitoring profile,baby weight at delivery,,2013-11,UNKNOWN,INTERVENTIONAL,['NA']
4332,NCT00527397,Self-Monitoring Blood Glucose Levels: Change From Baseline,Insulin Antibody Levels : Change From Baseline,,2007-08,TERMINATED,INTERVENTIONAL,['PHASE3']
4333,NCT03060980,Reduction in weight,,,2017-03-03,TERMINATED,INTERVENTIONAL,['PHASE3']
4334,NCT00549133,"Evaluation of the effect of irbesartan on nitric oxide (NO), which has key role in the endothelial dysfunction and the development of pressure vasomotor response, compared to standard therapy (atenolol)","Evaluation of the effect of irbesartan on chronic inflammatory process and tendency for procoagulation, associated with endothelial dysfunction, compared to atenolol.",,2003-10,COMPLETED,INTERVENTIONAL,['PHASE4']
4335,NCT02080377,Number of women willing to be randomised,Clinical Outcome,,2014-07,COMPLETED,INTERVENTIONAL,['PHASE3']
4336,NCT02418091,Change in Blood Pressure,Change in taking medicine as prescribed,,2015-03,COMPLETED,INTERVENTIONAL,['NA']
4337,NCT06223490,Skin fold thickness and estimation of total body fat,,,2023-11-01,RECRUITING,INTERVENTIONAL,['NA']
4338,NCT05649137,Semaglutide 7.2 mg versus Placebo: Number of participants who achieve body weight reduction greater than or equal to (>=) 5% (yes/no),Semaglutide 7.2 mg versus Semaglutide 2.4 mg: Number of treatment emergent severe or blood glucose confirmed symptomatic hypoglycaemic episodes,,2023-01-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
4339,NCT03160196,Proportions of participants with normal Hb1Ac,,,2018-01,UNKNOWN,INTERVENTIONAL,['NA']
4340,NCT05919927,Sum score of the Z-scores of the performed standardized neuropsychological tests,,,2018-06-07,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
4341,NCT05243810,Incidence of intervention-related adverse events collected throughout the trial,Quantitative progression of local inflammatory biomarkers over the course of the intervention versus screening and baseline.,,2022-11-28,COMPLETED,INTERVENTIONAL,['NA']
4342,NCT01698697,Area under the glucose infusion rate curve,GIRmax: The maximal GIR (glucose infusion rate),,2002-09-02,COMPLETED,INTERVENTIONAL,['PHASE1']
4343,NCT01388361,Change From Baseline in HbA1c (%) (Glycosylated Haemoglobin),Number of Severe and Minor Treatment Emergent Hypoglycaemic Episodes,,2011-09,COMPLETED,INTERVENTIONAL,['PHASE3']
4344,NCT02214641,Glycated hemoglobin (HbA1C),Summary of Diabetes Self-Care Activities (SDSCA),,2014-10,COMPLETED,INTERVENTIONAL,['NA']
4345,NCT05407961,Part B: Change from Baseline in Total Clamp Disposition Index (cDI),Part A & B: Change from Baseline in Glucagon Concentration at Fasting and Post meal during sMMTT,,2022-06-07,COMPLETED,INTERVENTIONAL,['PHASE1']
4346,NCT01572402,Postprandial plasma concentrations of gastrointestinal peptides,Postprandial plasma lipids,,2012-01,COMPLETED,INTERVENTIONAL,['NA']
4347,NCT05452993,diabetic retinopathy screening rate,consistance between artificial intelligence and ophthalmologist re-read for doubtful images,,2022-09,UNKNOWN,INTERVENTIONAL,['NA']
4348,NCT06072287,Illness-related distress,Cognitive and Behavioural Responses to Symptoms,,2023-06-28,RECRUITING,OBSERVATIONAL,['NA']
4349,NCT01396837,Number of Participants Experiencing Adverse Events,Percent of Reduction in Wound Size Over 12 Weeks (ITT Population),,2014-05,COMPLETED,INTERVENTIONAL,['PHASE2']
4350,NCT02202161,Number of Participants With Fecal Occult Blood Monitoring for Symptomatic or Visible Gastrointestinal Bleeding or Asymptomatic Occult Bleeding,Sitagliptin Steady State PK Parameters When Co-dosed With Metformin-AUC(0-10),,2014-08-27,COMPLETED,INTERVENTIONAL,['PHASE2']
4351,NCT05109520,"Time in range (TIR, 70-180 mg/dL)","Treatment satisfaction measured by the Diabetes Treatment Satisfaction Questionnaire, status (DTSQs)",Hospitalization,2021-09-08,COMPLETED,OBSERVATIONAL,['NA']
4352,NCT02537704,Change in body weight,Change in liver enzymes [AST and ALT],,2015-09,UNKNOWN,INTERVENTIONAL,['NA']
4353,NCT02961517,Effect of sociodemographic characteristics,Preference for online,,2016-12,UNKNOWN,OBSERVATIONAL,['NA']
4354,NCT05057806,ATPmax production,Patient-Reported Outcomes Measure Information System (PROMIS),,2021-01-13,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
4355,NCT04259047,Decline in Verbal Memory,,Dementia,2021-10-25,RECRUITING,INTERVENTIONAL,['PHASE2']
4356,NCT01347671,Change in mean daily pain intensity score,Plasma concentration,,2011-05,COMPLETED,INTERVENTIONAL,['PHASE2']
4357,NCT02771821,Glycated Hemoglobin,Waist Circumference,,2014-08,COMPLETED,INTERVENTIONAL,['NA']
4358,NCT02662400,Improvement in insulin sensitivity after stem cell transplantation,Improvement in β cell function after stem cell transplantation,,2016-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
4359,NCT00957268,AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Alogliptin,Observed Effect at 24 Hours Post-dose (E24) of the Baseline-corrected Glucagon-like Peptide-1 (GLP-1) Concentration,,2009-09,COMPLETED,INTERVENTIONAL,['PHASE1']
4360,NCT04354142,Carbohydrate (CHO) Counting Efficiency (Time to count),Implementation outcomes: Acceptability,,2018-07-12,COMPLETED,INTERVENTIONAL,['NA']
4361,NCT00682097,"AUC0-24h, Cmax",Parameters of glucose metabolism,,2008-05,COMPLETED,INTERVENTIONAL,['PHASE1']
4362,NCT04361097,Creatinine Clearance,Lactate,,2018-08-07,COMPLETED,INTERVENTIONAL,['NA']
4363,NCT02823600,Usability of the RetinaVue Hand-Held 100 Camera,Pre-and Post-eye Exam Rates in the Diabetic Dialysis Population,,2016-07,COMPLETED,INTERVENTIONAL,['NA']
4364,NCT02475421,Metabolic clearance rate of glucagon,The volume of distribution of glucagon,,2015-05,COMPLETED,INTERVENTIONAL,['NA']
4365,NCT01452893,difference in cognitive function before and after physical stress,differences in counterregulatory hormonal response to physical stress,,2011-03,COMPLETED,OBSERVATIONAL,['NA']
4366,NCT05760768,gestation weight gain（GWG）,diastasis recti abdominis（RDA）,,2021-12-01,COMPLETED,INTERVENTIONAL,['NA']
4367,NCT02934893,Hemoglobin A1C,Patient satisfaction questionnaire,,2015-04,UNKNOWN,INTERVENTIONAL,['NA']
4368,NCT03161912,Mean change of visual acuity (VA) from baseline to 12 months as evaluated in routine clinical practice per cohort and per country.,"Mean change in VA by number of injections during the first 6 months, the first year, and the 2-year treatment period.",,2017-11-24,COMPLETED,OBSERVATIONAL,['NA']
4369,NCT03710928,Hemoglobin A1C change,Highly Processed Food Withdrawal Scale (ProWS),,2020-01-03,RECRUITING,INTERVENTIONAL,['NA']
4370,NCT01270763,High density lipoprotein cholesterol,Physical activity/fitness,,2009-07,COMPLETED,OBSERVATIONAL,['NA']
4371,NCT01940965,"Safety over 52 weeks assessed by treatment emergent adverse event (TEAE), vital signs, 12-lead electrocardiogram (ECG), and laboratory data",Absolute change in body weight,,2013-09,COMPLETED,INTERVENTIONAL,['PHASE3']
4372,NCT02478853,"Implementation of the new care framework assessed with interviews, chart audit and questionnaires",Fidelity of care to framework measure with chart audit,,2015-03,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
4373,NCT01720446,"Time From Randomisation to First Occurrence of a MACE, Defined as Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke",Change From Baseline to Last Assessment in the Trial in Other Treatment Outcomes: Vital Signs (Pulse Rate),,2013-02-21,COMPLETED,INTERVENTIONAL,['PHASE3']
4374,NCT03066830,Change From Baseline in Hemoglobin A1c (HbA1c) at Week 26,Percentage of Participants With HbA1c <7.0% at Week 26,Percentage of Participants With Hypoglycemic Events,2017-02-24,COMPLETED,INTERVENTIONAL,['PHASE3']
4375,NCT00001859,,,,1999-06-04,COMPLETED,OBSERVATIONAL,['NA']
4376,NCT04965051,HbA1c,Insulin dose,,2021-08,UNKNOWN,INTERVENTIONAL,['NA']
4377,NCT02119689,The ACE/ACE2 ratio within EPC's,The balance of the RAS (renin-angiotensin system) within EPCs,Fluorescein angiogram findings,2011-10-30,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
4378,NCT00425009,HbA1c at 13 weeks,Blood lipids at 13 weeks,,2004-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4379,NCT03512132,Anti-inflammatory effect,,,2018-04-24,RECRUITING,OBSERVATIONAL,['NA']
4380,NCT05071287,Gut Metabolomics,Glycemic Control,Fecal Metabolomics,2021-06-03,COMPLETED,INTERVENTIONAL,['NA']
4381,NCT01819844,"Average Blood Glucose Over the Closed-loop Control Period, as Determined From GlucoScout Measurements.",Accuracy of the CGM Device Using the GlucoScout Measurements as the Standard.,,2013-03,COMPLETED,INTERVENTIONAL,['NA']
4382,NCT02662114,Change in HbA1c after switch to Tresiba®,"Reason(s) for discontinuing Tresiba®, if applicable and available",,2015-12-08,COMPLETED,OBSERVATIONAL,['NA']
4383,NCT00494013,Change From Baseline to 24 Week Endpoint in Hemoglobin A1c (HbA1c),Number of Injections of Basal Insulin Analog at Endpoint,,2007-08,COMPLETED,INTERVENTIONAL,['PHASE3']
4384,NCT01893125,Pain Intensity Numerical Rating Scale,Neuropathic Pain Symptom Inventory,,2013-08,COMPLETED,INTERVENTIONAL,['PHASE2']
4385,NCT04270942,Safety and tolerability of teplizumab treatment,Change in T-cell Subpopulations,,2020-03-02,COMPLETED,INTERVENTIONAL,['PHASE2']
4386,NCT05963022,Change from Baseline in Hemoglobin A1c (HbA1c),Percentage of Participants Who Achieved Weight loss of ≥15%,,2023-08-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
4387,NCT04620876,Visualization and image analysis of a structure of interest,,,2019-10-01,RECRUITING,INTERVENTIONAL,['NA']
4388,NCT00231530,The percent change in body weight and change in Hemoglobin A1c from enrollment to Week 60.,"Change from enrollment or baseline to Week 60 in BMI, waist circumference, glucose tolerance, lipid profile; safety measures, such as adverse events, throughout study.",,2001-01,COMPLETED,INTERVENTIONAL,['PHASE3']
4389,NCT05671250,Wound area regression rate,rate of partial wound closure of ≥ 50%,Adverse effects,2021-07-15,COMPLETED,INTERVENTIONAL,['PHASE2']
4390,NCT04087941,Change in 24-hour Morphine Milligram Equivalents (MME),Efficacy- Change in Average Pain Intensity,,2019-11,UNKNOWN,INTERVENTIONAL,['PHASE2']
4391,NCT01264809,Change in daily physical activity measured by SenseWear Pro3 Armband®. Participants were instructed to wear the monitor for seven days during all waking hours except bathing.,Benefits obtained after the physical activity counseling,,2011-03,UNKNOWN,INTERVENTIONAL,['NA']
4392,NCT04467606,Rate of foot infection and readmission for foot ulcer,Self-efficacy regarding diabetes-related foot ulcer self-management,,2020-08-01,COMPLETED,INTERVENTIONAL,['NA']
4393,NCT02692716,"Time From Randomisation to First Occurrence of a Major Adverse Cardiovascular Event (MACE) Composite Endpoint Consisting of: Cardiovascular Death, Non-fatal Myocardial Infarction or Non-fatal Stroke",Change in Triglycerides - Ratio to Baseline,,2017-01-17,COMPLETED,INTERVENTIONAL,['PHASE3']
4394,NCT00392028,"blood,tissue and bone drug levels",,,2006-11,WITHDRAWN,INTERVENTIONAL,['NA']
4395,NCT03008057,"serum Fasting blood suger,",serum YKL40,,2017-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
4396,NCT00496145,"Hemoglobin A1c, Health Distress, Symptoms of Hypoglycemia, Symptoms of Hyperglycemia","Amount of exercise,self-efficacy, communication with physician,fatigue, activity limitation,physician visits",,2002-08,COMPLETED,INTERVENTIONAL,['NA']
4397,NCT03757845,Quantity of ERBB receptors expressed on atrial endothelial cells,Quantity of specific lipids in plasma,,2018-12-15,TERMINATED,INTERVENTIONAL,['NA']
4398,NCT04217759,Change in diabetes risk score from week 0 to week 13,Facilitation (PA) score,,2017-10-01,COMPLETED,INTERVENTIONAL,['NA']
4399,NCT05550480,Time spent with glucose value <3.0 mmol/l (level 2 hypoglycemia),Hypoglycemia awareness,,2022-09-08,RECRUITING,INTERVENTIONAL,['NA']
4400,NCT01615081,Acute 3-h changes from baseline in the postprandial concentration of glucose,ad libitum energy intake (EI),,2012-05,COMPLETED,INTERVENTIONAL,['NA']
4401,NCT04380077,postoperative vitreous hemorrhage rate,visual acuity,,2020-05-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4402,NCT00925977,Treatment satisfaction,Hypoglycemic events,,2009-07,TERMINATED,INTERVENTIONAL,['NA']
4403,NCT01207934,Post-treatment Glucose Disposal. I.e. Glucose Disposal After Treatment With Leptin or Placebo.,Post-treatment Plasma Leptin Levels,,1998-08,COMPLETED,INTERVENTIONAL,['NA']
4404,NCT02463487,Number of Participants Who Achieved Complete Healing or Coverage of the Study Wound,Number of Participants With Wound Dehiscence After Hospital Discharge,,2015-06-02,COMPLETED,INTERVENTIONAL,['NA']
4405,NCT03597568,Vascular endothelial function,Oxidative stress,,2019-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4406,NCT04614038,Non-healing status based on change in wound area over 12 weeks,Effect of various patient biometry and wound conditions on non-healing status based on change in wound area over 12 weeks,,2022-01-01,RECRUITING,OBSERVATIONAL,['NA']
4407,NCT01033773,Total Number of Hypoglycemia Events (Blood Glucose < 60mg/dL) Within 24 Hours of Baseline Visit,Change in Hemoglobin A1C From Baseline to End of Intervention at 30 Days,,2007-09,COMPLETED,INTERVENTIONAL,['NA']
4408,NCT02262806,Serum triglycerides,,,2014-10-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
4409,NCT01703208,Percentage of Participants Who Discontinued From Study Drug Due to an Adverse Event in a Sub-Study of Participants Taking Insulin Excluding Data After Background AHA Change,Percentage of Participants Achieving a Target A1C <7.0 % (53 mmol/Mol) at Week 18 in a Sub-Study of Participants Taking Insulin,Number of Participants With an Event Per 100 Person-years of the Event of the First Hospitalization for Heart Failure (Exploratory),2012-10-05,TERMINATED,INTERVENTIONAL,['PHASE3']
4410,NCT04660305,Area under the glucose infusion-rate curve of insulin aspart,,,2020-12-02,COMPLETED,INTERVENTIONAL,['PHASE1']
4411,NCT00012688,,,,na,COMPLETED,INTERVENTIONAL,['NA']
4412,NCT02671136,Counts of Each Subgingival Bacterial Species,,,2016-08-18,TERMINATED,INTERVENTIONAL,['NA']
4413,NCT04280016,Wound measurement size,Waist circumference,,2021-05-14,UNKNOWN,INTERVENTIONAL,['NA']
4414,NCT00641043,HbA1c Change From Baseline to Week 24,Percentage of Patients Who Have an HbA1c Lowering by 0.5% at Week 24,,2008-03,COMPLETED,INTERVENTIONAL,['PHASE3']
4415,NCT06080802,HRQOL using Minnesota Living with Heart Failure Questionnaire for quality-of-life evaluation (MLFHQ),Change in body weight,,2023-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
4416,NCT01726764,Change in Area Under Curve (AUC) 0-24h of metformin,Change in messenger RiboNucleic Acid (mRNA),Hypericin/hyperforin,2013-01,COMPLETED,INTERVENTIONAL,['PHASE1']
4417,NCT03859401,Number of hypoglycemic occurrences in relation to exercise activity,CGM-based High Blood Glucose Index,Total Amount of Rescue Carbohydrates,2019-04-12,COMPLETED,INTERVENTIONAL,['NA']
4418,NCT03135964,The reduction rate of pressure ulcer size,The reduction rate of diabetic foot ulcer size,,2011-02,COMPLETED,INTERVENTIONAL,['NA']
4419,NCT06246435,Assessment of body mass index ( BMI in kg/m^2)as anthropometric measurements,estimation of lipid profile,,2014-02-20,COMPLETED,OBSERVATIONAL,['NA']
4420,NCT05188625,Attendance rate,Foetal outcome 2,,2021-01-13,COMPLETED,INTERVENTIONAL,['NA']
4421,NCT00501709,lnsulin independence,,,2007-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4422,NCT04362917,Measurement of beta cell function during the first phase of the first clamp procedure,Measurement of beta cell function during of Second Phase of the first clamp procedure,"Test-retest variability of the above mentioned variables (first phase, second phase, Unmethylated and methylated DNA, fasting PI:C",2017-11-14,COMPLETED,OBSERVATIONAL,['NA']
4423,NCT05444153,Participants acheiving body weight reduction greater than or equal to (>=) 5% (Yes/No),Change in Control of Eating Questionnaire (CoEQ) score - Craving for Savory domaina,,2022-10-06,WITHDRAWN,INTERVENTIONAL,['PHASE3']
4424,NCT00543621,"HbA1c, Fasting blood glucose,blood pressure, weight loss",,,2005-05,COMPLETED,INTERVENTIONAL,['PHASE4']
4425,NCT03238898,pain intensity on a 0-10 severity scale,the Cramp Threshold Frequency (CTF),,2014-09-27,COMPLETED,INTERVENTIONAL,['PHASE2']
4426,NCT06057662,Problem Areas in Diabetes (PAID),,,2023-08-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
4427,NCT00997711,"The composite of death, nonfatal myocardial infarction (MI), or Target- Vessel Revascularization (TVR) at 12 months post procedure.",Stent thrombosis (ARC criteria),,2009-04,COMPLETED,INTERVENTIONAL,['PHASE4']
4428,NCT05597943,Malama app as intervention,Postpartum hemoglobin A1c level,,2023-05-01,RECRUITING,INTERVENTIONAL,['NA']
4429,NCT02186080,Difference between baseline and peak serum LPS,mRNA expression level of inflammatory markers in the adipose tissue,,2014-07,COMPLETED,INTERVENTIONAL,['NA']
4430,NCT00776854,Decrease of Bioburden Effect In diabetic Foot Ulcer,,,2008-11,UNKNOWN,INTERVENTIONAL,['PHASE1']
4431,NCT01595594,Clinical Attachment Level,Microbial Load,,2010-03,COMPLETED,INTERVENTIONAL,['PHASE3']
4432,NCT05983562,To determine the feasibility of conducting such an RCT: Retention as measured by the number of participants that complete the study,Overall acceptability,,2023-06-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4433,NCT01402232,contrast-induced nephropathy,Follow-up major adverse cardiovascular and clinical events,,2013-01,UNKNOWN,OBSERVATIONAL,['NA']
4434,NCT01517412,Change in HbA1c From Baseline to Week 24,Change in Diabetes Treatment Satisfaction Questionnaire Score (DTSQs) From Baseline to Week 24,,2012-02,COMPLETED,INTERVENTIONAL,['PHASE3']
4435,NCT04123067,Degree of Disability or Dependence in the Daily Activities,"Concentration of Stress Response Markers Including Cortisol, Norepinephrine and Epinephrine",,2020-09-01,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4436,NCT02294474,Change in HbA1c From Baseline to Week 26,Percentage of Participants With Treatment-Emergent Anti-insulin Antibodies (AIAs),Change in Daily Insulin Dose From Baseline to Week 26,2015-01,COMPLETED,INTERVENTIONAL,['PHASE3']
4437,NCT01370837,Induration Size as a Response to Intracutaneous Candida Albicans.,,,2012-05,COMPLETED,INTERVENTIONAL,['NA']
4438,NCT02160184,Percentage of time in target range (3.9-8.0 mmol/l) YSI glucose during the in clinic overnight visit.,,,na,UNKNOWN,INTERVENTIONAL,['NA']
4439,NCT03400501,Lower beta hydroxybutyrate levels,Measure of beta hydroxybutyrate levels between the 2 groups.,,2017-10-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
4440,NCT01228526,Percent of study ulcers healed,,,2010-08,COMPLETED,OBSERVATIONAL,['NA']
4441,NCT03648918,Autoantibody Measurement,,,2001-08,RECRUITING,OBSERVATIONAL,['NA']
4442,NCT03083899,Patient reported outcome,Diabetes Dependent quality of Life,,2017-03-01,COMPLETED,INTERVENTIONAL,['NA']
4443,NCT02448498,Change in Hemoglobin A1c across study visits,"Change in Dietary Intake, as measured by Food Frequency Questionnaire",,2016-02,COMPLETED,INTERVENTIONAL,['NA']
4444,NCT00501488,,,,2006-03,COMPLETED,OBSERVATIONAL,['NA']
4445,NCT05949957,Glucose Tolerance Changes,Social-emotional development (Children),Child's Sleep Habits,2023-10-20,RECRUITING,INTERVENTIONAL,['NA']
4446,NCT01748552,Number of Participants With 1 or More Serious Adverse Event(s) (SAEs),Change From Baseline in C-Peptide Area Under the Effective Concentration Curve From Time 0 to 6 h Postdose [AUEC(0-6)],,2012-12,COMPLETED,INTERVENTIONAL,['PHASE1']
4447,NCT03174821,The change of 8-hydroxy-deoxyguanosine (8-OHdG),The change of superoxide dismutase (SOD),,2010-10-20,COMPLETED,INTERVENTIONAL,['NA']
4448,NCT03247608,Re-admissions rate,Biometrics change,,2015-11,COMPLETED,INTERVENTIONAL,['NA']
4449,NCT00306176,Cardiovascular risk factors alterations,,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE4']
4450,NCT05840796,interleukin (IL)-6,lipid profile,,2014-04-01,COMPLETED,INTERVENTIONAL,['NA']
4451,NCT03686917,CHAT-P Score,Multicultural Quality of Life Index,,2018-10-01,COMPLETED,OBSERVATIONAL,['NA']
4452,NCT06007157,24-hour Blood Pressure,Hydration state,,2023-03-01,RECRUITING,INTERVENTIONAL,['NA']
4453,NCT05651919,"Comparison of the inflammatory profile of PBMC from T2D+MS patients vs non T2D+MS patients, according to the presence or not of HFpEF or HFmrEF",,,2023-05-23,RECRUITING,OBSERVATIONAL,['NA']
4454,NCT03997331,Change in HbA1c,Median Adherence to Metformin,,2020-05,UNKNOWN,INTERVENTIONAL,['NA']
4455,NCT00859599,Number of subjects who completely healed and time to 100% wound reduction.,"Time to 50% wound reduction, Subjects with increased ulcer and/or wound reduction less than 20%, Wound status, Elimination of gram-positive and anaerobic bacteria from the wound, Hospitalization caused of foot ulcer, Presence and level of amputation",,2008-08,UNKNOWN,INTERVENTIONAL,['PHASE3']
4456,NCT01868529,Area under the glucose infusion rate curve,Area under the serum insulin concentration curve at steady state,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE1']
4457,NCT06085339,Feasibility: Retention Rate,Screen Time,,2023-10-23,RECRUITING,INTERVENTIONAL,['NA']
4458,NCT02616809,Evidence of change in blood glucose following changes in posture and increasing energy expenditure,,,2014-07,COMPLETED,INTERVENTIONAL,['PHASE3']
4459,NCT03911323,Sensitivity and specificity,,,2018-10-01,UNKNOWN,OBSERVATIONAL,['NA']
4460,NCT01906086,high sensitive C reactive protein (mg/l),Adiponectin (ng/ml),,2012-09,COMPLETED,INTERVENTIONAL,['NA']
4461,NCT05459701,VCAM-1 (ng/ml),,,2022-05-01,RECRUITING,INTERVENTIONAL,['PHASE4']
4462,NCT01053078,Cerebral Blood Flow,Hypoglycemia Symptom Score,,2009-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4463,NCT00468754,Variability of blood glucose characterised by the standard deviation of the mean blood glucose,Daily insulin requirement,,2003-07,COMPLETED,INTERVENTIONAL,['NA']
4464,NCT00791128,% of Excess Weight Loss (EWL),HbA1c Values at 12 Months,,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2']
4465,NCT05248412,Health outcomes,Healthcare service utilization,Burden of diseases due to indirect effect of COVID-19,2021-06-21,RECRUITING,OBSERVATIONAL,['NA']
4466,NCT02768220,Change in AGE levels,Change in weight,,2017-12-01,WITHDRAWN,INTERVENTIONAL,['PHASE4']
4467,NCT04035993,Accuracy of the HEADWIND-model: Diagnostic accuracy of the hypoglycaemia warning system (HEADWIND) to detect hypoglycaemia (blood glucose <3.9mmol/l and <3.0mmol/l) quantified as the area under the receiver operator characteristics curve (AUC ROC).,Cognitive and emotional trust in the recommendations of the EWS,,2019-10-07,COMPLETED,INTERVENTIONAL,['NA']
4468,NCT04522882,Glucose level modification,Medication intake,,2020-09-09,COMPLETED,INTERVENTIONAL,['NA']
4469,NCT04944264,Connor-Davidson Resilience Scale (CD-RISC),Implementation Facilitators,,2020-10-01,COMPLETED,INTERVENTIONAL,['NA']
4470,NCT04448262,inflammatory cells,perceived Health state,,2019-07-10,TERMINATED,OBSERVATIONAL,['NA']
4471,NCT04011228,Specifying the microRNAs in saliva in diabetic patients,Correlation of the percentage of the content of fat in the skeletal muscle with miRNA´s in diabetic patients.,,2016-02-29,UNKNOWN,OBSERVATIONAL,['NA']
4472,NCT02293577,Time with blood glucose >300 mg/dL,Physical Activity,,2014-11,COMPLETED,OBSERVATIONAL,['NA']
4473,NCT03379792,Energy Expenditure,,,2018-03-08,COMPLETED,OBSERVATIONAL,['NA']
4474,NCT05111301,CGM Time Above 180 mg/dL,Coefficient of Variation (CV),Unanticipated Adverse Device Effects,2021-11-30,COMPLETED,INTERVENTIONAL,['NA']
4475,NCT03664921,Numeric Pain Scale,Adverse Events,,2018-11-15,COMPLETED,INTERVENTIONAL,['PHASE2']
4476,NCT01307410,Incidence of CVD events,Annual incidence of microvascular complications,,2011-03,UNKNOWN,OBSERVATIONAL,['NA']
4477,NCT04697758,Safety as Assessed by Incidence of Adverse Events (AEs),,,2020-12-10,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4478,NCT04549415,Number of participants with newly diagnosed diabetes mellitus,Lipid profile markers,,2018-01-01,COMPLETED,INTERVENTIONAL,['PHASE4']
4479,NCT00412230,,,,2006-10,COMPLETED,OBSERVATIONAL,['NA']
4480,NCT05068895,Metabolic profiles of lower extremity artery disease,Pathway analysis of differential metabolites,,2021-06-01,UNKNOWN,OBSERVATIONAL,['NA']
4481,NCT00005665,,,,na,UNKNOWN,INTERVENTIONAL,['PHASE2']
4482,NCT02076880,Change of area under the curve of post prandial glycemia,"Change in insulin sensitivity, Change in insulin secretion, Change in incretins",,2013-11,UNKNOWN,INTERVENTIONAL,['NA']
4483,NCT00579436,Adipocyte Size After Fish Oil Treatment,Insulin Resistance After Fish Oil Regiment,,2007-01,COMPLETED,INTERVENTIONAL,['NA']
4484,NCT06231771,Proportion of patients with complete healing/closure of the target ulcer at any time during the 6-weeks period.,The proportion of patients with at least 50% closure of target ulcer during the 6-weeks period,,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4485,NCT01269996,To evaluate the treatment efficacy,proportion of patients with HbA1c <6.5% in 1 year,,2011-05,COMPLETED,INTERVENTIONAL,['PHASE4']
4486,NCT01596244,Weight (kg),Body Mass Index (kg/m2),,2008-04,COMPLETED,INTERVENTIONAL,['NA']
4487,NCT05229445,time in range,,,2022-07-05,COMPLETED,INTERVENTIONAL,['NA']
4488,NCT00327912,Gastro-intestinal side effects,Eating pattern,,2006-04,UNKNOWN,INTERVENTIONAL,['PHASE4']
4489,NCT05295706,Change in HbA1C,Change in the Behavioral Strategies - Engagement and Intentions score,,2022-06-01,UNKNOWN,INTERVENTIONAL,['NA']
4490,NCT04872647,Change of HOMA2-IR,EVS,,2020-12-18,UNKNOWN,INTERVENTIONAL,['NA']
4491,NCT05822609,Change in kidney cortical relaxation rates (R2*),Change in total daily insulin dose,,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
4492,NCT03763474,Change from 6 months glycosylated hemoglobin at 12 months in the 2 groups,Diabetes Treatment Satisfaction Questionnaire (DTSQ) score in the 2 groups,,2017-04-01,COMPLETED,INTERVENTIONAL,['NA']
4493,NCT05070741,Change in intraepidermal nerve fibers (IENF),Utah Early Neuropathy Scale (UENS),,2020-07-27,TERMINATED,INTERVENTIONAL,['NA']
4494,NCT00360217,Lowering of triglyceride level,Alteration of LDL particle size,,2006-01,COMPLETED,INTERVENTIONAL,['NA']
4495,NCT04769115,Predicting diabetic foot complications,,,2021-02-24,COMPLETED,INTERVENTIONAL,['NA']
4496,NCT05042505,Changes from baseline to month 12 in liver and pancreatic fat content.,"Safety assessment at months 3, 6, 9 and 12",,2022-01-01,RECRUITING,INTERVENTIONAL,['NA']
4497,NCT02813863,The area under the plasma concentration-time curve (AUC) of metformin,The number of volunteers with adverse events as a measure of safety and tolerability,,2015-12,COMPLETED,INTERVENTIONAL,['PHASE1']
4498,NCT01426685,sudden cardiac death,non-fatal cardiovascular event,,2007-08,UNKNOWN,OBSERVATIONAL,['NA']
4499,NCT00942188,Change From Baseline in the Glycosylated Hemoglobin (HbA1c) at 12 Weeks,Pharmacokinetics Measured by Serum Concentration at End of Dosing (12 Weeks),,2009-06,COMPLETED,INTERVENTIONAL,['PHASE2']
4500,NCT03572699,Sensitivity and specificity of the AI in detecting any grade of diabetic retinopathy,Sensitivity and specificity of the AI in detecting sight threatening diabetic retinopathy (referable retinopathy defined as severe non proliferative retinopathy or greater),,2018-07-11,UNKNOWN,OBSERVATIONAL,['NA']
4501,NCT04474808,Feet Care Feelings,,,2020-08-01,COMPLETED,INTERVENTIONAL,['NA']
4502,NCT05844748,"The Effect of Training Given by Motivational Interview Technique on Self-Efficacy Perception, Level of Adjustment to Disease and Metabolic Parameters in Type 2 Diabetes Patients",,,2022-02-01,COMPLETED,INTERVENTIONAL,['NA']
4503,NCT01121835,Percentage of patients with Glycosylated Haemoglobin (HbA1c) <7% with no documented symptomatic hypoglycemia (confirmed by a Plasma Glucose (PG) ≤ 56 mg/dL [3.1 mmol/L],Biochemistry and lipid profile,,2010-02,COMPLETED,INTERVENTIONAL,['PHASE4']
4504,NCT03868813,Users' Expectation from a Health Coaching System,,,2019-07-01,COMPLETED,OBSERVATIONAL,['NA']
4505,NCT01460446,Change in Glycosylated Hemoglobin A1c (HbA1c) From Baseline to Week 24,The Diabetes Treatment Satisfaction Questionnaire at Baseline (DTSQs) Score and the Diabetes Treatment Satisfaction Questionnaire for Change From Baseline (DTSQc) Score,,2011-10,COMPLETED,INTERVENTIONAL,['NA']
4506,NCT01496430,Change From Baseline in Trough Sitting Clinic Systolic Blood Pressure,Change From Baseline to Week 6 and Week 24 in AUC for Glucagon During OGTT,,2012-01,TERMINATED,INTERVENTIONAL,['PHASE3']
4507,NCT05814406,HbA1C (24 Weeks) lowering effect,HbA1c lowering effect,,2023-01-12,RECRUITING,INTERVENTIONAL,['PHASE3']
4508,NCT01109043,Changes in systolic and diastolic BP,Assessment of quality of life (SQ-8 Short Form Health Survey),,2009-06,COMPLETED,OBSERVATIONAL,['NA']
4509,NCT03837262,Recruitment and retention,WPAI questionnaire,,2019-03-25,COMPLETED,INTERVENTIONAL,['NA']
4510,NCT01929512,"metformin, rosuvastatin AUClast","Metformin, rosuvastatin Vd/F",,2013-06,COMPLETED,INTERVENTIONAL,['PHASE1']
4511,NCT02273180,Change in HbA1c From Baseline to Week 26,Percentage of Participants With Treatment Emergent Anti-insulin Antibodies (AIAs),Change in Daily Insulin Dose From Baseline to Week 26 and Week 52,2014-10,COMPLETED,INTERVENTIONAL,['PHASE3']
4512,NCT02289612,Satiety-producing effect for each pudding and control product,3-Day food records,Heart rate and blood pressure,2014-11,COMPLETED,INTERVENTIONAL,['NA']
4513,NCT01138488,Area under the serum insulin aspart concentration-time curve,Maximum observed insulin aspart concentration of NN5401 (insulin degludec/insulin aspart) observed,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE1']
4514,NCT04692220,Variables associated with the presence of an Adverse Drug Events or Drug-Related Problems,Number and type of Adverse Drug Events and Drug-Related Problems,,2011-11-01,COMPLETED,OBSERVATIONAL,['NA']
4515,NCT05561517,Plasma glucose,,,2023-05-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4516,NCT05236335,Cardiac Output (L/min),Exercise capacity (METs),,2022-02-01,COMPLETED,INTERVENTIONAL,['NA']
4517,NCT01487798,Frequency of hypoglycaemic episodes,Diabetes Treatment Satisfaction Questionaire,,2002-06,COMPLETED,INTERVENTIONAL,['PHASE4']
4518,NCT01527643,"Cmax, maximum insulin aspart concentration",Incidence of hypoglycaemic events,,2003-11-11,COMPLETED,INTERVENTIONAL,['PHASE1']
4519,NCT02548000,Quadriceps Muscle Quality measure by echo intensity,Quadriceps muscle power capacity measure by rate of torque development.,,2015-07,COMPLETED,INTERVENTIONAL,['NA']
4520,NCT03466398,Hemoglobin A1c,DKA Admission Rates,,2018-04-11,WITHDRAWN,INTERVENTIONAL,['NA']
4521,NCT03632759,Proportion of individuals with peak MMTT stimulated C-peptide >0.017 pmol/mL.,,,2018-08-15,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
4522,NCT02250677,Differences in physical performance between two groups of statin treated patients,,,2014-04,COMPLETED,OBSERVATIONAL,['NA']
4523,NCT00639457,Insulin-stimulated Glucose Disposal Rate,Myocardial Contractility-DBP,,2005-01,COMPLETED,INTERVENTIONAL,['NA']
4524,NCT06292624,Muscle oxygenation,Functional mobility,,2023-08-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4525,NCT02945449,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability],Assessment of the efficacy of injecting Wharton Jelly derived Mesenchymal Stem Cells by SHIM/IIEF/EHS questionnaire,,2017-01-04,COMPLETED,INTERVENTIONAL,['PHASE1']
4526,NCT01370616,Percentage of Participants With Favorable Clinical Response Assessments at Discontinuation of Intravenous (IV) Study Therapy (DCIV),Percentage of Participants Who Discontinued Treatment Due to an AE,,2011-09-02,COMPLETED,INTERVENTIONAL,['PHASE3']
4527,NCT02194595,"Mean beta-cell function over the 8-week treatment period, measured using the Insulin Secretion-Sensitivity Index-2 (ISSI-2)",Baseline-adjusted glycemic control at 8 weeks,Baseline-adjusted insulin sensitivity at 20 weeks,2014-09,COMPLETED,INTERVENTIONAL,['PHASE3']
4528,NCT00780715,HbA1c Change,,,2008-12,COMPLETED,INTERVENTIONAL,['PHASE4']
4529,NCT02896010,Yield of Recruitment,Adherence to physical activity goal,,2016-10-10,COMPLETED,INTERVENTIONAL,['NA']
4530,NCT01486940,HbA1c (glycosylated haemoglobin),Incidence of adverse events,,2002-03,COMPLETED,INTERVENTIONAL,['PHASE3']
4531,NCT02953249,Wound healing change after tooth extraction through epithelialization,Radiographic analysis of bone repair,,2016-09,UNKNOWN,OBSERVATIONAL,['NA']
4532,NCT01871831,Influence of the blood sample's partial pressure on blood glucose measurement results,,,2013-06,COMPLETED,INTERVENTIONAL,['NA']
4533,NCT04264572,Change in hemoglobin A1C for patients with poorly controlled type 2 diabetes mellitus,Change in diabetes quality of life for patients with poorly controlled type 2 diabetes mellitus as measured by Diabetes Quality of Life (DQoL) instrument,,2020-01-21,RECRUITING,INTERVENTIONAL,['NA']
4534,NCT04544527,all-cause mortality,chronic complications of diabetes,,2020-09-01,RECRUITING,OBSERVATIONAL,['NA']
4535,NCT02065674,,,,2014-02,AVAILABLE,EXPANDED_ACCESS,['NA']
4536,NCT00705536,Relative Bioavailability (Area Under the Curve [AUC] for Insulin + Recombinant Human Hyaluronidase [rHuPH20] / AUC for Insulin Alone),Area Under the Glucose Infusion Rate Curve From 0 to 360 Minutes After Injection (AUC[GIR{0-360}]),,2007-12,COMPLETED,INTERVENTIONAL,['PHASE1']
4537,NCT01997021,Area under the insulin curve in response to meal tolerance test,24-hour Glycemic variability,,2013-11,COMPLETED,INTERVENTIONAL,['NA']
4538,NCT00775333,"Sensory function (Semmens-Weinstein), motor function (Abductor Pollicis Brevis (APB)-strength, grip strength)","Pillar pain, cold intolerance, and patient satisfaction.",,2003-12,COMPLETED,OBSERVATIONAL,['NA']
4539,NCT03491241,left ventricle ejection fraction,,,2017-01-01,COMPLETED,INTERVENTIONAL,['NA']
4540,NCT02666521,Frequency of mild hypoglycaemic episodes,Frequency of severe hypoglycaemic episodes,Incidence and severity of hypoglycaemic episodes,2012-07-20,COMPLETED,OBSERVATIONAL,['NA']
4541,NCT00729326,Change in Time-averaged Glucose During a 24 Hour Period,Episodes of Hypoglycemia (Overall),,2008-08,COMPLETED,INTERVENTIONAL,['PHASE4']
4542,NCT01545024,Glycemic control,autonomic nerve disturbance,,2011-09,UNKNOWN,OBSERVATIONAL,['NA']
4543,NCT02145572,"Differences in metabolite concentrations measured by mass spectrometry, comparing blood and urine samples from obese adolescents with type 2 diabetes, obese adolescents without diabetes, and age-matched healthy non-obese controls.",,Validation of presence of DENND1A isoform in the urine of adolescent females with polycystic ovarian syndrome,2014-05,COMPLETED,OBSERVATIONAL,['NA']
4544,NCT02868320,change in HbA1c,Rate of hospital/ER admissions,,2014-04,COMPLETED,INTERVENTIONAL,['NA']
4545,NCT03422965,Perifoveal vessel density,Foveal Avascular Zone,,2017-05-08,UNKNOWN,INTERVENTIONAL,['NA']
4546,NCT05491252,Change in Glycemic Control (HbA1c),Self Care Behaviors,,2022-04-21,COMPLETED,INTERVENTIONAL,['NA']
4547,NCT04952766,Protective humoral response after vaccination,Clinical protection after vaccination,,2021-03-26,COMPLETED,INTERVENTIONAL,['PHASE4']
4548,NCT05407376,Change in HbA1c between baseline and 6 months,Analyze the difference in difference of patient-reported nutritional security between the intervention and control group.,,2021-11-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4549,NCT04840368,"Changes in Peak Oxygen Consumption (VO2peak), expressed in mL/Kg/min","Change in Executive function, assessed by the Trail making test",,2021-05-03,UNKNOWN,INTERVENTIONAL,['NA']
4550,NCT00545727,Blood glucose level,,,2006-07,COMPLETED,INTERVENTIONAL,['NA']
4551,NCT00871312,Wound closure,The level of wound pain,,2007-05,TERMINATED,INTERVENTIONAL,['NA']
4552,NCT05953532,Measure of Engagement in Personal Healthcare,Glycemic control,,2023-11-01,RECRUITING,INTERVENTIONAL,['NA']
4553,NCT06083675,Change in glycated haemoglobin (HbA1c),Change in AHA Life's Simple 7 summary score,,2024-01-26,WITHDRAWN,INTERVENTIONAL,['PHASE3']
4554,NCT03052283,"Development and evaluation of a diary for assessment and quantification of abdominal symptoms, a CF-specific PROM following FDA recommendations","Effects of a new therapy with CFTR-modulator on abdominal symtoms, quantified with the CFAbd-Score",,2017-01-26,RECRUITING,OBSERVATIONAL,['NA']
4555,NCT01176656,prevalence of hypoglycemia and impact of hypoglycemia,"Treatment adherence and modification related to hypoglycemia, including health status, glycemic control and healthcare utilization",,2010-09,COMPLETED,OBSERVATIONAL,['NA']
4556,NCT01575301,Change in HbA1c between baseline and 6 months,,,2011-03,COMPLETED,INTERVENTIONAL,['NA']
4557,NCT00993720,insulin-dose,"weight change from baseline, change in fructosamine from baseline",,2009-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
4558,NCT01482455,Blood flow,Interstitial insulin concentration,,2011-12,COMPLETED,INTERVENTIONAL,['NA']
4559,NCT03761186,Change in insulin use,Time taken to complete the Trail making test A+B,Frequency of intake of different foods measured by a Food frequency questionnaire (FFQ),2018-12-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4560,NCT00494559,Comparison of pioglitazone and placebo on 8 months follow-up neointima volume by intravascular ultrasound (IVUS).,"Comparison of pioglitazone and placebo on the changes in the levels of inflammatory markers (hsCRP, IL-6, TNF-α, adiponectin).",,2007-07,COMPLETED,INTERVENTIONAL,['PHASE4']
4561,NCT00768651,Weight Change From Baseline After 6 Months of Therapy,Blood Glucose Laboratory Value Before Mixed Meal Tolerance Test (MMTT) After the 3 Month Washout Period,,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2']
4562,NCT01192711,Blood levels of glycosylated hemoglobin,Frequency and times of hypoglycemic events with regard to occurrence during the day (24 hours) and total treatment duration (24 weeks),,2009-05,UNKNOWN,INTERVENTIONAL,['PHASE3']
4563,NCT03730727,Postprandial blood glucose concentrations.,Postprandial blood glucose control.,,2017-10-09,COMPLETED,INTERVENTIONAL,['NA']
4564,NCT00508430,Pain severity rating,Clinical's global impression of change,,2007-07,TERMINATED,INTERVENTIONAL,['PHASE2']
4565,NCT05727592,Fasting blood glucose,Renal profile,,2023-03-20,COMPLETED,INTERVENTIONAL,['NA']
4566,NCT04597697,"AUC,Ico,0-inf,SD, Area under the serum insulin icodec concentration-time curve after a single dose","tmax,Ico,SD, Time to maximum observed serum insulin icodec concentration after a single dose",,2020-12-22,COMPLETED,INTERVENTIONAL,['PHASE1']
4567,NCT01524770,Pharmacokinetics: Maximum Concentration (Cmax) for Dulaglutide,Pharmacokinetics: Time to Maximum Concentration (Tmax) for Dulaglutide,,2012-03,COMPLETED,INTERVENTIONAL,['PHASE1']
4568,NCT05074147,Percentage of treated patients achieving remission from the diabetic foot osteomyelitis at the end of follow-up,Rates of major amputation in each group of patients.,,2022-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
4569,NCT06023810,Wagner's ulcer classification scale,Watson Patient Satisfaction Assessment Form According to Healing Processes,,2023-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
4570,NCT01534013,Percentage Time in Euglycaemia,Insulin Requirement in Units/kg/hr,,2011-08,COMPLETED,INTERVENTIONAL,['NA']
4571,NCT02835495,Adherence to the Lifestyle Weight Loss Intervention,,Cholesterol (Lipid Panel),2017-11-15,COMPLETED,INTERVENTIONAL,['NA']
4572,NCT02426606,Postprandial blood insulin,,,2014-11,COMPLETED,INTERVENTIONAL,['NA']
4573,NCT01785134,Insulin Sensitivity at 2 Years,Blood Lipids,,2006-05,COMPLETED,INTERVENTIONAL,['NA']
4574,NCT04676906,The apparent elimination half-life of each of the 3 study compounds and their active metabolite after a single iv dose of each of the 3 study compounds,,,2020-11-26,COMPLETED,INTERVENTIONAL,['PHASE1']
4575,NCT00656682,% Change in Body Weight,% Change in Body Weight,,2008-04,COMPLETED,INTERVENTIONAL,['NA']
4576,NCT05937984,Change in PROMIS-29 v2.0 Profile,Change in nerve conduction assessments,,2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
4577,NCT02317172,Changes in subjective dry mouth score,Satisfaction of the edible gel-based artificial saliva,,2012-10,COMPLETED,INTERVENTIONAL,['NA']
4578,NCT04177420,"Geriatric Depression Scale-15, GDS-15",,,2018-03-23,UNKNOWN,INTERVENTIONAL,['NA']
4579,NCT01323088,"Abdominal obesity, visceral fat","insulin sensitivity by a 3-hour hyperinsulinemic-euglycemic clamp, oral glucose tolerance test, liver fat and intramyocellular lipid by 1H-magnetic resonance spectroscopy.",,2010-08,COMPLETED,INTERVENTIONAL,['NA']
4580,NCT04621045,Acceptability of PATH intervention,Change from baseline in Barriers Exercise Self-efficacy (BARSE) scale at 12 weeks,,2020-10-27,COMPLETED,INTERVENTIONAL,['NA']
4581,NCT05933616,Correlation between blood glucose and patterns,"Association between the onset of change in glucose, vital signs and VOC spectra",,2023-04-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4582,NCT01478776,postprandial ASP,gene expression of C5L2,,2011-12,UNKNOWN,INTERVENTIONAL,['PHASE4']
4583,NCT01960179,"Safety over 24 and 52 weeks assessed by treatment emergent adverse event (TEAE), vital signs, 12-lead electrocardiogram (ECG), and laboratory data.",Absolute change in body weight,,2013-11,COMPLETED,INTERVENTIONAL,['PHASE3']
4584,NCT05224258,Primary Effectiveness Endpoint for Age 7-17 - Percent of Time in Range (TIR 70-180 mg/dL [3.9 -10.0 mmol/L]),Secondary Effectiveness Endpoint 2 for Age 7-17 - Percent of Time in Range (TIR 70-180 mg/dL [3.9 -10.0 mmol/L]),,2022-03-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4585,NCT04712409,Change in GIP dynamic profile,Metabolic syndrome remission rates,Late morbidity,2020-08-16,RECRUITING,INTERVENTIONAL,['NA']
4586,NCT03478254,Adherence to Regional Guidelines for the Immunization of Adults With Type 1 Diabetes Mellitus (T1DM,Number of Participants Who Have Taken Related Sick Leaves,,2017-12-01,COMPLETED,OBSERVATIONAL,['NA']
4587,NCT00592072,Telephone Search,,,2005-07,COMPLETED,INTERVENTIONAL,['NA']
4588,NCT03136822,Recovery of the wound 100%,Recovery of the wound 80%,,2017-04-26,COMPLETED,INTERVENTIONAL,['NA']
4589,NCT02185963,Functional HDL-C,Patients with LDL-C < 70 mg/dl and HDL > 40 mg/dl in men; > 50 in women,,2014-10,COMPLETED,INTERVENTIONAL,['PHASE4']
4590,NCT00634868,The wound healing process,,,2008-08,TERMINATED,INTERVENTIONAL,['NA']
4591,NCT04887077,Change in daily physical activity from baseline to 3 months,Change in weight bias internalisation from baseline to 9 months,Perceived exertion during the APA sessions,2021-06-10,UNKNOWN,INTERVENTIONAL,['NA']
4592,NCT01951287,plasma glucose levels,Plasma Insulin Levels,,2013-08,COMPLETED,INTERVENTIONAL,['NA']
4593,NCT00797888,HbA1c,diabetes self-care activities,,2008-09,COMPLETED,INTERVENTIONAL,['NA']
4594,NCT04311021,The main study parameter will be the current prevalence of IAH and exposure to SH in the past 12 months.,Answers to questionnaire,,2020-01-23,UNKNOWN,OBSERVATIONAL,['NA']
4595,NCT00311298,Weight gain,Mortality,,2006-04,COMPLETED,INTERVENTIONAL,['PHASE3']
4596,NCT00274118,Change from baseline in glomerular filtration rate GFR after five years of treatment.,Resting 12-lead ECG,,1997-07,COMPLETED,INTERVENTIONAL,['PHASE3']
4597,NCT00979628,"Mean Blood Glucose Levels (Measured in mg/dL) at Randomization Are Compared to Mean Blood Glucose Levels After First Day of Treatment Among Subjects Treated With Basal Plus, Basal -Bolus and SSRI Treatments","Number of Patients With Hypoglycemia Events (Blood Glucose Levels < 70 mg/dL) During Their Hospital Stay That Are Treated With Basal Plus, Basal-bolus and SSRI Treatments",,2010-01,COMPLETED,INTERVENTIONAL,['PHASE4']
4598,NCT03885362,MARD between Libre and YSI,Missing glucose data,,2019-12-11,COMPLETED,INTERVENTIONAL,['NA']
4599,NCT02639130,total AUC Glucose over 4 hour following the meal,,,2008-02,COMPLETED,INTERVENTIONAL,['PHASE4']
4600,NCT00266240,"HbA1c mean change from baseline, compared to placebo.",Pharmacokinetic and exposure-response relationship,,2005-11,COMPLETED,INTERVENTIONAL,['PHASE2']
4601,NCT04815772,The advantages of including the effect of diabetes and smoking on periodontal disease in the 2018 classification compared to the 1999 classification,,,2020-11-01,COMPLETED,OBSERVATIONAL,['NA']
4602,NCT04235621,% of Patients with Change in Treatment,,,2019-12-20,TERMINATED,OBSERVATIONAL,['NA']
4603,NCT01005498,Laboratory findings and body composition,,,2009-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4604,NCT01600534,Change in glycosylated hemoglobin,Change in weight after pregnancy,,2012-05,COMPLETED,INTERVENTIONAL,['NA']
4605,NCT00766441,Occurrence of hypoglycemia,"Body weight, fasting blood sugar, HbA1c, triglycerides, total cholesterol, LDL-C, HDL-C. CGMS to define glycaemic excursions",,2008-08,TERMINATED,INTERVENTIONAL,['PHASE4']
4606,NCT01257412,change in glycosylated haemoglobin A1c (HbA1c).,mean change from baseline in fasting plasma glucose (FPG),,2012-01,SUSPENDED,INTERVENTIONAL,['PHASE3']
4607,NCT02432547,Number of intravitreal aflibercept injections over 24 months,Mean change in treatment interval over time,Development of new proliferative diabetic retinopathy on wide-field fluorescein angiography,2017-06-15,COMPLETED,INTERVENTIONAL,['PHASE4']
4608,NCT04440839,Specialty Consultation,Amputation,,2020-03-01,COMPLETED,INTERVENTIONAL,['NA']
4609,NCT03941184,Incidence Rate of SCAD,SCAD recurrence,Odds of validated rheumatoid arthritis in SCAD cases compared to controls,1995-01-01,COMPLETED,OBSERVATIONAL,['NA']
4610,NCT03669770,Changes in Glycaemic control between baseline and follow-up,,Health-related quality of life,2017-09-22,COMPLETED,OBSERVATIONAL,['NA']
4611,NCT02162004,Percentage of time CGM values are in the target range 3.9-8.0 mmol/l in the time period 8:00-17:00.,Positive Incremental Area Under the Curve,Mean absolute relative difference.,2014-06,TERMINATED,INTERVENTIONAL,['NA']
4612,NCT03449433,Pharmacokinetics (PK): Insulin Lispro or Insulin Aspart Area Under the Concentration Curve From Zero to Seven Hours (AUC 0-7h) Following Administration of Each Study Arm,Pharmacodynamics (PD): Change From Baseline Area Under the Concentration Curve of Glucose Relative to a Mixed Meal Tolerance Test (MMTT),,2018-03-15,COMPLETED,INTERVENTIONAL,['PHASE1']
4613,NCT04383990,Hypoglycemia incidence,Acute diabetes complications,,2020-02-28,COMPLETED,INTERVENTIONAL,['NA']
4614,NCT00325364,To assess the change in baseline to endpoint in HbA1c in Type II diabetic patients comparing inhaled human insulin to injectable insulin,To assess the pharmacokinetics on inhaled human insulin in a subgroup of patients,,2006-04,COMPLETED,INTERVENTIONAL,['PHASE3']
4615,NCT03875755,Rate of patients requiring insulin therapy during pregnancy,Conservation of serum and plasma; cord fluid. The samples may be used for further analyses ancillary studies and which could be beneficial for GDM care based on evolution in scientific knowledge. This biolgical collection is optional,,2020-03-04,RECRUITING,INTERVENTIONAL,['NA']
4616,NCT00899483,The difference in the mean left ventricular end-systolic volume index (LVESVI) after CABG and the amount of new permanent injury detected in the late CMRI study,Glycaemic control will be assessed 2 hours pre-operatively and 72 hours post-operatively. Measurement timings will be standardized allowing comparison of glycaemic control during different time-periods.,,2009-07,UNKNOWN,INTERVENTIONAL,['NA']
4617,NCT01767389,"For treatment utilization patterns: treatment modification (discontinuation of the index ADA, switching of the index and concomitant ADA, and add-on therapy) will be assessed.",,,2012-09,COMPLETED,OBSERVATIONAL,['NA']
4618,NCT02566317,Mean Change in Sitting Time at Work From Baseline to 12 Months,Clustered Metabolic Risk Score From Baseline to 12 Months,Dynamic Glucose Control,2016-01-15,COMPLETED,INTERVENTIONAL,['NA']
4619,NCT00739180,"Abdominal obesity, visceral fat","Insulin sensitivity and secretion, glucose tolerance",,2007-11,COMPLETED,INTERVENTIONAL,['NA']
4620,NCT01951677,Safety,Efficacy,,2013-07,COMPLETED,INTERVENTIONAL,['PHASE1']
4621,NCT05266963,Patient-reported change in pancreatic exocrine insufficiency (PEI) symptoms,,,2022-09-02,ENROLLING_BY_INVITATION,INTERVENTIONAL,['EARLY_PHASE1']
4622,NCT01744236,"Changes from baseline following 12-week treatment with GLP-1RA or DPP-4i (long-term effects) on pancreatic exocrine function, measured as fecal Elastase-1.",Changes from baseline following infusion of GLP-1RA (acute effects*) and changes from baseline following 12-week treatment with GLP-1RA or DPP-4i (long-term effects) on the following gastrointestinal parameters:,,2013-04,COMPLETED,INTERVENTIONAL,['PHASE4']
4623,NCT02660827,Age 2-13 Years Old Subjects Change in A1C,Age 7-13 Years Old Subjects PLGM Performance - Event Rate Without Hypoglycemia at YSI-FST <=65 mg/dL,,2016-04-18,COMPLETED,INTERVENTIONAL,['NA']
4624,NCT02521116,Difference of oxygen saturation of retinal vessels between DVA and Oxymap T1,Difference of retinal vessel diameter between DVA and Oxymap T1,,2016-02,COMPLETED,INTERVENTIONAL,['NA']
4625,NCT04832984,Change in body weight,Change in anthropometry measures,,2022-03-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4626,NCT04153929,Absolute Change in HbA1c From Baseline to 16 Weeks,Percentage of Patients With 10% or Greater Body Weight Loss From Baseline to 16 Weeks,,2020-04-30,COMPLETED,INTERVENTIONAL,['PHASE2']
4627,NCT03826472,Fasting Glucose Measured Using Continuous Glucose Monitoring,Inhibitory Control Task (Percent Correct),,2019-03-08,COMPLETED,INTERVENTIONAL,['PHASE2']
4628,NCT02237352,House localization,Protein expression,Albuminuria,2014-09-15,UNKNOWN,OBSERVATIONAL,['NA']
4629,NCT00194259,Effects of OSA on weight,,,2001-08,UNKNOWN,OBSERVATIONAL,['NA']
4630,NCT03870997,Number of Participants With Self-reported Influenza Vaccination in People With Diabetes,,,2018-09-12,COMPLETED,INTERVENTIONAL,['NA']
4631,NCT03178773,Change in HBA1c From Baseline,Change in Partner Distress Scale From Baseline,,2017-07-18,COMPLETED,INTERVENTIONAL,['PHASE2']
4632,NCT00461630,Major Vascular Event,Mortality,,2007-01,COMPLETED,INTERVENTIONAL,['PHASE3']
4633,NCT05916131,The number of participants recruited to reach 20 participants that complete the intervention,Percentage of participants finding message content helpful (positive) at the end of the intervention,,2023-09-19,RECRUITING,INTERVENTIONAL,['NA']
4634,NCT01817959,"Area Under the Curve (AUC) for the Serum C-peptide Level During the First 2 Hours of an MMTT (Mixed Meal Tolerance Test), Normalized by the Number of Islet Equivalent (IEQ)/kg",β-cell Function as Assessed by Transplant Estimated Function (TEF) in Efficacy Population 1,Frequency of Patients Positive/Negative for Autoantibodies Against Class II Human Leucocyte Antigen (HLA) in Efficacy Population 1,2012-10,COMPLETED,INTERVENTIONAL,['PHASE3']
4635,NCT03284996,Early detection of diabetic nephropathy in patients with type 2 diabetes mellitus by measuring changes in renal resistive index using Doppler ultrasonography,,,2017-10-01,UNKNOWN,OBSERVATIONAL,['NA']
4636,NCT02326337,Wound closure within 12 weeks with the use of Topical Wound Oxygen Therapy (TWO2),Economic Analysis,,2014-10,UNKNOWN,INTERVENTIONAL,['NA']
4637,NCT03205150,Change From Baseline in Alanine Aminotransferase (ALT) at Week 12,Change From Baseline in Aspartate Aminotransferase (AST) at Week 12,,2017-10-04,COMPLETED,INTERVENTIONAL,['PHASE2']
4638,NCT01978613,Number of treatment emergent adverse events recorded,Maximum observed NNC0113-0987 plasma concentration,,2013-11,COMPLETED,INTERVENTIONAL,['PHASE1']
4639,NCT06201611,The mean nerve action potential amplitude (sural and tibial nerves) between Arm 1 and Arm 3 at 24 weeks follow-up.,The proportion of patients who progress to develop severe neuropathy,,2024-01-15,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
4640,NCT02373592,Foot ulceration,Glycosilated hemoglobin control targets,"Sub-group analyses, intervention group only",2015-09,COMPLETED,INTERVENTIONAL,['NA']
4641,NCT01238484,Range of Motion,Pain,,2010-08,TERMINATED,INTERVENTIONAL,['NA']
4642,NCT05903482,Gastric volume in pediatric patients on GLP-1 RA,,,2023-06-06,RECRUITING,OBSERVATIONAL,['NA']
4643,NCT02890693,Self-reported symptoms of depression (mother) measured by Edinburgh Postnatal Depression Scale,Laboratory (mother): miRNA,"Self-reported life events (mother, partner) measured by Life Events Questionnaire",2016-09,COMPLETED,INTERVENTIONAL,['NA']
4644,NCT02288585,Change in LDL-C,Change in blood lipids,Change in Advanced Glycation End products (AGEs),2014-10,COMPLETED,INTERVENTIONAL,['NA']
4645,NCT04198350,Safety of the procedure with regards to opthalmic complications,,,2022-09-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4646,NCT02422420,Weight Change,,,2013-03,COMPLETED,INTERVENTIONAL,['NA']
4647,NCT03235492,Salivary glycated albumin vs. glycosylated hemoglobin (HbA1c),,,2017-08-24,WITHDRAWN,INTERVENTIONAL,['NA']
4648,NCT04633941,Weight,Physical Activity Level,,2020-06-01,COMPLETED,OBSERVATIONAL,['NA']
4649,NCT05967312,Proportion of patients with ACR test in the last 12 months,"Proportion of patients with newly diagnosed albuminuria (i.e., since randomisation)",,2022-11-18,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
4650,NCT05990933,Monocyte count,Distribution of monocyte subset,,2023-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
4651,NCT02836574,Change in Renal Function,Treatment emergent adverse events,,2016-09,COMPLETED,INTERVENTIONAL,['PHASE2']
4652,NCT02872922,Percentage of the endothelium-dependent vasodilation (%FMD),Percentage of the endothelium-independent vasodilation (%NMD),,2016-12-10,COMPLETED,INTERVENTIONAL,['NA']
4653,NCT00456963,new hypertension or initiation of any antihypertensive treatment during the treatment period of the trial.,variations of fasting blood glucose.,,2007-09,TERMINATED,INTERVENTIONAL,['PHASE4']
4654,NCT01572090,Change in body fat,Change in BMI,,2006-01,UNKNOWN,INTERVENTIONAL,['NA']
4655,NCT04672031,Difference in birth weight,IUFD or stillbirth,,2021-07-08,RECRUITING,INTERVENTIONAL,['NA']
4656,NCT00645840,Effect of Anakinra Treatment on PBMC Gene Expression for Patients,C-peptide Secretory Capacity,,2008-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4657,NCT02004886,Number of Participants Discontinuing Study Treatment Due to an AE,Change From Baseline in 3-hour Insulin Total AUC at Week 4,,2006-08-11,COMPLETED,INTERVENTIONAL,['PHASE2']
4658,NCT00262197,LDL-cholesterol levels and test rates in the 12 months post-intervention.,Charlson comorbidity score,,2001-12,COMPLETED,INTERVENTIONAL,['NA']
4659,NCT00747149,Percentage of Subjects Achieving Canadian Low Density Lipoprotein Cholesterol (LDL-C) Target Goals (i.e. LDL-C ≤ 2.0 mmol/L) After 12 Weeks of Rosuvastatin Therapy,Incidence of Adverse Events and Abnormal Laboratory Values After 12 Weeks of Therapy,,2008-05,COMPLETED,INTERVENTIONAL,['PHASE4']
4660,NCT05066230,Proportion of eyes improving ≥2 steps on the ETDRS Diabetic Retinopathy Severity Scale (DRSS),Safety and Tolerability of KSI-301 5 mg compared to sham treatment,,2021-08-30,TERMINATED,INTERVENTIONAL,['PHASE3']
4661,NCT02451917,Number of Hypoglycemic Events,,Estimated Glomerular Filtration Rate (eGFR) Calculated by CKD-EPI,2013-12,COMPLETED,INTERVENTIONAL,['PHASE4']
4662,NCT02026232,Effect of HCQ on Fasting Blood Glucose,Effect of HCQ on Fasting Low Density Lipoprotein,,2012-03,TERMINATED,INTERVENTIONAL,['NA']
4663,NCT05014789,Serious Adverse Events,CGM Metrics by time of day,,2021-08-19,COMPLETED,INTERVENTIONAL,['NA']
4664,NCT01489189,Mean Change in Visual Acuity From Baseline,Number of Eyes With Greater Than or Equal to 10 Letter Vision Loss,,2012-03,COMPLETED,INTERVENTIONAL,['PHASE3']
4665,NCT00360698,Patients With Glycosylated Haemoglobin (HbA1c) Value < 7%,Rate of Severe Symptomatic Hypoglycemia,,2006-07,COMPLETED,INTERVENTIONAL,['PHASE4']
4666,NCT00319189,Insuline release,Plasma endothelin-1,,2002-11,COMPLETED,INTERVENTIONAL,['PHASE4']
4667,NCT06309654,Superoxide dismutases (SOD),,,2021-09-13,COMPLETED,INTERVENTIONAL,['NA']
4668,NCT01754142,"Effectiveness of Kombiglyze XR as assessed by change from baseline in Hemoglobin A1c (HbA1c), Fasting plasma glucose (FPG), and 2-hour post-prandial glucose (2-hr PPG)","Safety information related to overdose, drug-to-drug interaction and laboratory abnormalities based on incidence rates of AEs",,2012-11-24,COMPLETED,OBSERVATIONAL,['NA']
4669,NCT04283162,The rate of the progression of diabetic retinopathy,Changes in metabolic biomarkers such as HbA1c,,2020-03-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
4670,NCT02388100,HbA1c obtained from venous versus capillary measurements at one point in time for each participant.,,,2015-03,COMPLETED,OBSERVATIONAL,['NA']
4671,NCT03092882,Change from Baseline in A1c at 6 months,,,2017-03-03,COMPLETED,INTERVENTIONAL,['NA']
4672,NCT03939442,diabetes remission,,,2019-02-10,COMPLETED,OBSERVATIONAL,['NA']
4673,NCT03636529,serum uric acid,Serum triglycerides,,2010-06-01,COMPLETED,INTERVENTIONAL,['NA']
4674,NCT00622089,The following parameters will be evaluated at Week 12 and Week 24: • Proportion of subjects who reach the lipid goal as defined in the protocol from baseline • Proportion of subjects who meet the HbA1c goal as defined in the protocol from baseline,,,2008-01,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
4675,NCT05040971,Change to normoglycemia (Normoglycemia is defined as having both HbA1c below 6.0% (below 42 mmol/mol) and FPG below 5.5 mmol/L (below 99 mg/dL),Change in lipids - Very low density lipoprotein (VLDL) cholesterol,,2021-09-06,COMPLETED,INTERVENTIONAL,['PHASE3']
4676,NCT01890629,Mean Amplitude Glycemic Excursion,Glucose Standard Deviation in CGMS data,,2013-05,COMPLETED,INTERVENTIONAL,['PHASE4']
4677,NCT00904202,"Average daily pain intensity (BPI Questions 3,4,5, and 6)","Safety assessments include adverse events; dermal assessments/sensory testing, clinical laboratory tests, vital sign measurements and physical/neurological examination",,2003-01,COMPLETED,INTERVENTIONAL,['PHASE4']
4678,NCT02007278,Glycemic Variability Measured by Mean Amplitude of Glucose Excursions (MAGE),"Number of Patients With Any Adverse Events, Serious Adverse Events and Death",,2014-01-03,COMPLETED,INTERVENTIONAL,['PHASE4']
4679,NCT05925920,Safety and Tolerability of ENT-03,effect on insulin and insulin sensitivity,,2023-06-13,RECRUITING,INTERVENTIONAL,['PHASE1']
4680,NCT02553213,Change of blood glucose,,Changes of body composition,2015-07,UNKNOWN,INTERVENTIONAL,['NA']
4681,NCT02843139,It is expected that the identification of circulating miRNAs as potential biomarkers may facilitate to the diagnosis of obese preschoolers at high risk for developing diabetes.,,,2014-04,COMPLETED,OBSERVATIONAL,['NA']
4682,NCT00639626,Blood Sugar,Lean Body Mass,,2008-08,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
4683,NCT00348374,Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at End of Treatment,Change From Baseline in Standard Deviation of 24-hour Glucose Values Measured by Continuous Glucose Monitoring System (CGMS),,2006-06,COMPLETED,INTERVENTIONAL,['PHASE3']
4684,NCT05794789,Change from baseline in children's moderate to vigorous physical activity to 6 months,Social Identity,,2023-08-10,RECRUITING,INTERVENTIONAL,['NA']
4685,NCT04803357,Health of baby using delivery and post delivery well baby assessments,,,2021-04-10,RECRUITING,INTERVENTIONAL,['NA']
4686,NCT02947620,Change in LDL Cholesterol,"Change in Insulin, HOMA-β, HOMA-IR after 4, 8, 12, and 16 weeks of treatment with investigational products compared to baseline.",,2015-08,COMPLETED,INTERVENTIONAL,['PHASE3']
4687,NCT00347100,A1c values,Adverse events including hypoglycemia,,2006-06,COMPLETED,INTERVENTIONAL,['PHASE4']
4688,NCT04139369,"Overall mean methylation percentage (%) of CpGs cytosine-guanosine islands within the promoter regions of INS, PTPN-22,HLA-G genes between T1DM and healthy children and adolescents",,,2012-05,COMPLETED,OBSERVATIONAL,['NA']
4689,NCT02065752,Plasma concentration of metformin following the single dose of drug administration,Percentage of participants with adverse events as a measure of safety and tolerability,,2014-02,COMPLETED,INTERVENTIONAL,['PHASE1']
4690,NCT00260234,"Safety - will be evaluated by the incidence, grade, and type of adverse events, changes in laboratory parameters, evaluation of the implant site and physical exams.",Functional duration - will be determined by stimulated C-peptide from OGTT.,,2005-11,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4691,NCT04167410,Rates of hypoglycaemia development,,,2017-09-15,COMPLETED,INTERVENTIONAL,['NA']
4692,NCT01305434,change in 2 hour post prandial blood glucose,"number of subjects with adverse changes in creatinine, AST, ALT, and blood pressure due to intervention",,2011-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4693,NCT03453970,"Change from baseline diastolic blood pressure (DBP) at 6 months, change from baseline diastolic blood pressure at 12 months and change from baseline diastolic blood pressure at 18 months.","Change from the baseline level of adherence to the diet at 6 months, change from the baseline level of adherence to the diet at 12 months and change from the baseline level of adherence to the diet at 18 months.",Participation in the program,2018-12-01,UNKNOWN,INTERVENTIONAL,['NA']
4694,NCT05752591,Genetic predisposition,,,2018-05-25,COMPLETED,OBSERVATIONAL,['NA']
4695,NCT01387737,"Safety and Tolerability Assessed by Adverse Events, Hypoglycemic Events",Change in Blood Pressure,,2011-05,COMPLETED,INTERVENTIONAL,['PHASE3']
4696,NCT01013571,Percentage of subjects reaching target HbA1c <=7.0% without severe hypoglycemia,Adherence with the patient-managed monitoring algorithm,,2009-10,COMPLETED,INTERVENTIONAL,['PHASE4']
4697,NCT01425905,Insulin Resistance at 12 months in CB depression prevention versus HE control group.,"CB, depression, prevention, group, will, show, greater, improvements, in, mediators, (eating, behavior, fitness, and stress biomarkers) than the HE control group.",,2011-08-23,COMPLETED,INTERVENTIONAL,['PHASE2']
4698,NCT00996437,"Safety (Injected-related, Ocular Drug-related and Systemic Drug-related)",Very Severe Visual Acuity Loss (Defined as <20/800),,2010-06,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
4699,NCT04759469,Exercise enjoyment and acceptability,Adherence rates,,2018-12-01,COMPLETED,INTERVENTIONAL,['NA']
4700,NCT06141967,patients real positive for each screening technique,Nurse's satisfaction with the use of Withings Sleep Analyzer,,2023-11-30,RECRUITING,INTERVENTIONAL,['NA']
4701,NCT02649374,Bacterial population diversity,,,2016-02,COMPLETED,INTERVENTIONAL,['NA']
4702,NCT03699709,change (from baseline) in healthy and unhealthy food purchases (measured using the Healthy/Unhealthy Food Acquisition Survey) at 6 months and 12 months,"Process evaluation: intervention dose received (i.e., number of lessons included in the curriculum completed by participants)",,2020-02-27,COMPLETED,INTERVENTIONAL,['NA']
4703,NCT03601884,"Difference in Diabetes Management Self-Efficacy Scale (DMSES) scores between OHP+TAU (experimental group) and TAU alone (control group), and within OHP plus TAU across time","Difference in HbA1c between OHP+TAU (experimental group) and TAU alone (control group), and within OHP plus TAU across time",,2018-10-05,COMPLETED,INTERVENTIONAL,['NA']
4704,NCT05370781,Change in Regimen Adherence,Change in Adherence to gender norms,,2022-05-01,RECRUITING,INTERVENTIONAL,['NA']
4705,NCT04446767,Wound assessment,,,2020-06-30,COMPLETED,INTERVENTIONAL,['NA']
4706,NCT01958671,Percentage of Participants Discontinuing Study Treatment Due to an AE,Change From Baseline in DBP at Week 26,,2013-10-09,COMPLETED,INTERVENTIONAL,['PHASE3']
4707,NCT03020264,Number of confirmed or severe hypoglycemia,Number of death due to hypoglycemia,,2017-11-28,TERMINATED,INTERVENTIONAL,['NA']
4708,NCT02386982,24-hour glucose change,"Composite measure of adverse events monitoring, physical examinations,12 lead ECGs, vital sign,and safety laboratory measurement",,2015-03,COMPLETED,INTERVENTIONAL,['PHASE1']
4709,NCT02478762,Foetal glycated hemoglobin,Treatment satisfaction,,2015-03,TERMINATED,INTERVENTIONAL,['PHASE3']
4710,NCT01983007,Arterial dilation,,,2012-01,COMPLETED,INTERVENTIONAL,['NA']
4711,NCT03557697,Change in Average Plasma Glucose Concentration measured by Hemoglobin A1c (HbA1c) Levels,Minutes of Sleep as Measured by ActiGraph Watch,,2021-03-01,COMPLETED,INTERVENTIONAL,['NA']
4712,NCT00004360,,,,1995-09,COMPLETED,OBSERVATIONAL,['NA']
4713,NCT02386540,Number of emergency department visits,"Qualitative analysis of action plans (Health coach documentation notes will be analyzed, data will be coded to identify themes such as type of goals, barriers to care, and resources identified in the action plan)",,2015-02-06,COMPLETED,INTERVENTIONAL,['NA']
4714,NCT00395603,Percentage reduction in ldl-c at end-point after 6 weeks.,,,2006-09,TERMINATED,INTERVENTIONAL,['PHASE3']
4715,NCT00211471,tyo investigate the use of anecortave acetate in rubeosis iridis,mean change in VA(ETDRS) from baseline to 24 months,,2002-03,TERMINATED,INTERVENTIONAL,['PHASE2']
4716,NCT00039026,Change in HbA1c from Baseline to Week 30,Change in body weight from Baseline to each intermediate visit and Week 30,,2002-02,COMPLETED,INTERVENTIONAL,['PHASE3']
4717,NCT02047643,Count of Participants Experiencing a Hypoglycemic Event During Scheduled Exercise,Count of Participants With Hypoglycemia in the Post Exercise Period,,2014-03-12,COMPLETED,INTERVENTIONAL,['NA']
4718,NCT02203240,Change in insulin sensitivity,Change in gut permeability,,2014-06,COMPLETED,INTERVENTIONAL,['NA']
4719,NCT01517555,Area under the curve of post prandial plasma glucose,Adverse events,,2006-10,COMPLETED,INTERVENTIONAL,['PHASE1']
4720,NCT05446415,Changes mRNA expression levels of active L cells,,,2020-02-05,RECRUITING,INTERVENTIONAL,['NA']
4721,NCT02138006,Cardiovascular Mortality,Morbidity of Cardiovascular Complications,,1982-09,COMPLETED,INTERVENTIONAL,['NA']
4722,NCT03705260,Hemoglobin A1C,Change in rate of symptomatic hypoglycemia requiring medical intervention,,2018-11-26,COMPLETED,INTERVENTIONAL,['NA']
4723,NCT04063046,early prognosis (Delirium),intraoperative vasopressor use,,2019-11-12,UNKNOWN,INTERVENTIONAL,['NA']
4724,NCT00138567,Change from baseline in HbA1c at 104 weeks,Change in HOMA B between 52 weeks and 104 weeks,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE3']
4725,NCT04233580,Number of Participants Who Healed,Tissue Oxygenation (StO2) of the Dorsal Foot,,2020-07-09,COMPLETED,INTERVENTIONAL,['NA']
4726,NCT01953393,Beta-cell function,,,2006-04,COMPLETED,INTERVENTIONAL,['NA']
4727,NCT00998686,"To demonstrate safety and tolerability of dutogliptin as assessed by vital signs, adverse event reporting, routine clinical laboratory assessments, and ECG",To demonstrate maintenance or lowering of HbA1c and fasting plasma glucose,,2009-11,TERMINATED,INTERVENTIONAL,['PHASE3']
4728,NCT01208558,Change of waist circumference,Change of quantity and dosage of blood sugar-lowering drugs,,2010-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
4729,NCT04091373,Area under the plasma concentration time curve,"Incidence of treatment-emergent adverse events, including those related to changes in vital signs (including body temperature, heart rate, blood pressure) and safety laboratory evaluations (including hematology, chemistry, plasma glucose, urinalysis).",,2019-09-27,COMPLETED,INTERVENTIONAL,['PHASE1']
4730,NCT05761886,Proportion of items self-reported by pharmacist - Fidelity,Change in barriers to medication adherence,,2023-05-16,RECRUITING,INTERVENTIONAL,['NA']
4731,NCT04149548,The number of diabetic fetuses who will have undesirable effects,,,2019-11-05,UNKNOWN,OBSERVATIONAL,['NA']
4732,NCT02821104,C4 Copy Number,Insulin Sensitivity,,2016-06,COMPLETED,OBSERVATIONAL,['NA']
4733,NCT05004948,Change in Glycated hemoglobin% (HbA1c%),The maximum oxygen uptake (VO2max),,2019-01-01,COMPLETED,INTERVENTIONAL,['NA']
4734,NCT04910997,Peak aerobic capacity (fitness),Depression questionnaire,,2021-06-01,WITHDRAWN,INTERVENTIONAL,['NA']
4735,NCT02413060,HbA1c,,,2015-03,UNKNOWN,INTERVENTIONAL,['NA']
4736,NCT00404963,"Safety will be monitored by assessing adverse reactions,changes in laboratory values (hematology, clinical chemistry, urinalysis),changes in vital signs (oral body temperature,60 second respiratory rate, blood pressure and heart rate), and ECG changes.","Blood levels of GSK376501 Effects of GSK376501 on the body, by measuring changes in insulin, glucose, and other markers",,2006-10,COMPLETED,INTERVENTIONAL,['PHASE1']
4737,NCT03792399,Change of score for self efficacy,Change in exercise amount (time spent in sedentary behavior),,2016-03-07,COMPLETED,INTERVENTIONAL,['NA']
4738,NCT05863793,Peroneal Motor Nerve Conduction Velocity,Sural Sensory Nerve Conduction Velocity,,2021-09-01,RECRUITING,INTERVENTIONAL,['NA']
4739,NCT06037252,Percent Change From Baseline in Body Weight,Pharmacokinetics (PK): Steady State Area Under the Concentration Time Curve (AUC),,2023-09-21,RECRUITING,INTERVENTIONAL,['PHASE2']
4740,NCT03242343,Occurrence of safety events,,,2017-11-29,COMPLETED,INTERVENTIONAL,['NA']
4741,NCT02681094,Change From Baseline in HbA1c at Week 24,Change in Total Body Weight at 24 Weeks,,2016-02-26,COMPLETED,INTERVENTIONAL,['PHASE3']
4742,NCT00737126,Change in albumin excretion rate,"Change in serum homocysteine, thrombomodulin and von Willebrand factor.",,2004-01,COMPLETED,INTERVENTIONAL,['NA']
4743,NCT01076023,"Incidence of cardiovascular events, including fatal and non-fatal acute coronary syndromes (acute myocardial infarction [AMI] or unstable angina), fatal or non-fatal stroke, and other cardiovascular death.",Outcomes of current anti-diabetic treatment,,2010-02,UNKNOWN,OBSERVATIONAL,['NA']
4744,NCT01770561,Performance longevity,Physical duration,,2012-10,COMPLETED,INTERVENTIONAL,['NA']
4745,NCT04640064,Hb A1C pre and post Confinement in Latin American children with Type 1 Diabetes,,,2020-11-22,UNKNOWN,OBSERVATIONAL,['NA']
4746,NCT01961466,Correlations between glycemic balance (HbA1c) and the score on the Bortner self-questionnaire,Scores on the scales,,2010-12-01,COMPLETED,OBSERVATIONAL,['NA']
4747,NCT00871507,Incremental glucose AUC after an oral glucose tolerance test (OGTT),Safety and Tolerability,,2009-04,COMPLETED,INTERVENTIONAL,['PHASE1']
4748,NCT04975230,Continuous Glucose Monitor (CGM) data downloaded directly from each participant's existing or provided blinded Dexcom G6 [trademark],Diabetes Symptom Checklist Revised (34-item),,2022-04-29,COMPLETED,INTERVENTIONAL,['NA']
4749,NCT00204282,Nurse practitioner run group visits will improve compliance with established American Diabetes Association guidelines for screening and preventive care,Compliance with established American Diabetes Association guidelines for screening and preventive care will lower cardiovascular risk,,2003-08,COMPLETED,INTERVENTIONAL,['NA']
4750,NCT01833988,Percentage of Time With a Low Plasma Glucose Reading (Less Than 70mg/dl) in the Bionic Pancreas Arm as Compared to Insulin Pump Arm,Difference Between Closed-loop (Bionic Pancreas Arm) and Open-loop (Insulin Pump Arm) in Number of Carbohydrate Interventions for Hypoglycemia at Night,Difference Between Closed-loop (Bionic Pancreas Arm) and Open-loop (Insulin Pump Arm) in Mean Insulin Total Daily Dose,2013-04,COMPLETED,INTERVENTIONAL,['NA']
4751,NCT03734445,Change in Homeostatic Model Assesment for Insulin Resistance (HOMA-IR) from baseline to 12 and 24 weeks,Changes in Intestinal microbiota patterns from baseline to 12 and 24 weeks,Changes in plasma zinc from baseline to 12 and 24 weeks,2020-01-09,UNKNOWN,INTERVENTIONAL,['NA']
4752,NCT02750098,Aqueous humor glucose concentration,Hemoglobin A1c,,2016-05,UNKNOWN,INTERVENTIONAL,['NA']
4753,NCT01191268,Change From Baseline to 26-week Endpoint in Glycosylated Hemoglobin (HbA1c),"Number of Participants With Treatment Emergent Adverse Events up to 26 Weeks, 52 Weeks, and 4 Weeks After Last Dose",,2010-11,COMPLETED,INTERVENTIONAL,['PHASE3']
4754,NCT03329651,Difference in postprandial glycemic control as assessed by mean blood glucose concentration during a 4 hour mixed-meal tolerance test,Difference in peripheral glucose uptake as assessed by rate of glucose disappearance from blood,,2017-11-10,COMPLETED,INTERVENTIONAL,['NA']
4755,NCT02974699,Plasma Amino Acid Levels,Change in Plasma Amino Acid Levels,,2017-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
4756,NCT00770575,Change in the intima-media thickness of the common carotid artery.,Change from Baseline in Pulse wave velocity.,,2005-06,COMPLETED,INTERVENTIONAL,['PHASE2']
4757,NCT02691312,Number of participants diagnosed with retinopathy,,,2016-07,COMPLETED,OBSERVATIONAL,['NA']
4758,NCT02643797,Systolic blood pressure (SBP); mmHg units,Morisky Medication Adherence Scale (MMAS) - patient-reported outcome,Cost-effectiveness using the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model,2016-03-07,COMPLETED,INTERVENTIONAL,['PHASE3']
4759,NCT04449120,Change in fasting insulin level,Change in culinary habits measured by Culinary Habits Frequency Questionnaire (CHFC),,2020-06-01,COMPLETED,INTERVENTIONAL,['NA']
4760,NCT05401708,Correlation between blood and urinary tests and complications in patients with type 1 and 2 diabetes mellitus and prediabetes (cross-sectional),,,2022-07,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
4761,NCT05929170,"Assessing the results of gastric sleeve surgery, by weight loss","Assessing the half and one-year results of gastric sleeve surgery, weight loss. (We try to find a confluence between the perioperative parameters and the expected outcome)",,2021-04-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
4762,NCT01044602,"Resolution of obesity co-morbidities including hypertension, OSA, and hyperlipidemia",Identify predictors of success with regard to improved co-morbidities and velocity of weight loss,,2010-01,COMPLETED,INTERVENTIONAL,['NA']
4763,NCT00071422,,,,2003-10,COMPLETED,INTERVENTIONAL,['PHASE2']
4764,NCT04253860,Pain perception,C Reactive Protein ultra-sensible,,2019-02-01,TERMINATED,INTERVENTIONAL,['PHASE3']
4765,NCT04614623,Hemoglobin A1c (HbA1c) Change From Baseline to 6 months (End of study),Mean blood glucose (MBG) Change From Baseline to 6 months (End of study),PedsQL-Diabetes Module Change from Baseline to 6 months (study end),2020-11-01,UNKNOWN,INTERVENTIONAL,['NA']
4766,NCT00487981,Pain Rating at 6 Months Post Activation Compared to Baseline,,,2007-02,TERMINATED,INTERVENTIONAL,['PHASE4']
4767,NCT02001480,ECG surrogate markers compared to cardiac events,Continuous glucose monitoring is performed to identify episodes of hypoglycaemia,,2013-10,COMPLETED,INTERVENTIONAL,['NA']
4768,NCT05708859,Reduction of total non-calcified coronary plaque volume,Change in HgA1c lab values in the blood.,,2024-01-02,RECRUITING,INTERVENTIONAL,['PHASE4']
4769,NCT01253278,Number of Participants with Clinically Significant Effects,Change from baseline to day 14 in C-peptide,,2010-03,COMPLETED,INTERVENTIONAL,['PHASE1']
4770,NCT00678522,"GFR, clearance of sodium and lithium, fractional excretion of sodium and lithium, U-AQP-2, total sodium excretion, albumin excretion rate and free water clearance.","AVP, Ang-II, Aldo, ANP, BNP, PRC, BP, HR.",,2007-09,COMPLETED,INTERVENTIONAL,['PHASE4']
4771,NCT04384471,Self-reported acute diabetes complication,"Impact on stress, anxiety and depression for children and adolescents",,2020-04-29,COMPLETED,OBSERVATIONAL,['NA']
4772,NCT04296825,"Changes in lipid profiles (total cholesterol, total triglyceride, high-density lipoprotein cholesterol and low-density lipoprotein cholesterol in millimole per liter)","Changes in gut hormones (amylin, ghrelin, GLP-1, PP and PYY in petagram per milliliter)",,2018-06-01,COMPLETED,INTERVENTIONAL,['PHASE1']
4773,NCT00340639,,,,2003-01-28,COMPLETED,OBSERVATIONAL,['NA']
4774,NCT04410718,Plasma glucose levels and left ventricular ejection fraction,Diabetes status and change high-sensitivity troponins,,2020-04-20,COMPLETED,OBSERVATIONAL,['NA']
4775,NCT06264661,Insomnia,Gene expression analysis of PER2,,2022-08-08,COMPLETED,INTERVENTIONAL,['NA']
4776,NCT05647226,HbA1C <6.5% (48mmol/mol),HbA1C <6.5% (48mmol/mol),,2022-01-09,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
4777,NCT01823406,Difference in the levels of TCA cycle metabolites between groups during euglycemia and hyperglycemia,,,2012-05,COMPLETED,INTERVENTIONAL,['NA']
4778,NCT01781754,Levels of gene expression for UCP2 (RQ),Improved metabolic state,,2013-01,UNKNOWN,OBSERVATIONAL,['NA']
4779,NCT05364190,The cumulative mean of daily diuresis,The progression of heart failure severity,,2022-06-04,RECRUITING,INTERVENTIONAL,['PHASE3']
4780,NCT05770154,Peak torque,Dynamic balance,,2023-03,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
4781,NCT00797823,Effectiveness of Closed Loop Diabetes Control,Percent of Time Venous Blood Glucose <70 mg/dl,,2008-11,COMPLETED,INTERVENTIONAL,['PHASE2']
4782,NCT03726697,Admission to NICU for hypoglycemia,Pain scale,,2018-11-01,COMPLETED,INTERVENTIONAL,['NA']
4783,NCT05210530,Incidence of adverse events with causality related to VCTX210A units and/or the surgical procedures required to implant and explant the VCTX210A units.,The percentage of graft cells per unit that have differentiated into endocrine/beta cells as determined by immunohistochemical staining.,,2022-01-24,COMPLETED,INTERVENTIONAL,['PHASE1']
4784,NCT04833660,Quality of life after intervention to be assessed with Short Form 36-Item Health Survey,,,2021-04-30,UNKNOWN,INTERVENTIONAL,['NA']
4785,NCT05510531,Change in outcome expectancy,Participants perspective of the intervention,,2017-03-08,COMPLETED,INTERVENTIONAL,['NA']
4786,NCT00994266,Difference of glucose concentrations (fasting and post-prandial) at week 24 and at the beginning of the study considering the adjusted insulin doses during treatment,Difference of triglycerides and cholesterol concentrations at week 24 and at the beginning of the study,,2009-10,COMPLETED,INTERVENTIONAL,['PHASE3']
4787,NCT03049228,Cellular respiration ex vivo,Basal energy metabolism,,2017-03-21,COMPLETED,OBSERVATIONAL,['NA']
4788,NCT03712501,Triacylglycerol,Superoxide dismutase 3,,2017-10-01,COMPLETED,INTERVENTIONAL,['NA']
4789,NCT02480062,Glycated haemoglobin (HbA1c),Cost,,2016-04,COMPLETED,INTERVENTIONAL,['NA']
4790,NCT01601574,Change in HbA1c,Secondary Endpoints,,2012-05,COMPLETED,INTERVENTIONAL,['PHASE3']
4791,NCT03246997,Overall satisfaction score,Self Efficacy for Eating/Cooking Fruit and Vegetables by Condrasky,,2017-06-21,COMPLETED,INTERVENTIONAL,['NA']
4792,NCT02773381,Area under the serum glucose concentration-time curve,Area under the paracetamol plasma concentration-time curve,,2016-06-02,COMPLETED,INTERVENTIONAL,['PHASE1']
4793,NCT01898026,Postprandial Glycemia,Satiety Score,Safety,2013-07,UNKNOWN,INTERVENTIONAL,['NA']
4794,NCT01238276,,,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA']
4795,NCT00151749,addition of WelChol® to current antidiabetic therapy,other oral drugs,,2004-06,COMPLETED,INTERVENTIONAL,['PHASE3']
4796,NCT04135248,Rate of self-reported hypoglycaemia,Number of days needed to break the fast,,2019-04-18,UNKNOWN,OBSERVATIONAL,['NA']
4797,NCT03927859,Number of bookings made through the TOP program,Number of self-reported booking made outside of TOP,,2018-07-05,UNKNOWN,INTERVENTIONAL,['NA']
4798,NCT04647773,Compare the change from baseline in Average Daily Pain Score （ADPS） between HSK16149 and placebo at week 13.,Pharmacokinetic (PK) characteristics of HSK16149 capsules in Chinese patients with diabetic peripheral neuropathic pain.,,2020-12-02,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
4799,NCT00081328,Treatment Failure (Loss of Glycemic Control),Comorbidity -- Triglycerides Dyslipidemia,,2004-05,COMPLETED,INTERVENTIONAL,['PHASE3']
4800,NCT00770302,Pharmacokinetic variables for saxagliptin after single and multiple oral doses of 5 mg saxagliptin,"Safety variables (adverse events reported, vital sign measurements, electrocardiograms, physical examinations, and clinical laboratory tests after single and multiple oral doses of 5 mg saxagliptin",,2008-10,COMPLETED,INTERVENTIONAL,['PHASE1']
4801,NCT03461510,fMRI performance in relation to dysglycemia,,,2017-12-05,COMPLETED,INTERVENTIONAL,['NA']
4802,NCT01390480,Increase and function of regulatory T-cells,Calcium levels,,2010-11,COMPLETED,INTERVENTIONAL,['PHASE4']
4803,NCT02631265,Percentage of time of capillary blood glucose levels spent below 4 mmol/L,Relative difference between capillary blood glucose levels and sensor glucose levels,,2016-01,COMPLETED,INTERVENTIONAL,['NA']
4804,NCT00999635,Reduction in peak pressure,Comparison of cost,,2006-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
4805,NCT05228522,Glucose Tolerance,Dietary behaviors,,2021-12-12,RECRUITING,INTERVENTIONAL,['NA']
4806,NCT00695474,"Vitamin D status and its association with inflammation, glycemic control, lipids and blood pressure.","Lifestyle (exercise, sun exposure, food intake)",,2008-06,COMPLETED,OBSERVATIONAL,['NA']
4807,NCT03793101,Visual acuity,Corneal Incision thickness,,2018-01-01,UNKNOWN,OBSERVATIONAL,['NA']
4808,NCT05133765,"Comparison of TIR in blood glucose values during, and 1-hour after, dynamic physical exercise",To compare the influence of carbohydrate feeding before versus during exercise on the physiological responses to dynamic physical exercise,Comparison of the maximum iG concentration,2021-09-14,COMPLETED,INTERVENTIONAL,['NA']
4809,NCT05852132,Incidence of proliferative diabetic retinopathy (PDR),,,2024-05-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
4810,NCT02537470,Glycosylated haemoglobin A1c (HbA1c) at Week 12,"Safety endpoints include AEs, incidence of urinary tract infections, incidence of genital fungal infections, vital signs, ECGs and standard laboratory tests",,2015-07,COMPLETED,INTERVENTIONAL,['PHASE2']
4811,NCT05678712,time below range (CGM),Sensitivity and specificity of algorithm,Diabetes-related quality of life,2022-03-09,COMPLETED,INTERVENTIONAL,['NA']
4812,NCT04904406,Changes in body weight of ≥2 kg,Cardiac biomarkers,Cardiac MRI substudy secondary outcome lipid,2020-10-22,UNKNOWN,INTERVENTIONAL,['PHASE4']
4813,NCT00000154,,,,1976-10,COMPLETED,INTERVENTIONAL,['PHASE3']
4814,NCT00106808,Change in HBA1c from baseline to Week 24,To assess safety and tolerability of both Muraglitazar regimens relative to pioglitazone regimen when administered for up to 24 weeks,,2005-08,COMPLETED,INTERVENTIONAL,['PHASE3']
4815,NCT02161250,resistant starch effects,,,2014-04,COMPLETED,INTERVENTIONAL,['NA']
4816,NCT03944616,HbA1c,Dietary Practices,,2019-06-06,COMPLETED,INTERVENTIONAL,['NA']
4817,NCT04081883,Comparison between biosensor to CGMS responses,,,2023-01-27,COMPLETED,INTERVENTIONAL,['NA']
4818,NCT03117998,Change in Average Daily Total Insulin Use,Continuous Glucose Monitoring (CGM) - Change in Percent Time Spent in Hypoglycemia (Blood Glucose Range <55 mg/dL) at Week 12,,2017-09-19,COMPLETED,INTERVENTIONAL,['PHASE2']
4819,NCT03880760,Change in concentration of blood glucose (AC),Change in concentration of TGF-β1,,2018-08-01,COMPLETED,INTERVENTIONAL,['NA']
4820,NCT01866137,Changes in copeptin levels after a psychological stress test in healthy volunteers,Changes in copeptin levels after a psychological stress test in patients with central diabetes insipidus,,2013-03,COMPLETED,OBSERVATIONAL,['NA']
4821,NCT04043065,Beta-cell secretion,"Appetite, satiety, and general well-being",,2019-01-28,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
4822,NCT05266885,High incidence of HTN in Diabetics,,,2019-11-01,COMPLETED,OBSERVATIONAL,['NA']
4823,NCT02871180,Hypoglycemia,Blood glucose profile,,2003-03,COMPLETED,INTERVENTIONAL,['NA']
4824,NCT05025540,AUC,mPA,,2021-06-01,COMPLETED,OBSERVATIONAL,['NA']
4825,NCT00046462,To determine the difference in glycemic control as measured by HbA1C between substituting the TZD with insulin glargine and adding a third oral agent in patients who fail a TZD/sulfonylurea or TZD/metformin combination therapy,Change in serum lipid profile,,2001-11,COMPLETED,INTERVENTIONAL,['PHASE3']
4826,NCT05687656,Wound Healing area using digital image,Adverse events,Presence of protease levels,2022-10-06,RECRUITING,INTERVENTIONAL,['NA']
4827,NCT03272269,Incidence of all adverse events reported for subjects,Assessment of residual beta cell function and markers of metabolic control,Assessment of T lymphocyte immune response to IMCY-0098,2017-08-23,COMPLETED,INTERVENTIONAL,['PHASE1']
4828,NCT01467323,HbA1c (glycosylated haemoglobin A1c),Occurrence of adverse events,,1998-04,COMPLETED,INTERVENTIONAL,['PHASE3']
4829,NCT00021918,,,,2001-04,COMPLETED,OBSERVATIONAL,['NA']
4830,NCT02341690,"Changes in Physical activity from baseline to 52 weeks, measured with accelerometrics","Body temperature, measured by an ear thermometer",Changes in physical activity habits and diabetic motivation from baseline to 52 weeks - patients will be asked to answer 4 questions regarding their physical activity habits,2015-01,COMPLETED,INTERVENTIONAL,['NA']
4831,NCT05214573,3-point MACE,Severe genitourinary tract infection,,2021-12-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
4832,NCT05211869,Technology Use,Technology Use,Cost,2022-11-07,RECRUITING,INTERVENTIONAL,['NA']
4833,NCT00983775,(time to) maximal glucose infusion rate,(time to) maximal insulin concentration,,2009-11,COMPLETED,INTERVENTIONAL,['NA']
4834,NCT02948777,LDL Pool Size of ApoB100 Before and After Evolocumab,Mean ApoB48 iAUC Before and After Evolocumab,,2016-10,COMPLETED,INTERVENTIONAL,['PHASE4']
4835,NCT00450710,Evaluate safety and efficacy of the ileal interposition associated with a sleeve gastrectomy and the ileal interposition associated with a diverted sleeve gastrectomy.,Hormonal effect and effect of the operations on diabetes related and total mortality.,,2006-03,COMPLETED,INTERVENTIONAL,['PHASE4']
4836,NCT05395377,Patient-Centered Outcomes,,,2017-12-18,COMPLETED,INTERVENTIONAL,['NA']
4837,NCT01394341,Plasma liraglutide concentration (pmol/L),Cardiovascular risk factors (lipids and blood pressure),,2011-09,COMPLETED,INTERVENTIONAL,['PHASE4']
4838,NCT00359801,Time to Persistent Decline in FEV1 Exceeding 20% From Baseline,Change in Glycosylated Hemoglobin (HbA1c) From Baseline,,2006-07,COMPLETED,INTERVENTIONAL,['PHASE4']
4839,NCT01972542,Changes of Triglyceride,Changes of incretin,,2013-06,COMPLETED,INTERVENTIONAL,['NA']
4840,NCT01798264,Number of Subjects With Study Drug-Related Adverse Events,Change in Weight From Baseline to 4 Weeks,,2009-02,COMPLETED,INTERVENTIONAL,['PHASE1']
4841,NCT04981613,"Urinary protein remission rate, %","Time of participants achieving end stage renal disease (ESRD) or requiring dialysis or kidney transplantation, or blood creatinine doubling, or renal death, or all-cause death, days","Number of participants with treatment-related adverse events as assessed by reproductive toxicity (menorrhea or amenorrhea or infertility), %",2021-07-28,RECRUITING,INTERVENTIONAL,['NA']
4842,NCT03089463,Perfusion measurement,Ulceration incident,,2017-11-27,SUSPENDED,OBSERVATIONAL,['NA']
4843,NCT01326533,Insulin Sensitivity,Beta Cell Function,,2011-03,COMPLETED,INTERVENTIONAL,['PHASE4']
4844,NCT03419624,Change in HbA1c from baseline (week 0) to week 28,Proportion of patients achieving HbA1c of ≤ 7% at week 28 compared to baseline,,2018-02-19,TERMINATED,INTERVENTIONAL,['PHASE3']
4845,NCT04234217,Plasma norepinephrine levels,,,2019-11-26,RECRUITING,INTERVENTIONAL,['NA']
4846,NCT04835350,The safety of the prototype device Pancreas4ALL,Quality of life of patient living on closed loop system Pancreas4ALL,,2021-02-19,UNKNOWN,INTERVENTIONAL,['NA']
4847,NCT03006952,N terminal brain natriuretic peptide (NT-pro BNP),serum creatinine concentrations,,2015-04,COMPLETED,INTERVENTIONAL,['PHASE4']
4848,NCT00574912,Maximum Glucose Infusion Rate,,,2007-03,COMPLETED,INTERVENTIONAL,['PHASE1']
4849,NCT03249259,Cognitive function,Glucose metabolism,Hypoglycemia,2016-03-10,COMPLETED,INTERVENTIONAL,['PHASE3']
4850,NCT01684722,Change in Estimated Glomerular Filtration Rate,Change in NT-proBNP,,2010-07,COMPLETED,INTERVENTIONAL,['NA']
4851,NCT00708578,HbA1c values,Fasting Blood Glucose level,,2008-05,COMPLETED,INTERVENTIONAL,['PHASE4']
4852,NCT06000813,IMB barrier sum score,Diabetes self-efficacy,,2024-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
4853,NCT01318109,Change From Baseline in Glycosylated Hemoglobin (Week 12).,Change From Baseline in Blood Glucose Measured by the Meal Tolerance Test (Week 12).,,2008-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
4854,NCT02672176,Diabetes Self-Efficacy Measured Using the Diabetes Empowerment Scale Short Form (DES-SF)- Scores at 9-months,Perceived Stress Measured by PSS,PROMIS Physical Function,2016-02,COMPLETED,INTERVENTIONAL,['NA']
4855,NCT06300047,Lost to Followup,Clinical Outcome 6,,2024-04-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
4856,NCT02493309,Blood glucose Area Under the Curve (AUC),Blood Pressure,,2014-10,COMPLETED,INTERVENTIONAL,['NA']
4857,NCT00551876,Percent change in fasting LDL-C from baseline to the average of the Week 6/Week 12 measurements,Well tolerated in patients in Diabetic patients,,2001-12,COMPLETED,INTERVENTIONAL,['PHASE3']
4858,NCT02517320,Change form baseline in UACR,Adverse events,,2015-07,COMPLETED,INTERVENTIONAL,['PHASE2']
4859,NCT05048264,Change in blood glucose measures,,,2023-05-04,RECRUITING,OBSERVATIONAL,['NA']
4860,NCT01692002,Study 3: Incremental area under the insulin profile,Insulin,,2013-01,COMPLETED,INTERVENTIONAL,['NA']
4861,NCT00593489,Insulin Prescription Rate - the Number of Insulin-eligible Patients Per 12 Months Who Are Prescribed Insulin in Each Family Physician (FP) Practice,Physician Score for Self-efficacy of Insulin Initiation & Titration,,2006-07,COMPLETED,INTERVENTIONAL,['NA']
4862,NCT00187785,retention of medical information,patient satisfaction,,2005-09,TERMINATED,INTERVENTIONAL,['NA']
4863,NCT02159144,browning of subcutaneous white adipose,,,2014-06,COMPLETED,INTERVENTIONAL,['NA']
4864,NCT06115876,Conversion to Pre-Diabetes,,,2022-05-23,RECRUITING,OBSERVATIONAL,['NA']
4865,NCT00788840,Weight change,Glycaemic control,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE4']
4866,NCT03959423,Change in Percentage of Euglycemia,Change in Percent of Time in Hypoglycemic Range (<70 mg/dL),,2019-07-24,COMPLETED,INTERVENTIONAL,['NA']
4867,NCT05580120,A Measure of Quality of Life in the Elderly,,,2021-11-15,COMPLETED,INTERVENTIONAL,['NA']
4868,NCT01041599,Correlation between albuminuria and arterial stiffness,,,2009-10,COMPLETED,OBSERVATIONAL,['NA']
4869,NCT00031239,,,,2001-09,COMPLETED,OBSERVATIONAL,['NA']
4870,NCT00233311,,,,2004-03,COMPLETED,OBSERVATIONAL,['NA']
4871,NCT04287439,Change in pain severity,Change in Quality of life status,,2018-06-08,COMPLETED,INTERVENTIONAL,['NA']
4872,NCT05067075,Average percentage time in target glucose range,neonatal hypoglycemia,postpartum 2 hour 75 gram OGTT results from mother,2021-11-01,COMPLETED,INTERVENTIONAL,['NA']
4873,NCT01094899,"evaluate the MicroScanner, alterations quantitative and qualitative bone in the foot in patients with type 1 diabetes 2 with or without neuropathy",correlation involving bone and extension of neuropathy Assessment criteria associated with biological abnormalities qualitative and quantitative bone in diabetic subjects,,2010-03-10,COMPLETED,INTERVENTIONAL,['NA']
4874,NCT03126513,Efficacy of G-POEM in gastroparesis in percentage of scintigraphic improvement at 4hrs,security of G-POEM in gastroparesis,,2017-04-01,COMPLETED,INTERVENTIONAL,['NA']
4875,NCT01721811,Retinal oximetry during hyperglycemia,,,2012-10,UNKNOWN,INTERVENTIONAL,['NA']
4876,NCT02691481,Glucose area under the curve 0-240 minutes,,,2014-05,COMPLETED,INTERVENTIONAL,['NA']
4877,NCT01572753,AUC 0-24h; Area under the semaglutide concentration curve from time 0-24 hours after the 10th dosing,t1/2; the terminal half-life of semaglutide,,2012-04-12,COMPLETED,INTERVENTIONAL,['PHASE1']
4878,NCT05324462,Change in local laboratory measured Glycated Haemoglobin A1c (HbA1c),Comparison between the daily dose of basal insulin and IDegLira,,2022-03-22,COMPLETED,OBSERVATIONAL,['NA']
4879,NCT00291590,Reduction in glycated hemoglobin levels,Improvement in health status and diabetes self-care practices,,2001-07,COMPLETED,INTERVENTIONAL,['PHASE3']
4880,NCT05377320,Imaging surveillance,,,2024-06,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
4881,NCT00514618,The Primary Outcome Measure Will be the Time Interval From Start of Induction to Delivery.,"Other Outcome Measures Will be Number of Doses of Medication Required, Oxytocin Requirements, and Route of Delivery.",,2006-03,TERMINATED,INTERVENTIONAL,['NA']
4882,NCT01630928,Change in blood pressure,Effect of RDN on subclinical organ injury: Impedance cardiography,,2013-03,COMPLETED,INTERVENTIONAL,['NA']
4883,NCT01394055,Pharmacodynamic (PD) effects of RM-131 on gastric emptying,Pharmacokinetics (PK) of RM-131,,2011-07,COMPLETED,INTERVENTIONAL,['PHASE1']
4884,NCT02882477,C-Peptide levels in blood in response to Glucose Challenge - Oral Glucose tolerance test ( OGTT ) and Intra venous glucose tolerance test IVGTT,,,2016-12,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
4885,NCT04924400,Percentage of patients who complete the study,Total cost of care over 6 months.,,2022-03,UNKNOWN,INTERVENTIONAL,['NA']
4886,NCT00084110,,,,1993-08,TERMINATED,OBSERVATIONAL,['NA']
4887,NCT00508599,Insulin resistance and orthostatic response,"Change in glucose, insulin, and orthostatic impairment.",,2003-01,COMPLETED,INTERVENTIONAL,['NA']
4888,NCT05924932,glycated hemoglobin,mean sensor glucose value,Safety and Tolerability,2022-12-01,RECRUITING,OBSERVATIONAL,['NA']
4889,NCT03371303,exit orders after hospitalization,,,2017-11-01,UNKNOWN,OBSERVATIONAL,['NA']
4890,NCT03331289,Change in EGP From Baseline to Post-oral Glucose Load.,,,2018-02-28,COMPLETED,INTERVENTIONAL,['PHASE4']
4891,NCT03888157,Change in HbA1c (mmol/mol),Changes in quality of life (EQ VAS),,2019-03-10,COMPLETED,OBSERVATIONAL,['NA']
4892,NCT00037258,,,,2001-09,COMPLETED,OBSERVATIONAL,['NA']
4893,NCT00528879,Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF]),Adjusted Percentage of Participants Achieving Hemoglobin A1c (HbA1C) ≤6.5% at Week 24 (Last Observation Carried Forward [LOCF]),Number of Participants With Orthostatic Hypotension,2007-09,COMPLETED,INTERVENTIONAL,['PHASE3']
4894,NCT01382121,Psychological: Self-Efficacy,Changes in variability (standard deviation),,2010-09,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
4895,NCT01904032,Change in Center for Epidemiologic Studies Depression (CES-D) Score From Baseline (Month 0) to Month 6 for the High Dose Cohort Versus Low Dose Cohort,Change in Diastolic Blood Pressure From Baseline (Month 0) to Month 6 for the High Dose Cohort Versus Low Dose Cohort,,2013-11-21,COMPLETED,INTERVENTIONAL,['PHASE2']
4896,NCT06305351,Proportion of participants who discontinued study medication due to an AE,t1/2 of plasma K-833,,2023-12-07,RECRUITING,INTERVENTIONAL,['PHASE1']
4897,NCT01689129,Change from baseline in HbA1c,Number of Patients with various types of Hypoglycemia Events,,2012-09,COMPLETED,INTERVENTIONAL,['PHASE3']
4898,NCT06279234,Number of Participants With Change From Baseline in Physical Examination,Renal Clearance (CLr),,2024-02-20,RECRUITING,INTERVENTIONAL,['PHASE1']
4899,NCT05611684,blood lipid changes,Inflammation factors,,2022-06-01,RECRUITING,INTERVENTIONAL,['PHASE4']
4900,NCT04249778,"Number of Participants With Hospital Admissions, Emergency Department Visits, Urgent Clinic Visits for Heart Failure (HF) and Death After Admission With Acute Decompensated Heart Failure (ADHF)",Number of Participants With Acute Kidney Injury,,2020-07-29,COMPLETED,INTERVENTIONAL,['PHASE4']
4901,NCT03597035,Left Ventricular Mass,,,2018-07-17,TERMINATED,INTERVENTIONAL,['PHASE4']
4902,NCT02791295,Weight change,Retention of weight change,,2016-10-04,COMPLETED,INTERVENTIONAL,['NA']
4903,NCT02509429,Time spent with blood glucose <70 mg/dl,Score of the Hypo Fear Survey,,2015-06-16,COMPLETED,INTERVENTIONAL,['PHASE2']
4904,NCT03127696,Proportion of subjects with at least 20% lean-associated microbiota in recipients after FMT compared with subjects receiving lifestyle intervention alone up to week 24,Changes in liver stiffness to assess improvement of other metabolic disease weeks 24 compared with baseline,,2017-04-26,COMPLETED,INTERVENTIONAL,['NA']
4905,NCT01664247,Change From Baseline in Glycosylated Haemoglobin (HbA1c) (%),Change From Baseline in Patient Reported Health-related Quality of Life Using the Short-Form 36 Health Survey Version 2 (SF-36®v2),,2012-10-01,COMPLETED,INTERVENTIONAL,['PHASE3']
4906,NCT00961662,Change From Baseline HbA1c After Six Months of Treatment in Patients With Type 2 Diabetes Mellitus,Body Weight Loss (Compared to Baseline),,2008-02,COMPLETED,INTERVENTIONAL,['PHASE2']
4907,NCT01190436,Percentage of Participants With Decrease in Heart Rate by at Least 10 Bpm at Week 12,Number of Participants With Adverse Events (AEs),,2009-12,COMPLETED,INTERVENTIONAL,['PHASE4']
4908,NCT02315495,Blood glucose concentrations at pre-defined intervals,half-emptying time (T50),,2015-04-03,COMPLETED,INTERVENTIONAL,['PHASE3']
4909,NCT00014911,Percent of Participants That Achieved Insulin Independence With Adequate Control of Blood Glucose Levels at One Year Post Final Islet Transplantation.,Percent of Participants With Detectable Fasting Basal C-Peptide Levels,,2001-04,COMPLETED,INTERVENTIONAL,['PHASE2']
4910,NCT00308256,Patient's acceptance of the disease evaluated by an analogical visual scale rating,Episodes number of severe hypoglycaemia having required an intervention of a third party or a hospitalization.,,2006-03,COMPLETED,INTERVENTIONAL,['NA']
4911,NCT02532101,Blood glucose level,Beta Cell Function,,2014-12,TERMINATED,INTERVENTIONAL,['NA']
4912,NCT04800679,Extent of neovascular tissues in disc-diameter measured by investigator according to the wide-field FAG,Central retinal thickness according to macular OCT,,2020-03-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
4913,NCT02772783,Nucleus Accumbens Blood Flow,"Functional Connectivity of Nucleus Accumbens, Hypothalamus and Other Brain Areas Involved in Intake Regulation",Metabolomics,2016-07,COMPLETED,INTERVENTIONAL,['NA']
4914,NCT00945204,"The percentage of participants reaching target control of HbA1c (7.0), and blood pressure (<140/80) and cholesterol (<4 mmol/l),",Control of risk factors in all patients with type 2 diabetes in participating practices using anonymised routine data,,2007-05,COMPLETED,INTERVENTIONAL,['NA']
4915,NCT02901860,cardio-metabolic risk,Obesity,,2012-01,COMPLETED,OBSERVATIONAL,['NA']
4916,NCT03791125,PK profile of Salvianolic acid A following administration of multiple doses assessed by time of occurrence of Cmax [tmax],,,2018-11-20,UNKNOWN,INTERVENTIONAL,['PHASE1']
4917,NCT00879203,,,,2008-11,COMPLETED,OBSERVATIONAL,['NA']
4918,NCT05352815,Change in glycated haemoglobin (HbA1c),"Number of clinically significant hypoglycaemic episodes (level 2) (below 3.0 mmol/L (54 mg/dL), confirmed by BG meter) or severe hypoglycaemic episodes (level 3)",,2022-06-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
4919,NCT04032561,Sleep Duration,HbA1c,,2019-01-08,COMPLETED,OBSERVATIONAL,['NA']
4920,NCT04259606,Brachial - ankle index,Lipid profile,,2018-08-17,UNKNOWN,INTERVENTIONAL,['NA']
4921,NCT01722227,Mean weekly blood glucose concentrations.,HbA1c,,2012-11,WITHDRAWN,INTERVENTIONAL,['PHASE3']
4922,NCT04210024,Change in Health Literacy,,,2019-05-03,COMPLETED,INTERVENTIONAL,['NA']
4923,NCT04256447,Urinary sodium concentrations,,,2018-05-02,COMPLETED,OBSERVATIONAL,['NA']
4924,NCT01144728,Evolution of Fasting Plasma Glucose (FPG),Change in Weight,,2010-05,COMPLETED,INTERVENTIONAL,['PHASE4']
4925,NCT01694758,Percentage of patients in the benchmarking group achieving pre-set targets for HbA1c1,The LDL cholesterol parameter of the primary and secondary objectives according to ATP III guidelines,,2012-11,COMPLETED,OBSERVATIONAL,['NA']
4926,NCT02973412,HBA1C level (%) measured from a blood sample,Continuous Glucose Monitoring (CGM),,2016-12-07,RECRUITING,OBSERVATIONAL,['NA']
4927,NCT02057497,Association of defined G protein- and FTO-related genotypes with the presence of T2DM or T1DM from a blood sample; also other genes of potential relevance for the evolution of obesity and/or diabetes.,Association of defined G protein- and FTO-related genotypes with the T2DM risk of healthy volunteers from a blood sample.,,2017-10-09,WITHDRAWN,OBSERVATIONAL,['NA']
4928,NCT01445899,Efficacy (Stratum II),Anatomical changes in retina and retinal nerve fiber layer morphology (Stratum II),,2012-02,COMPLETED,INTERVENTIONAL,['PHASE2']
4929,NCT06150690,Glycated hemoglobin,Islet area,,2012-08-21,RECRUITING,OBSERVATIONAL,['NA']
4930,NCT01618552,Physician use of self-efficacy enhancing interviewing techniques,Healthcare Climate Questionnaire,,2013-04,COMPLETED,INTERVENTIONAL,['NA']
4931,NCT04335513,Continuous glucose monitor (CGM) % time >140 mg/dL,Diabetes attitude survey change over time,Change in Diabetes Knowledge from 6 month to 12 months follow-up.,2020-04-30,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
4932,NCT04298684,Percentage of patients in each group who had at least a 20% decrease in one or more nodules of more than 2 cm at 2 years.,Percentage of adiponectin receptor expression in thyroid tissues after TN surgery,,2021-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
4933,NCT00837096,Number of Participants With 100% Wound Closure,,,2007-06,TERMINATED,INTERVENTIONAL,['NA']
4934,NCT02336217,Number of hypoglycemic episodes,ADDQOL score,,2014-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
4935,NCT01607944,Glucose turnover,Palmitate turnover and oxidation,,2012-04,COMPLETED,OBSERVATIONAL,['NA']
4936,NCT05674110,Change in Diabetes knowledge,Change in Hemoglobin A1c,,2023-01-09,RECRUITING,INTERVENTIONAL,['NA']
4937,NCT06035536,Percentage of index ulcers healed at 12 weeks,Change in pain levels during the clinical investigation,"Cost to closure (both treatment groups; all wounds, and only closed wounds)",2023-06-08,RECRUITING,INTERVENTIONAL,['NA']
4938,NCT01467401,HbA1c (glycolated haemoglobin),Number and severity of hypoglycaemic episodes,,2002-08-19,COMPLETED,INTERVENTIONAL,['PHASE4']
4939,NCT01859598,the Change of Hypoglycemia During Follow-up.,Overall Weight Gain From Visit 1 to Visit 3,,2011-12,COMPLETED,OBSERVATIONAL,['NA']
4940,NCT05217290,The Effect of Health Education Given to Prediabetes Patients by Video Conferencing on Self-Management and Exercise Status,,,2022-01,UNKNOWN,INTERVENTIONAL,['NA']
4941,NCT03366337,Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 12,,,2017-12-26,COMPLETED,INTERVENTIONAL,['PHASE2']
4942,NCT00803608,The first occurrence of a plantar ulcer or pre-ulcer in subjects who have had one previously healed plantar ulcer,,,2009-02,COMPLETED,INTERVENTIONAL,['PHASE2']
4943,NCT04614870,Positive predictive value of the device in the determination of infection in wounds with clinical signs of infection,Likelihood of infection,,2022-05-01,RECRUITING,OBSERVATIONAL,['NA']
4944,NCT01529528,The Change in HbA1c from baseline to week24,change from baseline to week 24 in HOMA-IR,,2011-05,COMPLETED,INTERVENTIONAL,['PHASE3']
4945,NCT02580513,Insulin Sensitivity,Heart rate,,2016-01,COMPLETED,INTERVENTIONAL,['NA']
4946,NCT00241423,Time-averaged serum glucose during a 24-hour period,To compare the effects of exenatide and placebo on serum glucose,,2005-10,COMPLETED,INTERVENTIONAL,['PHASE2']
4947,NCT02639507,average (mean) improvement in Best Corrected Visual Acuity (BCVA) as measured with Snellen visual acuity,,,2015-06,COMPLETED,OBSERVATIONAL,['NA']
4948,NCT00012753,,,,na,COMPLETED,INTERVENTIONAL,['PHASE3']
4949,NCT00709319,Change in Optical Coherence Tomography Central Subfield Thickness From Baseline to 6 Months,Surgical Complications From Baseline to Six Months,,2005-07,COMPLETED,OBSERVATIONAL,['NA']
4950,NCT04730882,Myocardial Microvascular Perfusion (measured by contrast-enhanced ultrasound),E-selectin,,2021-04-06,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
4951,NCT04194515,bile acid profile,,,2020-01-01,UNKNOWN,OBSERVATIONAL,['NA']
4952,NCT01878045,End-Stage Renal Disease,Death,,2013-11-07,SUSPENDED,OBSERVATIONAL,['NA']
4953,NCT01364584,Peak Oxygen Consumption (VO2 Peak),Echocardiographic Measures - Lateral E:E',,2010-10,COMPLETED,INTERVENTIONAL,['NA']
4954,NCT02488057,Beta Cell Function,Presence of genetic polymorphisms,,2016-05,COMPLETED,INTERVENTIONAL,['PHASE4']
4955,NCT00949221,"Comparison of the effect of 2 strategies of real time continuous glucose monitoring vs conventional SMBG on glycated haemoglobin = HbA1c measured at inclusion, 3, 6, 9, 12 months",Medico-economic evaluation,,2009-09,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
4956,NCT01128985,The concentration of canagliflozin and major metabolites (M5 and M7) in blood will be measured by protocol-specified pharmacokinetic parameters.,"The safety and tolerability of canagliflozin will be determined by monitoring adverse events and findings from laboratory evaluations, vital signs measurements, and ECG measurements reported.",,2010-03,COMPLETED,INTERVENTIONAL,['PHASE1']
4957,NCT05804890,Comparing Activated Carbon Cloth Dressing and Silver-Based Dressing in a Diabetic Foot Ulcer Population.,,,2022-08-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
4958,NCT05497674,rongliflozin:Cmax ratios of geometric means of rongliflozin+probenecid relative to rongliflozin alone.,the number of participants with adverse events (AE) in Cohort B,,2022-02-21,COMPLETED,INTERVENTIONAL,['PHASE1']
4959,NCT00967798,Number of Participants With Conversion to Cystic Fibrosis Related Diabetes,Change in Percent Predicted FEV1,,2010-05,TERMINATED,INTERVENTIONAL,['PHASE3']
4960,NCT00642434,Number of Participants Assessed for Change in Markers of Inflammation (PAI-1) Following Treatment Compared to Baseline,,,2004-01,COMPLETED,INTERVENTIONAL,['PHASE4']
4961,NCT04282005,Assessment of liver inflammation and fibrosis,"Assessment of bile acids in fasting and postprandial phase in response to a mixed meal test (MMT) in a subset of patients (total no.=18; 6 RYGB, 6 SG, 6 lifestyle intervention)",,2020-02-13,UNKNOWN,INTERVENTIONAL,['NA']
4962,NCT02849080,Participants Who Achieve HbA1c <7.0% (53 mmol/Mol) ADA Target (Yes/no),Change in DTSQ- Sustainability,,2016-09-20,COMPLETED,INTERVENTIONAL,['PHASE3']
4963,NCT04355832,Change in the level of catecholamines in plasma,,,2020-06-24,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
4964,NCT01467375,Frequency of hypoglycaemic episodes,HbA1c (glycosylated haemoglobin),,2001-01-08,COMPLETED,INTERVENTIONAL,['PHASE3']
4965,NCT01596920,"Complete closure of the index wound, defined as 100% re-epithelialization as determined by the Investigator, anytime up to the Day 84 Visit",percent of wounds achieving complete closure,,2012-04,COMPLETED,INTERVENTIONAL,['PHASE4']
4966,NCT01472666,Postprandial triglyceride response,"Postprandial apolipoprotein-48 (apoB-48), 6 hour",,2011-10,COMPLETED,INTERVENTIONAL,['NA']
4967,NCT04857346,Clinical attachment level,Interleukin-6,,2020-06-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
4968,NCT03933956,Change in amino acid metabolome signature,,,2020-01-09,TERMINATED,INTERVENTIONAL,['PHASE3']
4969,NCT00549757,Percentage of Participants With All Cause Mortality (Extension Phase),Percentage of Participants With Occurrence of Secondary Renal Composite Endpoint (Extension Phase),Percentage of Participants With Angioedema/Angioedema-like Events or Colorectal Events (Extension Phase),2007-10,TERMINATED,INTERVENTIONAL,['PHASE3']
4970,NCT01525693,"The primary endpoint of this study is the overall proportion of patients whose HbA1c is less than 6.5%, measured at the end of one year follow up.",The clinical effectiveness of each regimen measured by the proportion of patients reaching the target glycemic control,,2012-04,UNKNOWN,OBSERVATIONAL,['NA']
4971,NCT04910178,"fatty liver staging (0, I, II, and III)",Changes in total protein and albumin,,2020-12-01,COMPLETED,INTERVENTIONAL,['PHASE4']
4972,NCT05881213,Cmax of CKD-378,,,2023-06-01,COMPLETED,INTERVENTIONAL,['PHASE1']
4973,NCT00956800,"Columbus Research Foundation will take the objective data that constitutes the defined end-points of the study and enter it for each patient into an Access data base, using the established data base management system of Columbus Research Foundation.",,,2009-09,COMPLETED,INTERVENTIONAL,['NA']
4974,NCT03705195,Difference in insulin secretion and incretin effect between two matched clamps (presence and absence of low dose gliclazide),"Insulin secretory response analysed by KCNJ11 Genotype (E23K, E23E, K23K)",,2018-08-03,COMPLETED,INTERVENTIONAL,['NA']
4975,NCT03994536,Level of empowerment,Clinic attendance 2,,2019-08-15,RECRUITING,INTERVENTIONAL,['NA']
4976,NCT00239148,To evaluate the safety and tolerability of repeated subcutaneous doses of E1 in combination with G1 in patients with type 1 diabetes,To evaluate the pharmacokinetic (PK) profile and clinical effects of repeated subcutaneous doses of E1 in combination with G1 in patients with type 1 diabetes,,2005-06,COMPLETED,INTERVENTIONAL,['PHASE1']
4977,NCT02767596,Change in body weight,,,2016-07-12,TERMINATED,INTERVENTIONAL,['PHASE4']
4978,NCT04532385,Change from baseline in TNF-α at week 12,Change from baseline in body water at week 12,,2018-06-12,COMPLETED,INTERVENTIONAL,['NA']
4979,NCT05067621,Change in Protein Density Fat Fraction (PDFF),Triglycerides,Changes in liver fibrosis,2023-07-17,RECRUITING,INTERVENTIONAL,['PHASE2']
4980,NCT00202670,,,,2004-01,TERMINATED,OBSERVATIONAL,['NA']
4981,NCT00685984,Post-occlusive hyperaemia endothelium-dependent brachial artery dilation,biologic markers of endothelial function,,2008-01,COMPLETED,OBSERVATIONAL,['NA']
4982,NCT05112146,Post-prandial glucose,T max glucose,,2018-08-20,COMPLETED,INTERVENTIONAL,['NA']
4983,NCT01766778,Change of Glycosylated Hemoglobin A1c (HbA1c) From Baseline to Month 12,"Number of Patients With Adverse Events, Serious Adverse Events and Death as an Assessment of Overall Safety and Tolerability",,2013-05-13,COMPLETED,INTERVENTIONAL,['PHASE4']
4984,NCT01648647,,,,2012-05,COMPLETED,OBSERVATIONAL,['NA']
4985,NCT00789191,HbA1c (Glycosylated Haemoglobin A1c),Self-measured 9-point Plasma Glucose Profile,,2008-11,COMPLETED,INTERVENTIONAL,['PHASE3']
4986,NCT06140537,Albuminuria,safety and tolerability,,2024-02-01,RECRUITING,INTERVENTIONAL,['PHASE4']
4987,NCT00160732,decrease in incidence of hypoglycemic events,absence of complications from the procedure and side effects of the medication,,2003-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4988,NCT00403091,Lipids,Smoking cessation advice,,2005-04,COMPLETED,INTERVENTIONAL,['NA']
4989,NCT03121755,Total cellular cholesterol on leukocytes collected from the subjects,,,2015-01-21,COMPLETED,OBSERVATIONAL,['NA']
4990,NCT02505516,Number of diabetic patients on metformin therapy,,,2013-06,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
4991,NCT01747356,12-month TVF occurrence,Patient related adverse events,,2013-02,COMPLETED,INTERVENTIONAL,['NA']
4992,NCT00354939,Frequency of subjects with conventionally detected hypoglycemia,,,2003-10,COMPLETED,INTERVENTIONAL,['PHASE4']
4993,NCT02306005,Factors influencing relationship between insulin treatment and lipoproteins,Development of Diabetic kidney disease,,2014-11,UNKNOWN,OBSERVATIONAL,['NA']
4994,NCT02026817,"metformin, rosuvastatin AUClast","Metformin, rosuvastatin AUCinf",,2013-12,COMPLETED,INTERVENTIONAL,['PHASE1']
4995,NCT05477173,Measures frequency of psychiatric problems with diabetes mellitus type 1,,,2022-08-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
4996,NCT04286464,Swabs during respiratory infection,Sputum,,2003-09,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
4997,NCT03103126,The effects of home-based combined exercise on insulin sensitivity compared to physical activity advice during the 6 week study period,Self-efficacy to regulate exercise scale,,2019-05-01,WITHDRAWN,INTERVENTIONAL,['NA']
4998,NCT00987363,AngioRNM and/or AngioTC changes,Clinically objective improvement in the ischemic limb,,2009-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
4999,NCT00931034,Change in body weight from baseline to week 24,"Analyze circumference measurements & body composition; blood glucose, HbA1c, insulin, lipid profile, blood pressure & questionnaire responses on food cravings and quality of life",,2007-03,COMPLETED,INTERVENTIONAL,['NA']
5000,NCT06280053,Wound Healing,Incidence of Safety Events,,2016-03-02,COMPLETED,INTERVENTIONAL,['NA']
5001,NCT00825253,,,,2007-03,COMPLETED,INTERVENTIONAL,['PHASE1']
5002,NCT03095651,Maximal Glucose Infusion Rate,Apparent Terminal Half-life,,2017-04-12,COMPLETED,INTERVENTIONAL,['PHASE1']
5003,NCT00762112,Adverse event occurrence.,Change from baseline in inflammation marker C-reactive protein.,,2003-11,TERMINATED,INTERVENTIONAL,['PHASE3']
5004,NCT03842683,Optimal Time Shift of Continuous Glucose Monitoring Measurements,Area Under the Receiver Operating Characteristics Curve of the Hypoglycemia Prediction,,2016-06-06,COMPLETED,OBSERVATIONAL,['NA']
5005,NCT04255381,Safety: Number of Participants Who Experienced an Adverse Event,Percent Time AP System Active,,2018-10-01,COMPLETED,INTERVENTIONAL,['NA']
5006,NCT04028076,Change in Hemoglobin A1c,Adherence to Refills and Medications Scale for Diabetes (ARMS-D),,2019-07-10,COMPLETED,INTERVENTIONAL,['NA']
5007,NCT04531631,first phase insulin response to glucose,Area under curve of GLP-1 levels,,2020-09-30,COMPLETED,INTERVENTIONAL,['PHASE2']
5008,NCT00639080,,,,2008-03,COMPLETED,OBSERVATIONAL,['NA']
5009,NCT03577158,Number of hypoglycaemias,Rate-of-change of glucose during exercise (ROCe) and recovery (ROCr),,2018-06-01,COMPLETED,INTERVENTIONAL,['NA']
5010,NCT00291356,"Safety and tolerability: side effects and relevant changes in blood pressure, heart rate and ECG measurements, blood and urine measurements, the amount of fluid taken in and excreted, and kidney function will be monitored over course of study.",Amount and percentage of glucose excreted in urine by kidneys. Effect of compounds on lipid metabolism analysed.,,2006-01,COMPLETED,INTERVENTIONAL,['PHASE2']
5011,NCT01308008,Six Minute Walk Distance,Physical Activity,,2011-11,COMPLETED,INTERVENTIONAL,['NA']
5012,NCT01375166,Retinal blood flow velocities,,,2013-03-06,TERMINATED,OBSERVATIONAL,['NA']
5013,NCT03359837,Change in hemoglobin A1c (HbA1c),Subgroup analysis,,2018-01-20,COMPLETED,INTERVENTIONAL,['PHASE4']
5014,NCT00734474,Glycosylated Hemoglobin (HbA1c) Change From Baseline,Antibodies to LY2189265,Number of Participants With Adjudicated Cardiovascular Events at 104 Weeks,2008-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
5015,NCT01478672,SF-36,EQ-5D,,2011-03,COMPLETED,INTERVENTIONAL,['NA']
5016,NCT05403437,Evaluation of PGP severity,Evaluation of Body Mass Index (BMI),,2022-06-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
5017,NCT05487755,change in 2- Hours Postprandial blood glucose,Change in serum malondialdehyde (MDA) .,,2022-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
5018,NCT02443155,Area Under the Concentration-time Curve (AUC) 0-4h of Mixed Meal Tolerance Test (MMTT) Stimulated C-peptide at Week 54 Relative to Baseline,Cmax of Glucose at Week 80 Relative to Baseline,,2015-11-10,COMPLETED,INTERVENTIONAL,['PHASE2']
5019,NCT04009239,Glucose control in response to mTRF,Difference in substrate oxidation rhythms between experimental conditions,,2019-01-15,COMPLETED,INTERVENTIONAL,['NA']
5020,NCT03605979,Glycemia measured by continuous glucose monitoring (CGM) and pump,,,2012-07-01,COMPLETED,OBSERVATIONAL,['NA']
5021,NCT05250999,Toronto Clinical Neuropathy scoring system,,,2021-07-15,COMPLETED,INTERVENTIONAL,['NA']
5022,NCT00153179,Difference in Insulin-mediated Skeletal Muscle Glucose Utilization Between Test Agent and Placebo,,,2005-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5023,NCT03586830,Number of Participants With Treatment Emergent Adverse Events (TEAEs),Number of Participants With Greater Than or Equal to (>=) 5 Percent (%) Weight Loss at Week 12,,2018-06-26,COMPLETED,INTERVENTIONAL,['PHASE2']
5024,NCT02120755,Reduction in Wound Size,,,na,WITHDRAWN,INTERVENTIONAL,['PHASE4']
5025,NCT04038931,Evaluating autoimmune response to AIPs,,,2019-10-01,UNKNOWN,OBSERVATIONAL,['NA']
5026,NCT02211651,Quantity of macrophages,,,2013-12,COMPLETED,OBSERVATIONAL,['NA']
5027,NCT01943357,Metabolic control HbA1C,Health care utilization,,2013-09,COMPLETED,INTERVENTIONAL,['NA']
5028,NCT01147276,Glucagon response to hypoglycemia,Catecholamine response to hypoglycemic,,2010-09,COMPLETED,INTERVENTIONAL,['PHASE4']
5029,NCT03436992,Change in Flow-Mediated Dilation (FMD),,,2018-04-17,COMPLETED,INTERVENTIONAL,['NA']
5030,NCT01833403,Insulin Sensitivity,,,2013-04,COMPLETED,INTERVENTIONAL,['NA']
5031,NCT00790699,"The Primary Outcome Will be Measured by HbA1c Values Taken at Screening, Baseline and After Three Months.","The Secondary Outcome Will Measure Patient Satisfaction, Opinions and Attitudes Toward Using the Multiple Injection Port for Insulin and Symlin Administration Compared to Standard Symlin Injections (Measured Through Using Questionnaires).",,2009-08,TERMINATED,INTERVENTIONAL,['NA']
5032,NCT01486901,Maximum serum insulin concentration (Cmax),Adverse events,,2006-05,COMPLETED,INTERVENTIONAL,['PHASE1']
5033,NCT00228865,"Using repetitive respiratory quotients, we will assess the success of the reversal of the abnormal underlying metabolism in diabetic patients from primarily fat metabolism to carbohydrate metabolism.",,,2003-06,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
5034,NCT00519623,Pharmacodynamics of the PassPort(R) Transdermal Insulin Delivery System in Type 1 Diabetes Patients (GIRmax),Skin Response to the Application of the PassPort(R) Transdermal Insulin Delivery System in Type 1 Diabetes Patients,,2007-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5035,NCT06314061,Time in range (TIR) of CGM glucose levels,Complications,Staff experience,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
5036,NCT01868230,Child Length,,,2014-06,COMPLETED,INTERVENTIONAL,['NA']
5037,NCT01496443,AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours Postdose Pharmacokinetic Parameter for TAK-875,,,2012-01,COMPLETED,INTERVENTIONAL,['PHASE1']
5038,NCT05462756,Change from Baseline in HbA1c,Treatment Experience for Diabetes Injection Device at Week 26 - Experience Questionnaire (DID-EQ),,2022-08-11,COMPLETED,INTERVENTIONAL,['PHASE3']
5039,NCT02655666,Change in Glycosylated Hemoglobin (A1C),Percentage of Time in the Hyperglycemic Range,,2015-04,TERMINATED,OBSERVATIONAL,['NA']
5040,NCT02764905,change in A1C,change in indices will be collected before initiation of intervention and will be measured again after 3 months and 12 months,,2016-11,COMPLETED,OBSERVATIONAL,['NA']
5041,NCT00716092,GLP-1 (Glucagon Like Peptide 1) AUEC (0-2h) (Area Under Effect Curve) Change From Baseline at Day 28,Plasma Glucose Area Under Effect Curve (AUEC) (0-3h) Change From Baseline at Day 28,Exploratory Sensitivity Analysis of Plasma Glucose AUEC (0-3h) Change From Baseline at Day 28,2008-07,COMPLETED,INTERVENTIONAL,['PHASE2']
5042,NCT03222765,Sudomotor Index,depressive symptoms,,2015-03-15,UNKNOWN,INTERVENTIONAL,['NA']
5043,NCT05411458,Heart rates,Health Related Quality of Life,,2021-05-01,COMPLETED,INTERVENTIONAL,['NA']
5044,NCT05325892,IDH,,,2022-03-01,UNKNOWN,OBSERVATIONAL,['NA']
5045,NCT01507038,Change from baseline in HbA1c at week 12,"Change from baseline in 1,5-anhydroglucitol at week 12",,2011-12,COMPLETED,INTERVENTIONAL,['PHASE2']
5046,NCT03215914,Endogenous Glucose Production,Endogenous Glucose Production,,2017-08-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
5047,NCT00501202,The mean of the last 7 average daily DPN scores of the first treatment period on days when study drug is taken.,"The means of the last 7 average daily DPN pain scores with no use of rescue medication, the last 7 current daily DPN pain scores, the last 7 maximum daily DPN pain scores, and the last 7 daily sleep interference scores.",,2007-03,COMPLETED,INTERVENTIONAL,['PHASE2']
5048,NCT04372316,changes of inferior whorl length （IWL）from baseline at 8 weeks,changes of corneal nerve fibre tortuosity （CNFT) from baseline at 8 weeks,,2017-12-25,UNKNOWN,INTERVENTIONAL,['PHASE2']
5049,NCT00306098,a1c less than 6.5 without severe hypoglycemia,assessment of EXN to improve islet survival at time of islet transplantation - number of subjects achieving insulin independence with a single infusion,,2000-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
5050,NCT00289848,Change From Baseline in Hemoglobin A1c (HbA1c) at Week 18,Change From Baseline in 2-hr Post-Meal Glucose (PMG) at Week 18,,2006-03,COMPLETED,INTERVENTIONAL,['PHASE3']
5051,NCT00567775,Area under the serum insulin curve,Time to maximum serum insulin concentration,,2002-10-21,COMPLETED,INTERVENTIONAL,['PHASE2']
5052,NCT05395000,Success rate of glucagon administration,Preferences in relation to the teaching method of administering the two forms of glucagon,,2021-03-19,COMPLETED,INTERVENTIONAL,['NA']
5053,NCT00508937,LDL subclasses,Apolipoprotein A1,,2007-02,COMPLETED,INTERVENTIONAL,['NA']
5054,NCT04145154,Changing the dimensions of the ulcer area,Change in pain intensity,,2018-06-05,COMPLETED,INTERVENTIONAL,['NA']
5055,NCT04263168,Changes in glycemic index prior and following bariatric surgery,,,2020-03-01,WITHDRAWN,INTERVENTIONAL,['NA']
5056,NCT00568074,HbA1c,adverse events,,2003-12-16,COMPLETED,INTERVENTIONAL,['PHASE4']
5057,NCT03455257,Change in per capita food expeditures,Change in Grip Strength,,2017-04-25,UNKNOWN,INTERVENTIONAL,['NA']
5058,NCT02371876,Percent of Self-Test Fingerstick Blood Glucose (BG) Results Within +/- 15mg/dL (<100mg/dL) and Within +/- 15% (>=100mg/dL) of Laboratory Glucose Method,Percent of Responses From Persons With Diabetes That Either 'Strongly Agree' or 'Agree' or Are 'Neutral' With Questionnaire Statements Regarding Views/Behaviors Related to Self-Monitoring Blood Glucose,,2015-02,COMPLETED,INTERVENTIONAL,['NA']
5059,NCT03037593,incidence of gestational diabetes,Shoulder Dystocia,,2017-06-01,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5060,NCT04075032,Change (1 log units) of Bacteroidetes per gram of feces,"Evaluation of genotype frequencies for 60 single nucleotide polymorphisms (SNPs) related to the incidence of obesity, metabolism, diabetes and cardiovascular diseases",,2018-06-10,COMPLETED,INTERVENTIONAL,['NA']
5061,NCT03495089,Presence of diabetic neuropathy diagnosed by EMG,Utah Early Neuropathy Scale,,2015-05,COMPLETED,INTERVENTIONAL,['NA']
5062,NCT04014192,Change from baseline to post-treatment in islet alpha cell secretory function.,"Change from baseline to post-treatment in urinary output of uric acid, sodium, calcium, and phosphorus.",,2019-09-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
5063,NCT01795248,Change in glucose tolerance,Deterioration in glycaemic status,Changes in bonemarkers,2012-07,COMPLETED,INTERVENTIONAL,['PHASE4']
5064,NCT01213901,"Anatomic site, abdomen versus deltoid, that offers the most consistent(superior) absorption of insulin",Injection technique which allows the most comfortable method of inserting the needle subcutaneously,,2010-09,COMPLETED,INTERVENTIONAL,['NA']
5065,NCT02577536,Number of women delivering at each gestational week,Number of live births,,2017-09-25,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
5066,NCT02726490,efficacy of glyburide compared to glucovance,neonatal hypoglycemia,,2016-07,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1']
5067,NCT05479565,The values of highly sensitive CRP in pregnant women with gestational diabetes are higher compared to healthy pregnant women.,,,2020-09-01,COMPLETED,OBSERVATIONAL,['NA']
5068,NCT02958072,Healing of malleoli ulcer (YES/NO),"Z scores of combined plasma concentration of growth factors, cytokines and inflammatory markers",,2016-11,COMPLETED,INTERVENTIONAL,['NA']
5069,NCT01703637,Change From Baseline in Hemoglobin A1c (A1C) Levels at Week 12,The side effect of each drug.,change from baseline in content of NOS,2012-10,UNKNOWN,INTERVENTIONAL,['NA']
5070,NCT01994291,Mean Letter Change From Baseline at Week 12 in Best Corrected Visual Acuity (BCVA),Plasma Concentration of PF-04634817 up to Week 12,Number of Participants With Change in Ophthalmoscopy Examination Results in Study Eye After Administration of Ranibizumab or Masked Sham Therapy at Week 8,2013-11,TERMINATED,INTERVENTIONAL,['PHASE2']
5071,NCT02165228,Metabolic Syndrome Extent,Mindfulness,,2010-01,COMPLETED,INTERVENTIONAL,['NA']
5072,NCT00998595,the fraction of each group that participates in postpartum follow up and glucose tolerance testing 4-12 weeks post partum.,the fraction of women in each group that attends a referral visit,,2009-06,COMPLETED,INTERVENTIONAL,['NA']
5073,NCT02630277,Assess ocular and non-ocular adverse events,,,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
5074,NCT01459133,Efficacy of Inhaled Insulin versus Subcutaneous Insulin in a patient who receives inadequate response from subcutaneous alone.,,,2013-05,WITHDRAWN,INTERVENTIONAL,['NA']
5075,NCT03565666,Percentage of Time Where Glucose is Less Than 54 mg/dL,,Mean Absolute Relative Difference Between Senseonics Eversense CGM and Contour Next One Glucose Meter,2018-07-09,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
5076,NCT02623608,"Area under the curve (AUC) of postprandial triglyceridemia (0-4h) after each intervention, compared to the reference meal","Area under the curve of postprandial glycemia (0-4h) after each intervention, compared to the reference meal",,2015-08,COMPLETED,INTERVENTIONAL,['NA']
5077,NCT00846391,Change From Baseline in 24-hour Weighted Mean Glucose (WMG) at Week 4,,,2008-12,TERMINATED,INTERVENTIONAL,['PHASE2']
5078,NCT03511885,"Proportions of hospital coronary patients and high risk individuals in primary care achieving European lifestyle, risk factors and therapeutic targets for cardiovascular disease prevention",,,2016-08-23,COMPLETED,OBSERVATIONAL,['NA']
5079,NCT00396227,Change from baseline in HemoglobinA1c (HbA1c),Incidence of prespecified adverse events while on treatment with study drug,,2006-10,COMPLETED,INTERVENTIONAL,['PHASE3']
5080,NCT06129526,Number of participants who suffer from bleeding events as defined by the Bleeding Academic Research Consortium (BARC) criteria during the entire follow-up period.,"Number of participants who suffer from the secondary safety end points which are Atrial fibrillation, Palpitations, Arrhythmias, Heart failure, Pneumonia, Peripheral edema, Diarrhea.",,2023-12,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
5081,NCT00663624,to determine whether initiation of hyperglycemia management in the ED with scheduled aspart insulin for patients versus usual care with type 2 diabetes will result in a decrease in subsequent hospital length of stay.,"to determine diff. in the mean BG during the ED stay, the mean BG achieved during hospital, frequency of hypoglycemia during the ED and hospital visits among those treated with the scheduled protocol insulin regimen vs. usual hyperglycemia mgmt",,na,WITHDRAWN,INTERVENTIONAL,['PHASE4']
5082,NCT05977309,Comparison of the effects of topical ozone therapy and placebo on the healing of diabetic foot ulcers.,Comparison of topical ozone therapy and placebo groups for diabetic foot ulcer infection,,2023-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
5083,NCT02548741,Plasma methylglyoxal (MG) concentration (μM),The urine imidazolinone (IMZ) concentration (nM),,2015-09,UNKNOWN,INTERVENTIONAL,['NA']
5084,NCT01009580,Change in Glycosylated Haemoglobin (HbA1c),Rate of Nocturnal Confirmed Hypoglycaemic Episodes,,2009-11-05,COMPLETED,INTERVENTIONAL,['PHASE3']
5085,NCT03436628,Change in Hemoglobin A1c (HbA1c),Change in Parental Monitoring,,2018-03-01,COMPLETED,INTERVENTIONAL,['NA']
5086,NCT00287651,Serial fundus photography,,,2005-11,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
5087,NCT05468411,Overall liking for meals,,,2019-11-01,COMPLETED,INTERVENTIONAL,['NA']
5088,NCT01728467,Change in plasma glucose following treatment with RVX000222 compared to placebo,Change in insulin secretion and insulin sensitivity following treatment with RVX000222 compared to placebo,,2012-11,COMPLETED,INTERVENTIONAL,['PHASE2']
5089,NCT00448903,total healing with intact skin or a significant improvement defined as a reduction of ulcer area > or = 50% or one degree reduction on Wagner Classification.,incidence of major bleeding and the incidence of adverse events.,,2007-03,COMPLETED,INTERVENTIONAL,['PHASE3']
5090,NCT02469207,Number of donors from which induced Pluripotent Stem Cells were generated,Levels of baseline and stimulated gut hormones detected,,2016-01,UNKNOWN,OBSERVATIONAL,['NA']
5091,NCT01447251,Number of participants with a change in their seven serum biomarker panel results,Number of participants with increased Continuous Positive Airway Pressure (CPAP)Compliance,,2011-09,COMPLETED,INTERVENTIONAL,['NA']
5092,NCT00865592,To demonstrate safety and tolerability of dutogliptin,To demonstrate maintenance or lowering of fasting blood glucose,,2009-03,TERMINATED,INTERVENTIONAL,['PHASE3']
5093,NCT04930276,the glycemic qualification rate,pregnancy outcome,,2021-03-05,UNKNOWN,INTERVENTIONAL,['NA']
5094,NCT01883622,"Glucose variability indexes during first, second and third trimester of pregnancy","Association between HbA1c and glucose variability indicators in the three trimesters pf pregnancy, in the three groups of women",,2004-01,COMPLETED,OBSERVATIONAL,['NA']
5095,NCT00975065,Hemoglobin A1c at 24 weeks,"Hypoglycemic events, Gastro-Intestinal events, other adverse events at each visit",,2009-08,COMPLETED,INTERVENTIONAL,['PHASE4']
5096,NCT02861781,comparison of miRNA,changes in miRNA in plasma level,,2016-02-02,RECRUITING,OBSERVATIONAL,['NA']
5097,NCT02745821,"Prevalence of number of vessels fulfilling each of 4 permutations of fractional flow reserve (FFR) and coronary flow reserve (CFR) ie FFR ≤0.80 CFR ≥2.0, FFR ≤0.80 CFR <2.0, FFR >0.80 CFR ≥2.0 and FFR >0.80 CFR <2.0.",Change in index of microvascular resistance (IMR) in target vessel,,2016-06,TERMINATED,INTERVENTIONAL,['NA']
5098,NCT02193113,Number of participants with Adverse Events as a measure of safety and tolerability,Best Corrected Visual Acuity as measured by ETDRS EVA,Change in retinal thickness from baseline,2014-07-18,COMPLETED,INTERVENTIONAL,['PHASE1']
5099,NCT05464186,Fat mass,Diastolic blood pressure,Food and beverage intake pattern,2022-12-28,RECRUITING,INTERVENTIONAL,['NA']
5100,NCT05998525,changes in cardiac epicardial fat volume quantified in cm3 and evaluated by simple cardiac tomography.,Mortality due to cardiovascular causes,,2021-06-21,COMPLETED,INTERVENTIONAL,['PHASE3']
5101,NCT01775579,"metformin, rosuvastatin AUC","Metformin, Rosuvastatin Vd/Fss",,2013-01,COMPLETED,INTERVENTIONAL,['PHASE1']
5102,NCT03680482,glycemic response in blood,Insulin response in blood,Through food provided ad libitum (objective appetite),2016-01-11,COMPLETED,INTERVENTIONAL,['NA']
5103,NCT03167411,AUC0-inf (Area Under the Plasma Concentration-time Curve From Time 0 to Infinity),Urinary Glucose Excretion (UGE),,2017-05-24,COMPLETED,INTERVENTIONAL,['PHASE1']
5104,NCT02214329,Gait,Functional Performance,,2014-02,UNKNOWN,INTERVENTIONAL,['NA']
5105,NCT00576862,Evolution of efficacy parameters between first study visit (V1) and last study visit (V5),,,2002-11,COMPLETED,INTERVENTIONAL,['PHASE4']
5106,NCT01422421,important secondary composite endpoint,new onset or deterioration of heart failure,,2011-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4']
5107,NCT00659646,Number of Participants With a Clinical Cure at Visit 3 (Day 7),Lipsky Wound Score,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE2']
5108,NCT02137031,HbA1c,Frequency of Diabetic Ketoacidosis,,2012-09,COMPLETED,INTERVENTIONAL,['NA']
5109,NCT03884647,DELPHI's reliability,,,2020-04-01,COMPLETED,OBSERVATIONAL,['NA']
5110,NCT05123196,Change from baseline in the weekly mean 24-hour average NRS score at Week 12 in treatment period,Proportion of CGIC responder at each assessment point,,2021-11-16,COMPLETED,INTERVENTIONAL,['PHASE2']
5111,NCT02013843,Body mass index standard deviation score,Change in quality of life assessed by PedsQL,cost effectiveness,2013-03,COMPLETED,INTERVENTIONAL,['NA']
5112,NCT00460499,glycemic control,free fatty acid levels,,2004-07,COMPLETED,INTERVENTIONAL,['PHASE1']
5113,NCT04841837,Time in range,Body composition (fat and muscle mass),,2021-04-15,RECRUITING,INTERVENTIONAL,['NA']
5114,NCT02690766,Change in Body Weight,,,2015-03,COMPLETED,INTERVENTIONAL,['NA']
5115,NCT00661921,Change from baseline in HbA1c at week 14 (end of treatment),,,2008-06,WITHDRAWN,INTERVENTIONAL,['PHASE2']
5116,NCT01338870,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12,Percentage of Participants With Greater Than or Equal to (>=) 1% or >= 2% Loss in Body Weight From Baseline,,2011-06,COMPLETED,INTERVENTIONAL,['PHASE2']
5117,NCT03891056,Number of participans with normal glycosylated hemoglobin levels,Comparison postoperative pain in sleeve and bypass with analogue assessment scale of postoperative pain.,,2019-01-15,UNKNOWN,INTERVENTIONAL,['NA']
5118,NCT01277614,decrease body mass index,,,2010-09,COMPLETED,INTERVENTIONAL,['NA']
5119,NCT05661149,Percentage time spent in the euglycaemic range specific for pregnancy (63-140 mg/dL),,,2023-05-11,COMPLETED,OBSERVATIONAL,['NA']
5120,NCT00441363,Change in Baseline to End of Study in HbA1c,Number of Serious Adverse Events Experienced by the Subjects,,2005-02,TERMINATED,INTERVENTIONAL,['PHASE3']
5121,NCT05723185,Analyse and compare the function of the two outpatient clinic models,,,2023-02-13,RECRUITING,OBSERVATIONAL,['NA']
5122,NCT02816749,Wound healing time(days),Negative bacterial culture time (days),,2016-06,UNKNOWN,INTERVENTIONAL,['PHASE4']
5123,NCT03435198,Absolute and relative change in concentration of measured volatile organic compounds in human breath in subjects with type 1 diabetes during hypoglycemia compared to euglycemia measured by proton-transfer-reaction time-of-flight mass spectrometry.,Identify differences in patterns of exhaled VOCs in people who have hypoglycemia unawareness,,2018-03-01,COMPLETED,OBSERVATIONAL,['NA']
5124,NCT05892861,The change of cognitive function from baseline at 3 and 6 months,The change of dietary control belief from baseline at 3 and 6 months,The change of health behavior frequency per week from baseline at 3 and 6 months,2021-06-03,COMPLETED,INTERVENTIONAL,['NA']
5125,NCT00882882,Bioequivalence based on AUC and Cmax,,,2001-06,COMPLETED,INTERVENTIONAL,['PHASE1']
5126,NCT04583813,Maintenance of sinus rhythm after the blanking period,Safety endpoint: Incidence of adverse events,Changes in patient's functional capacity,2021-09,UNKNOWN,INTERVENTIONAL,['PHASE4']
5127,NCT00091949,"Recurrent Fatal or Non-fatal Stroke, or Fatal or Non-fatal Myocardial Infarction","Composite Outcome of Fatal or Non-fatal Stroke, Fatal or Non-fatal MI or Episode of Serious Congestive Heart Failure",,2005-02,COMPLETED,INTERVENTIONAL,['PHASE3']
5128,NCT05790785,Change in biomarkers of vascular health during the first 24 months of type 1 diabetes diagnosis,Smoking and substance use,,2023-12-01,RECRUITING,OBSERVATIONAL,['NA']
5129,NCT00254501,Change in Hemoglobin A-1C From Baseline,Change in Diabetes Knowledge and Empowerment (Patient Self-efficacy) From Baseline to 12 Months,,2005-11,COMPLETED,INTERVENTIONAL,['PHASE3']
5130,NCT04086043,Changes in glycosylated hemoglobin from baseline to 6 months,Changes in blood urea nitrogen (BUN) up to 2 years,,2019-09-10,UNKNOWN,INTERVENTIONAL,['NA']
5131,NCT02233179,Daily Physical Activities,,,2009-06,COMPLETED,INTERVENTIONAL,['NA']
5132,NCT00710008,"ATP-Synthesis, liver lipid content, skeletal muscle lipid content",,,2006-02,COMPLETED,INTERVENTIONAL,['NA']
5133,NCT06041971,Mean Sensor Glucose Value,,,2023-11-01,RECRUITING,INTERVENTIONAL,['NA']
5134,NCT01547104,fasting oxidatively modified nucleosides 8-oxodG and 8-oxoGuo,Body Weight,,2012-04,UNKNOWN,INTERVENTIONAL,['PHASE4']
5135,NCT04154579,Change in Pulse Oximetry from Week 1 to Week 16,Weekly Post-Session Survey,HeRe We Ed Week 16 Survey,2019-07-01,TERMINATED,INTERVENTIONAL,['NA']
5136,NCT04219709,Glycemic threshold for hypothalamic activation,Blood glucose level at which participant reports symptoms of hypoglycemia.,,2020-01-03,RECRUITING,INTERVENTIONAL,['NA']
5137,NCT00715663,Patient and doctor's convenience,Patient satisfaction on devices,,2007-02,COMPLETED,OBSERVATIONAL,['NA']
5138,NCT00538174,Urine safety markers,24h urine,,2007-11,COMPLETED,INTERVENTIONAL,['PHASE1']
5139,NCT00579150,Primary Outcome,Secondary Outcome Measure,,2009-01,TERMINATED,OBSERVATIONAL,['NA']
5140,NCT05542147,Endothelial Function,Platelet aggregation induced by arachidonic acid,Haematopoietic stem/progenitor cells (HSPCs),2022-07-03,RECRUITING,INTERVENTIONAL,['NA']
5141,NCT02345291,• Change from the baseline week to Week 3 in the weekly average daily pain intensity as measured on an 11-point numerical pain scale (NPS),Incidence of treatment-emergent AEs (TEAEs),,2015-04,COMPLETED,INTERVENTIONAL,['PHASE2']
5142,NCT04082702,Waist circumference: Number of participants above the recommended level,Cortisol (ng/mL),,2013-02-22,COMPLETED,INTERVENTIONAL,['NA']
5143,NCT00943371,15-Hour weighted mean plasma glucose (WMG) concentration,4-Hour weighted mean plasma glucose (WMG) concentration,,2007-08,TERMINATED,INTERVENTIONAL,['PHASE1']
5144,NCT01515553,"Cmax, maximum concentration",Adverse events,,2007-01,COMPLETED,INTERVENTIONAL,['PHASE1']
5145,NCT01070238,Lower postprandial glucose and insulin responses after isomaltulose ingestion than after sucrose,,,na,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5146,NCT02488616,Percentage of time of glucose levels spent between 3.9 and 10.0 mmol/L,Number of days with hypoglycemic events less than 3.1 mmol/L,,2018-03,WITHDRAWN,INTERVENTIONAL,['PHASE2']
5147,NCT03716401,Cross-sectional (multi-centre collaboration),Longitudinal (multi-centre collaboration),Exeter Microvasculature Assessment Cohort - Thickness of the sublingual glycocalyx,2018-09-01,RECRUITING,OBSERVATIONAL,['NA']
5148,NCT02404207,Change in lipid profile,Change in waist circumference,,2015-03,COMPLETED,INTERVENTIONAL,['NA']
5149,NCT00314717,Self-blood-glucose-monitoring results,perceptions of diet treatments,,2006-04,COMPLETED,INTERVENTIONAL,['PHASE2']
5150,NCT05463874,Diabetes Distress as measured by the Problem Areas in Diabetes - Teen Version (PAID-T),Diabetes distress as measured by the Problem Areas in Diabetes - Teen version (PAID-T),Time in Range,2022-10-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
5151,NCT06316115,Introductory Information Form,Meggit-Wagner classification of diabetic foot,State Anxiety scale (STAI),2023-12-12,RECRUITING,INTERVENTIONAL,['NA']
5152,NCT05596656,positive skin prick test,,,2018-02-01,COMPLETED,OBSERVATIONAL,['NA']
5153,NCT02598986,AUC of serum glucose,,,2013-06,COMPLETED,INTERVENTIONAL,['NA']
5154,NCT01215097,HbA1c Change From Baseline at Week 24,Number With HbA1c at Least Lowering 0.5%,,2010-10,COMPLETED,INTERVENTIONAL,['PHASE3']
5155,NCT02338921,Glycemic target goal achievement rate,Glycemic target goal achievement rate,body weight change,2015-01,COMPLETED,INTERVENTIONAL,['PHASE4']
5156,NCT06280703,Part C: PK: Concentration of LY3938577,Part C: PD: Glucose infusion rate (GIR) of LY3938577,,2024-05-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
5157,NCT01274715,Change in Hemoglobin A1C,,,2011-01,COMPLETED,INTERVENTIONAL,['NA']
5158,NCT04051008,Change in Nutritional Quality of Purchases,Nutritional Quality of Foods Consumed,,2019-10-14,COMPLETED,INTERVENTIONAL,['NA']
5159,NCT01192373,Exercise capacity and oxygen consumption,metabolic and hormonal profile,,2010-09,COMPLETED,INTERVENTIONAL,['PHASE2']
5160,NCT00617565,2-hr postprandial plasma glucose (PPPG) excursion,Fasting plasma glucose,,2003-07-08,COMPLETED,INTERVENTIONAL,['PHASE3']
5161,NCT04058730,Glycosylated Haemoglobin less than 6.5 mg/dl,,,2015-04-01,UNKNOWN,INTERVENTIONAL,['NA']
5162,NCT01857076,Diabetes remission evaluated by patients glycemic rates,Number of Late Adverse Events,,2013-02,COMPLETED,INTERVENTIONAL,['NA']
5163,NCT04976361,Measurement of retinal thickness,,,2019-03-01,COMPLETED,INTERVENTIONAL,['NA']
5164,NCT05787990,Presence of Diabetes Nephropathy,Severity of diabetes peripheral neuropathy,,2021-10-14,RECRUITING,OBSERVATIONAL,['NA']
5165,NCT01219465,C peptide release test,Immunologic reconstitution parameters,,2010-09,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5166,NCT04255238,Chages from baseline HbA1c at Week24,,,2020-06-30,UNKNOWN,INTERVENTIONAL,['PHASE3']
5167,NCT04497805,Proportions of subjects who achieved complete wound closure.,Durability of complete wound closure for the additional 24 weeks.,,2020-09-08,RECRUITING,INTERVENTIONAL,['PHASE2']
5168,NCT02366273,Evaluation of correlation between diabetes and psoriasis,,,2015-02-01,COMPLETED,OBSERVATIONAL,['NA']
5169,NCT06326489,Variations in HbA1c,changes in The Pediatric Quality of Life Inventory™ 4.0 Short Form 15 Generic Core Scales questionnaire scores,,2024-03-11,RECRUITING,INTERVENTIONAL,['PHASE4']
5170,NCT02320721,Change in HbA1c From Baseline to Week 26,Percentage of Participants Requiring Rescue Therapy Over the 26 Weeks of Treatment,"Hypoglycemia (Any Hypoglycemia, Documented Symptomatic Hypoglycemia, Severe and/or Confirmed Hypoglycemia) Event Rate Per Participant Year During the 26 Weeks of Treatment",2015-01,COMPLETED,INTERVENTIONAL,['PHASE3']
5171,NCT02887677,Ambulatory systolic aortic pressure,HbA1c,,2016-10,TERMINATED,INTERVENTIONAL,['PHASE4']
5172,NCT03356457,• Measurement of hormone changes during hypoglycemia,cognitive function,,2017-11-30,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
5173,NCT05682495,Pharmacokinetics parameters of Metformin in the fed state: AUC0-inf (if applicable),The incidence and severity of adverse events/serious adverse events,,2023-01-31,COMPLETED,INTERVENTIONAL,['PHASE1']
5174,NCT05686421,Comfort Level Rating of Device C on 0-5 Scale,Time Duration to Adjust for Number of Motion Artifacts Present with Device C Imaging,,2023-03-30,COMPLETED,INTERVENTIONAL,['NA']
5175,NCT05720377,Body Mass Index,IL-6,,2024-02-01,WITHDRAWN,INTERVENTIONAL,['NA']
5176,NCT03968224,Change in Weight,Change in Triglycerides level,Change in Cytokines Level,2018-07-07,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
5177,NCT02353416,Advanced glycation end products levels,,,2011-02,COMPLETED,INTERVENTIONAL,['NA']
5178,NCT00335465,adverse events,changes of myocardial structure and left ventricular systolic and diastolic function,,2005-09,COMPLETED,INTERVENTIONAL,['PHASE4']
5179,NCT00415688,Hemoglobin A1c,Serum lipoproteins,,2004-07,COMPLETED,INTERVENTIONAL,['PHASE4']
5180,NCT00772174,Increase in High-Density Lipoprotein cholesterol levels.,"The change from Baseline in Laboratory Parameters (hematology, chemistry and urinalysis).",,2007-01,COMPLETED,INTERVENTIONAL,['PHASE3']
5181,NCT00658463,"Fractional Catabolic Rates (FCR)of VLDL1-apoB, VLDL2-apoB, IDL-apoB, LDL-apoB and HDL-apoA-I","Production Rates (PR) of VLDL1-apoB, VLDL2-apoB, IDL-apoB, LDL-apoB and HDL-apoA-I",,2006-01,COMPLETED,INTERVENTIONAL,['PHASE4']
5182,NCT00182026,A1c,incremental cost/quality-adjusted life-year [QALY],,2005-06,UNKNOWN,INTERVENTIONAL,['NA']
5183,NCT01806194,Change in Hemoglobin A1c,Change in Weight,Blood Pressure,2012-01,COMPLETED,INTERVENTIONAL,['NA']
5184,NCT05561595,Internalized Health-Related Stigma Scale,,,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
5185,NCT00174642,Insulin doses,Adverse events,,2004-12,COMPLETED,INTERVENTIONAL,['PHASE3']
5186,NCT02384902,Serum creatinine (and blood urea nitrogen (BUN) (mg/dL) were measured by colorimetric method and enzymatic colorimetric method using commercial assay kit.,"Serum levels of high sensitive C- reactive protein (hs-CRP) (mg/L) were quantified by using an ultrasensitive latex-enhanced immunoturbidimetric assay (Randox Laboratory Ltd., Belfast, United Kingdom).",Fasting blood sugar (FBS) and lipid profile concentrations (mg/dl) were measured using commercially available enzymatic reagents adopted to an auto-analyzer system.,2014-05,COMPLETED,INTERVENTIONAL,['NA']
5187,NCT01433406,Adverse events,,,2011-10,COMPLETED,INTERVENTIONAL,['PHASE3']
5188,NCT04284722,Incidence of Perioperative Hyperglycemia,Mortality,,2020-02,UNKNOWN,INTERVENTIONAL,['PHASE4']
5189,NCT05904847,Diabetes Management Self-Efficacy Scale for Patients with Type 2 Diabetes,Blood Glucose Level,,2023-06-16,COMPLETED,INTERVENTIONAL,['NA']
5190,NCT06256549,"Compared with Semaglutide, the changes of HbA1c compared with baseline after continuous administration of GZR18 injection for 24 weeks",The overall incidence of adverse events and the incidence of serious adverse events,,2023-08-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
5191,NCT03950973,Change in HbA1c as measured by an HbA1c machine,Change in Unmet Social Risk Factors as measured by participant questionnaire,,2019-06-26,COMPLETED,INTERVENTIONAL,['NA']
5192,NCT03614780,temperature,fasting glucose,,2017-07-11,COMPLETED,INTERVENTIONAL,['NA']
5193,NCT05061459,Expression levels of circANKRD36 in the development and progression of DN.,Correlation between expression levels of circANKRD36 and pro-inflammatory cytokine (TNF-α and IL-6) in the development and progression of DN.,,2021-10,UNKNOWN,OBSERVATIONAL,['NA']
5194,NCT04631653,diagnostic accuracy,Referral rate of diabetic retinopathy,,2020-12-01,UNKNOWN,INTERVENTIONAL,['NA']
5195,NCT01945099,"Peak post-prandial venous glucose levels obtained after breakfast, lunch, and dinner between CL alone and CL+PH20preRx and CL+INS-PH20",Peak post-prandial insulin levels following meals,Area Under Curve meal-related insulin excursion following meals,2013-09,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
5196,NCT00950079,Incidence of contrast-induced nephropathy,myocardial infarction,,2008-02,UNKNOWN,INTERVENTIONAL,['PHASE4']
5197,NCT01998113,insulin treatment,Neonatal Intensive Care Unit (NICU) admittance,,2013-03,COMPLETED,OBSERVATIONAL,['NA']
5198,NCT02059161,Percentage of Participants Who Develop Insulin Neutralizing Antibodies Up Through Week 24,Bolus Insulin Dose Per kg of Body Weight at Week 24,,2013-10-17,COMPLETED,INTERVENTIONAL,['PHASE3']
5199,NCT01220557,Changes in Glycemic Control Measured by A1c,Evaluation of the Diabetes Education Course,,2010-09,COMPLETED,INTERVENTIONAL,['NA']
5200,NCT04888598,Vessel density,Vessel density,,2021-06-01,RECRUITING,OBSERVATIONAL,['NA']
5201,NCT00790309,Determine to what extent improvements in glycemic control can be attributed to caloric restriction after weight loss surgery,Determine changes in inflammatory markers after weight loss surgery,,2008-12,COMPLETED,OBSERVATIONAL,['NA']
5202,NCT02598791,food intake,procollagen type 1 N-terminal propeptide (P1NP),,2015-10-01,COMPLETED,INTERVENTIONAL,['NA']
5203,NCT00057317,,,,2001-12,COMPLETED,INTERVENTIONAL,['PHASE2']
5204,NCT04698330,Change in HbA1c,Hypoglycemic events,,2022-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
5205,NCT00903851,Mean change from baseline to Week 3 in average pain intensity as measured from patient diaries using Brief Pain Inventory Question 5.,"Assessment of safety was based on AEs, skin assessment, physical examination, vital signs, clinical laboratory data, and plasma lidocaine levels",,2002-04,COMPLETED,INTERVENTIONAL,['PHASE4']
5206,NCT03459573,Hemoglobin A1c,Self-Monitoring of Blood Glucose,Life Satisfaction,2018-02-23,UNKNOWN,INTERVENTIONAL,['NA']
5207,NCT02944110,PPG excursions measured as incremental area under curve (iAUC),Gastric inhibitory peptide (GIP) and Glucagon like peptide-1 (GLP-1) pmol/l,,2016-04,UNKNOWN,INTERVENTIONAL,['NA']
5208,NCT03604224,Change From Baseline in Mean Weight,,,2018-09-05,COMPLETED,OBSERVATIONAL,['NA']
5209,NCT02565368,Cmax of Lobeglitazon and metformin,Vd/F of Lobeglitazon and metformin,,2015-07,COMPLETED,INTERVENTIONAL,['PHASE1']
5210,NCT00744237,Change From Baseline in Mean Glycosylated Hemoglobin (HbA1c) at Week 26,Change From Baseline in Insulin Resistance Based on Homeostasis Model Assessment of Insulin Resistance (HOMA-IR),,2008-08,COMPLETED,INTERVENTIONAL,['PHASE4']
5211,NCT04642313,"Effect of magnesium and/ or potassium on serum electrolytes (Mg, K) among insomnia patients with diabetes mellitus",Gender and age based response to magnesium and/ or potassium on insomnia patients with diabetes mellitus,Effect of magnesium and/ or potassium on quality liver function tests (LFTs) among insomnia patients with diabetes mellitus,2020-10-26,UNKNOWN,INTERVENTIONAL,['NA']
5212,NCT00167570,Durability during household and community mobility.,"User perceptions of comfort, fit, and function.",,2003-04,COMPLETED,OBSERVATIONAL,['NA']
5213,NCT05862311,Evaluation of bone metabolism biomarkers in different periodontal conditions,Plaque index,,2020-03-12,COMPLETED,INTERVENTIONAL,['NA']
5214,NCT00569907,,,,2007-01,COMPLETED,OBSERVATIONAL,['NA']
5215,NCT05535322,Major acute cardiovascular events,Therapeutic inertia,,2014-01-01,COMPLETED,OBSERVATIONAL,['NA']
5216,NCT03609996,Clinical regression of neovascularization not requiring further treatment beyond RBZ,,,2018-06-01,UNKNOWN,OBSERVATIONAL,['NA']
5217,NCT01393873,rapid changes in the level of retinopathy,,,2011-07,TERMINATED,OBSERVATIONAL,['NA']
5218,NCT01956929,Change in Glucagon-induced endogenous glucose production.,Change in glucagon-induced alterations in whole body protein metabolism and resting energy expenditure.,,2013-10,COMPLETED,INTERVENTIONAL,['PHASE1']
5219,NCT05491954,Changes in glycemic control over late gestation as measured by A1c,The number of neonatal hypoglycemic episodes,,2022-08-01,RECRUITING,OBSERVATIONAL,['NA']
5220,NCT04159766,Change in plasma glucagon,,,2019-10-16,COMPLETED,INTERVENTIONAL,['PHASE2']
5221,NCT02142309,"The primary outcome is maintenance of metabolic control (glycemic durability), defined as time to primary failure with a HbA1c value >7% on maximally tolerated doses of the assigned drug.",Continuous glucose monitoring for 72 consecutive hours at least once each year of follow-up,Changes of triglyceride level from baseline each year of follow up,2005-10,UNKNOWN,INTERVENTIONAL,['PHASE4']
5222,NCT03767543,Change in glycated hemoglobin (HbA1c)%,Annualized rate of hypoglycemia (<3.0 mmol/L) over 26 weeks,,2019-03-11,COMPLETED,INTERVENTIONAL,['PHASE3']
5223,NCT02586831,Proportion of regulatory T cells,Incidence of immune response adverse events,,2024-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5224,NCT00551564,Insulin resistance,Body composition,,2007-07-31,COMPLETED,INTERVENTIONAL,['PHASE1']
5225,NCT00337610,Change From Baseline in A1C at Week 18,Change From Baseline in A1C at Week 30,,2006-06,COMPLETED,INTERVENTIONAL,['PHASE3']
5226,NCT05928013,Vibration Perception Threshold (volts) as measured by person with diabetes,,,2023-04-19,RECRUITING,INTERVENTIONAL,['NA']
5227,NCT01740778,Blood Glucose Reading,Pain Scale Rating,,2009-08,COMPLETED,OBSERVATIONAL,['NA']
5228,NCT06085378,The proportion of patients with modified rankin scale (mRS) 0-2 scores at 90±7 days,Changes of Montreal cognitive assessment (MoCA) from baseline to 90±7 days,"Incidence, severity, and causality of adverse events (AE) and serious adverse events (SAE) during the intervention",2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
5229,NCT00804921,Intra-ocular pressure variation after intra-vitreous injection of bevacizumab,,,na,COMPLETED,INTERVENTIONAL,['PHASE2']
5230,NCT04684602,Assessment of osteoarthritis via Western Ontario and McMaster Osteoarthritis Index (WOMAC) change from baseline at 6 and 12 months.,,,2020-07-09,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5231,NCT03739580,Salvage limb rate (for CLI patients),Major Adverse Events at 12-month Post Procedure,,2016-10-01,UNKNOWN,INTERVENTIONAL,['NA']
5232,NCT02501343,Changes in venous blood pH,Changes in hunger and satiety scores,,2015-03,COMPLETED,INTERVENTIONAL,['NA']
5233,NCT05646147,Reliability of standard bedside tests and the maximal systolic acceleration (ACCmax),Wound healing and ACCmax,,2023-07,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
5234,NCT01658501,Evaluation of dose response of Glymera as measured as the change from baseline in HbA1c after 20 weeks of dosing with Glymera compared to placebo and active comparator,Proportion of subjects reaching HbA1c targets (<7.0%) after 20 weeks of dosing,,2012-07,COMPLETED,INTERVENTIONAL,['PHASE2']
5235,NCT03951298,Change in regional brain volumes over time,Change in disease severity score,,2018-08-10,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
5236,NCT04260438,"Cmax of CKD-501, D759, D150, CKD-393",,,2020-04-08,COMPLETED,INTERVENTIONAL,['PHASE1']
5237,NCT01657630,Study device acceptance,preprandial SMBG (self monitoring blood glucose),,2012-09,COMPLETED,OBSERVATIONAL,['NA']
5238,NCT06328010,Data collection of 5000 patients,Different types of wounds/injuries heal rate,,2024-04-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
5239,NCT01247363,Number of Participants With Clinically Significant Adverse Effects,Number of Hypoglycemic Events,,2010-11,COMPLETED,INTERVENTIONAL,['PHASE1']
5240,NCT02685774,Cmax of Metformin,Vd/F of Metformin,,2016-02,COMPLETED,INTERVENTIONAL,['PHASE1']
5241,NCT03560323,Cardiac Function,Myocardial energetics,,2019-01-07,RECRUITING,INTERVENTIONAL,['PHASE1']
5242,NCT01356381,"Measure: effect of treatment on insulin sensitivity, assessed as glucose Rd (rate of glucose disposal).",,,2011-04,COMPLETED,INTERVENTIONAL,['PHASE4']
5243,NCT01651845,"Evaluate effectiveness of the UHN handheld PRODIGI™ imaging device for real-time and non-invasive detection and tracking of pathogenic bacterial presence, contamination and infectious status in complex wounds over time.",,,2012-07,UNKNOWN,OBSERVATIONAL,['NA']
5244,NCT03823664,Cardiorespiratory fitness,Pulmonary functions,,2018-11-01,COMPLETED,OBSERVATIONAL,['NA']
5245,NCT00917553,The Mean Change in the Foveal Sensitivity of Matrix Frequency Doubling Perimetry (FDP) From Baseline in the Treated Group Compared to the Placebo Group,Number of Participants Who Developed Vitreous or Preretinal Hemorrhage,,2009-07,COMPLETED,INTERVENTIONAL,['PHASE2']
5246,NCT02183935,Change in BMI (BMI SDS),"Change in emotional and behaviour problems, body image and eating disorder symptoms",Safety profile of DJL in adolescents.,2014-07,COMPLETED,INTERVENTIONAL,['PHASE3']
5247,NCT06294704,time spent within glycemic target 70-180 mg/dL,Time spent in level 2 hypoglycemia (< 50 mg/gdl),,2024-03-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
5248,NCT03271580,macrophage phenotyping,,,2020-02-01,TERMINATED,OBSERVATIONAL,['NA']
5249,NCT01058772,C-section rate,Indication for Cesarean Section,,2010-03,COMPLETED,INTERVENTIONAL,['NA']
5250,NCT04315909,Wound Size,Pro-Oxidant Antioxidant Balance at baseline and after the intervention,,2019-08-28,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
5251,NCT03713437,Levels of differentially methylated insulin DNA from infancy to early adulthood in people with cystic fibrosis,Correlation between level of differentially methylated insulin DNA and use of CFTR modulator therapy.,,2019-04-04,COMPLETED,OBSERVATIONAL,['NA']
5252,NCT02232503,The prevalence of diabetic retinopathy as the proportion of patients with DR (any stage) in a given subgroup according to DM duration,Evaluate the impact of risk factors on the prevalence of Diabetic Retinopathy and Diabetic Macular Edema,Identification of patients with extreme phenotypes and family history of DM with eye complications,2015-02,COMPLETED,OBSERVATIONAL,['NA']
5253,NCT06089070,Feasibility of CGM use measured with Feasibility of Intervention Measure.,Problem Areas in Diabetes,,2023-01-01,RECRUITING,INTERVENTIONAL,['NA']
5254,NCT05777317,Lower limb pain responder rate,Average change in body weight,,2023-04-24,RECRUITING,INTERVENTIONAL,['NA']
5255,NCT00229437,Change from Baseline in composite measure of maximal nerve conduction velocity (Nerve Conduction Studies).,Change from Baseline in quality of life index (SF-36 Health Survey).,,2005-03,COMPLETED,INTERVENTIONAL,['PHASE2']
5256,NCT05575609,height anthropometric measurement,,,2022-11-01,COMPLETED,OBSERVATIONAL,['NA']
5257,NCT00134329,Relation of erectile dysfunction with sex steroids,"Optimalisation of the healthcare for diabetic patients, so that the quality of life for male diabetic patients can be improved",,2005-05,COMPLETED,OBSERVATIONAL,['NA']
5258,NCT04858321,Insulin sensitivity,Cardiac output,,2021-05-24,COMPLETED,INTERVENTIONAL,['NA']
5259,NCT03939624,Cardiovascular death,Heart failure,,2018-10-01,COMPLETED,OBSERVATIONAL,['NA']
5260,NCT01175811,Change in Haemoglobin A1c (HbA1c) From Baseline to 24 Week Endpoint,Percentage of Participants Experiencing a Severe Hypoglycemic Episode,,2011-02,COMPLETED,INTERVENTIONAL,['PHASE4']
5261,NCT03725657,Measure of sleep expenditure through wrist accelerometer,Measure of insulin dosage,,2018-10-29,COMPLETED,OBSERVATIONAL,['NA']
5262,NCT01645332,Reduction of A1c level,Adverse events,,2012-07,COMPLETED,INTERVENTIONAL,['PHASE3']
5263,NCT06095492,Spot urine protein-creatinine ratio,Changes in HbA1c,,2023-10-30,RECRUITING,INTERVENTIONAL,['NA']
5264,NCT04093635,Management of diabetic foot ulcers.,,,2019-11,UNKNOWN,OBSERVATIONAL,['NA']
5265,NCT04324736,Assess the prevalence of severe forms among hospitalized patients with diabètes and COVID-19,describe the care management of hospitalized subjects with diabetes and COVID-19,,2020-03-10,COMPLETED,OBSERVATIONAL,['NA']
5266,NCT01255384,,,,2010-12,UNKNOWN,OBSERVATIONAL,['NA']
5267,NCT01897532,"Time to the First Occurrence of Any of the Following Adjudication-confirmed Components of the Primary Composite Endpoint 3-point Major Adverse Cardiovascular (CV) Events (3-point MACE): CV Death, Non-fatal Myocardial Infarction (MI) or Non-fatal Stroke.","Time to the First Occurrence of Any of the Following Adjudication-confirmed Components: Renal Death, Sustained End Stage Renal Disease (ESRD), or Sustained Decrease of 40% or More in Estimated Glomerular Filtration Rate (eGFR).",,2013-07-10,COMPLETED,INTERVENTIONAL,['PHASE4']
5268,NCT05662332,Change from Baseline in Hemoglobin A1c (HbA1c),Change from Baseline in Treatment Experience in Diabetes Injection Device Experience Questionnaire (DID-EQ) in Device Characteristics,,2023-01-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
5269,NCT00401115,"Safety and tolerability as assessed by visual acuity, intraocular pressure, slit lamp and indirect ophthalmoscope",Visual Acuity,,2006-09,COMPLETED,INTERVENTIONAL,['PHASE1']
5270,NCT05521737,Nerve Conduction Velocity,Genetic expression,,2021-11-01,RECRUITING,INTERVENTIONAL,['NA']
5271,NCT01468116,,,,2011-03,UNKNOWN,OBSERVATIONAL,['NA']
5272,NCT01680926,insulin demand per day,body weight,,2009-07,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
5273,NCT00551538,Combined morning and evening mean 2 hour postprandial plasma glucose during each 24 hour inpatient period.,Insulin dose and body weight,,2003-05,COMPLETED,INTERVENTIONAL,['PHASE4']
5274,NCT01325987,HbA1C,AUC for c-peptide and glucose after MMTT,,2011-03,COMPLETED,INTERVENTIONAL,['NA']
5275,NCT05613400,The change in the TH BMD after 18 months of simvastatin compared with ezetimibe,The changes in TBS after 18 months of simvastatin compared with ezetimibe,,2022-04-13,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE4']
5276,NCT00745433,HbA1c,Variability in FPG (Fasting Plasma Glucose),,2008-01,COMPLETED,OBSERVATIONAL,['NA']
5277,NCT05993871,Demonstrate the findings of nerve ultrasound CSA of right ulnar nerve.,Diabetic neuropathy quality of life evaluation using Euro quality of life -5 dimensions -5 levels scale.,,2023-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
5278,NCT00409240,"Percent of Patients Achieving Hemoglobin A1C Goal, LDL Cholesterol Goal, and Systolic Blood Pressure Goal From the Enrollment Until the End of the Study",,,2006-10,COMPLETED,INTERVENTIONAL,['PHASE3']
5279,NCT04931030,Change from baseline urine microalbuminuria at 12 weeks,Change from baseline Interleukin-6 (IL-6) at 12 weeks,,2019-03-15,COMPLETED,INTERVENTIONAL,['NA']
5280,NCT06227221,The primary endpoint of the study is the change from baseline of serum C-peptide area under the curve (AUC) over 2 hours following a mixed meal,"Drug safety: gastrointestinal symptoms, rashes, fatigue, bleeding, anemia, infections, cardiovascular events, etc.",,2024-06,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
5281,NCT00936234,Endothelial Function,Number and Function of Progenitor Cells,,2009-07,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
5282,NCT02009514,Glucose below 4.0 mmol/l,Glucose below 4.0 mmol/l during specified time intervals,Standard deviation of glucose during specified time intervals,2002-10,COMPLETED,INTERVENTIONAL,['PHASE4']
5283,NCT02653027,Change in Fasting Glucose,Change in Fasting Insulin,,2018-01-01,WITHDRAWN,INTERVENTIONAL,['NA']
5284,NCT03072563,Composite outcome,,,2017-03-07,UNKNOWN,OBSERVATIONAL,['NA']
5285,NCT04183257,Homeostatic Model Assessment of Insulin Resistance,Glycated Hemoglobin (HbA1C),,2016-09-30,COMPLETED,INTERVENTIONAL,['PHASE4']
5286,NCT02687152,Change in cutaneous microvascular endothelial function,,,2014-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5287,NCT01416766,Change in blood pressure (BP),Satisfaction,,2011-08,COMPLETED,INTERVENTIONAL,['NA']
5288,NCT03462069,Assessment of PD parameters in blood,Assessment of pharmacokinetic (PK) parameters: tmax,,2018-03-12,COMPLETED,INTERVENTIONAL,['PHASE2']
5289,NCT02486484,vision before and after ziv-aflibercept,central macular thickness before and after ziv-aflibercept,,2015-03,UNKNOWN,INTERVENTIONAL,['PHASE2']
5290,NCT00867386,Patient and graft survival.,Reversal or halting of diabetic complications,,2006-12,COMPLETED,OBSERVATIONAL,['NA']
5291,NCT00421733,Change From Baseline to the Last On-treatment Measurement in Urine Albumin to Creatinine Ratio (UACR) Levels Determined From the First Morning Void (FMV) Urine Collections Comparing Placebo to the Combined Paricalcitol Treatment Groups (1 Mcg and 2 Mcg).,Change From Baseline to the Last On-treatment Observation in Intact Parathyroid Hormone (iPTH) Levels.,,2006-12,COMPLETED,INTERVENTIONAL,['PHASE2']
5292,NCT01114542,Area under the glucose infusion rate curve during one dosing interval of Insulin Degludec at steady state,Area under the concentration-time curve during one dosing interval at steady state for insulin glargine,,2010-05-03,COMPLETED,INTERVENTIONAL,['PHASE1']
5293,NCT01952145,Change From Baseline in HbA1c (Glycosylated Haemoglobin),Number of Treatment Emergent Confirmed Hypoglycaemic Episodes,,2013-09-20,COMPLETED,INTERVENTIONAL,['PHASE3']
5294,NCT03821220,Physical activity level assessed through average weekly steps,Vitamin C intake 0<mg/day<2500,,2019-02-15,UNKNOWN,INTERVENTIONAL,['NA']
5295,NCT05199350,Determination of autonomic dysfunction by subject,Establish the absence of any relationship of autonomic dysfunction (AD) to any other vital signs parameters.,,2021-11-17,COMPLETED,OBSERVATIONAL,['NA']
5296,NCT03236558,"Variability of the diversity of antigen-receptors' repertoires, expressed by regulatory T cells from type I diabetes patients and healthy controls.",Ratio between TCR diversities expressed by Treg cells vs. conventional T cells.,,2018-03,WITHDRAWN,INTERVENTIONAL,['NA']
5297,NCT03895229,Time to Maximum drug concentration in plasma (tmax),Half life( t½) of drug in plasma,,2018-10-01,COMPLETED,INTERVENTIONAL,['PHASE1']
5298,NCT00325650,Time of progression to type 2 diabetes,Change from baseline in HDL-Cholesterol and triglycerides (TG),,2006-05,TERMINATED,INTERVENTIONAL,['PHASE3']
5299,NCT02860611,Difference in T helper cytokines between groups,,,2013-02,COMPLETED,OBSERVATIONAL,['NA']
5300,NCT00342927,Diabetes and diabetic kidney disease.,Blood pressure and serum lipids.,,2001-03-07,RECRUITING,OBSERVATIONAL,['NA']
5301,NCT04302168,Birthweight,Gene expression of glucose transporters,,2020-04-01,RECRUITING,INTERVENTIONAL,['NA']
5302,NCT06176599,Effective rate,Urinary microalbumin/urinary creatinine,,2022-09-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
5303,NCT01564485,Systolic BP Pressure,,Change in Treatment by PCP,2008-07,COMPLETED,INTERVENTIONAL,['NA']
5304,NCT05035368,The mean difference in glucose infusion rate (GIR) from baseline,Change in average (previous 3 days) daily insulin requirements,,2021-09-30,WITHDRAWN,INTERVENTIONAL,['PHASE2']
5305,NCT03338439,Diastolic Blood Pressure,Vascular event,,2017-07-01,COMPLETED,OBSERVATIONAL,['NA']
5306,NCT04457440,Changes in 2-hr oral glucose tolerance (mg/dl),Changes in dietary composition,,2020-07-01,SUSPENDED,INTERVENTIONAL,['NA']
5307,NCT05378620,Change in Baseline Self-Efficacy for Diabetes Scale at 6 months,Change in Baseline Glycosylated Hemoglobin A1C (HbA1c) at 6 months; % Units,Participant Satisfaction,2022-10-17,RECRUITING,INTERVENTIONAL,['NA']
5308,NCT02461589,Change in HbA1c (Glycosylated Haemoglobin),Change in Systolic and Diastolic Blood Pressure,,2015-09-21,COMPLETED,INTERVENTIONAL,['PHASE2']
5309,NCT02154100,Arterial Stiffness,Body Composition,,2014-04,COMPLETED,INTERVENTIONAL,['PHASE2']
5310,NCT02340507,Daily blood glucose profile (easured for each low and high GI treatment as the area under the curve over 24 hours using CGMS),Energy intake (The amount of food consumed at the ad libitum lunch is measured by weighed quantities (in grams converted to kilocalories) based on the difference of the weight of food before and after consumption),,2013-05,COMPLETED,INTERVENTIONAL,['NA']
5311,NCT02767440,change in parent weight over 6 months,change in home food environment over 6 months,,2016-06,COMPLETED,INTERVENTIONAL,['NA']
5312,NCT00121966,HbA1c following two years of treatment,urine albumin/creatinine ratio,,2003-01,COMPLETED,INTERVENTIONAL,['PHASE4']
5313,NCT03366532,Mortality,,,1980-08,COMPLETED,OBSERVATIONAL,['NA']
5314,NCT02473081,Hemoglobin A1c,,,2012-10,COMPLETED,INTERVENTIONAL,['NA']
5315,NCT04041739,detect magnitude of fungal infection as an etiology causing persistent non healed diabetic foot osteomyelitis,detect response of healing of resistant infected osteomyelitis to antifungal therapy,,2020-01,UNKNOWN,OBSERVATIONAL,['NA']
5316,NCT03558581,Glycemic control - HbA1< 7%,Improve Knowledge assessed by questionaries DKNA,Improve attitude and coping of Diabetes assessed by questionaries ATT-19,2016-11,UNKNOWN,INTERVENTIONAL,['NA']
5317,NCT00235014,Phase A: microalbuminuria; Phase B: progression from microalbuminuria to macroalbuminuria.,"Course of albumin excretion over time, GFR, blood pressure (BP), incidence of major CV events, overall and CV mortality, HbA1c, progression of retinal changes.",,1997-03,COMPLETED,INTERVENTIONAL,['PHASE4']
5318,NCT00212901,reducing proteinuria,"side-effects of hypotension, postural symptom",,2004-08,COMPLETED,INTERVENTIONAL,['NA']
5319,NCT01238289,mean percent change Hemoglobin A1c (HbA1c),"Body mass index, blood pressure and lipid changes",,2006-09,COMPLETED,INTERVENTIONAL,['NA']
5320,NCT01548248,Change in HbA1c (glycosylated haemoglobin),Number of adverse events,,2006-01,COMPLETED,OBSERVATIONAL,['NA']
5321,NCT03793673,Social Determinants of Health Tool,Cost to Payor as as assessed using the Team Costs- YA,Standard Care - Tools Questions,2019-01-20,COMPLETED,INTERVENTIONAL,['NA']
5322,NCT03289338,Time for resolution of active Charcot foot,Time for radiologic resolution/reduction on MRI,,2016-06-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
5323,NCT03660371,BCVA,,,2018-09-04,COMPLETED,INTERVENTIONAL,['NA']
5324,NCT05535842,"Changes in diabetes knowledge among patients and carers in the intervention group using GLOW Quiz at baseline, interim (3 months) and end-of-trial (6 months).",GLOW App usability perception among patients and carers in the intervention group will be measured at the end-of-trial (6 months).,,2022-11-28,RECRUITING,INTERVENTIONAL,['NA']
5325,NCT00692237,"Left Ventricular Torsion Defined as Change in Ventricular Mid-wall Rotation (°) Measured by Cine-Cardiac Magnetic Resonance (CMR) Imaging With Tagging, Before and After Three Months of Treatment With Sildenafil and Placebo (100 mg/Day).",Ejection Fraction (EF) Defined as the Volume of Blood Ejected With Each Beat Was Measured on Cine-Cardiac Magnetic Resonance (CMR) Images Before and After Three Months Treatment With Sildenafil and Placebo (100 mg/Day).,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE4']
5326,NCT03150901,dIABETIC FOOT ULCERS INCIDENCE,,,2015-02-20,COMPLETED,OBSERVATIONAL,['NA']
5327,NCT04941794,Chronic Heart Failure,6 minutes walk test,HOMA-IR,2021-07-01,RECRUITING,OBSERVATIONAL,['NA']
5328,NCT00804414,Compare the proportion of patients in the two arms who have complete healing of target ulcer,,,2008-10,COMPLETED,INTERVENTIONAL,['PHASE3']
5329,NCT05268081,Questionnaire for the assessment of general practitioners' confidence in managing type-2 diabetes and cholesterol,Questionnaire for the assessment of practice staffs' confidence in managing type-2 diabetes and cholesterol at 12 and 24 month,,2022-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
5330,NCT00795262,Comparison of relative change of systolic BP/diastolic BP and urinary albumin excretion from baseline in diabetic patients treated with quinapril plus lipoic acid versus quinapril and placebo.,"Comparison of patients treated with quinapril plus lipoic acid versus quinapril plus placebo in the following areas: a) Changes from baseline in high sensitivity C-reactive protein, adiponectin, and leptin",,2008-07,COMPLETED,INTERVENTIONAL,['NA']
5331,NCT03880162,Change from baseline in intrahepatic triglyceride content,Change from baseline in insulin sensitivity,Length of hospital stay,2019-05-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
5332,NCT01771185,Hb A1a,Lipidic control,,2012-10,UNKNOWN,INTERVENTIONAL,['NA']
5333,NCT03823092,polarization sensitivity,,,2017-11-09,UNKNOWN,OBSERVATIONAL,['NA']
5334,NCT00712478,Evaluate improvement of diabetes control with fasting glycemia and after diner glycemia measurements,Evaluate improvement of diabetes control with fasting glycemia and after diner glycemia measurements,,2007-09,COMPLETED,OBSERVATIONAL,['NA']
5335,NCT03341026,Accuracy,Reliability,,2020-06,UNKNOWN,INTERVENTIONAL,['NA']
5336,NCT05552339,Number of patients with Urine albumin-creatinine ratio (UACR) values between 30 and 299 mg/g and above 300 mg/g,Location of HCP,,2023-08-18,RECRUITING,OBSERVATIONAL,['NA']
5337,NCT01063361,serum lipids,"creatine, urea, and c-peptides in 24 hour urine collection",,2010-02,COMPLETED,INTERVENTIONAL,['PHASE2']
5338,NCT01437332,,,,2011-09,UNKNOWN,OBSERVATIONAL,['NA']
5339,NCT02776007,Libre-user evaluation questionnaire,Glycemic control measured by HbA1c,Average fasting blood glucose level,2016-07,COMPLETED,INTERVENTIONAL,['NA']
5340,NCT00592527,HbA1c,Incidence of adverse events,,2004-04,COMPLETED,INTERVENTIONAL,['PHASE3']
5341,NCT03710083,Mean Absolute Relative Difference (MARD),,,2019-02-28,COMPLETED,INTERVENTIONAL,['NA']
5342,NCT05019807,Follow-up rate in patients with diabetic macular edema receiving education materials about diabetes and its complications.,,,2020-12-18,COMPLETED,INTERVENTIONAL,['NA']
5343,NCT05107063,Percentage Change Rate From Baseline in the Modification of Diet in Renal Disease(MDRD) Estimated Glomerular Filtration Rate (eGFR) at Week 24 After Routine Care of Pravastatin Administration,Number of Participants With Treatment-emergent Adverse Events After Routine Care of Prevastatin Administration,,2016-01-20,COMPLETED,OBSERVATIONAL,['NA']
5344,NCT06147232,Change in dynamic R2*-weighted signal (BOLD) as an indirect measure of renal blood oxygenation,Difference in Kidney Function after 12 weeks treatment with sotagliflozin vs placebo,Ethnicity,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
5345,NCT00262548,"All participants will receive an intervention on diet and physical activity counseling, which will be carefully monitored.","Other variables will be: proinflammatory cytokines - tumor necrosis factor (TNF)-alpha, interleukin-6 (IL-6), IL-12, Th2/Th3 cytokines -IL-4, IL-10 and transforming growth factor beta (TGF-beta)",,2005-10,COMPLETED,INTERVENTIONAL,['PHASE4']
5346,NCT00443521,Vitreous haemorrhage,Safety and Tolerance of the treatment,,2005-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
5347,NCT05336071,Area under the plasma concentration versus time curve (AUC0-inf ) of INS068 injection,Number of subjects with adverse events and the severity of adverse events,,2022-05-12,COMPLETED,INTERVENTIONAL,['PHASE1']
5348,NCT00255645,,,,2005-09,TERMINATED,OBSERVATIONAL,['NA']
5349,NCT05806957,Specificity of the Ophthal-360 Software to detect diabetic retinopathy in fundus images,,,2023-06-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
5350,NCT01387165,The achievement of the planned completed number of questionnaires.,Assessment of fasting blood glucose,,2004-10,COMPLETED,OBSERVATIONAL,['NA']
5351,NCT03710850,Glucose disposal,Suppression of lipolysis,,2018-05-01,COMPLETED,INTERVENTIONAL,['NA']
5352,NCT00007098,,,,1995-05,COMPLETED,OBSERVATIONAL,['NA']
5353,NCT04879511,Glycemic control(HbA1c%),circulating neuregulin-4 level,,2018-02-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
5354,NCT01557972,Death,Macrovascular complications,,1999-11,UNKNOWN,OBSERVATIONAL,['NA']
5355,NCT00094770,Change From Baseline in HbA1c at Week 52,Number of Participants With Drug-related LAEs at Week 104,,2004-09,COMPLETED,INTERVENTIONAL,['PHASE3']
5356,NCT04601740,Change in Glycated haemoglobin (HbA1c ),"Diabetes Treatment Satisfaction Questionnaire, status (DTSQs), change in absolute treatment satisfaction",,2020-11-17,COMPLETED,OBSERVATIONAL,['NA']
5357,NCT03089528,intubation difficulty,adverse outcomes related to tracheal intubation.,,2017-04-01,COMPLETED,INTERVENTIONAL,['NA']
5358,NCT02440282,Heart rate,,,2012-01,COMPLETED,OBSERVATIONAL,['NA']
5359,NCT03809299,Insulin sensitivity,Autophagy level,,2019-06-20,COMPLETED,INTERVENTIONAL,['NA']
5360,NCT03484689,Dropout rate,The Audit of Diabetes-Dependent Quality of Life (ADDQOL),,2018-07-14,COMPLETED,INTERVENTIONAL,['NA']
5361,NCT04732208,Sensitivity and Specificity of the AI in detecting any grade of diabetic retinopathy in those with established diabetes mellitus (DM),To compare the diagnostic ability of the AI in mydriatic and non-mydriatic eyes,,2022-04-20,COMPLETED,OBSERVATIONAL,['NA']
5362,NCT00099905,Change from baseline in HbA1c at 24 weeks,Change from baseline in fasting lipids at 24 weeks,,2004-04,COMPLETED,INTERVENTIONAL,['PHASE3']
5363,NCT02946541,HbA1c,HbA1c response rate,,2013-07,COMPLETED,INTERVENTIONAL,['PHASE3']
5364,NCT06329674,Changes in HbA1c,,,2021-04-27,COMPLETED,INTERVENTIONAL,['PHASE3']
5365,NCT00571220,Change in incretin,,,2005-09,COMPLETED,OBSERVATIONAL,['NA']
5366,NCT02971228,"Safety and Tolerability as Measured by Adverse Events, Local Tolerability of Infusion Site Reactions, and Clinical Laboratory Parameters",Bionic Pancreas User Opinion Survey,,2016-11,COMPLETED,INTERVENTIONAL,['PHASE2']
5367,NCT04386187,gamma-glutamyltransferase (GGT),Triglycerides,Triglycerides,2020-07-28,COMPLETED,INTERVENTIONAL,['NA']
5368,NCT01109212,Urinary Albumin Excretion (µg/min) levels in the overnight urine specimen.,Albuminuria remission rates,,2007-03,COMPLETED,INTERVENTIONAL,['PHASE2']
5369,NCT05793788,Opening link within SMS Text message,Completion rate of one screening/test,,2023-03-09,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
5370,NCT03387735,UCLA Loneliness Scale,Falls Requiring Medical Attention,,2018-01-01,COMPLETED,INTERVENTIONAL,['NA']
5371,NCT01392027,Validation of glycoprotein panel as a pancreatic cancer biomarker,,,2011-04,COMPLETED,INTERVENTIONAL,['NA']
5372,NCT01029886,Change in HbA1c From Baseline to Week 26,Assessment of Event Rate of Treatment-emergent Hypoglycemic Events,,2010-01,COMPLETED,INTERVENTIONAL,['PHASE3']
5373,NCT02651480,Blood pressure,Quality of Life and Mood,,2016-02,SUSPENDED,INTERVENTIONAL,['NA']
5374,NCT03717233,Forefoot plantar pressure,Measures of fall risk,,2018-10-18,COMPLETED,INTERVENTIONAL,['NA']
5375,NCT00262704,lipid control,,,2001-12,COMPLETED,INTERVENTIONAL,['NA']
5376,NCT00574834,Changes in Insulin Sensitivity,,,2007-03,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1']
5377,NCT02622672,Fasting glucose,high sensitivity interleukin (hs-IL-6),,2016-01-04,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
5378,NCT02586519,Rate of Wound Resolution,Complication Rates,,2016-06,TERMINATED,INTERVENTIONAL,['NA']
5379,NCT00972452,"The overall aim of the project is to determine whether or not acute exercise training influences postprandial metabolic, vascular or autonomic nervous system responses in individuals with insulin resistance or T2D.",,,2009-08,COMPLETED,INTERVENTIONAL,['NA']
5380,NCT01892280,Change in glycemic control from baseline to 1 year,Psychosocial factors (self-report surveys),,2013-11,COMPLETED,INTERVENTIONAL,['NA']
5381,NCT00935129,Treatment satisfaction,continuous glucose measurements,,2009-08,COMPLETED,INTERVENTIONAL,['NA']
5382,NCT03444064,Adverse Events,Stimulated C-peptide level,,2018-02-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
5383,NCT01058889,"System availability, acceptance, transmission rate",HbA1c,,2009-11,UNKNOWN,INTERVENTIONAL,['PHASE3']
5384,NCT01000519,"Hemoglobin A, Glycosylated (Hba1c). Measuring unit: percentage",Cholesterol,,2002-12,COMPLETED,INTERVENTIONAL,['NA']
5385,NCT01099163,glycosylated hemoglobin,oxidative stress (MDA),,2009-01,COMPLETED,INTERVENTIONAL,['NA']
5386,NCT01666028,Time spent in the target glucose range from 3.9 to 10.0 mmol/l based on subcutaneous glucose monitoring (CGM) adjusted for sensor error.,"Number of episodes of hypoglycaemia, severe hypoglycaemia as well as nature and severity of any other adverse events.",Duration of use of the closed-loop system at home.,2012-11,COMPLETED,INTERVENTIONAL,['PHASE2']
5387,NCT05700513,Fasting blood glucose,High-sensitivity C-reactive protein level,,2023-07-28,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5388,NCT01235429,hemoglobin A1c,Quality of life,,2009-10,COMPLETED,INTERVENTIONAL,['NA']
5389,NCT02075307,DNA damage in peripheral blood mononuclear cells,Insulin resistance,Thiol/Redox changes,2014-01,COMPLETED,INTERVENTIONAL,['NA']
5390,NCT02796378,Physical performance measured by VO2-max,Difference in mitochondrial function measured by respirometry,,2016-06,UNKNOWN,INTERVENTIONAL,['PHASE4']
5391,NCT03655223,Incidence Rates: Number of newborns who screen positive comparative to the whole sample,Impact of Screening: Semi-structured parent interviews.,,2018-10-15,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
5392,NCT00209417,Assessment of the Incidence Rate of Contrast Medium-Induced Nephropathy (CIN) Between Iodixanol and Iopamidol in Patients With Impaired Renal Function.,Assessment of Overall Image Quality Between Iodixanol and Iopamidol in Patients Undergoing Contrast-enhanced Multi-detector-row Helical Computed Tomography (MDCT) Examination.,,2005-06,TERMINATED,INTERVENTIONAL,['PHASE4']
5393,NCT01478737,Reoperation,Rebleeding,,2011-11,COMPLETED,INTERVENTIONAL,['PHASE2']
5394,NCT02772926,Serum levels of Carboxymethyl-lysine,,,2015-10,COMPLETED,INTERVENTIONAL,['NA']
5395,NCT04591704,Lung involvement,,,2020-03-20,UNKNOWN,OBSERVATIONAL,['NA']
5396,NCT05681286,C-reactive protein to serum albumin ratio in type 2diabetic patients with diabetic nephropathy,,,2023-08-04,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
5397,NCT01621516,Change in the stimulated serum C-peptide leveS (mean area under the curve [AUC] after hypercemic clamp test,,,2012-06,COMPLETED,OBSERVATIONAL,['NA']
5398,NCT00854035,Safety and Tolerability,Fasting plasma glucose,,2009-02,COMPLETED,INTERVENTIONAL,['PHASE3']
5399,NCT02657083,"to evaluate the safety and efficacy of blood glucose control using the DreaMed MD-AID in children and adolescents with T1D during and after planned physical activity, in a controlled in-hospital environment.",to evaluate the physiologic responses and risk of hypoglycemia among children and adolescents with T1D after afternoon exercise during closed-loop control in a controlled in-hospital environment,,2016-01,COMPLETED,INTERVENTIONAL,['NA']
5400,NCT02847091,Percent change from baseline in insulin dose,Safety assessed by biochemistry,,2016-07-29,COMPLETED,INTERVENTIONAL,['PHASE4']
5401,NCT03879642,Hypoglycemia Fear Survey,Child Hemoglobin A1c,,2015-10-01,COMPLETED,INTERVENTIONAL,['NA']
5402,NCT06242808,Adherence,Self-efficacy and knowledge around food procurement and healthy eating,,2024-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
5403,NCT05628662,Percentage of CGM time in glucose range 70-180 mg/dl during the study.,Number of acute metabolic events during the study,,2021-10-22,COMPLETED,INTERVENTIONAL,['NA']
5404,NCT00897390,Metformin PK Parameter Tmax,"Electrocardiogram (ECG), Vital Sign, and Physical Finding Abnormalities",,2009-06,COMPLETED,INTERVENTIONAL,['PHASE1']
5405,NCT06155487,"Part B (MAD): Heat pain tolerance (The Maximum temperature that the subject can tolerate, ℃)",Part B (MAD): Number of participants with SAE,,2023-11-27,RECRUITING,INTERVENTIONAL,['PHASE1']
5406,NCT05563987,Change in Diabetes Distress Scale,Psychological flexibility,,2021-10-01,COMPLETED,INTERVENTIONAL,['NA']
5407,NCT01536652,HbA1c (glycosylated haemoglobin),Incidence of hypoglycaemic episodes,,2006-01,COMPLETED,OBSERVATIONAL,['NA']
5408,NCT04404699,Correlation of stimulation TcPO2 parameters with the type of peripheral arterial flow,Correlation of stimulation TcPO2 parameters with macrocirculation parameters,,2018-01-01,COMPLETED,OBSERVATIONAL,['NA']
5409,NCT05238012,HbA1c levels,non HDL-C levels,,2022-07-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
5410,NCT06048653,Executive function,,,2022-08-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
5411,NCT01967186,C-peptide derived from the Mixed Meal Tolerance Test (MMTT),,,2007-04,UNKNOWN,INTERVENTIONAL,['NA']
5412,NCT03061227,Brain activity,Change in hormone levels,,2017-02-10,COMPLETED,INTERVENTIONAL,['NA']
5413,NCT00551590,To asses the effect of sitagliptin compared to placebo and to coadministration of sitagliptin and the GLP-1 receptor antagonist exendin(9-39)NH2 on the incretin effect after an oral glucose challenge.,"Plasma glucagon, plasma GIP, plasma GLP-1, Insulin, C-peptide, plasma glucose profiles. 13CO2 exhalation kinetics assessing gastric emptying",,2007-12,COMPLETED,INTERVENTIONAL,['PHASE1']
5414,NCT04732611,Blood Glycose,Endothelial function,,2021-03,UNKNOWN,INTERVENTIONAL,['NA']
5415,NCT03561987,Evaluate the association of the cardiovascular benefit of the obese patient after bariatric surgery with the basic mechanisms of adipose tissue (metabolic profile),Determine the association of the cardiovascular prognosis modification (risk subgroups) with the basal metabolic profile.,,2013-11-06,UNKNOWN,OBSERVATIONAL,['NA']
5416,NCT06330987,Fetal Autonomic Nervous sysTem Evaluation (FANTE),Obstetric Complications and mode of Delivery,,2019-08-13,RECRUITING,OBSERVATIONAL,['NA']
5417,NCT05857007,Comparison of CGM with fingerstick blood glucose values in critical care setting.,,,2023-07-19,RECRUITING,OBSERVATIONAL,['NA']
5418,NCT01725412,Microabluminuria,Serum Thiamine Level,Inflammatory Markers,2012-11,UNKNOWN,INTERVENTIONAL,['PHASE4']
5419,NCT01518101,Proportion of patients preferring each treatment regimen,Investigator preference and subjective reasons of preference to each treatment,,2012-01,COMPLETED,INTERVENTIONAL,['PHASE4']
5420,NCT00223613,Development of clinical type 1 diabetes,Changes in serum metabolite patterns (metabolomics),,1997-08,UNKNOWN,INTERVENTIONAL,['PHASE3']
5421,NCT05184868,Area under Curve for Glucose Infusion Rate,,,2022-01-03,COMPLETED,INTERVENTIONAL,['PHASE1']
5422,NCT04899271,Proportion of patients with HbA1c <7% and daily insulin requirement <0.50 IU/Kg/day,Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs),,2020-12-14,TERMINATED,INTERVENTIONAL,['PHASE2']
5423,NCT05421780,Change in blood amino acid concentration,Change in blood pressure,,2022-06-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
5424,NCT05336929,HbA1c values,Diabetes Knowledge Level,Roy Adaptation Model Interview results,2016-06-01,COMPLETED,INTERVENTIONAL,['NA']
5425,NCT00939250,Glycosylated Hemoglobin,Quick Inventory of Depressive Symptoms - Self Report,,2009-10,COMPLETED,INTERVENTIONAL,['PHASE4']
5426,NCT01961024,VLDL-TG storage in adipose tissue,18F-THA fractional storage,,2014-01,COMPLETED,OBSERVATIONAL,['NA']
5427,NCT00825643,Incidence of serious adverse drug reactions (SADRs) including major hypoglycaemia,Body weight and its change from trial start,,2008-04,COMPLETED,OBSERVATIONAL,['NA']
5428,NCT04128995,Glycemic Control,Diabetic Kidney Disease,,2019-12-15,RECRUITING,INTERVENTIONAL,['PHASE4']
5429,NCT02133729,Metabolic index value,Prevalence of abnormal glucose tolerance in women with GDM,Adiponectin level,2011-06,COMPLETED,INTERVENTIONAL,['NA']
5430,NCT05974878,Functionality,Anxiety level,,2023-05-18,COMPLETED,INTERVENTIONAL,['NA']
5431,NCT02687256,Time to an infusion set failure due to an occlusion,signs of infection at insulin infusion site,,2016-03,COMPLETED,INTERVENTIONAL,['PHASE1']
5432,NCT00906529,Length of Hospitalization Stay,Time to becoming medically stable for discharge,,2009-05,WITHDRAWN,INTERVENTIONAL,['PHASE4']
5433,NCT05069727,Time in Range( 70-180 mg/dl),Severe Hypoglycemia,Total Daily Insulin,2021-11-21,COMPLETED,INTERVENTIONAL,['NA']
5434,NCT04375449,Glucose-iAUC(0-180min),GLP-1-iAUC(0-120min),,2020-05-04,COMPLETED,INTERVENTIONAL,['NA']
5435,NCT00886366,"Safety variables (AE, BP, pulse, plasma glucose, laboratory variables and ECG)","Pharmacodynamic variables (P-Glucose, S-Insulin and C-peptide)",,2009-04,TERMINATED,INTERVENTIONAL,['PHASE1']
5436,NCT01202461,Best-corrected visual acuity,Central subfield macular thickness,,2010-08,COMPLETED,INTERVENTIONAL,['PHASE1']
5437,NCT02681887,change in beta-islet cell function,change in TNF-alpha,,2016-09,UNKNOWN,INTERVENTIONAL,['PHASE3']
5438,NCT01425255,sleep quality,Glycemic control,,2011-08,WITHDRAWN,OBSERVATIONAL,['NA']
5439,NCT02236754,Mean BPND (non-displaceable binding potential),,,2013-07,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1']
5440,NCT05115682,Exercise-induced Changes in 24 Hour Interstitial Glucose Concentration,Metabolic Response to Exercise,,2021-11-10,UNKNOWN,INTERVENTIONAL,['NA']
5441,NCT02248272,Serum levels of glucose,Lipidemic profile,,2011-10,COMPLETED,INTERVENTIONAL,['NA']
5442,NCT03083795,Self-reported social support,Weight,,2017-04,UNKNOWN,INTERVENTIONAL,['NA']
5443,NCT03087877,Interference Effect for the G6 CGM,Duration of interference effect for the G6 CGM,,2017-02-03,COMPLETED,INTERVENTIONAL,['NA']
5444,NCT05232071,Assessment of the effect of lanifibranor alone compared to placebo and the effect of lanifibranor in combination with empagliflozin compared to placebo on absolute change in HbA1c from baseline (Week 0) to Week 24,,,2022-06-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
5445,NCT00838903,Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 104,Change From Baseline in Body Weight at Week 156,,2009-02,COMPLETED,INTERVENTIONAL,['PHASE3']
5446,NCT03371082,Immunogenicity,Efficacy - The number and percentage of subjects who achieve a HbA1c of < 7.0%,,2017-10-31,COMPLETED,INTERVENTIONAL,['PHASE3']
5447,NCT06191614,Change in fasting plasma glucose (FPG) after 12 of DEXINEURO® tab administration compared to baseline,,,2022-05-19,COMPLETED,OBSERVATIONAL,['NA']
5448,NCT02730377,Time to Inadequate Glycaemic Control,Change in Pulse,,2016-03-28,COMPLETED,INTERVENTIONAL,['PHASE4']
5449,NCT02241993,Difference between very large sensor accuracy errors (≥50% from reference glucose) with the simultaneous use of four sensors vs one sensor.,Difference between mean absolute relative difference with the simultaneous use of four sensors vs one sensor.,,2010-07,COMPLETED,OBSERVATIONAL,['NA']
5450,NCT01855763,Neonatal morbidity,Maternal hypertensive complications,treatment acceptability and cost of drug,2008-12,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
5451,NCT03197324,AUC0-inf (Area Under the Plasma Concentration-time Curve From Time 0 to Infinity),,,2017-07-24,COMPLETED,INTERVENTIONAL,['PHASE1']
5452,NCT01007266,To evaluate the effect of a minimally invasive intervention (the buddy system) on hemoglobin A1c levels in adolescents with T2DM.,"To assess changes between groups in body weight, number of home glucose monitor checks, compliance with medications, adherence to visit schedule, and psychological well-being.",,2009-10-09,COMPLETED,INTERVENTIONAL,['PHASE2']
5453,NCT02689362,Absolute variation of the values obtained in the baseline for the HbA1c,"Absolute variation of the values obtained in the baseline for the parameter, body weight.",,2017-08-08,COMPLETED,INTERVENTIONAL,['PHASE2']
5454,NCT01375491,MMP Activity,CRP,,2009-10,COMPLETED,INTERVENTIONAL,['PHASE4']
5455,NCT00131846,New onset type 2 diabetes (WHO criteria 1998),Gout (American College of Rheumatology 1997 criteria C),,2004-04,COMPLETED,INTERVENTIONAL,['PHASE4']
5456,NCT02405767,Change in impedance,Impedance of different wound tissues,,2015-04,COMPLETED,INTERVENTIONAL,['NA']
5457,NCT00222846,Dietary adherence,Waist circumference,,2004-05,COMPLETED,INTERVENTIONAL,['NA']
5458,NCT01921881,Glucose area under curve (AUC) 0-2 hours,Other metabolic markers,,2013-09,COMPLETED,INTERVENTIONAL,['PHASE1']
5459,NCT05161897,"Change in glucose tolerance [Time Frame: baseline, 10 days, 20 days, and 30 days]","Change in dietary intake [Time Frame: baseline, 10 days, 20 days, and 30 days]",,2022-04,UNKNOWN,INTERVENTIONAL,['NA']
5460,NCT05198674,Office Systolic Blood Pressure change at 6 months - Subgroup Diabetes (Type II),Evaluation of slope of eGFR,,2021-10-20,RECRUITING,INTERVENTIONAL,['NA']
5461,NCT01035281,To evaluate the efficacy of nabilone compared to placebo in the treatment of diabetic neuropathy-associated peripheral neuropathic pain (DPN).,To evaluate safety and tolerability of nabilone for the treatment of neuropathic pain in subjects with diabetic peripheral neuropathy.,,2008-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
5462,NCT00116207,Global [11C]HED Retention Index (RI),Inflammation,,2000-01,COMPLETED,INTERVENTIONAL,['PHASE3']
5463,NCT06110143,Prevalence of gestational diabetes,,,2021-11-13,RECRUITING,INTERVENTIONAL,['NA']
5464,NCT02487680,Area under the curve for Glucose after ingestion of a test meal,Area under the curve for insulin after ingestion of a test meal,,2015-06,COMPLETED,INTERVENTIONAL,['NA']
5465,NCT00736632,"Hypertension (24h Blood Pressure, Central Blood Pressure, and Office BP)",Urine Calcium to Creatinine Ratio.,,2006-05,COMPLETED,INTERVENTIONAL,['NA']
5466,NCT02315092,Comparison of number/variety of bacteria obtained by fluorescence-guided sampling vs. standard practice,Assessment of the clinical functionality of the K2 Imaging Device,,2014-12,COMPLETED,OBSERVATIONAL,['NA']
5467,NCT00266695,Sustained Moderate Visual Loss (SMVL),Number of Participants Receiving Treatment With Panretinal Photocoagulation,,2006-01,COMPLETED,INTERVENTIONAL,['PHASE3']
5468,NCT05182359,The relation of prescription rates of cardioprotective medications (SGLT2i or GLP1 RA) to CVD-T2D test risk assessment in the Informed group vs. Uninformed group.,"Survey of healthcare providers on the impact of SomaLogic's CVD-T2D calculator on patient care, medication prescription, and risk perception.",The change in prescription rates of cardioprotective medications (SGLT2i or GLP1 RA) after revealing the Metabolic Factors test results at the end of the study in the Informed group.,2022-01-26,COMPLETED,INTERVENTIONAL,['NA']
5469,NCT04363710,Weight in kilogram and height in meters will be combined to report BMI in Kg/m^2,,,2017-05-31,COMPLETED,INTERVENTIONAL,['NA']
5470,NCT02388958,Postpartum weight change measured in kilograms,Change in dietary choices during versus after pregnancy measured with the Personal Diabetes Questionnaire,,2014-06,COMPLETED,OBSERVATIONAL,['NA']
5471,NCT01594567,Blood Pressure (BP) Analysis,,,2012-03,UNKNOWN,OBSERVATIONAL,['NA']
5472,NCT00552903,For patients with diabetes: blood HbA1c at target level (7% or less),"Improvement in body mass index, health-related quality of life (15D instrument), amount of exercise, diet, smoking cessation; for patients with heart failure also use of emergency services and NYHA class",,2007-11,UNKNOWN,INTERVENTIONAL,['PHASE3']
5473,NCT03527667,Proportion of CO readings completed,Cigarettes per day,,2018-06-22,COMPLETED,INTERVENTIONAL,['NA']
5474,NCT01039116,2 year change in insulin resistance via HOMA-IR,"Change in dietary intakes of energy, fat, carbohydrate and selected essential nutrients. Change in minutes/day spend in moderate- and high-intensity physical activity. Improvement or stabilization of self-esteem.",,2005-03,COMPLETED,INTERVENTIONAL,['NA']
5475,NCT01351181,SPAQ score,,,2011-06,UNKNOWN,INTERVENTIONAL,['NA']
5476,NCT01714895,Normalized current signal from the CGM devices,,,2011-10,COMPLETED,INTERVENTIONAL,['NA']
5477,NCT02490085,Percentage of time of plasma glucose concentrations spent in the target range,Number of patients experiencing at least one hypoglycemic event requiring treatment,,2015-10,COMPLETED,INTERVENTIONAL,['PHASE2']
5478,NCT03814434,Radiographic Bone height Gain,Periimplant Pocket probing depth,,2018-05-28,UNKNOWN,INTERVENTIONAL,['NA']
5479,NCT03224234,Number of Participants Experiencing Insulclock Device Malfunctions,Change in Diabetes Quality of Life Clinical Trial Questionnaire-Revised (DQLCTQ-R) Score,,2017-11-29,COMPLETED,INTERVENTIONAL,['NA']
5480,NCT02768506,Weight loss,Diabetes remission,,2009-09,COMPLETED,OBSERVATIONAL,['NA']
5481,NCT03609697,Percent weight change,Carotid artery intima-media thickness (cIMT),,2018-08-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
5482,NCT00449553,Change from baseline in glycosylated hemoglobin.,"Change from baseline in fasting lipoproteins (total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein-cholesterol and triglycerides).",,2001-06,COMPLETED,OBSERVATIONAL,['NA']
5483,NCT00001733,,,,1998-03-06,COMPLETED,OBSERVATIONAL,['NA']
5484,NCT04064437,Vertebral fracture detected with VFA,Osteocalcin,Microalbuminuria,2019-07-29,COMPLETED,OBSERVATIONAL,['NA']
5485,NCT03365531,Hepatic Triglyceride by MRS,Diet Tolerability,,2018-03-01,TERMINATED,INTERVENTIONAL,['NA']
5486,NCT02709707,Accuracy of blood glucose measurements as performed by lay users,Assessment by lay users of the ease of use of the iGlucose Blood Glucose Monitoring System,,2016-03,COMPLETED,OBSERVATIONAL,['NA']
5487,NCT00133718,Reduction in 10-year absolute CHD risk,Effects on health related quality of life,,2002-01,COMPLETED,INTERVENTIONAL,['PHASE4']
5488,NCT02641184,Major adverse cardiovascular events (MACE),New-onset diabetes,,2015-12,UNKNOWN,OBSERVATIONAL,['NA']
5489,NCT05001815,Time in range (TIR) at 34 weeks of gestation,"Questionnaires (Self-rated Depression Scale, SDS)",,2021-12-15,UNKNOWN,INTERVENTIONAL,['NA']
5490,NCT02764021,Changes in glycated hemoglobin (HbA1c) at the end of 6 weeks of isoenergetic low carbohydrate diet compared to 6 weeks of the recommended antidiabetic control diet.,Changes in insulin-like growth factor-binding protein 3 (IGFBP-3) at baseline to week 6 will be compared to changes from week 6 to 12. Changes in IGFBP-3 will be assessed from week 12 to 36.,,2016-04,COMPLETED,INTERVENTIONAL,['NA']
5491,NCT02481141,Change From Baseline in Fasting Blood Glucose,Change From Baseline in Triglycerides (Component of Lipid Profile),,2014-07,COMPLETED,INTERVENTIONAL,['NA']
5492,NCT01190904,Composite outcome of all-cause mortality,MACCE,,2010-01,COMPLETED,OBSERVATIONAL,['NA']
5493,NCT02113163,"AUC following single and repeat single oral administration of metformin eicosapentaenoate, metformin hydrochloride and Vascepa",,,2014-03,COMPLETED,INTERVENTIONAL,['PHASE1']
5494,NCT02420054,Change of insulin secretion,Insulin signalling cascade proteins,,2015-04,UNKNOWN,INTERVENTIONAL,['NA']
5495,NCT02282423,Transcription Factor Response to Exercise,,,2014-05,TERMINATED,INTERVENTIONAL,['NA']
5496,NCT01724554,Mean Change in Capillary Non-Perfusion,,,2012-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5497,NCT01377844,Change From Baseline in Hemoglobin A1c at 24 Weeks,Percentage of Subjects Achieving HbA1c <7%,,2011-12,COMPLETED,INTERVENTIONAL,['PHASE2']
5498,NCT00714441,"Distress. Patient distress will be assessed across several measures including: the 20-item CES-D, the 17-item DDS, the PHQ8, and screening items from the SCID to rule out psychosis.",Lipids,,2008-07,COMPLETED,INTERVENTIONAL,['NA']
5499,NCT02516358,Change in glycaemic blood levels during ICU stay,Neuron Specific Enolase (NSE) blood levels and glycaemic disorders,,2015-09,UNKNOWN,OBSERVATIONAL,['NA']
5500,NCT04456166,Incidence of gastric ultrasonography score as low risk (grade 0 or 1),The incidence of nausea and vomiting,,2020-06-22,COMPLETED,OBSERVATIONAL,['NA']
5501,NCT00820807,Mean changes in blood HbA1c values from baseline to end of study,"Mean changes in total body fat, lean tissue and abdominal fat as determined by DEXA [distribution or absolute changes]",,2009-01,TERMINATED,INTERVENTIONAL,['NA']
5502,NCT01179672,Mean Change From Baseline at 12-Week Endpoint in the Weekly Mean of Pain Severity Score,Mean Change From Baseline at 12 Week Endpoint in the SDS Total Score,,2011-04,COMPLETED,INTERVENTIONAL,['PHASE3']
5503,NCT01613807,Hemoglobin A1C,Birthweight of Infant,,2008-10,COMPLETED,INTERVENTIONAL,['PHASE4']
5504,NCT01203774,HbA1c at Three Months of Each Period of Treatment,Compliance and Patient Satisfaction,,2010-09,COMPLETED,INTERVENTIONAL,['PHASE4']
5505,NCT04417127,Viral Suppression,Change in glycated hemoglobin (HbA1c),,2020-11-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
5506,NCT02061059,The cost-effectiveness of shoes produced with and without plantar pressure measurements.,Differences in plantar pressures between the two shoes produced.,,2014-03,UNKNOWN,INTERVENTIONAL,['NA']
5507,NCT04817514,Supraspinatus tendon thickness measurement,,,2021-11-01,UNKNOWN,INTERVENTIONAL,['NA']
5508,NCT02248311,Subclinical Cardiovascular Diseases,Ischemic events,,2014-09,UNKNOWN,OBSERVATIONAL,['NA']
5509,NCT02309138,Large for Gestational Age (LGA) Infant,Neonatal Composite Morbidity,,2015-08-11,COMPLETED,INTERVENTIONAL,['NA']
5510,NCT00442767,"Assess the Mean Area Under the Curve (AUC) for Blood Glucose Concentration in Subjects Treated With Pramlintide + Insulin, Compared to Insulin Alone","Measure of Glucagon Concentration in Subjects Treated With Pramlintide + Insulin, Compared to Insulin Alone.",,2007-02,COMPLETED,INTERVENTIONAL,['PHASE4']
5511,NCT01301456,Number of Participants With Clinically Significant Abnormalities in Laboratory Measurements,Number of Participant With Anti-Drug Antibodies (ADA): Stage 2,,2011-03,COMPLETED,INTERVENTIONAL,['PHASE1']
5512,NCT06098625,Change in spot urine protein-creatinine ratio,Changes in HbA1c,,2023-11-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
5513,NCT01153516,Response in Glucagon AUC at Baseline vs. Following Gastric Bypass,,,2010-06,COMPLETED,OBSERVATIONAL,['NA']
5514,NCT02643277,Comparison of the glycaemic outcome measured as improvement in HbA1c (≤ 7.0% (53mmol/mol)) in the intervention group in comparison with the conventional care.,Adherence to the prescription,,2014-12,COMPLETED,INTERVENTIONAL,['NA']
5515,NCT02292810,Glucose level,Autonomic control,,2014-11,UNKNOWN,INTERVENTIONAL,['NA']
5516,NCT06074458,Change in percentage of participants who remain on AID as measured by medical record review,Episodes of severe hypoglycemia as measured by chart review,,2024-01-29,RECRUITING,INTERVENTIONAL,['NA']
5517,NCT03433573,Point Accuracy Determined as % within Consensus Error Grid Zone A,,,2018-02-16,COMPLETED,INTERVENTIONAL,['NA']
5518,NCT00510952,Change From Baseline to 24 Week Endpoint in Hemoglobin A1c (HbA1c),Total Daily Insulin Dose Per Body Weight (Units/Kilograms) at Endpoint,,2007-08,COMPLETED,INTERVENTIONAL,['PHASE3']
5519,NCT03189732,Change in adipose tissue lipolysis in response to exercise,Change in lactate production in response to exercise,,2015-10-01,COMPLETED,INTERVENTIONAL,['NA']
5520,NCT04006392,Participants With a 30% or Greater Change in Visual Analog Scale (VAS) Pain Scores,,,2019-02-15,TERMINATED,INTERVENTIONAL,['NA']
5521,NCT06335225,HbA1c,Waist hip ratio,,2024-03-13,RECRUITING,INTERVENTIONAL,['NA']
5522,NCT01389505,Functional Macular Evaluation,Structural Macular Evaluation,,2011-02,UNKNOWN,INTERVENTIONAL,['PHASE2']
5523,NCT02458027,Blood Pressure,Energy/Fatigue,,2015-07,COMPLETED,INTERVENTIONAL,['NA']
5524,NCT01843959,"Percentage of the population in the U.A.E that are positive for adenovirus -36, specifically in children.",,,2013-03,COMPLETED,OBSERVATIONAL,['NA']
5525,NCT01755416,"Blood Glucose Measures in Subjects on Closed Loop With Insulin and Liraglutide, Compared to the Closed Loop With Insulin Alone",,,2013-01,COMPLETED,INTERVENTIONAL,['PHASE2']
5526,NCT02008942,Time to 99% Inhibition of Serum Thromboxane,,,2014-01,COMPLETED,INTERVENTIONAL,['PHASE3']
5527,NCT03006081,Improvement of retinal nonperfusion,Factors associated with the progression of retinal nonperfusion 3 (Anatomical),Safety outcome; Adverse effect of intravitreal aflibercept (Eylea) injection,2016-05,UNKNOWN,INTERVENTIONAL,['PHASE2']
5528,NCT00730275,Area Under the Concentration-time Curve (AUC) From Time 0 to Infinity Following a Single Dose of Sitagliptin,Plasma Dipeptidyl Peptidase-4 (DPP-4) Activity Following a Single Dose of Sitagliptin or Placebo,,2008-07-18,COMPLETED,INTERVENTIONAL,['PHASE1']
5529,NCT02087124,Dose-response of whey protein as pre-meal on apolipoprotein B48 after a high-fat meal in subjects with the metabolic syndrome measured as incremental Area Under the Curve (iAUC -15 - 360 min),Gastric inhibitory peptide (GIP) responses measured as incremental Area Under the Curve (AUC -15 - 360 min),Responses of satiety visual analog scale (VAS) measured as incremental Area Under the Curve (AUC -15 - 360 min),2014-03,COMPLETED,INTERVENTIONAL,['NA']
5530,NCT00069576,Number of Children at the 5-10 Year Followup With BMI ≥ 95th Percentile for Age and Sex,Number of Children at 5-10 Year Follow-up With Impaired Fasting Glucose ≥100 mg/dL,Mean Gestational Age at Birth,2002-10,COMPLETED,INTERVENTIONAL,['NA']
5531,NCT03550443,Time to onset of a ≥ 30% decrease in eGFR from baseline or ESRD,Change in eGFR from baseline at each evaluation time point,,2018-05-30,TERMINATED,INTERVENTIONAL,['PHASE3']
5532,NCT06124495,Area under the plasma concentration versus time curve (AUC) 0-inf (Metformin only),Number of participants with adverse events (AEs),,2023-01-13,COMPLETED,INTERVENTIONAL,['PHASE1']
5533,NCT00228904,To evaluate objective testing performed including nerve conduction velocity in diabetic patients treated with pulsatile intravenous insulin therapy,"To obtain patient questionnaires and perform objective testing to analyze, compare and measure progress",,2005-02,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
5534,NCT03034759,overall time in target (70-180mg/dl),corrective bolus after meal during intervention phase,,2019-10-01,WITHDRAWN,INTERVENTIONAL,['NA']
5535,NCT02662010,Change in Advanced Glycation Endproducts (AGE) Levels,Change in HbA1C Levels,,2016-03,COMPLETED,OBSERVATIONAL,['NA']
5536,NCT04132128,HbA1c,HbA1C for measuring glucose control,,2015-11-25,COMPLETED,INTERVENTIONAL,['NA']
5537,NCT04465721,Adherence,Lipid profile,,2021-06-14,RECRUITING,INTERVENTIONAL,['NA']
5538,NCT01581476,Albumin creatinine ratio,Quality of Life and Health Economics,,2009-01,COMPLETED,INTERVENTIONAL,['PHASE3']
5539,NCT03956173,QTc prolongation.,Oxidative stress markers (8-oxoGuo),,2018-12-01,COMPLETED,OBSERVATIONAL,['NA']
5540,NCT03009864,changes of albumin-to-creatinine ration,the rate of doubling the baseline with serum creatinine value,,2017-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
5541,NCT01038050,"Number of endothelial progenitor cells, endothelial function(FMD)",,,2009-10,UNKNOWN,INTERVENTIONAL,['PHASE4']
5542,NCT00135096,"Compare change in weight from baseline to study week 52 in the per-protocol population of premeal Apidra vs postmeal Apidra, in patients receiving Lantus as basal insulin",,,2004-08,COMPLETED,INTERVENTIONAL,['PHASE3']
5543,NCT03258723,Change in Hemoglobin A1c (HbA1c),Change in Sugar-sweetened Beverage Intake (Teaspoons Per Day),,2018-07-30,TERMINATED,INTERVENTIONAL,['PHASE4']
5544,NCT01066715,Mean change from baseline (Day 0 pre-dose) in HbA1c at Day 182,Serum levels of XOMA 052 (select sites only),,2010-01,COMPLETED,INTERVENTIONAL,['PHASE2']
5545,NCT05483816,Changes in brain activity and connectivity through functional Magnetic Resonance Imaging (fMRI) between somatotopic and non somatotopic stimulation at feet,changes in speed and cadence in the 10 meter and 6 min walk test,Changes in reflex,2022-06-30,RECRUITING,INTERVENTIONAL,['NA']
5546,NCT00573261,Assessing the Change of Parameters of Autonomic Nerve Function Such as Heart Rate Variability by Means of the LifeShirt System Upon Treatment of Pregabalin vs. Placebo in Patients With Diabetes and Peripheral Neuropathy.,To Assess the Change in Disability Scale Upon Treatment of Pregabalin in Comparison to Placebo.,,2006-03,COMPLETED,INTERVENTIONAL,['PHASE4']
5547,NCT04414280,Time in range,The Parent's fear of hypoglycemia scale - modified version of the Hypoglycemia Fear Survey for use with parents,"Correlation between 'duration of type 1 diabetes of the patient (years)' and 'quality of life in partners of T1D patients using hybrid closed-loop therapy', the latter being measured by the DIDP-FM questionnaire. Note: only in case of substudy",2020-03-12,RECRUITING,OBSERVATIONAL,['NA']
5548,NCT04875780,Percent weight change,User feedback as assessed by an online exit questionnaire,Diabetes incidence,2021-06-01,RECRUITING,INTERVENTIONAL,['NA']
5549,NCT03767478,"Primary outcome measure: sural nerve conductivity measured using a nerve conduction study at 6 months. This includes conduction velocity (m/s), calculated using distance and latency (ms), and sensory nerve action potential (SNAP) amplitude (μV).",Secondary outcome measure: device credibility and expectancy measured using modified credibility and expectancy questionnaire.,,2023-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
5550,NCT00549887,"The estimation of the direct costs associated with switching, in either direction, between a rapid-acting analog therapy and a short-acting human insulin therapy within the first year following the switch.","The estimation of the total costs (direct and indirect) associated with switching, in either direction, between rapid-acting analog and short-acting human insulin within the first year following the switch",,2007-09,COMPLETED,OBSERVATIONAL,['NA']
5551,NCT01711385,Occurrence of follow-up visit to physician regarding screening result,Improved periodontal measures,,2009-04,COMPLETED,INTERVENTIONAL,['NA']
5552,NCT00035750,,,,2001-09,COMPLETED,OBSERVATIONAL,['NA']
5553,NCT06159192,• Numerical Rating Pain Scale,,,2024-03-01,RECRUITING,INTERVENTIONAL,['NA']
5554,NCT03015519,Time to reach half of the maximum plasma concentration (t1/2) of albiglutide: Part A,Change from Baseline in Children's Depression Inventory 2 Self Report Short Version [CDI 2: SR(S)],,2017-08-14,WITHDRAWN,INTERVENTIONAL,['PHASE3']
5555,NCT01023113,"Comparison of the two methods in relation to visual field loss in terms of MD,CPSD and each quadrants loss of fields",Effect on macular edema in terms of OCT thickness,,2009-09,UNKNOWN,INTERVENTIONAL,['NA']
5556,NCT01520753,Fasting serum glucose,Incidence of adverse events,,1999-03,COMPLETED,INTERVENTIONAL,['PHASE3']
5557,NCT00135941,"To compare improvements from baseline in patient reported outcomes (quality of life, treatment satisfaction) when aggressively treated with insulin glargine plus rapid acting insulin glulisine vs treatment with Premix insulin","change in A1c (baseline to week 24), reported hypo events (throughout the trials), correlation between patient reported outcomes and glucose variability as measured by CGMS (baseline, week 8 and week 20).",,2005-08,COMPLETED,INTERVENTIONAL,['PHASE3']
5558,NCT04590833,Processing speed,BMI,,2021-06-01,UNKNOWN,INTERVENTIONAL,['NA']
5559,NCT05195333,World Health Organization Quality of life Short Form for measurement of quality of life,Body mass index (BMI) measurement,,2022-02-01,COMPLETED,INTERVENTIONAL,['NA']
5560,NCT01122446,Adverse Events,First-phase Insulin Response From IvGTT Over Time,,2009-04,COMPLETED,INTERVENTIONAL,['PHASE2']
5561,NCT05786703,CHANGE IN BLOOD PRESSURE LEVEL,,,2020-01-01,COMPLETED,OBSERVATIONAL,['NA']
5562,NCT01501201,overall mortality,"cost, cost-effectiveness and cost utility",,2011-08-08,RECRUITING,INTERVENTIONAL,['PHASE4']
5563,NCT02310932,cholesterol,medication adherence,,2015-02,COMPLETED,INTERVENTIONAL,['NA']
5564,NCT06033508,inflammatory markers,,,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
5565,NCT02503943,"Lipid profile (triglyceride, total cholesterol, LDL-c; HDL-c; mmol/L) change","Insulin resistance assessed by fasting serum insulin and HOMA-IR, and control rate of diabetes.",,2015-05,UNKNOWN,INTERVENTIONAL,['PHASE4']
5566,NCT06111183,Incidence of Wound Closure,Incidence of target ulcer related hospital visits,,2023-07-21,RECRUITING,INTERVENTIONAL,['PHASE2']
5567,NCT01793350,Efficacy of BC-DN-01,Safety of BC-DN-01,,2013-06,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5568,NCT04295889,Cost-effectiveness of the screening.,Usability scores of the two screening methods.,Role of health literacy in albuminuria screening.,2019-11-14,UNKNOWN,INTERVENTIONAL,['NA']
5569,NCT05331339,HbA1c,Mean fasting glucose,,2022-11-02,COMPLETED,OBSERVATIONAL,['NA']
5570,NCT02325271,Placental growth factor,Blood pressure,,2015-02,COMPLETED,OBSERVATIONAL,['NA']
5571,NCT03374774,Proportion of patients who are using BIAsp 30 as their primary insulin,Diabetes Pen Experience Measure (DPEM) Scores (frequency of each item),,2017-11-13,COMPLETED,OBSERVATIONAL,['NA']
5572,NCT00821665,Hyperglycemia,Hyperglycemia,,2007-03,COMPLETED,INTERVENTIONAL,['NA']
5573,NCT01217112,The Change From Baseline in Mean Serum High Density Lipoprotein Cholesterol Concentration After 91 Days (13 Weeks) of Treatment,The Change From Baseline in Mean Beck Depression Inventory-II (BDI-II) Score at the End of 91 Days (13 Weeks) of Treatment,,2010-10,COMPLETED,INTERVENTIONAL,['PHASE2']
5574,NCT01303315,Decrees in HbA1c of at least 0.5 points and Weight loss of at least 3% of total body weight after 6 month of treatment,Glycemic and metabolic parameters,,2011-01,TERMINATED,INTERVENTIONAL,['NA']
5575,NCT00967642,"Reintervention, Myocardial Infarction, Cardiovascular Death",,,2006-08,TERMINATED,INTERVENTIONAL,['NA']
5576,NCT02650596,left ventricular ejection fraction measured by 3D echocardiography,differences in the incidences of treatment-emergent adverse events,,2016-01,UNKNOWN,INTERVENTIONAL,['NA']
5577,NCT02762695,Systolic and Diastolic Blood Pressure,Medication adherence,,2016-05-04,UNKNOWN,INTERVENTIONAL,['NA']
5578,NCT01977859,Difference in level of B-type Natriuretic Peptide (BNP),Difference in responses of lean and obese subjects,,2013-11,COMPLETED,INTERVENTIONAL,['PHASE1']
5579,NCT01533142,weight loss,remission of diabetes mellitus type 2,,2012-02,UNKNOWN,OBSERVATIONAL,['NA']
5580,NCT02343354,Change in post 75 gram glucose load 2-hour glucose value in mothers and fathers,Change in diastolic blood pressure in mothers and fathers,,2014-11,COMPLETED,INTERVENTIONAL,['NA']
5581,NCT03972215,Differences of serum C-peptide levels between BBR and placebo treatment groups during the 2-hour hyperglycemic clamp study.,Differences of blood glucose levels between BBR and placebo treatment groups during the 2-hour hyperglycemic clamp study.,Heart rate and QT-interval duration using electrocardiogram before and after drug treatment.,2019-10-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
5582,NCT02655627,HbA1c,Euro Quality of Life-5 Dimension,cholesterol levels,2015-04,COMPLETED,INTERVENTIONAL,['NA']
5583,NCT01643382,Incidence of Poor Graft Function After Kidney Transplant,,,2012-08,COMPLETED,INTERVENTIONAL,['NA']
5584,NCT03238963,Percentage of Participants With Any Ocular Adverse Events Over the On-treatment Period,Percentage of Participants With Adverse Events Other Than Ocular Adverse Events Over On-treatment Period,,2017-09-19,COMPLETED,INTERVENTIONAL,['PHASE2']
5585,NCT01891474,Glucose Variability assessed by 3 day SMBG,Michigan Diabetes Knowledge Test,,2013-08,COMPLETED,INTERVENTIONAL,['NA']
5586,NCT04277780,# od hospital re-admissions,Severity of first hypoglycemic event,,2018-10-31,TERMINATED,INTERVENTIONAL,['NA']
5587,NCT02871817,Amsler Grid,Assess repeatability of mobile application testing,,2016-07,UNKNOWN,OBSERVATIONAL,['NA']
5588,NCT06007508,Does early administration of insulin glargine result in a change in ICU length of stay when compared to usual care for the treatment of diabetic ketoacidosis?,The change in duration of elevated anion gap when compared to usual care,,2022-05-31,TERMINATED,INTERVENTIONAL,['PHASE2']
5589,NCT02471040,Cognitive Function,,,2013-05-14,COMPLETED,INTERVENTIONAL,['PHASE1']
5590,NCT04474535,Macrovascular complications,Association between c-peptide and complications,,2020-03-03,UNKNOWN,OBSERVATIONAL,['NA']
5591,NCT05543083,Insulin Resistance,Adiposity,Intervention Acceptability,2023-06-02,RECRUITING,INTERVENTIONAL,['NA']
5592,NCT01868594,Changes in the Mean Value of HbA1c,Satisfaction of Diabetes Treatment Based on Diabetes Treatment Satisfaction Questionnaire Data,,2013-05-07,COMPLETED,INTERVENTIONAL,['PHASE4']
5593,NCT05164263,SAFETY and TOLERABILITY Outcomes,Efficacy outcomes,,2021-04-01,RECRUITING,INTERVENTIONAL,['PHASE4']
5594,NCT01710527,Apparent First-order Elimination or Terminal Rate Constant,Assessment of Subject Well-being Questionnaire,,2012-05-09,COMPLETED,INTERVENTIONAL,['PHASE2']
5595,NCT04199676,Accuracy of immediate glucose tolerance testing,Transition to primary care,,2020-09-01,RECRUITING,OBSERVATIONAL,['NA']
5596,NCT01638260,Change in weight from baseline and end of treatment (26 weeks) and end of follow-up (52 weeks),Health-care related costs,,2012-10,TERMINATED,INTERVENTIONAL,['PHASE4']
5597,NCT02849899,Diabetes event,The cost-effectiveness ratio,,2018-10-26,RECRUITING,INTERVENTIONAL,['PHASE3']
5598,NCT01185574,Metabolic control,depressive symptoms,,2009-10,COMPLETED,INTERVENTIONAL,['NA']
5599,NCT05801432,The change in coronary atherosclerosis detected by initial and follow-up CCTA,,,2021-08-24,RECRUITING,OBSERVATIONAL,['NA']
5600,NCT01142895,,,,2010-05,COMPLETED,OBSERVATIONAL,['NA']
5601,NCT00222768,Method development of dose-responsive measurement of insulin-stimulated glucose uptake of adipose tissue using 18-FDG and Positron Emission Tomography,To assess regional variation in insulin-stimulated glucose uptake in adipose tissue.,,2005-04,COMPLETED,OBSERVATIONAL,['NA']
5602,NCT05492071,Brachial Artery Mean Flow Velocity,,Magnitude of Maximum Mean Flow Velocity Change,2022-08-08,COMPLETED,INTERVENTIONAL,['NA']
5603,NCT06178094,Waist circumference value,,,2022-02-21,COMPLETED,INTERVENTIONAL,['NA']
5604,NCT06191094,Rates of post-operative vitreous hemorrhage,Number of patients with intra-operative bleeding,,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
5605,NCT01824017,The consistency of an ELISA-based RLIP76 assay in the serum of human subjects with metabolic syndrome.,"Effect size of correlation of RLIP76 levels with treatment measures of metabolic syndrome such as hemoglobin A1c, LDL, and triglyceride levels.",,2012-12,COMPLETED,INTERVENTIONAL,['NA']
5606,NCT02420262,Change in HbA1c (Glycosylated Haemoglobin),Responder for HbA1c Below or Equal to 6.5 %,,2015-07-26,COMPLETED,INTERVENTIONAL,['PHASE3']
5607,NCT00999375,"Change in glycemic control, change in dietary intake","Change in social cognitive mediators of behavior; change in psychosocial status; change in body composition, lipids, oxidative stress, and inflammation",,2009-09-18,COMPLETED,INTERVENTIONAL,['PHASE2']
5608,NCT02206607,Change From Reference in Weighted-Mean-Daily-Glucose (WMDG) on Day 1,Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs),,2014-09,COMPLETED,INTERVENTIONAL,['PHASE1']
5609,NCT00804596,Percentage of Participants Rated as <=3 (Comprehension of Labeling),Number of Capillary Blood Results Within +/- 15mg/dL or +/- 20% of Laboratory Glucose Method,,2008-12,COMPLETED,INTERVENTIONAL,['NA']
5610,NCT02312063,Correlation of Plasma Levels of EPA and DHA With HbA1c Reduction,Correlation of Estimated Seafood Intake With HbA1c Reduction,,2015-02,COMPLETED,INTERVENTIONAL,['PHASE4']
5611,NCT02714660,Mean Score on Burden of Treatment Questionnaire,,,2016-02,COMPLETED,OBSERVATIONAL,['NA']
5612,NCT02371694,Glycaemic excursion,Number of hypoglycaemic events in the 24h post-test meal,,2015-02,COMPLETED,INTERVENTIONAL,['NA']
5613,NCT04556851,HbA1c change from baseline at week 24,Percentage of Patients Required Use of Rescue Therapy or Dropout due to Hyperglycemia,,2020-09-29,COMPLETED,INTERVENTIONAL,['PHASE3']
5614,NCT01456806,HbA1c,Quality of Care Indicators,,2006-12,COMPLETED,INTERVENTIONAL,['NA']
5615,NCT05243160,PANSS-6 (positive and negative syndrome scale),Adverse interactions,,2022-02-11,UNKNOWN,INTERVENTIONAL,['NA']
5616,NCT05565924,The functional balance,Fasting blood glucose level,,2022-01-02,COMPLETED,INTERVENTIONAL,['NA']
5617,NCT01353391,"A composite of: pregnancy loss, preterm birth, birth injury, moderate/severe respiratory distress, neonatal hypoglycemia, and NICU admission > 24 hours.",Shoulder dystocia,,2011-05-25,COMPLETED,INTERVENTIONAL,['PHASE3']
5618,NCT03161327,Positive Predictive Value of Digital ABI in Diagnosing PAD,,,2017-07-15,COMPLETED,INTERVENTIONAL,['NA']
5619,NCT00767208,Apparition of exogenous glucose in plasma in the postprandial phase and its effect on carbohydrate and lipid metabolism,Carbohydrate and lipid oxidation,,2005-01,COMPLETED,INTERVENTIONAL,['NA']
5620,NCT02204839,24 hour blood glucose area under the curve,Ketonaemia,,2014-01,COMPLETED,INTERVENTIONAL,['NA']
5621,NCT01342484,Change From Baseline in Glycosylated Haemoglobin (HbA1c) (%) After 12 Weeks of Treatment,Change From Baseline in Fasting Plasma Glucose (FPG) After 12 Weeks of Treatment,,2011-04,COMPLETED,INTERVENTIONAL,['PHASE2']
5622,NCT01573949,Health-Related Quality of Life (HRQoL),Creatinine Level as a Measure of Renal Function,,2011-12,COMPLETED,INTERVENTIONAL,['NA']
5623,NCT04124484,HBA1c,body weight,,2017-10-17,COMPLETED,INTERVENTIONAL,['PHASE2']
5624,NCT00926068,Complete ulcer closure,Incidence of improved ulcers,,2010-02,UNKNOWN,INTERVENTIONAL,['PHASE2']
5625,NCT04631913,Beta-cell function,,,2020-08-14,UNKNOWN,OBSERVATIONAL,['NA']
5626,NCT02631512,Performance of Woulgan Gel as primary dressing in diabetic foot ulcer in terms of reduced wound size in sqcm.,Useability of Woulgan as primary dressing in diabetic foot ulcer measured as degree of pain (100 mm VAS).,,2015-10,COMPLETED,INTERVENTIONAL,['PHASE4']
5627,NCT02979860,Insulin Resistance,Metabolic Measures,Acceptability/Feasibility,2017-07-01,COMPLETED,INTERVENTIONAL,['NA']
5628,NCT02131246,Mean plasma glucose concentration,Area under the serum insulin aspart concentration-time curve,,2014-05,COMPLETED,INTERVENTIONAL,['PHASE1']
5629,NCT00497003,Endothelial function and insulin stimulated endothelial function,Insulin stimulated glucose uptake,,2004-02,COMPLETED,INTERVENTIONAL,['PHASE4']
5630,NCT06297850,Agreement between glucose,Agreement between glucose readings when at high glucose levels,Mortality,2024-04-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
5631,NCT03864432,Cmax of Gemigliptin,,,2019-07-02,COMPLETED,INTERVENTIONAL,['PHASE1']
5632,NCT03359590,The Frequency of Hypoglycaemic Episodes With Sitagliptin vs Placebo Treatment.,,,2018-03-21,COMPLETED,INTERVENTIONAL,['PHASE2']
5633,NCT01038089,Brachial artery flow-mediated dilation,"Blood markers of inflammation, oxidative stress, insulin resistance",,2010-01,COMPLETED,INTERVENTIONAL,['NA']
5634,NCT03215043,Glucose,alanine aminotransferase,visceral fat area,2017-07-02,COMPLETED,INTERVENTIONAL,['NA']
5635,NCT05542537,Household Food Insecurity as assessed by the U.S. Department of Agriculture self-report food insecurity measure,Skin carotenoid level as assessed by The Veggie Meter,,2022-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
5636,NCT04626089,Viral Load,Incidence of adverse event,,2021-02,WITHDRAWN,INTERVENTIONAL,['PHASE2']
5637,NCT03870724,Type 2 diabetes,,,2019-08-27,COMPLETED,OBSERVATIONAL,['NA']
5638,NCT01105429,"Safety and Tolerability of the investigational drug, as assessed by adverse event monitoring, physical examinations, clinical laboratory determinations, electrocardiograms (ECG), and vital sign assessments",Excretion of the investigational drug and metabolites from the body,,2010-05,COMPLETED,INTERVENTIONAL,['PHASE1']
5639,NCT05174078,Change in participants' body weight,Nutrition Education: Self-Efficacy for Managing Chronic Diseases Scale,,2022-02-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
5640,NCT02645448,Concentration of glucose and hyperglycemia prevalence,Correlation between heart rate variability and glucose 24 hours,,2014-11,COMPLETED,INTERVENTIONAL,['NA']
5641,NCT03890822,Minimal lumen area,Change in minimal lumen area,,2019-03-25,UNKNOWN,OBSERVATIONAL,['NA']
5642,NCT02710617,System accuracy criteria (see description),,,2016-03,COMPLETED,INTERVENTIONAL,['NA']
5643,NCT00205725,Effects of olanzapine/ziprasidone/haloperidol on glucose regulation,Explore treatment-related effects on glucose effectiveness,,2000-11,COMPLETED,INTERVENTIONAL,['NA']
5644,NCT02426294,Evidence of efficacy of glycemic control indicated by the mean changes of HbA1c (%) at week 26 from baseline,Evidence of efficacy of glycemic control indicated by the mean changes of HbA1c (%) at week 12 from baseline,,2015-02,UNKNOWN,INTERVENTIONAL,['PHASE4']
5645,NCT01788241,Patient Perceived Health Status,Biochemical correlates,,2009-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
5646,NCT03840928,RAPID-3 (MD-HAQ with visual analogue scale for pain and patient global measure for overall health),,,2015-04-01,RECRUITING,OBSERVATIONAL,['NA']
5647,NCT00788853,Percentage of diabetic patients having diabetic eye complications,"Minimum duration of diabetes associated with 10% incidence of diabetic complications (CVD, nephropathy and retinopathy)",,2008-11,COMPLETED,OBSERVATIONAL,['NA']
5648,NCT04585776,Percentage of Time With Sensor Glucose Values Between 70 and 180 Milligrams Per Deciliter (mg/dL) With Continuous Glucose Monitoring (CGM),Product of Insulin to Carbohydrate Ratio and Total Daily Dose (ICR×TDD),,2020-10-30,COMPLETED,INTERVENTIONAL,['PHASE2']
5649,NCT02211261,Number of Participants With Positive Anti-drug Antibody (ADA) Result,"Observed Accumulation Ratio Based on Cmax (Rac,Cmax) of PF-06293620 (MAD Cohorts)",,2014-09-15,COMPLETED,INTERVENTIONAL,['PHASE1']
5650,NCT04734015,Change in Adult Participant Fasting HbA1c,Change in Depression and Depressive symptoms - Adult and Youth participants,Change in Diabetes Empowerment - Adult participants,2021-06-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
5651,NCT05377268,Assessment of lipohypertrophy by US machine,,,2023-03-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
5652,NCT00145392,,,,2002-09,COMPLETED,OBSERVATIONAL,['NA']
5653,NCT02079376,improvement of HbA1c,Relationship between blood TG level and the GCM efficacy,,2013-11,UNKNOWN,INTERVENTIONAL,['NA']
5654,NCT01649466,Rate of confirmed hypoglycemic events,Change from baseline in Treatment Satisfaction Questionnaire for Medication (TSQM-9) at 24 week,,2012-08,COMPLETED,INTERVENTIONAL,['PHASE4']
5655,NCT04156685,Part B : AUClast under fed condition,Part B : t1/2 under fed condition,,2019-08-06,COMPLETED,INTERVENTIONAL,['PHASE1']
5656,NCT02724566,Delta between Glucose Infusion Rate,Clinic sign of apelin toxicity,,2016-05,COMPLETED,INTERVENTIONAL,['PHASE1']
5657,NCT04955691,Time in the optimal glucose range,Time spent with hyperglycemia,Human Factors,2021-07-29,RECRUITING,INTERVENTIONAL,['NA']
5658,NCT03474393,Change in HbA1c,DTSQ,,2018-11-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
5659,NCT03237767,Glycaemic control (measured using arm-mounted Freestyle Libre continuous glucose monitor),Physical activity,,2018-05-01,TERMINATED,INTERVENTIONAL,['NA']
5660,NCT04631965,Emergency admissions,Change in employment status,Adolescent-friendliness of healthcare services in pediatric and adult hospitals,2017-09-01,UNKNOWN,OBSERVATIONAL,['NA']
5661,NCT04973644,HbA1c concentration,Diabetes Treatment Satisfaction Questionnaire,,2021-08-21,UNKNOWN,INTERVENTIONAL,['NA']
5662,NCT05099770,Primary Composite Endpoint,Secondary Composite Endpoint,,2022-01-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
5663,NCT01969357,the change from baseline in HbA1c at 12 week,"Change From Baseline in Body Weight at Week 4,8,12",,2011-06,COMPLETED,INTERVENTIONAL,['PHASE2']
5664,NCT02623478,Pharmacokinetics (PK): Area under the Concentration Curve (AUC) of Insulin Lispro,Pharmacodynamics (PD): AUC of Glucose Following a Meal,,2018-01,WITHDRAWN,INTERVENTIONAL,['PHASE1']
5665,NCT01055652,To evaluate the pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with type 2 diabetes by assessment of AUC and Cmax of dapagliflozin,"To evaluate the pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with type 2 diabetes by assessmentof AUC0-t, tmax, t1/2, CL/F.",,2010-01,COMPLETED,INTERVENTIONAL,['PHASE1']
5666,NCT04272840,Transfer/KM Level 3: Change in average dietary GI,"Maternal Weight, during pregnancy",,2019-10-24,UNKNOWN,INTERVENTIONAL,['NA']
5667,NCT05590442,The rate of mild cognitive impairment occurrence,Montreal Cognitive Assessment (MoCA) score,,2022-09-01,RECRUITING,OBSERVATIONAL,['NA']
5668,NCT04829045,Homeostasis model assessment- insulin resistance (HOMA-IR),Incident of treatment adverse events in terms of intensity (grades 1 - 5),,2021-05-27,COMPLETED,INTERVENTIONAL,['NA']
5669,NCT00198757,at 52 weeks of maintenance,changes in medication costs and health related quality of life.,,2002-07,COMPLETED,INTERVENTIONAL,['NA']
5670,NCT02957513,Diabetes Self-Care Activities,Average Blood Sugar (A1c),,2016-11-01,UNKNOWN,INTERVENTIONAL,['NA']
5671,NCT05516797,Difference in change in 14-day CGM-derived TIR,Difference in Change in HbA1c,"Difference in change in the CGM-derived metric, Mean amplitude of glucose excursion, from Baseline to 3-month Post-Dietary Change period",2022-09-22,COMPLETED,INTERVENTIONAL,['NA']
5672,NCT02971865,Consumer Assessment of Healthcare Providers and Systems (CAHPS),Patient Health Questionnaire-9 (PHQ-9,,2015-06,COMPLETED,INTERVENTIONAL,['NA']
5673,NCT06260254,Matsuda insulin sensitivity index in the morning after exposure to high vibration,Evening neurobehavioural accuracy,,2024-02-05,RECRUITING,INTERVENTIONAL,['NA']
5674,NCT01002768,Baseline-adjusted hypoglycaemic symptoms score at nadir plasma glucose concentration,Hypoglycaemic symptoms score during recovery from hypoglycaemia,,2009-10,COMPLETED,INTERVENTIONAL,['PHASE1']
5675,NCT00597233,Prandial blood glucose lowering profile,Serious adverse events,,2002-10,COMPLETED,INTERVENTIONAL,['PHASE4']
5676,NCT00726778,"To test phenotype-genotype associations between each one of the AIMs and measures of FI, SI and AIRg after adjusting for body composition in a sample of AA, HA and EA prepubertal children.",,,2004-05,COMPLETED,OBSERVATIONAL,['NA']
5677,NCT03727035,Expression of CD163 gene,Quantify the levels of CD163,,2018-02-10,UNKNOWN,OBSERVATIONAL,['NA']
5678,NCT00843479,Distinctive Beta-cell Function From the Arginine Stimulation Test in Normoglycemic Subjects After Sixty-five Years Old in Comparison With Middle-age Normoglycemic Subjects.,GLP-1 Area Under the Curve (AUC),,2009-06,COMPLETED,OBSERVATIONAL,['NA']
5679,NCT02381119,change in fasting insulin levels,20 nutrition-related SNPs (single nucleotide polymorphisms),,2015-05,COMPLETED,INTERVENTIONAL,['NA']
5680,NCT04344301,Acceptability of Intervention Measure (AIM),,Stigma Scale for Chronic Illness (SSCI-8),2020-08-31,COMPLETED,INTERVENTIONAL,['NA']
5681,NCT01023698,Stabilization of proliferative diabetic retinopathy,,,2009-04,UNKNOWN,INTERVENTIONAL,['PHASE4']
5682,NCT04091854,C peptide,8-iso PGF2α,,2018-12-12,UNKNOWN,OBSERVATIONAL,['NA']
5683,NCT02467972,Change in satiety,Change in biochemical parameters,,2012-04,COMPLETED,INTERVENTIONAL,['NA']
5684,NCT03318913,High performance liquid chromatography,,,2017-10-23,COMPLETED,INTERVENTIONAL,['NA']
5685,NCT04485871,Fasting white adipose tissue NLRP3 inflammasome activation,Physical activity,,2019-12-19,RECRUITING,INTERVENTIONAL,['NA']
5686,NCT05863884,Blood Glucose Level,Diabetes Self-Management Score,COVID-19 Vaccination Confidence and Uptake,2022-02-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
5687,NCT00766909,Insulin Sensitivity,plasma glucagon,,2008-03,COMPLETED,INTERVENTIONAL,['PHASE4']
5688,NCT00110864,Effect on change in average daily insulin dose,Effect on lipid levels,,2005-05,COMPLETED,INTERVENTIONAL,['PHASE2']
5689,NCT03027726,microRNA expression in circulating exosomes and in blood peripheral mononuclear cells,Inflammation and biochemical cardiovascular disease risk factors,Confounding variable: Socio-demographic variables:,2017-03-07,COMPLETED,INTERVENTIONAL,['NA']
5690,NCT05329415,Rifampicin/Isoniazid/Pyrazinamide Cmax 2 hours post-dose,Mean daily subcutaneous glucose measurement,,2022-02-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
5691,NCT00822198,intraepidermal nerve fiber density in ankle and thigh,clinical assessment of peripheral neuropathy,,2006-03,COMPLETED,INTERVENTIONAL,['NA']
5692,NCT02001532,Agatston Score (CT),,,2014-05,COMPLETED,OBSERVATIONAL,['NA']
5693,NCT02081599,Change From Baseline in HbA1c,Change From Baseline in 2-hour Postprandial Plasma Glucose,,2014-01,COMPLETED,INTERVENTIONAL,['PHASE4']
5694,NCT03298542,Number of Participants With Treatment Related AEs and SAEs Reported From Week 52 to Week 78,Incidence of Antibodies to Golimumab,,2017-10-16,COMPLETED,INTERVENTIONAL,['PHASE1']
5695,NCT02903615,Glucose control,Follow-up of glycemic control and insulin secretion,,2016-09,COMPLETED,INTERVENTIONAL,['NA']
5696,NCT00770835,Increase from Baseline in the number of Endothelial Progenitor Cells (CD34+KDR+).,Urinary albumin excretion.,,2009-03,COMPLETED,INTERVENTIONAL,['PHASE4']
5697,NCT05662930,Heart Rate,Health related Quality of life,,2016-06-01,COMPLETED,OBSERVATIONAL,['NA']
5698,NCT03651622,Change in Time in Clinical Hypoglycemia - Randomization 3,Change in Time in Target Glucose Range - Randomization 3,,2018-11-12,COMPLETED,INTERVENTIONAL,['NA']
5699,NCT04212325,patient satisfaction: survey,,,2019-12-10,COMPLETED,INTERVENTIONAL,['NA']
5700,NCT06252051,Immunogenicity,Inflammatory interleukin measurements,,2021-01-05,COMPLETED,INTERVENTIONAL,['PHASE4']
5701,NCT00430755,"Detection of Medical Problems (by Number of Problems Reported by Computer Assisted History, That Were Not Reported by Physician Taken History)",,,2005-08,COMPLETED,INTERVENTIONAL,['NA']
5702,NCT05282680,Cardiovascular complications in diabetes,Diabetes progression,,2014-02-01,RECRUITING,OBSERVATIONAL,['NA']
5703,NCT00108901,Cognition (Executive function),Academic achievement,,2003-06,COMPLETED,INTERVENTIONAL,['PHASE2']
5704,NCT00468364,,,,2003-07,COMPLETED,OBSERVATIONAL,['NA']
5705,NCT04653220,Change in postprandial blood glucose over 240 minutes period,Change in postprandial plasma active GLP-1 over 240 minutes period,,2019-11-13,COMPLETED,INTERVENTIONAL,['NA']
5706,NCT01248481,Change in HbA1c,Postprandial Blood Glucose,,2010-09,COMPLETED,OBSERVATIONAL,['NA']
5707,NCT01095965,HbA1c as a measure of glycemic control,Body mass index,,2010-04,COMPLETED,INTERVENTIONAL,['NA']
5708,NCT00995540,Injection tolerability,C-peptide,,2009-11,TERMINATED,INTERVENTIONAL,['PHASE2']
5709,NCT02545062,The differences between the MoCa test score in diabetics and in a control group of non diabetics,"The relation between the MoCa test score and the presence of macrovascular complication, ischemic heart disease, non-fatal myocardial infarct, stable and unstable angina, heart failure, non-fatal stroke, peripheral vascular disease",,2014-05,UNKNOWN,INTERVENTIONAL,['NA']
5710,NCT00364377,Lowering of Fasting Glucose,,,2006-08,COMPLETED,INTERVENTIONAL,['PHASE4']
5711,NCT02982798,Cmax of Metformin and rosuvastatin,,,2017-07-06,COMPLETED,INTERVENTIONAL,['PHASE1']
5712,NCT00455598,Change and % change from baseline Adiponectin,concomitant medications,,2007-02,COMPLETED,INTERVENTIONAL,['PHASE2']
5713,NCT01714102,Reduction in Insulin resistance,Changes in gene expression in stool,,2012-10,COMPLETED,INTERVENTIONAL,['NA']
5714,NCT00971516,Healing profile of cytokines,,,2009-10,COMPLETED,INTERVENTIONAL,['NA']
5715,NCT00018616,,,,1999-10,COMPLETED,INTERVENTIONAL,['PHASE2']
5716,NCT01600937,Physical Activity Behavior,Musculo-skeletal disturbances,,2012-10,COMPLETED,INTERVENTIONAL,['NA']
5717,NCT03550105,Glycemic Control,Carry Over Effect of Muscle Endurance,,2018-06-05,COMPLETED,INTERVENTIONAL,['NA']
5718,NCT03037970,Successful wound healing for at least two consecutive measurements. (Efficacy),Complication rate,,2017-01-30,UNKNOWN,INTERVENTIONAL,['PHASE2']
5719,NCT02104804,Change in HbA1c From Baseline to Week 24,Analysis of Change in Mean Total Daily Dose of Insulin From Baseline to Week 24,,2014-05-07,COMPLETED,INTERVENTIONAL,['PHASE3']
5720,NCT03708380,Continuation with the dietary intervention after initial period when study participants may choose to pay for meals developed on their own,Fourth Point-of-Care HbA1c Test,,2019-03-25,TERMINATED,INTERVENTIONAL,['NA']
5721,NCT04506151,Glycemic control,Mood,,2021-01-19,RECRUITING,INTERVENTIONAL,['NA']
5722,NCT01517321,"Incidences of adverse experiences and change in vital sign, safety lab etc. as parameters of safety and tolerability",Fasting plasma glucose,,na,COMPLETED,INTERVENTIONAL,['PHASE3']
5723,NCT00657319,HbA1C,"General conditions (reason of switch, BMI, selected laboratory parameters, quality of care)",,2007-10,COMPLETED,OBSERVATIONAL,['NA']
5724,NCT03343782,Adverse events,Hemoglobin A1c (HbA1c) level,,2017-11-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5725,NCT02200666,Adverse event incidence,,,2014-10-03,COMPLETED,OBSERVATIONAL,['NA']
5726,NCT02403427,postprandial glucose,Glucose variability parameters,Patients' acceptances to use VoiceDiab system,2015-03,UNKNOWN,INTERVENTIONAL,['NA']
5727,NCT01215955,Change From Baseline to 24 Week Endpoint in Glycated Hemoglobin (HbA1c),Percentage of Participants With Severe Hypoglycemic Episodes,,2010-12,COMPLETED,INTERVENTIONAL,['PHASE4']
5728,NCT00684086,self-efficacy to manage diabetes,communication with physicians,,2007-04,COMPLETED,INTERVENTIONAL,['NA']
5729,NCT05721599,Change from baseline calf circumference,,,2023-04-13,RECRUITING,INTERVENTIONAL,['NA']
5730,NCT01834378,HOMA IR,,,2009-10,COMPLETED,INTERVENTIONAL,['NA']
5731,NCT00461331,Number of Participants With Glycemic Control (Glucose Levels Between 180-300 mg/dL) 24 to 100 Hours After Line Change,"Oxidative Stress Marker 48, 72 and 96 Hours After Keeping the Same Pump Infusion Line in Place",,2004-10,COMPLETED,INTERVENTIONAL,['PHASE4']
5732,NCT05442918,Venous blood gas levels,,,2020-01-15,COMPLETED,OBSERVATIONAL,['NA']
5733,NCT00801892,"Physical Activity, Steps Walked",Fatigue/Inertia,,2009-04,COMPLETED,INTERVENTIONAL,['PHASE3']
5734,NCT01477112,Changes in oxidative status,Serum and erythrocyte folates.,,2010-01,COMPLETED,INTERVENTIONAL,['NA']
5735,NCT05074667,Proportion of Participants with sustained CGM use,Mean change in BMI from baseline,,2021-12-01,COMPLETED,INTERVENTIONAL,['NA']
5736,NCT00638716,Reduction of HbA1c From Baseline,Reduction in Fasting Body Weight From Baseline,,2008-02,COMPLETED,INTERVENTIONAL,['PHASE2']
5737,NCT02586155,Incidence of First Occurrence of Adjudication-confirmed Narrowly Defined MACE,Change in Estimated Glomerular Filtration Rate (eGFR) From Baseline Over Time Within and Between Treatment Groups for Subjects With Impaired Renal Function at Baseline (eGFR <60 mL/Min/1.7m2),,2015-11,COMPLETED,INTERVENTIONAL,['PHASE3']
5738,NCT05041244,Wound closure,Adverse events,,2019-05-01,COMPLETED,INTERVENTIONAL,['NA']
5739,NCT01089556,Change From Week 8 to Week 16 Endpoint in 24 Hour Average Pain Item Score on the Brief Pain Inventory (BPI) Modified Short Form,Number of Participants Who Discontinued From Study Between Week 8 and Week 16 Endpoint,Number of Participants Who Discontinued From Study Between Baseline and Week 8 Endpoint,2010-03,COMPLETED,INTERVENTIONAL,['PHASE3']
5740,NCT01351675,Time-to-first event of the composite endpoint,"Frequency, intensity, and relationship to study drug of adverse events and serious adverse events, as well as clinical and laboratory test abnormalities.",,2011-06-30,TERMINATED,INTERVENTIONAL,['PHASE3']
5741,NCT05039034,Prevalence rate of dyslipidemia,,,2016-01-01,COMPLETED,OBSERVATIONAL,['NA']
5742,NCT03358121,Asprosin dynamics,,,2017-07-11,COMPLETED,OBSERVATIONAL,['NA']
5743,NCT01077323,"Incidence Rates Per 100,000 Person-Years of Likely Acute Pancreatitis (During ""Past Use"" Period) - Time on Drug Analysis","Incidence Rates Per 100,000 Person-Years of Likely Acute Pancreatitis Among Initiators of Exenatide, Diabetics Initiating Other Antidiabetic Drugs, and the Non-diabetes Cohort - Intent to Treat Analysis",,2004-09,COMPLETED,OBSERVATIONAL,['NA']
5744,NCT00551356,Change from baseline to endpoint in 2h postprandial blood glucose excursion after breakfast,Total Insulin Doses,,2002-11,COMPLETED,INTERVENTIONAL,['PHASE3']
5745,NCT04623697,Stimulated insulin secretion,Fasting blood glucose,,2020-11-01,RECRUITING,OBSERVATIONAL,['NA']
5746,NCT02384941,Change From Baseline in A1C at Week 24,Percent Change From Baseline in Body Weight at Week 24,,2015-03,COMPLETED,INTERVENTIONAL,['PHASE3']
5747,NCT01103648,C reactive protein,Tumor necrosis factor alpha,,2005-06,COMPLETED,INTERVENTIONAL,['NA']
5748,NCT01254552,Prevalence of Occult Myocardial Scar on Delayed-enhanced MRI in Asymptomatic Patients With Type 2 Diabetes Mellitus,Number of Patients With and Without Occult Myocardial Scar on Cardiac MRI According to the Degree of Stenosis,,2010-08,COMPLETED,INTERVENTIONAL,['PHASE4']
5749,NCT00418366,Determination of the pharmacokinetics of MK0431 (sitagliptin phosphate) in patients with renal insufficiency compared to healthy volunteers,Safety and tolerability in patients with renal insufficiency,,2003-01,COMPLETED,INTERVENTIONAL,['PHASE1']
5750,NCT02677454,Mean Absolute Relative Difference (MARD),questionnaire,,2015-06,COMPLETED,INTERVENTIONAL,['NA']
5751,NCT01931280,Change in glycosylated hemoglobin,Change in weight after pregnancy,,2013-09,COMPLETED,INTERVENTIONAL,['NA']
5752,NCT04383314,Change in Self-reported physical function of participants after intervention,Number of participants with Osteoarthritis,,2021-09-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
5753,NCT02898506,FPIR (1+3min serum insulin level after iv glucose infusion),Serum C-peptide AUC,,2016-03,COMPLETED,INTERVENTIONAL,['PHASE2']
5754,NCT05686694,State Anxiety Scale,,,2023-11-15,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
5755,NCT00461617,Hemoglobin A1C (HbA1C),One-hour postprandial glucose level (PPG1),,2006-08,COMPLETED,INTERVENTIONAL,['PHASE3']
5756,NCT00382096,Change from baseline in HbA1c,Change from baseline in body weight,,2006-09,COMPLETED,INTERVENTIONAL,['PHASE3']
5757,NCT05998460,GGE adherence,Changes in the soluble receptor for advanced glycation end-products (sRAGE),,2024-01-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
5758,NCT06185491,Coefficient of variation of individual HGI distribution,"Glycation gap, determined from comparison between HbA1C measured and HbA1C derived from glycated albumin",,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
5759,NCT03332771,Change From Baseline in Hemoglobin A1c at Week 52,Percentage of Participants With Adverse Events (AEs),Percentage of Participants With Hypoglycemic Events,2017-12-01,COMPLETED,INTERVENTIONAL,['PHASE3']
5760,NCT01991795,"Composite of Cardiovascular (CV) Death, MI or Stroke",All-cause Death,Permanent Discontinuation of Study Medication Due to Any Bleeding Event,2014-02-10,COMPLETED,INTERVENTIONAL,['PHASE3']
5761,NCT04873050,Regression to normoglycemia,Change in body weight,,2022-01-13,RECRUITING,INTERVENTIONAL,['PHASE4']
5762,NCT00326573,"HbA1C at 6 months, end of intervention and one year follow up",quality of life at baseline and end of one year intervention,,2001-10,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5763,NCT03980808,Frequency of Engagement in Diabetes-Related Health Behaviors,,,2020-10-29,COMPLETED,INTERVENTIONAL,['NA']
5764,NCT00572650,Pharmacokinetic measures,Safety and tolerability measures,,2007-10,COMPLETED,INTERVENTIONAL,['PHASE1']
5765,NCT04702490,Safety and tolerability of MET409 with or without empagliflozin (incidence of adverse events),Pharmacodynamic profile of MET409 alone or in combination with empagliflozin,,2020-12-15,UNKNOWN,INTERVENTIONAL,['PHASE2']
5766,NCT05692518,Creation of a patent anastomosis,,,2022-12-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
5767,NCT00501657,Gastric emptying rate,"Intragastric distribution, gastrointestinal hormone release (GLP-1, GIP), glycemia, insulinemia, appetite",,2007-07,COMPLETED,INTERVENTIONAL,['PHASE1']
5768,NCT00004364,,,,1995-12,UNKNOWN,OBSERVATIONAL,['NA']
5769,NCT05531877,No undersizing,Adequate Girth,,2020-08-01,RECRUITING,INTERVENTIONAL,['NA']
5770,NCT00303394,HbA1c,Insulin signaling- and cytokine- gene expression profiles derived from muscle and fat biopsy samples.,,2004-04,COMPLETED,INTERVENTIONAL,['PHASE2']
5771,NCT00869128,Sleep Efficiency,,,1995-11,COMPLETED,INTERVENTIONAL,['PHASE2']
5772,NCT00434850,Proportion of Insulin-independent Subjects,"Acute Insulin Response to Glucose, Insulin Sensitivity, and Disposition Index (DI)",,2006-10,COMPLETED,INTERVENTIONAL,['PHASE2']
5773,NCT05709938,Mid night blood glucose level,,,2019-11-01,COMPLETED,INTERVENTIONAL,['PHASE4']
5774,NCT03268005,Change in Glycosylated Haemoglobin (HbA1c),Change From Baseline in Body Mass Index (BMI),,2017-09-19,COMPLETED,INTERVENTIONAL,['PHASE3']
5775,NCT05110625,Change from Baseline Glycated Hemoglobin (HbA1C) at 6 months,Quantification of alcohol consumption - FISTERRA,Follow-up rate,2021-12-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
5776,NCT02287532,"Efficacy data: change in HbA1c, measured at 1 year minus the value baseline",,,2013-02,COMPLETED,INTERVENTIONAL,['NA']
5777,NCT02716870,Inflammation,,,2015-06,UNKNOWN,OBSERVATIONAL,['NA']
5778,NCT02205996,To examine the effect of hypoglycaemia on platelet surface expression of platelet activation markers P-selectin and fibrinogen binding.,To measure changes in markers of inflammation (high sensitivity C-reactive protein) and endothelial function using EndoPat 2000,To assess the effects of hypoglycaemia on participants scores on cognitive function tests,2011-11,COMPLETED,INTERVENTIONAL,['NA']
5779,NCT04733612,Change from Baseline Quality of Life Assessed by SF-36v2 at 6 months,Change from Baseline Energy Intake at 6 months,,2016-06-30,COMPLETED,INTERVENTIONAL,['NA']
5780,NCT05896319,Change in residual socket volume,Change in pain assessment,,2022-09-07,COMPLETED,INTERVENTIONAL,['NA']
5781,NCT02557620,Area under the semaglutide concentration-time curves,Area under the the single dose concentration-time curve,,2015-09,COMPLETED,INTERVENTIONAL,['PHASE1']
5782,NCT03093636,% Time Within Target Range,,,2017-04-17,COMPLETED,INTERVENTIONAL,['NA']
5783,NCT02218619,C-peptide measurement as reflection of insulin secretion,liver function tests,,2015-08,UNKNOWN,INTERVENTIONAL,['PHASE2']
5784,NCT01159249,"Measure AEs, vital signs, laboratory evaluations",HOMA-B,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE3']
5785,NCT02009670,"Fat oxidation, energy expenditure",Breath sampling 13CO2,,2014-02,COMPLETED,INTERVENTIONAL,['NA']
5786,NCT01248143,Assess the effects of green tea and FPP on the levels of C-reactive proteins,Assess the effect of green tea and fermented papaya preparation on development of atheroma and drug therapy outcomes,,2010-11,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
5787,NCT02068508,Number of Participants Who Experience at Least One Adverse Drug Reactions (ADRs),Number of Participants Who Received Specific Daily Dose of Insulin Product at Each Time Points,,2009-07-30,COMPLETED,OBSERVATIONAL,['NA']
5788,NCT03282981,Measurement of timolol serum during the treatment phase,The time to wound closure between the two groups,,2018-06-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
5789,NCT02839044,"Absolute change in ongoing calcium deposition quantified as volumetric bone metabolic rate (CSUVMEAN x cm3) in the femoral artery between baseline and 6 months after baseline, as determined by 18F-NaF PET/CT imaging.",,,2016-06,COMPLETED,INTERVENTIONAL,['NA']
5790,NCT01845064,Determine the pharmacokinetic of DM199 after single and multiple doses,Determine changes in immune cell populations by FACS analysis.,,2013-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5791,NCT00455520,Change From Baseline (at Randomization) in Average Pain Intensity on an 11-point Numerical Rating Scale (NRS) Over the Last Week of the Double-blind Maintenance Period at Week 12,Change From Baseline in Brief Pain Inventory (BPI) Total Pain Score Over the Last Week of the Maintenance Period at Week 12.,,2007-04,COMPLETED,INTERVENTIONAL,['PHASE3']
5792,NCT04604093,Impact on time above 180 mg/dL in subjects with type 2 diabetes,,,2020-10-20,COMPLETED,OBSERVATIONAL,['NA']
5793,NCT01185236,change of ApoB/ApoA1,safety,,2010-09,UNKNOWN,INTERVENTIONAL,['PHASE4']
5794,NCT03726762,Weight loss,HA1C,,2015-04,COMPLETED,INTERVENTIONAL,['NA']
5795,NCT00692562,kidney function,autoantibodies,,2005-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5796,NCT05713266,All cause higher level of care utilization,Highly likely+somewhat likely COVID-19 related healthcare utilization,,2022-10-31,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
5797,NCT02002091,Number of Patients With Erectile Dysfunction,Number of Patients That Died From Cardio Vascular Cause,,2009-01,COMPLETED,OBSERVATIONAL,['NA']
5798,NCT03324776,Percentage change from baseline HbA1c,Percent of time that Blood glucose (BG) is under 70 mg/dL on CGMS,,2017-10-16,COMPLETED,INTERVENTIONAL,['PHASE3']
5799,NCT02505334,Change in Glycosylated Haemoglobin (HbA1c) (Week 26),Change in Calcitonin,,2015-07-21,COMPLETED,INTERVENTIONAL,['PHASE3']
5800,NCT00279045,Time from randomization to the primary action point (monotherapy failure).,"Comparison of effects of long-term treatment with Rosiglitazone, Metformin, Glyburide: - maintenance/restoration of beta-cell function: HOMA IS, progression of microalbuminuria, fibrinolytic markers (PAI-1,fibrinogen, CRP).",,2000-01-03,COMPLETED,INTERVENTIONAL,['PHASE3']
5801,NCT02978807,Prevalence of Gestational Diabetes via venous 75 gm oral glucose tolerance test,"Specificity, Sensitivity, positive predictive value, and negative predictive value of alternative point of care screening strategies",,2012-07,COMPLETED,OBSERVATIONAL,['NA']
5802,NCT03905863,Percentage Reduction in Ulcer Area (cm^2).,Number of Adverse Events,,2019-06-04,COMPLETED,INTERVENTIONAL,['NA']
5803,NCT00351936,Change From Baseline in Triglycerides,,,2005-12,COMPLETED,INTERVENTIONAL,['PHASE4']
5804,NCT03240432,Time spent with glucose level <70 mg/dL,Time spent with glucose level <54 mg/dL,Glycemic variability (coefficient of variation),2017-09-26,COMPLETED,INTERVENTIONAL,['NA']
5805,NCT00441844,Monocyte function,Plasma biomarkers,,2002-10,COMPLETED,INTERVENTIONAL,['PHASE2']
5806,NCT04970719,Rescue treatment,Time to recovery,,2021-07-10,UNKNOWN,INTERVENTIONAL,['PHASE3']
5807,NCT02983812,Hospital readmission within 30 days of discharge,Total health care cost utilization in 6 months after discharge,,2017-01-23,COMPLETED,OBSERVATIONAL,['NA']
5808,NCT03787511,Proportion of patients with small fiber neuropathy,values of the DN4 questionnaire in diabetic patients,,2019-03-05,RECRUITING,INTERVENTIONAL,['NA']
5809,NCT00499356,Incident foot ulcers,,,2002-05,COMPLETED,INTERVENTIONAL,['NA']
5810,NCT00658957,The percentage of patients who remain free of signs and symptoms of infection until the end of the study,Treatment emergent Adverse Events,,2008-04,TERMINATED,INTERVENTIONAL,['PHASE2']
5811,NCT04261361,Glycemic control,DM-specific distress,,2018-12-12,COMPLETED,INTERVENTIONAL,['NA']
5812,NCT00913393,Measure: change from baseline in 24-hour urinary ACR for each arm compared with placebo,Measure: Change from baseline in serum creatinine for each FG-3019 arm compared with placebo,,2009-02,TERMINATED,INTERVENTIONAL,['PHASE2']
5813,NCT01476449,Mean Change in Early Treatment for Diabetic Retinopathy Study (ETDRS) Eye Chart Vision.,"Percentage of Patients Anatomically ""Dry.""",,2011-11,COMPLETED,INTERVENTIONAL,['PHASE2']
5814,NCT00971997,Percentage of Participants Achieving Hemoglobin A1c (HbA1c) Below 6.5% at Week 48 Endpoint,Number of Hypoglycemia Episodes Participants Experienced at Any Time From Baseline Through Week 48,,2009-09,COMPLETED,INTERVENTIONAL,['PHASE4']
5815,NCT00858013,The Durability of Nateglinide in Comparison With Those of Glimepiride Based on the Withdrawal Rate,HOMA-IR,,2009-04-24,COMPLETED,INTERVENTIONAL,['PHASE4']
5816,NCT00555490,mortality or using dialysis,,,2001-04,COMPLETED,INTERVENTIONAL,['PHASE1']
5817,NCT01348685,subjective appetite and short term food intake,,,2007-01,COMPLETED,INTERVENTIONAL,['NA']
5818,NCT05362968,Lipid control,Diabetes risk hormones,,2023-01-01,RECRUITING,INTERVENTIONAL,['PHASE1']
5819,NCT05447806,Average hospital length of stay (LOS),Hospital revenue,Provider's practice performance,2022-07-15,RECRUITING,INTERVENTIONAL,['NA']
5820,NCT01895387,Plasma Lp-PLA2 activity,PBMC Lp-PLA2 activity,LDL particle size,2012-01,COMPLETED,INTERVENTIONAL,['NA']
5821,NCT04289818,Change from Baseline HbA1c at 6 months,Change of Body mass index at 6 months,,2018-02-01,COMPLETED,INTERVENTIONAL,['NA']
5822,NCT00977262,PBMC gene expression profiles,Endothelial function,,2009-10,COMPLETED,INTERVENTIONAL,['NA']
5823,NCT03506750,Changes of intraocular VEGF and PLGF of patients with proliferative diabetic retinopathy post-IVC (intravitreous injection of Conbercept).,Effect of IVC on postoperative complications,,2017-06-03,UNKNOWN,INTERVENTIONAL,['PHASE4']
5824,NCT06247748,Baseline-corrected difference of Corrected QT interval after multiple subcutaneous injections of JY09 injection,Immunogenicity,Relative abundance,2023-10-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
5825,NCT05765903,Number of moderate-high risk participants with 30-day post-discharge hospital readmission,90-day post-discharge emergency department usage,,2024-03-31,WITHDRAWN,INTERVENTIONAL,['NA']
5826,NCT05217953,Change in HbA1c,AUC of glucose below 3.5 mmol/l,,2022-06-30,RECRUITING,INTERVENTIONAL,['NA']
5827,NCT03595267,Kidney Failure Risk,,,2019-10-01,RECRUITING,OBSERVATIONAL,['NA']
5828,NCT00925717,Investigate LDL-C goal achievement rate according to ADA recommendation,Investigate reduction of 10-year risk for CHD by using UKPDS risk engine,,2009-05,COMPLETED,OBSERVATIONAL,['NA']
5829,NCT05094401,Mean change in HbA1c,Change in Medications,,2021-10-04,TERMINATED,INTERVENTIONAL,['PHASE3']
5830,NCT01099397,"Number of Participants Diagnosed With Prediabetes or Normal Glucose, by 2 Measurements (Fasting Glucose Measurement and Glucose Measurement After a 2-hour Oral Glucose Tolerance Test [OGTT]), at Three Timepoints During Antihypertensive Treatment",,,2009-05,COMPLETED,OBSERVATIONAL,['NA']
5831,NCT02749890,Change from baseline in HbA1c,Measurement of anti-insulin antibodies from baseline,,2016-05-09,COMPLETED,INTERVENTIONAL,['PHASE3']
5832,NCT02825251,Change in Glycosylated Haemoglobin (HbA1c),Number of Subjects With at Least One Non-routine Change-of-infusion-sets Categorised by Reasons for Change-of-infusion-sets,,2016-07-06,COMPLETED,INTERVENTIONAL,['PHASE3']
5833,NCT03455543,Change in Pain Intensity,Changes in Nerve Conduction Studies of Amplitude Between Baseline and End of Treatment at 4 Months.,Exploratory Endpoint: Changes in Intraepidermal Nerve Fiber Density (IENFD) at the Distal Thigh and Distal Leg - Part B,2018-03-26,COMPLETED,INTERVENTIONAL,['NA']
5834,NCT04383197,Insulin secretion,Body composition,,2019-12-10,UNKNOWN,INTERVENTIONAL,['NA']
5835,NCT03810378,Hemoglobin A1c (HbA1c),Blood pressure,Adherence to diet protocols,2019-06-05,COMPLETED,INTERVENTIONAL,['NA']
5836,NCT05818995,albuminuria,,,2022-07-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
5837,NCT03254979,Implementation of the recommended clinical intervention by health care porfessionals,Lifestyle change at patient level,,2017-03-15,COMPLETED,INTERVENTIONAL,['NA']
5838,NCT01808690,Change in Insulin Sensitivity,Change in Aortic Wall Sheer Stress (WSS),Change in Brachial Artery Distensibility,2013-03,COMPLETED,INTERVENTIONAL,['PHASE3']
5839,NCT03264352,Composite of Major Adverse Cardiovascular and Cerebrovascular Events,Cancer,,2018-02-01,RECRUITING,INTERVENTIONAL,['PHASE4']
5840,NCT03648996,Carotid Femoral Pulse Wave Velocity (cfPWV),Insulin-stimulated Leg Blood Flow,,2018-11-01,COMPLETED,INTERVENTIONAL,['PHASE2']
5841,NCT04955834,Change value of glycosylated hemoglobin (HbA1c),Abnormal findings,,2021-07-27,RECRUITING,INTERVENTIONAL,['PHASE3']
5842,NCT02144909,Change from Baseline diabetes management functioning as measured by the Problem Areas in Diabetes questionnaire at 3 months and 6 months,Change from Baseline weight in kg at 3 months and 6 months,Change from Baseline dietary patterns as a questionnaire at 3 months and 6 months,2013-11,COMPLETED,INTERVENTIONAL,['NA']
5843,NCT00300105,"Adverse events, laboratory variables, physical examination, cardiac evaluation, hypoglycemic events, electrocardiogram, vital signs (blood pressure and pulse), body weight","Central obesity (waist circumference, hip circumference and waist/hip ratio)",,2005-10,TERMINATED,INTERVENTIONAL,['PHASE3']
5844,NCT01984567,Plasma oxyphytosterol concentrations,Markers reflecting antioxidant capacity,,2013-04,UNKNOWN,INTERVENTIONAL,['NA']
5845,NCT01187069,HbA1c,Problem Areas In Diabetes scale (PAID),,2009-08,COMPLETED,INTERVENTIONAL,['NA']
5846,NCT01000688,Forearm vasodilator response to intra-arterial infusion of acetylcholine (endothelium-dependent) following treatment with vildagliptin and following active control with acarbose,Effect of vildagliptin on ex vivo mononuclear cell responses to various stimuli,,2010-01,COMPLETED,INTERVENTIONAL,['PHASE3']
5847,NCT01050803,BMI,Audit of Diabetes-Dependent Quality of Life (ADDQOL),,2009-08,COMPLETED,INTERVENTIONAL,['NA']
5848,NCT03335501,Change in plasma glucose levels 1 hour after the meal,Number of hypoglycemic events less than 3.3 mmol/L (>20 minutes).,,2018-04-01,WITHDRAWN,INTERVENTIONAL,['PHASE2']
5849,NCT01450592,Percentage of complex carbohydrate intake from total carbohydrate by Indian diabetic population,Percentage of diabetic population with glycaemic control,,2012-05,COMPLETED,OBSERVATIONAL,['NA']
5850,NCT05043636,Cardivascular Autonomic Neuropathy assesed by Vagus,Blood pressure in supine and standing position,,2019-09-01,UNKNOWN,OBSERVATIONAL,['NA']
5851,NCT04234581,Hemoglobin A1c,2-AAA,,2019-08-13,TERMINATED,INTERVENTIONAL,['NA']
5852,NCT04760444,Self-Care Activities,Diabetes Distress,,2021-05-15,COMPLETED,INTERVENTIONAL,['NA']
5853,NCT00663000,To evaluate a correlation between IGF-I and glucose tolerance in patients with acromegaly.To evaluate changes of impaired glucose tolerance by different treatment options for acromegaly.,"Evaluate a correlation between body weight/BMI, age, family history of diabetes,duration of acromegaly and current medical treatment for acromegaly and glucose tolerance / insulin resistance",,2008-04,COMPLETED,OBSERVATIONAL,['NA']
5854,NCT05944029,Weight,,,2023-02-20,RECRUITING,INTERVENTIONAL,['NA']
5855,NCT00143338,"To assess in patients with type 2 diabetes mellitus the effects, if any, on lung lining fluid cell count and differential within subjects after 12 weeks of inhaled insulin therapy compared to 12 weeks of subcutaneous short-acting therapy.","(1) Albumin and fibrinogen concentrations, and airway appearance in the above subjects. (2) routine safety, tolerance, and efficacy in the above subjects.",,2004-11,COMPLETED,INTERVENTIONAL,['PHASE2']
5856,NCT00695682,This is a pilot study to study the safety and tolerability of intravitreal Infliximab in patients with refractory diabetic macular edema and choroidal neovascularization (CNV),Incidence and severity of adverse events,,2008-06,UNKNOWN,INTERVENTIONAL,['PHASE1']
5857,NCT01377558,Change in HbA1c-level (haemoglobin A1c),Follow up of all parameters mentioned above,,2011-04,UNKNOWN,INTERVENTIONAL,['NA']
5858,NCT05417425,Incidence in wound closure by week 12 of treatment,Increase in physical function and ambulation,,2022-09-01,RECRUITING,INTERVENTIONAL,['NA']
5859,NCT01710371,Optimal PET-determined mean pancreatic Volume of Distribution (VT) of 18F-AV-133,,,2012-12,COMPLETED,INTERVENTIONAL,['PHASE1']
5860,NCT00867022,Serum Noradrenalin level,"Heart rate variability: LF, VLF, HF",,2004-08,COMPLETED,OBSERVATIONAL,['NA']
5861,NCT03932084,Glucose fluctuation,Blood lipids,,2017-02-01,UNKNOWN,INTERVENTIONAL,['NA']
5862,NCT02325960,Mean amplitude of glycemic excursions (MAGE) change from baseline by continuous glucose monitoring system (CGMS),body composition,Exploratory Objective assessed by the relationships between oxidative stress and inflammatory markers and MAGE,2015-01,COMPLETED,INTERVENTIONAL,['PHASE4']
5863,NCT05713448,Prevalence of patients with type 1 diabetes and obesity,,,2021-02-24,RECRUITING,OBSERVATIONAL,['NA']
5864,NCT02838147,Neonatal hypoglycemia,Macrosomia,,2016-09,UNKNOWN,INTERVENTIONAL,['PHASE3']
5865,NCT00285844,Adipose Cell Size Distribution,Adipose Tissue Gene Expression,Insulin-Mediated Glucose Uptake,2005-10,COMPLETED,INTERVENTIONAL,['PHASE1']
5866,NCT03392441,Change in Structural MRI,,,2017-11-30,COMPLETED,INTERVENTIONAL,['NA']
5867,NCT01600924,Independent predictors of reduced muscle and bone strength,Relation of changes in predictors with reduced muscle and bone strength,,2016-09,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
5868,NCT04910763,Changes in Hormonal Response to Feeding,Changes in Ad libitum Energy Intake - Free Living,,2019-06-12,TERMINATED,INTERVENTIONAL,['NA']
5869,NCT01628627,"Change in Nerve Conduction Velocity of the Deep Peroneal, Tibial, or Sural Nerve",Number of patients with treatment-related adverse events,,2006-05,COMPLETED,INTERVENTIONAL,['PHASE4']
5870,NCT00363948,tolerability,Plasma glucose,,2006-08,COMPLETED,INTERVENTIONAL,['PHASE3']
5871,NCT03974139,cerebrospinal fluid /plasma leptin ratio,Score of the Dutch Eating Behaviour Questionnaire (DEBQ),,2020-07-03,RECRUITING,INTERVENTIONAL,['PHASE2']
5872,NCT00675493,Change in HbA1c from baseline,Number of adverse drug reactions (ADR),,2008-05,COMPLETED,OBSERVATIONAL,['NA']
5873,NCT05802927,Postprandial blood glucose,Appetite,,2023-07-05,COMPLETED,INTERVENTIONAL,['NA']
5874,NCT05181917,TIme in range,Prediction capacity of the model of postprandial glucose values,Actions carried out by participants,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
5875,NCT05670600,Change in pain level at 4th and 8th weeks compared to baseline.,Effect of neuropathic pain on quality of life at 4 and 8 weeks change from initial state,,2021-07-19,COMPLETED,INTERVENTIONAL,['NA']
5876,NCT01939496,Change From Baseline in the Mean 24-Hour Systolic Blood Pressure (SBP) to Week 6,"Change From Baseline in the Difference in Seated Heart Rate (HR) and Standing HR to Day 2, to Week 3, and to Week 6",,2013-10,COMPLETED,INTERVENTIONAL,['PHASE4']
5877,NCT06289387,"Role of the PNPLA3, TM6SF2, GCKR, MBOAT7 and HSD17B13 genetic variants in the development and progression of MASLD.",Correlation between serum creatinine levels (eGFR) and the genetic variants,,2024-01-20,RECRUITING,OBSERVATIONAL,['NA']
5878,NCT04298515,Nefratin-1 in insulin resistance,,,2020-03-02,UNKNOWN,INTERVENTIONAL,['NA']
5879,NCT00839878,Percentage of diabetic patients having diabetic nephropathy,"Minimum duration of diabetes associated with 10% incidence of diabetic complications (CVD, nephropathy and retinopathy)",,2009-03,COMPLETED,OBSERVATIONAL,['NA']
5880,NCT06143215,Recurrence rate,Minor amputation rate,,2023-12-06,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
5881,NCT02709057,Incident diabetes,The change in insulin sensitivity during a 3 year follow-up,Incident cardiovascular disease,2016-04,UNKNOWN,INTERVENTIONAL,['NA']
5882,NCT02746627,Glycemic Control (HbA1c),Coping,,2014-01,COMPLETED,INTERVENTIONAL,['NA']
5883,NCT03865290,Change in effect of Gastrointestinal symptoms on Quality of Life,Severity of gastrointestinal symptoms - Nepean Dyspepsia index,,2019-04-02,RECRUITING,INTERVENTIONAL,['PHASE2']
5884,NCT01409889,Participant Weight,Minutes of Physical Activity,,2011-05,COMPLETED,INTERVENTIONAL,['NA']
5885,NCT03537131,"Time to hypoglycaemia during the exercise challenge, before and after dapagliflozin treatment.","Concentration of plasma potassium, sodium, calcium and pH at each 10min interval during exercise challenge",,2018-06-02,TERMINATED,INTERVENTIONAL,['PHASE2']
5886,NCT02793505,Spontaneous abortion,Pregnancy complications,,2014-01,COMPLETED,OBSERVATIONAL,['NA']
5887,NCT06320054,Clinical Outcomes,Patient Reported Outcomes,,2024-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
5888,NCT01129232,Prevalence of virus infected islets in pancreatic biopsies,Glycosylated hemoglobin A1 (HbA1c),,2011-01,TERMINATED,INTERVENTIONAL,['PHASE2']
5889,NCT05728411,Rate of foot ulceration,Mean or median self-efficacy for diabetes,"Utilization (outpatient visits, emergency room visits, hospitalizations) - any vs. none and number",2023-10-02,RECRUITING,INTERVENTIONAL,['NA']
5890,NCT00385528,"Psychological distress, quality of life",health care utilization,,2002-11,COMPLETED,INTERVENTIONAL,['PHASE4']
5891,NCT04529473,Glycated haemoglobin (HbA1c),Blood Pressure,Adverse Events (AE),2021-02-03,COMPLETED,INTERVENTIONAL,['NA']
5892,NCT03908021,profile the oral bacteria related to caries and periodontal disease of children with type 1 diabetes mellitus,,,2019-08-01,COMPLETED,OBSERVATIONAL,['NA']
5893,NCT01932775,"Mean percentage of blood glucose measurements in the target range 70 to 140 mg/dl, as calculated by all premeal and bedtime glucose values measured ≥ 24 hours after start of therapy",Mean daily blood glucose as calculated by premeal and bedtime blood glucose values: Overall and per treatment day,,2013-05,COMPLETED,INTERVENTIONAL,['PHASE3']
5894,NCT02348294,Increase in erythema index,,,2015-02,UNKNOWN,INTERVENTIONAL,['NA']
5895,NCT05619406,Primary Outcome,Secondary Outcome,,2022-08-20,RECRUITING,INTERVENTIONAL,['NA']
5896,NCT05870358,Biochemical Findings: RANKL/OPG,,,2021-02-18,COMPLETED,INTERVENTIONAL,['PHASE4']
5897,NCT00005168,,,,1984-08,COMPLETED,OBSERVATIONAL,['NA']
5898,NCT03178019,Intergroup analysis of the associations between DPP4 activity and markers of inflammation,"Intergroup analysis of the associations between DPP4 activity and insulin resistance indexes, heart rate and blood pressure variability, and measures of adiposity",,2014-02-01,COMPLETED,OBSERVATIONAL,['NA']
5899,NCT03987308,The percentage of patients with at least a 0.7% change in the absolute value of glycated hemoglobin,The percentages of subjects with greater than 3% weight loss,,2019-07-01,UNKNOWN,INTERVENTIONAL,['NA']
5900,NCT01186003,Reduction in Rebound Hyperglycemia (Blood Glucose Levels Over 180 mg/dl),Reduction in Time to Get Back to Control of Glycemia (140-180 mg/dl) if Rebound Hyperglycemia Occurs,,2010-08,COMPLETED,INTERVENTIONAL,['NA']
5901,NCT01732705,Insulin sensitivity,,Glycogen content in skeletal muscle,2012-09,COMPLETED,INTERVENTIONAL,['NA']
5902,NCT04857073,Birth weight,Number of NICU admission,,2021-04-10,COMPLETED,INTERVENTIONAL,['NA']
5903,NCT00862433,Measure Vitamin E Kinetics,,,2014-10-10,COMPLETED,INTERVENTIONAL,['PHASE1']
5904,NCT03316261,greater than 10% risk for multiple beta-cell autoantibodies/type 1 diabetes,,,2017-10-19,RECRUITING,OBSERVATIONAL,['NA']
5905,NCT04930224,oestradiol,,,2019-07-01,COMPLETED,OBSERVATIONAL,['NA']
5906,NCT03626909,Patients meeting their HgbA1c treatment goal,Community Health Worker adherence,,2018-01-14,COMPLETED,OBSERVATIONAL,['NA']
5907,NCT01416649,Sleep duration and sleep efficiency,,,2011-02-01,COMPLETED,OBSERVATIONAL,['NA']
5908,NCT05135039,The rate of progression from prediabetes to diabetes one year after the intervention in both groups of subjects.,Changes in the number of CD4 T cells after one year intervention in the two groups.,,2022-01-01,RECRUITING,INTERVENTIONAL,['NA']
5909,NCT02722655,Intelligence quotient evaluation,Hypertension,,2008-03,RECRUITING,OBSERVATIONAL,['NA']
5910,NCT00612950,2.phase insulin response measured as incremental area under the curve from 10-120 minutes,"2.phase insulin response measured as incremental area under the curve from 10-120 minutes, after 4 weeks of insulin treatment",,2006-10,COMPLETED,INTERVENTIONAL,['NA']
5911,NCT01794091,"All cause mortality, cardiovascular death, myocardial infarction or stroke",,,2013-08,UNKNOWN,INTERVENTIONAL,['PHASE1']
5912,NCT04262700,A1c change from baseline after 12 weeks,,,2020-02-07,UNKNOWN,INTERVENTIONAL,['NA']
5913,NCT00969592,fractional and total glucose infusion rates,fractional and total insulin areas under the curve (AUC),,2007-11,COMPLETED,INTERVENTIONAL,['PHASE1']
5914,NCT03821662,Change from Baseline Glycated hemoglobin (HbA1C),Change from Baseline Medication Adherence Assessment Scale,,2019-04-11,COMPLETED,INTERVENTIONAL,['NA']
5915,NCT05408234,Ankle Brachial Index,,,2022-06,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5916,NCT01197898,Change From Baseline in Extent of Presence/Absence of Epithelial Tongue.,,,2010-12,COMPLETED,INTERVENTIONAL,['PHASE4']
5917,NCT00740051,HbA1c Change From Baseline at Week 18 (Final Analysis),The Change in FPG From Baseline by Visit Over Time,,2008-08,COMPLETED,INTERVENTIONAL,['PHASE3']
5918,NCT05140304,Mean area of FAZ in various stages of diabetic retinopathy and difference between these groups in superficial and deep capillary plexuses,,,2021-11-30,UNKNOWN,INTERVENTIONAL,['NA']
5919,NCT00542334,Frequency and magnitude of nocturnal hypoglycemia,Patient satisfaction with continuous glucose sensing,,2008-09,COMPLETED,OBSERVATIONAL,['NA']
5920,NCT06215352,Gestational weight gain,,,2024-01-09,RECRUITING,OBSERVATIONAL,['NA']
5921,NCT02660242,Glycemic Response During Exercise and Early Recovery,CGM Metrics During Late Recovery - Time > 250 mg/dL,,2016-01,COMPLETED,INTERVENTIONAL,['PHASE2']
5922,NCT05765214,CRC-KPSS change and screening uptake,,,2023-05-01,RECRUITING,INTERVENTIONAL,['NA']
5923,NCT02057952,Change in Body Weight From Baseline to 6 Months.,Change in Diastolic Blood Pressure Baseline to 12 Months,,2012-04,COMPLETED,INTERVENTIONAL,['NA']
5924,NCT02058147,Change in HbA1c From Baseline to Week 30,Percentage of Participants With Severe Symptomatic Hypoglycemia,,2014-02,COMPLETED,INTERVENTIONAL,['PHASE3']
5925,NCT04019431,Body Mass Index change from baseline,Safety (subjective unit) change from baseline,,2019-07-01,COMPLETED,INTERVENTIONAL,['NA']
5926,NCT05708040,Time in Range,Health-Related Quality of Life in Patients with Type 1 Diabetes,,2022-08-19,COMPLETED,INTERVENTIONAL,['NA']
5927,NCT04787978,"Change in cardiovascular health (a composite measure of blood pressure, cholesterol, glucose, physical activity, smoking status, and body mass index).",Change in Patient Activation,,2020-02-29,COMPLETED,INTERVENTIONAL,['NA']
5928,NCT01794143,"Time to HbA1c>=7%, while receiving metformin and the randomly assigned study medication","Time to HbA1c>7.5%, while receiving metformin and the randomly assigned study medication.","Time to HbA1c>7.5%, while receiving study medications and basal insulin",2013-05,COMPLETED,INTERVENTIONAL,['PHASE3']
5929,NCT00495014,"Adverse reactions and changes in laboratory values, vital signs, and/or ECGs following each dose",Body weight following 14 days of repeat dosing with GSK376501.,,2007-06,COMPLETED,INTERVENTIONAL,['PHASE1']
5930,NCT00476918,"Visual acuity, no of treatments, duration of efficacy","intraocular pressure, retinal thickness",,2006-07,UNKNOWN,INTERVENTIONAL,['PHASE1']
5931,NCT02695810,Mean amplitude of glycaemic excursions (MAGE) as assessed by continuous glucose monitoring,Responsiveness to interventions in individuals with different glucose tolerance status (impaired fasting glycaemia vs. impaired glucose tolerance),,2016-02-24,COMPLETED,INTERVENTIONAL,['PHASE2']
5932,NCT05067452,Change in food security severity from baseline to twelve weeks by study arm,Change in diabetes self-efficacy from baseline to twelve weeks by study arm,Change in health-related quality of life (healthy days) from twelve weeks to twenty-four weeks by study arm,2021-11-08,RECRUITING,INTERVENTIONAL,['NA']
5933,NCT01123187,Composite criteria: insulin independence and Glycosylated Hemoglobin (HbA1c) under 8% at one year after the transplantation,Evaluation of kidney function,,2003-03,COMPLETED,INTERVENTIONAL,['NA']
5934,NCT04295031,metformin daily dose in diabetic outpatients type 2,renal filtration rate,,2019-10-09,UNKNOWN,OBSERVATIONAL,['NA']
5935,NCT04940962,Kinetics of the appearance of endocannabinoids produced by visceral adipose tissue explants in culture medium estimated by the area under the curve in obese subjects and in controls.,,,2021-09-29,RECRUITING,INTERVENTIONAL,['NA']
5936,NCT01473329,HbA1c,Changes in Lipids,,2009-01,COMPLETED,INTERVENTIONAL,['NA']
5937,NCT02410005,24h urine 24hr urine albuminuria,,Estimated glomuerula filtration rate (eGFR),2014-10,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
5938,NCT01328821,To assess safety and tolerability of CTP-499,"To assess Pharmacokinetics, Pharmacodynamics and relative bioavailability",,2011-03,COMPLETED,INTERVENTIONAL,['PHASE1']
5939,NCT02893072,intravenous glucose,,,2015-11,UNKNOWN,INTERVENTIONAL,['NA']
5940,NCT05507697,Change of nerve conduction velocities in the lower extremity,Change of glycosylated hemoglobin (HbA1c),,2022-05-19,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
5941,NCT01056198,Bates-Jensen Wound Assessment Score - Modified (BWAT-m),Percent of Wound Area Change From Baseline at the End of 12 Week Follow-up,,2010-02,COMPLETED,INTERVENTIONAL,['PHASE4']
5942,NCT03047200,Restoration of sustained euglycemia without exogenous insulin or with reduced insulin dosage in patients who underwent pancreatic islet cell after kidney transplantation,To assess total islet mass needed to achieve sustained euglycemia with or without exogenous insulin.,,2008-07,WITHDRAWN,INTERVENTIONAL,['PHASE1']
5943,NCT01882907,Non-inferiority of HbA1C Change From Baseline in Vildagliptin + Metformin Group Compared With Pioglitazone + Metformin Group,"the Mean Changes of Insulin, C-peptide, HOMA-IR, HOMA-beta From Baseline Between Vildagliptin + Metformin and Pioglitazone + Metformin Groups",the Numbers of Participants With Adverse Events Between Vildagliptin + Metformin and Pioglitazone + Metformin Groups,2009-12,COMPLETED,INTERVENTIONAL,['PHASE4']
5944,NCT00709683,Incidence of major hypoglycaemic events reported as serious adverse drug reactions,"Average post-breakfast (90-120 mins), post-lunch (90-120 mins), post-dinner (90-120 mins) plasma glucose level",,2008-05,COMPLETED,OBSERVATIONAL,['NA']
5945,NCT05305326,Telocytes,,,2021-12-01,UNKNOWN,OBSERVATIONAL,['NA']
5946,NCT01079195,Reduction in Systolic Blood Pressure and Diastolic Blood Pressure From Baseline to Study End,Evaluation of Adverse Events (AEs) Leading to Discontinuation of Tarka and a Summary of All AEs Possibly or Probably Related to Tarka by Frequency and Severity,,2007-10,COMPLETED,OBSERVATIONAL,['NA']
5947,NCT06251323,Hemoglobin A1c,,,2025-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
5948,NCT04819178,Diabetic ketoacidosis,Hypoglyceamia,,2021-06-01,WITHDRAWN,OBSERVATIONAL,['NA']
5949,NCT03256747,Glucose levels,Oxygenation tissue,,2017-09-15,COMPLETED,INTERVENTIONAL,['NA']
5950,NCT04720170,Intra-epidermal Nerve Fiber Density,Patency of Lateral Plantar Artery,Medial Plantar Sural Nerve Action Potential Amplitude,2021-02-15,UNKNOWN,INTERVENTIONAL,['NA']
5951,NCT00348231,daily profile of blood glucose,QOL,,2004-11,UNKNOWN,INTERVENTIONAL,['NA']
5952,NCT04767672,Glycated hemoglobin,Fecal Short-Chain Fatty Acids (SCFA),Blood pressure,2021-05-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
5953,NCT05107544,Time change in range,Change in mood of adolescents,,2021-09-04,COMPLETED,INTERVENTIONAL,['NA']
5954,NCT00973271,The effect of DCCR on triglycerides in subjects without diabetes mellitus who have very high triglycerides over a period of 84 days,The effects of DCCR on Apo B and non-HDL in subjects without diabetes mellitus who have very high triglycerides over a period of 84 days,,2011-03,WITHDRAWN,INTERVENTIONAL,['PHASE3']
5955,NCT02776098,Compare change in mean lean body mass (LBM) from baseline to end of study,Compare Intramyocellular lipid (IMCL) accumulation from baseline to end of study,,2016-05,COMPLETED,OBSERVATIONAL,['NA']
5956,NCT03006471,Number of Participants With a Dipper Reverse Circadian Blood Pattern at Week 12,Number of Participants With Prediabetes Plus Prehypertension at Week 12,,2016-03-30,COMPLETED,INTERVENTIONAL,['PHASE4']
5957,NCT05021705,renal biopsy,,,2016-01,COMPLETED,OBSERVATIONAL,['NA']
5958,NCT05654285,"Glucose, insulin, glucagon, glucagon-like peptide-1 (GLP-1), peptide tyrosine tyrosine (PYY), glucose-dependent insulinotropic polypeptide (GIP), pancreatic polypeptide (PP), leptin, and ghrelin",,,2016-02-08,COMPLETED,INTERVENTIONAL,['NA']
5959,NCT05772169,Prevalence of Hypercortisolism,Effect of Treatment on Non-neoplastic Hypercortisolism,,2023-03-31,RECRUITING,INTERVENTIONAL,['PHASE4']
5960,NCT00754130,Number of Participants Who Discontinued Study Drug Due to an AE,"Plasma Pharmacokinetic Parameter: Day 5 to Day 1 Accumulation Ratio for AUC (0-24hr), Cmax, and C24hr",,2008-09,COMPLETED,INTERVENTIONAL,['PHASE1']
5961,NCT01676220,Change in HbA1c From Baseline to Month 6 Endpoint,Percentage of Participants With Hypoglycemia (All and Nocturnal) Events From Baseline up to Month 12,,2012-08,COMPLETED,INTERVENTIONAL,['PHASE3']
5962,NCT05786521,6 minute walking distance,,,2023-04-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4']
5963,NCT04506216,Eating disorders in men and women,Blood glucose monitoring,,2020-09-01,COMPLETED,INTERVENTIONAL,['NA']
5964,NCT03290768,Program Completion Rate (%),Coaching Participation Rate,,2017-09-13,COMPLETED,INTERVENTIONAL,['NA']
5965,NCT04828304,Efficacy PLASOMA - wound surface area reduction,Patient acceptability,,2021-05-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
5966,NCT03165110,Percent of Responses From Persons With Diabetes That Either 'Strongly Agree' or 'Agree' or Are 'Neither Agree Nor Disagree' With Questionnaire Statements Regarding Success in Interpreting the Expanded Graph and My Readings View in the Onyx App System,Average Change in Total Daily Insulin Dose From Study Start to End of Study,,2017-03-17,COMPLETED,INTERVENTIONAL,['NA']
5967,NCT00556751,"Development of resting ECG abnormalities, specifically isolated non-specific ST-segment and T-wave abnormalities",,,1985-01,COMPLETED,OBSERVATIONAL,['NA']
5968,NCT01342263,Healthcare utilization,Health outcomes,,2011-05,COMPLETED,INTERVENTIONAL,['NA']
5969,NCT01102452,The daily blood glucose level will be monitored by the CGMS (continuous glucose monitoring system)device,,,2010-04,COMPLETED,INTERVENTIONAL,['NA']
5970,NCT06173232,Primary Objective,,Exploratory Endpoint,2023-11-20,RECRUITING,OBSERVATIONAL,['NA']
5971,NCT04437485,Hemoglobin A1c at 6 Months,Depressive Symptoms,,2020-10-14,COMPLETED,INTERVENTIONAL,['PHASE2']
5972,NCT03136289,Adolescent prediabetes and diabetes.,,,2013-12,COMPLETED,OBSERVATIONAL,['NA']
5973,NCT04795726,Proportion of participants with progression of non-proliferative diabetic retinopathy (NPDR),Change in severity of diabetic retinopathy (DR),,2021-03-10,COMPLETED,INTERVENTIONAL,['NA']
5974,NCT00351000,Change From Baseline on Fasting Insulin,,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE4']
5975,NCT00800683,HbA1c Change From Baseline at Week 12,"Clinically Relevant Drug-related Abnormalities for Blood Chemistry, Pulse Rate, Laboratory Parameters and ECG",,2008-12,COMPLETED,INTERVENTIONAL,['PHASE3']
5976,NCT00627471,Mean difference in HbA1c (efficacy),"Minor, severe and nocturnal Hypoglycaemic events (safety)",,2008-01,TERMINATED,INTERVENTIONAL,['PHASE4']
5977,NCT02812498,glycosylated hemoglobin HbA1c,Cost analysis by patient estimation through a questionnaire of the overall cost and time saved thanks to the service,,2015-01,COMPLETED,INTERVENTIONAL,['NA']
5978,NCT01322035,Measure erythrocyte G6PD levels in diabetic vs. non-diabetic morbidly obese patients undergoing laparoscopic Gastric Bypass.,Measure hepatocyte G6PD levels in diabetic vs. non-diabetic morbidly obese patients undergoing laparoscopic gastric bypass.,,2009-12,COMPLETED,OBSERVATIONAL,['NA']
5979,NCT06173245,Change of subfoveal choroidal thickness (SFCT),Change of visual acuity (VA),,2021-02-01,COMPLETED,INTERVENTIONAL,['NA']
5980,NCT00841087,Rate of Nocturnal Major and Minor Hypoglycaemic Episodes,Systolic Blood Pressure (BP),,2009-01,COMPLETED,INTERVENTIONAL,['PHASE2']
5981,NCT00979368,Exposure to the investigational drug will be measured to assess safety and tolerability,To assess the single dose Pharmacokinetics of BMS-816336,,2009-11,COMPLETED,INTERVENTIONAL,['PHASE1']
5982,NCT01718015,"Concentrations of IGF-I and II, sCD-163, VEGF, NGF and BDNF in cerebrospinal fluid and blood.","Nerve conduction studies: Nerve velocity, Amplitude, F-waves, Motor Unit Number Estimate (dominating arm and non-dominating leg)",Protein profile of the cerebrospinal fluid using mass spectrometry.,2012-11,UNKNOWN,OBSERVATIONAL,['NA']
5983,NCT04863755,Change from Baseline Blood Pressure at 4 months,Change from Baseline HDL cholesterol at 4 months,,2017-05-09,COMPLETED,INTERVENTIONAL,['NA']
5984,NCT05210972,Coronary artery disease severity,Correlation of HbA1c to CAD severity,,2021-07-01,COMPLETED,OBSERVATIONAL,['NA']
5985,NCT04848480,Change in Glycosylated Haemoglobin (HbA1c) at Week 26,Change in Body Weight,,2021-04-30,COMPLETED,INTERVENTIONAL,['PHASE3']
5986,NCT03893422,CRP,Hospital Anxiety and Depression Scale,,2017-10-22,COMPLETED,INTERVENTIONAL,['NA']
5987,NCT03044132,Time (days) required for wound bed preparation (granular bed after placement of DermACELL AWM).,"The number of adverse events after DermACELL AWM application including infection, hospitalization, and reoperation.",,2017-01-15,COMPLETED,INTERVENTIONAL,['NA']
5988,NCT02668328,Mean Amplitude of Glycemic Excursion (MAGE),,,2016-09,WITHDRAWN,INTERVENTIONAL,['NA']
5989,NCT00833677,Diabetes Self Efficacy,Diabetes Specific Conflict,,2009-02,COMPLETED,INTERVENTIONAL,['NA']
5990,NCT01682759,Percentage of Participants Who Discontinued From the Study Due to an Adverse Event Excluding Data After Glycemic Rescue,Percentage of Participants Achieving a Hemoglobin A1C of <7.0% at Week 54,,2012-09-10,COMPLETED,INTERVENTIONAL,['PHASE3']
5991,NCT00708175,Percent Change From Baseline to Month 12 in Bone Mineral Density in the Total Proximal Femur by Dual-Energy-Ray Absorptiometry (DXA),Percent Change From Month 12 to Month 18 in Bone Mineral Density in the Total Proximal Femur by DXA,Number of Participants With Fracture,2008-05,COMPLETED,INTERVENTIONAL,['PHASE4']
5992,NCT03320031,glucose variability,hypoglycemia,,2017-06-03,UNKNOWN,INTERVENTIONAL,['PHASE4']
5993,NCT03088670,Mean change of HbA1c,Adverse event,,2013-04-23,COMPLETED,INTERVENTIONAL,['PHASE3']
5994,NCT05843929,Diabetic foot exam: dermatologic examination,Diabetes Self-Care,,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
5995,NCT03893526,Blood Glucose,Plasma Concentrations of Amino Acids,,2019-01-25,COMPLETED,INTERVENTIONAL,['PHASE4']
5996,NCT01376323,Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 12,Number of Participants With HbA1c < 7.0% and < 6.5%,,2011-07-13,COMPLETED,INTERVENTIONAL,['PHASE2']
5997,NCT04820556,"Significant (p<0,05) correlation (r>0,5) between abundance of Faecalibacterium genus and concentration of lipopolysaccharide",,,2021-04-12,COMPLETED,OBSERVATIONAL,['NA']
5998,NCT00714844,,,,2007-01,COMPLETED,OBSERVATIONAL,['NA']
5999,NCT00810290,HgbA1c,Change in quality of life.,,2004-07,COMPLETED,INTERVENTIONAL,['NA']
6000,NCT04127994,Impact of 3 stroke diet in glycemic variability compared to a 6 stroke diet,Impact of 3 stroke diet in weight loss compared to a 6 stroke diet,,2018-08-17,RECRUITING,INTERVENTIONAL,['NA']
6001,NCT02793427,Serum AGEs,,,2011-02,UNKNOWN,INTERVENTIONAL,['NA']
6002,NCT03895697,Time to plasma glucose recovery,Immunogenicity - Occurrence of anti-drug antibodies,,2019-03-26,COMPLETED,INTERVENTIONAL,['PHASE3']
6003,NCT03238547,Diagnostic Sensitivity and Specificity,,,2017-08-01,COMPLETED,OBSERVATIONAL,['NA']
6004,NCT01001611,Change from baseline in Glycosylated Hemoglobin (HbA1c),"Change from baseline in glycemic parameters (Fasting Plasma Glucose, C-peptide, Homeostasis Model Assessment of Insulin Resistance(HOMA-IR), Homeostasis Model Assessment of β-cell function(HOMA-β), Quantitative Insulin Check Index(QUICKI))",,2009-10,COMPLETED,INTERVENTIONAL,['PHASE3']
6005,NCT01717183,Percentage of complete wound closure,Change in wound surface area,,2013-04,UNKNOWN,INTERVENTIONAL,['NA']
6006,NCT02872402,Weight retention,Time physically active,,2016-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
6007,NCT03889210,Rate of change in plasma glucose concentration,Correlation with physical activity,,2019-04-01,COMPLETED,INTERVENTIONAL,['NA']
6008,NCT00914524,The change in the urinary protein/creatinine ratio from baseline to the end of treatment.,The change of creatinine clearance,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE2']
6009,NCT04484987,Adipose tissue gene expression,Peripheral diurnal rhythmicity in in peripheral mononuclear blood cells,,2020-11-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
6010,NCT03021187,Change in HbA1c (Week 26),Change in DTSQs: Individual Items and Treatment Satisfaction Score (6 of the 8 Items Summed),,2017-02-02,COMPLETED,INTERVENTIONAL,['PHASE3']
6011,NCT03769948,Diabetic retinopathy indicator (yes/no),,,2022-02,UNKNOWN,OBSERVATIONAL,['NA']
6012,NCT02748122,Change in score on Quality of Life questionnaire,,,2015-10,TERMINATED,INTERVENTIONAL,['NA']
6013,NCT02169531,Change from Baseline Hemoglobin A1c (HbA1c) at up to 27 weeks.,Change from Baseline Lipid Profile at up to 27 weeks.,Change from Baseline Symptoms at up to 27 weeks.,2014-03,COMPLETED,INTERVENTIONAL,['PHASE1']
6014,NCT05971082,remission of fatty liver disease,,,2023-08-24,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
6015,NCT02081118,Change in baseline in glycosylated haemoglobin (HbA1c) at 16 weeks,Glycated albumin,Number of Participants with Immunogenicity by HM11260C,2014-02,COMPLETED,INTERVENTIONAL,['PHASE2']
6016,NCT06045221,Change from Baseline in Hemoglobin A1c (HbA1c),Change from Baseline in Short Form 36 Version 2 (SF-36-v2) Acute Form Domain Summary Scores,,2023-09-22,RECRUITING,INTERVENTIONAL,['PHASE3']
6017,NCT03003806,Percentage of glucose readings below 54 mg/dl (3.3 mmol/l),Diabetes treatment satisfaction questionnaire,,2017-10-02,COMPLETED,INTERVENTIONAL,['NA']
6018,NCT01332071,Cmax of Metformin Hydrochloride,,,2009-11-24,COMPLETED,INTERVENTIONAL,['PHASE1']
6019,NCT01251757,Adherence to Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin Receptor Blockers (ARBs),Percentage With Good (<=100mg/dL) Low Density Lipoprotein (LDL) Control,,2011-08,COMPLETED,INTERVENTIONAL,['NA']
6020,NCT04859348,APGAR Score,,,2020-11-01,COMPLETED,INTERVENTIONAL,['NA']
6021,NCT01444534,Quality of Life,Self-monitoring of blood glucose (SMBG),,2011-09,COMPLETED,INTERVENTIONAL,['NA']
6022,NCT05714761,Percentage of participants with at least 72 hours of CGM data downloaded.,Negative predictive value (NPV),,2023-02-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
6023,NCT00065793,apoB concentration of LDL with apoC-III,,,2003-07,COMPLETED,OBSERVATIONAL,['NA']
6024,NCT00135330,Change in ASIiAUC During a Hyperglycemic Clamp Test.,Pedal Edema Score,,2005-10,COMPLETED,INTERVENTIONAL,['PHASE3']
6025,NCT01686828,Insulin Sensitivity Quantified by Matsuda Index,Changes in Adipose Tissue Gene Expression,,2013-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6026,NCT04133922,change in insulin sensitivity between baseline and 2 hour insulin clamp,change in pulse wave velocity between baseline and 2 hour insulin clamp,,2019-10-14,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1']
6027,NCT03514108,Met-HeFT combined endpoint: Death or hospitalization with worsening heart failure or acute myocardial infarction or stroke or urgent heart failure visit,Met-HeFT secondary endpoint: Hospitalization or death caused by lactate acidosis.,,2018-03-01,RECRUITING,INTERVENTIONAL,['PHASE4']
6028,NCT04332354,glycemic profile after bariatric surgery,identification of predictive factors for diabetes remission 1 year after surgery,,2016-03-30,COMPLETED,OBSERVATIONAL,['NA']
6029,NCT00746642,"Mellitor technology feasibility will be established by comparing Mellitor glucose measurements results to ""gold standard, Yellow Springs"" glucose analyzer, or a comparable. Interdevice variability should be within 10%.",,,2009-10,UNKNOWN,INTERVENTIONAL,['NA']
6030,NCT01790724,Physical Activity,Psychosocial outcomes,,2013-01,COMPLETED,INTERVENTIONAL,['NA']
6031,NCT05098327,HOMA-IR,TLR-4,,2021-08-01,WITHDRAWN,INTERVENTIONAL,['PHASE3']
6032,NCT05208424,Short-term outcome,,,2020-02-27,COMPLETED,OBSERVATIONAL,['NA']
6033,NCT02963922,Participants Losing at Least 5% of Baseline Body Weight,Change in Laboratory Parameters (Biochemistry) - Thyroid Stimulating Hormone,,2017-02-06,COMPLETED,INTERVENTIONAL,['PHASE3']
6034,NCT03788642,Ulcer Healing Rate,Clinical Success - Complications,,2019-01-15,COMPLETED,INTERVENTIONAL,['NA']
6035,NCT02803489,Sensitivity and specificity of the tele-notifications,"Clinical events including medical consultations, hospitalizations and adverse events",,2016-04-08,TERMINATED,INTERVENTIONAL,['NA']
6036,NCT01790308,the percentage of the patients who maintain glucose control 1 year after short intensive therapy,the remission rate differ from interventions in newly-diagnosed type 2 diabetic patients,,2013-02,UNKNOWN,INTERVENTIONAL,['PHASE4']
6037,NCT02268916,Social Participation,,Physical Function,2015-06-01,COMPLETED,INTERVENTIONAL,['NA']
6038,NCT00095082,HbA1c,Insulin Treatment Satisfaction,,2004-09,COMPLETED,INTERVENTIONAL,['PHASE3']
6039,NCT01840358,Frequency of hypoglycemias,Frequency of hyperglycemias,,2013-04,UNKNOWN,INTERVENTIONAL,['NA']
6040,NCT03803072,Weekly adherence rates for time restricted eating (TRE),Change between baseline and post-intervention visceral fat area,,2019-01-18,COMPLETED,INTERVENTIONAL,['NA']
6041,NCT05358444,Survey Administration Feasibility as assessed by mean time for administration of surveys to participants,Change in caregiver attitudes regarding child health behaviors,,2022-07-08,COMPLETED,INTERVENTIONAL,['NA']
6042,NCT00771693,"Co- primary platelet response variables: U46619 stimulated platelet P- selectin activation, platelet-leukocyte aggregation, platelet-platelet aggregates and platelet-monocyte aggregates.",To elucidate if short-term lowering of blood glucose by insulin infusion (pretreatment standardization of blood glucose) reduces platelet activity in patients with T2DM.,,2007-05,COMPLETED,INTERVENTIONAL,['PHASE4']
6043,NCT05370560,Type 2 diabetes mellitus,,,2010-12-01,COMPLETED,OBSERVATIONAL,['NA']
6044,NCT00109720,Blood glucose level,Diabetes Related Quality of life,,2002-08,COMPLETED,INTERVENTIONAL,['NA']
6045,NCT05193929,Percentage of index ulcers healed,Changes in wound quality of life from screening visit to end of study ( per W-QoL),Cost to Closure,2021-12-15,RECRUITING,INTERVENTIONAL,['NA']
6046,NCT01528254,Time to Initial Treatment Failure,"Percentage of Participants With Adverse Events, Serious Adverse Events and Death",,2012-03-30,COMPLETED,INTERVENTIONAL,['PHASE4']
6047,NCT01201460,,,,2009-04,COMPLETED,OBSERVATIONAL,['NA']
6048,NCT03580226,Uric Acid,,Management,2015-01,COMPLETED,OBSERVATIONAL,['NA']
6049,NCT01440140,Percentage of CGM (Continuous glucose monitoring) values in target (3.9 - 8.0 mmol/l).,Glycaemic control assessed by fructosamine and HbA1c,,2012-12,COMPLETED,INTERVENTIONAL,['PHASE2']
6050,NCT02112071,endothelial function measured by brachial artery flow mediated vasodilation,24-hour albuminuria,,2009-10,COMPLETED,INTERVENTIONAL,['NA']
6051,NCT04030091,Endothelial function,Diabetes treatment satisfaction questionnaire,,2019-09-06,COMPLETED,INTERVENTIONAL,['PHASE4']
6052,NCT05009602,Diagnostic accuracy,Inter- and intra-rater reliability,,2022-03-14,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
6053,NCT04662164,AEs,fasting plasma glucose,,2025-12,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6054,NCT00370942,Efficacy variables Dose response (change from baseline in HbA1c) at stipulated date in each treatment group,Long term safety variables,,2006-04-01,TERMINATED,INTERVENTIONAL,['PHASE2']
6055,NCT02038764,Number of Participants With Serum Anti-PF-06342674 Antibody Response Listed by Visit,Accumulation Ratio (Rac) on Day 71,,2014-06-04,COMPLETED,INTERVENTIONAL,['PHASE1']
6056,NCT01024790,Depression,,,2009-09,COMPLETED,INTERVENTIONAL,['PHASE1']
6057,NCT00971243,Change in HbA1c From Baseline to Week 24,"Adverse Events, Laboratory Tests, Vital Signs, Etc.",,2009-08,COMPLETED,INTERVENTIONAL,['PHASE2']
6058,NCT01796418,Brachial ankle pulse wave velocity (PWV),Blood pressure,,2013-03,UNKNOWN,INTERVENTIONAL,['NA']
6059,NCT03464812,Program completion,Patient and referring provider satisfaction,,2017-08-04,COMPLETED,INTERVENTIONAL,['NA']
6060,NCT00995787,"Safety variables (AE, BP, pulse, plasma glucose, laboratory variables, weight and ECG","Pharmacodynamic variables: 24 h plasma glucose, Insulin",,2009-10,COMPLETED,INTERVENTIONAL,['PHASE1']
6061,NCT03052400,Hemoglobin A1c,Basal Insulin Dose,,2017-02-03,TERMINATED,INTERVENTIONAL,['PHASE2']
6062,NCT01667783,Change in HbA1c from baseline to final data collection,Change in insulin secretion,,2012-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
6063,NCT05771090,Characteristics of volatile organic compound (VOC) signals measured by the Sokru device,Oxygen saturation,,2023-04-01,COMPLETED,INTERVENTIONAL,['NA']
6064,NCT04874415,Moderate to Vigorous Physical Activity (MVPA),Daily Step Count,,2021-11-16,RECRUITING,INTERVENTIONAL,['NA']
6065,NCT04247451,Efficiency of nutritional therapy: Dietary intake (food diary; in Kcal) compared to caloric need (indirect calorimetry; Kcal),"Evaluation of choice for oral nutritional supplements, enteral nutrition and parenteral nutrition (%)",,2020-01-01,RECRUITING,INTERVENTIONAL,['NA']
6066,NCT00082251,,,,na,COMPLETED,INTERVENTIONAL,['PHASE3']
6067,NCT05024032,Percentage of Participants Who Achieve ≥5% Body Weight Reduction,Mean Change From Baseline in Fasting Insulin (Pooled Doses of Tirzepatide 10 mg and 15 mg),,2021-09-01,COMPLETED,INTERVENTIONAL,['PHASE3']
6068,NCT00797563,Number of Capillary and Venous Results Within +/- 15mg/dL or +/- 20% of Laboratory Glucose Method,Number of Partipants Who Gave These Ratings for Overall Testing Experience With This Meter,,2008-11,COMPLETED,INTERVENTIONAL,['NA']
6069,NCT02016846,Glucose levels 2 hours after 75 gr OGTT,,,2014-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
6070,NCT00211536,Incidence of Severe Hypoglycemia Events,Low Blood Glucose Index (LBGI);,,2002-06,COMPLETED,INTERVENTIONAL,['PHASE3']
6071,NCT00933491,Radiographic Bone Level,,,2008-11,COMPLETED,OBSERVATIONAL,['NA']
6072,NCT04254029,Variation of mitral E' velocity,Variation of blood pressure.,,2016-11-01,COMPLETED,INTERVENTIONAL,['PHASE4']
6073,NCT03520608,prevalnce of irrational use of pain reliever drugs,Generalized Anxiety Disorder Screener (GAD-7),,2018-05-01,UNKNOWN,OBSERVATIONAL,['NA']
6074,NCT04956094,Proportion of patients diagnosed with gestational diabetes mellitus,,,2021-06-21,RECRUITING,OBSERVATIONAL,['NA']
6075,NCT01713023,Compare the effects of fructose and glucose and TAS1R2 in postprandial metabolism of individuals with type 1 diabetes,Effect of fructose or glucose on leptin levels,,2013-03,COMPLETED,INTERVENTIONAL,['NA']
6076,NCT01857167,insulin resistance,,,2013-06,COMPLETED,INTERVENTIONAL,['NA']
6077,NCT03257501,System Related adverse device effects,,,2017-08-22,COMPLETED,OBSERVATIONAL,['NA']
6078,NCT00838916,Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 52,Albiglutide Plasma Concentrations at Week 8 and Week 24,,2009-02,COMPLETED,INTERVENTIONAL,['PHASE3']
6079,NCT04626323,Mean differenceGlomerular filtration rate (GFR),Costs of care and health care utilization,,2021-05-25,RECRUITING,INTERVENTIONAL,['PHASE2']
6080,NCT00477191,Change in CRP Levels From Baseline to 6 Months of Treatment in Subjects With Psoriasis and Metabolic Syndrome,Change in the Safety and Tolerability of Etanercept in Patients With Psoriasis and Metabolic Syndrome Over a 6-month Period.,,2007-05,TERMINATED,INTERVENTIONAL,['NA']
6081,NCT01279317,Postprandial Glycemic Incremental Area Under the Curve,,,2010-09,COMPLETED,INTERVENTIONAL,['NA']
6082,NCT05443802,Metabolic complications,Episode of severe hypoglycaemia in patients suffering from first ketoacidosis episode,,2022-08-16,RECRUITING,INTERVENTIONAL,['NA']
6083,NCT02469558,insulin sensitivity,,Quality of Life,2015-09,COMPLETED,INTERVENTIONAL,['NA']
6084,NCT00904592,"incidence rate of proliferative diabetic retinopathy, panretinal photocoagulation",Symptoms scores of TCM,,2008-09,COMPLETED,INTERVENTIONAL,['NA']
6085,NCT06021158,Percentage of time of glucose levels spent in the target range (3.9-10.0 mmol/L),"Area under the sensor glucose concentration-time curve (AUC) from 0-1 hours, 0-2 hours, 0-3 hours, 0-4 hours, and 0-5 hours after the end of announced exercise periods",,2023-12-20,RECRUITING,INTERVENTIONAL,['PHASE2']
6086,NCT01752127,in-segment late lumen loss (mm)at 12month,procedure success rate,,2011-07,UNKNOWN,INTERVENTIONAL,['PHASE3']
6087,NCT04365400,Change in HbA1c From Baseline to Week 26,"Change in HbA1c From Baseline to Weeks 4, 8, 12, 16 and 20",,2020-10-13,TERMINATED,INTERVENTIONAL,['PHASE2']
6088,NCT00722371,Change From Baseline in A1C at Week 54,Change From Baseline in 2-Hour PMG at Week 54,,2008-09-05,COMPLETED,INTERVENTIONAL,['PHASE3']
6089,NCT06249399,Bladder Sensation,Patient Information Form,,2023-05-03,COMPLETED,INTERVENTIONAL,['NA']
6090,NCT00507936,"Efficacy of each ABT-894 dose (1 mg, 2 mg, or 4 mg BID) versus placebo in the treatment of pain due to DNP",Clinician Global Impression: Severity (CGI-S) and Patient Global Impression: Change (PGI-C),,2007-08,COMPLETED,INTERVENTIONAL,['PHASE2']
6091,NCT04461041,Left Ventricular (LV) mass,Hematocrit,,2021-04-01,COMPLETED,INTERVENTIONAL,['PHASE4']
6092,NCT00330330,To evaluate the pharmacologic activity of ISIS 113715,,,2003-02,COMPLETED,INTERVENTIONAL,['PHASE2']
6093,NCT00747006,Lunch Plasma Glucose Excursion - Amendment 1 (Humalog Treated Type 2 Subjects),Lunch Plasma Glucose AOC(0-240) - Amendment 1 (Humalog Treated Type 2 Subjects),,2008-09,TERMINATED,INTERVENTIONAL,['PHASE2']
6094,NCT00559884,Urine:,lab tests:,,2007-11,COMPLETED,INTERVENTIONAL,['PHASE1']
6095,NCT05926947,Post prandial insulemia,Short Form 12 (SF-12) questionnaire,,2023-07-05,RECRUITING,INTERVENTIONAL,['NA']
6096,NCT03144869,Acceptability,Parental fear of hypoglycaemia,,2017-09-01,COMPLETED,INTERVENTIONAL,['NA']
6097,NCT05792072,Changes in brain plasticity,influence on nerve conduction,,2023-05-02,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
6098,NCT02660736,Peak plasma concentration (Cmax) for albiglutide in session 1 and 2,Composite of urinalysis parameters as a measure of safety,,2016-02,COMPLETED,INTERVENTIONAL,['PHASE1']
6099,NCT06055582,Glycemic indices as per Continuous glucose monitoring system (CGMS) & HbA1c (%),,,2022-02-11,COMPLETED,INTERVENTIONAL,['NA']
6100,NCT00758082,Comparison of HbA1c means,Number of hypoglycemias (moderate and severe) during the 3-month period,,2008-07,COMPLETED,INTERVENTIONAL,['PHASE3']
6101,NCT02271776,systemic insulin sensitivity,skeletal muscle and adipose tissue gen and protein expression,,2014-10,COMPLETED,INTERVENTIONAL,['NA']
6102,NCT00951912,Percentage Change in Low Density Lipoprotein Cholesterol,Total Energy Intake at Follow-up,,2009-08,COMPLETED,INTERVENTIONAL,['NA']
6103,NCT01175824,Change in HbA1c From Baseline to 24 Weeks Endpoint (Intention-to-Treat Population),The Number of Participants With Severe Hypoglycemic Episodes,,2011-04,COMPLETED,INTERVENTIONAL,['PHASE4']
6104,NCT03243253,"association between densities of fast food (FFR) and full service restaurants (FSR) with mortality from CVD and stroke, and the prevalence of type 2 diabetes (T2D).",,,2011-01-01,COMPLETED,OBSERVATIONAL,['NA']
6105,NCT00756613,The Long Term Effect of Intensive Glycemic Control in Type 2 Diabetes on Major Cardiovascular Complication.,Patients Reported Health Related Quality of Life,,2008-02-01,COMPLETED,OBSERVATIONAL,['NA']
6106,NCT04426708,The single dose pharmacokinetics of HMS5552 will be described by estimating parameters of AUCinf;,The single dose pharmacokinetics of HMS5552 will be described by estimating parameters of fu;,,2019-02-18,COMPLETED,INTERVENTIONAL,['PHASE1']
6107,NCT06147466,Time in target range,Perceived social support,,2023-03-01,RECRUITING,OBSERVATIONAL,['NA']
6108,NCT02963753,To determine serum glucose levels in both groups during 75 gram oral glucose tolerance test screening,,,2016-01,COMPLETED,OBSERVATIONAL,['NA']
6109,NCT02639637,Forearm Blood Flow,Heart Rate,,2015-12,COMPLETED,INTERVENTIONAL,['PHASE4']
6110,NCT01698775,Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event (Phase A: 24-week Placebo Controlled Period + Phase B: 30-week Active Controlled Period),Change From Baseline in eGFR at Week 54,,2012-10-02,COMPLETED,INTERVENTIONAL,['PHASE3']
6111,NCT04237883,Aggregate Focus Quality Measure order rates at the first visit,Number of Open Tests,,2019-11-01,COMPLETED,INTERVENTIONAL,['NA']
6112,NCT00095654,death,Renal Events,,2001-07,COMPLETED,INTERVENTIONAL,['PHASE3']
6113,NCT02475499,Incident pancreatic cancer,,,2014-03,COMPLETED,OBSERVATIONAL,['NA']
6114,NCT00729196,Percent change in weight,Change in HbA1c,,2005-07,COMPLETED,INTERVENTIONAL,['NA']
6115,NCT00941447,Blood Glucose,Quality of Life,,2009-04,COMPLETED,INTERVENTIONAL,['NA']
6116,NCT06241638,HbA1c in the two groups,,,2022-07-01,COMPLETED,INTERVENTIONAL,['NA']
6117,NCT01684748,Insulin Sensitivity by Intravenous Glucose Tolerance Testing (Change Over Time),,Collagen Gene Expression in Skeletal Muscle (Change Over Time),2009-02,COMPLETED,INTERVENTIONAL,['PHASE4']
6118,NCT04319003,Change in sugary beverage (coffee/tea) consumption using beverage frequency questionnaires,,,2018-08-03,COMPLETED,INTERVENTIONAL,['NA']
6119,NCT05830318,System Usability Scale,Cardiovascular events,,2023-08-23,RECRUITING,OBSERVATIONAL,['NA']
6120,NCT00147251,Changing LDL Cholesterol,Changing Blood Pressure,,2003-05,COMPLETED,INTERVENTIONAL,['PHASE4']
6121,NCT00007800,,,,2000-05,COMPLETED,INTERVENTIONAL,['PHASE2']
6122,NCT03738865,Severe Hypoglycemia Rescue,Hypoglycemia Resolution,,2018-09-27,COMPLETED,INTERVENTIONAL,['PHASE3']
6123,NCT02280174,"Measurement of the Area Under the Curve of Plasma apoB-48 Levels During Postprandial Period (Time 0,2,4,6,8 Hours)",,,2014-09,UNKNOWN,INTERVENTIONAL,['PHASE4']
6124,NCT04861324,Maternal Lipids,Maternal serum carotenoids,,2021-04-28,COMPLETED,INTERVENTIONAL,['NA']
6125,NCT02970838,Change in HbA1c value,Change in diet history,,2012-11,COMPLETED,INTERVENTIONAL,['NA']
6126,NCT02989688,Blood glucose response curve,Flavour acceptability scale for ONS product,,2015-01,COMPLETED,INTERVENTIONAL,['NA']
6127,NCT02255682,Difference in myalgia,Difference in mitochondrial function,,2015-01,COMPLETED,INTERVENTIONAL,['PHASE4']
6128,NCT00717483,,,,2008-07,COMPLETED,OBSERVATIONAL,['NA']
6129,NCT00449605,Change from baseline in glycemic measure HbA1c,Relative change from baseline in HDL-C,,2007-03,TERMINATED,INTERVENTIONAL,['PHASE3']
6130,NCT05681884,Primary Objective,Mean change in CST,,2023-05-16,RECRUITING,INTERVENTIONAL,['PHASE2']
6131,NCT03823027,Tolerability measured as evaluation of Adverse Events,Performance measured as changes in body fat %,Explorative Endpoint on changes in microbiome diversity (species not defined),2019-01-28,COMPLETED,INTERVENTIONAL,['NA']
6132,NCT01542476,Change in Patient-Reported Outcomes (PRO) using World Health Organization 5 (WHO-5) item Well-being Index: Insulin Treatment Appraisal Scale (ITAS),Adverse events,,2006-08,COMPLETED,OBSERVATIONAL,['NA']
6133,NCT01865279,Area under the glucose infusion rate curve (trial part 2 only),Area under the serum insulin concentration curve,,2005-12,COMPLETED,INTERVENTIONAL,['PHASE1']
6134,NCT04529278,Weight Loss at Week 26,Therapeutic monitoring,,2021-01-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
6135,NCT01472809,Safety and tolerability,Pharmacodynamics,,2011-12,SUSPENDED,INTERVENTIONAL,['PHASE1']
6136,NCT06229795,Effect on,Effect on,,2023-11-07,RECRUITING,INTERVENTIONAL,['PHASE3']
6137,NCT02166294,Number of participants with adverse events,Time to Initial Wound Closure,,2014-06,TERMINATED,INTERVENTIONAL,['NA']
6138,NCT00829062,The aim of this project is to present evidence based practice to Missouri Medicaid to expand coverage of continuous subcutaneous insulin infusion (CSII) in pediatric patients with diabetes. - Hemoglobin A1C,Glycemic variability as shown by continuous glucose recording,,2009-01,WITHDRAWN,INTERVENTIONAL,['NA']
6139,NCT02416193,Trail Making Test Part B,Semantic Fluency Test,,2015-09-23,TERMINATED,INTERVENTIONAL,['PHASE2']
6140,NCT00846638,Drinking outcome,,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE3']
6141,NCT04799327,Change from baseline in body weight,Concentration of SHR20004 in plasma at steady state,,2021-03-29,UNKNOWN,INTERVENTIONAL,['PHASE2']
6142,NCT01580098,HbA1c,Number of Hospitalisations,,2010-02,COMPLETED,INTERVENTIONAL,['NA']
6143,NCT01782105,Weight change during pregnancy,Optimize the intervention before measuring its impact on the prevention of gestational diabetes mellitus on a larger scale.,,2011-12,COMPLETED,INTERVENTIONAL,['NA']
6144,NCT05346614,Rate of diabetes remission,Compliance,,2022-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6145,NCT01172743,,,,2009-06,TERMINATED,OBSERVATIONAL,['NA']
6146,NCT04989634,Incidence of gestational diabetes mellitus,Incidence of premature birth,,2019-07-01,UNKNOWN,INTERVENTIONAL,['NA']
6147,NCT06283277,Third trimester clavicle length measurement,Neonatal actual clavicle length,,2024-05-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
6148,NCT00473330,Percentage of Patients Who Gained ≥ 15 Letters in Their Best Corrected Visual Acuity (BCVA) Score From Baseline at Month 24,Mean Change From Month 36 in Central Foveal Thickness in the Study Eye at Month 48,,2007-06,COMPLETED,INTERVENTIONAL,['PHASE3']
6149,NCT02471794,Change in A1C using the A1C blood test,Change in low-density lipoprotein cholesterol (LDL) using LDL measurement,,2015-12,COMPLETED,INTERVENTIONAL,['NA']
6150,NCT05738577,glycemic control according to apelin level,Detection of the relation of apelin and lipid profile in diabetic patients,,2023-02-25,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
6151,NCT00131144,time to progression of diabetic retinopathy,time to moderate vision loss,,1999-11,COMPLETED,INTERVENTIONAL,['PHASE3']
6152,NCT02934113,Change in Weight,,,2016-09,COMPLETED,INTERVENTIONAL,['NA']
6153,NCT02042664,intracardiac triglyceride,,,2011-01,COMPLETED,INTERVENTIONAL,['PHASE3']
6154,NCT03202979,Change of item 5 score in Brief Pain Inventory Short Form (BPI-SF) scale,Frequency of treatment-related adverse events,,2017-05-16,COMPLETED,INTERVENTIONAL,['PHASE2']
6155,NCT02196350,percentage of participants that reach normoglycemia,change in indices for hepatic insulin resistance,,2014-09,COMPLETED,INTERVENTIONAL,['NA']
6156,NCT06059833,magnesium perecentage,,,2023-09,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
6157,NCT02397421,Change in LV end systolic volume (absolute value and indexed for BSA) or LV end diastolic volume (absolute value and indexed for BSA),"The safety of dapagliflozin use in diabetic, heart failure patients with regard to worsening HF, hospitalization and death will be evaluated",,2015-03,COMPLETED,INTERVENTIONAL,['PHASE4']
6158,NCT04222231,Change in insulin sensitivity by blood-flow restriction or classical resistance training,Changes in skeletal muscle mass by blood-flow restriction or classical resistance training,Changes in skeletal muscle strength by blood-flow restriction or classical resistance training,2019-10-28,RECRUITING,INTERVENTIONAL,['NA']
6159,NCT03520660,Phase I - SVR 12,Phase II: Change in Ishak fibrosis score,,2018-10-19,RECRUITING,INTERVENTIONAL,['PHASE4']
6160,NCT00136188,Change in renal endothelial function,,,2009-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
6161,NCT03936634,Arm B - Auto-antibody positive first degree family members,Arm B - Auto-antibody positive first degree family members - Framework,,2016-11-14,UNKNOWN,OBSERVATIONAL,['NA']
6162,NCT05342545,Frequency of UACR testing order for CKD in patients with T2DM who have not had such testing within the past year,Frequency of new clinical diagnosis of CKD in patients with T2DM who have not had UACR assessment within the past year,Frequency of referral to a nephrologist,2022-12-01,RECRUITING,INTERVENTIONAL,['NA']
6163,NCT03610178,NR3C1,Methylation of candidate genes,,2015-08,UNKNOWN,INTERVENTIONAL,['NA']
6164,NCT01472328,Skeletal muscle insulin sensitivity,,,2012-03,COMPLETED,INTERVENTIONAL,['NA']
6165,NCT01943214,Body constitution of type II diabetes mellitus patients,Diabetic neuropathy of type II diabetes mellitus patients,,2013-07,UNKNOWN,OBSERVATIONAL,['NA']
6166,NCT00867425,Change in weight,Health Related Quality of Life,,2009-04,COMPLETED,INTERVENTIONAL,['NA']
6167,NCT02050984,Reduction of hypertension medication prescription,Reduction of hypertension medication prescription,Adverse events,2010-01,UNKNOWN,OBSERVATIONAL,['NA']
6168,NCT02274272,Change in blood fat,Change in the DM marker,,2014-10,COMPLETED,INTERVENTIONAL,['PHASE2']
6169,NCT03405415,Assessment of glucose concentrations,,,2018-01-27,COMPLETED,INTERVENTIONAL,['NA']
6170,NCT01590758,Number of Participants With Clinical Response,Number of Participants With Treatment-emergent Adverse Events (TEAE),,2014-06,COMPLETED,INTERVENTIONAL,['PHASE3']
6171,NCT06117449,HbA1C level,,,2024-04-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
6172,NCT02154347,Change From Baseline in HbA1c,,,na,COMPLETED,INTERVENTIONAL,['PHASE4']
6173,NCT01779596,exercise induced blood flow,exercise induced Flow Mediated Dilation,,2011-05,COMPLETED,INTERVENTIONAL,['PHASE4']
6174,NCT04015388,"Evaluate performance of glucose predictive models, clinical decision support algorithms, and performance measures in simulated real-time setting.","Further development of GlyCU system functionality (simulation, training, and clinical decision support capabilities) and identification of necessary steps for integration with the OSUWMC electronic health record database.",,2014-08-19,COMPLETED,OBSERVATIONAL,['NA']
6175,NCT02226003,Percentage of Participants Who Discontinued Study Medication Due to an AE - All Participants as Treated Excluding Rescue Approach,Change From Baseline in Sitting Diastolic Blood Pressure at Week 26 - Full Analysis Set Excluding Rescue Approach,,2014-09-23,COMPLETED,INTERVENTIONAL,['PHASE3']
6176,NCT06320600,The currency analysis of diabetes classification,To establish a model for predicting diabetic neuropathy,To establish a model for hypoglycemic therapy,2023-07-01,RECRUITING,OBSERVATIONAL,['NA']
6177,NCT00225225,modification of the diet prevents weight gain.,develop specific dietary recommendations,,2002-10,TERMINATED,INTERVENTIONAL,['NA']
6178,NCT03942471,Change in HbA1c Measurements after Mindfulness Training,,,2015-10-14,COMPLETED,INTERVENTIONAL,['NA']
6179,NCT01663220,,,,2012-05,COMPLETED,OBSERVATIONAL,['NA']
6180,NCT04058626,Diagnostic Accuracy,,,2019-03-04,COMPLETED,OBSERVATIONAL,['NA']
6181,NCT00675740,between-group difference in flow-mediated dilation of the brachial artery,relative effects of treatment on parameters of - glucose metabolism - inflammatory plasma markers - markers of endothelial function - cellular markers in muscle and fat biopsies,,2004-01,COMPLETED,INTERVENTIONAL,['PHASE4']
6182,NCT05388643,Gestational Diabetes Mellitus,Patient Satisfaction with Diabetes Screening Method,,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6183,NCT03334643,Postprandial glycemic response,,,2018-06-04,COMPLETED,INTERVENTIONAL,['NA']
6184,NCT05252728,Differences of β diversity of gut microbiota between diabetic groups and healthy control.,,,2019-02-01,COMPLETED,OBSERVATIONAL,['NA']
6185,NCT05176132,Prevalence of unrecognized obesity-related diseases,SDOI attitude to physical activity questionnaire,,2020-09-01,RECRUITING,OBSERVATIONAL,['NA']
6186,NCT06327711,Fasted Insulin,Conicity Index,Urine biomarkers - inflammation,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6187,NCT01068197,Change in BMI z-score between the two dietary groups,"Differences in subjective, hormonal, and metabolic between the two dietary arms",,2003-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
6188,NCT02759107,Number of Participants With One or More Serious Adverse Event(s) (SAEs),Pharmacodynamics (PD): Ratio of AUC of Glucose on Day 23 to Baseline (Part C),,2016-05-11,COMPLETED,INTERVENTIONAL,['PHASE1']
6189,NCT01129557,Cumulative Incidence of Aldosterone Breakthrough in Subjects Who Completed the 9-month Study Protocol.,Pre- and Post-treatment Serum Aldosterone in Subjects With and Without Aldosterone Breakthrough.,,2009-09,TERMINATED,INTERVENTIONAL,['PHASE4']
6190,NCT02036892,Hemoglobin A1c,Center for Epidemiological Studies Depression Scale,,2012-02,UNKNOWN,INTERVENTIONAL,['PHASE3']
6191,NCT03168633,HbA1C values of patients after 6 months,percentage of messages opened and read,,2015-07,COMPLETED,INTERVENTIONAL,['NA']
6192,NCT00850096,Continuous Glucose Monitoring (CGM),Overall Glycemic Control,,2009-01,COMPLETED,INTERVENTIONAL,['PHASE2']
6193,NCT01586442,PIIINP,,,2012-03,COMPLETED,INTERVENTIONAL,['PHASE3']
6194,NCT01068665,Change in Glycosylated Haemoglobin (HbA1c),Change in Fasting Plasma Glucose (FPG),,2010-03,COMPLETED,INTERVENTIONAL,['PHASE3']
6195,NCT04905680,"Behaviour, self-efficacy and attitudes",Systolic and Diastolic Blood pressure,,2021-05-04,UNKNOWN,INTERVENTIONAL,['NA']
6196,NCT00996658,Change From Baseline in HbA1c (Glycosylated Hemoglobin) After 24 Weeks,Change From Baseline in Fasting Plasma Glucose (FPG) After 18 Weeks,,2009-10,COMPLETED,INTERVENTIONAL,['PHASE3']
6197,NCT06245252,fasting blood glucose levels,score of fatigue severity scale,,2024-02-10,RECRUITING,INTERVENTIONAL,['NA']
6198,NCT02517242,Glycated Hemoglobin,Presence of asyntomatic hypoglycemias,,2015-05,UNKNOWN,INTERVENTIONAL,['PHASE4']
6199,NCT02191111,Change in Service Counts From Baseline to End of Intervention Period,,,2014-07,COMPLETED,INTERVENTIONAL,['NA']
6200,NCT01137695,Glucose control,adverse effects,,2010-05,UNKNOWN,INTERVENTIONAL,['PHASE3']
6201,NCT02014740,Echocardiographic Epicardial Fat Thickness,,,2014-03,COMPLETED,INTERVENTIONAL,['PHASE4']
6202,NCT00110448,"Aortic and peripheral vascular events, which needs internal medicine and/or surgical medical treatment",,,2002-12,COMPLETED,INTERVENTIONAL,['PHASE4']
6203,NCT03059719,Incidence of treatment-emergent AE (safety and tolerability),PB-119 blood concentration,,2015-04-08,COMPLETED,INTERVENTIONAL,['PHASE1']
6204,NCT04708145,DRSS Level Achievement in the VOYAGE study,Incidence of Adverse Events,,2021-06-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4']
6205,NCT05322200,"Compare the regression of vulnerable coronary plaque (necrotic core) assessed using histologically validated ""Plaque Maps"" derived from CT Coronary angiography in patients with raised HbA1c admitted with ACS and treated with oral Semaglutide or placebo.",Evaluate the effect of oral Semaglutide on levels of biomarkers of oxidative stress.,,2022-08-31,RECRUITING,INTERVENTIONAL,['PHASE4']
6206,NCT05078697,microbiota,,,2021-04-01,UNKNOWN,OBSERVATIONAL,['NA']
6207,NCT00172406,,,,na,COMPLETED,OBSERVATIONAL,['NA']
6208,NCT04790526,HBA1c,Joint error position test,,2021-07-12,COMPLETED,INTERVENTIONAL,['NA']
6209,NCT06222086,Physical activity level assessment with multi-sensor activity tracking,Upper extremity functional exercise capacity (percentage of the expected value (%)),,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6210,NCT04145804,The achievable percentage of time in range (TIR) 70 - 180 mg/dL for the whole study population after 3 months.,Percentage of time spend in Auto Mode,,2020-01-01,UNKNOWN,INTERVENTIONAL,['NA']
6211,NCT02217306,Contrast Sensitivity,,,2014-01,COMPLETED,OBSERVATIONAL,['NA']
6212,NCT00000159,,,,1983-08,COMPLETED,INTERVENTIONAL,['PHASE3']
6213,NCT05207020,Collect glucose values (after a test meal),,,2021-12-01,COMPLETED,INTERVENTIONAL,['NA']
6214,NCT03369145,Leukocyte cell-derived chemotaxin 2 (LECT2),Body fat percentage,,2017-12-11,COMPLETED,INTERVENTIONAL,['NA']
6215,NCT05134662,Changes from baseline in fasting serum glucose and insulin as measured by Homeostasis Model Assessment for Insulin Resistance 2 (HOMA-IR2),Change from baseline in hemoglobin A1c (HbA1c),Change from baseline metformin concentrations,2022-02-01,COMPLETED,INTERVENTIONAL,['PHASE1']
6216,NCT00787670,To determine whether surgically induced weight loss decreases the risk of CVD in morbidly obese subjects with Type 2 Diabetes Mellitus (T2DM),To elucidate the mechanisms by which surgically induced weight loss reduces over time the risk of CVD in morbidly obese subjects with T2DM.,,2008-11,COMPLETED,INTERVENTIONAL,['NA']
6217,NCT01279928,,,,2010-03,COMPLETED,OBSERVATIONAL,['NA']
6218,NCT04737499,Change of Concentration of HbA1c,Change of Score of Quality of life,,2016-07-05,COMPLETED,INTERVENTIONAL,['NA']
6219,NCT01471509,Change in blood glucose concentration,Change in serum insulin concentration,,1982-08,SUSPENDED,INTERVENTIONAL,['NA']
6220,NCT01966393,Percentage of time of glucose levels (as measured by continuous glucose sensor) spent in the hypoglycemic range.,Number of patients with at least one hypoglycemic event with or without symptoms below 3.0 mmol/L based on glucose sensor reading,,2014-04,COMPLETED,INTERVENTIONAL,['PHASE2']
6221,NCT02552355,Glucose Tolerance,Glucose Profiles From Real-Time Continuous Glucose Monitoring,,2015-08,COMPLETED,INTERVENTIONAL,['PHASE2']
6222,NCT01223339,Urinary Glucose Excretion over 24 hours for the Multiple Dose Cohort,,,2010-10,COMPLETED,INTERVENTIONAL,['PHASE1']
6223,NCT05453357,Overall Feasibility of Remote Glucose Monitoring,Changes in self-efficacy,,2024-04-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
6224,NCT01527539,HbA1c,Occurence of hypoglycaemic episodes,,2001-11-23,COMPLETED,INTERVENTIONAL,['PHASE3']
6225,NCT06144788,Changes in HbA1c at the 12 week from the baseline,,,2023-11,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
6226,NCT03631186,Change in HbA1c,Patient completed the study under treatment with semaglutide (yes/no),,2018-09-12,COMPLETED,OBSERVATIONAL,['NA']
6227,NCT00810823,"What is the factor ""X"" that cause the remission of type 2 diabetes after gastric bypass",,,2009-01,COMPLETED,OBSERVATIONAL,['NA']
6228,NCT04128150,Evolution of retina diseases,,,2018-01-17,UNKNOWN,OBSERVATIONAL,['NA']
6229,NCT05849753,Percent sensor glucose time-in-range,Technology Attitudes,,2023-07-26,RECRUITING,OBSERVATIONAL,['NA']
6230,NCT01023243,Completion of foot exam,Patient report in validation of Natural Language Processing,,2010-01,COMPLETED,INTERVENTIONAL,['NA']
6231,NCT03398356,Serum Levels of DMA at Different Time Points,,,2017-10-20,COMPLETED,INTERVENTIONAL,['PHASE4']
6232,NCT03704103,Number of participants meeting HgbA1c <7%,Hypoglycemia,iSage Product Satisfaction Survey (iSage group only),2018-08-28,COMPLETED,INTERVENTIONAL,['NA']
6233,NCT00473525,Evaluation of Dose Response in HbA1c (%),Incidence of Adverse Events,,2007-07,COMPLETED,INTERVENTIONAL,['PHASE2']
6234,NCT06136793,Participant Cardiometabolic Disease Markers: Waist circumference,Household Supports for cardiometabolic disease reduction measures: Family Collective-Efficacy,,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6235,NCT05836194,The International Clinical Diabetic Retinopathy Disease Severity Scale within the 2-fields fundus photography and Ultra-Wide field scanning laser ophthalmoscopy (Optomap) imaging and statistical comparison,Number of predominantly peripheral lession(PPL) with Optomap imaging,,2023-02-01,RECRUITING,OBSERVATIONAL,['NA']
6236,NCT02475070,Glucagon Response to Meal,Incretin Hormones,,2016-01,COMPLETED,INTERVENTIONAL,['PHASE4']
6237,NCT03139864,Comparison of substrate utilization between infants with type 1 diabetes and infants without type 1 diabetes during exercise,Comparison between infants during 10 days before and 4 days after exercise of blood glucose modification,,2017-04-04,UNKNOWN,INTERVENTIONAL,['NA']
6238,NCT04216875,Change in score result before and after the introduction of the diabetes score criteria for treatment of diabetes patients in the primary care setting,Evaluation of practice tool used for the documentation and evaluation of the diabetes score,,2018-01-01,COMPLETED,OBSERVATIONAL,['NA']
6239,NCT01816906,Postural Sway During Shod Standing,Ankle Strength Right 2,Vibration Perception Threshold,2012-04,COMPLETED,INTERVENTIONAL,['NA']
6240,NCT04092959,Change from Baseline Systolic Blood Pressure at 3 months,Time and Frequency of Adverse Reactions and Serious Adverse Events through the study completion,,2019-09-20,UNKNOWN,INTERVENTIONAL,['NA']
6241,NCT00817973,Triglyceride levels,Incretin levels,,na,COMPLETED,INTERVENTIONAL,['NA']
6242,NCT01300338,Mean Change in Diastolic Blood Pressure,,,2011-03,COMPLETED,INTERVENTIONAL,['NA']
6243,NCT03500016,Cardiorespiratory fittness/maximal oxygen consumption,Plasma and tisue metabolomics,Lipid profile,2018-02-26,COMPLETED,INTERVENTIONAL,['NA']
6244,NCT04561609,Change in Monofilament test,Change in skin temperature,,2020-05-02,UNKNOWN,INTERVENTIONAL,['NA']
6245,NCT01607684,Frequency of gastric peristalsis,Influence of age on parameters of diabetic polyneuropathy measurable by magnetic marker imaging,,2012-01,COMPLETED,INTERVENTIONAL,['PHASE2']
6246,NCT01226966,Percentage of patients still in liraglutide treatment and having a HbA1c (glycosylated haemoglobin) value below 7.0%,Change in Body Weight at Month 24,,2010-09,COMPLETED,OBSERVATIONAL,['NA']
6247,NCT01840085,The proportion of all subjects reporting Adverse Events and Serious Adverse Events related to study treatment,,Proportion of all subjects treated and terminating prematurely due to adverse events related to study treatment.,2015-12,TERMINATED,INTERVENTIONAL,['PHASE3']
6248,NCT04710940,Completion of diabetes self-management training (Aim 3),Hemoglobin A1C (HbA1C) (Aim 3),Predictors of guideline-concordant diabetes care (Clinical utilization) (Aim 1),2021-01-13,COMPLETED,INTERVENTIONAL,['NA']
6249,NCT03455868,"Change in areal bone mineral density at lumbar spine, hip and radius",Change in cutaneous Advanced glycation end products (AGEs),Prevalence and incidence of non-vertebral fractures,2018-03-15,RECRUITING,OBSERVATIONAL,['NA']
6250,NCT01259206,Increased Calcaneal Spur Incidence in Patients With Obesity and Type 2 Diabetes Mellitus,,,2009-02,COMPLETED,OBSERVATIONAL,['NA']
6251,NCT00742547,HbA1c,incidence of diabetes-related complications,,2008-10,COMPLETED,INTERVENTIONAL,['NA']
6252,NCT05789251,standardized breakfast test resuslt compare to oral induced hyperglycemia test,,,2023-06-19,RECRUITING,INTERVENTIONAL,['NA']
6253,NCT03961659,Change of olfactory brain activation by fMRI,Olfactory threshold test,,2019-05,UNKNOWN,INTERVENTIONAL,['NA']
6254,NCT01941199,"Cmax,ss of DA-1229 and metformin",,,2013-07,COMPLETED,INTERVENTIONAL,['PHASE1']
6255,NCT01104142,,,,2009-04,COMPLETED,OBSERVATIONAL,['NA']
6256,NCT01693133,Percentage of subjects with complete closure of the study ulcer,Cost effectiveness of treatment,Safety,2012-07,COMPLETED,INTERVENTIONAL,['NA']
6257,NCT03438162,Medication adherence assessment method,Adverse events questionnaire,,2018-04-01,COMPLETED,INTERVENTIONAL,['NA']
6258,NCT01375322,To compare the change from baseline in blood pressures (DBP/SBP) to 16-week regimen between Amtrel® and Co-Diovan®,To compare the response rate (defined as SBP < 130 mmHg and DBP < 80 mmHg) at the end of study,,2007-06,COMPLETED,INTERVENTIONAL,['PHASE4']
6259,NCT05296044,Changes in HbA1c,,,2022-04-05,UNKNOWN,INTERVENTIONAL,['PHASE3']
6260,NCT01762657,Insulin Requirements Among Patients Treated with Oral Cyclosporine and Oral Lansoprazole,Glucagon C-peptide (under the curve) and Hemoglobin A1C levels among patients with existing type 1 diabetes treated with Cyclosporine and Lansoprazole,,2014-09,WITHDRAWN,INTERVENTIONAL,['PHASE3']
6261,NCT04371653,Number of Participants With an Increase in Flora Diversity in Fecal Samples,Monitor subjects' health information,,2023-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
6262,NCT05421715,Evolution of glycemic control hemoglobin (HbA1c) between inclusion and 6 months,Evolution of knowledge about diabetes and glycemic targets between inclusion and T6 months,,2023-04-11,RECRUITING,INTERVENTIONAL,['NA']
6263,NCT05724888,Retention for follow-up measurements,BREQ2 (Behavioral Regulation in Exercise Questionnaire-2) change,,2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6264,NCT01263483,Change From Baseline in Glycosylated Hemoglobin (Week 12).,Change From Baseline in Glucagon Measured by Meal Tolerance Testing (AUC (0-2)).,,2007-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
6265,NCT05686655,sleep problems as frequent awakening during the night,,,2023-02-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
6266,NCT00256607,1) Determine the cross-sectional relationship between baseline levels of novel CVRF and the,,,2007-06,COMPLETED,OBSERVATIONAL,['NA']
6267,NCT04684030,The change of glycated hemoglobin (HbA1c) level,The number of participants with improved clinical glycometabolic parameters,,2020-08-28,UNKNOWN,INTERVENTIONAL,['NA']
6268,NCT02753400,"Change in Aqueous Humor Concentration of the Following Biomarkers:IL-6, IL-8, IP-10, PDGF-AA, TGFβ-1, MCP-1, IL-1β, and VEGF, to be Reported in pg/mL Values",,,2016-05,COMPLETED,INTERVENTIONAL,['PHASE2']
6269,NCT05591391,Time in range,Treatment satisfaction questionnaire,,2022-09-28,RECRUITING,INTERVENTIONAL,['NA']
6270,NCT04390295,Adjusted Mean Change in HbA1c Levels,The number of volunteers with adverse events as a measurement of safety,,2017-11-02,UNKNOWN,INTERVENTIONAL,['PHASE3']
6271,NCT05073978,maternal outcomes,,,2020-12-01,COMPLETED,OBSERVATIONAL,['NA']
6272,NCT01086189,Postprandial glucose and insulin,Postprandial satiety,,2009-12,COMPLETED,OBSERVATIONAL,['NA']
6273,NCT01023581,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26,Change From Baseline in Fasting Plasma Glucose Over Time,,2009-11,COMPLETED,INTERVENTIONAL,['PHASE3']
6274,NCT02815943,lipid metabolism,physical activity,,2015-08,COMPLETED,INTERVENTIONAL,['NA']
6275,NCT04058639,wound healing time in weeks,,,2019-10-01,RECRUITING,INTERVENTIONAL,['NA']
6276,NCT00240175,Quantitative measures of plantar pressure,,,2005-08,COMPLETED,INTERVENTIONAL,['PHASE1']
6277,NCT03010319,"Percentage of Subjects With Complete Wound Closure, as Assessed by the Investigator, at or Before Week 12 of the Treatment Phase","Rate of Wound Closure, as Assessed by Computerized Planimetry.",,2017-01,COMPLETED,INTERVENTIONAL,['NA']
6278,NCT01147731,The pharmacokinetic parameters (AUC and Cmax) of R and S-warfarin isomers with and without albiglutide,The effect of albiglutide on the pharmacodynamics of warfarin as determined by the International Normalisation Ratio (INR).,,2010-06-04,COMPLETED,INTERVENTIONAL,['PHASE1']
6279,NCT02434094,Human factors feedback,,,2015-04,COMPLETED,OBSERVATIONAL,['NA']
6280,NCT05348551,Assessment of the proportion of pediatric patients with access to remote monitoring,Evaluation of patients' (and parents') perception of telemonitoring using a scale,,2022-05-20,UNKNOWN,OBSERVATIONAL,['NA']
6281,NCT01754467,Acceptability of NEAT!,Changes in Total Sedentary Time,,2013-02,COMPLETED,INTERVENTIONAL,['NA']
6282,NCT02186353,Change from week 0 in peripheral insulin sensitivity (assessed by frequently-sampled oral glucose tolerance test) at week 12,Change from week 0 in physical activity (assessed by accelerometry) at week 12,,2014-09,WITHDRAWN,INTERVENTIONAL,['NA']
6283,NCT01416324,Adverse events relative to placebo,Measurement of the apparent volume of distribution (V/F) of the study drug,,2011-06-15,COMPLETED,INTERVENTIONAL,['PHASE1']
6284,NCT01070433,The incidence of complete healing of the target ulcer.,Absolute and percentage change in ulcer surface area from baseline to endpoint.,,2012-09,COMPLETED,INTERVENTIONAL,['PHASE2']
6285,NCT04889053,The prevalence and incidence rate of CAC in T2DM,The effect of statins on the occurrence and development of CAC in patients with T2DM,,2021-06-01,RECRUITING,OBSERVATIONAL,['NA']
6286,NCT05051436,Oral glucose tolerance test,Hemoglobin A1C,Muscle biopsy,2021-12-13,RECRUITING,INTERVENTIONAL,['PHASE4']
6287,NCT00696982,"arterial stiffness, defined as change in augmentation index measured by means of a non-invasive technique using the commercially available SphygmoCor System, and the results of the 24 hour blood pressure monitoring","The secondary end results would be oxidative stress parameters, as evaluated by oxidized LDL and Isoprostanes, and markers of inflammatory status, including measurements of pro-inflammatory interleukins and performance of highly sensitive CRP test.",,2008-06,UNKNOWN,INTERVENTIONAL,['NA']
6288,NCT01192139,Metformin Cmax,"Safety: Clinically Significant Laboratory, Vital Sign, Physical Examination, and Electrocardiogram (ECG) Abnormalities",,2009-11,COMPLETED,INTERVENTIONAL,['PHASE1']
6289,NCT04120623,the effect of dapagliflozin combined with CSII on glucose profile,"the effects of dapagliflozin combined with CSII on lipid metabolism(total cholesterol in mmol/l, total glyceride in mmol/l)",,2019-10-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
6290,NCT01168297,Diabetes,,,2010-07-06,COMPLETED,OBSERVATIONAL,['NA']
6291,NCT00604383,Percentage of Participants Who Had Sustained Moderate Visual Loss (SMVL) as Defined as a Visual Acuity Loss of ≥15 Letters Measured Twice During a 6-month Period,Change From Baseline up to 36 Months in Mental and Physical Components of the Medical Outcomes Study 36-Item Short Form (SF-36) Health Status Questionnaire,,2001-03,COMPLETED,INTERVENTIONAL,['PHASE3']
6292,NCT05327595,Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,PD: Change from Baseline to Day 28 in Oral Glucose Tolerance (OGTT) 2 Hour Glucose,,2022-05-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
6293,NCT03737799,Diabetes type defined by insulin requirement at 3 years,Wellbeing (SF12 questionnaire),,2016-08-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
6294,NCT04339530,HOMA-IR (Homeostasis modelling assessment-Insulin resistance),Augmentation index,,2019-07-01,SUSPENDED,OBSERVATIONAL,['NA']
6295,NCT03960814,Age at death of cardiovascular disease,,,2019-05-21,COMPLETED,OBSERVATIONAL,['NA']
6296,NCT03901898,Number of patients who have attended screening,,,2019-07-16,COMPLETED,INTERVENTIONAL,['NA']
6297,NCT00348855,"Number of patients who reach all the therapeutic goals defined by the guidelines in the total study population, in the sub-group of patients with hypertension, but free of type-2 diabetes (T2D), and in the sub-group with hypertension and T2D.","Levels of blood pressure, LDL-Cholesterol, tobacco consumption in the whole population plus levels of HbA1c and aspirin use in the TD2 population",,2006-11,COMPLETED,INTERVENTIONAL,['PHASE4']
6298,NCT06028386,Days to complete wound closure,Changes in quality of life,,2023-08-15,RECRUITING,INTERVENTIONAL,['NA']
6299,NCT01947790,The changes of LVM,The changes of endothelial function,,2013-09,COMPLETED,INTERVENTIONAL,['PHASE4']
6300,NCT03414736,Frequency of GI AEs,Adverse events (AEs),,2018-01-19,COMPLETED,INTERVENTIONAL,['PHASE1']
6301,NCT04243746,Serum high density lipoprotein (HDL) (mmol/L),Incidence of treatment-emergent adverse events [Safety ],,2020-03-03,COMPLETED,INTERVENTIONAL,['NA']
6302,NCT02596581,gingival crevicular fluid chemerin level,clinical attachment level,,2014-07,COMPLETED,INTERVENTIONAL,['NA']
6303,NCT00950209,"To determine whether an acute elevation of plasma insulin, secondarily to plasma insulin infusion, modulates the production and the clearance rates of intestinal TRL-apoB48 in type 2 diabetic patients in the fed state",To determine if this is a direct effect of insulin or an indirect effect due to the decrease of plasma FFA or the decrease of plasma glucose.,,2008-04,COMPLETED,INTERVENTIONAL,['NA']
6304,NCT00554281,Decrease in HYPO score,Number of patients who decide to continue using the device,,2006-10,COMPLETED,INTERVENTIONAL,['PHASE3']
6305,NCT01937702,injection pain,variability of injection pain,,2014-04,COMPLETED,INTERVENTIONAL,['PHASE1']
6306,NCT03017352,Change in HbA1c,hsCRP (High-Sensitivity C-Reactive Protein),,2016-12,COMPLETED,INTERVENTIONAL,['PHASE2']
6307,NCT01613937,HbA1c,hours of physical activity per week at all time points,,2009-12,COMPLETED,INTERVENTIONAL,['NA']
6308,NCT00327418,or unstable angina or resuscitated cardiac arrest or stroke.,baseline in various lipid and lipoprotein parameters.,,1997-01,COMPLETED,INTERVENTIONAL,['PHASE4']
6309,NCT02672436,The ulcer closure rate,Adverse event incidence,,2017-03-15,COMPLETED,INTERVENTIONAL,['PHASE2']
6310,NCT01917760,pharmacokinetic characteristics of γ-aminobutyric acid (GABA),serological characteristics,Exploratory measures,2013-07,COMPLETED,OBSERVATIONAL,['NA']
6311,NCT01465152,Change of % HbA1c (glycosylated haemoglobin) in blood,Treatment compliance,,2002-03-06,COMPLETED,INTERVENTIONAL,['PHASE4']
6312,NCT02200991,Change from baseline in postprandial plasma glucose at Day 29 after a standardized breakfast,Proportion of patients with adverse events,,2014-08,COMPLETED,INTERVENTIONAL,['PHASE4']
6313,NCT04477694,Comparison of stomach ache and other effects in diabetic and non-diabetic patients in colonoscopy under sedoanalgesia,,,2020-12-27,RECRUITING,OBSERVATIONAL,['NA']
6314,NCT01113801,Change in Log Transformed (In) Serum Creatinine From Baseline to 12 Month Endpoint,Estimated Glomerular Filtration Rate (eGFR) Slope of Change From Baseline Through 12 Months,,2010-07,TERMINATED,INTERVENTIONAL,['PHASE2']
6315,NCT02374879,System Accuracy (SA) evaluation,,,2015-02-01,COMPLETED,INTERVENTIONAL,['NA']
6316,NCT00000153,,,,1984-12,COMPLETED,INTERVENTIONAL,['PHASE3']
6317,NCT05040009,Screening for diabetic foot and diabetic complication in patients attending at Diabetic center,,,2021-12-01,UNKNOWN,INTERVENTIONAL,['NA']
6318,NCT00940797,Insulin sensitivity,"Creatinine, Total Cholesterol, HDL, Triglycerides, Uric acid, AST, ALT, FA, DHL",,2008-07,COMPLETED,INTERVENTIONAL,['PHASE2']
6319,NCT04815278,Blood Pressure at Month 12,Medication Covariates,Scores on Effort-Reward Imbalance Scale,2021-09-17,RECRUITING,INTERVENTIONAL,['NA']
6320,NCT05281614,Adverse events of vedolizumab treatment as a measure of safety and tolerability,Change in T1D antibody titers,,2022-09-21,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
6321,NCT01263509,Number of Participants With Adverse Events.,Change From Baseline in Glucagon Measured by Meal Tolerance Testing (AUC (0-2)) (Final Visit).,,2007-06,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
6322,NCT03051243,Percentage of patient with mean blood glucose levels,TTD (total daily dose) of insulin,,2017-10-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
6323,NCT05216796,Decrease in cerebral gluatamate,,,2022-05-18,RECRUITING,INTERVENTIONAL,['NA']
6324,NCT03059550,Percentage of OGTT performed after an acute coronary syndrome,Profile of the patients according to their glucose abnormalities,,2013-03-01,UNKNOWN,OBSERVATIONAL,['NA']
6325,NCT01622816,ETDRS Letter Score,ETDRS Letter Score Consistency,,2012-03,COMPLETED,OBSERVATIONAL,['NA']
6326,NCT02938026,Change of weight,,,2016-05-01,COMPLETED,INTERVENTIONAL,['NA']
6327,NCT01363609,food-stimuli related neuronal activity in reward and satiety circuits as represented by BOLD fMRI signal change from baseline (%),GLP-1 analog treatment related changes in obese patients with type 2 diabetes in brain arterial blood flow.,,2011-10,COMPLETED,INTERVENTIONAL,['NA']
6328,NCT03982381,"Time to first occurence of a confirmed composite endpoint of death, myocardial infarction, stroke, heart failure, diabetic nephropathy, retinopathy or foot ulcer.",Health-related quality of life with respect to diabetes treatment satisfaction.,,2019-09-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4']
6329,NCT01686620,Change in HbA1C,Daily blood glucose measures,,2012-08,COMPLETED,INTERVENTIONAL,['PHASE2']
6330,NCT03700502,resting-state functional Magnetic Resonance Imaging,,,2016-06-05,UNKNOWN,OBSERVATIONAL,['NA']
6331,NCT01710748,Neointimal hyperplasia volume obstruction,Target vessel failure,,2012-10,UNKNOWN,INTERVENTIONAL,['PHASE3']
6332,NCT03638349,Scaled preference questionnaires on new blood glucose monitoring digital tool.,Preference questionnaires on new blood glucose monitoring digital tool based on insulin or non-insulin using subjects,,2018-07-17,COMPLETED,OBSERVATIONAL,['NA']
6333,NCT03907423,serum levels of Sortilin,,,2019-04-01,COMPLETED,INTERVENTIONAL,['NA']
6334,NCT02899572,Measurement of HbA1c according to the randomisation group,,,2015-06,UNKNOWN,INTERVENTIONAL,['NA']
6335,NCT00279305,Area Under the Stimulated C-peptide Curve Over the First 2 Hours of a 4-hour Mixed Meal Tolerance Test (MMTT) Administered at 1 Year,,,2005-08,COMPLETED,INTERVENTIONAL,['PHASE2']
6336,NCT03988413,Change of urinary routine,Proportional dose-response relationship between pharmacokinetic parameters Cmax and AUC of SYHA1402,,2019-08-05,COMPLETED,INTERVENTIONAL,['PHASE1']
6337,NCT01009528,Outcome and process measures from the danish diabetes guideline,Interview data concerning the impact of the electronic feedback system in the intervention clinics,,2007-03,COMPLETED,INTERVENTIONAL,['NA']
6338,NCT05234281,Changes in level of patient activation,Changes in level of functioning,,2021-05-01,RECRUITING,INTERVENTIONAL,['NA']
6339,NCT04468243,Point of Care HbA1c Test,,,2021-04-01,TERMINATED,INTERVENTIONAL,['NA']
6340,NCT03360981,Major adverse cardiac events (MACE),stem cells isolated in epicardial fat.,,2017-09-20,UNKNOWN,INTERVENTIONAL,['PHASE4']
6341,NCT02713997,Maximal acute C-peptide response to glucose (ACRmax),Severe Adverse Events,,2016-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4']
6342,NCT04635280,"Description of Patient satisfaction and experience at Day 90 by the ""You and your management by your home healthcare provider"" questionnaire","Evolution of patients' clinical profile : Percentage of time spent over a 4-week period in glycemic target range, in hypoglycaemia and in hyperglycaemia",,2021-05-10,COMPLETED,INTERVENTIONAL,['NA']
6343,NCT02366767,Safety of Automatic Closed Loop Insulin Delivery System in Adolescents and Adults With Type 1 Diabetes,Efficacy of Hybrid Closed-loop System in Comparison With Control,,2014-06,COMPLETED,INTERVENTIONAL,['NA']
6344,NCT02145611,Change from baseline in the central blood pressure after 12 weeks of vildagliptin x glibenclamide treatment,,,2013-07,COMPLETED,INTERVENTIONAL,['PHASE4']
6345,NCT01536028,Area under the GIR (glucose infusion rate)-curves in the first two hours post-dosing,Hypoglycaemic episodes,,2006-04,COMPLETED,INTERVENTIONAL,['PHASE1']
6346,NCT03358264,Vascular function,,,2017-01-01,UNKNOWN,INTERVENTIONAL,['NA']
6347,NCT02106585,fe(total) (fraction of systemically available drug excreted into the urine over entire collection interval),,,2014-03,COMPLETED,INTERVENTIONAL,['PHASE1']
6348,NCT04892069,Change in Glycated Haemoglobin (HbA1c),Change in the occurrence of severe hypoglycaemic events before and after initiation of treatment,,2021-05-27,COMPLETED,OBSERVATIONAL,['NA']
6349,NCT05574335,Acceptable T cell phenotype signature by the change from baseline in the CD4 Treg/Tem ratio,Insulin use (U/kg/day),,2023-04-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6350,NCT05369078,Collect and evaluate TEAEs (including clinical AEs and Lab AEs) of THR-1442 in healthy subjects during study,Select and evaluate pharmacokinetic characteristics(Cmax) of THR-1442 in healthy subjects during the study,,2021-12-01,UNKNOWN,INTERVENTIONAL,['PHASE1']
6351,NCT01906970,"Measurement accuracy, glucose control quality, safety, handling and functionality of ClampArt®",,,2013-06-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
6352,NCT04195477,Change in BMI,Change in Physical Activity,,2020-10-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
6353,NCT00948116,Development of contrast induced nephropathy (CIN) which will be defined as an increase in Cr of ≥ 44 μmol/l within 72 hours post-procedure.,,,2009-07,UNKNOWN,OBSERVATIONAL,['NA']
6354,NCT04961931,urine phosphorus concetration,,,2019-01-01,UNKNOWN,INTERVENTIONAL,['NA']
6355,NCT06149793,"Feasibility, safety, tolerability",,,2023-12-30,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
6356,NCT01611168,"Lipids (LDLc, HDLc, cholesterol, and triglyceride)",,,2012-04,COMPLETED,INTERVENTIONAL,['NA']
6357,NCT05481801,Vaccination adherence,Death,,2022-09-01,COMPLETED,OBSERVATIONAL,['NA']
6358,NCT00001346,,,,1992-11,COMPLETED,OBSERVATIONAL,['NA']
6359,NCT03071692,"Number of patients with first occurrence of nonfatal MI, nonfatal ischemic stroke, coronary revascularization, or CV death.",Nonfasting Remnant Cholesterol Endpoint,,2017-03-23,TERMINATED,INTERVENTIONAL,['PHASE3']
6360,NCT05786534,Weight will be measured before and after the trial,,,2022-12-09,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
6361,NCT04315545,fasting and postprandial insulin,fasting and postprandial stable glucose isotopes,MP,2020-02-06,RECRUITING,OBSERVATIONAL,['NA']
6362,NCT01208701,Fractional excretion of sodium,Augmentations index,,2010-05,COMPLETED,INTERVENTIONAL,['PHASE2']
6363,NCT01209416,Effects of ghrelin during basal and hyperinsulinemic conditions,,,2012-06,COMPLETED,INTERVENTIONAL,['NA']
6364,NCT04278742,Wound healing,Behaviour score assessed by questionnaire,,2018-12-03,UNKNOWN,INTERVENTIONAL,['NA']
6365,NCT01787669,Proportion of eyes that have central macular thickness <300 microns 6 months after switching,Mean change in central macular thickness (CMT) as measured by OCT.,Mean change in BCVA (best corrected visual acuity),2013-06,COMPLETED,INTERVENTIONAL,['PHASE2']
6366,NCT01731431,"Composite criterion of neonatal complications associated with gestational diabetes: macrosomia or birth weight ≥ 90th percentile for gestational age, neonatal hypoglycemia and neonatal hyperbilirubinemia","Rates of caesarean section, preterm delivery rate, neonatal mortality rate, number of neonatal and maternal trauma related to delivery, number of respiratory distress, number of prenatal visits, number of days of hospitalization",,2012-05-18,COMPLETED,INTERVENTIONAL,['PHASE3']
6367,NCT03100383,Gestational Weight Gain (GWG).,Eating behavior,,2013-11-01,COMPLETED,OBSERVATIONAL,['NA']
6368,NCT03877003,"Plasma lipids (total cholesterol, HDL cholesterol and triglycerides) in mg/dL",Analysis of microbiota diversity (expressed as concentrations of different microorganisms.,,2018-11-01,COMPLETED,INTERVENTIONAL,['NA']
6369,NCT01085682,Incidence of Type 2 Diabetes Mellitus,,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE4']
6370,NCT02400450,LDL-Cholesterol,Food Consumption Patterns,,2016-09,WITHDRAWN,INTERVENTIONAL,['NA']
6371,NCT04107207,Blood Sugar Levels,vulvovaginal health,,2019-11-11,COMPLETED,INTERVENTIONAL,['NA']
6372,NCT02629705,Insulin sensitivity assessed by hyperinsulinemic clamp: M-value,Glycemia during OGTT,"Markers of systemic inflammation including lymphocyte activation, cytokines and adipokines",2015-10,COMPLETED,INTERVENTIONAL,['NA']
6373,NCT01334151,Speed of absorption,,,2011-03,COMPLETED,INTERVENTIONAL,['PHASE1']
6374,NCT02863276,Postoperative protein balance (leucine) (umol/kg/h),Postoperative glucose metabolism: Glucose clearance (ml/kg/min),,2009-12,COMPLETED,INTERVENTIONAL,['NA']
6375,NCT03652389,reduction in the levels of HbA1c,,,2018-12-18,COMPLETED,INTERVENTIONAL,['NA']
6376,NCT04028089,Glycaemic excursion during an oral glucose tolerance test,Time of delivery,Epigenetic modification,2019-07-15,UNKNOWN,INTERVENTIONAL,['NA']
6377,NCT00057304,,,,2003-06,COMPLETED,INTERVENTIONAL,['PHASE2']
6378,NCT02072096,Percentage of Participants Achieving and Maintaining Individualized Glycated Hemoglobin A1c (HbA1c) Targets Without Clinically Significant Hypoglycemia,Change From Baseline of Estimated Glomerular Filtration Rate (eGFR),Change From Baseline in Mini-mental State Examination (MMSE) Score,2014-02,TERMINATED,INTERVENTIONAL,['PHASE4']
6379,NCT00001203,,,,1985-04-22,COMPLETED,OBSERVATIONAL,['NA']
6380,NCT05119179,Previously unidentified cis-eQTLs associated with change in gene expression due to GLP-1 challenge,Polygenic prediction model for GLP-1 therapy-associated outcomes,,2021-11-22,RECRUITING,INTERVENTIONAL,['PHASE4']
6381,NCT01447979,estimation of the failure rates of system components,percent time of active CTR,,2012-03,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
6382,NCT05873920,atrial fibrillation recurrence,,,2023-05-09,RECRUITING,OBSERVATIONAL,['NA']
6383,NCT00812539,Subject and provider satisfaction with the intervention.,Subject knowledge of diabetes and motivation,,2009-02,COMPLETED,INTERVENTIONAL,['NA']
6384,NCT01763346,Steady State Beta Cell Compensation,,Glycemia,2013-06,COMPLETED,INTERVENTIONAL,['NA']
6385,NCT00543959,Body fluid gain from baseline after 12 weeks,Fasting plasma glucose after 12 weeks,,2006-06,TERMINATED,INTERVENTIONAL,['PHASE2']
6386,NCT04501341,Decreasing total daily dose of insulin (>= 30%),HbA1c,,2016-03-14,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6387,NCT06283992,Proportion of Participants Who Login to the Portal,Proportion of participants that are re-admitted,,2024-03-31,RECRUITING,INTERVENTIONAL,['NA']
6388,NCT05600179,Changes in epivascular glia after Dexamethasone implant in patients with diabetic retinopathy and inflammatory macular edema,,,2021-01-01,COMPLETED,OBSERVATIONAL,['NA']
6389,NCT02650206,Macrophage polarization: % M2 macrophages in adipose tissue and peripheral blood according to positivity for cell surface markers (measured by flow cytometry).,Macrophage polarization: M1 to M2 ratio in adipose tissue and peripheral blood according to cell surface markers (measured by flow cytometry),,2015-01,COMPLETED,INTERVENTIONAL,['PHASE1']
6390,NCT03964987,ARNm expression,,,2018-01-01,COMPLETED,OBSERVATIONAL,['NA']
6391,NCT05478070,Maternal outcomes,,,2022-05-15,RECRUITING,INTERVENTIONAL,['NA']
6392,NCT01398995,Comparison of glucose excursion (change in blood glucose) between baseline and the end of exercise between the four conditions.,Ratio of respiratory quotient (RQ) at the beginning of exercise to RQ at the end of exercise compared between the four conditions.,,2011-05,TERMINATED,INTERVENTIONAL,['NA']
6393,NCT03794739,Altered TMEM219 expression in pancreatic islets/beta cells in diabetes.,Altered TMEM219-peripheral regulating factors in diabetes.,,2020-08-08,RECRUITING,OBSERVATIONAL,['NA']
6394,NCT03363464,All-cause mortality,"Acute kidney injury (Inpatient, any position)",,2017-10-16,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
6395,NCT01497600,Area under the glucose infusion rate curve,Adverse events,,2004-02,COMPLETED,INTERVENTIONAL,['PHASE1']
6396,NCT04789473,Polygenic Risk Score Prediction for Gestational Diabetes,Impact of Social Determinants of Health on Risk,,2021-06-24,UNKNOWN,OBSERVATIONAL,['NA']
6397,NCT01605422,"Effect of pulse consumption on satiety in acute, single bolus controlled feeding trials.",,,2011-10,UNKNOWN,OBSERVATIONAL,['NA']
6398,NCT03760991,Change in glycated hemoglobin (HbA1c),Number of participants with health care utilization,,2018-12-18,COMPLETED,INTERVENTIONAL,['PHASE4']
6399,NCT01772251,Adverse events and serious adverse events occurence,• To assess the pharmacodynamic effect of multiple doses of Oshadi Icp as measured by the area under the glucose concentration-time curve,• Evaluating the total daily injected insulin dose during administration of Oshadi Icp vs. placebo,2013-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6400,NCT03657537,Cognitive composite score (global score),Symbol Digit Modalities Test (SDMT),,2018-09-17,COMPLETED,INTERVENTIONAL,['PHASE1']
6401,NCT01431807,Adverse events,,,2011-09-01,COMPLETED,INTERVENTIONAL,['PHASE3']
6402,NCT00344903,,,,2007-09,COMPLETED,OBSERVATIONAL,['NA']
6403,NCT04747639,iAUC insulin 250,gastro-intestinal symptoms,,2015-10-28,COMPLETED,INTERVENTIONAL,['NA']
6404,NCT01776099,metabolic improvement of type 2 diabetes,,,2012-11,UNKNOWN,INTERVENTIONAL,['NA']
6405,NCT03459079,Change in intrahepatic triglycerides (IHTG) quantified by proton magnetic resonance and spectroscopy (¹H-MRS),Change in plasma biomarkers of liver fibrosis.,,2018-08-14,COMPLETED,INTERVENTIONAL,['PHASE2']
6406,NCT04822740,Glycemic variability by the coefficient of variation of blood glucose in percent,Patient satisfaction,,2022-12-07,TERMINATED,INTERVENTIONAL,['NA']
6407,NCT00910130,,,,2008-07,UNKNOWN,OBSERVATIONAL,['NA']
6408,NCT00720889,Total body insulin sensitivity,Glycerol turnover and free fatty acid concentration,,2008-07,COMPLETED,OBSERVATIONAL,['NA']
6409,NCT02660047,Left ventricular filling pressure (= early peak filling rate / peak mitral annulus longitudinal motion),Brown adipose tissue,Hypoglycaemic episodes,2015-08,COMPLETED,INTERVENTIONAL,['PHASE4']
6410,NCT01973361,Change in wound surface area,Number of wounds healed,,2013-12,COMPLETED,INTERVENTIONAL,['NA']
6411,NCT06230705,Cardiovascular Risk Factor Knowledge,,,2024-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6412,NCT00004572,,,,na,UNKNOWN,OBSERVATIONAL,['NA']
6413,NCT06005142,Fasting Glycemia,Microbiota composition by 16S rRNA gene sequencing,,2023-07-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
6414,NCT03192410,Major cardiovascular events,Cognitive function,Circulating fatty acids,2002-04,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
6415,NCT00821795,"For Transition From Inpatient to Outpatient Care, Evaluate Glycemic Control in Subjects Randomized to Receive 70/30 NPH/Regular Insulin or Aspart Analog 70/30 Mix Bid- Main Outcome Will be HbA1c During Transition Outpatient Therapy Phase.",Twice Daily Blood Glucose Monitoring Using Telehealth Transmitter,,2009-03-11,COMPLETED,INTERVENTIONAL,['PHASE4']
6416,NCT03645109,Changes in the parameters that make up the glycemic profile,"Changes in calcium, phosphorus and vitamin D3",,2020-02-28,COMPLETED,INTERVENTIONAL,['NA']
6417,NCT03683888,Epicardial fat thickness (EAT),Hemoglobin A1c (HbA1c) percentage (%),,2018-06-01,COMPLETED,INTERVENTIONAL,['NA']
6418,NCT01648153,Change from baseline in fasting plasma glucose and weighted mean glucose AUC (0-4hrs) post-Mixed Meal Test (MMT),t1/2,,2012-08,COMPLETED,INTERVENTIONAL,['PHASE2']
6419,NCT00713921,Develop and quantify methods for evaluating bladder dysfunction in diabetes and stroke. Develop pilot data of medical therapy (Toviaz) in diabetic and stroke bladder dysfunction.,,,2009-09-15,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1']
6420,NCT05926414,HbA1c (%) changes,,,2023-07,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
6421,NCT04665570,Mean change in HbA1c,Descriptive analysis of adverse events (AEs),,2020-12-21,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
6422,NCT03794336,Overall Gastrointestinal tolerability,Medication possession ratio (MPR),,2019-06-29,COMPLETED,INTERVENTIONAL,['PHASE4']
6423,NCT03544684,24 hour glycaemic profile,,,2015-03-09,COMPLETED,INTERVENTIONAL,['NA']
6424,NCT01559025,Beta cell function,Glycemic variability,,2014-03,UNKNOWN,INTERVENTIONAL,['PHASE3']
6425,NCT02050074,Change in the gut hormone glucagon-like peptide 1 (GLP-1),,,2014-01,COMPLETED,INTERVENTIONAL,['PHASE4']
6426,NCT02769481,Change From Baseline in HbA1c at Week 60,Superiority of Bexagliflozin Over Glimepiride in HbA1c Reduction at Week 60.,,2016-08-15,COMPLETED,INTERVENTIONAL,['PHASE3']
6427,NCT04550585,Low-literacy based education on diabetes knowledge,,,2017-04-01,COMPLETED,OBSERVATIONAL,['NA']
6428,NCT04627402,Macular thickness,Incidence of complications,,2020-11-12,UNKNOWN,INTERVENTIONAL,['NA']
6429,NCT01255254,Metabolic control,Inflammation,,2010-08,UNKNOWN,INTERVENTIONAL,['PHASE1']
6430,NCT04916132,Prevalence,Death,,2021-08-10,RECRUITING,OBSERVATIONAL,['NA']
6431,NCT02587975,Serum concentration of C-terminal telopeptide after treatment in comparison with the baseline,,,2016-06,UNKNOWN,INTERVENTIONAL,['PHASE4']
6432,NCT02210845,Three months average blood glucose (A1c),A1c,body mass index (BMI),2018-07,UNKNOWN,INTERVENTIONAL,['NA']
6433,NCT03694470,"The proportion of patients who were new users of SGLT-2 inhibitors in 2015, 2016, 2017",Number of participants with co-morbidities,,2018-04-15,COMPLETED,OBSERVATIONAL,['NA']
6434,NCT00872326,Angiographic evaluation of angiogenesis and vasculogenesis at target limb,Ankle-Brachial pressure index,,2007-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6435,NCT00788879,Fruit and Vegetable Intake,Confirmed Awareness: Confirmation of recognition of messages,,2003-02,COMPLETED,INTERVENTIONAL,['NA']
6436,NCT01364428,Change in Glycosylated Haemoglobin (HbA1c),Rate of Nocturnal Confirmed Hypoglycaemic Episodes,,2011-06,COMPLETED,INTERVENTIONAL,['PHASE3']
6437,NCT00206258,Area under the curve for glucose,Glucagon and gastric emptying,,2002-07,COMPLETED,INTERVENTIONAL,['PHASE3']
6438,NCT01784471,Changes in total peripheral resistance as assessed by impedance cardiography (ICG) from baseline to day 30,,,2012-11,COMPLETED,INTERVENTIONAL,['NA']
6439,NCT00518882,Change in Glycosylated A1c (HbA1c) at Week 26,"Hypoglyceamic Episodes, Weeks 26-78",,2007-08,COMPLETED,INTERVENTIONAL,['PHASE3']
6440,NCT03578887,Weight Regain,,,2019-06-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
6441,NCT03668470,HbA1c level,coefficients of variation (CV),,2019-01-31,COMPLETED,INTERVENTIONAL,['PHASE2']
6442,NCT05823948,Change in glycated haemoglobin (HbA1c),,,2023-04-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
6443,NCT03874715,Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax) of Insulin Aspart Following Administration of Either SAR341402 (Switching Arm) or NovoLog (Non-switching Arm),Pharmacokinetics: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Insulin Aspart Following Administration of Either SAR341402 (Switching Arm) or NovoLog (Non-switching Arm),,2019-03-11,COMPLETED,INTERVENTIONAL,['PHASE3']
6444,NCT04103671,progression rate of severe non proliferative diabetic retinopathy,The change of quality of life,,2019-12-04,RECRUITING,INTERVENTIONAL,['NA']
6445,NCT04860336,Large for gestational age (LGA),Nutrition Substudy: large for gestational age birthweight,Nutrition Substudy: Maternal fasting free fatty acids,2021-04-01,RECRUITING,OBSERVATIONAL,['NA']
6446,NCT02845557,Area under the curve for incretin hormone,Incretin effect,,2013-02,COMPLETED,OBSERVATIONAL,['NA']
6447,NCT03767608,Comparison between groups,,,2016-01,COMPLETED,OBSERVATIONAL,['NA']
6448,NCT06100796,Response Rate,,,2023-10-01,RECRUITING,OBSERVATIONAL,['NA']
6449,NCT03162237,Blood glucose,Cytokine detection,,2013-07,COMPLETED,INTERVENTIONAL,['NA']
6450,NCT04683211,Iodine supplementation,,,2021-01-05,COMPLETED,OBSERVATIONAL,['NA']
6451,NCT04083248,Acceptability of intervention: Semi-structured Diabetes Study Acceptability Interview Guide,,,2019-09-20,TERMINATED,INTERVENTIONAL,['NA']
6452,NCT00804986,Change in Hemoglobin A1C (HbA1c) From Baseline to Week 12 Endpoint,Percent of Participants Domain Scores Indicating No Problems on European Quality of Life (EuroQol) at Baseline and Week 12 Endpoint,,2008-12,COMPLETED,INTERVENTIONAL,['PHASE2']
6453,NCT01414556,"glucagon/insulin(c-peptide) absolute, incremental and area under curve values",plasma gut hormones and nutrients,,2011-05,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
6454,NCT05094037,Number of foot ulcers,,,2023-12-04,RECRUITING,INTERVENTIONAL,['NA']
6455,NCT06288529,Development of post-contrast acute kidney injury,,,2023-07-15,COMPLETED,OBSERVATIONAL,['NA']
6456,NCT05641402,Experienced Acceptability of the text messages for people with type 2 diabetes,Rating of fidelity to intended behaviour change technique,,2022-07-14,RECRUITING,INTERVENTIONAL,['NA']
6457,NCT04070794,"AUC0-∞ of gemigliptin, LC 15-0636 and metformin",,,2019-11-01,UNKNOWN,INTERVENTIONAL,['PHASE1']
6458,NCT04439903,"Technology Expectation and Technology Acceptance Questionnaires: Perceived Ease of Use, Usefulness and Trustworthiness of the System at Baseline and Week 5 (Post-intervention)",Diabetes Distress Scale at Baseline and Week 5 (Post-intervention),Potential Correlation Between System Use and Changes in Perceived Emotional Burden at Baseline and Week 5 (Post-intervention),2020-10-12,COMPLETED,INTERVENTIONAL,['NA']
6459,NCT02445911,Number of Participants With One or More Treatment-Emergent Adverse Events,Accumulation Index (AI),,2015-06,COMPLETED,INTERVENTIONAL,['PHASE1']
6460,NCT05934409,"Change in cardiac non-esterified fatty acid (NEFA) uptake, oxidation and esterification",Change in glycerol turnover,,2023-11-01,RECRUITING,INTERVENTIONAL,['NA']
6461,NCT02027259,Change in 10-year UKPDS coronary event risk and PHQ-9 depression scores.,,,2012-01-19,COMPLETED,INTERVENTIONAL,['NA']
6462,NCT04883424,Diabetes Attitude Scale,,,2021-01-01,COMPLETED,INTERVENTIONAL,['NA']
6463,NCT06334068,Number of days at home after surgery (DAH-30).,Quality of Recovery15 (QoR-15),Change in diabetic management at 30 days,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6464,NCT00956735,Lipids and lipoproteins,Mood and perceived stress,,2009-08,COMPLETED,INTERVENTIONAL,['NA']
6465,NCT02002975,Changes From Baseline in Metabolic Syndrome Parameters (Diastolic Blood Pressure) at Final Assessment Point,"Association Between Patient Baseline Characteristics, Including Any Metabolic Syndrome-related Risk Factors, and Onset of New Cerebral and Cardiovascular Events",,2007-10-16,COMPLETED,OBSERVATIONAL,['NA']
6466,NCT05579626,Number of Participants with death,All cause mortality,,2023-03-14,RECRUITING,INTERVENTIONAL,['NA']
6467,NCT01109316,Mean of Last Five 7-point Self Monitored Blood Glucose (SMBG) Taken on Day 6 for Insulin Lispro 6D and Day 2 for Insulin Lispro 2D and Day 6 for Insulin Aspart 6D Pump Reservoir In-use,Change From Baseline to 8 Weeks Endpoint for Each Treatment in Blood Pressure,,2010-04,COMPLETED,INTERVENTIONAL,['PHASE3']
6468,NCT01372163,Number of participants with Adverse Events as a measure of safety and tolerability.,"Urinary recovery and renal clearance of PF-05190457 will be estimated via comparison of the plasma AUC and urinary excretion to provide AE0-τ, AE0-τ%, and CLR as the data permit.",,2011-07,TERMINATED,INTERVENTIONAL,['PHASE1']
6469,NCT01832441,Abolition or reduction of insulin by >50 percentage,Improvement in HbA1C levels,,2014-09,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6470,NCT01316835,,,,2010-12,UNKNOWN,OBSERVATIONAL,['NA']
6471,NCT04216654,association between microalbuminuria and infection by H. pylori in type 2 diabetic patients.,,,2019-07-01,COMPLETED,OBSERVATIONAL,['NA']
6472,NCT04387448,Percentage change in Urine Albumin-to-Creatinine Ratio (UACR),Plasma PK parameters: area under the plasma concentration-time curve (AUC),,2020-07-28,TERMINATED,INTERVENTIONAL,['PHASE2']
6473,NCT02758275,Changes of mean score adherence to treatment from baseline at 6 and 12 months,Changes of mean systolic blood pressure from baseline at 6 and 12 months,,2016-04-28,COMPLETED,INTERVENTIONAL,['NA']
6474,NCT00532506,,,,na,COMPLETED,INTERVENTIONAL,['PHASE2']
6475,NCT03159546,System Related adverse device effects,,,2017-05-13,COMPLETED,OBSERVATIONAL,['NA']
6476,NCT04515992,Change from baseline of HbA1c,,,2018-03-01,COMPLETED,INTERVENTIONAL,['NA']
6477,NCT03191201,"Change from baseline in glucose homeostasis status, assessed by a dynamic two-step hyperglycaemic clamp investigation.",Change from baseline in the Homeostasis Model Assessment (HOMA-2) index at 28 days,Change from baseline in circulating miRNAs,2017-06-21,TERMINATED,INTERVENTIONAL,['PHASE4']
6478,NCT01613105,Data collection on pre treatment concomitant diseases,Safety variables will be summarized using descriptive statistics based on adverse events collection,,2008-04,COMPLETED,OBSERVATIONAL,['NA']
6479,NCT05147961,"Development of type 2 diabetes, diagnosed by fasting or post-challenge plasma glucose concentrations meeting the American Diabetes Association criteria.",Bioinformatics and systems biology methodologies,,2022-05-25,RECRUITING,INTERVENTIONAL,['NA']
6480,NCT03159052,The number of volunteers with adverse events as a measure of safety,Adjusted Mean Change in Fasting Plasma Glucose,,2017-06,UNKNOWN,INTERVENTIONAL,['PHASE3']
6481,NCT00326222,PAM - Patient activation measure,Triglyceride,,2006-05,COMPLETED,INTERVENTIONAL,['NA']
6482,NCT04976517,readmission,,,2021-08-01,UNKNOWN,OBSERVATIONAL,['NA']
6483,NCT04926415,Change in Adiponectin Plasma Concentration induced by sham taVNS,Changes in Autonomic Function induced by sham taVNS,,2021-06-14,COMPLETED,INTERVENTIONAL,['NA']
6484,NCT01103414,Change From Baseline in Fasting Plasma Glucose (FPG) at Week 12.,Changes in LDL Particle Size Subfractions From Baseline to Week 12,,2010-09,COMPLETED,INTERVENTIONAL,['PHASE2']
6485,NCT01901861,Release of incretins hormones,,,2013-07,COMPLETED,INTERVENTIONAL,['NA']
6486,NCT03789695,Difference in annual eGFR decline (slopes) between dabigatran and warfarin patients,,,2018-11-14,UNKNOWN,INTERVENTIONAL,['PHASE4']
6487,NCT02683135,"Difference in glycemic control assessed by continuous glucose monitoring in low-carbohydrate, low-carbohydrate plus post-meal walking, and high-carbohydrate low-fat arm.",Change from baseline in flow mediated dilation of brachial artery after 4 days of intervention.,Change from baseline in body weight after a single meal and 4 days of intervention.,2015-11,COMPLETED,INTERVENTIONAL,['NA']
6488,NCT05181826,Independent performance measure of sensitivity and specificity of a multi-analyte blood test,Ascertain Sample Stability,,2019-05-21,RECRUITING,OBSERVATIONAL,['NA']
6489,NCT01448174,normalization of serum LDL cholesterol,,,2011-10,COMPLETED,INTERVENTIONAL,['PHASE4']
6490,NCT01514305,Absolute Relative Difference (%) to Reference Standard,,,2011-11,COMPLETED,OBSERVATIONAL,['NA']
6491,NCT02673138,Differences in BHB (Beta-hydroxybutyrate) Levels Following Interruption of Basal,Differences in Glucagon Levels Following the Interruption of the Basal Subcutaneous Insulin Infusion,,2016-01,COMPLETED,INTERVENTIONAL,['NA']
6492,NCT02911948,Change in Glycosylated Haemoglobin (HbA1c),Change From Baseline in Patient Reported Outcomes (PROs) of Treatment: EuroQol-5D (EQ-5D-5L) Questionnaire,,2016-09-21,COMPLETED,INTERVENTIONAL,['PHASE3']
6493,NCT00859079,time to reach a plasma glucose below 115 mg/dl,number of hypoglycaemic episodes,,2006-06,COMPLETED,INTERVENTIONAL,['PHASE4']
6494,NCT00097500,Beta-cell Function After 52 Weeks of Therapy,"M-value at Baseline, Week 52 and Week 56",,2004-09,COMPLETED,INTERVENTIONAL,['PHASE3']
6495,NCT04504305,effect of investigational product on diabetic individual suffering from diabetic neuropathy assessed by 11 point numeric rating scale.,effect of investigational product on diabetic individual suffering from diabetic neuropathy assessed by Neuropathy total symptom score - 6 .,,2020-07-23,COMPLETED,INTERVENTIONAL,['NA']
6496,NCT00130481,Low density lipoprotein,Glycated hemoglobin (HbA1c),,2005-04,COMPLETED,INTERVENTIONAL,['NA']
6497,NCT05990595,Glycosylated hemoglobin (HbA1C),Small-dense LDL-cholesterol,"Center for Epidemiologic Studies Depression Scale (CES-D), NIMH",2023-07-07,RECRUITING,INTERVENTIONAL,['NA']
6498,NCT01091896,Recurrent vitreous hemorrhage incidence after vitrectomy,Visual outcome,,2010-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
6499,NCT00723307,Difference in progression of carotid intima-media thickness (measured in millimetres) between groups treated with metformin and placebo,Difference in progression of carotid total plaque volume (measured in cubic millimetres) between groups treated with metformin and placebo,,2009-02,COMPLETED,INTERVENTIONAL,['PHASE4']
6500,NCT06130917,Numeric pain rating scale,,,2023-11-05,RECRUITING,INTERVENTIONAL,['NA']
6501,NCT05847400,predictors of CKD among T2DM patients attending Assiut University Hospitals. To classify our patients into stages according to KDIGO guidelines,the possible risk factors contributing to progessing CKD in T2DM patients.,,2024-03-01,RECRUITING,OBSERVATIONAL,['NA']
6502,NCT03519529,sex hormone-binding globulin,SD,,2015-01-01,COMPLETED,OBSERVATIONAL,['NA']
6503,NCT00842426,Body Mass Index,Patient and Physician Satisfaction,,2009-06,COMPLETED,INTERVENTIONAL,['PHASE2']
6504,NCT02587936,"All Cause Hospitalizations for Patients With a Triad of Chronic Kidney Disease, Diabetes and Hypertension",30-day All Cause Readmissions (for Those Patients Who Have an Index Hospitalization),,2016-07-18,COMPLETED,INTERVENTIONAL,['NA']
6505,NCT04385862,To assess the validity of the Dexcom G6 CGM system measurements in IV insulin therapy patients hospitalized in the intensive care unit of the CHUM compared to the blood glucose measurements made using the Accuchek Inform II glucometer,"Assess the obstacles to the integration of the use of the CGM in the intensive care unit, namely the technical problems encountered and remote data management.",,2020-07-27,WITHDRAWN,OBSERVATIONAL,['NA']
6506,NCT04094415,Change in HbA1c (measured in mmol/mol),Patient completed the study under treatment with semaglutide (yes/no),,2019-10-28,COMPLETED,OBSERVATIONAL,['NA']
6507,NCT02421055,Number of Participants With Complete Diabetes Remission at 3 Months,BMI Reduction,,2015-06,COMPLETED,OBSERVATIONAL,['NA']
6508,NCT05596812,Feasibility of the novel risk stratification screening tool,Health service outcomes - Short-form Patient Satisfaction Questionnaire (PSQ-18),,2022-08-23,RECRUITING,INTERVENTIONAL,['NA']
6509,NCT00411411,Restoration of the Insulinotropic Effect of GIP,"Examination of GLP-2, Somatostatin, Glucagon, Peptide-YY and Two Glycaemic Control Parameters (HbA1c and Fasting Plasma Glucose)",,2007-02,COMPLETED,INTERVENTIONAL,['PHASE3']
6510,NCT03519841,Generation and validation of predictive models by ISUP and MARD measures,Safety evaluation: paucity of adverse events,,2018-04-13,COMPLETED,INTERVENTIONAL,['NA']
6511,NCT00937326,Apparent Volume of Distribution After Oral Administration (Vd/F) at Day 1 and Day 28,Change From Baseline in HOMA-percentage of Beta Cell Function at Day 28,,2009-08-19,COMPLETED,INTERVENTIONAL,['PHASE2']
6512,NCT00979459,Maximum Plasma Concentration (Cmax) for MK-1006,Number of Participants Who Discontinued Study Medication Due to an Adverse Event,,2009-09,COMPLETED,INTERVENTIONAL,['PHASE1']
6513,NCT01828125,Incremental area under the curve of plasma glucose concentrations,Time for 75% of glucagon appearance,,2013-04,WITHDRAWN,INTERVENTIONAL,['PHASE2']
6514,NCT00763087,daily step count,skin breakdown,,2008-09,COMPLETED,INTERVENTIONAL,['NA']
6515,NCT01585051,24 hour mean blood pressure,HOMA,,2009-01,COMPLETED,INTERVENTIONAL,['PHASE3']
6516,NCT00737074,Final opening or closure of macular hole,Post-operation best corrected visual acuity,,2002-01,COMPLETED,OBSERVATIONAL,['NA']
6517,NCT02041286,Number of Self-Test Fingerstick Blood Glucose (BG) Results Within +/- 15 mg/dL (<100 mg/dL) and Within +/- 15% (>=100 mg/dL) of Laboratory Glucose Method,Number of Subject Responses That Strongly Agree or Agree or Are Neutral With Questionnaire Statements,,2014-01,COMPLETED,INTERVENTIONAL,['NA']
6518,NCT02311075,Change from Baseline in EET concentration during endothelial stimulation,Change from Baseline in ROS concentration during endothelial stimulation,,2014-12,COMPLETED,INTERVENTIONAL,['NA']
6519,NCT03324438,Pediatric Diabetes Quality of Life Scale - Change from baseline and every 12 weeks up to 72 weeks (18 mo),Biological Markers of T1D Complications - Change from baseline and every 24 weeks up to 72 weeks (18 mo),,2017-11-01,COMPLETED,INTERVENTIONAL,['NA']
6520,NCT04437641,Smoking prevalence,Parental smoking evolution,,2019-10-22,UNKNOWN,OBSERVATIONAL,['NA']
6521,NCT01192659,"To identify risk factors for lymphopenia, defined as an absolute lymphocyte count < 500 cells/μl, or investigator reported lymphopenia, in the SAVOR study population.",To evaluate whether risk factors for low lymphocyte counts or decreasing lymphocyte count differ between saxagliptin users and non-users.,,2010-05,COMPLETED,OBSERVATIONAL,['NA']
6522,NCT02260609,100% granulation of wound as determined by the investigator,Closure of wound defined by 100% re-epithelialization,,2014-10,COMPLETED,INTERVENTIONAL,['PHASE4']
6523,NCT02285205,changes from baseline in controlled attenuation parameters (CAP),,,2014-11,COMPLETED,INTERVENTIONAL,['PHASE4']
6524,NCT02023489,change in myocardial glycogen content,change in myocardial lipid composition,differences in hepatic energy metabolism/ATP synthesis,2013-07,UNKNOWN,INTERVENTIONAL,['NA']
6525,NCT05581225,"Changes in geometric perfusion deficits (GPD) on the superficial and deep retinal vascular layers on SS-OCTA, considering macular region and midperiphery.","Changes in mean luminous sensitivity in dB, evaluated by Microperimetry.",,2022-12-02,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
6526,NCT01043510,Area under the glucose infusion rate curve during one dosing interval at steady state,Area under the Insulin Degludec concentration-time curve during one dosing interval at steady state,,2010-01,COMPLETED,INTERVENTIONAL,['PHASE1']
6527,NCT00473811,"Our outcomes are recruitment and retention rates, as well as physiological measures (HbA1c, blood pressure, and body mass index), dietary GI scores and acceptability of the intervention",,,2005-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6528,NCT05238142,Primary Effectiveness Endpoint - Percent of time in range (TIR 70-180 mg/dL),Secondary Effectiveness Endpoint - Percent of time in range (TIR 70-180 mg/dL),,2022-02-25,RECRUITING,INTERVENTIONAL,['NA']
6529,NCT02251301,Change from baseline in glycemic control assessed by continuous glucose monitoring at end of week 12 of intervention,Change from baseline in peak oxygen uptake as a measure of aerobic fitness at end of week 12 of intervention.,Change from baseline in task switching capabilities at end of week 12 of intervention.,2015-01,COMPLETED,INTERVENTIONAL,['NA']
6530,NCT00272402,Clinical inertia,Direct Medical Costs,,2006-02,COMPLETED,INTERVENTIONAL,['NA']
6531,NCT03480022,Free Androgen Index (FAI),Diastolic Blood Pressure (BP),,2018-09-26,COMPLETED,INTERVENTIONAL,['PHASE3']
6532,NCT02464878,The Proportion of GLASSIA Versus Control CIT06 Subjects Achieving Insulin Independence After First Infusion of Single Donor Islets.,"Cardiovascular Events [Death, Cerebrovascular Accident (CVA), Myocardial Infarction (MI)] and Changes in Atherogenic Profile for GLASSIA Treated Versus Control Subjects",,2017-01,COMPLETED,INTERVENTIONAL,['PHASE2']
6533,NCT03723486,Change in HOMA-IR,Gut Hormone,,2015-11,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
6534,NCT03406377,Change in HbA1c in Subjects With Type 2 DM,Change From Baseline of Fasting Plasma Glucose (FPG).,,2018-04-02,COMPLETED,INTERVENTIONAL,['PHASE2']
6535,NCT03574909,Perinatal mortality,Sepsis,,2018-09,UNKNOWN,INTERVENTIONAL,['PHASE3']
6536,NCT04523155,Change in Glucose Metabolism,Change in Triglycerides,,2020-08-24,COMPLETED,INTERVENTIONAL,['NA']
6537,NCT00614783,Produced SCOUT DS measurement algorithm.,Intra- and inter-day Scout test reproducibility.,,2007-05,COMPLETED,OBSERVATIONAL,['NA']
6538,NCT04345107,GIP concentration changes before and after meal.,"Stable Valley concentration (ctrough, SS).",,2020-05-01,COMPLETED,INTERVENTIONAL,['PHASE1']
6539,NCT01083433,Glycemic Control,Diabetes Knowledge,,2010-05,COMPLETED,INTERVENTIONAL,['NA']
6540,NCT00972244,Adjusted Mean Change in HbA1c Levels,Proportion of Participants Achieving Glycemic Response Defined as HbA1c <7%,,2009-08,COMPLETED,INTERVENTIONAL,['PHASE2']
6541,NCT00373178,Novel cardiovascular risk factors modification,Lipid and glucose regulation,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE4']
6542,NCT01402388,"Lifestyle impact on GLP-1, HbA1c and fasting glycaemia.",,,2007-10,COMPLETED,INTERVENTIONAL,['NA']
6543,NCT06278207,Participants' comedications at baseline in a cohort of participants with CKD and T2D who initiate finerenone.,"Proportion of participants who down-titrate from 20 mg daily dose to a 10 mg dose daily at the 1, 3, 6, and 12 months mark",,2024-02-15,RECRUITING,OBSERVATIONAL,['NA']
6544,NCT04587414,Change in total mean daily step count,"Changes in the mean daily number of moderate-to-vigorous PA bouts lasting at least 1, 5 and 10 minutes.",,2019-03-06,UNKNOWN,INTERVENTIONAL,['NA']
6545,NCT05704491,SPEZ,,,2023-01-30,RECRUITING,OBSERVATIONAL,['NA']
6546,NCT05472142,Change in DSMES Referrals,Change in A1c Levels,,2023-05-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
6547,NCT03234101,All-cause mortality,,,2016-06,UNKNOWN,OBSERVATIONAL,['NA']
6548,NCT03030300,partial-remission rate,,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE4']
6549,NCT01965509,To assess HbA1C levels after treatment,To assess Fasting blood glucose levels,To assess number of participants with Adverse Events as a Measure of Safety and Tolerability,2012-05,COMPLETED,INTERVENTIONAL,['PHASE2']
6550,NCT04796428,Primary Objective,Secondary Objectives - biomarkers,Safety Objectives,2021-06-30,UNKNOWN,INTERVENTIONAL,['PHASE4']
6551,NCT00652509,"Program satisfaction, behavioral and emotional outcomes.","Blood sugar level, blood pressure, lipids, cost, comorbidities.",,2008-05-01,COMPLETED,INTERVENTIONAL,['NA']
6552,NCT01112696,Glucose Sensor Accuracy When Compared to Laboratory Standard (YSI): Proportion of Glucose Sensor Readings That Met Accuracy Criteria,Device Related Moderate or Device Related Severe Adverse Events,,2010-04,COMPLETED,INTERVENTIONAL,['NA']
6553,NCT01846312,Fluctuation in islet autoantibodies titers,Fluctuation in T-cell specificity profiling (mainly for CD8 (cluster of differentiation 8) T-cells),,2013-05,COMPLETED,OBSERVATIONAL,['NA']
6554,NCT03367377,Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,Pharmacodynamics (PD): Average Glucose from 7-Point Glucose Profiles,,2018-01-03,COMPLETED,INTERVENTIONAL,['PHASE1']
6555,NCT01837069,"Number of Partipants That Experienced Death, Myocardial Infarction, Stroke, Transient Ischemic Attack, Myocardial Necrosis, or Venous Thromboembolism",Modified Composite of Cardiovascular Events,Each Individual Endpoint of the Composite of Cardiovascular Events,2014-02,TERMINATED,INTERVENTIONAL,['PHASE4']
6556,NCT03566524,Change in Arginine production,Change in Insulin secretion,,2018-07-01,COMPLETED,INTERVENTIONAL,['NA']
6557,NCT04707469,Change From Baseline in Glycated Haemoglobin (HbA1c) (Week 52),Change From Baseline in Pulse (Week 68),,2021-01-15,COMPLETED,INTERVENTIONAL,['PHASE3']
6558,NCT04054843,Maternal plasma afamin levels In first trimester GDM prediction,,,2019-09-01,COMPLETED,OBSERVATIONAL,['NA']
6559,NCT01173315,Evidence of clinically neuropathy confirmed by nerve conduction velocities,nephropathy indices were determined by 3 times urine microalbumin concentration using Enzyme Immuno Assay commercial kit,,2007-06,COMPLETED,INTERVENTIONAL,['PHASE2']
6560,NCT06229847,"mindful eating, its subgroups and diabetes control in patients with type 2 diabetes","mindful eating, its subgroups and the presence of obesity in patients with type 2 diabetes",,2019-07-01,COMPLETED,OBSERVATIONAL,['NA']
6561,NCT05570877,Time to complete healing,Safety of use,,2022-01-11,RECRUITING,INTERVENTIONAL,['NA']
6562,NCT00766298,"Effects of physical activity and weight loss, alone or in combination, on intramyocellular lipid, intermuscular adipose tissue and abdominal AT, oxidative capacity and insulin resistance.",Assess the mechanisms by which these interventions may prevent the development of diabetes,,2004-06,COMPLETED,INTERVENTIONAL,['NA']
6563,NCT05975827,2-week reduction rate of wound area,2-week wound healing rate,,2023-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6564,NCT05422235,Changes passive ankle stiffness compared with baseline and last measurement and Follow-up,Changes vibration test compared with baseline and last measurement and Follow-up,,2022-11-12,RECRUITING,INTERVENTIONAL,['NA']
6565,NCT04021199,Genetic diagnosis of atypical diabetes: More comprehensive genetic tests,,,2018-10-22,COMPLETED,INTERVENTIONAL,['NA']
6566,NCT05660538,Change from Baseline in the Weekly Average of Daily Pain Intensity on a Numeric Pain Rating Scale (NPRS),Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs),,2022-12-20,COMPLETED,INTERVENTIONAL,['PHASE2']
6567,NCT00122421,Compliance with process measures at 30 days after the index primary care visit,Percentage of pharmacist recommendations accepted by primary care providers within 30 days after index visit,,2003-06,COMPLETED,INTERVENTIONAL,['NA']
6568,NCT03370874,Proportions of subjects who achieved complete wound closure,Proportions of subjects who achieved complete wound closure at every visit by the classification of ulcer locations,,2018-06-27,COMPLETED,INTERVENTIONAL,['PHASE3']
6569,NCT02881060,Increase in plasma glucose,Difference in glucose sensor data between the study period with and without alcohol - Number of hypoglycaemia episodes (glucose sensor value < 4.0 mmol/l),,2016-08,COMPLETED,INTERVENTIONAL,['PHASE4']
6570,NCT03087032,"change in HbA1c level after 24 weeks,with a noninferiority margin of 0.3%",changes in serum lipid profile,,2019-01-10,UNKNOWN,INTERVENTIONAL,['PHASE4']
6571,NCT02035566,Re-hospitalization,Compliance with recommended (by discharging physician/primary health professional) drug therapy use for heart failure,,2011-02,COMPLETED,INTERVENTIONAL,['NA']
6572,NCT00408824,,,,2006-09,UNKNOWN,OBSERVATIONAL,['NA']
6573,NCT00395512,Change From Baseline to Week 26 in Glycosylated Hemoglobin (HbA1c),Change From Baseline in Mean HDL Particle Size,,2006-11,COMPLETED,INTERVENTIONAL,['PHASE3']
6574,NCT00648284,,,,2004-03,COMPLETED,OBSERVATIONAL,['NA']
6575,NCT02719756,Dynamics (delta from the baseline) of blood glucose variability - integral index of glycemia (LBGI-HBGI) after 3 months of therapy,Percentage of diabetes mellitus patients achieved individual target HbA1c,,2016-04,UNKNOWN,INTERVENTIONAL,['PHASE4']
6576,NCT04979312,Prevention of gestational diabetes mellitus and preeclampsia,Examine role of sleep as a potential mechanism in changing blood pressure in pregnancy,,2024-07,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
6577,NCT01516255,Maximum time-matched mean difference between the baseline subtracted QTci intervals,Serial electrocardiography,,2006-07,COMPLETED,INTERVENTIONAL,['PHASE1']
6578,NCT02016911,Area under the semaglutide plasma concentration curve,Maximum observed SNAC plasma concentration,,2013-12-12,COMPLETED,INTERVENTIONAL,['PHASE1']
6579,NCT01898286,Hypoglycemic Events,Change From Baseline in Glucagon-stimulated C-peptide AUC at Early Termination Visit,Glycemic Control (Change From Baseline in % HbA1c),2013-10,TERMINATED,INTERVENTIONAL,['PHASE3']
6580,NCT00488527,Number of severe hypoglycemia,- Change in body weight initial visit vs. final visit,,2007-04,COMPLETED,INTERVENTIONAL,['PHASE4']
6581,NCT02589873,Body weight lost,Stress and well-being,,2015-09,COMPLETED,INTERVENTIONAL,['NA']
6582,NCT04756102,diagnosis of gestational diabetes,,,2018-01-30,COMPLETED,OBSERVATIONAL,['NA']
6583,NCT03708029,Complete Wound Closure,Percent(%) Healed,,2018-11-13,UNKNOWN,INTERVENTIONAL,['NA']
6584,NCT01135992,HbA1c (Glycosylated Haemoglobin),Rate of Nocturnal Confirmed Hypoglycaemic Episodes,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE3']
6585,NCT00518362,To access the efficacy of TW compared to ARB in treatment of heavy proteinuria of diabetic nephropathy,To investigate the safety and tolerability of TW vs ARB. To access whether TW can delay the progression to ESRD or creatinine-doubling in diabetic nephropathy with heavy proteinuria.,,2007-07,COMPLETED,INTERVENTIONAL,['NA']
6586,NCT01570140,Health Related Quality of Life,Clinical parameters,,2012-05,COMPLETED,OBSERVATIONAL,['NA']
6587,NCT05296447,To evaluate the long-term safety of RGX-314,Proportion of participants with any sight-threatening ocular diabetic complications,,2022-04-04,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
6588,NCT01926522,Change from Baseline of 10-metres walk test,Followup change from Baseline of the Glycated Hemoglobin (HbA1c),,2013-09,COMPLETED,INTERVENTIONAL,['NA']
6589,NCT00489229,Measuring arterial stiffness (pulse wave velocity and augmentation index),"Measuring fasting blood sugar and 2 hours post prandial sugars, fasting insulin level, HbA1c, and total cholesterol level.",,2002-10,COMPLETED,INTERVENTIONAL,['PHASE3']
6590,NCT02937441,Optic Nerve Sheath diameters will be measured from 3 mm back of globe.,,,2016-08,COMPLETED,OBSERVATIONAL,['NA']
6591,NCT01420016,Predicted Annual Rate of Change in 10-year Risk of Fatal or Nonfatal Heart Attack or Stroke,,,2012-08-20,COMPLETED,INTERVENTIONAL,['NA']
6592,NCT00005365,,,,1993-02,COMPLETED,OBSERVATIONAL,['NA']
6593,NCT06113341,Participant downloaded and actively used the app (Yes/No),Change in laboratory measured FPG,,2024-05-07,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
6594,NCT04461405,Feasibility of the intervention,Patient Health Questionnaire-9,,2020-08-01,COMPLETED,INTERVENTIONAL,['NA']
6595,NCT00710424,Number of Responders at the 30% Improvement Level at the End of Treatment,Change From Baseline in Mean Intoxication 0-10 Numerical Rating Scale Score at the End of Treatment,,2005-07,COMPLETED,INTERVENTIONAL,['PHASE3']
6596,NCT00761176,The Incidence of Wounds Reaching Complete Closure,,,2008-07,TERMINATED,INTERVENTIONAL,['NA']
6597,NCT03762096,Change in endothelial function,Effects of resveratrol on molecular signaling,,2018-03-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
6598,NCT01770054,Prevalence of metabolic syndrome,Genetic testing,determination of the prevalence of hyperinsulinemia,2013-01,COMPLETED,OBSERVATIONAL,['NA']
6599,NCT02373332,inhibition of platelet activation,,,2013-08,COMPLETED,OBSERVATIONAL,['NA']
6600,NCT01706211,"To determine the effectiveness of BRL 49653C (2 mg bd) compared to placebo when added to sulphonylurea therapy, for 24 weeks in out-patients with NIDDM.","To assess the clinical safety of BRL 49653C (2 mg bd) compared to placebo when added to sulphonylurea therapy, for 24 weeks in out-patients with NIDOM.",,1998-10,COMPLETED,INTERVENTIONAL,['PHASE3']
6601,NCT05166785,Changes in HbA1c in participants in DPP-TOAT is similar to those in In-Person DPP,Adherence to the DPP-TOAT is greater than the in-person DPP,,2022-10-05,RECRUITING,INTERVENTIONAL,['NA']
6602,NCT04350879,Risk of unplanned pregnancy,,,2020-03-12,COMPLETED,OBSERVATIONAL,['NA']
6603,NCT00872560,Weighing of reflux of insulin,Reactions at injection sites,,1998-01-20,COMPLETED,INTERVENTIONAL,['PHASE3']
6604,NCT01409330,whole body insulin sensitivity,pancreatic fat,,2011-02,COMPLETED,INTERVENTIONAL,['NA']
6605,NCT00804297,mean glucose level for the non-octreotide group is higher than the octreotide group,number of hypoglicemic events,,2005-06,COMPLETED,INTERVENTIONAL,['PHASE3']
6606,NCT01147692,The effect of albiglutide on the pharmacokinetics of simvastatin,The pertinent plasma pharmacokinetic parameters of simvastatin with and without albiglutide,,2010-05-19,COMPLETED,INTERVENTIONAL,['PHASE1']
6607,NCT03258086,Assessment of vitamin D level (ng/ml),,,2016-11-01,COMPLETED,INTERVENTIONAL,['NA']
6608,NCT01071850,Mean change from baseline in Hemoglobin A1c (HbA1c),Proportion of subjects achieving target goal of HbA1c <6.5%,,2010-03-03,COMPLETED,INTERVENTIONAL,['PHASE2']
6609,NCT00924937,"Combined apparition of hard cardiovascular events (myocardial infarction, revascularization, ischemic stroke, documented peripheral artery disease or cardiovascular death) after a median follow-up of 7 years.",Subgroup analysis,Further Studies,2009-11,COMPLETED,INTERVENTIONAL,['NA']
6610,NCT05681468,Effect of diets on LDL-cholesterol levels by comparing groups at 6 months of intervention (i.e. control low fat diet and the 2 keto groups) and changes over time within each group (i.e. baseline vs. 6 months).,Effect of diets on inflammatory markers (C-reactive protein (CRP)) by comparing groups at 6 months of intervention (i.e. control low fat diet and the 2 keto groups) and changes over time within each group (i.e. baseline vs. 6 months).,Change in fatty acid composition to confirm adherence to the diets at 6 months,2023-09-18,RECRUITING,INTERVENTIONAL,['NA']
6611,NCT00655902,Change in Insulin sensitivity (ISI composite) from 3h OGTT,Changes in Metabolomic profile in blood and urine,,2008-04,COMPLETED,INTERVENTIONAL,['NA']
6612,NCT04545411,Change in Vascular Endothelial Function,,,2021-02-22,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6613,NCT06031428,Hemoglobin A1C,"Quality of Life (Short Form Health Survey, SF-12)",,2023-12-01,RECRUITING,INTERVENTIONAL,['PHASE2']
6614,NCT00994682,"Liver Histology (Using Kleiner et al Criteria, Hepatology 2005)",Bone Mineral Density,,2008-12,COMPLETED,INTERVENTIONAL,['PHASE4']
6615,NCT01455064,Clarke Error Grid Analysis,,,2011-10,COMPLETED,OBSERVATIONAL,['NA']
6616,NCT04692688,Percent of Subjects with an improvement in Diabetic Retinopathy Severity Score (DRSS),Mean Change in Central Subfield Thickness (CST),,2021-04-08,COMPLETED,INTERVENTIONAL,['PHASE2']
6617,NCT02020629,Glucagon response to hypoglycemia,Catecholamines,HbA1c,2013-12,COMPLETED,INTERVENTIONAL,['PHASE4']
6618,NCT01433393,HbA1c,,,na,COMPLETED,INTERVENTIONAL,['PHASE3']
6619,NCT01237509,Hypoglycaemia associated EEG changes during sleep,,,2009-01,COMPLETED,OBSERVATIONAL,['NA']
6620,NCT02624830,Metabolic control,Insulin secretory response to a glucagon test,,2019-02-15,UNKNOWN,INTERVENTIONAL,['PHASE4']
6621,NCT05306028,Blood glucose control rate,HbA1C control rate,Overall survival，OS,2022-08-01,RECRUITING,INTERVENTIONAL,['NA']
6622,NCT02499185,"Number of participants diagnosed with AKI stage 2 or 3 using the updated rifle ""KDIGO"" guidelines",Number of participants who need renal replacement therapy,persistence of renal dysfunction at 30 days,2015-04-01,TERMINATED,INTERVENTIONAL,['PHASE4']
6623,NCT04963777,Change in frequency of hypoglycemia,Change in serum metabolite concentration,,2022-03-29,RECRUITING,INTERVENTIONAL,['NA']
6624,NCT04149262,1-hour glucose levels on Novorapid,Occlusion events in Novorapid,,2019-11-15,UNKNOWN,INTERVENTIONAL,['PHASE4']
6625,NCT03921216,Interstitial fluid-to-serum ratio for LDL cholesterol,,,2019-04-17,SUSPENDED,OBSERVATIONAL,['NA']
6626,NCT01075997,The primary endpoint will be improvement of glycemic control as measured by glycosylated hemoglobin (A1c).,"To compare mean blood glucose levels,the number of hypo- and hyperglycemic events,the duration of time spent in target blood glucose range,the perceived level of diabetes-related stress and the perceived effect of diabetes on quality of life.",,2007-11,UNKNOWN,INTERVENTIONAL,['NA']
6627,NCT04177303,Change in GLP-1 (glucagon like peptide) and GIP (gastric inhibitory peptide) postprandial secretion,Change in gut microbiome analysis,,2019-11-29,UNKNOWN,INTERVENTIONAL,['PHASE3']
6628,NCT02099110,Percentage of Participants Who Discontinued Study Treatment Due to an AE: Including Rescue Approach,Change From Baseline in Sitting Systolic Blood Pressure at Week 26: Excluding Rescue Approach,,2014-04-22,COMPLETED,INTERVENTIONAL,['PHASE3']
6629,NCT00889486,change from baseline in gastric half-emptying time,change from baseline in gastroparesis symptoms and health-related quality of life,,2009-04,COMPLETED,INTERVENTIONAL,['PHASE2']
6630,NCT01621308,glycaemic regulation,Macrovascular complications of diabetes,,2012-12,COMPLETED,OBSERVATIONAL,['NA']
6631,NCT05592288,Blood Glucose Measurement,Brand Loyalty Scale,,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6632,NCT02229227,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26,Number of Participants With Clinically Significant Change in Electrocardiogram (ECG) Parameters,,2014-11-21,COMPLETED,INTERVENTIONAL,['PHASE3']
6633,NCT00806572,4-hour C-peptide AUC,Insulin usage,,2002-05,TERMINATED,INTERVENTIONAL,['PHASE2']
6634,NCT00696722,Acetylcholine induced vasodilation,assessment of vascular inflammation by determination of adhesion molecule levels,,2008-06,COMPLETED,INTERVENTIONAL,['PHASE2']
6635,NCT04774224,The primary endpoint of the study is the change from baseline of plasma C-peptide area under the curve (AUC) over 2 hours following a mixed meal.,"The composite outcome assessing both the frequency, and when relevant, the severity of all adverse events.",,2020-10-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
6636,NCT01754415,International Physical Activity Questionnaire (IPAQ),The physical fitness assessment,,2010-02,COMPLETED,INTERVENTIONAL,['NA']
6637,NCT03592355,Days until third available appointment,Revenue from virtual or in-person visit,,2018-04-13,TERMINATED,INTERVENTIONAL,['NA']
6638,NCT00994513,Endothelial function,Pulse wave velocity,,2009-07,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
6639,NCT00006331,,,,na,UNKNOWN,OBSERVATIONAL,['NA']
6640,NCT05061602,Biomechanical and Viscoelastic Properties,Lower Limb Function,,2021-09-20,COMPLETED,OBSERVATIONAL,['NA']
6641,NCT05513729,The activity of CEPT in pmol/mL/min,The activity of CEPT in pmol/mL/min,,2022-08-18,RECRUITING,OBSERVATIONAL,['NA']
6642,NCT05159856,Prevalence of cardivascular autonomic neuropathy assed by VagusDevice in children and adolescent with type 1 diabetes (T1D) > 12 months,The association between early markers of diabetic complications and glycemic control,,2022-05-03,RECRUITING,OBSERVATIONAL,['NA']
6643,NCT03717194,Global Longitudinal Strain (GLS),Body Fat Mass,,2019-06-01,COMPLETED,INTERVENTIONAL,['PHASE3']
6644,NCT00324792,changes in urinary LTE4 excretion and HbA1c after 3-month intensive insulin therapy versus baseline,sICAM-1 plasma levels,,2006-05,COMPLETED,INTERVENTIONAL,['NA']
6645,NCT01497522,Change from baseline in glycosylated hemoglobin (HbA1c) at 12 weeks between treatment groups,"Number of patients with adverse events (including hypoglycemia), serious adverse events and death",,2011-12,COMPLETED,INTERVENTIONAL,['PHASE3']
6646,NCT01903070,ΔAUCGLP-1-OGTT(0-240),,,2013-07-11,COMPLETED,INTERVENTIONAL,['PHASE4']
6647,NCT03806920,hepatic insulin extraction,additional endocrine parameters,,2016-11-05,COMPLETED,INTERVENTIONAL,['NA']
6648,NCT01909908,Incidence of adverse events,,,2013-02,TERMINATED,INTERVENTIONAL,['NA']
6649,NCT04907214,Change in Liver Steatosis at 3 Months,Change in the Plasma Inflammatory Cytokine IL-6 After 3 Months,,2021-07-29,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6650,NCT02336945,"Glucose variability as measured by AGP Interquartile Range, (IQR) obtained via System-Pro Sensor.",Assessment of ambulatory glucose profiles (AGPs) generated by the Software,,2015-01,COMPLETED,OBSERVATIONAL,['NA']
6651,NCT01915550,Proper Glycemic Control,,,2012-04,COMPLETED,INTERVENTIONAL,['PHASE3']
6652,NCT04320069,Percentage of Time >180 mg/dL,Coefficient of Variation,,2020-06-09,COMPLETED,INTERVENTIONAL,['NA']
6653,NCT02537834,Change from Baseline in HbA1c at 52 weeks,Change in Free Fatty Acid,,2015-08,COMPLETED,INTERVENTIONAL,['PHASE4']
6654,NCT01232608,Atherosclerosis,Visceral obesity,,2010-06,COMPLETED,INTERVENTIONAL,['NA']
6655,NCT05265741,Number of Participants with Gestational Diabetes Mellitus (GDM) Week 8 to post-delivery throughout their entire pregnancy,Gestational age at Delivery,,2021-11-09,RECRUITING,OBSERVATIONAL,['NA']
6656,NCT00575874,Change in HbA1c from baseline for rivoglitazone HCl compared to that for placebo,Change in Fasting Plasma Glucose from baseline for rivoglitazone HCl compared to that for placebo. Change in HbA1c from baseline compared to that for pioglitazone HCl,,2007-08,COMPLETED,INTERVENTIONAL,['PHASE2']
6657,NCT04129424,The preprandial insulin dose of insulin pump at the end of the 6-day follow-up,The frequency of errors in patency of needle fixation,,2019-12-01,UNKNOWN,INTERVENTIONAL,['NA']
6658,NCT06017349,The results were analyzed by consensus error grid (CEG),Accessibility evaluation Questionnaire for non-invasive glucose meter,,2022-09-21,COMPLETED,INTERVENTIONAL,['NA']
6659,NCT01684956,Aggregate mean difference in tmax between the delivery methods (the insulin and glucagon data will be evaluated separately),Difference in mean visual analog pain score between insulin and glucagon with intradermal injection,,2012-08,UNKNOWN,INTERVENTIONAL,['PHASE2']
6660,NCT01228981,Phenotypes of Diabetic Retinopathy progression.,,,2010-03,COMPLETED,OBSERVATIONAL,['NA']
6661,NCT02459106,Levels of miRNA will be measured as well as the adipose tissue specific miRNA.,,,2015-05-27,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
6662,NCT02315300,Glucose Levels < 65 mg/dl,Association anf temporal coincidence of glycemic variability as assessed by changes in glucose excursion as well as mean amplitude of glycemic excursion (MAGE),,2014-11,COMPLETED,INTERVENTIONAL,['NA']
6663,NCT03624062,Immunologic Analysis,Insulin Use,,2020-08-31,RECRUITING,INTERVENTIONAL,['PHASE1']
6664,NCT00715585,A1C,dietary behavior,,2008-06,COMPLETED,INTERVENTIONAL,['NA']
6665,NCT05951283,1. Change in Corneal nerve fibre density (CNFD),Quality of life questionnaire,,2023-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6666,NCT01194258,Change From Baseline in Glycosylated Hemoglobin A1C (HbA1C) at the End of Each Treatment Period,Mean Daily PPG Excursions,,2010-08,COMPLETED,INTERVENTIONAL,['PHASE2']
6667,NCT00253786,"Composite endpoint of time to first occurrence of (1) Doubling of serum creatinine, (2) Need for chronic dialysis or renal transplantation, or (3) Death in Protocol B",Urinary protein/creatinine ratio in Protocol B,,2005-11-11,COMPLETED,INTERVENTIONAL,['NA']
6668,NCT00516048,Incidence of Potentially Immune-related Treatment-emergent Adverse Events,Change in Hemoglobin A1c (HbA1c) From Baseline to Endpoint,,2007-08,COMPLETED,INTERVENTIONAL,['PHASE3']
6669,NCT01632163,Change in HbA1c,Anti-lixisenatide antibody assessment,,2012-10,COMPLETED,INTERVENTIONAL,['PHASE3']
6670,NCT00170742,regression of neovascularization.,Determine tolerability and safety,,2003-12,TERMINATED,INTERVENTIONAL,['PHASE3']
6671,NCT00311922,A1C,Patient satisfaction,,2006-03,COMPLETED,INTERVENTIONAL,['NA']
6672,NCT05441982,24-hour glycemic control,Monocyte chemoattractant protein-1,,2023-09-21,RECRUITING,INTERVENTIONAL,['NA']
6673,NCT04632849,Total Treatment Effect (TTE),Treatment Optimization Scale,,2020-11-01,COMPLETED,INTERVENTIONAL,['NA']
6674,NCT02000687,determine the rate of allosensitization in patients after failed islet transplantation,,,2008-12,RECRUITING,OBSERVATIONAL,['NA']
6675,NCT00448344,The Impact of a Family-supported Intervention on Rates of Abstinence From Cigarettes Compared to a Standard Intervention,The Impact of a Family-supported Intervention on Abstinence at 12-month Follow-up,,2008-02,COMPLETED,INTERVENTIONAL,['NA']
6676,NCT05992545,Changes in Diabetes Self-Management Behaviors for Older Koreans (DSMB-O) scores,"Change in lipid profiles, including total cholesterol, triglycerides, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol (mg/dL)",Persistent changes in Diabetes Self-Management Behaviors for Older Koreans (DSMB-O) scores,2022-06-13,COMPLETED,INTERVENTIONAL,['NA']
6677,NCT05689424,Percentage of suppression of endogenous glucose production,,,2024-01-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
6678,NCT02637154,Change in glycaemic variability,Influence of changes in marker of bone turnover: aminoterminal telopeptide of type I collagen (INTP - ng/ml),,2015-10-15,UNKNOWN,INTERVENTIONAL,['NA']
6679,NCT01564498,Blood cholesterol,circulating biomarkers of cardiovascular disease and type II diabetes risk,,2012-04,UNKNOWN,INTERVENTIONAL,['PHASE1']
6680,NCT00807092,Change in IAUC (Incremental Area Under the Curve) for Postprandial Glucose (0-4 Hours) Over 3 Main Meals,Hypoglycaemia Based on Self-reported Episodes,,2008-12,COMPLETED,INTERVENTIONAL,['PHASE4']
6681,NCT01466075,Percent of Self-Test Fingerstick Blood Glucose Results Within +/- 15mg/dL (<75mg/dL) or Within +/- 20% (>=75mg/dL) of Laboratory Glucose Method,Number of Subjects Able to Perform Given Tasks Using Product Labeling for Instruction,,2011-11,COMPLETED,INTERVENTIONAL,['NA']
6682,NCT04251156,Subjects who achieve body weight reduction equal to or above 5% (yes/no),Change in calcitonin,,2020-12-08,COMPLETED,INTERVENTIONAL,['PHASE3']
6683,NCT00688701,Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12,Percentage of Patients Requiring Rescue Therapy During the Double-Blind Treatment Period,Number of Patients With Symptomatic Hypoglycemia and Severe Symptomatic Hypoglycemia,2008-05,COMPLETED,INTERVENTIONAL,['PHASE3']
6684,NCT05377502,Serum glucose levels,,,2021-12-15,RECRUITING,OBSERVATIONAL,['NA']
6685,NCT02908555,Glycemic control,Executive functioning,,2016-01,COMPLETED,OBSERVATIONAL,['NA']
6686,NCT04215536,"Composite outcome of Stroke, MI, and Mortality",,,2019-07-08,COMPLETED,OBSERVATIONAL,['NA']
6687,NCT05923632,Quality of Life Scale for Children with Type 1 Diabetes (PedsQL 3.0),Diabetes Management Self-Efficacy Scale in Adolescents with Type 1 Diabetes,,2023-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6688,NCT05766488,Hemoglobin A1c,Perceived or experienced benefits and barriers to device use,,2023-07-24,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
6689,NCT05162183,Relative Hazard of change in HbA1c from baseline to 26 weeks of treatment (end of follow-up),,,2019-09-01,COMPLETED,OBSERVATIONAL,['NA']
6690,NCT04881799,Change in body mass index,,,2022-07-07,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
6691,NCT00503152,Development of persistent microalbuminuria (i.e. urinary albumin excretion rate >20 µg/min in at least 2 of 3 consecutive overnight urine collections confirmed in two consecutive visits). Whenever a patient will be found to have 2 of 3 collections in the,Regression to low-normal albuminuria (i.e. urinary albumin excretion rate <7 µg/min in at least 2 of 3 consecutive overnight urine collections confirmed in two consecutive visits); Albuminuria (considered as a continuous variable); Serum creatinine (v,,2007-05,COMPLETED,INTERVENTIONAL,['PHASE3']
6692,NCT00310297,"Time to GLUmax (Tmax, min)","Time to maximum concentration (Tmax, min)",,2004-11,COMPLETED,INTERVENTIONAL,['PHASE1']
6693,NCT03510624,Area under the curve (AUC) blood glucose concentrations during an OGTT,"Concentration(t) (C(t))rebaudioside A, steviol and steviol glucuronide",,2018-11-09,COMPLETED,INTERVENTIONAL,['PHASE1']
6694,NCT01862939,incremental area under the curve (IAUC) blood glucose,determine blood concentrations of DS-7309,,2011-04,COMPLETED,INTERVENTIONAL,['PHASE1']
6695,NCT04859205,To compare the level of confidence in treating individuals with type 1 diabetes measured at 3 months to the level of confidence measured at baseline.,Satisfaction of the platform.,,2021-05-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
6696,NCT05151705,Pharmacokinetics parameters of INS068 and SHR20004: AUC0-inf,Pharmacodynamic：Serum c-peptide,,2021-12-20,UNKNOWN,INTERVENTIONAL,['PHASE1']
6697,NCT05642793,rate of postvitrectomy complication,postvitrectomy BCVA,,2022-04-01,RECRUITING,INTERVENTIONAL,['PHASE2']
6698,NCT05958927,Retinal nerve fiber thickness and macular thickness in pregnant women with impaired blood sugar and/or gestational DM,,,2023-04-13,RECRUITING,OBSERVATIONAL,['NA']
6699,NCT01478607,Percentage change in health related quality of life (HRQOL) total score as assessed by the disease specific Norfolk scale,Treatment satisfaction using the Self-Assessment of Treatment (SAT) questionnaire at week 12/End Of Study visit,,2011-11,COMPLETED,INTERVENTIONAL,['PHASE3']
6700,NCT01692938,Repeatability of Microperimetry Tests in Normal and With Pathology Participants Based on 3 Microperimetry Tests Taken for Each Participant for a Given Operator-device Combination.,,,2012-10,COMPLETED,OBSERVATIONAL,['NA']
6701,NCT01359904,Hemoglobin A1c Levels,the Number of Infections Related to Vascular Access in Dialysis Among Those Who Receive a Higher Glucose Concentration in the Dialysate and Those Who Receive the Standard Concentration,,2011-05,COMPLETED,INTERVENTIONAL,['NA']
6702,NCT02146651,Pharmacokinetic endpoint: Cmax(Lisp),"Safety and Tolerability: adverse events, local tolerability, vital signs variations, ECG, laboratory safety parameters.",,2014-05,COMPLETED,INTERVENTIONAL,['PHASE2']
6703,NCT00929812,"Changes in satiety scale, total and acylated ghrelin concentrations.","Changes in glucose, insulin and NEFA concentrations.",,2006-06,UNKNOWN,INTERVENTIONAL,['PHASE3']
6704,NCT00469092,Glycosylated Haemoglobin A1c (HbA1c),Number of Subjects Reporting Treatment Emergent Adverse Events,,2007-05,COMPLETED,INTERVENTIONAL,['PHASE4']
6705,NCT01782092,Lowered A1C Levels,,,2012-08,COMPLETED,OBSERVATIONAL,['NA']
6706,NCT03426423,Continuous smoking abstinence,Continuous smoking abstinence,Exploratory microbiota outcome,2018-03-01,TERMINATED,INTERVENTIONAL,['NA']
6707,NCT04660630,change of triglyceride,Compliance rate of low density lipoprotein cholesterol,Health self assessment,2020-01-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
6708,NCT01283854,Diagnosis of gestational diabetes mellitus,"Obstetric outcomes (rates of medical intervention during labour, birth weight, newborn anthropometrics and incidence of newborn hypoglycemia)",,2011-06,COMPLETED,INTERVENTIONAL,['NA']
6709,NCT04423302,Fasting plasma glucose concentration at V3 with a 3 times a day regimen,Proportion of subjects having an improvement or a deterioration of their glycemic status from V1,,2020-07-08,COMPLETED,INTERVENTIONAL,['NA']
6710,NCT05446948,the efficiency of stripping membrane,best corrected visual acuity (BCVA),Post-operative complications,2022-07-11,COMPLETED,INTERVENTIONAL,['NA']
6711,NCT00286468,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26.,Change From Baseline in Body Weight (Week 26).,,2006-04,COMPLETED,INTERVENTIONAL,['PHASE3']
6712,NCT05822674,Stress hyperglycemia Ratio,Inflammatory markers,,2022-01-01,COMPLETED,OBSERVATIONAL,['NA']
6713,NCT01183104,Number of Participants With Hypoglycaemia,Change From Baseline in Body Weight at 52 W,,2010-08,COMPLETED,INTERVENTIONAL,['NA']
6714,NCT05840497,Gestational diabetes,Maternal and fetal pregnancy outcomes,,2023-03-01,RECRUITING,INTERVENTIONAL,['NA']
6715,NCT00673894,Postprandial Glucose Area Under the Curve (AUC),Fructosamine,,2008-04,COMPLETED,INTERVENTIONAL,['NA']
6716,NCT04058015,in-hospital mortality,,,2019-06-03,COMPLETED,OBSERVATIONAL,['NA']
6717,NCT01075698,The effects of ARB therapy and that of standard therapy except ARB on the biomarker levels (UACR and BNP),"The effect of the two treatments on the incidence of events, and the relationship between the incidence of events and the biomarker levels (UACR, BNP, urine 8-hydroxy-2-deoxyguanosine, serum adiponectin, serum high-molecule adiponectin, eGFR)",,2009-07,COMPLETED,INTERVENTIONAL,['PHASE4']
6718,NCT04694053,Fournier's gangrene evolution after treatment,,,2020-11-04,COMPLETED,OBSERVATIONAL,['NA']
6719,NCT01853072,Percentage of Participants Who Develop Macular Edema Within 90 Days Following Cataract Surgery (Day 0),Percentage of Participants With With a > 10-letter Loss in BCVA From Day 7 to Any Visit,,2013-06,COMPLETED,INTERVENTIONAL,['PHASE3']
6720,NCT01130480,Successful rate of blood glucose control (the proportion of patients with HbA1c <7%),To evaluate the change of quality of life in the 6 months by the health questionnaire SF-36,,2010-05-31,COMPLETED,INTERVENTIONAL,['NA']
6721,NCT02916667,Offspring of participants with GDM with higher Chrono Biological score will be reported with higher birth weight (+100 gr) compared to offspring of participants with GDM with lower Chrono Biological score.,Offspring of participants with GDM with higher Chrono Biological score will be reported with higher birth weight above the 90 percentile compared to offspring of participants with GDM with lower Chrono Biological score.,,2016-11,UNKNOWN,INTERVENTIONAL,['NA']
6722,NCT00777621,Glucoregulatory function,,,2008-04,COMPLETED,INTERVENTIONAL,['NA']
6723,NCT01034618,Glucose and insulin homeostasis.,Plasma amino acid profiles,,2007-12,COMPLETED,INTERVENTIONAL,['NA']
6724,NCT03695913,Participant Satisfaction With Continuous Glucose Monitoring,Utility of CGM Feedback for Changing Diet,,2018-10-16,COMPLETED,INTERVENTIONAL,['NA']
6725,NCT03781024,Patients' perspective through a patient led Survey of Health and quality of life via patient reported outcome measures using Visual analogue scale given at Baseline and follow up. Measuring effectiveness and quality of life from 0 to 10,Visual Analogue scales,,2018-12-01,UNKNOWN,OBSERVATIONAL,['NA']
6726,NCT02730962,Insulin Sensitivity,Adverse Event Rates,,2016-06,TERMINATED,INTERVENTIONAL,['PHASE2']
6727,NCT02408705,"Area under the curve of the endogenous glucose production from (=EGP) from begin of the hypoglycaemic clamp 5.5 mmol/L period until the end of recovery period (4.0 mmol/L), calculated from stable isotope labelled plasma glucose",Change in fasting plasma glucose during each period detected by blood at the begin of the visits and measured by a laboratory (tube: lithium heparin plasma),Number of self-reported hypoglycaemic episodes during each period,2015-01,COMPLETED,INTERVENTIONAL,['PHASE2']
6728,NCT02408120,Mean Daily BG Levels,Mean Daily Dose of Insulin,,2015-10,COMPLETED,INTERVENTIONAL,['PHASE4']
6729,NCT04198857,Neonatal hypoglycemia,Glucose readings over glycemic target,,2021-10-18,RECRUITING,INTERVENTIONAL,['NA']
6730,NCT02212925,Assessment of tolerability by investigator on a 4-point scale,Area under the curve of plasma glucose,,2006-11,TERMINATED,INTERVENTIONAL,['PHASE1']
6731,NCT02568501,Change in HbA1c by 3 months,Glucose Monitoring Adherence by 6 months,,2016-01,COMPLETED,INTERVENTIONAL,['PHASE3']
6732,NCT05300022,Intervention Retention,Child Perceived CGM Benefits and Burdens,Child BMI Z-score,2022-11-10,RECRUITING,INTERVENTIONAL,['NA']
6733,NCT03945903,,,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA']
6734,NCT02481479,The change in LVEF from baseline to 6 months,Change in log-scale in NT-pro BNP,,2015-06,COMPLETED,INTERVENTIONAL,['PHASE4']
6735,NCT02512276,Medication Adherence,Healthcare Utilization - Hospitalizations,,2015-08,COMPLETED,INTERVENTIONAL,['NA']
6736,NCT02703155,proportion of annual screening for Cystic Fibrosis Related Diabetes(CFRD) in children between 10years and 17 years with Cystic Fibrosis(CF) using the Home OGTT device.,Variability- timing of sample,,2015-10,UNKNOWN,INTERVENTIONAL,['NA']
6737,NCT04132934,Proportion of patients with at least one Hypoglycemia event,,,2019-03-11,COMPLETED,OBSERVATIONAL,['NA']
6738,NCT01077401,Deaths Due to Myocardial Infarction,Mean Change in Retinal Thickness at Month 6,,2010-02,COMPLETED,INTERVENTIONAL,['PHASE2']
6739,NCT03997409,Change in HbA1c,Change in Diabetes Burden as Measured by the Problem Areas in Diabetes: Teen Version (PAID-T) Report,,2019-11-18,COMPLETED,INTERVENTIONAL,['NA']
6740,NCT02086955,Effectiveness of nurse-led intervention for high risk patients with diabetic foot ulceration/amputation,,,2013-02,UNKNOWN,INTERVENTIONAL,['NA']
6741,NCT03117829,Change in brain blood flow from baseline to 12 weeks,Change in brain blood flow from 12 weeks to 6 month post intervention,,2017-03-15,COMPLETED,INTERVENTIONAL,['NA']
6742,NCT05043467,Incidence of major adverse events (AEs) and any AEs that occurred during the administration period of lobeglitazone,"Changes in glycated hemoglobin (HbA1c) and glucose, lipid parameters",,2019-01-02,COMPLETED,OBSERVATIONAL,['NA']
6743,NCT03262415,Mean absolute relative difference (MARD),,,2017-02-17,COMPLETED,OBSERVATIONAL,['NA']
6744,NCT01342042,To compare treatment arms in terms of change from baseline to endpoint in HbA1c,To compare treatment arms in terms of change from baseline to endpoint in body weight,,2011-03,UNKNOWN,INTERVENTIONAL,['PHASE2']
6745,NCT01446705,Health Care Quality: Affect of HIE on LDL Levels of Participants.,Health Care Quality: Care Sensitive Admissions,,2012-12,COMPLETED,OBSERVATIONAL,['NA']
6746,NCT05753696,proteinuria,urinary albumin/ creatine,,2023-04-01,RECRUITING,INTERVENTIONAL,['NA']
6747,NCT00372086,HbA1c,adiponectin,,2003-08,COMPLETED,INTERVENTIONAL,['PHASE4']
6748,NCT01793909,Change in Muscle Oxygen Saturation,,,2012-06,COMPLETED,INTERVENTIONAL,['NA']
6749,NCT05939869,Risk of CVD Event,,,2023-07-01,RECRUITING,OBSERVATIONAL,['NA']
6750,NCT06038669,DBS kit assay performance,Interviews,,2023-10-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
6751,NCT05887791,Glucose iAUC,Satiety assessment,Amino acids,2023-06-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
6752,NCT02224118,Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs),Number of Participants Exhibiting Anti-Drug Antibodies for CNTO 3649 at any Visit,,2009-07,COMPLETED,INTERVENTIONAL,['PHASE1']
6753,NCT03644004,Performing oral glucose tolerance test in order to detect type 2 diabetes,,,2018-10-30,COMPLETED,OBSERVATIONAL,['NA']
6754,NCT01318083,Change From Baseline in Glycosylated Hemoglobin (Week 12).,Change From Baseline in Blood Glucose Measured by the Meal Tolerance Test (Week 12).,,2008-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
6755,NCT01729117,Change in BMI,Severe Hypoglycemic Events,,2009-05,COMPLETED,INTERVENTIONAL,['NA']
6756,NCT06025110,Change from baseline in beta-cell function as compared to placebo at week 52.,Assess the incidence and severity of adverse,,2023-01-23,RECRUITING,INTERVENTIONAL,['PHASE2']
6757,NCT00060931,Change from baseline in HbA1c at 5 months,"Blood pressure at 3 and 5 months Body weight at 3 and 5 months Lab levels (glucose, insulin, triglycerides, cholesterol, and albumin:creatinine ratio) at 3 and 5 months.",,2001-06,COMPLETED,INTERVENTIONAL,['PHASE4']
6758,NCT03333044,Percent of patients that experience a reduction in HbA1c of >0.5%,Referral to community services,,2019-07-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
6759,NCT03714594,Glucose Metabolism,,,2018-07-24,COMPLETED,INTERVENTIONAL,['PHASE2']
6760,NCT04000867,Overall Pain reduction,Improved Activities of daily living,,2019-08-01,UNKNOWN,INTERVENTIONAL,['NA']
6761,NCT02026830,Causative microorganisms and their antibiotic sensitivity patterns in diabetic patients with a foot infection in Turkey.,,,2014-01,COMPLETED,OBSERVATIONAL,['NA']
6762,NCT05677685,CFU (Colony Forming Units),Adverse Events,,2023-01-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6763,NCT03549104,Fear of Hypoglycemia,Glycemic Variability,,2019-01-14,COMPLETED,INTERVENTIONAL,['NA']
6764,NCT03850314,LDL Cholesterol levels,HbA1C levels,,2019-03,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
6765,NCT00789035,Change of Glycosilated Haemoglobin A1c (HbA1c) From Baseline After 12 Weeks of Treatment,Trough Concentrations of Empagliflozin in Plasma,,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2']
6766,NCT00741702,systolic blood pressure,"Change in diastolic blood pressure, change in urine albumin status and incidence of adverse events",,2001-09,COMPLETED,INTERVENTIONAL,['NA']
6767,NCT01618409,Patient Understanding of their Medication Regimen,Self-reported Adherence,,2011-03,COMPLETED,INTERVENTIONAL,['NA']
6768,NCT01686711,Glycosylated Hemoglobin (HbA1c),,,2012-09,COMPLETED,INTERVENTIONAL,['PHASE4']
6769,NCT03967561,Glycated Hemoglobin levels (HbA1c),"Physical activity levels, evaluated by International Physical Activity Questionnaire (IPAQ) - Long Form.",,2019-06-10,UNKNOWN,INTERVENTIONAL,['NA']
6770,NCT01505803,"Inflammation & oxidative stress (CRP, TNF-α, IL-1, IL-2, IL-6, IL-10 F2 isoprostanes, NF-κB, MPO, other)",Plasma fatty acids,,2010-07,COMPLETED,INTERVENTIONAL,['PHASE1']
6771,NCT02670915,Change in the Percentage of HbA1c,Change in Anti-insulin Aspart Antibody Development: Total,,2016-05-04,COMPLETED,INTERVENTIONAL,['PHASE3']
6772,NCT04313803,Cost of care for fee-for-value patients (specifically PMPM savings),Evaluation of HEDIS performance for those using CGM compared to historical utilization and the broader T2DM cohort within Intermountain Healthcare.,,2020-04-01,UNKNOWN,OBSERVATIONAL,['NA']
6773,NCT01387425,Success rates and safety at week 24 in the varenicline vs placebo. Success rates will be defined as the Continuous Quit Rate since last visit. Maintain abstinence during this period of time with end-expiratory exhaled CO measurements ≤ 10 ppm.,"""Change from Baseline in BMI""",,2011-06,COMPLETED,INTERVENTIONAL,['NA']
6774,NCT01488474,Minimal current threshold for distal motor response at needle tip nerve contact,,,2012-01,COMPLETED,OBSERVATIONAL,['NA']
6775,NCT05413928,Core body temperature response to meal consumption,Heart rate response to meal consumption,,2023-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6776,NCT02548650,Maximal Platelet Aggregation in DM,Maximal Platelet Aggregation in Non-DM,,2016-03-25,COMPLETED,INTERVENTIONAL,['PHASE4']
6777,NCT01041690,Intra- and post-operative bleedings were recorded.,Best Corrected Visual Acuity,,2007-06,COMPLETED,INTERVENTIONAL,['NA']
6778,NCT02098746,Frequency of Serious Adverse Drug Reactions,Change From Baseline in Fasting Insulin Level,,2011-06,COMPLETED,OBSERVATIONAL,['NA']
6779,NCT04177147,Number of participants with hypoglycemia during the study period,"Number of participants with changes to prescriptions for diabetes or antibiotics: new, refilled, changed, or discontinued","Number of A1c, glucose, and creatinine blood tests",2016-01-14,COMPLETED,INTERVENTIONAL,['NA']
6780,NCT05743387,Mean HbA1c (in percent),Occurrence of Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs),Change in dosage of lipid-lowering medications prescribed by CC-VHWs or healthcare professionals,2023-05-13,RECRUITING,INTERVENTIONAL,['NA']
6781,NCT00309751,Percent Change From Baseline Low Density Lipoprotein Cholesterol (LDL-C),Number of Patients Attaining National Cholesterol Education Program (NCEP) LDL-C Target,,2005-12,COMPLETED,INTERVENTIONAL,['PHASE3']
6782,NCT02558452,Development of donor specific antibodies (DSA),Quality of life measures,,2016-12,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
6783,NCT00025883,"Triglycerides at Baseline, 6 Months, and 12 Months on Treatment With Metreleptin",,,2001-10,COMPLETED,INTERVENTIONAL,['PHASE2']
6784,NCT02789800,Evaluation of Intervention Effectiveness - Change in Self-Management outcomes,Evaluation of Intervention Effectiveness - Change in Patient-Centredness,,2016-04-22,COMPLETED,INTERVENTIONAL,['NA']
6785,NCT00005152,Coronary heart disease (CHD),,,1980-08,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
6786,NCT01612741,Data collection on pre treatment concomitant diseases,Safety variables will be summarized using descriptive statistics based on adverse events collection,,2008-04,COMPLETED,OBSERVATIONAL,['NA']
6787,NCT05925556,change in Self-Care Inventory from baseline to 6 weeks; higher score = better self-care; range 1-5; also change over ecological momentary assessment period,change in Quality of Marriage Index and intimacy subscale from Personal Assessment of Intimacy in Relationships from baseline to 6 weeks; higher numbers = better; range = 1 to 7; also change over ecological momentary assessment period,change in self-efficacy subscale from Multidimensional Diabetes Questionnaire from baseline to 6 weeks; higher numbers = greater efficacy; range = 0 to 100%; also change over ecological momentary assessment period,2023-08-02,RECRUITING,INTERVENTIONAL,['NA']
6788,NCT02772263,Change in rate of EMS calls over 1 year,Change in Canadian Diabetes Risk (CANRISK) score over 1 year,,2013-11,COMPLETED,INTERVENTIONAL,['NA']
6789,NCT02114476,Diabetes mellitus,metabolic syndrome,,2014-03,UNKNOWN,INTERVENTIONAL,['NA']
6790,NCT00793143,Excessive weight loss,QOL (15D and BAROS),,2008-04,COMPLETED,OBSERVATIONAL,['NA']
6791,NCT02375932,Glycemic Control (HbA1c control (% patients < 7.0% and mean HbA1c levels),Patient assessment of visit communication (measures of communication quality using validated instruments),,2015-03,COMPLETED,INTERVENTIONAL,['NA']
6792,NCT02127216,Improvement in hemoglobin A1c,Adherence to diabetes care plan,,2014-06,UNKNOWN,INTERVENTIONAL,['NA']
6793,NCT01413126,Change from baseline in glucose homeostasis at eight hours,Change from baseline in appetitive sensations at twelve hours,,2009-10,COMPLETED,INTERVENTIONAL,['NA']
6794,NCT03767556,EVALUATION OF LUNG VOLUMES AND CAPACITIES,EVALUATION OF INSPIRATORY MUSCLE STRENGTH,,2018-12-15,COMPLETED,INTERVENTIONAL,['NA']
6795,NCT04185844,Slope of the GFR,Slope of change in proteinuria over time,,2020-08-31,RECRUITING,OBSERVATIONAL,['NA']
6796,NCT00958061,Determine the prevalence of lifetime and current psychiatric conditions including PTSD among women who served during the Vietnam Era.,Characterize the level of current disability in women who served during the Vietnam Era.,,2010-03-01,COMPLETED,OBSERVATIONAL,['NA']
6797,NCT01663519,In shoe plantar pressure measurement,Gait analysis,Cost and cost analysis,2008-01,COMPLETED,INTERVENTIONAL,['NA']
6798,NCT03993132,Incidence Rate of Expanded Major Adverse Cardiovascular Event (MACE) Composite Outcome - ITT Analysis,Incidence Rate of Hospitalization for Heart Failure (HF) - ITT Analysis,,2018-10-01,COMPLETED,OBSERVATIONAL,['NA']
6799,NCT02845466,Level of Applied Growth Factors in Chronic Wound Fluid,Levels of Healing Biomarkers in Chronic Wound Fluid,,2018-08,UNKNOWN,INTERVENTIONAL,['PHASE3']
6800,NCT06173804,Acceptability,MoCA,,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6801,NCT00745498,Recurrent VH Incidence (Early and Late),Postoperative Resolution of Neovascularization,,2008-06,COMPLETED,INTERVENTIONAL,['NA']
6802,NCT03254849,Blood Pressure reduction,,,2017-12-08,COMPLETED,INTERVENTIONAL,['PHASE4']
6803,NCT02634515,"PD: GIRmax, maximum glucose infusion rate",Assessment of local tolerability at the injection site,,2014-12,COMPLETED,INTERVENTIONAL,['PHASE1']
6804,NCT03341013,Maximum observed plasma concentration of MEDI0382,Clinical laboratory assessments (urinalysis),,2017-11-30,COMPLETED,INTERVENTIONAL,['PHASE1']
6805,NCT03355092,Mean reduction in HbA1c,,,2018-02-23,WITHDRAWN,INTERVENTIONAL,['NA']
6806,NCT04834089,Proportion of patients with change in COVID-19 disease progression profile after administration of anti-SARS-CoV-2 serum,Deaths,Proportion of patients with change in COVID-19 disease progression,2021-05,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6807,NCT00832481,To investigate the effects of monotherapy of either repaglinide or metformin on glucose excursion after 3 months treatment in newly diagnosed type 2 diabetes patients in China,,,2009-01,UNKNOWN,INTERVENTIONAL,['NA']
6808,NCT01117584,Change from baseline in HbA1c at Week 12,Achievement of target goal (HbA1c <6.5%) at Week 12,,2010-04-06,COMPLETED,INTERVENTIONAL,['PHASE2']
6809,NCT03989232,Change in HbA1c,Change in Pulse Rate,,2019-06-19,COMPLETED,INTERVENTIONAL,['PHASE3']
6810,NCT01496625,"Interaction of key parameters of phenotype with genetic variants, and characterization of new experimental models of eye health and disease.",,,2012-06-18,RECRUITING,OBSERVATIONAL,['NA']
6811,NCT01477476,Frequency of Adverse Events,,,2012-03,WITHDRAWN,INTERVENTIONAL,['PHASE2']
6812,NCT05443568,Change in HbA1c (Glycated haemoglobin),"DTSQs (Diabetes Treatment Satisfaction Questionnaire, status), change in absolute treatment satisfaction",,2023-03-09,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
6813,NCT03682640,Stimulated C-peptide during an MMTT,Change in stimulated C-peptide,,2018-09,UNKNOWN,INTERVENTIONAL,['PHASE2']
6814,NCT01373450,Change From Baseline in Beta Cell Sensitivity to Glucose (Φ) After a Single Dose of OXM,"Change From Baseline in Insulinotrophic Effect (ISR/G) After Single Doses of 0.6 mg Lg, or 1.2 mg Lg, Compared With Single Doses of Placebo or OXM",,2011-06,COMPLETED,INTERVENTIONAL,['PHASE1']
6815,NCT00162799,Increase of insulin sensitivity in apparently healthy men and woman evaluate by means of i.v. glucose tolerance test (PTEVGMR).,Reduction antropometric measures associated with insulin resistance and arterial hypertension.,,2002-07,COMPLETED,INTERVENTIONAL,['PHASE2']
6816,NCT01456026,Postprandial Change from Baseline in Flow Mediated Dilatation,Postprandial Change from Baseline in Microcirculation (Laser-Doppler measurements of reactive hyperemia at the hand),,2009-06,COMPLETED,INTERVENTIONAL,['NA']
6817,NCT05973422,Serious adverse device effects (SADE),System Usability Scale (SUS) at baseline and 15 days for the Pump Assembly,,2024-05-31,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6818,NCT04624737,Progression to severe retinopathy,Comparison of algorithms prediction to human prediction.,,2020-12-21,RECRUITING,OBSERVATIONAL,['NA']
6819,NCT04874116,Change in Medication Adherence,Change in CollaboRATE,,2021-05-26,RECRUITING,INTERVENTIONAL,['NA']
6820,NCT02114814,Hemoglobin A1c,Health-related Quality of Life (SF-12),,2012-06,COMPLETED,INTERVENTIONAL,['NA']
6821,NCT03315052,Acute cellular rejection (ACR),Infection,,2019-01,WITHDRAWN,INTERVENTIONAL,['PHASE4']
6822,NCT01131676,"Time to the First Occurrence of Any of the Following Adjudicated Components of the Primary Composite Endpoint (3-point MACE): CV Death (Including Fatal Stroke and Fatal MI), Non-fatal MI (Excluding Silent MI), and Non-fatal Stroke.",Percentage of Participants With the Composite Microvascular Outcome,,2010-07,COMPLETED,INTERVENTIONAL,['PHASE3']
6823,NCT00717223,Literacy levels and HbA1c,,,2007-06,COMPLETED,OBSERVATIONAL,['NA']
6824,NCT02136602,To study interventricular septal thickness in fetus of diabetic mother and correlate it with good glycemic control.,,,2012-01,COMPLETED,OBSERVATIONAL,['NA']
6825,NCT01253694,Proportion of subjects with resolution of diabetic macular edema compared to baseline as determined by mean foveal thickness on Spectralis < 300 microns.,Evaluate the main change in BCVA (best corrected visual acuity) score over time,,2011-03,WITHDRAWN,INTERVENTIONAL,['PHASE2']
6826,NCT02940418,Safety of using allogenic ASC assessed by any adverse events,,,2017-02-19,UNKNOWN,INTERVENTIONAL,['PHASE1']
6827,NCT05920096,Acceptability - nurses' (intervention providers) satisfaction with the intervention,Preliminary evidence of effectiveness - point prevalence smoking abstinence at follow-up,,2023-08-01,RECRUITING,INTERVENTIONAL,['NA']
6828,NCT00661908,,,,2004-03,COMPLETED,OBSERVATIONAL,['NA']
6829,NCT01758016,vascular complications in pregnancy,,,2012-11,UNKNOWN,OBSERVATIONAL,['NA']
6830,NCT05189470,Complete healing,Change in Wound-QoL global score from baseline to end of follow-up,One-year amputation rate,2022-03-10,RECRUITING,INTERVENTIONAL,['NA']
6831,NCT00124397,Flow mediated vasodilatation (FMD) on atorvastatin,CV events,,2001-07,COMPLETED,INTERVENTIONAL,['PHASE4']
6832,NCT00213070,,,,na,COMPLETED,INTERVENTIONAL,['PHASE3']
6833,NCT00456898,the biotransformation of codeine to morphine and the safety and tolerability of DVS SR,,,2007-01,COMPLETED,INTERVENTIONAL,['PHASE1']
6834,NCT02514954,"Delta AUCBG,0-2h",Local tolerability,,2015-07,COMPLETED,INTERVENTIONAL,['PHASE1']
6835,NCT02632032,Changes in HbA1c,Changes in weight,,2013-07,COMPLETED,INTERVENTIONAL,['NA']
6836,NCT00696657,HbA1c,Percentage of Subjects Developing Anti-semaglutide Antibodies,,2008-06-03,COMPLETED,INTERVENTIONAL,['PHASE2']
6837,NCT04074603,The glucose fluctuation,Assessment of safety and tolerance,,2019-09-01,COMPLETED,INTERVENTIONAL,['NA']
6838,NCT02411929,Area Under the Plasma Concentration-Time Profile From Time Zero to Time of the Last Quantifiable Concentration (AUC Last) (Dose Normalized to 1 mg) and Absolute Oral Bioavailability (F) (Period 1),Number of Participants Discontinuing Study Drug Due to Adverse Events (Periods 1 and 2),,2014-10-29,COMPLETED,INTERVENTIONAL,['PHASE1']
6839,NCT00320112,Change in Glycemic Control (HbA1c),Number of Participants With Insulin Starts at 6 Months,,2007-02,COMPLETED,INTERVENTIONAL,['PHASE3']
6840,NCT00259896,Pharmacodynamic measurements during 7 days of dosing.,Pharmacokinetic measurements during 7 days of dosing.,,2005-10,COMPLETED,INTERVENTIONAL,['PHASE1']
6841,NCT00543010,,,,2002-11,TERMINATED,INTERVENTIONAL,['PHASE3']
6842,NCT00303134,Insulin independence 12 months after final islet infusion,Mixed meal test,,2003-08-01,TERMINATED,INTERVENTIONAL,['PHASE1']
6843,NCT02460978,Adjusted Mean Change From Baseline in HbA1c at Week 24,Percentage of Subjects With HbA1c Reduction From Baseline to Week 24 Last Observation Carried Forward (LOCF) >= 0.5% and Without Severe Hypoglycemia Events at Week 24,,2015-07-08,COMPLETED,INTERVENTIONAL,['PHASE3']
6844,NCT01951235,Change in HbA1c,"Safety will be assessed by the incidence of adverse events (AEs), physical examination, relevant changes on laboratory tests, vital signs, and 12-lead electrocardiograms (ECG)",,2013-01,COMPLETED,INTERVENTIONAL,['PHASE2']
6845,NCT05666128,Change in HbA1c(%),,,2022-06-17,RECRUITING,INTERVENTIONAL,['PHASE2']
6846,NCT05729516,change in glycemic control,changes in perceived diabetes self-efficacy,,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6847,NCT00858897,Glutathione Concentration,,,2007-06,COMPLETED,INTERVENTIONAL,['NA']
6848,NCT04562454,fluctuation of blood glucose after eating different food,,,2020-10-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
6849,NCT06148259,Change in prostate symptoms,,,2021-03-12,COMPLETED,INTERVENTIONAL,['NA']
6850,NCT05329844,AUC0-t of Vildagliptin for the test and the reference products,Number of treatment-related adverse events (AE) for the test and the reference products as assessed by guidance predefined in the protocol,,2014-02,COMPLETED,INTERVENTIONAL,['NA']
6851,NCT04684836,Continuity of care as assessed by attendance at follow-up appointment,Ease of use and access to telemedicine based on Telehealth Usability Questionnaire (TUQ),,2021-03-15,COMPLETED,OBSERVATIONAL,['NA']
6852,NCT04240171,HbA1c %,IL-34 (pg./ml),,2020-12-01,COMPLETED,OBSERVATIONAL,['NA']
6853,NCT02976012,• Ocular and systemic safety evaluation for adverse events at any time point through 52 weeks:,Proportion of enrolled eyes requiring intraoperative endolaser in a PRP pattern at the time of initial vitrectomy,,2016-06,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6854,NCT06037499,Blood glucose measurement using BGMS,,,2023-03-03,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
6855,NCT05073835,Weight loss,GLP-1 levels,,2022-11-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
6856,NCT05320510,Change of HbA1c concentration,Change of TC concentration,,2022-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6857,NCT03138356,PK assessment: Cmax (Maximum observed plasma concentration),"Laboratory assessments (hematology, clinical chemistry and urinalysis)",,2017-05-25,COMPLETED,INTERVENTIONAL,['PHASE1']
6858,NCT01255293,Retinal redetachment rate,Silicone oil emulsification rate,,2010-11,COMPLETED,INTERVENTIONAL,['NA']
6859,NCT05321368,Blood Pressure Control as assessed by percentage of participants with controlled Blood Pressure,Change in Health-Related Quality of Life as assessed by the PROMIS 29,,2023-10-16,RECRUITING,INTERVENTIONAL,['NA']
6860,NCT01493934,Change of glycemia,insulin resistance,,2010-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6861,NCT02187913,resistant starch effects,,,2014-07,UNKNOWN,INTERVENTIONAL,['NA']
6862,NCT01907113,Cmax (Maximum Concentration of the Analyte in Plasma),Assessment of Tolerability by Investigator,,2009-07,COMPLETED,INTERVENTIONAL,['PHASE1']
6863,NCT02377583,Depression (CDI) score,Hippocampal volume and mean diffusion,,2012-08,UNKNOWN,OBSERVATIONAL,['NA']
6864,NCT01697618,Area under the serum insulin curve,Serum glucose excursions (EXC),,1997-04,COMPLETED,INTERVENTIONAL,['PHASE2']
6865,NCT05274295,Reduction rate of the wound size,Improvement Wound pain,,2022-02-28,UNKNOWN,INTERVENTIONAL,['NA']
6866,NCT05851469,Clinical performance,Adverse events,,2023-05-31,COMPLETED,INTERVENTIONAL,['NA']
6867,NCT05725330,self-management scale,anthropometric measurements (Body Mass Index),,2023-02-25,RECRUITING,INTERVENTIONAL,['NA']
6868,NCT01392898,Body weight change (measured body weight at 26 weeks minus baseline body weight),Measuring change in insulin dose (insulin dose at 26 weeks minus insulin dose at baseline),,2012-02,UNKNOWN,INTERVENTIONAL,['NA']
6869,NCT04838431,LGA,,,2018-06-01,TERMINATED,OBSERVATIONAL,['NA']
6870,NCT05937152,Change in pain intensity,Pain relief at 24 weeks,,2024-04,RECRUITING,INTERVENTIONAL,['PHASE2']
6871,NCT03323996,Semi-Structured interviews,,,2017-07-26,UNKNOWN,OBSERVATIONAL,['NA']
6872,NCT06046833,Metrics of Glucose Variability,Hypoglycemia episodes,GIQLI questionnaire,2024-01-08,RECRUITING,INTERVENTIONAL,['NA']
6873,NCT04104451,SAE,Change in A1c,,2019-11-12,COMPLETED,INTERVENTIONAL,['PHASE1']
6874,NCT00889785,Lipids,self-care behaviors,,2009-06,COMPLETED,INTERVENTIONAL,['NA']
6875,NCT00569465,arterial blood pressure decrease,oxidative parameters decrease,,2005-01,TERMINATED,INTERVENTIONAL,['PHASE4']
6876,NCT06313164,Reduced glutathione (GSH) levels in erythrocyte hemolysate change in patients with type 2 diabetes mellitus,Postprandial Insulin (PPI) Levels Change in Patients with Type 2 Diabetes Mellitus,,2023-06-20,COMPLETED,INTERVENTIONAL,['NA']
6877,NCT00813930,Six-month United Kingdom Prospective Diabetes Study (UKPDS) risk engine score. The UKPDS risk engine is a validated scoring system that uses multiple clinical characteristics to predict new coronary heart disease risks in patients with type 2 diabetes.,"Six-month: HbA1c, seated systolic blood pressure, serum Total Cholesterol concentration, serum HDL-C concentration, Total/HDL-C ratio value, LDL-C concentration, self-reported smoking status, adherence to medications and lifestyle measures.",,2008-11,UNKNOWN,INTERVENTIONAL,['NA']
6878,NCT04524832,"Area under the semaglutide plasma concentration-time curve during a dosing interval at steady state (AUC0-24h,sema,SS)",Change in blood pressure,,2020-09-29,COMPLETED,INTERVENTIONAL,['PHASE1']
6879,NCT03988140,Change from baseline Peri-implant Probing Depth (PPD) at 24 months.,Markers on peri-implant crevicular fluid,,2014-11-01,COMPLETED,INTERVENTIONAL,['NA']
6880,NCT02750007,Number of Treatment Emergent Adverse Events(TEAEs),The minimum dose of HS-20004 that could keep plasma glucose under 6.1 mmol/L in Type 2 Diabetic Patients,,2015-12,UNKNOWN,INTERVENTIONAL,['PHASE1']
6881,NCT06031987,63-140 mg/dL Time in Range,fetal:Meconium aspiration,,2022-01-26,RECRUITING,INTERVENTIONAL,['NA']
6882,NCT06236256,Improvement of glucose measures in older individuals,Grip strength,WHO-5,2024-01-09,RECRUITING,INTERVENTIONAL,['NA']
6883,NCT01850199,Median blood glucose (Interquartile range),Time from glucose criteria for insulin prescription to actual insulin starting,,2014-01,COMPLETED,INTERVENTIONAL,['NA']
6884,NCT00505375,Area Under the Stimulated C-peptide Curve Over the First 2 Hours of a 4 Hour Mixed Meal Tolerance Test at the 2 Year Visit,,,2008-02,COMPLETED,INTERVENTIONAL,['PHASE2']
6885,NCT01043445,"The effect of this newly discovered GPR 119 agonist on gut hormone responses, in particular GLP-1 in response of the different meals administered to the subjects","Glucose homeostasis, gall bladder contraction in response of the different meals administered to the subjects",,2009-09,COMPLETED,INTERVENTIONAL,['NA']
6886,NCT00044421,Reduction in the progression of DPN measured by composite score,"Vibration sensation;Electrophysiology of tibial, peroneal and sural nerves;Neurological signs;Neuropathic symptoms;Clinical global impression of change;Health outcome measures",,2002-07,COMPLETED,INTERVENTIONAL,['PHASE3']
6887,NCT05610124,Food Intake,Change in Fatigue Level,,2023-02-01,RECRUITING,INTERVENTIONAL,['NA']
6888,NCT04293367,Change in Post-absorptive Lipid Oxidation,Glucose Disposal Rate (GDR) during the Hyperinsulinemic-Euglycemic Clamp,,2009-06-01,COMPLETED,INTERVENTIONAL,['NA']
6889,NCT06268990,Insulin sensitivity,Tolerability of repeated FMT,,2023-01-01,RECRUITING,INTERVENTIONAL,['NA']
6890,NCT05294861,Gut Microbiome,Overall Glycemia,,2022-04-28,UNKNOWN,INTERVENTIONAL,['NA']
6891,NCT00642681,To measure Serum FDKP AUC,,,2007-12,COMPLETED,OBSERVATIONAL,['NA']
6892,NCT00654121,body weight gain.,,,2000-02,COMPLETED,INTERVENTIONAL,['PHASE2']
6893,NCT01638429,Gastric Emptying,% Stool Dry Weight,,2012-04,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
6894,NCT02128581,Calories consumed during buffet meal test,,,2014-05,COMPLETED,INTERVENTIONAL,['PHASE1']
6895,NCT03180281,"Fasting blood glucose,glycosylated hemoglobin(GHbA1c)",Incidence of hypoglycemia,,2017-07-01,UNKNOWN,INTERVENTIONAL,['NA']
6896,NCT00371306,Maternal glucose at delivery,Infant complications,,2002-09,UNKNOWN,INTERVENTIONAL,['NA']
6897,NCT01280695,Change From Baseline in Fasting Plasma Glucose,Change From Baseline in High Molecular Weight Adiponectin,,2011-02,COMPLETED,INTERVENTIONAL,['PHASE2']
6898,NCT01655186,Mean change in body weight as measured by Dual Energy X-ray Absorptiometry (DXA),"Frequency, intensity and relationship of study drug to adverse events and serious adverse events, as well as clinical, and laboratory test result abnormalities",,2012-09-30,WITHDRAWN,INTERVENTIONAL,['PHASE2']
6899,NCT01780272,The number of electroencephalogram (EEG) identified arousals,Total sleep time,,2013-01,COMPLETED,INTERVENTIONAL,['PHASE1']
6900,NCT01818310,Amputation-free survival,Quality of life outcome,Blood glucose and pancreatic function response,2012-09,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
6901,NCT05537480,Obtain CGM data concomitant with OGTT to determine what CGM metrics obtained in pregnant women with and without a high risk of GDM correlate best with the diagnostic OGTT (obtained via the 2-step and 1-step approaches),Determine what CGM metrics obtained in pregnant women correlate best with the need for pharmacologic management of GDM,,2022-01-14,RECRUITING,INTERVENTIONAL,['NA']
6902,NCT01235819,change in insulin requirement,C peptide response,,2010-11,COMPLETED,INTERVENTIONAL,['PHASE4']
6903,NCT05685927,Changes in parameters defining sarcopenia in relation to weight-loss or glycemic improvement,"Correlation analyses of primary measures with metabolic parameters including insulin resistance, HbA1c, metabolic economy, bioenergetics, and low-grade systemic inflammation (hs-CRP)",EMG assessment of myopathic changes,2022-11-01,RECRUITING,OBSERVATIONAL,['NA']
6904,NCT00101751,HbA1c and Incidence of hypoglycemia,Postprandial glucose from 8-point SMBG spontaneously reported adverse events; any changes from baseline,,2004-10,COMPLETED,INTERVENTIONAL,['PHASE4']
6905,NCT00910767,Percentage of plasma glucose values in target (3.9 - 8.0 mmol/L),Percentage of plasma glucose and CGM values below 3.0 mmol/L,,2009-02,COMPLETED,INTERVENTIONAL,['NA']
6906,NCT00478322,"Assessment of ECGs, physical examinations and laboratory values for adverse events",,,2007-04,COMPLETED,INTERVENTIONAL,['PHASE2']
6907,NCT00500331,Change From Baseline (Week 0) in Glycosylated Hemoglobin (HbA1c) (%) at Week 12,Number of Participants With Change From Baseline in Standard Laboratory Parameters of Potential Clinical Concern,,2007-01-23,COMPLETED,INTERVENTIONAL,['PHASE2']
6908,NCT03987919,Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg),Percentage of Participants Achieving an HbA1c Target Value of <5.7%,,2019-07-30,COMPLETED,INTERVENTIONAL,['PHASE3']
6909,NCT04033042,Risk/benefit analysis,Number of encountered Device Deficiencies,,2019-09-18,COMPLETED,INTERVENTIONAL,['NA']
6910,NCT05299502,Fasting plasma glucose,Gestational Diabetes Mellitus diagnosis,,2022-06-30,RECRUITING,INTERVENTIONAL,['NA']
6911,NCT00877123,interleukin-10 level,hs-CRP level,,2009-06,COMPLETED,INTERVENTIONAL,['PHASE4']
6912,NCT01934686,Proportion of patients having HbA1c ((Glycosylated Haemoglobin) as measured during survey) less than 7%,Proportion of patients having diabetic eye complications,,2013-09,COMPLETED,OBSERVATIONAL,['NA']
6913,NCT00925119,Change in Free Fatty Acid Kinetics,Change in Insulin,,2009-12,TERMINATED,INTERVENTIONAL,['PHASE4']
6914,NCT05161793,CGM - Tele-monitoring effects on HbA1c,CGM-Tele-monitoring effects on protocol driven enhancement of therapy with Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) and sodium-glucose cotransporter -2 (SGLT-2) inhibitors,,2022-05-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
6915,NCT00697580,insulin sensitivity,adiposity,,2005-05,COMPLETED,INTERVENTIONAL,['NA']
6916,NCT05610111,CGM-measured percent time in range 70-180 mg/dL,CGM-measured coefficient of variation during the day,,2023-01-18,RECRUITING,INTERVENTIONAL,['NA']
6917,NCT00962065,Change From Baseline at Day 28 in 24-hour Urinary Glucose Excretion,Change From Baseline at Day 28 in Triglycerides,,2009-08,COMPLETED,INTERVENTIONAL,['PHASE2']
6918,NCT03179254,Postoperative blood glucose level,,,2010-03-22,COMPLETED,INTERVENTIONAL,['PHASE4']
6919,NCT06329544,Degree of fibrosis,,,2024-04-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6920,NCT05791955,MyChart letter opened,Completion rate of one screening/test,,2023-05-23,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6921,NCT01455883,Change in HbA1c,,,2013-02,WITHDRAWN,INTERVENTIONAL,['PHASE3']
6922,NCT03325322,Effect on Mesenchymal stem cell function including cell migration,Number of participants with treatment-related adverse events including hospitalization,,2018-01-02,SUSPENDED,INTERVENTIONAL,['PHASE2']
6923,NCT02282397,Phase 2 (T1DM),Phase 2 (T1DM) - Insulin Use Outcomes,Phase 1 (T2DM) - Post-Hoc A1C Outcome,2014-09,COMPLETED,INTERVENTIONAL,['NA']
6924,NCT01858545,Number of Participants With Complete Wound Closure,,,2013-05,TERMINATED,INTERVENTIONAL,['NA']
6925,NCT00664183,Ultrasound,"Ultrasound, OCT, Safety",,2008-03,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
6926,NCT04510506,Combined Triple Label Surveillance and Randomized substudies: Change in insulin sensitivity (Si) over time,Both substudies: Change in percent time <70 mg/dL,,2020-11-19,RECRUITING,INTERVENTIONAL,['NA']
6927,NCT03321279,"Change in mean daily step count from the baseline period to the intervention period, using a wearable pedometer (Nokia Steel) to measure step count.","Functional decline from admission to 3 months post-discharge, measured using validated survey assessments.",,2018-01-11,COMPLETED,INTERVENTIONAL,['NA']
6928,NCT04501406,The proportion of pioglitazone-treated patients relative to placebo achieving an improvement of ≥2 points in non-alcoholic fatty liver disease activity score (NAS) without an increase in fibrosis stage.,Mean change in liver fibrosis,Glycemic control,2020-12-15,RECRUITING,INTERVENTIONAL,['PHASE2']
6929,NCT00572052,HbA1c,Quality of Life,,2002-12,COMPLETED,INTERVENTIONAL,['PHASE4']
6930,NCT01709851,Point Accuracy of the microdialysis signal,Rate accuracy of the microdialysis signal,,2012-11,COMPLETED,OBSERVATIONAL,['NA']
6931,NCT04054934,"Affects of reversal circadian clock on sleep quality among both healthy and T1DM adolescents (mainly T1DM), controlled for BMI-SDS, and mean HbA1c in T1D patients.",Metabolic parameters according to night/day sleep cycle among healthy and among T1D patients,,2022-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
6932,NCT02809963,Liver fat content,potassium,,2015-11,COMPLETED,INTERVENTIONAL,['PHASE4']
6933,NCT01973972,Hemoglobin A1c,Estimated Costs of Intervention Strategies,,2014-12-12,COMPLETED,INTERVENTIONAL,['NA']
6934,NCT00101530,,,,2004-09,COMPLETED,OBSERVATIONAL,['NA']
6935,NCT00639665,Hemodynamic Measurements,Blood Pressure,,2008-01,COMPLETED,OBSERVATIONAL,['NA']
6936,NCT02370537,Part B: Baseline Corrected Cmax for Total EPA+DHA Following Administration of EPANOVA® and OMACOR®.,,,2015-03,COMPLETED,INTERVENTIONAL,['PHASE2']
6937,NCT04101669,Change in HbA1c,Questionnaire,,2019-09-09,RECRUITING,INTERVENTIONAL,['NA']
6938,NCT00815217,"wound measurements, healing of wounds, pictures of wounds",,,2009-02,UNKNOWN,INTERVENTIONAL,['NA']
6939,NCT00948324,beta cell function;fast blood glucose;,,,2008-06,SUSPENDED,INTERVENTIONAL,['PHASE4']
6940,NCT04113694,Novolog Subjects - Rate of Infusion Set Failure at the End of Day 6,Novolog Subjects - Rate of Infusion Set Failure at the End of Day 7.,,2019-10-14,COMPLETED,INTERVENTIONAL,['NA']
6941,NCT01107015,HBA1c at One Year,,,2008-06,COMPLETED,INTERVENTIONAL,['NA']
6942,NCT05362578,Change in American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptoms Index-Daily Diary (ANMS GCSI-DD),Electrocardiogram (ECG),36-Item Short Form Survey Instrument (SF-36) to measure quality of life (QOL),2022-09-08,RECRUITING,INTERVENTIONAL,['NA']
6943,NCT03249610,Number of subjects with reduced Body Mass Index,Number of subjects with reduced Fasting Blood Glucose,,2014-03-11,COMPLETED,INTERVENTIONAL,['NA']
6944,NCT04033705,"The time spent within, above and below the target glucose range (4-10mmol/L) in the post operative period",Post operative infections,,2019-06-11,COMPLETED,OBSERVATIONAL,['NA']
6945,NCT00802269,Pain (NRS-11 scale),,,2008-03,COMPLETED,INTERVENTIONAL,['PHASE4']
6946,NCT00324584,frequency of hypoglycemic episodes (<70 mg/dl),,,2003-04,COMPLETED,INTERVENTIONAL,['PHASE3']
6947,NCT06118931,Average 24-hour glucose total area under the curve (AUC) over 7 days,TRE fasting window adherence,Safety and Adverse Events,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6948,NCT06176703,Glycemic control,Quality of life,,2023-11-22,RECRUITING,INTERVENTIONAL,['NA']
6949,NCT04037098,Decreased of gestational diabetes incidence,,,2022-07-31,WITHDRAWN,INTERVENTIONAL,['NA']
6950,NCT05174975,Change in Glycosylated hemoglobin(HbA1c) levels,Change in Diabetic Positive Characteristics,,2021-10-20,COMPLETED,INTERVENTIONAL,['NA']
6951,NCT01915849,Area Under the Postprandial Curve (AUC) for Rate of Appearance (Ra) of Exogenous Glucose,,,2013-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
6952,NCT03702465,Difference in glucose regulation between the control and intervention arm,Number of participant withdrawals in the trial,,2018-11-26,COMPLETED,INTERVENTIONAL,['NA']
6953,NCT01530048,"Cmax, maximum concentration",Adverse events,,2006-03,COMPLETED,INTERVENTIONAL,['PHASE1']
6954,NCT02506582,Blood glucose level by 2-h oral glucose tolerance tests (OGTTs),,,2013-06,COMPLETED,INTERVENTIONAL,['NA']
6955,NCT01874080,Point estimates and 90% CIs for the ratio of geometric means for AUC(INF) for Saxagliptin and Metformin in the 5/500 mg FDC XR (Mt. Vernon/Humacao) and 5/500 mg FDC XR (Mt. Vernon),"Safety assessments based on adverse event reports and the results of vital sign measurements, ECGs, physical examinations, and clinical laboratory tests",,2013-06,COMPLETED,INTERVENTIONAL,['PHASE1']
6956,NCT03536910,Changes in copeptin levels after general or spinal anesthesia,,,2018-05-01,COMPLETED,INTERVENTIONAL,['NA']
6957,NCT00614055,Change in Glycosylated Haemoglobin (HbA1c),Physical Examination,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE2']
6958,NCT03799185,Prevalence of dyslipidemia,Prevalence of cardiovascular associated risk factors,Dietary assessment,2016-01-04,COMPLETED,OBSERVATIONAL,['NA']
6959,NCT05795972,glycemic control,akkermania levels,,2020-06-01,RECRUITING,INTERVENTIONAL,['NA']
6960,NCT01826162,"Fat oxidation, energy expenditure",Appetite VAS scoring,,2013-04,COMPLETED,INTERVENTIONAL,['NA']
6961,NCT06148376,Precentage of patients whose prandial insulin is wthdrawn,Diabetes treatment satisfaction,,2023-12-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
6962,NCT03029390,Insulin sensitivity,Creatinine levels,,2016-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4']
6963,NCT03851978,Change in vaccination rates,Barriers to receiving vaccination,,2018-11-01,COMPLETED,INTERVENTIONAL,['NA']
6964,NCT01893242,Time to the first occurrence of either component of the composite endpoint: end stage renal disease or cardiovascular death,Time to the first occurrence of any component of composite outcome of end-stage renal disease and all-cause mortality,,2013-12,WITHDRAWN,INTERVENTIONAL,['PHASE3']
6965,NCT00651378,Percent change in LDL-C level from baseline to the study endpoint.,"Adverse events, laboratory test results, vital signs.",,2004-09-01,TERMINATED,INTERVENTIONAL,['PHASE4']
6966,NCT01961674,Temperature at supraclavicular region,Glycaemic response,,2013-11,COMPLETED,INTERVENTIONAL,['NA']
6967,NCT01260246,To demonstrate improvement in liver disease (based on liver biopsy)with sitagliptin.,In individuals with NASH and DM2: To determine the correlation between changes in histology with changes in hepatic fat demonstrated by MRI and changes in fibrosis by Fibroscan.,,2010-12,TERMINATED,INTERVENTIONAL,['NA']
6968,NCT04553380,Incidence of hypoglycemia,Daily doses of insulin at the study end point.,,2020-12-01,UNKNOWN,INTERVENTIONAL,['NA']
6969,NCT02177747,Diabetic retinopathy grading,,,2013-11,COMPLETED,INTERVENTIONAL,['NA']
6970,NCT04354740,Major adverse cardiac events (MACEs),In hospital mortality,,2020-07,UNKNOWN,OBSERVATIONAL,['NA']
6971,NCT06283849,sedentary time,,,2024-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
6972,NCT00504816,blood hormone levels,vital signs,,2007-04,COMPLETED,INTERVENTIONAL,['PHASE1']
6973,NCT03658317,renal resistive index,stage of diabetic nephropathy,,2018-09,UNKNOWN,INTERVENTIONAL,['NA']
6974,NCT03347968,Maximum international normalized ratio (INRmax),Clinical laboratory assessment (urinalysis),,2017-11-27,COMPLETED,INTERVENTIONAL,['PHASE1']
6975,NCT01480362,Time until wound closure within the maximum study treatment time,Adverse Events,,2011-11,COMPLETED,INTERVENTIONAL,['NA']
6976,NCT00919347,"The primary outcome will be to quantify, using the ANSR ANX 3.0 technology, the prevalence of cardiac autonomic neuropathy (CAN), diabetic autonomic neuropathy (DAN),referred to as advanced autonomic nervous system dysfunction in non-diabetic patients.",The strength of various comorbidities as predictors of autonomic dysfunction in both diabetics and non-diabetics will be evaluated. The differential effect of these various comorbidities in Type I versus Type II diabetes on ANS dysfunction and neuropathy,,2009-06,COMPLETED,OBSERVATIONAL,['NA']
6977,NCT04324424,The single dose pharmacokinetics of HMS5552 will be described by estimating parameters of AUCinf,The single dose pharmacokinetics of HMS5552 will be described by estimating parameters of CLr (if applicable),,2019-04-23,COMPLETED,INTERVENTIONAL,['PHASE1']
6978,NCT05736536,Changes of readiness to change for weight loss (behaviour),Changes in body fat composition (anthropometric),,2023-04-01,COMPLETED,INTERVENTIONAL,['NA']
6979,NCT06032988,Effects of probiotics supplementation on glycemic control (HbA1c),Effects of probiotics supplementation on changes in gut microbiota diversity (alpha- and beta-diversity),,2023-08-23,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
6980,NCT00302042,Change in Weight,Change in Dietary Composition,,2005-05,COMPLETED,INTERVENTIONAL,['NA']
6981,NCT02717078,Change in hemoglobin A1c from baseline to week 12,24-hour diet recall,,2017-06-19,COMPLETED,INTERVENTIONAL,['NA']
6982,NCT04771403,Percent of Time With Sensed Glucose <70 mg/dl,Mean Amount of Insulin Delivered Per Day (in Units/Day),,2021-02-23,COMPLETED,INTERVENTIONAL,['NA']
6983,NCT04223895,"Cmax of each main component or metabolite of the component after single dose of CKD-386 F1, CKD-386 F2 and D012, D326, D337","Cmax of each main component or metabolite of the component after single dose of CKD-386 F1, CKD-386 F2 and D326, D337",,2020-02-01,UNKNOWN,INTERVENTIONAL,['PHASE1']
6984,NCT05196958,Weight loss,Impact of aGLP1 on the treatment already in place to regulate blood glucose,,2022-01-25,RECRUITING,INTERVENTIONAL,['NA']
6985,NCT03933696,Cognition,Melatonin Levels,,2019-01-02,RECRUITING,INTERVENTIONAL,['NA']
6986,NCT05222490,Estimate of a difference in temperature between two feet per subject,To evaluate the usability of FeeSee device by patient and healthcare providers,,2021-07-13,UNKNOWN,INTERVENTIONAL,['NA']
6987,NCT02587286,Change in HbA1c,Change in HbA1c,mHealth intervention satisfaction,2015-03,COMPLETED,INTERVENTIONAL,['NA']
6988,NCT05663515,Hazard ratio of primary diagnosis of pancreatic cancer among exenatide exposed population,,,2024-03-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
6989,NCT00349128,Change in fasting triglycerides.,Assessment of lipid and glucose metabolisms.,,2004-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
6990,NCT05838209,clinical attachment level,clinical attachment levels,,2023-04-05,RECRUITING,INTERVENTIONAL,['NA']
6991,NCT04336800,To build a registry of diabetic volunteers by inviting them to get a LiverMultiScanand collecting their contact information to seek interest in participating in future studies.,To use multi-parametric MRI (LiverMultiScan) of the liver to assess liver health,,2020-04-01,COMPLETED,OBSERVATIONAL,['NA']
6992,NCT04474496,Workplace Preventative Actions to Decrease Risk of COVID-19 Exposure,Sources of Stress During COVID-19,,2020-07-27,COMPLETED,OBSERVATIONAL,['NA']
6993,NCT03912480,glucose-c peptide release test,Continuous dynamic blood glucose,,2019-01-05,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
6994,NCT02243176,Absolute Change From Baseline in HbA1c at Week 24 (DAO),Change From Baseline in Body Weight,,2014-09,COMPLETED,INTERVENTIONAL,['PHASE4']
6995,NCT01885546,User's ability to obtain the enhanced meter feature,,,2013-07,COMPLETED,INTERVENTIONAL,['NA']
6996,NCT01154348,Safety and pharmacokinetics of multiple-dose oral co-administration of S-707106 and metformin in fed state in patients with type 2 diabetes mellitus,The effect of multiple doses of metformin on pharmacokinetics of S-707106,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE1']
6997,NCT06278935,Participant satisfaction,DFU-related outcomes,,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
6998,NCT01288300,Changes in glycosylated hemoglobin (Hba1c)from baseline at 3 and 6 months,Changes in diabetes self-empowerment from baseline to 3 and 6 months,,2011-03,COMPLETED,INTERVENTIONAL,['NA']
6999,NCT04498156,Preferences regarding chronic kidney disease in T2D,Time point of communicated CKD diagnosis,,2020-09-16,COMPLETED,OBSERVATIONAL,['NA']
7000,NCT02094911,Change in fasting insulin,Process indicators,,2011-10,UNKNOWN,INTERVENTIONAL,['NA']
7001,NCT06264271,difference in HbA1c,differences in coefficient of variation,,2022-02-01,COMPLETED,OBSERVATIONAL,['NA']
7002,NCT02035059,Development of Gestational Diabetes in second/third trimester,,,2014-05-01,COMPLETED,OBSERVATIONAL,['NA']
7003,NCT02174146,leptin levels in gingival tissue,clinical attachment level,,2013-09,COMPLETED,INTERVENTIONAL,['NA']
7004,NCT00989547,insulin production,"Insulin Dose, Autoantibody levels, T-cell functional response assays, Cytokine levels",glycated hemoglobin (HbA1c),2008-09,UNKNOWN,INTERVENTIONAL,['PHASE1']
7005,NCT00853944,Islet function as measured by hyperglycemic clamp,Change in insulin requirement (absolute and % decrease from pre-transplant dose),,2009-07,TERMINATED,INTERVENTIONAL,['PHASE3']
7006,NCT00224276,,,,na,COMPLETED,OBSERVATIONAL,['NA']
7007,NCT04164966,Characterization of circulating β cell-specific exosomes in children with T1D and healthy normal controls using baseline samples,,,2019-11-27,RECRUITING,OBSERVATIONAL,['NA']
7008,NCT00899470,Metformin T-half and T-max,Number of Participant With Clinically Relevant Physical Examination Abnormalities,,2009-06,COMPLETED,INTERVENTIONAL,['PHASE1']
7009,NCT01880827,Splanchnic blood flow,GIP and GLP-1 blood concetrations,,2013-01,COMPLETED,INTERVENTIONAL,['PHASE1']
7010,NCT01213563,efficacy and safety of an intensive glycaemic protocol after bariatric surgery,,,2009-01,TERMINATED,INTERVENTIONAL,['NA']
7011,NCT01865292,Area under the glucose infusion rate curve,Area under the insulin degludec/insulin glargine curve,,2006-08,COMPLETED,INTERVENTIONAL,['PHASE1']
7012,NCT03165877,Objective satiety,Adherence to treatment,,2016-05-31,COMPLETED,INTERVENTIONAL,['NA']
7013,NCT02977039,Glycemic control,quality of life,,2019-11,WITHDRAWN,INTERVENTIONAL,['NA']
7014,NCT05256303,"Total cost, hospitalization",Percent of day lying down,Qualitative interviews,2022-02-16,COMPLETED,INTERVENTIONAL,['NA']
7015,NCT05394571,ratio of patients who reached the HbA1c target of equal to or below 7%,The effect of the level of physical activity on the HbA1c changes,,2021-08-15,COMPLETED,OBSERVATIONAL,['NA']
7016,NCT01588106,Reduction in HbA1c,,,2012-06,COMPLETED,OBSERVATIONAL,['NA']
7017,NCT04907019,AUC0-∞,CLz/F,,2021-07-06,COMPLETED,INTERVENTIONAL,['PHASE1']
7018,NCT03380988,Postprandial glucose response,,,2015-11,COMPLETED,INTERVENTIONAL,['NA']
7019,NCT01549964,Change From Baseline in Glycosylated Hemoglobin (HbA1c),Change From Baseline in Fasting Plasma Glucose (FPG),,2012-04,TERMINATED,INTERVENTIONAL,['PHASE3']
7020,NCT04612595,increasing by 50% of the serum creatinine level from baseline,,,2018-08-01,UNKNOWN,OBSERVATIONAL,['NA']
7021,NCT02085876,"To determine a correlation coefficient > 0.80, alpha 0.05 and beta 0.20 between the MRI markers relevant.",To determine the correlation between the unsaturated fat measurements and MRI Lipidomics Spectro analysis.,,na,UNKNOWN,OBSERVATIONAL,['NA']
7022,NCT01150292,Platelet function induced by collagen,Evaluation of cellular and plasmatic redox status,,2010-05,COMPLETED,INTERVENTIONAL,['NA']
7023,NCT01084005,HbA1c Change From Baseline to Week 24,Number of Patients With Rescue Therapy,,2010-03,COMPLETED,INTERVENTIONAL,['PHASE3']
7024,NCT01232491,Change From Baseline in Body Weight,Rate of Nocturnal Treatment Emergent Hypoglycaemic Episodes,,2010-10-29,COMPLETED,INTERVENTIONAL,['PHASE4']
7025,NCT04627103,Weight Loss,Albumin - Nutritional Status,,2021-10-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
7026,NCT01528059,Glycemic control,Nutritional status assessment,,2012-02,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
7027,NCT01081938,Glycaemic parameters assessment,"Incidence of symptomatic, nocturnal and severe hypoglycemias",,2010-02,TERMINATED,INTERVENTIONAL,['PHASE4']
7028,NCT05104047,Gracely Pain Scale,Subjective Peripheral Neuropathy Screen (SPNS),Neurological Sensory Testing (NST),2019-07-29,COMPLETED,INTERVENTIONAL,['NA']
7029,NCT00986700,fasting glucose level,,,2009-10,COMPLETED,INTERVENTIONAL,['NA']
7030,NCT02626156,Time Spent in Minutes Engaging in Physical Activities,Knowledge Questionnaire of Study Instructions,,2015-06-01,COMPLETED,INTERVENTIONAL,['PHASE2']
7031,NCT05878431,Neuropathic Pain Impact on Quality of Life Questionnaire (NePIQOL),,,2022-01-01,COMPLETED,INTERVENTIONAL,['NA']
7032,NCT03240289,Patient satisfaction and feedback,Diabetes self-efficacy (Measured using the Perceived Diabetes Self-Management Scale),,2013-12,COMPLETED,INTERVENTIONAL,['NA']
7033,NCT04372355,HbA1c change at Week 8 in comparison to Baseline,HbA1c change at Week 12 in comparison to Baseline,,2019-06-19,COMPLETED,INTERVENTIONAL,['PHASE2']
7034,NCT04934228,Adipose Tissue Sample: Efficacy of 4-week supply of Clonidine Compared VS 4-week supply of control condition using hydrochlorothiazide (HCTZ) and a separate placebo treatment,,,2021-07-01,RECRUITING,INTERVENTIONAL,['PHASE1']
7035,NCT04854512,Change in HbA1c,HbA1c response (Metformin DR vs. metformin IR),,2021-05-18,SUSPENDED,INTERVENTIONAL,['PHASE3']
7036,NCT01961622,Time spent in the target glucose range from 3.9 to 10.0 mmol/l based on subcutaneous glucose monitoring,Continuous subcutaneous glucose monitoring (CGM) based outcome during day period between 08:00 to 23:00,Effect of study intervention based on pre-study glycaemic control,2014-04,COMPLETED,INTERVENTIONAL,['NA']
7037,NCT05360537,Change from Baseline Reactive Hyperemia Index at 3 and 9 months,Change of intra and extra-hospital mortality,,2021-04-01,COMPLETED,INTERVENTIONAL,['PHASE4']
7038,NCT03078478,Number of Severe or BG-confirmed Symptomatic Hypoglycaemic Episodes During Maintenance 2 (36 Weeks),Change in Body Weight From Baseline to End of Treatment (up to 88 Weeks),,2017-03-13,COMPLETED,INTERVENTIONAL,['PHASE3']
7039,NCT00659711,"Change in Reactive Oxygen Species (ROS) Generation by MNC, Protein and mRNA Expression of p47phox Subunit of NADPH Oxidase, in MNC's of Obese Type 2 Diabetic Patients",Change in Oxidative Stress From Baseline to 12 Weeks,,2008-03,COMPLETED,INTERVENTIONAL,['NA']
7040,NCT04705558,change in glycated hemoglobin,change in Body composition,,2020-07-20,UNKNOWN,INTERVENTIONAL,['NA']
7041,NCT01697631,HbA1c (glycosylated haemoglobin),"Hypoglycaemic episodes (minor, major or nocturnal)",,2002-07-22,COMPLETED,INTERVENTIONAL,['PHASE4']
7042,NCT02859116,Tissue collection,,,2016-07-21,COMPLETED,OBSERVATIONAL,['NA']
7043,NCT04251559,Gestational diabetes mellitus risk faktors,,,2014-01-01,COMPLETED,INTERVENTIONAL,['NA']
7044,NCT01388192,Change of glucose metabolism after pancreaticoduodenectomy,,,2011-11,UNKNOWN,OBSERVATIONAL,['NA']
7045,NCT01931137,Area under the serum insulin 338 concentration-time curve,Number of treatment emergent adverse events,,2013-08,COMPLETED,INTERVENTIONAL,['PHASE1']
7046,NCT01078103,,,,2005-07,COMPLETED,OBSERVATIONAL,['NA']
7047,NCT05145452,Muscle endurance,Physical performance,,2021-01-14,SUSPENDED,INTERVENTIONAL,['NA']
7048,NCT02488213,Glicemic control,Adherence to nutritional counseling,,2015-01,UNKNOWN,INTERVENTIONAL,['NA']
7049,NCT04127084,changes of 8-OH-dG,Change in angiotensin,,2019-10-15,UNKNOWN,INTERVENTIONAL,['PHASE4']
7050,NCT01076842,The primary endpoint is the improvement in A1C goal measured in mean reduction in A1c levels over 24 weeks.,Hypoglycemia weight waist-hip ratio frequency of hypoglycemia weight FBGL lipid levels CBC CMP biometric parameters of activity heat flux galvanic skin response heart rate level of physical activity and energy expenditure,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE4']
7051,NCT01318135,Number of Participants With Adverse Events.,Change From Baseline in Blood Glucose Measured by the Meal Tolerance Test (Final Visit).,,2009-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
7052,NCT02057172,Change in baseline in glycosylated haemoglobin (HbA1c) at 12 weeks,Number of subjects attaining goal glycosylated haemoglobin (HbA1c) <7%,Assess the immunogenicity of HM11260C,2014-01,COMPLETED,INTERVENTIONAL,['PHASE2']
7053,NCT01422876,Change From Baseline in Glycosylated Hemoglobin (HbA1c) for Treatment Naive Patients,Occurrence of Treat to Target Efficacy Response for Treatment Naive Patients,,2011-08,COMPLETED,INTERVENTIONAL,['PHASE3']
7054,NCT01659294,diabetes distress (DDS),Depressive Symptoms Severity,,2012-08,COMPLETED,INTERVENTIONAL,['NA']
7055,NCT02938832,Diabetes incidence,Quality of Life,,2016-10,UNKNOWN,INTERVENTIONAL,['PHASE4']
7056,NCT02478190,ED Length of Stay,Return ED visit for any reason,,2015-06,COMPLETED,INTERVENTIONAL,['NA']
7057,NCT03460899,Changes in Platelet Activation Marker Adenosin Diphosphate (%),Changes in Coagulation Marker Fibrinogen (g/L),,2018-02-12,COMPLETED,INTERVENTIONAL,['NA']
7058,NCT03804905,Lacking medication insurance,Time from allocation to use of Trillium Health Partners outpatient pharmacy,Health care costs,2024-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
7059,NCT02157350,Proliferative diabetic retinopathy progression/regression.,"Retinal vessel geometry (caliber, fractals and tortuosity)",Retinal areas of non-perfusion.,2014-08,COMPLETED,INTERVENTIONAL,['PHASE3']
7060,NCT03755479,Achieving glucose values more than 67% in Time in Range (70-180 mg/dl),Time spend in Auto Mode,,2019-02-01,COMPLETED,OBSERVATIONAL,['NA']
7061,NCT05741437,2. Cmax of CKD-378: Maximum plasma concentration of the drug,,,2023-04-11,COMPLETED,INTERVENTIONAL,['PHASE1']
7062,NCT00611988,Maximal treadmill walking distance,,,2006-08,COMPLETED,INTERVENTIONAL,['PHASE2']
7063,NCT03143816,Change in Time in Range (%) (70-180 mg/dl) With TI on CGM,Hypoglycemia Frequency (%) (Below the Target <70mg/dl) on CGM,,2017-09-30,COMPLETED,INTERVENTIONAL,['PHASE4']
7064,NCT00799643,"The Primary Outcome for the TINSAL-T2D Study is Change in HbA1c Level From Baseline to Week 48 From Baseline, Compared Between Treatment Groups.","Response Rates in Patients Initially Treated With Lifestyle Modification, Insulin Secretagogue, Metformin or Combination Therapy",,2008-11,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
7065,NCT00366301,Percentage Reduction in C-reactive Protein (CRP),,,2006-08,TERMINATED,INTERVENTIONAL,['PHASE4']
7066,NCT00364988,Renal function,,,2005-01,COMPLETED,INTERVENTIONAL,['NA']
7067,NCT04143802,Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,Change from Baseline in Mean Daily Plasma Glucose (PG),,2019-12-18,COMPLETED,INTERVENTIONAL,['PHASE1']
7068,NCT01991054,Change in Hba1c (%) in study groups,serum albumin,,2013-12,COMPLETED,INTERVENTIONAL,['PHASE4']
7069,NCT04085926,Percentage of participants with healed foot ulcers at 12 weeks,"Sick-leave from work (number of days per participant) during treatment period (average 12 weeks) and during the period after treatment end up to 12 months later, assessed with study-specific questionnaire and Swedish Social Insurance Agency's system data",,2019-08-02,RECRUITING,INTERVENTIONAL,['NA']
7070,NCT01307137,Compare changes in weight and hemoglobin A1c between participants receiving peer-led care (with or without TAP intervention) and those receiving UC over 12 months.,"Compare changes in health care utilization (physician visits, emergency visits, and days in hospital) among treatment groups (UC, PC, and TAP).",,2011-06,UNKNOWN,INTERVENTIONAL,['NA']
7071,NCT03009513,Area under the plasma concentration versus time curve (AUC),,,2017-01,COMPLETED,INTERVENTIONAL,['PHASE1']
7072,NCT04246814,Change in complete ulcer healing,Short Form-36 Health Survey questionnaire,,2019-08-27,COMPLETED,INTERVENTIONAL,['NA']
7073,NCT05958264,Determination of DeBacker Score of sublingual microcirculation of children,Differences of DeBacker Score of sublingual microcirculation with parameters of healthy children in the same age categories,,2023-02-01,RECRUITING,OBSERVATIONAL,['NA']
7074,NCT04371042,Registry creation,,,2019-09-01,RECRUITING,OBSERVATIONAL,['NA']
7075,NCT04400344,Current state of diabetic foot care education and knowledge base among diabetic educators,,,2020-06-13,UNKNOWN,OBSERVATIONAL,['NA']
7076,NCT00525889,Incidence and severity of adverse events and laboratory anomalies,HbA1c levels,,2007-08,COMPLETED,INTERVENTIONAL,['PHASE1']
7077,NCT05687643,Peak plantar strain,Regional Peak Plantar pressure,,2022-07-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
7078,NCT04493177,"Prevention of overweight/obesity mothers, determined by loss in body mass index (BMI)",Changes in blood concentration of lipids: intervention,,2020-08-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
7079,NCT00334919,Cytokines,Lipids,,2006-05,COMPLETED,INTERVENTIONAL,['PHASE2']
7080,NCT01817127,Human milk glycans,Human Milk Transcriptomics,Alkaline phosphatase levels,2009-04-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
7081,NCT05894252,Quality of life Short Form 36 Health Survey Questionnaire (SF-36) t2,Health Locus Control (Multidimensional Health Locus of Control form C- MHLC) t2,,2023-06,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
7082,NCT03385265,Parent Diabetes Distress,Behavioral Pediatric Feeding Assessment Scale_Problem,,2018-01-01,COMPLETED,INTERVENTIONAL,['NA']
7083,NCT01842282,Hepatic Steatosis by MRI,Weight,,2013-07-19,TERMINATED,INTERVENTIONAL,['PHASE2']
7084,NCT05427916,Number of Participants With Healing Complication,Patient Satisfaction,,2022-07-12,TERMINATED,INTERVENTIONAL,['NA']
7085,NCT05863611,Frailty has an effect on balance in patients with type 2 diabetes.,Frailty has an effect on the risk of falling in patients with type 2 diabetes.,,2023-05-20,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
7086,NCT01497301,Change in Hemoglobin A1C,Change in LDL cholesterol,,2012-02,COMPLETED,INTERVENTIONAL,['NA']
7087,NCT00379548,Insulin resistance assessed by HOMA,,,2005-11,COMPLETED,INTERVENTIONAL,['NA']
7088,NCT02212067,Area under the serum insulin concentration time curve from 10-120 minutes after a 25 g glucose bolus i.v. infusion (IVGTT).,Slope of the ISR vs. glucose curve (dose-response relationship),,2014-08-11,COMPLETED,INTERVENTIONAL,['PHASE1']
7089,NCT03655067,Center for Epidemiological Studies - Depression Scale (CES-D),Problem Areas in Diabetes - Teen version,,2020-12-15,COMPLETED,INTERVENTIONAL,['NA']
7090,NCT02676401,Adverse events,Change from baseline in Urine Albumin to Creatinine Ratio (UACR),,2016-02,COMPLETED,INTERVENTIONAL,['PHASE2']
7091,NCT01000363,"Patients who participate in the diabetes group visits should achieve improvement in Clinical outcomes - better A1C levels, reduced blood pressure, reduced cholesterol levels",behavioral outcomes,,2009-11,COMPLETED,OBSERVATIONAL,['NA']
7092,NCT01366287,"Safety: Safety labs, vital signs, ECGs, physical examinations and adverse event monitoring.",,,2011-01,COMPLETED,INTERVENTIONAL,['PHASE1']
7093,NCT01839071,Fat tissue biopsy,Blood collection,,2010-06,COMPLETED,INTERVENTIONAL,['NA']
7094,NCT00001987,Diabetes control,,,1976-02-01,RECRUITING,OBSERVATIONAL,['NA']
7095,NCT00202748,Change in self-reported activity,Quality of life,,2004-03,UNKNOWN,INTERVENTIONAL,['PHASE3']
7096,NCT02609243,change in hepatic fat content confirmed by proton magnetic resonance spectroscopy by 3 T MR imaging,change in distribution of body fat confirmed by MR-Imaging by 3 T whole body imager,,2013-07,UNKNOWN,INTERVENTIONAL,['NA']
7097,NCT04097483,Diabetes Distress Scale (DDS),Research nurse qualitative and quantitative evaluation about Treatment Adherence and diseases management.,,2017-01,COMPLETED,INTERVENTIONAL,['NA']
7098,NCT00175253,,,,2005-11,COMPLETED,INTERVENTIONAL,['PHASE2']
7099,NCT01946451,Gene expression in patients with idiopathic and secondary epiretinal membranes in proliferative diabetic retinopathy.,,,2012-06,UNKNOWN,OBSERVATIONAL,['NA']
7100,NCT01243424,The First 3-point Major Adverse Cardiovascular Events (3P-MACE),CGM Sub-study : Change From Baseline in the Inter-quartile Range of Diurnal Glucose Variability (Millimoles/ Litre) to End of Study,,2010-11-11,COMPLETED,INTERVENTIONAL,['PHASE3']
7101,NCT03516422,Wound healing,Reduction in bacterial colonization,,2018-11,UNKNOWN,INTERVENTIONAL,['NA']
7102,NCT01087502,HbA1c Change From Baseline to Week 12,Plasma Concentration of Linagliptin at Trough,,2010-03,COMPLETED,INTERVENTIONAL,['PHASE3']
7103,NCT02856516,Area under the blood glucose curve (AUC 0-240),AUC (0-30min) for insulin,,2016-07,COMPLETED,INTERVENTIONAL,['NA']
7104,NCT06148688,International Physical Activity Questionnaire,Blood Sugar Monitoring Form,,2023-03-27,RECRUITING,INTERVENTIONAL,['NA']
7105,NCT00767351,,,,2008-10,COMPLETED,OBSERVATIONAL,['NA']
7106,NCT00845468,,,,2006-01,COMPLETED,OBSERVATIONAL,['NA']
7107,NCT00082381,Change in Glycosylated Hemoglobin (HbA1c),Change in Rate of Hypoglycemic Events,,2003-06,COMPLETED,INTERVENTIONAL,['PHASE3']
7108,NCT01593215,Insulin Secretion,Glucose,,2012-05,COMPLETED,INTERVENTIONAL,['PHASE2']
7109,NCT02956811,Change in left ventricular (LV) Mass by Cardiac MRI at 52 weeks,Change in diastolic function and global longitudinal strain,,2017-02-14,COMPLETED,INTERVENTIONAL,['PHASE4']
7110,NCT05459987,Feasibility of an intensive multidisciplinary program based on lifestyle changes in coronary heart disease patients recently diagnosed with prediabetes that are referred to the Centre EPIC.,"Evolution of the HOMA-IR between the start of the program, the end of intervention (3 months) and the follow-up visit (6 months).",,2022-03-15,COMPLETED,INTERVENTIONAL,['NA']
7111,NCT04106050,Change in Nerve Excitability from Baseline (Day 1) to Last Treatment Visit (Day 8) as Determined by Compound Muscle Action Potential Threshold Tracking (CMAP-TT) in the Median Nerve of Healthy Participants,Time to Reach Maximum Observed Concentration (Tmax),,2020-09-30,WITHDRAWN,INTERVENTIONAL,['PHASE1']
7112,NCT02276859,Postprandial glycemia,Mean amplitude of glycemic excursion,,2014-10,COMPLETED,INTERVENTIONAL,['PHASE4']
7113,NCT02512523,Mean amplitude of glucose excursion (MAGE),"Safety (All AE including SAE, hypoglycemia, laboratory tests, vital sign, and physical examination)",,2015-08,UNKNOWN,INTERVENTIONAL,['PHASE4']
7114,NCT01527630,"Cmax, maximum insulin aspart concentration","t½, terminal half-life",,2002-11-16,COMPLETED,INTERVENTIONAL,['PHASE1']
7115,NCT01145066,Leptin,PBMC Leukotriene Stimulation,,2009-05,COMPLETED,INTERVENTIONAL,['PHASE2']
7116,NCT02160717,Beta-Cell Function measured as Disposition Index,,,2014-05,COMPLETED,OBSERVATIONAL,['NA']
7117,NCT04642378,Time in target glucose range,Daily insulin dose,,2021-10-01,UNKNOWN,INTERVENTIONAL,['NA']
7118,NCT00923962,Coronary metabolite uptake,,,2009-06,COMPLETED,INTERVENTIONAL,['NA']
7119,NCT03380832,Vestibular threshold,,,2017-08-01,UNKNOWN,OBSERVATIONAL,['NA']
7120,NCT00399347,,,,2005-01,COMPLETED,OBSERVATIONAL,['NA']
7121,NCT02045758,Non-Inferiority of Analyte Levels,,,2014-12,UNKNOWN,INTERVENTIONAL,['NA']
7122,NCT03437135,presence or not of an ear wax cap,frequency selectivity of the patient,,2015-12-01,COMPLETED,OBSERVATIONAL,['NA']
7123,NCT02620787,Tedizolid Tissue Penetration,Tedizolid AUC in Plasma,,2016-02-23,COMPLETED,INTERVENTIONAL,['PHASE1']
7124,NCT01301287,HbA1c,Insulin concentration during oral glucose tolerance test,,2010-01,UNKNOWN,INTERVENTIONAL,['NA']
7125,NCT00493935,,,,2006-03,COMPLETED,OBSERVATIONAL,['NA']
7126,NCT04259775,Percent of patients at target range from baseline to 26 weeks,Problem Areas in Diabetes Scale (PAID),,2022-09,WITHDRAWN,INTERVENTIONAL,['NA']
7127,NCT00283049,Change in Hemoglobin A1c (HbA1c) From Baseline to Week 12,"Rate of Hypoglycemia, Symptomatic Hypoglycemia, Severe Hypoglycemia and Serious Hypoglycemia",,2006-02,TERMINATED,INTERVENTIONAL,['PHASE4']
7128,NCT05141565,Mortality,,,2021-05-17,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
7129,NCT01351922,"Percentage of patients having complications (dyslipidemia and hypertension, cardiovascular complications, peripheral vascular disease, diabetic nephropathy and diabetic eye complications)",,,2011-04,COMPLETED,OBSERVATIONAL,['NA']
7130,NCT01341717,Reduction in HbA1c from baseline,Change in lipid profile from baseline,,2012-02,COMPLETED,INTERVENTIONAL,['PHASE4']
7131,NCT01842620,Geometric Means for Maximum Plasma Concentration of the Study Drug (Oxemet) to the Reference Drug (Glafornail) From 0 to 36 h,Time to Reach Maximum Plasma Concentration (Tmax) of the Study Drug (Oxemet) and the Reference Drug (Glafornail) Over Period,,2013-03-13,COMPLETED,INTERVENTIONAL,['PHASE4']
7132,NCT01868568,Area under the insulin aspart concentration curve,Area under the serum insulin 454 concentration curve,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE1']
7133,NCT01410357,SF-36 Health Survey at 60 Weeks; Physical Health Component,Comparison of ISMI (Stigma Resistance) Score Between TTIM and TAU at 60 Weeks,Comparison of PMHSMS (Perceived Mental Health Self-Management Scale) Score Between TTIM and TAU at 60 Weeks,2011-07,COMPLETED,INTERVENTIONAL,['NA']
7134,NCT00732160,Insulin Secretion,Insulin Sensitivity,,2008-09,COMPLETED,INTERVENTIONAL,['NA']
7135,NCT04201938,insulin sensitivity (%S),cytokines levels,,2018-02-01,COMPLETED,INTERVENTIONAL,['NA']
7136,NCT00535925,"""Number of Participants With Overall Fatal and Non-fatal, Major Adverse Cardiovascular Events (MACEs)""","""Number of Participants Who Achieved of BP, HbA1c and Total, HDL and LDL Cholesterol Goals at the End of Intervention Phase""",,2005-10,COMPLETED,INTERVENTIONAL,['PHASE4']
7137,NCT06067451,To determine the impact of SMART Goal setting on BMI z-scores To determine the impact of SMART Goal setting on BMI z-scores,Temporal changes in Lipids,,2023-12-10,RECRUITING,INTERVENTIONAL,['NA']
7138,NCT02324010,Gastric emptying,Appetite,,2015-07,COMPLETED,INTERVENTIONAL,['PHASE2']
7139,NCT01282970,"Safety and tolerability of BI 135585 will be assessed in a descriptive way using physical examinations (occurence of findings), vital signs, electrocardiograms, laboratory tests, and incidence and severity of adverse events.",Exploratory evaluation of the pharmacodynamics of BI 135585 by measuring of cortisol and cortisone and their metabolites in urine,,2011-02,COMPLETED,INTERVENTIONAL,['PHASE1']
7140,NCT02702440,Body weight,,,2015-05,UNKNOWN,OBSERVATIONAL,['NA']
7141,NCT03002155,Chair Stand Test (5x Sit-to-Stand) at 12-week Session,Adverse Events,Recruitment,2017-01,COMPLETED,INTERVENTIONAL,['NA']
7142,NCT01325064,subclinical organ damage,,,2010-06,COMPLETED,OBSERVATIONAL,['NA']
7143,NCT01010594,Change in Hba1c,change in fruit intake,,2009-11,TERMINATED,INTERVENTIONAL,['NA']
7144,NCT04444375,Manchester Foot Pain and Disability Index,,,2017-12-01,COMPLETED,OBSERVATIONAL,['NA']
7145,NCT04688671,Change From Baseline to Week 4 in the Weekly Average of the Daily Pain Score as Derived From the Subject's Responses on the Pain Intensity Numerical Rating Scale (PI-NRS),Change in the Daily Amount of Acetaminophen Use From Baseline to Week 4,,2020-11-09,COMPLETED,INTERVENTIONAL,['PHASE2']
7146,NCT00364767,"enzymes involved in fatty acid oxidation, oxidative phosphorylation and glycolysis in skeletal muscle","insulin sensitivity (oral glucose tolerance test) and related factors (adiponectin, HbA1c)",,2004-10,COMPLETED,INTERVENTIONAL,['NA']
7147,NCT05586542,Adverse events,Cost,,2022-10-03,RECRUITING,INTERVENTIONAL,['PHASE1']
7148,NCT05276778,Patients' acceptance of diabetic retinopathy screenings in general practice,,,2022-02-28,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
7149,NCT02736253,The cases applied amputation(minor or major) and The cases applied major amputation,To Decide Independent Risk factors for AMPUTATION and - for MAJOR AMPUTATION.,,2012-06,COMPLETED,OBSERVATIONAL,['NA']
7150,NCT03368937,System Suitability,,,2017-12-08,COMPLETED,INTERVENTIONAL,['NA']
7151,NCT03993990,Foot infection and recurrence of foot ulcer,Self-efficacy regarding diabetes-related foot ulcer self-management,,2019-08-01,WITHDRAWN,INTERVENTIONAL,['NA']
7152,NCT01216618,Safety,Pharmacodynamic,,2010-10,COMPLETED,INTERVENTIONAL,['PHASE3']
7153,NCT00457938,"Project specific: improvement in serum triglycerides, insulin resistance, liver triglyceride content, liver volume, Hgb A1c,",,,2006-04,COMPLETED,INTERVENTIONAL,['NA']
7154,NCT00314379,Endothelial function by a non-invasive method of FMD,"Predefined in the protocol submitted to the EC approved prior to study beginning and the Inform Consent Form signed by all study participants prior to study related procedures, serum was preserved for the analysis of oxidative and inflammatory markers.",,2006-04,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
7155,NCT01647438,Change in Saturated Fat (% of Daily Kilo-calories From Fat) Intake,,,2012-08,COMPLETED,INTERVENTIONAL,['NA']
7156,NCT05928637,Cmax,,,2023-07-10,COMPLETED,INTERVENTIONAL,['PHASE1']
7157,NCT05870462,Changes in the mean frequency (%) of circulating ALDHhiSSClow primitive progenitor cells in individuals treated with semaglutide versus usual care for 6 months,Changes in the frequency (%) of circulating ALDHhiSSChi pro-inflammatory granulocyte precursors in individuals treated with semaglutide versus usual care for 6 months,,2023-04-29,RECRUITING,INTERVENTIONAL,['PHASE4']
7158,NCT05489536,Incidence of GDM,Physical Activity,,2023-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
7159,NCT03589092,GDM Identification,Clinical outcomes determination,,2017-01-01,UNKNOWN,OBSERVATIONAL,['NA']
7160,NCT02015299,change from baseline carotid-(right) femoral arterial Pulse Wave Velocity (PWV) at 26 weeks,Subclinical vascular inflammation (FDG PET-CT),Lifestyle,2014-03,COMPLETED,INTERVENTIONAL,['PHASE3']
7161,NCT01619059,Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24,Percentage of Participants Achieving a Therapeutic Glycemic Response (Hemoglobin A1c [HbA1C]) <7.0% at Week 24 (Last Observation Carried Forward [LOCF]),,2012-06,COMPLETED,INTERVENTIONAL,['PHASE3']
7162,NCT03798717,Mean AUC (Area Under the Curve) Plasma [Glucose],Change in Inflammatory Status,,2019-02-20,COMPLETED,INTERVENTIONAL,['NA']
7163,NCT05593874,Clinical failure,Time-to-additional-intervention,,2022-10-10,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
7164,NCT05188573,Clinical performance of test: Specificity,Stage Shift,,2022-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
7165,NCT00534014,To determine the optimal oral dose of vitamin C and E to reduce surrogate markers of atherosclerosis (blockages in blood vessels) following the consumption of an atherogenic high fat lunch in type 2 diabetic individuals.,"To study the effects of vitamin C on fibrinogen, insulin, glucose, PAI-1, adiponectin, free MDA, Oxy LDL,CRP, cholesterol, and FFA.",,2006-01,COMPLETED,INTERVENTIONAL,['NA']
7166,NCT00842361,Rate of Nocturnal Major and Minor Hypoglycaemic Episodes,Systolic BP (Blood Pressure),,2009-01,COMPLETED,INTERVENTIONAL,['PHASE2']
7167,NCT03627455,MACE,,,2003-01-01,COMPLETED,OBSERVATIONAL,['NA']
7168,NCT04997460,Correlation of glycated hemoglobin and glycemic variability,Correlation of hypoglycemia and glycemic variability,C-peptide concentration in different pregnancy trimesters,2021-01-11,UNKNOWN,OBSERVATIONAL,['NA']
7169,NCT00036192,,,,2002-02,COMPLETED,INTERVENTIONAL,['PHASE2']
7170,NCT02505308,Maximal Insulin Secretion (composite measure) following formal stimulation (GPAIS) test,Faecal elastase,,2015-03-04,COMPLETED,INTERVENTIONAL,['NA']
7171,NCT01816672,Compare time to heal in Wagner 1 and 2 diabetic foot ulcers at 12 weeks treated with AutoloGel versus usual and customary care,Number of patients with adverse events as a measure of tolerability,,2013-04,TERMINATED,INTERVENTIONAL,['NA']
7172,NCT03451201,Endothelial Dependent Mediated Vascular Dilation,Endothelial independent vascular dilation,,2015-01,COMPLETED,INTERVENTIONAL,['NA']
7173,NCT04682054,counts of each cell type,,,2021-01-15,UNKNOWN,INTERVENTIONAL,['NA']
7174,NCT01344278,Primary outcome: meeting the postpartum weight goal,physical activity,,2011-04,COMPLETED,INTERVENTIONAL,['NA']
7175,NCT03615755,Serum creatinine,,,2016-12-27,COMPLETED,INTERVENTIONAL,['NA']
7176,NCT00985842,Oxygen in tissue,,,2009-11-01,COMPLETED,INTERVENTIONAL,['NA']
7177,NCT03571217,choroidal thickness (CT),,,2014-10-01,RECRUITING,OBSERVATIONAL,['NA']
7178,NCT02820298,T1/2 (Apparent Terminal Elimination Half-life),,,2016-06-20,COMPLETED,INTERVENTIONAL,['PHASE1']
7179,NCT02330939,postprandial incremental glucose AUC,,,2014-06,UNKNOWN,INTERVENTIONAL,['NA']
7180,NCT00106236,hemoglobin A1c,health-related QOL (Quality of Life),,2003-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7181,NCT01501877,Point prevalence abstinence from smoking,,,2011-12,COMPLETED,INTERVENTIONAL,['NA']
7182,NCT03332836,Number of participants with adverse events,AUC of HM12460A,,2017-10-25,TERMINATED,INTERVENTIONAL,['PHASE1']
7183,NCT05656924,Difference in step counts between the two groups,Difference in Prosthesis Evaluation Questionnaire (PEQ) scores in the two groups,,2023-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
7184,NCT05555095,"Patient satisfaction, 1-item researcher generated question",,,2022-09-26,RECRUITING,OBSERVATIONAL,['NA']
7185,NCT00671424,Serum sodium and potassium concentrations:,weight:,,2008-03,COMPLETED,INTERVENTIONAL,['PHASE1']
7186,NCT06017544,MACE,,,2021-01-01,RECRUITING,OBSERVATIONAL,['NA']
7187,NCT03607799,Glucose area-under-the-curve (glucose AUC),Gestational diabetes mellitus,Maternal pregnancy complications,2020-11-26,RECRUITING,INTERVENTIONAL,['NA']
7188,NCT06035523,Percentage of index ulcers (the ulcers being treated in the study) healed at 12 weeks,Change in subjects reported pain levels (NPRS),Cost to closure,2021-12-29,RECRUITING,INTERVENTIONAL,['NA']
7189,NCT00494312,"Incidence of liver inflammation or injury greater than 3 times the upper limit of normal, as monitored by serum alanine aminotransaminase elevation.","Change from Baseline or greater than 1.5 times the upper limit of normal (whichever is greater) in the level of alanine aminotransferase, aspartate aminotransferase, total or direct bilirubin, alkaline phosphatase or gamma-glutamyl transpeptidase.",,2000-10,COMPLETED,INTERVENTIONAL,['PHASE4']
7190,NCT06254274,Change From Baseline in Hemoglobin A1c (HbA1c),Change From Baseline in Fasting Serum Glucose,,2024-02-26,RECRUITING,INTERVENTIONAL,['PHASE2']
7191,NCT02923323,Association between interstitial glucose concentration and EEG power,Association between interstitial glucose concentration and neurocognitive functions,DTI assessment of brain MRI according to HbA1c,2016-03-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
7192,NCT05631119,collect biospecimen samples,,,2022-12-15,COMPLETED,OBSERVATIONAL,['NA']
7193,NCT02055014,Glycated haemoglobin (HbA1c),Weight,,2013-07,UNKNOWN,INTERVENTIONAL,['PHASE4']
7194,NCT05768958,Ad libitum energy intake (KJ) after exercise compared with rest,Borg RPE,,2023-03-22,RECRUITING,INTERVENTIONAL,['NA']
7195,NCT03794232,Incidence of blood sugar reversal to normal after intervention,Body weight,,2016-05-30,COMPLETED,INTERVENTIONAL,['NA']
7196,NCT04755647,To measure the methemoglobin percent level during NORS compared to hypotonic saline administration in participants withe DFU,To measure the efficacy of NORS compared to placebo on the change in wound area in participants with DFU,,2021-02-23,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7197,NCT01725126,Change From Baseline in Fasting Plasma Glucose (Safety Laboratory) Values During the Double-blind Treatment Period of Part B and C,Tmax of Metformin During the Double-blind Treatment Period of Part C,,2013-02-10,COMPLETED,INTERVENTIONAL,['PHASE2']
7198,NCT03112005,Number of subject eyes whose EyeArt results match the reading center grading for identifying vision threatening diabetic eye disease (severe NPDR or PDR or surrogate markers for CSME).,,,2017-04-17,COMPLETED,OBSERVATIONAL,['NA']
7199,NCT00438698,Change in Fasting Glucose,Urinary C-peptide,,2004-09,COMPLETED,INTERVENTIONAL,['NA']
7200,NCT02811484,Change in HbA1c,Change in total dose insulin,,2016-06,WITHDRAWN,INTERVENTIONAL,['PHASE4']
7201,NCT00802152,Hemoglobin A1c (HbA1c) or Systolic blood pressure (SBP),Patient-entered device data,,2009-05,COMPLETED,INTERVENTIONAL,['NA']
7202,NCT04228003,Decreased Gastrointestinal Symptoms,Improvement in A1C,,2021-01-15,WITHDRAWN,INTERVENTIONAL,['NA']
7203,NCT01182493,Between Group Difference in HbA1c When Comparing CSII to MDI,Safety - Diabetic Ketoacidosis Incidence,,2010-12,COMPLETED,INTERVENTIONAL,['NA']
7204,NCT02227862,Change in HbA1c From Baseline to 24 Weeks,Proportion of Patients With HbA1c < 7%,,2014-06,COMPLETED,INTERVENTIONAL,['PHASE3']
7205,NCT06228898,changes in hematologic inflammatory markers with glycemic control,,,2022-01-15,COMPLETED,OBSERVATIONAL,['NA']
7206,NCT05278806,Hypertension control,Breast cancer screening rates,,2022-03-24,COMPLETED,INTERVENTIONAL,['NA']
7207,NCT03595384,Participant Satisfaction With Overall Program,Waist Circumference,,2018-04-29,COMPLETED,INTERVENTIONAL,['NA']
7208,NCT01115088,"Effects of stevia, aspartame, and sucrose on food intake, satiety, and postprandial glucose and insulin levels.",Satiating effects by examining food consumption,,2006-01,COMPLETED,INTERVENTIONAL,['NA']
7209,NCT02712255,Physical activity,Physical activity,Habitual sedentary behavior,2016-03,WITHDRAWN,INTERVENTIONAL,['NA']
7210,NCT00757588,Adjusted Mean Change From Baseline in A1C Levels (Last Observation Carried Forward [LOCF]),Change From Baseline in Mean Total Daily Dose of Insulin (MTDDI) (LOCF),Percentage of Participants With Reported and Confirmed Hypoglycemia,2008-11,COMPLETED,INTERVENTIONAL,['PHASE3']
7211,NCT02413567,Device or procedure related Serious Adverse Events (SAEs) and Unanticipated Adverse Device Effects (UADEs),,,2015-03-23,COMPLETED,INTERVENTIONAL,['NA']
7212,NCT04824586,Intraoperative level of glucose,Insulin quantities,,2019-06-01,COMPLETED,INTERVENTIONAL,['PHASE4']
7213,NCT03506776,change from baseline foot assessment as evidenced by a diabetic foot ulcer,change from baseline foot assessment evidenced by presence or absence of redness,,2017-08-21,COMPLETED,INTERVENTIONAL,['NA']
7214,NCT00879697,Total Walking Distance,,,2005-07,COMPLETED,INTERVENTIONAL,['PHASE3']
7215,NCT04662398,Erectile dysfunction,,,2020-12-05,COMPLETED,INTERVENTIONAL,['NA']
7216,NCT02360527,"Retinal neurodegeneration among three groups of type 2 diabetic patients patients with AD, patients with MCI and patients without AD or MCI.",,,2014-09,COMPLETED,OBSERVATIONAL,['NA']
7217,NCT00712673,Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24,Percentage of Patients With Glycosylated Hemoglobin (HbA1c) Level Less Than or Equal to 6.5% at Week 24,Number of Patients With Symptomatic Hypoglycemia and Severe Symptomatic Hypoglycemia,2008-06,COMPLETED,INTERVENTIONAL,['PHASE3']
7218,NCT02798744,Change from baseline in Total PYY at 24 weeks,Change from baseline in liver functioning to 24 weeks,,2016-12,COMPLETED,INTERVENTIONAL,['PHASE4']
7219,NCT00322075,patients´satisfaction,,,2006-04,COMPLETED,INTERVENTIONAL,['PHASE4']
7220,NCT00747175,"Safety variables (AE, BP, pulse, plasma glucose, laboratory variables and ECG)",Pharmacodynamic variables,,2008-08,COMPLETED,INTERVENTIONAL,['PHASE1']
7221,NCT03367806,All-cause mortality,Cancer mortality,,1999-01,COMPLETED,OBSERVATIONAL,['NA']
7222,NCT01503892,Increased intraepidermal nerve fiber density,Subjective improvement,,2011-12,UNKNOWN,INTERVENTIONAL,['NA']
7223,NCT00464594,FPG >= 140mg/dl and HbA1c >= 7.0%,,,2007-04,UNKNOWN,INTERVENTIONAL,['NA']
7224,NCT05443191,Change in Glycated haemoglobin (HbA1c ),"DTSQs, change in absolute treatment satisfaction",,2022-10-20,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
7225,NCT02289235,Change in score of fatty liver in fibroscan,Number of patients with adverse events,,2019-05-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
7226,NCT00263393,The proportion of individuals with correct knowledge about the effects of behavioural determinants of the risk of cardiovascular disease,The risk factor levels of the population identified as high risk.,,2005-12,COMPLETED,INTERVENTIONAL,['PHASE4']
7227,NCT04492384,rate of letal outcomes depending on pre-existing disease,,,2020-06-29,COMPLETED,OBSERVATIONAL,['NA']
7228,NCT03170752,Proportion of patients who are comprehensively screened to the number of eligible patients seen in the intervention group compared to the control group as assessed by the completeness of CV Screening Checklist data collection form.,The patient and NP factors that influence participation in the CASP as assessed by content analysis of patient and NP feedback questionnaires.,,2017-09-28,COMPLETED,INTERVENTIONAL,['NA']
7229,NCT02023411,SUV Max on PET/CT Scan at 12 Months,Clinical Events,,2014-01,COMPLETED,INTERVENTIONAL,['PHASE2']
7230,NCT00382473,The degree of improvement in fat oxidation during submaximal exercise obtained by indirect calorimetry after subjects have completed an eight week aerobic exercise program.,Increase in fat oxidation from non-plasma sources after the eight week intervention.,,2006-09,TERMINATED,INTERVENTIONAL,['NA']
7231,NCT02535169,Changes in the oral disposition index measured by oral glucose tolerance test,,,2014-05,COMPLETED,INTERVENTIONAL,['NA']
7232,NCT00829660,A composite cardiovascular outcome defined as the time after randomisation to the first occurrence of any one of the following: -Cardiovascular death -Non-fatal MI -Non-fatal stroke -Hospitalisation for Unstable Angina -Hospitalisation for Heart Failure,"Resource use, costs and cost effectiveness",,2009-02-17,COMPLETED,INTERVENTIONAL,['PHASE4']
7233,NCT03053336,Change in physical activity level (counts/min from accelerometers),Blood pressure (mmHg),Social support for exercise assessed using a 6 item questionnaire,2017-02-21,COMPLETED,INTERVENTIONAL,['NA']
7234,NCT04237311,Semen quality assessment,Semen quality assessment,,2020-05-01,UNKNOWN,OBSERVATIONAL,['NA']
7235,NCT03170089,Patient awareness,Oral hygiene,,2017-06-30,UNKNOWN,INTERVENTIONAL,['NA']
7236,NCT01881919,Risk of getting hyperuricemia assessed by the measure of plasma uric acid.,Metabolomic and metabonomic profiling of blood plasma,Primary health assessment,2013-02,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
7237,NCT00712439,The primary study objective is to assess the relative efficacy of G-ER versus placebo in reducing the mean daily pain score from the baseline week to end of efficacy treatment period (Treatment Week 4) in patients with DPN.,"Secondary efficacy measures will include changes from baseline in average daily sleep interference scores, SF-MPQ, BPI,NPS, PGIC, and CGIC.",,2006-04,COMPLETED,INTERVENTIONAL,['PHASE2']
7238,NCT05365152,Time required for blood sugar to reach target,,,2022-04-01,RECRUITING,INTERVENTIONAL,['NA']
7239,NCT00434772,glucose,hospitalisation days,,2007-12,COMPLETED,INTERVENTIONAL,['PHASE2']
7240,NCT02155023,difference between calibrated measurements and reference,evaluate necessary run-in procedures by assessment of error over time,Malfunction of the systems,2014-01,COMPLETED,INTERVENTIONAL,['NA']
7241,NCT03196024,Change in tobacco use,Support for healthy behaviors,,2017-10-05,COMPLETED,INTERVENTIONAL,['NA']
7242,NCT00005135,,,,1991-09,COMPLETED,OBSERVATIONAL,['NA']
7243,NCT01306981,Best corrected visual acuity,Extent of retinal neovascularisation,,2011-03-30,COMPLETED,INTERVENTIONAL,['PHASE4']
7244,NCT03936023,"Relative hazard of composite outcome of Stroke, MI, and Mortality",,,2017-09-22,COMPLETED,OBSERVATIONAL,['NA']
7245,NCT02579395,Objective Physical Activity via accelerometer,Physical Activity Partner Investment Scale,,2015-10,COMPLETED,INTERVENTIONAL,['NA']
7246,NCT01535677,Maximum concentration (Cmax),Safety profile description in term of Safety Labs,,2013-04,COMPLETED,INTERVENTIONAL,['PHASE1']
7247,NCT01087086,Glucose Profile,Fatty Liver biomarkers / Non invasive liver scoring system.,,2010-01,COMPLETED,INTERVENTIONAL,['NA']
7248,NCT05203471,Proportion of patients receiving guideline-concordant vascular and infectious disease care processes,Proportion of patients undergoing amputation,Patient retention rate,2023-02-16,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
7249,NCT03602846,APGAR Score,Method of Delivery,Glycated Hemoglobin (HbA1c),2015-01,COMPLETED,OBSERVATIONAL,['NA']
7250,NCT02089126,HbA1c Changes,,,2014-06,UNKNOWN,INTERVENTIONAL,['PHASE3']
7251,NCT01427257,Pharmacokinetics,Safety/Tolerability,,2012-02,COMPLETED,INTERVENTIONAL,['PHASE1']
7252,NCT01032629,"Major Adverse Cardiovascular Events (MACE) Composite of Cardiovascular (CV) Death, Non-Fatal Myocardial Infarction (MI), and Non-Fatal Stroke",Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C) to High-Density Lipoprotein-Cholesterol (HDL-C) Ratio at End-of-Treatment,,2009-12-09,COMPLETED,INTERVENTIONAL,['PHASE3']
7253,NCT03473262,Changes in Fasting Plasma Glucose From Baseline to Week 24,Percentage of Patients With At Least 1 Episode of Genitourinary Tract Infections Between Baseline and Week 24,,2017-01-01,COMPLETED,OBSERVATIONAL,['NA']
7254,NCT02042339,ICG (indocyanine green) video angiography,High performance 3D LifeViz™ system,Endothelial progenitor cells,2019-12,UNKNOWN,INTERVENTIONAL,['PHASE3']
7255,NCT00882726,Safety and tolerability of a single IV or SC administration of CNTO 3649 in healthy participants; Safety and tolerability of multiple SC injections of CNTO 3649 in Type 2 Diabetic Patients,"Pharmacokinetics, pharmacodynamics and immunogenicity of CNTO 3649 following single and multiple administrations.",,2009-02,COMPLETED,INTERVENTIONAL,['PHASE1']
7256,NCT01726777,"Change in plasma glucose concentration 2 hours after consuming 75g oral glucose (2 hour PC glucose, or 2hrPC glucose)",Correlation between changes in serum 25-hydroxy-vitamin D concentration (25(OH)D) and changes in 2 hour PC glucose,Urinary calcium:creatinine ratio,2012-10,COMPLETED,INTERVENTIONAL,['PHASE2']
7257,NCT06060886,Number of patients with a therapeutic response to aripiprazole or paliperidone,Number of patients with side effects,,2023-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
7258,NCT06156137,The composite adverse outcomes,,,2023-08-01,RECRUITING,OBSERVATIONAL,['NA']
7259,NCT04441658,The changes in HbA1C level,The changes in blood glucose level,,2020-04-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7260,NCT00701155,Incidence of serious ADRs incl. major hypoglycemias,Variability in fasting Blood Sugar and average plasma glucose levels,,2007-07,COMPLETED,OBSERVATIONAL,['NA']
7261,NCT01064687,Change From Baseline to 26 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c),Pharmacokinetics: Area Under the Concentration Curve (AUC) for LY2189265,,2010-02,COMPLETED,INTERVENTIONAL,['PHASE3']
7262,NCT02305381,Change in HbA1c (Glycosylated Haemoglobin),HbA1c Below or Equal to 6.5% (48 mmol/Mol) American Association of Clinical Endocrinologists (AACE) Target,,2014-12-01,COMPLETED,INTERVENTIONAL,['PHASE3']
7263,NCT00796744,The Primary Efficacy Parameter Will be the Proportion of Ulcers Healed by 12 Weeks as Defined as 100 % Epithelialized With no Drainage.,The Time to Re-epithelialization of the Ulcer Site.,,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2']
7264,NCT01181440,Proportion of patients with complete wound closure,Recurrence of the ulcer,,1994-09,COMPLETED,INTERVENTIONAL,['PHASE3']
7265,NCT04938869,Change in Diabetes Treatment Satisfaction Questionnaire (DTSQ) survey score,Incidence of adverse events,,2021-10-05,COMPLETED,INTERVENTIONAL,['NA']
7266,NCT04849143,Wound size reduction,,,2021-09-01,RECRUITING,INTERVENTIONAL,['NA']
7267,NCT02607345,the difference in glycemic index between 25gr. Zusto® and 25gr. Glucomedics®,,,2015-02,COMPLETED,INTERVENTIONAL,['NA']
7268,NCT03847779,Changes in average spectral amplitude of the entire frequency range between baseline and after stimulus,,,2019-02-04,COMPLETED,INTERVENTIONAL,['NA']
7269,NCT01977560,Skeletal muscle insulin sensitivity,Skeletal muscle mitochondrial metabolites,,2013-10,COMPLETED,INTERVENTIONAL,['NA']
7270,NCT04472962,The area over the curve (AOC).,Satiety (assessed by visual analog scale after pre-exercise meal) during the in-clinic period,,2020-08-14,COMPLETED,INTERVENTIONAL,['NA']
7271,NCT04495881,HbA1c change,Glycated Albumin（GSA）change,,2020-01-01,RECRUITING,INTERVENTIONAL,['PHASE4']
7272,NCT05795309,Percentage time spent in glucose target (3.9-10mmol/L),Percentage time spent in hyperglycaemia (>10mmol/L),,2023-08-16,RECRUITING,INTERVENTIONAL,['NA']
7273,NCT05243238,MNSI score for neuropathy,,,2020-03-01,COMPLETED,INTERVENTIONAL,['NA']
7274,NCT06145360,Number of participants achieved HbA1c level i.e. <7%,systolic blood pressure and diastolic blood pressure,,2023-12-31,RECRUITING,INTERVENTIONAL,['PHASE4']
7275,NCT03581266,Investigate glucose kinetics after ingestion of wheat and rye breads,,,2015-06-01,COMPLETED,INTERVENTIONAL,['NA']
7276,NCT00470418,Safety Assessments: Number of Participants With Adverse Events,Changes From Baseline in Clinical Measures of Cognition at Terminal Visit,,2007-01,COMPLETED,INTERVENTIONAL,['PHASE2']
7277,NCT01494298,ApoB Levels in African American Men With Diabetes and Those Without.,Lipoprotein a [Lp(a)] in African Americans With Diabetes and Without.,,2011-12,COMPLETED,OBSERVATIONAL,['NA']
7278,NCT03961347,Adverse Event and/or Serious Adverse Event,,,2020-02-01,RECRUITING,INTERVENTIONAL,['PHASE2']
7279,NCT06188013,differential proteins of exosomes,,,2024-01-02,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
7280,NCT04143321,Seattle angina questionnaire 1,Seattle angina questionnaire 5,Exercise tolerance test 3,2018-09-10,COMPLETED,INTERVENTIONAL,['PHASE4']
7281,NCT00552734,Decrease in A1c of at least 0.4% in the insulin guidance software group as compared to the control group at 6 months and/or 1 year.,"Hypoglycemic episodes, weight gain, insulin dose, frequency of self monitoring of glucose",,2005-07,COMPLETED,OBSERVATIONAL,['NA']
7282,NCT03748810,Changes in fasting plasma glucose from baseline to week 156 (3-year),Percentage of patients with at least 1 episode of genitourinary tract infections between baseline and week 156 (3-year),,2016-01-01,COMPLETED,OBSERVATIONAL,['NA']
7283,NCT01257451,To evaluate the proportion of vildagliptin treated patients achieving HbA1c reduction and/or proportion reaching investigator defined target HbA1c relative to placebo,To assess the responder rates of patients treated with vildagliptin as compared to placebo,,2010-12,COMPLETED,INTERVENTIONAL,['PHASE3']
7284,NCT02713555,Change from baseline diabetes status at 12 months after surgery,Assessment of changes in Glucagon levels from baseline,,2016-07,COMPLETED,INTERVENTIONAL,['NA']
7285,NCT00102466,Change from baseline in HbA1c at 52 weeks,Patients with reduction in HbA1c >/= 0.5% after 52 weeks,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE3']
7286,NCT02667327,Incidence of complete wound closure at Week 12 based on investigator assessment,Time in days to first complete wound closure of the target ulcer based on investigator assessment over the 12 week treatment period,,2018-11-21,TERMINATED,INTERVENTIONAL,['PHASE3']
7287,NCT00212290,Beta-amyloid in spinal fluid (sub-study),"Blood levels of insulin, insulin degrading enzyme, cortisol and inflammatory markers",,2002-11,COMPLETED,INTERVENTIONAL,['PHASE4']
7288,NCT00755846,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Day 85.,Mean Percent Incidence of Marked Hyperglycemia (Fasting Plasma Glucose ≥ 200 mg/dL).,,2005-03,COMPLETED,INTERVENTIONAL,['PHASE2']
7289,NCT03067480,Time Spent in Target Range,,,2017-06-06,TERMINATED,INTERVENTIONAL,['NA']
7290,NCT00711490,Change in Visual Acuity From Baseline to 6 Months,"Change in Fluid Leakage in the Macula of the Study Eye From Baseline to 12 Months, as Measured on Fluorescein Angiography (FA)",,2008-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7291,NCT02970357,The DIAPASON questionnaire,Psychological indicators,,2016-01-26,COMPLETED,INTERVENTIONAL,['NA']
7292,NCT04665999,Insulin sensitivity computed using a Kalman filter-base algorithm embedding a model of glucose-insulin dynamics.,,,2021-01-15,COMPLETED,OBSERVATIONAL,['NA']
7293,NCT03601910,Cmax of CKD-380 and D308,,,2018-07-16,UNKNOWN,INTERVENTIONAL,['PHASE1']
7294,NCT05315037,Assess glucose response to different resistance training methods,To assess for correlation between lactate and glucose using different resistance training methods,,2023-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
7295,NCT04264793,Change in HbA1c,Change in Diabetes Treatment Satisfaction Score,,2011-11-20,COMPLETED,INTERVENTIONAL,['NA']
7296,NCT04537676,Quality of Life Score (ulcer-specific),,,2020-09-15,UNKNOWN,OBSERVATIONAL,['NA']
7297,NCT01635361,Operation of the NMS,Professional relationships,,2012-08,COMPLETED,INTERVENTIONAL,['NA']
7298,NCT03298295,Area of inflammation (mm2),Macrophage marker gene expression (fold change),,2018-02-01,RECRUITING,INTERVENTIONAL,['NA']
7299,NCT03464045,occurence of renal cancer,occurence of other urinary tract cancers,,2016-11-16,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
7300,NCT05772507,relative wound area reduction (RWAR),Nature and incidence of Treatment Adverse Effects as assessed in percentage for each dressing,,2023-08-22,RECRUITING,INTERVENTIONAL,['NA']
7301,NCT03204240,Change in beta cell function,Change in muscle fatigue,,2018-01-01,COMPLETED,INTERVENTIONAL,['NA']
7302,NCT01564550,VLDL1 and VLDL2-triglyceride secretion rate (µmol/min),,,2012-11,COMPLETED,OBSERVATIONAL,['NA']
7303,NCT02582242,Change in Glycosylated Haemoglobin (HbA1c),Change From Baseline in Patient-reported Treatment Satisfaction as Assessed by the Diabetes Treatment Satisfaction Questionnaire (Status) (DTSQs),,2015-10-19,COMPLETED,INTERVENTIONAL,['PHASE4']
7304,NCT01690572,MACE-rate,OCT-measurement,,2012-10,TERMINATED,INTERVENTIONAL,['NA']
7305,NCT03113448,Visual analog scale (0-100 mm.),Neuropathic Pain Scale (NPS),,2017-01-19,COMPLETED,INTERVENTIONAL,['PHASE3']
7306,NCT03572166,The primary outcome is the overall diagnostic accuracy - defined as the proportion of correct diagnoses - of each diagnostic procedure in differentiating patients with central diabetes insipidus from patients with primary polydipsia.,Frequency of test preference at follow up visit,,2018-09-03,COMPLETED,INTERVENTIONAL,['NA']
7307,NCT01680341,Change From Baseline in HbA1c (Glycosylated Haemoglobin) (%),Number of Treatment Emergent Nocturnal (00:01-05:59) Confirmed Hypoglycaemic Episodes,,2012-08-31,COMPLETED,INTERVENTIONAL,['PHASE3']
7308,NCT00856284,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 104,Change From Baseline in Body Weight Over Time,,2009-03,COMPLETED,INTERVENTIONAL,['PHASE3']
7309,NCT00001395,,,,1994-03,COMPLETED,OBSERVATIONAL,['NA']
7310,NCT04863313,Change of blood glycated hemoglobin (HbA1c) concentration from baseline to week 12.,Adherence to the intervention at week 12.,,2021-03-11,COMPLETED,INTERVENTIONAL,['NA']
7311,NCT04185558,Incidence of complete wound closure by 12 weeks,Number of patients showing a consistence wound closure post healing determination,,2019-12-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
7312,NCT03144271,Number of Adverse Events,Morning fasting glucagon,,2007-06-11,COMPLETED,INTERVENTIONAL,['PHASE1']
7313,NCT03280914,Control rate of hypertension,Medical cost,,2017-08-01,COMPLETED,OBSERVATIONAL,['NA']
7314,NCT04537884,Ocular and systemic safety and tolerability of a single intravitreal injection of UBX1325 evaluated by the incidence of dose limiting toxicities (DLTs) and treatment emergent adverse events (TEAEs),Plasma concentration of UBX1325 following a single intravitreal injection,,2020-10-08,COMPLETED,INTERVENTIONAL,['PHASE1']
7315,NCT06327633,Change of olfactory brain activation by fMRI,Change of metabolism,,2024-01-01,RECRUITING,INTERVENTIONAL,['NA']
7316,NCT00585494,Prevalence of Hyperglycemia in the Elective Orthopedic Population,Prevalence of Adverse Outcomes in the Hyperglycemic Elective Orthopedic Population.,,2007-12,COMPLETED,OBSERVATIONAL,['NA']
7317,NCT01843127,Area under the concentration-time curve (AUC) of plasma glucagon during the standard meal test (SMT),"Adverse events, physical examinations, clinical laboratory determinations, electrocardiograms (ECG), and vital sign assessments.",,2013-04,COMPLETED,INTERVENTIONAL,['PHASE1']
7318,NCT00231673,Change in peroneal nerve conduction velocity (NCV) from baseline to the end of the double-blind phase.,"Changes from baseline to the end of the double-blind phase in NCVs of the sural sensory nerve and ulnar (motor and sensory) nerve, and changes in amplitudes and latencies of the peroneal motor, sural sensory, and ulnar nerves. Adverse event reporting.",,2001-07,COMPLETED,INTERVENTIONAL,['PHASE2']
7319,NCT02607410,improvement in HbA1c levels,improvement on alpha cell function with a meal test,,2010-01,COMPLETED,INTERVENTIONAL,['PHASE4']
7320,NCT04891575,Change in tobacco use,,,2021-09-11,RECRUITING,INTERVENTIONAL,['NA']
7321,NCT05806190,Time spent in hypoglycaemia,Hospital Anxiety and Depression (HADS) Score,,2023-04-17,COMPLETED,OBSERVATIONAL,['NA']
7322,NCT05451147,OBJECTIVE PARAMETERS,SUBJECTIVE PARAMETERS,,2018-09-03,COMPLETED,INTERVENTIONAL,['PHASE3']
7323,NCT03807596,Gain in clinical attachment level,,,2017-03-16,COMPLETED,INTERVENTIONAL,['NA']
7324,NCT01492959,Change in HbA1c (glycosylated haemoglobin),Adverse events: Serious and non-serious,,2004-03-23,COMPLETED,OBSERVATIONAL,['NA']
7325,NCT04082585,Correlation of Global Health Scores to Social Determinants of Health,Change from Baseline - HDL Cholesterol Ratio,,2019-09-04,COMPLETED,OBSERVATIONAL,['NA']
7326,NCT01924767,Assessment of Tolerability by Investigator,Serum Insulin,,2007-07,COMPLETED,INTERVENTIONAL,['PHASE1']
7327,NCT00727896,"Behavioural changes resulting in diet, better adherence to treatment.","Reduction in HbA1c, other glycemic measures and improvement in blood lipid parameters",,2008-08,COMPLETED,INTERVENTIONAL,['PHASE1']
7328,NCT01178723,blood glucose balance,lipid profile,,na,UNKNOWN,INTERVENTIONAL,['NA']
7329,NCT00397631,Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24,Change From Baseline in 2-hour PPG (Post-prandial Glucose) at Week 24,,2006-12-19,COMPLETED,INTERVENTIONAL,['PHASE3']
7330,NCT00906919,A1C,Cholesterol levels,,2004-04,COMPLETED,INTERVENTIONAL,['NA']
7331,NCT00831129,Change in High-sensitivity C-reactive Protein,Change in Body Mass Index,,2006-09,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
7332,NCT03155568,failure rate,Duration of motor blockade,,2017-06-15,UNKNOWN,INTERVENTIONAL,['NA']
7333,NCT00867594,To determine the safety and tolerability of multi-doses of Oramed oral insulin in people with type 1 diabetes,To determine if oral insulin is likely to improve glycemic stability assessed by the reduction of the frequency and severity of hypoglycemic episodes in people with unstable type 1 diabetes,,2008-07,COMPLETED,INTERVENTIONAL,['PHASE2']
7334,NCT03983499,HbA1c Blood Value,Generalized Anxiety Disorder 7-item (GAD-7),,2015-07-16,COMPLETED,INTERVENTIONAL,['NA']
7335,NCT03847701,MAGE comparison following 3 months of intake of a diet either high or low in SDS,Characterisation of the percent of compliance to H-SDS diet in free living conditions,,2019-06-25,UNKNOWN,INTERVENTIONAL,['NA']
7336,NCT00854113,VZ/F,,,2009-02,COMPLETED,INTERVENTIONAL,['PHASE1']
7337,NCT04564872,HbA1c Change From Baseline at Week 24,Percentage of Patients Required Use of Rescue Therapy or Dropout due to Hyperglycemia and Week 52,,2020-11-13,COMPLETED,INTERVENTIONAL,['PHASE3']
7338,NCT04322032,Cmax,,,2020-04-06,UNKNOWN,INTERVENTIONAL,['PHASE1']
7339,NCT01221519,"Measure: rate and extent of absorption of AZD1656 following single-dose administration of Tablets A, B, and C, administered before food intake and following administration of Tablet B after food intake, by assessment of tmax of AZD1656.","pharmacodynamics of AZD1656 following single-dose administration of Tablets A, B, and C, given before food intake and following administration of Tablet B after food intake, by assessment of AUC(0-4) for insulin",,2010-09,COMPLETED,INTERVENTIONAL,['PHASE1']
7340,NCT05147896,Change in structural arterial wall characteristics,"Correlations between changes in rate of cIMT reduction, % of endothelial function improvement and rate of arterial stiffness reduction on one hand and changes in concentration of sdLDL, % of HbA1c and concentration of hsCRP on the other",,2022-05-01,RECRUITING,INTERVENTIONAL,['NA']
7341,NCT01008345,level of oxidized LDL cholesterol at end of study,small dense LDL level,,2008-09,COMPLETED,INTERVENTIONAL,['PHASE4']
7342,NCT05263401,Postprandial P-glucose,Differences in circulating concentrations of gastrin,,2022-01-01,COMPLETED,INTERVENTIONAL,['NA']
7343,NCT00335413,Changes in glomerular filtration rate,Changes in fractional albumin clearance,,2006-06,COMPLETED,INTERVENTIONAL,['PHASE4']
7344,NCT03197363,Death or the occurrence of diseases,,,2018-11-05,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
7345,NCT03397147,Child Sleep Quality,Parental Diabetes Distress,,2018-07-05,COMPLETED,INTERVENTIONAL,['NA']
7346,NCT00296400,Urinary Protein/Creatinine Ratio at Week 52 [LOCF],Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 52,,2006-02,COMPLETED,INTERVENTIONAL,['PHASE2']
7347,NCT02737423,"Improvement in painful diabetic neuropathy by the use of vitamin D Injections (600,000 IU) assessed with the DN4 Neuropathic Pain Diagnostic Questionnaire","Improvement in painful diabetic neuropathy by the use of vitamin D Injections (600,000 IU) assessed with the SF-Mac Gill Pain Questionnaire.",,2012-06,COMPLETED,INTERVENTIONAL,['NA']
7348,NCT03607448,System Performance,System Related Adverse Device Effects,,2018-07-23,COMPLETED,OBSERVATIONAL,['NA']
7349,NCT01783327,Change from baseline quality of life over 12 months,Change from baseline quality adjusted life years over 12 months,,2012-07,COMPLETED,INTERVENTIONAL,['NA']
7350,NCT00361608,,,,2008-07,WITHDRAWN,OBSERVATIONAL,['NA']
7351,NCT04303468,Postprandial glycaemic response during a 2 hour oral glucose tolerance test (OGTT),Plasma glutamate concentration,,2020-09-29,COMPLETED,INTERVENTIONAL,['NA']
7352,NCT04853615,SGLT2i proves protective effect,SGLT2i is non inferior to allopurinol,,2021-07-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
7353,NCT01826409,Glucose profiles during meal tolerance test,Change in lipid profiles,,2008-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
7354,NCT00728598,"Vitreous levels and serum levels of Fractalkine, VEGF, other growth factor.",,,1998-01,COMPLETED,OBSERVATIONAL,['NA']
7355,NCT00141076,Insulin sensitivity as measured by FS-IVGTT,Thermic effect of food,,2003-10,COMPLETED,INTERVENTIONAL,['NA']
7356,NCT04618744,Number of treatment-related adverse events,Percent change in liver fat content,,2020-11-24,COMPLETED,INTERVENTIONAL,['PHASE2']
7357,NCT02304497,PRF levels of insulin like growth factor -1 (IGF-1),,,2013-03,COMPLETED,OBSERVATIONAL,['NA']
7358,NCT01080976,Search Engine Preference,,,2010-03,COMPLETED,OBSERVATIONAL,['NA']
7359,NCT04379726,TASK 4: incidence of post-transplant diabetes in subjects without CFRD,TASK 3: variations of other respiratory and muscle-performance parameters,,2020-07-01,UNKNOWN,OBSERVATIONAL,['NA']
7360,NCT04764786,the between-group difference in postprandial glycemia changes after the dietary interventions,,,2019-04-01,COMPLETED,INTERVENTIONAL,['NA']
7361,NCT02898155,Rate of potentially avoidable admissions,Standardized Rate of potentially avoidable admissions,,2016-06,COMPLETED,OBSERVATIONAL,['NA']
7362,NCT06104358,Sleeping Metabolic Rate (SMR) change from Baseline to 6 Months (26 weeks),,,2023-11-17,WITHDRAWN,INTERVENTIONAL,['PHASE2']
7363,NCT04735042,Change from Baseline of total bacterial load,Triglycerides,,2020-10-07,UNKNOWN,OBSERVATIONAL,['NA']
7364,NCT03283657,Intent to treat questionnaire: Participant initiation of treatment to intensive lifestyle (ILI) or Metformin,,,2017-11-01,COMPLETED,INTERVENTIONAL,['NA']
7365,NCT05074732,Reduction in violence,Improving overall functioning level,,2019-12-01,RECRUITING,OBSERVATIONAL,['NA']
7366,NCT06007404,Monocyte /macrophage populations by flow cytometry,Triglycerides (MMTT),,2023-09-06,RECRUITING,OBSERVATIONAL,['NA']
7367,NCT03008395,Hemoglobin A1c,Diabetes Distress,,2017-10,WITHDRAWN,INTERVENTIONAL,['NA']
7368,NCT02615353,Insulin Sensitivity,Body Composition,,2016-05-13,COMPLETED,INTERVENTIONAL,['NA']
7369,NCT00501878,Pupil diameters were measured.,blood pressure and heart rate were measured,,2007-05,COMPLETED,INTERVENTIONAL,['PHASE4']
7370,NCT03753087,Change in 6-minute walking distance (6MWD),Change in Minnesota Living With Heart Failure Questionnaire (MLHFQ) score,,2019-01-16,COMPLETED,INTERVENTIONAL,['PHASE4']
7371,NCT00690755,Alterations in PKC-zeta mRNA in Vastus Lateralis Skeletal Muscles,,,2000-05,COMPLETED,OBSERVATIONAL,['NA']
7372,NCT00340938,,,,2004-11-08,COMPLETED,INTERVENTIONAL,['PHASE1']
7373,NCT02702011,Change From Baseline in 24 Hour UGE on Day 7,,,2016-03-20,COMPLETED,INTERVENTIONAL,['PHASE2']
7374,NCT06069583,Self-efficacy for diabetes management,Cost effectiveness (HbA1c),"Experience with Support platform (Barriers, facilitators, satisfaction, fidelity) - Health Care Provider",2024-01-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
7375,NCT02513888,fasting glucose (mg/dL),TC (mg/dL),,2013-02-01,COMPLETED,INTERVENTIONAL,['NA']
7376,NCT05144750,Change in Food Security,Self Reported Improved Health,,2021-12-06,COMPLETED,INTERVENTIONAL,['NA']
7377,NCT01858532,Time to the First Occurrence of a Component of the Composite Renal Endpoint in the Intent-to-Treat (ITT) Responder Set (as Randomized),Time to the Cardiovascular Composite Endpoint in the Intent-to-Treat (ITT) Responder Set (as Randomized),,2013-05-17,TERMINATED,INTERVENTIONAL,['PHASE3']
7378,NCT06320756,Therapist Satisfaction feedback collected through 3 quantitative questions and 1 free text qualitative question on the app,Change in mental health distress as measured by the Diabetes Distress Scale (DDS-17),,2024-02-23,RECRUITING,INTERVENTIONAL,['NA']
7379,NCT04227626,Average plasma glucose over the closed-loop control period,Dextrose dosing (g/kg),,2021-04,WITHDRAWN,INTERVENTIONAL,['NA']
7380,NCT02180152,Weight gain after postprandial walks in obese pregnant women.,,,2015-03,WITHDRAWN,INTERVENTIONAL,['NA']
7381,NCT02706977,Change in Visual Acuity assessed by the Standard Snellen Static Chart,,,2016-01,COMPLETED,INTERVENTIONAL,['PHASE1']
7382,NCT00678145,Change in the counterregulatory responses to hypoglycemia compared to controls,Symptom scores,,2008-03,UNKNOWN,INTERVENTIONAL,['PHASE2']
7383,NCT01667016,Target Lesion Failure (TLF),Clinical Procedural Success,,2012-08,COMPLETED,OBSERVATIONAL,['NA']
7384,NCT02356848,Ulceration,step count,,2015-09-03,COMPLETED,INTERVENTIONAL,['NA']
7385,NCT02588729,"Oral glucose tolerance test (OGTT), fasting and 2 hours blood glucose level after intake up til 75gr glucose (1.75gr/kg body weight)",HbA1c,,2015-10,COMPLETED,INTERVENTIONAL,['NA']
7386,NCT01476384,Glycocalyx permeability,Microvascular density,,2010-10,COMPLETED,INTERVENTIONAL,['NA']
7387,NCT02459691,Change in weight from baseline,Clinically significant weight loss,,2014-09,COMPLETED,INTERVENTIONAL,['NA']
7388,NCT06189638,Clinical response,Wound infection Score and Total Wound Score,,2024-01-08,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
7389,NCT01777893,Incidence of type 2 diabetes,In a sub-group: Insulin Growth factor 2 (IGF-II) and IGF-II receptor (IGF2R),Direct and indirect costs.,2013-06,COMPLETED,INTERVENTIONAL,['NA']
7390,NCT02536768,HIV viral supression using lab data,,,2015-09,COMPLETED,INTERVENTIONAL,['NA']
7391,NCT02188823,Hemoglobin A1c,Body weight,,2014-07,TERMINATED,INTERVENTIONAL,['NA']
7392,NCT00511719,"Intra-patient and inter-patient comparison of CV % between treatments was based on a t-test.for bioavailability (ie, SI AUC0-540 min) & bioeffect (ie, GIR AUC0-540 min)","Safety variables included adverse events (AEs), clinical laboratory tests, HbA1c, pulmonary function tests, electrocardiograms, vital signs, physical examinations, and diabetes-specific signs",,2004-02,COMPLETED,INTERVENTIONAL,['PHASE2']
7393,NCT04107935,Change From Baseline in Glycemic Control,Change From Baseline in Medication Adherence Across 3 Month Intervals for 12 Months,,2020-02-04,TERMINATED,INTERVENTIONAL,['NA']
7394,NCT06135532,salivary IL-13 level (pg/ml),serum IL-13 level (pg/ml),,2018-10-01,COMPLETED,INTERVENTIONAL,['NA']
7395,NCT00470860,Knowledge related to blood pressure and lipid management for diabetes patients,,,2004-12,COMPLETED,INTERVENTIONAL,['NA']
7396,NCT02423434,Comparison of Manual versus Automated Image analysis,Determination of the Factors associated with CCM Parameters and their Longitudinal Change,,2014-09,COMPLETED,OBSERVATIONAL,['NA']
7397,NCT04282395,Change from baseline in depressive symptoms at 24 months,Change from baseline in social support at 12 months,,2020-01-25,RECRUITING,INTERVENTIONAL,['NA']
7398,NCT00467649,The Percentage of Patients Achieving HbA1c <=7% at Week 24 With no Gain in Body Weight From Baseline and no Incidence of Severe Hypoglycemia,Phase 2: Change in Body Weight at Week 36,Hypoglycemia Adverse Events,2007-05,COMPLETED,INTERVENTIONAL,['PHASE4']
7399,NCT05029583,Prevalence of presumed advanced NASH based on biochemical and FibroScan results,Health-related quality of life by study arm,,2021-08-11,RECRUITING,INTERVENTIONAL,['NA']
7400,NCT00574405,"Change in Mixed-meal-stimulated Peak C-peptide Value (Via Mixed-meal Tolerance Test) After 12 Months of Insulin Pump Therapy, Compared With MDI.",Patient Satisfaction With Mode of Therapy and Patient Compliance With Treatment Recommendations.,,2005-04,COMPLETED,INTERVENTIONAL,['NA']
7401,NCT01749020,Determine if the consumption of DC rich in polyphenols can induce a change in insulin sensitivity,Determine if the consumption of DC rich in polyphenols can induce a change in high sensitivity CRP,,2012-03,COMPLETED,INTERVENTIONAL,['NA']
7402,NCT00996645,Primary Disease-Related Outcomes: mean BP and mean LDL level.,Efficacy of intervention,,2010-07,COMPLETED,INTERVENTIONAL,['NA']
7403,NCT01135446,Total 24-hour Urinary Glucose Excretion as a Measure of Pharmacodynamic Effect,Dapagliflozin and Dapagliflozin 3-O-glucuronide (Metabolite of Dapagliflozin) Concentrations to Characterize Dapagliflozin Pharmacokinetics,,2010-05,COMPLETED,INTERVENTIONAL,['PHASE1']
7404,NCT06112691,The accuracy,The percent of false positive detection of DR,,2022-02-01,RECRUITING,OBSERVATIONAL,['NA']
7405,NCT05410080,The diagnostic value of middle cerebral artery (MCA) Doppler indices in predicting adverse perinatal outcome among diabetic pregnant patients,The diagnostic value of ductus venosus Doppler indices in predicting adverse perinatal outcome among diabetic pregnant patients.,,2022-06-15,RECRUITING,OBSERVATIONAL,['NA']
7406,NCT03406923,Change in diabetes control,Experiences and perceptions of the intervention processes and outcomes,,2018-12-04,COMPLETED,INTERVENTIONAL,['NA']
7407,NCT00335712,Fasting Blood Glucose at week 8,"Other glycemic control parameters (e.g., HbA1c, glycoalbumin)",,2006-06,COMPLETED,INTERVENTIONAL,['PHASE2']
7408,NCT04035395,Rate of Change in Hemoglobin A1c,Rate of Change in Self-efficacy: Diabetes Self-Efficacy Scale,,2016-09-29,COMPLETED,INTERVENTIONAL,['NA']
7409,NCT01605773,Triglyceride levels post standardised fat tolerance test,Change in FPG (fasting plasma glucose),,2001-11-08,COMPLETED,INTERVENTIONAL,['PHASE4']
7410,NCT00905528,Change in eGFR after 1 year,,,2002-01,COMPLETED,OBSERVATIONAL,['NA']
7411,NCT00690066,C-peptide area under the concentration curve (AUC) response (MMTT),Changes in levels of glutamic acid decarboxylase (GAD) or islet antigen 2 (IA-2) autoantibodies,,2008-06-11,COMPLETED,INTERVENTIONAL,['PHASE2']
7412,NCT03374020,The level of agreement between NOTAL-OCT and commercial OCT in detecting fluid in the 10 central degrees of the macula.,,,2017-01-17,COMPLETED,OBSERVATIONAL,['NA']
7413,NCT02204280,"The urine UbA52 levels in 30 patients with type 2 diabetic mellitus,30 patients with diabetic nephropathy，30 patients with proteinuria due to nondiabetic renal disease and 30 healthy persons",,,2014-08,COMPLETED,OBSERVATIONAL,['NA']
7414,NCT00700648,Incidence of SAEs (serious adverse event),Other safety & efficacy measures,,2008-03,COMPLETED,OBSERVATIONAL,['NA']
7415,NCT03338023,Change From Baseline in Hemoglobin A1c (HbA1c) (LY2963016 Noninferior to Lantus®),Rate of Documented Symptomatic Hypoglycemia,,2018-03-23,COMPLETED,INTERVENTIONAL,['PHASE3']
7416,NCT06305286,Number of Participants who are insulin-independent post- first and final transplant,Number of Participants with glycosylated hemoglobin (HbA1c) <7.0%,Change in variability after final islet cell transplant and years after discontinuation of AT-1501,2024-03-04,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7417,NCT01597531,Type 2 diabetes remission,First Phase Insulin secretion,,2012-06,TERMINATED,INTERVENTIONAL,['PHASE4']
7418,NCT04214600,Change of Glycated Hemoglobin A1c (Hb A1c) After the Cognitive Behavioral Therapy Sessions,Change of Depression Score on Beck's Depression Index,,2019-04-30,COMPLETED,INTERVENTIONAL,['NA']
7419,NCT00989976,diabetes risk as assessed by disposition index,,,2009-02,COMPLETED,INTERVENTIONAL,['NA']
7420,NCT03445377,Sensor Glucose readings within target range,Total daily insulin dose,,2018-07-16,COMPLETED,INTERVENTIONAL,['NA']
7421,NCT05585697,Plasma concentration of Osteocalcin,trabecular separation distance,,2022-10-07,COMPLETED,OBSERVATIONAL,['NA']
7422,NCT04945161,"Primary endpoint:Q-RT-PCR, for the inflammation stage and the remodeling stage",Secondary endpoint (5): wound reduction rate of each target gene in each group,Safety endpoint(3):Change from baseline in laboratory tests,2021-02-23,COMPLETED,INTERVENTIONAL,['NA']
7423,NCT01445951,Change From Baseline to Week 24 in HbA1c,Proportion of Responders Achieving HbA1c <= 7.0%,Severe Hypoglycemia Event Rate,2011-09,COMPLETED,INTERVENTIONAL,['PHASE3']
7424,NCT06290544,Prevalence of cardiovascular disease in type 1 diabetes patients,Stratify type 1 patient by glucose control using HbA1c and Ambulatory Glucose Profile metrics.,,2021-11-29,RECRUITING,INTERVENTIONAL,['NA']
7425,NCT00525304,Medical service use patterns,Quantitative and qualitative survey ratings,,2007-09,COMPLETED,INTERVENTIONAL,['NA']
7426,NCT01370707,Change from baseline in HbA1c at week 24,Glycemic variability,,2011-04,COMPLETED,INTERVENTIONAL,['PHASE3']
7427,NCT04263376,Changes in human gut microbiota,,,2019-04-24,COMPLETED,OBSERVATIONAL,['NA']
7428,NCT05335863,Areas under the glucose metabolism curve for the determination of the glycemic index,,,2021-11-03,COMPLETED,INTERVENTIONAL,['NA']
7429,NCT01977391,"All-cause and cardiovascular mortality in elderly Korean men and women according to BMI, waist circumference, and presence of diabetes",Survival probability among study populations,,1999-08,COMPLETED,OBSERVATIONAL,['NA']
7430,NCT01657318,,,,2012-09-01,TERMINATED,OBSERVATIONAL,['NA']
7431,NCT00806897,Change in HbA1c from baseline,Change in body weight,,2009-01,COMPLETED,OBSERVATIONAL,['NA']
7432,NCT06005012,Change in fibrosis due to NAFLD,Change in ALT,,2023-07-25,RECRUITING,INTERVENTIONAL,['PHASE2']
7433,NCT03862547,intracavernous p75NTR,"clinical staging of ED and NGF,TrKa,p75NTR",,2019-01-30,UNKNOWN,INTERVENTIONAL,['NA']
7434,NCT02228252,Effect on apolipoprotein B48 of whey protein as pre-meal after a high-fat meal in subjects with the metabolic syndrome measured as incremental Area Under the Curve (iAUC -15 - 360 min).,Gastric inhibitory peptide (GIP) responses measured as incremental Area Under the Curve (AUC -30/-15 - 360 min),Responses of satiety visual analog scale (VAS) measured as incremental Area Under the Curve (AUC -30/-15 - 360 min),2014-08,COMPLETED,INTERVENTIONAL,['NA']
7435,NCT04337723,ABI/WIFI adoption,ABI/WIFI sustainability,,2020-03-10,COMPLETED,INTERVENTIONAL,['NA']
7436,NCT05007197,Effectiveness of education,,,2021-01-01,UNKNOWN,INTERVENTIONAL,['NA']
7437,NCT00577590,Percent Change in Plasma Triglycerides,,,2003-10,COMPLETED,INTERVENTIONAL,['NA']
7438,NCT02967900,Correlation of OCT Measurement of blood vessel density with rate of wound healing,"Correlation of OCT Measurement of blood vessel density at baseline, with rate of wound healing",,2017-10-01,COMPLETED,OBSERVATIONAL,['NA']
7439,NCT04988594,Changes from baseline in parameters associated with glucose homeostasis,Changes in oxidative stress parameters,,2021-02-01,COMPLETED,INTERVENTIONAL,['NA']
7440,NCT02501161,Time From Randomisation to Inadequate Glycaemic Control and Need for Treatment Intensification,Change in TRIM-D,,2016-01-31,COMPLETED,INTERVENTIONAL,['PHASE3']
7441,NCT01922492,Changes of insulin secretory function,Adverse effects,,2008-05,UNKNOWN,INTERVENTIONAL,['NA']
7442,NCT02045290,Change in insulin resistance (IR) from baseline to 13 weeks,Change in Adipose IR from baseline to 13 weeks,,2014-01,COMPLETED,INTERVENTIONAL,['PHASE3']
7443,NCT00869102,Insulin secretion,,,2009-05,WITHDRAWN,INTERVENTIONAL,['NA']
7444,NCT04944316,24-hour Carbohydrate to Insulin Ratio,Interleukin (IL) - 1 (IL-1) and interleukin-6 (IL-6),Diet Acceptability,2022-01-19,COMPLETED,INTERVENTIONAL,['NA']
7445,NCT03979768,Number of Participants with undiagnosed type 2 diabetes,Explore if there was any difference in the number of participants with a high risk of developing type 2 diabetes in the risk test only (RTO)- group and the group that also offered a HbA1c-measurement (HbA1c-group),,2016-09-15,COMPLETED,INTERVENTIONAL,['NA']
7446,NCT05767255,To compare the percentage of hypoglycemia,Evaluate associated adverse effects,,2022-12-01,RECRUITING,INTERVENTIONAL,['PHASE3']
7447,NCT04631159,Change from baseline HbA1c through a mobile app.,The number of participants who have related every day steps as assessed by Mi Smart Band 4.,,2020-05-01,UNKNOWN,INTERVENTIONAL,['NA']
7448,NCT04888390,Oxygen consumption (VO2),MEP (maximal exspiratory pressure),,2021-04-20,RECRUITING,INTERVENTIONAL,['NA']
7449,NCT01680211,Change in Blood Sugar and lipid profiles,Clinical laboratory evaluations,,2012-04,COMPLETED,INTERVENTIONAL,['NA']
7450,NCT01535105,Frequency of Impaired Glucose Homeostasis among obese adolescents in high risk diabetes prone population,Description of the metabolic profile in obese adolescents,,2012-08,UNKNOWN,OBSERVATIONAL,['NA']
7451,NCT01945216,Change From Baseline in Glycosylated Hemoglobin (HbA1c),Change From Baseline in Fasting Blood Glucose,,2010-07-08,COMPLETED,OBSERVATIONAL,['NA']
7452,NCT03563794,blood glucose,hypoglycemia,,2018-06-10,UNKNOWN,INTERVENTIONAL,['PHASE4']
7453,NCT04869800,Cmax of CKD-398,Vd/F of CKD-398,,2021-05-27,COMPLETED,INTERVENTIONAL,['PHASE1']
7454,NCT05150041,Change in HbA1c(%),changes in patient satisfaction level,,2020-04-07,COMPLETED,INTERVENTIONAL,['NA']
7455,NCT01785771,Change in HbA1c between Week 39 and Day 0,,,2013-05,TERMINATED,INTERVENTIONAL,['PHASE3']
7456,NCT03404037,Serum Endostatin Level as a Marker for Coronary Artery Calcification in Type 2 Diabetic Patients with Coronary Heart Disease,,,2017-03-02,COMPLETED,OBSERVATIONAL,['NA']
7457,NCT02305199,Postoperative glucose level,Postoperative Stress hormone level,,2015-01-01,WITHDRAWN,INTERVENTIONAL,['NA']
7458,NCT01475435,Evaluate level change of oxidative stress biomarkers in crevicular gingival fluid and whole saliva on diabetes type 2 individuals,,,2011-08,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
7459,NCT01552811,Difference in pancreatic uptake of % injected dose (ID) [11]5-hydroxy tryptophan between healthy volunteers and patients with long-standing type 1 diabetes,,,2012-03,COMPLETED,OBSERVATIONAL,['NA']
7460,NCT00694278,,,,2008-06,UNKNOWN,OBSERVATIONAL,['NA']
7461,NCT01490658,NN4440 (2/500) Cmax (maximum plasma concentration) combination tablet,Vital signs,,2006-06,COMPLETED,INTERVENTIONAL,['PHASE1']
7462,NCT00194896,Changes in Beta Cell Function Assessed by Fasting and Stimulated C-peptide Measured at 36 Months.,Patients Positive for T Cell Responses to Islet Proteins at 36 Months.,,2000-02,COMPLETED,INTERVENTIONAL,['NA']
7463,NCT02583919,Change in HbA1C,"Safety and Tolerability will be assessed by determining the incidence, severity, dose-relationship adverse-effects, and changes in laboratory evaluations within each dose cohort",,2015-09,COMPLETED,INTERVENTIONAL,['PHASE2']
7464,NCT05658744,Behavior change,,,2019-12-25,COMPLETED,INTERVENTIONAL,['NA']
7465,NCT03007186,Blood glucose measurements,Insulin level,Result of oral glucose tolerance test,2016-10,COMPLETED,OBSERVATIONAL,['NA']
7466,NCT01042301,Identification and characterization of new CD8+ T lymphocytes related to type 1 diabetes and its evolution (2009-2012),Identification and characterization of new profiles of humoral and cellular markers (including T cell reactivity and miRNA) related to type 1 diabetes (2010-2014).,,2007-09,COMPLETED,INTERVENTIONAL,['NA']
7467,NCT00865683,Insulin sensitivity,Interleukin-6 (IL-6),,2009-04,UNKNOWN,INTERVENTIONAL,['PHASE1']
7468,NCT00732602,plasma-glucagon Area Under Curve at 0-90 min. and 90-180 min.,,,2008-01,COMPLETED,INTERVENTIONAL,['NA']
7469,NCT05521061,HbA1C levels,Total daily dose of insulin,,2022-05-28,RECRUITING,INTERVENTIONAL,['NA']
7470,NCT04903496,"The proportion of non-diabetic patients with established cardiovascular disease, or chronic kidney disease, or at high cardiovascular risk among all non-diabetic patients","Serum creatine concentration (μmol/L) at the latest visit for all patients, as well as the trends for inpatients over time (2015, 2017, and 2019 respectively)",,2021-09-06,COMPLETED,OBSERVATIONAL,['NA']
7471,NCT03323281,Measuring memory,Measuring memory,Measurement of cognition by the Mini Mental State Examination (MMSE),2019-12-07,RECRUITING,OBSERVATIONAL,['NA']
7472,NCT01947569,The incidence of treatment-emergent adverse events.,2-hour area under the curve (AUC) average of C-peptide at 12 months after completion of administration of assigned therapy (Protocol Month 15).,,2013-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7473,NCT02212158,Change in Baseline HA1c at 12 months post baseline,Change from baseline in Children's Hope Scale at 60 weeks,,2014-09,UNKNOWN,INTERVENTIONAL,['NA']
7474,NCT04669912,Changes in percentage of time spent in range 70-180 mg/dL during second month of lockdown compared to before lockdown,Evolution of glucose sensor use compared to before lockdown.,,2021-01-15,COMPLETED,OBSERVATIONAL,['NA']
7475,NCT00562172,Glucose Homeostasis and glycemic control status,"Insulin resistance parameter, Hypoglycemic episode, symptomatic, Weight change, Lipid profile, Inflammatory markers (CRP, Adiponectin, etcs), Patient satisfaction with diabetes treatment, Urine analysis, Creatinine",,2007-09,COMPLETED,INTERVENTIONAL,['PHASE4']
7476,NCT03334370,Change of the proportion of patients who have achieved a HbA1c <7.5%.,"Service utilization outcomes measured by hospital attendance rates at baseline and 12, 24, 36 and 48 months after enrollment.",,2010-09,COMPLETED,OBSERVATIONAL,['NA']
7477,NCT02057848,Plasma glucose,,,2011-07,COMPLETED,INTERVENTIONAL,['NA']
7478,NCT03332849,Number of participants with adverse events,AUC of HM12470,,2015-07-28,UNKNOWN,INTERVENTIONAL,['PHASE1']
7479,NCT01884714,Measure circulating inflammatory markers and fatty acids associated with obesity and diabetes.,Measure standard clinical and anthropometric parameters in obese and diabetic participants following a standardized meal.,,2011-07,COMPLETED,INTERVENTIONAL,['NA']
7480,NCT03787836,Exercise responders following additional exercise program,Body mass index,,2019-05-01,COMPLETED,INTERVENTIONAL,['NA']
7481,NCT01217892,Adjusted Mean Change in HbA1c Levels,"Proportion of Participants With HbA1c<7.0% at Week 16, in Participants Who Had HbA1c ≥7.0% at Baseline.",,2010-11,COMPLETED,INTERVENTIONAL,['PHASE3']
7482,NCT00368953,"""In-stent late lumen loss"" at follow-up-angiography (9 months)","Combined MACE (cardiac death, myocardial infarction, emergency bypass, stent thrombosis, target lesion revascularization)",,2006-09,COMPLETED,INTERVENTIONAL,['PHASE4']
7483,NCT00325117,Change from baseline to endpoint on HbA1c at 12 weeks,Adverse events profile after 12 weeks of treatment,,2006-04,COMPLETED,INTERVENTIONAL,['PHASE3']
7484,NCT03704818,Digit Symbol Substitution Performance Response to Hypoglycemia,,,2018-10-08,COMPLETED,INTERVENTIONAL,['PHASE1']
7485,NCT05243368,Ulcer evaluation,Concentration of stromal cell-derived factor 1 (SDF-1) and vascular endothelial growth factor A (VEGFA),Hydration status,2023-10-20,RECRUITING,INTERVENTIONAL,['NA']
7486,NCT00326196,The Hypothesis Being Tested is That a Strategy of Initial Surgical Revascularization is Superior to Percutaneous Intervention in Preventing Death or Myocardial Infarction in Diabetics With Severe Ischemic Heart Disease Assessed up to 4 Years.,,,2006-07,TERMINATED,INTERVENTIONAL,['PHASE4']
7487,NCT01420198,Caloric intake,Blood pressure,,2015-01,COMPLETED,INTERVENTIONAL,['NA']
7488,NCT01837680,Glycemic Control,Neonatal Hypoglycemia,,2013-03,COMPLETED,INTERVENTIONAL,['NA']
7489,NCT04625751,Change in blood levels of gastrointestinal hormones and markers of metabolism following meal test,,,2021-04-07,RECRUITING,OBSERVATIONAL,['NA']
7490,NCT04971252,Estimate risk of thrombosis or bleeding for the 3 study groups by plateletcrit,,,2021-07-07,COMPLETED,OBSERVATIONAL,['NA']
7491,NCT05259644,Change in Body Weight,Change in fasting blood glucose,Change in the IWQOL (The Impact of Weight on Quality of Life) questionnaire,2022-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
7492,NCT02744820,Number of Participants with Serious and Non-Serious Adverse Events,Time to reach steady state,Preliminary effect on %HbA1c (Cohort 4 only),2016-04,TERMINATED,INTERVENTIONAL,['PHASE1']
7493,NCT03769883,Pancreatic beta-cell function (Per protocol),Satiety,Fat tissue metabolic function,2018-12-12,UNKNOWN,INTERVENTIONAL,['NA']
7494,NCT04233034,C-peptide,DKA,,2020-07-09,COMPLETED,INTERVENTIONAL,['PHASE3']
7495,NCT02810613,"A collection of samples for the purpose of (bio)medical laboratory assays including immunological, metabolic, transcriptional or biological analyses.",,,2016-05-31,WITHDRAWN,OBSERVATIONAL,['NA']
7496,NCT01620333,Area under the insulin aspart curve in the interval from 0 to 24 hours (BIAsp 70),Adverse events,,2000-02,COMPLETED,INTERVENTIONAL,['PHASE1']
7497,NCT00005184,,,,1985-12,COMPLETED,OBSERVATIONAL,['NA']
7498,NCT01892020,2-hour PPG (Postprandial Plasma Glucose) Increment Following a Standard Meal Test,Incidence of AEs (Adverse Event),,2013-06,COMPLETED,INTERVENTIONAL,['PHASE4']
7499,NCT01423266,"Change from Baseline in adiposity (and body composition; i.e., % body fat))",Change from Baseline in levels of quality of life,Change in Cardiac Function,2009-12,COMPLETED,INTERVENTIONAL,['NA']
7500,NCT05676034,To assess the safety and tolerability of AMX0035in adult participants with Wolfram syndrome,To evaluate the effect of AMX0035 on HbA1c levels,,2023-03-03,RECRUITING,INTERVENTIONAL,['PHASE2']
7501,NCT03617757,Incidence of DM,Capacity of the studied population to join intensive lifestyle intervention,,2017-10-01,COMPLETED,INTERVENTIONAL,['NA']
7502,NCT01030679,Change from baseline in fasting plasma glucose at 8 weeks,Adverse event profile after 8 weeks of treatment,,2007-07,COMPLETED,INTERVENTIONAL,['PHASE2']
7503,NCT04023487,"Change in glycemic control, using Glycated Hemoglobin (HbA1C)",Change in cost to payor,Background Information,2019-10-22,COMPLETED,INTERVENTIONAL,['NA']
7504,NCT02691897,HbA1c,Number of patients with adverse events,,2019-07,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
7505,NCT03823339,Change in laboratory measured glycosylated haemoglobin A1c (HbA1c),"Reason(s) for discontinuing treatment with Xultophy® during the treatment period, if applicable",,2019-01-29,COMPLETED,OBSERVATIONAL,['NA']
7506,NCT00001625,,,,1997-04-03,COMPLETED,OBSERVATIONAL,['NA']
7507,NCT06190938,"The Demographic characteristics were classified into four groups: Gender, Financial status, Educational level, and Profession.",,,2022-06-23,COMPLETED,OBSERVATIONAL,['NA']
7508,NCT00604344,HbA1c,Insulin antibodies,,2003-04,COMPLETED,INTERVENTIONAL,['PHASE3']
7509,NCT04836221,Feasibility of an active management strategy for comorbidities,Provider perspectives on acceptability of active management of comorbidities,Preliminary changes in social support,2021-05-05,COMPLETED,INTERVENTIONAL,['NA']
7510,NCT00487162,Wound Infection,Hemodynamic Instability,,2007-06,TERMINATED,INTERVENTIONAL,['NA']
7511,NCT04984200,Overall agreement between the results from multiple EyeArt operations,,,2021-07-13,COMPLETED,OBSERVATIONAL,['NA']
7512,NCT01324505,Area under the levonorgestrel concentration-time curve,Percentage of subjects experiencing adverse events,,2011-03,COMPLETED,INTERVENTIONAL,['PHASE1']
7513,NCT02131701,improvement in physical fitness,changes in body composition,changes in muscle strength,2006-10,COMPLETED,INTERVENTIONAL,['NA']
7514,NCT00797524,Retinal leakage and retinal thickness.,,,2008-11,COMPLETED,OBSERVATIONAL,['NA']
7515,NCT05312450,The change of postprandial blood glucose,Serum metabolomics,,2022-03-10,RECRUITING,OBSERVATIONAL,['NA']
7516,NCT02413398,Adjusted Mean Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24,Adjusted Mean Change From Baseline in Seated Systolic Blood Pressure (SBP) at Week 24.,,2015-06-15,COMPLETED,INTERVENTIONAL,['PHASE3']
7517,NCT03068078,"Glycemic control, dyslipidemia and metabolic markers",Gut dysbiosis,,2016-11,COMPLETED,INTERVENTIONAL,['NA']
7518,NCT01148680,ß score evaluation 6 months after first infusion (group 1 'immediate registration on infusion waiting list') or 6 months after inclusion (group 2: 'delayed registration on infusion waiting list'),Evaluation of side effects and iatrogenic effects,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE3']
7519,NCT05854979,Gastric Volume in RLD Position,Incidence of aspiration,,2023-08-09,RECRUITING,OBSERVATIONAL,['NA']
7520,NCT05517772,Semi-structured interviews,Patient reported outcomes,,2022-06-16,COMPLETED,OBSERVATIONAL,['NA']
7521,NCT01678820,Number of Participants Who Discontinued Study Drug Due to an Adverse Event,Percentage of Participants With A1C Level <7% at Week 16,,2012-10-10,TERMINATED,INTERVENTIONAL,['PHASE3']
7522,NCT05546281,"Forced food categorization task according to the categories ""healthy / unhealthy""",Type 1 Diabetes Distress Scale (T1-DDS),,2022-10-01,RECRUITING,OBSERVATIONAL,['NA']
7523,NCT02875782,Self-reported 7-day point-prevalence smoking abstinence,Self-reported quit attempt numbers over the past 12 months.,,2011-01,COMPLETED,INTERVENTIONAL,['NA']
7524,NCT01816633,Time to heal,Number of patients with adverse events as a measure of tolerability,,2013-10,TERMINATED,INTERVENTIONAL,['NA']
7525,NCT02214017,Glycemia,Lipids,Blood Pressure,2011-10,COMPLETED,INTERVENTIONAL,['NA']
7526,NCT00340678,Number of Participants With Decline in GFR,Glomerular Volume,,1995-08,COMPLETED,INTERVENTIONAL,['PHASE3']
7527,NCT00372814,Metabolic Control: Hemoglobin A1c (HbA1c),"Regimen Adherence: Diabetes Management Scale (DMS), Twenty-Four Hour Recall Interview, Glucose Meter Downloads",,2007-03,COMPLETED,INTERVENTIONAL,['NA']
7528,NCT01643031,"Rate of elevation of troponin or CK-MB (above the upper limit of normal, and above 3 times the upper limit of normal) measured 20-24 hours after the PCI.","Rate of major adverse cardiovascular endpoints including death, myocardial infarction or urgent target vessel revascularization at 30 days",,2012-08,UNKNOWN,INTERVENTIONAL,['PHASE4']
7529,NCT06120569,HbA1C less than 7%,ratio of albumin (mcg/L) to creatinine (mg/L)ratio,,2024-09-18,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
7530,NCT01968668,Change of urinary albumin-to creatinine ratio,Change in serum potassium concentration,,2013-10-28,COMPLETED,INTERVENTIONAL,['PHASE2']
7531,NCT00220207,Hemoglobin A1c,,,2003-09,COMPLETED,INTERVENTIONAL,['NA']
7532,NCT00949351,Assess short-term safety of the combination of aliskiren 300 mg/valsartan 160 mg /enalapril 20 mg in patients with diabetic nephropathy,Change of Urinary TGFb1 compare to baseline,,2009-09,UNKNOWN,INTERVENTIONAL,['PHASE4']
7533,NCT03645421,Number of Patients Who Experienced Adverse Events (AEs),Number of Patients With Antidrug Antibody (ADA) Response to MEDI0382,,2018-08-10,COMPLETED,INTERVENTIONAL,['PHASE2']
7534,NCT05692934,Pharmacokinetics parameters of Metformin in the fast and fed state: AUC0-inf (if applicable),The incidence and severity of adverse events/serious adverse events,,2023-01-31,COMPLETED,INTERVENTIONAL,['PHASE1']
7535,NCT00236379,Change in the Disposition Index derived from the Frequently Sampled Intravenous Glucose Tolerance Test (which shows how the body regulates glucose),Changes in measurements of metabolism and glucose regulation; changes in results of tests and questionnaires evaluating the effectiveness and safety (including laboratory tests and anthropomatic measurements) of medications used to treat schizophrenia,,na,COMPLETED,INTERVENTIONAL,['PHASE4']
7536,NCT02128815,change from baseline A1C after one year,change from baseline in quality of life at 1 year,,2015-01,COMPLETED,INTERVENTIONAL,['NA']
7537,NCT05156736,Burden of atherosclerotic plaque assessed via coronary computed tomography angiography,Incidence of hypertension in mm Hg measured by Omron digital BP apprataus,,2023-03-15,RECRUITING,OBSERVATIONAL,['NA']
7538,NCT03413215,Composite primary endpoint,Composite secondary endpoint,,2019-03-01,UNKNOWN,INTERVENTIONAL,['NA']
7539,NCT00427271,glomerular filtration rate,,,2003-03,UNKNOWN,INTERVENTIONAL,['PHASE4']
7540,NCT00296374,Urinary Protein/Creatinine Ratio in Patients With Type 1 or 2 Diabetes.,Relationship Between Renal Effects and Lipid Changes: eGFR and ApoB/ApoA-1 Ratio,,2006-02,COMPLETED,INTERVENTIONAL,['PHASE2']
7541,NCT02800252,Periodontal pockets with mean probing depth (PD) ≥5mm,Plaque index (%),Glycated hemoglobin,2016-06,UNKNOWN,INTERVENTIONAL,['NA']
7542,NCT04496921,Change in serum vitamin K levels from baseline at 6 months,Glycemic marker levels,,2020-08-10,WITHDRAWN,INTERVENTIONAL,['NA']
7543,NCT03598621,"Cmax,sema,SD, the maximum plasma semaglutide concentration after a single dose subcutaneous semaglutide administration","Number of site-initiated technical complaints with or without co-reported adverse events: DV3372 device, 1.0 mg/mL versus PDS290 semaglutide pen-injector, 1.34 mg/mL",,2018-07-23,COMPLETED,INTERVENTIONAL,['PHASE1']
7544,NCT03371108,Treatment-induced Anti-Insulin Antibody (TI-AIA) is the Primary Endpoint,Efficacy - HbA1c Control,,2017-10-31,COMPLETED,INTERVENTIONAL,['PHASE3']
7545,NCT01271777,Glucose Infusion Rate (GIR),Changes in HGP (Hepatic Glucose Production),,2011-01,COMPLETED,INTERVENTIONAL,['PHASE2']
7546,NCT00073268,,,,2002-12,COMPLETED,INTERVENTIONAL,['PHASE1']
7547,NCT04035031,Area under the curve for glucagon-like peptide I in oral glucose tolerance test clamp,Area under the curve for somatostatin in oral glucose tolerance test clamp following dapagliflozin compared with placebo,,2020-01-09,COMPLETED,INTERVENTIONAL,['PHASE3']
7548,NCT02949024,Number of Participants With Treatment Emergent Adverse Events and Serious Adverse Events,CLS-TA Injections,,2016-11-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7549,NCT01382628,Structural and metabolic changes,Relationship between collagen changes and system changes,,2011-05,COMPLETED,OBSERVATIONAL,['NA']
7550,NCT04256460,Change of BMI from baseline at 12 months,Change of Low density lipoprotein cholesterol from baseline at 12 months,Change of C-reaction protein from baseline at 12 months,2019-12-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
7551,NCT02540993,"The First Occurrence of the Composite Endpoint of Onset of Kidney Failure, a Sustained Decrease of eGFR ≥40% From Baseline Over at Least 4 Weeks, or Renal Death","The First Occurrence of the Composite Endpoint of Onset of Kidney Failure, a Sustained Decrease in eGFR of ≥57% From Baseline Over at Least 4 Weeks, or Renal Death",,2015-09-17,COMPLETED,INTERVENTIONAL,['PHASE3']
7552,NCT00602914,Blood samples for PK and PD will be collected,"Feedback from study participants and staff on their overall impression with the MicronJet device, using questionnaires",,2008-03,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
7553,NCT01098994,Demonstrate the presence of HDL dysfunction among individuals with the Haptoglobin 2/1 and 2/2 compared to those with the Hp 1/1 phenotype and improvement in HDL dysfunction with natural d-α-tocopherol supplementation,Assessment of adherence to the clinical trial study protocol in a random sample of individuals with type 1 diabetes recruited from the ACR and CHP/EDC Diabetes Registries,,2010-02,COMPLETED,INTERVENTIONAL,['NA']
7554,NCT02640118,PPG excursions measured as incremental area under curve (iAUC),"glucagon, gastrin, cholecystokinin, GIP, GLP-1, oxyntomodulin",,2015-08,COMPLETED,INTERVENTIONAL,['NA']
7555,NCT02864212,Invasive blood pressure,,,2014-09,UNKNOWN,OBSERVATIONAL,['NA']
7556,NCT00655330,urinary albumin excretion or proteinuria at week 48,,,2008-05,UNKNOWN,INTERVENTIONAL,['NA']
7557,NCT00768040,"Change From Baseline in Central Retinal Thickness in Patients With Type 1 or Type 2 Diabetes, After 12 Weeks of Treatment",,,2008-09,TERMINATED,INTERVENTIONAL,['PHASE2']
7558,NCT03921593,Quantification of Quality of Life,Estimate cost-effectiveness of pancreas transplantation,,2018-11-04,UNKNOWN,OBSERVATIONAL,['NA']
7559,NCT02915250,Delta AUC BG 0-2h (area under the blood glucose concentration-time curve),Hypoglycaemic events,,2016-10,COMPLETED,INTERVENTIONAL,['PHASE1']
7560,NCT01435707,fasting blood glucose,visual analogue scale of subjective pain,,2011-09,COMPLETED,INTERVENTIONAL,['NA']
7561,NCT02587104,"The proportion of product related Adverse Events (AEs), Serious Adverse Events (SAEs), and Unanticipated Adverse Events",Cost effectiveness of treatment of dHACM,,2015-06,COMPLETED,INTERVENTIONAL,['NA']
7562,NCT01798420,Hemoglobin A1C LEVEL,Glucose levels,Weight,2012-04,COMPLETED,OBSERVATIONAL,['NA']
7563,NCT05369052,Vital signs - heart rate,Clinical response calculated with percentage of subjects with resolution of DFI signs and symptoms and requiring no further therapy as assessed by Investigators,,2022-05-03,RECRUITING,INTERVENTIONAL,['PHASE3']
7564,NCT00963768,The number of patients with adverse events as a measure of safety and tolerability,Renal glucose threshold,,2007-06,COMPLETED,INTERVENTIONAL,['PHASE1']
7565,NCT00994253,"The primary objective is to assess the effect of a multimodal drug therapy regimen including the renin inhibitor Tekturna (aliskiren), an ACE inhibitor, and a calcium channel blocker on coronary flow reserve (CFR) in hypertensive Type II diabetics.","Secondary measures include evaluation of serum and urine biomarkers related to endothelial function, the renin-angiotensin system, oxidative stress, and inflammation.",,2009-08,WITHDRAWN,INTERVENTIONAL,['PHASE4']
7566,NCT04677699,Diagnosis of Celiac Disease,Severity of disease at diagnosis,,2020-12,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
7567,NCT06065852,Facilitate translational and epidemiological research,,,2009-11-06,RECRUITING,OBSERVATIONAL,['NA']
7568,NCT00106704,Change From Baseline in A1C at Week 24,Change From Baseline in FPG at Week 24,,2005-03,COMPLETED,INTERVENTIONAL,['PHASE3']
7569,NCT03792646,Postural Balance (sway velocity) change from baseline,Inflammatory biomarkers - plasma concentration change from baseline (Tumor necrosis factor-alpha),,2018-05-01,UNKNOWN,INTERVENTIONAL,['NA']
7570,NCT00001313,,,,1992-05-10,COMPLETED,OBSERVATIONAL,['NA']
7571,NCT03262116,Percentage of Time Spent With CGM Glucose < 54 mg/dl,Total Daily Dose of Insulin,,2019-03-19,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
7572,NCT02895867,Change in Hemoglobin A1C (A1C),Change in c-reactive protein level,,2016-05,COMPLETED,INTERVENTIONAL,['NA']
7573,NCT01186965,Process data,Diabetes knowledge,,2011-01,COMPLETED,INTERVENTIONAL,['NA']
7574,NCT02498990,Change from Baseline in HbA1c (mmol/mol) at 12 and 24 months,"Change from Baseline in 2-hour Glucose (mmol/l) and Insulin (mU/l) by Glucose tolerance test at 7 weeks, 6, 12 and 24 months",,2015-08,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
7575,NCT00667732,The Percentage of Intent to Treat Participants Randomized and Treated in Each Arm Who Had Lab-measured A1c <6.5% at 24 Weeks of Treatment,The Percentage of Per Protocol Participants Randomized and Treated in Each Arm Who Had Lab-measured A1c <6.5% at 24 Weeks of Treatment,,2007-03,COMPLETED,INTERVENTIONAL,['PHASE4']
7576,NCT01861392,Postural balance training diabetic type 2,Quality of life of diabetics type 2,,2013-05,UNKNOWN,INTERVENTIONAL,['NA']
7577,NCT04978649,Composite of Major Renal Events,Cancer,,2021-09-01,WITHDRAWN,INTERVENTIONAL,['PHASE4']
7578,NCT01184768,Number of subjects with new diagnosis of type 2 diabetes,Effect of vitamin D status on glucose tolerance,,2008-01,COMPLETED,OBSERVATIONAL,['NA']
7579,NCT06259318,Optimism,,,2023-06-21,COMPLETED,INTERVENTIONAL,['NA']
7580,NCT02140424,Rate of bone mineral accrual,Change bone microarchitectural parameters in patients with diabetes vs. controls,Association of bone mineral accrual with moderate-to-vigorous physical activity,2013-08,RECRUITING,OBSERVATIONAL,['NA']
7581,NCT00824694,Principal endpoints will be measured 48 weeks after group assignment and include the number of medication changes and HbA1c. Interim analysis will include HbA1c measurement at 3 mont intervals.,"Secondary endpoints include changes in patient attitudes toward SMBG, daily carbohydrate consumption, physical activity level, BMI, and medication compliance (for subjects on OHA).",,2009-03,COMPLETED,INTERVENTIONAL,['NA']
7582,NCT01067924,Change in physical activity as measured by the GODIN physical activity questionnaire,"Change in Hemoglobin A1C, BMI, six minute walk-test, QoL, and self-efficacy.",,2009-09,COMPLETED,INTERVENTIONAL,['NA']
7583,NCT02317835,Detection of hot spots on a foot thermal map image,,,2015-07,COMPLETED,INTERVENTIONAL,['PHASE1']
7584,NCT06057077,change in HA1c and mounts of insulin of basal and bolus which will be taken daily is the same or decreased after one year of follow up,the change in weight after follow up of one year,,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7585,NCT01410773,Number of Self-Test Fingerstick Blood Glucose (BG) Results Within +/-15mg/dL(<75 mg/dL) or Within +/- 20% (>=75 mg/dL) of Laboratory Glucose Method,Number of Alternative Site (AST) Palm Blood Glucose (BG) Results Within +/- 15mg/dL (<75mg/dL) or Within +/- 20% (>=75mg/dL) of Laboratory Glucose Method,,2011-07,COMPLETED,INTERVENTIONAL,['NA']
7586,NCT05674981,Change from baseline in Cys-C (Cystatin C) level at 6 months,Change from baseline in gut microbiota at 6 months,,2023-04-24,RECRUITING,INTERVENTIONAL,['NA']
7587,NCT01058733,physicians' labour time and frequency of contact with the online communication system required for reviewing the patients' information and sending recommendations,,,2006-10,COMPLETED,INTERVENTIONAL,['NA']
7588,NCT06256172,"5 readings of Respiratory Data (FEV1, FVC, FEV1/FVC ratio) in L using the Respiratory unit in Medlink is acquired and the average value is reported.",,,2023-06-16,COMPLETED,INTERVENTIONAL,['NA']
7589,NCT05654142,"Assess changes in weight at baseline 0, 6, 12,24 and 52",,,2023-04-17,RECRUITING,INTERVENTIONAL,['NA']
7590,NCT00308373,,,,2004-07,COMPLETED,INTERVENTIONAL,['NA']
7591,NCT01984372,Incidence of AEs (Adverse Events) by preferred term,Incidence of severe hypoglycaemia,,2013-11-06,COMPLETED,OBSERVATIONAL,['NA']
7592,NCT01443741,Variation in HbA1c,Severe hypoglycemia over 6 months and quality of life,,2012-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
7593,NCT01679899,Markers of bone remodeling,Calcitonin,Levels of aminotransferases,2012-12,COMPLETED,INTERVENTIONAL,['PHASE4']
7594,NCT03495908,Evaluate the Change In HbA1c Between Groups After 12 Weeks of Treatment. Non-inferiority Hypothesis.,"Evaluate the Change In HbA1c Between Groups After 12 Weeks of Treatment. Intent-to-treat Population Secondary Outcome, Non-inferiority Hypothesis.",Evaluate the Change in Glucose Patterns Between Groups Based on 7-point Glucose Profiles.,2018-04-09,COMPLETED,INTERVENTIONAL,['NA']
7595,NCT02685345,change in 24 hour weighted mean glucose,change in derived glucagon AUC,,2016-01,COMPLETED,INTERVENTIONAL,['PHASE2']
7596,NCT04490941,Glycated haemoglobin (HbA1c),triglyceride concentration,,2020-07-22,RECRUITING,INTERVENTIONAL,['NA']
7597,NCT02121483,t1/2,Change From Baseline in 8-point Plasma Glucose Profile Over 24 h After Study Drug Intake,,2014-06,COMPLETED,INTERVENTIONAL,['PHASE1']
7598,NCT02623998,Number of Participants With Severe Hypoglycemic Episodes,Change in Waist Circumference,,2016-07-09,COMPLETED,INTERVENTIONAL,['PHASE3']
7599,NCT01575483,Adverse events occurrence,"Effectiveness of Onglyza® measured by Hemoglobin A1c (HbA1c), fasting plasma glucose (FPG) and 2-hr post-prandial glucose (2-hr PPG) comparing baseline data",,2012-03-01,COMPLETED,OBSERVATIONAL,['NA']
7600,NCT01135901,Diabetes mellitus type 2,,,2010-04,COMPLETED,INTERVENTIONAL,['NA']
7601,NCT02815722,The area under the plasma concentration-time curve (AUC) of Simvastatin,The number of volunteers with adverse events as a measure of safety and tolerability,,2013-07,COMPLETED,INTERVENTIONAL,['PHASE1']
7602,NCT00837577,Change From Baseline in Hemoglobin A1c (HbA1c) at Week 12,Change From Baseline in Fasting Plasma Glucose (FPG) at Week 12,,2009-02-05,COMPLETED,INTERVENTIONAL,['PHASE3']
7603,NCT01863914,Primary patent rate of AV fistula,Composite outcome measurement of the overall shunt-related complication rate,Composite outcome measurement of systemic pro-inflammatory response,2012-11,COMPLETED,INTERVENTIONAL,['PHASE2']
7604,NCT01814267,Assess the incremental cost-effectiveness ratio from the french health system perspective,Assess acceptability of telemedicine care (compliance and satisfaction) for patients and nurses.,,2013-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
7605,NCT04586907,Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,PK: Maximum Concentration (Cmax) of LY3537021,,2020-11-23,COMPLETED,INTERVENTIONAL,['PHASE1']
7606,NCT02222506,Safety and tolerability of the KLOX BioPhotonic System in patients with diabetic foot ulcers.,Wound volume reduction over time.,Impact of treatment on Health-related quality of life.,2013-04,COMPLETED,INTERVENTIONAL,['NA']
7607,NCT01009138,Depressive Symptoms (CES-D Score),Health-care Costs: Medication Intake,,2009-11,COMPLETED,INTERVENTIONAL,['NA']
7608,NCT00683020,Changes in the Mental Component Summary of the SF-12 Health Survey,Changes in Diastolic Blood Pressure (DBP),,2009-04,COMPLETED,INTERVENTIONAL,['NA']
7609,NCT01862263,Percentage of patients with hyperglycemic events evaluated with CGM,"Number of patients with adverse events, serious adverse events and death as evaluation of safety and tolerability of coadministration of vildagliptin with insulin",,2013-05,TERMINATED,INTERVENTIONAL,['PHASE4']
7610,NCT02813161,Death,Patient Reported Outcome,,2015-02,RECRUITING,OBSERVATIONAL,['NA']
7611,NCT01972724,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24,Change From Baseline in Fasting Plasma Glucose at Week 24,,2013-12-16,COMPLETED,INTERVENTIONAL,['PHASE4']
7612,NCT00741390,"Difference in Lancing Pain for Device Pair at Visit 2. (For Subjects Assigned to Arms A, B, C Only)",Reported Device Preference Within Lancing Pair at Visit 2,,2008-08,COMPLETED,INTERVENTIONAL,['NA']
7613,NCT03509454,The microvascular function by estimating the glycocalyx thickness,peripheral neuropathy,,2016-04-01,COMPLETED,OBSERVATIONAL,['NA']
7614,NCT02405260,Change in HbA1c (Glycosylated haemoglobin),Pulse,,2015-03,COMPLETED,INTERVENTIONAL,['PHASE2']
7615,NCT00537719,Change from baseline of the time to 50% gastric emptying (gastric emptying t½) of the solid and liquid components of a meal at 72 hours after dosing in healthy volunteers.,Exploratory correlation of % contents remaining in stomach after a meal.GSK716155 concentration before meal & at the time gastric emptying is complete. Safety and tolerability parameters each visit.,,2007-12-07,COMPLETED,INTERVENTIONAL,['PHASE1']
7616,NCT00928005,Cardiovascular structure and function,Body composition,,2009-07,COMPLETED,INTERVENTIONAL,['PHASE4']
7617,NCT01735123,"Intestinal permeability will be determined at the age of 3, 6, 9 and 12 months with the lactulose/mannitol test Intestinal permeability at the age of 9 months assessed with the lactulose/mannitol test",Serum metabolic profile,Intestinal microbiome,2013-01,COMPLETED,INTERVENTIONAL,['NA']
7618,NCT05865353,Shear data,,,2023-02-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
7619,NCT05670379,Adverse events,,,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
7620,NCT01915264,Incidence of severe hypoglycemia or documented symptomatic or asymptomatic hypoglycemic events reported as adverse events,Number of patient with adverse event (Tolerability),,2015-08,WITHDRAWN,OBSERVATIONAL,['NA']
7621,NCT04633642,Change From Baseline Myofibroblasts Formation (Myofibroblasts Content) at 6 Weeks,Wound Size,,2017-11-01,COMPLETED,INTERVENTIONAL,['NA']
7622,NCT05814965,hs-CRP,,,2023-04-05,RECRUITING,INTERVENTIONAL,['NA']
7623,NCT00008801,,,,na,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7624,NCT04665284,Number of participants reported adverse events,Frequency of participants achieved FBS level within normal range,Mean score of diabetes mellitus quality of life,2019-06-01,COMPLETED,INTERVENTIONAL,['PHASE4']
7625,NCT01692028,HOMA-IR,Blood pressure,,2012-02,COMPLETED,OBSERVATIONAL,['NA']
7626,NCT05935514,Change in HbA1c% at 6 months,Percentage of patients achieving 10% weight loss at 12 months,Change in glucose variability (coefficient of variation) at 12 months,2023-08-22,RECRUITING,INTERVENTIONAL,['NA']
7627,NCT04516759,Clinical Improvement by Day 14,Intubation/Mechanical Ventilation,,2020-08-12,COMPLETED,INTERVENTIONAL,['PHASE2']
7628,NCT00553280,Summary of Adverse Events,Change From Baseline in Short-Form McGill Pain Questionnaire: Present Pain Intensity Scores,,2008-02,COMPLETED,INTERVENTIONAL,['PHASE3']
7629,NCT05621811,Change in the American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index - Daily Diary total score from baseline to week 12,,,2023-01-03,RECRUITING,INTERVENTIONAL,['PHASE2']
7630,NCT03139019,Outcome measure: Measure of decrease in weight loss across 16 weeks,,,2014-06,COMPLETED,INTERVENTIONAL,['NA']
7631,NCT01890876,Glucose tolerance,Cardiovascular fitness,,2013-06,COMPLETED,INTERVENTIONAL,['NA']
7632,NCT06315127,Donor milk supplementation and exclusive breastfeeding rate at 4 months,Exploring donor milk supplementation and head circumference measurements,Exploratory outcome: exploring donor milk supplementation and maternal cortisol concentrations,2023-11-28,RECRUITING,INTERVENTIONAL,['NA']
7633,NCT02437084,Insulin Secretion Rate Area Under the Curve (ISR-AUC),OGTT Insulin AUC,,2015-05,COMPLETED,INTERVENTIONAL,['PHASE4']
7634,NCT00167115,Fasting plasma HDL cholesterol,Episodes of hypoglycemia,,2004-12,COMPLETED,INTERVENTIONAL,['NA']
7635,NCT00569998,Evaluation of overall pen preference,Adverse events,,2003-08,COMPLETED,INTERVENTIONAL,['PHASE3']
7636,NCT01537445,Kidney function,Kidney hemodynamics and oxygenation,,2012-02,UNKNOWN,OBSERVATIONAL,['NA']
7637,NCT01778348,"Time spent overnight in the target glucose range (3.9 to 8.0 mmol/l), as assessed by adjusted continuous subcutaneous glucose monitoring (CGM)",Episodes of symptomatic hypoglycaemia,Utility Evaluation,2013-12,COMPLETED,INTERVENTIONAL,['PHASE2']
7638,NCT01275040,Between group differences in HbA1c categories,Between group differences in patients where LDL cholestrol and creatinine was measures,,2010-06,UNKNOWN,INTERVENTIONAL,['NA']
7639,NCT01967589,Number of treatment emergent adverse events (TEAEs) recorded,Change in body weight,,2013-10,COMPLETED,INTERVENTIONAL,['PHASE1']
7640,NCT02573519,Difference in total gastrointestinal transit time between diabetic patients and healthy subjects,Difference in regional transit times in diabetic patients´s 3D-transit before and after Malone antegrade continence enema,,2015-10,TERMINATED,INTERVENTIONAL,['NA']
7641,NCT03451838,the number of paticipants who will have babies with macrosomias,,,2018-03-03,UNKNOWN,OBSERVATIONAL,['NA']
7642,NCT05144984,Change in HbA1c,Number of treatment-emergent adverse events (TEAEs),,2021-11-29,COMPLETED,INTERVENTIONAL,['PHASE2']
7643,NCT00339833,Change in the Average Serum Insulin Concentration During the Last 40 Min of Clamp,,,2003-03,COMPLETED,INTERVENTIONAL,['PHASE4']
7644,NCT03890588,Number of Patients With Referral to Nephrology,,,2019-04-17,COMPLETED,INTERVENTIONAL,['NA']
7645,NCT02450097,Change from baseline in fasting serum insulin in 6 months.,,,2013-12,COMPLETED,INTERVENTIONAL,['NA']
7646,NCT04782934,Incidence of sensor failure,Post explantation follow-up,"Assessment of influence of interference substances (i.e. ethanol, lactate, ketones, paracetamol, acetylsalicylic acid, sorbitol, fructose, aspartame, ibuprofen, caffeine and ascorbic acid [Vitamin C])",2021-02-25,COMPLETED,INTERVENTIONAL,['NA']
7647,NCT04557228,Change in Insulin-stimulated blood flow,Change in Vascular function,,2023-03-17,RECRUITING,INTERVENTIONAL,['NA']
7648,NCT01747967,Correlation between residual insulin secretion and T-cell responses against beta-cell antigens.,Correlation between residual insulin and glucagon secretion.,,2011-11-15,COMPLETED,INTERVENTIONAL,['NA']
7649,NCT02044718,The number of participants with preventable adverse events,Quality of the chart review,,2011-11,COMPLETED,OBSERVATIONAL,['NA']
7650,NCT00783315,Weight,Lipid levels,,2008-02-01,COMPLETED,INTERVENTIONAL,['NA']
7651,NCT06185790,Faecal microbiome composition analyses via DNA isolation,Blood ketone concentration,,2024-01-05,RECRUITING,INTERVENTIONAL,['NA']
7652,NCT03249506,Incidence Rate of the Composite of All-cause Mortality (ACM) or Hospitalization for Heart Failure (HF),Percentage of Participants With Below Knee Lower Extremity (BKLE) Amputation,,2016-05-12,COMPLETED,OBSERVATIONAL,['NA']
7653,NCT01974544,"Change in the microvascular complications of type 2 diabetes, specifically peripheral and sympathic neuropathy.",How many patients not requiring antidiabetic agents,,2013-05,UNKNOWN,INTERVENTIONAL,['NA']
7654,NCT05292066,Toronto clinical neuropathy score,,,2022-10,NOT_YET_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
7655,NCT01827280,Change from Baseline in microcirculation function at 30 days,Change from Baseline in endothelial function at 30 days,Change from Baseline in incretins and inflammation markers at 30 days,2013-04,COMPLETED,INTERVENTIONAL,['PHASE4']
7656,NCT03738982,"Change in the percentage of time spent in hypoglycaemia (glucose level below 3, 9 mmol/L or 70 mg/dl)",Evaluation of usability and the treatment satisfaction of PEPPER system by using non-validated questionnaires.,,2018-01-09,COMPLETED,INTERVENTIONAL,['NA']
7657,NCT02500628,Heart Rate Variability (Frequency Domain),Number of Patients Reporting Side Effects From the Medication,,2015-07,COMPLETED,INTERVENTIONAL,['PHASE2']
7658,NCT04570735,Correlation between morphometric and functional and metabolic biomarker data obtained by magnetic resonance spectroscopy (MRS) in 3 different patient groups,Correlation between metabolic MRS biomarkers and urine and plasma metabolites quantification.,,2020-10-07,UNKNOWN,OBSERVATIONAL,['NA']
7659,NCT01312207,visual acuity change after surgery,Optical coherence tomography findings,,2011-02,UNKNOWN,OBSERVATIONAL,['NA']
7660,NCT02811874,HbA1c,Weight,,2009-02,COMPLETED,INTERVENTIONAL,['NA']
7661,NCT05345327,Rate of decline in eGFR,Quality of life measured by EQ-5D-5L,,2023-01-01,RECRUITING,INTERVENTIONAL,['PHASE3']
7662,NCT02229097,postprandial glycaemia,fructosamine,,2014-10,COMPLETED,INTERVENTIONAL,['PHASE4']
7663,NCT01231308,The primary end-point will be the control of hyperglycemia (HbA1c <6.5% + FG<126mg/dl).,"Short (2 yrs) and long term (5 yrs.) achievement of 'adequate"" glycemic control, mean change in HbA1c from baseline.",,2010-10,UNKNOWN,INTERVENTIONAL,['NA']
7664,NCT04432337,Variation in the plasma concentration of cytokines IL-1β and IL18,Compare the plasma levels of IL-1β and IL18,Compare the plasma concentration of reactive protein C (CRP) the level of activation of the NLRP3 inflammasome in circulating blood monocytes.,2021-01-01,WITHDRAWN,INTERVENTIONAL,['NA']
7665,NCT01053793,Glycemic response,Bioavailability of polyphenols from potatoes,,2010-01,COMPLETED,INTERVENTIONAL,['NA']
7666,NCT03970772,Changes in glucose values from baseline to 30 minute,"Coefficient of Variation, by CGM",,2019-04-15,COMPLETED,INTERVENTIONAL,['NA']
7667,NCT06191328,HbA1c,Serum lipid profile,,2024-01-31,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
7668,NCT02032173,Number of Participants With a Stable BCVA in the Study Eye at 24 Months Compared With BCVA at 6 Months,Evaluation of the Spaced Out Follow-up on Visual Functions and Quality of Life,,2014-05-19,TERMINATED,INTERVENTIONAL,['PHASE3']
7669,NCT00221455,"Clinical Outcome Measures: HbA1c, LDL,and the presence or absence of clinically significant proteinuria.",Technology Adoption will be measured by tracking the patient usage of the various portal features,,2004-09,COMPLETED,INTERVENTIONAL,['PHASE1']
7670,NCT00659828,Weight,Bone Mineral Density,,2005-06,COMPLETED,INTERVENTIONAL,['PHASE2']
7671,NCT00690235,Weight Loss With Pramlintide in Persons With Schizophrenia Who Have Gained Weight Taking Olanzapine or Clozapine,,,2007-11,COMPLETED,INTERVENTIONAL,['PHASE4']
7672,NCT02854202,Plasma glucose,Change in body weight,,2012-08,UNKNOWN,INTERVENTIONAL,['NA']
7673,NCT00494663,"1. The primary efficacy endpoint will be change from baseline to the end of treatment (Study Visit 6, Week 16) in HbA1c","1. Change from baseline to Week 8 in total and LDL-cholesterol (LDL-C) 2. Change from baseline to the end of treatment (Week 16) in the following : Seated blood pressure (systolic, diastolic and mean arterial pressure) Fasting blood glucose",,2007-07,TERMINATED,INTERVENTIONAL,['PHASE2']
7674,NCT02097342,To study the effect of Linagliptin on insulin sensitivity by performing euglycemic hyperinsulinemic clamp in patients with type 2 diabetes mellitus.,To study the effects of Linagliptin on glycemic control and beta cell function in patients with type 2 diabetes mellitus 6 months,To study the effect of voglibose on glucagon like peptide1 (GLP1) secretion and insulin resistance in patients with type 2 diabetes mellitus 6 months,2013-12,UNKNOWN,INTERVENTIONAL,['PHASE4']
7675,NCT02628392,change in HbA1c,change in triglyceride,,2015-11,COMPLETED,INTERVENTIONAL,['NA']
7676,NCT04879758,"Changes in Calories Burn between baseline and 4-week post-intervention, and between baseline and 6-month follow-up","Changes in Self-reported Psychological Status between baseline and Immediate post-intervention, between baseline and 4-week post-intervention, and between baseline and 6-month follow-up",,2021-07-07,RECRUITING,INTERVENTIONAL,['NA']
7677,NCT05640869,Change in A1c,Physical activity change,"Change in Processes of Change for Weight Loss including the following processes: emotional re-evaluation, weight consequences evaluation, supporting relationships, and weight management actions",2023-02-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
7678,NCT00607347,Correlation of area under curve (AUC) up to 24 hour time point of atenolol plasma drug concentrations and glucose/insulin values obtained from OGTT and triglycerides,"HDL-cholesterol, fatty acids, total cholesterol",,2008-02,COMPLETED,INTERVENTIONAL,['NA']
7679,NCT04124211,Safety of FMT,Blood chemistry panel,,2019-08-25,UNKNOWN,INTERVENTIONAL,['NA']
7680,NCT03538743,Number of Participants With Abnormal Electrocardiogram (ECG) Interval,Renal Clearance (CLr) of PF-06882961 on Day 28,,2018-06-25,COMPLETED,INTERVENTIONAL,['PHASE1']
7681,NCT00445354,hemoglobin A1c,diabetes medications,,2007-03,COMPLETED,INTERVENTIONAL,['PHASE3']
7682,NCT05294536,Area under the plasma concentration-time curve from time zero to time t (AUC0-t),"Adverse Event, Serious Adverse Event",,2020-06-22,COMPLETED,INTERVENTIONAL,['PHASE1']
7683,NCT05872711,Change of time in range (TIR) 70-180 mg/dl after following a LCD or a MD in adolescents with T1DM.,Change in LDL cholesterol,,2023-04-19,RECRUITING,INTERVENTIONAL,['NA']
7684,NCT01429467,Correlation of HbA1c and level of cortisol,Change in levels of cortisol following CGM,,2012-08,COMPLETED,INTERVENTIONAL,['NA']
7685,NCT01144975,"Safety assessed by pre- and post-treatment serial measurements of vital signs, clinical laboratory assessments, daily fasting blood glucose measured by the subject using a glucose monitor, and treatment-emergent adverse events.","Anti-diabetic activity measured by HbA1c, FPG, OGTT, C-peptide, and insulin collected at time points specified in the protocol.",,2010-05,COMPLETED,INTERVENTIONAL,['PHASE2']
7686,NCT01920984,"Vitreous levels of Fractalkine, Cyr61, and VEGF of patients with proliferative diabetic retinopathy",,,2005-01,COMPLETED,INTERVENTIONAL,['NA']
7687,NCT06305208,Change in the number and dose of anti-diabetic medications,Changes in health-related quality of life scores (EuroQol-5D-5L),,2024-02-01,RECRUITING,OBSERVATIONAL,['NA']
7688,NCT01285232,"To determine the effect of anakinra on insulin secretion, as derived from hyperglycemic clamps .",Effects of anakinra on fat cell morphology and gene expression,,2011-01,UNKNOWN,INTERVENTIONAL,['NA']
7689,NCT02101229,Time spent in blood glucose range [70-180 mg/dl],time spent below 70 mg/dl and above 180 mg/dl,,2014-05,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
7690,NCT05267925,Homeostatic Model Assessment of Insulin Resistance,Blood urea nitrogen (BUN),PROMIS-29 Health-related Quality of Life,2022-01-08,TERMINATED,INTERVENTIONAL,['NA']
7691,NCT04619836,Effects to quality of care with questionnaire,How to guide patients,,2020-06-26,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
7692,NCT03042442,Rate of patients with loss of > 5% body weight,"Assessing the survival rate by phone-calls follow-up every 6 months, up to 2 years",,2017-01-01,COMPLETED,OBSERVATIONAL,['NA']
7693,NCT01792206,The change in brachial artery Flow Mediated Dilataion with paracalcitol (1mcg/day)compared with placebo for 3 months.,Biomarker Measurement,,2009-09,UNKNOWN,INTERVENTIONAL,['NA']
7694,NCT05789550,The prevelance of H PYLORI Infection in type 2 DM,,,2023-04-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
7695,NCT00909480,Change in HbA1c From Baseline,"Number of Subjects Having the Adverse Event ""Incorrect Dose Administered""",,2009-05,COMPLETED,INTERVENTIONAL,['PHASE4']
7696,NCT01397942,Insulin sensitivity,Urine and blood samples,,2011-05,COMPLETED,INTERVENTIONAL,['NA']
7697,NCT02147860,DiAs time within target,,,2014-05,COMPLETED,INTERVENTIONAL,['NA']
7698,NCT03311516,The ratio of normoglycemia values to total glucose values,Usability of the insulin pump,,2019-10-10,UNKNOWN,INTERVENTIONAL,['NA']
7699,NCT03315988,"Change from Baseline 3-hour post-challenge glucose levels at 1, 8 and 12 weeks.","Semi-structured interviews with the completers, at the end of the study, to investigate perception responses having been on a vegan diet.",,2017-10-04,COMPLETED,INTERVENTIONAL,['NA']
7700,NCT05343884,Diagnostic Failure,Secondary end-points,,2022-03-15,RECRUITING,INTERVENTIONAL,['NA']
7701,NCT02077127,Genetic association,,,2011-09,COMPLETED,OBSERVATIONAL,['NA']
7702,NCT00703235,,,,na,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
7703,NCT04226027,Change in HbA1c value,PAID Score,,2020-01-17,UNKNOWN,INTERVENTIONAL,['NA']
7704,NCT01171703,Occlusion of the stent or bypass,Restenosis measured by Duplex Ultrasound or CTA,,2010-11,UNKNOWN,INTERVENTIONAL,['PHASE4']
7705,NCT03351478,Change From Baseline in Hemoglobin A1c (HbA1c) % at Week 26,Percentage of Participants With HbA1c <7.0% at Week 26,,2017-11-27,COMPLETED,INTERVENTIONAL,['PHASE3']
7706,NCT04256005,Area Under the Curve following second Carbohydrate load measured by continuous glucose monitoring,Mean Heart Rate (HR) during the exercise trials,,2021-06-01,COMPLETED,INTERVENTIONAL,['NA']
7707,NCT03407599,"AUC(IAsp),0-12h, area under the serum insulin aspart concentration-time curve from 0 to 12 hours",Number of hypoglycaemic episodes,,2018-01-08,COMPLETED,INTERVENTIONAL,['PHASE1']
7708,NCT05745090,Composite endpoint based on first occurrence of all-cause death or cardiovascular events,All-cause hospitalization,Proportion of study subjects with reduced left ventricular diastolic function,2022-11-10,RECRUITING,OBSERVATIONAL,['NA']
7709,NCT01567254,Blood glucose values before and after listening to the recording.,"The delta of HA1C between before and after three months of periodic listening to auditory guided imagery, compared to listening to music.",,2012-04,COMPLETED,INTERVENTIONAL,['NA']
7710,NCT01619592,Quality of Life (QoL),,,2012-06,COMPLETED,INTERVENTIONAL,['NA']
7711,NCT00238498,Change from baseline in HbA1c at 12 weeks,Change from baseline in HOMA IR at 12 weeks,,2004-07,COMPLETED,INTERVENTIONAL,['PHASE2']
7712,NCT01782547,Change in Hemoglobin A1c,Change in Diabetes Knowledge,Telehealth intervention satisfaction,2013-06,COMPLETED,INTERVENTIONAL,['NA']
7713,NCT05253768,Percentage of change in weight compared with baseline.,Safety of FMT,,2024-03,RECRUITING,INTERVENTIONAL,['PHASE2']
7714,NCT00876980,HbA1C,Fasting glucose & fructosamine microalbuminuria blood pressure lipids endothelial function,,2008-05,COMPLETED,INTERVENTIONAL,['NA']
7715,NCT01127308,Number of Participants Experiencing an Adverse Event (AE),,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE1']
7716,NCT01484262,Diabetes-related quality of life assessed by ADDQoL (Audit of Diabetes-Dependent Quality of Life),Total cost of patient education,,2011-11-14,COMPLETED,OBSERVATIONAL,['NA']
7717,NCT00681460,newborn weight,"parameters of metabolic control in mother and newborn, insulin resistance, inflammatory reaction, oxidative stress, fetal growth,",,2008-05,COMPLETED,INTERVENTIONAL,['NA']
7718,NCT00978796,The primary objective of this pilot study is to compare 24-hour blood glucose values (overnight and pre- and post- prandial glucoses) in adult subjects with type 1 diabetes receiving either sitagliptin or placebo,Time spent in hypoglycemic and hyperglycemic excursions recorded on the DexCom STS continuous glucose monitor (CGM) at 3 time periods throughout the study,,2009-09,COMPLETED,INTERVENTIONAL,['PHASE4']
7719,NCT01983813,Adherence of medical regimen/treatment to all of the Guideline Advantage criteria that apply.,"Control of blood pressure, low density lipoprotein cholesterol and hemoglobin A1c.",,2014-03-19,COMPLETED,INTERVENTIONAL,['NA']
7720,NCT03838783,Time in range within 6 hours,Change in TRIM-D Score,,2018-05-15,UNKNOWN,INTERVENTIONAL,['PHASE4']
7721,NCT01923688,Incidence of Severe Hypoglycemia,,,2011-08,COMPLETED,INTERVENTIONAL,['NA']
7722,NCT04755660,Physical activity,Hemoglobin A1c,,2021-03-15,COMPLETED,INTERVENTIONAL,['NA']
7723,NCT01327209,,,,2010-12,COMPLETED,OBSERVATIONAL,['NA']
7724,NCT00939276,Percentage of patients who develop macular edema within 90 days following cataract surgery,Mean change in best-corrected visual acuity (BCVA) from baseline to Day 90,,2009-08,TERMINATED,INTERVENTIONAL,['PHASE3']
7725,NCT05054712,To describe the prevalence of metabolic liver diseases (NAFLD and GH) by different diagnostic approaches in the population of patients with T1D.,To study the relationship between metabolic liver diseases in patients with T1D and the presence of microvascular and macrovascular complications.,,2021-09-01,UNKNOWN,OBSERVATIONAL,['NA']
7726,NCT05694520,The incidences of adverse maternofetal outcomes,Change from baseline the inflammatory factors at 2 months,,2023-06-10,RECRUITING,INTERVENTIONAL,['NA']
7727,NCT04494139,Healthy food intake,Systolic Blood pressure,,2020-11-01,UNKNOWN,INTERVENTIONAL,['NA']
7728,NCT04513587,Change in Waist circumference,Change in Sense of coherence,,2019-09-01,RECRUITING,INTERVENTIONAL,['NA']
7729,NCT05915338,Fırst follow - up survey,Last test survey,Durabılıty test for both groups,2022-10-01,COMPLETED,OBSERVATIONAL,['NA']
7730,NCT00163683,"The primary outcomes include: HBAIc and lipids (Cholesterol, HDL-cholesterol, Triglycerides) at study entry and 6 months after dietary intervention","Key secondary outcomes include: TNF-a, IL-6, High sensitivity CRP, plasma carotenoids and serum fatty acids.",,2003-01,COMPLETED,INTERVENTIONAL,['NA']
7731,NCT05834868,Change in Glycosylated Haemoglobin (HbA1c) After 26 Weeks of Treatment,Change From Baseline in 2-hour Postprandial Glucose (PPG) Excursion at Week 26,,2022-05-06,RECRUITING,INTERVENTIONAL,['PHASE3']
7732,NCT04946799,Fasting insulin at follow-up,International Physical Activity Questionnaire - Short Form at baseline,,2021-07-01,COMPLETED,INTERVENTIONAL,['NA']
7733,NCT06048757,Change in daily insulin dose requirement,App usability,,2023-08-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
7734,NCT02126423,Kirby Bauer disc diffusion antimicrobial susceptibility,,,2014-05,COMPLETED,OBSERVATIONAL,['NA']
7735,NCT06040164,Change in 2-oleoyl-glycerol (2-OG) levels in saliva and plasma,Oral health impact profile,,2023-10-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
7736,NCT00994812,Miscarriage rates,Effects of metformin versus placebo on the rates of gestational diabetes during pregnancy,,2002-08,COMPLETED,INTERVENTIONAL,['PHASE3']
7737,NCT05331586,Excessive gestational weight gain,Pelvic Floor and sexual disorders during pregnancy,,2022-07,UNKNOWN,INTERVENTIONAL,['NA']
7738,NCT00673621,AUCF 0-360 min of serum insulin,,,2008-05,COMPLETED,INTERVENTIONAL,['PHASE1']
7739,NCT05353686,Primary endpoint,,,2019-02-25,COMPLETED,INTERVENTIONAL,['PHASE2']
7740,NCT06240403,SAT microvascular endothelial cell β-galactosidase,,,2024-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
7741,NCT04639726,Post-prandial glycemic excursion.,Beta-cell function II,Plasma peptide,2020-09-28,COMPLETED,INTERVENTIONAL,['NA']
7742,NCT02551900,Change from baseline in cutaneous blood flow,Change from baseline in Peripheral arterial stiffness,,2014-09-01,COMPLETED,INTERVENTIONAL,['NA']
7743,NCT05942079,Change in adherence to treatment,,,2022-09-15,RECRUITING,OBSERVATIONAL,['NA']
7744,NCT01101204,Antiinflammatory effects of combined antidiabetic and hypolipemic treatment,Coagulation parameters,,2012-07,UNKNOWN,INTERVENTIONAL,['NA']
7745,NCT03362151,Delta glucose (maximum rise from baseline glucose) mg/dL,percent time glucose <70 mg/dL,,2018-01-01,COMPLETED,INTERVENTIONAL,['NA']
7746,NCT04682626,A1c,25OHD,,2020-12-25,COMPLETED,INTERVENTIONAL,['NA']
7747,NCT00334711,HbA1c reduction,Incidence of Hypoglycemia,,2004-01,COMPLETED,INTERVENTIONAL,['NA']
7748,NCT06068114,Pyloric distensibility,Autonomic function testing,,2022-10-05,RECRUITING,OBSERVATIONAL,['NA']
7749,NCT01045954,Determine the mean value for the slop between the variables of total daily dose versus total basal dose.,"Determine the slope between the other variables: weight, total daily dose, total basal dose, insulin correction carbohydrate rate, correction factor",,2010-01,UNKNOWN,INTERVENTIONAL,['NA']
7750,NCT04549324,The association between sleep apnea and systolic function in patients with diabetic nephropathy.,Association between 2D atrial global strain as determined during echocardiography and sleep apnea in patients with diabetic nephropathy.,,2020-10-01,COMPLETED,OBSERVATIONAL,['NA']
7751,NCT00417924,Patient satisfaction post-examination,,,2004-10,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
7752,NCT00734253,Change in serum creatinine from baseline to end of study.,"SCr slope, change in PCR, Cystatin C slope and change from baseline.",,2008-08,COMPLETED,INTERVENTIONAL,['PHASE2']
7753,NCT02991534,Referrals to Health Promotion and Disease Prevention Services,Depression screen (PHQ-4),,2016-11-15,COMPLETED,INTERVENTIONAL,['NA']
7754,NCT01395303,,,,2011-04,COMPLETED,OBSERVATIONAL,['NA']
7755,NCT04595396,Weight Loss,Early complications,,2012-09-01,COMPLETED,OBSERVATIONAL,['NA']
7756,NCT01119404,,,,2003-06,UNKNOWN,OBSERVATIONAL,['NA']
7757,NCT02790060,Fear of hypoglycemia score,Standard Deviation (SD) of recorded Home Monitoring of Blood Glucose (HMPG),,2015-06,COMPLETED,OBSERVATIONAL,['NA']
7758,NCT05308095,Diagnostic accuracy of the hypoglycaemia warning system using in-vehicle data to detect hypoglycaemia quantified as the area under the receiver operating characteristics curve (AUROC).,Technology acceptance of the hypoglycaemia warning system,,2022-04-13,COMPLETED,INTERVENTIONAL,['NA']
7759,NCT00406991,Retinal blood flow,Retinal arterial diameter,,2003-06,COMPLETED,INTERVENTIONAL,['PHASE2']
7760,NCT00005205,,,,1987-08,COMPLETED,OBSERVATIONAL,['NA']
7761,NCT04749693,time in 70 - 180 mg/dL glycemic range,incidence of the system on the necessary healthcare professional charge,,2021-05-17,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
7762,NCT06268392,Ultrasound fetal weight estimation,,,2024-02-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
7763,NCT05096858,Insulin use,,,2020-06-01,RECRUITING,OBSERVATIONAL,['NA']
7764,NCT04521712,Pancreatic beta cell function,Maternal diabetes mellitus,,2021-09-17,RECRUITING,INTERVENTIONAL,['NA']
7765,NCT06327815,Change in HbA1c from baseline,To evaluate the difference in adherence of FDC versus co-administered dual therapy by Morisky Medication Adherence Scale-8 (MMAS-8) questionnaire in Chinese patients with T2DM.,SDBG (Standard Deviation of Blood Glucose),2024-03-31,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
7766,NCT00004992,Development of diabetes,,,1996-07,COMPLETED,INTERVENTIONAL,['PHASE3']
7767,NCT03008824,Differences in B12 levels between GDM and Controls,Predictors of abnormal post-natal OGTT in the first trimester,Validation of newborn adiposity measured by skin-fold thickness and objective measurement by PEAPOD,2012-09,UNKNOWN,OBSERVATIONAL,['NA']
7768,NCT04192019,Time to hypoglycaemia,Any adverse events,,2023-04,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1']
7769,NCT02969798,Glucose tolerance status,,,2014-01-01,RECRUITING,INTERVENTIONAL,['NA']
7770,NCT03382873,Weight loss,Decreased Glycemia,,2018-02-08,UNKNOWN,INTERVENTIONAL,['NA']
7771,NCT01340768,Percentage of Participants With at Least One Symptomatic Hypoglycemic Event,Percentage of Participants With at Least One Symptomatic or Asymptomatic Hypoglycemic Event,,2010-06-22,COMPLETED,INTERVENTIONAL,['PHASE3']
7772,NCT01071772,Exercise capacity,Regional left ventricular function before and after maximum exercise(regional 2D tissue velocity and strain),,2009-04,COMPLETED,INTERVENTIONAL,['PHASE2']
7773,NCT00739336,Body Weight,Questionnaires,,2008-07,COMPLETED,INTERVENTIONAL,['NA']
7774,NCT01146886,Assessment of tolerability by the investigator,Total urinary corticosteroids (5α-THF + 5β-THF + THE + UFF + UFE) as an indicator of the activation of the HPA axis,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE1']
7775,NCT01945918,Change in body mass index (BMI) from baseline to 18 months,Evidence of documented self-management support for patients through medical record review,Change in patient-reported diabetes self-care rating from baseline to 18 months,2013-10,COMPLETED,INTERVENTIONAL,['NA']
7776,NCT02423798,Sensor Survival,,,2015-04,COMPLETED,INTERVENTIONAL,['NA']
7777,NCT01460251,DiaPep277-specific antibodies,Daily insulin dose adjusted to body weight at study end,,2012-01,TERMINATED,INTERVENTIONAL,['PHASE3']
7778,NCT03648281,Change in HbA1c,Patient completed the study under treatment with semaglutide (yes/no),,2018-08-24,COMPLETED,OBSERVATIONAL,['NA']
7779,NCT03900286,A change from baseline in HbA1c,The Three Factor Eating Questionnaire,,2020-01-16,RECRUITING,INTERVENTIONAL,['NA']
7780,NCT03650712,age- and sex-based nomograms for OGIS (oral glucose insulin sensitivity),evaluate the relationships between age and sex-based quantiles for c-peptide and number of pulmonary exacerbations in the previous 12 months,Correlation between CGM standard deviation of sensor glucose values and b-cell glucose sensitivity,2019-07-01,COMPLETED,INTERVENTIONAL,['NA']
7781,NCT05249881,Change in glycemic Index in Diabetes mellitus type-2 Patients,Weight Changes in Obese People,,2022-03-10,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
7782,NCT00486941,Self-reported physical activity,Glucose tolerance (OGTT),,2003-02,COMPLETED,INTERVENTIONAL,['PHASE3']
7783,NCT04939766,Change in burden of diabetes following activation of closed loop,Glycemic variability,,2021-06,UNKNOWN,INTERVENTIONAL,['NA']
7784,NCT05633784,Change in tolerance capacity,Assessment of physical activity.,,2022-08-18,RECRUITING,INTERVENTIONAL,['NA']
7785,NCT00677313,"To provide metreleptin, an investigational medication, under a treatment protocol to subjects with lipodystrophy that is associated with diabetes mellitus and/or hypertriglyceridemia","Information on the efficacy of metreleptin as assessed by its effects on fasting triglyceride concentrations, HbA1c, and fasting glucose concentrations in subjects with lipodystrophy that is associated with diabetes mellitus and/or hypertriglyceridemia",,2009-03,COMPLETED,INTERVENTIONAL,['NA']
7786,NCT02223793,Change in ad Hoc Risk Score (Measure on a Scale From Min 4 to Max 14),8-week Change in Total Cholesterol,Effect of Heart Age and Tailord CVD Advice After 1 Year,2014-09,UNKNOWN,INTERVENTIONAL,['NA']
7787,NCT03682445,Change in HbA1c level.,,,2019-11-04,COMPLETED,INTERVENTIONAL,['NA']
7788,NCT04410055,Oxygen consumption,Attention levels,,2012-01-08,UNKNOWN,INTERVENTIONAL,['NA']
7789,NCT03024788,prevalence of retinopathy,incidence of retinopathy,,2017-01,UNKNOWN,OBSERVATIONAL,['NA']
7790,NCT03165812,Type 2 Diabetes Mellitus (T2DM) patients in SADJB-SG group achieving glycated hemoglobin (HbA1c) level of less than 7% (with or without diabetes medications) in 2 years as compare to patients in IMT group.,Identification of genetic biomarkers.,,2017-04-01,UNKNOWN,INTERVENTIONAL,['NA']
7791,NCT06299098,Percent change in total fat mass,Severity of TEAEs,,2024-03-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
7792,NCT00589459,Prevalence of undiagnosed pre-diabetes or undiagnosed diabetes,,,2001-10-01,COMPLETED,OBSERVATIONAL,['NA']
7793,NCT00851773,Adverse events,Antibody development against N9535,,2009-02,COMPLETED,INTERVENTIONAL,['PHASE1']
7794,NCT05784220,Fasting blood glucose at final visit < 7 mmol/L measured by lab test,Change in blood pressure,Objective scoring of program coach audits,2019-06-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
7795,NCT05066542,Percent Weight Loss Efficacy,% Fat,,2021-06-11,UNKNOWN,INTERVENTIONAL,['NA']
7796,NCT05953818,Brain magnetic resonance high-resolution structural imaging was performed to observe the changes of brain structure,The cognitive function of the two groups was evaluated and analyzed by the Chinese version of Montreal Cognitive Assessment Scale (MoCA),,2023-05-30,RECRUITING,OBSERVATIONAL,['NA']
7797,NCT00225628,4) Compliance to guidelines regarding the screening and management of osteoporosis,2) Physician satisfaction regarding follow-up of abnormal test results,,2000-09,COMPLETED,INTERVENTIONAL,['NA']
7798,NCT04027530,Renal oxygenation measured by BOLD-MRI (R2*),Total insulin extraction,,2020-12-10,COMPLETED,INTERVENTIONAL,['PHASE4']
7799,NCT04307511,changes of Maximum Amplitude (MA) detected by TEG,,,2020-04-20,RECRUITING,INTERVENTIONAL,['PHASE4']
7800,NCT01690962,Mood,Quality of life,Acceptability of vegan diet,2012-11,COMPLETED,INTERVENTIONAL,['NA']
7801,NCT02679287,Hemoglobin A1c,Hemoglobin A1c by Study Session,,2016-02,COMPLETED,INTERVENTIONAL,['NA']
7802,NCT06007430,Body Mass Index (BMI),Rate Pressure Product,,2023-03-01,RECRUITING,INTERVENTIONAL,['PHASE2']
7803,NCT00907881,Correlation Between HbA1c Values at Week 12 and Hypoglycemia Scores,Correlation Between HbA1c Values at Baseline and Hypoglycemia Scores at Week 12,,2009-08,COMPLETED,OBSERVATIONAL,['NA']
7804,NCT03895437,Treatment effect on log-transformed MMTT C-peptide area under the curve (AUC),Events of Special Interest,,2019-06-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
7805,NCT04203927,Myocardial microvascular perfusion,Pulse Wave Velocity ( PWV),,2020-02-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
7806,NCT00906659,macular volume (measured in mm3),,,2006-01,COMPLETED,OBSERVATIONAL,['NA']
7807,NCT03970161,GCL+ thickness in the macular region obtained using the 3D Macula (v) mode,,,2019-05-29,UNKNOWN,INTERVENTIONAL,['NA']
7808,NCT02863354,Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0,"Change in Area of Total Retinal Capillary Non-perfusion, as Assessed by the Central Reading Center",,2016-08,COMPLETED,INTERVENTIONAL,['PHASE2']
7809,NCT02066350,Endothelial function,Oral glucose tolerance test,,2014-01,COMPLETED,INTERVENTIONAL,['NA']
7810,NCT01455870,Change in HbA1c between Week 52 and Day 0,,,2013-05,COMPLETED,INTERVENTIONAL,['PHASE3']
7811,NCT00413465,"Renal plasma flow, Glomerular filtration rate, Plasma cytokine content, Endotoxemia score, Plasma angiotensin II and renin content, Plasma thromboxane B2 content, Plasma PAI-1 content","Mean arterial pressure, Heart rate, Oxygen saturation, Body temperature,",,2006-11,UNKNOWN,INTERVENTIONAL,['NA']
7812,NCT06336122,Number of participants with change in A1c,Social Network Scale,,2024-02-21,RECRUITING,INTERVENTIONAL,['NA']
7813,NCT01974778,BAT activity,,,2014-03,TERMINATED,INTERVENTIONAL,['NA']
7814,NCT01684813,Number of patients who achieve inhibition of platelet aggregation greater that 50%,Number of participants who are non-responsiveness to antiaggregation therapy as a measure of efficacy,,2012-10,COMPLETED,INTERVENTIONAL,['PHASE4']
7815,NCT04915014,The Excess Weight Loss percentage (EWL%),Change of physical activity assessed by the International Physical Activity Index (IPAQ) score.,,2021-07-23,RECRUITING,INTERVENTIONAL,['NA']
7816,NCT05542901,Joint Position Sense,Functional Capacity,,2022-09-13,COMPLETED,INTERVENTIONAL,['NA']
7817,NCT05436041,Variance and Within-Provider Covariance of Patient Change in Diet Quality (measured via Healthy Eating Index),Impact of Nutri on Patient Diet Quality (measured via Healthy Eating Index),Impact of Nutri on PCP Diet Counseling Competency,2022-06-14,COMPLETED,INTERVENTIONAL,['NA']
7818,NCT02549924,Mean amplitude of glucose excursions (MAGE),Body and visceral fat %,,2016-09,TERMINATED,INTERVENTIONAL,['PHASE2']
7819,NCT04770532,Change in HbA1c (glycated haemoglobin),Change in body weight,,2021-03-05,COMPLETED,INTERVENTIONAL,['PHASE3']
7820,NCT01049737,"Left ventricular mass index by cardiac ultrasonography, Intima media thickness by carotid ultrasonographic investigation and tonometry for measurements of the carotid, femoral and radial pulse pressure wave form and pulse wave velocity",Cardiovascular morbidity and mortality,,2005-05,COMPLETED,OBSERVATIONAL,['NA']
7821,NCT00699686,Change in endothelial progenitor cell count,Change in body weight,,2008-05,COMPLETED,INTERVENTIONAL,['PHASE4']
7822,NCT01744392,Medication Possession Ratio at 6 Months,Pulse at 6 Months,,2013-02,COMPLETED,INTERVENTIONAL,['NA']
7823,NCT03565770,Difference between the rate of glycosylated hemoglobin (HbA1c) before randomization (baseline) and the rate of glycosylated hemoglobin after 6 months coaching (measure M6).,Binary variable attendance = 80% honored appointments,,2018-09-29,UNKNOWN,INTERVENTIONAL,['NA']
7824,NCT02129985,remission rate of type 2 diabetes at a year.,the beta cell function change,number of hypoglycemia and severe hypoglycemia during the study,2014-02,UNKNOWN,INTERVENTIONAL,['PHASE4']
7825,NCT06066515,Achievement of body weight reduction ≥5% (yes/no) from baseline to Week 76,Relative change from baseline to Week 76 in liver fat content (%),,2023-11-15,RECRUITING,INTERVENTIONAL,['PHASE3']
7826,NCT01746017,Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,Change From Baseline in C-Peptide Area Under the Effective Concentration Curve From Time Zero to 6 Hours [AUEC(0-6)],,2012-12,COMPLETED,INTERVENTIONAL,['PHASE1']
7827,NCT01354925,Difference in mean 4-point SMBG during days 23-30 of treatment between the two groups.,,,2011-09,COMPLETED,INTERVENTIONAL,['PHASE4']
7828,NCT04223973,Estimation of A1C based on average blood glucose measured by continuous glucose sensor,Compare pump tolerance for the active group (Medtrum Pump) vs Control Group Patients (comparator device) in order to assess non inferiority,,2020-01-29,COMPLETED,INTERVENTIONAL,['NA']
7829,NCT04513704,"Area under the semaglutide plasma concentration - time curve during a dosing interval after the 10th dosing (AUC0-24h,sema,day10)","Time to maximum observed semaglutide plasma concentration after the 10th dosing (tmax,0-24h,sema,day10)",,2020-08-28,COMPLETED,INTERVENTIONAL,['PHASE1']
7830,NCT00310752,,,,2006-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7831,NCT04504396,Change in HbA1c,Change in Body Mass Index,,2020-06-23,COMPLETED,INTERVENTIONAL,['PHASE3']
7832,NCT02316054,"cardiac death,or Q-wave myocardial infarction (MI), or the need for myocardial revascularization > 3 months after SPECT",myocardial revascularization > 3 months after SPECT,,2007-11,COMPLETED,OBSERVATIONAL,['NA']
7833,NCT04246190,"AUClast of CKD-501, D759 and CKD-396",,,2020-02-24,UNKNOWN,INTERVENTIONAL,['PHASE1']
7834,NCT00109369,Glycemic control,Functional status,,2003-06,COMPLETED,INTERVENTIONAL,['NA']
7835,NCT02208206,Analysis of gene expression,,,2014-07,COMPLETED,OBSERVATIONAL,['NA']
7836,NCT00225342,Angina status at 3 months,Biochemical markers of inflammation at 3 months,,na,WITHDRAWN,INTERVENTIONAL,['PHASE4']
7837,NCT05385211,Exocrine pancreatic insufficiency,,,2022-04-30,COMPLETED,OBSERVATIONAL,['NA']
7838,NCT00157222,,,,2005-05,UNKNOWN,OBSERVATIONAL,['NA']
7839,NCT02146079,Area under the plasma semaglutide concentration-time curve,Number of treatment emergent adverse events (TEAEs) from baseline to follow-up,,2014-05-21,COMPLETED,INTERVENTIONAL,['PHASE1']
7840,NCT00317915,Development of overt nephropathy,,,na,COMPLETED,INTERVENTIONAL,['PHASE3']
7841,NCT01995656,Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,Pharmacokinetics: Area Under the Curve (AUC) of LY3108743,,2013-12,COMPLETED,INTERVENTIONAL,['PHASE1']
7842,NCT00861042,Subject withdrawal due to adverse events,Quality of life assessments during specific site visits,,2002-04,COMPLETED,INTERVENTIONAL,['PHASE2']
7843,NCT02691273,10 percentage improvement in the quality of life questionnaire,,,2015-03,COMPLETED,INTERVENTIONAL,['NA']
7844,NCT05896644,Change in number of ED Visits,Change in blood pressure,,2023-06-20,RECRUITING,INTERVENTIONAL,['NA']
7845,NCT00435019,Glycosylated Haemoglobin A1c (HbA1c),Observed Insulin Antibody Values,,2007-02,COMPLETED,INTERVENTIONAL,['PHASE3']
7846,NCT03090464,Change from baseline to end of study (Month 6) in HbA1c levels,Proportion of patients in both cohorts who intensify antihyperglycemic treatment from Visit 1,Change in baseline to Month 6 in Morisky Medication Adherence Scale (8-item) (adherence),2017-05-08,COMPLETED,OBSERVATIONAL,['NA']
7847,NCT05147701,Safety (adverse events),,,2022-02-01,RECRUITING,INTERVENTIONAL,['PHASE1']
7848,NCT05565534,"Number of in-person, virtual or phone contacts with the NP",Number of participants with Chemotherapy Dose Reductions,,2023-02-28,RECRUITING,INTERVENTIONAL,['NA']
7849,NCT00659932,Hemoglobin A1C (HbA1C),Diabetes Quality of Life (ADDQoL),,2002-05,COMPLETED,INTERVENTIONAL,['NA']
7850,NCT02331420,Cardiac autonomic function (heart rate variability measurements on 24-hour Holter ECG recordings),,,2015-02,UNKNOWN,INTERVENTIONAL,['NA']
7851,NCT04123054,Change in HbA1c levels,Mean sensor glucose level during:,Recurrent themes from semi-structured interviews,2020-03-05,RECRUITING,INTERVENTIONAL,['NA']
7852,NCT02393872,Body mass index (BMI),,,2016-01,UNKNOWN,INTERVENTIONAL,['NA']
7853,NCT03825926,Edinburgh postpartum depression scale (EPDS) follow up GDM or non-GDM,Expenditure on GDM after the diagnosis,,2019-06-01,RECRUITING,OBSERVATIONAL,['NA']
7854,NCT02249897,CML SERUM LEVELS,MULTIFOCAL ELECTRORETINOGRAPHY,,2015-01,COMPLETED,INTERVENTIONAL,['PHASE4']
7855,NCT05975541,Fecal calprotectin levels identification,assessment of the circadian rhythm trough MEQ questionnaire,,2023-10-01,RECRUITING,OBSERVATIONAL,['NA']
7856,NCT02827669,HbA1c,,,2016-06,COMPLETED,INTERVENTIONAL,['NA']
7857,NCT00109434,Hypoglycemia defined as <=70 mg/dL.,Changes in epinephrine and glucagon levels.,,2004-06,COMPLETED,OBSERVATIONAL,['NA']
7858,NCT01301196,Sedentary behaviour,Psychosocial indicators,,2010-10,UNKNOWN,INTERVENTIONAL,['NA']
7859,NCT02692313,Flow mediated dilation (FMD) of the brachial artery,,,2016-06,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
7860,NCT00523913,"The safety profile (adverse events, laboratory parameters and other observations) of BRL49653C administered for 52 weeks will be evaluated.","The efficacy profile (HbA1c, FPG and Insulin) of BRL49653C administered for 52 weeks will be evaluated.",,2005-11,COMPLETED,INTERVENTIONAL,['PHASE3']
7861,NCT00133692,First occurrence of death or nonfatal myocardial infarction (MI) or nonfatal stroke,Compliance,,1997-09,COMPLETED,INTERVENTIONAL,['PHASE4']
7862,NCT05484817,Prevalence of impaired cardiac function in type 2 diabetes diagnosed by echocardiography,Biomarker measured by blood test,,2022-06-01,RECRUITING,OBSERVATIONAL,['NA']
7863,NCT03542487,Patient A1c,Flowsheet Entry Values (descriptive),,2018-05-01,COMPLETED,INTERVENTIONAL,['NA']
7864,NCT02086539,Enrollment into the Habit Formation study,,,2014-04,COMPLETED,INTERVENTIONAL,['NA']
7865,NCT04601753,Change in Glycated haemoglobin (HbA1c ),"Diabetes Treatment Satisfaction Questionnaire, status (DTSQs), change in absolute treatment satisfaction",,2020-11-12,COMPLETED,OBSERVATIONAL,['NA']
7866,NCT04451915,The occurrence of materno-fetal complications,Number of complications in each subgroup of the late GDM management group,,2020-11-30,RECRUITING,INTERVENTIONAL,['NA']
7867,NCT04909632,The differentiation of tongue features mellitus and pre-diabetes,The tongue coating metabolic markers in patients with diabetes,,2020-03-01,UNKNOWN,INTERVENTIONAL,['NA']
7868,NCT00407641,"the composite event rate in death (any cause), myocardial infarction and stroke",Lipid profile,,2009-03,WITHDRAWN,INTERVENTIONAL,['PHASE4']
7869,NCT05353699,"Implementation change: Change from Baseline Implementation at 3, 6,9 months",Qualitative assessment-maintenance:,,2022-05-01,UNKNOWN,INTERVENTIONAL,['NA']
7870,NCT05413369,Change in HbA1c from baseline to Week 24,Change in fasting C-peptide,,2022-07-07,COMPLETED,INTERVENTIONAL,['PHASE3']
7871,NCT03174288,Augmentation Index-Change from baseline,Microvascular Blood Volume-Change from baseline,,2015-08,COMPLETED,INTERVENTIONAL,['NA']
7872,NCT00833716,AUC of NN9535,"Laboratory safety, adverse events",,2009-02-02,COMPLETED,INTERVENTIONAL,['PHASE1']
7873,NCT01109797,"Measure and compare change in self-efficacy and change in diabetes knowledge, diabetes quality of life, family conflict, and treatment satisfaction for and between the two groups.",Make exploratory baseline comparisons between the two groups of HgbA1c,,2010-04,COMPLETED,INTERVENTIONAL,['NA']
7874,NCT02725502,Effect of Linagliptin on insulin requirement in T1DM patients,Effect of linagliptin on glucagon level during mixed meal test in T1DM patients,,2013-07,UNKNOWN,INTERVENTIONAL,['NA']
7875,NCT01066039,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Month 6,Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs),,2010-04,COMPLETED,INTERVENTIONAL,['PHASE4']
7876,NCT04711226,Efficacy- Insulin independence,Efficacy- HbA1c,Exploratory- Pharmacokinetic Parameters- (t1/2),2021-02-19,WITHDRAWN,INTERVENTIONAL,['PHASE2']
7877,NCT05581264,Difference in Glycated hemoglobin (HbA1c) level between experimental group and control group across time,Difference in health related quality of life HRQOL scale scores between experimental group and control group across time,,2021-09-28,COMPLETED,INTERVENTIONAL,['NA']
7878,NCT01023646,"Glucose, Insulin, Free Fatty Acids.","Fasting and non-fasting plasma lipids and lipoproteins, C reactive protein (CRP), HbAIc.",,2007-12,COMPLETED,INTERVENTIONAL,['NA']
7879,NCT04689074,Biological samples collection for establishment of the first National Microbiome Biobank,,,2021-02-03,COMPLETED,OBSERVATIONAL,['NA']
7880,NCT00850798,"The primary study outcomes are a composite of macrovascular events and a composite of microvascular events, considered both jointly and separately.","The secondary outcomes are death from any cause, disability from any cause, total coronary events, total cerebrovascular events, heart failure, peripheral vascular events, all cardiovascular events, and hospitalization for 24 hours or more.",,2009-02,UNKNOWN,INTERVENTIONAL,['NA']
7881,NCT01618188,Area under the glucose infusion rate curve,Time to maximum glucose infusion rate,,2012-06-11,COMPLETED,INTERVENTIONAL,['PHASE1']
7882,NCT04916314,HbA1c,Diabetes related quality of life and distresses; EQ5D score,Participants' experience of using the app-based support,2021-07-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
7883,NCT01419652,periprocedural glucose,,,2009-07,COMPLETED,INTERVENTIONAL,['PHASE4']
7884,NCT04884425,Change in the EQ-5D-5L tool score,,,2021-06,UNKNOWN,INTERVENTIONAL,['NA']
7885,NCT02715934,Provider referral,Patient participation,Summary of Diabetes Self-care Activities Measure (SDSCA),2016-04,COMPLETED,INTERVENTIONAL,['NA']
7886,NCT02733991,Mean Number of Sensor Glucose Hypoglycaemic Events Below or Equal to 55 mg/dL Per Patient/Week.,Mean Time Spent of Sensor Glucose Values Within Range and Including 70-180 mg/dL.,,2016-12,COMPLETED,INTERVENTIONAL,['NA']
7887,NCT00970060,Dermal and epidermal nerve fiber densities,"Clinical assessments of neuropathy, pain, body mass index, muscle strength, and glycemic control (glycosylated hemoglobin or A1C)",,2008-06,COMPLETED,INTERVENTIONAL,['NA']
7888,NCT06317142,Postprandial hepatic and muscle glucose uptake determined by Fluorodeoxyglucose-Positron emission tomography ([18F]-FDG-PET) combined with oral glucose tolerance test (OGTT),Whole body gluconeogenesis after acipimox treatment determined by deuterated water,Body composition determined by Bodpod,2024-04-01,RECRUITING,OBSERVATIONAL,['NA']
7889,NCT00220961,Prevention of Type 2 Diabetes,Change in Atherosclerosis,,2004-01,COMPLETED,INTERVENTIONAL,['PHASE3']
7890,NCT00687453,Hemoglobin A1c Change From Baseline,Any Adverse Event Other Than Hypoglycemia,,2003-02,TERMINATED,INTERVENTIONAL,['PHASE4']
7891,NCT01170468,The incidence of DM,time to develop DM,,2011-12,TERMINATED,INTERVENTIONAL,['PHASE3']
7892,NCT04522921,Change in fat mass/fat free mass,Inflammatory markers,,2020-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
7893,NCT02347787,Short Form Health Survey (SF-12) Physical Component Score (PCS),Hospital Admission - Mean Length of Stay (Among Participants With Hospitalization),,2015-01-28,COMPLETED,INTERVENTIONAL,['NA']
7894,NCT01508897,"Cmax, maximum concentration",Adverse events,,2004-05-28,COMPLETED,INTERVENTIONAL,['PHASE1']
7895,NCT01771835,Quantification of retinal venous pressure (RVP),Quantification of ET-1 in correlation with RVP,,2011-08,COMPLETED,OBSERVATIONAL,['NA']
7896,NCT01877590,Alpha-lipoic acid regress the left ventricular mass,The change of endothelial dysfunction before and after alpha-lipoic acid intervention.,,2013-11,COMPLETED,INTERVENTIONAL,['PHASE4']
7897,NCT02470156,Wellness Coaching Program Effectiveness on Goal Success,Economic Assessment of the Intervention,,2012-05,COMPLETED,INTERVENTIONAL,['NA']
7898,NCT00184574,HbA1c,Other glycemic variables,,2005-04,COMPLETED,INTERVENTIONAL,['PHASE3']
7899,NCT02077309,Effect of linagliptin on vascular inflammation of the carotic artery,Effect of linagliptin on biomarkers of vascular inflammation,,2014-08,TERMINATED,INTERVENTIONAL,['PHASE3']
7900,NCT05330390,Blood drug concentration,,,2022-04-04,UNKNOWN,OBSERVATIONAL,['NA']
7901,NCT02402374,Proportion of patients with complete wound closure,,,2018-04-12,UNKNOWN,INTERVENTIONAL,['NA']
7902,NCT02547337,Intestinal blood flow acquired with PET and DWI (ml ml-1 min-1),,,2015-09-10,COMPLETED,OBSERVATIONAL,['NA']
7903,NCT02225951,3-hr postprandial glucose response,,,2014-07,TERMINATED,INTERVENTIONAL,['NA']
7904,NCT01478841,Peripheral insulin-sensitivity,biochemical parameters,,2008-10,COMPLETED,INTERVENTIONAL,['NA']
7905,NCT03266133,Self-reported sleep duration,Preeclampsia,,2017-11-27,COMPLETED,INTERVENTIONAL,['NA']
7906,NCT02444325,effect of group prenatal care on maternal diabetes self-care activities as measured Diabetes Self-Care Activities Measure,Contraception,,2015-05,COMPLETED,INTERVENTIONAL,['NA']
7907,NCT05304325,"Adipose tissue fibrosis using qRT-PCR, immunoblotting, histochemistry and immunohistochemistry","Inflammation in adipose tissue using qRT-PCR, immunoblotting and immunohistochemistry",,2012-04-25,UNKNOWN,OBSERVATIONAL,['NA']
7908,NCT00505960,HbA1c,BP control,,2007-09,COMPLETED,INTERVENTIONAL,['PHASE1']
7909,NCT02154997,Post prandial blood glucose levels,,,2014-11,UNKNOWN,OBSERVATIONAL,['NA']
7910,NCT02132338,Glycated hemoglobin level before and after intervention,body mass index,Loss of participants in the intervention by forfeit,2014-06,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
7911,NCT02911792,GFR (Glomerular Filtration Rate) Change After Treatment,,,2016-12-20,COMPLETED,INTERVENTIONAL,['PHASE4']
7912,NCT04099745,Accuracy of different blood glucose monitoring systems (CGM and FGM) with intravenous blood glucose level as the gold standard,forty-day blood glucose fluctuation of FGM,,2019-10-01,UNKNOWN,INTERVENTIONAL,['NA']
7913,NCT02009254,blood glucose,food intake,subjective appetite,na,COMPLETED,INTERVENTIONAL,['NA']
7914,NCT05558878,Effect of Ambroxol on Superoxide dismutase,Effect of Ambroxol on clinical outcome : Pain assessment using the Numeric rating scale NRS,,2022-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
7915,NCT01077505,AUC0-24 of norethindrone and ethinyl estradiol after OC alone in Period 1 and after OC with albiglutide in Period 2.,Predose serum levels of progesterone after OC alone and after OC with albiglutide.,,2010-03-15,COMPLETED,INTERVENTIONAL,['PHASE1']
7916,NCT04006938,Fasting blood sugar level,,,2019-07,UNKNOWN,INTERVENTIONAL,['NA']
7917,NCT00252694,Number of Participants With a 3-step or Greater Increase in Early Treatment of Diabetic Retinopathy Study (EDTRS) Severity Scale,Rate of Change in Urinary Albumin Excretion Rate (UAER).,,2001-08,COMPLETED,INTERVENTIONAL,['PHASE3']
7918,NCT05899023,Percent of Patients who Complete at least One In-Person Follow-up Outpatient Visit,Percent of Patients who Start on Diabetes Medications within 6 Months of Diagnosis,,2024-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
7919,NCT01028846,Endogenous Glucose Production (EGP),,,2011-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4']
7920,NCT00202033,HbA1c,blood glucose testing frequency,,2004-09,COMPLETED,INTERVENTIONAL,['PHASE4']
7921,NCT01158625,"Blood pressure, nighttime blood pressure and 24 h blood pressure",Urine albumin excretion,,2010-08,COMPLETED,INTERVENTIONAL,['NA']
7922,NCT00353691,Change in HbA1c from baseline to Week 24 or last evaluable ontreatment value.,Mean change in body mass index (BMI) from baseline to Wk 12 and Wk 24 or last evaluable on-treatment value,,2002-10,COMPLETED,INTERVENTIONAL,['PHASE3']
7923,NCT00162175,Compare change from baseline in HbA1c after 24 weeks of treatment with muraglitazar + glyburide vs placebo + glyburide,"Change in FPG from basline to W24, proportion of subjects receiving therapeutic response at W24, percent change of fasting lipid levels from baseline to W11/12, change in hs-CRP from baseline to W24",,2003-07,COMPLETED,INTERVENTIONAL,['PHASE3']
7924,NCT03556631,hemoglobin A1c in percentage,weight in kilograms,,2020-09-01,COMPLETED,INTERVENTIONAL,['PHASE4']
7925,NCT04499768,VD at 3 months postoperatively,BCVA at 3 months postoperatively,,2018-06-01,UNKNOWN,OBSERVATIONAL,['NA']
7926,NCT03179085,The Patient Activation Measure (PAM),Nutritional Measures,,2017-08-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
7927,NCT03881995,Brain insulin sensitivity,Body weight,Hypoglycemia time of day,2019-03-18,TERMINATED,INTERVENTIONAL,['PHASE4']
7928,NCT03489967,Change in glucose levels 15 minutes after hypoglycemic treatment,Number of patients requiring a second treatment 15 minutes after the first hypoglycemic treatment,,2018-04-18,COMPLETED,INTERVENTIONAL,['NA']
7929,NCT06330480,Effectiveness of the albuminuria screening,Cost-effectiveness of screening strategies compared to standard of care: treatment effectiveness based on actual observed event rates,"Overall effectiveness of broader population-based screening strategies applied to screening on heart failure, coronary artery disease, and type 2 diabetes.",2024-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
7930,NCT00073281,,,,2003-08,COMPLETED,INTERVENTIONAL,['PHASE1']
7931,NCT03195868,"total nerve fiber density,",NTSS- Nueropathy Total Symptom Score,,2019-09-30,COMPLETED,INTERVENTIONAL,['NA']
7932,NCT02056210,CD34+ stem cell mobilization in diabetic vs non diabetic subjects,EPC (endothelial progenitor cell) mobilization within diabetic patients,,2014-02,COMPLETED,INTERVENTIONAL,['PHASE4']
7933,NCT03790579,Dietary acid load,,,2014-01-05,COMPLETED,OBSERVATIONAL,['NA']
7934,NCT05071820,Percent weight lost at 12 months from baseline weight,change in hemoglobin A1c,,2023-01-01,RECRUITING,INTERVENTIONAL,['NA']
7935,NCT03421379,Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia,PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM,,2018-02-21,COMPLETED,INTERVENTIONAL,['PHASE3']
7936,NCT00701181,Mean Change from Baseline in the Best Corrected Visual Acuity Score,Mean Changes in Macular Volume from Baseline,,2008-06,TERMINATED,INTERVENTIONAL,['PHASE2']
7937,NCT03890900,Change from baseline hemoglobin A1c to 3 and 6 months,Change from baseline LDL cholesterol to 3 months and 6 months,,2020-03-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7938,NCT02830048,Decrease in fasting plasma glucagon concentration,Pre-dose plasma concentration of glibenclamide,,2016-07,COMPLETED,INTERVENTIONAL,['PHASE2']
7939,NCT00849056,Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 52,Change From Baseline in Body Weight at Week 156,,2009-01,COMPLETED,INTERVENTIONAL,['PHASE3']
7940,NCT00803660,The percentage of patients achieving the BP<130/80 mmHg,The number and percentage of patients with positive proteinuria by treatment groups,,2008-11,COMPLETED,OBSERVATIONAL,['NA']
7941,NCT00745342,"Glycemic control, assessed by hemoglobin A1c","Parent involvement in diabetes management tasks, measured using the Diabetes Family Responsibility Questionnaire (youth and parent versions)",,1999-03,COMPLETED,INTERVENTIONAL,['NA']
7942,NCT00886574,Maximal and mean intima media thickness (IMT) of both common carotid artery of the cilostazol group in comparison with the aspirin group,Events of hemorrhagic vascular complication,,2009-04,UNKNOWN,INTERVENTIONAL,['PHASE4']
7943,NCT05383209,Percentage of subjects improving ≥2 steps in the Diabetic Retinopathy Severity Scale (DRSS) score each EYP-1901 dose level versus the sham IVT injection group.,Rates of ocular (study eye and fellow eye) and non-ocular Treatment-Emergent Adverse Events,,2022-08-31,RECRUITING,INTERVENTIONAL,['PHASE2']
7944,NCT00800085,The systematic and simultaneous determination of markers of functional beta cell mass and immune status allows stratification according to the stage of the pathogenic process rather than according to a late metabolic consequence of this process,,,2006-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
7945,NCT02001805,Body Composition,Activity level and diet,,2010-12,UNKNOWN,OBSERVATIONAL,['NA']
7946,NCT00472095,Hemoglobin A1c,,,2007-06,COMPLETED,INTERVENTIONAL,['NA']
7947,NCT01318122,Number of Participants With Adverse Events.,Change From Baseline in Blood Glucose Measured by the Meal Tolerance Test (Final Visit).,,2008-05,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
7948,NCT02915198,"Time in days to death, non-fatal myocardial infarction, stroke, hospitalization for unstable angina, or symptom-driven coronary revascularization",Time in days to Diabetes Outcome,,2023-04-03,RECRUITING,INTERVENTIONAL,['PHASE4']
7949,NCT05269589,Hemoglobin A1C (HbA1C),Blood pressure,,2022-02-18,RECRUITING,INTERVENTIONAL,['NA']
7950,NCT01950806,Change in biomarkers of insulin resistance compared with control diet,Change in plasma lipid profile compared with control diet,,2014-01,COMPLETED,INTERVENTIONAL,['NA']
7951,NCT00618007,HbA1c,Fasting Insulin,,2008-02,COMPLETED,INTERVENTIONAL,['PHASE2']
7952,NCT01085773,Glycated hemoglobin (HbA1c).,"Adherence, Anthropometry,Blood pressure, Lipid profile, VO2max and quality of life.",,2005-02,COMPLETED,INTERVENTIONAL,['PHASE2']
7953,NCT04108299,Satisfaction Questionnaire Score,Change in International Physical Activity Questionnaire (IPAQ)-short version Score,,2021-04-21,COMPLETED,INTERVENTIONAL,['NA']
7954,NCT00616811,Safety and tolerability in patients with T2DM and severe renal insufficiency over 24 weeks of treatment,Efficacy of vildagliptin versus sitagliptin in patients with T2DM and severe renal insufficiency by assessing the hemoglobin A1c (HbA1c ) and fasting plasma glucose (FPG) reduction from baseline,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE3']
7955,NCT06171230,Pain intensity measured with the Numeric Rating Scale (NRS),Pain Disability Index (PDI) Limitations in daily activities,,2024-03-01,RECRUITING,INTERVENTIONAL,['NA']
7956,NCT03095196,All cause deaths.,,,2012-09-01,COMPLETED,OBSERVATIONAL,['NA']
7957,NCT03479671,Insulin Sensitivity,,,2020-01-01,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
7958,NCT05915260,The association of pericardial- and epicardial fat with myocardial function and MACE after 5 year,"Characterization of the progression of diabetic cardiomyopathy over 5 years, including LV+RV function, the coronary microvascular function, the coronary macrovascular function, fibrosis, aortic stiffness, per and epicardial fat, perfusion of other organs",,2023-04-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
7959,NCT02518334,Oral glucose tolerance test,,,2012-03,COMPLETED,INTERVENTIONAL,['NA']
7960,NCT00646542,To evaluate the safety and tolerability in patients with T2DM and moderate or severe renal insufficiency over 24 weeks of treatment,To explore the efficacy of vildagliptin (50 mg qd) versus placebo in patients with T2DM and moderate or severe renal insufficiency.,,2005-03,COMPLETED,INTERVENTIONAL,['PHASE3']
7961,NCT03263728,Prevalence of myocardial ischaemia,Major adverse cardiovascular events,,2017-08-10,COMPLETED,INTERVENTIONAL,['NA']
7962,NCT03511521,Glycemic Control,Percentage of Glucose Values Within the Hypoglycemic Range,,2018-03-27,TERMINATED,INTERVENTIONAL,['PHASE4']
7963,NCT01469312,Change in Blood Glucose,,,2010-04,COMPLETED,INTERVENTIONAL,['NA']
7964,NCT02863419,Change in HbA1c (Week 26),Change in DTSQs: Individual Items and Total Treatment Satisfaction Score (6 of the 8 Items Summed),,2016-08-10,COMPLETED,INTERVENTIONAL,['PHASE3']
7965,NCT00479258,To Assess Pulmonary Safety and Glycemic Control of Exubera Over a 12 Month Controlled Period,7 Point Home Glucose,,2007-10,TERMINATED,INTERVENTIONAL,['PHASE3']
7966,NCT05819138,Change in Carotid and Radial Artery Pulse Wave Velocity (CR-PWV),Change in Renal Vascular Resistance (RVR),,2023-06-21,RECRUITING,INTERVENTIONAL,['PHASE3']
7967,NCT01331317,Change in plasma NT-proBNP,Change in Urinary Albumin Excretion Rate,,2010-04,COMPLETED,INTERVENTIONAL,['PHASE4']
7968,NCT01879800,Mean Change in Participants World Health Organization Quality of Life Measure- Physical Score: Change From Baseline to 3 and 6 Month Follow-up.,Mean Change in Hamilton Anxiety Rating Scale (HAM-A) From Baseline to 3 and 6 Month Follow-up,,2012-08,COMPLETED,INTERVENTIONAL,['NA']
7969,NCT01151072,Area under the serum Insulin Degludec concentration-time curve (only for subcutaneous administration),Back-extrapolated initial serum Insulin Degludec concentration after single-dose (only for intravenous administration),,2010-06,COMPLETED,INTERVENTIONAL,['PHASE1']
7970,NCT02124590,Change in Acylcarnitine/Carnitine ratio,Change in Mitochondrial Function,,2014-06,COMPLETED,INTERVENTIONAL,['NA']
7971,NCT01387334,HbA1c,compliance of home-based resistive exercise training,,2007-02,COMPLETED,INTERVENTIONAL,['PHASE2']
7972,NCT03980236,Change in A1c,,,2019-05-06,TERMINATED,INTERVENTIONAL,['NA']
7973,NCT05860842,Change in peak power output (PPO),,,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
7974,NCT05925933,Metabolomics profile,,,2023-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
7975,NCT00568854,Kinetics of Mycobacterial-specific Immune Response After BCG Vaccination,,,2007-04,TERMINATED,INTERVENTIONAL,['NA']
7976,NCT05472272,Percent of participants achieving significant weight loss and diabetes remission,Metabolomic profiling performed by liquid chromatography mass spectrometry,,2022-08-03,RECRUITING,INTERVENTIONAL,['NA']
7977,NCT00513630,"Composite of cardiovascular events which were defined as death from a cardiovascular cause, death from any cause, nonfatal myocardial infarction, nonfatal stroke or arterial revascularization",new peripheral vascular events,,2004-06,COMPLETED,INTERVENTIONAL,['PHASE4']
7978,NCT05656963,Specific link between high incidence of thrombotic events in patients with membranous nephropathy and diabetic nephropathy,,,2021-09-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
7979,NCT04233489,Change in Brief Infant Toddler Social Emotional Assessment (BITSEA) score,Change in M/CHAT R/F score,,2020-01-03,TERMINATED,INTERVENTIONAL,['NA']
7980,NCT01889914,changes from baseline in insulinoresistance measured by biological tests of hyperinsulinemic euglycemic clamp in the two groups of treatment 6 months after the start of the treatment.,"change from baseline in weight at three, six, nine and twelve months in the two groups.",,2012-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
7981,NCT05163964,The change of baseline continuous glucose monitoring (CGM) profile among prediabetes adults at 6 months.,The change of chronotype among prediabetes adults at 6 months.,,2022-01-01,RECRUITING,OBSERVATIONAL,['NA']
7982,NCT03159832,The maximum plasma concentration (Cmax) of SHR3824,The number of volunteers with adverse events as a measure of safety and tolerability,,2015-06,UNKNOWN,INTERVENTIONAL,['PHASE1']
7983,NCT03771417,Skeletal Muscle Mass,Mitochondrial Function,,2019-01-16,COMPLETED,INTERVENTIONAL,['NA']
7984,NCT05697484,diabetes control,Usability and satisfaction,,2023-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
7985,NCT03020485,Change in post prandial Blood glucose for 180 minutes period,,,2014-12,COMPLETED,INTERVENTIONAL,['NA']
7986,NCT06239636,Safety as assessed by number of treatment related adverse events accoridng to CTCAE v 5.0,Score in diabetes treatment satisfaction questionnaire,,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
7987,NCT00358059,Treatment adherence,Diabetes-related quality of life,,2000-10,COMPLETED,INTERVENTIONAL,['PHASE3']
7988,NCT00917267,Change in HbA1c From Baseline to Week 26.,Assessment of Event Rate of Treatment-emergent Hypoglycemic Events,,2009-07,COMPLETED,INTERVENTIONAL,['PHASE3']
7989,NCT01421147,Change From Baseline up to 24 Weeks in Hemoglobin A1c (HbA1c),Rate Per 30 Days of Hypoglycemic Events,,2011-08,COMPLETED,INTERVENTIONAL,['PHASE3']
7990,NCT03673969,Excess weight loss,Diarrhoea,,2019-02-01,WITHDRAWN,INTERVENTIONAL,['NA']
7991,NCT05160974,• Incidence (%) of SAEs in patients who are treated with Qtern,• Clinically significant results from urinalysis,,2021-12-30,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
7992,NCT03365349,Change from baseline IPQR (Illness Perception Questionnaire) score at 3 months,comparison of the two groups concerning answers to qualitative interviews at T 3 months after the intervention,,2012-02-01,COMPLETED,INTERVENTIONAL,['NA']
7993,NCT00949663,"The effects of GIP, xenin-25, or a combination of GIP plus xenin-25 on insulin secretion and blood glucose levels",We will develop an assay to measure the normal fasting and postprandial concentrations of endogenous xenin-25 and determine whether they are altered in T2DM.,,2009-10,COMPLETED,INTERVENTIONAL,['PHASE1']
7994,NCT03664089,Weight loss,Glycemia and Associated Biomarkers of Insulin Resistance and Metabolic Health: Lipid Panel,,2018-09-10,COMPLETED,INTERVENTIONAL,['NA']
7995,NCT01210664,Number of Participants Experiencing Severe or Life Threatening Laboratory Abnormalities,Hemoglobin A1c,,2010-11,COMPLETED,INTERVENTIONAL,['PHASE1']
7996,NCT02542631,Change in A1C From Baseline to the Completion of 24 Weeks of Basal and Bolus Insulin Therapy,Number of Participants With Severe Hypoglycemic Event,Change in Quality of Life From Baseline to Week 24,2015-08-01,COMPLETED,INTERVENTIONAL,['NA']
7997,NCT05615558,Insulin sensitivity,Diabetes treatment satisfaction measured by the diabetes treatment satisfaction questionnaire,,2022-04-01,RECRUITING,INTERVENTIONAL,['NA']
7998,NCT00540488,Adjusted area under the curve (adj-AUC) of glucose response,Adjusted peak for glucose and insulin response;peak time for glucose and insulin response; Adj-AUC for insulin response; change in glucose and insulin; subjective gastrointestinal tolerance,,2002-08,COMPLETED,INTERVENTIONAL,['PHASE3']
7999,NCT01602718,change in short physical performance battery,change in inflammation,,2012-06,COMPLETED,INTERVENTIONAL,['NA']
8000,NCT05033899,Quality of recovery after surgery (QoR40),serum markers of stress response: interleukin 6 ( IL-6),,2021-05-01,COMPLETED,INTERVENTIONAL,['NA']
8001,NCT03202680,Change in insulin sensitivity index (Si),Apo A1 measurements.,,2017-07-06,COMPLETED,INTERVENTIONAL,['NA']
8002,NCT00669630,Diet History Questionnaire; 7 - Day Physical Activity Recall,"Blood pressure; Total cholesterol, HDL, LDL, Triglycerides; Glucose level; Hemoglobin A1C (Diabetics only)",,2008-09,COMPLETED,INTERVENTIONAL,['NA']
8003,NCT04382521,Participant's mean ratings of message utility to measure acceptability of the text-message intervention,Change in physical function measured by 6-minute test,,2020-09-22,COMPLETED,INTERVENTIONAL,['NA']
8004,NCT01060605,"Evidence of insulin independence with adequate control of blood glucose (<140 mg/mL fasting; < 180 mg/mL post prandial, after the final infusion","renal and liver function, white blood cells count, total lymphocytes and lymphocytes subpopulations (CD24, CD19), hemoglobin, fibrinogen (FG), cross-linked fibrin degradation products, C-reactive protein (CRP)",,2001-10,COMPLETED,INTERVENTIONAL,['PHASE3']
8005,NCT01151891,Pedal puncture wounds,Infection in pedal puncture wounds,,2010-06,COMPLETED,OBSERVATIONAL,['NA']
8006,NCT03547635,"The Number of Participants Meeting Criteria of Complete Wound Closure, as Assessed by the Investigator at or Before Week 12 of the Treatment Phase, Which is Confirmed Closed Two Weeks Later.",,,2018-05-03,COMPLETED,INTERVENTIONAL,['NA']
8007,NCT05908448,Accuracy,,,2024-02-07,RECRUITING,OBSERVATIONAL,['NA']
8008,NCT05527847,Change in blood glucose (hemoglobin A1C),Adherence to Refills and Medicines Scale for Diabetes (ARMS-D) Score,,2023-02-13,COMPLETED,INTERVENTIONAL,['NA']
8009,NCT04881123,A change of urine albumin-to-creatinine ratio (UACR) of > 30% from Baseline to Day 168,PK trough SER150 concentrations (pre-dose),,2021-08-18,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
8010,NCT02037867,Liver and cardiovascular-related mortality,All-cause mortality,,2013-05,RECRUITING,OBSERVATIONAL,['NA']
8011,NCT03612037,Glycemic control,Blood lipids,,2016-09-01,COMPLETED,INTERVENTIONAL,['NA']
8012,NCT00504712,Change in Arterial Stiffness,Change in IMT,,2006-02,COMPLETED,INTERVENTIONAL,['PHASE4']
8013,NCT00276367,,,,2006-10,WITHDRAWN,OBSERVATIONAL,['NA']
8014,NCT02146404,Brain lactate concentration,Hormone response,,2014-08,COMPLETED,INTERVENTIONAL,['NA']
8015,NCT05165368,Pain Intensity Level,Pain Quality Assessment,,2023-08-01,RECRUITING,INTERVENTIONAL,['NA']
8016,NCT04943523,Grip strength,Erythrocyte fatty acid profile,,2022-05-01,RECRUITING,INTERVENTIONAL,['NA']
8017,NCT03675074,Change in HbA1c,Change in weight,Improvement in metabolic comorbidities,2018-09-12,WITHDRAWN,INTERVENTIONAL,['NA']
8018,NCT02230618,Incidence of Adverse Events (AEs),The reason for initiating or intensifying treatment with Ryzodeg™,,2015-11-24,COMPLETED,OBSERVATIONAL,['NA']
8019,NCT00542399,Total daily basal and bolus insulin,documentation of hypoglycemic and hyperglycemic episodes,,2007-11,COMPLETED,INTERVENTIONAL,['PHASE4']
8020,NCT02185482,change in depression using SCL-90 depression scale,Glycemic control measured using glycosylated hemoglobin levels,Global assessment of improvement using Patient Global Impression,2014-08,COMPLETED,INTERVENTIONAL,['NA']
8021,NCT00320008,Years of life years gained,Diabetic neuropathy,,1992-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
8022,NCT00598871,Number of Participants With Treatment Emergent Adverse Events (TEAEs) After Treatment With Thymosin Beta 4 in the Target Eye of Diabetic Patients During Vitrectomy,Number of Participants With Corneal Epithelial Wound Healing at Day 14 (End of Treatment),,2007-12,TERMINATED,INTERVENTIONAL,['PHASE2']
8023,NCT01052025,To examine the efficacy of curcumin on the delay of degenerative beta-cells in pancrease for protection of Type 2 Diabetes in patients with impaired glucose tolerance (Pre-diabetes),"To examine the efficacy of curcumin on the reduction of blood sugar level, lipid profile, insulin resistance status and oxidative stress status in Pre-diabetes patients",,2009-08,UNKNOWN,INTERVENTIONAL,['PHASE4']
8024,NCT05960604,"Difference of mean CCE, dP/dt, SVI, CPI, Ea at the 30th second of passive leg raising by hypertension and diabetes mellitus",Predictive factors of hypotension,Days out of hospital 30,2023-12-25,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
8025,NCT00704236,Glucose Disposal Rate,"Fasting Plasma Glucose,Postprandial Plasma Glucose,HbA1c,triglyceride,cholesterol,HDL-c and LDL-c,lipid levels ,body weight, blood pressure",,2006-09,COMPLETED,INTERVENTIONAL,['PHASE4']
8026,NCT01238978,Percent of patients in each of the two treatment groups presenting no hypoglycemia (confirmed events with SMBG and severe episodes) after 24 wk of randomized therapy added to their ongoing metformin background therapy.,"Glycemic control assessed by A1C, and the mean of 6 Points self-monitoring of blood glucose (SMBG) at baseline and after 24 weeks.",,2010-10,COMPLETED,INTERVENTIONAL,['PHASE4']
8027,NCT04605497,Average time-in-range over a 24 hour period,Average time-in-range while asleep,,2021-02-11,RECRUITING,INTERVENTIONAL,['NA']
8028,NCT00119938,"Composite measure of diabetes self-care activities, developed from the Summary of Diabetes Self-Care Measure","Biological markers of diabetes care (hemoglobin A1c, blood pressure, LDL cholesterol)",,2004-09,COMPLETED,INTERVENTIONAL,['NA']
8029,NCT00506662,Change in Glycosylated Haemoglobin (HbA1c) at Month 7,"Mean Number of Total Hypoglycaemic Episodes, Months 5-7",,2007-07,TERMINATED,INTERVENTIONAL,['PHASE4']
8030,NCT01156597,Increased HDL-Cholesterol and Decreased Triglycerides,Cholesterol Efflux Capacity of HDL,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE3']
8031,NCT02384148,Difference of period length,Difference of amplitude,,2011-06,UNKNOWN,OBSERVATIONAL,['NA']
8032,NCT05177250,Bisphenol A and paraben detection in urine samples of diabetic (n=50) and non diabetic persons (n=50),,,2022-02-20,RECRUITING,INTERVENTIONAL,['NA']
8033,NCT05631535,Changes in body weight,Changes in perception of health-related quality of life,,2023-01-04,RECRUITING,INTERVENTIONAL,['NA']
8034,NCT01652729,Change in HbA1c (Glycosylated Hemoglobin) From Baseline to Week 28,Change in 2-hour Postprandial Glucose Concentrations From Baseline to Week 16 (Visit 8),,2013-02,COMPLETED,INTERVENTIONAL,['PHASE3']
8035,NCT01895569,Glycemic variability,Glyco-metabolic control,Insulin-resistance parameters,2013-06,UNKNOWN,INTERVENTIONAL,['PHASE4']
8036,NCT00521742,Change in the walking distance during a standardized 6-minute walk test.,Change in Body Weight,,2001-03,COMPLETED,INTERVENTIONAL,['PHASE3']
8037,NCT02535299,physiological parameter:glycosylated hemoglobin A1c,physiological parameter:TNF-α,,2016-06,UNKNOWN,INTERVENTIONAL,['PHASE4']
8038,NCT01724736,Change in the ratio of Bacteroidetes to Firmicuites ratio in the stool comparing the baseline value to the completion of study value.,Gastrointestinal Symptoms,,2012-11,COMPLETED,INTERVENTIONAL,['NA']
8039,NCT04999124,Diabetes complications,haemoglobin A1c (%),,2020-01-01,RECRUITING,INTERVENTIONAL,['NA']
8040,NCT03925948,Change in Health literacy as assessed by the Newest Vital Sign,Change in Diabetes self-efficacy measured with Stanford Diabetes Self-Efficacy scale,Change in Quality of Life as assessed by the EuroQol Quality of Life scale,2015-05-06,COMPLETED,INTERVENTIONAL,['NA']
8041,NCT03723707,Percent of Patients Who Reach Consensus Target HBA1c,,,2018-12-03,COMPLETED,INTERVENTIONAL,['NA']
8042,NCT02389114,Food intake,Physiological Outcomes,,2013-06,COMPLETED,INTERVENTIONAL,['NA']
8043,NCT02342834,Plasma glucose response during the Oral Glucose Tolerance Test,Endothelial function assessed as the reactive hyperemia index by an EndoPAT device,,2015-01,COMPLETED,INTERVENTIONAL,['NA']
8044,NCT00673543,Time point at which glucose elevation occurs after glucocorticoid administration (greater than 50% increase in the patient's baseline blood) glucose level.,Pre-corticosteroid insulin amount,,2008-05,COMPLETED,OBSERVATIONAL,['NA']
8045,NCT01678183,Improvement in hemoglobin A1c,Improvement in blood pressure.,Lipid levels,2012-09,COMPLETED,INTERVENTIONAL,['NA']
8046,NCT00410436,Change in HbA1c,"serum C-reactive protein,",,2006-10,COMPLETED,INTERVENTIONAL,['PHASE4']
8047,NCT00615264,Change From Baseline in Glucagon-stimulated C-peptide AUC at 24 Months,Change From Baseline in Mixed-meal Stimulated C-peptide AUC at 24 Months,,2005-09,COMPLETED,INTERVENTIONAL,['PHASE3']
8048,NCT03061851,The proportion of patients with HbA1c <7% after 48 weeks of maltose software intervention,The total score of Kessler's psychological distress scale after 48 weeks of intervention was higher than baseline.,,2017-01-25,UNKNOWN,INTERVENTIONAL,['NA']
8049,NCT03819153,"Time to first occurrence of a composite primary outcome event defined as persistent eGFR decline of greater than or equal to 50 percentage from trial start, reaching ESRD, death from kidney disease or death from cardiovascular disease",Number of severe hypoglycaemic episodes,,2019-06-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
8050,NCT02483949,Change from baseline to 6 months of moderate and vigorous physical activity (walking).,Change from baseline to 6 months in Low Glycemic Index foods.,,2015-06,COMPLETED,INTERVENTIONAL,['NA']
8051,NCT01121471,change in plasma glucose AUC,change in body composition,,2004-12,COMPLETED,INTERVENTIONAL,['NA']
8052,NCT01931644,Biospecimen & Clinical Data Collection,,,2013-07,RECRUITING,OBSERVATIONAL,['NA']
8053,NCT02927639,Change in Self-Care Inventory (SCI) Score From Baseline to 6 Months,Change in Hemoglobin A1c (HbA1c) From Baseline to 6 Months,,2018-07-31,COMPLETED,INTERVENTIONAL,['NA']
8054,NCT04927858,Prevalence of a History of CVD Among Swedish Patients With T2DM Who Started Empagliflozin Treatment Between 1st of January 2015 and 31st of December 2017,,,2018-04-02,COMPLETED,OBSERVATIONAL,['NA']
8055,NCT00846248,insulin resistance,,,2006-01,COMPLETED,INTERVENTIONAL,['NA']
8056,NCT01774942,Glycosylated hemoglobin (HbA1a),high-sensitivity C-reactive protein (hsCRP),Retention of implants,2008-06-01,COMPLETED,INTERVENTIONAL,['NA']
8057,NCT01889810,Change in Insulin Resistance,Health Status,,2013-08,COMPLETED,INTERVENTIONAL,['NA']
8058,NCT06177210,Establish a cohort of participants who achieved T2D remission through bariatric surgery,Qualitative interviews,,2022-06-01,RECRUITING,OBSERVATIONAL,['NA']
8059,NCT01353833,Kinetic parameters of Treg proportions variation within CD4+ T cells in peripheral blood,Improvement of residual secretion of insulin assessed by the AUC of peptide C during a standardized test meal in IL-2 vs placebo treated patients,,2011-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8060,NCT02443753,Safety and Tolerability will be evaluated as the incidence of AEs and SAEs/UADEs.,Efficacy as measured by Change in HbA1c (%),,2015-05,TERMINATED,INTERVENTIONAL,['NA']
8061,NCT03815552,time in range,time of hypoglycemia,,2018-10-08,COMPLETED,INTERVENTIONAL,['NA']
8062,NCT00001853,Diabetes and Heart Disease Risk,,,1998-10-21,RECRUITING,OBSERVATIONAL,['NA']
8063,NCT03903965,OCT Angiography parameters,aqueous humor cytokines levels,,2018-09-01,COMPLETED,OBSERVATIONAL,['NA']
8064,NCT04800861,glycemic control,average per patient,,2021-01-01,COMPLETED,OBSERVATIONAL,['NA']
8065,NCT05951140,Improve eating behavior towards healthier choices,Calculation of the Polygenic Risk Score,,2020-10-01,COMPLETED,INTERVENTIONAL,['NA']
8066,NCT01227473,"insulin resistance, as measured by the homeostatic model assessment-insulin resistance (HOMA-IR)",Insulin resistance as measured by the HOMA-IR,,2010-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8067,NCT02914691,Change in Urinary Peptide Patterns (Proteomics),,,2015-08,COMPLETED,INTERVENTIONAL,['PHASE4']
8068,NCT00960791,"Total recovery of radioactive dose, rate and routes of excretion of total radioactivity, metabolic pattern and metabolic profile, and PK variables of AZD1656 (AUC, Cmax, tmax, t1/2, Total Ae, CL/F and CLR)",Plasma Glucose,,2009-07,COMPLETED,INTERVENTIONAL,['PHASE1']
8069,NCT00064714,Change in basal C-peptide level,,,2003-07,COMPLETED,INTERVENTIONAL,['PHASE2']
8070,NCT00264901,Comparison of the change from baseline to end of treatment,Within-subject variation of before-breakfast SMPG values at Visit 2 and Visit 3,,2005-10,COMPLETED,INTERVENTIONAL,['PHASE4']
8071,NCT03739125,Change from baseline in Glycosylated Hemoglobin (HbA1c),Evaluate safety of CKD-501 from number of participants with adverse events,,2017-11-07,COMPLETED,INTERVENTIONAL,['PHASE3']
8072,NCT01472588,Weight Loss,Physical Activity,,2007-09,COMPLETED,INTERVENTIONAL,['PHASE2']
8073,NCT04383041,Summary of Diabetes Self-Care Activities for Diabetes and Kidney Disease (SDSCA) Score,DTSQ Participation rate,,2020-07-02,COMPLETED,OBSERVATIONAL,['NA']
8074,NCT01590836,Area under the glucose infusion rate curve during one dosing interval,Maximum observed serum insulin aspart concentration,,2012-04,COMPLETED,INTERVENTIONAL,['PHASE1']
8075,NCT06131411,Glycated haemoglobin (HbA1c),Adherence to Mediterranean Diet,,2023-11-07,RECRUITING,INTERVENTIONAL,['NA']
8076,NCT01691365,Oxidative damage,Antioxidant status,Infections,2008-09,COMPLETED,INTERVENTIONAL,['PHASE4']
8077,NCT03206294,Measurement of biological test glycosylated haemoglobin evolution between the entrance and discharge,,,2017-03-08,COMPLETED,INTERVENTIONAL,['NA']
8078,NCT02490098,Mean day-and-night glucose levels,Total carbohydrate intake,,2018-01,WITHDRAWN,INTERVENTIONAL,['PHASE2']
8079,NCT03404700,Difference of insulin levels compared between different test breakfasts,"Difference in total energy intake (kcal) compared between Remote Food Photography Method (RFPM), 7-day food record and 24-hour recall",,2018-05-22,COMPLETED,INTERVENTIONAL,['NA']
8080,NCT05059860,Time Control IQ system not in use,Hospital Anxiety and Depression questionnaire,Gold Hypoglycaemia questionnaire,2023-06-09,RECRUITING,OBSERVATIONAL,['NA']
8081,NCT00478972,Relative change from baseline in body weight,Safety: Overview of adverse events,,2007-04,TERMINATED,INTERVENTIONAL,['PHASE3']
8082,NCT00544921,A Dose-Ranging Study to Evaluate the Phamacokinetics and Safety of Six Single-Dose Levels of GLY-230 in Healthy Subjects,,,2005-10,COMPLETED,INTERVENTIONAL,['PHASE1']
8083,NCT03801824,Post meal blood glucose level,Maternal weight gain,Level of post-meal blood glucose,2014-04,COMPLETED,INTERVENTIONAL,['NA']
8084,NCT00953186,Ulcer healing,QoL,,2002-06,COMPLETED,INTERVENTIONAL,['PHASE4']
8085,NCT01741480,ICU Transfer,Mortality,,2013-02,COMPLETED,INTERVENTIONAL,['NA']
8086,NCT02949739,>7% reduction in weight,Reduction of ≥5 cm waist circumference,,2015-01,COMPLETED,INTERVENTIONAL,['NA']
8087,NCT05733195,GDM（Pregnancies with gestational diabetes mellitus and no gestational diabetes）,,,2022-05-04,RECRUITING,OBSERVATIONAL,['NA']
8088,NCT01734785,HbA1c Change From Baseline After 24 Weeks Double-blind Randomized Treatment,Body Weight Change From Baseline After 24 Weeks of Double-blind Treatment,,2013-01,COMPLETED,INTERVENTIONAL,['PHASE3']
8089,NCT05479214,Maternal Blood glucose readings,Neonatal outcomes,,2022-07-29,COMPLETED,INTERVENTIONAL,['PHASE4']
8090,NCT02855307,Percentage of time of plasma glucose levels spent below 3.9 mmol/L,Mean time (minutes) to the first hypoglycemic event,,2016-09,COMPLETED,INTERVENTIONAL,['PHASE2']
8091,NCT02449460,all cause mortality,Cardiovascular mortality,,2012-07,UNKNOWN,OBSERVATIONAL,['NA']
8092,NCT05259033,Change in glycated haemoglobin (HbA1c),Number of severe hypoglycaemic episodes (level 3),,2022-04-11,COMPLETED,INTERVENTIONAL,['PHASE3']
8093,NCT06006468,Number of multi-islet autoantibody positive participants,Number of participants developing Coeliac disease,,2023-02-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
8094,NCT00825383,glucose and lipid metabolism,"calcium isotope absorption in the gastrointestinal tract, stool mineral content, 24 h urinary mineral concentration, and serum chemistry including mineral concentration.",,1993-01,COMPLETED,INTERVENTIONAL,['NA']
8095,NCT02461511,glycated hemoglobin measure,hopitalization,,2015-03,WITHDRAWN,OBSERVATIONAL,['NA']
8096,NCT04327622,Prevalence of diabetes foot complications: neuropathy risk,Association between foot risk variables and the presence of a foot ulcer,,2020-03-03,COMPLETED,OBSERVATIONAL,['NA']
8097,NCT01232673,Major limb amputation,Tissue perfusion measurements,,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2']
8098,NCT01969084,Phosphocreatine (PCR) Recovery Time After Exhaustive or up to 6 Minutes of Leg Exercise.,Changes in Circulating Endothelial Progenitor Cell Phenotypes,,2013-10,COMPLETED,INTERVENTIONAL,['PHASE4']
8099,NCT02402361,Risk factors and determinants for neuropathic pain,,,2016-04-01,COMPLETED,OBSERVATIONAL,['NA']
8100,NCT00013052,,,,na,COMPLETED,INTERVENTIONAL,['NA']
8101,NCT04168372,Rate of appearance of blood glucose from gluconeogenesis,Whole body fructose oxidation,,2019-09-15,RECRUITING,INTERVENTIONAL,['NA']
8102,NCT04578964,Determining the effect of cardiovascular risk factors on the mean age of the first acute coronary syndrome,Model for calculating the acute coronary syndrome age,,2014-01-02,RECRUITING,OBSERVATIONAL,['NA']
8103,NCT04497532,Amniotic fluid index (AFI) after 2 weeks,,,2021-03-20,UNKNOWN,INTERVENTIONAL,['NA']
8104,NCT01556594,Number of Participants With at Least One Adverse Event,Area Under the Curve (AUC0-last) of Baseline Adjusted Glucagon,,2012-03,COMPLETED,INTERVENTIONAL,['PHASE2']
8105,NCT01677013,C-peptide,adverse event,,2011-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8106,NCT00400283,To determine the safety and the tolerability of ascending multiple oral doses of NNC 55 0414 in patients with type 2 diabetes.,,,2001-01-19,COMPLETED,INTERVENTIONAL,['PHASE1']
8107,NCT01068171,decrease in size of wound,non-healing wound,,2010-05,WITHDRAWN,INTERVENTIONAL,['NA']
8108,NCT04577976,Safety of the SMBG devices. The safety of self-monitoring of blood glucose (SMBG) when used to manage diabetes in a pediatric patient population will be characterized: Serious Adverse events,,,2020-09-23,TERMINATED,OBSERVATIONAL,['NA']
8109,NCT05857943,Sensitivity and Specificity,,,2023-03-29,COMPLETED,INTERVENTIONAL,['NA']
8110,NCT04090840,Weight loss,Hemoglobin a1c,,2019-08-01,UNKNOWN,INTERVENTIONAL,['NA']
8111,NCT03908242,Plasma concentrations of salvianolic acid A,,,2019-04-08,UNKNOWN,INTERVENTIONAL,['PHASE1']
8112,NCT01686139,Frequency of Adverse Events,,,2016-03,UNKNOWN,INTERVENTIONAL,['PHASE1']
8113,NCT01724385,The percentage of eyes that vitreous hemorrhage has been completely resolved,The change in best corrected visual acuity (BCVA) from baseline,Numbers of injection,2012-08,COMPLETED,INTERVENTIONAL,['PHASE4']
8114,NCT03840278,The Ratio of Cumulative Drug Doses Delivered to Cumulative Drug Doses Attempted for Insulin and Dasiglucagon,Mean Grams of Carbohydrate Per Day to Treat or Prevent Hypoglycemic Events (Reported Daily by Subjects),,2019-05-15,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
8115,NCT01049412,Daily Average Blood Glucose (Avg. BG) at Week 8 Endpoint as Measured by the 8-Point Self-Monitored Blood Glucose (SMBG) Profiles,Glycemic Variability in Fasting Blood Glucose (FBG) at Week 8 Endpoint,,2010-01,COMPLETED,INTERVENTIONAL,['PHASE2']
8116,NCT00824603,We will determine whether attendees' self-reported confidence and use of insulin with persons with type 2 diabetes changes after they attend the CME program.,pre-CME training level of patient's A1c when starting insulin therapy compared to post-CME training level of patient's A1c when starting insulin therapy,,2006-06,COMPLETED,OBSERVATIONAL,['NA']
8117,NCT01041768,Proportion of patients achieving diabetes complete remission (HbA1c 6% or below) or diabetes control (HbA1c between 7% and 6.1%) on free diet and with no antidiabetic medical therapy.,Stable reduction of preoperative HbA1c; BMI; mortality/morbidity; Major components of the metabolic syndrome; Diabetes complications; Improvement of beta-cell function; insulin resistance reduction ; Overall and CV disease mortality.,,2009-03,UNKNOWN,INTERVENTIONAL,['NA']
8118,NCT04020445,"change in risk of hypoglycemia from baseline to 3, 6, 9 and 12 months",,,2016-01-01,COMPLETED,OBSERVATIONAL,['NA']
8119,NCT03615807,Number of Participants Experiencing Clinical Failure,Number of Participants Experiencing Adverse Events Related to the Antibiotic Therapy,,2017-02-16,COMPLETED,INTERVENTIONAL,['NA']
8120,NCT04875858,Serotype-specific immunogenicity assessed by opsonophagocytic killing assay.,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,,2021-05-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
8121,NCT00826904,Change in maternal postprandial lipemia,Correlation of neonatal adiposity and fetal growth,,2007-10,COMPLETED,OBSERVATIONAL,['NA']
8122,NCT03383146,Number of Participants With Anti-relamorelin Antibody Testing Results by Visit,,,2018-02-01,TERMINATED,INTERVENTIONAL,['PHASE3']
8123,NCT00629681,"Correlation between global status (as measured by the Clinical Global Impression of Change [CGIC] and the Patient Global Impression of Change [PGIC]) and changes in pain, anxiety, and sleep parameters",Course of mean pain score of patient's daily pain diary (NRS),,2004-11,COMPLETED,INTERVENTIONAL,['PHASE4']
8124,NCT01284608,Diabetes,Fracture Risk Assessment Tool (FRAx) assessment,,2011-03,COMPLETED,OBSERVATIONAL,['NA']
8125,NCT03479619,Volume (uL) of blood in the capillary tube,The intensity of pain perceived by the patient assessed with the use of the VAS (Visual Analog Scale).,,2018-03-06,COMPLETED,INTERVENTIONAL,['NA']
8126,NCT01023945,Change in plasma glucose levels,Change in serum insulin levels,,2009-11-07,COMPLETED,INTERVENTIONAL,['PHASE1']
8127,NCT03002545,questionnaire SF-36,,,2016-12,COMPLETED,INTERVENTIONAL,['NA']
8128,NCT05813496,To compare the relative change in NCS parameters between the study arms,To assess safety of Thiotacid® as per the nature and severity of the recorded adverse events.,,2022-10-26,RECRUITING,INTERVENTIONAL,['PHASE4']
8129,NCT00754403,Change from randomization in Glycosylated Hemoglobin,Change from randomization in Creatine Phosphokinase,,2005-07,COMPLETED,INTERVENTIONAL,['PHASE4']
8130,NCT01828242,HbA1C,Fasting Blood Glucose,Iron status,2013-01,COMPLETED,INTERVENTIONAL,['PHASE2']
8131,NCT01779115,Prevalence rates of Diabetes,Number of visits to physician offices,,1998-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
8132,NCT05560971,Insulin sensitivity M value change before and 8 weeks after POA vs placebo intake,"Serum; fasting glucose, insulin, LDL cholesterol, hsCRP, circulating inflammatory cytokines (TNF-a, IL-6), FABP4, glucagon",,2022-11-01,RECRUITING,INTERVENTIONAL,['NA']
8133,NCT00082238,,,,2003-03,COMPLETED,INTERVENTIONAL,['NA']
8134,NCT03995238,Step Length Symmetry,World Health Organization Disability Assessment Scale 2.0,Socket Comfort Score,2019-10-09,RECRUITING,INTERVENTIONAL,['NA']
8135,NCT04624321,Change of long-term blood glucose concentration measured as glycated hemoglobin at one year,Insulin secretion,"Change of long-term blood glucose concentration measured as glycated hemoglobin in participants with and without Mild Obesity-related Diabetes, respectively.",2021-01-01,RECRUITING,INTERVENTIONAL,['NA']
8136,NCT02197078,Number of Participants With Stroke,Number of Participants With Acute Renal Failure Requiring Dialysis,,2014-07-30,COMPLETED,OBSERVATIONAL,['NA']
8137,NCT02230891,Change in Cardiac Global Longitudinal Strain,Change in Troponin T Measured Using a High Sensitivity Assay,,2014-10-01,COMPLETED,INTERVENTIONAL,['PHASE2']
8138,NCT06227819,Establish equivalence of BVA-200 to BVA-100,Usability,,2023-05-23,COMPLETED,OBSERVATIONAL,['NA']
8139,NCT01953757,Pain,Quality of life,Acceptability of vegan diet,2013-09,COMPLETED,INTERVENTIONAL,['NA']
8140,NCT02634879,Physician performance,Patient satisfaction,,2016-01,COMPLETED,INTERVENTIONAL,['NA']
8141,NCT00312364,"Incidence of complete healing of target ulcer at endpoint or 90 days, whichever is earlier.","Incidence, intensity, and seriousness of adverse events. Changes in irritation scores.",,2005-12,COMPLETED,INTERVENTIONAL,['PHASE2']
8142,NCT02693938,Glucose Infusion Rate,,Glycemic variability,2019-11-13,COMPLETED,INTERVENTIONAL,['NA']
8143,NCT05251480,Impact of Treatment on Quality of Life (WoundQoL),Mean and median reduction in wound area at 12 weeks,,2022-12-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
8144,NCT03517527,Exercise Decisional Balance Scale,,,2015-10-25,COMPLETED,INTERVENTIONAL,['NA']
8145,NCT00548808,Change From Baseline to 48 Week Endpoint in Hemoglobin A1c (HbA1c),Safety: Number of Participants With Serious and Non-Serious Adverse Events,,2007-11,COMPLETED,INTERVENTIONAL,['PHASE4']
8146,NCT03505268,The impact of telehealthcare intervention on the change of the glycemic control in children with type 1 diabetes,,,2018-05-01,UNKNOWN,INTERVENTIONAL,['NA']
8147,NCT04839575,Symptom Severity Reduction,,,2021-04-06,TERMINATED,INTERVENTIONAL,['PHASE2']
8148,NCT05478967,Incidence of VH,Changes of BCVA,,2019-08-08,COMPLETED,INTERVENTIONAL,['NA']
8149,NCT01830998,MMSE Olfactory function dementia,,,2012-01,UNKNOWN,OBSERVATIONAL,['NA']
8150,NCT03394313,Mortality,,,2017-09-15,RECRUITING,OBSERVATIONAL,['NA']
8151,NCT02921425,Systolic and Diastolic Blood Pressure,Change in Patient Activation,,2014-07-01,COMPLETED,INTERVENTIONAL,['NA']
8152,NCT02741050,Self-Report Changes in Physical Activity from Baseline to 6 Months,Self-Report Changes in Physical Activity from 6 Months to 12 Months,,2016-08,TERMINATED,INTERVENTIONAL,['NA']
8153,NCT02761018,Reduction in hemoglobin a1c,,,2017-08-08,COMPLETED,INTERVENTIONAL,['NA']
8154,NCT06289933,Cmax,,,2024-03,RECRUITING,INTERVENTIONAL,['PHASE1']
8155,NCT00642798,Pharmacokinetics of sitagliptin after administration of single and multiple 100-mg doses of sitagliptin to healthy chinese adult subjects.,,,2008-03,COMPLETED,INTERVENTIONAL,['PHASE1']
8156,NCT06067139,2-hour post-load glucose (2hPG) (mg/dL),"Insulin resistance score (probability ranking, Calculated using the insulin and C-peptide concentrations converted to pmol/L)",,2023-08-01,RECRUITING,INTERVENTIONAL,['NA']
8157,NCT05276128,glucose tolerance,Appetite sensations,Cognitive test variable,2022-03-20,COMPLETED,INTERVENTIONAL,['NA']
8158,NCT02738151,Change From Baseline in HbA1c to Week 24,"Hypoglycemia (Any, Severe and/or Confirmed Hypoglycemia: Nocturnal ) Event Rate Per Participant Year During Study Period",Change From Baseline in Total Diabetes Treatment Satisfaction Questionnaire (DTSQ) Status at Week 12 and Week 24,2016-05-19,COMPLETED,INTERVENTIONAL,['PHASE4']
8159,NCT00844090,Change in HbA1c Over Baseline,,,2009-07,COMPLETED,INTERVENTIONAL,['NA']
8160,NCT04078308,Change from baseline number of hypoglycemic Unawareness episodes at 12 months after intravenous transplantation of autologous bone marrow derived Mesenchymal Stem Cells,Changes from baseline serum cytokines levels in patients' blood at 12 months after intravenous transplantation of autologous bone marrow derived Mesenchymal Stem Cells,,2015-07-06,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8161,NCT05626413,The risk of cardiovascular disease and events among patients with diabetes,,,2015-01-01,RECRUITING,OBSERVATIONAL,['NA']
8162,NCT03098654,Retention in HIV care,Cost-effectiveness of integrating NCD screening and care with HIV screening and care,,2018-02-05,COMPLETED,INTERVENTIONAL,['NA']
8163,NCT00340093,,,,2002-08-23,COMPLETED,INTERVENTIONAL,['PHASE1']
8164,NCT00153088,Non-transition to overt nephropathy,Change in renal parameters Composite endpoint,,2003-01,COMPLETED,INTERVENTIONAL,['PHASE4']
8165,NCT06217302,eGFR at the end of the wash-out period following the treatment period,"Time to ≥40% eGFR decline from baseline, end-stage kidney disease, renal replacement therapy, or death from renal causes",Mean total daily insulin dose during the treatment period,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
8166,NCT05377333,Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,PK: Area Under the Concentration Versus Time Curve (AUC) of LY3457263,,2022-06-02,COMPLETED,INTERVENTIONAL,['PHASE1']
8167,NCT00619697,HbA1c,Safety profile,,2003-12,COMPLETED,INTERVENTIONAL,['PHASE4']
8168,NCT04847856,"To compare the mean differences in the: Blood glucose level, BMI, Waist circumference between intervention and control groups","To compare the mean differences in the: HbA1C, Serum cholestrol, and blood pressure between intervention and control groups",To explore the knowlege and skills gained by nurse staff as a result of their participation in the trial intervention.,2020-03-30,COMPLETED,INTERVENTIONAL,['NA']
8169,NCT05573477,Hemoglobin A1c (HbA1c) (ATB-1011+ATB-1012 vs. ATB-1011),Changes in glycemic parameters,Extension period: Changes in MSDBP,2022-11-16,RECRUITING,INTERVENTIONAL,['PHASE3']
8170,NCT01366794,Release of gut hormones,Insulin secretion,,2011-09,COMPLETED,INTERVENTIONAL,['NA']
8171,NCT00914706,Change in monitoring frequency,,,2009-06,COMPLETED,OBSERVATIONAL,['NA']
8172,NCT02461914,Composite measure the plasma concentrations of warfarin,Incidence of adverse events and serious adverse events,,2015-08-01,COMPLETED,INTERVENTIONAL,['PHASE1']
8173,NCT04274660,Change in diabetes self-management as assessed by the Diabetes Self-Care Activities Measure,Cost effectiveness,,2017-09-08,COMPLETED,INTERVENTIONAL,['NA']
8174,NCT03066089,Change in Postprandial sugar,"SGPT,SGOT,ALP,Creatinine,TLC,DLC & Hb",,2015-12-14,COMPLETED,INTERVENTIONAL,['PHASE4']
8175,NCT00885846,Fasting Blood Glucose,Fasting Cortisol,,2007-06,COMPLETED,INTERVENTIONAL,['NA']
8176,NCT01772680,Oral glucose Tolerance Test,Fructosamine,,2012-11,COMPLETED,INTERVENTIONAL,['NA']
8177,NCT03333525,Change Postprandial Glucose Concentrations,Postprandial insulin need,,2013-09-10,COMPLETED,INTERVENTIONAL,['NA']
8178,NCT04418427,Time to worsening of DME disease activity in the study eye.,"Incidence of clinically significant findings via physical examinations, ocular examinations, imaging, and laboratory evaluation",,2020-05-28,COMPLETED,INTERVENTIONAL,['PHASE2']
8179,NCT04255264,Inflammatory status,,,2019-08-01,UNKNOWN,OBSERVATIONAL,['NA']
8180,NCT00506298,The primary efficacy endpoint will measure change in fasting plasma glucose from Baseline to Day 90,"The exploratory efficacy endpoints will measure change in the following parameters: HOMA Index, HgbA1C, fructosamine, LDL, HDL, OGTT, triglycerides and total cholesterol from Baseline to Day 90",,2007-07,COMPLETED,INTERVENTIONAL,['PHASE2']
8181,NCT01742741,Effect size of Control-to-Range (CTR) vs. Continuous Glucose Monitor (CGM)-augmented insulin pump treatment in an outpatient setting.,Time spent in target range,Reliability of inter-device connections between DiAs and the CGM and between DiAs and the insulin pump.,2013-05,COMPLETED,INTERVENTIONAL,['NA']
8182,NCT00842192,HbA1c,Number of adverse drug reactions (ADR),,2009-04,COMPLETED,OBSERVATIONAL,['NA']
8183,NCT01106885,Participant cardiovascular risk index,Resource use,,2005-05,COMPLETED,INTERVENTIONAL,['NA']
8184,NCT03141892,System related adverse device effects and serious adverse effects,,,2017-04-13,COMPLETED,OBSERVATIONAL,['NA']
8185,NCT00578890,no osteomyelitis spreading and wound healing and no osteomyelitis relapse 12 months after wound healing,ulcer relapse 12 months after healing,,2008-06,WITHDRAWN,INTERVENTIONAL,['PHASE4']
8186,NCT01701557,time to normalization of bicarbonate and pH,the length of treatment,,2007-11,COMPLETED,INTERVENTIONAL,['NA']
8187,NCT01067118,The primary endpoint for this third phase is daytime (6 am to midnight) average glucose values.is percent of CGMS glucose values in range (70-180 mg/dL) for the third week fo sensor data in each group.,,,2010-04,WITHDRAWN,INTERVENTIONAL,['PHASE2']
8188,NCT01388153,Difference of postprandial Area under curve from 0 to 4 hours (AUC(0-4)) of blood glucose following sucrose load without (Day 1) and with Glucobay (Day 2),Tmax of serum insulin following sucrose load without (Day 1) and with Glucobay (Day 2),,2011-06,COMPLETED,INTERVENTIONAL,['PHASE1']
8189,NCT01268644,HbA1c,Change in HbA1c From Baseline to Week 20 on Leptin Therapy,,2010-09,TERMINATED,INTERVENTIONAL,['PHASE1']
8190,NCT06313008,Troponin (ng/ml),FBG (mg/dl),,2023-08-10,RECRUITING,INTERVENTIONAL,['NA']
8191,NCT05050019,the incidence of disruptions to insulin pump therapy or continuous glucose monitoring in patients with diabetes mellitus as a result of hospitalization or medical test,,,2021-10-01,UNKNOWN,OBSERVATIONAL,['NA']
8192,NCT03001336,Diabetic retinopathy which is diagnosed by the measurement of fundus fluorescein angiography. (Diabetic retinopathy is clinically graded based on the international clinical diabetic retinopathy severity scales.),24h-albuminuria,,2010-12,COMPLETED,OBSERVATIONAL,['NA']
8193,NCT01355536,The prevalence of Diabetes Mellitus,Serum levels of insulin,,2006-10,COMPLETED,OBSERVATIONAL,['NA']
8194,NCT03652649,Type 2 diabetes remission,Hunger scale scores,,2017-11-01,UNKNOWN,INTERVENTIONAL,['NA']
8195,NCT05052918,Carotid ultrasound,,,2021-09-08,RECRUITING,INTERVENTIONAL,['NA']
8196,NCT01629277,Primary efficacy outcome measure,Secondary efficacy outcome measure,,2011-07,COMPLETED,INTERVENTIONAL,['PHASE2']
8197,NCT00229658,Annual Event Rate of Patient-Ascertained Severe Hypoglycemia (PASH) During the Adjustment Period,Change in Body Weight From Baseline at Month 6,,2005-09,COMPLETED,OBSERVATIONAL,['NA']
8198,NCT01524705,Coefficient of Variation at 26 Weeks Minus Coefficient of Variation at Baseline,Weight Change During Trial,HbA1C Levels,2012-08,COMPLETED,INTERVENTIONAL,['PHASE4']
8199,NCT03372005,Blood pressure,,,2017-09-12,UNKNOWN,INTERVENTIONAL,['NA']
8200,NCT04451109,Rate of overall vaginal delivery,Rate of caesarean sections,,2020-12-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
8201,NCT05040087,β-CELL FUNCTION - PRIMARY OUTCOME #2c.,COST EFFECTIVENESS - to be explored only if additional (ancillary) funding can be obtained,,2021-09-01,RECRUITING,INTERVENTIONAL,['NA']
8202,NCT05856149,Percent weight change three months post intervention,Program Evaluation - Program Satisfaction,,2023-04-19,RECRUITING,INTERVENTIONAL,['NA']
8203,NCT01002339,Primary Outcome Measure (Glucose Intolerance),Percentage of Patients Using Acetylsalicylic Acid (ASA),,2010-02,TERMINATED,INTERVENTIONAL,['PHASE4']
8204,NCT05333159,Major adverse cardiovascular and cerebrovascular events (MACCEs),Changes of plasma lipid parameters,,2021-09-01,RECRUITING,OBSERVATIONAL,['NA']
8205,NCT01012037,HbA1c Change From Baseline at Week 12,The Occurrence of a Treat to Target Efficacy Response (HbA1c <6.5 %) After 12 Weeks of Treatment,,2009-11,COMPLETED,INTERVENTIONAL,['PHASE2']
8206,NCT04356742,Change from the baseline in HbA1c (%) after 24 weeks,Change from the baseline in weight after 24 weeks,,2020-05-26,COMPLETED,INTERVENTIONAL,['PHASE3']
8207,NCT04096313,Analytical verification of Allegro - Urine Albumin comparison,,,2020-03-25,COMPLETED,OBSERVATIONAL,['NA']
8208,NCT05556954,The percent change in foot ulcer surface area (cm2) after 12 weeks of observation for either infected or non-infected diabetic foot ulcers,Proportion of participants that reach a 50% reduction in surface area of the DFU for both cohorts,,2022-10-13,RECRUITING,OBSERVATIONAL,['NA']
8209,NCT02198209,Liver glucokinase activity (chronic effect),Acute insulin response to glucose and the disposition index,,2019-12,WITHDRAWN,INTERVENTIONAL,['PHASE4']
8210,NCT03936036,"Relative hazard of composite outcome of Stroke, MI, and Mortality",,,2017-09-22,COMPLETED,OBSERVATIONAL,['NA']
8211,NCT02804932,Change in skeletal muscle mitochondrial function,,,2016-06,UNKNOWN,INTERVENTIONAL,['NA']
8212,NCT01159847,The effects of sitagliptin on β cell function and insulin sensitivity of LADA patients,The possible immunomodulatory effects of sitagliptin on LADA patients,,2010-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8213,NCT06000371,"Dimensions of diabetic foot ulcer (manual measurement of length, width and depth of the ulcer by metal ruler).",,,2020-04-25,COMPLETED,OBSERVATIONAL,['NA']
8214,NCT04570527,Number of patient death during the follow up period,six-min walk distance (6MWD),,2019-01-01,UNKNOWN,OBSERVATIONAL,['NA']
8215,NCT00523835,,,,2002-04,COMPLETED,OBSERVATIONAL,['NA']
8216,NCT03721991,insulin production,metabolic parameters quality of life,,2018-10-10,UNKNOWN,INTERVENTIONAL,['NA']
8217,NCT01108276,Overall decrease in wound size,,,2010-05,WITHDRAWN,INTERVENTIONAL,['PHASE4']
8218,NCT00167778,Local Dynamic Stability (Ankle During Turning With the Prosthesis on the Outside of the Turn),How Bothersome Was Your Pain?,,2005-01,COMPLETED,INTERVENTIONAL,['NA']
8219,NCT03970122,Urine PK parameters: CLR,,,2019-05-29,COMPLETED,INTERVENTIONAL,['PHASE1']
8220,NCT00790491,"Validate the AUGMENT dietary and physical activity assessments using dietary recalls and accelerometer data,",Survey participating providers and patients to assess acceptability of AUGMENT within a clinical setting.,,2007-10,COMPLETED,INTERVENTIONAL,['NA']
8221,NCT05095610,HbA1c difference,Insulin dose,,2021-11-01,COMPLETED,OBSERVATIONAL,['NA']
8222,NCT04663061,Change in Body Weight,International Physical Activity Questionnaire (IPAC) short form: sitting time,,2021-06-09,RECRUITING,INTERVENTIONAL,['NA']
8223,NCT03033407,glycated hemoglobin levels,change in blood pressure within each group,,2014-10,COMPLETED,INTERVENTIONAL,['NA']
8224,NCT04756011,Evaluation of health-related quality of life (HRQL),,,2020-03-15,COMPLETED,OBSERVATIONAL,['NA']
8225,NCT05239572,"Uptake of health education (health promotion, awareness of risk factors)",Cost-effectiveness of NCD interventions,Impact of training of community health volunteers on their performance in NCD interventions.,2022-03-31,COMPLETED,INTERVENTIONAL,['NA']
8226,NCT02748018,SAP Cohort: Time in Hypoglycemic Range for subjects with baseline A1c ≤ 8%,SAP Cohort: Change in A1C for all subjects,,2017-05-25,RECRUITING,INTERVENTIONAL,['NA']
8227,NCT00231894,2 Hour Glucose From Glucose Tolerance Test US Sample,Change From Baseline in Serum HDL at 3 Months (3 Months-baseline) China Site,,2005-05,COMPLETED,INTERVENTIONAL,['PHASE4']
8228,NCT04907760,Risk factors for type 2 diabetes in participants,program compliance,,2021-10-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
8229,NCT01415037,Change in detection of posterior vitreous detachment: 20MHz annular array versus 10MHz single element,,,2011-10,COMPLETED,OBSERVATIONAL,['NA']
8230,NCT02066766,Proportion of patients having HbA1c ((Glycosylated Haemoglobin) as measured during survey) less than 7%,Proportion of patients having diabetic eye complications,,2015-04-22,COMPLETED,OBSERVATIONAL,['NA']
8231,NCT03234946,Body Mass Index,Steps per day,,2017-06-19,UNKNOWN,INTERVENTIONAL,['NA']
8232,NCT00790257,Inflammatory/immunological reaction and insulin production,- Encapsulated human islets function and biocompatibility,,2008-11,WITHDRAWN,INTERVENTIONAL,['PHASE1']
8233,NCT03977116,ventricular arrhythmias recurrence,hospitalization for heart failure worsening,,2017-01-01,COMPLETED,INTERVENTIONAL,['PHASE4']
8234,NCT01417845,Exercise Capacity,,,2011-09,COMPLETED,INTERVENTIONAL,['NA']
8235,NCT03687827,"Percentage of Time Spent in Glycaemic Target Range 70-180 mg/dL (3.9-10.0 mmol/L) Both Inclusive, Using Flash Glucose Monitoring (FGM)",Mean Glucose Levels Using Flash Glucose Monitoring (FGM),,2018-10-02,COMPLETED,INTERVENTIONAL,['PHASE4']
8236,NCT04181996,6 month change in FDG uptake TBR (Tissue to Blood Ratio) in the MDS (Maximum Disease Segment),Levels of Interleukin-6 (IL-6) (pg/ml) and its change.,Exploratory outcomes - the effect on quality of life outcomes,2020-08-01,RECRUITING,INTERVENTIONAL,['PHASE3']
8237,NCT00110240,Change from baseline in HbA1c at 24 weeks,Patients with endpoint HbA1c <7% after 24 weeks,,2005-04,COMPLETED,INTERVENTIONAL,['PHASE3']
8238,NCT06246279,Reynolds Adjustment Screening Inventory for Adolescents,Glycemic Control - Hemoglobin A1C,,2022-12-01,RECRUITING,INTERVENTIONAL,['NA']
8239,NCT01898702,Glycosylated hemoglobin A,Health services utilization,,2013-05,UNKNOWN,INTERVENTIONAL,['NA']
8240,NCT01660386,The acute phase and second phase of insulin secretion and C peptide secretion,"Alpha cell function,GLP-1 response",,2012-07,UNKNOWN,INTERVENTIONAL,['PHASE4']
8241,NCT00880139,Arteriolar to venous ratio,"Systolic/diastolic arterial blood pressure, pulse rate",,2009-06,TERMINATED,OBSERVATIONAL,['NA']
8242,NCT05965336,Biomechanical modulation of ankle stiffness,Changes induced by biofeedback in biomechanics during gait,,2024-05,RECRUITING,INTERVENTIONAL,['NA']
8243,NCT03103854,HbA1C at 12 months,HbA1C at 3 months,,2014-01-01,UNKNOWN,INTERVENTIONAL,['NA']
8244,NCT00005530,,,,1994-05,COMPLETED,OBSERVATIONAL,['NA']
8245,NCT04249102,To evaluate the change in baseline hypoglycemia after 8-week Continuous Glucose Monitoring system use,To evaluate the change in the quality of life of patients with and without impaired hypoglycemia awareness using Continuous Glucose Monitoring system in comparison to Flash Glucose Monitoring system.,,2020-03-12,UNKNOWN,INTERVENTIONAL,['NA']
8246,NCT01700868,hemoglobin A1C (diabetes management),24-Hour Multi-Pass Dietary Recalls,,2014-07,COMPLETED,INTERVENTIONAL,['NA']
8247,NCT02283411,Safety of the Abbott Sensor Based Glucose Monitoring Systems Was Characterized by Adverse Device Effects and Serious Adverse Device Effects Experienced by Study Participants.,The Point Accuracy of the Device Performance Was Evaluated in Reference to Capillary Blood Glucose (BG).,,2014-11,COMPLETED,INTERVENTIONAL,['NA']
8248,NCT02068885,"Total Energy Expenditure, Assessed by Indirect Calorimetry Using Stable Isotopes",Change in Self-reported Binge Eating Score,Effect Modification by Amylase Gene Copy Number,2014-08-17,COMPLETED,INTERVENTIONAL,['NA']
8249,NCT03566472,SDBG,,,2018-06-12,UNKNOWN,OBSERVATIONAL,['NA']
8250,NCT01934712,Area under the serum insulin aspart concentration-time curve,Area under the glucose infusion rate (GIR) curve,,2013-08-30,COMPLETED,INTERVENTIONAL,['PHASE1']
8251,NCT01417897,Nitrotyrosine,intact Proinsulin,,2011-09,UNKNOWN,INTERVENTIONAL,['PHASE4']
8252,NCT00005266,,,,1990-09,COMPLETED,OBSERVATIONAL,['NA']
8253,NCT00798785,Evidence of clinically relevant beta cell graft function,,,2006-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8254,NCT00231387,"The effect of 52 wks oral treatment with rosiglitazone in comparison to placebo on change from baseline of the plaque total wall volume in the carotid artery, in patients with type 2 dm and vascular disease/hypertension, using cardiac mri.","These include magnetic resonance endpoints related to plaque lipid content, volume, plaque size and fibrous cap thickness. Colour duplex measurements, laboratory assays for glycaemia and lipids.",,2002-09,COMPLETED,INTERVENTIONAL,['PHASE3']
8255,NCT00301392,Cumulative incidence of diabetes based on 1 positive OGTT or fasting glucose levels,Number of adverse events,,2006-04,COMPLETED,INTERVENTIONAL,['PHASE4']
8256,NCT02574195,Percentage of patients with diabetes mellitus type 1 and type 2diabetes mellitus complications,"Structure of antidiabetic therapy (% insulin, % OAD mono, % OAD dual, % OAD triple)",,2015-08,COMPLETED,OBSERVATIONAL,['NA']
8257,NCT00686283,exercise adherence,cardiorespiratory fitness,,2007-08,COMPLETED,INTERVENTIONAL,['PHASE1']
8258,NCT00295828,Regression of iris neovascularization and prevention of development of neovascular glaucoma,Development of neovascular glaucoma.,,2006-01,COMPLETED,INTERVENTIONAL,['PHASE1']
8259,NCT01123122,Islet cell function,,,2011-09,WITHDRAWN,INTERVENTIONAL,['NA']
8260,NCT04959487,Change in food insecurity severity from baseline to six months by study arm,Change in diabetes self-efficacy from baseline to six months by study arm,Durability in scores of food security from six to twelve months in the intervention arm.,2021-08-23,RECRUITING,INTERVENTIONAL,['NA']
8261,NCT01013792,Percent Diabetic Foot Ulcer Area Reduction From Baseline to Last Treatment Visit,,,2009-11,TERMINATED,INTERVENTIONAL,['NA']
8262,NCT04030611,pulse examinatin,,,2019-01-01,UNKNOWN,OBSERVATIONAL,['NA']
8263,NCT01297946,Percentage of time of plasma glucose concentrations spent in target range (4.0-10.0 mmol/l from 4:00p.m.-11:00p.m. and 4.0-8.0 mmol/l from 11:00p.m.-7:00a.m.),Number of subjects with at least one exercise-induced plasma glucose measurement below 3.0 mmol/l.,,na,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8264,NCT02522494,Resistance to Treatment Questionnaire (RTQ),Diabetes Self-Efficacy,,2016-07-01,COMPLETED,INTERVENTIONAL,['NA']
8265,NCT00276497,Reduction in conversion of IGT to diabetes,benefits of the drug on anthropometric variables and biochemical parameters,,2003-10,COMPLETED,INTERVENTIONAL,['PHASE1']
8266,NCT00145093,To determine the effect of Baker's yeast treatment on glycemicic control and insulin resistance when given in combination with oral blood glucose lowering therapy to patients with type 2 diabetes mellitus,"To determine the effect of Baker's yeast treatment on serum lipids, blood pressure, body fat percentage and BMI when given in combination with oral blood glucose lowering therapy to patients with type 2 diabetes mellitus",,2004-08,COMPLETED,INTERVENTIONAL,['PHASE3']
8267,NCT05453344,Change in HbA1c,rtCGM measurements,,2022-08-10,RECRUITING,INTERVENTIONAL,['NA']
8268,NCT06117631,Determine how parent support coaching and other predictors relate to infant and toddler growth in Latino children in first 2 years of life.,,,2023-07-01,RECRUITING,INTERVENTIONAL,['NA']
8269,NCT01264263,"Measurement of intima media thickness, visit 2","hs-C-Reactive Protein, visit 2",,2011-01,COMPLETED,OBSERVATIONAL,['NA']
8270,NCT04125329,Incidence of Treatment-Emergent and Treatment-Chronic Adverse Events of human umbilical cord mesenchymal stem cells for diabetic nephropathy patient,Changes in eGFR before and after treatment; Changes in 24h urine protein quantification before and after treatment,,2020-04-01,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
8271,NCT03641352,Change from baseline in Glycosylated Hemoglobin,Change from baseline in Apo-AⅠ,,2018-05-02,UNKNOWN,INTERVENTIONAL,['PHASE3']
8272,NCT01029444,Evaluate the effectiveness of Pulsed IV Insulin Therapy on the stabilization of blood glucose levels on patients with brittle or uncontrolled diabetes,,,2007-03,TERMINATED,INTERVENTIONAL,['PHASE3']
8273,NCT05225337,Change in percent body weight,Change in medication effect score (MES),,2022-02-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
8274,NCT00044408,Reduction in neuropathic symptoms,"Vibration sensation;Neurological signs;Electrophysiology of peroneal, tibial and sural nerves;Relief of symptoms as measured by VAS;Composite scores of nerve function;Clinical global impression of change",,2002-07,COMPLETED,INTERVENTIONAL,['PHASE3']
8275,NCT00222885,Triple tracer PET method development for in vivo imaging of skeletal muscle metabolism,Testing of mathematical modeling of PET data,,2002-12,COMPLETED,OBSERVATIONAL,['NA']
8276,NCT05105919,Incomplete platelet aggregation inhibition by aspirin at 7 days.,Platelet aggregation response to various agonists,,2021-08-26,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
8277,NCT04419779,Demonstrate superiority of Revita DMR to sham in improving glycemic control,Demonstrate superiority of Revita DMR to sham in elimination of insulin use at 24 weeks,,2021-03-08,RECRUITING,INTERVENTIONAL,['NA']
8278,NCT04962399,rs1800796,,,2021-08-01,UNKNOWN,OBSERVATIONAL,['NA']
8279,NCT04322071,Thematic Analysis,,,2020-02-26,UNKNOWN,OBSERVATIONAL,['NA']
8280,NCT01964521,Changes in Signs and Symptoms of Local Infection,Levels of Pain in Connection to Dressing Changes.,,2014-02,COMPLETED,INTERVENTIONAL,['NA']
8281,NCT00359996,hemoglobin A1c,Urine microalbumin levels,,2000-06,COMPLETED,INTERVENTIONAL,['NA']
8282,NCT06055036,Cardiovascular Health,"Identify the organizational context and resources necessary to align, coordinate, and sustain academic-community-government partnerships focused on advancing cardiovascular health equity.",,2023-08-24,RECRUITING,INTERVENTIONAL,['NA']
8283,NCT03207893,Medication changes,change in psychological functioning (attitude towards glucose monitoring questionnaire),,2018-07-19,COMPLETED,INTERVENTIONAL,['NA']
8284,NCT06020846,Blood glucose level,,,2023-09-01,RECRUITING,INTERVENTIONAL,['NA']
8285,NCT02703337,Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Curve From Time Zero to 5 Hours (AUC[0-5h]) (Part B),Pharmacodynamics (PD): Area Under the Concentration Curve From Time Zero to 5 Hours (AUC[0-5h]) of Glucose Relative to a Mixed Meal Tolerance Test (MMTT) (Part B),,2016-03,COMPLETED,INTERVENTIONAL,['PHASE1']
8286,NCT05908968,Reduction in wound area,Complete wound closure,,2017-09-19,COMPLETED,INTERVENTIONAL,['NA']
8287,NCT04203563,Change from Baseline in American Heart Association's Life's Simple 7 score at 12 Weeks,Change from Baseline Stress at 12 Weeks,,2019-08-20,COMPLETED,INTERVENTIONAL,['NA']
8288,NCT03646292,liver fat change measured by MRI-PDFF in co-localized regions of interest within each of nine liver segments,The changes in inflammation status,,2018-12-19,UNKNOWN,INTERVENTIONAL,['PHASE4']
8289,NCT00626249,Differences in exposure to fumaryl diketopiperazine (FDKP),Additional safety parameters,,2007-08,COMPLETED,INTERVENTIONAL,['PHASE1']
8290,NCT03920397,Glycemic control after an adipose tissue-derived stem/stromal cells,Oral cholecalciferol 2000UI/day supplementation,,2015-03-01,COMPLETED,INTERVENTIONAL,['NA']
8291,NCT02726100,"The proportion of patients achieving at least two ""ABC"" goals",Mean change in the Summary of Diabetes Self-Care Activities (SDSCA) from baseline to 24 month,Mean change in estimated glomerular filtration rate (GFR),2017-08-01,COMPLETED,INTERVENTIONAL,['NA']
8292,NCT01600950,Pharmacodynamics: Duration of Action of LY2963016 and Lantus,Pharmacokinetics: Area Under the Concentration-time Curve (AUC) of LY2963016 and Lantus,,2012-05,COMPLETED,INTERVENTIONAL,['PHASE1']
8293,NCT05364476,Change of HbA1c after 16 weeks intervention,Change in EQ-5D-5L score,,2022-04-11,COMPLETED,INTERVENTIONAL,['NA']
8294,NCT02533453,Percentage of Participants With Adverse Events(AEs) and Serious Adverse Event(SAEs),"Evaluation of ""Subjective Improvement of Main Indication""",,2016-01-28,COMPLETED,INTERVENTIONAL,['PHASE4']
8295,NCT01809730,Transfusion within 48 hours post-op,,,2012-05,WITHDRAWN,OBSERVATIONAL,['NA']
8296,NCT02895113,Changes in renal function in diabetic patients treated with aspirin,Relationship between changes of Thromboxane B2 excretion and renal function in diabetic patients treated with aspirin,,2017-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
8297,NCT04853030,Time above range 180 mg/dl,Mean glucose,,2021-04-06,COMPLETED,INTERVENTIONAL,['NA']
8298,NCT02443532,HbA1c (between-group difference in variation from baseline),"Severe hypoglycemia (incidence of episodes of hypoglycemia requiring hospitalization and/or help from third parties, self-reported)",,2012-03,TERMINATED,INTERVENTIONAL,['NA']
8299,NCT01462266,Change From Baseline in Daily Insulin Dose at Week 24,Time to Achieve the Fasting Glucose Target,,2012-01-13,COMPLETED,INTERVENTIONAL,['PHASE3']
8300,NCT01298076,Visual acuity gain,Safety,,2010-10,COMPLETED,INTERVENTIONAL,['PHASE2']
8301,NCT05357534,average running speed,,,2022-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
8302,NCT04453605,Incidence of microvascular complication,Change of HbA1c through study completion (an average of 5 year),,2008-01-01,COMPLETED,OBSERVATIONAL,['NA']
8303,NCT00295334,"adherence, HbA1c, Glc","LDL, HDL, TG",,2006-02,UNKNOWN,INTERVENTIONAL,['PHASE2']
8304,NCT02211235,The percentage of time spent > 140 mg/dl on CGM,The number of excursions > 200mg/dl in 24 hours for one week,Characterize the relationships between markers of glycemia,2014-08,COMPLETED,OBSERVATIONAL,['NA']
8305,NCT06015685,Change in feasibility of intervention measure (FIM) scores,Change in urine microalbumin,,2023-10-20,RECRUITING,INTERVENTIONAL,['NA']
8306,NCT00388388,Effect of 6 months of losartan or hydrochlorothiazide on media/lumen ratio of gluteal subcutaneous resistance arteries in otherwise normal subjects who fulfill criteria for pre-hypertension and pre-diabetes,"Safety and tolerability of 6 month therapy with losartan or hydrochlorothiazide, and effect on media thickness, lumen diameter and vascular function of gluteal subcutaneous resistance arteries, and serum and tissue inflammatory markers in same subjects",,2007-03,TERMINATED,INTERVENTIONAL,['PHASE2']
8307,NCT01415544,Calibrate near-infrared spectroscopy-based glucose meter,Compare Noninvasive to invasive techniques,,2011-06,UNKNOWN,OBSERVATIONAL,['NA']
8308,NCT00398619,"Assessment of ECGs, laboratory results and physical exams for adverse events",,,2006-11,COMPLETED,INTERVENTIONAL,['PHASE1']
8309,NCT02460354,Change in mean urine osmolality,Change in mean urine volume,,2015-09,TERMINATED,INTERVENTIONAL,['PHASE1']
8310,NCT00456352,Treatment success based on patients' glycemic control.,"Physiologic measurements, Comorbidity improvement, Improvement in QOL.",,2007-04,COMPLETED,INTERVENTIONAL,['PHASE4']
8311,NCT06107816,Evaluate the impact of a F&V Rx on DSME/S retention in low-income adults.,Evaluate the impact of a F&V Rx on Food insecurity,Assess program implementation outcomes - Clinic/providers/staff - Implementation Outcomes Questionnaire (IOQ),2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
8312,NCT02871882,Change in Postprandial Glucose,,,2016-09-15,COMPLETED,INTERVENTIONAL,['PHASE2']
8313,NCT05821322,Change in plasma glucose during exercise,Carbohydrate needed (g),,2023-07-01,RECRUITING,INTERVENTIONAL,['NA']
8314,NCT03865914,change in eGFR and urine protein from baseline,,,2017-11-30,RECRUITING,OBSERVATIONAL,['NA']
8315,NCT01413204,Change in Hemoglobin A1c (A1C) From Baseline (NGSP Value),"Safety and Tolerability Assessed by Adverse Events, Hypoglycemic Events, Laboratory Tests, 12-lead ECG and Vital Signs",,2011-07,COMPLETED,INTERVENTIONAL,['PHASE3']
8316,NCT04417270,Comparison of values between two devices,,,2020-06-12,COMPLETED,INTERVENTIONAL,['NA']
8317,NCT03598855,Changes in vascular function,Change cerebrovascular function,Change in insulin sensitivity,2017-06-01,COMPLETED,INTERVENTIONAL,['NA']
8318,NCT01050166,Evidence of safety and efficacy of MRI imaging of transplanted human labeled islets,,,2008-08-15,COMPLETED,OBSERVATIONAL,['NA']
8319,NCT02933788,platelet reactivity testing,"Observation of Clinical laboratory data(total cholesterol, HDL, LDL and triglyceride",,2016-10,UNKNOWN,INTERVENTIONAL,['PHASE4']
8320,NCT00656435,The severity of intraoperative bleeding and vitreous clear-up time.,Percentage of prolonged vitreous clear-up (≥ 3 weeks) and recurrent hemorrhage rate.,,2006-12,COMPLETED,INTERVENTIONAL,['PHASE3']
8321,NCT00838799,Change in mean daily pain rating,50% reduction in pain,,2009-02,COMPLETED,INTERVENTIONAL,['PHASE2']
8322,NCT02377531,Composite Perinatal morbidity,Maternal weight gain,,2015-03,UNKNOWN,INTERVENTIONAL,['NA']
8323,NCT01531569,"Terminal phase half-life of secoisolariciresinol, enterodiol and enterolactone.",Inflammatory markers,,2011-12,COMPLETED,INTERVENTIONAL,['PHASE2']
8324,NCT05263011,"Changes in plasma tumor necrosis factor (TNF)-alpha, concentration",,,2022-06-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
8325,NCT05331469,Hba1c reduction,Weight changes after intervention,,2021-07-19,UNKNOWN,INTERVENTIONAL,['PHASE4']
8326,NCT02559128,Exercise capacity,Endothelial function,,2013-12,UNKNOWN,OBSERVATIONAL,['NA']
8327,NCT00292994,Metabolic Syndrome Score,,,2004-04,UNKNOWN,INTERVENTIONAL,['NA']
8328,NCT00681161,"blood glucose level, composite autonomic system score (CASS), homeostasis assessment model (HOMA), insulin sensitivity index (ISI)",,,2006-03,COMPLETED,INTERVENTIONAL,['NA']
8329,NCT06190158,The magnitude of non-suppressible and renin-independent aldosterone production.,,,2024-07,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
8330,NCT02563522,Proportion of Subjects With a Target Wound Closure by the 4-month Follow-up Visit,,,2017-06-27,TERMINATED,INTERVENTIONAL,['PHASE3']
8331,NCT06069076,Evulate the diagnostic value of serum cathepsin S and chromogranin A for Diabetic kidney disease.,correlate the levels of serum Cathepsin S and chromogranin A with HbA1c and eGFR in type 2 diabetic patients based on urinary Albumin- Creatinine Ratio.,,2023-11-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
8332,NCT03765164,Diagnosis-Treatment,Workup Costs,,2018-11-05,COMPLETED,INTERVENTIONAL,['NA']
8333,NCT03183726,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,Wound size and depth measurement,,2016-01-11,COMPLETED,OBSERVATIONAL,['NA']
8334,NCT06033664,Number of participants with a percentage change in Hemoglobin A1C (HbgA1C),Change in food insecurity,,2023-11-06,RECRUITING,INTERVENTIONAL,['NA']
8335,NCT01843881,"Change in Total Disposition Index from Study 1 (Exendin 9,39) to Study 2 (saline)",,,2012-03,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
8336,NCT02559843,total antioxidant capacity,fasting blood glucose,,2014-11,COMPLETED,INTERVENTIONAL,['PHASE4']
8337,NCT01492283,The Incretin effect,Plasma glucagon response,,2011-12,COMPLETED,OBSERVATIONAL,['NA']
8338,NCT01635062,The Change in Circulating RAS Activity After Calcitriol/Placebo Therapy,Change in Urine Protein After Calcitriol/Placebo Therapy,,2012-09,COMPLETED,INTERVENTIONAL,['NA']
8339,NCT02836808,Diabetes control after 4 visits in a structured multidisciplinary program for patients with diabetes,Quality of life after 4 visits in a structured multidisciplinary program for patients with diabetes,Social-economic impact of living and eating expenses of a multidisciplinary intervention for patients with diabetes,2013-10-31,RECRUITING,INTERVENTIONAL,['NA']
8340,NCT05431686,"Perceived benefit of the SMA intervention content, as measured by user satisfaction surveys summary statistics (mean and standard deviation as well as percent answering a specific Likert level)",CGM Benefits and Burdens scale,,2022-02-16,RECRUITING,INTERVENTIONAL,['NA']
8341,NCT06290947,Improvement in Aerobic Capacity,Change in Body Mass Index (BMI),,2022-03-06,COMPLETED,INTERVENTIONAL,['NA']
8342,NCT03037255,Number of patients who died from any cause by the end of the study censoring period,Number of patients who received guideline recommended therapy during the study period,,2003-01,COMPLETED,OBSERVATIONAL,['NA']
8343,NCT03208309,Cholesterol,,,2013-01,COMPLETED,INTERVENTIONAL,['PHASE2']
8344,NCT01785108,"Change in C-peptide (90 minute value and AUC mean 0-120 min) during a Mixed Meal Tolerance Test from baseline to month 6, 15 and 30","Fasting C-peptide, change between baseline and month 6, 15 and 30",,2013-02,COMPLETED,INTERVENTIONAL,['PHASE2']
8345,NCT00157482,"LDL-cholesterol, at 16 weeks of treatment. LDL-cholesterol is measured at -4, 0, 8, 12 and 16 weeks.","Urinary albumin excretion, at -4, 0, 8 and 16 weeks",,2005-01,COMPLETED,INTERVENTIONAL,['PHASE2']
8346,NCT00625833,Change from baseline in weekly average pain score,Modified Brief Pain Inventory-Short Form,,2007-12,TERMINATED,INTERVENTIONAL,['PHASE2']
8347,NCT00737776,HbA1c change,Diabetes Fear of Self-Injection Questionnaire (D-FISQ),,2008-05,COMPLETED,OBSERVATIONAL,['NA']
8348,NCT02839031,Glycated hemoglobin (HbA1c) level,,,2015-03-11,TERMINATED,INTERVENTIONAL,['NA']
8349,NCT05383404,measured degree of dehydration,,,2022-06-25,RECRUITING,OBSERVATIONAL,['NA']
8350,NCT00588172,Change in glucose area under the curve after a mixed meal in response to metformin,Change in glucose disappearance and suppression of endogenous glucose production in response to metformin,,2010-06,WITHDRAWN,INTERVENTIONAL,['PHASE4']
8351,NCT03388723,Epigenetic signatures in the cord blood of the offspring of GDM mothers.,Qualitative and quantitative comparison of epigenetic signatures in the offspring of GDM mothers [Indian and Danish cohort].,,2014-09-02,COMPLETED,OBSERVATIONAL,['NA']
8352,NCT00448526,time to the doubling of sCr,% change of urinary albumin and protein excretion from baseline,,1997-12,TERMINATED,INTERVENTIONAL,['NA']
8353,NCT03954834,Change From Baseline in Hemoglobin A1c (HbA1c),Pharmacokinetics (PK): Steady State Area Under the Concentration Time Curve (AUC) of Tirzepatide,,2019-06-03,COMPLETED,INTERVENTIONAL,['PHASE3']
8354,NCT02417935,Change From Baseline to 12 Weeks in the Weekly Mean of the 24-Hour Average Pain Score on the 11-Point Numeric Rating Scale (NRS),Number of Participants With a 30% and 50% Reduction in the Weekly Mean of the 24-Hour Average Pain Score on the 11-Point NRS at 12 Weeks,,2015-04,COMPLETED,INTERVENTIONAL,['PHASE4']
8355,NCT00592904,Mean Change From Baseline in SF-MPQ Current Pain Intensity (CPI): From Baseline to Week 48,Mean Change From Baseline in Short Form 36 Item (SF-36) Health Survey: Physical and Mental Component Scores From Baseline to Week 48/EOT,,2008-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
8356,NCT01182480,Patient Engagement,Glycemic Control,,2010-05,COMPLETED,INTERVENTIONAL,['NA']
8357,NCT03059277,Change in Central Subfield Thickness (CST),Number of Intravitreal Injections,,2018-06-01,WITHDRAWN,INTERVENTIONAL,['PHASE4']
8358,NCT05367063,Change in myocardial micro-perfusion,Change in resting mocardial blood flow,,2022-01-05,RECRUITING,INTERVENTIONAL,['PHASE4']
8359,NCT05337644,Positive Intraoperative Indocyanine green test,,,2022-01-21,COMPLETED,OBSERVATIONAL,['NA']
8360,NCT01550809,The Area Under the Curve (AUC) of the Glucose Infusion Rate (GIR) During the 5-hour Postprandial Period (AUC-GIR0-5h).,The Area Under the Curve (AUC) of Plasma Glucose (PG) Above the Threshold of 140 mg/dl (AUC-PG>140).,,2010-02,COMPLETED,INTERVENTIONAL,['PHASE3']
8361,NCT05418569,Self/Parent-reported questionnaires on hypoglycemia frequency,Self-reported smartphone application usage satisfaction,,2021-07-01,RECRUITING,INTERVENTIONAL,['NA']
8362,NCT05960656,Ketone Body Turnover (ketogenesis) during Study 2,Plasma Free Fatty Acids (FFS) Study 2,,2023-10-05,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
8363,NCT02988427,Diabetes Self-efficacy,Clinical Outcomes,,2016-12,WITHDRAWN,OBSERVATIONAL,['NA']
8364,NCT04013919,Glucose levels,,,2019-09-20,UNKNOWN,OBSERVATIONAL,['NA']
8365,NCT01126580,Change From Baseline to 26-week Endpoint in Glycosylated Hemoglobin (HbA1c),Measurement of LY2189265 Drug Concentration for Pharmacokinetics: Area Under the Concentration Curve (AUC),,2010-05,COMPLETED,INTERVENTIONAL,['PHASE3']
8366,NCT00676208,Change in Confidence in Ability to Perform Teamwork,Change in Professionals' Attitudes About Diabetes,,2008-04,COMPLETED,INTERVENTIONAL,['NA']
8367,NCT03090451,Non-insulin mediated glucose uptake (NIMGU),Time spent in hyperglycemia,,2017-05-01,COMPLETED,INTERVENTIONAL,['NA']
8368,NCT06094491,A1c,Low density lipoproteins,,2023-11,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
8369,NCT00511472,Number of Participants Who Experienced an Adverse Event During the Study,Number of Participants Who Experienced an Adverse Event During the Outpatient Treatment Period,,2007-07,COMPLETED,INTERVENTIONAL,['PHASE1']
8370,NCT03602963,Accuracy of the Dexcom G5 mobile continuous glucose monitoring (CGM) system by comparison of sensor glucose measurements with capillary blood glucose determinations,Patients' and parents' satisfaction with the Dexcom G5 mobile CGM system will be evaluated by a standardized questionnaire,,2018-07-09,COMPLETED,OBSERVATIONAL,['NA']
8371,NCT02214719,Glucose control - A1c,Long term use,,2014-08,COMPLETED,INTERVENTIONAL,['NA']
8372,NCT02530450,The Primary Outcome Measure Was Change in HgbA1c,"% Time Spent in Hypoglycemia, Hyperglycemia, and Euglycemia",,2011-05,COMPLETED,OBSERVATIONAL,['NA']
8373,NCT06314048,Diabetes distress measured at baseline and 12 months post-diagnosis.,,,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
8374,NCT00233259,Hemoglobin A1c,Social support,,2006-03,COMPLETED,INTERVENTIONAL,['NA']
8375,NCT03415295,Gestational diabetes mellitus,,,2012-08-01,COMPLETED,OBSERVATIONAL,['NA']
8376,NCT05291013,Muscular insulin sensitivity,Metabolomics,,2022-07-01,UNKNOWN,INTERVENTIONAL,['NA']
8377,NCT05307042,Decline renal concentration ability,Decline in kidney-function,,2022-05,UNKNOWN,OBSERVATIONAL,['NA']
8378,NCT01546766,Pupillary response,Pupillary response.,,2007-02,COMPLETED,OBSERVATIONAL,['NA']
8379,NCT01067963,"Primary outcomes utilized in this study will be disease burden (measured as diabetes-related distress), quality of life (measured as health related QOL), and glycemic health (measured as hemoglobin A1C).",Secondary exploratory outcomes for quality of life include measures of health-related quality of life for diabetes and overall quality of life.,,2009-12,TERMINATED,INTERVENTIONAL,['NA']
8380,NCT02159417,The feasibility of the application of the action ETP in the MAPLS,The satisfaction of the staffs as for the implementation and the realization of the experiment,,2013-11,COMPLETED,INTERVENTIONAL,['NA']
8381,NCT05758467,Cardiovascular health and oral health,,,2019-07-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
8382,NCT03934593,The change in HbA1c,Occupational physical activity,Spiritual coping,2017-01-01,UNKNOWN,INTERVENTIONAL,['NA']
8383,NCT00451113,Safety and efficacy of Sitagliptin in an elderly population with type 2 diabetes,,,2006-11,COMPLETED,INTERVENTIONAL,['PHASE2']
8384,NCT03252964,Program Completion Rate (%),Coaching Participation Rate,,2017-07-28,COMPLETED,INTERVENTIONAL,['NA']
8385,NCT04447859,Gastrointestinal adverse events (GI-AEs),,,2020-02-23,UNKNOWN,INTERVENTIONAL,['PHASE3']
8386,NCT01834144,"Time Spent in Hypoglycaemia in the 12-hour Period Following Exercise, Defined as an Interstitial Glucose Reading <4.0mmol/L and Measured by Continuous Glucose Monitor.","Glycaemic Variability, Measured by the Mean Amplitude of Glycaemic Excursions (MAGE), in the 12-hour Period Following Exercise. This is Calculated From the Same Continuous Glucose Monitor Data as the Primary Outcome.",,2013-05,TERMINATED,INTERVENTIONAL,['NA']
8387,NCT00663260,Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF],Adjusted Mean Change From Baseline in Total Body Weight (kg) at Week 24 (Last Observation Carried Forward [LOCF]),,2008-06,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
8388,NCT06114186,percentage of time with severe hyperglycemia,,,2024-01-16,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
8389,NCT00481897,"Assignment to the diet intervention, decreases the prevalence of work absenteeism, as measured by the proportion of days that a participant is absent from work, compared with assignment to a control group.",Assignment to the diet intervention program promotes adherence and acceptability.,,2007-05,COMPLETED,INTERVENTIONAL,['NA']
8390,NCT06035406,PK parameters：AUC0-∞；,Incidence and severity of adverse events (AEs),,2023-09,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
8391,NCT02927678,"Rate of remission of osteomyelitis at one year after the cessation of antibiotic treatment, evaluated by white blood cell SPECT/CT (Single Photon Emission Computed Tomography/Computed Tomography).",Negative predictive value of White Blood Cell SPECT/CT performed at the end of antibiotic treatment to predict the remission of osteomyelitis at one year.,,2014-01,UNKNOWN,OBSERVATIONAL,['NA']
8392,NCT00229684,Endogenous creatinine clearance,"The safety and tolerability of tesaglitazar in type 2 diabetics by assessments of adverse events, laboratory values, electrocardiogram, pulse, blood pressure, body weight, and physical examination.",,2004-09,TERMINATED,INTERVENTIONAL,['PHASE2']
8393,NCT00539890,Mean change in HbA1c from baseline to treatment week 24,,,2005-11,COMPLETED,INTERVENTIONAL,['PHASE3']
8394,NCT02197299,Skeletal muscle total carnitine content,,,2014-08,UNKNOWN,INTERVENTIONAL,['PHASE2']
8395,NCT00808431,"Growth trajectories (using BMI, waist circumference), body composition","Physical activity accelerometry change over time, parental self-efficacy, child feeding questionnaire (parental food habits), identification of medical home",,2008-07,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
8396,NCT01983046,fat oxidation,Hormones that influence energy metabolism - Circulating metabolites - Inflammatory markers - plasma SCFA content; - Indirect markers of insulin sensitivity - Appetite (VAS-scoring).,,2013-09,COMPLETED,INTERVENTIONAL,['NA']
8397,NCT02545049,"The First Occurrence of the Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction, Non Fatal Stroke, or Hospitalization for Heart Failure.","The First Occurrence of the Composite Endpoint of Onset of Kidney Failure, a Sustained Decrease in eGFR of ≥57% From Baseline Over at Least 4 Weeks, or Renal Death",,2015-09-17,COMPLETED,INTERVENTIONAL,['PHASE3']
8398,NCT02100475,Change From Baseline in HbA1c (Glycosylated Haemoglobin),Number of Treatment-emergent Confirmed Hypoglycaemic Episodes,,2014-04,COMPLETED,INTERVENTIONAL,['PHASE3']
8399,NCT01455415,Average Diabetic Peripheral Neuropathy (DPN) Pain Based on a Numeric Rating Scale (NRS) Over the Last 7 Days of Each Treatment Period (Week 6 of Each Treatment Period),PGIC Score at the End of Period 1 (Week 6) - Categorized Scores,,2011-12,COMPLETED,INTERVENTIONAL,['PHASE3']
8400,NCT04325347,Change in number of awakenings during the night between experimental and control intervention.,"Nature, severity and impact of insomnia",,2021-01-27,UNKNOWN,INTERVENTIONAL,['NA']
8401,NCT02665689,Difference of Best Corrected Visual Acuity Measured in ETDRS Letters Score Between Month 12 Baseline Visit,Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment,,2016-01-18,TERMINATED,INTERVENTIONAL,['PHASE4']
8402,NCT04084886,Number of patients with genotype TCF7L2 by PCR,,,2019-09-01,UNKNOWN,OBSERVATIONAL,['NA']
8403,NCT01527656,"Cmax, maximum insulin aspart concentration",Incidence of hypoglycaemic events,,2003-12,COMPLETED,INTERVENTIONAL,['PHASE1']
8404,NCT01319331,To assess participant safety & feasibility of study drug administration,Assess the effects of AAT on glycemic variability and A1c.,,2010-10,COMPLETED,INTERVENTIONAL,['PHASE1']
8405,NCT06066944,Measure the intensity of neuropathy induced pain,,,2024-02-25,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
8406,NCT03336528,Mean Daily Blood Glucose Concentration in Discharged Patients.,Number of Episodes of Severe Hyperglycemia in Discharged Patients,Number of Participants Experiencing Acute Kidney Injury in Discharged Patients,2018-01-02,COMPLETED,INTERVENTIONAL,['PHASE4']
8407,NCT03651908,Radiographic parameters - Change in bone level,clinical parameters - Changes in relative clinical attachment level,,2017-09-05,COMPLETED,INTERVENTIONAL,['NA']
8408,NCT01067209,"Primary outcome measure: cardiac function, myocardial fat deposition","Plasma lipidomics, liver fat deposition",,2010-01,COMPLETED,OBSERVATIONAL,['NA']
8409,NCT01215903,Plasma and serum inflammatory markers,Fatty acids of phospholipids in skeletal muscle,,2007-11,COMPLETED,INTERVENTIONAL,['PHASE2']
8410,NCT05062460,Rate of adherence,Number of patients with brachial plexus palsy,,2021-07-15,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
8411,NCT02441504,Change in Cutaneous Capillary Density in twelve weeks of aerobic physical activity,,,2014-01,COMPLETED,INTERVENTIONAL,['NA']
8412,NCT01298518,Change From Baseline in Post-Prandial Glucose Area Under the Concentration-Time Curve From Time 2 to 6 Hours (AUC 2-6) After a Mixed Meal Tolerance Test (MMTT) at Day 28,Area Under the Concentration-Time Curve AUC (0-24) of PF-04620110,,2011-02,COMPLETED,INTERVENTIONAL,['PHASE1']
8413,NCT03914183,The percentage of participants in the mCPN group who demonstrate an improvement (vs baseline performance) in the recommended site rotation techniques relative to the proportion of that in the control group.,the percentage of participating patients who decide to continue using mCPN upon study completion,,2018-10-15,COMPLETED,INTERVENTIONAL,['NA']
8414,NCT06159543,8-iso-PGF2 alpha,Lean body mass,,2024-03-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
8415,NCT01264523,Fat-free mass,Satiety assessment,,2009-09,COMPLETED,INTERVENTIONAL,['NA']
8416,NCT05829811,Detection of neurological disorders,Analysing of potential precipitating factors for DFU,,2023-09-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
8417,NCT00624767,To evaluate the effect on postprandial glycemic control of intranasal insulin compared to NovoLog,To evaluate the pharmacokinetics of intranasal insulin compared to NovoLog,,2008-03,COMPLETED,INTERVENTIONAL,['PHASE2']
8418,NCT02360878,Change in postprandial glucagon-like peptide-1 (GLP-1) secretion from baseline 3 weeks after explantation,Change in postprandial glucosedependent insulinotropic peptide (GIP) from baseline 3 weeks after explantation,Change in caloric intake as measured by ad libitum meal test 3 weeks after explantation,2013-02,COMPLETED,OBSERVATIONAL,['NA']
8419,NCT05408936,NT-proBNP,,,2022-06-03,RECRUITING,OBSERVATIONAL,['NA']
8420,NCT02686996,Change in insulin sensitivity measured by euglycaemic glucose clamp,Change in Resting systolic and diastolic blood pressure,Change in Other Tissue Analyses,2017-02-13,UNKNOWN,INTERVENTIONAL,['NA']
8421,NCT04560062,Proportion of patients with access to health care of diabetes,Proportion of patients with at least one disease complication,,2020-10-13,UNKNOWN,OBSERVATIONAL,['NA']
8422,NCT02661581,Glycemic Control measured by HbA1c,"Weight measured on a high quality, calibrated digital scale, with the participant wearing clothes, but no shoes",,2013-11,UNKNOWN,INTERVENTIONAL,['NA']
8423,NCT05491850,Effect of moderate physical activity on early symptoms of peripheral diabetic neuropathy in type-II diabetes,,,2021-10-01,COMPLETED,INTERVENTIONAL,['NA']
8424,NCT01518205,Proportion of subjects obtaining the ulcer healing (Class 0A according to TEXAS classification) after 12 month from the study starts.,proportion of subjects with major amputation (these are usually below the knee or above the knee)- in agreement with the approved amendment,,2012-02,COMPLETED,INTERVENTIONAL,['NA']
8425,NCT00840541,CSME,,,2009-01,COMPLETED,OBSERVATIONAL,['NA']
8426,NCT02973321,Change From Baseline in HbA1c to Week 26,Change From Baseline in Pharmacodynamic Biomarkers to Week 26 - Waist and Hip Circumferences,,2016-12-02,COMPLETED,INTERVENTIONAL,['PHASE2']
8427,NCT00969566,The change of HbA1c,Homeostatic model assessment of insulin resistance (HOMA-IR),,2009-01,COMPLETED,INTERVENTIONAL,['PHASE4']
8428,NCT04686201,Percentage of uncontrolled Diabetes Mellitus patients who have good control diabetes after using Diabetes Mobile Application,,,2019-08-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
8429,NCT00044668,"Change in concentrations of fasting plasma glucose and lipids from Baseline Visit 2 (Day 1) to Week 24, to Week 52, and to each intermediate visit",,,2002-08,COMPLETED,INTERVENTIONAL,['PHASE3']
8430,NCT01724645,HbA1C :Glycated Hemoglobin,Heart rate,Lipid modifying (oral medication),2010-09,COMPLETED,INTERVENTIONAL,['NA']
8431,NCT03414892,the mean change in glucose area under curve (AUC) from baseline.,the mean changes of post-prandial blood glucose from baseline,the changes of GA (Glycated albumin) from baseline,2018-01-03,COMPLETED,INTERVENTIONAL,['PHASE1']
8432,NCT04616014,Number of Participants With Treatment-related Adverse Events.,Change From Screening in Liver Steatosis,,2021-03-01,COMPLETED,INTERVENTIONAL,['PHASE2']
8433,NCT01281605,To compare the change in HbA1c between two study groups at Week 24.,To evaluate the incidence of adverse events.,,2011-01,COMPLETED,INTERVENTIONAL,['NA']
8434,NCT01006291,Change in Glycosylated Haemoglobin (HbA1c),Rate of Nocturnal Confirmed Hypoglycaemic Episodes,,2009-11,COMPLETED,INTERVENTIONAL,['PHASE3']
8435,NCT02175459,"Change from baseline in metabolic status (normal glucose tolerance, impaired glucose tolerance, diabetes)","islet cell areas (beta, Alpha and delta cell positive area)",change in gene expression analysis among different groups of baseline metabolic status,2010-08,RECRUITING,OBSERVATIONAL,['NA']
8436,NCT00182494,3. Impact on incidence of diabetes,3. Sustained changes in eating & activity patterns,,2005-02,UNKNOWN,INTERVENTIONAL,['PHASE4']
8437,NCT00356421,Change From Baseline in Glycosylated Hemoglobin (HbA1c) Percent (%),Change in Fasting Lipids From Baseline,Subject Reported Quality of Life From Baseline as Determined From Phase V System Measurement,2006-11,TERMINATED,INTERVENTIONAL,['PHASE4']
8438,NCT01369069,Number of Participants With Severe Hypoglycemia (Blood Glucose < 40mg/dL),Stroke Specific Quality of Life (SSQOL),Death,2012-04,COMPLETED,INTERVENTIONAL,['PHASE3']
8439,NCT01863667,Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event,Change From Baseline in Body Weight at Week 54,,2013-07-08,TERMINATED,INTERVENTIONAL,['PHASE3']
8440,NCT00179127,Time of Acidosis Correction,Total Hospital Stay,,2004-08,COMPLETED,INTERVENTIONAL,['NA']
8441,NCT05939349,Glycemic control,Nutrition knowledge,Provider satisfaction survey,2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
8442,NCT02742233,Completely healing time of the participants'target ulcer during the treatment period.,Proportion of participants with complete healing during the treatment period.,New ulcers,2015-11,UNKNOWN,INTERVENTIONAL,['PHASE4']
8443,NCT04612868,"Sensitivity and Specificity, Based on Two Macula-centered Images (One Image From Each Eye of the Patient)","Imageability, Based on Four Images (One Macula Centered Image and One Optic Disc Centered Image Per Eye)",,2020-10-16,COMPLETED,INTERVENTIONAL,['NA']
8444,NCT02798250,Percentage of time below 4.0 mmol/L,Total glucagon delivery,,2016-06,COMPLETED,INTERVENTIONAL,['PHASE2']
8445,NCT02018809,Statin Adherence,Morisky Medication Adherence Scale (MMAS),,2014-01,COMPLETED,INTERVENTIONAL,['NA']
8446,NCT02763267,Insulin secretory response,Change in insulin secretory response,,2016-02,COMPLETED,OBSERVATIONAL,['NA']
8447,NCT01616563,Number of Participants That Have Reversal of Metabolic Syndrome,Changes in Continuous Metabolic Syndrome Risk Score,,2012-10,COMPLETED,INTERVENTIONAL,['NA']
8448,NCT05525117,HbA1c,Proportion of patients achieving a reduction in HbA1c,systolic blood pressure,2023-07-04,RECRUITING,INTERVENTIONAL,['NA']
8449,NCT04190251,Medication adherence (longitudinal data),Patients' satisfaction,,2016-04-14,COMPLETED,INTERVENTIONAL,['NA']
8450,NCT05695651,Investigate the association between TyG index and HOMA IR with the risk of macrovascular and microvascular complications of type 2 diabetes,Percentage of diabetic patients who developed vascular complications.,,2023-02-07,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
8451,NCT01879137,Discriminative value of copeptin after arginine infusion in the differential diagnosis of polyuria-polydipsia syndrome.,,,2013-06,COMPLETED,OBSERVATIONAL,['NA']
8452,NCT04328181,quality of the images,Statistical comparison between SPCCT and DECT,,2021-01-29,RECRUITING,INTERVENTIONAL,['NA']
8453,NCT01785043,Assess the effects on endothelial function of a three month treatment with Liraglutide compared to Sitagliptin.,The evaluation of other emerging potential cardiovascular risk factors,,2013-03,COMPLETED,INTERVENTIONAL,['PHASE4']
8454,NCT01736059,Incidence and severity of ocular adverse events,The number of stem cells isolated and injected into the study eye,Incidence and severity of systemic adverse events,2012-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
8455,NCT02796170,Change in Blood Pressure From Baseline to 6 Weeks Measured by ABPM,Change in Urinary AGT Levels From Baseline to 6 Weeks,,2016-03,COMPLETED,INTERVENTIONAL,['PHASE4']
8456,NCT02025673,"Serum levels of betatrophin in type 2 diabetes patients, gestational diabetes patients and pregnant women",Correlation of betatrophin concentration with other variables,,2013-08,UNKNOWN,OBSERVATIONAL,['NA']
8457,NCT06273761,Medication adherence,Beliefs in medicines,,2024-02-06,RECRUITING,INTERVENTIONAL,['NA']
8458,NCT01911104,Change in ATPmax,Change in in vivo and in vitro mitochondrial function,Promoter methylation,2013-10-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
8459,NCT00781001,Spontaneous Pain Score,Adverse events,,2008-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8460,NCT04818242,Time in Range (TIR) Between 70-180 mg/dL,Number of Participants With Problems With Sensor Insertion,,2021-04-19,COMPLETED,INTERVENTIONAL,['NA']
8461,NCT03566693,Phase 2: Change in CGM time in target range,Phase 2: Change in CGM time-hypoglycemic,Phase 1 and Phase 2: Safety Events - Other adverse events,2018-07-30,COMPLETED,INTERVENTIONAL,['NA']
8462,NCT00566215,Improvement or reversal of type 2 diabetes mellitus,Improvement of insulin sensitivity as measured by insulin tolerance test.,,2007-07,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8463,NCT00624013,HbA1C (%),Quality of Life,,2006-09,COMPLETED,INTERVENTIONAL,['PHASE4']
8464,NCT02701894,HbA1c,HOMA- IR,,2012-12,UNKNOWN,OBSERVATIONAL,['NA']
8465,NCT03297931,Food intake,,,2017-07-19,UNKNOWN,INTERVENTIONAL,['NA']
8466,NCT05483972,Change in Adult and Offspring Waist Measurements,,,2022-10-04,COMPLETED,INTERVENTIONAL,['NA']
8467,NCT04856670,Aqueous humor concentrations of inflammatory mediators at the onset of manual cataract surgery and following femtosecond laser treatment,Prevalence and severity of postoperative flare,,2021-05-25,UNKNOWN,OBSERVATIONAL,['NA']
8468,NCT03511898,Incidence of dose-limiting toxicities up to the Day 14 visit,Occurrence of laboratory abnormalities up to the end of the study,,2018-05-18,COMPLETED,INTERVENTIONAL,['PHASE1']
8469,NCT00116792,In-stent and In-segment late lumen loss,(There are 3 more secondary endpoints not listed here.),,2004-03,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
8470,NCT06313138,Symptom burden,Health literacy,,2023-07-15,COMPLETED,INTERVENTIONAL,['NA']
8471,NCT03521934,"Number of Total Occurrences of Cardiovascular (CV) Death, Hospitalizations for Heart Failure (HHF) and Urgent Visits for Heart Failure (HF)",Change From Baseline in Estimated Glomerular Filtration Rate (eGFR),,2018-06-15,TERMINATED,INTERVENTIONAL,['PHASE3']
8472,NCT05867797,prognosis risk factors and outcomes of AKI in patients with DKA,,,2023-05-20,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
8473,NCT04819815,Chronotropic index,Life Quality,,2020-01-20,COMPLETED,OBSERVATIONAL,['NA']
8474,NCT01878682,"The accuracy of the VibraTip® device, as measured by a comparison with the Gold Standard, the 10g Semmes Weinstein Monofilament (MF) Test by a Diabetologist.",,,2014-02-06,COMPLETED,OBSERVATIONAL,['NA']
8475,NCT05195138,Feasibility: overall study retention,Type 2 diabetes stigma,,2023-05-31,RECRUITING,INTERVENTIONAL,['NA']
8476,NCT04856800,Maternal glycemic variability (GV),Weight of placenta,,2021-12-01,COMPLETED,INTERVENTIONAL,['NA']
8477,NCT03972982,remission rate,,,2019-06-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
8478,NCT01944904,The Effects of Xyloologosarcharide (XOS) on colonic flora in volunteers with abnormal glucose levels,The Effects of Xyloologosarcharide (XOS) on glucose and insulin,The effects of Xylooligosaccharide (XOS) on body weight and body composition,2013-09,COMPLETED,INTERVENTIONAL,['NA']
8479,NCT00330954,,,,2006-06,COMPLETED,OBSERVATIONAL,['NA']
8480,NCT01712061,Percent Reduction From Baseline in Urinary Albumin to Creatinine Ratio (UACR) at Week 12,"Summary of Plasma PF-04634817 Pharmacokinetic (PK) Concentrations at Day 1 and Weeks 1, 4, 8 and 12",Number of Participants With Increased Fasting Blood Glucose,2012-12,COMPLETED,INTERVENTIONAL,['PHASE2']
8481,NCT00479466,Change From Baseline to Week 12 in Fasting Plasma Glucose (FPG),Change From Baseline to Week 12 in 2-Hour Post Prandial Glucose (PPG),,2007-07,TERMINATED,INTERVENTIONAL,['PHASE2']
8482,NCT01427920,Change in HbA1c (Glycosylated Haemoglobin) - PP,Patient Reported Outcomes Evaluated: Treatment-Related Impact Measures for Diabetes (TRIM-D) - Total Score,,2011-09,COMPLETED,INTERVENTIONAL,['PHASE4']
8483,NCT04464694,Early postoperative vitreous haemorrhage,Mean Best-corrected visual acuity (BCVA) at Month 6,,2020-09-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
8484,NCT05707481,Change in Health related Quality of Life,"Change in Patients health related Knowledge, Attitude and Practice",,2023-08-22,RECRUITING,INTERVENTIONAL,['NA']
8485,NCT03109587,Change in microbiota composition,Change in inflammation in the gut,,2018-06-01,COMPLETED,INTERVENTIONAL,['NA']
8486,NCT05169060,Change from baseline of omega-3 index at 16 and 24 weeks,Change from baseline in urine microalbuminuria levels after 16 and 24 weeks.,,2023-06-12,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8487,NCT05917249,Change of the perfusion index at the end of the first session compared to baseline readings.,The total remission rate,,2023-06-07,COMPLETED,INTERVENTIONAL,['NA']
8488,NCT01724190,IDAA1c,,,2012-11,COMPLETED,INTERVENTIONAL,['NA']
8489,NCT03184337,Change in body mass index,Change in self-assessed general health,,2017-04-24,COMPLETED,INTERVENTIONAL,['NA']
8490,NCT03956927,Organizational advantages and limitations,,,2019-05-24,COMPLETED,OBSERVATIONAL,['NA']
8491,NCT05326490,Change in HbA1c,,,2022-05-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
8492,NCT04917458,Evaluating the effects of cholecalciferol for depression symptoms with BDI II score,Evaluating the effects of cholecalciferol against C-Peptide,,2021-01-18,UNKNOWN,INTERVENTIONAL,['PHASE2']
8493,NCT04102202,To evaluate the effect of BOL-DP-o-05 on preservation of beta-cell function,To assess the percent of subjects who require a daily insulin dose < 0.5 IU/kg body weight,,2020-11-15,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8494,NCT03444363,Laboratory findings,Clinical findings,,2013-09-20,COMPLETED,INTERVENTIONAL,['NA']
8495,NCT03118050,Amino acid transporter expression,Muscle protein synthesis,,2017-05-28,COMPLETED,INTERVENTIONAL,['NA']
8496,NCT01504412,Mean Change in Average Daily Pain Score From Baseline Among Participants Who Received DS5565 for Pain Associated With Diabetic Peripheral Neuropathy,Mean Change in Short Form-McGill Pain Questionnaire From Baseline Among Participants Who Received DS5565 for Pain Associated With Diabetic Peripheral Neuropathy,,2012-01,COMPLETED,INTERVENTIONAL,['PHASE2']
8497,NCT00398892,HbA1c change for lipoic acid vs placebo,Urine ACR change for lipoic acid vs placebo,,2009-12,UNKNOWN,INTERVENTIONAL,['PHASE2']
8498,NCT04666987,Change in Glycated Haemoglobin (HbA1c),Treatment simplification (decrease in insulin dose or number of concomitant OADs) (yes/no),,2020-10-21,COMPLETED,OBSERVATIONAL,['NA']
8499,NCT00027456,,,,2001-11,COMPLETED,INTERVENTIONAL,['PHASE2']
8500,NCT01406496,Post-prandial blood glucose excursions following three different meals and three different timings of insulin bolus.,,,2011-08,UNKNOWN,INTERVENTIONAL,['NA']
8501,NCT01671306,,,,2011-01,COMPLETED,OBSERVATIONAL,['NA']
8502,NCT04889183,Change from baseline to week 24 in urinary albumin:creatinine ratio (UACR),high sensitivity C-reactive protein (CRP),,2022-03-14,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE3']
8503,NCT02241889,Percent of Time With Sensed Glucose Between 70-180 mg/dl,Percent of Time of CBG>180 mg/dl,,2015-01,COMPLETED,INTERVENTIONAL,['NA']
8504,NCT03884920,HB-A1c,Lipid Profile,Kidney Function,2019-03-20,COMPLETED,OBSERVATIONAL,['NA']
8505,NCT00697450,Weight effect,Improvement in HbA1c levels,,2008-07,COMPLETED,OBSERVATIONAL,['NA']
8506,NCT04198935,Adherence to the the program,,,2020-05,UNKNOWN,INTERVENTIONAL,['NA']
8507,NCT02046395,Change in Urine Microalbumin Creatinine Ratio,Change in the Level of Urinary Free Light Chains,,2012-01,COMPLETED,INTERVENTIONAL,['PHASE4']
8508,NCT03143803,Mean amplitude glycemic excursion,Number of hypoglycemia episodes,,2017-05-05,COMPLETED,INTERVENTIONAL,['NA']
8509,NCT00268645,"For efficacy: FBG (Fasting Blood Glucose), HbA1c",For safety: ICA (Insulin Cell Antibody),,2004-09,COMPLETED,INTERVENTIONAL,['PHASE4']
8510,NCT02290418,Composite measure of success of bariatric surgery as measured by Bariatric Analysis and Reporting Outcome System (BAROS),"Change in Quality of Life, as measured by Moorehead-Ardelt Questionnaire II","Change in Body Mass Index (BMI), measured in kg/m2",2012-01,UNKNOWN,INTERVENTIONAL,['NA']
8511,NCT00973726,"Changes in amplitude/implicit times, changes in dark adaptation, changes in vessel caliber, changes in Optical coherence tomography (OCT)",,,2009-09,UNKNOWN,INTERVENTIONAL,['NA']
8512,NCT00144144,Clinical laboratory data,Changes in BNP· Changes in hs-CRP· Medical cost-effectiveness,,2004-09,UNKNOWN,INTERVENTIONAL,['PHASE4']
8513,NCT00264589,cardiac function at rest and during exercise,substrate utilization during exercise,,2005-12,COMPLETED,INTERVENTIONAL,['PHASE4']
8514,NCT03766620,Body Weight Change,Albumin Levels,Physician Product Satisfaction,2018-11-29,COMPLETED,OBSERVATIONAL,['NA']
8515,NCT01481675,Diabetes resolution at 12 months after surgery,Changes in PYY response to glucose,,2007-05,COMPLETED,OBSERVATIONAL,['NA']
8516,NCT02590016,Neonatal hypoglycemia,Proportion of participants needing insulin-glucose-infusion in the observational arm,,2015-09,UNKNOWN,INTERVENTIONAL,['PHASE4']
8517,NCT01128205,"The proportion adequate control of blood glucose, blood glucose and blood pressure or blood glucose and blood lipid, and blood glucose, blood pressure and blood lipid.",,,2010-06,COMPLETED,OBSERVATIONAL,['NA']
8518,NCT01089569,HbA1c Change,Change From Baseline in Weight Changes,,2010-04,COMPLETED,INTERVENTIONAL,['NA']
8519,NCT00810992,Body mass index,Intima media thickness HbA1C Lipid status Platelet activation markers as prognostic biomarkers,,2009-01,COMPLETED,INTERVENTIONAL,['NA']
8520,NCT03138447,Basal Insulin Dose,Office Contacts,,2017-03-30,COMPLETED,INTERVENTIONAL,['NA']
8521,NCT06144593,24-hour average sensor glucose,Fasting plasma concentrations of triacylglycerols,Explorative outcomes - Qualitative evaluation to assess feasibility of the dietary strategy,2024-01,RECRUITING,INTERVENTIONAL,['NA']
8522,NCT03853941,Change in healthcare professionals' communication style,Fidelity of delivery,,2019-03-21,COMPLETED,INTERVENTIONAL,['NA']
8523,NCT01880736,Change From Baseline in HbA1c (%) Glycosylated Haemoglobin),Number of Treatment Emergent Nocturnal (00:01-05:59 am) Confirmed Hypoglycaemic Episodes in the Maintenance Period,,2013-06,COMPLETED,INTERVENTIONAL,['PHASE3']
8524,NCT03770052,HbA1c at 24 week,total bilirubin,,2018-10-24,COMPLETED,INTERVENTIONAL,['PHASE4']
8525,NCT04005430,The primary outcome measure of the study is safety assessment.,Secondary outcome are assessment of anatomical changes in the macula as measured via optical coherence tomography (OCT).,,2019-04-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
8526,NCT05496907,Effectiveness of Intervention using HbA1c levels,Mental Health Outcome,,2022-07-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
8527,NCT04422145,All cause mortality at study endpoint with each participant having a minimum follow up of 12 months and the final analysis of data being done 58 months after the first participant was recruited (this is study endpoint.),Assessment of differences in mortality rate between type 1 and type 2 diabetes participants,,2013-02-01,COMPLETED,INTERVENTIONAL,['NA']
8528,NCT04285450,Homeostasis model assessment of insulin resistance (HOMA-IR),,,2019-10-27,COMPLETED,INTERVENTIONAL,['NA']
8529,NCT03648138,Hypothetical beverage choice,Negative reactions to the label,,2020-01-17,COMPLETED,INTERVENTIONAL,['NA']
8530,NCT04016987,changes in serum hemoglobin A1c level,Adverse events,,2020-09-08,UNKNOWN,INTERVENTIONAL,['NA']
8531,NCT05102149,Change in HbA1c,,,2021-09-30,RECRUITING,INTERVENTIONAL,['PHASE3']
8532,NCT00602472,HbA1c Change From Baseline to Week 24,Percentage of Patients Who Have a HbA1c Lowering by 0.5% at Week 24,,2008-02,COMPLETED,INTERVENTIONAL,['PHASE3']
8533,NCT03998046,Number of Participants Who Achieved 5% Weight Loss Goal at 6 Months,Number of Participants Who Achieved 5% Weight Loss Goal in 12 Months,,2019-12-16,COMPLETED,INTERVENTIONAL,['NA']
8534,NCT04016584,"Success (evaluated by a Yes/No format) recruiting and completing a new targeted diabetes and insulin education program, Diabetes Pueblo, for Latino adults with type 2 diabetes.",Participant evaluation of Diabetes Pueblo evaluated by questionnaire,"Menopausal status, pregnancy status, and gestational diabetes history for women determined by questionnaire",2019-05-10,COMPLETED,INTERVENTIONAL,['NA']
8535,NCT02280564,Change from Baseline in HbA1c at 4 months,Change from Baseline in Quality of Life measures at 4 months,,2011-03,COMPLETED,INTERVENTIONAL,['NA']
8536,NCT04157738,Caregiver Treatment Adherence at 1 Month and 4 Months Post-intervention,Glycemic Variability (GV) at 1 Month and 4 Months Post-intervention,,2019-11-27,COMPLETED,INTERVENTIONAL,['PHASE4']
8537,NCT05337826,The co-primary implementation outcomes,Diabetes health related quality of life measures,,2022-04-20,RECRUITING,INTERVENTIONAL,['NA']
8538,NCT06303453,PainDETECT Tool,,,2024-02-25,RECRUITING,INTERVENTIONAL,['NA']
8539,NCT05833958,Change in glycosylated haemoglobin (HbA1c),Medication tolerability,,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
8540,NCT03334175,Palatability of Supplement,Change in Low Density Lipoprotein Levels,Number of Participants Who Had Plasma Metabolomics Performed,2018-05-21,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8541,NCT01068678,Change in Glycosylated Haemoglobin (HbA1c),Change in Body Weight,,2010-02,COMPLETED,INTERVENTIONAL,['PHASE3']
8542,NCT01823458,Attendance at exercise classes,LDL cholesterol,,2012-04,COMPLETED,INTERVENTIONAL,['NA']
8543,NCT00285233,"Monitor the incidence, timing, and severity of adverse events as well as their relationship to the islet transplant procedure and additional protocol-regulated treatment products during the first year after islet transplantation.","Assess, in a selected group of islet allotransplant recipients, the autoimmune and alloimmune responses to transplanted islets at intervals during the first year posttransplant.",,2000-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8544,NCT05118217,Dynamic Vessel Analysis,Body Mass Index,,2021-11-18,UNKNOWN,OBSERVATIONAL,['NA']
8545,NCT01828229,Insulin sensitivity,visceral adiposity,aerobic fitness,2009-01,COMPLETED,INTERVENTIONAL,['NA']
8546,NCT01488279,Insulin Sensitivity,Change in Insulin Secretion (AIRg or Acute Insulinogenic Response to Glucose),,2012-09,COMPLETED,INTERVENTIONAL,['NA']
8547,NCT00737815,Fasting insulin,Gene Expression,,2007-06,COMPLETED,INTERVENTIONAL,['NA']
8548,NCT03414216,Any recurrence of any ulcer at same location,,,2018-03-01,UNKNOWN,INTERVENTIONAL,['NA']
8549,NCT04653779,The preference regarding convenience of medication,TSQM-9 scores,,2020-12,UNKNOWN,INTERVENTIONAL,['PHASE4']
8550,NCT02998970,Left Ventricular (LV) mass Changes,Plasma catecholamine levels,,2017-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
8551,NCT01699737,Change in glycosylated hemoglobin (HbA1c) after administration of JTT-851,Pharmacokinetics of JTT-851 and its metabolites,Relationship between dose and response of JTT-851,2012-09,COMPLETED,INTERVENTIONAL,['PHASE2']
8552,NCT04114682,Magnetic Resonance Imaging metrics for liver fibro-inflammation in patients with type 2 diabetes,longer term evaluation of clinical outcomes,,2020-01-27,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
8553,NCT01181453,Complete wound closure,Percent of wound closure by study end,,1998-12,COMPLETED,INTERVENTIONAL,['PHASE3']
8554,NCT04403841,Disease awareness,,,2017-08-01,COMPLETED,INTERVENTIONAL,['NA']
8555,NCT00306384,Percentage of Participants With Treatment-emergent Adverse Events (TEAEs),Percentage of Participants With a Clinical Response,,2006-03,COMPLETED,INTERVENTIONAL,['PHASE3']
8556,NCT05343624,Time in Range,Hypoglycemia,,2020-06-18,COMPLETED,INTERVENTIONAL,['NA']
8557,NCT01322789,Safety,Immunologic reconstitution parameters,,2008-09,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8558,NCT01987206,time spent in safe blood glucose range,glucose level extremes and need for outside intervention,,2014-07,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
8559,NCT01022658,"Vago-sympathetic activity, arterial stiffness, endothelial function",,,2010-01,COMPLETED,INTERVENTIONAL,['NA']
8560,NCT00683657,Change From Baseline in 24-Hour Mean Weighted Glucose (MWG) at Week 4,Change From Baseline in 2-Day Average Fasting Plasma Glucose (FPG) at Week 4,,2008-07,COMPLETED,INTERVENTIONAL,['PHASE3']
8561,NCT00546351,Number of Participants Experiencing the Occurrence of at Least One Serious Adverse Event (SAE) During the Evaluation Period From Entry Visit 1 Through End of Treatment (Approximately 6.5 Years).,Average Quality of Life Using the SF-36 Health Survey - Mental Component Summary (MCS) at Last Visit.,,2004-05,COMPLETED,INTERVENTIONAL,['PHASE3']
8562,NCT06001801,Change in weight,Change in reported diet quality,,2023-09-18,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
8563,NCT00184821,,,,2004-06,COMPLETED,OBSERVATIONAL,['NA']
8564,NCT02948673,Insulin sensitivity,Mitochondrial reactive oxygen species production,,2016-05,COMPLETED,INTERVENTIONAL,['NA']
8565,NCT05179135,Change in blood glucose during exercise,Plasma growth hormone area under the curve during exercise and in the recovery period after the exercise session.,,2022-01-19,COMPLETED,INTERVENTIONAL,['NA']
8566,NCT03949582,Blood insulin,Energy intake 72 hours post study visit,,2019-05-01,UNKNOWN,INTERVENTIONAL,['NA']
8567,NCT01736865,Disposition Index,Number of Participants With Change in Glycemia,Effect of Vitamin D Supplementation on Plasma Concentrations of Surrogate Biomarkers of Cholesterol Absorption (Campesterol and β-sitosterol) and Endogenous Synthesis (Lathosterol and Desmosterol),2012-12,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
8568,NCT01065298,Reduction of insulin requirement by ≥ 50% by the end of 6 months of ABMSCT and Improvement in Glucagon stimulated C - peptide levels .,Any reduction in requirement of insulin dosage and any improvement of HbA1c levels as compared to controls.,,2009-11,COMPLETED,OBSERVATIONAL,['NA']
8569,NCT01402037,evaluate the hyperglycemic clamp to measure the functional beta cell mass test,evaluate the continuous glucose monitoring to measure within- and between-day glycemic variability,,2011-07,UNKNOWN,INTERVENTIONAL,['NA']
8570,NCT00641251,LDL cholesterol < 100 mg/dl,,,2008-02,COMPLETED,INTERVENTIONAL,['NA']
8571,NCT03025984,compliant diabetes care,,,2016-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
8572,NCT06047262,Change in HbA1c in blood of patients for dapansutrile compared to placebo,Change in fasting plasma glucose for dapansutrile compared to placebo,,2023-11,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
8573,NCT02813421,Percentage Time Within Target Blood Glucose (Range: 70-180 mg/dL),Number of Participants With Satisfaction of Transition to Pump Therapy,,2016-03,COMPLETED,INTERVENTIONAL,['NA']
8574,NCT01055223,Number of Low Impact Fractures in Males and Females After 12 Months of Exposure to TZD,Number of Hip Fractures Combined in Males and Females After 12 Months of Exposure to TZD,,2009-05,COMPLETED,OBSERVATIONAL,['NA']
8575,NCT00824668,,,,2007-08,COMPLETED,INTERVENTIONAL,['PHASE1']
8576,NCT01693406,Change in infant percent body fat from birth to 4 months,Change in Antioxidant capacity of human milk,Change in Human Milk Nutrient Composition,2012-08,COMPLETED,OBSERVATIONAL,['NA']
8577,NCT03573856,Change from 0 to 12 months in fasting insulin,Change from 0 to 12 months in fasting glucose,Potential for sustained delivery,2018-07-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
8578,NCT04591782,Impact of gut microbiome in glycemic response to pom juice vs. sugar water,,,2019-02-01,COMPLETED,INTERVENTIONAL,['NA']
8579,NCT03789578,"AUCSema,0-tz, area under the plasma semaglutide concentration-time curve from 0 hours to last quantifiable observation after a single dose",Binding antibodies and in vitro neutralising antibodies (semaglutide only): Occurrence of anti-semaglutide neutralising antibodies cross reacting with endogenous GLP-1,,2019-01-17,COMPLETED,INTERVENTIONAL,['PHASE1']
8580,NCT01195532,"AUC0-t, AUC0-∞, Cmax, Tmax, T1/2, and MRT in plasma will be determined with gliclazide concentrations by non-compartment methods.",,,2010-01,UNKNOWN,OBSERVATIONAL,['NA']
8581,NCT01058577,"plasma ion concentrations (sodium, potassium, chloride, calcium, magnesium) and osmolarity",blood glucose concentration,,2001-12,COMPLETED,INTERVENTIONAL,['PHASE1']
8582,NCT01768611,Plasmatic Creatinine,,,2004-10,COMPLETED,OBSERVATIONAL,['NA']
8583,NCT03558867,"Mean change in glycated haemoglobin (HbA1C, %) from baseline",Liver fat,Gut microbiome (exploratory),2018-06-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
8584,NCT04025853,Evaluate the effectiveness of biomarkers to differentiate osteomyelitis from deep soft tissue infections in patients with diabetic foot ulcers.,,,2015-06,COMPLETED,OBSERVATIONAL,['NA']
8585,NCT01298245,The differences in the distribution of candidate genotypes and alleles between the study groups,the frequencies of haplotypes of different single nucleotide polymorphisms,,2011-02,UNKNOWN,OBSERVATIONAL,['NA']
8586,NCT01384045,Composite Measure of Guideline Concordance,Individual measures of guideline concordance,,2009-02,COMPLETED,INTERVENTIONAL,['NA']
8587,NCT00965458,2-Hour C-peptide Area Under the Curve (AUC) Result in Response to Standardized Mixed Meal Tolerance Test (MMTT),Hemoglobin A1c,,2011-03,TERMINATED,INTERVENTIONAL,['PHASE2']
8588,NCT05747352,Glucose time,Glucose time,,2023-06-05,COMPLETED,OBSERVATIONAL,['NA']
8589,NCT00622856,consumption of health services,Changes in the wellbeing of adolescents and their parents,,2008-02,COMPLETED,INTERVENTIONAL,['NA']
8590,NCT01513590,Change From Baseline in HbA1c (Glycosylated Haemoglobin),Number of Treatment Emergent AEs (Adverse Events),,2012-01-16,COMPLETED,INTERVENTIONAL,['PHASE3']
8591,NCT02700503,Subject's BMI calculation Charted on CDC Stature for Age and Weight for Age Percentiles chart,Dietary records,,2015-11,COMPLETED,INTERVENTIONAL,['NA']
8592,NCT04743856,Change from baseline in Step counts at 12 months,Triglycerides over all timepoints for 12 months,,2022-03-29,RECRUITING,INTERVENTIONAL,['NA']
8593,NCT06077461,State-Trait Anxiety Scale,,,2023-12-01,RECRUITING,INTERVENTIONAL,['NA']
8594,NCT03206827,Changes in the intake of nutrients and nutritional status of participants as a measure of diet modification,Genotoxicity testing of human fecal water in 2D and 3D cell cultures,,2016-11-29,COMPLETED,INTERVENTIONAL,['NA']
8595,NCT01324739,glucose,"insulin, c-peptide",,2010-05,COMPLETED,INTERVENTIONAL,['NA']
8596,NCT01927315,Circulating progenitor cells,Triglycerides,,2013-08,COMPLETED,INTERVENTIONAL,['PHASE4']
8597,NCT04380844,Diabetes Knowledge Questionnaire,,,2021-02-01,UNKNOWN,INTERVENTIONAL,['NA']
8598,NCT01530347,correlation between the acetone values generated by study device and oxygen,Clarke Error Grid (segment 1 only),,2012-03,TERMINATED,INTERVENTIONAL,['PHASE1']
8599,NCT03907202,Safety laboratory parameter - urinalysis.,Fridericia's corrected QT interval (QTcF).,,2018-04-17,TERMINATED,INTERVENTIONAL,['PHASE1']
8600,NCT03313960,Hemoglobin A1c,Health-related Quality of Life,,2017-10-05,UNKNOWN,INTERVENTIONAL,['PHASE4']
8601,NCT02214056,Percentage of eligible patients who actually received the mobile team exam,GP and patient acceptability of the mobile team exam,,2015-02,COMPLETED,OBSERVATIONAL,['NA']
8602,NCT02328599,Change in HbA1c,HbA1c < 6.5%,change in albuminuria,2018-04-10,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
8603,NCT02059564,PK profile of acetaminophen,Safety and tolerability,,2013-12,UNKNOWN,INTERVENTIONAL,['PHASE1']
8604,NCT03314714,Assessment of intramyocellular lipid composition via mass spectrometry,,,2017-04-03,COMPLETED,INTERVENTIONAL,['NA']
8605,NCT01978925,Medication Adherence,Quality of Life,Fasting plasma glucose for diabetic patients,2013-11,COMPLETED,INTERVENTIONAL,['NA']
8606,NCT01939366,Change in Average Pain Intensity.,,,2013-09-27,COMPLETED,INTERVENTIONAL,['PHASE2']
8607,NCT00830791,Plasma AUC (0-infinity) After Administration of a Single Oral Dose of 5 mg of MK-0941 Among Participants With Severe Renal Insufficiency vs Matched Controls,Plasma Glucose Concentration After Administration of a Single Oral Dose of 5 mg of MK-0941 to Participants With Severe Renal Insufficiency Versus Matched Controls,,2009-01,TERMINATED,INTERVENTIONAL,['PHASE1']
8608,NCT01567033,Body Mass Index,Survey,,2012-04-26,COMPLETED,INTERVENTIONAL,['NA']
8609,NCT05015738,"Instructional Materials Motivation Survey (IMMS), 10. week (after the course finished)","Opinion Form on Diabetes Education Program supported by digital tools, for only experimental group, 10. week (at the end of the course)",,2020-10-01,COMPLETED,INTERVENTIONAL,['NA']
8610,NCT01241474,Change in insulin sensitivity assessed by hyperinsulinemic-euglycemic-eu-aminoacidemic clamp,Change in plasma inflammatory markers,,2009-02,COMPLETED,INTERVENTIONAL,['NA']
8611,NCT02206919,Popliteal FMD MRI technique correlates with albuminuria in those with early diabetic disease,Dietary risk factors related to chronic disease,,2014-06,UNKNOWN,OBSERVATIONAL,['NA']
8612,NCT05333718,clusters of type 2 diabetes,Metabolomics and genetic profile related to diabetes,,2022-03-08,RECRUITING,OBSERVATIONAL,['NA']
8613,NCT02299388,Change in Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitors.,"Change in Pulse Pressure, Mean Arterial, Diastolic and Nocturnal Blood Pressures.",Change in Urinary Sodium Excretion,2014-10,COMPLETED,INTERVENTIONAL,['PHASE4']
8614,NCT01753024,Screening and risk factors of exocrine pancreatic insufficiency in critically ill adult patients receiving enteral nutrition,Effects of pancreatic enzyme supplementation on nutritional status and clinical outcomes in critically ill patients with sepsis,,2012-01,COMPLETED,OBSERVATIONAL,['NA']
8615,NCT03906786,Adherence to self-care behaviors. The Diabetes Self-Care Inventory-Revised,,,2019-03-07,UNKNOWN,INTERVENTIONAL,['NA']
8616,NCT00423501,Absolute change from baseline in HbAlc,"AEs, laboratory parameters, primary pharmacokinetic parameters",,2007-02,COMPLETED,INTERVENTIONAL,['PHASE2']
8617,NCT05473286,Change in Glycated haemoglobin (HbA1c ),"Diabetes Treatment Satisfaction Questionnaire, status (DTSQs), change in absolute treatment satisfaction",,2022-09-30,WITHDRAWN,OBSERVATIONAL,['NA']
8618,NCT04141878,Change in DDPP Neuropsychological Test Battery,Change in Glycated Hemoglobin (Hemoglobin A1C),,2021-05-26,RECRUITING,INTERVENTIONAL,['NA']
8619,NCT00787839,"Ability of Different Screening Tests Which Can be Performed Opportunistically (During Outpatient Visits -- at Any Time of Day, Regardless of Meal Status) to Predict Findings With the Oral Glucose Tolerance Test (in the Morning, After an Overnight Fast)",Cost to Identify a Single Case of High-risk Dysglycemia or Previously Unrecognized Diabetes,,2009-06,COMPLETED,OBSERVATIONAL,['NA']
8620,NCT00379379,"Hypoglycemic activity, plasma insulin level, HOMA index","Triglyceride, cholesterol, free fatty acid",,2005-01,COMPLETED,INTERVENTIONAL,['NA']
8621,NCT00440375,"metabolic bone markers before and after the intervention,",association between the changes in bone turnover parameters and plasma cytokine levels,,2005-06,COMPLETED,INTERVENTIONAL,['PHASE4']
8622,NCT02659748,Insulin sensitivity,Bacterial microbiota,,2014-01,UNKNOWN,INTERVENTIONAL,['NA']
8623,NCT03412006,Change in urinary albumin to creatinine ratio (UACR),Number of patients with serious adverse events,,2018-02-02,COMPLETED,INTERVENTIONAL,['PHASE2']
8624,NCT06132477,Effect of GLP1-RA on Glycemic control,,,2024-02-01,RECRUITING,INTERVENTIONAL,['PHASE4']
8625,NCT03934944,Change in foot care behaviour as measured by the SDSCA,Proportion of participants who developed a new diabetic foot ulcer,,2019-02-10,UNKNOWN,INTERVENTIONAL,['NA']
8626,NCT02692547,Descriptive endpoints,Descriptive endpoints,,2016-02,WITHDRAWN,INTERVENTIONAL,['NA']
8627,NCT04266379,Difference in percent of time spent with blood glucose level below 70 mg/dL,Weight and Body Mass Index (BMI),,2020-05-13,UNKNOWN,INTERVENTIONAL,['NA']
8628,NCT05994937,Percent Change in Concentration of Tumor Necrosis Factor-alpha (TNFα) Biomarkers,,,2023-12-26,RECRUITING,INTERVENTIONAL,['NA']
8629,NCT05198284,Referrals,,,2021-11-01,RECRUITING,OBSERVATIONAL,['NA']
8630,NCT00935051,"MMP-1/TIMP-1 ratio at Week 0 assessed by ELISA and percent change in wound area of diabetic foot ulcer between week 0, week 4 and week 12","Correlation between MMP9, MMP13, MMP9/TIMP1 and MMP13/ TIMP1 ratios and wound healing expressed by the percent change in wound area between week 0, week 4 and week 12.",,2009-05,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
8631,NCT00206401,HbA1C,Glucose excursions,,2004-11,COMPLETED,INTERVENTIONAL,['PHASE4']
8632,NCT02053272,Change from baseline to the end of treatment in mean glycosylated haemoglobin A1c (HbA1c) level.,Change from baseline to the end of study in mean Cannabis Withdrawal Scale (CWS) total score.,,2014-02,COMPLETED,INTERVENTIONAL,['PHASE2']
8633,NCT02027753,Response rate (percentage of patients who meet the target HbA1c ≤7%) at week 24 (6 months) after adding insulin therapy,Number of Patients with Adverse Events,,2013-12,COMPLETED,INTERVENTIONAL,['PHASE4']
8634,NCT04461821,Change in Concentration of exhaled metabolites of pharmacotherapy,"Change in clinical endpoint (blood pressure, mmHg) for correlation between clinical endpoint and the abundance of exhaled metabolites",,2020-09-11,RECRUITING,OBSERVATIONAL,['NA']
8635,NCT04837989,Social Comparison Scale,Brief Illness Perception Questionnaire,,2021-02-01,TERMINATED,INTERVENTIONAL,['NA']
8636,NCT00093015,Time to All-cause Mortality or End Stage Renal Disease (ESRD),Time to Hospitalization Due to Acute Myocardial Ischemia,,2004-08-01,COMPLETED,INTERVENTIONAL,['PHASE3']
8637,NCT04351945,Endocrine changes and their correction in heart and lung tranplant donors,Evidence of clinically definite postoperative complications,,2020-05-20,UNKNOWN,OBSERVATIONAL,['NA']
8638,NCT02235935,OCT results,Visual Acuity,,2014-09,UNKNOWN,OBSERVATIONAL,['NA']
8639,NCT02131896,lipid profile,Endothelial function,,2014-12-01,TERMINATED,INTERVENTIONAL,['NA']
8640,NCT03640988,"Skin perfusion, effect on oxygenation level, by visit","Wound healing, effect on wound closure, by visit",,2019-04-25,TERMINATED,INTERVENTIONAL,['NA']
8641,NCT02420470,"Functional and structural connectivity relationships of multiple brain regions and biomarkers of brain alterations, and the changes in relationships and biomarkers at 2.5 years.",Lifestyle and its changes at 2.5 years,,2015-04,RECRUITING,OBSERVATIONAL,['NA']
8642,NCT01751932,Mean Absolute Relative Difference (MARD),Accuracy of sensors per glycemic range and trial phase,,2013-01,COMPLETED,INTERVENTIONAL,['NA']
8643,NCT01733758,"Mean HbA1c at Baseline, Week 24, and Change From Baseline at Week 24",Time to Study Withdrawal for Any Reason,,2013-02,COMPLETED,INTERVENTIONAL,['PHASE3']
8644,NCT04699734,Indication of pain relieved extremity,Distribution of evoked pain,,2020-09-08,RECRUITING,INTERVENTIONAL,['NA']
8645,NCT00428961,,,,2002-07,COMPLETED,OBSERVATIONAL,['NA']
8646,NCT02804165,Identification of gene-enterovirus interaction effect on T1D onset,"""Precipitating"" effect of enterovirus infection on T1D.",,2017-01,WITHDRAWN,INTERVENTIONAL,['NA']
8647,NCT04289753,Diabetes Overtreatment in the Elderly,Rate of Hypoglycemia Requiring Urgent Care Among Previously Tightly Controlled,Diabetes Overtreatment in the Elderly by Ethnicity,2020-09-01,COMPLETED,INTERVENTIONAL,['NA']
8648,NCT05032001,Change from baseline in visceral fat measured by bioimpedance in kg at weet twelve,,Change from baseline in A1c level at week twelve,2021-08-01,UNKNOWN,INTERVENTIONAL,['NA']
8649,NCT01387984,,,,2010-04,COMPLETED,OBSERVATIONAL,['NA']
8650,NCT00694057,To evaluate the safety and tolerance of HE3286 10 mg per day (5 mg BID) compared to placebo from baseline to week 12.,To evaluate the effect of HE3286 on insulin sensitivity over time.,,2008-06,COMPLETED,INTERVENTIONAL,['PHASE2']
8651,NCT01311401,New incidences of Type II Diabetes Mellitus in Circassians minority in Israel,,,2009-10,UNKNOWN,OBSERVATIONAL,['NA']
8652,NCT01768403,"Number and percentage of subjects achieving the LDL-C goals, according to the Third Joint European Task Force (TJETF) guidelines.","The association between achievement of LDL-C goals, according to the Third Joint European Task Force / NCEP ATP III / 2004 updated NCEP ATP III guidelines, and patient and physician variables, assessed by multivariate logistic regression models",,2010-09,COMPLETED,OBSERVATIONAL,['NA']
8653,NCT02703324,Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Curve From Time Zero to 5 Hours (AUC[0-5h]),Pharmacodynamics (PD): Area Under the Concentration Curve From Time Zero to 5 Hours (AUC[0-5h]) of Glucose Relative to a Mixed Meal Tolerance Test (MMTT),,2016-03,COMPLETED,INTERVENTIONAL,['PHASE1']
8654,NCT00762190,Left ventricular mass index by body surface area measured by echocardiogram.,"Change from Baseline in apolipoproteins (AI, B).",,2003-11,TERMINATED,INTERVENTIONAL,['PHASE3']
8655,NCT00282659,"Blood pressure, cardiac output, systemic vascular resistance, thoracic fluid content, total cholesterol, low density lipoprotein, high density lipoprotein, triglycerides, and blood glucose",,,2006-01,COMPLETED,INTERVENTIONAL,['PHASE4']
8656,NCT01099865,,,,2009-12,COMPLETED,OBSERVATIONAL,['NA']
8657,NCT02010528,parental diabetes-related distress,psychosocial characteristics,objective measures,2013-12,COMPLETED,OBSERVATIONAL,['NA']
8658,NCT01044537,Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf),Change From Baseline in Ratio of Insulin Area Under Curve (Insulin AUC) to Glucose Area Under Curve (Glucose AUC) After a Mixed Meal Tolerance Test (MMTT) on Day 1,,2010-02,COMPLETED,INTERVENTIONAL,['PHASE1']
8659,NCT04831606,Percentage of healed lesions on the total lesions treated for each arm,Healing time,Evaluation of cost-effectiveness of using EmoLED for the treatment of ulcers,2021-07-31,RECRUITING,INTERVENTIONAL,['NA']
8660,NCT02438943,Proportion of persons attending health centers in the Southeast Health region with normal lipid values,Proportion of persons attending health centers in the Southeast Health region with normal blood pressure values,,2014-02,UNKNOWN,INTERVENTIONAL,['NA']
8661,NCT02440555,Sensitivity of detection of type 2 diabetes,To evaluate the numbers of patients screened by self-administered questionnaire and diagnosed as diabetics using fasting glucose.,,2014-11,COMPLETED,OBSERVATIONAL,['NA']
8662,NCT04773834,Body Mass Index (BMI) (kg/m2),dDPP platform meal log (food item and calories/day),,2021-02-01,RECRUITING,INTERVENTIONAL,['NA']
8663,NCT00422058,Mean Change From Baseline in Body Weight at Week 20,Change From Baseline in Blood Pressure at Week 104,,2007-01-10,COMPLETED,INTERVENTIONAL,['PHASE2']
8664,NCT05717205,mucosal nerve length density (MNLD),Immunohistochemical differences,,2023-02-16,RECRUITING,INTERVENTIONAL,['NA']
8665,NCT00993824,Hypoglycemia Percentage of Time <70 mg/dL Average by Group,,,2009-09,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
8666,NCT02128932,Change in HbA1c From Baseline,"Subjects Who Achieve HbA1c ≤6.5% (48 mmol/Mol), American Association of Clinical Endocrinologists (AACE)",,2014-08-04,COMPLETED,INTERVENTIONAL,['PHASE3']
8667,NCT05752279,Hospital free days (HFD) up to day-28 after study enrolment,Cumulative potassium replacement,Cost-effectiveness,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
8668,NCT04736225,HbA1C,self-care behavior,,2010-06-01,COMPLETED,INTERVENTIONAL,['NA']
8669,NCT04534439,Mean change in urine albumin to creatinine ratio (UACR) in APX-115 group compared to placebo group,,,2020-08-24,COMPLETED,INTERVENTIONAL,['PHASE2']
8670,NCT04585204,the difference of GDM detection rate of 50 gr- 100 gr OGTT and 75 gr OGTT,,,2020-10-01,UNKNOWN,INTERVENTIONAL,['NA']
8671,NCT02199028,Duration of Insulin Infusion Set Wear as a Measure of the Effect of Hyaluronidase Treatment,Pain Tolerability of Hyaluronidase Injections,,2014-07,COMPLETED,INTERVENTIONAL,['PHASE1']
8672,NCT01065402,The daily blood glucose level will be monitored by the continuous glucose monitoring system (CGMS) device Medtronic MiniMed.,,,2010-02,UNKNOWN,INTERVENTIONAL,['NA']
8673,NCT06127251,Retention Rate in each group,Changes in T2D risk score,Change in the Outcome Expectations for Exercise Scale questionnaires.,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
8674,NCT04215523,"Composite outcome of Stroke, MI, and Mortality",,,2019-07-08,COMPLETED,OBSERVATIONAL,['NA']
8675,NCT02752880,The Percentage Change in HbA1c Level From Baseline to 12 Weeks,The Percentage Change in 2hPG From Baseline to Week 12,,2016-06,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
8676,NCT05324930,Change in DFU size,Complete wound healing,,2021-12-02,COMPLETED,INTERVENTIONAL,['NA']
8677,NCT00955669,Magnetic resonance angiography,,,2009-08,COMPLETED,INTERVENTIONAL,['PHASE1']
8678,NCT06268808,HbA1c,Frequency of hypoglycaemia events,,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
8679,NCT03736785,Change From Baseline in HbA1c,Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) of LY3209590,,2018-11-15,COMPLETED,INTERVENTIONAL,['PHASE2']
8680,NCT02682563,Effective Renal Plasma Flow (ERPF) in ml/Min,Kidney Injury Molecule-1 (KIM-1) in ng/mmol,Systolic Blood Pressure,2016-02,COMPLETED,INTERVENTIONAL,['PHASE4']
8681,NCT05789706,Change from pre-intervention baseline in hemoblobin A1c,Change in Medication Adherence Score from baseline,,2021-03-24,COMPLETED,INTERVENTIONAL,['NA']
8682,NCT00511667,Participants Discontinued Because of Any Clinical Adverse Experience,Concentration of MK-0941 at 24 Hours (C24hr) After Multiple Doses of MK-0941,,2007-05,COMPLETED,INTERVENTIONAL,['PHASE1']
8683,NCT03158415,Lived experience,Diabetes Distress,,2017-05-01,COMPLETED,INTERVENTIONAL,['NA']
8684,NCT04081766,Frequency of total episodes of hypoglycaemia,Time to the first hypoglycaemic attack,,2020-02-09,COMPLETED,INTERVENTIONAL,['NA']
8685,NCT03047486,Glucose Time below range (hypoglycemia < 70 mg/dl) from CGM recording,HbA1c,Medical time at each consultation,2017-02-01,COMPLETED,OBSERVATIONAL,['NA']
8686,NCT03294369,Prevalence of cardiovascular disease,,,2011-04-01,UNKNOWN,OBSERVATIONAL,['NA']
8687,NCT03986073,Glycosylated hemoglobin (HbA1c),GLP-1 (glucagon-like peptide-1),,2020-01-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
8688,NCT03234491,PostPrandial Blood Glucose,Venous Glucose Levels,,2017-11-22,COMPLETED,INTERVENTIONAL,['PHASE1']
8689,NCT00258804,"Patient satisfaction before, during and after Ramadan.",,,2005-05,COMPLETED,INTERVENTIONAL,['PHASE4']
8690,NCT00605449,drug plasma levels of GSK376501:,"GSK376501 Day 7 AUC(0-24), Cmax, tmax and t1/2.",,2008-01,COMPLETED,INTERVENTIONAL,['PHASE1']
8691,NCT01270542,"The Effect of an Anti-VEGF (Vascular Endothelial Growth Factor) Agent, Bevacizumab, on Levels of Vitreous and Aqueous Growth Factor Levels (pg/mL) in Eyes With Traction Retinal Detachment Due to PDR",Improvement of Visual Outcomes in Patients Given Pre-operative Adjunctive Bevacizumab in Eyes Undergoing PDR Surgery.,,2009-06,COMPLETED,INTERVENTIONAL,['NA']
8692,NCT01945996,Acceptability 2: Would Patients Recommend the Program to Family or Friends?,Change in Summary of Diabetes Self-care Activities - Carb Spacing Sub Score,,2013-09,COMPLETED,INTERVENTIONAL,['NA']
8693,NCT02468037,Improvement in glucose area under the curve.,Improvement in insulin secretory capacity,,2012-04,COMPLETED,INTERVENTIONAL,['NA']
8694,NCT05145465,Waist size (cm),,,2021-09-01,UNKNOWN,INTERVENTIONAL,['NA']
8695,NCT03312478,Odds of Type 1 Diabetes Mellitus child having a diabetic parent,Characterization of diabetes education,,2017-10-13,COMPLETED,INTERVENTIONAL,['PHASE4']
8696,NCT03666923,Incidence of dose-limiting toxicities up to the Day 14 visit,Occurrence of laboratory abnormalities up to the end of the study,,2018-09-17,COMPLETED,INTERVENTIONAL,['PHASE1']
8697,NCT03723759,"AUCIAsp,0h-t - Area under the serum insulin aspart concentration-time curve from 0 to t hours after investigational medicinal product (IMP) administration, where t is end of exposure",Number of hypoglycaemic episodes in the treatment emergent period,,2018-10-26,COMPLETED,INTERVENTIONAL,['PHASE1']
8698,NCT02971202,Whole-body Glucose Utilization (Rd),Adipose Tissue Insulin Sensitivity,,2016-12,COMPLETED,INTERVENTIONAL,['PHASE1']
8699,NCT02745808,Safety and Tolerability assessed by Adverse Events,Improvement in penile colour Doppler ultrasonography,,2015-09,UNKNOWN,INTERVENTIONAL,['PHASE1']
8700,NCT06319716,Hemoglobin A1c (HbA1c) Levels,International Physical Activity Questionnaire (IPAQ) Short-Version Score,,2024-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
8701,NCT03983187,the standard deviation of blood glucose,time in range,,2019-06-15,UNKNOWN,INTERVENTIONAL,['NA']
8702,NCT00407849,Safety of intravitreal triamcinolone acetonide after 12 months of treatment.,,,2006-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8703,NCT03217630,Prevalence of full stomach,Mean gastric emptying time of clear liquid and light meal,Risk factors of delayed stomach empty in diabetic patients,2017-07-01,COMPLETED,OBSERVATIONAL,['NA']
8704,NCT05591690,Time spent with glucose levels above range,,,2020-11-01,COMPLETED,OBSERVATIONAL,['NA']
8705,NCT04862923,Change in glycated haemoglobin (HbA1c),"Diabetes Treatment Satisfaction Questionnaire, status (DTSQs), change in absolute treatment satisfaction",,2021-05-12,COMPLETED,OBSERVATIONAL,['NA']
8706,NCT06025513,Standard pharmacokinetics/pharmacodynamics (PK/PD) endpoints as applicable after injection of a rapid-acting mealtime insulin,,,2024-02-16,RECRUITING,INTERVENTIONAL,['NA']
8707,NCT01703286,Change From Baseline in Flow Mediated Vasodilation (FMD) Under Fasted Condition on Day 28,Number of Patients With Adverse Events,,2012-10,COMPLETED,INTERVENTIONAL,['PHASE1']
8708,NCT01648985,"Number of Stroke (fatal, non-fatal)",Number of patients with Diabetes,Number of patients with Small Vessel Disease SVD,2010-05,COMPLETED,OBSERVATIONAL,['NA']
8709,NCT03687580,Incidence of complete (100%) wound closure,Time to complete (100%) wound closure,,2019-02-01,UNKNOWN,INTERVENTIONAL,['NA']
8710,NCT03740581,Number of participants with complete wound closure (epithelialisation) at 12 weeks in both intensive and conventional treatment groups.,Incidence of any amputation.,,2017-11-01,UNKNOWN,INTERVENTIONAL,['NA']
8711,NCT00576784,The proportion of patients with an increase in HbA1c by 0.5 % after 6 months of treatment compared to baseline HbA1c value,Absolute change of HbA1c Insulin resistance according to minimal model and HOMA-S analysis change of insulin resistance according to minimal model and HOMA-S analysis to baseline first phase insulin response,,2005-04,COMPLETED,INTERVENTIONAL,['PHASE4']
8712,NCT05715307,Glycated haemoglobin (HbA1c) control rate,Number of participants with abnormal Renal function,,2023-02-09,RECRUITING,INTERVENTIONAL,['NA']
8713,NCT02059174,M1 Glargine Metabolite PK: Maximum Plasma Concentration (Cmax),M1 Glargine Metabolite PK: Area Under the Plasma Concentration Versus Time Curve Over the Second 12 Hours After Dosing (AUC12-24),,2014-02-10,COMPLETED,INTERVENTIONAL,['PHASE1']
8714,NCT03242018,Change From Baseline in HbA1c at Week 26 Comparing Sotagliflozin 400 mg Versus Placebo,Percentage of Participants With Treatment-emergent Adverse Events (TEAEs),Percentage of Participants With Hypoglycemic Events,2017-08-16,COMPLETED,INTERVENTIONAL,['PHASE3']
8715,NCT04684420,Maximum Observed Plasma Concentration (Cmax) of Metformin,Time to Reach Maximum Observed Plasma Concentration (Tmax) of Metformin,,2020-12-22,COMPLETED,INTERVENTIONAL,['PHASE1']
8716,NCT04577183,Number of Participants With Reduction in Wound Size,,,2018-07-11,COMPLETED,INTERVENTIONAL,['NA']
8717,NCT04827615,Body weight,,,2019-07-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
8718,NCT01272804,Percent Change From Baseline in Glucose Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) at Day 14,Change From Baseline in Lactate Level at Day 6 and 14,,2011-02,COMPLETED,INTERVENTIONAL,['PHASE1']
8719,NCT00926133,The prevalence of abnormal glucose regulation defined by an oral glucose tolerance test (OGTT).,Study the relationship between abnormal glucose regulation and prognosis after STEMI.,,2005-11,UNKNOWN,OBSERVATIONAL,['NA']
8720,NCT05142020,Significantly different proteins at 32-34 gestational weeks,,,2022-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
8721,NCT02754219,Pharmacokinetic(Cmax of Evogliptin),,,2016-09-22,COMPLETED,INTERVENTIONAL,['PHASE1']
8722,NCT01474083,Pharmacokinetic parameters of GK1-399 from plasma concentrations,Pharmacodynamic parameters of plasma glucose,,2011-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8723,NCT00545870,To investigate the change in macular edema and the absolute change in visual acuity. To investigate the change of neovascularisation.,,,2008-06,COMPLETED,INTERVENTIONAL,['PHASE3']
8724,NCT04014413,The efficacy of FMT in treating dysbiosis-associated disorder will be assessed by number of patients who have improvement in clinical symptoms (depends on each disease as stated in outcome),Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0,Any improvement or deterioration or recurrence of the underlying condition by clinical judgement of doctors,2019-07-15,RECRUITING,INTERVENTIONAL,['NA']
8725,NCT03458715,Glycated hemoglobin (HbA1c),Hypoglycemia event,,2017-09-21,UNKNOWN,INTERVENTIONAL,['PHASE4']
8726,NCT05501483,Changes in fat cell lipolysis after 6 months of treatment,Changes in fat cell heterogeneity after 6 months of treatment,Changes in tissue cellularity after 6 months of treatment (explorative outcome),2023-02-08,RECRUITING,INTERVENTIONAL,['NA']
8727,NCT00377117,,,,2006-05,COMPLETED,OBSERVATIONAL,['NA']
8728,NCT03230123,Percent reduction in glycated hemoglobin,Percent increase in GLP-1,,2016-05,UNKNOWN,INTERVENTIONAL,['NA']
8729,NCT04972955,New diagnosis of maternal diabetes or prediabetes based on 75g OGTT,Cost component analysis of CGM vs. 75g OGTT,,2023-07-04,RECRUITING,OBSERVATIONAL,['NA']
8730,NCT03504592,Completeness and accuracy of blood glucose record,Unscheduled health care access episodes,,2018-05-01,COMPLETED,INTERVENTIONAL,['NA']
8731,NCT01821079,Area under the plasma concentration-time profile from time zero extrapolated to infinite time (AUCinf),Plasma Decay Half-Life (t1/2),,2013-03,COMPLETED,INTERVENTIONAL,['PHASE1']
8732,NCT04385758,Diabetes Distress (using DDS),Self-Reported Hypoglycemia and Hyperglycemia,,2020-07-13,COMPLETED,INTERVENTIONAL,['NA']
8733,NCT05742243,Beta-cell function at 48 weeks,Adverse events,,2023-02-13,RECRUITING,INTERVENTIONAL,['PHASE2']
8734,NCT00600626,HbA1c,changes in body weight and vital signs,,2004-01,COMPLETED,INTERVENTIONAL,['PHASE3']
8735,NCT03261362,Clamp test,Mixed Meal Test,,2016-03,COMPLETED,INTERVENTIONAL,['NA']
8736,NCT04235504,HbA1c 6 Months Change Between AHCL and MDI,Hypoglycemic Events,HbA1c 12 Months Change Between Groups,2020-07-13,COMPLETED,INTERVENTIONAL,['NA']
8737,NCT02033239,Area under the glucose infusion rate curve,Maximum observed serum insulin aspart concentration,,2014-01,COMPLETED,INTERVENTIONAL,['PHASE1']
8738,NCT02705053,"Change in Hemoglobin A1c (HbA1c) (%) from baseline (week 2) to end of week 15 (end of study), with A1c measured at weeks 7 and 11 as well for repeated measures.","Time with glucose ≤ 70 mg/dL, overall",,2016-02,COMPLETED,INTERVENTIONAL,['PHASE3']
8739,NCT05293340,"Time in range (TIR) between 140 and 180 mg/dL [TIR (140-180)]- Change from Prior to Intervention, to Final Two Weeks of Intervention",Regression analysis between average composite acceptability score on the weekly Avocado Acceptability Questionnaire and motives underlying the selection of food assessed by the Food Choice Questionnaire (FCQ),,2022-03-31,TERMINATED,INTERVENTIONAL,['NA']
8740,NCT02229110,The number of participants with change in allocation of care after intervention,Number of participants who meet their treatment goals,,2013-10,COMPLETED,INTERVENTIONAL,['NA']
8741,NCT02151188,Glucose response of different treatments,Gastric emptying rate,,2014-03,COMPLETED,INTERVENTIONAL,['NA']
8742,NCT04219514,"Risk scores for severe hypoglycemia, non-severe daytime hypoglycemia, non-severe nighttime hypoglycemia",Exploratory causal estimates of different treatment regimens and hypoglycemia rates,,2020-02-10,COMPLETED,OBSERVATIONAL,['NA']
8743,NCT00073034,,,,2004-01,TERMINATED,INTERVENTIONAL,['PHASE2']
8744,NCT02647320,Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 12,Count of Participants With HbA1c Less Than 7.0% at Week 12,,2016-01,COMPLETED,INTERVENTIONAL,['PHASE2']
8745,NCT03037528,Glycemic Control,Depressive Symptoms,,2017-01-27,COMPLETED,INTERVENTIONAL,['NA']
8746,NCT02379078,Decisional Conflict in Patients With Diabetes,Intention to Engage in Shared Decision-making in Health Care Providers,,2016-03,COMPLETED,INTERVENTIONAL,['NA']
8747,NCT01035528,change from baseline to endpoint in myocardial diastolic velocity E',glucose control,,2005-04,UNKNOWN,INTERVENTIONAL,['PHASE4']
8748,NCT00835757,The difference in means between DTI parameters (FA and MD) measured in the sural nerve between subjects with DPN and healthy control subjects.,The association between DTI parameters and clinical and electrophysiological measures of DPN,,2008-09,COMPLETED,OBSERVATIONAL,['NA']
8749,NCT05884775,Change in Hemoglobin A1C (HbA1c),Total Number of Reports Viewed by Patients via PRO Interactive Dashboard,,2025-02-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
8750,NCT02964247,Change in HbA1c,Subjects Who Achieve Weight Loss by 3% or More,,2017-03-03,COMPLETED,INTERVENTIONAL,['PHASE3']
8751,NCT00537303,Glycosylated Haemoglobin A1c (HbA1c),Cardiovascular Risk Marker: High-sensitivity C-reactive Peptide,,2007-10,COMPLETED,INTERVENTIONAL,['PHASE4']
8752,NCT01781013,Change from baseline in depression outcome at 6-months,Change from baseline in diabetes self-care score in 6 months,Change from baseline to 6 months in percentage of patients satisfied with care received for depression,2010-06,COMPLETED,INTERVENTIONAL,['NA']
8753,NCT01870297,Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,Pharmacodynamics (PD): Change From Baseline to Day 28 in Fasting Glucose,,2013-06,COMPLETED,INTERVENTIONAL,['PHASE1']
8754,NCT01205308,non-cholesterol sterols,,,2010-01,COMPLETED,INTERVENTIONAL,['NA']
8755,NCT01426802,Evaluate the safety and tolerability of vildagliptin 50 mg bid,,,2010-10,COMPLETED,INTERVENTIONAL,['PHASE4']
8756,NCT04956263,Concentration-time curve in plasma glucose (AUC(0-120min) ),Objectives for Insulin Requirements,,2021-06-17,COMPLETED,INTERVENTIONAL,['PHASE2']
8757,NCT02541838,Change in protective stepping as determined by the number of steps it take to recover from a balance perturbation from baseline to 3 months and baseline to 6 months,Change in mobility as measured by the modified physical performance test,,2016-05,TERMINATED,INTERVENTIONAL,['NA']
8758,NCT05867017,Measure of free plasma glucose (FPG),Body Weight,,2023-07-10,RECRUITING,OBSERVATIONAL,['NA']
8759,NCT03061461,Wound size,Satisfaction,,2017-02-23,UNKNOWN,INTERVENTIONAL,['NA']
8760,NCT00437112,"Compare, in insulin-naive patients with type 2 diabetes on one or more oral antihyperglycemic medications, a regimen adding mealtime HIIP versus a regimen adding insulin glargine with respect to change in HbA1c from baseline to endpoint.",Patient reported outcome of Experience with Insulin Therapy Questionnaire,,2007-02,COMPLETED,INTERVENTIONAL,['PHASE3']
8761,NCT00159211,Abdominal adipose tissue (on scan) variation at 6 month,inflammation gene expression in sub-cutaneous fat,,2005-05,TERMINATED,INTERVENTIONAL,['NA']
8762,NCT04630691,No difference,,,2012-12-01,COMPLETED,OBSERVATIONAL,['NA']
8763,NCT00600067,HbA1c Change From Baseline Week 0 to Week 56,Percent Weight Loss From Baseline to Week 56,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE2']
8764,NCT02239458,Oral Disposition Index,,,2015-06,UNKNOWN,INTERVENTIONAL,['NA']
8765,NCT00817505,"Pharmacokinetic variables ( Area under the plasma concentration vs. time curve (AUC), maximum plasma concentration (Cmax), time to reach maximum plasma concentration (tmax), terminal elimination half-life (t½) and apparent oral clearance (CL/F)","Safety Variables (AEs, BP, pulse, electrocardiogram (ECG), hypoglycaemic symptoms and laboratory variables)",,2008-12,COMPLETED,INTERVENTIONAL,['PHASE1']
8766,NCT00558935,measurements of dyslipidemia,lipid functionality,,2007-10,TERMINATED,INTERVENTIONAL,['NA']
8767,NCT00652405,Pancreatic Polypeptide (PP),Cytokines excreted from PBMCs after in vitro stimulation with LPS,,2008-05,COMPLETED,INTERVENTIONAL,['NA']
8768,NCT00248157,long-term safety and tolerability,monitor long-term efficacy,,2005-11,TERMINATED,INTERVENTIONAL,['PHASE3']
8769,NCT05678543,Offspring birthweight,,,2023-01-01,RECRUITING,OBSERVATIONAL,['NA']
8770,NCT03535935,Change in spot urine albumin-to-creatinine ratio,Change in lipids,Change in biomarkers related to inflammation and fibrosis,2018-07-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
8771,NCT01551667,Humoral immune response,Presence / absence of clonal complexes of the S. aureus strains,,2012-11,COMPLETED,OBSERVATIONAL,['NA']
8772,NCT00128089,Diabetes medication reduction,Patient satisfaction,,2005-08,TERMINATED,INTERVENTIONAL,['PHASE1']
8773,NCT00304603,Percent change in weight,Number of patients with adverse events,,2004-04,COMPLETED,OBSERVATIONAL,['NA']
8774,NCT01226043,Patient Overall Preference,Percentage of Patients Who Discontinued Investigational Product During the Observational Phase,Number of Patients With Hypoglycemic Events,2010-10,COMPLETED,INTERVENTIONAL,['PHASE4']
8775,NCT03149770,Change in Epinephrine Levels,,,2017-09-18,COMPLETED,INTERVENTIONAL,['PHASE2']
8776,NCT03410173,Changes of cognitive function assessed by cognitive function scale after 12 weeks.,Fasting serum insulin.,,2017-01,UNKNOWN,INTERVENTIONAL,['NA']
8777,NCT02222376,Ulcer size,,Healing time,2013-10,COMPLETED,INTERVENTIONAL,['PHASE3']
8778,NCT02953977,Change from baseline weight,Changes in Stages of Change for healthy eating and physical activity,,2018-06-15,COMPLETED,INTERVENTIONAL,['NA']
8779,NCT00196235,,,,1995-01,COMPLETED,OBSERVATIONAL,['NA']
8780,NCT04221360,AUClast of D390 and CKD-375,CL/F of D390 and CKD-375,,2020-01-29,UNKNOWN,INTERVENTIONAL,['PHASE1']
8781,NCT02685475,Sensory block duration,Rescue analgesic consumption,,2015-02,COMPLETED,OBSERVATIONAL,['NA']
8782,NCT06211556,Difference in change in FGF21 incremental area-under-the-curve,Difference in change in fasting plasma alanine aminotransferase,Difference in change in lipid parameters,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
8783,NCT00446472,Completely healed wounds,,,2007-04,UNKNOWN,INTERVENTIONAL,['NA']
8784,NCT04914910,Difference between treatment groups in change in TIR (3.9-10.0 mmol/l) from baseline to Week 14,Total daily carbohydrate intake,Difference in number of severe hypoglycaemia events (cognitive impairment requiring external assistance for recovery).,2021-06-08,COMPLETED,INTERVENTIONAL,['NA']
8785,NCT04016974,"AUC0-24h,sema,SS, area under the semaglutide concentration-time curve during a dosing interval (0-24 hours) at steady state",Number of treatment-emergent hypoglycaemic episodes,,2019-10-08,COMPLETED,INTERVENTIONAL,['PHASE1']
8786,NCT05498116,Change in Albuminuria,Change in Large Elastic Artery Stiffness,,2023-01-26,RECRUITING,INTERVENTIONAL,['PHASE4']
8787,NCT00463502,,,,na,COMPLETED,INTERVENTIONAL,['PHASE4']
8788,NCT00676923,,,,2008-03,COMPLETED,OBSERVATIONAL,['NA']
8789,NCT04738032,Diabetes self-management behaviors,,,2020-08-26,COMPLETED,OBSERVATIONAL,['NA']
8790,NCT05786612,Percentage wound area reduction during the investigational test period of four weeks,Total treatment costs during the investigational test period based on the number of dressings used during the investigation and the unit price of the products,,2023-01-30,COMPLETED,INTERVENTIONAL,['NA']
8791,NCT04007809,Evaluation and follow-up of quality of life: DisabKids Questionnaires,Production of prediction model of β-cell mass evolution,,2019-06-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
8792,NCT01341392,Amlodipine AUC,Amlodipine Tmax,,2011-04,COMPLETED,INTERVENTIONAL,['PHASE1']
8793,NCT03259724,HbA1c,HOMA-IR,,2017-01-30,UNKNOWN,OBSERVATIONAL,['NA']
8794,NCT01406665,oGTT (WHO criteria)-defined impaired glucose tolerance or diabetes,Findrisk diabetes questionnaire score,,2010-10,COMPLETED,OBSERVATIONAL,['NA']
8795,NCT00371982,"adiposity (total fat mass, adipocyte morphology), atherogenic markers and insulin sensitivity",and the impact of fish oil on systemic inflammatory markers and adipose tissue inflammatory genes.,,2002-12,TERMINATED,INTERVENTIONAL,['NA']
8796,NCT04982380,Glycosylated albumin,Serum lipid spectrum,,2021-07-31,UNKNOWN,INTERVENTIONAL,['PHASE4']
8797,NCT04300205,Altered pain experience associated with chronic wounds,,,2020-02-25,COMPLETED,INTERVENTIONAL,['NA']
8798,NCT01301833,Number of Participants With Adverse Events,Change From Baseline in Fasting Immuno Reactive Insulin (IRI) at Week 52,,2011-02,COMPLETED,INTERVENTIONAL,['PHASE3']
8799,NCT04382794,Death,Clinical parameter of acute lung disease,,2020-05-14,COMPLETED,OBSERVATIONAL,['NA']
8800,NCT05158478,repeatability precision,,,2022-02-22,COMPLETED,INTERVENTIONAL,['NA']
8801,NCT04016558,Hemoglobin A1c (HbA1c),Self-compassion - Diabetes (SCS-D),,2019-09-15,COMPLETED,INTERVENTIONAL,['NA']
8802,NCT05439473,Effect of treatment with Curalin on the change in plasma HbA1c,Safety of Curalin as assessed by adverse events,,2021-08-03,COMPLETED,INTERVENTIONAL,['PHASE2']
8803,NCT04887688,Laser Speckle imaging,Wound swabs,,2022-10-05,RECRUITING,INTERVENTIONAL,['NA']
8804,NCT00071409,"assess efficacy and safety based on arginine stimulated C peptide, fasting C peptide, average daily insulin dose, fasting glucose, glycosylated hemoglobin (Hb A1c), and AEs",,,2003-10,COMPLETED,INTERVENTIONAL,['PHASE2']
8805,NCT01533428,Percent Change in the Average Daily Pain Score From Baseline to Between Weeks 2 and 8,"Safety Assessed Through Adverse Events (AE) and Serious Adverse Events (SAE), Vital Signs, and Laboratory Analyses From Baseline to Week 12",,2012-02,COMPLETED,INTERVENTIONAL,['PHASE3']
8806,NCT00908778,"Ultrasound, OCT, and clinical exam","Ultrasound ,OCT ,Safety, and Clinical Exam",,2008-10,UNKNOWN,INTERVENTIONAL,['PHASE3']
8807,NCT05710900,Type 2 diabetes remission,"Feedback of the intervention with participants, RDs and pharmacists",,2023-07-15,RECRUITING,INTERVENTIONAL,['NA']
8808,NCT01804881,The Change in EEQ (Emotional Eater Questionnaire) Score is the Primary Outcome Measure in This Study.,Change in Weight,,2013-03,COMPLETED,INTERVENTIONAL,['NA']
8809,NCT00641407,Change in hemoglobin A1c (HbA1c) level from baseline to end point for each treatment group.,"Percentage of subjects achieving HbA1c ≤7%, incidence of self-reported hypoglycaemic episodes, comparison of SMPG values from 8-point profiles, insulin doses, and body weight.",,2007-01,COMPLETED,INTERVENTIONAL,['PHASE4']
8810,NCT05856318,QRISK3,Diabetes Risk,,2023-06,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
8811,NCT02620553,Evaluation of Blood Glucose Levels,T-cell responses related to potential immune response to Insulin,,2007-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8812,NCT03403231,Engagement in Recommended Behaviors to Prevent Type 2 Diabetes,Physical Activity,,2018-02-01,COMPLETED,INTERVENTIONAL,['NA']
8813,NCT00998881,Change From Baseline in HbA1c at Week 12,Change From Baseline in 2-hour Postprandial Plasma Glucose at Week 12,,2009-09,COMPLETED,INTERVENTIONAL,['PHASE3']
8814,NCT02367534,hemorrhage,C-peptide,,2008-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8815,NCT05855980,Wound healed,Functional outcome: FHSQ,,2023-05-22,RECRUITING,INTERVENTIONAL,['NA']
8816,NCT02433678,Difference in the Percent Change in Fasting Nuclear Factor Kappa-light-chain-enhancer of Activated B Cells Activation (DNA Binding Activity) in Mononuclear Cells Before and After Dapagliflozin Use,Changes in Expression of Inflammatory Mediators,Change in Hypertension Mediators,2015-11,COMPLETED,INTERVENTIONAL,['PHASE4']
8817,NCT03165227,Percentage of patients with drug related Adverse Events (AEs),Change from baseline in log transformed Urine albumin creatinine ratio (UACR) measured in 10-hour urine,,2017-10-17,COMPLETED,INTERVENTIONAL,['PHASE1']
8818,NCT04689425,Wound area reduction rate,Amputation rate at 8 weeks,,2021-03-30,RECRUITING,INTERVENTIONAL,['PHASE3']
8819,NCT00957762,"To compare different methods of body composition analyses with the gold standard 4-compartment monitoring to determine accuracy and validity of those alternative, but less labor-intensive techniques.",To cross-validate the derived regression equations against the gold standard 4-compartment model in an independent group of persons with SCI.,,2009-08,UNKNOWN,OBSERVATIONAL,['NA']
8820,NCT01511393,"Annual incidence of MTC in the US to identify any possible increase related to the introduction of liraglutide, exenatide once-weekly, and other GLP-1 receptor agonists into the US market.","Environmental exposures (occupational history, radioiodine exposure, nuclear fallout)",,2012-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
8821,NCT00520182,"Triglyceride level, glycated hemoglobin level, fasting plasma glucose","Weight, BMI, waist hip circumference, insulin resistance using HOMA (fasting glucose to fasting insulin ration), HDL-Cholesterol level.",,2004-03,UNKNOWN,INTERVENTIONAL,['PHASE3']
8822,NCT00419718,Area under the plasma insulin profile in the interval,Maximum plasma insulin concentration,,2005-10,COMPLETED,INTERVENTIONAL,['PHASE1']
8823,NCT05783115,visual analogue scale,skin temperature,,2022-01-01,RECRUITING,INTERVENTIONAL,['NA']
8824,NCT02671968,"Change in the total number of low glucose events (<55 mg/dl), between baseline and outcome phase (week 22-26) in CGM group and control group (change = subtracting number of follow up events from number of baseline events",,,2016-02,COMPLETED,INTERVENTIONAL,['NA']
8825,NCT04449198,Skeletal Muscle Mitochondrial Function,Change in Post Occlusive Reactive Hyperemia (PORH),,2020-10-14,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
8826,NCT02353975,The accumulative excretion rate of SHR3824 and its metabolites in urine and feces,The number of volunteers with adverse events as a measure of safety and tolerability.,,2014-05,COMPLETED,INTERVENTIONAL,['PHASE1']
8827,NCT00797069,To compare the postprandial glycemic response of patients with type 2 diabetes consuming single servings of a standard liquid nutrition product and two diabetes-specific liquid nutrition products.,To compare the postprandial insulinemic response of patients with type 2 diabetes consuming single servings of a standard liquid nutrition product and two diabetes-specific liquid nutrition products.,,2008-11,COMPLETED,INTERVENTIONAL,['PHASE3']
8828,NCT02116426,Final diagnosis of ACS non ST + (yes/no),Number of patients taken in charge that day by ambulance staff.,,2015-07-29,COMPLETED,OBSERVATIONAL,['NA']
8829,NCT02034695,The proportion of patients who have achieved a HbA1c level <7%.,"Service utilization outcomes measured by GOPC consultation, SOPC consultation, A&E and hospital attendance rates in the past 12 months.",,2010-09,COMPLETED,OBSERVATIONAL,['NA']
8830,NCT04332003,Time to complete wound closure.,Change in oxygenation at the wound site,,2021-01-01,WITHDRAWN,INTERVENTIONAL,['NA']
8831,NCT04616053,HbA1c,Lipids - triglycerides,,2021-09,UNKNOWN,INTERVENTIONAL,['NA']
8832,NCT05897528,Hospital Mortality,,,2021-10-14,COMPLETED,OBSERVATIONAL,['NA']
8833,NCT05936242,Postprandial glucose response,,,2021-05-18,RECRUITING,OBSERVATIONAL,['NA']
8834,NCT01251211,Average pain intensity on numerical scales in a self diary by the patient,Predictors of the response,Evaluate pain relief at 24 weeks,2010-10,COMPLETED,INTERVENTIONAL,['PHASE4']
8835,NCT00063583,The primary endpoint will be the change in renal function from baseline to the end of the study period (12 months).,• Determine the relationship between % change in TGF-b1 levels and the change in GFR,,2003-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8836,NCT00881530,"Clinical Relevant Abnormalities for Physical Examination, Vital Signs, ECG and Laboratory Measurements",Change From Baseline in Fasting Plasma Glucose (FPG) Over Time,,2009-03,COMPLETED,INTERVENTIONAL,['PHASE2']
8837,NCT01303055,beta cell function evaluated from 75 g OGTT,"1,5-AG level",,2011-02,UNKNOWN,INTERVENTIONAL,['NA']
8838,NCT02139943,Percentage of Participants With Adverse Events,,,2014-05,COMPLETED,INTERVENTIONAL,['PHASE2']
8839,NCT01926925,Plasma levels of markers of endothelial activation and vascular inflammation,,,2001-05,COMPLETED,OBSERVATIONAL,['NA']
8840,NCT04893135,RANKL/OPG level,Sudoscan measurement,,2021-10-11,COMPLETED,INTERVENTIONAL,['NA']
8841,NCT05351359,step count,body mass index,,2022-04-25,RECRUITING,INTERVENTIONAL,['NA']
8842,NCT00137046,Annual Rate of Change in Carbon Monoxide Diffusion Capacity (DLco),Insulin Antibodies,,2002-05,TERMINATED,INTERVENTIONAL,['PHASE3']
8843,NCT01298882,Total insulin secretion concentration,,,na,COMPLETED,INTERVENTIONAL,['PHASE2']
8844,NCT05794581,To assess area under the curve (AUC) in glucose metabolism during MMTT,Area under the acetaminophen concentration-time (AUC),,2023-03-21,RECRUITING,INTERVENTIONAL,['PHASE1']
8845,NCT00481598,"glycogen metabolism, gluconeogenesis, after 3 months of treatment;",,,2006-01,COMPLETED,INTERVENTIONAL,['NA']
8846,NCT00065377,,,,2003-07,COMPLETED,INTERVENTIONAL,['PHASE1']
8847,NCT02024477,CD 34+ Cell Function,Arterial Stiffness,,2013-11,COMPLETED,INTERVENTIONAL,['PHASE4']
8848,NCT00559767,,,,2006-06-30,COMPLETED,OBSERVATIONAL,['NA']
8849,NCT05486065,Change in Glycosylated Haemoglobin (HbA1c),Number of Treatment-emergent Severe Hypoglycaemic Episodes,,2022-08-08,COMPLETED,INTERVENTIONAL,['PHASE2']
8850,NCT05816941,HbA1c test,Sulcus bleeding index (SBI),,2016-01-03,COMPLETED,INTERVENTIONAL,['NA']
8851,NCT01514149,Glycosylated Hemoglobin Change From Baseline (CFB) to Week 18,Time to Hyperglycemia Rescue,,2011-09,TERMINATED,INTERVENTIONAL,['PHASE2']
8852,NCT03050827,Ocular Nerve Fiber Density,Autonomic Function Tests - Root Mean Square of the Successive Differences,,2014-05-01,COMPLETED,INTERVENTIONAL,['PHASE3']
8853,NCT02716623,Participant compliance with study specific CR diet,Presence of Tumor M2-PK,,2016-03,COMPLETED,INTERVENTIONAL,['NA']
8854,NCT01844037,Change in office systolic blood pressure (SBP) from baseline to 6 months,Change in office SBP,,2014-07,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
8855,NCT06214520,HbA1c,Usability of the Empower+ app and Motivational Interviewing module,,2024-01-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
8856,NCT02383940,Change From Baseline in Hemoglobin A1C (A1C) at Week 12,Change From Baseline in Number of Hypoglycemic Events/Day (<=70 mg/dL) by Self-Monitored Blood Glucose (SMBG) at Week 12,,2015-04,COMPLETED,INTERVENTIONAL,['PHASE2']
8857,NCT00506961,The percentage of patients achieving the combined treatment goal of LDL-C < 100mg/dl and non-HDL-C < 130 mg/dl at week 12 with rosuvastatin treatment compared with simvastatin treatment,Percentage of patients achieving the LDL-C goal of <70 mg/dL at Week;The mean percent change from baseline in lipid profile at week 4 and week 12;,,2006-06,COMPLETED,INTERVENTIONAL,['PHASE4']
8858,NCT02147431,Change in mean glucagon concentration during hypoglycaemia (change from target level 5.5 mmol/L to nadir (target 2.5 mmol/L)),Time from termination of insulin infusion at nadir to reach plasma glucose level 4.0 mmol/L,,2014-05-21,COMPLETED,INTERVENTIONAL,['PHASE1']
8859,NCT04575389,the association of serum uric acid (SUA) level with metabolic risk factors in patients with type 2 diabetes,,,2020-10-01,UNKNOWN,OBSERVATIONAL,['NA']
8860,NCT00967837,To measure progress of wound healing in subjects that have failed conventional wound care healing treatments for 60 days,,,2006-01,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
8861,NCT04564586,Inactivity,Hemoglobin A1c,,2020-01-01,UNKNOWN,INTERVENTIONAL,['NA']
8862,NCT02762370,Change From Baseline for Average Blood Glucose (mg/dL),Area Under the Effect (AUE) Curves for Average Blood Glucose - FX006 Versus TCA IR,Change in Average Blood Glucose From Baseline (Hour -48 to Hour -1) to Hour 1 to Hour 48 for FX006 32 mg Relative to TCA IR 40 mg.,2016-04,COMPLETED,INTERVENTIONAL,['PHASE2']
8863,NCT02073058,Clinical point accuracy as assessed by the Consensus Error Grid,"Composite measure: Clinical point accuracy (Clarke Error Grid), trend accuracy (R-deviation, Rate Error Grid and Continuous Glucose Error Grid) and lag time, performance of notifications (sensitivity and false notifications) and questionnaire responses.",,2014-02,COMPLETED,OBSERVATIONAL,['NA']
8864,NCT05282264,Acceptability of hybrid closed-loop systems,Hypoglycemia Fear,,2022-04-01,COMPLETED,OBSERVATIONAL,['NA']
8865,NCT00519935,Metabolic Control: Hemoglobin A1c (HbA1c),Quality of life,,2001-07,COMPLETED,INTERVENTIONAL,['NA']
8866,NCT04026139,3-m timed up and go test [TUG],,,2017-08-01,COMPLETED,INTERVENTIONAL,['NA']
8867,NCT05033054,Change in serum klotho levels at 12 week,Change in serum magnesium levels at 12 weeks,,2022-11-20,RECRUITING,OBSERVATIONAL,['NA']
8868,NCT04807959,Reduction of Visceral Adiposity,Increase of Intracellular Fluid,,2016-10-27,COMPLETED,OBSERVATIONAL,['NA']
8869,NCT01147861,Weighted mean AUC for glucose,"Weighted mean AUC for NEFA, glycerol, triglycerides, insulin, and C-peptide",,2010-07-01,COMPLETED,INTERVENTIONAL,['PHASE1']
8870,NCT02488252,Change in spot urine albumin-to-creatinine ratio,Rate of CKD stage transition,,2015-07,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
8871,NCT05487833,%triglyceride reduction,incidence of hypoglycemia,,2022-11,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
8872,NCT02504658,Total Self-Efficacy Score on the Physical Activity and Healthy Food Efficacy Scale for Children,"Number of text message responses to Goal Setting Question, as a measure of Adherence",,2011-12,COMPLETED,INTERVENTIONAL,['PHASE1']
8873,NCT00574340,Percent Changes in Endothelial Function as Measured by Flow Mediated Dilation by 2D Doppler Ultrasound on Day 2,,,2007-05,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
8874,NCT05232812,Radiation exposure of 3-[11C]-OHB,,,2022-06-01,COMPLETED,INTERVENTIONAL,['NA']
8875,NCT01718093,To determine the glucose lowering effect of metformin and sitagliptin alone and as combination therapy when used as adjuncts to insulin in adolescents with T1DM.,,,2012-10,COMPLETED,INTERVENTIONAL,['PHASE4']
8876,NCT02399826,Proportion of ulcers completely healed by amniotic memrane versus standard care,Proportion of ulcers healed by amniotic membrane versus standard care,,2015-03,UNKNOWN,INTERVENTIONAL,['NA']
8877,NCT04930588,The receptor ErbB4 in saliva,Body Mass Index (BMI),,2021-06-01,UNKNOWN,OBSERVATIONAL,['NA']
8878,NCT05752851,Fecal 16S rRNA gene sequencing,,,2023-02-01,RECRUITING,OBSERVATIONAL,['NA']
8879,NCT00253760,a global metabolic spectrum detectable by H-NMR,,,2004-02,COMPLETED,INTERVENTIONAL,['NA']
8880,NCT00336323,Percentage of Participants With <250 Microns or ≥ 50% Reduction in Retinal Thickening From Baseline Over All Study Visits,Distribution of Change in Visual Acuity Over All Study Visits,Change in Central Subfield Thickness From 3 to 6 Weeks Among Eyes That Received 2.5mg Bevacizumab at 6 Weeks and Had Within >11% Increase in Change of Central Subfield Thickness From 6 Weeks to 9 Weeks,2006-06,COMPLETED,INTERVENTIONAL,['PHASE2']
8881,NCT00643760,Change From Baseline in the Mean 24-hour Average Pain Intensity (API) Score at End of Maintenance Treatment (EOMT) Using Last Observation Carried Forward (LOCF) Data,Change From Baseline in Emotional Functioning as Assessed by the Profile of Mood States-Brief Form (POMS-B) at EOMT Using LOCF Data,,2008-03,COMPLETED,INTERVENTIONAL,['PHASE2']
8882,NCT01704378,Occurrence of adverse events,7-point blood glucose profile,,2001-04-18,COMPLETED,INTERVENTIONAL,['PHASE4']
8883,NCT02176681,Mean glucose value of CGM [M] to be averaged from day 2 and day 3 of CGM,Mean HbA1C and Glycated albumin,,2014-06,COMPLETED,INTERVENTIONAL,['PHASE4']
8884,NCT00729365,"Development of Microalbuminuria (High Urine Albumin). Hypertension, Urine and Blood Markers Will Also be Evaluated for Assessment of Kidney Disease State.",We Will Assess Changes in the Relative Stiffness of Your Arteries (Endothelial Dysfunction) in Persons With Type 1 Diabetes Over the 5year Study.,,2008-07,TERMINATED,INTERVENTIONAL,['PHASE3']
8885,NCT00815789,"Change in the outcome (SBP, Hb A1c, or LDL) from baseline to the 12 month evaluation.","Changes in CVD related health behaviors (e.g., aspirin use, medication adherence, exercise, and diet) as well as changes in stroke and CHD risk as assessed by the UPKDS risk engine",,2008-12,COMPLETED,INTERVENTIONAL,['NA']
8886,NCT02265809,"Change from baseline of CD4 T regulatory cells, CD4 T effector cells and CD25 expression on T regulatory cells during treatment with ultra low dose IL-2",Safety and tolerability,Recruitment analysis,2014-10-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8887,NCT05465616,Insulin Resistance,Fasting glucose,,2022-06-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
8888,NCT02925312,Percentage Change in Hemoglobin A1C From Baseline to 3 Months,Frequency of Eye Exams,,2014-11,COMPLETED,INTERVENTIONAL,['NA']
8889,NCT02862730,Percent of Time With Sensed Glucose Between 3.9-10 mmol/L,Mean Amount of Glucagon Delivered,,2016-10,COMPLETED,INTERVENTIONAL,['NA']
8890,NCT00119535,� Optimal timing of photocoagulation (prior to intervention and 12 months after interventions,� Meeting retinopathy screening and surveillance guidelines � Patient satisfaction with care � Resource utilization (during study and previous 12 months) � Intervention Costs (conclusion of study),,2004-08,COMPLETED,INTERVENTIONAL,['NA']
8891,NCT01154881,Area under the glucose infusion rate curve from 0-24 hours at steady state,Area under the insulin degludec concentration-time curve from 0-24 hours at steady state,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE1']
8892,NCT03411213,Can diffuse optical tomography detect microvascular function?,Predicting coronary artery disease before angiography,,2016-01-11,COMPLETED,INTERVENTIONAL,['NA']
8893,NCT02082028,Change in HbA1c levels from baseline,Participants satisfaction with SMBG meter assessed by Visual Analog Scale (VAS),,2012-06-27,COMPLETED,INTERVENTIONAL,['NA']
8894,NCT01511861,,,,2010-11,UNKNOWN,OBSERVATIONAL,['NA']
8895,NCT00937703,Comparison HbA1c means of the 2 groups profiting from a telemonitoring system compared to the reference group.,"Effective number of patients carrying on the use of the system in routine care, at their own expense and in agreement with their physician",,2008-12,COMPLETED,INTERVENTIONAL,['NA']
8896,NCT02524782,Part B: Change in LDL-C from baseline to Day 36,"Part B: Pharmacokinetics of MEDI4166, time to maximum observed plasma drug concentration (Tmax)",,2015-10-07,COMPLETED,INTERVENTIONAL,['PHASE1']
8897,NCT02577159,Changes in fasting lipoprotein profiles,Changes in biomarkers for renal and hepatic function,,2015-07-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
8898,NCT05890690,Difference in maximal increase in copeptin levels in plasma (pmol/l),,,2023-06-02,RECRUITING,INTERVENTIONAL,['NA']
8899,NCT00437554,Efficacy : Change in HbA1c between baseline and endpoint,"Safety: episodes of hypoglycemia, adverse events, laboratory values including hematology, blood chemistry and urinalysis, vital sign and physical examination, Frequency with hypoglycemic episode",,2006-08,COMPLETED,INTERVENTIONAL,['PHASE3']
8900,NCT01136746,Percentage of Capillary Plasma Glucose Measurements Within the Range of 71 to 179 mg/dL Throughout the Hospital Study Period,Number of Participants With Major Adverse Cardiovascular Events (MACE),,2011-03,TERMINATED,INTERVENTIONAL,['PHASE3']
8901,NCT03125694,Change from baseline in mean glycated hemoglobin (A1C) levels by sitagliptin vs. pioglitazone,,,2015-02-01,COMPLETED,INTERVENTIONAL,['PHASE3']
8902,NCT06125873,It controls blood Glycated hemoglobin level in type 2 diabetic patients.,Moringa leaf powder effect on body weight of patients,,2023-03-15,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE2']
8903,NCT02476409,Change in Body Weight at 48 Hours Stratified by Copeptin,Change in Body Weight at Day 8,,2015-07,COMPLETED,INTERVENTIONAL,['PHASE4']
8904,NCT00573456,The primary end point is to determine the therapeutic effects of far infrared radiation on all types of diabetes.,"The secondary end point of the study is to evaluate the therapeutic effects of far infrared radiation on other types of diabetes complications including blindness, heart and blood vessel disease and kidney failure.",,2006-05,UNKNOWN,INTERVENTIONAL,['PHASE1']
8905,NCT03920098,Pandemic Anxiety Scale,Offspring body fat,,2019-06-01,UNKNOWN,OBSERVATIONAL,['NA']
8906,NCT00522210,Hemoglobin A1C,Diabetes Quality of Life Questionaire-youth version,,2008-03,COMPLETED,INTERVENTIONAL,['NA']
8907,NCT04210128,severe hyperglycemia,,,2019-12-20,COMPLETED,OBSERVATIONAL,['NA']
8908,NCT02802215,Number of participants with gestational diabetes by measuring plasma glucose levels ( mg / dl ).,Maternal adverse effects,,2016-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
8909,NCT00962806,Determine whether intensive exercise improves mitochondrial function by P31 MRS and mitochondrial number by peripheral blood analyses.,"Determine whether intensive exercise improves body composition, by DXA, and intramyocellular fat content, by 1H MRS.",,2009-08,UNKNOWN,INTERVENTIONAL,['NA']
8910,NCT04564742,"The hierarchical composite endpoint of Death (CV death followed by non-CV death), Hosp due to heart failure (adjudicated followed by investigator reported), Non-fatal MI, AF/flutter event, New onset of T2DM, last visit NYHA class, and weight loss ≥5%",Time to death of any cause,,2020-12-22,COMPLETED,INTERVENTIONAL,['PHASE3']
8911,NCT02082184,HbA1c at 6 Months,Change in Diabetes Treatment Satisfaction Questionnaire (DTSQc) Scores From Day 1 to Day 194.,,2014-03,COMPLETED,INTERVENTIONAL,['NA']
8912,NCT01878370,Proportion of patients with perfect composite high risk score,cholesterol (LDL),Each metric within the composite scores,2013-06,COMPLETED,INTERVENTIONAL,['NA']
8913,NCT00479609,"Insulin sensitivity,","Glucose tolerance, HbA1c levels, Abdominal obesity, prostate safety, Sexual function, Sleepiness, Urinary symptoms, Hypogonadal symptoms score",,2007-04,UNKNOWN,INTERVENTIONAL,['PHASE3']
8914,NCT05833100,Hematocrit Measurement,β-Ketone Testing of Subject Plasma Samples,,2022-08-15,TERMINATED,INTERVENTIONAL,['NA']
8915,NCT01069926,"Change-from-baseline variables will be calculated for the safety variables listed below, as the post-treatment value minus the value at baseline",To evaluate the safety of AZD1656 in T2DM patients with various degrees of renal impairment. To describe the pharmacodynamics of AZD1656 in T2DM patients with various degrees of renal impairment by assessment of 24-hours glucose profile,,2010-03,COMPLETED,INTERVENTIONAL,['PHASE1']
8916,NCT01683331,The Incidence of New Onset of Diabetes After Transplant (NODAT) 12 Months After Kidney Transplantation,The Incidence of New Onset of Diabetes After Transplant (NODAT) 24 Months After Kidney Transplantation,"Incidence of Impaired Fasting Glycemia and Impaired Glucose Tolerance 6, 12 and 24 Months After Transplantation.",2012-08,COMPLETED,INTERVENTIONAL,['PHASE4']
8917,NCT04977011,Anxiety Visual Analog Scale.,Richards-Campbell Sleep Scale,,2019-01-02,COMPLETED,INTERVENTIONAL,['NA']
8918,NCT03961256,Progression From Prediabetes to Diabetes,Adverse Events for Exenatide SR Intervention,,2019-05-09,COMPLETED,INTERVENTIONAL,['PHASE2']
8919,NCT05591339,F-glucose,Time to Type-2 diabetes development,,2023-12-01,RECRUITING,INTERVENTIONAL,['PHASE4']
8920,NCT01909245,"Proportion of subjects who are insulin independent, hypoglycemia free, AND with hemoglobin A1c < or = 6.5% at 5 years post-transplant",Proportion of subjects who are free of severe hypoglycemic episodes AND have a hemoglobin A1c < or = 7.0%,Incidence of Gastrin-17 use for treatment of islet graft dysfunction AND incidence of change or early discontinuation of Gastrin-17 treatment,2013-10-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
8921,NCT02836873,Change From Baseline in HbA1c at 24 Weeks,Change From Baseline in HbA1c in Subjects With Stage 3b CKD (eGFR 30 to 44 mL/Min/1.73 m2) at Week 24,,2016-09-23,COMPLETED,INTERVENTIONAL,['PHASE3']
8922,NCT05095389,DFU Closure Rate,Percent Reduction of Wound Area,,2023-02-28,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
8923,NCT03491436,blood glucose 2 hours after meal 3,,,2017-05-01,WITHDRAWN,INTERVENTIONAL,['NA']
8924,NCT00916357,Postprandial Glucose (PPG) Excursion Following a Liquid Meal,Time to Percentage of Insulin Exposure (as Measured by Area Under the Curve [AUC]),,2009-07,COMPLETED,INTERVENTIONAL,['PHASE2']
8925,NCT02445508,Glucagon-like peptide-1 (GLP-1): Incremental and total area under the Concentration-Time Curve,Appetite as assessed by Visual analog scale score,,2015-05,COMPLETED,INTERVENTIONAL,['NA']
8926,NCT02637245,Changes in disease state characteristics in response to therapy,Changes in visual acuity using ETDRS visual acuity assessment,,2015-05,COMPLETED,OBSERVATIONAL,['NA']
8927,NCT01739868,To identify new biomarkers,Number of patients with others cardiovascular risk factors,,2011-04,UNKNOWN,INTERVENTIONAL,['NA']
8928,NCT00480805,To determine the antihypertensive effectiveness of HYZAAR as compared to Ramipril as measure by SiSBP at Week 4,To determine the safety anf tolerability of HYZAAR as compared to Ramipril as seen in overall adverse experiences for the duration of the study,,2001-08-08,COMPLETED,INTERVENTIONAL,['PHASE3']
8929,NCT01258075,Percent Change in Hemoglobin A1c (HbA1c) From Baseline to Month 6,Number of Participants Requiring Rescue Medication Who Initially Met Rescue Criteria,,2011-02-24,COMPLETED,INTERVENTIONAL,['PHASE4']
8930,NCT02256189,Glucagon Counterregulation to Hypoglycemia,,,2015-04,COMPLETED,INTERVENTIONAL,['PHASE4']
8931,NCT00505882,The change in weight (kg) will be compared between as well as within the placebo and the pramlintide treatment group from baseline to the end of the study.,mixed meal tolerance test-the C-peptide area under the curve The HOMA R and McAuley's index HbA1c The event rate of severe hypoglycemia Waist circumference Cardio C-reactive protein level DQOL Safety parameter,,2007-07,WITHDRAWN,INTERVENTIONAL,['PHASE4']
8932,NCT00544518,The change of HbA1c from baseline to the end of treatment,the changes of fasting and after standard meal glucose and insulin level and plasma lipid level,,2007-10,UNKNOWN,INTERVENTIONAL,['PHASE2']
8933,NCT05643768,Change from baseline insulin sensitivity after 6 weeks of IMST,Change from baseline Nitric Oxide-mediated Endothelial Dependent Dilation (EDD),Change from baseline proteomic analysis,2023-06-30,RECRUITING,INTERVENTIONAL,['NA']
8934,NCT05939895,To diagnose missed cases of prediabetes.,,,2020-01-01,RECRUITING,OBSERVATIONAL,['NA']
8935,NCT00469365,"The primary outcome was the number of days from the index date until the next date on which the patient filled a prescription for any qualified medication, or until the end of the study follow-up period.","Secondary outcomes included indicators for whether the patient filled any medication within 30 days for their chronic disease, and whether the patient filled any medication within 30 days.",,2006-01,COMPLETED,INTERVENTIONAL,['PHASE3']
8936,NCT05267990,rate of major coronary heart disease,medical expenditure,,2022-03-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
8937,NCT01901055,HbA1C Level,Vigilance,,2014-02-13,TERMINATED,INTERVENTIONAL,['NA']
8938,NCT00005481,,,,1996-09,COMPLETED,OBSERVATIONAL,['NA']
8939,NCT01702012,Change in HbA1c (%),Change in fasting blood glucose (mg/dl),,2013-01,COMPLETED,INTERVENTIONAL,['NA']
8940,NCT00016835,,,,2001-10-17,COMPLETED,INTERVENTIONAL,['PHASE2']
8941,NCT00845793,Changes in the results of the nutrition quality questionnaire,Changes in anthropometric measures Changes in physical activity levels,,2009-04,UNKNOWN,INTERVENTIONAL,['NA']
8942,NCT01552408,Incidence and Severity of Ocular and Non-ocular Adverse Events (AE's) Through Month 36.,Mean Change in Peripheral Visual Field as Measured by Goldmann Visual Field at Screen and Month and 36.,,2012-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
8943,NCT03549390,Insulin area under the curve (AUC),Physical fitness and suitability to exercise.,,2018-10-30,COMPLETED,INTERVENTIONAL,['NA']
8944,NCT03764410,blood test for glycated hemoglobin,,,2016-12-20,COMPLETED,INTERVENTIONAL,['NA']
8945,NCT02241317,Hypoglycaemia,,,2014-06,UNKNOWN,OBSERVATIONAL,['NA']
8946,NCT00162357,Evaluate symptom-free heart blockages that develop following initial opening in patients with Type II diabetes mellitus based on Cardiolite imaging,Compare patient hospital and out-patient cost for cardiac care for each group of patients (MPI versus standard care).,,2004-04,COMPLETED,INTERVENTIONAL,['PHASE4']
8947,NCT00006426,,,,1998-08,COMPLETED,INTERVENTIONAL,['PHASE1']
8948,NCT00213122,,,,na,COMPLETED,INTERVENTIONAL,['PHASE3']
8949,NCT04153981,Number or Participants With Hypoglycemic Events,Change From Week 4 in Insulin Treatment Satisfaction Questionnaire (ITSQ),,2019-12-16,COMPLETED,INTERVENTIONAL,['PHASE4']
8950,NCT06141941,Glucose values,,,2021-06-01,RECRUITING,INTERVENTIONAL,['NA']
8951,NCT03736486,"Success (evaluated by Yes/No format) recruiting and establishing a pilot cohort of 100 Latino adults with Type 2 Diabetes and creating data collection methods to describe genetics, biology, behavior, psychology, & environment in Type 2 Diabetes",Trust in physician measured by the Trust in Physician (TPS) questionnaire,"Success measured by the number of health care workers trained, upskilled, and employed to be community health care workers (Especialistas) and the number of participant encounters with a trained health care worker",2017-08-24,COMPLETED,OBSERVATIONAL,['NA']
8952,NCT00868790,Number of Participants Who Discontinued Study Treatment Due to an AE,Percentage Change From Baseline (BL) After 4-Week Treatment in Low-Density Lipoprotein C (LDL-C) Levels,,2009-03-24,TERMINATED,INTERVENTIONAL,['PHASE2']
8953,NCT01633684,Bone mineral Density,,,2012-08,COMPLETED,OBSERVATIONAL,['NA']
8954,NCT04661917,Change from baseline in urine albumin-to-creatinine ratio (UACR) to the end of treatment (Visit 6),Frequency of treatment-emergent adverse events (TEAEs),,2021-05-31,WITHDRAWN,INTERVENTIONAL,['PHASE2']
8955,NCT01075347,Patients With Corneal Epithelial Healing Time Within 14 Days,"Patients With Corneal Complications Due to Delayed Surface Re-epithelization (e.g. Infectious Corneal Ulcer, Corneal Melting, Sterile Corneal Ulcer, Corneal Neovascularization)",,2007-03,COMPLETED,INTERVENTIONAL,['PHASE1']
8956,NCT02036554,"Change from Baseline in Development of NODAT (Fasting glucose ≥ 126 mg/dL, Random glucose ≥ 200 mg/dL) at 12 months",Prevalence of NODAT at 12 month(V6),,2013-03,UNKNOWN,INTERVENTIONAL,['PHASE4']
8957,NCT06273215,Pharmacokinetics of study drug,Genotype of OATP and BCRP,,2023-03-05,RECRUITING,INTERVENTIONAL,['PHASE4']
8958,NCT05856578,"Concentration of MBG, TIR, TAR, TBR, MAGE, MBG and LAGE","Concentration of adiponectin, leptin,IL-1,IL-6 andTNF-α",Incidence of hypoglycemia,2022-03-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4']
8959,NCT02137057,"Change of Heart rate variability during spinal anesthesia : total power, power of LF and HF, and LF/HF ratio",,,2014-05,COMPLETED,OBSERVATIONAL,['NA']
8960,NCT01660789,BMI,,,2012-01,COMPLETED,INTERVENTIONAL,['NA']
8961,NCT02651181,"Time in range of sensor glucose data between 70 mg/dL to 180 mg/dL,during day time (6am-12am)",Incidence of Severe Hypoglycemia,Total insulin dose,2016-06,COMPLETED,INTERVENTIONAL,['NA']
8962,NCT00245882,HbA1c,Factors influencing adherence to diabetes regimen,,2005-10,COMPLETED,INTERVENTIONAL,['NA']
8963,NCT04003259,Change in systolic and diastolic blood pressure (mmHg),Fitness index,,2009-01-01,COMPLETED,INTERVENTIONAL,['NA']
8964,NCT06219850,Assessed changes from cardiorespiratory fitness,Assessed changes in Circadian Rhythms,,2024-02-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
8965,NCT03866343,Insulin sensitivity,Microvascular function,,2018-09-07,COMPLETED,INTERVENTIONAL,['NA']
8966,NCT04108065,Gallbladder emptying,GDF15,,2019-10-02,COMPLETED,OBSERVATIONAL,['NA']
8967,NCT05912218,Lower limb atheroma plaque inflammation,Lower limb atheroma plaque progression,,2023-06-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
8968,NCT02645383,Visual analog score for pain,,,2014-05,COMPLETED,INTERVENTIONAL,['NA']
8969,NCT02360254,Change in HbA1c,Glucose variability,,2015-01,COMPLETED,OBSERVATIONAL,['NA']
8970,NCT03517111,Food Insecurity,Parent and Adolescent Diet - Refined Grains (oz),,2018-09-26,TERMINATED,INTERVENTIONAL,['NA']
8971,NCT01559896,"The change (baseline vs 2 hours, and baseline vs 2 days) in arterial stiffness measured as carotid-femoral pulse wave velocity","Changes in glucose and insulin concentrations and calculated HOMA-index, incretins, lipids, characteristics of the microcirculation, and non-invasively assessed upper-arm blood pressure and central aortic systolic blood pressure and heart rate changes",,2011-09,COMPLETED,INTERVENTIONAL,['NA']
8972,NCT01474538,Glycosylated Hemoglobin A1C (HbA1c) at Endpoint,Percentage of Participants With Hypoglycemic Events,,2011-12,COMPLETED,INTERVENTIONAL,['PHASE3']
8973,NCT03286751,Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Versus Time Curve (AUC),Glucodynamics: Total Amount of Glucose Infused (Gtot),,2017-10-13,COMPLETED,INTERVENTIONAL,['PHASE1']
8974,NCT00622323,"To determine the proportion of patients experiencing an adverse event and a list of the experienced adverse events, that would occur among Filipino patients with type 2 diabetes and inadequate glycemic control treated with exenatide",To evaluate the change from baseline to endpoint in HbA1c and body weight of Filipino patients with type 2 diabetes mellitus treated with exenatide who are taking metformin and/or a sulfonylurea but have not achieved adequate glycemic control.,,2008-02,COMPLETED,OBSERVATIONAL,['NA']
8975,NCT04529239,"Glucose biomarker data from the continuous glucose monitoring device, which will be analyzed as a function of different homeostasis responses from the 3 different cohorts of individuals (i.e., i) low to moderate risk; ii) high risk, iii) very high risk).",,,2020-08-31,COMPLETED,OBSERVATIONAL,['NA']
8976,NCT02033499,Mean Difference in Health-related Quality of Life Scores From Baseline to 52 Weeks,Number of Participants on Specified Diabetes Medications at Baseline and Follow-up,,2014-01,COMPLETED,INTERVENTIONAL,['NA']
8977,NCT06101368,Dynamometry lower limb,,,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
8978,NCT00768105,"Safety variables (AE, BP, pulse, weight, plasma glucose, laboratory variables and ECG)",Pharmacodynamic variables,,2008-09,COMPLETED,INTERVENTIONAL,['PHASE1']
8979,NCT00140647,"The change of the mean maximum carotid intimal medial thickness (IMT)evaluated across 12 segments involving the left and right common carotid, bifurcation and internal carotid arteries.",The change over time in the mean IMT across the common carotid far wall IMT of the right and the left carotid arteries.,,2001-07,COMPLETED,INTERVENTIONAL,['PHASE3']
8980,NCT04192409,Change in glucose level measured by HbA1C level,low density lipoprotein,,2020-01-01,COMPLETED,INTERVENTIONAL,['NA']
8981,NCT00975169,we plan to conduct a case-control study to test the association between single nucleotide polymorphisms (SNPs) in certain candidate genes and TZDs related peripheral edema,,,2009-02,UNKNOWN,OBSERVATIONAL,['NA']
8982,NCT05926388,Insulin Administration Observation Form 2,,,2022-01-10,COMPLETED,INTERVENTIONAL,['NA']
8983,NCT02459938,Percentage of subjects achieving normoglycemia,Area under the plasma concentration versus time curve (AUC),,2015-01,COMPLETED,INTERVENTIONAL,['PHASE1']
8984,NCT01571232,The Change in Central Foveal Thickness (Microns on High Resolution OCT).,The Change in Mean Central Amplitude on Multi-focal ERG From Baseline.,,2012-04,COMPLETED,INTERVENTIONAL,['PHASE2']
8985,NCT05640180,"Time to first occurrence of the composite endpoint of Cardiovascular (CV) death or non-fatal CV event (i.e. myocardial infarction, stroke, or hospitalization for heart failure)","Time to first occurrence of the following composite endpoint: onset of kidney failure, a sustained decrease in eGFR of ≥ 57% from baseline over at least 4 weeks or renal death",,2022-11-23,COMPLETED,OBSERVATIONAL,['NA']
8986,NCT03374176,Probing Depth,Total Count of All Teeth Lost Across All Participants,,2014-03,COMPLETED,INTERVENTIONAL,['PHASE3']
8987,NCT05476276,Daily 0-10 pain NRS,Opioid Use Questionnaire (OUQ),Neuropathy Examination,2022-09-21,RECRUITING,INTERVENTIONAL,['PHASE2']
8988,NCT02307695,Change of Mean amplitude of glycemic excursions (MAGE) from baseline in patients with type 1 diabetes treated with saxagliptin plus insulin or insulin alone by continuous glucose monitoring system (CGMS),Change of insulin dosage (U/kg/d) from baseline in patients with type 1 diabetes treated with saxagliptin plus insulin or insulin alone,,2014-11,UNKNOWN,INTERVENTIONAL,['PHASE4']
8989,NCT00941954,Change in ambulatory activity (walking),Change in ambulatory activity (walking),,2009-09,COMPLETED,INTERVENTIONAL,['NA']
8990,NCT02521506,number of hypoglycemic events,,,2015-03,COMPLETED,INTERVENTIONAL,['NA']
8991,NCT01487408,HbA1c (glycosylated haemoglobin),Adverse events,,2002-04,COMPLETED,OBSERVATIONAL,['NA']
8992,NCT02734277,Change in Beta Cell Function by MMTT-Stimulated Mean C-peptide Area Under the Curve (AUC),Severity of Grade 3 or Higher Adverse Events (AEs) of Interest,,2016-08-18,RECRUITING,OBSERVATIONAL,['NA']
8993,NCT01935804,"Change in mean percentage change in BMD at various sites by Dual energy X-ray absorptiometry(DXA) from baseline and at 6, 12 months in PIO versus MET treatment group.",Bone turnover Markers and other Biomarkers,Exploratory and safety outcomes,2009-01,COMPLETED,INTERVENTIONAL,['PHASE2']
8994,NCT03527641,Homeostasis model assessment of insulin resistance (HOMA-IR),Everyday Discrimination Scale,,2018-05-01,COMPLETED,INTERVENTIONAL,['NA']
8995,NCT02320344,Problem Areas in Diabetes,Triglycerides,,2013-07,COMPLETED,INTERVENTIONAL,['NA']
8996,NCT01621776,The Difference Between Pre- and 120 Minute Post-prandial Blood Glucose Concentrations at Lunch.,Difference Between Pre- and 120 Minute Post-prandial Blood Glucose Concentrations at Breakfast,,2011-06,COMPLETED,INTERVENTIONAL,['NA']
8997,NCT03480945,Endothelial function,,,2016-01-01,COMPLETED,OBSERVATIONAL,['NA']
8998,NCT01398592,demonstrate that the FPG after 14 days of treatment with Vildagliptin is superior to the FPG after 14 days of treatment with Sitagliptin,To assess the difference in FPG between vildagliptin and sitagliptin in patients with type 2 diabetes mellitus on concomitant treatment with metformin,,2011-06,COMPLETED,INTERVENTIONAL,['PHASE4']
8999,NCT06050577,Procollagen type 1 N-terminal propeptide (P1NP),Body mass index (BMI),Osteogenic potential,2023-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
9000,NCT00298129,,,,2004-02,COMPLETED,OBSERVATIONAL,['NA']
9001,NCT00696111,Sleep recording/polysomnography,24-hour hormonal profiles,,2007-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
9002,NCT00961909,Change in hemoglobin A1c (HbA1c),"Change in metabolic parameters: glucose, insulin, C-peptide",,2009-06,COMPLETED,INTERVENTIONAL,['PHASE1']
9003,NCT00289614,Increase in serum creatinine (SCr) at 48-72 hours post dose,Decrease in estimated glomerular filtration rate (eGFR) at 48-72 hours post dose; occurrence of adverse events,,2006-01,COMPLETED,INTERVENTIONAL,['PHASE4']
9004,NCT06235762,Heart Rate (HR) beats per minute (bpm),"Physical activity level (sedentary, moderate, advanced)",,2020-08-16,COMPLETED,INTERVENTIONAL,['NA']
9005,NCT02503865,Systolic/ Diastolic Blood Pressures (mm Hg),Immunoassay Cortisole in Blood,,2003-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9006,NCT05835596,General Practitioner attendance 1 year postpartum,Clinical cardiovascular follow-up at recruitment hospital: serum biomarkers associated to cardiovascular risk,,2023-12,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9007,NCT03470454,affection of estimated glomerular filtration rate,change in serum uric acid,Affection of albumin creatinine ratio,2018-07-01,COMPLETED,OBSERVATIONAL,['NA']
9008,NCT00680706,Effect of Thiamine Supplementation on Dyspnea,,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE2']
9009,NCT02346838,Change in insulin sensitivity.,Change in arterial stiffness.,,2014-01,COMPLETED,INTERVENTIONAL,['NA']
9010,NCT04437537,Wound Microbiome,Wound pH,,2022-05-15,UNKNOWN,OBSERVATIONAL,['NA']
9011,NCT03026218,Reduction in the number of individuals requiring pharmacotherapy for treatment of gestational diabetes,Reduction in the number of infants with neonatal hypoglycemia.,,2017-04-15,COMPLETED,INTERVENTIONAL,['NA']
9012,NCT00365495,Mitochondrial respiratory measurements. The investigations are carried out by two rounds - one before Christmas and one after.,mitochondrial production of free oxygen radicals,,2006-08,UNKNOWN,INTERVENTIONAL,['NA']
9013,NCT00151190,"HbA1c, Triglycerides, Cholesterol, Urine Microalbumin, Blood Pressure,","Patients' attitudes and knowledge about diabetes self-management, American Diabetes Association standards of care.",,2005-04,COMPLETED,INTERVENTIONAL,['PHASE3']
9014,NCT01144520,Ex vivo leukocyte function by measuring ROS production,Ex vivo NADPH oxidase gene and protein expression,,2010-03,TERMINATED,OBSERVATIONAL,['NA']
9015,NCT05184049,The change of resting-state functional Magnetic Resonance Imaging,Mean change of Montreal Cognitive Assessment,,2022-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
9016,NCT02015130,"Composite endpoint: All cause mortality, non-fatal myocardial infarction, coronary revascularization, cardiac arrest with resuscitation, heart failure, non-fatal stroke, progression of nephropathy or retinopathy, severe hypoglycaemia and cancer",Quality of life,All cause hospitalization,2013-10,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
9017,NCT03556098,plasma glucose concentration,Pulse,,2019-02-22,COMPLETED,INTERVENTIONAL,['NA']
9018,NCT04596631,Change from baseline in glycosylated haemoglobin (HbA1c),SNAC plasma concentrations,,2020-11-02,RECRUITING,INTERVENTIONAL,['PHASE3']
9019,NCT00272077,SMBG values,results of CGMS,,2005-04,COMPLETED,INTERVENTIONAL,['PHASE4']
9020,NCT05151276,The Turkish Multidimensional Diabetes Questionnaire,triglyceride,,2018-07-01,COMPLETED,INTERVENTIONAL,['NA']
9021,NCT03692884,The number of patients whoes Diabetic Kidney disease (DKD) is worsen,The number of patients who develop Diabetic foot,,2018-07-01,RECRUITING,OBSERVATIONAL,['NA']
9022,NCT01637324,,,,2011-05,COMPLETED,OBSERVATIONAL,['NA']
9023,NCT01240785,Birth Weight Per Arm,Child Outcome at 2 Years Per Arm,,2006-06,COMPLETED,INTERVENTIONAL,['PHASE4']
9024,NCT00570141,Percent Wounds Closed,,,2007-10,COMPLETED,INTERVENTIONAL,['PHASE4']
9025,NCT06066021,Change in the Diabetes Knowledge Questionnaire (DKQ - Portuguese version),Measure the change in BMI,,2023-10-13,RECRUITING,INTERVENTIONAL,['NA']
9026,NCT01821508,The primary endpoint will be the proportion of patients that present normalization of the albumin/creatinine ratio in isolated urine samples (normal value considered as an albumin/creatinine ratio of less than 30 μg/mg ).,Changes in hepatic fibrosis,,2013-04-18,COMPLETED,INTERVENTIONAL,['NA']
9027,NCT00764361,Number of Participants Without Adverse Events,Analyze the Molecular Changes in Pro-inflammatory Cytokine Levels That Occur in Diabetic Foot Ulcers as a Function of Healing Rate in the Presence /Absence of NanoDOX Hydrogel (1% Doxycycline Monohydrate Gel),,2009-01,COMPLETED,INTERVENTIONAL,['PHASE2']
9028,NCT01191983,Percentage of Participants Maintaining Hb Concentration Within the Target Range (10-12 g/dL) During EEP,Short Form-36 Health Survey (SF-36) score,,2010-08-13,COMPLETED,INTERVENTIONAL,['PHASE4']
9029,NCT04276207,Time to Recovery From Hyperglycemia Following Administration of LY900014 and Insulin Lispro (Humalog) After Pump Suspension,Pharmacokinetics (PK): Time to Maximum Observed Insulin Lispro Concentration (Tmax) Following Administration of LY900014 and Insulin Lispro (Humalog),,2020-02-25,COMPLETED,INTERVENTIONAL,['PHASE1']
9030,NCT00498147,Rates of cardiovascular events and other complications of diabetes compared to provincial and national rates,"The secondary outcomes will be total mortality, CV- related events, and other selected complications of diabetes.",,2007-07,UNKNOWN,OBSERVATIONAL,['NA']
9031,NCT01805297,Rate of Resolved Post-operative Vitreous Hemorrhage.,Changes in Mean Central Retinal Thickness.,,2013-03,COMPLETED,INTERVENTIONAL,['PHASE2']
9032,NCT00741026,Plasma Free Fatty Acid,Diastolic Blood Pressure,,2008-08,COMPLETED,INTERVENTIONAL,['NA']
9033,NCT02815657,The area under the plasma concentration-time curve (AUC) of valsartan,The number of volunteers with adverse events as a measure of safety and tolerability,,2013-04,COMPLETED,INTERVENTIONAL,['PHASE1']
9034,NCT02866565,Percentage of patients achieving 100% wound closure,change in quality of life assessed by the SF-36 QoL survey from baseline,,2023-06,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
9035,NCT01729286,Complete wound closure,Nonserious and serious adverse events,,2012-09,TERMINATED,INTERVENTIONAL,['NA']
9036,NCT02489942,Number of Patients With Adverse Drug Reactions (ADRs),Change From Baseline in Fasting Plasma Glucose (FPG) at the Last- Observation During Observation Period,,2015-06-12,COMPLETED,OBSERVATIONAL,['NA']
9037,NCT05797051,Microhyperspectral image of urine specimen,,,2023-05-30,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
9038,NCT03912909,Reduction in muscle sympathetic nerve activity,Change in glycemic control,,2018-08-01,RECRUITING,INTERVENTIONAL,['PHASE4']
9039,NCT01691989,Change from baseline in hemoglobin HbA1c,Safety: incidence of adverse events,,2012-12,COMPLETED,INTERVENTIONAL,['PHASE3']
9040,NCT05316298,Postoperative wound healing,Foot Function Index (FFI) scores,,2022-12-01,RECRUITING,OBSERVATIONAL,['NA']
9041,NCT02987556,Percentage of time spent in the tight glycemic control area 70-180 mg/dl continuously measured for 12 weeks,Percentage of time spent in blood glucose <70 mg/dl continuously measured for 12 weeks,,2017-03-30,COMPLETED,INTERVENTIONAL,['NA']
9042,NCT03859245,Hard Drusen in the Mid-periphery pathology,Triglycerides/HDL ratio,,2019-02-23,UNKNOWN,INTERVENTIONAL,['NA']
9043,NCT03617770,Sleep Regularity,Diabetes Distress,,2019-01-09,COMPLETED,INTERVENTIONAL,['NA']
9044,NCT03467659,Appetitive behavior,,,2017-02-16,COMPLETED,INTERVENTIONAL,['NA']
9045,NCT00422357,Blood pressure every two weeks.,,,2007-01,COMPLETED,INTERVENTIONAL,['PHASE1']
9046,NCT00754741,LDL-cholesterol Levels,Cardiovascular Morbidity and Mortality (Exploratory),,2008-07,COMPLETED,INTERVENTIONAL,['PHASE3']
9047,NCT01612468,Change in HbA1c,Quality of life,,2012-06,COMPLETED,INTERVENTIONAL,['PHASE4']
9048,NCT03527537,Composite Neonatal Outcome,Preeclampsia,,2021-05-04,RECRUITING,INTERVENTIONAL,['PHASE4']
9049,NCT00613951,Change in Glycosylated Haemoglobin (HbA1c),Physical Examination,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE2']
9050,NCT02017132,Changes in measurements of body mass indicators,Changes in blood pressure,Change in urinary cortisol-to-cortisone ratio,2013-04,UNKNOWN,INTERVENTIONAL,['NA']
9051,NCT02551874,Mean Change From Baseline in HbA1c at Week 24,Change From Baseline in the Mean Value of 24-hour Glucose at Week 2,,2015-10-20,COMPLETED,INTERVENTIONAL,['PHASE3']
9052,NCT03178253,percentage of hypothyroidism in patients of type 2 diabetes with diabetic nephropathy,,,2017-06-30,UNKNOWN,OBSERVATIONAL,['NA']
9053,NCT02366468,Mean Average Change From Baseline in Best Corrected Visual Acuity (BCVA) of the Study Eye From Month 1 to Study Treatment Completion (Month 12),Number of Participants With Change in Diabetic Retinopathy Study (DRS) Retinopathy Scale,,2015-02-23,COMPLETED,INTERVENTIONAL,['PHASE4']
9054,NCT00280865,Absolute change from baseline to end of randomized treatment period in fasting plasma glucose (FPG),"To evaluate diabetes-specific instruments, Audit of Diabetes Dependent Quality of Life (ADDQoL) and The Diabetes Treatment Satisfaction Questionnaire (DTSQ) (s and c) in the study population and estimate the effect size of the instruments in patients r",,2002-04,COMPLETED,INTERVENTIONAL,['PHASE2']
9055,NCT02232698,Time Spent <70 mg/dL,Change in Diabetes Treatment Satisfaction Questionnaire (DTSQc) Scores From Day 1 to Day 208,,2014-09,COMPLETED,INTERVENTIONAL,['NA']
9056,NCT03804125,"the number and type of suspected adverse drug reactions, including serious and non-serious cases",,,2021-09-01,WITHDRAWN,OBSERVATIONAL,['NA']
9057,NCT04507438,Change in Hemoglobin A1C,Change in creatinine,Change in albumin,2019-07-12,TERMINATED,INTERVENTIONAL,['PHASE2']
9058,NCT01516476,Change in hemoglobin A1c (HA1c),Safety (incidence of adverse events),,2011-11,TERMINATED,INTERVENTIONAL,['PHASE2']
9059,NCT05109949,Pulse wave velocity,Blood pressure,,2020-03-30,UNKNOWN,INTERVENTIONAL,['PHASE3']
9060,NCT02133118,"The course of weight (Kg) after starting individual SU's, pioglitazone or insulin as add-on therapy.","The course of the glycaemic control (HbA1c %) , up to five years after starting individual SU's, pioglitazone or insulin as add-on therapy.",,1998-01,COMPLETED,OBSERVATIONAL,['NA']
9061,NCT02572414,Adherence to Department of Health and Human Services physical activity guideline,Adherence to 5-a-Day diet guideline,,2015-01-08,COMPLETED,INTERVENTIONAL,['NA']
9062,NCT00101426,Efficacy,Safety,,2004-10,COMPLETED,INTERVENTIONAL,['PHASE3']
9063,NCT03937934,Change in number of days a week and minutes per day participants participate in physical activity and sedentary activity,Change in Systolic and/or Diastolic Hypertension mmHg,,2019-05-20,COMPLETED,INTERVENTIONAL,['NA']
9064,NCT04653805,Number of visits with the primary care team in the previous 12 months,,,2017-01,COMPLETED,OBSERVATIONAL,['NA']
9065,NCT05168605,Change in Blood pressure,,,2022-07-27,RECRUITING,INTERVENTIONAL,['NA']
9066,NCT03763669,Insulin resistance,Fetal sonographic parameters,,2018-11-14,COMPLETED,INTERVENTIONAL,['NA']
9067,NCT03082859,Mean 24-hour blood glucose concentrations (mmol/L),Glycaemic Variability (Glucose levels),Mood measured using the Brunel Scale of Mood States (BRUMS),2016-07,UNKNOWN,INTERVENTIONAL,['NA']
9068,NCT04255004,probability of healing at 24 months,rest pain,,2014-01,COMPLETED,INTERVENTIONAL,['NA']
9069,NCT03970044,MAGE,Blood Glucose Time In Range,,2019-07-02,COMPLETED,INTERVENTIONAL,['PHASE4']
9070,NCT00860392,Effects of increase in serum free fatty acid levels on ketogenesis as measured using a isotopic tracer and serum ketone body concentration in healthy lean subjects,Effects of increase in serum free fatty acid levels on ketogenesis as measured using a isotopic tracer and serum ketone body concentration in obese subjects,,2009-03-02,COMPLETED,INTERVENTIONAL,['PHASE1']
9071,NCT04978662,chronotype,treatment,,2021-07-06,UNKNOWN,OBSERVATIONAL,['NA']
9072,NCT05969015,Glycemic control,Diabetes Attitude Questionnaire (ATT-19),Adverse Events,2022-01-15,RECRUITING,INTERVENTIONAL,['NA']
9073,NCT01355718,Incidence of serious Adverse Drug Reactions (SADRs) including major (serious) hypoglycaemic episodes,Change in HbA1c,,2011-08,COMPLETED,OBSERVATIONAL,['NA']
9074,NCT01845857,"Change in Health Status (symptoms, activities limitations)",Change in Health Care Utilization,,2010-08,COMPLETED,INTERVENTIONAL,['NA']
9075,NCT03663738,HbA1c,Quality of life related to health,,2018-02-05,COMPLETED,INTERVENTIONAL,['NA']
9076,NCT00374426,,,,1998-03,COMPLETED,INTERVENTIONAL,['PHASE4']
9077,NCT04881994,"Maximum observed drug concentration of unbound finerenone (Cmax,u) in plasma",Number of participants with adverse events,Half-life associated with the terminal slope (t1/2) of finerenone,2014-03-25,COMPLETED,INTERVENTIONAL,['PHASE1']
9078,NCT00861952,Numeric pain scale (0-10) for immediate relief,Adverse event reports,,2010-01,WITHDRAWN,INTERVENTIONAL,['PHASE3']
9079,NCT01510093,Pharmacokinetic profiles of endogenous insulin and Insulin Aspart,Pharmacodynamic glucose profiles,,2012-05,COMPLETED,INTERVENTIONAL,['PHASE2']
9080,NCT00344240,Physical activity,,,2005-08,COMPLETED,INTERVENTIONAL,['NA']
9081,NCT01427998,Serum glucose,Plasma insulin,,1999-08,COMPLETED,INTERVENTIONAL,['PHASE3']
9082,NCT05957224,Change in plasma glucose concentration post oral intake of shake,"Sensory analysis of taste, texture, smell and appearance of shakes",,2023-11-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9083,NCT05668819,Change in PPG,Change in WHR,,2023-02-09,RECRUITING,INTERVENTIONAL,['NA']
9084,NCT03328546,Physical functioning,,,1989-01-01,COMPLETED,OBSERVATIONAL,['NA']
9085,NCT02310009,Beta-cell function,Glucose disposition,,2014-12,WITHDRAWN,INTERVENTIONAL,['NA']
9086,NCT05989867,steamed bun meal test result 3,glycemic control,,2023-03-01,RECRUITING,OBSERVATIONAL,['NA']
9087,NCT01775813,Insulin Sensitivity,High Density Lipoprotein,,2011-06,COMPLETED,INTERVENTIONAL,['PHASE4']
9088,NCT00961857,The area under the plasma concentration vs. time curve (AUC) after administration of sitagliptin/metformin (50/500 and 50/1000 mg/mg) FDC tablet and co-administration of corresponding doses of sitagliptin and metformin as individual tablets,Peak plasma concentration (Cmax) of sitagliptin and metformin after administration of sitagliptin/metformin (50/500 and 50/1000 mg/mg) FDC tablet and co-administration of corresponding doses of sitagliptin and metformin as individual tablets,,2005-12-01,COMPLETED,INTERVENTIONAL,['PHASE1']
9089,NCT04477707,Progression of non-proliferative diabetic retinopathy (NPDR),Change in severity of diabetic retinopathy (DR),,2020-07-23,COMPLETED,OBSERVATIONAL,['NA']
9090,NCT01224548,weight,hip circumference,,2010-10,COMPLETED,INTERVENTIONAL,['NA']
9091,NCT02699736,"Incidence of long-term virological, immunological and morbidity and mortality outcomes across different regions in Europe; and demographic, clinical, therapeutic and viral factors associated with these outcomes",Incidence of toxicities related to direct acting antivirals by regions,,1994-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
9092,NCT02946632,"Proportion of patients who met HbA1c < 6.5% without hypoglycaemia, weight gain, or discontinuation due to adverse events at 104 weeks",Changes in fat and lean mass from baseline to at 104 weeks,AEs/SAEs,2016-12,UNKNOWN,INTERVENTIONAL,['PHASE3']
9093,NCT01180530,The incidence of technical complaints related to adverse reactions,,,2010-10,COMPLETED,OBSERVATIONAL,['NA']
9094,NCT04201171,HRQOL,,,2017-01-01,COMPLETED,OBSERVATIONAL,['NA']
9095,NCT01616472,"New diagnoses of diabetes, hypertension, cataracts, osteoporosis, or avascular necrosis",,,2012-04,COMPLETED,OBSERVATIONAL,['NA']
9096,NCT00478335,24h Urine Volume,,,2007-05,COMPLETED,INTERVENTIONAL,['NA']
9097,NCT01857375,Insulin Dosing Accuracy (in units),Patient satisfaction with method of insulin administration measured by questionnaire.,,2009-10,COMPLETED,OBSERVATIONAL,['NA']
9098,NCT05877378,Health-related effects on quality of life.,,,2023-09-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9099,NCT02685449,Postprandial glycemia,The difference between the maximum and baseline glucose level,,2016-02,UNKNOWN,INTERVENTIONAL,['PHASE4']
9100,NCT06051318,Postprandial subcutaneous interstitial fluid glucose measured by continuous glucose monitor (CGM),Participant's gut microbiome species richness,,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9101,NCT02100319,Changes From Baseline in Home Blood Pressure on Final Assessment Point (up to Week 24),Percentage of Participants Who Had One or More Adverse Events,,2014-03-03,COMPLETED,OBSERVATIONAL,['NA']
9102,NCT05389254,The CCU occupancy rate,Major adverse cardiovascular events after 3 months,,2022-06,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9103,NCT02943486,Wound size change,Presence of Exudate,,2017-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9104,NCT01486875,Incidence of major hypoglycaemic events,Fasting Plasma Glucose (FPG),,2006-01,COMPLETED,OBSERVATIONAL,['NA']
9105,NCT01835730,Incidence and severity of adverse events including hypoglycemia,Pharmacodynamic Response,,2013-04,COMPLETED,INTERVENTIONAL,['PHASE1']
9106,NCT02325466,Mean Change in High Shear Blood Viscosity,Mean Change in Microvascular Blood Flow Composite Score,,2015-04,COMPLETED,INTERVENTIONAL,['PHASE3']
9107,NCT05120219,Pharmacokinetics parameters of SHR3824 and Metformin after multiple dose: AUCss,The incidence and severity of adverse events/serious adverse events,,2021-10-13,UNKNOWN,INTERVENTIONAL,['PHASE1']
9108,NCT00615212,drug plasma levels flurbiprofen:,Daily predose trough GSK376501 plasma concentrations when administered alone for 7 days (Days 4-13).,,2008-01-02,COMPLETED,INTERVENTIONAL,['PHASE1']
9109,NCT03669887,Proportion achieving body weight goal,% of achieving dietary intervention goal,,2018-09-12,COMPLETED,INTERVENTIONAL,['NA']
9110,NCT03243136,Type 2 diabetes,,,2004-01-01,COMPLETED,OBSERVATIONAL,['NA']
9111,NCT03863561,Validity of the SCPI with HbA1c,Responsiveness of the total SCPI score to an intervention,,2017-10-11,COMPLETED,OBSERVATIONAL,['NA']
9112,NCT06167499,Rate of glycated hemoglobin HBA1c,Evaluation of long-term complications over 18 months,,2024-02-09,RECRUITING,INTERVENTIONAL,['NA']
9113,NCT00758680,Number of Participants Who Discontinued Treatment Due to an AE,Least Squares Mean Change From Baseline in 24-Hour Weighted Mean Glucose (WMG),,2008-08,TERMINATED,INTERVENTIONAL,['PHASE1']
9114,NCT04135287,HbA1c,Fasting Plasma Glucagon,,2020-03-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
9115,NCT02109029,Part B: Pharmacokinetics: ISF-to-Serum Concentrations,,,2014-04,COMPLETED,INTERVENTIONAL,['PHASE1']
9116,NCT00625781,Perinatal morbidity and intrauterine growth,Children´s future health,,2008-02,COMPLETED,INTERVENTIONAL,['NA']
9117,NCT01902043,"Process of care indicators and the following outcomes of care: HbA1C, quality of life (QoL), Patient Assessment of Chronic Illness Care (PACIC)",,Knowledge of and participation in the activities/projects of the Programme cantonal Diabète (PcD),2011-09,UNKNOWN,OBSERVATIONAL,['NA']
9118,NCT00600366,HbA1c,Incidence of adverse events,,2004-03,COMPLETED,INTERVENTIONAL,['PHASE4']
9119,NCT01503164,Insulin Sensitivity (SI),Area Under the Curve Assessed by Oral Glucose Tolerance Test (OGTT),,2011-09,COMPLETED,INTERVENTIONAL,['NA']
9120,NCT04884633,Achieving good metabolic control of diabetes,The rate of significat glomerula filtration rate reduction,,2019-08-15,UNKNOWN,INTERVENTIONAL,['NA']
9121,NCT06061510,Diastolic blood pressure,Rate of smoking among participants,,2019-06-08,COMPLETED,INTERVENTIONAL,['NA']
9122,NCT05456984,Empower up,Diabetes treatment,,2022-05-03,COMPLETED,OBSERVATIONAL,['NA']
9123,NCT03987841,Hemoglobin A1c (A1C),Feasibility: Percentage of Sessions Attended,,2021-10-01,COMPLETED,INTERVENTIONAL,['NA']
9124,NCT00565318,Change in urinary excretion of: - Kidney injury molecule-1 (KIM-1) - Albumin,"Change in urinary excretion of: β2 microglobulin, macrophage inhibiting factor (MIF), monocyte chemo-attractant protein-1 (MCP-1), and other advanced glycation end-products (AGEs).",,2007-12,COMPLETED,INTERVENTIONAL,['PHASE4']
9125,NCT03587948,Diabetic eye diseases,,,2018-01-01,RECRUITING,OBSERVATIONAL,['NA']
9126,NCT00290927,Safety of HMR1964,"change in HbA1C from baseline to week 16,consecutive change in HbA1C every 4 wks,plasma glucose parameters, symptomatic hypoglycemia (comparison of HMR1964 intensive therapy, mono-or OHA combination therapy, with OHA therapy).",,2003-12,COMPLETED,INTERVENTIONAL,['PHASE3']
9127,NCT00461058,"Incidence of cardiovascular death, hospitalization or clinic visit for heart failure with i.v. administration of diuretics during 26 week treatment period.","Efficacy: Change from baseline to week 26 in Hemoglobin A1c (HbA1c), fasting plasma glucose (FPG), fasting plasma insulin (FPI) and lipid profile.",,2007-05,COMPLETED,INTERVENTIONAL,['PHASE2']
9128,NCT01752842,Change in Cardiac Systolic Function as Measured by Fractional Shortening Percent,Change in C24:0/C16:0 Ceramide Ratio,,2013-03,COMPLETED,INTERVENTIONAL,['NA']
9129,NCT02308735,Phosphatidylethanol Level,,,2014-03,TERMINATED,OBSERVATIONAL,['NA']
9130,NCT00537251,"Compare efficacy of insulin glargine & short acting insulin (Lispro), NPH insulin regime as basal insulin and regular insulin for meal insulin for metabolic control, evaluated by means of HbA1c .",,,2001-11,COMPLETED,INTERVENTIONAL,['PHASE3']
9131,NCT04154020,Mean time to healing of ulcers(s) in treated limb,Incidence of new ulcers on feet,,2019-11-30,COMPLETED,INTERVENTIONAL,['NA']
9132,NCT03242109,Diabetes,,,2005-03-01,COMPLETED,OBSERVATIONAL,['NA']
9133,NCT01577095,plasma glucose,plasma insulin,,2006-04,COMPLETED,INTERVENTIONAL,['PHASE2']
9134,NCT04018105,Area under the curve of D-Xylose,Area under the curve of GLP-1,,2022-12,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9135,NCT05614089,Time-in-range (TIR),Quality of Life (e.g. PedsQL Pediatric Quality of Life Inventory),,2023-03-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4']
9136,NCT03376490,Muscle strength (Leg extension),Vitamin D deficiency,,2012-01-01,COMPLETED,OBSERVATIONAL,['NA']
9137,NCT00763815,Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24,Percentage of Patients Requiring Rescue Therapy During Main 24-Week Period,Number of Patients With Symptomatic Hypoglycemia and Severe Symptomatic Hypoglycemia,2008-09,COMPLETED,INTERVENTIONAL,['PHASE3']
9138,NCT04357392,Number of patients with HbA1c <7% at 12 and 24 weeks,"Blood glucose fluctuation at 4, 12 and 24 weeks",,2020-05-20,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
9139,NCT05140551,To assess the implementation of COMPASS in terms of patient adherence to COMPASS online sessions and number and duration of therapist support calls attended.,,,2022-04-06,COMPLETED,INTERVENTIONAL,['NA']
9140,NCT03173391,Change from baseline in HbA1c,Incidence of Treatment-Emergent Adverse Events over time,,2017-07-18,COMPLETED,INTERVENTIONAL,['PHASE3']
9141,NCT04233203,MAGE,TIR-TAR-TUR,Severe adverse effects,2020-01-31,COMPLETED,OBSERVATIONAL,['NA']
9142,NCT06059326,Number of Participants With Treatment-Emergent Adverse Events (TEAEs),Change from baseline of HbA1c,,2019-01-22,COMPLETED,INTERVENTIONAL,['PHASE2']
9143,NCT05799781,Percent of time with sensed glucose between 70-180 mg/dl,Mean amount of insulin delivered per day,,2023-03-13,RECRUITING,INTERVENTIONAL,['NA']
9144,NCT06260605,Education,,,2023-12-19,COMPLETED,INTERVENTIONAL,['NA']
9145,NCT02903264,Gestational diabetes mellitus diagnosed by an endocrinologist,Leukocytosis as an indicator of inflammation,,2007-01,COMPLETED,OBSERVATIONAL,['NA']
9146,NCT00761852,To test the hypothesis that activation of protein kinase Cß (PKCß) impairs vascular reactivity in patients with diabetes mellitus,,,1999-05,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
9147,NCT02075281,Change from baseline in body weight at 20 weeks,"Change from baseline in blood lipid profile (e.g., cholesterol, and LDL-C level) at 20 week",Change from baseline in β-cell function at 20 week,2014-02,COMPLETED,INTERVENTIONAL,['PHASE2']
9148,NCT00839683,Exposure to the investigational drug will be measured to compare with and without the co-administration of other drugs,"To assess the effect of dapagliflozin on the PK of simvastatin acid (active metabolite of simvastatin), when coadministered in healthy subjects",,2009-02,COMPLETED,INTERVENTIONAL,['PHASE1']
9149,NCT00437775,,,,2007-01,UNKNOWN,OBSERVATIONAL,['NA']
9150,NCT02520076,To demonstrate AAT efficacy in preventing non-immunologic loss of transplanted islet mass in a single-donor islet transplant.,To demonstrate AAT efficacy in the prevention of long-term metabolic burn-out.,,2015-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9151,NCT00255541,Absolute change from baseline to end of randomized treatment period in glycosylated hemoglobin A1c (HbA1c),"Safety and tolerability of tesaglitazar by assessment of adverse events, laboratory values, electrocardiogram, pulse, blood pressure, hypoglycemic events, body weight, cardiac evaluation, and physical examination",,2004-09,TERMINATED,INTERVENTIONAL,['PHASE3']
9152,NCT00664534,Baseline Adjusted Glycosylated Hemoglobin (HbA1c) at Endpoint,Number of Participants With Adverse Events,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE4']
9153,NCT02582814,Vital Signs (Blood Pressure),Adjusted Change From Baseline in SBP in Subjects With Baseline SBP/DBP >= 140/90 mmHg,,2015-10-26,COMPLETED,INTERVENTIONAL,['PHASE3']
9154,NCT03544320,Change in hemoglobin A1c,Change in low-density lipoprotein (LDL) levels,Hospitalization,2018-07-09,COMPLETED,INTERVENTIONAL,['NA']
9155,NCT04797442,Fasting plasma glucose levels,Fat mass,,2021-07-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
9156,NCT00333671,"Retinal thickness by fast retinal thickness mapping by optical coherence tomography at times 0, 2, 4, 8, 10, 15, 20, 30, 60, 90, 120 and 180 minutes after the last swallow of glycerol.",dose dependent differences in the same time spectrum.,,2004-12,COMPLETED,INTERVENTIONAL,['NA']
9157,NCT06239506,alternative FRs,levels of FPG,,2022-01-01,RECRUITING,OBSERVATIONAL,['NA']
9158,NCT01930448,Change in Incretin Effect,Change in Body Composition,,2008-09,WITHDRAWN,OBSERVATIONAL,['NA']
9159,NCT04950283,Insulin sensitivity,,,2021-07-07,RECRUITING,OBSERVATIONAL,['NA']
9160,NCT01110746,3 hour incremental area under the glucose curve after a standardized high glycemic index meal.,"Draize scores at insulin infusion site at 24 hour and 72 hour follow-up visits, frequency of discomfort with insulin infusion, and severity of discomfort with insulin infusion (ratings of mild, moderate, or severe).",,2010-02,COMPLETED,INTERVENTIONAL,['PHASE3']
9161,NCT01956357,Glycated hemoglobin,Global Histone Deacetylases activity,Sleep quality.,2012-08,COMPLETED,INTERVENTIONAL,['NA']
9162,NCT01220310,Self-Efficacy,,,2008-10,COMPLETED,INTERVENTIONAL,['PHASE3']
9163,NCT03811288,Participants with a history of established cardiovascular disease (CVD),Participants with high risk of CVD according to the risk engine from the United Kingdom Prospective Diabetes Study (UKPDS),,2018-12-10,COMPLETED,OBSERVATIONAL,['NA']
9164,NCT02723266,Lifestyle Management,Number of subjects reporting an unplanned pregnancy,,2018-03-16,COMPLETED,INTERVENTIONAL,['NA']
9165,NCT00543816,,,,2003-08,TERMINATED,INTERVENTIONAL,['PHASE3']
9166,NCT01546181,photoreceptor density,,,2010-10,COMPLETED,OBSERVATIONAL,['NA']
9167,NCT03074630,Change in Plasma LDL Cholesterol,Urinary Sodium Excretion,,2016-05,COMPLETED,INTERVENTIONAL,['PHASE4']
9168,NCT01705639,Glucose tolerance,Activity,,2012-11,COMPLETED,INTERVENTIONAL,['PHASE3']
9169,NCT03711656,Sensitivity (SE) and specificity (SP) to predict Level 1 hypoglycemia,Number of Level 3: severe hypoglycemia,,2018-10-10,COMPLETED,INTERVENTIONAL,['NA']
9170,NCT02632929,Limb salvage,effective wound healing,Diabetic Foot Ulcer Quality of life Short Form survey,2015-05-30,COMPLETED,OBSERVATIONAL,['NA']
9171,NCT01834274,Change From Baseline in Glycosylated Hemoglobin (HbA1c),Change From Baseline in Fasting Plasma Glucose (FPG),,2013-06,TERMINATED,INTERVENTIONAL,['PHASE3']
9172,NCT03324191,Effect of tea extract on serum triacylglycerol concentration following a high fat meal,Effect of tea extract on whole body lipid oxidation following a high fat meal,,2017-10-10,COMPLETED,INTERVENTIONAL,['NA']
9173,NCT00743327,Evaluation for the development of incident diabetes,"Evaluation for other cardiovascular risk factors, markers of inflammation and immunological changes",,2008-10,TERMINATED,OBSERVATIONAL,['NA']
9174,NCT01322711,Evaluation of effect of Atorvastatin Therapy in Hypercholesterolemic Patients (n=30) and Diabetic Patients (n=30),,,2011-03,UNKNOWN,INTERVENTIONAL,['PHASE4']
9175,NCT05726006,To examine the prevalence of antibiotic resistance of invasive GBS isolates among non-pregnant people in Malaysia.,Detection of Sequence Type (ST),,2020-02-01,RECRUITING,OBSERVATIONAL,['NA']
9176,NCT03274362,Quality of life,Diabetes empowerment,,2017-09,UNKNOWN,INTERVENTIONAL,['NA']
9177,NCT01455909,Change in HbA1c,,,2013-02,WITHDRAWN,INTERVENTIONAL,['PHASE3']
9178,NCT04374578,Effect on glycemic variability,Effect on Glycemic Control,,2020-05-08,COMPLETED,OBSERVATIONAL,['NA']
9179,NCT04198441,Time to Maximum Wound Closure,,,2020-06-02,UNKNOWN,INTERVENTIONAL,['NA']
9180,NCT02866435,"Change from baseline (i.e., normal glucose levels) cerebral blood flow, measured in ml/min/100g, at hypoglycemia",,,2016-11,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
9181,NCT00229710,Body weight,"Central obesity (waist circumference, hip circumference, waist/hip ratio)",,2005-02,TERMINATED,INTERVENTIONAL,['PHASE3']
9182,NCT02914743,Dental care-seeking behavior,Change from baseline Hemoglobin A1c at 3 and 6 months,Clinician attitude towards the value of having a hygienist in the hospital setting,2016-11,COMPLETED,INTERVENTIONAL,['NA']
9183,NCT04286555,Systolic blood pressure (SBP),Symptoms experienced by participants as assessed by a questionnaire,,2021-06-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
9184,NCT00937872,Define the intravenous pharmacokinetics of SRT2104.,Potential systemic metabolite burden of SRT2104 following administration.,,2008-11-22,COMPLETED,INTERVENTIONAL,['PHASE1']
9185,NCT00521378,Daily glucodynamic profile of Oral HDV-Insulin,,,2007-09-17,COMPLETED,OBSERVATIONAL,['NA']
9186,NCT00776763,Growth Factors and Other Cytokines Measurements,,,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2']
9187,NCT00766857,Cardiac Magnetic Resonance (CMR) will be used to assess global cardiac function (LV ejection fraction).,Exercise capacity and performance will be assessed by a 6-minute walking test,,2009-05,COMPLETED,INTERVENTIONAL,['PHASE4']
9188,NCT01773798,Area under the glucose infusion rate curve,Area under the serum IAsp concentration-time curve,,2013-01,COMPLETED,INTERVENTIONAL,['PHASE1']
9189,NCT00222508,,,,2001-04,COMPLETED,OBSERVATIONAL,['NA']
9190,NCT03875625,Anthropomorphic measurements using BP machine,,,2019-04-01,RECRUITING,INTERVENTIONAL,['NA']
9191,NCT00995930,Change From Baseline in Plaque Burden (Aortic Vessel Wall Area and Carotid Vessel Wall Area),Pharmacokinetics: ACZ885 Serum Concentrations,,2009-12,COMPLETED,INTERVENTIONAL,['PHASE2']
9192,NCT00305344,Children With T1D Underwent a Single Autologous UCB Transfusion,,,2005-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9193,NCT04042285,Wound volume,Tissue integrity,,2019-02-01,UNKNOWN,INTERVENTIONAL,['NA']
9194,NCT05556005,Change from baseline Left ventricular functions at 3 months,Change from baseline Transforming growth factor beta 1 at 3 months,,2022-09-18,RECRUITING,INTERVENTIONAL,['PHASE2']
9195,NCT04831775,"Change in attention, visual scanning and motor speed at week 22",Change in perceived cognitive function at week 22,,2021-11-01,RECRUITING,INTERVENTIONAL,['NA']
9196,NCT04891627,"It was aimed to compare IL-34 levels by taking gingival crevicular fluid in systemic healthy, periodontitis and diabetic patients with periodontitis groups.","It was aimed to compare CSF-1 levels by taking gingival crevicular fluid in systemic healthy, periodontitis and diabetic patients with periodontitis groups.",,2021-01-06,COMPLETED,OBSERVATIONAL,['NA']
9197,NCT01494025,Change in Body Weight,,,2009-10,COMPLETED,INTERVENTIONAL,['NA']
9198,NCT03790787,"AUCτ,ss",,,2019-04-18,COMPLETED,INTERVENTIONAL,['PHASE1']
9199,NCT00448032,Safety,Pharmacokinetics/Pharmacodynamics,,2006-11,COMPLETED,INTERVENTIONAL,['PHASE1']
9200,NCT03353792,Brain Alternate Fuel Uptake,Change in Cognitive Function: Grooved Pegboard Test,,2017-11-01,TERMINATED,INTERVENTIONAL,['NA']
9201,NCT04025996,"Cross-sectional analyses will be performed to look at the association between diabetic retinopathy with left ventricular diastolic function, coronary flow reserve and urinary albumin excretion.",,,2018-02-20,UNKNOWN,OBSERVATIONAL,['NA']
9202,NCT01127997,Area under the curve of plasma glucose after meal,the mechanism of second-meal phenomenon,,2010-03,COMPLETED,OBSERVATIONAL,['NA']
9203,NCT02244736,Differences of endothelial function at baseline and during OGTT among the 3 groups.,Insulin resistance and endothelial function,,2013-02,COMPLETED,OBSERVATIONAL,['NA']
9204,NCT02206074,Pulmonary gas exchange via MedGraphics CardiO2 Cardiopulmonary Diagnostic Systems,Functional capacity measured by 6-Minute Walking Test (6MWT),,2012-05,COMPLETED,INTERVENTIONAL,['NA']
9205,NCT05449496,Post-transplant complications rates,Dietary complications,,2022-06-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
9206,NCT01288885,"Safety and Tolerability assessed by the incidence of adverse events, vital signs, physical examinations, 12-lead ECG and lab-tests",Pharmacodynamics assessed by ASP1941 glucose concentration changes in blood and urine,,2006-11,COMPLETED,INTERVENTIONAL,['PHASE1']
9207,NCT01463813,Cancer,,,2012-09,COMPLETED,INTERVENTIONAL,['NA']
9208,NCT01252979,Heteroplasmy,,,2010-12,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
9209,NCT06037369,DFU Quality of life,Diabetes-related foot self-care behavior,,2023-09-14,RECRUITING,INTERVENTIONAL,['NA']
9210,NCT00537277,Percentage of Subjects Achieving the Treatment Target of Glycosylated Haemoglobin (HbA1c) Below 7.0%,Number of Treatment Emergent Serious Adverse Events (SAEs),,2007-10,COMPLETED,INTERVENTIONAL,['PHASE4']
9211,NCT04436822,Percentage of Readings Within 20% Agreement,,,2020-07-15,COMPLETED,INTERVENTIONAL,['NA']
9212,NCT04088929,Impact of Pure Green CBD tablets on diabetic neuropathy pain using a daily self-reported pain scale score.,Impact on the use of sublingual tablets as the route of administration,,2019-09-30,COMPLETED,INTERVENTIONAL,['PHASE2']
9213,NCT04287387,Changes from baseline to post-treatment in composition in level of C-reative protein.,The linear relationship between gut microbiota and inflammation factors level.,,2020-03-02,UNKNOWN,INTERVENTIONAL,['PHASE4']
9214,NCT04513197,Development of endocrine dysfunction (diabetes & prediabetes) after acute pancreatitis,2) To evaluate whether severity of acute pancreatitis have an impact on the development of endocrine dysfunction or not?,,2019-03-01,UNKNOWN,OBSERVATIONAL,['NA']
9215,NCT05918653,Biomedical profile of diabetic patients,,,2022-12-15,COMPLETED,OBSERVATIONAL,['NA']
9216,NCT02308683,Post treatment mean HsCRP,Post treatment mean hgba1c,,2014-08,COMPLETED,INTERVENTIONAL,['PHASE1']
9217,NCT01029327,,,,2009-06,COMPLETED,OBSERVATIONAL,['NA']
9218,NCT02021890,improved physical fitness (physical activity exceeding 10 MET-hour/week,10% increase in 6-min walk test,,2011-09,COMPLETED,INTERVENTIONAL,['NA']
9219,NCT04386200,Change from baseline in Body Weight,Change from baseline in Quality of life by 36-item short form health survey (SF-36),,2019-02-13,UNKNOWN,INTERVENTIONAL,['NA']
9220,NCT03703544,Daily blood glucose profile,,,2017-12-15,COMPLETED,INTERVENTIONAL,['NA']
9221,NCT03985384,Rate of change in non-calcified plaque volume,Rate of change in total plaque volume,,2019-04-30,COMPLETED,INTERVENTIONAL,['PHASE4']
9222,NCT00740363,Insulin secretion,Cyclosporine/tacrolimus blood concentrations,,2008-09,COMPLETED,INTERVENTIONAL,['PHASE4']
9223,NCT03288610,Preoperative copeptin level,Day 28 mortality rate,,2017-01,COMPLETED,OBSERVATIONAL,['NA']
9224,NCT03889496,Correlation between the tracer uptake (counts) and beta cell mass (mg),,,2015-11-16,TERMINATED,INTERVENTIONAL,['NA']
9225,NCT01034319,stage of change,program attendance,,2009-12,UNKNOWN,INTERVENTIONAL,['PHASE2']
9226,NCT03552315,"The three-hour incremental area under the curve (iAUC) for capillary blood glucose, 0-180 minutes","The one-hour iAUC for intravenous Glucagon-like peptide 1 (GLP-1), 0-60 minutes",Difference in two-hour glucose (delta-glucose at 2h) from both capillary and intravenous blood.,2018-04-24,COMPLETED,INTERVENTIONAL,['NA']
9227,NCT01387659,Tolerability of Myfortic in combination with Simulect and Tacrolimus without steroids,Biopsy proven rejection,,2011-03,TERMINATED,INTERVENTIONAL,['NA']
9228,NCT00375492,Change From Baseline in Body Weight,Rate of Hypoglycemic Events,,2006-09,COMPLETED,INTERVENTIONAL,['PHASE3']
9229,NCT05162690,Intraepithelial nerve fiber density,corneal nerve fiber density,,2022-05-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
9230,NCT00141219,Daily Pain Rating Scale (DPRS)- Mean Pain Score (ITT Population),Duration Adjusted Average Change (DAAC) of (Unadjusted) Mean Pain Score,Daily Pain Rating Scale (DPRS)- Mean Pain Scores (Evaluable Population),2005-12,COMPLETED,INTERVENTIONAL,['PHASE3']
9231,NCT03805802,Fasting glucose,Inflammation: hsCRP,Waist circumference,2019-02-04,COMPLETED,INTERVENTIONAL,['NA']
9232,NCT02297620,Specify incidence rates of adverse drug reactions associated with a decrease in body fluids and their risk factors,Investigate the occurrence of adverse drug reactions other than the above,,2014-04,COMPLETED,OBSERVATIONAL,['NA']
9233,NCT04353869,Compare the plasma concentrations of glutamine in patients with various levels of cardiovascular (CV) risk.,characterize the transcriptomic program through modification gene expression and epigenetic changes related to KDM6B and TET2 activity in blood monocytes from patients with various levels of CV risk,,2020-11-16,RECRUITING,OBSERVATIONAL,['NA']
9234,NCT05799222,Hemoglobin A1c reduction,Program adherence,,2023-04-01,RECRUITING,OBSERVATIONAL,['NA']
9235,NCT03330366,Changes of blood glucose during OGTT,Changes of HbA1c,,2015-11-24,COMPLETED,INTERVENTIONAL,['NA']
9236,NCT05777746,"Composite of Estimated relative CVD risk (based on change in LDL-c , SBP and HbA1c)",Rate of Vitamin B12 and ferritin deficiency,Physical Activity (Metabolic Equivalent Tasks),2022-11-29,RECRUITING,INTERVENTIONAL,['NA']
9237,NCT04417725,Incidence and prevalence,Treatment patterns,,2008-04-01,COMPLETED,OBSERVATIONAL,['NA']
9238,NCT00327626,"Evaluate the effects of ISIS 113715 on insulin sensitivity, B-cell function, proinsulin/insulin ratio, fasting insulin, C-peptide and proinsulin.",,,2006-05-01,WITHDRAWN,INTERVENTIONAL,['PHASE2']
9239,NCT00422487,"Determine the effect of MBX-2044 after 14 days administration, on efficacy parameters",,,2006-10,COMPLETED,INTERVENTIONAL,['PHASE2']
9240,NCT03619031,Postprandial glucose response (AUC),Time to blood glucose peak,,2018-05-03,COMPLETED,INTERVENTIONAL,['NA']
9241,NCT06190756,Echocardiography,,,2023-11-22,RECRUITING,INTERVENTIONAL,['NA']
9242,NCT03301545,Change in Glycosylated Hemoglobin (HbA1c),Change in Fasting Blood Lipids,,2020-07-01,UNKNOWN,INTERVENTIONAL,['NA']
9243,NCT00621868,HbA1c level,Safety,,2008-03-26,COMPLETED,INTERVENTIONAL,['PHASE2']
9244,NCT03395509,Baseline prevalence of carotic plaques,The cost(-effectiveness) of the screening program,,2014-08-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
9245,NCT05259735,To assess the change Health related quality of life with the introduction of clinical guideline,To determine the number of participants who adhere to the guideline,,2022-07-17,COMPLETED,INTERVENTIONAL,['NA']
9246,NCT06084156,The primary pharmacokinetics parameter of AUC To assess the potential pharmacokinetic interaction between HSK7653 and metformin in health subjects.,"Pharmacodynamic responses of glucose, insulin and C-peptide will be evaluated",,2019-08-10,COMPLETED,INTERVENTIONAL,['PHASE1']
9247,NCT00393705,Hemoglobin A1c (HbA1c) at 16 Week Endpoint,Total Daily Insulin Dose at 4 Weeks and 12 Weeks,,2006-10,COMPLETED,INTERVENTIONAL,['PHASE4']
9248,NCT02259634,Quality of Life,Healthcare Utilization,,2014-06,TERMINATED,INTERVENTIONAL,['NA']
9249,NCT00749606,Weight,International Physical Activity Questionnaire,,2009-06,COMPLETED,INTERVENTIONAL,['NA']
9250,NCT01440257,Subject incidence of adverse events,Change from baseline in hemoglobin A1c,,2011-09,COMPLETED,INTERVENTIONAL,['PHASE2']
9251,NCT04443205,Foetal macrosomia,,,2020-06,UNKNOWN,OBSERVATIONAL,['NA']
9252,NCT00370656,Whether there is a reduction in subjective pain as assessed by the Brief Pain Inventory.,"Whether there has been an improvement in sleep continuity and subjective sleep, morning after cognitive and psychomotor performance, and quality of life (QoL).",,2007-02,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
9253,NCT02950272,cardiovascular events,,,2016-09,UNKNOWN,OBSERVATIONAL,['NA']
9254,NCT03010397,Phenotypic classification of DR in a 5-year period,mfERG assessement,,2016-12,COMPLETED,OBSERVATIONAL,['NA']
9255,NCT02304081,Glucagon / insulin ratio during hyperglycaemic clamp phase (AUCGluc270-390min / AUCIns270-390min),"Blood Lipids (Triglycerides [mg/dl]; total, HDL, LDL cholesterol [mg/dl])",,2015-01,COMPLETED,INTERVENTIONAL,['PHASE4']
9256,NCT05644717,Radiologic liver parameters,Frequency of adverse events in 6 months,,2023-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
9257,NCT00437398,Mean Number of Hypoglycemic Events After Transplant,Mean Glycated Hemoglobin (HbA1c) Since Transplant,,2006-07,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9258,NCT05378672,Plasma glucose change from baseline at 30 minutes after IMP injection or at the time of rescue by intravenous (IV) glucose,Plasma glucose change from baseline at 15 minutes after IMP injection or at the time of rescue by IV glucose,,2023-05-09,RECRUITING,INTERVENTIONAL,['PHASE3']
9259,NCT02186483,"Cmax,ss, AUCτ",Vd/Fss,,2014-08,COMPLETED,INTERVENTIONAL,['PHASE1']
9260,NCT06064721,peripheral circulation,,,2024-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9261,NCT02220920,Change in HbA1c From Baseline,"Percentage of Participants With ""Adverse Events"" and ""Hypoglycemia and Blood Glucose Decreased""",,2014-08,COMPLETED,INTERVENTIONAL,['PHASE4']
9262,NCT00693771,HbA1c values,Adverse events including hypoglycemia,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE4']
9263,NCT02088827,Blood Pressure,Blood glucose levels,,2015-01-01,COMPLETED,INTERVENTIONAL,['NA']
9264,NCT00353990,To define the bioavailability of a solution of insulin Aspart infused in the Duodenum,Explore any influence of PH/ insulin concentration on PK /PD parameters,,2006-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9265,NCT01653951,hemoglobin A1c,,,2011-08,COMPLETED,INTERVENTIONAL,['NA']
9266,NCT05840250,Glycemic control,Satisfaction with CGM device,,2023-05-15,SUSPENDED,INTERVENTIONAL,['NA']
9267,NCT02014259,Area under the semaglutide plasma concentration time curve,Maximum observed SNAC plasma concentration,,2013-12-11,COMPLETED,INTERVENTIONAL,['PHASE1']
9268,NCT02761434,Insulin sensitivity by matsuda & quicki Index,Energy substrate oxidation,,2016-04-13,COMPLETED,INTERVENTIONAL,['NA']
9269,NCT03950713,HbA1c values,Depression and Anxiety Stress Scale (DASS-21),,2017-01-01,COMPLETED,INTERVENTIONAL,['NA']
9270,NCT02067013,Cytokine Levels,Serum Pharmacokinetics,,2015-07,UNKNOWN,INTERVENTIONAL,['PHASE2']
9271,NCT03310749,"Gemigliptin AUCτ,ss Geometric Mean Ratio (and 90%CI)",Tmax,Incidence of treatment-emergent adverse events,2016-01-15,COMPLETED,INTERVENTIONAL,['PHASE1']
9272,NCT01568125,HbA1c,Content of dietary intake,,2010-01,UNKNOWN,OBSERVATIONAL,['NA']
9273,NCT05553275,first neonatal blood glucose level measured in mg/dL,Number of neonates that have Macrosomia,,2022-10-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
9274,NCT00569452,"Pilot trial to establish endpoints such as ""time within target range of a composite fasting day""","AUC, MAGE, HbA1c, body weight change",,2006-01,COMPLETED,INTERVENTIONAL,['NA']
9275,NCT03616392,"(Part 2) Css,max of CKD-501","(Part 2) Swing[(Css,max-Css,min)/Css,min] of CKD-501",,2018-07-25,COMPLETED,INTERVENTIONAL,['PHASE1']
9276,NCT05176197,Change in HbA1c,Hedonic survey,Compliance - fatty acid profile,2022-02-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
9277,NCT01518023,Fasting blood glucose,HbA1c,,2011-01,COMPLETED,OBSERVATIONAL,['NA']
9278,NCT04492722,Change From Baseline in Reduction of Urine Albumin to Creatinine Ratio (ACR) to Week 20,Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) to Week 12,,2020-10-01,TERMINATED,INTERVENTIONAL,['PHASE2']
9279,NCT02797730,PedsQL Family Impact score to assess Family Quality of Life,satisfaction score,,2016-05,COMPLETED,INTERVENTIONAL,['NA']
9280,NCT00481429,"The performance of baseline biochemical biomarkers in plasma and urine in distinguishing patients who respond to rosiglitazone from those that do not, as classified by a change in HbA1C at 12 weeks.",Effect of treatment on a variety of other novel potential predictive biomarkers and markers of insulin sensitisation in diabetic patients.,,2007-05,WITHDRAWN,OBSERVATIONAL,['NA']
9281,NCT01757587,Proportion of patients responding to treatment (HbA1c less than 7%),"Compare HbA1c and other clinical and laboratory parameters (fasting plasma glucose (FPG), fasting lipids, weight)",Evaluate more precisely the optimized glycemic control through a glycemic holter,2011-12,COMPLETED,INTERVENTIONAL,['PHASE4']
9282,NCT00884611,Percentage of Nights With CGM (Continuous Glucose Monitor) Sensor Values < 60 mg/dL,Mean Morning Blood Glucose (BG),,2007-05,COMPLETED,INTERVENTIONAL,['NA']
9283,NCT01569893,Glycated hemoglobin (HbA1c) levels,Number of visits with specialists in diabetic center,,2012-03,COMPLETED,INTERVENTIONAL,['NA']
9284,NCT01679197,Liver Histopathology,Body Weight,,2012-10-08,COMPLETED,INTERVENTIONAL,['PHASE2']
9285,NCT02190669,Document the glycemic response of individuals without diabetes and with type 1 or type 2 diabetes,,,2014-06,COMPLETED,OBSERVATIONAL,['NA']
9286,NCT03376802,Sleep energy expenditure,Pharmacokinetics,,2018-04-18,COMPLETED,INTERVENTIONAL,['PHASE1']
9287,NCT03737240,Change in Hemoglobin A1c (HbA1c),Total Daily Insulin Dose,,2019-01-15,COMPLETED,INTERVENTIONAL,['PHASE3']
9288,NCT01170208,Change in Weekly Mean Blood Glucose From Week 4 to Week 16,Incidence of Severe or Serious Hypoglycemia.,,2010-06,COMPLETED,INTERVENTIONAL,['NA']
9289,NCT03185078,VAS,,,2019-01-25,COMPLETED,INTERVENTIONAL,['NA']
9290,NCT01607385,Gastrointestinal Symptom Rating Scale,"Pharmcokinetic measures of GSK2330672, GSK1614235, GSK2313533, and GSK2313537.",,2012-05-18,COMPLETED,INTERVENTIONAL,['PHASE1']
9291,NCT00609856,Effect of pioglitazone vs. insulin glargine on beta-cell function and insulin sensitivity,Effect of pioglitazone vs. insulin glargine on BNP,,2004-04,COMPLETED,INTERVENTIONAL,['PHASE4']
9292,NCT05662462,The primary clinical outcome is the proportion of participants with an A1c <6.5% in the third trimester before delivery,Doctor-Patient Communication Scale,,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9293,NCT05550688,Weight Change after smoking cessation on incident T2DM in NAFLD-free individuals,Mediation analysis of smoking relapse on incident T2DM,,2007-01-01,COMPLETED,OBSERVATIONAL,['NA']
9294,NCT01511159,Ratio of the areas under the plasma NN 90-1170 curves,Adverse events,,2001-10,COMPLETED,INTERVENTIONAL,['PHASE1']
9295,NCT02013557,Percentage of patients that receive the 2-hour 75-g oral glucose tolerance test,Percentage of patients that receive any type of postpartum diabetes screening,,2014-01,TERMINATED,INTERVENTIONAL,['NA']
9296,NCT06146933,Analysis of system accuracy based on DIN EN ISO 15197,,,2023-11-01,COMPLETED,INTERVENTIONAL,['NA']
9297,NCT04094740,changes in serum hemoglobin A1c level,Adverse events,,2019-10-01,UNKNOWN,INTERVENTIONAL,['NA']
9298,NCT03476967,Cup area,,,2014-01,COMPLETED,OBSERVATIONAL,['NA']
9299,NCT00116545,flow mediated brachial artery vasoactivity,carbohydrate and lipid metabolism,,1997-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
9300,NCT00982644,Extension Trial (Primary Endpoint): Rate of Treatment Emergent Adverse Events (AEs),Main Trial (Secondary Endpoint): Rate of Nocturnal Confirmed Hypoglycaemic Episodes,,2009-09,COMPLETED,INTERVENTIONAL,['PHASE3']
9301,NCT03122093,TTG-IgA Serology,Presence of Celiac Disease Complications,,2017-05-01,COMPLETED,OBSERVATIONAL,['NA']
9302,NCT00231192,serum fructosamine,quality of life,,2005-10,WITHDRAWN,INTERVENTIONAL,['NA']
9303,NCT03429543,Percentage of Patients With Treatment Failure up to or at Week 26,Percentage of Patients Who Achieve HbA1c <7.0% at the End of 26 Weeks,,2018-03-20,COMPLETED,INTERVENTIONAL,['PHASE3']
9304,NCT00207207,Level of diabetic control as measured by 7-month HbA1c.,Number of hypoglycemic episodes.,,2003-07,COMPLETED,INTERVENTIONAL,['PHASE1']
9305,NCT05623111,Changes in daily neuropathic pain scores,Sensory function,,2024-01-01,RECRUITING,INTERVENTIONAL,['PHASE2']
9306,NCT00482079,To asses the effectiveness of MK0431 compared to placebo,To test the safety and tolerability of MK0431 in patients with type 2 diabetes,,2003-05-13,COMPLETED,INTERVENTIONAL,['PHASE2']
9307,NCT05804097,Major Amputations,"TcpO2 before, during and after HBOT",,2021-10-08,RECRUITING,INTERVENTIONAL,['PHASE4']
9308,NCT00541567,Absolute change from baseline in body weight (kg) and HbA1c (%),"Waist circumference, fasting glucose and insulin, HOMA analysis, blood lipids (triglycerides, total cholesterol, HDL-C, LDL-C, ApoB) and systolic/ diastolic blood pressure",,2008-03,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
9309,NCT04978441,"correlation between baseline personality characteristics, changing emotions throughout the day, and glycemic levels in patients with T1DM",,,2020-02-17,COMPLETED,OBSERVATIONAL,['NA']
9310,NCT01517269,Change in baseline of Diabetes Knowledge,Change in Baseline of Parent anxiety,,2010-04,COMPLETED,INTERVENTIONAL,['PHASE3']
9311,NCT02201602,Mean blood glucose level,Glycemic variability,,2014-08,COMPLETED,INTERVENTIONAL,['PHASE4']
9312,NCT04918784,Number of Participants With 100% Re-epithelialization,Number of Treatment Applications,Incidence of Adverse Events,2021-05-05,COMPLETED,INTERVENTIONAL,['NA']
9313,NCT00955747,Change in Hemoglobin A1C Level From Baseline,,,2007-04,COMPLETED,INTERVENTIONAL,['PHASE3']
9314,NCT04706377,serum vitamin B12 levels,Adverse events,,2018-02-01,COMPLETED,INTERVENTIONAL,['NA']
9315,NCT02738879,Percentage of Participants Who Experienced One or More Adverse Events (AEs),Percentage of Participants With A1C Goal <7.0% (<53 mmol/Mol at Week 30 and No Documented Hypoglycemia With Blood Glucose ≤70 mg/dL (≤3.9 mmol/L) up to Week 30,,2016-05-09,COMPLETED,INTERVENTIONAL,['PHASE3']
9316,NCT05268250,youth time in range,Brief Resilience Scale,,2024-02-23,RECRUITING,INTERVENTIONAL,['NA']
9317,NCT03310502,Skeletal muscle insulin sensitivity,Coronary flow reserve,,2002-04-17,RECRUITING,OBSERVATIONAL,['NA']
9318,NCT03861052,Change From Baseline in Hemoglobin A1c (HbA1c),Number of Participants With Anti-Tirzepatide Antibodies,,2019-05-07,COMPLETED,INTERVENTIONAL,['PHASE3']
9319,NCT00767000,Percentage of Participants Who Discontinued Study Medication Due to an Adverse Event,Percentage of Participants Achieving an HbA1c of <7.0% at Week 54 Who Maintain an HbA1c of <7.0%,,2008-10,TERMINATED,INTERVENTIONAL,['PHASE2']
9320,NCT02806700,Patient Activation,HbA1c,,2016-06,COMPLETED,INTERVENTIONAL,['NA']
9321,NCT04108455,Adverse Neonatal Events,Triglycerides,,2019-03-15,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
9322,NCT00722241,SEVEN.2 System accuracy as compared to Yellow Springs Instrument (YSI) venous blood glucose measurements,,,2008-05,COMPLETED,OBSERVATIONAL,['NA']
9323,NCT04564131,life quality,,,2021-04-01,UNKNOWN,INTERVENTIONAL,['NA']
9324,NCT01499524,To establish whether raised serum bile acids are associated with abnormalities in cholesterol and triglycerides in the mother and fetus mother and fetus.,"To establish the relationship between raised serum bile acids in the mother and fetus and abnormalities in: Glucose homeostasis, gut liver signaling hormones related to FGF 19 and C4 levels, Gut hormone secretion",,2011-11,COMPLETED,OBSERVATIONAL,['NA']
9325,NCT00597350,Area under the curve for insulin and glucose,Any adverse event experienced by the subjects,,2007-11,COMPLETED,OBSERVATIONAL,['NA']
9326,NCT00142701,,,,1999-04,COMPLETED,INTERVENTIONAL,['NA']
9327,NCT05776563,Change in magnetic resonance spectroscopy (MRS) to assess brain glucose changes,,,2024-03-01,RECRUITING,INTERVENTIONAL,['NA']
9328,NCT05966272,Change From Baseline in HbA1c after 20 weeks of treatment,Number of AEs During the Trial,,2023-08-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
9329,NCT02462057,Enrollment in 10% Level of Benefit,,,2015-06,COMPLETED,INTERVENTIONAL,['NA']
9330,NCT00896077,"Safety (based on AEs, vital signs assessments, resting 12-lead ECG evaluations, physical examination findings and clinical laboratory test results)","Pharmacodynamic (PD) assessments (blood will be collected for determination of serum cytokine, chemokine, insulin and FFA levels at time points noted previously)",,2009-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9331,NCT04276051,Number of Adverse Events Related to the Cryoablation,Fasting Insulin Level,,2020-10-23,COMPLETED,INTERVENTIONAL,['NA']
9332,NCT05626712,Number of Participants with Adverse Events,C-peptide during a 4-hour MMTT,,2023-04-07,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9333,NCT01921322,Time to Target,Glycemic Variability,,2013-04,COMPLETED,INTERVENTIONAL,['NA']
9334,NCT02437747,Clinical parameter of probing pocket depth,Clinical parameter of relative attachment level,,2014-06,COMPLETED,INTERVENTIONAL,['PHASE4']
9335,NCT02284815,Insulin per kg from baseline to 12 months follow-up,Immune system (Th1 and Th2 cytokines) change from baseline to 12 months follow-up,,2012-03,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
9336,NCT04010344,Change in Blood Pressure control by poverty status from Baseline,Change in the acceptability and usability of the Akoma pa app score as assessed by the Marshfield System Usability Survey,,2019-07-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
9337,NCT02898714,Quality of life,Work and school absenteeism,,2016-07,COMPLETED,OBSERVATIONAL,['NA']
9338,NCT03766438,Glycemic control as measured by hemoglobin A1c. Hemoglobin A1c will be measured from whole blood samples obtained and analyzed in a blinded fashion.,"Total cholesterol, HDL cholesterol, and triglycerides will be measured from the same blood sample used to derive the outcome measure. LDL-cholesterol will be calculated for each participant based on these values.",,2019-02-14,COMPLETED,INTERVENTIONAL,['NA']
9339,NCT02897557,Percentage of time in severe hyperglycemic range (defined as >/=250 mg/dL),Standard deviation and coefficient of variation of CGM values,,2016-09,COMPLETED,INTERVENTIONAL,['NA']
9340,NCT02800668,weight loss in kg,effect on blood pressure measured in mmHg,,2011-10,COMPLETED,OBSERVATIONAL,['NA']
9341,NCT02300779,Efficacy of the bowel preparation,Predictors of inadequate bowel preparation,,2014-12,COMPLETED,INTERVENTIONAL,['PHASE3']
9342,NCT01762826,OGTT result,Adverse obstetric outcome,,2012-09,UNKNOWN,OBSERVATIONAL,['NA']
9343,NCT01089179,,,,na,COMPLETED,INTERVENTIONAL,['PHASE1']
9344,NCT03737422,prediabetes,,,2018-01-01,COMPLETED,INTERVENTIONAL,['NA']
9345,NCT04236206,Glycemic Control,Medication Adherence,Diabetes-related Knowledge,2020-10-01,COMPLETED,INTERVENTIONAL,['NA']
9346,NCT04700813,pathogenic mutations causing type 2 diabetes,,,2019-09-13,UNKNOWN,OBSERVATIONAL,['NA']
9347,NCT05237219,Change in hemoglobin A1c level,Change in 24-hour blood pressure,,2022-05-01,WITHDRAWN,INTERVENTIONAL,['NA']
9348,NCT03323216,Interleukin 6 (IL-6) [µg/L],,,2018-04-01,UNKNOWN,OBSERVATIONAL,['NA']
9349,NCT00383877,HbA1c,Within-subject variation of self measured blood glucose (SMBG) before breakfast during the trial at the end of the trial,,2006-09,COMPLETED,INTERVENTIONAL,['PHASE3']
9350,NCT04838392,RIGHTEST Continuous Glucose Monitoring System Performance,RIGHTEST Glucose Monitoring System Related Adverse Device Effects,,2021-07,UNKNOWN,INTERVENTIONAL,['NA']
9351,NCT00315588,Insulin Independence.,"Reduction in Severe Hypoglycemia, Improvement in Hypoglycemia Awareness",,2000-12,COMPLETED,INTERVENTIONAL,['PHASE2']
9352,NCT05593926,HbA1c levels,To investigate usability,,2022-11-16,COMPLETED,INTERVENTIONAL,['NA']
9353,NCT05730998,urinalysis,urine culture,,2022-09-01,COMPLETED,INTERVENTIONAL,['NA']
9354,NCT01080157,"Validation of SCOUT DS algorithm, ROC performance equivalency to FPG and A1c for detection of abnormal glucose tolerance.","Receiver operator characteristic area under the curve, sensitivity, specificity, and postive & negative predictive values of the SCOUT DS, FPG, and A1C tests for detection of abnormal glucose tolerance, and the intra- & inter-day SCOUT DS test",,2010-03,COMPLETED,OBSERVATIONAL,['NA']
9355,NCT06302127,CVD 10-year risk,total cholesterol,,2024-04-20,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9356,NCT04928872,"Prediction models of postprandial plasma amino acid patterns in relation to the macronutrient content of predefined meals as assessed by plasma concentrations of amino acids, glucose, and/or triglycerides","Discordance of glucose measurement after an intake of the predefined meal as measured by a fingerstick, continuous glucose monitor, and certified laboratory",,2018-06-20,COMPLETED,OBSERVATIONAL,['NA']
9357,NCT02796456,Biological measure : Maternal apelinemia (Plasma Concentration),Placenta weight,,2016-04,COMPLETED,OBSERVATIONAL,['NA']
9358,NCT01552018,Inflammatory biomarkers,Gene expression of DPP-4 in adipose tissue and leukocytes,,2012-03,COMPLETED,INTERVENTIONAL,['PHASE4']
9359,NCT04809220,Change From Baseline in Hemoglobin A1c (HbA1c) at Week 26,Change From Baseline in Body Weight,,2021-04-13,COMPLETED,INTERVENTIONAL,['PHASE3']
9360,NCT01865474,Fibrinogen level reduction,Change of Thromboxane-B2 level,,2013-05,COMPLETED,INTERVENTIONAL,['PHASE4']
9361,NCT01671293,Change From Baseline in Weight Parameter,Change of Baseline in Waist Circumference,,2011-09,COMPLETED,INTERVENTIONAL,['NA']
9362,NCT06174129,Factors associated with atrial fibrillation,,,2022-06-01,COMPLETED,OBSERVATIONAL,['NA']
9363,NCT05172089,Aim 4,,,2021-01-31,TERMINATED,OBSERVATIONAL,['NA']
9364,NCT03544645,compare the impact of audiovisual educational materials verses printed educational materials,,,2017-07-16,COMPLETED,INTERVENTIONAL,['NA']
9365,NCT05144971,Nova StatStrip A Glucose/Creatinine Meter System,,,2021-10-28,COMPLETED,OBSERVATIONAL,['NA']
9366,NCT02456636,Mean Weight Change Over 24 Months; Adjusted,Mean Change in Stress Measured by PSS; Unadjusted Except for Affiliation,,2016-02-15,COMPLETED,INTERVENTIONAL,['NA']
9367,NCT04845685,CGM accuracy,CGM recorded hyperglycemia episodes,,2024-06-01,SUSPENDED,INTERVENTIONAL,['NA']
9368,NCT03096535,Difference in brown adipose tissue (BAT) activity after cooling versus no cooling.,Difference in resting energy expenditure after cooling versus no cooling,,2017-04-02,COMPLETED,INTERVENTIONAL,['NA']
9369,NCT05008276,Glomerular Filtration Rate (GFR),Renal oxygenation,,2021-09-27,RECRUITING,OBSERVATIONAL,['NA']
9370,NCT02491528,The change of relative baseline HbA1c,,,2015-06-19,COMPLETED,INTERVENTIONAL,['PHASE3']
9371,NCT03291249,Abnormal physical findings,change in HOMA/HOMA-IR scores,Mean serum concentrations of adiponectin,2017-12-01,WITHDRAWN,INTERVENTIONAL,['PHASE2']
9372,NCT02940873,Difference in severe hypoglycaemia between study arms,Quality of Life - general,Changes in treatment modality,2017-03-09,COMPLETED,INTERVENTIONAL,['NA']
9373,NCT03239717,Reduction of BCAA intake,Glucose tolerance,,2017-11-28,COMPLETED,INTERVENTIONAL,['NA']
9374,NCT00328601,,,,2005-02,COMPLETED,INTERVENTIONAL,['PHASE3']
9375,NCT01406717,Count and Percentage of Subjects With Potentially Immune-related Treatment-emergent Adverse Events (TEAEs),Change From Baseline in Total Cholesterol,,2013-03-01,COMPLETED,INTERVENTIONAL,['PHASE3']
9376,NCT02879383,"Change From Baseline at 12 Weeks in MR-PDFF, DMR vs Sham",,,2017-03-01,COMPLETED,INTERVENTIONAL,['NA']
9377,NCT02758899,Absolute Disc Glycosylation Levels,Rates of Fusion,,2014-03,TERMINATED,OBSERVATIONAL,['NA']
9378,NCT03112382,serum zinc,change from baseline in total serum Calcium at three months,,2015-11,COMPLETED,INTERVENTIONAL,['PHASE4']
9379,NCT02466880,Change in Hemoglobin A1c,Change in Cholesterol,,2015-04,COMPLETED,INTERVENTIONAL,['NA']
9380,NCT01003236,Change from baseline in urinary albumin-creatinine ratio,Change from baseline in serum creatinine,,2010-10,COMPLETED,INTERVENTIONAL,['PHASE2']
9381,NCT05505864,Objectively measured total sedentary behaviour,Validate the modified SIT-Q (no unabbreviated name) questionnaire,,2022-10-01,RECRUITING,INTERVENTIONAL,['NA']
9382,NCT04879251,Number of patients with diabetes who have a higher BP (blood pressure) value (Change from baseline after 1 and 2 year of COVID 19 pandemic),,,2021-04-26,COMPLETED,OBSERVATIONAL,['NA']
9383,NCT02039544,Change in Scores of TCM clinical symptom and the clinical scoring system of Toronto (TCSS),Change in Nerve conduction velocity,Number of participants with adverse events,2014-01,UNKNOWN,INTERVENTIONAL,['NA']
9384,NCT02791867,Reduction in glycated Haemoglobin measured: HBA1c,Reduction in serum triglyceride level (mmol/l),,2014-12,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9385,NCT02940379,Assessment of metoprolol PK parameter: AUC,Assessment of PK parameter: t1/2z,,2016-10,COMPLETED,INTERVENTIONAL,['PHASE1']
9386,NCT01276912,HbA1c >= 6.5%,HbA1c >= 7.0%,,2011-01,UNKNOWN,INTERVENTIONAL,['NA']
9387,NCT03520413,Hemoglobin A1c,Patient Health Questionnaire-8,,2018-12-21,COMPLETED,INTERVENTIONAL,['NA']
9388,NCT02750280,Incidence of wound healing,Incidence of ulcer recurrence,,2015-06,COMPLETED,INTERVENTIONAL,['NA']
9389,NCT00665145,Stem cells circulating in peripheral blood,Safety and Efficacy of SB-509,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE2']
9390,NCT03502304,Lipoproteins,Six minutes walking test,,2017-06-10,COMPLETED,INTERVENTIONAL,['NA']
9391,NCT06061172,Time spent in hospital during the preceding six months,Patient satisfaction with clinical performance as assessed by the European Task Force on Patient Evaluation of General Practice Care questionnaire,,2023-10-02,RECRUITING,INTERVENTIONAL,['NA']
9392,NCT00786500,HbA1c (glycosylated hemoglobin),"Body weight (BMI, hip-waist ratio)",,2007-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9393,NCT04572945,Percentage of foot abnormalities in diabetic CKD patient,,,2021-04-01,UNKNOWN,OBSERVATIONAL,['NA']
9394,NCT05295160,Concentration of fasting blood glucose < 126 mg/deciliter,Composition of the microbiome,,2020-09-25,COMPLETED,INTERVENTIONAL,['NA']
9395,NCT04750577,Change from baseline in log transformed Urine Albumin Creatinine Ratio (UACR) measured in 10-hour urine after 20 weeks of trial treatment,Number of patients achieving UACR decreases in First Morning Void urine of at least 20% from baseline after 20 weeks of trial treatment,,2021-04-27,COMPLETED,INTERVENTIONAL,['PHASE2']
9396,NCT04636411,Inflammation,Total or ionized Mg,,2020-11-01,COMPLETED,INTERVENTIONAL,['PHASE3']
9397,NCT02041598,Change in Baseline Hemoglobin A1c at 6-Months,Change in Baseline Lipid Profile at 6-Months,,2009-07-01,COMPLETED,INTERVENTIONAL,['NA']
9398,NCT03668301,Central venous oxygen saturation,,,2017-01,COMPLETED,OBSERVATIONAL,['NA']
9399,NCT00034255,,,,2001-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9400,NCT01472185,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24,Change From Baseline in Incremental Change of 2-hour Postprandial Serum Glucose at Week 24,,2011-11,COMPLETED,INTERVENTIONAL,['PHASE3']
9401,NCT00902161,Recovery Time (Rt[65] From Insulin-induced Hypoglycemia,Number of Participants Who Discontinued Study Treatment Due To AEs,,2009-05,COMPLETED,INTERVENTIONAL,['PHASE1']
9402,NCT02136199,Frequency of use of decision aids in clinical encounters by weekly reports,,,2014-09,COMPLETED,INTERVENTIONAL,['NA']
9403,NCT00484198,Change in Hemoglobin A1c From Baseline Through Week 26 Endpoint With Last Observation Carried Forward (LOCF) Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus,Drug-Related Treatment-Emergent Adverse Events Reported by ≥1% Participants Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy Treatment of Type 2 Diabetes Mellitus,,2007-04-23,COMPLETED,INTERVENTIONAL,['PHASE3']
9404,NCT05127291,Dual-task effect,,,2023-05-20,COMPLETED,INTERVENTIONAL,['NA']
9405,NCT00612794,To assess the safety and tolerability of exenatide administered once weekly by subcutaneous (SC) injection in subjects with type 2 diabetes mellitus.,To explore the pharmacodynamics of exenatide administered once weekly by SC injection in subjects with type 2 diabetes mellitus regarding the following: *fasting and postprandial glucose concentrations; *HbA1c; *Body weight.,,2007-09,COMPLETED,INTERVENTIONAL,['PHASE1']
9406,NCT02918175,Change in mean weekly step count,Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) score,Change in plasma metabolic profile,2017-08-02,COMPLETED,INTERVENTIONAL,['NA']
9407,NCT03581968,Percentage of time of sensor glucose levels spent in target range,Number of participants experiencing hypoglycemia requiring oral treatment during:,,2018-07-02,COMPLETED,INTERVENTIONAL,['NA']
9408,NCT03811561,Presence of at least 3 steps Early Treatment Diabetic Retinopathy Study (ETDRS) subject level progression.,"Change in Lipids: Total-cholesterol, High density lipoprotein (HDL)-cholesterol, low density lipoprotein (LDL)-cholesterol and triglycerides.",,2019-05-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
9409,NCT01440439,"Glucose excursion (which, as defined below, is the change in blood glucose between the start and finish of one hour of exercise)",Blood glucose,,2011-11,UNKNOWN,INTERVENTIONAL,['PHASE4']
9410,NCT01060332,"Body Constitution Questionnaire, BCQ",Diabetes Impact Measurement Scales,,2010-01,UNKNOWN,OBSERVATIONAL,['NA']
9411,NCT03315663,Effectiveness of Sweetch's PIP compared to usual care to lower A1C,Evaluation of whether intervention reduces blood pressure.,,2017-07-01,WITHDRAWN,INTERVENTIONAL,['NA']
9412,NCT06046976,MicroRNA 21 (Mir-21) expression,Superoxide Dismutase(SOD) enzyme activity (%),,2022-06-13,COMPLETED,INTERVENTIONAL,['NA']
9413,NCT06325202,Towler questionnaire,all-cause mortality,,2024-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9414,NCT02561338,"After 12-week Treatment, the Change From Baseline in HbA1c",Change From Baseline in FPG,,2015-09,COMPLETED,INTERVENTIONAL,['PHASE2']
9415,NCT03038789,"Descriptive analysis of the percentage (%) of adverse events (AEs), serious adverse events (SAEs), unexpected adverse events∙adverse drug reactions and AEs of special interest (AESI)",Number of Participants With Abnormal Laboratory Values,,2017-04-20,COMPLETED,OBSERVATIONAL,['NA']
9416,NCT00877864,The primary outcome will be A1c at the end of 6 months supervised exercise period.,,,2010-02,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
9417,NCT00765830,To evaluate the safety and tolerability in patients with T2DM and moderate or severe renal insufficiency over 52 weeks of treatment,To explore the efficacy of vildagliptin (50 mg qd) versus placebo in patients with T2DM and moderate or severe renal insufficiency,,2008-09,COMPLETED,INTERVENTIONAL,['PHASE3']
9418,NCT04262479,GAD65A titer in serum,Change in maximum C-peptide during Mixed Meal Tolerance Test (MMTT),,2020-03-02,COMPLETED,INTERVENTIONAL,['PHASE2']
9419,NCT01427569,The percent reduction in wound area at week 4 compared to the baseline visit,The percentage of lesions that demonstrate at least 50% reduction in area by the end of week 4 compared to baseline visit,,2012-03,COMPLETED,INTERVENTIONAL,['PHASE2']
9420,NCT05808972,Number of participants with composite endpoint achievement,Total insulin dose received,,2022-11-01,RECRUITING,INTERVENTIONAL,['PHASE4']
9421,NCT02122731,average daytime systolic and diastolic blood pressure,urine plasminogen and plasmin,,2010-11,COMPLETED,INTERVENTIONAL,['PHASE4']
9422,NCT00005441,,,,1993-04,COMPLETED,OBSERVATIONAL,['NA']
9423,NCT00605475,Mean Change From Baseline in Plasma Glucose Area Under the Curve (AUC) 0 - 4 Hours Following Oral Glucose Tolerance Test (OGTT ),"Number of Participants Reporting Death, Serious Adverse Events (SAEs), Adverse Events (AE) Above 5% Frequency",,2007-12,COMPLETED,INTERVENTIONAL,['PHASE2']
9424,NCT04169243,Time in Target at gestational week 32,Diet quality measuremen¨t,,2022-11-01,RECRUITING,INTERVENTIONAL,['NA']
9425,NCT01050205,Changes in Weight Between Baseline and Post-intervention (Assessed at 6 Months After Commencement of Intervention) Compared to Delayed Intervention Participants.,Changes in Diastolic Blood Pressure (BP) Between Baseline and Post-intervention (Assessed at 6 Months After Commencement of Intervention) Compared to Delayed Intervention Participants.,,2010-09,COMPLETED,INTERVENTIONAL,['NA']
9426,NCT01006915,To determine if lower extremity nerve decompression in patients suffering from symptomatic diabetic peripheral neuropathy significantly alleviates pain.,Quality of Life,,2010-03,COMPLETED,INTERVENTIONAL,['NA']
9427,NCT01265563,Change From Baseline in Urinary Albumin Excretion,"Urinary Alpha-1 Microglobulin, Inflammatory Cytokines and C-C Chemokines",,2011-01,COMPLETED,INTERVENTIONAL,['PHASE2']
9428,NCT00012675,,,,na,WITHDRAWN,OBSERVATIONAL,['NA']
9429,NCT04009889,HOMA-IR value in week 36-40,,,2018-04-05,COMPLETED,INTERVENTIONAL,['NA']
9430,NCT04882293,Describe the proportion of subjects who reduced levels of LDL cholesterol,Events and adverse reactions presented.,,2022-02-15,UNKNOWN,INTERVENTIONAL,['PHASE3']
9431,NCT00776607,Change in fasting serum C-peptide level over 24 months and (2) change in HbA1c level over 24 months in patients with LADA.,Hypoglycaemic events,,2007-04,UNKNOWN,INTERVENTIONAL,['NA']
9432,NCT06141590,Cmax,,,2023-03-11,COMPLETED,INTERVENTIONAL,['PHASE1']
9433,NCT02787785,All-Cause Mortality,Sudden Death in various subgroups,S-ICD device complications,2017-04-17,COMPLETED,INTERVENTIONAL,['NA']
9434,NCT05514548,Change in UACR from baseline to W16,Change in eGFR using cystatin C and the CKD-EPI formula from baseline to W16,,2022-10-19,RECRUITING,INTERVENTIONAL,['PHASE2']
9435,NCT02589756,persistent organic pollutants,Triglycerides,,2015-09,COMPLETED,INTERVENTIONAL,['NA']
9436,NCT01984489,Change From Baseline in HbA1c (Hemoglobin A1C) at Week 12,Change From Baseline in Body Weight at Week 12,,2012-06,COMPLETED,INTERVENTIONAL,['PHASE2']
9437,NCT01216865,Angiographic evaluation of angiogenesis at ischemic limb,Rate and extent of amputations,,2011-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9438,NCT00000532,,,,1992-02,COMPLETED,INTERVENTIONAL,['PHASE3']
9439,NCT01206400,pioglitazone effect on testosterone level,,,2010-09,UNKNOWN,OBSERVATIONAL,['NA']
9440,NCT02220257,Development of chronic complication of diabetes (retinopathy or neuropathy or nephropathy),,,2012-01,UNKNOWN,OBSERVATIONAL,['NA']
9441,NCT03867656,P1NP,Heart rate,,2019-02-26,COMPLETED,INTERVENTIONAL,['NA']
9442,NCT03353350,Change in Glycated Hemoglobin (HbA1c) (%),Treatment Emergent Adverse Events (TEAEs),,2017-12-05,COMPLETED,INTERVENTIONAL,['PHASE3']
9443,NCT06109597,Complications associated with gestational diabetes mellitus,,,2022-05-23,COMPLETED,OBSERVATIONAL,['NA']
9444,NCT04699864,Manual Analysis of Retinal Images - Severity of Diabetic Macular Edema (DME),Performance of NeoRetina Algorithm - Diabetic Macular Edema (DME),,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9445,NCT00005761,,,,2000-05-23,COMPLETED,OBSERVATIONAL,['NA']
9446,NCT04854330,Cardiac output,VEGF,,2021-04-26,UNKNOWN,INTERVENTIONAL,['NA']
9447,NCT04218305,1- Study of human serum fetuin-A and whether it is involved in insulin resistance,,,2016-01-01,COMPLETED,OBSERVATIONAL,['NA']
9448,NCT01267591,RHPAT,,,2009-01,UNKNOWN,OBSERVATIONAL,['NA']
9449,NCT04668612,Time in range (TIR) during 2 weeks receiving dual-wave bolus versus standard bolus for dinner.,Time above range (TAR) during 2 weeks receiving dual-wave bolus versus standard bolus,,2020-09-04,UNKNOWN,INTERVENTIONAL,['NA']
9450,NCT05593133,Dynamic Gait index,,,2021-01-05,COMPLETED,INTERVENTIONAL,['NA']
9451,NCT02883127,HbA1c,"Maternal after measurement of subcutaneous skin folds (biceps, triceps, suprailiac and subscapular).",,2015-08-01,COMPLETED,OBSERVATIONAL,['NA']
9452,NCT02416440,prevalence of diabetes mellitus and associated cardiometabolic and infectious risk factors using the oral glucose tolerance test,"inform health policy and public health programmes aimed at addressing the rise in NCDs in South Africa, which may also shape public health strategies in other African countries",,2014-01,COMPLETED,OBSERVATIONAL,['NA']
9453,NCT00462202,Observed ACR level from the first visit to the end of study,,,2007-04,TERMINATED,INTERVENTIONAL,['PHASE3']
9454,NCT01549769,Area under the curve,Maximum observed concentration,,2012-04-30,TERMINATED,INTERVENTIONAL,['PHASE1']
9455,NCT03437018,classification of diabetic retinopathy (DR),medical time necessary for examination and analyse,,2019-10-10,COMPLETED,OBSERVATIONAL,['NA']
9456,NCT04511416,changes in executive function Z-score,"changes in biomarkers, including fasting glucose (mmol/L) and insulin (mIU/L), insulin resistance (HOMA-IR index)",,2022-02-15,RECRUITING,INTERVENTIONAL,['PHASE3']
9457,NCT01438632,BG-AUC0-2h (mmol•min-1•l-1): area under the baseline-subtracted plasma glucose concentration time-curve from time 0 to 2 h after insulin injection and meal ingestion.,BG-AUC0-1h,,2011-09,COMPLETED,INTERVENTIONAL,['PHASE4']
9458,NCT04813146,Serum HbA1c concentration,,,2021-02-05,UNKNOWN,INTERVENTIONAL,['NA']
9459,NCT03590626,Change in liver fat,Change in Biochemical Markers,,2019-01-01,COMPLETED,INTERVENTIONAL,['NA']
9460,NCT00873821,Change From Baseline to Day 13 in Weighted Mean Plasma Glucose Concentration,,,2008-12,COMPLETED,INTERVENTIONAL,['PHASE1']
9461,NCT02280733,death,Wound related quality of life,,2005-01,RECRUITING,OBSERVATIONAL,['NA']
9462,NCT03345901,Diabetic Retinopathy Worsening or Diabetic Macular Edema (DME) Development (Composite Outcome),,,2018-01-15,TERMINATED,INTERVENTIONAL,['PHASE3']
9463,NCT04694326,Diabetes Unawaraness Prevalance,,,2017-04-20,COMPLETED,OBSERVATIONAL,['NA']
9464,NCT03208465,Percent change in global myocardial perfusion reserve (MPR) index,Absolute change in global MPR index,,2017-08-07,COMPLETED,INTERVENTIONAL,['PHASE4']
9465,NCT03046498,Measure change in number of program offerings implemented in the community,,,2017-02-02,COMPLETED,INTERVENTIONAL,['NA']
9466,NCT01714505,"Safety, Frequency of Hypoglycemia","Efficacy, Time Spent in Target Range",,2012-10,COMPLETED,INTERVENTIONAL,['NA']
9467,NCT01510665,Change in maternal biomarkers in pregnancy in the third trimester,Pregnancy complications,,2012-01,COMPLETED,INTERVENTIONAL,['NA']
9468,NCT00344500,Change in Predicted Trajectory of Mean Body Fat Percentage Per GLMM Analysis,,,2005-10,COMPLETED,INTERVENTIONAL,['NA']
9469,NCT04823312,Number of subjects with Duo Extended set failures due to unexplained hyperglycemia (i.e. suspected occlusion) at the end of Day 7.,"Number of subjects with a rate of infusion set survival of 7 days or greater, excluding those that kinked on insertion or accidentally pulled out.",,2021-03-18,UNKNOWN,INTERVENTIONAL,['NA']
9470,NCT00542204,Hemoglobin A1C,"Patient psychosocial well-being (e.g., diabetes-related emotional distress)",,2008-03,COMPLETED,INTERVENTIONAL,['NA']
9471,NCT01143727,Wound Appearance,Percent Change in Wound Area,,2010-07,COMPLETED,INTERVENTIONAL,['PHASE4']
9472,NCT00951899,Total Disposition Index,Lipid Values,,2009-08,COMPLETED,INTERVENTIONAL,['PHASE4']
9473,NCT00468442,Insulin independence,"reduction in insulin requirements, HbA1c, MAGE, LI, HYPO score, fasting glucose, beta score, quality of life",,2006-11,TERMINATED,INTERVENTIONAL,['PHASE2']
9474,NCT04229667,Proportion of patients demonstrating a change in self-reported medication adherence actions (30-day),"Proportion of patients demonstrating a change in disease control (defined as random blood sugar <200 mg/dL mmHg), among patients with diabetes at intake (defined as random blood sugar >=200 mg/dL at intake)",,2020-01-31,TERMINATED,OBSERVATIONAL,['NA']
9475,NCT02294123,Insulinemic index,,,2013-09,COMPLETED,INTERVENTIONAL,['NA']
9476,NCT01989962,"Cultural safety, bias and discrimination--change is being assessed",Patient experiences of healthcare service (Canadian Institute of Health Information (CIHI) Patient Experience Survey)--change is being assessed,Referrals (to whom and date)--change is being assessed,2014-02,UNKNOWN,INTERVENTIONAL,['PHASE2']
9477,NCT00011531,,,,2000-01,COMPLETED,INTERVENTIONAL,['PHASE2']
9478,NCT01766752,The primary endpoint is the percentage of actions the system supports either to capture BG values or provide insulin dose suggestions according to the REACTION algorithm.,,,2012-11,COMPLETED,INTERVENTIONAL,['PHASE3']
9479,NCT01017848,development of diabetes using a predicting formula,,,2009-11,COMPLETED,OBSERVATIONAL,['NA']
9480,NCT05533632,Number of Adverse Events,Change From Baseline in Heart Rate (Pulse) After 24 Weeks of Treatment,,2022-03-29,COMPLETED,INTERVENTIONAL,['PHASE4']
9481,NCT05897216,AUCt of CKD-383,,,2023-07-14,COMPLETED,INTERVENTIONAL,['PHASE1']
9482,NCT04952779,Incidence of Adverse Events (AEs) by preferred term,Change in Post Prandial Blood/Plasma Glucose (PPBG/PPPG),,2021-06-02,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
9483,NCT05397028,Efficacy of plant-based meal replacement system on A1-C levels,Efficacy of plant-based meal replacement system on insulin levels,,2022-12-08,TERMINATED,INTERVENTIONAL,['NA']
9484,NCT05779644,Abdominal fat distribution,,,2023-02-23,RECRUITING,INTERVENTIONAL,['NA']
9485,NCT00004363,,,,1995-12,COMPLETED,OBSERVATIONAL,['NA']
9486,NCT03786978,Short term readmission rate,Economic evaluation,,2015-09-09,COMPLETED,INTERVENTIONAL,['NA']
9487,NCT00572689,"glycemic control through insulin, glucose, c-peptide and glucagon assays",Exenatide Pharmacodynamics and Pharmacokinetics,,2013-08,WITHDRAWN,INTERVENTIONAL,['PHASE4']
9488,NCT00984750,Arterial blood pressure and dyslipidemia,,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE3']
9489,NCT04376112,Medication adherence,,,2020-10,WITHDRAWN,INTERVENTIONAL,['NA']
9490,NCT01497587,Area under the insulin detemir concentration curve,Insulin detemir half-life,,2005-08,COMPLETED,INTERVENTIONAL,['PHASE1']
9491,NCT04142710,Change in yearly health and care cost per person from baseline at 12 months,Mean change in the patients' duration of municipal emergency day care unit visits from baseline at 18 months,,2019-02-09,COMPLETED,INTERVENTIONAL,['NA']
9492,NCT00698802,HbA1c,Total daily insulin dosages,,2008-06,COMPLETED,INTERVENTIONAL,['PHASE2']
9493,NCT00064727,,,,2003-07-09,COMPLETED,INTERVENTIONAL,['PHASE2']
9494,NCT03983200,Nerve conduction velocity examination,Glycosylated serum albumin,,2019-06-15,UNKNOWN,INTERVENTIONAL,['NA']
9495,NCT03092063,Change in Diabetes Self-Management Behaviors (Revised Summary of Diabetes Self-Care Activities),Glycemic control,,2017-03-01,COMPLETED,INTERVENTIONAL,['NA']
9496,NCT06142006,SGLT2i and/or GLP-1 agonist use after DSS EHR template use,GFR,,2023-09-01,RECRUITING,OBSERVATIONAL,['NA']
9497,NCT00143156,The primary efficacy parameter is the endpoint End of Week 12 weekly mean pain score derived from the pain diary.,"End of Week 12 responder rates, Brief Pain Inventory - short form, sleep interference scores, Medical Outcome Study - Sleep Scale, Hospital Anxiety and Depression Scale, Patient Global Impression of Change, Neuropathic Pain Inventory Symptom Inventory.",,2005-03,COMPLETED,INTERVENTIONAL,['PHASE3']
9498,NCT03724383,Changes in Quality of Life on SF36,Left Atrial Pressure,,2018-09-06,UNKNOWN,INTERVENTIONAL,['NA']
9499,NCT04462081,Percentage of Liver Fat as Measured by MRI-PDFF,,,2013-01,COMPLETED,OBSERVATIONAL,['NA']
9500,NCT02839512,Change in glycosylated hemoglobin A1c,Weight loss (%TBWL),,2014-10,COMPLETED,INTERVENTIONAL,['NA']
9501,NCT02562573,Number of subjects with abnormal laboratory values and/or adverse events that are related to treatment,Change from baseline on fasting plasma glucose,,2015-05,COMPLETED,INTERVENTIONAL,['PHASE2']
9502,NCT00078052,cardiovascular disease,,,2003-09,COMPLETED,OBSERVATIONAL,['NA']
9503,NCT01313286,Maximum Observed Drug Concentration (Cmax),,,2011-03,COMPLETED,INTERVENTIONAL,['PHASE1']
9504,NCT04473209,serum resistin,clinical attachment loss,,2018-09-01,COMPLETED,INTERVENTIONAL,['NA']
9505,NCT04057521,Annual outpatient visit healthcare utilization per patient per 1000 patient years,Annual total healthcare expenditures per patient,,2016-04-01,COMPLETED,INTERVENTIONAL,['NA']
9506,NCT01349387,Comparison of expression of isoforms A and B of the insulin receptor using quantitative RT PCR,,,2011-05,COMPLETED,INTERVENTIONAL,['NA']
9507,NCT05648383,Change from Baseline in glycated hemoglobin [HbA1c] at 24 months (2nd follow-up),Change from Baseline in waist circumference [WC] at 24 months (2nd follow-up),Change form Baseline in the BMI z-score of children at 24 months (2nd follow-up),2022-10-01,RECRUITING,INTERVENTIONAL,['NA']
9508,NCT05161429,3-point major adverse cardiac events (MACE),Non-cardiovascular outcomes,,2021-07-01,RECRUITING,OBSERVATIONAL,['NA']
9509,NCT01064583,painfree walking distance,endothelial function,,2009-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9510,NCT01179165,Prevalence of cardiac abnormalities/disease according to different examination modalities,"Feasibility of transthoracic coronary Doppler examination/Coronary Flow Reserve, and diagnostic yield related to MRI",,2011-01,COMPLETED,OBSERVATIONAL,['NA']
9511,NCT04862390,Hypoglycemia incidence with fasting,Time below range (TBR),,2021-03-28,COMPLETED,OBSERVATIONAL,['NA']
9512,NCT03482674,Body weight reduction,Quality of life,,2018-01-02,UNKNOWN,INTERVENTIONAL,['NA']
9513,NCT02161276,The decline glycosylated hemoglobin A1C and blood glucose level,The clinical composite safety evaluation of Tangning Tongluo Capsule in the treatment of type II diabetes participants,,2014-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9514,NCT01263470,Change From Baseline in Glycosylated Hemoglobin (Week 12).,Change From Baseline in Glucagon Measured by Meal Tolerance Testing (AUC (0-2)).,,2007-01,COMPLETED,INTERVENTIONAL,['PHASE2']
9515,NCT00871572,Mean Change in Glycosylated Hemoglobin A1c (HbA1c),Change From Baseline to Endpoint for Total Cholesterol,,2009-03,COMPLETED,INTERVENTIONAL,['PHASE2']
9516,NCT01204216,Specific Aim 1: To Determine the Stability of MRBC (Mean RBC Age)Over Time at Stable Glycemia. The Hypothesis is MRBC Will be Stable in Subjects Without Diabetes and in Subjects With Diabetes at Stable Glycemic Control.,Specific Aim 2: To Determine the Impact of Glycemic Control on MRBC.,,2010-09-01,TERMINATED,INTERVENTIONAL,['NA']
9517,NCT03251755,PSQI,ABI,,2017-05-24,COMPLETED,INTERVENTIONAL,['NA']
9518,NCT04526613,"Prevalence of malnutrition, DM and helminth infections in LTBI individuals and their effects on biosignatures",,,2021-04-19,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
9519,NCT01683266,Change In HbA1c From Baseline to Month 6 Endpoint,Percentage of Participants With Hypoglycemia (All and Nocturnal) Events From Baseline to Month 12,,2012-09,COMPLETED,INTERVENTIONAL,['PHASE3']
9520,NCT02526069,Acceptability and feasibility of using SweetSpot,Well-being,Change in Valued Living (BEVS),2015-05,TERMINATED,INTERVENTIONAL,['NA']
9521,NCT00475345,"Incidence of nocturnal hypoglycemia (< 4mmol/L) occurring between 11pm and 7am, as determined with the Continuous Glucose Monitoring System (CGMS) and hemoglobin A1c","Nadir nocturnal BG, timing and duration of nocturnal hypoglycemia, fasting BG, lipid profile, psychosocial factors, total insulin dose, insulin sensitivity and body composition (weight, BMI, % fat, waist circumference).",,2000-08,COMPLETED,INTERVENTIONAL,['NA']
9522,NCT05759468,The primary endpoint is the change from baseline in UACR over the 6-month intervention period.,Assess the change in measure of fasting glucose as a measure of glycemic control over the 6 months intervention period.,,2023-04-13,RECRUITING,INTERVENTIONAL,['PHASE2']
9523,NCT01041859,Change From Double-Blind Baseline of the Average Pain Intensity Based on an 11-point Numerical Rating Scale(NRS) Over the Last Week of the Maintenance Period at Week 12,Change From Baseline in the EuroQoL-5 Dimension (EQ-5D) Health Status Index at the Week 12 Endpoint,,2009-12,COMPLETED,INTERVENTIONAL,['PHASE3']
9524,NCT04018482,"Comfort of Povidone Iodine vs Avenova 1-2 hours post treatment based on an 11-point numerical scale (0-10, with 0 being no pain, and 10 being extreme pain)",Change in colony forming unit (CFU) growth pre- and post-treatment with Povidone Iodine or Avenova to determine if Avenova is non-inferior to Povidone Iodine for ocular disinfection.,,2019-07-16,COMPLETED,INTERVENTIONAL,['PHASE4']
9525,NCT04093752,Mean Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg),Rate of Hypoglycemia With Blood Glucose < 54 mg/dL or Severe Hypoglycemia,,2019-12-09,COMPLETED,INTERVENTIONAL,['PHASE3']
9526,NCT01968876,Change from baseline in number of pills taken over number of pills prescribed at 12 weeks,,,2013-10-30,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1']
9527,NCT01599143,PSS-10,Toronto Mindfulness Scale (TMS),,2009-01,COMPLETED,INTERVENTIONAL,['PHASE1']
9528,NCT01018628,"To determine the pharmacokinetic profile of SRT2379 (25, 75, 250, 500, 1000, 2000, 3000 mg/day [fasted] and 500 mg/day [fed]) in healthy male volunteers after single and multiple dose administration in the fasted and fed states.",To identify other possible biomarkers suitable for future clinical assessment of oral SIRT1 activators.,,2009-12-07,COMPLETED,INTERVENTIONAL,['PHASE1']
9529,NCT01963156,Medication adherence,Full adherence to medications for the treatment of diabetes or cardiovascular disease,Rates of de-synchronization,2013-11,TERMINATED,INTERVENTIONAL,['NA']
9530,NCT04819256,HbA1c,Implementation of care model,,2020-12-07,TERMINATED,INTERVENTIONAL,['NA']
9531,NCT03790839,12-lead ECG,iAUC0-4h of GLP-1,,2019-01-31,COMPLETED,INTERVENTIONAL,['PHASE1']
9532,NCT04983277,UK Prospective Diabetes Study risk score,,,2021-07,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
9533,NCT04544553,Attendance rates in patients with diabetic macular edema receiving short messaging services,,,2019-01-24,COMPLETED,INTERVENTIONAL,['NA']
9534,NCT01831804,AUC(0-t) of GSK1278863 (Part B),,,2013-06-17,COMPLETED,INTERVENTIONAL,['PHASE1']
9535,NCT01476475,Change in HbA1c From Baseline to Week 24,Percentage of Participants With Documented Symptomatic and Severe Symptomatic Hypoglycemia,,2011-11,COMPLETED,INTERVENTIONAL,['PHASE2']
9536,NCT04963998,Incidence of Treatment-Emergent Adverse Events,Rate of change in percent of fibrin tissue,,2019-10-02,COMPLETED,INTERVENTIONAL,['NA']
9537,NCT00432965,Incidence of Complete Ulcer Closure Closure.,,,2002-05,COMPLETED,INTERVENTIONAL,['NA']
9538,NCT01119846,Part C: Summary of Change From Baseline in Fasted Insulin,"Part C: Summary of AUC0-24, AUC0-t of GSK1292263 and Sitagliptin When Co-administered",,2009-06-05,COMPLETED,INTERVENTIONAL,['PHASE2']
9539,NCT03598738,HbA1c change,,,2015-12-01,COMPLETED,INTERVENTIONAL,['NA']
9540,NCT04320719,number of patients with treatment,biological characteristics of patients,,2018-11-01,COMPLETED,OBSERVATIONAL,['NA']
9541,NCT06049225,Self-efficacy,Glycemic Management,Health Dashboard Usability,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9542,NCT00596427,Rate of Appearance of Exogenous Glucose (Glucose Absorption),Glucagon AUC,Glucose AUC,2007-11,COMPLETED,INTERVENTIONAL,['NA']
9543,NCT01159938,Postprandial Pulse Wave Velocity (PWV) in Type 2 Diabetes Mellitus (T2DM) Participants at 240 Minutes (Mins) Post-Breakfast,Change in Postprandial Pulse Wave Velocity (PWV),,2010-10,COMPLETED,INTERVENTIONAL,['PHASE4']
9544,NCT00259727,Insulin secretion after a single dose of HIV protease inhibitor versus placebo (insulin secretion assessed by using the hyperglycemic clamp technique),Hepatic glucose production during a somatostatin infusion in the fasting and hyperinsulinemic state after a single dose of HIV protease inhibitor,,2006-01,COMPLETED,OBSERVATIONAL,['NA']
9545,NCT03663803,changes in physical activity.,cholesterol,,2011-01-19,COMPLETED,INTERVENTIONAL,['NA']
9546,NCT00468403,Proportion of subjects with insulin independence,"Lipid profiles (triglycerides, total cholesterol, LDL cholesterol, HDL cholesterol)",,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2']
9547,NCT03055468,Depression Clinical Remission,,,2017-04-01,UNKNOWN,INTERVENTIONAL,['NA']
9548,NCT00548158,ETDRS visual acuity,retinal thickness measured by OCT,,2004-10,COMPLETED,OBSERVATIONAL,['NA']
9549,NCT04742829,number of patients with improved/worsened macular edema,number of patients with improved/worsened blood parameters related to diabetes,,2020-10-01,UNKNOWN,INTERVENTIONAL,['NA']
9550,NCT00001344,,,,1993-03,COMPLETED,INTERVENTIONAL,['PHASE2']
9551,NCT01440790,Incremental Area Under the Curve over 4 hours in serum TRAP (total peroxyl radical-trapping potential),Change from baseline in serum TRAP over 6 hours,,2010-08,COMPLETED,INTERVENTIONAL,['NA']
9552,NCT06204107,"Cmax of Empagliflozin, sitagliptin, metformin","Vd/F of Empagliflozin, sitagliptin, metformin",,2023-11-21,COMPLETED,INTERVENTIONAL,['PHASE1']
9553,NCT03325114,Hyperglycemia,,,2019-06-28,TERMINATED,INTERVENTIONAL,['PHASE2']
9554,NCT01472341,Homeostatic Model Assessment Fasting Beta Cell Function (HOMA % B) According to Quartiles of Proinsulin/Insulin (PI/I) Ratio,,,2008-11,COMPLETED,OBSERVATIONAL,['NA']
9555,NCT05383391,"Studying patients' knowledge, practice and barriers of foot self-care among diabetic patients attending Sohag University Hospital",,,2022-06-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
9556,NCT00238472,Change from baseline in postprandial glomerular filtration rate at 12 weeks,Change in insulin AUC (0-240 minutes) at 12 weeks,,2003-05,COMPLETED,INTERVENTIONAL,['PHASE4']
9557,NCT02316483,HBA1C >8.5% on total and gene-specific methylation.,,,2013-12,COMPLETED,OBSERVATIONAL,['NA']
9558,NCT00099151,,,,2002-03,COMPLETED,INTERVENTIONAL,['NA']
9559,NCT03358394,Mindfulness,,,2017-10-26,UNKNOWN,INTERVENTIONAL,['NA']
9560,NCT00405418,Self-monitored BG values whenever patient experiences symptoms possibly related to hypoglycemia.,Physical examination,,2006-11,COMPLETED,INTERVENTIONAL,['PHASE4']
9561,NCT00728143,Glycemic Index,Palatability,,1989-08,COMPLETED,INTERVENTIONAL,['NA']
9562,NCT01278121,Changes in microarray gene expression,"Inflammatory markers, hormonal dietary responses and blood lipids",,2011-02,COMPLETED,INTERVENTIONAL,['NA']
9563,NCT00590044,Number of Hypoglycemia Episodes After the Transition Period From Intravenous Insulin to Subcutaneous Insulin Between 2 Treatment Groups,Difference in Time in Hours to Resolution of DKA Between the 2 Groups,,2007-12,COMPLETED,INTERVENTIONAL,['PHASE4']
9564,NCT04288778,Percentage of Participants With Adverse Drug Reactions (ADRs),Percent Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Weeks 12 and 24,,2020-11-25,COMPLETED,INTERVENTIONAL,['PHASE4']
9565,NCT00361946,,,,2006-08,COMPLETED,OBSERVATIONAL,['NA']
9566,NCT04974528,Change in HbA1c,Change in HbA1c,Change in percent predicted Forced Expiratory Volume in 1 Second (FEV1),2021-09-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
9567,NCT02200627,Adverse event incidence,,,2014-09,COMPLETED,OBSERVATIONAL,['NA']
9568,NCT05386186,Reduction of hemoglobin A1c from baseline at the end of the trial.,The level of weight gain,,2022-01-01,RECRUITING,INTERVENTIONAL,['PHASE4']
9569,NCT00819975,Triglyceride levels,Incretin levels,,na,COMPLETED,INTERVENTIONAL,['NA']
9570,NCT03687320,Incidence of complete (100%) wound closure,Time to complete (100%) wound closure,,2019-12-02,UNKNOWN,INTERVENTIONAL,['NA']
9571,NCT01460095,one year change in glycated haemoglobin (HbA1c),One-year change in urinary albumin excretion,,2009-03,COMPLETED,INTERVENTIONAL,['NA']
9572,NCT06297239,prevalence of high level of Lp(a),,,2024-02-01,RECRUITING,OBSERVATIONAL,['NA']
9573,NCT00290940,Mean change from baseline in HbA1C after 12 weeks compared to placebo,Proportion of subjects discontinuing or requiring rescue for continued or worsening hyperglycemia,,2006-01,COMPLETED,INTERVENTIONAL,['PHASE2']
9574,NCT01888133,Change in steps/day,Change in A1c,,2013-04,TERMINATED,INTERVENTIONAL,['NA']
9575,NCT02646072,Level of aqueous inflammatory cytokines post treatment as assessed using Bio-plex Pro Assays,Changes from baseline in central subfield retinal thickness as assessed by optical coherence tomography,,2014-08,COMPLETED,INTERVENTIONAL,['PHASE4']
9576,NCT05183685,"HbA1c, defined as the amount of blood sugar attached to hemoglobin.","Number of attendances at a general practitioners' office, emergency department, hospital, and general out-patient clinic",Maintenance. It measures the sustained effect of the program. Cost-effectiveness will be measured by calculating the cost used in both groups.,2022-12-10,RECRUITING,INTERVENTIONAL,['NA']
9577,NCT00358033,"The number of patients who had non-compliance to ADA target goals in smoking, LDL cholesterol, blood pressure or Hb A1c.",,,2003-07,COMPLETED,INTERVENTIONAL,['PHASE3']
9578,NCT03635970,TcPO2,,,2018-05-18,COMPLETED,INTERVENTIONAL,['NA']
9579,NCT04300764,Change in mean daily step count during hospitalization,Change in life space assessment,,2026-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9580,NCT03159221,Change in Body Mass Index (weight status) at 6 months and at 12 months,Teen Quality of Life,,2011-04,COMPLETED,INTERVENTIONAL,['NA']
9581,NCT00758927,Percentage change of plasma small dense LDL measured by ultracentrifuge-non denaturing polyacrylamide gel electrophoresis,The percentage change of plasma HDL sub-fraction measured by ultracentrifuge-non denaturing polyacrylamide gel electrophoresis,,2009-07,UNKNOWN,INTERVENTIONAL,['PHASE4']
9582,NCT00465478,Exogenous insulin requirement; Hemoglobin A1C; Glucose and C-peptide level;,"lipid profile, autoantibody， Quality of life",,2006-03,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9583,NCT03071432,Change from baseline in dynamic cerebral autoregulation after induction of anesthesia,Clinical outcome,,2016-08-30,COMPLETED,INTERVENTIONAL,['NA']
9584,NCT01674049,Blood Glucose,Serum insulin,,2010-10,COMPLETED,INTERVENTIONAL,['NA']
9585,NCT05277532,Time in Glucose target range (4-10 mmol/L) for tissue glucose from CGM.,Time below Glucose target range (< 4 mmol/L) for tissue glucose from CGM.,,2022-05-18,RECRUITING,INTERVENTIONAL,['NA']
9586,NCT03125369,% of patient achieve HbA1c<6%,BMI change (kg/m^2),,2015-08,UNKNOWN,INTERVENTIONAL,['NA']
9587,NCT03010956,"Differences in flow mediated dilation (FMD) at baseline and 3, 6 and 12 months after the modification of the antidiabetic medication.",Endothelial glycocalyx and coronary flow reserve.,,2014-11,COMPLETED,OBSERVATIONAL,['NA']
9588,NCT03925805,Self-perceived health status (SF-12),Illness perception (IPQ-B),,2019-11-12,COMPLETED,OBSERVATIONAL,['NA']
9589,NCT05159622,Change in Water Consumption for Parents,Parent 100% Fruit Juice Consumption,Hip Circumference for Parents,2019-05-07,COMPLETED,INTERVENTIONAL,['NA']
9590,NCT04519853,"Patient reported tolerability of dietary intervention, Likert scale",Change in intestinal fatty acid binding protein (I-FABP),,2021-10-25,COMPLETED,INTERVENTIONAL,['NA']
9591,NCT02044848,Stimulated C-peptide in Response to a Standard Mixed Meal Tolerance Test,,,2014-02,TERMINATED,INTERVENTIONAL,['PHASE2']
9592,NCT00782639,Baseline and Change From Baseline Measurements for the One Participant With Contrast-Induced Nephropathy (CIN) at the 48 to 72 Hours After Injection of Contrast Media Visit,Number of Participants Who Died From Acute Renal Failure,,2009-03,TERMINATED,INTERVENTIONAL,['PHASE4']
9593,NCT02049034,Postprandial glucose kinetics,Postprandial and intestinal triglyceride-rich lipoproteins (TRL) kinetics,Post heparin lipoprotein lipase activity,2014-01,COMPLETED,INTERVENTIONAL,['PHASE4']
9594,NCT02779790,Blood pressure - diastolic blood pressure,,,2016-04,UNKNOWN,OBSERVATIONAL,['NA']
9595,NCT00239187,To assess the safety and tolerability of repeated subcutaneous doses of E1 in combination with G1 in patients with type 2 diabetes,To evaluate the pharmacokinetics (PK) profile and clinical effects of repeated subcutaneous doses of E1 in combination with G1 in patients with type 2 diabetes,,2005-09,COMPLETED,INTERVENTIONAL,['PHASE1']
9596,NCT03320694,maternal glycemic control,Neonatal hypoglycemia,,2016-02-01,COMPLETED,INTERVENTIONAL,['PHASE3']
9597,NCT00276393,Mean fasting glucose,Continuos glucose monitoring,,2002-07,COMPLETED,INTERVENTIONAL,['PHASE4']
9598,NCT00265473,Serious Adverse Events Related to Immunosuppressive Therapy.,Insulin Independent Multiple-donor Subjects.,,2005-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9599,NCT02065544,Hemoglobin A1c,Aerobic Fitness,,2012-02,COMPLETED,INTERVENTIONAL,['NA']
9600,NCT04986345,Change in ambulatory systolic and diastolic blood pressure,Change in plasma C-peptide,,2021-10-04,RECRUITING,INTERVENTIONAL,['NA']
9601,NCT00149435,Cardiac health,,,2005-09,COMPLETED,OBSERVATIONAL,['NA']
9602,NCT00776243,Difference of incretin secretion before and after intensive insulin therapy,Factors affecting incretin secretion,,2008-10,COMPLETED,OBSERVATIONAL,['NA']
9603,NCT02129868,Time spent with plasma glucose concentration in the target glucose range from 3.9 to 8.0 mmol/l.,Absolute relative difference between matched pairs of subcutaneous glucose sensor and reference plasma glucose.,nature and severity of any other adverse events,2014-04,COMPLETED,INTERVENTIONAL,['NA']
9604,NCT00995995,Cost-effectiveness of rosiglitazone,,,2008-10,COMPLETED,OBSERVATIONAL,['NA']
9605,NCT03788915,Weight change,HbA1C change,Retention rate change,2018-04-16,UNKNOWN,INTERVENTIONAL,['NA']
9606,NCT01364766,CGM usefulness score,Diabetes Comfort score,,2010-09,COMPLETED,OBSERVATIONAL,['NA']
9607,NCT04591639,Rate of change in myocardial T1 values with manganese enhanced cardiac MRI,Measures of glucose control like glycated haemoglobin (HbA1c) in millimoles per mole,,2020-08-19,RECRUITING,INTERVENTIONAL,['NA']
9608,NCT04916470,Change in body weight,Number of treatment emergent severe or clinically significant hypoglycaemia episodes,,2021-06-15,COMPLETED,INTERVENTIONAL,['PHASE3']
9609,NCT00279318,"Appearance of one or more islet cell autoantibodies: GADA, IAA, or IA-2A confirmed at two consecutive visits.",Development of T1DM,,2004-09,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
9610,NCT04857411,Change in Diastolic Blood Pressure,Newest Vital Sign (NVS),,2021-04-19,COMPLETED,INTERVENTIONAL,['NA']
9611,NCT03477838,Change in A1c,Glycemic Variability,,2018-04-26,COMPLETED,INTERVENTIONAL,['NA']
9612,NCT01348867,To assess the effectiveness of the nurse consultant led clinic in improving glycemic parameters in patients with type 2 diabetes,A comparison of the patients' utility of healthcare services,,2009-03,COMPLETED,INTERVENTIONAL,['NA']
9613,NCT02827903,change of HbA1c,,,2016-01-15,COMPLETED,INTERVENTIONAL,['PHASE3']
9614,NCT05379296,Change from Baseline Serum insulin at 12 months,Change from Baseline C-reactive protein at 12 months,,2022-01-01,WITHDRAWN,INTERVENTIONAL,['NA']
9615,NCT02402517,Exercise intensity,Substrate Oxidation,,2015-08,COMPLETED,INTERVENTIONAL,['NA']
9616,NCT01660009,Flow induced Dilation of the Brachial Artery (FMD%),Mitochondrial superoxide production,,2012-06,TERMINATED,INTERVENTIONAL,['NA']
9617,NCT03068065,Intrahepatic fat,WC,"Number of Participants with gliclazide, liraglutide or metformin adverse events as a measure of safety and tolerability",2014-05,COMPLETED,INTERVENTIONAL,['PHASE4']
9618,NCT03074383,Change in glycated hemoglobin from baseline at 12 months,Variation of Summary of Diabetes Self-Care Activities Questionnaire (SDSCA) from baseline at 12 months,,2017-03-20,COMPLETED,INTERVENTIONAL,['NA']
9619,NCT01684917,Metabolomic Biomarker Discovery - Changes in Blood Plasma Cholesterol,Body Weight,,2012-04,COMPLETED,INTERVENTIONAL,['NA']
9620,NCT02005848,Beta cell function,Safety parameters,,2014-04,COMPLETED,INTERVENTIONAL,['PHASE2']
9621,NCT02018627,Tmax,Dermal Response (Draize Scale Grade for Edema Formation),,2014-04,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
9622,NCT00593567,"Number of Participants With a Clinical Outcome of ""Clinical Cure""",Time to Positive Clinical Response,,2007-12,COMPLETED,INTERVENTIONAL,['PHASE2']
9623,NCT03104543,"Undertreatment of Hypertension (>=140/90 mmHg), Dyslipidemia (LDL >=160 mg/dL or Triglyceride >=150 mg/dL), and/or Glucose Intolerance (if Prediabetes, Hemoglobin A1c >=5.7% or Fasting Glucose >=100; if Diabetes, Hemoglobin A1c >=7%)",Primary Care Provider Attitudes,,2017-03-01,COMPLETED,INTERVENTIONAL,['NA']
9624,NCT03510078,Cardiac ischemic events,Length of hospitalization,,2018-04-17,RECRUITING,INTERVENTIONAL,['NA']
9625,NCT05000996,Estimated 10-year risk of atherosclerotic cardiovascular disease,Blood inflammatory proteins,,2021-08-19,RECRUITING,OBSERVATIONAL,['NA']
9626,NCT05498610,"Cmax,NNC0480-0389,SD Maximum plasma concentration of NNC0480-0389 after a single dose","Cmax,sema,SD The maximum plasma concentration of semaglutide after a single dose",,2022-08-11,COMPLETED,INTERVENTIONAL,['PHASE1']
9627,NCT06095622,Improvement in blood glucose levels,,,2023-03-15,COMPLETED,INTERVENTIONAL,['NA']
9628,NCT00035568,,,,2002-02,COMPLETED,INTERVENTIONAL,['PHASE4']
9629,NCT03407222,change in daily step count after 12 weeks of intervention,low-density lipoprotein cholesterol,,2018-04-01,UNKNOWN,INTERVENTIONAL,['NA']
9630,NCT01649297,HbA1c (Glycosylated Haemoglobin) Change From Baseline at Week 16,Fasting Plasma Glucose (FPG) Change From Baseline at Week 16,,2012-10,COMPLETED,INTERVENTIONAL,['PHASE2']
9631,NCT04824209,Variation in pro-diabetes inflammation markers over time upon endodontic intervention.,,,2021-02-09,COMPLETED,OBSERVATIONAL,['NA']
9632,NCT02672839,Pharmacokinetics Analysis- Maximum Concentration (Cmax),Severity of all Adverse Events graded according to the Common Terminology Criteria for Adverse Events (CTCAE),,2016-02,COMPLETED,INTERVENTIONAL,['PHASE1']
9633,NCT01204294,Incidence of Adverse Events (AEs),Glycosylated Haemoglobin A1c (HbA1c),,2010-09,COMPLETED,INTERVENTIONAL,['PHASE3']
9634,NCT02731716,Improvement in Provider Performance,Primary Care Spending,,2016-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
9635,NCT04866823,Acceptability of Study Measures,Change in Time Below Range (Hypoglycemia),,2021-10-20,COMPLETED,INTERVENTIONAL,['NA']
9636,NCT01558271,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks,Change From Baseline in Electrocardiogram Parameters at 26 Weeks and 52 Weeks,,2012-03,COMPLETED,INTERVENTIONAL,['PHASE3']
9637,NCT01593605,Glucose Control,Metabolic Markers,,2012-02,COMPLETED,INTERVENTIONAL,['NA']
9638,NCT02175537,Waist circumference,Health Profile Survey,Social Network Relationships,2014-06,COMPLETED,INTERVENTIONAL,['NA']
9639,NCT00386100,Change From Baseline in HbA1c at Week 80,"Percent Change From Baseline in Bone Alkaline Phosphatase (BSAP) at Weeks 20, 56, and 80",,2006-10,COMPLETED,INTERVENTIONAL,['PHASE4']
9640,NCT02184676,Autoreactive T lymphocytes,Incidence of autoantibodies,,2015-05-28,COMPLETED,INTERVENTIONAL,['NA']
9641,NCT01452178,Cardiovascular events - longitudinal outcome measure.,,,2005-11,COMPLETED,OBSERVATIONAL,['NA']
9642,NCT00100178,Mean Stimulated C-peptide Area Under the Curve,,,2004-05,COMPLETED,INTERVENTIONAL,['PHASE2']
9643,NCT01789957,Change in body weight from Day 1 of Protocol 2993-112 to Week 52 (or termination),,,2002-09,COMPLETED,INTERVENTIONAL,['PHASE3']
9644,NCT00258674,"Change Score for ""Blood Pressure (b.p.) <130/80 mmHg""","Change Score for ""Semiannual HbA1c Assessment"" (as Determined From Medicare Claims Data)",,2000-01,COMPLETED,INTERVENTIONAL,['NA']
9645,NCT01507116,Self-reported health and Quality of Life (QoL) (measured by the study questionnaire),Patient-centred diabetes care reported by people with diabetes and health care professionals measured by the study questionnaire,,2012-03,COMPLETED,OBSERVATIONAL,['NA']
9646,NCT06024928,Percent Time in Range,Mean glucose reading measured by Continuous Glucose Monitor (CGM),,2023-11-01,RECRUITING,INTERVENTIONAL,['NA']
9647,NCT04797416,Difference value,,,2019-08-01,UNKNOWN,INTERVENTIONAL,['NA']
9648,NCT01719003,HbA1c (Glycosylated Haemoglobin) Change From Baseline at Week 24,Body Weight Change From Baseline at Week 24,,2012-10,COMPLETED,INTERVENTIONAL,['PHASE3']
9649,NCT02122835,exercise capacity,nitrite flux during exercise,,2012-02,WITHDRAWN,INTERVENTIONAL,['NA']
9650,NCT02760303,Metabolic Control,Diabetes Quality of Life,,2015-09,COMPLETED,INTERVENTIONAL,['NA']
9651,NCT01021865,To determine whether hyperglycemia alters myocardial perfusion in subjects with type 2 diabetes,To determine whether GLP-1 modulates myocardial perfusion in subjects with type 2 diabetes.,,2010-02,COMPLETED,OBSERVATIONAL,['NA']
9652,NCT05572502,Glycated hemoglobin,medication usage,,2023-06-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9653,NCT00337324,"Daytime and night-time pain scores assessed at baseline, after FREMS/placebo, and 4 month follow-up",Partial tissue tension of oxygen and carbon dioxide by oxymetry,,2002-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
9654,NCT02558491,Glucose Variability (Coefficient of Variation),Total Rescue Carbohydrates (CHO) (Grams),,2015-09,COMPLETED,INTERVENTIONAL,['NA']
9655,NCT04650945,"Glucose time in range (3,9-10 mmol/l) (% pr day)",Time with active isCGM,,2021-01-04,TERMINATED,INTERVENTIONAL,['NA']
9656,NCT00788827,Number of Participants Who Experienced Adverse Events,Serum Creatinine,,2008-11,COMPLETED,INTERVENTIONAL,['PHASE1']
9657,NCT01440660,Multimodal testing/imaging procedures - Brain Imaging,Multimodal testing/ imaging modalities (raw data),,2012-01,COMPLETED,OBSERVATIONAL,['NA']
9658,NCT04315857,Time spent with an interstitial blood glucose level below 0.70 g/l and above 2.5 g/l,,,2020-06-09,COMPLETED,OBSERVATIONAL,['NA']
9659,NCT01034111,Safety and Tolerability of Sitagliptin After 4 Weeks of Treatment,Change From Baseline in Fasting Plasma Glucose at Week 4,,2010-03-01,COMPLETED,INTERVENTIONAL,['PHASE3']
9660,NCT03340467,Survival rate,Attachment site reactions,,2018-08-01,WITHDRAWN,INTERVENTIONAL,['NA']
9661,NCT06096311,Qualitative Results from Interviews,,,2022-04-01,RECRUITING,OBSERVATIONAL,['NA']
9662,NCT00796848,To evaluate the effectiveness of continuous glucose monitoring in the reduction of hypoglycemia unawareness.,To assess the levels of epinephrine production in youth diagnosed with hypoglycemia unawareness with and without continuous glucose monitor wear.,,2009-03,WITHDRAWN,INTERVENTIONAL,['NA']
9663,NCT05963594,"Incremental area under the curve (iAUC) of post-prandial glycemic excursion induced by Oligomalt relative to maltodextrin over the observation period: iAUC 0-1 hour, iAUC 0-2 hours, iAUC 0-3 hours.",Plasma peptide tyrosine (PYY),Plasma peptide tyrosine (PYY),2023-01-23,COMPLETED,INTERVENTIONAL,['NA']
9664,NCT05687968,Fasting glucose,Triglyceride (TG),,2023-01-16,RECRUITING,INTERVENTIONAL,['NA']
9665,NCT04016415,Change in Hemoglobin A1c from Baseline to 6 months,Change in Perceived Stress Scale-10 from Baseline to 6 months,,2020-07-28,RECRUITING,INTERVENTIONAL,['NA']
9666,NCT04982640,Acceptability as indicated by participant satisfaction ratings,Body Mass Index,,2022-10-24,RECRUITING,INTERVENTIONAL,['NA']
9667,NCT00286429,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26.,Change From Baseline in Body Weight (Week 26).,,2006-02,COMPLETED,INTERVENTIONAL,['PHASE3']
9668,NCT01409239,Difference Between Heart Rate Variability Between Intravenous and Subcutaneous Group,,,2011-07,COMPLETED,INTERVENTIONAL,['PHASE4']
9669,NCT05759676,Target lesion failure(Device-oriented composite endpoints),Procedural success rate,,2023-03-09,RECRUITING,OBSERVATIONAL,['NA']
9670,NCT00500175,incident foot ulcers,temperature spikes on foot zones,,2007-01,UNKNOWN,INTERVENTIONAL,['NA']
9671,NCT03229161,Compliance to the prescribed IWT-intervention,Physical fitness,BMI,2017-01-03,COMPLETED,INTERVENTIONAL,['NA']
9672,NCT02585674,Percentage of patients reaching fasting SMPG target range 90-130 mg/dL (5.0-7.2 mmol/L) at Week 16 (mean of the last 5 readings recorded over the last 2 weeks) without a severe hypoglycemic episode during the 16-week on-treatment period,Assessment of device Ease of Use using Ease of Use questionnaire,,2015-12,COMPLETED,INTERVENTIONAL,['PHASE3']
9673,NCT04927702,"For Participants With Venous Leg Ulcers, number of participants with 100 Percent Epithelialization (Closure) of Wound",Number of Product Applications,Number of participants with coverage of product by payor (insurance),2021-07-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
9674,NCT05026775,Rate of Initiation,Reduction of Cardiovascular Risk,Rate of Mortality,2022-03-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
9675,NCT00543361,This study will assess the lipid lowering effectiveness of MK0767 compared to metformin over the course of 52 weeks.,MK0767 will be safe and well tolerated.,,2003-05,TERMINATED,INTERVENTIONAL,['PHASE3']
9676,NCT05570305,Change from baseline in albuminuria after 4 weeks combined zibotentan and dapagliflozin treatment versus four weeks treatment with zibotentan alone.,Change in systolic and diastolic blood pressure,Change in copeptin,2022-10-06,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE2']
9677,NCT01934673,Proportion of patients having HbA1c ((glycosylated haemoglobin) as measured during survey) less than 7%,Proportion of patients having diabetic eye complications,,2013-09,COMPLETED,OBSERVATIONAL,['NA']
9678,NCT01095666,Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF]),Participants Achieving a Therapeutic Glycemic Response (Hemoglobin A1c [HbA1C]) <7.0% at Week 24 (Last Observation Carried Forward [LOCF]),,2010-06,COMPLETED,INTERVENTIONAL,['PHASE3']
9679,NCT03344341,Absolute change from baseline in HbA1c at Week 24,Percentage of patients with reduction of SBP ≥3 mmHg,The difference of the number between tablets taken and tablets prescribed,2017-12-15,TERMINATED,INTERVENTIONAL,['PHASE4']
9680,NCT05866380,Major adverse cardiovascular events,,,2022-03-23,RECRUITING,OBSERVATIONAL,['NA']
9681,NCT01515579,"Cmax, maximum concentration",Adverse events,,2006-04,COMPLETED,INTERVENTIONAL,['PHASE1']
9682,NCT01277965,Number of episodes of symptomatic or non-symptomatic hypoglycaemia,Duration of hypoglycaemia,,2010-03,COMPLETED,INTERVENTIONAL,['NA']
9683,NCT00916838,,,,2003-01,COMPLETED,OBSERVATIONAL,['NA']
9684,NCT00222807,,,,2003-08,COMPLETED,OBSERVATIONAL,['NA']
9685,NCT06317454,Identification of genetic factors affecting T1DM metabolic control,,,2021-11-11,RECRUITING,OBSERVATIONAL,['NA']
9686,NCT03686423,Apparent Diffusion Coefficient (ADC) in the Tibial Nerve,,,2018-11-28,COMPLETED,INTERVENTIONAL,['NA']
9687,NCT04733690,Satiety,,,2021-02-04,UNKNOWN,OBSERVATIONAL,['NA']
9688,NCT02091778,Change in Peri-wound Skin,,,2014-08,COMPLETED,INTERVENTIONAL,['NA']
9689,NCT00444600,Change in Visual Acuity From Baseline to 1 Year Grouped by Diffuse vs. Focal Edema as Characterized by the Investigator,Mean Change in Optical Coherence Tomography Retinal Volume From Baseline to 1 Year,Major Ocular Adverse Events During First Year of Follow-Up,2007-03,COMPLETED,INTERVENTIONAL,['PHASE3']
9690,NCT01028391,"Change From Baseline (i.e., Week 0 of the 24-week Base Study) in Hemoglobin A1c (HbA1c) at Week 54","Change From Baseline (i.e., Week 0 of the 24-week Base Study) in Fasting Plasma Glucose (FPG) at Week 54",,2007-09-01,COMPLETED,INTERVENTIONAL,['PHASE3']
9691,NCT01951859,Decrease in area or closure of wounds/fissures due to Homeopathic Anti-inflammatory Topical Cream,,,2013-08,UNKNOWN,INTERVENTIONAL,['NA']
9692,NCT05844137,Acceptability of intervention by participants,Change in medication adherence,,2023-09-18,COMPLETED,INTERVENTIONAL,['NA']
9693,NCT05190198,Modified Toronto Clinical Neuropathy Score (mTCNS),,,2022-01-15,COMPLETED,INTERVENTIONAL,['NA']
9694,NCT01671189,Glycemic Control (hemoglobin A1c),Appointment Adherence Rate,,2012-10,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
9695,NCT02033876,Change in Area Above Basal (AAB) for Glucose,Change in FGF-19,,2013-10,COMPLETED,INTERVENTIONAL,['PHASE2']
9696,NCT03374098,Changes in HbA1C values,Physical Activity,,2018-01-01,UNKNOWN,INTERVENTIONAL,['NA']
9697,NCT04280549,Protease Activated Receptor-1 Activation,,,2018-06-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
9698,NCT04979559,Oral glucose tolerance test mean change from baseline,Likelihood ratio of screening instrument compared to American Diabetes Association criteria,Participant's acceptance of mobile health application,2021-05-25,UNKNOWN,INTERVENTIONAL,['NA']
9699,NCT04908904,Area under the curve for glucose,Area under the curve for GIP,,2021-05-27,COMPLETED,INTERVENTIONAL,['NA']
9700,NCT00903799,clinical efficacy,medico-economic evaluation of ENTERRA therapy,,2009-06,COMPLETED,INTERVENTIONAL,['NA']
9701,NCT01261143,TSS,,,2010-08,COMPLETED,INTERVENTIONAL,['PHASE3']
9702,NCT01274364,Percentage of patients who attain 2 or more of the 'ABC' targets,Default rates at end of study,,2010-01,COMPLETED,INTERVENTIONAL,['NA']
9703,NCT02956759,Proportion of eyes progressing to any degree of PDR,Sensitivity & specificity of the diagnosis of any degree of PDR among study ophthalmologists,Patient vision-related quality of life (VRQOL); composite and individual domain scores of the NEI VFQ25 questionnaire.,2016-10,UNKNOWN,INTERVENTIONAL,['NA']
9704,NCT03700034,"Mean number of four selected ANC components delivered by the healthcare providers per visit, observed over two visits- the trial enrolment visit and the next routine ANC appointment.",Mean number of quality antenatal care components delivered in the enrolment visit,,2023-12,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9705,NCT02843399,Diabetes-related HCRU/costs,Medical Hypoglycemic events,Composite of A1C <7%/no weight gain/no hypoglycemia,2016-08-15,COMPLETED,OBSERVATIONAL,['NA']
9706,NCT03620266,Plasma levels of LDL cholesterol,Body composition with multi-frequency biothesiometry,,2021-09-30,RECRUITING,INTERVENTIONAL,['NA']
9707,NCT01955031,"To assess effectiveness of our telemonitoring program in Diabetes care, HbA1C assays will be compared between the two groups.The change of HbA1c between day 0, month 1,month 3, month 6, month 9 and month 12","For the telemonitoring arm, acceptability and satisfaction of the telemonitoring system by the health professionals with the number and time of connections leading to a medical decision (phone call or medical appointment) and a questionnaire",,2013-11,COMPLETED,INTERVENTIONAL,['NA']
9708,NCT02855684,Change in HbA1c from baseline,Change in daily basal insulin dose,,2016-08-24,COMPLETED,INTERVENTIONAL,['PHASE3']
9709,NCT05457088,Dietary intake of macro- and micro-nutrients,Protein carbonyls in plasma,,2021-11-01,RECRUITING,INTERVENTIONAL,['NA']
9710,NCT05076292,Incidence rate of hypoglycemia (PG < 3.9 mmol/l),Point accuracy with the Clarke Error Grid Analysis (CEGA) (using SMBG and YSI as the reference value),,2021-11-23,COMPLETED,INTERVENTIONAL,['NA']
9711,NCT02652754,Measurement of aCT1 peptide (Active Pharmaceutical Ingredient in Granexin) levels in blood,,,2015-09,COMPLETED,INTERVENTIONAL,['PHASE1']
9712,NCT03179137,Myocardial production of reactive oxygen species,Anti-cardiolipin antibodies in the blood of patients with symptoms of cardiac ischemia,,2016-10-01,UNKNOWN,OBSERVATIONAL,['NA']
9713,NCT05182970,Time to major CV event,Diabetes diagnosis,Hypoglycaemia,2021-12-02,RECRUITING,INTERVENTIONAL,['PHASE3']
9714,NCT01252056,nephropathy development,Adverse events,,2010-03,COMPLETED,INTERVENTIONAL,['PHASE4']
9715,NCT01776788,the glycemic remission rate in different groups,the time of glycemic remission in different groups,,2012-08,COMPLETED,INTERVENTIONAL,['PHASE4']
9716,NCT00862589,glucagon suppression,,,2006-10,COMPLETED,INTERVENTIONAL,['NA']
9717,NCT04234763,Postprandial 1H-NMR metabolites,Dietary Glycemic load(GL),,2019-08-01,UNKNOWN,INTERVENTIONAL,['NA']
9718,NCT03629301,Change in body weight,Number of participants achieving 5% of weight loss,,2018-09-17,COMPLETED,INTERVENTIONAL,['NA']
9719,NCT03622762,Soluble RAGE concentration,Aspartate aminotransferase,Weight and visceral fat %,2018-07-15,UNKNOWN,INTERVENTIONAL,['PHASE2']
9720,NCT03717896,plasma bicarbonate levels,hospital resource usage,Cognitive function: Test of Premorbid Functioning,2018-11-21,RECRUITING,INTERVENTIONAL,['PHASE2']
9721,NCT00852982,HbA1c,waist circumference,,2006-04,UNKNOWN,INTERVENTIONAL,['NA']
9722,NCT02579070,Percentage of patients developing a foot ulcer,Rate of change of score in quality of life from baseline and up to the final visit using the EQ-5D-5L,,2016-02-08,COMPLETED,INTERVENTIONAL,['NA']
9723,NCT02213146,Area under the curve (AUCins(0-1h)),Glucodynamics: Area under the glucose infusion rate - time curve from t=0 to 2 hours,,2014-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9724,NCT01589653,Change in HbA1c From Baseline,Change in Patient Reported Outcomes: Treatment-Related Impact Measures for Diabetes (TRIM-D)-Treatment Burden,,2012-05-26,COMPLETED,INTERVENTIONAL,['PHASE4']
9725,NCT04078854,Change in hemoglobin A1c (HbA1c) levels,Number of patients with mobility problems,,2020-07-08,TERMINATED,INTERVENTIONAL,['NA']
9726,NCT06065540,CagriSema versus semaglutide (2.4 mg/2.4 mg versus 2.4 mg and 1.0 mg/1.0 mg versus 1.0 mg): Relative change in body weight,"CagriSema (2.4 mg/2.4 mg and 1.0 mg/1.0 mg) versus semaglutide (2.4 mg and 1.0 mg), placebo and cagrilintide 2.4 mg: Number of severe hypoglycaemic episodes (level 3)",,2023-09-27,RECRUITING,INTERVENTIONAL,['PHASE3']
9727,NCT01706133,Change in hand grip strength (HS) as a physical performance test,Evaluation of individual and institutional impact,Quantify hospital readmissions,2013-06,COMPLETED,INTERVENTIONAL,['NA']
9728,NCT00041444,,,,2002-06,COMPLETED,OBSERVATIONAL,['NA']
9729,NCT00793481,Changes in Microvascular,,,2008-11,COMPLETED,OBSERVATIONAL,['NA']
9730,NCT05504239,Changes from baseline HbA1c at week 24,Changes from baseline in BMI at week 24,,2022-10,RECRUITING,INTERVENTIONAL,['PHASE3']
9731,NCT02906709,Percentage of Participants Who Discontinued Study Drug Due to an AE Including Data After Glycemic Rescue (Omarigliptin [Phase A+B]; Placebo→Omarigliptin [Phase B Only]),Percentage of Participants Achieving Hemoglobin A1c Goals (<6.5%) at Week 52 (Phase A+B),,2016-10-17,COMPLETED,INTERVENTIONAL,['PHASE4']
9732,NCT01016457,HbA1C,Mean glucose level,,2008-12,UNKNOWN,INTERVENTIONAL,['PHASE4']
9733,NCT06042153,Change in TIR (70-180 mg/dl),Total score of Kidney disease QoL short form,,2023-12-05,RECRUITING,INTERVENTIONAL,['PHASE4']
9734,NCT04509791,the area under the stimulated C-peptide response curve,"continuous glucose monitoring (CGM) measurements ( time in range, time above time below)",,2020-11-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
9735,NCT03006510,The proportion of patients (in each group) who ultimately have a hypoglycemic event,,,2017-01,COMPLETED,INTERVENTIONAL,['NA']
9736,NCT01584063,Physical Activity,"Metabolic (e.g., glucose)",,2004-02,COMPLETED,INTERVENTIONAL,['NA']
9737,NCT02472951,Insulin sensitivity,,,2015-08,COMPLETED,INTERVENTIONAL,['NA']
9738,NCT05637437,Health Related Quality of Life,Systolic and Diastolic Blood Pressure,,2023-08,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9739,NCT03049592,Utilization of LARC,Acceptability of contraceptive counseling intervention by patients and clinicians,,2016-07,COMPLETED,INTERVENTIONAL,['NA']
9740,NCT00595569,"Metabolic control (HbA1c, severe hypoglycemic events), psychological effects, diabetes knowledge","Changes in insulin doses, changes in weight",,2002-04,COMPLETED,OBSERVATIONAL,['NA']
9741,NCT05376930,"Changes from baseline in Adverse events (AEs) and adverse events of special interest (AESIs)* at Weeks 6, 12, 18, 24, 38, and 52 after administration of the IP","Proportion of subjects achieving HbA1c target of < 7% at Weeks 6, 12, 18, 24, 38, and 52 after administration of the IP",,2021-09-16,COMPLETED,INTERVENTIONAL,['PHASE3']
9742,NCT00225888,Subjects' hemoglobin A1c (A1c) values,Subjects' self-care behaviors,,2004-10,TERMINATED,INTERVENTIONAL,['NA']
9743,NCT02458495,Glycemic control (Change in participant's HbA1c level),"Time spent on website, 3 month assessment",,2015-08,COMPLETED,INTERVENTIONAL,['NA']
9744,NCT01651065,Weight,"Hemoglobin A1c (%, HbA1c)",Temporally investigate the causal induction of cascading changes in body weight between follow-ups on subsequent weight changes in other participants.,2011-06,COMPLETED,INTERVENTIONAL,['NA']
9745,NCT03676309,colesterol,Endothelial function,,2017-09-01,COMPLETED,INTERVENTIONAL,['PHASE2']
9746,NCT04114357,Change in the gut microbiome profile,Changes in Beta cell Health.,Changes in phenotype of Mucosal Associated invariant T (MAIT) cells,2020-06-22,COMPLETED,INTERVENTIONAL,['PHASE3']
9747,NCT00306644,Change from baseline of the composite intima-media thickness (IMT) in the carotid artery following 52 weeks of treatment.,Plaque occurrence & stenosis within the right carotid artery.,,2002-05,COMPLETED,INTERVENTIONAL,['PHASE4']
9748,NCT05141214,Short-term behavior modification,Satisfaction Survey,,2023-02-24,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
9749,NCT02180620,glucose concentrations,triglyceride concentrations,GLP-1 concentrations,2013-09,COMPLETED,INTERVENTIONAL,['NA']
9750,NCT05065372,Glomerular filtration rate,Insulin sensitivity,,2022-07-01,RECRUITING,INTERVENTIONAL,['PHASE1']
9751,NCT00174824,level recoded integer ETDRS retinopathy scale,the incidence of hypoglycemia,,2001-06,COMPLETED,INTERVENTIONAL,['PHASE4']
9752,NCT05472597,Incidence of metabolic syndrome,,,2022-11-29,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
9753,NCT00518427,Glycaemic controll will be asessed by HbA1c values,Incidence of symptomatic hypoglycemia and severe hypoglycemia,,2005-10,COMPLETED,INTERVENTIONAL,['PHASE4']
9754,NCT03715582,peak values of troponin and CKMB after PCI,occurrence of death,,2018-10-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
9755,NCT03243903,glycosylated hemoglobin (HbA1c),Self-monitoring of blood glucose(SMBG),Subject Satisfaction,2017-08-18,COMPLETED,INTERVENTIONAL,['NA']
9756,NCT00943501,Number and type of adverse events,Pharmacodynamics: Fasting Plasma Glucose (FPG) and insulin,,2009-11,COMPLETED,INTERVENTIONAL,['PHASE1']
9757,NCT00975286,Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24,"Change From Baseline in Treatment Satisfaction Score (Sum of Items 1, 4, 5, 6, 7 and 8 of DTSQ) at Week 24",Number of Patients With Symptomatic Hypoglycemia and Severe Symptomatic Hypoglycemia,2009-10,COMPLETED,INTERVENTIONAL,['PHASE3']
9758,NCT06214780,Change in time in range,Change in Percentage of time of varibles modes of automatization,,2024-01-22,RECRUITING,OBSERVATIONAL,['NA']
9759,NCT03626155,Mean 24-hour glucose,Respiratory Exchange Ratio (RER),,2018-06-01,COMPLETED,INTERVENTIONAL,['NA']
9760,NCT01497132,Beta cell function,Hypercalcemia,,2012-01,COMPLETED,INTERVENTIONAL,['PHASE4']
9761,NCT02518503,Number of participants with Incident type 2 diabetes,,,2012-07,COMPLETED,OBSERVATIONAL,['NA']
9762,NCT04605900,Change the 6 minutes walk test performance,Satisfaction with devices,,2017-03-13,COMPLETED,INTERVENTIONAL,['NA']
9763,NCT05386160,capillary non-perfusion zone of non-proliferative diabetic retinopathy,Determination of inflammatory factors in anterior aqueous humor,,2022-07-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
9764,NCT04854135,To Determine the Feasibility of Initiating a Continuous Glucose Monitoring in Patients With Diabetes at Hospital Discharge,Mean Change in Self-efficacy at 3 Months,,2021-04-13,TERMINATED,INTERVENTIONAL,['NA']
9765,NCT03014011,Psychomotor Speed,,,2017-06-13,COMPLETED,INTERVENTIONAL,['NA']
9766,NCT01245270,Plasma Insulin iAUC (Incremental Area Under the Curve; ng/ml*Min),Bioavailability in Urine,,2010-09,COMPLETED,INTERVENTIONAL,['NA']
9767,NCT05917587,blood flow response to insulin,Percentage of nitric oxide-dependent dilation,,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
9768,NCT03156361,Glucose area under the curve,total units Insulin,,2017-05-18,COMPLETED,INTERVENTIONAL,['PHASE2']
9769,NCT03616171,Number of Participants Enrolled in the Intervention Arm Who Complete the Study,Number of Participants Extending Sleep,,2017-08-30,COMPLETED,INTERVENTIONAL,['NA']
9770,NCT01455727,Hgb A1c change,Taiwan Geriatric Depression Scale(GDS) Score change,,2011-08,COMPLETED,INTERVENTIONAL,['NA']
9771,NCT05518448,EGP,Plasma β-OHB,,2022-05-03,RECRUITING,INTERVENTIONAL,['NA']
9772,NCT02099838,Change of HbA1c From Baseline at Week 12,Change of LDL From Baseline at Week 12,Change of DBil From Baseline at Week 12,2012-01,COMPLETED,INTERVENTIONAL,['PHASE4']
9773,NCT01316094,changes in Hemoglobin A1c (HbA1c),"safety assessed by the incidence of adverse events, vital signs, laboratory tests and 12-lead ECGs",,2011-01-18,COMPLETED,INTERVENTIONAL,['PHASE3']
9774,NCT01753362,HbA1c,Glucose Concentrations,,2012-12,COMPLETED,INTERVENTIONAL,['PHASE3']
9775,NCT03697369,Discontinuation rate differences,Glycemic control and metabolic parameters differences:BMI SDS,,2015-05-31,COMPLETED,OBSERVATIONAL,['NA']
9776,NCT06272851,comparison between choroidal thickness,,,2024-03-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
9777,NCT04291313,The prevalence of gestational diabetes (GDM),Prevalence of post partum hemorrhage > 500 ml,,2020-06-08,UNKNOWN,INTERVENTIONAL,['NA']
9778,NCT05962710,System Performance,,,2023-01-27,TERMINATED,OBSERVATIONAL,['NA']
9779,NCT01240837,Blood glucose concentrations,,,2010-11,COMPLETED,INTERVENTIONAL,['NA']
9780,NCT02604524,Time in range when using closed-loop compared with SAP.,Reduction of hypoglycemia episodes when using closed-loop,,2016-01,COMPLETED,INTERVENTIONAL,['NA']
9781,NCT05205928,Percentage of time of plasma glucose levels spent in target range (semaglutide vs placebo),"Glucagon, C-peptide, Paracetamol absorption after mixed meal tolerance test (in first 15 participants)",,2022-10-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
9782,NCT00309127,Death and/or ESRD defined as need for dialysis or plasma creatinine 500mmol/l,"Number of hospital admissions, total number of days of hospital stay and attendance at the Accident and Emergency Department",,2003-05,COMPLETED,INTERVENTIONAL,['NA']
9783,NCT05112588,Diabetes mellitus type 2,Glucose tolerance,,2021-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9784,NCT03394157,excess weight loss,Resolution of diabetes,,2011-01,COMPLETED,INTERVENTIONAL,['NA']
9785,NCT03745300,change in defect depth,change in modified Sulcus Bleding Index (mSBI),,2017-03-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
9786,NCT06157736,Describe evolution of the microbiome and metabolome during the early stages of new onset T1D,,,2023-10-06,RECRUITING,OBSERVATIONAL,['NA']
9787,NCT01951339,Changes From Baseline in 31P Measurement: pH,Change in (Non-invasively Measured) Deoxygenated Hemoglobin Concentration in the Vastus Lateralis During Exercise,,2013-10,COMPLETED,INTERVENTIONAL,['NA']
9788,NCT04964128,"Percentage of Time in Range (Phase 2, Software Release Tag 2.0)",,,2021-07-22,COMPLETED,INTERVENTIONAL,['NA']
9789,NCT01477957,Energy metabolism,Insulin sensitivity,,2012-09,RECRUITING,OBSERVATIONAL,['NA']
9790,NCT03723772,"AUCI287,τ,SS - Area under the serum insulin 287 concentration-time curve during one dosing interval at steady state",Positive cross-reactive anti-human insulin antibodies,,2018-11-29,COMPLETED,INTERVENTIONAL,['PHASE1']
9791,NCT03103867,Time in glucose target,hypoglycaemia fear in patients and caregivers,,2017-02-23,COMPLETED,INTERVENTIONAL,['NA']
9792,NCT01035801,AUC (Insulin and Blood Glucose),Frequency of Adverse Events,,2010-08-21,TERMINATED,INTERVENTIONAL,['PHASE1']
9793,NCT04626531,The Diabetes Quality of Life Scale,Website Analysis and Measurement Inventory,,2016-01-10,COMPLETED,INTERVENTIONAL,['NA']
9794,NCT00127634,To assess change in baseline to endpoint in HbA1c in type 1 diabetic patients.,To compare preprandial Human Insulin Inhalation Powder with preprandial injectable insulin in patients with type 1 diabetes with respect to glycemic control as assessed by the 8-point self-monitored blood glucose profiles,,2005-07,COMPLETED,INTERVENTIONAL,['PHASE3']
9795,NCT01680328,Injection Pain (VAS mm),Estimated Mean Differences in the Volume of Backflow (uL) in the Thighs After Different Injection Volumes and Speeds as Compared to Needle Insertion,,2012-08,COMPLETED,INTERVENTIONAL,['PHASE1']
9796,NCT00212641,Fasting Blood Glucose at 8 weeks,Pharmacodynamic parameters at all time points,,2005-06,COMPLETED,INTERVENTIONAL,['PHASE2']
9797,NCT02789033,Biopsies,,,2015-06,COMPLETED,INTERVENTIONAL,['PHASE3']
9798,NCT01286922,Insulin Sensitivity,Cardiorespiratory Fitness,,2009-07,COMPLETED,INTERVENTIONAL,['NA']
9799,NCT03814915,Glycemic deterioration,,,2012-10-15,COMPLETED,OBSERVATIONAL,['NA']
9800,NCT03862521,"Change in hormone (epinephrine, norepinephrine, glucagon) response to hypoglycemia",Change in lipid profile from baseline to 6 months,,2018-08-01,COMPLETED,INTERVENTIONAL,['NA']
9801,NCT04733508,Gene expression,,,2019-11-01,UNKNOWN,INTERVENTIONAL,['NA']
9802,NCT05762744,Exenatide effect on glucose disappearance rate,,,2016-06-01,TERMINATED,INTERVENTIONAL,['PHASE1']
9803,NCT00442858,,,,1999-01,COMPLETED,OBSERVATIONAL,['NA']
9804,NCT00006192,,,,2000-08,COMPLETED,OBSERVATIONAL,['NA']
9805,NCT02239354,Change in C-peptide,,,2014-09,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9806,NCT03772964,"Ex Vivo Cytokine Response of Peripheral Blood Mononucleocytes (PBMC) to Inflammatory Stimuli Compared to Baseline, Throughout Exposure, and Following Exposure to Metformin.",Measure Biogenesis of PBMCs.,,2019-01-22,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9807,NCT01490619,Change in Depressive symptoms from baseline to post intervention and change in Depressive symptoms over the two year study period.,Change in Glycemic Control from baseline to post-intervention and change in Glycemic Control over time during the two year study period.,,2011-10,COMPLETED,INTERVENTIONAL,['NA']
9808,NCT04763772,Step counts by Actigraphy.,,,2021-11-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
9809,NCT02380521,Subclinical atherosclerosis (as measured by cIMT) in patients with T2DM treated with exenatide once weekly,Endothelial dysfunction (as measured by flow mediated dilation of brachial artery) in patients with T2DM treated with exenatide once weekly,,2015-01,COMPLETED,INTERVENTIONAL,['PHASE4']
9810,NCT02479022,Number of treatment-emergent adverse events,Area under the glucose infusion rate-time curve,,2015-06,COMPLETED,INTERVENTIONAL,['PHASE1']
9811,NCT02712632,HbA1c reduction.,,,2016-06-20,COMPLETED,OBSERVATIONAL,['NA']
9812,NCT00804232,Primary Outcome Measure: the child's metabolic control as shown in HbA1C,"Quality of life, Satisfaction with care, Family impact and family climate, psychological variables, parental absenteeism from work; time use which is conditional on the child's diabetes etc), formal health care utilisation",,2008-01,UNKNOWN,INTERVENTIONAL,['NA']
9813,NCT01487369,Antibody titre findings,HbA1c (glycosylated haemoglobin),,2002-04,COMPLETED,OBSERVATIONAL,['NA']
9814,NCT01548885,MARD (Mean Absolute Relative Difference Between BGMS Results and Reference Method Results) Across the Overall Tested Glucose Range,MARD (Mean Absolute Relative Difference Between BGMS Results and Reference Method Results) Across the Low Glucose Range (<70mg/dL),,2012-03,COMPLETED,INTERVENTIONAL,['NA']
9815,NCT04230694,Number of Hypoglycemia Events during hospitalization,Number of Hyperglycemia Events during hospitalization,,2021-09-20,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
9816,NCT00996294,"Diabetes control, define by FSG and HbA1c",Diabetes control defined by FSG and HbA1c,,2007-11,UNKNOWN,INTERVENTIONAL,['NA']
9817,NCT03287297,Blood Glucose Level,,,2017-12-01,UNKNOWN,OBSERVATIONAL,['NA']
9818,NCT00053534,,,,2003-01,COMPLETED,OBSERVATIONAL,['NA']
9819,NCT02040038,Change in Physical Activity,Change in Lipid Levels,,2014-07,COMPLETED,INTERVENTIONAL,['NA']
9820,NCT00367055,Median Change From Baseline in the Insulin Secretory Capacity After a 36-month Treatment,Mean Change From Baseline in Insulin Sensitivity Index at Months 18 and 36,,2004-10,COMPLETED,INTERVENTIONAL,['PHASE4']
9821,NCT01620437,"Cmax, maximum insulin aspart concentration",Adverse events,,2003-11-29,COMPLETED,INTERVENTIONAL,['PHASE1']
9822,NCT02620774,Tazobactam Tissue Penetration,Number of Participants With Adverse Events,,2016-02-19,COMPLETED,INTERVENTIONAL,['PHASE1']
9823,NCT02198846,change of HbA1c,Percent of patients who reach target goal of HbA1c (<7.0%),,2014-06,UNKNOWN,INTERVENTIONAL,['NA']
9824,NCT03899883,Albumin Excretion Rate (AER),Change in serum uric acid (sUA),,2020-01-01,RECRUITING,INTERVENTIONAL,['PHASE2']
9825,NCT05694351,"Contextual appropriateness (questionnaire, 5-items Likert scale, higher score is best)",Well-being,,2023-12-01,RECRUITING,INTERVENTIONAL,['NA']
9826,NCT05572814,"Adoption of evidence-based CV-risk reduction and disease management therapies for HF, AF, and T2D/ASCVD. This data will be found in the patient's medical record.",Quality of Life Outcome-PAM,,2022-09-30,RECRUITING,INTERVENTIONAL,['NA']
9827,NCT03627377,Hemoglobin A1c or HbA1c,Smoking - Change in Smoking through Recall,,2018-12-28,UNKNOWN,INTERVENTIONAL,['NA']
9828,NCT01309620,Markers of oxidative damage,Vascular indices,,2009-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
9829,NCT03301519,Pancreatic Beta Cell Compensation for Insulin Resistance,Circulating adipokine levels,,2001-07-01,COMPLETED,OBSERVATIONAL,['NA']
9830,NCT00709475,"Incidence of serious adverse drug reactions, evaluated via number of major hypoglycaemic events",Fasting glucose level control compared to baseline as measured by FBG,,2008-05,COMPLETED,OBSERVATIONAL,['NA']
9831,NCT05035966,Prediabetes,,,2012-01-01,COMPLETED,OBSERVATIONAL,['NA']
9832,NCT02330848,Diet Quality assessed using the Alternative Healthy Eating Index (AHEI),Physical Activity assessed by the International Physical Activity Questionnaire (IPAQ),,2012-02,COMPLETED,INTERVENTIONAL,['NA']
9833,NCT01215331,Glycemic control,Acceptability of the treatment,,2010-08,COMPLETED,INTERVENTIONAL,['PHASE3']
9834,NCT02130804,Change in plasma C-peptide levels over a 2-hour oral glucose tolerance test,Change in physical activity,,2011-07,COMPLETED,INTERVENTIONAL,['PHASE1']
9835,NCT00480493,Worry,,,2004-06,COMPLETED,INTERVENTIONAL,['PHASE3']
9836,NCT00156364,Structural-functional relationships in diabetic nephropathy through detailed quantitative studies of Podocytes.,We will continue our study the natural history of diabetic nephropathy.,We have compared the development of calcineurin lesions in the native kidneys of 14 tacrolimus- and 12 calcineurin-treated pancreas transplant alone recipients cured of type 1 diabetes.,1981-01,COMPLETED,OBSERVATIONAL,['NA']
9837,NCT01769183,Proportion with complete regression of neovascularization on fundus photography at one month,Mean Change in Visual Acuity from Baseline to 5 Months,Proportion with partial regression of neovascularization on fundus photography,2013-02,COMPLETED,INTERVENTIONAL,['PHASE2']
9838,NCT01889095,Number Of Hypoglycemic events,,,2011-07,COMPLETED,INTERVENTIONAL,['PHASE4']
9839,NCT03155412,Adipogenic capacity of preadipocytes,Lipid metabolism,,2016-01,COMPLETED,OBSERVATIONAL,['NA']
9840,NCT00664027,To determine the effects of RTA 402 on glomerular filtration rate (as estimated by the MDRD formula) when administered for 28 days at dose of 25 mg followed by a dose of 75 mg for another 28 days in patients with diabetic nephropathy (stratum 2).,To determine the safety and tolerability of RTA 402 when the dose is escalated after 28 days in patients with diabetic nephropathy from 25 mg to 75 mg and continued for another 28 consecutive days.,,2008-04-30,COMPLETED,INTERVENTIONAL,['PHASE2']
9841,NCT05473078,Evaluate the attitudes by general practitioners towards pre-diabetes,,,2021-10-21,COMPLETED,OBSERVATIONAL,['NA']
9842,NCT00686712,Hemoglobin A1c Change From Baseline,Any Adverse Event Other Than Hypoglycemia,,2003-02,COMPLETED,INTERVENTIONAL,['PHASE4']
9843,NCT01141192,"Fasting glucose level before, mid-way through, and after the vitamin D3 supplement or placebo trial.",Serum 25-OH D levels in response to vitamin D3 supplement or placebo across a range of adiposity,,2010-01,COMPLETED,INTERVENTIONAL,['NA']
9844,NCT03011008,Mean amplitude of glycemic excursions (MAGE),Life quality evaluation,,2017-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
9845,NCT02491801,"Blood Glucose (Study 1, 2 and 3)",,"Food Intake Measured at 120 minutes (Study 1), and at 15 and 30 minutes (Study 3)",2015-03,COMPLETED,INTERVENTIONAL,['NA']
9846,NCT03242031,cost of treatment,,,2017-06-21,RECRUITING,INTERVENTIONAL,['NA']
9847,NCT03980990,Lactic Acidosis,All cause mortality at hospital discharge,,2019-06-17,UNKNOWN,INTERVENTIONAL,['PHASE4']
9848,NCT06288555,The accuracy of the Ipswich touch test,,,2023-12-21,COMPLETED,OBSERVATIONAL,['NA']
9849,NCT05791968,Continuous glucose monitoring,Body composition (weight and body fat),,2023-09,RECRUITING,INTERVENTIONAL,['NA']
9850,NCT04164784,HbA1c,UCAR,,2019-12-10,UNKNOWN,INTERVENTIONAL,['NA']
9851,NCT05349916,Postprandial glycemic response,Postprandial insulin response,,2021-12-07,COMPLETED,INTERVENTIONAL,['NA']
9852,NCT05235672,GADA in serum of subjects with T2D,,,2021-01-30,COMPLETED,OBSERVATIONAL,['NA']
9853,NCT03050645,Type 2 diabetes,"Questionnaires, physical activity (PAS 2), physical activity score",,2011-06,COMPLETED,OBSERVATIONAL,['NA']
9854,NCT00924105,Incidence of adverse events,Biological measures of glycemia and inflammation,,2009-06,COMPLETED,INTERVENTIONAL,['PHASE1']
9855,NCT03017703,Insulin sensitivity measured by a insulin clamp,Vascular function,,2016-12-01,COMPLETED,INTERVENTIONAL,['NA']
9856,NCT04880005,"Change in a binary indicator, composed by a composite endpoint of HbA1c, systolic blood pressure, low-density lipoprotein cholesterol, no smoking, and normal albuminuria",Change in quality of life measured by European Quality of life - EQ VAS,,2021-05-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9857,NCT05838872,Accuracy Evaluation: The Degree of Agreement (%) of the Minuteful - Kidney Urine Analysis Test System as Compared to the Comparator Device,Usability Evaluation: User Performance Analysis,,2021-12-09,COMPLETED,INTERVENTIONAL,['NA']
9858,NCT00241956,,,,2005-10,TERMINATED,OBSERVATIONAL,['NA']
9859,NCT04485351,Compare glycated hemoglobin levels of patients with diabetes from the University Hospital of Nancy between the period preceding and following the lockdown related to the COVID-19 pandemic.,"Describe the proportion of patients who (1) was tested for SARS-CoV-2 by PCR, (2) developped COVID-19 confirmed by PCR and (3) was hospitalized due to the severity of COVID-19.",,2020-07,UNKNOWN,OBSERVATIONAL,['NA']
9860,NCT01855087,Blood glucose level,,,na,COMPLETED,OBSERVATIONAL,['NA']
9861,NCT02632383,Glycemic control measured by HbA1c,Health Care Climate measured by HCCQ-questionnaire,,2015-12,COMPLETED,INTERVENTIONAL,['NA']
9862,NCT02669693,Post-prandial blood glucose concentration,,,2015-12,COMPLETED,INTERVENTIONAL,['NA']
9863,NCT03138616,Change in glucose metabolism,change in metabolism of calcium and phosphorus,,2016-11-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
9864,NCT04398030,"The Primary Endpoint is the Rate of Decline (s) Over Wear Time (DOI, Day 3, Day 5, Day 7) of the Natural Logarithm of the Area Under the Glucose Infusion Rate Curve [ln (AUC0-300(GIR))].",Mean Differences (Within Treatments Over Time Between Day 0 and Day 7) in Time-to-50% (Late) Maximum Insulin Concentration [t50%(Late)],,2020-07-17,COMPLETED,INTERVENTIONAL,['NA']
9865,NCT02844153,Percentage of patients receiving metformin,occurrence of lactic acidosis,,2014-03,UNKNOWN,OBSERVATIONAL,['NA']
9866,NCT01719406,"Achieving 30 minutes of daily exercise, four or more times each week",Eating 5 or more servings of vegetables and/or fruits each day,HemoglobinA1C,2012-11,COMPLETED,INTERVENTIONAL,['NA']
9867,NCT03531021,Adolescent Food Habits Checklist,Change in weight,,2018-05-03,COMPLETED,INTERVENTIONAL,['NA']
9868,NCT05694169,Primary Endpoints is as follows:,Second Secondary Endpoint,,2023-07-11,RECRUITING,INTERVENTIONAL,['PHASE1']
9869,NCT03129581,Weight,Body composition,,2017-09-01,COMPLETED,INTERVENTIONAL,['NA']
9870,NCT04190212,Glucose variability,Changes in blood biomarker concentrations,Link between glucose variability and atrial fibrillation symptom severity,2021-11-18,RECRUITING,INTERVENTIONAL,['NA']
9871,NCT04053621,hemoglobin A1c,arterial elasticity,,2021-01,UNKNOWN,INTERVENTIONAL,['NA']
9872,NCT05277558,Executive Function,,,2022-05-24,RECRUITING,OBSERVATIONAL,['NA']
9873,NCT03188263,Change in Glucose Levels (Area-under-the-curve) Measured by Performance on Oral Glucose Tolerance Test (OGTT),Changes in Circadian Phase Measured by Dim Light Melatonin Onset (DLMO),,2017-09-05,COMPLETED,INTERVENTIONAL,['NA']
9874,NCT03447925,Measures of the sites with plantar keratosis,,,2017-06-01,COMPLETED,INTERVENTIONAL,['PHASE2']
9875,NCT01923350,"In testing group, the number of women receiving a diabetes test per ADA Guidelines in the 6-month post-intervention period",Weight change from 6 to 9 months,,2011-12,COMPLETED,INTERVENTIONAL,['NA']
9876,NCT06147245,Change in HbA1c (mmol/mol),Screening for diabetic nephropathy - Urine albumin (mg)/creatinine (g) ratio,Participants' acceptance of intervention,2023-10-09,RECRUITING,INTERVENTIONAL,['NA']
9877,NCT00502710,Absolute change in hemoglobin A1c (HbA1c),"Adverse events (AEs), vital signs, laboratory parameters.",,2007-07,COMPLETED,INTERVENTIONAL,['PHASE2']
9878,NCT05463237,24-28. Visceral Adipokine Levels in Pregnant Women with Gestational Diabetes Between Weeks,,,2022-10-31,COMPLETED,OBSERVATIONAL,['NA']
9879,NCT02060916,To evaluate the efficacy of the food supplement PAZ320 on post-prandial glucose excursion,Number of Subjects with Adverse Events as a Measure of Safety and Tolerability,,2011-03,COMPLETED,INTERVENTIONAL,['PHASE2']
9880,NCT03509870,serious adverse events attributable to intervention,healing,,2018-06-01,TERMINATED,INTERVENTIONAL,['PHASE1']
9881,NCT02375139,Maximum of concentration (Cmax) of Evogliptin and Metformin,Area Under Curve(AUC)inf of Evogliptin and Metformin,,2015-04,COMPLETED,INTERVENTIONAL,['PHASE1']
9882,NCT00320060,,,,2001-10,COMPLETED,INTERVENTIONAL,['PHASE2']
9883,NCT03571659,1. Decrease in number of leaking Mas on FFA 2. Decrease in diffuse leakage on FFA,,,2014-12-22,COMPLETED,OBSERVATIONAL,['NA']
9884,NCT03031886,energy expenditure,,Nitrogen production,2016-01-20,COMPLETED,INTERVENTIONAL,['NA']
9885,NCT00214565,Absolute change from baseline to end of randomized treatment period in glycosylated hemoglobin A1c (HbA1c),Validate the Work Productivity and Activity Impairment-Diabetes Questionnaire (WPAI Diabetes) and the Diabetes Productivity Impairment Questionnaire (DPIQ) (US only).,,2004-08,TERMINATED,INTERVENTIONAL,['PHASE3']
9886,NCT05306990,Mean Change from baseline in Low Density Lipoprotein Cholesterol (LDL-C),,,2017-04-20,COMPLETED,INTERVENTIONAL,['NA']
9887,NCT00762138,Assess the incidence of hematological immunologic other ae's association with the application of AutoloGel on exuding wounds such as leg ulcers pressure ulcers and diabetics ulcers and during the management of mechanically or surgically debrided wounds,Absence of coagulopathies caused by inhibitors to coagulation Factor V as determined by a significant prolongation of the (PT) time. Depletion of Factor V activity with a positive Bethesda Assay,,2008-09,TERMINATED,INTERVENTIONAL,['NA']
9888,NCT02696070,Changes in Small Nerve Fiber Density by Assessment of a Skin Biopsy Comparing Baseline to Day 60,,,2015-07,COMPLETED,INTERVENTIONAL,['NA']
9889,NCT03204149,Safety,Wound Healing,,2017-06-14,TERMINATED,INTERVENTIONAL,['NA']
9890,NCT05878587,Numeric Pain Rating Scale,Ankle Brachial Index,Goniometer,2023-03-31,COMPLETED,INTERVENTIONAL,['NA']
9891,NCT04585191,Patient-Reported Outcome: Number of Participants with Self-Reported Hypoglycemia,Patient-Centered Outcome: Number of Participants with improved scores on Perceived Efficacy in Patient - Physician Interactions,"HbA1c Change from baseline to study completion, an average of 1 year",2020-11-02,RECRUITING,INTERVENTIONAL,['NA']
9892,NCT05711043,Proportion of subjects with a clinically relevant reduction of insulin dose after 12 months,Cost-effectiveness,,2023-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9893,NCT02457897,Hemoglobin A1C,Muscle Glucose Uptake,,2015-04-17,COMPLETED,INTERVENTIONAL,['PHASE2']
9894,NCT01654341,Changes in summary ordinal score on the Short Physical Performance Battery test,Mortality,,2013-12,COMPLETED,INTERVENTIONAL,['NA']
9895,NCT03936829,Average daily insulin dosage,HbA1c level,,2019-04-28,RECRUITING,INTERVENTIONAL,['NA']
9896,NCT05913726,Clinician preparation time,Clinician learning,,2023-08-01,RECRUITING,OBSERVATIONAL,['NA']
9897,NCT05171998,To determine whether SARS-CoV-2-specific T-cells cross-react with insulin producing cells in the pancreas of people with Type 1 diabetes.,To determine if expression of HLA A*02 and/or HLA A*24 is more common in Type 1 diabetes patients with SARS-CoV-2 cross-reactive T cells,,2021-01-01,COMPLETED,OBSERVATIONAL,['NA']
9898,NCT04786054,BED,NR3C1 Presence of variants of the GR gene (rs56149945; rs41423247),,2019-01-01,COMPLETED,INTERVENTIONAL,['NA']
9899,NCT04303754,Postprandial blood glucose,Appetite,,2020-06-24,COMPLETED,INTERVENTIONAL,['NA']
9900,NCT00657995,the incidence of severe hypoglycemia (< 40 mg/dl) during the intensive care period following pancreatic resection in patients monitored using the artificial pancreas,the total amount of insulin required for glycemic control after pancreatic resection,,2007-04,COMPLETED,INTERVENTIONAL,['NA']
9901,NCT01460368,Part B: Mean Change From Baseline in 12-lead Electrocardiogram (ECG) Corrected QT Intervals (LY2409021),Part B: Mean Change From Baseline in 12-lead Electrocardiogram (ECG) Corrected QT Intervals (Moxifloxacin),,2011-10,COMPLETED,INTERVENTIONAL,['PHASE1']
9902,NCT00860613,metabolic control,cost effectiveness,,2004-02,COMPLETED,INTERVENTIONAL,['NA']
9903,NCT00423488,"Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Endpoint, After 6 Weeks of Treatment",,,2005-07-12,COMPLETED,INTERVENTIONAL,['PHASE3']
9904,NCT03003507,Glycemic Variability,,,2009-10,COMPLETED,INTERVENTIONAL,['PHASE4']
9905,NCT01173939,"MACE (time to event): MACE (time to event): myocardial infarction, unstable angina, cardiovascular death, revascularization, fatal/nonfatal cerebrovascular accident, peripheral arteriopathy, aortic event",Frequency and type of adverse events,,2010-07,TERMINATED,INTERVENTIONAL,['NA']
9906,NCT01907516,Compliance With Home Blood Glucose Reporting,Subject Satisfaction,,2009-02,COMPLETED,INTERVENTIONAL,['NA']
9907,NCT02285881,"The between groups difference in the proportion of patients which achieve the treatment goals for HbA1c, blood pressure, and total cholesterol",The difference in coping style between baseline and 24 months within and between both groups as measured with the Diabetes Coping Measurement Questionnaire.,Process evaluation of the shared decision making ability of the general practitioners by using the Shared Decision Making Questionnaire.,2012-03,COMPLETED,INTERVENTIONAL,['NA']
9908,NCT01495975,Glycemic Control,Unplanned Readmission or ED Visit,,2011-12,COMPLETED,INTERVENTIONAL,['NA']
9909,NCT01204580,Adiponectin and Asymmetric Dimethylarginine (ADMA) plasma level changes,Change of Tumor Necrosis Factor- Alfa (TNF-Alfa),,2010-12,COMPLETED,INTERVENTIONAL,['PHASE4']
9910,NCT04235829,Correlation between early % total weight loss and % total weight loss 7 years following surgery.,Reduction or cessation in the treatment for either type 2 diabetes mellitus and hypertension 7 years following surgery..,,2012-04-01,COMPLETED,OBSERVATIONAL,['NA']
9911,NCT02520336,Postpartum Diabetes screening in GDM patients,,,2015-07,UNKNOWN,INTERVENTIONAL,['NA']
9912,NCT06139133,Gestational diabetes mellitus with 75g OGTT,,,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9913,NCT01785524,Change in Exercise Capacity - Claudication Onset Time (COT),Change In Vascular Function,,2013-02,COMPLETED,INTERVENTIONAL,['PHASE2']
9914,NCT00320021,Change in Serum Creatinine from baseline to week 26,,,2002-07,COMPLETED,INTERVENTIONAL,['PHASE2']
9915,NCT01025999,Determine if the improvements in glycemic control occurring early after RYGB can be reversibly inactivated and activated through delivery or exclusion of nutrients in the bypassed proximal small intestine.,"To evaluate whether improvements in glucose control occurring early after RYGB are related to altered insulin secretion, insulin sensitivity, or both.",,2010-01,COMPLETED,OBSERVATIONAL,['NA']
9916,NCT05945862,Triglycerides,Lifestyle,,2023-07-17,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9917,NCT00201227,practice adherence to diabetes guidelines,practice adherence to tobacco history taking guidelines,,2002-09,COMPLETED,INTERVENTIONAL,['NA']
9918,NCT01708044,Incremental area under the concentration-time curve (AUC(0-3 h)) of plasma glucose concentrations for each treatment,Safety,,2012-11,COMPLETED,INTERVENTIONAL,['PHASE1']
9919,NCT02646878,24 hour calibration requirement,,,2016-01,WITHDRAWN,INTERVENTIONAL,['NA']
9920,NCT03799796,Time-in-Range,Online peer support engagement,,2019-01-06,COMPLETED,INTERVENTIONAL,['NA']
9921,NCT00950963,Number of Patients With a Low Density Lipid (LDL) Value Less Than 100 mg/dL,Number of Patients With Hgb A1c Less Than 7 Percent at the End of the Study,Number of Total Emergency Department (ED) Visits and Hospital Admissions During the Follow up Period.,2005-09,COMPLETED,INTERVENTIONAL,['NA']
9922,NCT05905575,Change in health-related quality of life,Change in blood pressure control,,2023-06-09,RECRUITING,INTERVENTIONAL,['NA']
9923,NCT03904901,Anxety,BMI,,2018-07-20,UNKNOWN,INTERVENTIONAL,['NA']
9924,NCT03426540,best corrected visual acuity,central retinal thickness,,2017-01-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
9925,NCT02528162,Scale (1-4) with questionnaire on anxiety (six-item short form STAI),The frequency of an HbA1c ≥6.5%,,2015-10,COMPLETED,OBSERVATIONAL,['NA']
9926,NCT00659451,"Left ventricular mass, intraventricular septal thickness, fractional shortening; myocardial qualitative and diastolic function alteration; aortic strain and distensibility.",Heterogeneity of myocardial tissue; epicardial adipose tissue measurement,,2008-04,UNKNOWN,INTERVENTIONAL,['PHASE3']
9927,NCT03707171,Changes of cognitive function assessed by cognitive function scale after 12 weeks.,Change of waist-to-hip ratio,,2018-10-01,COMPLETED,INTERVENTIONAL,['PHASE3']
9928,NCT03315780,Change From Baseline in Glucose Area Under the Concentration Versus Time Curve From Time Zero to 4 Hours (AUC[0-4h]),Number of Participants Who Develop Hypoglycemic Events,,2017-10-28,COMPLETED,INTERVENTIONAL,['PHASE4']
9929,NCT00238862,Persistent corneal re-epithelialization (= lasting success),,,2005-10,COMPLETED,INTERVENTIONAL,['NA']
9930,NCT04037436,Feasibility - Adherence,Resource use,,2019-09-24,COMPLETED,INTERVENTIONAL,['NA']
9931,NCT02356224,SHR3824 and its metabolites of concentrations to characterize SHR3824 harmacokinetics.,The number of patients with adverse events as a measure of safety and tolerability,,2013-06,COMPLETED,INTERVENTIONAL,['PHASE1']
9932,NCT05375630,Grip Strength,Vitamin K status,,2022-03-21,RECRUITING,INTERVENTIONAL,['NA']
9933,NCT04004793,Incidence of patients with diabetes remission,Net change in Albuminuria,,2020-08-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4']
9934,NCT00793741,Brain glucose concentration as measured by NMR spectroscopy,,,2007-12,COMPLETED,OBSERVATIONAL,['NA']
9935,NCT06311799,Difference in WIC enrollment,RDN visit adherence,,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
9936,NCT03191435,Glycated hemoglobin in 12 weeks,Lung functions,,2017-07-11,UNKNOWN,INTERVENTIONAL,['NA']
9937,NCT02346669,40% decrease in insulin resistance compared to baseline,Maintenance of altered of enteric microbiota in the three diet groups,,2016-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
9938,NCT03129165,Primary adherence at baseline screening,Global change in estimated risk at 12th months,,2015-05-11,UNKNOWN,INTERVENTIONAL,['NA']
9939,NCT03829982,Postprandial glucose (mg/dL),Core body temperature (CBT) and skin temperature,,2018-07-13,COMPLETED,INTERVENTIONAL,['NA']
9940,NCT04667182,Change from Baseline in Area Under the Curve (AUC) of CGM,Time Below Range (TBR) <70 mg/dL,,2021-01-25,WITHDRAWN,OBSERVATIONAL,['NA']
9941,NCT05742373,Changes in sirtuin molecule tissue expression,Change in dietary nutritional intake,,2023-03-01,RECRUITING,INTERVENTIONAL,['NA']
9942,NCT01820871,fasting serum glucose and HbA1c,Lipid profile,,2012-11,COMPLETED,INTERVENTIONAL,['NA']
9943,NCT01870141,Change from baseline glycosylated haemoglobin (HbA1c) at 26th and 38th weeks [mmol/mol],Change from baseline Binge-Eating Disorders at 26th and 38th weeks (BES score),,2012-10,SUSPENDED,INTERVENTIONAL,['NA']
9944,NCT01614769,Incremental Weighted Average Blood Glucose Concentration Over 3 Hours of Hypoglycemic Recovery,,,2012-07-18,COMPLETED,INTERVENTIONAL,['PHASE1']
9945,NCT03871049,blood sugar,,,2020-01-10,COMPLETED,INTERVENTIONAL,['NA']
9946,NCT03590262,Change of hemoglobin A1c in percentage,Change of weight in kilograms,,2018-01-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
9947,NCT00993525,central macular thickness,,,2008-09,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9948,NCT02817152,"Probing depth change from baseline to 30, 90, and 180 days through periodontal probing","Plaque index change from baseline to 30, 90, and 180 days through periodontal probing",Glycated hemoglobin,2014-02,COMPLETED,INTERVENTIONAL,['NA']
9949,NCT00000466,,,,1987-09,COMPLETED,INTERVENTIONAL,['PHASE3']
9950,NCT05601310,There are differences in the metabolic profile of diabetic patients with or without combined acute myocardial infarction,,,2017-05-23,COMPLETED,OBSERVATIONAL,['NA']
9951,NCT02283632,Assess change in glycosylated hemoglobin A1c,,,2014-10,COMPLETED,INTERVENTIONAL,['NA']
9952,NCT02099123,Major cardiovascular events,Revascularisation procedure,New onset diabetes,2015-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4']
9953,NCT02454153,Change in Continuous Glucose Monitoring System Standard Deviation,Change in Continuous Glucose Monitoring System Mean Glucose,,2014-12,COMPLETED,INTERVENTIONAL,['NA']
9954,NCT00948311,,,,2008-12,COMPLETED,OBSERVATIONAL,['NA']
9955,NCT01131052,Mean of Weekly Fasting Blood Glucose Concentration,Mean of Glycosylated Hemoglobin (hbA1c),,2011-03,COMPLETED,INTERVENTIONAL,['PHASE4']
9956,NCT02664740,The relative reduction in wound surface area (%),The presence/absence of anti-phage antibodies in plasma samples,,2022-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9957,NCT00058981,,,,2002-10,TERMINATED,INTERVENTIONAL,['PHASE2']
9958,NCT01326130,Diabetes and Hypertension control,Effects on physician practice,,2011-04,UNKNOWN,INTERVENTIONAL,['NA']
9959,NCT02541734,Renal uptake as measured by uptake of 111In-exendin-4 on SPECT images and without co-infusion of Gelofusine.,Pancreas uptake as measured by uptake of 111In-exendin-4 on SPECT images,,2015-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9960,NCT01483651,Area Under the Curve for Glucose Above Baseline,,,2011-11,COMPLETED,INTERVENTIONAL,['NA']
9961,NCT05280925,Change in body mass index from baseline (Week 0) to Week 24,"Ease of Use and Treatment Effectiveness Questionnaire, Likert scale",Change in delay discounting from baseline (Week 0) to Week 24,2022-07-20,RECRUITING,INTERVENTIONAL,['NA']
9962,NCT04539288,T2DM,IGT,,2013-05-01,COMPLETED,OBSERVATIONAL,['NA']
9963,NCT03756688,Penile Length Change Between Baseline and Month 6,Erectile Function Among Groups - Evaluating Change From Baseline to 6 Months.,,2018-11-07,COMPLETED,INTERVENTIONAL,['NA']
9964,NCT04243850,measured glomerulair filtration rate (mGFR),proximal sodium excretion,,2020-07-01,WITHDRAWN,INTERVENTIONAL,['PHASE4']
9965,NCT03594565,Difference in skin irritation before and after regular application of nsFP according to the modified Draize scale.,Change in glycated hemoglobin 6 months after nsFP use,,2016-03,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
9966,NCT02444845,Number of patients with anemia secondary to CKD,Use of treatment modalities for the management of anemia secondary to CKD,,2011-05,COMPLETED,OBSERVATIONAL,['NA']
9967,NCT01517373,Change From Baseline in Glycosylated Hemoglobin (HbA1C) at Week 12,Number of Participants With Abnormal Laboratory Values,,2012-02,COMPLETED,INTERVENTIONAL,['PHASE2']
9968,NCT04894344,blood pressure,Physical activity,,2020-10-28,COMPLETED,INTERVENTIONAL,['NA']
9969,NCT03110796,"% of Wound Area Regression (WAR), as a measure of efficacy",,,2017-07-31,UNKNOWN,INTERVENTIONAL,['NA']
9970,NCT02516150,AOCGIR (Area Over the Curve for Glucose Infusion Rate),Maximum Change in GIR (Glucose Infusion Rate) From Baseline,,2016-03,COMPLETED,INTERVENTIONAL,['PHASE4']
9971,NCT01486680,Remission of type 2 diabetes mellitus/ glycaemic control,Quality of Life,Weight loss (excess weight loss and actual weight loss),2011-09,COMPLETED,INTERVENTIONAL,['NA']
9972,NCT00989898,The primary outcome measure is overnight glucose control as measured by plasma glucose concentration between midnight and 8:00 a.m. in the two Time Schedules (closed-loop control starting at 1800 or 2100).,,,2009-02,COMPLETED,INTERVENTIONAL,['NA']
9973,NCT05714683,Number (Incidence) of adverse events (AEs),Dose of Rybelsus,,2024-12-31,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
9974,NCT02365740,gastric emptying measure,postprandial glucose variability after double-wave insulin bolus,,2014-11,UNKNOWN,INTERVENTIONAL,['NA']
9975,NCT03447964,Comparison of plasma total ceramides concentration in type 2 diabetic patients versus type 1 diabetic patients.,- Correlation between sphingolipids species concentrations and macrovascular complications (cardiovascular disease history),,2017-04-04,COMPLETED,OBSERVATIONAL,['NA']
9976,NCT02497651,Postprandial response of glucagon-like peptide-1 (GLP-1),GLP-1 receptor expression in the skin,,2015-05,COMPLETED,INTERVENTIONAL,['NA']
9977,NCT02310555,Remission diabetes mellitus type II,Adverse effects in the long term,,2014-10,UNKNOWN,INTERVENTIONAL,['NA']
9978,NCT04877119,Predictive SFLT-1 / PLGF ratio cat-off point for preeclampsia,Correlation between SFLT-1 / PLGF ratio and placental histopathology,,2019-10-14,UNKNOWN,OBSERVATIONAL,['NA']
9979,NCT01220479,Bone mineral density and content,Body composition,,2001-09,COMPLETED,INTERVENTIONAL,['NA']
9980,NCT01092390,urine protein excretion,Biomarkers of oxidation and inflammation,,2010-03,COMPLETED,INTERVENTIONAL,['PHASE3']
9981,NCT01368081,Number of Patients With Drug Related Adverse Events,Change From Baseline in HbA1c,Confirmed Hypoglycaemic Adverse Events,2011-05,COMPLETED,INTERVENTIONAL,['PHASE3']
9982,NCT02769091,Percentage of Participants with Adverse Events,Change from baseline in liver fibrosis measured using transient elastography (with Fibroscan),,2016-09-30,WITHDRAWN,INTERVENTIONAL,['PHASE2']
9983,NCT01931631,Hemoglobin A1c,Beck Depression Inventory II (BDI-II),,2014-01,SUSPENDED,INTERVENTIONAL,['NA']
9984,NCT00960765,,,,2009-08,COMPLETED,OBSERVATIONAL,['NA']
9985,NCT02462863,Improvement of type 2 diabetes,,,2016-03-01,COMPLETED,INTERVENTIONAL,['NA']
9986,NCT01612520,the absolute change in HbA1c,,,2012-04,COMPLETED,INTERVENTIONAL,['NA']
9987,NCT03675919,remission rate,outpatient costs,,2018-09-15,COMPLETED,INTERVENTIONAL,['NA']
9988,NCT04658082,difference between core lab and non invasive glucose measurements,,,2020-10-07,COMPLETED,INTERVENTIONAL,['NA']
9989,NCT00407108,Facility of surgical maneuvers,,,2006-03,UNKNOWN,INTERVENTIONAL,['PHASE3']
9990,NCT00153023,"Change from baseline (Visit 6) in 24 hour proteinuria, after one year of treatment (study end) with telmisartan 80 mg versus valsartan 160 mg.","Change from baseline in BP endpoints (SBP, DBP and pulse pressure)",,2003-04,COMPLETED,INTERVENTIONAL,['PHASE4']
9991,NCT04562025,Adverse Events,Change in HbA1c,,2020-09-25,UNKNOWN,INTERVENTIONAL,['NA']
9992,NCT00401089,SANS,BMI Body Mass index,,2002-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
9993,NCT05134480,Graft failure,Endothelial cell density,,2022-01-21,RECRUITING,INTERVENTIONAL,['PHASE3']
9994,NCT02735031,Symptom score in response to insulin-induced hypoglycaemia,Glucose variability as measured by glucose sensor monitoring,Gastrointestinal side effects,2017-02-21,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
9995,NCT03568409,"Improvement of the overall glycemic control after 6 months of treatment with ABO-GLYC, as a result of reduction of HbA1c and/or post-prandial glycemic peak.",Control of the glycemia.,,2017-06-01,COMPLETED,INTERVENTIONAL,['NA']
9996,NCT04841304,Clinically significant arrhythmias,All-cause mortality,"Correlation between heart rate variability, daytime and nighttime heart rate, physical activity, and risk of arrhythmias",2021-06-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
9997,NCT02500329,endothelial function (reactive hyperemic index),Glycated albumin,,2014-09,UNKNOWN,INTERVENTIONAL,['PHASE4']
9998,NCT05944432,HbA1c,Frequency of hypoglycaemia events,,2023-07-14,RECRUITING,INTERVENTIONAL,['NA']
9999,NCT03854695,Assess serum IgG titers,Characterize microbiology,Assess microbiome,2019-02-01,WITHDRAWN,OBSERVATIONAL,['NA']
10000,NCT04975022,GIRmax,tGIRmax,,2019-12-10,COMPLETED,INTERVENTIONAL,['PHASE1']
10001,NCT02509065,Number of Subjects Discordant for Reaching a BG < 60 mg/dl for > 2 Consecutive Plasma Glucose Measurements During Inpatient Exercise Visit,Total Glucagon Dosing by the Bihormonal Bionic Pancreas From the Start of Exercise Until the End of the Visit,,2015-08,COMPLETED,INTERVENTIONAL,['NA']
10002,NCT00565162,"Superiority is based on observing clinically significant difference in glycaemic control (> than or = to 0,5 % HbA1c). Programs are defined as equally successful if the HbA1c differs less than 0,5 %.",,,2003-11,COMPLETED,INTERVENTIONAL,['PHASE4']
10003,NCT02881528,Between group difference in reduction in beta cell demand as measured by serum glucose (mmol/L) and C-peptide (ng/mL),Feasibility of a randomized controlled trial in children who are at high risk of T1D as measured by attrition rates (%),Between group difference in Immunological t-cell response to diabetes,2016-03-30,WITHDRAWN,INTERVENTIONAL,['PHASE4']
10004,NCT00256646,"The primary outcome measure is to define these unique processes and to elucidate underlying biochemical, metabolic, and genetic determinants of vascular disease complications in diabetes.",,,2007-06,COMPLETED,OBSERVATIONAL,['NA']
10005,NCT00855166,Adjusted Mean Change in Total Body Weight,Proportion of Participants With Body Weight Decrease ≥5%,Adjusted Percent Change in Bone Mineral Density (BMD) at Total Hip,2009-02,COMPLETED,INTERVENTIONAL,['PHASE3']
10006,NCT05174728,Placental mitochondrial function at delivery,Placental lipid metabolism,,2017-07-20,SUSPENDED,OBSERVATIONAL,['NA']
10007,NCT01963728,Change in Hemoglobin A1C (Glycosylated Hemoglobin),Mean Blood Glucose Values,,2013-11-27,TERMINATED,INTERVENTIONAL,['PHASE4']
10008,NCT03232034,Postprandial plasma GLP-1 area under the curve (mmol/L x 120 min).,Blood pressure,,2017-05-01,COMPLETED,INTERVENTIONAL,['NA']
10009,NCT06054035,Change in albuminuria,Numbers of patients showing resolution of chronic kidney disease (CKD),Interaction between diabetes risk cluster and intervention for change in albuminuria,2023-10-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
10010,NCT00814476,HbA1c,7 points glucose profile,,2009-01,COMPLETED,INTERVENTIONAL,['PHASE4']
10011,NCT01300260,Insulin Area Under the Curve (AUC) - Second Phase Response,Insulin Maximum Concentration (Cmax),Area Under the Insulin Concentration-time Curve (AUC),2011-02,COMPLETED,INTERVENTIONAL,['PHASE1']
10012,NCT04083456,Physical Activity,Self-Efficacy for Managing Chronic Disease,FitBit Use Adherence,2019-11-01,RECRUITING,INTERVENTIONAL,['NA']
10013,NCT04469790,Continuous glucose monitor measures,Cardiac autonomic nervous system measures,,2022-03-01,RECRUITING,INTERVENTIONAL,['NA']
10014,NCT02835183,Compare mean postprandial glucose level,Hyperglycemia events,,2017-01,WITHDRAWN,INTERVENTIONAL,['NA']
10015,NCT03455816,Quality of life assessment: Diabetes Quality of Life (DQoL) questionnaire.,Scale of adherence to treatment in patients with diabetes type 1,,2017-07-07,UNKNOWN,INTERVENTIONAL,['NA']
10016,NCT01262898,Gastric Half Emptying Time (GEt1/2),"Change From Baseline in Whole Bowel Transit Time, 100 % Gastric Emptying Time (Truncated at 240 Minutes), Small Bowel Transit Time, Colonic Transit Time as Determined by Wireless Motility Capsule (WMC)",,2011-05-03,COMPLETED,INTERVENTIONAL,['PHASE2']
10017,NCT05813249,NAFLD regression,Fibrosis regression,,2023-02-15,COMPLETED,INTERVENTIONAL,['PHASE4']
10018,NCT01346098,incidence of complications after pancreatic surgery,Incidence of endocrine and exocrine pancreatic insufficiency,,2010-07,COMPLETED,INTERVENTIONAL,['PHASE2']
10019,NCT03490318,"Sensitivity of the new pathway (ophthalmic grader pathway) in detecting active DMO/PDR, using the standard care pathway as the reference standard.","Proportions of patients unable to undergo imaging, with inadequate quality images or indeterminate findings.",,2017-10-26,COMPLETED,OBSERVATIONAL,['NA']
10020,NCT01584856,,,,2006-05,UNKNOWN,OBSERVATIONAL,['NA']
10021,NCT06197412,2-week reduction rate of wound area,Mortality,,2024-01-08,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
10022,NCT04520191,Number of participants with problems in their health care due to COVID-19 related isolation,,,2021-01-04,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
10023,NCT02004366,Differences in Glycemic Control,Outpatient Mortality,,2014-01,COMPLETED,INTERVENTIONAL,['PHASE4']
10024,NCT01897857,the compensatory changes in ulnar artery blood flow after radial artery cannulation,,,2013-07,COMPLETED,INTERVENTIONAL,['NA']
10025,NCT02055547,Average Concentration (Cave) of MK-8521 Corresponding to Slope of Insulin Secretion Rate/Glucose (ISR/G) During Graded Glucose Infusion (GGI) at Tmax After a Single Dose of MK-8521 (Part 3),Apparent Terminal Half-life (t1/2) for Plasma Concentration of Participants Treated With a Single Dose of MK-8521 (Part 3),,2013-05-10,COMPLETED,INTERVENTIONAL,['PHASE1']
10026,NCT03794973,Treatment effect on log-transformed MMTT C-peptide area under the curve (AUC),Immunologic,,2019-12-14,WITHDRAWN,INTERVENTIONAL,['PHASE2']
10027,NCT03240978,change of fasting glucose,rate of non-responsiveness in the alleviation of insulin resistance to exercise intervention,,2016-09,SUSPENDED,INTERVENTIONAL,['NA']
10028,NCT02078440,Pharmacokinetics,,,2014-01,COMPLETED,INTERVENTIONAL,['PHASE1']
10029,NCT03669536,Short Portable Mental Status Questionnaire (SPMSQ),,Anemia,2017-08-01,UNKNOWN,OBSERVATIONAL,['NA']
10030,NCT00236600,The percent change in body weight from the enrollment visit to week 60.,"Change from baseline to week 60 in absolute change in body weight, body mass index, waist circumference, fasting lipid profile; safety evaluations over study.",,2000-08,COMPLETED,INTERVENTIONAL,['PHASE3']
10031,NCT00627029,Medicare program expenditures,Claims-based and patient-reported quality of care,,2000-09,UNKNOWN,INTERVENTIONAL,['NA']
10032,NCT03771781,Peak Plasma Concentration (Cmax),Area under the plasma concentration versus time curves (AUC),,2018-04-16,COMPLETED,INTERVENTIONAL,['NA']
10033,NCT06185296,CGM time in range,Change in perceived competence in Diabetes,Insulin dosing time,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
10034,NCT01822717,Days per week participants performed foot inspection,Number of foot problems discovered,Acceptability,2010-09,COMPLETED,INTERVENTIONAL,['NA']
10035,NCT02910271,Prevalence of PAD in asymptomatic patients with T1DM assessed by ankle-branchial index.,Prevalence of asymptomatic atherosclerotic carotid disease in patients with asymptomatic PAD.,,2016-05,COMPLETED,OBSERVATIONAL,['NA']
10036,NCT05728567,Inflammatory factors,,,2017-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
10037,NCT00368368,"Vital signs, adverse events, laboratory parameters.","AUC, Tmax, Cmax, T1/2, CL/F, CLR for GK Activator (2) and metabolite. Glucose Cmax and Cmin, and percentage decrease in glucose from baseline.",,2006-01,COMPLETED,INTERVENTIONAL,['PHASE1']
10038,NCT05373212,CmaxTOTAL,Local tolerability,,2022-05-12,COMPLETED,INTERVENTIONAL,['PHASE1']
10039,NCT05442853,Time in target blood glucose range (BG 70-180mg/dL),Pain Score,,2022-11-02,RECRUITING,INTERVENTIONAL,['NA']
10040,NCT05737771,Cmax of DWC202213,,,2023-01-25,RECRUITING,INTERVENTIONAL,['PHASE1']
10041,NCT00541229,24-hour Weighted Mean Glucose (WMG),,,2007-08-24,COMPLETED,INTERVENTIONAL,['PHASE1']
10042,NCT03494010,Duration of use of hybrid closed-loop (HCL) system,fasting glucose levels,,2018-08-31,WITHDRAWN,OBSERVATIONAL,['NA']
10043,NCT00848315,The primary outcome is improvement in metabolic control (HbA1c).,Efficacy of the intervention,,2004-07,COMPLETED,INTERVENTIONAL,['PHASE2']
10044,NCT05729776,"TIR, TBR and TAR evaluation(glucose metrics by glucose sensor) after the consumption of pizza meal vs control meal","TIR, TBR and TAR evaluation(glucose metrics by glucose sensor) after ""Medtronic pizza management"" and""Tandem T slim pizza management""",,2022-12-01,COMPLETED,OBSERVATIONAL,['NA']
10045,NCT00985712,Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24 Endpoint,30-Day Adjusted Rates of Self-Reported Hyperglycemic Episodes at Any Time From Baseline Through Week 24,,2009-10,COMPLETED,INTERVENTIONAL,['PHASE4']
10046,NCT04783441,Time in Range (70-180 mg/dl),Incidence of post-transplant infections during study period,safety endpoint Hypoglycemia,2021-06-29,RECRUITING,INTERVENTIONAL,['NA']
10047,NCT01554644,Relative (%) area wound size change versus baseline in respondents to treatment following a 12-week treatment period,Change of clinical wound infection during treatment period,,2012-03,WITHDRAWN,INTERVENTIONAL,['NA']
10048,NCT01188200,The primary variable is glucose concentration,Additional measures of glucose concentration,,2009-12,COMPLETED,INTERVENTIONAL,['PHASE3']
10049,NCT06192108,Change from Baseline in Hemoglobin A1c: (HbA1c),Change from Baseline in Diabetes Treatment Satisfaction Questionnaire-Change (DTSQc) Scores,,2024-01-10,RECRUITING,INTERVENTIONAL,['PHASE3']
10050,NCT00596505,The changes of visual acuity,,,2007-04,COMPLETED,OBSERVATIONAL,['NA']
10051,NCT04632823,Change from Baseline Body Mass Index at 6 months,Change from Baseline Homeostasis ModelAssessment of Insulin Resistance at 6 months (HOMA-IR),,2018-09-01,UNKNOWN,INTERVENTIONAL,['NA']
10052,NCT03796975,Change of liver enzyme after 24 weeks treatment as assessed by blood test,Change of weight and waistline after 24 weeks treatment as assessed by standard measurement,,2018-06-28,COMPLETED,INTERVENTIONAL,['PHASE4']
10053,NCT03816605,Expression of IRS-1 and GLUT-1 in different group,,,2014-04,COMPLETED,OBSERVATIONAL,['NA']
10054,NCT01399138,Change from Baseline in Systolic and Diastolic Blood Pressure at 6 weeks,Change from Baseline in insulin sensitivity at 6 weeks,,2010-07,WITHDRAWN,INTERVENTIONAL,['NA']
10055,NCT01759121,the probability of vitreous haemorrhage,change of ischemia area,,2016-03,UNKNOWN,INTERVENTIONAL,['NA']
10056,NCT01569841,Average Time Within Glycaemic Target Range (Above 70 mg/dL and Below 130 mg/dL),Number of Treatment Emergent Confirmed Hypoglycaemic Episodes,,2012-04,COMPLETED,INTERVENTIONAL,['PHASE3']
10057,NCT04466618,"Change in Fasting Glucagon in the Presence or Absence of Exendin-9,39",,,2021-04-15,COMPLETED,INTERVENTIONAL,['PHASE3']
10058,NCT01722513,Primary Outcome,Secondary Outcome,,2012-11,UNKNOWN,INTERVENTIONAL,['PHASE4']
10059,NCT00111540,Change in lipids from Visit 1 to each protocol visit,,,2002-11,COMPLETED,INTERVENTIONAL,['PHASE3']
10060,NCT02565979,Change in Glucose Tolerance,Change in Quality of sleep,,2016-04,COMPLETED,INTERVENTIONAL,['NA']
10061,NCT06256497,Clinical effectiveness,,,2023-06-27,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
10062,NCT01323322,"To disentangle the relationship between race, SES, and health outcomes.",,,2009-07-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
10063,NCT02916589,"Changes in the extent of gingivitis, as determined by the severity of gingival bleeding, Before and after study procedures.","Change in levels of proinflammatory cytokines in serum and gingival fluid in relation to ginigival bleeding, Before and after study procedures.",,2016-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10064,NCT01672762,Change in HbA1c,"Safety assessed by the incidence of adverse events, vital signs, lab-tests and 12-lead ECGs",,2012-05-25,COMPLETED,INTERVENTIONAL,['PHASE3']
10065,NCT00415428,,,,2007-01,COMPLETED,OBSERVATIONAL,['NA']
10066,NCT01822548,Absolute Change in the Endothelial Progenitor Cell (EPC) Number,Absolute Change in HbA1C Compared to Baseline,,2010-10,COMPLETED,INTERVENTIONAL,['PHASE3']
10067,NCT03538015,Change in Hypoglycemia Symptom Score,Frequency of CGM-Determined Hypoglycemic Episodes,,2019-04-22,TERMINATED,INTERVENTIONAL,['PHASE2']
10068,NCT02063048,Absolute weight loss in pounds,Patient Engagement Measures,,2014-04,COMPLETED,INTERVENTIONAL,['NA']
10069,NCT06000462,"Inter-arms differences in mean BMI, waist circumference, waist hip ratio, body weight (kilogram, kg), Body fat (%), and Muscle mass (%)",Frequency of adverse event from dapagliflozin,,2023-12,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
10070,NCT01597713,Number of adverse events,Area under the serum insulin concentration-time curve (Trial part 2),,2012-05,COMPLETED,INTERVENTIONAL,['PHASE1']
10071,NCT02863523,Change From Baseline in Glycosylated Hemoglobin (%),Change From Baseline in Diabetes Regimen-Related Distress,Change in Depressive Symptoms,2014-09,COMPLETED,INTERVENTIONAL,['NA']
10072,NCT00547482,Glycemic control as measured by HbA1c: Difference in mean reduction between Control and Treatment Groups will be evaluated.,Device/procedure-related adverse events;hypoglycemic events; Proportion of subjects with HbA1c less than 7.0;reduction of weight for both groups;improvement of glycemic control as measured by HbA1c,,2007-09,TERMINATED,INTERVENTIONAL,['NA']
10073,NCT03349489,Decrease in glucose levels,Total amount of carbohydrates needed to treat hypoglycemic events,,2018-05-18,UNKNOWN,INTERVENTIONAL,['NA']
10074,NCT05265312,Number of participants referred to Medical Nutrition Therapy,Number of participants who complete a follow-up PCP/team visit,,2022-05-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
10075,NCT02636491,normal glucose level,glucose sensor readings,,2015-12,COMPLETED,INTERVENTIONAL,['NA']
10076,NCT01068041,Urinary Albumin/Creatinine Ratio (UACR),Urine Albumin Serum Creatinine and the estimated GFR (glomerular filtration rate) HbA1c,,2010-08,COMPLETED,INTERVENTIONAL,['PHASE2']
10077,NCT00905203,skeletal muscle oxygenation response,,,2009-02,UNKNOWN,INTERVENTIONAL,['NA']
10078,NCT02041832,First episode of atrial fibrillation,Correlation between echocardiographic parameters and incidence of atrial fibrillation,Correlation between biomarkers and incidence of atrial fibrillation,2013-10,COMPLETED,INTERVENTIONAL,['NA']
10079,NCT01804842,Rmax (0-24) of Plasma Glucose,,,2012-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10080,NCT03216460,Percentage of time in hyperglycemic range (defined as ≥ 250 mg/dL),Coefficient of variation,,2019-02-04,COMPLETED,INTERVENTIONAL,['NA']
10081,NCT03132129,Prevalence of early heart failure in type 2 diabetes,Remission of type 2 diabetes,,2017-10-24,RECRUITING,OBSERVATIONAL,['NA']
10082,NCT03197870,Percentage of Subjects With an Improvement in Study Eye Severity of Diabetic Retinopathy (DR) (ETDRS DR Severity Score or DRSS) of ≥ 2 Steps,Summary of Subjects Developing Center-involved DME or PDR or Worsening of >=2 Steps DRSS at Week 48 Based on Central Image Reading Center Evaluation,,2017-06-09,COMPLETED,INTERVENTIONAL,['PHASE2']
10083,NCT03675165,Diabetes Symptomatology (assessed using the Diabetes Symptoms Checklist - Revised),,Diabetes Risk (calculated using the Canadian Diabetes Risk Questionnaire),2018-08-28,COMPLETED,INTERVENTIONAL,['NA']
10084,NCT05759442,Fasting Blood Sugar,,,2023-01-01,COMPLETED,INTERVENTIONAL,['NA']
10085,NCT05566028,Change from baseline in HbA1c,Change from baseline in Fasting plasma glucose,,2022-10-01,RECRUITING,INTERVENTIONAL,['PHASE3']
10086,NCT00222924,To measure the functional capacity of mitochondria in skeletal muscle of those with T2DM and those at increased risk of developing T2DM,To assess whether exercise and diet can improve mitochondrial function and morphology.,,2003-12,COMPLETED,INTERVENTIONAL,['NA']
10087,NCT02220751,clinical attachment level,Salivary proteins levels,Density loss,2009-03,COMPLETED,INTERVENTIONAL,['PHASE3']
10088,NCT01422018,Changes in best-corrected visual acuity (BCVA),macular edema detected by optical coherent tomography,,2011-08,UNKNOWN,INTERVENTIONAL,['NA']
10089,NCT03070704,Incidence of treatment emergent Adverse Events (AEs),Number of patients withdrawn due to ineffective therapy,,2017-08-16,WITHDRAWN,OBSERVATIONAL,['NA']
10090,NCT03330951,Glycemic Control markers in pregnancy,Admission to neonatal intensive care unit,,2016-05,COMPLETED,OBSERVATIONAL,['NA']
10091,NCT00708266,Concentrations of IL-6 measured in effluent samples from subcutaneous tissue.,Cytokine concentrations measured in serum samples.,,2007-02,COMPLETED,INTERVENTIONAL,['NA']
10092,NCT05038176,A1c,,,2022-02-12,COMPLETED,INTERVENTIONAL,['NA']
10093,NCT00670722,HbA1c after switch from human insulin to modern insulin treatment,Number of adverse drug reactions (ADR),,2008-01,COMPLETED,OBSERVATIONAL,['NA']
10094,NCT00638573,,,,2006-01,COMPLETED,OBSERVATIONAL,['NA']
10095,NCT03234751,IV infusion of nesiritide at a 3pmol/kg rate,,,2017-07-13,COMPLETED,INTERVENTIONAL,['PHASE1']
10096,NCT01771445,IL6,Copeptin,,2011-12,COMPLETED,INTERVENTIONAL,['NA']
10097,NCT02091596,Clinical Response,,,2013-10,COMPLETED,INTERVENTIONAL,['PHASE2']
10098,NCT01757756,fasting HDL cholesterol,,,2012-10,COMPLETED,INTERVENTIONAL,['PHASE1']
10099,NCT03390959,Gait,Plantar Sensitivity,,2017-05-10,UNKNOWN,INTERVENTIONAL,['NA']
10100,NCT02607306,Change From Baseline in HbA1c (Glycosylated Haemoglobin) Tested for Non-inferiority of IDegLira vs IDeg and Superiority of IDegLira vs Lira,Plasma Concentrations of Liraglutide,,2015-11-18,COMPLETED,INTERVENTIONAL,['PHASE3']
10101,NCT02294110,sensorial loss with pin prick test,,,2014-11,COMPLETED,OBSERVATIONAL,['NA']
10102,NCT05607810,Severity of ocular and non-ocular AEs,"Incidence of clinically significant findings via physical examinations, ocular examinations, imaging, and laboratory evaluation",,2022-08-10,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
10103,NCT00969956,Time to retinopathy,Waistlines,,2012-04,TERMINATED,OBSERVATIONAL,['NA']
10104,NCT03893266,Collection of the needs of type 1 diabetic patients in therapeutic education in order to reconcile diabetes and work.,,,2019-04-26,COMPLETED,OBSERVATIONAL,['NA']
10105,NCT04008121,Binary assessment by the Principal Investigator of the feasibility of MB-102 imaging as compared to fluorescein dye,Number of participants with adverse events,,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
10106,NCT00637273,Change in HbA1c From Baseline to Week 26,Assessment on Event Rate of Treatment-emergent Hypoglycemic Events,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE3']
10107,NCT03458494,Glucose,CRP,,2018-02-15,UNKNOWN,INTERVENTIONAL,['NA']
10108,NCT00886821,Stage 2: Maximum Observed Plasma Concentration (Cmax) of PF-04856883 on Day 22,Stage 1: Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC[0 - Inf]) of PF-04856883 on Day 1,Stage 2: Number of Participants With Anti-Drug Antibodies,2008-10,COMPLETED,INTERVENTIONAL,['PHASE1']
10109,NCT05888454,HbA1c levels (%),Change in dose of pharmacological interventions for T2DM,,2023-07-24,RECRUITING,INTERVENTIONAL,['NA']
10110,NCT02124408,change in glycated hemoglobin levels,control of diabetic complications,,2013-11,UNKNOWN,INTERVENTIONAL,['NA']
10111,NCT00910507,Stage of Exercise Behavior,,,2007-09,COMPLETED,INTERVENTIONAL,['NA']
10112,NCT04142944,Time in hypo glycaemia,,,2019-12-11,COMPLETED,INTERVENTIONAL,['NA']
10113,NCT02700555,Incidence of newly developed diabetes mellitus,3-year recurrence-free survival & 5-year recurrence-free survival,,2016-02,TERMINATED,OBSERVATIONAL,['NA']
10114,NCT00174993,"Time to the Composite of All Cause Mortality, Non-Fatal Myocardial Infarction, Stroke, Acute Coronary Syndrome, Major Leg Amputation, Cardiac Intervention, Bypass Surgery or Leg Revascularization.",Time to Cardiovascular Mortality.,,2001-05,COMPLETED,INTERVENTIONAL,['PHASE3']
10115,NCT04766008,Increase in lactate of 20%,Metformin associated lactic acidosis,Death,2020-01-15,UNKNOWN,INTERVENTIONAL,['PHASE4']
10116,NCT03952130,Change From Baseline in Hemoglobin A1c (HbA1c),Percentage of Participants With HbA1c <7% and ≤6.5%,,2019-05-29,COMPLETED,INTERVENTIONAL,['PHASE3']
10117,NCT01807221,Percentage of Participants With a Relative Decrease in NT-proBNP of More Than 30% From Baseline to Day 90,Change From Baseline in EQ-5D-3L Questionnaire Scores at Specified Visits,Change From Baseline in Heart Rate at Specified Visits,2013-06-17,COMPLETED,INTERVENTIONAL,['PHASE2']
10118,NCT05704309,Cognitive Diagnoses,White matter microstructure,,2022-11-07,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
10119,NCT05960019,Change in HbA1c,Change in FBG,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability],2024-01-17,RECRUITING,INTERVENTIONAL,['NA']
10120,NCT00333853,Hemoglobin A1c (HbA1c),Measured hypoglycemia,,2003-08,COMPLETED,INTERVENTIONAL,['NA']
10121,NCT04864639,Emergency Department (ED) Visits Within 30 Days Post Discharge,Unplanned Readmissions to the Hospital Within 30 Days Post Discharge,,2021-08-04,COMPLETED,INTERVENTIONAL,['NA']
10122,NCT03459638,Risk of obstructive sleep apnea syndrome (OSAS),,,2018-03-09,COMPLETED,OBSERVATIONAL,['NA']
10123,NCT06130865,Fullerton Advanced Balance Scale (FAB),,,2023-11-05,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
10124,NCT02066831,HbA1c,quality of life,,2014-02,COMPLETED,INTERVENTIONAL,['NA']
10125,NCT05866406,Insulin sensitivity,Adipose tissue gene expression,,2023-11-01,RECRUITING,INTERVENTIONAL,['NA']
10126,NCT04592055,A1c,,,2020-03-20,UNKNOWN,OBSERVATIONAL,['NA']
10127,NCT03249974,Accuracy of Enlite sensor,skin reactions wih Enlite sensor,,2017-07-05,COMPLETED,OBSERVATIONAL,['NA']
10128,NCT03681704,ACR,,,2018-11-08,COMPLETED,INTERVENTIONAL,['PHASE1']
10129,NCT03010241,"The clinical symptoms and signs of patients were recorded by Michigan Diabetic Neuropathy Score(MDNS), and the changes of Michigan Diabetic Neuropathy Score(MDNS) were compared between the two groups before and after medication",Clinical symptoms and signs change The clinical symptoms and signs of the patients were compared before and after taking the medicine.,,2017-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
10130,NCT04087369,COPD control measure,Alcohol use,Projected scale cost(Maintenance),2019-12-01,WITHDRAWN,INTERVENTIONAL,['NA']
10131,NCT01403571,Weight,Fatty Acids (% composition),,2009-10,COMPLETED,INTERVENTIONAL,['PHASE2']
10132,NCT04180332,Catalase estimation,Antioxidant estimation,,2017-08-10,COMPLETED,INTERVENTIONAL,['NA']
10133,NCT03730168,concentration of serum intereukin6,concentration of serum tumour necrosis factor,,2018-05-13,COMPLETED,INTERVENTIONAL,['NA']
10134,NCT03867500,Difference in incorporation of 13-palmitate and D9-palmitate into intramyocellular lipid intermediates between overnight saline control study and overnight/insulin clamp niacin infusion study.,Effects of niacin on adipocyte lipolysis proteins,,2018-11-01,SUSPENDED,INTERVENTIONAL,['EARLY_PHASE1']
10135,NCT04792268,Number of wards and clinician end-users recruited to the study,Rates of communication with GP/CMHT regarding diabetes or dysglycaemia follow up,Assessment of the implementation of the eCDSS on inpatient ward settings,2022-05-01,COMPLETED,INTERVENTIONAL,['NA']
10136,NCT05159843,Knowledge in diabetes management,Mood of patient,,2022-01-10,UNKNOWN,INTERVENTIONAL,['NA']
10137,NCT04876053,HbA1c,,,2021-10-22,RECRUITING,INTERVENTIONAL,['NA']
10138,NCT06331429,Change Social Skills (Baseline-Pre-Post),Change Resilience (Baseline-Pre-Post),Glycaemic control (Baseline-Pre-Post),2024-08,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
10139,NCT00930865,Exposure to the investigational drug will be measured to compare with and without the co-administration of other drugs,"Explore potential pharmacodynamic (serum/urine electrolytes) effects of bumetanide + dapagliflozin following multiple doses of 1 mg bumetanide + 10 mg dapagliflozin, administered together, either simultaneously or after adaptation to either agent alone",,2009-07,COMPLETED,INTERVENTIONAL,['PHASE1']
10140,NCT01845870,determination of urinary albumin,determination of serum vitamin D metabolites,,2012-02,COMPLETED,OBSERVATIONAL,['NA']
10141,NCT02750930,Number of Participant With Positive Results of Anti-albiglutide Antibody Production Over Time,,,2016-10-07,TERMINATED,INTERVENTIONAL,['PHASE4']
10142,NCT00851019,Hemoglobin A1c change from baseline,All adverse events,,2009-02,COMPLETED,INTERVENTIONAL,['NA']
10143,NCT05843019,P kortisol,,,2023-04-12,RECRUITING,OBSERVATIONAL,['NA']
10144,NCT05344768,β-cell function analysis,,,2022-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
10145,NCT03334773,Hemoglobin A1c levels (HbA1c),Diabetes management self-efficacy,,2017-01-16,COMPLETED,INTERVENTIONAL,['NA']
10146,NCT01121172,Serum Apelin Levels,Frequency of G212A Polymorphism of Apelin Receptor in Obese Children and Adolescents,,2010-05,COMPLETED,OBSERVATIONAL,['NA']
10147,NCT00143247,Change in Carbon Monoxide Diffusing Capacity (mL/Min/mm Hg) by Time on Exubera Treatment,Number of Decliners in Carbon Monoxide Diffusing Capacity (ml/Min/mm Hg) by Duration of Exubera Treatment,,2003-03,TERMINATED,INTERVENTIONAL,['PHASE2']
10148,NCT01798914,,,,2008-10,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA']
10149,NCT02182895,Mean Daily Blood Glucose Levels During Hospital,Patient Satisfaction,,2014-07,COMPLETED,INTERVENTIONAL,['PHASE4']
10150,NCT05344196,C-peptide,Health behavior,,2022-03-01,COMPLETED,INTERVENTIONAL,['NA']
10151,NCT01957930,Ischemic Foot Ulcer,,Microvascular Endothelial Function,1984-01,COMPLETED,INTERVENTIONAL,['NA']
10152,NCT04467268,Total sleep time (TST),Multidimensional Assessment of Fatigue,,2017-04-15,COMPLETED,INTERVENTIONAL,['NA']
10153,NCT01762059,Percentage of Time Blood Glucose Values Less Than 70 mg/dl (Co-primary Outcome),Difference of Outcome Measures on Day 1 vs. Remaining Days (Days 2-5) During the Closed-loop Period.,Mean Blood Sugar as Measured by Continuous Glucose Monitor (CGM) Readings,2013-01,COMPLETED,INTERVENTIONAL,['NA']
10154,NCT02108197,glucose tolerance,,,2014-04,COMPLETED,INTERVENTIONAL,['NA']
10155,NCT03473704,Depression symptoms,Another disease,,2017-01-19,UNKNOWN,INTERVENTIONAL,['NA']
10156,NCT00847730,Ease of Use Assessment,,,2009-02,COMPLETED,INTERVENTIONAL,['NA']
10157,NCT02346175,Plasma glucose concentration of SHR3824,The number and type of adverse events reported,,2014-06,COMPLETED,INTERVENTIONAL,['PHASE1']
10158,NCT01637935,Incident Diagnosis of Bladder Cancer (10-year Analysis),Stage of Bladder Cancer (10 Year Analysis),,2004-07,COMPLETED,OBSERVATIONAL,['NA']
10159,NCT03448380,Safety of the FreeStyle Libre Flash Glucose Monitoring System,,,2018-02-27,COMPLETED,OBSERVATIONAL,['NA']
10160,NCT03658564,VAS,HOMA,,2018-09-30,UNKNOWN,INTERVENTIONAL,['NA']
10161,NCT00035711,,,,2001-09,COMPLETED,OBSERVATIONAL,['NA']
10162,NCT00409786,Change in Weight,Physical Activity,,2006-11,COMPLETED,INTERVENTIONAL,['NA']
10163,NCT01369823,The levels of HbA1c will be investigated on patients combining the pump therapy with continuous glucose monitoring over a period of three months.,To evaluate the % sensor usage,,2009-06,UNKNOWN,OBSERVATIONAL,['NA']
10164,NCT00845182,HbA1c,"Effect Pioglitazone, Exenatide, and Pioglitazone Plus Exenatide • Insulin Sensitivity • Inflammatory Cytokines • Glucagon and Free Fatty Acids • Plasma Lipids",,2007-06,COMPLETED,INTERVENTIONAL,['PHASE4']
10165,NCT02102048,Homeostatis Model Assessment-Insulin Resistance (HOMA-IR) value,insulinemia,,2009-01,UNKNOWN,INTERVENTIONAL,['NA']
10166,NCT05036876,Change in mean daily blood glucose concentration in hospitalized patients,"Average blood glucose (mg/dL), percentage time in target, percentage time below target, and percentage time above target in a subgroup of study participants.",,2021-10-10,COMPLETED,INTERVENTIONAL,['NA']
10167,NCT06053177,"The prevalence of undiagnosed fatty liver disease with evidence of fibrosis, obstructive sleep apnoea and heart failure in people with type 2 diabetes and prediabetes",Multi-morbidity screening,,2023-01-25,RECRUITING,OBSERVATIONAL,['NA']
10168,NCT03914547,Parents Hypoglycemia Fear,,,2019-10-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
10169,NCT05469659,Urine albumin-to-creatinine ratio (UACR),Albuminuria class,,2021-09-22,RECRUITING,INTERVENTIONAL,['PHASE2']
10170,NCT00416741,,,,2005-02,COMPLETED,OBSERVATIONAL,['NA']
10171,NCT01498926,Maximum serum insulin concentration,Adverse events,,2005-11,COMPLETED,INTERVENTIONAL,['PHASE1']
10172,NCT05565248,Assess the clinical efficacy of VCTX211 units via evaluation of C-peptide increase from the baseline.,The percentage of graft cells per unit that have differentiated into endocrine/beta cells as determined by immunohistochemical staining.,,2023-01-20,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10173,NCT05464784,Mean change from baseline in fasting serum triglyceride levels at Week 24,Mean change from baseline in lipids,,2022-08-22,RECRUITING,INTERVENTIONAL,['PHASE2']
10174,NCT01950650,Reasons for insulin omission/non-adherence reported by patient and physician,Impact of insulin treatment on life domains (patient survey),,2010-03,COMPLETED,OBSERVATIONAL,['NA']
10175,NCT01156246,To assess the effect of food on the pharmacokinetics of dapagliflozin and metformin.,To examine the safety and tolerability of the fixed-dose combination tablet of dapagliflozin and metformin.,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE1']
10176,NCT05090202,Heart failure hospitalization.,,,2022-12-30,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
10177,NCT02324218,"Occurrence of new HepB diagnosis among non-DM patients between 0-80 years of age, in the UK CPRD or HES.","New-onset or prevalent HepB diagnosis among new-onset or prevalent DM and DM-free (non-DM) patients between 0-80 years of age, in the UK, regardless of the onset of HepB in relation to the diagnosis of DM.",,2014-10,COMPLETED,OBSERVATIONAL,['NA']
10178,NCT03666117,Prevalence of Hepatomegaly in children and adolescents,,,2019-01-01,UNKNOWN,OBSERVATIONAL,['NA']
10179,NCT00065559,,,,2003-04,TERMINATED,INTERVENTIONAL,['NA']
10180,NCT04949867,Percentage of time with glucose values < 3.9 mmol/l as measured by the continuous glucose monitor,Sleep efficiency measured by ActiGraph GT9X Link,,2021-05-20,COMPLETED,INTERVENTIONAL,['PHASE4']
10181,NCT00118560,maximal exercise times on treadmill and calf ergometer,,,2005-06,COMPLETED,INTERVENTIONAL,['NA']
10182,NCT05350514,"Standardized uptake value ratio for cerebral to cerebellar comparison in young adults with Type 1 diabetes, Type 2 diabetes, and young adults without diabetes","Atlas based region of interest fractional anisotropy in young adults with Type 1 diabetes, Type 2 diabetes, and young adults without diabetes",,2022-07-19,COMPLETED,OBSERVATIONAL,['NA']
10183,NCT02940158,Postprandial Blood Insulin,,,2016-10,COMPLETED,INTERVENTIONAL,['NA']
10184,NCT02832999,Insulin sentivity,body weight,Inflammation,2016-01,COMPLETED,INTERVENTIONAL,['PHASE4']
10185,NCT05305287,Effect of pioglitazone on hepatic mitochondrial TCA cycle fluxes,Effect of pioglitazone on hepatic gene regulatory networks,,2022-11-01,RECRUITING,INTERVENTIONAL,['PHASE4']
10186,NCT05266625,Adverse Events,Adverse Events,,2022-02-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
10187,NCT05488119,Tracking people who complete the study,Changes in diabetes technology usage,,2025-03-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
10188,NCT05420051,Change from Baseline Moderate to Vigorous Physical Activity (MVPA) at 16 weeks,Change from Baseline in positive affect (Positive and Negative Affect Schedule [PANAS] positive affect items) at 16 weeks,Change in triglycerides (milligrams per deciliter),2022-10-12,RECRUITING,INTERVENTIONAL,['NA']
10189,NCT02721602,Acceptability of the intervention measured via family feedback indicating at least 90% approve of the sessions on post-intervention surveys.,Blood glucose control in parent with Type 2 diabetes,,2016-02,COMPLETED,INTERVENTIONAL,['NA']
10190,NCT00248131,long-term safety and tolerability,monitor long-term efficacy,,2005-11,TERMINATED,INTERVENTIONAL,['PHASE3']
10191,NCT01324011,Change in body weight,Change in psychosocial factors,,2011-01,COMPLETED,INTERVENTIONAL,['NA']
10192,NCT03793283,Concentration of Hemoglobin A1C (HbA1C).,Safety related adverse events.,,2019-01-01,COMPLETED,OBSERVATIONAL,['NA']
10193,NCT03971955,Blood collection,,,2019-07-08,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
10194,NCT05229640,Assess CFLD via abdominal imaging,,,2022-03-31,WITHDRAWN,INTERVENTIONAL,['NA']
10195,NCT02020343,Meal triglyceride (TG) absorption,,,2014-01,COMPLETED,OBSERVATIONAL,['NA']
10196,NCT01950637,"Level of patient dosing irregularity: missed, mistimed and reduced dose (HCP questionnaire)",Frequency of self-treated hypoglycaemia,,2012-01,COMPLETED,OBSERVATIONAL,['NA']
10197,NCT03564431,the neuroimaging of Type 2 Diabetes and Depression,,,2017-12-01,UNKNOWN,OBSERVATIONAL,['NA']
10198,NCT04533945,Change in Hemoglobin A1C (HbA1C),Duration of CGM use,,2020-03-25,COMPLETED,INTERVENTIONAL,['NA']
10199,NCT02971241,Young students survey,,,2015-10,COMPLETED,INTERVENTIONAL,['NA']
10200,NCT02961088,Global measures of adiposity with established clinical relevance - body weight,Measures of adiposity by established imaging techniques - visceral adipose tissue [VAT],,2016-08,UNKNOWN,OBSERVATIONAL,['NA']
10201,NCT05932966,Comparison of glycemic control obtained under closed loop according to the system used: SG versus CIQ,daily insulin dose,,2023-07-06,RECRUITING,OBSERVATIONAL,['NA']
10202,NCT05361148,Pancreas exocrine function,abnormal prior pro-insulin/insulin ratio and diabetes (subset),,2021-10-12,RECRUITING,OBSERVATIONAL,['NA']
10203,NCT03642470,HbA1c,psychological health (Child Behavior),,2018-06-05,COMPLETED,OBSERVATIONAL,['NA']
10204,NCT03121508,The Diabetes Self-Management Questionnaire,,,2017-04-24,WITHDRAWN,INTERVENTIONAL,['NA']
10205,NCT06262854,The composite primary endpoint of this study will be the incidence osteomyelitis recurrence or new osteomyelitis in adjacent sites or tissue infection at the site of osteomyelitis.,Direct medical costs,,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
10206,NCT00458016,Fasting Plasma Glucose Concentration,"Fasting serum triglycerides and free fatty acids, fasting serum insulin.",,2007-03,COMPLETED,INTERVENTIONAL,['PHASE2']
10207,NCT04541797,Cut-off value for myocardial perfusion index to predict ≥10% increase in myocardial blood flow as result of empagliflozin.,Improvement in exercise tolerance through performing a cardiopulmonary exercise test.,,2020-10-01,RECRUITING,INTERVENTIONAL,['NA']
10208,NCT02462421,Change in Fractional Excretion of Uric Acid (the Difference Between Data After Administration of Canagliflozin Minus Data Before Administration of Canagliflozin),Canagliflozin-induced Change in Fasting Plasma Glucose,,2015-06-01,TERMINATED,INTERVENTIONAL,['PHASE4']
10209,NCT04906226,Peripheral skin temperature will be measured with a skin thermometer,,,2021-08-01,COMPLETED,INTERVENTIONAL,['NA']
10210,NCT00921011,vessel wall changes over time that precede plaque buildup,development of cardiovascular disease,,2009-05,COMPLETED,OBSERVATIONAL,['NA']
10211,NCT00539851,,,,2005-11,COMPLETED,OBSERVATIONAL,['NA']
10212,NCT03978715,number of lower limb complications,,,2021-04-14,COMPLETED,OBSERVATIONAL,['NA']
10213,NCT01760447,Number of Participants Who Discontinued Study Drug Due to Experiencing an Adverse Event During Weeks 0-54,Percentage of Participants Initiating Insulin Glargine During Weeks 20-54,Baseline A1C,2011-12-07,COMPLETED,INTERVENTIONAL,['PHASE3']
10214,NCT01201161,amount of intraoperative intra-ocular bleeding,visual acuity,,2008-12,COMPLETED,INTERVENTIONAL,['PHASE2']
10215,NCT02867254,Sample collection from the periodontal pocket,,,2014-01,COMPLETED,OBSERVATIONAL,['NA']
10216,NCT01150617,Reduction of restenosis after peripheral angioplasty,Identification of new peripheral markers predictive of restenosis,,2008-12,TERMINATED,INTERVENTIONAL,['PHASE4']
10217,NCT02298803,Change in Corrected QT Interval During Day Time Hypoglycaemia,deltaQTc,,2015-01,COMPLETED,INTERVENTIONAL,['NA']
10218,NCT01390259,Hypoglycemic Events,Mean Glucose,,2010-01,COMPLETED,INTERVENTIONAL,['NA']
10219,NCT03864549,Mean value of the mean daily glucose charts after 2 weeks of treatment with the study products.,Duration of time until pharmacotherapy for glycemic control is indicated,,2020-01-08,COMPLETED,INTERVENTIONAL,['NA']
10220,NCT01453413,Percent of Subjects Outside Specified Blood Glucose (BG) Range -Estimated Versus Measured Blood Glucose,Percent of Subjects Outside a Second Specified Blood Glucose (BG) Range -Estimated Versus Measured Blood Glucose,,2011-10,COMPLETED,INTERVENTIONAL,['NA']
10221,NCT00998712,endothelial function,,,2009-08,UNKNOWN,OBSERVATIONAL,['NA']
10222,NCT04160156,Glucose Standard Deviation (mmol/L),,,2018-06-05,COMPLETED,OBSERVATIONAL,['NA']
10223,NCT02861144,Change of HbA1c,,,2011-02,COMPLETED,INTERVENTIONAL,['NA']
10224,NCT05584293,Real world data from medical devices and clinical outcome in a registry,,,2020-09-11,RECRUITING,OBSERVATIONAL,['NA']
10225,NCT04690907,Gestational weight gain (GWG),Eating habits III,,2020-12-03,COMPLETED,INTERVENTIONAL,['NA']
10226,NCT05148130,blood biochemistry indices,,,2018-09-11,UNKNOWN,OBSERVATIONAL,['NA']
10227,NCT00005130,,,,1984-01,COMPLETED,OBSERVATIONAL,['NA']
10228,NCT05473364,Preservation of Serum Potassium,,,2023-03-20,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10229,NCT02785445,Exact and ±1 agreement to compared device,User performance,,2015-10,COMPLETED,INTERVENTIONAL,['NA']
10230,NCT01336738,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12,Percentage of Participants With Greater Than or Equal to (>=) 1% or >= 2% Body Weight Loss From Baseline,,2011-06,COMPLETED,INTERVENTIONAL,['PHASE2']
10231,NCT03500640,Change in bodyweight,Change in physical function,Change in mood,2018-03-27,COMPLETED,INTERVENTIONAL,['NA']
10232,NCT02077946,Percent (%) of patients achieving at least 1 %-point HbA1c (glycosylated haemoglobin) reduction,Change in creatinine,,2014-02-10,COMPLETED,OBSERVATIONAL,['NA']
10233,NCT03481218,Personality traits associated with diabetes management,Differences in quality of life based on glycaemic control,,2018-01-30,COMPLETED,OBSERVATIONAL,['NA']
10234,NCT05251506,glycated hemoglobin level,success rate of measurement of blood glucose by laser lancing device,,2021-08-10,UNKNOWN,INTERVENTIONAL,['NA']
10235,NCT01549600,fasting serum glucose,,,2012-02,COMPLETED,INTERVENTIONAL,['NA']
10236,NCT01620424,The maximum insulin aspart concentration,Adverse events,,2001-02,COMPLETED,INTERVENTIONAL,['PHASE1']
10237,NCT01669616,To compare the accuracy of SCOUT DS versus random capillary glucose and several diabetes risk assessment questionnaires for detection of HbA1c-defined dysglycemia.,,,2012-08,COMPLETED,OBSERVATIONAL,['NA']
10238,NCT01269606,Area under the curve (AUC) for IM treatment group,Adverse Events (AEs),,2011-01,COMPLETED,INTERVENTIONAL,['PHASE1']
10239,NCT00212004,The time till the first cardiovascular composite endpoint,worsening of renal function,,2005-04,TERMINATED,INTERVENTIONAL,['PHASE4']
10240,NCT01425580,Left ventricle longitudinal function and/or functional reserve during rest and/or after exercise using tissue Doppler echocardiography,Global LV function (echocardiography) expressed as ejection fraction (EF),,2012-01,COMPLETED,INTERVENTIONAL,['PHASE2']
10241,NCT02629497,platelet reactivity,Oxylipin production,,2015-11,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
10242,NCT02906891,Reduction in the aggregate rate of nocturnal hypoglycemia in the Vigilant period versus the Baseline period as measured by meter or logged blood glucose values (mg/dL).,Improvement in self-reported psychosocial self-efficacy as compared to baseline measured using the Diabetes Empowerment Scale Short Form (DES-SF).,"Average ratings of ""acceptable"" or better from self-reported survey clinician feedback on the utility of Vigilant in managing patients.",2016-05,TERMINATED,INTERVENTIONAL,['NA']
10243,NCT04481243,Immunoglobulin G (IgG) Antibodies,,,2021-04-30,COMPLETED,INTERVENTIONAL,['PHASE4']
10244,NCT04456465,moderate and severe pain (VAS score ≥4),Anxiety screening/assessment: GAD-7 scale,,2018-04-01,COMPLETED,OBSERVATIONAL,['NA']
10245,NCT03950219,HbA1c,,,2019-03-01,UNKNOWN,OBSERVATIONAL,['NA']
10246,NCT03674957,Bone mineral density,"Early life health conditions from linked administrative health records, from the Manitoba Population Healthy Research Data Repository",,2016-03,TERMINATED,OBSERVATIONAL,['NA']
10247,NCT05939921,To assess the effect of metformin on Pancreatic fat and hepatic fat in T2DM patients.,,,2022-05-01,COMPLETED,INTERVENTIONAL,['NA']
10248,NCT01581658,Maximum Concentration,,,2012-04-01,COMPLETED,INTERVENTIONAL,['PHASE1']
10249,NCT02741037,Longitudinal % change in body weight,Longitudinal change in mother-daughter processes of mutual influence,,2016-01,COMPLETED,INTERVENTIONAL,['NA']
10250,NCT03123809,Changes of total gastroparesis symptom scores (TSS),Percentage of changes of gastric emptying retention of the radiolabeled meal (%) at 2-4 hrs,,2017-01-10,RECRUITING,INTERVENTIONAL,['NA']
10251,NCT06269107,Change in glycated haemoglobin (HbA1c),Number of severe hypoglycaemic episodes (level 3),,2024-02-15,RECRUITING,INTERVENTIONAL,['PHASE3']
10252,NCT00666861,,,,2008-04,TERMINATED,OBSERVATIONAL,['NA']
10253,NCT06072326,change from baseline in Urine Albumin-Creatinine Ratio (UACR),Change from baseline blood pressure,,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
10254,NCT02407626,Biomarker NT-proBNP,"Expression of TNF/IL1beta and microRNA (miR144, miR125b, miR208a)",,2015-09,TERMINATED,INTERVENTIONAL,['NA']
10255,NCT03514420,Percent Change From Baseline in Fasting Triglycerides Levels at End of the Treatment (Week 27),Number of Participants With Treatment-emergent Adverse Events (TEAEs),,2018-06-15,COMPLETED,INTERVENTIONAL,['PHASE2']
10256,NCT00490854,Mean change in Hemoglobin A1c (HbA1c) from baseline to the end of each treatment period of Primary Phase,Patient-reported outcomes questionnaires.,,2007-07,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
10257,NCT02348801,Change in hemoglobin A1c,Change in composite cognitive score,,2015-01,COMPLETED,INTERVENTIONAL,['NA']
10258,NCT05174052,The effect of Dapagliflozin on change in burden of atrial fibrillation,Effect of Dapagliflozin on change in AF Effect on Quality of Life Survey,Effect of Dapagliflozin on change in Validated Echocardiographic Indices & Biomarkers of Atrial Myopathy,2022-06-01,RECRUITING,INTERVENTIONAL,['PHASE3']
10259,NCT04902807,Generate a diagnosis and therapeutic-decision tools,3- Ancillary study (pilot study),,2021-06,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
10260,NCT01653210,High Blood Glucose Index (HBGI),Glycemic Changes During Luteal Phase,,2012-08,COMPLETED,OBSERVATIONAL,['NA']
10261,NCT02092896,Change from baseline in gastric emptying rate,Change from baseline in hypoglycemic symptom score,Frequency of Hypoglycemic episodes,2013-03,COMPLETED,INTERVENTIONAL,['PHASE3']
10262,NCT01901926,"Change in HbA1C levels from base line at 3, 6 and 9 months",Periodontal Pocket Depth,C-Reactive Protein,2012-12,UNKNOWN,INTERVENTIONAL,['NA']
10263,NCT02954016,The proportion of subjects affected by serious adverse device effects (SADEs) as defined by International Standards Organization (ISO) standard 14155:2011.,12 Month Weight Loss in Kilograms,,2016-03,UNKNOWN,INTERVENTIONAL,['NA']
10264,NCT00924573,Changes in HbA1c from baseline,Change in the ratio patients with < 7.0% of HbA1c,,2009-05,COMPLETED,INTERVENTIONAL,['PHASE3']
10265,NCT01568242,Vitreous temperature,,,2012-02,UNKNOWN,INTERVENTIONAL,['NA']
10266,NCT02698618,Delta IMR pre-PCI,Severe microcirculatory impairment,Severe microcirculatory impairment in subject with BMI = or > 30,2016-03,UNKNOWN,INTERVENTIONAL,['PHASE4']
10267,NCT02580877,Change in mIAA Autoantibody Titer From Baseline,,,2016-01,COMPLETED,INTERVENTIONAL,['PHASE2']
10268,NCT06312579,Gait speed,Community mobility,,2024-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
10269,NCT02180191,The comparison of the gut microbiota composition,The relationship between metabolic parameters and the gut microbiota composition,,2013-01,COMPLETED,OBSERVATIONAL,['NA']
10270,NCT01638351,Maximal muscle strength,Muscle oxygenation,,2011-12,COMPLETED,INTERVENTIONAL,['NA']
10271,NCT04060732,Severe hypoglycemia rate,Feasibility of the device,,2017-05-05,COMPLETED,OBSERVATIONAL,['NA']
10272,NCT05752955,Decrease anaemia prevalence in women,Dysglycaemia after a pregnancy affected by GDM,Cost of care,2022-06-06,RECRUITING,INTERVENTIONAL,['NA']
10273,NCT01155518,Insulin Resistance,,,2010-06,TERMINATED,INTERVENTIONAL,['PHASE2']
10274,NCT04278417,Change from Baseline in BCVA,Proportion of subjects with center-involved DME up to Week 96,,2020-11-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
10275,NCT04203823,Percentage of Time in Euglycemia - Cohort C,,,2020-07-20,COMPLETED,INTERVENTIONAL,['NA']
10276,NCT00567398,Change From the Baseline Value in HbA1c at Month 3 and 6,Change From Baseline of Left Ventricular (LV) Ejection Fraction as Determined by MRI at Month 6,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE3']
10277,NCT03165643,DNA methylation level in macrosomia,,,2014-03-06,COMPLETED,OBSERVATIONAL,['NA']
10278,NCT02689765,Change in fasting glucose and HbA1C,Calculated pancreatic β-cell function and insulin resistance,,2016-02,COMPLETED,INTERVENTIONAL,['PHASE4']
10279,NCT05590858,pericoronary Fat attenuation index (FAI),level of pro-inflammatory cytokines such as IL-2 and IL-6.,,2019-01-01,COMPLETED,OBSERVATIONAL,['NA']
10280,NCT01424306,Fasting Plasma Interleukin-6 on Day 9 of Each Diet Period,Adipose Tissue Inflammation - Tissue Expression of IFN-gamma mRNA,,2011-10,COMPLETED,INTERVENTIONAL,['NA']
10281,NCT02123732,Change in HbA1C concentrations and fasting glucose levels,,,2014-07,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10282,NCT04205942,change in microbial load,treatment related side effects - proliferative skin reaction,treatment related side effects - proliferative skin reaction,2016-08-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
10283,NCT00774124,maternal blood glucose control,infant birthweight,,2007-08,COMPLETED,INTERVENTIONAL,['NA']
10284,NCT03361098,Differences in neuronal activity in the central reward and satiety circuits in response to food-related stimuli by BOLD fMRI signal,Laboratory parameters,Exploratory: Microbiome,2017-09-18,COMPLETED,INTERVENTIONAL,['PHASE4']
10285,NCT04008836,Number of Participants With Accurate BGMS Fingerstick Results,Number of Participants With Accurate BGMS Venous Blood Results,,2019-06-10,COMPLETED,INTERVENTIONAL,['NA']
10286,NCT04054804,The questionnaire Orthotic and Prosthetic Users Survey (OPUS) will be used.,System Usability Scale (SUS). The score range from 0-100 and a SUS score above a 68 would be considered above average and anything below 68 is below average.,,2019-09-16,COMPLETED,OBSERVATIONAL,['NA']
10287,NCT00522470,,,,na,COMPLETED,INTERVENTIONAL,['PHASE4']
10288,NCT00327210,Feasibility,Improved knowledge,,2005-05,COMPLETED,INTERVENTIONAL,['NA']
10289,NCT06287437,Percent Change in Body Weight from 24 weeks,Energy intake at 24 weeks,Change of body weight at 24 weeksl from baseline,2024-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
10290,NCT03341299,Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Curve (AUC),Glucodynamics (GD): Area Under the Baseline Subtracted Glucose Concentration Curve,,2017-11-13,COMPLETED,INTERVENTIONAL,['PHASE1']
10291,NCT00404950,,,,2005-07,COMPLETED,OBSERVATIONAL,['NA']
10292,NCT05905588,Change in glycosylated hemoglobin (HbA1c),Number of participants with adverse events as a measure of safety and tolerability,,2023-03-01,RECRUITING,INTERVENTIONAL,['NA']
10293,NCT02794155,Change in HbA1c,Mean Mixed Meal Tolerance Test,,2016-06,COMPLETED,INTERVENTIONAL,['PHASE2']
10294,NCT02950142,Appropriateness,Laboratory test volume,Downstream or cascade clinical activities,2017-12-01,COMPLETED,INTERVENTIONAL,['NA']
10295,NCT02279407,Change From Baseline to Week 12 in % Liver Fat as Assessed by MRI (Comparison Versus Placebo),Change From Baseline to Week 12 in % Liver Fat (Comparison Between Active Treatment Groups),,2015-01,COMPLETED,INTERVENTIONAL,['PHASE2']
10296,NCT03270956,Procedure and/or product related adverse events,Renal specific adverse events,,2018-04-25,COMPLETED,INTERVENTIONAL,['PHASE2']
10297,NCT01889446,Post prandial insulin levels,,,2013-08,UNKNOWN,INTERVENTIONAL,['NA']
10298,NCT04746781,4 weeks of engagement in the Diabetes prevention program,Changes in Risk perceptions,,2021-02-17,COMPLETED,INTERVENTIONAL,['NA']
10299,NCT04729023,Best correct visual acuity,Working delay time,,2021-02-01,COMPLETED,INTERVENTIONAL,['NA']
10300,NCT00138593,Change from baseline in HbA1c at 52 weeks,Change from baseline in HOMA IR at 52 weeks,,2004-07,COMPLETED,INTERVENTIONAL,['PHASE3']
10301,NCT04281992,Incidence of Wound Closure,Incidence of bacteria distribution,,2020-01-28,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10302,NCT05094505,Changes from pre- to pos intervention on glycated haemoglobin,Changes from pre- to pos intervention in angiogenesis,Changes from pre- to pos intervention on lipid profile,2021-10-01,COMPLETED,INTERVENTIONAL,['NA']
10303,NCT00666172,"Measure endothelial function determined by brachial artery reactivity to stress, at baseline/following 6m program participation comparison of change between subj randomized to exercise with weight-loss intervention vs. those randomized to exerci...",,,2008-04-08,COMPLETED,INTERVENTIONAL,['PHASE2']
10304,NCT02808715,"Number of participants with deleterious mutations in the PRDM-16 locus, using standard genomic methods",,,2014-05,COMPLETED,OBSERVATIONAL,['NA']
10305,NCT01813773,Incidence and severity of adverse events of intravitreal aflibercept injection in the treatment of PDR.,Proportion of subjects with avoidance of vitrectomy,,2013-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
10306,NCT01042106,"Safety assessments include physical examination, laboratory variables and ECG.",Pharmacodynamics of DSP-8658 (how DSP-8658 acts in the body to affect glucose and lipid control): glucose and lipid levels will be measured at various time points throughout the study.,,2009-11,COMPLETED,INTERVENTIONAL,['PHASE1']
10307,NCT00658866,Pharmacokinetics in tissue,,,2008-02,COMPLETED,INTERVENTIONAL,['PHASE4']
10308,NCT01353118,"Composite of Fasting Glucose, Glycosylated Haemoglobin c and Rates of Type 2 Diabetes Mellitus Remission.",A Composite of Microvascular Complications,,2011-05,COMPLETED,INTERVENTIONAL,['NA']
10309,NCT00513214,Safety assessed by treatment-emergent adverse events.,,,2007-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10310,NCT02611596,hsCRP,prevalence of hs cTnT > 99th percentile,,2016-11,WITHDRAWN,INTERVENTIONAL,['NA']
10311,NCT04388228,percentage registered diagnoses of DM 2 in the EHR,percentage registered diagnoses of heart failure,Diabetes follow-up quality indicator,2022-01-30,WITHDRAWN,INTERVENTIONAL,['NA']
10312,NCT04245982,histological tissue evaluation,,,2019-01-01,COMPLETED,OBSERVATIONAL,['NA']
10313,NCT02676609,2-hour postmeal blood glucose values between 80 and 180 mg/dl,Mean 2-hour postmeal blood glucose level,,2016-02,COMPLETED,INTERVENTIONAL,['NA']
10314,NCT00387166,"Stress, psychosocial risk and resilient factors, socio-cultural factors, and bio-behavioral markers of cardiovascular risk",,,2006-10,COMPLETED,OBSERVATIONAL,['NA']
10315,NCT00784433,Glycemic control,CVD status,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE3']
10316,NCT02753803,AUC,,,2016-07-27,COMPLETED,INTERVENTIONAL,['PHASE1']
10317,NCT04031599,Relative decrease in glucose levels during exercise compared to pre-breakfast levels (sub-study),Mean time (minutes) to the first hypoglycemic event (sub-study),,2020-07-10,COMPLETED,INTERVENTIONAL,['NA']
10318,NCT02348099,Presence of Subclinical Lipohypertrophy,,,2015-03,UNKNOWN,OBSERVATIONAL,['NA']
10319,NCT02501772,urinary spot albumin creatine excretion ratio (UACR) change,,,2014-09,UNKNOWN,INTERVENTIONAL,['NA']
10320,NCT03312764,HbA1c reduction,Decreased cardiovascular risk,Implementation Context,2017-11-01,COMPLETED,INTERVENTIONAL,['NA']
10321,NCT04149067,0.5% in Hb1Ac and 1.5 kg in body weight,Evaluate the security of the treatment,,2017-06-05,COMPLETED,OBSERVATIONAL,['NA']
10322,NCT00758069,Change From Baseline in 24-hour Weighted Mean Plasma Glucose,Change From Baseline in Plasma Glucose,,2005-07-03,COMPLETED,INTERVENTIONAL,['PHASE2']
10323,NCT00151762,To evaluate safety and tolerability of colesevelam hydrochloride as add-on therapy,To assess effects on lipids and lipoproteins,,2004-12,COMPLETED,INTERVENTIONAL,['PHASE3']
10324,NCT02112721,Follow up Insulin Sensitivity Measure using Euglycaemic glucose clamp,Follow up Acute Insulin Secretory Response- Intravenous Glucose Tolerance Test,Follow Up Pain Impact Questionnaire (PIQ-6 questionnaire),2014-05,COMPLETED,INTERVENTIONAL,['PHASE4']
10325,NCT03442595,Percent Change in A1C,Composite of Risk for Hospitalizations and Emergency Room Visits Within 90 Days From Baseline,,2016-07-01,COMPLETED,OBSERVATIONAL,['NA']
10326,NCT01454700,difference in change in urine albumine excretion from baseline to end of study (12 months),difference in carotid intima media thickness (CIMT),,2011-12,COMPLETED,INTERVENTIONAL,['PHASE4']
10327,NCT01664650,homeostasis model assessment for insulin resistance (HOMA-IR),Adverse events,,2008-09,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
10328,NCT04639492,Post-treatment changes of intestinal flora,Incidence of treatment-emergent adverse events(TEAE),,2020-11-02,COMPLETED,INTERVENTIONAL,['NA']
10329,NCT05644548,Vascular density of the retina,the foveal avascular zone (FAZ) size of the retina,,2022-03-01,RECRUITING,OBSERVATIONAL,['NA']
10330,NCT03959865,HbA1c,Persistence,,2018-12-19,UNKNOWN,OBSERVATIONAL,['NA']
10331,NCT04760626,Change in HbA1c (glycated haemoglobin),"Number of clinically significant hypoglycaemic episodes (level 2) (below 3.0 mmol/L (54 mg/dL), confirmed by BG meter) or severe hypoglycaemic episodes (level 3)",,2021-03-01,COMPLETED,INTERVENTIONAL,['PHASE3']
10332,NCT02286128,Correlation between NF-кB dependent-proinflammation markers and osteoblast-specific gene expression in the MSC to measure the effects of NF-кB dependent-proinflammation on differentiation potential toward osteoblast in type 2 diabetes.,Correlation between NF-кB dependent-proinflammation markers and the expression of RAGE and its downstream signals in the MSC to measure effects of NF-кB dependent-proinflammation on cellular RAGE activation in type 2 diabetes.,,2014-11,COMPLETED,OBSERVATIONAL,['NA']
10333,NCT01305005,,,,2011-03,COMPLETED,OBSERVATIONAL,['NA']
10334,NCT03422471,Modified Oxford Method Assessment of Baroreflex Function,,,2017-09-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
10335,NCT02783807,Clinical Evaluation of Retina Camera Images from both Healthy and Diseased Subjects,,,2015-10,COMPLETED,INTERVENTIONAL,['NA']
10336,NCT03977662,Incidence of Insulin independence,Beta cell function as assessed by Insulin-Modified Frequently-Sampled Intravenous Glucose ToleranceTest (FSIGT),,2019-07-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10337,NCT00738140,To evaluate the effect of intensive lifestyle modification on insulin sensitivity in men receiving GnRH agonist therapy for prostate cancer.,To evaluate the effects of intensive lifestyle modification on other markers of cardiovascular disease risk.,,2007-09,COMPLETED,INTERVENTIONAL,['PHASE2']
10338,NCT01097681,Plasma concentration of ASP1941,"Safety assessed by adverse events, vital signs, laboratory tests and 12-lead ECGs",,2010-02-16,COMPLETED,INTERVENTIONAL,['PHASE1']
10339,NCT00005745,,,,1998-01,COMPLETED,OBSERVATIONAL,['NA']
10340,NCT05417880,Triglycerides,Satisfaction with treatment and life,,2022-08,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
10341,NCT05477511,Rate of DM in the young adult offspring,"Rate of impaired glucose regulation, obesity and adiposity, hypertension and various insulin indices",,2020-08-28,RECRUITING,OBSERVATIONAL,['NA']
10342,NCT00714129,Stable isotopic and magnetic resonance measures to determine the changes in lipid and carbohydrate metabolism after dietary intervention,"DEXA, insulin sensitivity and energy expenditure changes due to dietary intervention",,2007-09,COMPLETED,INTERVENTIONAL,['NA']
10343,NCT00210262,rate of ACE inhibitor use in index patients,Rate of retinopathy screening in all patients,,2002-10,COMPLETED,INTERVENTIONAL,['NA']
10344,NCT05057403,3-point MACE incidence rate,Non-alcoholic fatty liver disease prevalence,,2022-05-30,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
10345,NCT01884545,Triglycerides,Social Isolation,,2013-07,COMPLETED,INTERVENTIONAL,['NA']
10346,NCT03403582,Postprandial blood lipids,Postprandial inflammation,,2014-12,COMPLETED,INTERVENTIONAL,['NA']
10347,NCT05162014,Incidence Rate of Acute Pancreatitis,,,2021-12-20,COMPLETED,OBSERVATIONAL,['NA']
10348,NCT01799850,change in muscle glucose transporter expression,,,2002-03,COMPLETED,INTERVENTIONAL,['PHASE4']
10349,NCT01117311,Disposition Index,Gastric Emptying Half-time,,2011-03,COMPLETED,INTERVENTIONAL,['NA']
10350,NCT00770081,Assessment of treatment emergent adverse events (including hypoglycemia events and other events of special interest),To assess hemoglobin A1c (HbA1c) and fasting plasma glucose (FPG) reduction from baseline after 52 weeks of treatment,,2008-09,COMPLETED,INTERVENTIONAL,['PHASE3']
10351,NCT05437913,Change in Self-report psychological variables: interoceptive awareness (teens),Possible adverse effects,,2021-09-06,UNKNOWN,INTERVENTIONAL,['NA']
10352,NCT05946798,microvascular insulin-mediated dilation,endothelial cell NADPH oxidase expression,,2023-08-30,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
10353,NCT00590226,Mean AM BG (mg/dl),Number of Patients With Hypoglycemic Events,,2006-12,COMPLETED,INTERVENTIONAL,['PHASE4']
10354,NCT01472614,Reduction of A1c level,Adverse events,,2011-09,COMPLETED,INTERVENTIONAL,['PHASE3']
10355,NCT05486390,HbA1c,Healthcare cost,,2023-02-17,RECRUITING,INTERVENTIONAL,['NA']
10356,NCT01224886,Oxidative capacity,Physical fitness,,2010-10,RECRUITING,INTERVENTIONAL,['NA']
10357,NCT01357252,Change from baseline in HbA1c,Responder rates - proportion of subjects reaching predefined HbA1c targets,,2011-04,COMPLETED,INTERVENTIONAL,['PHASE3']
10358,NCT04881383,The sensitivity of the risk prediction function in detecting DM and pre-DM in primary care,Negative predictive value (NPV) of the risk prediction function in detecting DM and pre-DM in primary care,,2020-04-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
10359,NCT00669864,Change in HbA1c (Glycosylated Haemoglobin A1c),"Hypoglycaemic Episodes, Diurnal/Nocturnal",,2007-11,COMPLETED,INTERVENTIONAL,['PHASE4']
10360,NCT02003014,Number of Participants Reporting One or More Serious Adverse Drug Reactions,Change From Baseline Homeostasis Model Assessment of Insulin Resistance (HOMA-IR),,2009-02,COMPLETED,OBSERVATIONAL,['NA']
10361,NCT04257409,Fitness - senior fitness,Metabolism - myokines,,2019-01-01,UNKNOWN,INTERVENTIONAL,['NA']
10362,NCT00571506,determine if treatment with rosiglitazone or pioglitazone affects platelet function as assessed by spontaneous and agonist-induced platelet aggregation,"adipocytokine concentrations (adiponectin, leptin), hemostatic parameters (fibrinogen, plasminogen activator inhibitor-1), high-sensitivity C-reactive protein",,2004-05,COMPLETED,INTERVENTIONAL,['PHASE4']
10363,NCT00360984,prevention of severe hypoglycemia,Diabetes Quality Of Life of questionnaires.,,2003-05,COMPLETED,INTERVENTIONAL,['PHASE4']
10364,NCT00760344,Change from baseline in glycosylated hemoglobin,Body weight.,,2007-03,COMPLETED,INTERVENTIONAL,['PHASE2']
10365,NCT03720912,Change in HbA1c Level,FoH-C Frequency of Help,,2018-10-22,COMPLETED,INTERVENTIONAL,['NA']
10366,NCT02105597,Change in self-reported medication adherence,Change in health status,,2014-08,WITHDRAWN,INTERVENTIONAL,['NA']
10367,NCT04390711,Carbamylated-HDL levels alteration between the control and the T2DM patients with and without concomitant CAD.,,,2018-09-01,COMPLETED,OBSERVATIONAL,['NA']
10368,NCT00811460,Incremental area under insulin concentration time curve relative to basal insulin concentration,"Adverse events, laboratory parameters",,2008-11,COMPLETED,INTERVENTIONAL,['PHASE1']
10369,NCT04157673,Prospective memory,Working Memory,,2019-09-01,COMPLETED,INTERVENTIONAL,['NA']
10370,NCT02299791,Patients Indicated for ACE/ARB and Statin Who Had an Active Prescription for Both,,,2010-09,COMPLETED,INTERVENTIONAL,['NA']
10371,NCT03151837,Oral Glucose Tolerance Test,Hemoglobin(Hb),,2017-05-10,COMPLETED,INTERVENTIONAL,['NA']
10372,NCT02974816,Change in HbA1c from baseline,Number of hospitalizations(Change from baseline),,2017-05-15,COMPLETED,INTERVENTIONAL,['NA']
10373,NCT00910923,To assess the safety and tolerability of JNJ-38431055,"To assess the pharmacodynamic effects of JNJ-38431055 on plasma glucose and insulin, during a Meal Tolerance Test (MTT)",,2008-11,COMPLETED,INTERVENTIONAL,['PHASE1']
10374,NCT06324604,"Safety of multiple, ascending dose levels of MTX-101",anti-drug antibody (ADA) formation,Receptor occupancy of MTX-101,2024-06,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
10375,NCT00362128,Number of Participants With Hypertension,,,2007-01,COMPLETED,OBSERVATIONAL,['NA']
10376,NCT01095991,To evaluate the effect of AZD1656 on the steady-state PK of sitagliptin and vice versa by assessment of AUC0-24 and Cmax,"To evaluate the safety of AZD1656 with and without sitagliptin by assessment of adverse events (AEs), physical examination, electrocardiogram (ECG), pulse, blood pressure (BP), weight and FPG.",,2010-03,COMPLETED,INTERVENTIONAL,['PHASE1']
10377,NCT00284232,HbA1c %,Confidence in new instrument quality,,2004-10,COMPLETED,INTERVENTIONAL,['PHASE4']
10378,NCT02211963,Assessment of tolerability by investigator on a 4-point scale,Amount of glucose excreted in urine,,2007-02,COMPLETED,INTERVENTIONAL,['PHASE1']
10379,NCT03113006,Sensitivity and specificity of OCT angiography as an expression of disease activity in PDR,Change in quality of life between the groups,,2017-05-01,COMPLETED,INTERVENTIONAL,['NA']
10380,NCT03917758,Long term changes from baseline of renin-angiotensin-aldosterone system parameters,Changes in long term glicemic control,,2018-10-10,UNKNOWN,INTERVENTIONAL,['NA']
10381,NCT01268345,blood glucose value,,,2010-10,COMPLETED,INTERVENTIONAL,['NA']
10382,NCT00795015,Percent of blood glucose values in the target range 80-120 mg/dl,"Percent of patient days with a low blood glucose, defines as less than 60 mg/dl",,2006-04,COMPLETED,INTERVENTIONAL,['PHASE4']
10383,NCT04841668,Semantic verbal fluency,The percentage of time in glucose range (glucose level between 140-199 mg/dl),Number time awake,2021-04-10,RECRUITING,OBSERVATIONAL,['NA']
10384,NCT00699322,Glucose variability,"oxidative stress markers (oxidized LDL, N-carboxymethyl-lysine(CML), nitrotyrosine, 8-iso-prostaglandinF2α, 8-OhDG)",,2008-06,UNKNOWN,INTERVENTIONAL,['PHASE4']
10385,NCT00859898,Adjusted Mean Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24 (Last Observation Carried Forward) - Randomized Treated Participants,"Number of Participants With Marked Laboratory Abnormalities in Liver Function in 24 Week Double Blind Treatment Period, Including Data After Rescue - Randomized, Treated Participants",,2009-04,COMPLETED,INTERVENTIONAL,['PHASE3']
10386,NCT02929901,Hepatic steatosis,gut microbiota,,2016-12,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
10387,NCT02686476,Change in Liver Fat,subcutaneous fat,,2016-03,COMPLETED,INTERVENTIONAL,['NA']
10388,NCT06000735,Blood glucose time-in-range (TIR),,,2023-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
10389,NCT06272136,Glucose changes will be measured noninvasively and transcutaneously in dynamic states of glycaemia,,,2024-02-23,RECRUITING,INTERVENTIONAL,['NA']
10390,NCT00867555,postprandial fat oxidation,,,2008-10,COMPLETED,INTERVENTIONAL,['NA']
10391,NCT02875275,Change in postprandial plasma triglyceride over 360 minutes period,Change in postprandial plasma insulin over 360 minutes period,,2016-01-12,COMPLETED,INTERVENTIONAL,['NA']
10392,NCT03228459,Assessment of the impact of arterial ultrasound on cardiovascular events and mortality in a low/moderate cardiovascular risk population.,Association of spirometry alterations and cardiovascular events in a low/moderate cardiovascular risk population,,2015-01-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
10393,NCT00521105,"Medical outcomes: HbA1c, rates of severe hypoglycemia, rates of DKA","Associated costs to the family (time away from school and work, travel, etc)",,2005-08,COMPLETED,INTERVENTIONAL,['NA']
10394,NCT02300181,Difference in plasma glucose profile including AUC and Cmax after taking 50 g carbohidrate.,,,2014-10,COMPLETED,INTERVENTIONAL,['NA']
10395,NCT05831085,The event rate of major adverse cardiac or cerebrovascular events,The number of anti-anginal medications used,,2024-02-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
10396,NCT03746769,"Proportion of subjects who are insulin independent, free from severe hypoglycemia and have HbA1c less than or equal to 6.5% (""complete response"")","Proportion of subjects who are free of severe hypoglycemic episodes (SHE) and have a HbA1c less than or equal to 7.0% (""partial response"").",Improvement in Personal Glycemic State (PGS) score calculated from continuous glucose monitoring,2019-07-07,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10397,NCT05914857,2h plasma glucose on an oral glucose tolerance test (OGTT),"Creatinine, calculated eGFR, and Albumin/Creatinine Ratio (ACR)",,2023-12-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
10398,NCT01638299,Evaluation of the performance of the HHM system response to meal insulin while the subject is under close medical supervision in the Clinical Research Center (CRC) setting.,Number of Safety Events and any additional information that can be used for product development,,2012-07,COMPLETED,INTERVENTIONAL,['PHASE1']
10399,NCT02181244,glycosylated hemoglobin,plasma LDL cholesterol,tumor necrosis factor alpha,2013-05,COMPLETED,INTERVENTIONAL,['NA']
10400,NCT02809365,Improvement of diabetes treatment satisfaction measured by the 'Diabetes Treatment Satisfaction Questionnaire' (DTSQ),Reduction in hypoglycemic events <70 mg%,,2016-09,COMPLETED,INTERVENTIONAL,['NA']
10401,NCT01368549,To determine if Metanx® improves neuropathic symptoms as evaluated by the Neuropathy Total Symptom Score-6 (NTSS-6),To determine overall patient satisfaction with Metanx® using a 10-point satisfaction scale,,2011-01,UNKNOWN,OBSERVATIONAL,['NA']
10402,NCT04901143,Time in range,,,2021-07-17,COMPLETED,INTERVENTIONAL,['NA']
10403,NCT01611935,Number of Blood Products Transfused,Total Number of Complications,,2013-05-01,COMPLETED,INTERVENTIONAL,['PHASE2']
10404,NCT01082120,To evaluate the effect of AZD1656 on the steady state pharmacokinetics of Pioglitazone and vice versa by assessment of AUC (0-24) and Cmax.,"To evaluate the pharmacokinetics of the Pioglitazone metabolite hydroxyl pioglitazone, when pioglitazone is administered with and without AZD1656, by assessment of AUC(0-24), Cmax and tmax.",,2010-02,COMPLETED,INTERVENTIONAL,['PHASE1']
10405,NCT00010751,,,,1998-09,COMPLETED,INTERVENTIONAL,['PHASE2']
10406,NCT00222521,Hemoglobin A1c,Quality of life survey,,2003-04,COMPLETED,INTERVENTIONAL,['PHASE3']
10407,NCT00600236,,,,2004-09,COMPLETED,INTERVENTIONAL,['PHASE3']
10408,NCT04660240,Rate of Target Lesion Failure (TLF),Technical Success,,2020-10-01,RECRUITING,INTERVENTIONAL,['NA']
10409,NCT04166760,Difference in iAUC for insulin between WHE and speWHE,continuous glucose measurement (CGM),,2020-01-06,COMPLETED,INTERVENTIONAL,['NA']
10410,NCT01671514,"Change from baseline in pre-specified biomarker levels in blood, skeletal muscle, and urine",,"Change from baseline in quality of life, health, and nutrition questionnaires",2012-07,COMPLETED,INTERVENTIONAL,['NA']
10411,NCT02357420,Change From Baseline to Week 12 in Weekly Vomiting Episodes,Change From Baseline to Week 12 for Gastric Emptying (GE) as Measured by the Gastric Emptying Breath Test (GEBT) Half-time,,2015-01-29,COMPLETED,INTERVENTIONAL,['PHASE2']
10412,NCT02836704,Percentage of patients with at least one episode of hypoglycemia,Number of severe hypoglycemic events,,2016-09-09,COMPLETED,INTERVENTIONAL,['PHASE4']
10413,NCT05668507,Change in Diabetes Distress,Change in % Time in Range,,2023-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
10414,NCT03066440,Length of acidosis,Length of stay in the hospital,,2018-09-01,TERMINATED,INTERVENTIONAL,['PHASE4']
10415,NCT00950313,Increase in response rates to invitation to 2nd stage blood test,Increase in yield of OGTT positive results through filtering of high risk participants that pass 1st and 2nd stage screens,,2011-04,COMPLETED,INTERVENTIONAL,['NA']
10416,NCT05307731,"The changes of glycosylated hemoglobin, compared with baseline",any adverse events,,2022-03-15,RECRUITING,INTERVENTIONAL,['PHASE4']
10417,NCT01473017,Anxiety and/or depression in Type 2 Diabetes,Quality of life,,2011-11,UNKNOWN,INTERVENTIONAL,['NA']
10418,NCT00849537,Macula diameter,Diabetic retinopathy,,2008-04,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10419,NCT03192475,Change in Bodyweight,Change in Mood,,2013-01-28,COMPLETED,INTERVENTIONAL,['NA']
10420,NCT00387972,Change from baseline in blood glucose regulation after 26 weeks of treatment,"Change from baseline in glycemic parameters, insulin, body weight and waist circumference, and safety measures",,2006-05,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
10421,NCT05702073,Change in HbA1c,Change in scores of diabetes treatment satisfaction questionnaire status version (DTSQs),,2023-03-31,RECRUITING,INTERVENTIONAL,['PHASE3']
10422,NCT03055702,Attendance Rate of the scheduled clinic appointment,,,2016-11-01,UNKNOWN,INTERVENTIONAL,['NA']
10423,NCT01034826,"fasting serum glucose, fasting plasma insulin,post prandial serum glucose, post prandial plasma insulin, hbA1c",,,2007-02,COMPLETED,OBSERVATIONAL,['NA']
10424,NCT02243098,Area under the digoxin plasma concentration-time curve,Number of treatment emergent AEs (TEAEs),,2014-09-16,COMPLETED,INTERVENTIONAL,['PHASE1']
10425,NCT04052919,transthoracic echocardiography,Physical activity questionaire,,2018-02-01,COMPLETED,INTERVENTIONAL,['NA']
10426,NCT01855386,Percentage of patients with NAFLD and gestational diabetes.,"Insulin sensitivity expressed as the Matsuda Index, measured during an oral glucose tolerance test (OGTT).",,2013-01,TERMINATED,OBSERVATIONAL,['NA']
10427,NCT05550870,Cholesterol in mg/dl,,,2022-01-24,COMPLETED,INTERVENTIONAL,['NA']
10428,NCT00686634,Hemoglobin A1c (HbA1c) Change From Baseline,Number of Adverse Events,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE4']
10429,NCT04608890,"Percentage of patients with a change in eye movement test in each class Resistance, Velocity, Pursuit, Wideness and OKN measured by the eye-tracking based test",Percentage of patients with a change in eye movement test in the Velocity class,,2020-12-01,COMPLETED,OBSERVATIONAL,['NA']
10430,NCT04948918,Change in estimated glomerular filtration rate renal function (eGFR),Change in peak linear blood flow velocity in the trunk and in segmental renal arteries,,2020-09-20,COMPLETED,INTERVENTIONAL,['NA']
10431,NCT00744367,Absolute change from baseline in HbA1c,"Safety: adverse events, vital signs, physical examination, clinical laboratory tests, ECG and anti-taspoglutide antibodies.",,2008-10,COMPLETED,INTERVENTIONAL,['PHASE3']
10432,NCT00519142,change from baseline in HbA1c,change from baseline in fasting plasma glucose,,2007-08,COMPLETED,INTERVENTIONAL,['PHASE3']
10433,NCT04976881,Knowledge of reproductive risks,Folic acid use,,2022-05-06,RECRUITING,INTERVENTIONAL,['NA']
10434,NCT04690309,Metabolic control in patients treated with human insulin preparations insulin vs insulin analogues.,Metabolic control in patients treated with human insulin preparations insulin vs insulin analogues.,,2018-07-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
10435,NCT05070949,Self-compassion,Stress and depressive symptoms,,2021-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
10436,NCT01275027,HgA1c reduction,Diabetes medication,,2011-01,WITHDRAWN,INTERVENTIONAL,['PHASE2']
10437,NCT05130463,Change from baseline in HbA1c after 24 weeks of treatment,Number of Participants with Final effectiveness evaluation,,2022-03-22,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
10438,NCT00934570,Reduction in BMI,Improvement in physical activity,,2009-04,COMPLETED,INTERVENTIONAL,['PHASE4']
10439,NCT06292000,Peripheral insulin sensitivity,Sleep outcomes,,2024-02-01,RECRUITING,INTERVENTIONAL,['NA']
10440,NCT00366249,Number of Patients With Clinical Response of Cure Vs. Failure/Indeterminate.,Number of Patients With Microbiologic Response of Eradication.,,2007-01,COMPLETED,INTERVENTIONAL,['PHASE3']
10441,NCT05548205,Percentage Change in Hemoglobin A1c (HbA1c),Number of Hypoglycemic Events,,2024-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
10442,NCT03323827,ANT Acetylation,,,2016-11,UNKNOWN,OBSERVATIONAL,['NA']
10443,NCT00046150,Frequency of catheter occlusions,"Unexplained hyperglycemia, parameters of glycemic control",,2002-05,COMPLETED,INTERVENTIONAL,['PHASE3']
10444,NCT03877406,HbA1c,Insulin resistance,,2018-08-01,RECRUITING,INTERVENTIONAL,['PHASE4']
10445,NCT00875394,Change From Baseline in Glycosylated Hemoglobin A1C (A1C) at Week 24,,,2007-02-01,COMPLETED,INTERVENTIONAL,['PHASE3']
10446,NCT01702883,The primary measure will be adherence as measured by pharmacy refills in each group.,,,2012-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
10447,NCT04392570,To compare the serum osmolarities of patients with type 2 diabetes who are fasting for 17 hours and who are not fasting.,,,2019-05-15,COMPLETED,OBSERVATIONAL,['NA']
10448,NCT00420901,Endothelial function responders - Improvement in endothelial function,Changes in vascular inflammatory markers,,1999-01,COMPLETED,INTERVENTIONAL,['PHASE3']
10449,NCT03754608,Diagnostic Odds ratio for the MRI vascular cognitive impairment biomarker.,Correlation between the biomarker and cognition,,2018-11-07,COMPLETED,OBSERVATIONAL,['NA']
10450,NCT04534530,Cost-effectiveness analysis of routine screening for ischemic heart disease in T2DM patients,Budget impact analysis for Health Insurance of the most efficient strategy,,2023-06-05,RECRUITING,OBSERVATIONAL,['NA']
10451,NCT01072578,Calculation of derivation of pharmacokinetic variables,To examine the safety and tolerability of the combination of dapagliflozin and metformin,,2010-02,COMPLETED,INTERVENTIONAL,['PHASE1']
10452,NCT06068309,Proportion of days covered (PDC),Perception & Satisfaction Questionnaire (PSQ),,2022-07-01,RECRUITING,INTERVENTIONAL,['NA']
10453,NCT05459519,Changes in rate of platelet aggregation,Number of Participants with safety endpoint,,2022-07-20,RECRUITING,INTERVENTIONAL,['NA']
10454,NCT01154244,insulin resistance assessed using HOMA-IR,proportion of obesity in patients,,2009-09,COMPLETED,OBSERVATIONAL,['NA']
10455,NCT01317459,Change in HbA1c,DDS scales,,2011-03,UNKNOWN,INTERVENTIONAL,['NA']
10456,NCT01880242,Target Lesion Failure,Clinical Procedure Success,,2014-05-13,COMPLETED,OBSERVATIONAL,['NA']
10457,NCT01044368,The primary endpoint is the A1c level or the change in A1c level,"The secondary endpoints include severe hypoglycemia defined as requiring external aid, hospital admissions for any CVD related intervention, and adverse events such as unplanned hospitalizations for any cause that last more than 24 hours",,2010-01,SUSPENDED,INTERVENTIONAL,['NA']
10458,NCT05063734,"Change From Baseline in BCVA ETDRS Letter Score, at Month 3, in Treatment-naïve Subjects in Part B of the Study",Incidence of Ocular and Non-ocular Adverse Events (AEs) and Serious Adverse Events (SAEs),,2021-08-27,TERMINATED,INTERVENTIONAL,['PHASE2']
10459,NCT05377918,Anxiety,,,2022-01-31,COMPLETED,INTERVENTIONAL,['NA']
10460,NCT05225467,Blood ketone difference,Difference in ketone development between patient with and without diabetes mellitus.,Other,2022-03-15,COMPLETED,OBSERVATIONAL,['NA']
10461,NCT03642483,HbA1c,psychological health (Child Behavior),,2018-06-05,COMPLETED,OBSERVATIONAL,['NA']
10462,NCT01847313,MCP-1:Creatinine Ratio in Urine,sCD163:Creatinine Ratio in Urine,Safety in All Participants as Measured by Adverse Event Rate,2013-04,COMPLETED,INTERVENTIONAL,['PHASE3']
10463,NCT00877851,Between Group Differences in Goal Setting,Between Group Differences in Self-Efficacy and Barriers to Management of Diabetes,,2009-04,COMPLETED,INTERVENTIONAL,['NA']
10464,NCT02479516,Elevated HBA1c,Blood Pressure,Health Behaviour questionnaire,2015-11,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10465,NCT04242511,TB medication levels,,,2021-05,UNKNOWN,OBSERVATIONAL,['NA']
10466,NCT00101803,Change from baseline in HbA1c at 24 weeks,Patients with reduction in HbA1c >/= to 0.7% after 24 weeks,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE3']
10467,NCT04878120,Low blood glucose index (LBGI),Total number and amount of carbohydrate administered as rescue treatments,,2021-05-14,COMPLETED,INTERVENTIONAL,['NA']
10468,NCT00936663,Fasting Blood Glucose,Hypoglycemia,AUC for C Peptide,2009-07-06,TERMINATED,INTERVENTIONAL,['PHASE4']
10469,NCT01194245,Change From Baseline in Glycosylated Hemoglobin A1C (HbA1c) at the End of Each Treatment Period,Mean Daily Postprandial Glucose (PPG) Excursions,,2010-08,COMPLETED,INTERVENTIONAL,['PHASE2']
10470,NCT00232583,Beta-cell Function - C-peptide AUC (Area Under the Curve),Quality of Life Survey (QoL) - Willingness to Continue Insulin Treatment,,2003-11,COMPLETED,INTERVENTIONAL,['NA']
10471,NCT00530686,1)Presence or absence of hypoglycemic unawareness 2) To assess incidence of hypoglycemic episodes 3) To assess insulin requirements in patients who did not become insulin independent.,To assess the achievement of insulin independence at 12 month and 24 month post transplant in patients who underwent allo islet cell transplantation.,,2008-07,COMPLETED,INTERVENTIONAL,['PHASE1']
10472,NCT01971554,Number of Participants Who Discontinued Study Drug Due to an AE,Change From Baseline in 24-Hour Weighted Mean Glucose (24h-WMG) at Day 15,,2013-10-14,COMPLETED,INTERVENTIONAL,['PHASE1']
10473,NCT05766657,Body mass index (BMI),Metabolomic analysis,,2022-12-23,RECRUITING,INTERVENTIONAL,['NA']
10474,NCT03621384,Association between BsmI Polymorphisms in Vitamin D Receptor Gene and Diabetic Kidney Disease,,,2014-11,COMPLETED,OBSERVATIONAL,['NA']
10475,NCT00841347,The influence of sleep extension on leptin level for the obese teens group.,"Study the correlation between delta waves activity and psychological, behavioural, anthropometric and physiological markers of obesity and its co morbidities",,2009-02,COMPLETED,INTERVENTIONAL,['NA']
10476,NCT01877213,Diabetes-related readmissions,Duration of rehospitalizations,,2013-06,UNKNOWN,INTERVENTIONAL,['NA']
10477,NCT03389100,18F-MK6240 standardized update value ratio (SUVR),,,2018-07-24,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE2']
10478,NCT00214591,Absolute change from baseline to end of randomized treatment period in glycosylated hemoglobin A1c (HbA1c),"Safety and tolerability of tesaglitazar by assessment of adverse events, laboratory values, electrocardiogram, pulse, blood pressure, hypoglycemic events, body weight, cardiac evaluation, and physical examination",,2004-08,TERMINATED,INTERVENTIONAL,['PHASE3']
10479,NCT05382533,"Fasting glucose, mmol/l (group C, D)",Zinc (µmol/l),Zinc (µmol/24 h),2022-05-30,COMPLETED,INTERVENTIONAL,['NA']
10480,NCT00073294,,,,na,WITHDRAWN,INTERVENTIONAL,['NA']
10481,NCT02402439,Insulin independence,Incidence of adverse events,,2016-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
10482,NCT06068439,decline of renal function,Change of renal function class,,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
10483,NCT01678235,Postprandial glycemia,Difference between the maximum and baseline glycemia,Questionnaire: Glycemic Index Knowledge,2011-09,COMPLETED,INTERVENTIONAL,['PHASE4']
10484,NCT00806936,Percentage of patients achieving HbA1c below 7.0%,Comparison of scores of Insulin Treatment Appraisal Scale (ITAS),,2008-12,COMPLETED,OBSERVATIONAL,['NA']
10485,NCT02119819,Change From Baseline in Hemoglobin A1c (HbA1c) at Week 12,Change From Baseline in Insulin Levels,,2014-04,COMPLETED,INTERVENTIONAL,['PHASE2']
10486,NCT02821026,"The proportion of subjects with HbA1c ≤ 6.5% at 1 year AND free of severe hypoglycemic events from Day 28 to Day 365, inclusive, after the islet transplant",The incidence of discontinuation of immunosuppression,,2016-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10487,NCT02021591,Change in Score on the Summary of Diabetes Self-Care Activities Questionnaire (SDSCA),Change in Low-Density Lipoprotein,,2013-12,COMPLETED,INTERVENTIONAL,['NA']
10488,NCT05365425,Volume of carotid artery plaque,changes of gut microbiota,,2023-06-01,RECRUITING,INTERVENTIONAL,['PHASE4']
10489,NCT00778622,Mean Change From Baseline at Week 16 (95% Confidence Interval) in Glycosated Hemoglobin A1c (HbA1c) (Last Observation Carried Forward) - Full Analysis Set (FAS),Mean Change From Baseline at Week 16 (95% Confidence Interval) in Adiponectin - Full Analysis Set,Number of Participants Who Had a Normal Electrocardiogram (ECG) at Baseline and an ECG at Week 16 (or Termination Visit) Which Was Considered to be Abnormal With Clinical Significance - Safety Population,2009-11,COMPLETED,INTERVENTIONAL,['PHASE4']
10490,NCT04657003,Percentage of Participants Who Achieve ≥5% Body Weight Reduction from Randomization,Pharmacokinetics (PK): Steady State Area Under the Concentration Curve (AUC) of Tirzepatide,,2021-03-29,COMPLETED,INTERVENTIONAL,['PHASE3']
10491,NCT03542071,Child: Neonatal body fat%,Percentage of participants on GDM medication,,2018-07-20,TERMINATED,INTERVENTIONAL,['NA']
10492,NCT04705779,Change in Veggie Meter Score,Change in Glycosylated Hemoglobin,,2021-05-20,RECRUITING,INTERVENTIONAL,['NA']
10493,NCT01720719,Liver fat content(%),Muscle enzymes,,2013-05,UNKNOWN,INTERVENTIONAL,['PHASE4']
10494,NCT00500370,Change in Body Weight,Change in Glycosylated Hemoglobin (HbA1c),,2007-06,COMPLETED,INTERVENTIONAL,['PHASE2']
10495,NCT01310452,The change in liver fat content and visceral fat mass,Safety profile,,2011-01,UNKNOWN,INTERVENTIONAL,['NA']
10496,NCT00509925,"Total Energy Expenditure, Dietary Record Method","Hypoglycaemic Episodes, Diurnal/Nocturnal",,2007-07,TERMINATED,INTERVENTIONAL,['PHASE4']
10497,NCT03781232,Generation and validation of predictive models by Mean Absolute Relative Difference (MARD) measures,,,2018-11-22,COMPLETED,INTERVENTIONAL,['NA']
10498,NCT02054897,Change in HbA1c (Glycosylated Haemoglobin),Subjects Who Achieve (Yes/no):HbA1c Below or Equal to 6.5% (48 mmol/Mol) American Association of Clinical Endocrinologists Target,,2014-02-03,COMPLETED,INTERVENTIONAL,['PHASE3']
10499,NCT02278913,Glycemic control,Mortality,,2009-04,COMPLETED,INTERVENTIONAL,['PHASE4']
10500,NCT01484353,HBAIC before and after intervention,Blood pressure,,na,WITHDRAWN,INTERVENTIONAL,['NA']
10501,NCT02461225,Number of Participants With a 30% or Greater Change in Pain Rating on the Visual Analog Scale (VAS),Change in Pain Rating on the Visual Analog Scale (VAS),,2016-03-01,COMPLETED,INTERVENTIONAL,['NA']
10502,NCT03812614,Change from baseline in patient glycemic control at 6 months,Change in self-efficacy of support person,Change in self-efficacy of support person,2019-09-23,COMPLETED,INTERVENTIONAL,['NA']
10503,NCT04089280,Adverse gastrointestinal symptoms related to metformin treatment,Oxidative stress markers - TAS,,2018-10-16,COMPLETED,INTERVENTIONAL,['NA']
10504,NCT02088203,Levels of bioactive components from the Russian Tarragon Nutrasorb in the blood and urine,Glucose tolerance measured with an OGTT,,2014-02,COMPLETED,INTERVENTIONAL,['PHASE1']
10505,NCT04335396,presence of incresed non-HDL cholesterol level of the sera,Prevalence of polyneuropathy,,2018-05-28,UNKNOWN,OBSERVATIONAL,['NA']
10506,NCT05267457,Gestational diabetes mellitus,,,2012-08-01,COMPLETED,OBSERVATIONAL,['NA']
10507,NCT03706378,Insulin,,,2017-08-18,COMPLETED,INTERVENTIONAL,['NA']
10508,NCT05167513,Diabetes Quality of Life assessment using DQOL-13 questionnaire,Change from baseline in HbA1c % and fasting blood sugar FBS (mg/dl) to the last-observation on treatment,,2021-01-01,COMPLETED,INTERVENTIONAL,['PHASE4']
10509,NCT04825639,Prevalence of Acute Kidney Injury in the sepsis and DKA cohorts,Compare chloride levels in the AKI and non AKI groups,,2021-03-15,COMPLETED,OBSERVATIONAL,['NA']
10510,NCT02885909,Glucose target,Orexin-A,,2016-09,RECRUITING,INTERVENTIONAL,['PHASE4']
10511,NCT00728403,"HbA1c levels and insulin sensitivity index using 3 different indices: ISI, HOMA, QUICKI","Cholesterol, triglycerides, fasting & post-prandial blood glucose and insulin, C-reactive protein, lipid peroxidation, blood pressure, endothelial function, body fat composition",,2008-09,UNKNOWN,INTERVENTIONAL,['PHASE2']
10512,NCT03012074,Number of participants with type II diabetes who adhere to using mobile technologies to self-monitor multiple types of diabetes-related data,Medication adherence Survey,"Explore health care providers' perspectives on using real-time data, by conducting one-time, individual interviews over a 2 month period.",2017-03-02,COMPLETED,INTERVENTIONAL,['NA']
10513,NCT02718703,System Use Evaluation - HCP ( HealthCare Professional) questionnaire,,,2015-02,COMPLETED,INTERVENTIONAL,['NA']
10514,NCT02269098,Medication Adherence,Hypoglycemia,ED Visits and Hospitalizations,2012-02,COMPLETED,INTERVENTIONAL,['NA']
10515,NCT03744039,Description Charcot foot's treatment,Register of Charcot foot,,2019-01-01,COMPLETED,OBSERVATIONAL,['NA']
10516,NCT00353834,The Primary Endpoint Was the Change in FMD at the End of the Study Compared to Baseline Measurements in Subjects Treated With Exenatide Compared to Subjects Treated With Lantus.,"Fourth Will be Changes in Insulin, Glucose, C-peptide, Lipids, and FFA Responses Following the MTT in Subjects Treated With Exenatide Compared With Subjects Treated With Lantus at the End of the Study Compared to Baseline Measurement",,2006-08,COMPLETED,INTERVENTIONAL,['PHASE4']
10517,NCT00296296,Estimated Glomerular Filtration Rate (eGFR) 1 Year Following Transplantation,Count of Participants With Biopsy Proven Acute Rejection at One Year Post Transplantation,,2005-06,COMPLETED,INTERVENTIONAL,['PHASE4']
10518,NCT02234440,Reduction of portal pressure,Safety profile of the drugs like Random Blood Sugar (RBS) and serum lactate monitoring regularly.,,2014-09-01,COMPLETED,INTERVENTIONAL,['NA']
10519,NCT03436875,Microbiota,,,2023-01-01,WITHDRAWN,OBSERVATIONAL,['NA']
10520,NCT00706680,"Percentage of patients developing New Onset Diabetes post transplant, as identified by an oral glucose tolerance test",Incidence of acute rejection,,2008-02,UNKNOWN,INTERVENTIONAL,['PHASE4']
10521,NCT02015910,Percent Wounds Healed,,,2014-01,TERMINATED,INTERVENTIONAL,['PHASE4']
10522,NCT04505618,Correlation of Imaging,,,2019-10-01,RECRUITING,INTERVENTIONAL,['NA']
10523,NCT04573296,Change in body weight,change in liver function tests,Vitadio usability for HCPs,2020-02-26,COMPLETED,INTERVENTIONAL,['NA']
10524,NCT00977483,"Primary efficacy variable: Absolute change in the neuropathy impairment score lower limbs enlarged by 7 objective items (NISLL+7) between baseline (mean of Visit 0.3 and 0.4 or last available value before randomisation, respectively) and endpoint","NIS, NSC, TSS, LLF, QST, VDT, CDT and HP, QAE by means of the HRDB, amplitude CMAP, DL and MNCV on peroneal and tibial nerves, amplitude SNAP and latency on sural nerve, foot inspection, efficacy.",,1998-05,COMPLETED,INTERVENTIONAL,['PHASE3']
10525,NCT04638556,Nerve conduction velocity,,,2019-09-03,UNKNOWN,OBSERVATIONAL,['NA']
10526,NCT03552562,Total retinal blood flow (DVA and FDOCT),,Autonomic and sensomotoric neuropathy measurements,2018-11-21,UNKNOWN,INTERVENTIONAL,['NA']
10527,NCT00609102,Blood glucose,HbA1c levels,,2008-07,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
10528,NCT02529969,Triglyceride,C-Reactive Protein,,2015-07,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
10529,NCT05272839,Decrease of ≥ 0.5 points of percentage of HbA1c,Blood pressure,,2022-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
10530,NCT01778751,Diabetes Control,Depressive Symptoms,,2013-12,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
10531,NCT06321029,Feasibility of intervention and delivery modality,Diabetes Therapy-Related Quality of Life Questionnaire,,2023-10-19,RECRUITING,INTERVENTIONAL,['NA']
10532,NCT04243629,Time in target range,Number of hypoglycemia events,,2021-11-12,RECRUITING,INTERVENTIONAL,['NA']
10533,NCT00362323,TG / HDL-C ratio,Lipid and glycemic parameters,,2006-10,COMPLETED,INTERVENTIONAL,['PHASE3']
10534,NCT00563628,Retinal thickness after treatment,,,2007-10,UNKNOWN,INTERVENTIONAL,['PHASE4']
10535,NCT00140543,At 1 year:Incidence of biopsy-proven (kidney) rejection episodes.,* % of steroid free patients: at 6 months and 1 year.,,2002-02,COMPLETED,INTERVENTIONAL,['PHASE3']
10536,NCT02689479,The relationship between β cell mass calculated from the 11C-5-HTP PET scans and the MMTT C-peptide at 90 minutes,The incidence and severity of adverse events related to the PET investigation including allergic reactions,,2013-05,COMPLETED,INTERVENTIONAL,['NA']
10537,NCT05573685,To estimate the effect size for changes in pain experience (interference) in the Treatment App group compared to the Digital Control App group,To estimate the effect size for changes in confidence in dealing with chronic pain in the Treatment App group compared to the Digital Control App group,,2022-10-10,COMPLETED,INTERVENTIONAL,['NA']
10538,NCT00737633,Change in HbA1c From Baseline to Week 72,Percent Weight Change From Baseline to Week 72,,2008-08,TERMINATED,INTERVENTIONAL,['PHASE2']
10539,NCT00921882,Oral glucose tolerance test,Acceptability of screening test,,2008-06,COMPLETED,OBSERVATIONAL,['NA']
10540,NCT00877968,Post-prandial glycemic response,"Appearance, taste, texture, smell and overall acceptability",,2008-03,COMPLETED,INTERVENTIONAL,['PHASE2']
10541,NCT05608187,Compare incidence of serious adverse events (SAEs) between treatment groups,Presence of viable L. reuteri containing the pSIP_CXCL12 plasmid in wounds,"Analysis of L. reuteri containing the pSIP_CXCL12 plasmid in blood, feces, and perilesional skin",2022-09-26,RECRUITING,INTERVENTIONAL,['PHASE2']
10542,NCT04460612,Change in oxygenation of feet and lower legs,,,2021-05-26,COMPLETED,INTERVENTIONAL,['NA']
10543,NCT01964703,serum glucose (fasting and post 75g oral glucose tolerance test),serum insulin,"HOMA IR, QUICKI, HOMA beta, lipid profile, inflammatory markers",2013-04,COMPLETED,INTERVENTIONAL,['PHASE4']
10544,NCT04891887,Health related quality of life,Body weight,,2016-02,COMPLETED,INTERVENTIONAL,['NA']
10545,NCT02750527,number of familial hypercholesterolemia or pre-type-1-diabetes,,,2016-09,COMPLETED,OBSERVATIONAL,['NA']
10546,NCT05764200,24 hour intestinal gas concentrations,Urine metabolites,,2023-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
10547,NCT00262145,glucose and lipid uptake,lipid metabolism,,2005-10,COMPLETED,INTERVENTIONAL,['PHASE1']
10548,NCT02144337,Feasibility: Number of Participants With Adverse Events,Change in Parental Hypoglycaemia Fear Using the Hypoglycaemia Fear Survey (HFS-Parent),,2014-05,COMPLETED,INTERVENTIONAL,['NA']
10549,NCT03311802,fasting plasma glucose,,,2015-03-11,COMPLETED,OBSERVATIONAL,['NA']
10550,NCT01324557,Glycosylated hemoglobin (HbA1c) measurement,The frequency of hypoglycemic episodes,,2011-03,UNKNOWN,INTERVENTIONAL,['PHASE2']
10551,NCT02895139,Reduction of forefoot pressure to below safety threshold,Clinician confidence in orthotics service,,2016-07,COMPLETED,INTERVENTIONAL,['NA']
10552,NCT01937416,Cell transplantation related side effect,Skin microcirculation measurement,,2012-01,UNKNOWN,INTERVENTIONAL,['PHASE1']
10553,NCT04836546,Incidence of moderate and severe hypoglycemic and diabetic ketoacidosis events,,,2021-04-13,RECRUITING,INTERVENTIONAL,['NA']
10554,NCT00495885,change from baseline to 12 weeks for Sleep Maintenance Insomnia using patient reported Wake After Sleep Onset (pr-WASO),"Change from baseline to 12-week of ""General Productivity"" domain from Functional Outcomes of Sleep Questionnaire (FOSQ).",,2007-06,COMPLETED,INTERVENTIONAL,['PHASE3']
10555,NCT06108076,Cardiac Efficiency after chronic dosing (Left-ventricular function),Patient Reported Outcomes Measure Information System (PROMIS) - Physical Function,,2024-02,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
10556,NCT01576328,Primary objective of the study is to assess the safety and tolerability of MPC therapy,,,2012-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10557,NCT04739241,Change in HbA1c levels,Change in the scores of the Diabetes Quality Of Life Questionnaire (EsDQOL) from recruitment to month 12.,,2014-01-24,COMPLETED,INTERVENTIONAL,['PHASE4']
10558,NCT02694289,Units of Insulin used,"pro-BNP levels, pg/mL",,2016-11,WITHDRAWN,INTERVENTIONAL,['NA']
10559,NCT01585454,Gestational Weight Gain,Complications of Pregnancy and Delivery,,2012-03-27,WITHDRAWN,OBSERVATIONAL,['NA']
10560,NCT04288063,Change in muscle mass as measured by D3 creatinine dilution method,Muscle Strength,,2020-09-18,COMPLETED,OBSERVATIONAL,['NA']
10561,NCT03904056,Fluorescein leakage area of active new vessels (FLA),Electroretinography,,2014-01-01,COMPLETED,INTERVENTIONAL,['NA']
10562,NCT05456477,Ratio of incremental area under the curve (iAUC) for C-peptide to iAUC for glucose,Interleukin-6,,2022-10-07,COMPLETED,INTERVENTIONAL,['NA']
10563,NCT02250794,mean blood glucose for the duration of the hospital stay,frequency of hypoglycemia,Acute kidney injury,2014-10,WITHDRAWN,INTERVENTIONAL,['PHASE4']
10564,NCT05859958,Discharge disposition,,,2022-11-10,COMPLETED,OBSERVATIONAL,['NA']
10565,NCT03254095,Percentage of patients developing a foot ulcer,Time to ulceration,Body mass index,2016-09-01,COMPLETED,OBSERVATIONAL,['NA']
10566,NCT04011267,Change from Baseline of the Fuzzy classification of the diabetic neuropathy severity at 12-weeks,Quality Adjusted Life Years,,2019-08-01,COMPLETED,INTERVENTIONAL,['NA']
10567,NCT02594748,Change from baseline in Audit of Diabetes Dependent Quality of Life at 3-month follow up.,Change from baseline in Blood sugar at 3-month follow up.,,2015-07,SUSPENDED,INTERVENTIONAL,['NA']
10568,NCT04151849,Urinary aldosterone at 3 months,Urinary aldosterone at 12 months,Ferritin,2019-11-07,COMPLETED,OBSERVATIONAL,['NA']
10569,NCT04663685,Participant experience,Number of adverse events,,2020-10-05,UNKNOWN,INTERVENTIONAL,['NA']
10570,NCT00399425,Stage in Wagner's classification,Quality of life,,2001-06,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
10571,NCT01489644,Fasting repaglinide and metformin Cmax (maximum drug concentration) following individual administration,Vital signs,,2006-06,COMPLETED,INTERVENTIONAL,['PHASE1']
10572,NCT02304588,Frequency of Adverse Events,Relative Wound Area Regression of 40% or More at 6 Week,Reduced pain,2013-01,UNKNOWN,INTERVENTIONAL,['PHASE1']
10573,NCT05301816,Global impression of change in health status,,Device Safety,2022-07-05,RECRUITING,INTERVENTIONAL,['NA']
10574,NCT04185662,HbA1c,,,2019-12-01,UNKNOWN,INTERVENTIONAL,['NA']
10575,NCT00575588,Hemoglobin A1c (HbA1c) Change From Baseline to Week 52,Mean Slope of the Regressions of Change From Week 24 to Week 52 in HbA1c,Mean Slope of the Regressions of Change From Week 24 to Week 104 in HbA1c,2007-12,COMPLETED,INTERVENTIONAL,['PHASE3']
10576,NCT06095544,Hospital costs (US dollar),Perioperative complications,,2021-01-01,COMPLETED,INTERVENTIONAL,['NA']
10577,NCT04857398,Area under the serum insulin icodec concentration-time curve during one dosing interval at steady state,Terminal half-life for insulin icodec at steady state,,2021-04-28,COMPLETED,INTERVENTIONAL,['PHASE1']
10578,NCT05860413,Adherence to diet protocols,Insulin sensitivity,,2023-01-24,RECRUITING,INTERVENTIONAL,['NA']
10579,NCT01581073,"Composite renal outcome of chronic dialysis, kidney transplantation, eGFR 6 mL/min/1.73m2 or less, or eGFR less than 50% of initial value.",Number of Participants with Adverse Events baseline,,2012-02-16,COMPLETED,INTERVENTIONAL,['PHASE3']
10580,NCT01961388,The mean change in post-meal glucose levels from baseline at the end of observation period of up to 16 weeks,Incidence rate of adverse drug reactions in acarbose and metformin treated groups during 16 weeks observation period,,2015-08,WITHDRAWN,OBSERVATIONAL,['NA']
10581,NCT00384488,Weight loss,Reduction in progression to type 2 DM,,2004-05,COMPLETED,INTERVENTIONAL,['NA']
10582,NCT03503045,Overtreatment for glycemia,Deintensification of treatment,,2017-04-01,COMPLETED,OBSERVATIONAL,['NA']
10583,NCT05207995,Adverse effects associated with the therapy,,,2022-03-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10584,NCT00786175,,,,2008-10,WITHDRAWN,OBSERVATIONAL,['NA']
10585,NCT01197092,HbA1c Test (Glycated hemoglobin),"Vitamins B1,B2,B6,B 12, Vitamin D",,2010-11,UNKNOWN,INTERVENTIONAL,['PHASE2']
10586,NCT02061618,Hemoglobin A1c,Physical Activity,,2014-06,COMPLETED,INTERVENTIONAL,['NA']
10587,NCT03293914,"Difference in the daily rate of change of Glycated hemoglobin (HbA1C) during the year prior to baseline, compared to the period from baseline to post-intervention",Timeliness,,2017-09-18,COMPLETED,INTERVENTIONAL,['NA']
10588,NCT03455985,Change in HbA1c From Baseline to 24 Weeks,Fasting Glucose,,2018-05-01,TERMINATED,INTERVENTIONAL,['NA']
10589,NCT01449773,Change in the in vivo kinetics of intestinally derived apoB-48-containing lipoproteins between the two 8-week interventions,"Change in the plasma surrogates of cholesterol absorption (campesterol, beta-sitosterol) and synthesis (lathosterol) between the two 8-week interventions",,2008-04,COMPLETED,INTERVENTIONAL,['NA']
10590,NCT01307566,Change in Hemoglobine A1C from baseline,Change in ratio albumine to creatinine from baseline,,2011-03,COMPLETED,INTERVENTIONAL,['NA']
10591,NCT00811317,Average Blood Glucose Over the Closed-loop Control Period,Insulin and Glucagon Levels During Closed Loop and Open Loop Admissions of Diabetic Subjects Compared to the Comparable 24 Hour Period During the Admission of Non-diabetic Subject,,2008-05,COMPLETED,INTERVENTIONAL,['NA']
10592,NCT02138045,Evoked brain potentials (using standard electroencephalographic brain imaging).,OCT,Weight/body mass index,2014-05,COMPLETED,INTERVENTIONAL,['NA']
10593,NCT04164030,Change in diabetes distress measured using the Diabetes Distress Scale,,,2019-08-26,UNKNOWN,INTERVENTIONAL,['NA']
10594,NCT02192853,Correlation between the total and intact GLP-1 hormone during different doses of sitagliptin measured as total area under the curve (tAUC),Differences in Insulin measured as total Area under the curve (tAUC),,2013-05,COMPLETED,INTERVENTIONAL,['PHASE4']
10595,NCT04626570,Percentage of patients without food addiction,Evolution of quality of life,,2021-01-20,RECRUITING,INTERVENTIONAL,['NA']
10596,NCT00190502,C-peptide production,Insulin dose,,2000-11,UNKNOWN,INTERVENTIONAL,['NA']
10597,NCT04516694,HbA1c,Time in Range,,2020-09-10,COMPLETED,INTERVENTIONAL,['NA']
10598,NCT02868177,Changes in fasting glycemia,Changes in WHR (waist to hip ratio),Changes in physical activity score,2016-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
10599,NCT02817243,The area under the plasma concentration-time curve (AUC) of Simvastatin,The number of volunteers with adverse events as a measure of safety and tolerability,,2016-03,UNKNOWN,INTERVENTIONAL,['PHASE1']
10600,NCT02528019,Effects of treatment on the nominal change in arterial stiffness from baseline after 6 months of treatment as measured by cardio-ankle vascular index,Change from baseline in circulating inflammatory markers,,2015-08,UNKNOWN,INTERVENTIONAL,['PHASE4']
10601,NCT04844164,Change in 25(OH)D3 level,Serum vitamin D-binding protein,,2019-04-16,COMPLETED,INTERVENTIONAL,['PHASE1']
10602,NCT02732886,Proportion of subjects with a target ulcer which achieves complete wound closure in 8 weeks,Change amount and change rate of the target ulcer size after using the investigational device,,2016-03-29,COMPLETED,INTERVENTIONAL,['NA']
10603,NCT01684943,For Continuous Insulin Monitoring: Time to Maximum Plasma Insulin and Time to Maximum Continuous Insulin Monitoring Insulin,Multiplex PK: Average Number of Hypoglycemia Events Over the Last Month at Baseline Categorized According to Baseline Use of Insulin Analog Found to Have the Most Favorable PK Profile for Each Individual,,2010-07,COMPLETED,INTERVENTIONAL,['NA']
10604,NCT00099723,Blood work,,,2004-10,TERMINATED,INTERVENTIONAL,['PHASE1']
10605,NCT03361709,Mean change in corneal endothelial cell density before and after phacoemulsification,Intraocular pressure,,2018-01-01,WITHDRAWN,INTERVENTIONAL,['PHASE4']
10606,NCT01589445,Comparison of Changes in Fasting Serum Insulin (FSI)With Pioglitazone and Metformin,Comparison of Changes in Lipid Profiles With Pioglitazone and Metformin,,2008-11,COMPLETED,INTERVENTIONAL,['PHASE4']
10607,NCT04791449,wound healing time,,,2021-10-10,RECRUITING,INTERVENTIONAL,['NA']
10608,NCT04238494,Fat involution and trophicity in rectus femoris,measure the serum interleukin IL-1b and IL-18 rate,,2019-10-18,UNKNOWN,INTERVENTIONAL,['NA']
10609,NCT05254535,Proportion of Patients Who Complete Annual Diabetic Eye Screening,Mean Implementation Cost,,2023-03-28,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
10610,NCT00676260,Capillary filtration capacity.,Vascular Endothelium Growth Factor.,,2002-12,COMPLETED,INTERVENTIONAL,['PHASE2']
10611,NCT01089192,,,,na,COMPLETED,INTERVENTIONAL,['PHASE1']
10612,NCT00787306,mean systolic blood pressure,Proportion of adults with 3 cardiovascular risk factors under optimal control,,2008-10,COMPLETED,INTERVENTIONAL,['PHASE3']
10613,NCT05585502,Muscle and tendon stiffness differences between T2D patients and controls,Correlation between tissue glycation indicators (RAGE) and muscle-tendon stiffness in T2D patients and controls,,2022-12-10,RECRUITING,INTERVENTIONAL,['NA']
10614,NCT01474317,Percent of Self-Test Fingerstick Blood Glucose Results Within +/- 5to15mg/dL (<100mg/dL) or Within +/- 5to15% (>=100mg/dL) of Laboratory Glucose Method,Number of Subjects Able to Perform Given Tasks Using Product Labeling for Instruction,,2011-11,COMPLETED,INTERVENTIONAL,['NA']
10615,NCT06127823,Percentage of insulin-treated,Admission to neonatal intensive care unit (NICU),Total net costs,2024-01-03,RECRUITING,INTERVENTIONAL,['NA']
10616,NCT01512030,What is the long term development of diabetic neuropathy? Is there a significant deterioration or improvement in nerve conduction during the follow up period?,Nephropathy,,2011-12,COMPLETED,OBSERVATIONAL,['NA']
10617,NCT01161030,,,,2008-08,COMPLETED,INTERVENTIONAL,['NA']
10618,NCT03651180,"Incidence of the composite endpoint of cardiac death, definite and probable stent thrombosis, re-PCI, Target Vessel Revascularization and bleeding in the two groups of study","Incidence of every single adverse event (cardiac death, definite and probable stent thrombosis, re-PCI, Target Vessel Revascularization and bleeding) in the two groups of study",,2018-08-01,UNKNOWN,OBSERVATIONAL,['NA']
10619,NCT01030952,Change in Area Under Curve of 0-4 Hours Postprandial Glucose (AUCpp0-4hours) in Standardized Meal Test Using Continuous Glucose Monitoring System (CGMS),Change in Percent of 24 Hour Hyperglycemic Measurements,,2009-12,COMPLETED,INTERVENTIONAL,['PHASE4']
10620,NCT02398383,Glucagon levels,Glucagon levels,,2015-03,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
10621,NCT03167918,Changes in pulmonary function parameters,"Changes in glycosylated hemoglobinA1c, fasting plasma glucose, 2-hour postprandial blood glucose,",Changes in retrobulbar hemodynamics (RI),2014-07-21,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
10622,NCT02794792,Change from baseline in HbA1c with ipragliflozin once daily added on to metformin compared to placebo added on to metformin,Percentage of patients with AEs of special interest,,2016-05-11,COMPLETED,INTERVENTIONAL,['PHASE3']
10623,NCT00605007,The primary outcome of the study is to determine the mortality rate of COPD patients with corticosteroid-induce hyperglycemia.,,,2006-02,COMPLETED,OBSERVATIONAL,['NA']
10624,NCT01183468,C-peptide 2-hour AUC in Response to a Mixed-meal Tolerance Test at Week 52,,,2010-10,TERMINATED,INTERVENTIONAL,['PHASE1']
10625,NCT05936151,Change from Baseline in Glomerular Filtration Rate (GFR),Change from Baseline in Change in 24-hour (hr) Urinary Electrolytes (milligrams/24hr (mg/24h)),,2023-07-20,RECRUITING,INTERVENTIONAL,['PHASE2']
10626,NCT03753997,Change in HbA1c from baseline to 52 weeks follow-up,score of Diabetes Treatment satisfaction questionnaire - change (DTSQc) at week 52,Change in systolic and diastolic blood pressure from baseline to week 52,2019-01-01,RECRUITING,INTERVENTIONAL,['NA']
10627,NCT00671346,Possible effects of B-vitamin treatment on risk of developing cancer during the trial periods (completed by 2004 and 2005) and during post-trial follow-up.,"The possible effects of B-vitamin treatment on major cardiovascular events, all cause mortality and cause specific death during the trial periods (completed by 2004 and 2005) and during post-trial follow-up.",,1998-12,UNKNOWN,OBSERVATIONAL,['NA']
10628,NCT05318326,HbA1c change from baseline at week 24,Fasting lipids From Baseline at Week 24 and Week 52,,2022-01-01,RECRUITING,INTERVENTIONAL,['PHASE3']
10629,NCT05514535,Change in Glycated Haemoglobin (HbA1c),Change in Score of Short Form 36 Version 2 (SF-36 v2),,2022-08-29,RECRUITING,INTERVENTIONAL,['PHASE3']
10630,NCT04154904,Comparison of the Mean Relative Difference When Including Patterns in Hypoglycemia Prediction.,,,2020-08-11,COMPLETED,INTERVENTIONAL,['NA']
10631,NCT04313829,Measurement of Quality of Life (QoL) using the Euro Quality of Life 5 Dimension 5 Level (EQ-5D-5L) questionnaire,Measurement of HbA1c,,2017-08-01,COMPLETED,INTERVENTIONAL,['NA']
10632,NCT06174779,The proportion of subjects achieving body weight loss ≥ 5% from baseline,Change of IWQoL-Lite-CT(Physical function domain) from baseline,,2023-12-19,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
10633,NCT02953262,Any My HealtheVet Patient Portal Use,Use of Secure Messaging,,2019-07-22,COMPLETED,INTERVENTIONAL,['NA']
10634,NCT01984606,The change from baseline in HbA1c after 52 weeks of treatment.,The change in Diastolic Blood Pressure (DBP) from baseline after 52 weeks of treatment,,2015-01,WITHDRAWN,INTERVENTIONAL,['PHASE3']
10635,NCT01693302,Blood glucose area under the curve,Glucose values two hours after the beginning of the meal,,2007-08,COMPLETED,INTERVENTIONAL,['NA']
10636,NCT05389566,Co-existence of peripheral neuropathy and impaired dynamic postural control in people with diabetes,The impact of peripheral neuropathy on postural control (In quite stance),Muscle strength and peripheral neuropathy,2022-05-06,RECRUITING,OBSERVATIONAL,['NA']
10637,NCT03953963,Lack of serious adverse events (SAEs),Reduction in body weight,,2019-10-18,UNKNOWN,INTERVENTIONAL,['NA']
10638,NCT00126126,Amputee Mobility Predictor,Six-minute Walk Test,,2005-01,COMPLETED,INTERVENTIONAL,['NA']
10639,NCT05455242,Change in Behavior Automaticity,,,2021-01-16,COMPLETED,INTERVENTIONAL,['NA']
10640,NCT04732780,Hypoglycaemia Fear Survey 2 - Worry Subscale,,,2021-03-02,COMPLETED,OBSERVATIONAL,['NA']
10641,NCT05780905,bloodbrain barrier Ktrans,Inflammatory markers,,2023-04-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
10642,NCT02302612,Composite CVD Goal,Patient Activation Measure (PAM) - 13 items,,2015-01,COMPLETED,INTERVENTIONAL,['NA']
10643,NCT00135226,Number of Participants With First Occurrence of Any Major Bleed (Aspirin Comparison Only),Number of Participants With Any Incident Gastrointestinal (GI) Tract Cancer (Aspirin Comparison Only),Number of Participants With Event: Other Arrhythmia (Omega-3 Comparison Only),2005-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4']
10644,NCT00067951,Hemoglobin A1c (HbA1c) reduction after 24 weeks of treatment.,"Change in FPG, insulin,C-peptide, insulin sensitivity,beta cell function, free fatty acids, lipids. Change in weight, vital signs, clinical laboratory tests, and adverse experiences.",,2003-10-17,COMPLETED,INTERVENTIONAL,['PHASE3']
10645,NCT00744926,Absolute change from baseline in HbA1c,"Responder rates for HbA1c (target <=7.0%, <=6.5%); relative change in glucose, insulin, C-peptide and glucagon during a meal tolerance test; beta cell function.",,2008-08,COMPLETED,INTERVENTIONAL,['PHASE3']
10646,NCT00763451,Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24,Percentage of Patients Requiring Rescue Therapy During Main 24-Week Period,Number of Patients With Symptomatic Hypoglycemia and Severe Symptomatic Hypoglycemia,2008-09,COMPLETED,INTERVENTIONAL,['PHASE3']
10647,NCT04421755,Cooking skills,,,2019-07-16,COMPLETED,INTERVENTIONAL,['NA']
10648,NCT04725591,"The primary outcome is the time spent of the glucose level in the widened target range 3.9-10.0 mmol/L over the 2 last weeks of each cross-over period, as recorded by continuous subcutaneous glucose monitoring (CGM).",• Scoring of a questionnaire to evaluate the acceptance,,2023-01-19,RECRUITING,INTERVENTIONAL,['NA']
10649,NCT04682457,Change in C-peptide over a year,Change in dried blood spot C-peptide,,2019-11-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
10650,NCT04653532,The number and percentage of participants retained at 12-months.,Patient rapport with counsellor,Determine healthcare usage,2021-02-01,UNKNOWN,INTERVENTIONAL,['NA']
10651,NCT00682240,Retinal morphological changes with time secondary to laser treatment as assessed with optical coherence tomography (OCT).,"changes in retinal function as an effect of treatment, documented by visual acuity testing and microperimetry. The change in vascular leakage will be assessed by performing fluorescein angiography, flare counts will be performed monthly.",,2007-10,COMPLETED,INTERVENTIONAL,['PHASE4']
10652,NCT00857623,Change in Mean Numerical Rating Scale (NRS) Score From Baseline to Last 5 Days of Treatment,Change in Brief Pain Inventory-Short Form (BPI-SF) Pain Interference From Baseline to Day 28.,,2009-02,COMPLETED,INTERVENTIONAL,['PHASE2']
10653,NCT03130699,Systolic blood pressure (SBP); mmHg units,Adherence to Refills and Medications Scale (ARMS) - patient-reported outcome,Pay for Performance (P4P) Clinical Metrics,2017-06-22,COMPLETED,INTERVENTIONAL,['NA']
10654,NCT00594152,Rate of loss of creatinine clearance,Change in cardiac function,,1993-01,COMPLETED,INTERVENTIONAL,['PHASE3']
10655,NCT00242645,To test the effect of receiving computer tailored information about diabetes care before doctor visits and the differential effect of varying types of information,"Patient exit interviews after doctor visits about what happened during the visits, such as what was discussed, what tests and consults were ordered and what medications were added or changed.",,2004-06,TERMINATED,INTERVENTIONAL,['PHASE1']
10656,NCT04411342,Prevalence of Normoalbuminuric chronic kidney disease,,,2020-12-01,UNKNOWN,OBSERVATIONAL,['NA']
10657,NCT02506647,Pharmacokinetic effects,Safety assessment as measured by incidence and severity of adverse events,,2015-12,COMPLETED,INTERVENTIONAL,['PHASE1']
10658,NCT03802942,Total number of patients with at least 1 documented low (equal or below 70 mg/dL) glucose levels,30-day readmission rate,,2019-07-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
10659,NCT03908281,Liver fat (%),Continuous glucose monitoring,,2019-09-01,COMPLETED,INTERVENTIONAL,['NA']
10660,NCT03623113,Change in mean amplitude of glycaemic excursions (MAGE),Change in intake of dietary fibre,Change in urinary biomarkers of carbohydrate intake,2018-09-28,COMPLETED,INTERVENTIONAL,['NA']
10661,NCT03077893,Quantitative Sensory Testing (QST),Nerve Conduction Velocity (NCV) - Amplitude,,2017-03-09,COMPLETED,INTERVENTIONAL,['NA']
10662,NCT05456347,Visceral fat mass change.,Triglycerides change.,TNF-alpha change.,2021-07-01,COMPLETED,INTERVENTIONAL,['NA']
10663,NCT05098301,evaluate the performances of an insulin titration algorithm,measure time-in-range evolution adjustment of insulin therapy parameters,,2021-11-30,COMPLETED,OBSERVATIONAL,['NA']
10664,NCT02002143,Patients' control (decreased levels) of HemoglobinA1C (clinical),Patient Self-Management,,2014-01,UNKNOWN,INTERVENTIONAL,['NA']
10665,NCT00920725,Hours to achieve blood glucose less than 200mg/dl,,,2005-01,COMPLETED,INTERVENTIONAL,['NA']
10666,NCT02098980,Insulin Resistance,,,2014-05,UNKNOWN,INTERVENTIONAL,['NA']
10667,NCT05438251,Time to the ulcer grade down,Percentage of ulcer improvement,,2022-08-04,RECRUITING,INTERVENTIONAL,['PHASE4']
10668,NCT00451334,,,,na,UNKNOWN,OBSERVATIONAL,['NA']
10669,NCT00696163,Change in Quality of Life from baseline (using QoLD questionnaire),Efficacy,,2008-04,COMPLETED,OBSERVATIONAL,['NA']
10670,NCT01490918,The Change of Glycated Hemoglogin(HbA1c) From Baseline to 16 Weeks of Treatment,"Changes in Glucagon During Meal Tolerance Test Between 2 Group(Group 1 vs Group 2),","Changes in MAGE of Glucose During CGMS Between 2 Group(Group 1 vs Group 2),",2012-04,COMPLETED,INTERVENTIONAL,['PHASE4']
10671,NCT04168541,Area under the blood glucose curve (ACU 0-240 minutes),Insulinogenic index [Change in Ins30/Change in Glu30],,2018-02-05,COMPLETED,INTERVENTIONAL,['NA']
10672,NCT04743453,"Evaluate the mean ΔmGFR, between baseline and one year after randomization.",,,2021-08-17,UNKNOWN,INTERVENTIONAL,['PHASE4']
10673,NCT04552470,Number of Participants With Absolute Electrocardiogram (ECG) Values and Increased ECG Values From Time-Matched Baseline,Terminal Phase Half-Life (t1/2) of PF-06882961,,2020-10-26,COMPLETED,INTERVENTIONAL,['PHASE1']
10674,NCT03146845,Change in the Cardiff Wound Impact Schedule-Physical Symptoms of Daily Living (CWIS-PSDL) Scale Score From Baseline to the Week 6 Visit,Healthcare Resource Use - Number of Dressing Changes Required for Each Type of Wound Debridement,,2017-06-15,COMPLETED,INTERVENTIONAL,['NA']
10675,NCT03711682,Change in HbA1c,Change in Systolic Pressure,Change in Theoretical HbA1c,2018-03-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
10676,NCT02262208,Glycemic variability by continuous glucose monitoring system,Oxidative stress,,2014-01,UNKNOWN,INTERVENTIONAL,['NA']
10677,NCT03848637,Area under the plasma concentration of Metformin-time curve from time zero to time of last measurable concentration,Apparent volume of distribution of Metformin,,2019-04-14,UNKNOWN,INTERVENTIONAL,['PHASE1']
10678,NCT04285710,Bacterial Quantification Over Time,Subject Phototherapy Treatment Satisfaction: questionnaire,,2021-06,WITHDRAWN,INTERVENTIONAL,['NA']
10679,NCT03377244,Mean Percent Body Weight (Pounds) Change,Change in Perceived Family Support for Exercise and Dietary Habits,,2018-09-30,COMPLETED,INTERVENTIONAL,['NA']
10680,NCT04666818,MODD= Adimensional coefficient calculated as mean of the daily serum glucose difference.,Cesarean section,,2020-11-26,COMPLETED,OBSERVATIONAL,['NA']
10681,NCT03125772,Composite safety endpoint of Target Vessel Failure (TVF) rate at 12 months post-index procedure: • Cardiac Death related to target vessel • Target Vessel Myocardial Infarction (TV-MI) • Target Vessel Revascularization (TVR),Stent Thrombosis Rate,Procedural complication rate,2011-06,COMPLETED,INTERVENTIONAL,['NA']
10682,NCT02105103,The primary objective is to evaluate the Accu-Chek Insight Insulin Pump and associated pump devices in routine practice. This will be expressed by the rate of error messages per 100 patient years (confirmed by pump uploads).,"Evaluate type and frequency of pump signals, i.e. reminders, errors, warnings, alarms, maintenance messages",,2013-10,COMPLETED,INTERVENTIONAL,['NA']
10683,NCT03827382,metabolic control,Quality of life by SF-36 Questionnaire,,2019-02-01,RECRUITING,INTERVENTIONAL,['NA']
10684,NCT04258293,Platelet Count,,,2020-02-06,RECRUITING,OBSERVATIONAL,['NA']
10685,NCT01554631,Ratio of postprandial Area under curve from 0 to 4 hours (AUC(0-4)) of blood glucose following sucrose load with Glucobay (Day 1) and without Glucobay (Day 0),Safety parameters,,2012-03,COMPLETED,INTERVENTIONAL,['PHASE1']
10686,NCT00006163,,,,1997-09,COMPLETED,INTERVENTIONAL,['PHASE4']
10687,NCT01135433,Change from baseline in HbA1c,"Safety as reflected by adverse events, routine safety laboratories, vital signs, physical examinations and 12-lead electrocardiograms (ECGs)",,2010-05-15,COMPLETED,INTERVENTIONAL,['PHASE3']
10688,NCT01766362,Macular thickness,,,2011-10,COMPLETED,INTERVENTIONAL,['PHASE3']
10689,NCT01011868,Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) After 18 Weeks of Treatment,"The Occurrence of Treat to Target Efficacy Response, That is an HbA1c Under Treatment of <7.0% After 18, 54, and 78 Weeks of Treatment",Confirmed Hypoglycemic Events,2009-11,COMPLETED,INTERVENTIONAL,['PHASE2']
10690,NCT04591626,Change From Baseline in Hemoglobin A1c (HbA1c),Change From Baseline in Daily Mean Insulin Glargine Doses,,2020-12-07,COMPLETED,INTERVENTIONAL,['PHASE3']
10691,NCT02029989,Metabolic Syndrome (MetS),,,2010-02,COMPLETED,INTERVENTIONAL,['NA']
10692,NCT03305822,Pharmacokinetics (PK): Insulin Lispro Area Under the Plasma Concentration Curve Zero to 10 Hours (AUC[0-10) Following Each Treatment Arm,Pharmacodynamics (PD): Total Amount of Glucose Infused (Gtot) Over Duration of Clamp for Each Treatment Arm,,2017-10-11,COMPLETED,INTERVENTIONAL,['PHASE1']
10693,NCT01569243,physical activity,Engagement to program,,2012-06,COMPLETED,INTERVENTIONAL,['PHASE2']
10694,NCT01364337,blood pressure,"Urinary magnesium, potassium, sodium and creatinine",,2010-11,UNKNOWN,INTERVENTIONAL,['NA']
10695,NCT00481663,Number of participants Who Discontinued Study Treatment Due to An AE up to Week 158,Change From Baseline in Daily Seven-Point Fingerstick Glucose Average at Week 52,,2003-08-19,COMPLETED,INTERVENTIONAL,['PHASE2']
10696,NCT01510847,The Effect of 90-day Oral Testosterone Therapy in Chinese Males with Type 2 Diabetes (T2DM): OTeST,The Effect of 90-day Oral Testosterone Therapy in Chinese Males with Type 2 Diabetes (T2DM): OTeST,,2011-10,TERMINATED,INTERVENTIONAL,['PHASE4']
10697,NCT00607646,Change in level of catecholamines in blood from baseline,,,2010-10,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
10698,NCT00455858,Change in Glycosylated Haemoglobin A1c (HbA1c) at Week 20,Occurence of Hypoglycaemic Episodes,,2007-11,COMPLETED,INTERVENTIONAL,['PHASE4']
10699,NCT01645696,Number of participants with adverse events,antibodies against the glucose binding protein,,2012-06,COMPLETED,INTERVENTIONAL,['NA']
10700,NCT03952000,Endothelial function changes in response to exercise and feeding,Superoxide dismutase 3,,2019-01-03,COMPLETED,INTERVENTIONAL,['NA']
10701,NCT00320086,"Number of Subjects With Normal Urinary Protein Excretion in Healthy and Diabetic Children, Assessed Over 1 Day.",,,2005-08,COMPLETED,OBSERVATIONAL,['NA']
10702,NCT00763347,Change from baseline in glycosylated hemoglobin.,Clinical laboratory evaluation (urinalysis).,,2006-11,TERMINATED,INTERVENTIONAL,['PHASE2']
10703,NCT05101330,Assessing PML understanding at Week 2. (Pilot Trial B),,,2021-11-01,WITHDRAWN,INTERVENTIONAL,['NA']
10704,NCT06141434,Islet autoimmunity in the offspring,,,2022-12-01,RECRUITING,OBSERVATIONAL,['NA']
10705,NCT04484883,Resting Energy Expenditure (REE),,,2019-06-01,COMPLETED,OBSERVATIONAL,['NA']
10706,NCT02009878,Time of Maximal Increase From Baseline in Serum Sodium Concentration Following Tolvaptan Administration.,"Change From Baseline in Cumulative Urine Volume at 0-6 Hours, 0-12 Hours and 0-24 Hours.",,2013-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10707,NCT03182296,Pancreatic uptake of 68Ga-NODAGA-exendin-4,"C-peptide, HbA1c",,2016-11-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
10708,NCT02612805,Changes in levels of glycated hemoglobin,"Physical activity levels, evaluated by International Physical Activity Questionnaire (IPAQ) - Short Form.",,2015-11,COMPLETED,INTERVENTIONAL,['NA']
10709,NCT01294553,Number of Participants With an Adverse Event,Number of Participants With the Indicated Unexpected Adverse Events,,2004-06,COMPLETED,OBSERVATIONAL,['NA']
10710,NCT04341935,Changes in Glucose Llevels,Changes in chest structures,,2021-06-30,WITHDRAWN,INTERVENTIONAL,['PHASE4']
10711,NCT02695173,Incidence of urinary tract infections (UTI) complications,Incidence of pyelonephritis,,2017-01-01,COMPLETED,OBSERVATIONAL,['NA']
10712,NCT03607201,Mortality,,TIMI Score,2017-08-01,COMPLETED,OBSERVATIONAL,['NA']
10713,NCT01515657,Time to 99% Inhibition of Serum Thromboxane (TxB2),,,2012-01,COMPLETED,INTERVENTIONAL,['PHASE3']
10714,NCT02384018,C-peptide level after mixed meal tolerance test,The absence of severe hypoglycemic episodes,,2014-12,COMPLETED,INTERVENTIONAL,['PHASE1']
10715,NCT01678742,Difference in the incremental area under the curve (iAUC) for peptide YY (PYY) after food ingestion between high-protein and standard diet groups,Difference in the iAUC for glucose-dependent insulinotropic polypeptide (GIP) after food ingestion between high-protein and standard diet groups,Difference in the iAUC for glucagon after food ingestion between high-protein and standard diet groups,2012-08,COMPLETED,INTERVENTIONAL,['NA']
10716,NCT01055951,Device-related adverse outcome,Mechanical dysfunction and diabetes-related adverse outcome,,2009-05,COMPLETED,INTERVENTIONAL,['PHASE1']
10717,NCT03990857,Change is being assessed in Weigh,Use of services in the last year,,2019-09-01,UNKNOWN,INTERVENTIONAL,['NA']
10718,NCT01813305,Number of Participants With Complete Ulcer Closure During the Treatment Period,Percentage Change in Ulcer Size for Each Post-treatment Visit,Respiratory Rate Change From Baseline to Week 24,2014-07-09,COMPLETED,INTERVENTIONAL,['PHASE2']
10719,NCT03172494,Change in HbA1c,Plasma Concentration of Liraglutide,,2017-05-26,COMPLETED,INTERVENTIONAL,['PHASE3']
10720,NCT04479826,Time in ranges,,,2020-07-16,COMPLETED,INTERVENTIONAL,['NA']
10721,NCT03084965,Change in HbA1c,,,2017-05-12,COMPLETED,OBSERVATIONAL,['NA']
10722,NCT00676338,Percentage of Patients Achieving HbA1c <=7% at Week 26,Change in Diastolic Blood Pressure From Baseline to Week 26.,,2008-11,COMPLETED,INTERVENTIONAL,['PHASE3']
10723,NCT00887445,"Safety and tolerability parameters: adverse event, vital signs, 12-Lead ECG, continuous lead II ECG monitoring, laboratory safety variables and physical examination.",Interaction with Midazolam,,2008-07,TERMINATED,INTERVENTIONAL,['PHASE1']
10724,NCT01630759,Management decision comparison,Number of downloads missed,,2012-01,COMPLETED,INTERVENTIONAL,['NA']
10725,NCT05172947,Serum neopterin levels,"Measurement of serum level of LDL, cholesterol, HDL, Triglyceride",,2021-12-05,COMPLETED,INTERVENTIONAL,['NA']
10726,NCT01806506,Excess Weight Loss From Baseline,LDH Level,Pulmonary Function Changes at 12 Months,2008-11,COMPLETED,INTERVENTIONAL,['NA']
10727,NCT01862029,Change in Insulin Sensitivity - Post-roflumilast,,,2013-05-22,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10728,NCT00311324,Mean Hemoglobin A1c,Median number of minutes per day engaged in physical activity,,2001-02,COMPLETED,INTERVENTIONAL,['NA']
10729,NCT04143269,Subjective gastrointestinal symptoms,Nerve conduction study - amplitudes,,2020-01-20,COMPLETED,INTERVENTIONAL,['NA']
10730,NCT03944200,Maximum plasmaconcentration of drug in plasma(Cmax),Terminal elimination half-life(t1/2),,2019-02-07,COMPLETED,INTERVENTIONAL,['PHASE1']
10731,NCT02527525,glycemic variability,,,2016-04,COMPLETED,INTERVENTIONAL,['NA']
10732,NCT00313183,To assess the safety and tolerability of Symlin in adolescent subjects with type 1 diabetes,To evaluate the effects of Symlin compared to placebo in adolescent subjects with type 1 diabetes on various pharmacodynamic endpoints,,2006-04,COMPLETED,INTERVENTIONAL,['PHASE2']
10733,NCT02827890,"Css,max of Sitagliptin","swing[(Css,max-Css,min)/Css,min] of Sitagliptin",,2016-04,COMPLETED,INTERVENTIONAL,['PHASE1']
10734,NCT05866900,Coefficient of variation (%),Height Z-score,,2023-05-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
10735,NCT01835379,Percentage of Wounds Closed,Time to Wound Closure,,2013-05,COMPLETED,INTERVENTIONAL,['PHASE4']
10736,NCT00541372,"Preference of the patient and amount of experienced hypoglycaemic events, bruises, backflow of insulin, bleeding and pain (VAS-scale)","HbA1c levels 1,5 anhydroglucitol and fructosamine levels Insulin dose",,2007-09,COMPLETED,INTERVENTIONAL,['PHASE4']
10737,NCT01954771,Evaluation of Peak and Nadir Glucose Profiles From Continuous Glucose Monitoring System (CGMS),HbA1c(%) at Endpoint,,2013-06,COMPLETED,INTERVENTIONAL,['NA']
10738,NCT01354977,Peripheral Insulin Sensitivity (RD) Measured by the Change in Glucose Rates of Disappearance With Resveratrol or Placebo at Baseline and at 4 Weeks.,Muscle Mitochondrial Area,,2008-03,COMPLETED,INTERVENTIONAL,['PHASE2']
10739,NCT05418465,Rate of change in Estimated Glomerular Filtration Rate (eGFR) compared to baseline,Change in 24-hour urine protein ration from baseline.,Incidence of adverse reactions,2022-01-26,RECRUITING,INTERVENTIONAL,['NA']
10740,NCT05000463,Pain Assessment,,,2022-02-25,UNKNOWN,INTERVENTIONAL,['NA']
10741,NCT00309244,Change From Baseline in HbA1c to Week 52,Severe Hypoglycemia Event Rate,,2006-02,COMPLETED,INTERVENTIONAL,['PHASE3']
10742,NCT04154046,New ulcers incurred,Incidence of new ulcers on feet,,2019-11-01,COMPLETED,INTERVENTIONAL,['NA']
10743,NCT01296516,Incidence of glucose intolerance,Weight loss,,2011-02,COMPLETED,INTERVENTIONAL,['NA']
10744,NCT06255288,Procedural uncertainties - Number of patients willing to participate.,Drop out rates,,2024-01-23,RECRUITING,INTERVENTIONAL,['NA']
10745,NCT04464213,Rate of adverse event,Rate of cure rate,,2020-11-01,UNKNOWN,INTERVENTIONAL,['PHASE1']
10746,NCT05035849,Glycemic variations,Glycemic variations,,2020-01-30,COMPLETED,INTERVENTIONAL,['NA']
10747,NCT01527565,"Cmax, maximum insulin aspart concentration",Adverse events,,2003-01-20,COMPLETED,INTERVENTIONAL,['PHASE1']
10748,NCT02148991,Blood pressure measurement,Quality of Life questionnaire rating,Treatment compliance questionnaire rating,2014-07,COMPLETED,OBSERVATIONAL,['NA']
10749,NCT02814123,Percentage of time of plasma glucose levels spent in target range. Target range is defined to be between 3.9 and 10.0 mmol/L of regular insulin-plus-pramlintide closed-loop delivery vs. fast-acting insulin-alone closed-loop delivery.,"Gastrointestinal symptoms during the treatment optimization (i.e., the minimum 10 days prior to the 24-hour closed-loop visits) and during the 24-hour closed-loop visits.",,2017-01-13,COMPLETED,INTERVENTIONAL,['PHASE2']
10750,NCT00860288,To evaluate the efficacy of vildagliptin as add-on therapy to metformin in patients with T2DM by assessing changes in HbA1c with vildagliptin added to metformin to that of placebo added to metformin after 24 weeks of treatment,To evaluate the long-term efficacy of vildagliptin compared to sitagliptin over the entire study duration as add-on therapy to metformin in patients with T2DM.,,2009-02,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
10751,NCT02906579,Change From Time-Matched Baseline (Placebo Cycle) in Platelet Function Assessments: Collagen/Epinephrine Time to Aggregation,,,2016-09,COMPLETED,INTERVENTIONAL,['PHASE2']
10752,NCT05227196,"Cmax,0-24h.semaglutide,SS Maximum semaglutide plasma concentration at steady state","Ctau,24h,semaglutide,SS Semaglutide plasma concentration 24 hours after last dose at steady state",,2022-02-04,COMPLETED,INTERVENTIONAL,['PHASE1']
10753,NCT00644501,"Preservation of endogenous insulin secretion/beta-cell function, as measured by mixed-meal tolerance test stimulated C-peptide secretion.",improved metabolic control and the insulin dose required to maintain it.,,2008-09,COMPLETED,INTERVENTIONAL,['PHASE3']
10754,NCT02600091,Recruitment/Retention Rates,Acceptability,,2015-10-30,COMPLETED,INTERVENTIONAL,['NA']
10755,NCT01900834,Variation in CD8 (cluster of differentiation) +T-cell specificity profiling,Variation in HbA1c (glycosylated haemoglobin),,2013-07,COMPLETED,OBSERVATIONAL,['NA']
10756,NCT02262611,Change in diastolic blood pressure,Global assessment of tolerability by investigator on a 4-point scale,,2003-01,COMPLETED,OBSERVATIONAL,['NA']
10757,NCT02033889,Percentage of Participants Discontinuing Study Treatment Due to an AE (Including Rescue Approach),Percent Change From Baseline in Bone Biomarker PTH at Week 104 (Excluding Bone Rescue Approach),,2013-12-13,COMPLETED,INTERVENTIONAL,['PHASE3']
10758,NCT02088294,Change in Physical activity,Change in Dietary intake,Change in Intuitive eating,2014-05,COMPLETED,INTERVENTIONAL,['NA']
10759,NCT01296438,Area under the serum insulin aspart concentration-time curve,Area under the serum insulin aspart concentration-time curve,,2011-02,COMPLETED,INTERVENTIONAL,['PHASE1']
10760,NCT03214380,Change From Baseline in Hemoglobin A1c (HbA1c) Efficacy Estimand at Week 26,Number of Participants With HbA1c <7%,,2017-07-14,COMPLETED,INTERVENTIONAL,['PHASE3']
10761,NCT00351832,Change from baseline on HbA1c at 12 weeks,Change from baseline on fasting lipids at 12 weeks,,2006-06,COMPLETED,INTERVENTIONAL,['PHASE3']
10762,NCT03764631,Number of Participants With Dehydration,Number of Participants With Dehydration During Ramadan Periods,,2018-09-26,COMPLETED,OBSERVATIONAL,['NA']
10763,NCT01581099,Improvement in Metabolic Profile,,,2013-04,COMPLETED,OBSERVATIONAL,['NA']
10764,NCT01597154,Glycemic control determined by a standard fasting measure of glycosylated hemoglobin using internationally recognized DCCT assay,Cardiovascular structure and function,,2012-09,COMPLETED,INTERVENTIONAL,['NA']
10765,NCT01489163,postpartum body weight,postpartum glycemia,,2011-12,COMPLETED,INTERVENTIONAL,['NA']
10766,NCT02293837,Change From Baseline in 2-Hour C-peptide Mean Area Under the Curve (mAUC) in Pediatric Participants,Number of Participants Who Experienced Hypersensitivity Adverse Events,,2015-03-12,COMPLETED,INTERVENTIONAL,['PHASE2']
10767,NCT03808090,Urinary oxalate excretion,,,2013-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
10768,NCT02076568,Change from baseline in diabetes-specific empowerment on the adapted Diabetes Empowerment Scale at the 2-week and 6-month follow-up,Change from baseline in depressive symptoms on the CES-D at the 2-week and 6-month follow-up,,2014-02,COMPLETED,INTERVENTIONAL,['NA']
10769,NCT00562250,Maximum plasma concentration and exposure to glimepiride and dapagliflozin when administered alone and administered together,Recorded adverse events,,2008-05,COMPLETED,INTERVENTIONAL,['PHASE1']
10770,NCT01733901,All-cause mortality,Medication adherence,,2012-11,UNKNOWN,INTERVENTIONAL,['NA']
10771,NCT00401622,Change in A1C From Baseline to Week 52 Between the OneTouch® Ultra®2 and Control BGMS.,Change in Daily Glycemic Excursions Between the OneTouch® Ultra®2 and Control BGMS.,,2006-10-01,COMPLETED,INTERVENTIONAL,['NA']
10772,NCT02735837,Periodontal pocket,glycated hemoglobin (HbA1c),,2015-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
10773,NCT03370237,Diabetic foot ulcer risk score,Raters' level of confidence,,2017-07-01,COMPLETED,OBSERVATIONAL,['NA']
10774,NCT05343065,The percentage of time a participant's glucose value is between 70 and 180 mg/dL will not be inferior to baseline.,,,2022-07-05,COMPLETED,INTERVENTIONAL,['NA']
10775,NCT04564443,Proportion of wounds completely healed at or before 16 weeks,Kent Imaging - Snapshot camera,,2020-09-11,RECRUITING,INTERVENTIONAL,['NA']
10776,NCT03251846,HbA1c,Hypoglycemia,,2017-07-17,UNKNOWN,INTERVENTIONAL,['NA']
10777,NCT05275608,Change in metabolic control,Change in inflammatory status,,2022-11-07,RECRUITING,INTERVENTIONAL,['NA']
10778,NCT00006505,Insulin independence,change in lipid profiles,,2000-11-16,COMPLETED,INTERVENTIONAL,['PHASE2']
10779,NCT01364402,Incidence of Contrast Induced Nephropathy(CIN),Hospital mortality,,2011-08,UNKNOWN,INTERVENTIONAL,['PHASE3']
10780,NCT01889667,Evaluate the Safety and Tolerability of ORMD-0801.,The Effect of ORMD-0801 on Morning Fasting C-peptide Compared to Placebo,,2013-06,COMPLETED,INTERVENTIONAL,['PHASE2']
10781,NCT02077218,"Feasibility, defined by the percentage of patients that enroll onto the study, successful completion of all study measurements, ability of studies to be interpreted, and achievement of the recruitment goal",,Expression of Lp-PLA2,2014-02,COMPLETED,INTERVENTIONAL,['NA']
10782,NCT03525899,Time to macular hole closure,Best corrected visual acuity,,2017-11-01,COMPLETED,OBSERVATIONAL,['NA']
10783,NCT03808311,Major cardiovascular events,Kidney outcomes,Cost-effectiveness,2019-02-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
10784,NCT04794907,Risk Stratification,,,2022-12-31,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
10785,NCT03685357,"RBDSQ (""Rapid eye movement Sleep"" Behavior Disorder Screening Questionnaire)",,,2018-07-01,UNKNOWN,OBSERVATIONAL,['NA']
10786,NCT04178603,Muscle glucose uptake during exercise and enhanced insulin sensitivity in recovery from exercise.,Posttranslational modification of proteins in muscle biopsies.,Changes in gene-expression in muscle as a result of exercise and during subsequent insulin stimulation.,2018-07-05,COMPLETED,INTERVENTIONAL,['NA']
10787,NCT00643474,Change from baseline in HbAlc level; percentage of subjects reaching or maintaining the risk target (represented by a combination of LBGI<=2.5 together with HBGI<=5).,"Changes in HBGI & LBGI; blood glucose test frequency, blood glucose profile, diabetes therapy, urinary 8-isoPGF2alpha, blood pressure, creatinine clearance, lipid profile & BMI; QoL & Locus of Control analysis; hypoglycemic episodes; study-related SAEs.",,2008-03,COMPLETED,INTERVENTIONAL,['NA']
10788,NCT01846533,Osteoprosis in type 2 diabetic patients- a cohort study,,,2013-05,UNKNOWN,OBSERVATIONAL,['NA']
10789,NCT01072331,"Change From Baseline in Plasma Glucose Area Under the Curve (AUC) 0 to 2h (Breakfast, Lunch and Dinner)",Change From Baseline in Fasting Plasma Glucose,,2010-02,COMPLETED,INTERVENTIONAL,['PHASE3']
10790,NCT05475431,The eradication rate by the per-protocol analysis,,,2020-05-06,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
10791,NCT00046267,,,,na,COMPLETED,INTERVENTIONAL,['NA']
10792,NCT03209466,Ulcerated area,,,2017-05-11,UNKNOWN,INTERVENTIONAL,['PHASE4']
10793,NCT00827710,Percent of patients with BP < 130/80,Percent of patients with BP checked in past year,,2007-12,COMPLETED,INTERVENTIONAL,['NA']
10794,NCT03970720,Change in Hypoglycemia Symptom Recognition,Ratio of Self-Reported Hypoglycemic Episodes to Total Hypoglycemic Episodes,,2019-05-28,RECRUITING,INTERVENTIONAL,['PHASE2']
10795,NCT05979519,Percentage Change in fasting blood glucose,Change in blood pressure,,2023-09-26,RECRUITING,INTERVENTIONAL,['NA']
10796,NCT02916563,Number of Successful Glucose Readings,,,2016-07,COMPLETED,INTERVENTIONAL,['NA']
10797,NCT03060538,Percentage of Participants with Adverse Events (AE),Change from Baseline in Percentage of Participants with Anti-Therapeutic Antibodies (ATAs),,2017-03-05,COMPLETED,INTERVENTIONAL,['PHASE1']
10798,NCT01203111,Change in HbA1c level for patients with addition of glulisine at week 12,"Hypoglycemia (asymptomatic, symptomatic, nocturnal symptomatic, severe and nocturnal severe)",,2010-12,COMPLETED,INTERVENTIONAL,['PHASE4']
10799,NCT04642261,Change in liver fat content,Changes of diastolic blood pressure,,2021-01-01,COMPLETED,INTERVENTIONAL,['PHASE4']
10800,NCT05429554,improve the neurodegeneration and cardiovascular effect in diabetic patients,,,2022-06,RECRUITING,OBSERVATIONAL,['NA']
10801,NCT01357148,Number of Participants Taking Concomitant Medications,,,2009-03,TERMINATED,OBSERVATIONAL,['NA']
10802,NCT02663388,"Evaluation of folate mediated one-carbon metabolic pathway parameters (Folates, Vitamin B12, Methionine, Homocysteine) on severe obesity-related complications before and after bariatric surgery",Evaluation of DNA Methylation on severe obesity-related complications before and after bariatric surgery,,2016-01,RECRUITING,OBSERVATIONAL,['NA']
10803,NCT01240200,Diabetes Treatment Satisfaction Questionnaire: Change (DTSQc) Score,Number of Hypoglycemic Events,,2011-01,COMPLETED,INTERVENTIONAL,['PHASE4']
10804,NCT04565756,The primary objective of the study is to evaluate the ocular safety and tolerability (by incidence of ocular adverse events) of EXN407 ophthalmic solution in Dose Expansion phase.,To evaluate the percentage (%) of changes in ocular structural measures as assessed using ophthalmoscopy.,,2020-11-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10805,NCT02115347,AUC From Hour 0 to Infinity (AUCinf) for Ertugliflozin,Number of Participants Who Experienced an Adverse Event,,2014-09-19,COMPLETED,INTERVENTIONAL,['PHASE1']
10806,NCT03446261,Change from baseline to week 8 in ApoB/ApoA1 ratio,Change from baseline to week 8 in FPG,,2018-02-23,COMPLETED,INTERVENTIONAL,['PHASE4']
10807,NCT03099928,Qualitative data,Change in optimism,,2015-03-01,COMPLETED,OBSERVATIONAL,['NA']
10808,NCT04406792,Participants with gestational diabetes that complete the recommended screening for Type 2 Diabetes Mellitus (T2DM),Participants with gestational diabetes who develop T2DM,,2024-01-31,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
10809,NCT01770964,change in pain severity rating,,,2012-12,UNKNOWN,INTERVENTIONAL,['PHASE4']
10810,NCT03670797,Oral mucosal alterations,Salivary glands function,,2018-12-25,COMPLETED,OBSERVATIONAL,['NA']
10811,NCT05393843,plasmatic glycated haemoglobin,therapy for diabetes,,2018-05-01,TERMINATED,INTERVENTIONAL,['PHASE4']
10812,NCT04100070,Impact on glycaemic control all along the study,Impact on glycaemic control upon age classes,,2019-09-02,UNKNOWN,INTERVENTIONAL,['NA']
10813,NCT05521256,Number of adverse events,"For i.v. cohort and oral cohort- AUC0-∞,6856,SD/dose: Area under the NNC0113-6856 plasma concentration-time curve from 0 to infinity after a single dose divided by the dose administered",,2022-08-26,COMPLETED,INTERVENTIONAL,['PHASE1']
10814,NCT01134458,Cardiovascular Disease (CVD) Risk Knowledge Assessment,,,2010-12,COMPLETED,INTERVENTIONAL,['NA']
10815,NCT03377335,Subclinical atherosclerosis,microRNAs,,2017-12-22,UNKNOWN,INTERVENTIONAL,['PHASE4']
10816,NCT00795704,Hemoglobin A1C,Change From Baseline in Self-Monitoring Blood Glucose (SMBG) Averages,,2008-04,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
10817,NCT00605137,Incidence of hypoglycaemic episodes,Insulin doses,,2004-05-21,COMPLETED,INTERVENTIONAL,['PHASE3']
10818,NCT05753124,Birth weight (in percentiles),Maternal and infant blood and urine samples,,2015-05,RECRUITING,OBSERVATIONAL,['NA']
10819,NCT00866801,Coronary flow reserve,Diabetic autonomic neuropathy,,2009-04,COMPLETED,OBSERVATIONAL,['NA']
10820,NCT03617081,Number of treatment emergent adverse events (TEAEs),"Cmax,SNAC,SD; the maximum plasma concentration of SNAC in plasma after a single dose of oral NNC0113-2023",,2018-08-09,COMPLETED,INTERVENTIONAL,['PHASE1']
10821,NCT03195140,Hypoglycemia < 70 mg/dL,High Blood Glucose Index (HBGI),,2017-08-11,COMPLETED,INTERVENTIONAL,['NA']
10822,NCT03437902,"Lipid profile in diabetic patients (TC,TG,HDL-c,LDL-c).",Quality of life of diabetic patients and this will be evaluated by using Quality of Life Questionnaire (Short Form 36 questions (SF-36)) .,,2018-02-24,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
10823,NCT01665716,OVADIA 2: Age at menopause,,,2011-07,COMPLETED,OBSERVATIONAL,['NA']
10824,NCT04214665,AUC0-t,(AUC0-inf - AUC0-t) / AUC0-inf,,2014-12-30,COMPLETED,INTERVENTIONAL,['PHASE1']
10825,NCT05176210,Incidence of dose-limiting toxicity (DLT) during the DLT observation period,Pharmacokinetics of PS1 - CL/F,,2023-12,RECRUITING,INTERVENTIONAL,['PHASE1']
10826,NCT01038102,Hepatic steatosis by MRT,Changes in adipose tissue gene expression and lipogenic enzyme activity,,2009-02,COMPLETED,INTERVENTIONAL,['NA']
10827,NCT00390962,,,,2006-11,COMPLETED,OBSERVATIONAL,['NA']
10828,NCT01865318,Area under the glucose infusion rate curve,Area under the serum insulin degludec curve,,2006-09,COMPLETED,INTERVENTIONAL,['PHASE1']
10829,NCT03211858,Change in Glycated Hemoglobin A1c (HbA1c) From Baseline to Week 26,"Percentage of Participants With Treatment-Induced, Treatment-Boosted and Treatment-Emergent Anti-insulin Aspart Antibodies (AIAs)","Change in Daily Insulin Dose From Baseline to Day 1, Week 26 and Week 52",2017-08-02,COMPLETED,INTERVENTIONAL,['PHASE3']
10830,NCT04943861,Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) scores,,,2023-11-14,RECRUITING,INTERVENTIONAL,['NA']
10831,NCT03005600,Development and validation of composite risk score for GDM with the risk factors of interest and/or point-of-care HbA1c,Identification and the impact of other novel risk factors on the diagnosis of GDM and other adverse maternal outcomes,,2016-02,UNKNOWN,OBSERVATIONAL,['NA']
10832,NCT02971618,HbA1c (glycosylated haemoglobin),change of systolic and diastolic blood pressure,,2017-02-21,COMPLETED,OBSERVATIONAL,['NA']
10833,NCT00399724,Incidence of severe hypoglycaemia,"Quality of Life and treatment satisfaction before, during and at the end of treatment using the Diabetes Treatment Satisfaction Questionnaire",,2002-03,COMPLETED,INTERVENTIONAL,['PHASE4']
10834,NCT02461641,Mean adjusted heal rate,Length of time to 100% healing of foot ulcer,,2015-03,COMPLETED,INTERVENTIONAL,['NA']
10835,NCT00141492,,,,2004-10,COMPLETED,INTERVENTIONAL,['PHASE2']
10836,NCT00943787,Maximum Epinephrine Response (LBGI Groups),Maximum Epinephrine Response (ADRR Groups),,2006-01,COMPLETED,INTERVENTIONAL,['NA']
10837,NCT01805700,Changes in blood glucose level in all patients as a measure of tolerability,"Changes in heart rate, systolic and diastolic blood pressure in all patients.",,2010-01,COMPLETED,INTERVENTIONAL,['NA']
10838,NCT04178525,Difference in proportions of ulcers completely healed for experimental group compared to control group.,To track diabetic ulcer recurrence for experimental group compared to control group in patients whose wound completely healed.,,2018-08-02,TERMINATED,INTERVENTIONAL,['NA']
10839,NCT02388984,"The total effective rate of Fundus changes, the severity of diabetic retinopathy change from baseline at the end of week 24 compared to placebo",The severity of macular edema change from baseline at the end of week 24 compared to placebo,,2013-05,UNKNOWN,INTERVENTIONAL,['PHASE3']
10840,NCT05950659,Plantar ulcer recurrence,,,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
10841,NCT02485327,Assessment of PD parameter: area under the glucose infusion rate curve (GIR) necessary to maintain euglycemia during the euglycemic clamp over 8 hours,Assessment of PD parameter: time to GIRmax (GIR-Tmax),,2015-07,COMPLETED,INTERVENTIONAL,['PHASE1']
10842,NCT00886340,Number of Participants Who Met Weight Loss Goal of 5% Weight Loss,Quality of Life,,2005-09,COMPLETED,INTERVENTIONAL,['PHASE2']
10843,NCT02561546,glycosylated hemoglobin (A1C),postprandial glucose (PPG),,2015-12,UNKNOWN,INTERVENTIONAL,['PHASE2']
10844,NCT05229705,Trail Making Test,Timed Up and Go Test,,2022-09-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
10845,NCT05280496,HbA1C,Weight,,2022-06-01,RECRUITING,INTERVENTIONAL,['PHASE3']
10846,NCT01089855,The decrease of neuropathic pain in diabetic patients using Brief Pain Inventory scale (BPI),Evaluate the quality of life,,2009-12,COMPLETED,INTERVENTIONAL,['PHASE4']
10847,NCT04790617,Acute care service use,Medication adherence,,2021-03-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
10848,NCT03794531,Number of participants with self-reported medically-diagnosed chronic diseases,Difference in the number of participants with self-reported medically-diagnosed chronic diseases living urban vs. rural area,"Risk of clinically-measured metabolic syndrome (e.g. high blood pressure, elevated adiposity, elevated blood glucose, and out-of-normal-range blood lipids), according to dietary and psychosocial risk factors",2019-03-01,RECRUITING,OBSERVATIONAL,['NA']
10849,NCT04460326,Postprandial Glucose Control,Percent of Postprandial Time Spent With Hypoglycemia,,2020-12-07,COMPLETED,INTERVENTIONAL,['PHASE3']
10850,NCT05710913,Diabetes mellitus type II remission rate postoperatively,,,2023-01-05,RECRUITING,OBSERVATIONAL,['NA']
10851,NCT02272296,Tmax (min),T-INSAUC50% (min),Tolerability,2015-02,COMPLETED,INTERVENTIONAL,['PHASE4']
10852,NCT04118153,Change in frequency of TfH within total CD4 T cells (%),,,2021-03-05,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
10853,NCT03943979,Stability of changes in food intake,Change in neuropsychological test:Symbol digit modalities test (SDMT; Smith A. 1982).,,2016-02-25,COMPLETED,INTERVENTIONAL,['PHASE2']
10854,NCT02121340,Hemoglobin A1c,,Diabetes self management,2014-05,COMPLETED,INTERVENTIONAL,['NA']
10855,NCT01807351,Number of subjects develope Diabetes Mellitus,,,2012-07,COMPLETED,OBSERVATIONAL,['NA']
10856,NCT01714011,Tapering off of previous psychoactive medication.,The proportion of reversed metabolic syndrome components among schizophrenia patients after treated with either aripiprazole or ziprasidone,Total cholesterol and LDL cholesterol among schizophrenia patients after treated with either aripiprazole or ziprasidone.,2009-05,COMPLETED,INTERVENTIONAL,['PHASE4']
10857,NCT05908513,Change of body weight over time points,,,2021-10-15,WITHDRAWN,INTERVENTIONAL,['PHASE1']
10858,NCT01197742,Documentation of the characteristics consecutive patients with acute STEMI or NSTEMI in daily hospital routine in Germany,Verification of the implementation of a therapy according to the guidelines for STEMI / NSTEMI in daily hospital routine,,2007-10,COMPLETED,OBSERVATIONAL,['NA']
10859,NCT05274880,Cmax of CKD-393,,,2022-06-21,COMPLETED,INTERVENTIONAL,['PHASE1']
10860,NCT00563394,Reduction in clinical signs and symptoms of the infection,Wound Depth,,1994-08,COMPLETED,INTERVENTIONAL,['PHASE3']
10861,NCT01434901,The effects of Bethanechol on insulin secretion rates,,,2011-08-15,COMPLETED,INTERVENTIONAL,['PHASE1']
10862,NCT05286632,Evaluation of changes in Perceived Stress,,,2022-07-18,RECRUITING,INTERVENTIONAL,['NA']
10863,NCT03011021,Adverse effects,Life quality evaluation,,2017-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10864,NCT04874532,Diabetes Self-Management,Qualitative experience with hypoglycemia and its prevention,,2021-06-04,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
10865,NCT03344692,Total area under the post-prandial triglycerides concentration-time curve from meal-time until 8h (AUC0-8h) after standardized high fat meal.,Effect of treatment with alirocumab versus placebo on fasting and post-prandial and glucose homeostasis following a standardized high-fat meal,,2019-02-12,COMPLETED,INTERVENTIONAL,['PHASE3']
10866,NCT01843855,Change in Total Disposition Index from Study 1 (pre-RYGB) to Study 2 (post-RYGB),,,2011-06,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
10867,NCT01125956,Hemoglobin A1c,Experience of peer counseling,,2009-07,COMPLETED,INTERVENTIONAL,['NA']
10868,NCT03157960,Changes in uric acid (µmol/L),,,2012-02-01,COMPLETED,INTERVENTIONAL,['NA']
10869,NCT02846662,Number of participants with 50% reduction in PHQ-9 score a 3-month assessment,"Proportion of participants who improve level of activity, as evaluated by the short form of the Behavioral Activation for Depression Scale (BADS)",,2016-09-19,COMPLETED,INTERVENTIONAL,['PHASE3']
10870,NCT00728286,Thrombus area,Factors affecting thrombus area,,2008-10,COMPLETED,OBSERVATIONAL,['NA']
10871,NCT01421459,Change From Baseline up to 24 Weeks in Hemoglobin A1c (HbA1c),Rate Per 30 Days of Hypoglycemic Events,Percentage of Participants With Treatment Emergent Antibody Response (TEAR),2011-09,COMPLETED,INTERVENTIONAL,['PHASE3']
10872,NCT01212328,Multiple CVD risk factor control targets,Prescriber and patient acceptability of the Digital Support software and care coordinator with management guidelines.,,2010-10,UNKNOWN,INTERVENTIONAL,['NA']
10873,NCT02205372,Frequency and nature of treatment-emergent adverse events and serious adverse events.,Change from baseline in blood pressure,,2014-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10874,NCT02276131,Successful completion of frequent and risk-related tasks (Measure: Percent of tasks successfully completed),,,2015-01,COMPLETED,INTERVENTIONAL,['NA']
10875,NCT01487070,Evidence of advancement of tractional detachment post injection of Macugen before surgical intervention.,Evaluate regression of neovascularization and progression of macular traction utilizing OCT and Fundus photographs,,2011-04,COMPLETED,INTERVENTIONAL,['PHASE1']
10876,NCT04568486,Hemoglobin A1c,Health-related quality of life measures,,2020-10-01,RECRUITING,INTERVENTIONAL,['NA']
10877,NCT04054076,Pressure time integral,Relation of different types of insoles and risk factors to pressure time integral,Costs for the assistive devices,2020-01-01,COMPLETED,INTERVENTIONAL,['NA']
10878,NCT04155645,Laboratory assessments: Clinical urinalysis,PD analysis: Levels of dyslipidemia related biomarkers.,,2019-11-21,COMPLETED,INTERVENTIONAL,['PHASE1']
10879,NCT02979756,Macrosomia,Lifestyle impact of GDM,,2016-11-14,COMPLETED,INTERVENTIONAL,['NA']
10880,NCT05348733,Descriptive summary of secondary therapies used in participants with CKD and T2D.,Occurrence of hyperkalemia,Occurrence of newly diagnosed diabetic retinopathy or progression of existing disease at treatment initiation,2022-06-13,RECRUITING,OBSERVATIONAL,['NA']
10881,NCT05273073,Mean difference of homeostasis model assessment of insulin resistance (HOMA-IR),"Changes in gut microbial profiles (i.e., gut microbial composition, alpha diversity, beta diversity, and functional analysis)",,2018-03-01,COMPLETED,INTERVENTIONAL,['NA']
10882,NCT01787318,Peak Post-Prandial Glucose Excursions,Area Under Curve meal-related insulin excursion following meals,,2013-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
10883,NCT00673465,Pharmacodynamic: Change From Baseline in 24-hour Plasma Glucose (AUC/Duration) at Week 4 (Part 2 - India),Pharmacokinetic: Mean Plasma Tmax (Part 2 - India),,2008-04-17,COMPLETED,INTERVENTIONAL,['PHASE1']
10884,NCT00501683,Urine & Fecal collection at Day -1 & days 1-5.,"Adverse events (AEs), vital signs, ECGs and clinical laboratory assessments at each day for up to 10 days",,2006-11,COMPLETED,INTERVENTIONAL,['PHASE1']
10885,NCT03874754,Change in Mental Well Being,Change in Brain-Derived Neurotrophic Factor Level (in Sweat),,2019-08-01,COMPLETED,INTERVENTIONAL,['NA']
10886,NCT05164562,musculoskeletal disorders of upper limb,,,2022-01-07,UNKNOWN,OBSERVATIONAL,['NA']
10887,NCT02248714,Change From Baseline in Glucose Coefficient of Variation(CV),Change From Baseline in HOMA-IR,,2014-03,COMPLETED,INTERVENTIONAL,['NA']
10888,NCT01098357,Incidence of complete wound closure,Safety Safety Measures,,2010-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10889,NCT04831060,Characterization of a panel of cytokines in gingival fluid of patients with periodontitis versus without periodontitis,Characterization of proteases (MMP) present in gingival fluid and unstimulated saliva,,2023-02-15,RECRUITING,OBSERVATIONAL,['NA']
10890,NCT01257815,The change in mean Best Corrected Visual Acuity (BCVA),Proportion of patients with 10 and 15 letter improvement or loss in BCVA,,2011-01,COMPLETED,INTERVENTIONAL,['PHASE4']
10891,NCT01114321,The primary outcome is the plasma glucose concentration measured 120 min after the oral glucose surcharge intake.,Urinary glucose measurement,,2010-05,UNKNOWN,INTERVENTIONAL,['NA']
10892,NCT05527574,Changes in frailty status in response to the exercise intervention,Changes in cognitive health,,2019-11-30,RECRUITING,INTERVENTIONAL,['NA']
10893,NCT05081583,Metformin area under the concentration vs. time curve (AUC) ratio (exposure/baseline),Midazolam half-life ratio (exposure/baseline),,2021-09-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
10894,NCT04918732,Prevalence of NAFLD in risk groups followed by the general practitioner,To assess the work productivity and absenteism of the patient.,,2021-05-05,RECRUITING,INTERVENTIONAL,['NA']
10895,NCT01340079,Change from Baseline in hemoglobin a1c at 8 weeks after completion of the intervention.,Change from Baseline in physical activity at 8 weeks after completion of the intervention.,,2011-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10896,NCT05182580,Number of Completed Care Encounters Among All Clinic Patients (With and Without Diabetes) Per Retina Specialist Clinic Hour,Number of Participants Who Were Very Satisfied or Satisfied With Autonomous AI,,2022-03-20,COMPLETED,INTERVENTIONAL,['NA']
10897,NCT00890331,Parental involvement and Disease care behaviors,"Glycohemoglobin levels, Adverse effects and Blood glucose variability",,2007-04,COMPLETED,INTERVENTIONAL,['PHASE1']
10898,NCT01792284,Hemoglobin A1c (HbA1c) at 12 Weeks,Percentage of Participants With HbA1c <7.0% and ≤6.5% at 12 Weeks,,2013-02,COMPLETED,INTERVENTIONAL,['PHASE3']
10899,NCT00823680,Absolute change in mean daily plasma glucose,"Adverse events, lab parameters, vital signs, body weight",,2009-04,COMPLETED,INTERVENTIONAL,['PHASE2']
10900,NCT03173963,Effect of empagliflozin on change in cortical interstitial fractional volume [Vv(Int/cortex) over the 3-year study period.,Effect of empagliflozin on development or progression of diabetic retinopathy determined by changes from baseline to 3 years of at least 2 Early Treatment of Diabetic Retinopathy Study levels in grading of standardized retinal photographs.,,2017-05-27,WITHDRAWN,INTERVENTIONAL,['PHASE3']
10901,NCT03263351,Insulin secretion,Daily cortisol output,,2017-10-01,RECRUITING,INTERVENTIONAL,['NA']
10902,NCT01854723,Difference in A1C between groups at 6 months,Difference in number of visits with clinical pharmacist,,2013-04,WITHDRAWN,INTERVENTIONAL,['PHASE4']
10903,NCT05041491,Glycemia,Skeletal muscle content of COX4,,2021-11-30,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
10904,NCT01193296,Glycemic variability assessed by MAGE (Mean Amplitude of Glycemic Excursion),"Unrecognized hypoglycemic periods recorded by CSGM, frequency and duration",,2010-06,COMPLETED,INTERVENTIONAL,['PHASE4']
10905,NCT06147323,Changes in quality of life,,,2023-11-13,RECRUITING,INTERVENTIONAL,['NA']
10906,NCT03675464,Number of participants with Hypertension,Genetic variations linked to lipolysis,,2018-09-20,UNKNOWN,OBSERVATIONAL,['NA']
10907,NCT01486043,Length of Insulin Therapy (Days),Hemoglobin A1c,,2011-12,TERMINATED,INTERVENTIONAL,['NA']
10908,NCT02050399,Cardiovascular responses during isometric exercise,,,2013-08,COMPLETED,INTERVENTIONAL,['NA']
10909,NCT04155619,Insulin secretion,"Glycemic (""Peripheral"") Rhythm Phase",,2021-04-26,RECRUITING,INTERVENTIONAL,['NA']
10910,NCT02394158,Development of Gestational Diabetes at any point during the course of pregnancy,Cost effectiveness of the intervention,Fetal hyperinsulinaemia,2015-01-27,UNKNOWN,INTERVENTIONAL,['PHASE4']
10911,NCT02888691,Percentage of Time Spent in Euglycemia,TNF-alpha,Ketones,2016-08,COMPLETED,INTERVENTIONAL,['NA']
10912,NCT00482950,HbA1c,,,2007-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
10913,NCT05826678,Hypoglycemic Confidence Scale (HCS) change over 6 month study period,Family/social-level factors impacting technological device for care management,,2022-09-22,RECRUITING,INTERVENTIONAL,['NA']
10914,NCT01864603,HIV Incidence,Total Costs of Programming (ART),,2013-04,COMPLETED,INTERVENTIONAL,['NA']
10915,NCT05296642,Change in Pain Pressure Threshold (PPT),Change in Heat Pain Threshold (HPT),,2022-08-01,WITHDRAWN,INTERVENTIONAL,['NA']
10916,NCT03313752,Effect of dapagliflozin on myocardial insulin sensitivity,Gut microbiota composition change from baseline,,2017-12-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
10917,NCT00229931,"Main Outcome Measures Will be Quantitative Changes in OCT Central Thickness, Visual Acuity, and Number of Snellen Acuity Lines Gained/Lost.","Rate of Elevated Intraocular Pressures, Retinal Detachment, Infection, and Vitreous Hemorrhage.",,2005-11,COMPLETED,INTERVENTIONAL,['NA']
10918,NCT00984867,Adjusted Mean Change in HbA1c Levels,Proportion of Participants Achieving a Therapeutic Glycemic Response Defined as a Reduction in HbA1c of ≥0.7% Compared to Baseline,,2009-10,COMPLETED,INTERVENTIONAL,['PHASE3']
10919,NCT01525225,"Number of Participants With Adverse Events (AEs) , Serious Adverse Events (SAEs), AEs Leading to Discontinuation, Death",Number of Participants With Marked Chemistry or Hematology Laboratory Abnormalities,,2012-09,TERMINATED,INTERVENTIONAL,['PHASE1']
10920,NCT05400863,change in BMI z-score between the two groups at 12 weeks,improvement of A1C due to metformin between the 2 groups at 12 weeks,metformin-induced rise in GDF15 in both groups at 12 weeks,2022-04-21,RECRUITING,INTERVENTIONAL,['NA']
10921,NCT03363100,A1c,,,2017-12-05,COMPLETED,INTERVENTIONAL,['NA']
10922,NCT03440736,Percentage of patients achieving Psoriasis Area and Severity Index (PASI) Score of 90 at week 28,"Percentage change from Baseline in Participant's self-assessed pain, itching and scaling",,2018-02-28,COMPLETED,INTERVENTIONAL,['PHASE4']
10923,NCT05752292,Completion of recommended postpartum diabetes screening.,Uptake of a lifestyle program for diabetes prevention.,,2023-04-13,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
10924,NCT03260998,corrected QT dispersion,,,2017-08,UNKNOWN,OBSERVATIONAL,['NA']
10925,NCT05226182,Usability and acceptance of the application in patients and healthcare professionals,"Possible change,impact on personal clinical parameters: bodyweight",,2021-10-01,UNKNOWN,INTERVENTIONAL,['NA']
10926,NCT01280188,Change from Baseline in 24-hour Urine Volume,Participants with Adverse Events Summarized by Incidence and Severity,,2011-01,COMPLETED,INTERVENTIONAL,['PHASE3']
10927,NCT03516864,Tissue oxygenation is detected on both the MIMOSA Imager and Kent camera.,,,2018-06-01,UNKNOWN,OBSERVATIONAL,['NA']
10928,NCT02373865,Number of Hypoglycemic Episodes (HE) Under Treatment With Sitagliptin Compared to Glimepiride,Glycemic Variability (Profile) of Sitagliptin Compared to Glimepiride,,2015-09,TERMINATED,INTERVENTIONAL,['PHASE4']
10929,NCT02774733,The correlation between the pulmonary function parameters and the retrobulbar circulation parameters in 48 T2DM patients,"HbA1c, FPG, 2hPG, WC,BMI, DBP, SBP, and blood-fat in 48 T2DM patients",,2015-08,COMPLETED,OBSERVATIONAL,['NA']
10930,NCT01542775,change from baseline in soluble receptor for advanced glycation endproducts (sRAGE) after 12 weeks of aerobic exercise,energy expenditure,,2010-01,COMPLETED,INTERVENTIONAL,['NA']
10931,NCT00960973,AIRg (acute insulin response to glucose) using FSIGT (frequently sampled intravenous glucose tolerance test),insulin sensitivity (FSIGT),,2009-09,COMPLETED,INTERVENTIONAL,['PHASE4']
10932,NCT03886974,Needs assessment for transition of care,,,2018-09-07,COMPLETED,OBSERVATIONAL,['NA']
10933,NCT01023165,Researchers will assess whether restoring metabolic integrity to diabetic patients improves quality of life and complications associated with diabetes,,,2009-11,UNKNOWN,INTERVENTIONAL,['PHASE3']
10934,NCT00633282,"Improved metabolic parameters(glucose, lipid, liver enzymes, etc.)",the ratio of withdrawing because of inefficiency,,2008-03,COMPLETED,INTERVENTIONAL,['PHASE2']
10935,NCT00737347,change in body weight,change in body composition,,2003-09,COMPLETED,INTERVENTIONAL,['PHASE3']
10936,NCT02641548,Time to healing of deep heel fissures,Number of participants with complications,,2015-12,UNKNOWN,INTERVENTIONAL,['NA']
10937,NCT03506022,Prevalence of obstructive sleep apnea syndrome confirmed by polysomnography an apnea hypopnea Index ≥ 15,,,2018-01-12,COMPLETED,INTERVENTIONAL,['NA']
10938,NCT02605200,Change in the Pediatric Quality of Life Inventory Transplant Module (PedsQL),Change in the Behavior Assessment System for Children (BASC) Score,,2016-07-07,COMPLETED,INTERVENTIONAL,['NA']
10939,NCT05687890,Changes in urine protein creatinine ratio (UPCR) at Week 12,"Percentage of subjects achieving UPCR ≥30%, ≥40%, and ≥50% reduction from baseline",,2023-05-23,RECRUITING,INTERVENTIONAL,['PHASE2']
10940,NCT05593549,Autophagic Flux Protein Expression,Blood Pressure,,2023-01-01,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
10941,NCT06267391,HbA1c,Incidence of adverse events,,2024-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
10942,NCT05205876,Feasibility of the Eddii App as measured by frequency of use,User Engagement measured through app analytics,,2021-01-02,COMPLETED,INTERVENTIONAL,['NA']
10943,NCT01055808,Changes in Health Related Quality of Life (ITR-QOL) in insulin treated type 2 diabetes at baseline and 12 weeks after a significant change in insulin treatment regimen,Change from baseline in use of concomitant oral hypoglycemic drugs,,2010-01,COMPLETED,OBSERVATIONAL,['NA']
10944,NCT00444899,HbA1c,,,2007-03,COMPLETED,INTERVENTIONAL,['NA']
10945,NCT01537016,"To identify EPA wounds using WOUNDCHEK™ Protease Status diagnostic test, and to compare the healing outcomes of two treatment regimes (PROMOGRAN®, a protease modulating therapy and current standard of care) on chronic wounds with EPA.",Reduction in wound area and cost effectiveness,,2013-07,UNKNOWN,INTERVENTIONAL,['NA']
10946,NCT05099900,Experiences and technology usage among women,,,2021-11-08,UNKNOWN,OBSERVATIONAL,['NA']
10947,NCT02716064,"The experience of patients, family members, primary health care providers, volunteers and community organizations with the TAPESTRY-CM program",Developmental decision evaluation - I,,2014-12,COMPLETED,INTERVENTIONAL,['NA']
10948,NCT03010215,Score change of the AOFAS Hallux metatarsophalangeal interphalangeal scale,Change in clinical evaluation with VAS,,2010-01,UNKNOWN,INTERVENTIONAL,['NA']
10949,NCT02987335,Rate of Glucose Disposal (RD).,Insulin Secretion,,2010-12,COMPLETED,OBSERVATIONAL,['NA']
10950,NCT01480895,Change in HOMA.,BMI changes after delivery.,,2007-03,COMPLETED,INTERVENTIONAL,['NA']
10951,NCT04209348,Change in Physical Activity Assessed by ActiGraph Monitoring Device From Baseline to Follow-up,Birthweight-for-gestational-age Z-score,,2020-08-21,COMPLETED,INTERVENTIONAL,['NA']
10952,NCT04716790,Wound Size,Health-related quality of life,,2021-04-20,UNKNOWN,INTERVENTIONAL,['NA']
10953,NCT00495794,Change in Systolic Blood Pressure,LDL Control,,2008-08,COMPLETED,INTERVENTIONAL,['NA']
10954,NCT02935712,Safety of AZD8601 by assessing number of subjects with clinically significant urinalysis (Part B),,,2016-12-16,COMPLETED,INTERVENTIONAL,['PHASE1']
10955,NCT01101269,Change in renal blood flow (RBF),Change in Proteinuria,,2010-02,TERMINATED,INTERVENTIONAL,['NA']
10956,NCT00924430,"Simvastatin and simvastatin acid: Cmax, tmax, AUC0-t, AUC, lz, and t1/2, as well as CL/F and Vz/F for simvastatin only","Safety and tolerability assessments including adverse events, clinical laboratory tests, electrocardiogram (ECG) and vital signs",,2009-06,COMPLETED,INTERVENTIONAL,['PHASE1']
10957,NCT04022993,Antibody Response,Achievement of Glycated Hemoglobin < 7%,,2018-07-04,COMPLETED,INTERVENTIONAL,['PHASE3']
10958,NCT01906294,"routine treatment data (composite of e.g. diagnostics, kind and dosage of pharmacological diabetes treatment)",,,2013-08,TERMINATED,OBSERVATIONAL,['NA']
10959,NCT02616263,Change in metatarsal phalangeal joint angle (degrees) in people with diabetes from baseline and at a 3-year period,,,2016-03,COMPLETED,INTERVENTIONAL,['NA']
10960,NCT05685875,Severe malaria,Severe malaria with kidney failure,,2022-06-07,RECRUITING,OBSERVATIONAL,['NA']
10961,NCT04222738,Variation of mitral E' velocity,Variation of lipid profile.,,2016-12-01,COMPLETED,INTERVENTIONAL,['PHASE4']
10962,NCT00873639,Change in HbA1c,Number of adverse drug reactions (ADR),,2009-04,COMPLETED,OBSERVATIONAL,['NA']
10963,NCT02081001,Time to Reach 50% of Maximum Glucagon Concentration (Glucagon T50%-Early),Infusion Site Discomfort Score at 30 Minutes,,2014-03,COMPLETED,INTERVENTIONAL,['PHASE2']
10964,NCT04591691,"Proportion of participants with complete wound healing by week 12, defined as complete wound closure where there is skin re-epithelialization without drainage or dressing requirements",,,2020-10-14,RECRUITING,OBSERVATIONAL,['NA']
10965,NCT03363360,HDL-C,blood pressure,,2016-12-01,UNKNOWN,OBSERVATIONAL,['NA']
10966,NCT02065895,Glucose Area Under the Curve (AUC) Breakfast,Peak and Nadir Postprandial Glucose Concentration,Nighttime Time-in-target 5.0-8.33mmol/l (Controller Set-point Plus and Minus 15 mg/dL),2013-12,COMPLETED,INTERVENTIONAL,['NA']
10967,NCT03917576,Maximum heart rate,Heart rate post each HIIT-interval,,2018-01-04,COMPLETED,INTERVENTIONAL,['NA']
10968,NCT02877771,Agreement between algorithm-recommended pump action,,Reference blood glucose,2016-08,COMPLETED,INTERVENTIONAL,['PHASE1']
10969,NCT02111096,Change From Baseline to 6 Months in Hepatic Fat Fraction,Number of Participants With Hypoglycemic Events,,2014-04,TERMINATED,INTERVENTIONAL,['PHASE2']
10970,NCT04645992,Intraoccular pressure measurement,Intraoccular pressure measurement,,2020-11-20,UNKNOWN,INTERVENTIONAL,['NA']
10971,NCT00029848,Change in body weight,Metabolic parameters,,2001-10,COMPLETED,INTERVENTIONAL,['PHASE3']
10972,NCT03113110,OGTT-derived 2-hour blood glucose level,,,2017-01-15,COMPLETED,INTERVENTIONAL,['PHASE2']
10973,NCT05262257,Mini-Mental State Examination(MMSE),glycated hemoglobin(HbA1c、GHb),,2022-04-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
10974,NCT02648217,Change in HbA1c (%) (Glycosylated Haemoglobin),Number of Treatment Emergent Nocturnal (00:01-05:59 am) Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes,,2016-01-04,COMPLETED,INTERVENTIONAL,['PHASE3']
10975,NCT00365170,Relative risk of major maternal hypoglycaemia,Other Adverse Events,,2002-09,COMPLETED,INTERVENTIONAL,['PHASE4']
10976,NCT01722474,"To compare the ability of the non-invasive ASI Device to determine arterial stiffness as compared to SphygmoCor, CR-2000 CV Profiler and VP-1000.",,,2012-10,TERMINATED,INTERVENTIONAL,['NA']
10977,NCT00404027,PPOS scores,Hemoglobin A1c,,2007-06-04,COMPLETED,OBSERVATIONAL,['NA']
10978,NCT04709549,Ideal Cardiovascular Health,Binge Eating,,2021-02-10,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
10979,NCT00205660,Change in Whole Body Sensitivity (mg/kg/Min),,,2005-02,COMPLETED,INTERVENTIONAL,['PHASE4']
10980,NCT02753491,decreasing 300 cal daily food intake,loosing weight,,2015-10,COMPLETED,INTERVENTIONAL,['NA']
10981,NCT03166423,Incidence rate of healing until 60 days or less,Incidence of treatment-emergent adverse events (Safety and Tolerability) of a formulation of snail slime and natural extracts in ulcer wounds in diabetics foot,,2015-11-12,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
10982,NCT05875519,Glycemic level recorded before local anesthesia administration and 30 minutes following local anesthesia injection using glucometer,Healing score of the extraction socket,,2023-05-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
10983,NCT01103245,Plasma Glucose,,,2010-03,COMPLETED,INTERVENTIONAL,['PHASE1']
10984,NCT05619237,Quality Improvement,Patient satisfaction - overall satisfaction,,2022-12-06,COMPLETED,INTERVENTIONAL,['NA']
10985,NCT01652716,Change in HbA1c (Glycosylated Hemoglobin) From Baseline to Week 28,Change in 2-hour Postprandial Glucose Concentrations From Baseline to Week 16,,2013-01,COMPLETED,INTERVENTIONAL,['PHASE3']
10986,NCT01106131,Change from baseline in Glycosylated Hemoglobin (HbA1c),"Evaluate safety of CKD-501 from physical exam, vital sign, laboratory test, adverse events",,2010-05,COMPLETED,INTERVENTIONAL,['PHASE3']
10987,NCT00542724,Change in HbA1c,,,2006-09,COMPLETED,INTERVENTIONAL,['PHASE3']
10988,NCT01250639,,,,2010-08,UNKNOWN,OBSERVATIONAL,['NA']
10989,NCT02848053,Incidence of diabetes,Number of participants with abnormal blood glucose values (in mmol/L),,2016-08,UNKNOWN,OBSERVATIONAL,['NA']
10990,NCT01306214,Change From Baseline in HbA1c After 18 Weeks of Treatment,Change From Baseline in HbA1c After 52 Weeks of Treatment,,2011-02,COMPLETED,INTERVENTIONAL,['PHASE3']
10991,NCT01628445,Change in A1c,Postprandial glucose reduction through measurement of 7 point glucose profile,,2012-08,TERMINATED,INTERVENTIONAL,['PHASE3']
10992,NCT03481374,VO2 max,,,2016-07-01,COMPLETED,INTERVENTIONAL,['NA']
10993,NCT00869908,Number of serious adverse drug reactions and major hypoglycaemic events reported as serious adverse drug reactions,Change in PPG (postprandial glucose),,2008-11,COMPLETED,OBSERVATIONAL,['NA']
10994,NCT04552002,Waist circumference,Microbiome sequencing,,2020-10,UNKNOWN,INTERVENTIONAL,['PHASE3']
10995,NCT00240253,To evaluate the efficacy and safety of adding Symlin to an established regimen of insulin glargine in subjects with type 2 diabetes.,"To evaluate the effects of adding Symlin to an established regimen of insulin glargine in subjects with type 2 diabetes on markers of cardiovascular risk, fasting serum lipids, fasting plasma glucose, waist circumference, and patient-reported outcomes.",,2005-10,COMPLETED,INTERVENTIONAL,['PHASE4']
10996,NCT04919603,Change in liver steatosis quantified by MRI-PDFF (percentage),Cardiovascular risk,,2021-06-15,UNKNOWN,INTERVENTIONAL,['NA']
10997,NCT06273631,Change of time in range (TIR),Change in autoimmunity from baseline,,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
10998,NCT05865717,Physical activity which will be measured using a questionnaire developed by the American College of Lifestyle Medicine and Loma Linda University,Prevalence of Chronic Diseases according to each profession and BMI,,2023-02-15,COMPLETED,OBSERVATIONAL,['NA']
10999,NCT02347514,glycosylated hemoglobin,Summary of Diabetes Self-Care Activities (SDSCA),,2014-11,COMPLETED,INTERVENTIONAL,['NA']
11000,NCT01477853,Number of Participants Who Discontinued Study Drug Due to an Adverse Event,Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 16,,2011-10-24,TERMINATED,INTERVENTIONAL,['PHASE3']
11001,NCT03803345,Maternal meal and snack distribution,Dietary data from food record app.,Birth head circumference,2019-03-28,COMPLETED,OBSERVATIONAL,['NA']
11002,NCT00834938,"Describe the endogenous response of incretins, orexins and anorexins to a mixed meal test in obese patients with DM2, in patients with DM2 undergoing RYGB with remission of DM2 and in patients without remission.",,,2007-07,COMPLETED,OBSERVATIONAL,['NA']
11003,NCT00021788,,,,2000-07,COMPLETED,INTERVENTIONAL,['PHASE2']
11004,NCT04343872,Change in Glycosylated Hemoglobin (HbA1c),,,2020-12-10,COMPLETED,INTERVENTIONAL,['NA']
11005,NCT01204593,Change in hemoglobin A1c (HbA1c) values (following the reference of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC)),Symptomatic hypoglycemias,,2010-11,COMPLETED,INTERVENTIONAL,['PHASE4']
11006,NCT06006689,Change in UACR(urinary albumin ⁃ to ⁃ creatinine ratio).,TCM syndrome,Change in MCP-1.,2023-09-04,RECRUITING,INTERVENTIONAL,['PHASE2']
11007,NCT01816165,State 3 Mitochondrial Oxygen Consumption,Vascular Markers,Counterregulatory Hormones,2011-06,COMPLETED,INTERVENTIONAL,['PHASE3']
11008,NCT01790438,Change From Baseline to 26 Weeks in Hemoglobin A1c (HbA1c),Change From Baseline to 26 Weeks in European Quality of Life (EQ-5D-3L) - Visual Analog Scales (VAS) Scores,,2013-03,COMPLETED,INTERVENTIONAL,['PHASE3']
11009,NCT02324491,"Safety and tolerability assessed by adverse events, laboratory evaluations, ECGs, vital signs, physical examinations",Change in Patient Reported Outcomes (PRO) scores,,2014-12,TERMINATED,INTERVENTIONAL,['PHASE2']
11010,NCT00834626,Percentage of Participants Having Remission of Type 2 Diabetes,Percentage of Participants Achieving Remission in Hypertension,,2008-01,COMPLETED,INTERVENTIONAL,['NA']
11011,NCT03658031,Incidence rate of T2DM,,,2019-03-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
11012,NCT02967354,[11C]5-hydroxy-tryptophan Uptake in the Pancreas,Hepatic Fat Content,,2013-01,COMPLETED,INTERVENTIONAL,['NA']
11013,NCT06051565,Degree of vascular stenosis,Serum transferrin saturation,,2021-11-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11014,NCT03338855,Corrected Glucose Disposal Rate (cGDR) Measured as Change in Rate of Disposal (Delta RD) Basal vs High Insulin After 5 Weeks of Treatment,,Fibroblast Growth Factor 21 (FGF21) Area Under the Curve (AUC) in Plasma After 5 Weeks of Treatment,2018-03-05,COMPLETED,INTERVENTIONAL,['PHASE4']
11015,NCT00384215,To determine whether glycemic control as measured by HbA1c is different between insulin glargine [rDNA Origin] injection and pioglitazone when added to subjects who fail monotherapy with SU or metformin.,Compare cost of therapy for hyperglycemia treatment,,2001-12,COMPLETED,INTERVENTIONAL,['PHASE4']
11016,NCT05007262,diabetic retinopathy(DR)progression rate,Efficacy of traditional Chinese medicine syndrome.,,2021-08-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
11017,NCT01101945,"To demonstrate safety and tolerability of dutogliptin/PHX1149Tas assessed by vital signs, adverse event reporting, and routine clinical laboratory assessments",To demonstrate maintenance or lowering of HbA1c and fasting blood glucose,,2007-07,TERMINATED,INTERVENTIONAL,['PHASE2']
11018,NCT02268214,Adjusted Mean Change in HbA1c From Baseline at Week 24,Subjects With HbA1c Reduction From Baseline to Week 24 (LOCF) >= 0.5% and Without Severe Hypoglycemia Events,,2014-11-11,COMPLETED,INTERVENTIONAL,['PHASE3']
11019,NCT01789593,Digit Symbol Substitution Test (DSST) score,Paced Auditory Serial Addition Task (PASAT) score,,2013-01-14,COMPLETED,INTERVENTIONAL,['PHASE1']
11020,NCT05838755,"Change from baseline in the weekly average of average daily pain intensity at Week 12, assessed on the Numeric Rating Scale (NRS)","Number of participants with greater than or equal to ≥ 50 % reduction from baseline in the weekly average of average daily pain intensity at Week 12, assessed on the NRS",,2023-09-20,RECRUITING,INTERVENTIONAL,['PHASE2']
11021,NCT01816997,Glucose homeostasis,Chronic complications of diabetes,,2012-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
11022,NCT03861546,SMA program retention rate,Change in diet,,2019-03-03,COMPLETED,INTERVENTIONAL,['NA']
11023,NCT02759484,Blood Pressure Control,Intermediate Behavior: Medication Adherence,Intervention Costs,2015-03,COMPLETED,INTERVENTIONAL,['NA']
11024,NCT01349166,supervised physical training on cardiometabolic and inflammatory biomarkers,relationships between cortisol secretion and the postprandial inflammatory responses depending on the level of glucose tolerance,,2008-02,UNKNOWN,INTERVENTIONAL,['NA']
11025,NCT01281098,Regression of retinal neovascularization,Need for vitrectomy due to occurrence of vitreous hemorrhage or retinal detachment,,2010-03,COMPLETED,INTERVENTIONAL,['PHASE2']
11026,NCT04525573,Fat Reduction,General Health Improvement,,2020-08-07,WITHDRAWN,OBSERVATIONAL,['NA']
11027,NCT03495284,Fasting blood glucose,Triglycerides,,2018-02-19,COMPLETED,INTERVENTIONAL,['NA']
11028,NCT00619034,Diameter of retinal blood vessels,Influence on retinal blood flow in diabetes,,2007-09,COMPLETED,INTERVENTIONAL,['NA']
11029,NCT02045563,Determination of the existence of liver steatosis measured by magnetic resonance spectroscopy spectrometry,Measurement of monocyte expression of LDL receptors,,2007-10-15,COMPLETED,OBSERVATIONAL,['NA']
11030,NCT05585268,Proportion of patients with one or more PIMs deprescribed,Mean number of total medications,,2022-10-03,COMPLETED,INTERVENTIONAL,['NA']
11031,NCT04980040,Percentage of Participants With Unexpected Adverse Drug Reactions (ADRs),Percentage of Participants With Overall Improvement and Final Effectiveness Assessment,,2014-04-19,COMPLETED,OBSERVATIONAL,['NA']
11032,NCT02993809,Survival without major amputation,Thermography,,2018-03,UNKNOWN,INTERVENTIONAL,['PHASE1']
11033,NCT01255163,Number of Participants With Incidence of Nausea,Body Mass Index (BMI),,2010-11-21,TERMINATED,INTERVENTIONAL,['PHASE2']
11034,NCT03954418,Amniotic fluid,,,2019-06-01,COMPLETED,INTERVENTIONAL,['NA']
11035,NCT02096874,Peripheral retinal ischemia,,,2013-06,COMPLETED,INTERVENTIONAL,['PHASE4']
11036,NCT01730014,Incidence of adverse events (AE),The maximal GIR (glucose infusion rate) observed,,2012-10,COMPLETED,INTERVENTIONAL,['PHASE1']
11037,NCT05822648,Change over time in HbA1c,Change over time in self-reported caloric intake,,2023-04-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
11038,NCT05293015,EFFICACY: TIR（Time in Range）,QUALITY OF LIFE:living quality,,2022-04-01,UNKNOWN,INTERVENTIONAL,['NA']
11039,NCT02181127,Continuous Glucose Monitor (CGM) Glucose Total Area Over the Curve and Less Than 60 mg/dl,Episodes of Nausea Per Day on Glucagon vs Placebo,,2014-11,COMPLETED,INTERVENTIONAL,['NA']
11040,NCT04317703,bioequivalence study,,,2020-08-19,COMPLETED,INTERVENTIONAL,['PHASE1']
11041,NCT04493814,Association between quantity of Visceral adipose Tissu and Liver Stiffness,Build an algorithm with Visceral adipose Tissue mesured and biological markers to predict fibrosis.,,2020-07,UNKNOWN,OBSERVATIONAL,['NA']
11042,NCT02294643,late lumen loss measured by quantitative coronary angiography,renal impairments as measured by increased microalbuminuria or decreased creatinine clearance,,2009-04,COMPLETED,INTERVENTIONAL,['PHASE3']
11043,NCT04935749,Epidemiology,,,2021-07-01,RECRUITING,OBSERVATIONAL,['NA']
11044,NCT05874141,Number of participants with Cancer,Correlate the presence of each co-morbidity with the extent of diabetes control,,2023-11-15,RECRUITING,INTERVENTIONAL,['NA']
11045,NCT00393510,Number of Participants With Limb Salvage,Time of Ulcer Healing,,2000-11,COMPLETED,INTERVENTIONAL,['PHASE2']
11046,NCT01784965,Change in Weight Reported at 14 Weeks,Insulin Resistance in the Liraglutide vs.Placebo Group After Calorie Restriction,,2009-12,COMPLETED,INTERVENTIONAL,['PHASE3']
11047,NCT00886665,Short-form (sf)- McGill pain questionnaire (SF-MPQ),Nerve conduction study,,2008-07,UNKNOWN,INTERVENTIONAL,['PHASE3']
11048,NCT01030770,Number of patients requiring pars plana vitrectomy at week 7.,Grading of lens clarity using LOCS II (lens opacities classification system version II),,2010-07,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
11049,NCT05648903,Intervention primary outcome- Change in Hba1c (mmol/l),Intervention secondary outcomes- diabetes remission,Other study outcomes- engagement with the programme,2022-01-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
11050,NCT03727854,Change in HbA1c From Baseline,Change in Homeostatic Model Assessment of β-cell Function (HOMA-beta) From Baseline,,2018-08-27,COMPLETED,INTERVENTIONAL,['NA']
11051,NCT06026813,Plantar pressure,Balance,,2024-03-07,RECRUITING,OBSERVATIONAL,['NA']
11052,NCT05055804,"Standard OTC Glucose, A1C & Laboratory Results in Comparison to ELG Device During Non-Fasting Event",,,2021-08-11,UNKNOWN,INTERVENTIONAL,['NA']
11053,NCT03932630,Percentage of time in target glucose range (3.9 - 10.0 mmol/L),Percentage of time when pump was in Auto-mode,,2019-12,WITHDRAWN,INTERVENTIONAL,['NA']
11054,NCT01087645,Number and severity of adverse events (AEs) recorded,The uptake in blood of oral NN9925,,2010-03-12,COMPLETED,INTERVENTIONAL,['PHASE1']
11055,NCT00641953,"Change from Baseline to endpoint (Day 29) in the average of neuropathic foot daily pain ""24 - Hour Average Pain"" scores",Change in weekly average sleep disturbance,,2007-08,COMPLETED,INTERVENTIONAL,['PHASE2']
11056,NCT01929798,time spent in safe blood glucose range,glucose level extremes and need for outside intervention,,2013-11,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
11057,NCT01910194,AUCISEC(0-10min),,,2013-12,COMPLETED,INTERVENTIONAL,['PHASE2']
11058,NCT02036619,The glucose tolerance status 3 months postpartum in women with recent GDM.,The prevalence of women with a fasting plasma glucose ≥ 92-99mg/dl in early pregnancy to have a normal 75g OGTT between 26-28 weeks of pregnancy.,,2014-04,COMPLETED,OBSERVATIONAL,['NA']
11059,NCT00187564,4. Trolox equivalent antioxidant capacity (TEAC) (measurement of total antioxidant status),2. Urine albumin/creatinine ratio,,2004-08,COMPLETED,INTERVENTIONAL,['NA']
11060,NCT00833027,Change From Baseline in HbA1c at Week 24,Change From Baseline in HbA1c at Week 12,,2008-03-01,COMPLETED,INTERVENTIONAL,['PHASE4']
11061,NCT04473430,"Differences in mean percentage time-in-hypoglycemia (< 70 mg/dL) during the intervention phase, compared to control in both phases (i.e. intervention-control vs. control-intervention).",Number of hospitalization or emergency room visits for diabetes ketoacidosis,,2020-11-05,COMPLETED,INTERVENTIONAL,['NA']
11062,NCT00552175,Change From Baseline at Week 12 in Average Pain Severity Rating Using Diaries for the Combined Duloxetine Arms (40 mg + 60 mg),Change From Baseline in Beck Depression Inventory-II (BDI-II) Total Score at Week 12,,2007-11,COMPLETED,INTERVENTIONAL,['PHASE3']
11063,NCT00505947,improvement in best corrected visual acuity,anatomical improvement of diabetic macular edema and improvement in diabetic retinopathy,,2007-07,TERMINATED,INTERVENTIONAL,['PHASE3']
11064,NCT05259475,Change in liver fat content.,Change in the composition of gut microbiota from baseline due to the diet intervention.,,2021-08-20,COMPLETED,INTERVENTIONAL,['NA']
11065,NCT03331861,Change in Minute Ventilation to Carbon Dioxide Production (VE/VCO2) Slope,Heart Failure Hospitalizations,Fasting Sugar,2019-02-15,RECRUITING,INTERVENTIONAL,['PHASE2']
11066,NCT00503464,,,,2006-09,UNKNOWN,OBSERVATIONAL,['NA']
11067,NCT04899791,Change in blood cholesterol levels,Change in body weight,,2021-05-24,COMPLETED,INTERVENTIONAL,['NA']
11068,NCT03907189,Correlation of foot temperature data and daily activity in patients with emergent inflammation.,Correlation of foot temperature data and daily activity in patients without inflammation to the plantar foot.,Usage rate for the activity monitor,2019-03-25,UNKNOWN,OBSERVATIONAL,['NA']
11069,NCT00334399,,,,na,COMPLETED,INTERVENTIONAL,['PHASE3']
11070,NCT03159559,myocardial perfusion reserve index (MPRI),,,2017-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
11071,NCT05510518,Number of obese women that will be diagnosed with late GDM diagnosis by the OGTT,neonatal hospitalization in intensive care rate,,2022-08,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
11072,NCT04279184,Psychometric validation of ICIQ-UI SF (questionnaire used to assess urinary incontinence),Objective characterization of urinary incontinence in women with and without diabetes,,2016-01,UNKNOWN,OBSERVATIONAL,['NA']
11073,NCT00954447,Change From Baseline in HbA1c After 24 Weeks,Change From Baseline in Incremental Post-prandial Glucose (iPPG) After 24 Weeks of Treatment,Number of Patients With HbA1c < 6.5 Percent,2009-08,COMPLETED,INTERVENTIONAL,['PHASE3']
11074,NCT02896140,Change in Hemoglobin A1C (A1C),Change in c-reactive protein level,,2016-04,COMPLETED,OBSERVATIONAL,['NA']
11075,NCT03141073,Change from baseline in HbA1c,Incidence of Treatment-Emergent Adverse Events over time,,2017-10-15,COMPLETED,INTERVENTIONAL,['PHASE3']
11076,NCT05132660,Electroretinogram,HbA1c,,2022-07-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['EARLY_PHASE1']
11077,NCT02053116,Change from baseline in Weighted Mean Daily Glucose (WMDG) when compared to placebo,Change from baseline in very low density lipoprotein (VLDL),,2014-03,TERMINATED,INTERVENTIONAL,['PHASE2']
11078,NCT00256256,FDG-uptake in the brain and heart visualized by Positron emission tomography with and without GLP-1,Laboratory values (insulin secretion and counter-regulatory hormones),,2005-11,COMPLETED,INTERVENTIONAL,['NA']
11079,NCT06030544,HbA1c,Presence of sediment in urine,,2022-02-25,RECRUITING,INTERVENTIONAL,['PHASE2']
11080,NCT00167934,Effects of Medication on Insulin Secretion at Skeletal Muscle (Glucose Disposal),,,2004-12,COMPLETED,INTERVENTIONAL,['NA']
11081,NCT03115112,Change in HbA1c From Baseline to Week 24,Change in SBP in Subjects From Baseline at Week 24,,2017-10-12,COMPLETED,INTERVENTIONAL,['PHASE3']
11082,NCT01218256,Muscle strength,Glycemic control,,2007-07,COMPLETED,INTERVENTIONAL,['PHASE1']
11083,NCT03029702,Proportion of participants who report suitability of the study procedures,Cord blood c-peptide,,2018-02-28,COMPLETED,INTERVENTIONAL,['PHASE4']
11084,NCT04821921,Hemoglobin A1c (HbA1c),,,2021-04-09,COMPLETED,OBSERVATIONAL,['NA']
11085,NCT01260376,Effects of exercise and antilipolysis on FFA and VLDL-TG kinetics,,,2011-04,COMPLETED,INTERVENTIONAL,['NA']
11086,NCT03047668,change in blood glucose profile in the mixed-meal tolerance test (MMTT) - combined parameter,change in parameters of autonomic neuropathy - measures of cardio-autonomic neuropathy (SANN),,2013-05,UNKNOWN,INTERVENTIONAL,['NA']
11087,NCT00251875,7. user metrics,,,2005-07,UNKNOWN,INTERVENTIONAL,['NA']
11088,NCT00752440,Inspiratory muscle strength,Variability of heart rate,,2006-08,UNKNOWN,INTERVENTIONAL,['PHASE4']
11089,NCT04807348,percentage of HbA1c change from baseline,number of participants with lab abnormality,,2021-05-17,UNKNOWN,INTERVENTIONAL,['PHASE3']
11090,NCT01060540,Weight,Moderate Intensity Physical Activity,,2010-08,COMPLETED,INTERVENTIONAL,['NA']
11091,NCT06258473,Hypertension and Diabetes control,Hypertension and diabetes care cascade,,2024-01-01,RECRUITING,INTERVENTIONAL,['PHASE1']
11092,NCT00618995,Urinary 11-Dehydrothromboxane B2 (11-dTxB2),Prostaglandin I Metabolite (PGI-M),,2007-08,COMPLETED,INTERVENTIONAL,['PHASE1']
11093,NCT02608905,Monocyte Inflammatory Protein Nuclear Factor Kappa-B (NFkappaB) (%),Arterial Flow Mediated Dilatation (%),,2015-11,TERMINATED,INTERVENTIONAL,['PHASE4']
11094,NCT02538705,Area of diabetic foot ulcers,Transcutaneous oxygen pressure,,2015-08,COMPLETED,INTERVENTIONAL,['NA']
11095,NCT04409795,Glycated hemoglobin (HbA1c),Area under the plasma concentration versus time curve (AUC) of C-peptide,,2021-08-26,ENROLLING_BY_INVITATION,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
11096,NCT03675360,Change in Hemoglobin A1c,Change in Body Weight,Change in Estimated Atherosclerotic Cardiovascular Disease Risk,2018-09-25,COMPLETED,INTERVENTIONAL,['NA']
11097,NCT00939289,CGM System(s) performance (relative to YSI and/or SMBG) evaluated by standard accuracy metrics,"Documentation of all reported Adverse Device Effects, Serious Adverse Device Events, and Unanticipated Adverse Device Effects",,2008-07,COMPLETED,OBSERVATIONAL,['NA']
11098,NCT04937348,"Anthropometrics: body weight [kg], length [cm], head circumference [cm].",Impact of maternal adipokines on breast milk composition.,,2019-12-13,COMPLETED,OBSERVATIONAL,['NA']
11099,NCT02001753,Changes of endothelium-dependent arterial dilation before and after CMR in type 2 diabetes,Changes of endothelial progenitor cells before and after CMR in peripheral blood,,2013-12,COMPLETED,INTERVENTIONAL,['PHASE4']
11100,NCT03315598,Change from baseline Numeric rating scale pain score (0-10) at 8 weeks,5-pointed patient satisfaction scale,,2017-05-15,COMPLETED,INTERVENTIONAL,['NA']
11101,NCT04780425,Change in mean glaciated heamoglobin (HbA1c) at three months,Change in mean WHO quality of life (WHOQoL BREF) score at three months,,2021-01-26,COMPLETED,INTERVENTIONAL,['NA']
11102,NCT00638209,Insulin effect on cortical function (spectral analysis),,,2008-02,UNKNOWN,INTERVENTIONAL,['NA']
11103,NCT02077452,"Safety and tolerability of HMS5552 will be assessed by adverse event monitoring, physical examinations, 12 lead ECGs, vital sign, and safety laboratory measurements.","Insulin, C-peptide, glucagon and glucagon-like peptide 1 up to 6hr post-dose following single dose and steady state (fasting and postprandial)",,2014-03,COMPLETED,INTERVENTIONAL,['PHASE1']
11104,NCT03279263,Changes in HbA1c between active treatment groups and placebo at Week 12,Changes in Body Weight,,2017-09-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
11105,NCT00315016,blood pressure by home measurements,plasma angiotensins and bradykinins,,2007-01,COMPLETED,INTERVENTIONAL,['PHASE2']
11106,NCT01500928,Device-related adverse outcome,Product quality (MTBF),,2011-07,UNKNOWN,INTERVENTIONAL,['NA']
11107,NCT05232305,Anthropometric Measurements - Hip Circumference,Anthropometric Measurements - Hip Circumference,,2022-03-01,UNKNOWN,INTERVENTIONAL,['NA']
11108,NCT06207838,Between group difference in the percentage of time spent within range with sensor glucose (SG) between 70-180 mg/dL (TIR) (3.9-10.0 mmol/L).,Difference in physical capacity indices listed in screening visit: Four Square Step,,2023-09-14,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
11109,NCT04642911,Overall survival of subject with diabetes 2 type with gene therapy drug product (Mesenchymal Stem Cell) in a Ukraine Association of Biobank bio-sponsored clinical trial who agree to participate in this study,,,2020-10-15,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
11110,NCT02302079,Percent change from baseline in excess central subfield thickness (CST) in the study eye as assessed by spectral domain-optical coherence tomography (SD-OCT) at Month 3,Absolute and percent change from baseline in excess CST in the study eye as assessed by SD-OCT at Months 1 and 2,,2015-01-12,COMPLETED,INTERVENTIONAL,['PHASE2']
11111,NCT00219102,Change from baseline in diastolic blood pressure after 12 weeks,Achieve mean sitting blood pressure control target of < 130/80 mmHg after 12 weeks,,2005-06,COMPLETED,INTERVENTIONAL,['PHASE3']
11112,NCT02317003,Change in total energy expenditure by accelerometry at 3 months compared to baseline,Adherence of doctors and patients to the suggested strategy,,2015-03-16,COMPLETED,INTERVENTIONAL,['NA']
11113,NCT02209662,Complete wound closure within 12 weeks,Improvement in wound healing for the patient to return to function over the 12 weeks,,2014-10,UNKNOWN,INTERVENTIONAL,['NA']
11114,NCT02907346,Change in A1c,,,2016-09-01,COMPLETED,INTERVENTIONAL,['NA']
11115,NCT02984644,Change in EGP With Pancreatic Clamp: Study 3,Change in Glucagon Using Pancreatic Clamp: Study 3,,2017-09-06,COMPLETED,INTERVENTIONAL,['PHASE3']
11116,NCT03076112,Glycated hemoglobin,25-hydroxyvitamin D,,2017-04-25,COMPLETED,INTERVENTIONAL,['PHASE3']
11117,NCT06127433,Intergroup remission rate at 24 week,,,2023-03-07,RECRUITING,INTERVENTIONAL,['PHASE4']
11118,NCT02625636,Number of patients with adverse events,Assessment of PK parameter (recombinant glucagon and SAR438544): partial AUCs (AUC0-t),,2015-12,COMPLETED,INTERVENTIONAL,['PHASE1']
11119,NCT01323348,Change in HbA1c,Body Mass Index,,2011-10,COMPLETED,INTERVENTIONAL,['PHASE3']
11120,NCT04275804,Ulcer size,Foot function,,2022-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
11121,NCT04650165,DR severity level,mfERG assessement,,2021-06-01,RECRUITING,OBSERVATIONAL,['NA']
11122,NCT00950716,Lipid levels,"Cognitive-psychological-behavioral assessments: a) Depression Anxiety and Stress Scale (DASS21). b) Diabetes Empowerment Scale (C-DES). c) Summary of Diabetes Self Care Activities (SDSCA, Chinese version).",,2009-09,COMPLETED,INTERVENTIONAL,['NA']
11123,NCT01176578,Skeletal muscle capillarization,Cardiorespiratory Fitness,,2011-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
11124,NCT00370721,visual acuity,pan retinal photocoagulation,,2006-03,UNKNOWN,INTERVENTIONAL,['PHASE3']
11125,NCT02224417,HbA1c levels,Glucose testing within range,,2015-03,COMPLETED,INTERVENTIONAL,['NA']
11126,NCT01773473,Change From Baseline in Hemoglobin A1c (HbA1c) at Week 26,"Change From Baseline in 1,5-Anhydroglucitol (1,5-AG) at Week 26",,2013-01,COMPLETED,INTERVENTIONAL,['PHASE4']
11127,NCT01622634,Metabolic Syndrome Risk Factors,Satiety,,2012-02,COMPLETED,INTERVENTIONAL,['NA']
11128,NCT03428932,Changes in Gray Matter Volume in the Brain,Changes in WASI-II Perceptual Reasoning Index (PRI),,2018-02-01,COMPLETED,INTERVENTIONAL,['NA']
11129,NCT05000021,Diabetes Distress Levels,Coefficient of Variation (CV) calculated from Continuous Glucose Monitoring (CGM),Hemoglobin A1c,2022-06-27,RECRUITING,INTERVENTIONAL,['NA']
11130,NCT01286090,The change from baseline in Gastroparesis Cardinal Symptoms Index (GCSI) score,The type of adverse events reported,,2003-07,TERMINATED,INTERVENTIONAL,['PHASE4']
11131,NCT04979377,Prevalence of hyperandrogenic PCOS in T1DM,Influence of hyperandrogenism on chronic complications,,2020-03-09,RECRUITING,OBSERVATIONAL,['NA']
11132,NCT01145547,Mean Area Under the Curve for Rise in Breakfast Post-prandial.,,,2009-04,COMPLETED,INTERVENTIONAL,['NA']
11133,NCT01536431,Safety,T cell (immune) response to islet cell antigens,,2012-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11134,NCT00318461,Change in Glycosylated A1c (HbA1c) at Week 104,Hypoglycaemic Episodes at Week 104,,2006-05,COMPLETED,INTERVENTIONAL,['PHASE3']
11135,NCT01599338,"Change in appetite, desire to eat, pleasure in eating","Change in plasma ghrelin, leptin, and HbA1c levels",,2011-01,COMPLETED,INTERVENTIONAL,['NA']
11136,NCT00545337,Change of HbA1c,"Blood glucose parameters, hypoglycemic episodes and dosage of the mealtime and basal insulins",,2004-09,COMPLETED,INTERVENTIONAL,['PHASE3']
11137,NCT00933972,Creatinine clearance; Pk parameters; adverse events,Blood glucose; meal tolerance test,,2009-06,COMPLETED,INTERVENTIONAL,['PHASE1']
11138,NCT00333151,HbA1c,Glycaemic control,,2006-05,COMPLETED,INTERVENTIONAL,['PHASE3']
11139,NCT00095030,Change in baseline HbA1c after 52 weeks,Change in lipids after 52 weeks; safety and efficacy when administered with metformin after 52 weeks,,2004-02,COMPLETED,INTERVENTIONAL,['PHASE3']
11140,NCT02653300,Change in MRI-Proton Density Fat Fraction (MRI-PDFF),Mean Fibrosis Score CAP™ (FibroMax),,2018-09-20,COMPLETED,INTERVENTIONAL,['PHASE2']
11141,NCT01526733,Early Insulin Exposure (%AUC[0-60]),Duration of Insulin Action (AUMC[0-360]/AUC[0-360]),,2011-12,COMPLETED,INTERVENTIONAL,['PHASE4']
11142,NCT00108615,Effects of pioglitazone and metformin on ectopic lipid accumulation,Effects of pioglitazone and metformin on beta cell responsiveness,,2004-01,COMPLETED,INTERVENTIONAL,['PHASE4']
11143,NCT04572802,Gensini score,,,2020-10-10,COMPLETED,OBSERVATIONAL,['NA']
11144,NCT02207374,Number of Treatment Emergent Adverse Events (TEAEs),Change in Glycosylated Haemoglobin A1c (HbA1c),,2014-08-04,COMPLETED,INTERVENTIONAL,['PHASE3']
11145,NCT01648582,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks,Change From Baseline in EQ-5D Visual Analog Scale Score,,2012-07,COMPLETED,INTERVENTIONAL,['PHASE3']
11146,NCT00334581,The difference of urinary albumin excretion rate change,Adverse events,,2006-05,COMPLETED,INTERVENTIONAL,['PHASE4']
11147,NCT02597257,11-point Numeric Rating Scale,11-point Numeric Rating Scale,,2015-08,UNKNOWN,INTERVENTIONAL,['PHASE2']
11148,NCT02268292,Metabolic syndrome,Arterial stiffness,,2012-08,COMPLETED,INTERVENTIONAL,['PHASE4']
11149,NCT00012623,,,,na,COMPLETED,OBSERVATIONAL,['NA']
11150,NCT02385890,Subjective Appetite,Energy/fatigue measured by VAS questionnaire,,2016-10,COMPLETED,INTERVENTIONAL,['NA']
11151,NCT02248077,Complete Ulcer Closure,,,2014-10,WITHDRAWN,INTERVENTIONAL,['PHASE4']
11152,NCT04823442,BAT glucose uptake,Changes in pancreatic and gut hormones,,2021-01-21,COMPLETED,INTERVENTIONAL,['NA']
11153,NCT02631083,Substrate oxidation,,,2014-11-14,COMPLETED,INTERVENTIONAL,['NA']
11154,NCT00290979,Non-inferiority in the efficacy and safety of HMR1964 as compared with Insulin lispro,6-month safety data,,2004-12,COMPLETED,INTERVENTIONAL,['PHASE3']
11155,NCT02204670,Hepatic Triglyceride Content,Post-prandial glucose,,2014-07,COMPLETED,OBSERVATIONAL,['NA']
11156,NCT05212519,Whether suffering from gestational diabetes,,,2022-01-01,UNKNOWN,OBSERVATIONAL,['NA']
11157,NCT03745937,Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs Through the End of the Follow-up Period,Percentage of Participants Achieving Greater Than 5% Body Weight Loss From Baseline to the End of the Treatment Extension Period,,2019-01-07,COMPLETED,INTERVENTIONAL,['PHASE2']
11158,NCT01697228,Hemoglobin A1c,Baseline differences between vitamin D deficient & sufficient subjects,,2012-10,COMPLETED,INTERVENTIONAL,['NA']
11159,NCT01076088,Change From Baseline in Hemoglobin A1C (A1C) at Week 24,Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24,,2010-11-15,COMPLETED,INTERVENTIONAL,['PHASE3']
11160,NCT02544321,Hyperemia Peripheral Arterial Tonometry (RH-PAT): Reactive Hyperemia Index (RHI),Metabolic Markers - Insulin,,2015-09,COMPLETED,INTERVENTIONAL,['PHASE2']
11161,NCT04510493,unmatched win ratio after treatment with canakinumab compared to Placebo (composite endpoint),Number of antidiabetic treatment at three months,,2020-10-23,COMPLETED,INTERVENTIONAL,['PHASE3']
11162,NCT02169518,Paraoxonase activity is measured using a semi-automated microtitre plate method.,,,2012-07-05,RECRUITING,OBSERVATIONAL,['NA']
11163,NCT02989831,Difference in center of pressure displacement (balance) between the two conditions.,Difference in anteroposterior velocity of the centre of pressure displacements between the two conditions (insoles 'on' or 'off'),,2014-04,COMPLETED,INTERVENTIONAL,['NA']
11164,NCT00862251,Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) After Switching to Treatment With Ezetimibe/Simvastatin vs Doubling the Dose of Statin (Simvastatin or Atorvastatin).,Percent Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP),,2009-04,COMPLETED,INTERVENTIONAL,['PHASE3']
11165,NCT03478969,"Treatment Satisfaction: Accu-Chek® Micropump System vs. Mylife™ OmniPod®, Measured by the Difference in the Diabetes Technology Questionnaire (DTQ) Total Change Score","Amount of Waste, Inferred by Total Material Consumption",,2018-05-17,COMPLETED,INTERVENTIONAL,['NA']
11166,NCT05705869,Diagnosis of heart failure within 6 months,People diagnosed with HFrEF receiving GDMT within 6 months,"The number of patients in the NT-proBNP/echocardiography group with echocardiographic features of potential amyloid as assessed by the US2.ai algorithm report conclusion of ""amyloid to be considered""",2022-12-22,RECRUITING,INTERVENTIONAL,['NA']
11167,NCT05427890,Differences in behaviour intention between arms,Empirical evidence of using PMT constructs in developing interventions,Objective Risk Score,2022-06-20,COMPLETED,INTERVENTIONAL,['NA']
11168,NCT03193229,Total number of steps per day,Pace of steps per day,Sedentary minutes per day,2017-05-15,COMPLETED,INTERVENTIONAL,['NA']
11169,NCT02967653,"Raw Urine Osmolality value at 12 week follow-up, adjusted for baseline (UOsm in mOsm/Kg)","Raw Self-Reported Fluid Intake value 12 week follow-up, adjusted for baseline","Subgroup Analyses - Raw Urine Osmolality value at 12 week follow-up, adjusted for baseline in patients UOsm <300mOsm/Kg",2017-07-13,COMPLETED,INTERVENTIONAL,['PHASE2']
11170,NCT04316052,International Restless Leg Syndrome Study Group Rating Scale: (International tool for finding the severity of RLS),The Pittsburgh Sleep Quality Index (PSQI).,Epworth Sleepiness Scale (ESS),2020-02-15,COMPLETED,INTERVENTIONAL,['NA']
11171,NCT04018365,HbA1c change at Week 24 of the treatment from baseline,Postprandial glucose for 2 hours over time,,2019-09-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
11172,NCT06141980,Efficacy outcome_Proportion of subjects achieving HbA1c target of < 7.0 %,,,2023-12,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
11173,NCT03855514,Length of time that a wound achieves complete wound closure (CWC),Time to complete wound closure (CWC) by or on 24 weeks,,2019-02-08,UNKNOWN,INTERVENTIONAL,['NA']
11174,NCT01447147,Subject incidence of adverse events,Change from baseline in first morning urinary albumin:creatinine ratio (ACR),,2011-10,COMPLETED,INTERVENTIONAL,['PHASE2']
11175,NCT02542059,Beta cell mass measured by uptake of 68Ga-exendin in the pancreas on PET images,Comparing uptake of 68Ga-exendin in the pancreas with blood glucose and insulin measured after glucose ingestion and arginine infusion,,2015-08,RECRUITING,OBSERVATIONAL,['NA']
11176,NCT01740921,change of baseline skin maximum hyperaemia at 4 months,change of baseline capillary density at 4 months,change of baseline adipose tissue inflammation at 4 months,2011-01,COMPLETED,INTERVENTIONAL,['NA']
11177,NCT01128829,The Effect of Sucralose on Insulin Concentration (Area Under the Curve; AUC),,,2010-05,COMPLETED,INTERVENTIONAL,['NA']
11178,NCT01542463,Fasting plasma glucose (FBG),Hypoglycaemic episodes,,2004-09,COMPLETED,OBSERVATIONAL,['NA']
11179,NCT01649570,Incidence of hypoglycaemia,"Glycaemic control parameters: Glycosylated haemoglobin A1c (HbA1c), fasting plasma glucose (FPG) and post-prandial plasma glucose (PPPG)",,2002-03,COMPLETED,INTERVENTIONAL,['PHASE4']
11180,NCT04518566,Patient activation score as measured by patient activation measure,HbA1c,,2021-05-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
11181,NCT01733134,Dyspnea,Rehospitalization,,2013-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
11182,NCT00224796,To determine the effect of V.A.C. ® Therapy on the incidence of complete wound closure.,To determine the effect of V.A.C. ® Therapy on the quality of life,,2002-05,COMPLETED,INTERVENTIONAL,['PHASE4']
11183,NCT02937987,Change of Weight,,,2016-04,COMPLETED,OBSERVATIONAL,['NA']
11184,NCT00543738,,,,2003-06,TERMINATED,INTERVENTIONAL,['PHASE3']
11185,NCT01736228,to establish the efficacy and safety of DIABECELL,Improvement in the quality-of-life of xenotransplant recipients,,2012-11,COMPLETED,INTERVENTIONAL,['PHASE2']
11186,NCT03304938,Pittsburgh Insomnia Rating Scale,Diastolic Blood Pressure,,2018-02-01,COMPLETED,INTERVENTIONAL,['NA']
11187,NCT02567994,Change of HbAlc from baseline at Week 24,,,2015-04,COMPLETED,INTERVENTIONAL,['PHASE3']
11188,NCT03741972,Change in cardiac biomarkers,Improve in the 6-minute walk,,2018-12-21,COMPLETED,OBSERVATIONAL,['NA']
11189,NCT03620773,Glomerular Filtration Rate (GFR),Aortic Stiffness & Wall Shear Stress,Epigenetic profiling,2018-10-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11190,NCT05189938,Establish a relationship between laboratory-derived HbA1c and average glucose levels,,,2021-12-20,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
11191,NCT00005262,,,,1990-07,COMPLETED,OBSERVATIONAL,['NA']
11192,NCT04208282,Primary,Exploratory outcomes,Adverse Events,2017-07-01,COMPLETED,INTERVENTIONAL,['NA']
11193,NCT02769585,Change in weight (BMI),Degree of weight loss in obese versus overweight,,2013-07,COMPLETED,INTERVENTIONAL,['NA']
11194,NCT03132181,Mode of action,Metabolism,,2017-04-24,COMPLETED,INTERVENTIONAL,['PHASE2']
11195,NCT00611884,Change in Glycosylated Haemoglobin (HbA1c),Physical Examination,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE2']
11196,NCT00786825,Brain Glycogen Turnover Rate,,,2004-12,COMPLETED,INTERVENTIONAL,['PHASE2']
11197,NCT04191525,HOMA-IR,Waist perimeter,Mediterranean diet adherence score,2018-09-10,COMPLETED,INTERVENTIONAL,['NA']
11198,NCT02773875,Amount of time sensor glucose levels are >250 mg/dl,Percent of time in range between 70-180 mg/dl,,2016-05,UNKNOWN,INTERVENTIONAL,['NA']
11199,NCT05980455,Scoring Change in Nausea Severity by GCSI-DD,Mean Change from Baseline in Quality of Sleep Scores,,2023-07-10,RECRUITING,INTERVENTIONAL,['NA']
11200,NCT05506215,Percentage of ulcer closed at 12 weeks,The type and number of serious adverse events experienced,,2022-07-10,TERMINATED,INTERVENTIONAL,['NA']
11201,NCT01735253,Hemoglobin A1C,oral glucose tolerance test,insulin level,2009-12,COMPLETED,INTERVENTIONAL,['NA']
11202,NCT02308059,Pain scores on the visual analog scale,Neuropathic pain scores on the Leeds Assessment of Neuropathic Symptoms and Signs pain scale,,2012-04,COMPLETED,OBSERVATIONAL,['NA']
11203,NCT00607230,concentration of autoreactive t-cells,"Concentration of TNF, TNF-receptors, other cytokines, and c-peptide levels",,2007-11,COMPLETED,INTERVENTIONAL,['PHASE1']
11204,NCT00781313,The primary aim is to ascertain the emergency preparedness among our families with diabetes mellitus and to obtain a percentage of unprepared to the ones who are prepared.,,,2008-06,COMPLETED,OBSERVATIONAL,['NA']
11205,NCT01068652,Glycosylated Haemoglobin (HbA1c),Mean of 8-point Plasma Glucose (PG) Profile After 50 Weeks of Treatment,,2010-03,COMPLETED,INTERVENTIONAL,['PHASE4']
11206,NCT02092220,Percentage of Time Spent With CGMG Concentration < 60 mg/dL During Days 2 to 11,Number of Participants With Skin Rash,CGM Mean Absolute Relative Differences (MARD) Versus Time-stamped Blood Glucose (BG) Values From Meter Downloads,2014-04,COMPLETED,INTERVENTIONAL,['NA']
11207,NCT03031834,Changes in blood pressure response to standing,,,1999-01,COMPLETED,INTERVENTIONAL,['PHASE4']
11208,NCT02259088,Mean Average Change From Baseline in Best-Corrected Visual Acuity (BCVA) (Letters) to Month 1 Through 12,Mean Number of Ranibizumab Re-treatments Received in the Study Eye From Month 3 Onward,,2014-11-05,COMPLETED,INTERVENTIONAL,['PHASE3']
11209,NCT02011633,"metformin, rosuvastatin AUClast","Metformin, rosuvastatin AUCinf",,2013-10,COMPLETED,INTERVENTIONAL,['PHASE1']
11210,NCT01867307,Change From Baseline of Renal Tubular Maximum Reabsorptive Capacity for Glucose (TmG) at End of Empagliflozin Treatment (Day 14),,,2013-06,COMPLETED,INTERVENTIONAL,['PHASE2']
11211,NCT03591458,Ratio of Self-Reported Hypoglycemic Episodes to Total Hypoglycemic Episodes,Hypoglycemia Fear Survey Score,,2018-08-01,TERMINATED,INTERVENTIONAL,['PHASE2']
11212,NCT05921097,Comparison of axon-reflex flare responses with QST,Comparison of axon-reflex flare responses with NC-Stat DPNCheck,DPN severity and pain,2023-06-17,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
11213,NCT01507272,AUC (area under the curve),"t½, terminal half-life",,1999-03,COMPLETED,INTERVENTIONAL,['PHASE1']
11214,NCT05606471,Muscle protein breakdown rate,Right vastus lateralis muscle fibre pennation angle,,2021-09-15,RECRUITING,INTERVENTIONAL,['PHASE4']
11215,NCT03417076,absolute bioavailability (Fp.o.) of bexagliflozin tablets,adverse events,,2018-08-01,WITHDRAWN,INTERVENTIONAL,['PHASE1']
11216,NCT00929838,Hemoglobin A1c (HbA1c) at 12 Months Post Randomization,,,2008-08,COMPLETED,INTERVENTIONAL,['NA']
11217,NCT04088851,"The gluconeogenic flux rates from pyruvate (lactate, alanine) and glycerol are higher in patients with T2D compared to the healthy control group.",,,2019-09-11,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
11218,NCT00225277,Nominal Change From Baseline in Percent Atheroma Volume,Number of Subjects Experiencing Any of the Composite Endpoint C Cardiovascular Events,Number of Cardiovascular Events as Adjudicated by the Clinical Endpoint Committee,2003-07,COMPLETED,INTERVENTIONAL,['PHASE3']
11219,NCT02258945,Eating behaviours of adult patients with Type 1 diabetes using continuous subcutaneous insulin infusion therapy measured using food diaries and food surveys.,Cardiometabolic risks of adult patients with Type 1 diabetes who are using insulin pump therapy.,,2014-04,COMPLETED,OBSERVATIONAL,['NA']
11220,NCT00403884,Visual acuity,reduction of retinal edema,,2004-10,UNKNOWN,INTERVENTIONAL,['NA']
11221,NCT02759289,Change in platelet activity in response to arsenic exposure measured by Regression models,,,2015-11,COMPLETED,OBSERVATIONAL,['NA']
11222,NCT03622424,weight loss of >5.0% in at least 35% of prediabetic subjects or in at least 25% of diabetic subjects on Gelesis200.,"improvement in FPG status, post-OGTT plasma glucose status, or post-OGTT plasma glucose AUC in ≥50% of subjects on Gelesis200.",Number of TEAE for Gelesis200 similar to placebo or clinically acceptable.,2017-08-22,COMPLETED,INTERVENTIONAL,['NA']
11223,NCT00177138,"Time-to-event analysis will be used to analyze categorical end points that include graft failure, patient survival, biopsy documented rejection episode and non-compliance.","The continuous outcome variable, weekly or bi-weekly serum creatinine levels, will be analyzed using a two-way repeated-measures analysis of variance.",,2004-07,TERMINATED,INTERVENTIONAL,['PHASE4']
11224,NCT02289066,markers of bone turnover (bone specific alkaline phosphatase and C terminal,Evaluation of the relationship between periodontal disease and diabetes control and complications,,2013-11,COMPLETED,OBSERVATIONAL,['NA']
11225,NCT00434499,Improvement in insulin resistance,Improvement in endothelial dysfunction,,2007-02,WITHDRAWN,INTERVENTIONAL,['PHASE2']
11226,NCT01829477,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24,Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24,,2013-04,TERMINATED,INTERVENTIONAL,['PHASE3']
11227,NCT05838586,iAUC of SBP,Net iAUC of HR,,2023-07-31,RECRUITING,INTERVENTIONAL,['NA']
11228,NCT01774058,"The measurement of the blood flow volume is done with the Sono TT FlowLab (em-Tec GmbH, Munich) ultrasound instrument on the common femoral artery in diabetics and non-diabetics after ilomedin administration.",,,2012-10,UNKNOWN,INTERVENTIONAL,['PHASE2']
11229,NCT01855490,Effect of exenatide on metabolic responses to an oral (as a mixed meal) or intravenous glucose challenge in subjects with established T1D with or without residual insulin production.,"Effect of exenatide on insulin secretion, glucagon secretion, GLP-1 and GIP levels, and gastric emptying in these patients with T1D. - effect of exenatide on residual insulin production",,2012-01,COMPLETED,INTERVENTIONAL,['PHASE1']
11230,NCT04971655,State-Trait Anxiety Inventory (STAI),,,2021-08-04,UNKNOWN,INTERVENTIONAL,['NA']
11231,NCT01180608,cerebral neurobiological effect of pregabaline as treatment for neuropathic pain,cerebral neurobiological changes in relationship with dose dependent therapeutic effect of treatment with pregabaline,,2010-09,UNKNOWN,INTERVENTIONAL,['NA']
11232,NCT02008851,Number of adverse events related to study procedures or investigational product,Number of renal-specific adverse events,Changes in renal function over time,2013-12,TERMINATED,INTERVENTIONAL,['PHASE1']
11233,NCT01746563,Macular Evaluation,Structural Macular Evaluation,,2011-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11234,NCT02111291,Time to Well-established Granulation Tissue,Adverse Event,,2014-04,COMPLETED,INTERVENTIONAL,['PHASE4']
11235,NCT01087073,"Lipids (HDL, LDL, total cholesterol, triglycerides)",Processes of care,,2009-01-01,COMPLETED,INTERVENTIONAL,['NA']
11236,NCT02452086,"The blood serum level of VEGF(pg/ml), VEGFR-2(pg/ml), HIF-1α(pg/ml) and NO (pg/ml)",Ankle Brachial Index(ABI),,2013-06,COMPLETED,INTERVENTIONAL,['NA']
11237,NCT00839527,Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 52,Change From Baseline in Body Weight at Week 104 and Week 156,,2009-02,COMPLETED,INTERVENTIONAL,['PHASE3']
11238,NCT02246712,"Kinetic parameters (AUC, Cmax, Tmax, apparent total clearance, and apparent volume of distribution) of tramadol enantiomers were estimated.",Pain scores on the visual analog scale,,2008-06,COMPLETED,INTERVENTIONAL,['PHASE4']
11239,NCT02490124,Contrast Enhanced Ultrasound,,,2014-12,COMPLETED,OBSERVATIONAL,['NA']
11240,NCT03776448,Fasting venous blood glucose,Gastrointestinal symptoms,,2019-01,UNKNOWN,INTERVENTIONAL,['NA']
11241,NCT05552872,Survival at 7 Days,SOFA Indexs,,2022-09-01,RECRUITING,OBSERVATIONAL,['NA']
11242,NCT02799953,changes in systolic and diastolic blood pressure,changes in answering hypertension knowledge questions,,2016-03,COMPLETED,INTERVENTIONAL,['NA']
11243,NCT00933530,"Characterize the pharmacokinetic profile of SRT2104 (0.03, 0.1, 0.25, 0.5, 1.0, 2.0, and 3.0 g/day) when administered as a single dose and when administered as once daily for 7 consecutive days.",,,2008-05,COMPLETED,INTERVENTIONAL,['PHASE1']
11244,NCT01691287,Metabolic Control measured as HbA1c level,Number of Diabetic Keto Acidosis events,,2012-10,COMPLETED,INTERVENTIONAL,['NA']
11245,NCT04142424,Number of subjects experiencing adverse events and serious adverse events,Fraction of dose excreted unchanged into the urine from time t1 to t2 [fe(t1-t2)],,2019-10-28,COMPLETED,INTERVENTIONAL,['PHASE1']
11246,NCT06101901,Rate of patients who remain in a diabetic kidney disease clinical trial to trial completion,,,2024-11,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
11247,NCT01890954,Percent of Time Spent Near Normoglycemia,,,2013-08,COMPLETED,INTERVENTIONAL,['NA']
11248,NCT04379427,Performance and accuracy of heart rate,,,2019-03-25,COMPLETED,INTERVENTIONAL,['NA']
11249,NCT00368693,Complete ulcer closure will be defined as complete re-epithelialization without the presence of any callus and/or exudate.,,,2005-08,TERMINATED,INTERVENTIONAL,['PHASE3']
11250,NCT00123643,Flow Mediated Dilation,,,2003-05,COMPLETED,INTERVENTIONAL,['PHASE4']
11251,NCT01357135,Percentage of Participants With Strict Changes in Initial Dual Therapy,,,2009-07-15,COMPLETED,OBSERVATIONAL,['NA']
11252,NCT04317430,Estimated glomerular filtration rate (eGFR),Change of Urinary podocalyxin level,Change of Urinary 8-hydroxy-2' -deoxyguanosine (8-OHdG) level,2020-02-01,COMPLETED,INTERVENTIONAL,['PHASE3']
11253,NCT05993741,Plaque Control Record (PCR),Oral Health Related Quality of Life(OHRQoL),,2023-01-01,RECRUITING,INTERVENTIONAL,['NA']
11254,NCT04029298,Change in hemoglobin A1c,Adherence to treatment,,2023-03-01,WITHDRAWN,INTERVENTIONAL,['NA']
11255,NCT04190511,Weight change during pregnancy,,,2019-12-10,COMPLETED,INTERVENTIONAL,['NA']
11256,NCT05949008,Change in total body weight from baseline,Percent change in % body fat from baseline,,2023-11-22,RECRUITING,INTERVENTIONAL,['PHASE4']
11257,NCT00018122,,,,na,UNKNOWN,OBSERVATIONAL,['NA']
11258,NCT05195502,Evaluation of metabolic profile,Colonic biofilm,,2022-07-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
11259,NCT03270592,"Health related quality of life, EQ-5D",EQ-VAS,,2009-09-17,COMPLETED,INTERVENTIONAL,['NA']
11260,NCT00212329,,,,2005-09,COMPLETED,OBSERVATIONAL,['NA']
11261,NCT04213547,Qualitative data from focus group,BMI,,2020-09-16,RECRUITING,INTERVENTIONAL,['NA']
11262,NCT05925010,postprandial blood glucose,difference between fasting blood glucose value and postprandial blood glucose value,,2023-01-02,RECRUITING,INTERVENTIONAL,['NA']
11263,NCT05603273,wound size and depth,blood flow,,2023-12-13,RECRUITING,INTERVENTIONAL,['NA']
11264,NCT05370014,Change in patient-reported outcomes measurement information system (PROMIS) Global Health Scale,Change in Modified Medical Outcomes Study Social Support Survey Instrument (mMOS-SS),,2023-01-03,RECRUITING,INTERVENTIONAL,['NA']
11265,NCT01091909,postoperative complications,Delayed wound healing,,2010-03,COMPLETED,INTERVENTIONAL,['NA']
11266,NCT01143168,Rate of reducing exogenous insulin requirement; Hemoglobin A1c; Fast blood glucose (FBG) and postmeal blood glucose (PBG); C-peptide levels.,Serious adverse event frequency and severity,,2010-08,UNKNOWN,INTERVENTIONAL,['PHASE1']
11267,NCT04098575,Percentage of Participants With Antidiabetic and Cardiovascular Co-medication,Fasting Plasma Glucose (FPG),,2019-09-16,COMPLETED,OBSERVATIONAL,['NA']
11268,NCT05505565,Progression of prediabetes,Glycemic metrics,,2023-06-05,RECRUITING,INTERVENTIONAL,['NA']
11269,NCT01027585,,,,2009-05,COMPLETED,OBSERVATIONAL,['NA']
11270,NCT01698528,Glycemic Control as Determined by the Change in Absolute HbA1c Level,Time Health Care Providers and Subjects Spend on Managing the Insulin Titration,,2012-10,COMPLETED,INTERVENTIONAL,['NA']
11271,NCT01130012,Number of at risk participants developing GDM during pregnancy,The effect of intervention on fetal growth,,2005-04,COMPLETED,INTERVENTIONAL,['NA']
11272,NCT00538642,Insulin Sensitivity,LDL Cholesterol,,2007-08,COMPLETED,INTERVENTIONAL,['NA']
11273,NCT04420650,Change in subjective feeling of hunger and food craving,Diffusion-weighted imaging,,2020-05-26,COMPLETED,INTERVENTIONAL,['NA']
11274,NCT04808804,RNFL thickness,,,2021-06,UNKNOWN,OBSERVATIONAL,['NA']
11275,NCT05028140,Glycated hemoglobin,Adverse events,,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
11276,NCT04093284,Blood glucose profile,Sensitivity Questionnaire of Patients,,2019-09-12,UNKNOWN,INTERVENTIONAL,['NA']
11277,NCT00102297,Pharmacokinetics,Bioactivity on urinary and plasma markers,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE1']
11278,NCT03445247,changes of proteinuria,changes of systolic and diastolic blood pressure,,2017-07-01,UNKNOWN,INTERVENTIONAL,['NA']
11279,NCT01830348,The proportion of subjects with a target ulcer which achieves complete wound closure (skin re-epithelialization without drainage or dressing requirements) up to 10 weeks (confirmed at a study visit 2 weeks later).,Time to the visit where the target ulcer achieves confirmed complete wound closure,"Incidence of target ulcer recurrence, time to ulcer recurrence, and number of days target ulcer remains closed after confirmed complete wound closure has been established.",2013-02,TERMINATED,INTERVENTIONAL,['PHASE3']
11280,NCT05099939,Change in lung function,CFRD diagnosis,,2021-11-25,RECRUITING,OBSERVATIONAL,['NA']
11281,NCT05786001,Oxygenation in lower limb angiosomes assessed by hyperspectral imaging.,,,2023-04-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
11282,NCT00644241,"Increment in glucagon stimulated C - peptide levels at the end of 6 months of ABMSCT, as compared to baseline",Improvement of HbA1c levels as compared to baseline,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE2']
11283,NCT00131755,Glycemic control (measured by blood glucose),Side effects,,2005-02,COMPLETED,INTERVENTIONAL,['PHASE4']
11284,NCT03286816,the effect of exogenous lactate on brain lactate concentrations during euglycemia and hypoglycemia between T1DM patients with normal awareness of hypoglycemia and T1DM patients with impaired awareness of hypoglycemia,Changes in immune cell cytokine production capacity in response to hypoglycemia compared to euglycemia and in response to lactate infusion compared to placebo,,2016-11,COMPLETED,INTERVENTIONAL,['NA']
11285,NCT02734745,accuracy of freestyle Libre flash monitoring,Evaluate the accuracy of the Free Style Libre for each day of use and during hyperglicemia ( >180 mg / dl ),,2016-04-01,UNKNOWN,INTERVENTIONAL,['NA']
11286,NCT01664637,Change from baseline in symptoms associated with diabetic gastroparesis,"Adverse events (AEs), vital signs, ECGs, clinical laboratory parameters",,2012-08,TERMINATED,INTERVENTIONAL,['PHASE2']
11287,NCT02345967,Number of Adverse Events,,,2015-01,COMPLETED,INTERVENTIONAL,['NA']
11288,NCT01239849,Percentage of subjects in the total LDL cholesterol group achieving their LDL cholesterol target after 8 weeks of treatment.,"5. Safety of atorvastatin through laboratory assessment, physical examination, vital signs, and adverse events.",,2009-02,UNKNOWN,INTERVENTIONAL,['PHASE4']
11289,NCT01634282,Incidence and severity of adverse events,,,2009-08,COMPLETED,INTERVENTIONAL,['PHASE3']
11290,NCT02883842,Change in glucose level measured by HbA1C level,Change in low-density lipoprotein cholesterol (LDL-C) level,,2016-08,COMPLETED,INTERVENTIONAL,['NA']
11291,NCT04670666,Change from baseline in glycated hemoglobin (HbA1c) levels.,Incidence and severity of adverse events recorded during the study.,,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
11292,NCT01608932,Number of emergency hospitalisations,"Anxiety and depression status as measured by Hospital Anxiety and Depression Scale, HADS.",,2012-04,COMPLETED,INTERVENTIONAL,['NA']
11293,NCT06283264,1-Prevalence of coeliac disease among diabetic type 2 patient 2-its effect on glycemic control,,,2024-03-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
11294,NCT04112875,Changes in Endothelium-dependent and endothelium-independent vasodilation,Body composition by DXA,,2016-04,COMPLETED,INTERVENTIONAL,['NA']
11295,NCT01106651,Change in HbA1c From Baseline to Week 26,Percent Change in Total Hip Bone Mineral Density (BMD) From Baseline to Week 26,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE3']
11296,NCT01087567,The need for rescue therapy,"A1c,C-peptide. Time to normoglycemia and rescue therapy. Mean glucose, mean FBG, HOMA-B, HOMA-IR. Hypoglycemic events (minor and major. Tolerability based on side effects.",,2010-07,COMPLETED,INTERVENTIONAL,['PHASE4']
11297,NCT01414920,Change from Baseline in Glycosylated Hemoglobin (HbA1c),Change from Baseline in Fasting Plasma Glucose,,2011-08,COMPLETED,INTERVENTIONAL,['PHASE2']
11298,NCT02472717,The change in the proportion of patients achieving an ACR 20% improvement response in patients with psoriatic arthritis receiving liraglutide for 12 weeks compared to placebo,"The effect(s) of liraglutide on the enumeration of circulating T-cell subpopulations, and on activation of circulating T-cell subpopulations",The effect of liraglutide on levels of infiltrating dermal T cells and cytokines in psoriatic skin plaques from patients with psoriatic arthritis receiving liraglutide therapy for 12 weeks compared to those receiving placebo,2015-05,WITHDRAWN,INTERVENTIONAL,['PHASE2']
11299,NCT02648854,Cmax of Metformin,Vd/F of Metformin,,2015-10,COMPLETED,INTERVENTIONAL,['PHASE1']
11300,NCT01250106,Insulin resistance,body weight,,2010-11,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11301,NCT02845024,Periodontal pocket depth,glycated hemoglobin (HbA1c),,2014-09,COMPLETED,INTERVENTIONAL,['NA']
11302,NCT04523454,Questionnaire - Number of women who have had the importance of a planned pregnancy explained to them,,,2020-10-02,COMPLETED,OBSERVATIONAL,['NA']
11303,NCT02928952,Problem Areas in Diabetes Scale (PAID) -(Measures Diabetes Distress),Summary of Diabetes Self-Care Activities (SDSCA)- - Medication Adherence,Insomnia Severity Index (ISI),2016-11-01,COMPLETED,INTERVENTIONAL,['NA']
11304,NCT01250340,Changes of isoprostanes after study drug administration.,,,2010-08,UNKNOWN,INTERVENTIONAL,['PHASE4']
11305,NCT06125119,Diabetyping,Diabetyping,Self-reported experiences with capillary blood sampling in an at home setting,2024-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
11306,NCT02019446,Side effects from laser treatment,Quality of Life,,2018-07,UNKNOWN,INTERVENTIONAL,['NA']
11307,NCT05577390,The Impact of INF® Therapy and Standard Physical Therapy on Heart Rate Variability,The impact of INF® Therapy and Standard Physical Therapy on inflammation,,2024-01-08,RECRUITING,INTERVENTIONAL,['NA']
11308,NCT04416269,Mean daily BG concentration,Patient antihyperglycemic drug preference survey,,2020-08-07,RECRUITING,INTERVENTIONAL,['PHASE4']
11309,NCT01049152,-Hemodialysis tolerability -Hypoglycemia numbers -Hyperglycemia numbers -Inflammation markers,variations of glycemia during the night; insulin-sensitivity,,2009-07-31,COMPLETED,OBSERVATIONAL,['NA']
11310,NCT02153879,HDL particles size and number assessed by nuclear magnetic resonance (NMR) and reported as nm and micromol/L,"Apolipoprotein A1 (Apo A1), apolipoprotein A2 (Apo A2), paraoxonase (PON) HDL concentration (g/l - mg/l)",Lecithin-cholesterol acyltransferase (LCAT) and cholesteryl ester transfer protein (CETP) activity (AU - pmol/h*μl) and mass (microg/ml),2009-02,COMPLETED,INTERVENTIONAL,['PHASE4']
11311,NCT02406586,Change in Flow-mediated Dilation,Change in Expression of Inflammatory Biomarker C-Reactive Protein (CRP),,2009-07,COMPLETED,INTERVENTIONAL,['NA']
11312,NCT00719108,The area under the GIR-time curve at steady state from 240 to 300 minutes (AUCGIR-SS),"PD Endpoints: Area under the GIR-time curve from 0 to 7 hours, GlR at steady state. PK Endpoints: AUCINS-SS, AUCINS0-7h, CLtot, VSS, t1/2 ,Terminal rate constant Safety Endpoints: AE, Lab assessments, Vital signs, Phy Exam, ECG & Hypoglycemia.",,2008-07,COMPLETED,INTERVENTIONAL,['PHASE1']
11313,NCT02370680,change in platelet aggregation,Safety as measured by the number and system class of adverse events reported in each treatment arm,urinary metabolites of prostacyclin and thromboxane,2015-02,COMPLETED,INTERVENTIONAL,['PHASE1']
11314,NCT05738655,Hormone analysis,,,2023-03-01,RECRUITING,INTERVENTIONAL,['NA']
11315,NCT02077348,"Insulin and growth hormone signalling, expressed as CHANGE in phosphorylation of intracellular target proteins and CHANGE in mRNA expression of target genes in muscle- and fat-tissue.",Ghrelin,,2014-05,COMPLETED,INTERVENTIONAL,['NA']
11316,NCT02678390,Plasma Ketone Concentrations,Plasma Insulin Concentrations,,2015-09,COMPLETED,INTERVENTIONAL,['NA']
11317,NCT04171557,All-cause Mortality,Cause specific mortality: Cardiovascular,All-cause Mortality,2019-11-20,UNKNOWN,OBSERVATIONAL,['NA']
11318,NCT04081064,Insulin sensitivity,Fasting Plasma glucose,Heart rate during exercise sessions,2019-01-15,UNKNOWN,INTERVENTIONAL,['NA']
11319,NCT01753921,Unique signal measured in Hertz,,,2011-11,COMPLETED,OBSERVATIONAL,['NA']
11320,NCT05080530,Change from baseline in serum vitamin D.,,,2021-10-29,RECRUITING,INTERVENTIONAL,['NA']
11321,NCT04270097,Genetic risk variants associated with increased risk of T2D in Emiratis,,,2016-03-23,UNKNOWN,OBSERVATIONAL,['NA']
11322,NCT00672204,The Proportion of Insulin-independent Subjects With Full Islet Graft Function,,,2007-11,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11323,NCT02327286,Incident diabetes mellitus,Weight at one year post randomization,,2015-01,COMPLETED,INTERVENTIONAL,['NA']
11324,NCT04708574,Change in nutrition assessment from baseline to post intervention,Change in steps per day from baseline to post intervention,,2006-03-08,COMPLETED,INTERVENTIONAL,['NA']
11325,NCT01586481,Healing duration of the diabetic foot ulcer,Compliance of patients to footwear,,2011-06,COMPLETED,INTERVENTIONAL,['PHASE3']
11326,NCT05568277,Diabetes Self-Efficacy Scale,,,2023-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
11327,NCT03211182,blood sugar,Metabolic syndrome,,2012-03-07,UNKNOWN,INTERVENTIONAL,['NA']
11328,NCT05497232,Patient survival & pancreas graft survival & renal graft survival,,,2022-09-01,RECRUITING,INTERVENTIONAL,['NA']
11329,NCT00631774,The primary objective of this study is to evaluate the effect of a diet program including Glucerna SR as a meal replacement on postprandial glucose response after using Glucerna SR for 24 weeks in obese Asian subjects with type 2 diabetes,"evaluate the efficacy and safety of a meal replacement program with Glucerna SR vs. an EDP based on the nutrition therapy recommendations from the ADA on anthropometric measurements, lipid profile, meal-related metabolic changes and quality of life",,2007-11,COMPLETED,INTERVENTIONAL,['NA']
11330,NCT03768973,Changes in intrapulmonary shunt fraction,,,2019-02-01,UNKNOWN,OBSERVATIONAL,['NA']
11331,NCT05984238,Percentage of patients off insulin at 24 weeks [efficacy],Secondary efficay endpoint 1 - HbA1c 48 weeks,,2023-08-03,RECRUITING,INTERVENTIONAL,['NA']
11332,NCT02801942,"Percentage of Leukocyte Subsets Including CD15s+ Memory Conv T Cells, CD69+ Memory Conv T Cells, Helios+ Memory Conv T Cells and Ki67+ Memory Conv T Cells in iLN",Number of Participants Who Appreciated Receiving Study Feedback,,2016-07-25,COMPLETED,INTERVENTIONAL,['NA']
11333,NCT00013117,,,,na,COMPLETED,INTERVENTIONAL,['NA']
11334,NCT02465515,Time to First Occurrence of Major Adverse Cardiovascular Events (MACE) During Cardiovascular (CV) Follow-up Time Period,Change From Baseline in Heart Rate,,2015-07-01,COMPLETED,INTERVENTIONAL,['PHASE4']
11335,NCT01680185,Glycosylated hemoglobin (HbA1c),Serum creatinine,,2012-08,COMPLETED,INTERVENTIONAL,['PHASE3']
11336,NCT05543564,BCVA,,,2019-02-01,COMPLETED,OBSERVATIONAL,['NA']
11337,NCT00541983,Glycated hemoglobin (HbA1c) at Days 0 and 28.,Assessment of inflammatory markers CRP and ESR collected at time points specified in the protocol.,,2007-09,COMPLETED,INTERVENTIONAL,['PHASE1']
11338,NCT05362058,Change from Baseline in Hemoglobin A1c (HbA1c),Change from Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L),,2022-06-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
11339,NCT02621580,"The rate of structural and functional changes to the retinal thickness following PASCAL PRP in severe PDR patients, assessed by optical coherence tomography.",,,2012-09,COMPLETED,INTERVENTIONAL,['NA']
11340,NCT05984771,Measurement of electrochemical skin conductance,vitamin B12 levels,,2021-01-10,COMPLETED,INTERVENTIONAL,['NA']
11341,NCT01153438,change in glucose tolerance after surgery (measured by glucose area under the curve),change in glucose tolerance before and after a GLP-1 receptor blocker is administered,,2011-04,COMPLETED,OBSERVATIONAL,['NA']
11342,NCT01283113,Visceral fat level,,,2010-08,COMPLETED,OBSERVATIONAL,['NA']
11343,NCT01922817,Magnitude of epinephrine release at 2.5mmol/L,,,2012-09,COMPLETED,INTERVENTIONAL,['PHASE3']
11344,NCT04416503,HbA1c levels (%),,,2018-07-01,COMPLETED,INTERVENTIONAL,['NA']
11345,NCT03320993,Plasma Glucose,AUC-PG,Hormones and metabolites,2018-10-25,COMPLETED,INTERVENTIONAL,['NA']
11346,NCT03433248,GFR,Blood Pressure (Dinamap®),Glucagon (mg/L),2017-11-09,UNKNOWN,INTERVENTIONAL,['PHASE4']
11347,NCT02081326,Change in HbA1c values in juvenile onset type 1 diabetics,Autoimmunity in juvenile onset type 1 diabetes (AOO<21 years),COVID-19 and BCG Adaptive Study: Reported Rates of Infectious Diseases,2015-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
11348,NCT01172093,presence of OSA,glycemic control,,2007-01,COMPLETED,OBSERVATIONAL,['NA']
11349,NCT01227538,Assessment of whether two-hour urinary C-peptide response to mixed-meal (measured as area under the curve on the graph) can be used assess residual beta-cell function in the first 5 years after diagnosis of Type 1 diabetes.,To assess whether urinary C-peptide response to mixed-meal is reproducible in non-observed setting.,,2011-04,COMPLETED,OBSERVATIONAL,['NA']
11350,NCT02977884,Healthcare expenses,Absenteeism: Sick days on record at Ohio University Human Resources,,2012-08,COMPLETED,INTERVENTIONAL,['NA']
11351,NCT01248364,"Change From Baseline in Glucose Metabolism (Pre-meal and Postprandial Glucose), PPG iAUC 5h, at Day 28","Change From Baseline in Rate of Endogenous Glucose Production: iAUC 5h, at Day 28",,2010-11,COMPLETED,INTERVENTIONAL,['PHASE2']
11352,NCT00380380,Evaluate the effects of acute effects of vildagliptin on gastric emptying,Effect on satiety,,2006-01,COMPLETED,INTERVENTIONAL,['PHASE3']
11353,NCT05874726,Tissue sample repository,,,2023-07-19,RECRUITING,OBSERVATIONAL,['NA']
11354,NCT01225939,Compare the pharmacokinetics (Cmax and AUC) of the oral solution and the oral solid formulation of AZD8329.,"Investigate the safety and tolerability of AZD8329 administered as two different oral formulations.(Safety variables: Adverse events, Vital Signs, Clinical chemistry, Electrocardiogram (p ECG))",,2010-11,COMPLETED,INTERVENTIONAL,['PHASE1']
11355,NCT00605787,Plasma lipids,Safety blood parameters,,2002-01,COMPLETED,INTERVENTIONAL,['PHASE2']
11356,NCT02727348,Blood pressure or heart rate changes more than 30% of baseline after spinal or block is considered significant,S-LANSS score in who receive FSNB versus SAB.,,2014-05,COMPLETED,INTERVENTIONAL,['NA']
11357,NCT00763412,CRP,C-Peptide,,2006-11,COMPLETED,INTERVENTIONAL,['NA']
11358,NCT01144065,Comparison of hair cortisol and testosterone levels between the patients with acute MI and the 2 control groups,Correlation of hair cortisol and testosterone with the burden of coronary atherosclerosis in the MI group,,2010-08,COMPLETED,OBSERVATIONAL,['NA']
11359,NCT06177054,insulin need per kg,Hyperechogenicity detected by ultrasound,,2023-12-08,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
11360,NCT01182701,"Determine the effectiveness of a cognitive/behavioral intervention program in improving health outcomes of quality of life, general health, glycemic control, and depression.",Determine the effectiveness of a cognitive/behavioral intervention program in enhancing adherence to self-management strategies.,,2004-08,COMPLETED,INTERVENTIONAL,['NA']
11361,NCT05199090,Change-from-baseline in weight,,,2022-02-10,COMPLETED,INTERVENTIONAL,['PHASE2']
11362,NCT00754988,Mean changes in HbA1c,"Safety: Adverse events, vital signs, physical examination, clinical laboratory tests, ECG and anti-taspoglutide antibodies.",,2008-10,COMPLETED,INTERVENTIONAL,['PHASE3']
11363,NCT05597605,"Primary Initial Performance Objectives: Confirm the ability to (c) recharge the SENSOR, ED and CHARGER.",Secondary Performance Objective: Assessment of procedural success for the implantation and explantation procedure,Exploratory Analysis: Histopathology analysis of the biopsy,2022-09-21,COMPLETED,INTERVENTIONAL,['NA']
11364,NCT00162344,Examine the prevalence of ischemic heart disease in population of patients with diabetes mellitus and atypical chest pain.,"Determine the relative value of ETT, Duke Treadmill Score (DTS), MPI, ejection fraction (EF), clinical risk factors, and C-Reactive Protein (CRP) values for identifying patients at risk for cardiac events.",,2003-12,COMPLETED,INTERVENTIONAL,['PHASE4']
11365,NCT00487526,control of type 2 diabetes in non obese adults,"CCK FFA,Cholesterol,Ghrelin,C-peptide,HbA1c,Gastrin,GIP,Triglycerides,Insulin",,2007-06,UNKNOWN,INTERVENTIONAL,['PHASE1']
11366,NCT03315728,Understand the influence of community context on the implementation of the QI Strategy as assessed by the Consolidated Framework for Implementation Research,Glycated hemoglobin (A1C),,2017-10-26,COMPLETED,OBSERVATIONAL,['NA']
11367,NCT01443156,Work Schedule,Preventive care habits,,2012-01,COMPLETED,OBSERVATIONAL,['NA']
11368,NCT02290301,Time-to-event for the primary composite MACE(Major Adverse Cardiovascular Events) endpoint,,,2013-06-28,COMPLETED,OBSERVATIONAL,['NA']
11369,NCT00612144,Adjusted mean changes in HbA1c from baseline to the last visit,Abnormal change from baseline in clinical laboratory,,2007-12,COMPLETED,INTERVENTIONAL,['PHASE4']
11370,NCT01928420,Change in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog)Score,APO-E genotyping,Pharmacokinetic analysis,2007-04,COMPLETED,INTERVENTIONAL,['PHASE2']
11371,NCT05562206,Accuracy,Visual Analog Scale (VAS) for site discomfort,,2022-08-30,RECRUITING,INTERVENTIONAL,['NA']
11372,NCT03128229,Proximal tubular injury,Proposed mediators of tubular dysfunction and injury,,2017-06-01,COMPLETED,OBSERVATIONAL,['NA']
11373,NCT01839448,Presence/absence of abnormal glucose metabolism,Oral glucose tolerance test results if necessary,Number of pregnancies,2014-03-27,COMPLETED,OBSERVATIONAL,['NA']
11374,NCT05422846,ulcer depth (mm),sleep quality score,kinesiophobia score,2022-08-01,COMPLETED,INTERVENTIONAL,['NA']
11375,NCT03534687,Quantify the change in basal circulating sRAGE after 12-weeks of supervised aerobic exercise training.,Quantify the change in insulin sensitivity after 12-weeks of supervised aerobic exercise training.,,2018-12-20,COMPLETED,INTERVENTIONAL,['NA']
11376,NCT01962506,Non-inferiority of a single-sampling strategy of hs-cTn and copeptin compared with the dual hs-cTn sampling for the early diagnosis of NSTE-ACS in a selected cohort of consecutive patients admitted at the Emergency Department.,,,2012-12,UNKNOWN,OBSERVATIONAL,['NA']
11377,NCT03590158,Glycaemia,Objective sleep,Plasma proteome,2018-07-17,COMPLETED,INTERVENTIONAL,['NA']
11378,NCT03940300,Improve cardio-metabolic health in adults with (non-insulin treated) type 2 diabetes or at risk for type 2 diabetes as measured by hemoglobin A1c.,Improve glycemic control measured by continuous glucose monitoring (CGM),Participant experience with the program evaluated by questionnaire,2019-01-28,TERMINATED,INTERVENTIONAL,['NA']
11379,NCT06295874,Patient Introduction Form,Patient Follow-up Form,Comfort Rating Scale,2023-01-05,RECRUITING,INTERVENTIONAL,['NA']
11380,NCT05456906,preventable hospitalizations and/or preventable emergency department visits,,,2022-06-01,RECRUITING,OBSERVATIONAL,['NA']
11381,NCT01823510,Thrombus Formation,Platelet Reactivity Index (PRI),,2013-07,COMPLETED,INTERVENTIONAL,['PHASE4']
11382,NCT02413762,Macrovascular complication of diabetes mellitus - prevalence and incidence,Progression to NAFLD or NASH,,2015-03,COMPLETED,OBSERVATIONAL,['NA']
11383,NCT02855645,Plasma Blood Sugar,,,2016-07,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
11384,NCT02923453,HbA1c,serum creatinine,,1998-03,COMPLETED,INTERVENTIONAL,['PHASE2']
11385,NCT04535830,the between-group difference in mean HbA1c,"the between-group difference in mean time in other biochemical indexes,such as LDL-C,TC,TG and so on",,2019-04-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
11386,NCT02446054,the change of glycosylated hemoglobin (HbA1c),the patients' compliance questionnaire,,2014-02,COMPLETED,INTERVENTIONAL,['NA']
11387,NCT05129891,"AUC0-24h,API,day10; area under the API plasma concentration-time curve from 0 to 24 hours after the 10th dose","tmax, API,day10; time from the 10th dose to maximal observed plasma concentration of API",,2021-11-03,COMPLETED,INTERVENTIONAL,['PHASE1']
11388,NCT00970424,Hemoglobin A1c Level (HbA1c),Fasting Plasma Glucose Level (FPG),,2009-08,TERMINATED,INTERVENTIONAL,['PHASE3']
11389,NCT00391040,"HbA1c decrease, reduction of hypoglycemia, acute complications","treatment satisfaction, ability for diabetes management, diabetes knowledge",,2003-11,COMPLETED,INTERVENTIONAL,['NA']
11390,NCT05734989,Number of patients referred to PCPs (Primary Care Providers) for CKD screening,,,2024-04,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
11391,NCT00801164,"The primary study endpoints are periodontal evaluation including clinical attachment level, pocket depth, plaque index, suppuration and gingival index score.","Secondary endpoints include glycated hemoglobin A1c (HbA1c) and systemic biomarkers (LPS, TNF-a, CRP, IL-6, serum insulin and glucose). Tertiary outcome measures include staining, calculus, opportunistic Candida infection, and patient satisfaction.",,2008-12,COMPLETED,INTERVENTIONAL,['PHASE1']
11392,NCT01779362,"Insulin Sensitivity, M/I",ß-cell Function Measured by Hyperglycemic Clamp Techniques at M12,,2013-04,COMPLETED,INTERVENTIONAL,['PHASE3']
11393,NCT00490867,Forearm blood flow,,,2004-07,COMPLETED,INTERVENTIONAL,['PHASE2']
11394,NCT03386344,Change From Baseline in Hemoglobin A1c (HbA1c) at Week 26,Percentage of Participants With Adverse Events (AEs),,2018-02-19,TERMINATED,INTERVENTIONAL,['PHASE3']
11395,NCT05862818,Difference in plasma triglyceride level between Meal Conditions and Shift Work,Difference in plasma free fatty acids level between Meal Conditions and Shift Work,,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
11396,NCT04931836,Chain in Serum Short Chain Fatty Acids (SCFA),Body Composition,,2021-07-29,RECRUITING,INTERVENTIONAL,['NA']
11397,NCT01950663,Per Patient Referral Accuracy,,,2013-09,COMPLETED,INTERVENTIONAL,['NA']
11398,NCT03821961,Change in Uptake value of 18F-FDOPA PET/CT from baseline,Change in MAQOL scores of questionnaire from baseline,,2018-09-03,UNKNOWN,INTERVENTIONAL,['NA']
11399,NCT02263677,Change in Liver steatosis,,,2014-03,WITHDRAWN,INTERVENTIONAL,['PHASE4']
11400,NCT02089451,Area under the serum insulin aspart concentration-time curve (only for subcutaneous administration),Maximum observed serum insulin aspart concentration (only for subcutaneous and intramuscular administration),,2014-03-17,COMPLETED,INTERVENTIONAL,['PHASE1']
11401,NCT03649243,allergenic to propolis analysis,obtaining biopses,,2015-10,COMPLETED,OBSERVATIONAL,['NA']
11402,NCT01050218,Change From Baseline in Mean Pain Score on the Numeric Rating Scale (NRS).,,,2006-07,TERMINATED,INTERVENTIONAL,['PHASE3']
11403,NCT03903757,RNA sequencing analysisin adipose tissues,Linear regression to correlate epigenetic biomarkers with HOMA index,,2019-12,UNKNOWN,OBSERVATIONAL,['NA']
11404,NCT03859817,Variations in ketone levels,Changes in glycated hemoglobin (HbA1c),,2019-04-16,UNKNOWN,OBSERVATIONAL,['NA']
11405,NCT05990374,Effects of different GLP-1 on blood glucose,Effects of different GLP-1 on body fat mass,,2023-08-01,RECRUITING,INTERVENTIONAL,['NA']
11406,NCT03194945,proportion of subjects with optimal glycemic control,Incidence of adverse events,,2017-11-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
11407,NCT02768948,number of differentiation marker,,,2017-05-05,COMPLETED,INTERVENTIONAL,['NA']
11408,NCT04797429,HbA1c [%] (change over a period of 7 months intervention and 7 months follow-up with 4 measurement dates),Biochemical parameters,,2020-11-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
11409,NCT00959595,Touch thresholds in the sole of the foot (Semmes-Weinstein monofilaments),fMRI,,2008-11,COMPLETED,INTERVENTIONAL,['PHASE3']
11410,NCT05013008,Mean Change in Plasma Biomarker Levels After 36 Months of Treatment Versus 4 Months of Treatment in a Set of 27 Pre-defined Biomarkers,,,2021-08-18,COMPLETED,INTERVENTIONAL,['PHASE2']
11411,NCT00237237,Change from baseline in HbA1c at 52 weeks,Patients with reduction in HbA1c >/= to 7% after 52 weeks,,2005-10,COMPLETED,INTERVENTIONAL,['PHASE3']
11412,NCT02273193,Fasting Glucose will be obtained during the first trimester of pregnancy,Hemoglobin A1c will be obtained during the second trimester of pregnancy (between 24-28 weeks),,2014-10-14,COMPLETED,OBSERVATIONAL,['NA']
11413,NCT04098679,IQ,Adiposity,,2019-09-30,RECRUITING,OBSERVATIONAL,['NA']
11414,NCT00916292,Safety and tolerability of a single dose of FGF-1 topically administered in normal volunteers given an artificial dermal wound,Serum levels of FGF-1 after topical administration,,2012-11,UNKNOWN,INTERVENTIONAL,['PHASE1']
11415,NCT00031200,,,,2001-09,COMPLETED,OBSERVATIONAL,['NA']
11416,NCT02858076,E-ETDRS Visual Acuity Letter Score (Area Under the Curve From Baseline),Retinal Neovascularization on Clinical Exam,,2016-11,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
11417,NCT03991299,Change in Body Weight at 1 Month,,,2021-04-29,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11418,NCT01586780,"Blood glucose, insulin, amino acids, ghrelin and incretins",Subjective satiety,,2009-08,COMPLETED,INTERVENTIONAL,['NA']
11419,NCT00542698,increased physical activity,"BP, BMI, & HgA1c (a long term measure of blood glucose)",,2004-07,COMPLETED,INTERVENTIONAL,['PHASE1']
11420,NCT01852214,P2Y12 Reaction Units,Platelet Reactivity Index,,2013-02,COMPLETED,INTERVENTIONAL,['NA']
11421,NCT01570751,Change From Baseline (Visit 18) in Glycosylated Haemoglobin (HbA1c) at the End of Each 16 Week Treatment Period,Number of Adverse Events (AEs),,2012-04,COMPLETED,INTERVENTIONAL,['PHASE3']
11422,NCT06073457,Anastomosis Patency,,,2023-11-06,RECRUITING,INTERVENTIONAL,['NA']
11423,NCT00753766,Percent of Screened Participants That Are Eligible and Choose Participation,Percentage of Participants Who Need to Return to the Operating Room,,2005-10,TERMINATED,INTERVENTIONAL,['NA']
11424,NCT02282254,Percentage of time of plasma glucose levels spent below 4 mmol/L,Total number of hypoglycemic events requiring treatment,,2014-10,COMPLETED,INTERVENTIONAL,['PHASE2']
11425,NCT00842010,Inpatient Mortality,Frequency of steroid use,,2006-03,COMPLETED,OBSERVATIONAL,['NA']
11426,NCT04892199,The primary endpoint is the change from baseline in glycated haemoglobin A1c (HbA1c).,Insulin sensitivity and beta cell function,,2021-09-01,RECRUITING,INTERVENTIONAL,['PHASE4']
11427,NCT04340908,Difference in NTproBNP between the treatment and control study arms,Post operative atrial fibrillation,,2021-01-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
11428,NCT01985711,Change in Patient Health Questionnaire-9 items (PHQ-9) score,Change in general self-efficacy,,2014-05,UNKNOWN,INTERVENTIONAL,['NA']
11429,NCT01339143,Glycemic Variability,hypoglycemia,,2010-04,UNKNOWN,INTERVENTIONAL,['PHASE4']
11430,NCT01890122,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26 (or Early Termination),Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥2.0%,,2013-09,COMPLETED,INTERVENTIONAL,['PHASE3']
11431,NCT01302743,Decrease in LDL Cholesterol,,,2010-11,TERMINATED,INTERVENTIONAL,['NA']
11432,NCT01192152,Metformin Cmax,"Safety: Clinically Significant Laboratory, Vital Sign, Physical Examination, and/or 12-Lead Electrocardiogram (ECG) Abnormalities",,2009-11,COMPLETED,INTERVENTIONAL,['PHASE1']
11433,NCT03458338,Point prevalence of chronic kidney disease measured by lab values,Risk factors for chronic kidney disease measured by lab values and questionnaire,,2010-12-08,COMPLETED,OBSERVATIONAL,['NA']
11434,NCT03078933,Wound Closure rate,,,2017-03-20,UNKNOWN,INTERVENTIONAL,['NA']
11435,NCT04725799,Measurement of Glucose Concentration,,,2018-05-24,COMPLETED,OBSERVATIONAL,['NA']
11436,NCT04584242,Changes from baseline LSM (Liver Stiffness measurement) at week 24 (±7days),Prognostic factor of the Improvement of HbA1 between baseline and week 24 (±7days) within and between arms,,2020-09-03,UNKNOWN,INTERVENTIONAL,['PHASE4']
11437,NCT03792685,"The change and differences in postprandial substrates (carbohydrate, fat and protein) utilization levels associated with investigated single nucleotide polymorphisms.",The change and differences in postprandial plasma metabolites profiles associated with investigated single nucleotide polymorphisms.,,2009-09-24,COMPLETED,INTERVENTIONAL,['NA']
11438,NCT00251680,Change from Baseline in fasting plasma Low Density Lipoprotein cholesterol,Physical Examination,,2005-10,COMPLETED,INTERVENTIONAL,['PHASE3']
11439,NCT01553968,Exercise-induced changes in acetylcarnitine concentrations and dynamics of acetylcarnitine restoration after exercise,Blood plasma glucose,,2012-04,COMPLETED,INTERVENTIONAL,['NA']
11440,NCT02663245,Glycaemic control measured by HbA1c,evaluation of quality of life using spanish version of diabetes quality of life questionnaire (EsDQOL),,2015-12,COMPLETED,INTERVENTIONAL,['NA']
11441,NCT06067685,Correlation coefficient between triglyceride levels and birthweight,Correlation coefficient between triglyceride levels and cord c-peptide levels,,2023-08-10,RECRUITING,OBSERVATIONAL,['NA']
11442,NCT05487079,Number of distinct phenotypes of type 2 diabetes within this population,Rate of progression of vascular disease within this population,,2022-01-17,RECRUITING,OBSERVATIONAL,['NA']
11443,NCT04917393,Rate of SADEs,Change in Glycemic control - fasting glucose,,2021-09-13,RECRUITING,INTERVENTIONAL,['NA']
11444,NCT01248442,Increase and function of peripheral regulatory T-cells,calcium levels,,2009-11,COMPLETED,INTERVENTIONAL,['PHASE4']
11445,NCT05904262,Foot Sole Sensation Evaluation,Muscle strength,,2023-06-06,COMPLETED,OBSERVATIONAL,['NA']
11446,NCT02149992,overall mean glucose,metabolic differences,steady state,2014-11,UNKNOWN,INTERVENTIONAL,['NA']
11447,NCT04757519,Change in Weight at 6 Months,Impact of Weight on Quality of Life,,2021-02-18,RECRUITING,INTERVENTIONAL,['NA']
11448,NCT01261052,Measurement of the Effectiveness of APD and FMPD/APD Intervention in Adapting to Reduced Insulin Sensitivity,Measurement of APD and FMPD/APD Interventions in Controlling Post-prandial Blood Glucose With Reduced Insulin Sensitivity.,,2010-11,COMPLETED,INTERVENTIONAL,['PHASE2']
11449,NCT00151697,Body weight,adverse effects,,2005-05,COMPLETED,INTERVENTIONAL,['PHASE3']
11450,NCT00991549,"a reduced percentage of the calories introduced in the form of fat of at least 6.6%, in absolute value, in at least 25% of the subjects","relation between weight loss and change in insulin sensitivity, beta cell function, and insulin-mediated suppression of plasma non-esterified fatty acids",,2004-12,COMPLETED,INTERVENTIONAL,['NA']
11451,NCT03773731,EC50 of insulin in terms of intraplatelet VASP (vasodilator-stimulated phosphoprotein)-phosphorylation: group differences after 12 weeks of training,Fatty Liver Index (FLI),,2019-01-04,UNKNOWN,INTERVENTIONAL,['NA']
11452,NCT00631345,Fasting Glucose,Physical Activity,,2007-08,COMPLETED,INTERVENTIONAL,['NA']
11453,NCT05688631,Dietary antioxidant capacity,Total body water,,2021-01-03,COMPLETED,OBSERVATIONAL,['NA']
11454,NCT02282046,implant complications,resonance frequency analysis,,2014-05,COMPLETED,OBSERVATIONAL,['NA']
11455,NCT01788527,Glycemic Control in pregnant group,Study Contacts,,2013-03,COMPLETED,INTERVENTIONAL,['NA']
11456,NCT03985293,Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 16,Number of Participants With Treatment Emergent ECG Abnormalities,,2019-10-15,COMPLETED,INTERVENTIONAL,['PHASE2']
11457,NCT04407182,Symptom resolution,Time to return to normal activity,Change in myocardial enzymes,2020-05-04,COMPLETED,INTERVENTIONAL,['PHASE2']
11458,NCT03795389,DM199 urine concentrations of KLK1,Urine Kidney Injury Molecule-1 (Kim1),Blood glucose,2019-02-12,COMPLETED,INTERVENTIONAL,['PHASE1']
11459,NCT03334214,"Percentage of Participants With Adverse Events, Graded by Severity, That Were Related to Treatment With IONIS DGAT2Rx",Absolute Change in Hemoglobin A1C (HbA1C),,2017-11-03,COMPLETED,INTERVENTIONAL,['PHASE2']
11460,NCT03038373,Evidence of clinically definition of remission of type 2 diabetes by by fasting blood glucose level < 7.0 mmol and HbA1c <6.5%,,,2012-04,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
11461,NCT01293461,"To assess the safety and tolerability of CBX129801 when administered SC by adverse events, injection site assessments, clinical laboratory tests, vital signs, physical examinations, and electrocardiograms.",To evaluate the technique of vibration perception threshold (VPT) in patients with type 1 diabetes (Part 2 only),,2011-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11462,NCT00204009,,,,1992-07,COMPLETED,OBSERVATIONAL,['NA']
11463,NCT02036450,Time to adjudicated stroke or systemic arterial embolism,Time to death by any cause,Change from baseline in quality of life,2014-01,COMPLETED,INTERVENTIONAL,['NA']
11464,NCT00629707,Cerebral Edema Measured by MR Imaging (Apparent Diffusion Coefficient),"Brain NAA/Creatine Ratio & Brain Lactate Measured by MR Spectroscopy, Cerebral Blood Flow & Oxygen Saturation Measured by MR Perfusion Weighted Imaging & Near Infrared Spectroscopy, Mental Status Evaluated by Glasgow Coma Scale Scores.",,2008-06,COMPLETED,INTERVENTIONAL,['NA']
11465,NCT01396954,,,,2007-11,UNKNOWN,OBSERVATIONAL,['NA']
11466,NCT02806830,Comparison of the overall scores of the ocular discomfort questionnaire after the 2 first intravitreal injection in naïve patients,,,2016-04,COMPLETED,INTERVENTIONAL,['NA']
11467,NCT00698048,Vasopressin and copeptin levels,,,2008-08,COMPLETED,OBSERVATIONAL,['NA']
11468,NCT00142922,fitness,Diabetes Related emaitonal distress,,2002-10,COMPLETED,INTERVENTIONAL,['NA']
11469,NCT00214474,Changes in Minutes of Vigorous Exercise,Changes in Body Mass Index (BMI),,2002-11,COMPLETED,INTERVENTIONAL,['NA']
11470,NCT03091517,Change in HbA1c levels (Effectiveness),Degree of user satisfaction with the GlycoLeap program (Maintenance),,2017-06-22,COMPLETED,INTERVENTIONAL,['NA']
11471,NCT02700334,Glycosylated Hemoglobin,Diastolic Blood Pressure,,2016-10,COMPLETED,INTERVENTIONAL,['PHASE4']
11472,NCT00932087,Level of plasma isoprostane and lipoperoxides,TXA2 and PF4 levels after platelet activation of control platelet exposed to LDL,,2009-02,COMPLETED,OBSERVATIONAL,['NA']
11473,NCT01111370,the Proportion of G4 CGM System in Agreement With the Reference Standard,,,2010-02,COMPLETED,INTERVENTIONAL,['NA']
11474,NCT03591900,number of thalassemic patients with impaired glucose tolerance,control of diabetic thalassemic patients on insulin pump,,2014-04,COMPLETED,INTERVENTIONAL,['NA']
11475,NCT01051830,Quality of life,Activities of Daily life,,2010-01,COMPLETED,INTERVENTIONAL,['NA']
11476,NCT03816618,Ulcer size,,,2020-01-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
11477,NCT00647439,,,,2008-03-27,COMPLETED,OBSERVATIONAL,['NA']
11478,NCT03570632,Rate of hypertensive disorders of pregnancy,Neonatal morbidity,Neonatal body composition,2019-07-08,RECRUITING,INTERVENTIONAL,['PHASE4']
11479,NCT01623388,Evaluate blood sugar variability in Type I diabetics for differences in epigenetic signatures between Type I diabetics with little glycemic variability as compared to those with more pronounced glycemic changes.,,,2013-01,WITHDRAWN,OBSERVATIONAL,['NA']
11480,NCT02473926,Change From Baseline in Objective Physical Activity at 4 Months,Change From Baseline in Physical Function at 4 Months,,2015-12,COMPLETED,INTERVENTIONAL,['NA']
11481,NCT05163587,lipid profile,body composition,,2021-03-26,COMPLETED,INTERVENTIONAL,['NA']
11482,NCT04239586,Metabolic control of diabetes measured by HbA1c in mmol/mol,"Effect on secretion of incretin hormones, assessed by oral glucose tolerance tests",,2017-04-18,UNKNOWN,INTERVENTIONAL,['PHASE4']
11483,NCT00246844,,,,2005-10-26,COMPLETED,OBSERVATIONAL,['NA']
11484,NCT04567550,To evaluate the effect of RGX-314 on DR by the Early Treatment Diabetic Retinopathy Study (ETDRS)-Diabetic Retinopathy Severity Scale (-DRSS) at week 48,To evaluate the incidences of ocular inflammation following SCS RGX-314 administration,,2020-11-20,RECRUITING,INTERVENTIONAL,['PHASE2']
11485,NCT01447524,Change from baseline in insulin secretion at 7 days.,,,2010-01,COMPLETED,INTERVENTIONAL,['NA']
11486,NCT00334113,7-Day Physical Activity Recall (PAR),,,2009-01,COMPLETED,INTERVENTIONAL,['NA']
11487,NCT06153537,Change in glycated haemoglobin (HbA1c),Change in laboratory measured FPG,,2023-11-29,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
11488,NCT03092960,Number and Percentage of Men Achieving 5% Weight Loss or More,Change in Psychosocial Well-being: Number and Percentage of Participants Who Had no Problems With Anxiety and Depression Domain in Utility-based Quality of Life Measured by EuroQol EQ-5D,,2017-04-03,COMPLETED,INTERVENTIONAL,['NA']
11489,NCT00855439,Confirmed Clinical Neuropathy (CCN),Cardiac Autonomic Neuropathy,Intra-epidermal Nerve Fiber Density,2008-06,COMPLETED,INTERVENTIONAL,['NA']
11490,NCT01103817,Change in Endothelial Function after Treatment with Vitamin D,Comparison of Urinary Albumin/Creatinine Ratio,,2010-03,COMPLETED,INTERVENTIONAL,['PHASE2']
11491,NCT00473382,Percentage of Patients Who Gained ≥ 15 Letters in Their Best Corrected Visual Acuity (BCVA) Score From Baseline at Month 24,Mean Change From Month 36 in Central Foveal Thickness in the Study Eye at Month 48,,2007-06,COMPLETED,INTERVENTIONAL,['PHASE3']
11492,NCT00385333,Fluorescence anisotropy,The difference in fluorescence anisotropy values within subjects under room air and 100% oxygen exposure (one minute exposure time).,,2006-09-29,COMPLETED,INTERVENTIONAL,['PHASE2']
11493,NCT04343131,Percentage of time spent with glucose levels between 70-140 mg/dl,,,2014-11,COMPLETED,INTERVENTIONAL,['NA']
11494,NCT06286878,Platelet aggregation using ADP,Platelet aggregation using ASPI at 30 (± 5) days after study therapy,Analyze the primary objective of the study in the following pre-specified subgroups:,2021-12-08,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
11495,NCT03585153,Pancreas Volume Index,Urinary C-peptide/creatinine,,2014-02-19,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
11496,NCT02341261,Change in Quality of Life (NQOL-DN) Questionnaire Results,,,2015-11,UNKNOWN,INTERVENTIONAL,['NA']
11497,NCT01694212,Change of Central Macular Thickness,IL-12 concentration,,2012-10,COMPLETED,INTERVENTIONAL,['NA']
11498,NCT00005131,,,,1985-07,COMPLETED,OBSERVATIONAL,['NA']
11499,NCT01755156,Percentage of Participants Who Experienced an Adverse Event Which Were Included Under the System Order Class of Investigations (Phase A+B),Percentage of Participants Requiring Glycemic Rescue Therapy at or Before Week 104 (Phase A+B),,2013-01-11,COMPLETED,INTERVENTIONAL,['PHASE3']
11500,NCT05910840,Change from Baseline Hemaglobin A1c (HbA1c) at 18 months,Cost effectiveness (QOL),"Experience with Support-t platform (Barriers, facilitators, satisfaction, fidelity) - Health Care Provider",2023-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
11501,NCT00575172,"Cardiovascular events 1)Sudden death 2)New development or recurrence of apoplexy or TIA 3)New development or recurrence of AMI or and angina pectoris 4)Newly developed ASO, amputation of leg due to ASO","1)Total mortality 2)Changes in the mean IMT of common carotid arteries 3)Changes in the pulse wave velocity (PWV) (rt & 1t baPWV), ABI",,2003-03,COMPLETED,OBSERVATIONAL,['NA']
11502,NCT04672655,Change in Hemoglobin A1c (HbA1c) over time,Change in Glucose Monitoring System Satisfaction Survey - Version: Type 1 Diabetes (GMSS-T1D),,2021-02-17,RECRUITING,INTERVENTIONAL,['NA']
11503,NCT05357742,Hemoglobin A1c (HbA1c),Self-Care Behavior,,2022-08-01,RECRUITING,INTERVENTIONAL,['NA']
11504,NCT01469468,"If the data permit, terminal elimination half-life of simvastatin and simvastatin acid",,,2011-11,COMPLETED,INTERVENTIONAL,['PHASE1']
11505,NCT02632877,assessing change of ulcerated area,mRNA levels of Matrix metalloproteinase-1 (MMP-1),,2014-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11506,NCT01351857,The proportion of subjects who fail to attend at least one outpatient adult endocrinology visit during the second year after transition to adult diabetes care.,In the 2 year transfer to adult care-Frequency of A1C (glycated hemoglobin test),,2012-04,COMPLETED,INTERVENTIONAL,['PHASE4']
11507,NCT01068743,Metformin PK Parameter Cmax,"Safety: Clinically Significant Laboratory, Vital Sign, Physical Examination, and/or 12-Lead Electrocardiogram (ECG) Abnormalities",Metformin PK Parameter Tmax,2010-02,COMPLETED,INTERVENTIONAL,['PHASE1']
11508,NCT06334042,Serum Chromium Level,Lipid Profile,,2024-02-01,RECRUITING,OBSERVATIONAL,['NA']
11509,NCT03167684,Glycemic control (mean 24-hour and nocturnal glucose),Systemic inflammation,Subjective sleep quality,2017-05-01,UNKNOWN,INTERVENTIONAL,['NA']
11510,NCT03708419,Disposition index,DNA analysis,,2018-06-04,COMPLETED,INTERVENTIONAL,['NA']
11511,NCT05205005,Glygocalyx integrity - perfused boundary region,Popliteal artery flow mediated dilation,,2022-05-25,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
11512,NCT06236607,Glucose time-in-range (TIR) of 70-180 mg/dL,Diabetic Ketoacidosis events,,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
11513,NCT00339781,,,,2005-02,COMPLETED,OBSERVATIONAL,['NA']
11514,NCT03922087,Number of participant with gestational complications.,Number of participant with postnatal depression.,,2018-11-20,COMPLETED,OBSERVATIONAL,['NA']
11515,NCT00971815,Changes in the 24-hour AUC of free plasma cortisol,Plasma-Inflammation markers,,2009-05,COMPLETED,INTERVENTIONAL,['NA']
11516,NCT01060917,skin tissue glucose concentration,"serum and urine electrolyte concentrations (sodium, potassium, chloride, calcium, magnesium, urea, osmolarity, pH, lactate, p(O2), standard bicarbonate, p(CO2), blood glucose concentration",,2003-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11517,NCT05983289,Number of Participants With Treatment-Emergent Adverse Events (TEAEs),Inhibition Rate of Dipeptidyl Peptidase 4 (DPP4) Activities following single dose administration,,2018-05-08,COMPLETED,INTERVENTIONAL,['PHASE1']
11518,NCT02030249,Bone mass,Muscle (handgrip) strength,Urinary N-terminal telopeptide,2014-01,UNKNOWN,INTERVENTIONAL,['NA']
11519,NCT06184815,Changes in Glycemic Control Measured by A1c,Changes in Glycemic Control Measured by severe hypoglycemia,,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
11520,NCT03882463,Time spent hypoglycemia,Number of hypoglycemia,,2019-04-30,COMPLETED,INTERVENTIONAL,['NA']
11521,NCT02548702,Change from baseline in number of participants reporting one or more sessions of sport per week measured by the UK Single Item Questionnaire,Change from baseline in control of blood glucose concentration as measured by HPA1c (mmol/mol),,2015-10,UNKNOWN,INTERVENTIONAL,['NA']
11522,NCT00565799,"1) insulin sensitivity, 2) beta cell function and 3) plasma markers of inflammation",Identify genes and proteins in adipocytes from obese patients that affect clinical presentation versus those that are affected by obesity for future study.,,2007-11,TERMINATED,INTERVENTIONAL,['PHASE2']
11523,NCT02081352,Incidence of wound closure,Quality of wound healing,Rate of wound healing in crossover arm,2014-08,UNKNOWN,INTERVENTIONAL,['PHASE4']
11524,NCT02316821,"Change in glomerular filtration rate (GFR) measured by inulin clearance after 16 weeks of study drug administration, compared to baseline GFR",Profiles of pharmacokinetics of plasma RTA 402 concentration: Trough (Pre-dose) and peak (2-4 hours post dose) concentrations of study drug at steady state,,2014-12,COMPLETED,INTERVENTIONAL,['PHASE2']
11525,NCT00542620,Glycosylated Haemoglobin A1c (HbA1c),"Percentage of Children Assessing Insulin Therapy Injection Pain as ""Very Happy Face""",,2007-09,COMPLETED,INTERVENTIONAL,['PHASE4']
11526,NCT05124834,Analysis of system accuracy based on DIN EN ISO 15197,,,2022-01-15,COMPLETED,INTERVENTIONAL,['NA']
11527,NCT00280046,HbA1c,Quality of Life,,2003-11,COMPLETED,INTERVENTIONAL,['PHASE3']
11528,NCT03689608,Postprandial glucose AUC,Postprandial triglyceride,Change in autophagic flux (DIRECT-Fast4flux),2018-09-26,COMPLETED,INTERVENTIONAL,['NA']
11529,NCT02928016,Capillary blood glucose,,,2014-09,COMPLETED,INTERVENTIONAL,['NA']
11530,NCT05430139,Reference Intervals,,,2022-10-31,RECRUITING,OBSERVATIONAL,['NA']
11531,NCT02749032,GLP-1 feedback inhibition,Incidence of Treatment-Emergent Adverse Events - Safety and tolerability,,2011-11,COMPLETED,INTERVENTIONAL,['PHASE1']
11532,NCT02980978,A1c (Laboratory Assessment),,Aspirin Use (as Noted in EMR),2016-04,COMPLETED,INTERVENTIONAL,['NA']
11533,NCT00271700,- Lab glucose values (percent of routine glucose readings between 60 and 180 mg/dL),- Quality of insulin orders using explicit criteria,,2010-05,COMPLETED,INTERVENTIONAL,['NA']
11534,NCT01296633,Medication regimen knowledge,Patient-provider communication assessment,,2011-02,COMPLETED,INTERVENTIONAL,['NA']
11535,NCT05259449,Assessed changes from Body composition: Fatmass and Fat-free mass.,Assessed changes from cardiorespiratory fitness,,2022-03-10,RECRUITING,INTERVENTIONAL,['NA']
11536,NCT04582435,"AUCIco,τ,SS, Area under the serum insulin icodec concentration-time curve during one dosing interval at steady state","t½,Ico,SS, Terminal half-life for insulin icodec at steady state",,2020-10-16,COMPLETED,INTERVENTIONAL,['PHASE1']
11537,NCT01826370,Frequency of Adverse Events and Serious Adverse Events,Change From Baseline to Week 24 of Fasting Blood Sugar,,2012-05,TERMINATED,OBSERVATIONAL,['NA']
11538,NCT00362778,Glycemic control,High-sensitivity C-reactive protein levels,,2006-01,COMPLETED,INTERVENTIONAL,['PHASE4']
11539,NCT04137705,Assessment of repeatability (precision under the same conditions in the same subjects: 2 separate MRI acquisitions on the same scanner) of body composition and multiple organ metrics.,Assessment of the reproducibility (precision under different measurement conditions: same participants scanned on separate MRI scanners at both 1.5T and 3T) of multiparametric MRI for the assessment of body composition and multiple organ metrics.,Assessment of the mean differences in body composition and multiple organ metrics between healthy participants and those with type 2 diabetes acquired with multiparametric MRI.,2019-11-04,RECRUITING,OBSERVATIONAL,['NA']
11540,NCT01964963,Change From Baseline in Glycosylated Hemoglobin (HbA1c),Change From Baseline in Fasting Blood Glucose,,2011-08-03,COMPLETED,OBSERVATIONAL,['NA']
11541,NCT01786941,Changes in Branched-chain Amino Acid Metabolism in Pre-Diabetes at Baseline and post-intervention,Changes in Insulin Sensitivity at Baseline and post-intervention,,2012-06,COMPLETED,INTERVENTIONAL,['NA']
11542,NCT01651117,Change in Glucose Control (Stage 2: Non-mentors v. Mentors),Change in Depression Symptoms (Stage 2: Non-mentors v. Mentors),,2012-09-01,COMPLETED,INTERVENTIONAL,['NA']
11543,NCT00962962,Fasting Plasma Glucose,Measures of Glucose control,,2009-07,COMPLETED,INTERVENTIONAL,['NA']
11544,NCT00155610,,,,na,TERMINATED,OBSERVATIONAL,['NA']
11545,NCT03921203,ApoB48 levels in blood and interstitial fluid,,,2019-04-17,COMPLETED,OBSERVATIONAL,['NA']
11546,NCT03964571,Reduction in size of wound,Reduction in size of wound,,2019-10-09,RECRUITING,INTERVENTIONAL,['NA']
11547,NCT03248206,Change from baseline result of Manual tactile test at 12 weeks,Change from baseline result of peak torque of shoulder internal rotation assessing by Bi-planar isokinetic dynamometer (BID) at 12 weeks,,2017-08-23,COMPLETED,INTERVENTIONAL,['NA']
11548,NCT02274103,HbA1c,"Adherence to diabetes treatment using the Diabetes Self Management Profile (DSMP) (Harris et al, 2001).",,2010-03,COMPLETED,INTERVENTIONAL,['PHASE4']
11549,NCT02864914,Incidence of diabetic ketoacidosis (DKA),Incidence of severe genital infections,,2016-03-15,COMPLETED,OBSERVATIONAL,['NA']
11550,NCT02051504,Maximal oxygen uptake,Prefrontal cortex oxygenation during exercise,Body composition,2010-03,COMPLETED,OBSERVATIONAL,['NA']
11551,NCT00747409,postprandial blood glucose at the end of the study and its change from baseline.,diastolic myocardial function,,2004-07,UNKNOWN,INTERVENTIONAL,['PHASE4']
11552,NCT00410033,"Insulin aspart specific, human insulin specific and cross reacting antibodies",Incidence of hypoglycaemic episodes,,1989-12,COMPLETED,INTERVENTIONAL,['NA']
11553,NCT00257257,Absolute change in HbA1C from baseline to Month 6.,"Fasting glucose, fasting insulin, C-peptide, HOMA analysis, body weight, HDL-cholesterol, triglycerides, blood pressure, safety (physical examination, vital signs, laboratory tests, adverse events).",,2005-03,COMPLETED,INTERVENTIONAL,['PHASE3']
11554,NCT02856633,Successful diagnosis of patient's condition by Vitaliti software as compared to patient's Medical Record,,,2016-07,COMPLETED,OBSERVATIONAL,['NA']
11555,NCT05130385,Evaluation of the sensitivity and specificity of High-Res-OCT for retinal fluid,Evaluation of the segmentation quality of the retinal layers using High-Res-OCT,Correlation of pathological changes with fundus color photographs,2021-11-30,RECRUITING,OBSERVATIONAL,['NA']
11556,NCT00257218,Incidence of diabetes mellitus,insulin sensitivity,,2006-01,UNKNOWN,INTERVENTIONAL,['NA']
11557,NCT03938389,Change from Baseline to 26 weeks in β-cell function (first-phase insulin secretion),Change in Central Aortic Pressure (mmHg) from Baseline to 26 weeks,,2020-02-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4']
11558,NCT04054284,Number of patients with adverse event,Fasting Glucose,Waist Circumference,2019-07-01,COMPLETED,INTERVENTIONAL,['NA']
11559,NCT00467376,Adverse events,"blood glucose parameters, hypoglycemic episodes and dosage of the mealtime and Lantus.",,2007-01,COMPLETED,INTERVENTIONAL,['PHASE3']
11560,NCT01637350,,,,2012-08,UNKNOWN,OBSERVATIONAL,['NA']
11561,NCT03070678,Area under the concentration-time curve from 0 to infinity (AUC0 ∞),Total 24-hour UGE (urinary glucose excretion) after each dose with sotagliflozin,,2017-03-14,COMPLETED,INTERVENTIONAL,['PHASE1']
11562,NCT00997191,Best Corrected Visual acuity,Central Macular Thickness,,2009-10,COMPLETED,INTERVENTIONAL,['PHASE3']
11563,NCT03892265,"Prevalence of CVD risk factors and diseases and their association with social and environmental determinants in an established longitudinal cohort of ~3,000 Haitian adults",Incidence of CVD risk factors and CVD during ~7 years of follow-up and their association with social and environmental determinants,,2019-03-08,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
11564,NCT03682250,QT intervals corrected for heart rate,Percentage of time below 3.5 mmol/L,,2018-09-17,UNKNOWN,OBSERVATIONAL,['NA']
11565,NCT03237975,Short form of the sense of coherence questionnaire (SOC-13),Diabetes Self-Efficacy Scale (DSES),,2017-03-27,UNKNOWN,INTERVENTIONAL,['NA']
11566,NCT05932953,"Prevalence of children,with current skin intolerance (eczema symptoms measured by questionnaire) to an insulin pump and/or blood glucose sensor assessed by an autoquestionnary.",Search for risk factors associated with skin side effect,,2022-05-15,RECRUITING,OBSERVATIONAL,['NA']
11567,NCT03916016,Blood Pressure,Blood glucose concentration,,2015-12-09,COMPLETED,INTERVENTIONAL,['NA']
11568,NCT00700856,"A composite endpoint including: all-causes mortality, non fatal myocardial infarction (MI) - including silent MI- , non fatal stroke, unplanned coronary revascularization",events of heart failure evaluated according to the American Heart Association and the American Diabetes Association consensus on glitazones and heart failure,,2008-09,UNKNOWN,INTERVENTIONAL,['PHASE4']
11569,NCT01172977,Functional outcome six months after the cerebral ischemia,Mortality,,2010-08,COMPLETED,OBSERVATIONAL,['NA']
11570,NCT01628341,Percentage of insulin-treated patients experiencing at least one hypoglycaemia (severe/non-severe),"Change in planned daily activities; work: effectiveness, missing hours or days for sick leave",,2012-05,COMPLETED,OBSERVATIONAL,['NA']
11571,NCT02543684,serum insulin changes over time,,,2013-11,COMPLETED,INTERVENTIONAL,['NA']
11572,NCT03864705,Plasma metformin levels,,,2019-03-01,UNKNOWN,OBSERVATIONAL,['NA']
11573,NCT05952219,Cmax,,,2023-06-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
11574,NCT04163874,Mean score of the Emotional Burden section of the Diabetes Distress Scale,Each participant's total insulin delivery,,2020-02-14,COMPLETED,INTERVENTIONAL,['NA']
11575,NCT03258242,Mean change from baseline in Chinese medicine syndrome score chart at 48 weeks,Frequency and severity of ocular and non-ocular adverse events over time,Change of retinal blood flow density,2017-08-31,UNKNOWN,INTERVENTIONAL,['PHASE2']
11576,NCT03821636,Rate of type 2 diabetes remission,change in prealbumin levels,,2019-06-16,RECRUITING,INTERVENTIONAL,['NA']
11577,NCT06147518,Percentage of patients with glycemic control at 24 weeks (HBA1c <7.0 %),Number of patients with Mortality/ Liver transplantation in both groups,,2023-12-20,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
11578,NCT00607087,Percentage of Patients With at Least One Unexplained Hyperglycemia and/ or Confirmed Infusion Set Occlusion,Total Daily Bolus Insulin Dose,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE4']
11579,NCT00849342,Change in body weight and BMI,Change in blood pressure,,2008-12,COMPLETED,OBSERVATIONAL,['NA']
11580,NCT06044064,Incidence of PDAC at 3 years,• Incidence of PDAC at baseline • Incidence of resectable PDAC at baseline • Incidence of resectable PDAC at 3 years,,2023-12-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
11581,NCT04215445,Comparison of change in retinal and choroidal vascular perfusion density in proteinuric and non-proteinuric chronic kidney disease patients treated with SGLT2-inhibitor,,,2019-12-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
11582,NCT04439630,postprandial insulin concentrations,subjective appetite variables,,2020-07-01,COMPLETED,INTERVENTIONAL,['NA']
11583,NCT05764811,measure the severity of fatty liver via MRI,measure the body mass index (BMI) before and after the treatment,,2020-03-06,COMPLETED,INTERVENTIONAL,['NA']
11584,NCT02010684,Change From Baseline in Depression Measures at 6 Months,Change From Baseline in Self-Efficacy (Diabetes Empowerment Scale) at 6 Months,,2009-04,COMPLETED,INTERVENTIONAL,['NA']
11585,NCT01875341,Primary end-point: change in daytime and night-time mean systolic blood pressure,plasma renin and aldosterone,,2004-12,COMPLETED,INTERVENTIONAL,['PHASE3']
11586,NCT01249742,Patients' Evaluation of Quality of Care,Degree of use of intervention,,2009-02,COMPLETED,INTERVENTIONAL,['NA']
11587,NCT03553030,Major Adverse Cardiac Events (MACE).,,,2015-01-01,COMPLETED,OBSERVATIONAL,['NA']
11588,NCT04507061,Mean change in urinary albumin-to-creatinine ratio (UACR) from baseline to the average of multiple time points during treatment,Number of subjects with early discontinuations,,2020-09-01,COMPLETED,INTERVENTIONAL,['PHASE2']
11589,NCT04451837,Hba1c,,,2020-09-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
11590,NCT00634998,Changes in aldose reductase enzyme levels,Changes in Neuropathic Pain Scale (NPS) measurement and quantitative sensory testing in the lower extremities via touch discrimination with Semmes-Weinstein monofilaments and vibratory sensation testing,,2007-11,COMPLETED,INTERVENTIONAL,['PHASE1']
11591,NCT03619356,Change in spectral THG strength distribution,Quantify the extent of diseases in spectral THG strength distribution,,2018-02-05,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
11592,NCT05170880,HbA1c levels,,,2019-02-11,COMPLETED,INTERVENTIONAL,['NA']
11593,NCT01326442,body weight,Glucose homeostasis,,2011-04,COMPLETED,INTERVENTIONAL,['PHASE3']
11594,NCT01865331,Frequency of adverse events (AEs),Area under the glucose infusion rate curve,,2006-12,COMPLETED,INTERVENTIONAL,['PHASE1']
11595,NCT05477030,Glycated Hemoglobin (HbA1c),Endothelial disfunction,,2022-02-23,RECRUITING,INTERVENTIONAL,['NA']
11596,NCT03698396,Incidence of procedure related adverse events,Insulin independence achieved,,2019-08-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11597,NCT00883259,Incidence of gestational DM in high-risk patients,Intrauterine deaths,,2013-09,UNKNOWN,INTERVENTIONAL,['PHASE4']
11598,NCT02074384,Portion of Study Participants Reporting Greater Utility From AGP vs. Traditional Glucose Data Reports,,,2014-03,COMPLETED,INTERVENTIONAL,['NA']
11599,NCT01978886,prevalence of known and unknown diabetes diabetes,diabetes influence on the prognosis of frozen shoulder,,2013-12,COMPLETED,OBSERVATIONAL,['NA']
11600,NCT03878290,Resilience,Inflammatory burden,,2017-08-03,COMPLETED,INTERVENTIONAL,['NA']
11601,NCT01986881,Change From Baseline in Hemoglobin A1C (A1C) at Week 18 - Excluding Rescue Approach (Metformin With Sulfonylurea Add-on Glycemic Sub-study),Change From Baseline in Sitting Diastolic Blood (DBP) Pressure at Week 18 (Excluding Rescue Approach) (Metformin With Sulfonylurea Add-on Glycemic Sub-study),,2013-11-04,COMPLETED,INTERVENTIONAL,['PHASE3']
11602,NCT02536859,Area under the glucose infusion rate curve,Area under the glucose infusion rate curve,,2015-08-31,COMPLETED,INTERVENTIONAL,['PHASE1']
11603,NCT02160639,"Change from baseline fasting glucose at 3, 9, 15, and 27 months","Change from baseline food security at 3, 9, 15, and 27 months",,2015-01,UNKNOWN,INTERVENTIONAL,['NA']
11604,NCT02614768,Percentage of Test-to-Reference Measurement Pairs With an Absolute Relative Difference (ARD) ≤15%,,,2015-07,COMPLETED,INTERVENTIONAL,['NA']
11605,NCT02228629,Comparison of peak pressure sub-metatarsal 2 and hallux in usual house shoes versus the CrocsRx clogs,,,2014-10,UNKNOWN,INTERVENTIONAL,['NA']
11606,NCT00814294,The primary objective of this trial is to compare the reduction in mean glycated hemoglobin levels (HbA1c) between 2 doses of oral HDV-I and placebo in type 2 diabetic patients on background metformin therapy at the end of 18 weeks of treatment.,"To evaluate the effects of oral HDV-I versus placebo on frequency of hypoglycemic events, body weight, and lipid levels",,2008-12,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
11607,NCT05347459,Prevention of decline in cognitive function associated with type 2 diabetes,Better cognitive performance in the intervention group at baseline,Reduced serum inflammatory markers in intervention group,2022-03-02,RECRUITING,OBSERVATIONAL,['NA']
11608,NCT01288729,Length of Wear of Infusion Site,,,2011-01,COMPLETED,INTERVENTIONAL,['NA']
11609,NCT02932436,difference in E/E' ratio between 12 weeks after baseline and at baseline,difference in E/E' ratio (change from baseline (V1) to 12 weeks follow-up) in the subgroup of patients with HbA1c 6.5%-6.9%,association analysis for selected SNPs,2016-10-10,COMPLETED,INTERVENTIONAL,['PHASE4']
11610,NCT05325710,FINDRISC score,,,2022-03-20,RECRUITING,INTERVENTIONAL,['NA']
11611,NCT00638560,PGC-1alpha mRNA expression in skeletal muscle PPARgamma mRNA expression in skeletal muscle Serum malondialdehyde concentration,body weight glucose infusion rate during the steady state of an euglycemic-hyperinsulinemic clamp VO2max,,2008-03,COMPLETED,INTERVENTIONAL,['PHASE1']
11612,NCT00660075,"Measurement of the Area Under the Curve of Plasma Triglycerides (TG) Levels During Postprandial Period (Time 0,2,4,6,8 Hours)",,,2008-02,COMPLETED,INTERVENTIONAL,['PHASE3']
11613,NCT04365517,Biochemical parameter of acute lung disease,Cytokine-inflammatory profile,,2021-12-29,UNKNOWN,INTERVENTIONAL,['PHASE3']
11614,NCT02757183,Usage and Adoption of the smart phone based mobile health application,Adherence to Prescribed Medication,,2016-04,UNKNOWN,OBSERVATIONAL,['NA']
11615,NCT03106727,Antenatal Care,CHW Retention,,2017-03-01,COMPLETED,INTERVENTIONAL,['NA']
11616,NCT02502929,Biological risk for type 2 diabetes,,,2015-11,COMPLETED,INTERVENTIONAL,['NA']
11617,NCT01047813,Blood glucose levels,Stress levels,,2009-09,UNKNOWN,OBSERVATIONAL,['NA']
11618,NCT05414396,Changes in biomarkers,,,2018-03-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
11619,NCT03626324,Successful Home-use Performance,,,2018-07-25,COMPLETED,INTERVENTIONAL,['NA']
11620,NCT02834663,Central Macular Thickness(CMT),Safety Parameters,,2016-08,COMPLETED,INTERVENTIONAL,['PHASE4']
11621,NCT01869101,Diabetes prevention treatment decisions by physician,Subject initiation and persistence with diabetes prevention interventions,BMI,2013-06,UNKNOWN,OBSERVATIONAL,['NA']
11622,NCT01273311,,,,2010-12-22,COMPLETED,OBSERVATIONAL,['NA']
11623,NCT03534544,Youth and parent preferences for automated insulin delivery systems,Quality of life,,2018-08-23,COMPLETED,OBSERVATIONAL,['NA']
11624,NCT03229850,Insulin Levels,,,2021-02-01,SUSPENDED,INTERVENTIONAL,['NA']
11625,NCT04543422,Toronto Clinical Scoring System,,,2019-01-01,COMPLETED,INTERVENTIONAL,['NA']
11626,NCT01923597,Effect of green tea (epigallocatechin gallate) in albuminuria in diabetic patients and nephropathy.,Effect of green tea (epigallocatechin gallate) on plasma lipids in patients with diabetic nephropathy.,Effect of Green Tea (epigallocatechin gallate) in the glomerular filtration rate in patients with diabetic nephropathy.,2013-11,COMPLETED,INTERVENTIONAL,['PHASE2']
11627,NCT02422043,self-efficacy (Self-efficacy of Diabetes Management),socio-cognitive profile,,2015-01-28,COMPLETED,INTERVENTIONAL,['NA']
11628,NCT00564018,C-peptide Area Under the Curve,Glycemic Control as Determined by HgbA1c Values at 6 Months After Diagnosis,,2006-09,TERMINATED,INTERVENTIONAL,['NA']
11629,NCT00328302,Mesangial expansion,24 hour ambulatory blood pressure,,2000-09,UNKNOWN,INTERVENTIONAL,['PHASE4']
11630,NCT00323349,Scores on motivation to change behavior scale after the intervention,Scores on scales of perceived barriers to healthy lifestyle choices,,2003-04,COMPLETED,INTERVENTIONAL,['NA']
11631,NCT02374788,HbA1c (mmol/mol),Change in Smoking and snuffing habits,Hospital Anxiety and Depression Scale (HADS),2013-11,COMPLETED,INTERVENTIONAL,['NA']
11632,NCT04119167,Level of fasting blood sugar,,,2019-08-01,UNKNOWN,OBSERVATIONAL,['NA']
11633,NCT02165579,"(1.) wound healing,",(5.) recurrent ulcers.,,2014-06,COMPLETED,OBSERVATIONAL,['NA']
11634,NCT02179788,Peak Change in Milk Output,,,2014-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11635,NCT05414149,CRT,postoperative fibrovascular proliferation progression,,2021-09-01,COMPLETED,INTERVENTIONAL,['NA']
11636,NCT04700254,DASS (Anxiety),Eating Attitudes Test (EAT-26),,2020-12-28,COMPLETED,OBSERVATIONAL,['NA']
11637,NCT00000160,,,,1972-01,COMPLETED,INTERVENTIONAL,['PHASE3']
11638,NCT00493051,Effect of GAM501 on the incidence of complete ulcer closure,Safety and tolerance,,2007-11,COMPLETED,INTERVENTIONAL,['PHASE2']
11639,NCT03889236,Percentage change from baseline in the Microvascular Health Index in the fasting mimicking diet or food supplement group compared to the placebo group,Percentage change from baseline in specific urinary heparan sulfate domains in the fasting mimicking diet or food supplement group compared to the placebo,,2018-05-03,COMPLETED,INTERVENTIONAL,['NA']
11640,NCT00055042,,,,2003-02,COMPLETED,INTERVENTIONAL,['PHASE1']
11641,NCT01470807,estimation of the failure rates of system components,percent time of active CTR,,2011-10,COMPLETED,INTERVENTIONAL,['NA']
11642,NCT02821585,Change in Waist Circumference,Glycemic variability,,2016-01,COMPLETED,INTERVENTIONAL,['NA']
11643,NCT03398590,Acceptability,Calorie intake,,2017-04-12,COMPLETED,INTERVENTIONAL,['NA']
11644,NCT05131451,Number of Participants Who Get Screened With a Diabetic Eye Exam,Follow-up Rates With an Eye Care Provider,,2021-11-24,COMPLETED,INTERVENTIONAL,['NA']
11645,NCT01056497,insulin secretion and insulin sensitivity To determine whether ALA ameliorates or prevents impairment of insulin secretion and insulin sensi,To determine the role of oxidative stress and inflammation in the pathogenesis of lipotoxicity,,2010-02,COMPLETED,INTERVENTIONAL,['PHASE4']
11646,NCT02631928,"PK: Cins.max, maximum observed insulin concentration",Changes in Electrocardiogram recordings,,2016-02,COMPLETED,INTERVENTIONAL,['PHASE1']
11647,NCT01393860,Measure: Change in blood pressure,Measure: Change in potassium levels,,2010-12,COMPLETED,OBSERVATIONAL,['NA']
11648,NCT04383639,Postprandial insulin,"Satiety measured by a Visual Analogue Scale (see ""Description"" for details)",,2021-05-03,COMPLETED,INTERVENTIONAL,['NA']
11649,NCT02771093,Changes From Baseline in the Standard Deviation (SD) of 24-hour Blood Glucose Values,Number of Participants Reporting One or More Treatment-emergent Adverse Events,,2016-09-08,COMPLETED,INTERVENTIONAL,['PHASE4']
11650,NCT00135083,"To show non-inferiority between treatment groups (insulin glargine plus insulin glulisine administered once a day, twice a day, or 3 times a day) in the change in glycemic control as measured by hemoglobin A1C.",,,2004-08,COMPLETED,INTERVENTIONAL,['PHASE3']
11651,NCT00086502,Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24,Change From Baseline in FPG (Fasting Plasma Glucose) at Week 24,,2004-06,COMPLETED,INTERVENTIONAL,['PHASE3']
11652,NCT00682149,Amelioration of antioxidative capacity in diabetic patients by polyphenol containig antioxidants,treatment of type 2 diabetes by polyphenol containing antioxidants,,2008-05,UNKNOWN,INTERVENTIONAL,['NA']
11653,NCT00976924,blood glucose value,,,2009-07,COMPLETED,INTERVENTIONAL,['NA']
11654,NCT02552277,"Percent change in the epidermal nerve fiber density (ENFD) at 6 months, compared to baseline",Adverse Events (AEs),,2015-10-27,COMPLETED,INTERVENTIONAL,['PHASE2']
11655,NCT03474939,Change in copeptin concentration,,,2017-04-03,COMPLETED,INTERVENTIONAL,['PHASE4']
11656,NCT01997411,Area Under the Effect Concentration Time Curve (AUEC0-1.5) of Baseline-Adjusted Glucose From Time Zero up to 90 Minutes,Time to Achieving ≥25 mg/dL Rise in Plasma Glucose Above Nadir Level Within 30 Minutes,Percentage of Participants With >= 25 mg/dL Rise in Plasma Glucose Within 30 Minutes,2013-11,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
11657,NCT01218061,The main objective of the study is to understand the pathophysiological mechanisms involved in switching from pre-diabetes to type 2 diabetes and to identify new biomarkers of type 2 diabetes risk in this population,"Relation between ""working hours and conditions"" and metabolic disease",,2010-06,UNKNOWN,INTERVENTIONAL,['NA']
11658,NCT00967993,The Primary Outcome of This Trial Will be the Change in Serum Phosphorus From Baseline to End of Treatment After a Four Week Treatment Period.,"The Incidence of Treatment-emergent Adverse Events (New or Worsened From Study Drug Initiation) Will be Summarized by Body System, Severity, Type of Adverse Event, and Presumed Relationship to the Study Drug.",,2010-01,COMPLETED,OBSERVATIONAL,['NA']
11659,NCT04073914,Change in Parent Stress using the Perceived Stress Scale (PSS),,,2017-06-29,COMPLETED,INTERVENTIONAL,['NA']
11660,NCT02048839,Type 2 Diabetes,Metabolic syndrome and cardiovascular morbidity,Obesity,2014-01,COMPLETED,OBSERVATIONAL,['NA']
11661,NCT01946347,Changes of endothelial function (measured by EndoPat),Insulin sensitivity measured as glucose disposal during clamp,,2013-09,COMPLETED,INTERVENTIONAL,['NA']
11662,NCT02084251,Safety/Adverse Event Outcome Measure,,,2014-02,COMPLETED,INTERVENTIONAL,['PHASE1']
11663,NCT00869414,Change in the Mean Minutes Per 24 Hour Day in the Hyperglycemic Range of > 180 mg/dL.,,,2009-07,TERMINATED,INTERVENTIONAL,['NA']
11664,NCT00612040,Change in Glycosylated Haemoglobin (HbA1c),Physical Examination,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE2']
11665,NCT00283751,HbA1c,Change in body weight,,2003-03,COMPLETED,INTERVENTIONAL,['PHASE3']
11666,NCT02779816,Visual analog scale for ease of use,,,2017-05-01,TERMINATED,INTERVENTIONAL,['NA']
11667,NCT01045590,Change from baseline in the ratio (IAAT:SAT) between the intra-abdominal adipose tissue area (IAAT) and abdominal subcutaneous adipose tissue area [SAT] after 12 months treatment with oral glibenclamide plus rosiglitazone compared to oral glibenclamide p,Comparisons will be made between glibenclamide plus rosiglitazone and glibenclamide plus placebo treatment groups on Change from baseline after 6 and 12 months treatment with respect the following,,2003-12,COMPLETED,INTERVENTIONAL,['PHASE4']
11668,NCT03785301,HbA1c,FGM accuracy,,2018-12-20,UNKNOWN,INTERVENTIONAL,['NA']
11669,NCT01336777,Adipose Cell Size,Gene Expression,,2009-08,UNKNOWN,OBSERVATIONAL,['NA']
11670,NCT04326569,Copeptin dosage,,,2020-06,UNKNOWN,INTERVENTIONAL,['NA']
11671,NCT00931125,Efficacy of preoperative intravitreal ranibizumab,Retinal circulation integrity.,,2009-03,UNKNOWN,INTERVENTIONAL,['PHASE2']
11672,NCT03340831,Change in hypoglycemic events,Change in Hypoglycemia Confidence PRO scores,,2017-10-20,UNKNOWN,OBSERVATIONAL,['NA']
11673,NCT00964964,Total number of periods where carbohydrate supplementation is needed during the treatment,Number of periods with low blood sugar during treatment,,2009-08,COMPLETED,INTERVENTIONAL,['PHASE1']
11674,NCT04261738,Hba1c,Glucagon,,2022-09-02,RECRUITING,INTERVENTIONAL,['NA']
11675,NCT00654745,Change From Week 0 (Baseline) in Mean 24-hour Ambulatory Blood Pressure Monitoring (ABPM) Systolic Blood Pressure (SBP) After 12 Weeks of Active Treatment,Number of Participants Achieving Mean Seated Systolic and Diastolic Blood Pressure Reductions at Week 18,,2008-05,COMPLETED,INTERVENTIONAL,['PHASE4']
11676,NCT02297399,Tolerability of the bowel preparation (analogue visual scale),Adverse events,,2014-12-02,COMPLETED,INTERVENTIONAL,['PHASE3']
11677,NCT03099837,Influence of prenatal and early postnatal factors on child health,,,2013-01-10,UNKNOWN,OBSERVATIONAL,['NA']
11678,NCT02206568,Pharmacokinetics of URAL,Number of subjects with adverse events,,2014-06,WITHDRAWN,INTERVENTIONAL,['PHASE1']
11679,NCT02355158,Summary of Neuropathic Pain Symptom Inventory (NPSI),,,2014-06,COMPLETED,INTERVENTIONAL,['PHASE2']
11680,NCT00842075,HbA1c Value After 28 Days,Weight Change After 28 Days Intervention Period,,2006-12,COMPLETED,INTERVENTIONAL,['NA']
11681,NCT03441750,Rate of newly diagnosed diabetes,,,2017-04-25,COMPLETED,INTERVENTIONAL,['PHASE4']
11682,NCT04090580,Impact of dapagliflozin in glycemic variability,Impact of dapagliflozin in waist circumference,,2019-08-27,UNKNOWN,INTERVENTIONAL,['PHASE4']
11683,NCT00982293,The primary outcome measure is the improvement in Subject's hemoglobin A1c level after 13 weeks of treatment compared to baseline.,,,2009-09,TERMINATED,INTERVENTIONAL,['PHASE2']
11684,NCT01014832,Frequency of hypoglycemia,,,2008-12,COMPLETED,INTERVENTIONAL,['NA']
11685,NCT00949416,,,,2009-06,UNKNOWN,OBSERVATIONAL,['NA']
11686,NCT04665128,Reducing the glucose levels of hyperglycemic patients in the emergency department may improve clinical outcomes and have a positive effect on post-discharge prognosis.,,,2020-12-15,UNKNOWN,OBSERVATIONAL,['NA']
11687,NCT00085800,,,,2004-05,COMPLETED,OBSERVATIONAL,['NA']
11688,NCT00351585,Durability of this effect after a 2-week washout,Chance from baseline in glucagon secretion at 12 weeks,,2004-07,COMPLETED,INTERVENTIONAL,['PHASE3']
11689,NCT00985361,Hemoglobin A1c,,,2009-10,COMPLETED,INTERVENTIONAL,['NA']
11690,NCT01356953,Blood Pressure - Ambulatory blood pressure monitoring (ABPM),,,2008-10,COMPLETED,INTERVENTIONAL,['NA']
11691,NCT05557227,"Time to hypoglycemia Secondary endpoints: Blood glucose variability, volume of intravenous glucose needed to maintain glucose above 5 mmol/l, respiratory exchange ratio.",Time in Range,,2022-12-15,RECRUITING,INTERVENTIONAL,['NA']
11692,NCT05006508,Change of long-term blood glucose concentration measured as glycated hemoglobin at end of follow-up,Change of Patient Health Questionnaire 9-item scale,,2021-08-16,RECRUITING,INTERVENTIONAL,['NA']
11693,NCT01673191,Mean Change in Intraocular Pressure,,,2012-11,COMPLETED,INTERVENTIONAL,['PHASE2']
11694,NCT00189774,,,,na,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
11695,NCT05445284,Retention feasibility,Diabetes-related emergency department visits,,2023-10-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
11696,NCT02423850,Wound healing change quantified using digital imaging method,Wound duration is compared to outcome of the wound,Quality of life (Questionaires) using 36-Item Short Form Survey (SF-36) is compared to outcome of the wound,2015-08,COMPLETED,OBSERVATIONAL,['NA']
11697,NCT01755468,"Baseline-adjusted beta-cell function at 2 years, measured by Insulin Secretion-Sensitivity Index-2 (ISSI-2).",Baseline-adjusted glycemic control at 2-years.,insulin sensitivity,2013-04,COMPLETED,INTERVENTIONAL,['PHASE3']
11698,NCT02102737,Correlation between measure of insulin resistance measurement by scintigraphy and hyperinsulinemic euglycemic clamp,strain by speckle tracking echocardiography,,2014-05-13,COMPLETED,INTERVENTIONAL,['PHASE2']
11699,NCT00388050,"Treatment Action, adherence",Acceptability,,2006-07,COMPLETED,INTERVENTIONAL,['NA']
11700,NCT03304158,Mean fasting blood glucose level,,,2017-06-01,COMPLETED,INTERVENTIONAL,['NA']
11701,NCT03106480,Prevalence of hypertension,Prevalence of sub-clinical atherosclerosis,,2016-10-06,UNKNOWN,OBSERVATIONAL,['NA']
11702,NCT01855399,Percent Glycosylated Hemoglobin,,,2014-09-09,COMPLETED,INTERVENTIONAL,['NA']
11703,NCT01369082,Duration of sustained islet allograft function,Donor-specific alloantibodies,,2011-05,COMPLETED,OBSERVATIONAL,['NA']
11704,NCT00240383,"To compare, after 24 weeks of oral administration of double-blind treatment, the change from baseline in hemoglobin A1c (HbA1c) achieved with the highest dose and subsequent doses of BMS-298585 versus the lowest dose of BMS-298585 in subjects with Type 2","To assess, after 12 and 24 weeks of oral administration of double-blind therapy, the percent change from baseline in fasting lipids (total cholesterol,low density lipoprotein cholesterol,HDL-C, TG, non-HDL chol",,2002-05,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
11705,NCT01608724,Absolute Change From Baseline in Haemoglobin A1c (HbA1c),Change From Baseline in 2-hour Postprandial Plasma Glucose (2h-PPG),,2012-11,COMPLETED,INTERVENTIONAL,['PHASE4']
11706,NCT02988011,Gene expression in adipose tissue,Epigenetic changes assessed as DNA methylation,,2016-02-28,UNKNOWN,INTERVENTIONAL,['NA']
11707,NCT04016662,CGM Measured Time <70 mg/dL,Hypoglycemia Unawareness,Patient Reported Questionnaires,2020-09-28,COMPLETED,INTERVENTIONAL,['PHASE4']
11708,NCT02211495,Number of Day Until 50% Healing of Leg Ulcer,"Quality of Life (PAID, EQ5D, VAS, SF-12)",,2014-07,COMPLETED,INTERVENTIONAL,['NA']
11709,NCT01649167,,,,2009-02,COMPLETED,OBSERVATIONAL,['NA']
11710,NCT01318564,Patients' Adherence to Unit Dose Packaging Devices,,,2011-03,COMPLETED,OBSERVATIONAL,['NA']
11711,NCT04222686,Variation of exercise-induced urinary albumin excretion,Change in uricemia concentration,,2017-12-20,COMPLETED,INTERVENTIONAL,['PHASE4']
11712,NCT03433677,Rate of Infusion Set Failures,Number of Participants With Severe Hypoglycemic Events,,2018-02-21,COMPLETED,INTERVENTIONAL,['PHASE3']
11713,NCT04025281,Endothelial Function (EF) Assessment,Office Blood Pressure,,2019-07-09,COMPLETED,INTERVENTIONAL,['NA']
11714,NCT04161859,Prevalence of the use of nutraceutical in clinical practice,,,2017-05-01,COMPLETED,OBSERVATIONAL,['NA']
11715,NCT02695121,Incidence of bladder cancer,Incidence of compsite cancer outcomes,,2017-01-01,RECRUITING,OBSERVATIONAL,['NA']
11716,NCT05067231,Genetic Variants in the NPPA and NPPB gene of the Natriuretic Peptide family associated with the Cardiovascular and Metabolic Diseases,,,2022-01-01,RECRUITING,OBSERVATIONAL,['NA']
11717,NCT02251418,Ulcer area,Ulcer area,,2015-02,COMPLETED,INTERVENTIONAL,['NA']
11718,NCT01436201,Pharmacokinetics: Time of Maximum Observed Drug Concentration (Tmax) of Digoxin,,,2011-09,COMPLETED,INTERVENTIONAL,['PHASE1']
11719,NCT02834923,Sugar-sweetened beverages,Weight,,2016-10,COMPLETED,INTERVENTIONAL,['NA']
11720,NCT04881890,Adherence with food tracking,Change in body weight per participant over the study period,Change in physical symptoms,2020-10-05,COMPLETED,INTERVENTIONAL,['NA']
11721,NCT02506296,Difference in response to a standard DPPIV therapy,differences in time spent in hypoglycaemia,,2014-10,COMPLETED,INTERVENTIONAL,['NA']
11722,NCT01146678,Lixisenatide maximum plasma/serum peak concentration (LIX-Cmax),Time to GIRmax (GIR-Tmax),,2010-06,COMPLETED,INTERVENTIONAL,['PHASE1']
11723,NCT01408628,Frequency of Hypoglycemia,Severity of Self-reported Hypoglycemia,,2011-08,COMPLETED,INTERVENTIONAL,['NA']
11724,NCT01784211,Part A: Pharmacokinetics: Maximum Drug Concentration (Cmax) of LY2605541 and Insulin Glargine: Intra-Participant Variability,Part B: Pharmacokinetics: Cmax of LY2605541 and Insulin Glargine: Exercise Versus Non-Exercise,,2013-02,COMPLETED,INTERVENTIONAL,['PHASE1']
11725,NCT01019486,Coronary Blood Flow Assessment With Regadenoson Stress by Cardiac MRI Between Non-diabetic and Type 1 Diabetic Subjects.,Myocardial Perfusion Index,,2009-11,COMPLETED,INTERVENTIONAL,['PHASE4']
11726,NCT01578837,Change in Mean 24 hour Systolic Ambulatory Blood Pressure at 12 weeks,Change in lipids at 12 weeks,,2014-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11727,NCT00012649,,,,na,COMPLETED,OBSERVATIONAL,['NA']
11728,NCT05092477,Illness Perceptions Questionnaire (IPQ scores),Beliefs about Medicines Questionnaire (BMQ scores),,2022-01-27,COMPLETED,INTERVENTIONAL,['NA']
11729,NCT00527995,Improvement of flow mediated dilatation of the brachial artery following a single dose of 100mg Sildenafil.,Change in hemodynamics and cardiovascular parasympathetic and sympathetic nerve function using time domain and frequency domain indexes of heart rate variability (HRV) and baroreflex sensitivity (BRS) following a single dose of 100mg Sildenafil.,,2001-08,COMPLETED,INTERVENTIONAL,['PHASE3']
11730,NCT06075121,Blood sugar,,,2023-06-12,RECRUITING,INTERVENTIONAL,['NA']
11731,NCT00194298,SUV measurement from PET scan,,,2002-10,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
11732,NCT06150508,Lipid profile,Lifestyle questionnaire,Satisfaction rate,2023-11,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
11733,NCT01623648,Plasma glucose,Change in body weight,,2013-02,UNKNOWN,INTERVENTIONAL,['NA']
11734,NCT04530383,Change in BK channel gene expression,Pharmacokinetics of metformin,,2022-02-14,RECRUITING,INTERVENTIONAL,['PHASE2']
11735,NCT02790892,Decrease diabetes related distress,Increase emotional,,2016-04,COMPLETED,INTERVENTIONAL,['NA']
11736,NCT05275803,Microorganism,IL-1β、IL-6、TNF-α,,2023-06-08,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
11737,NCT00063128,test the hypothesis that preprandial HIIP plus insulin glargine is noninferior to preprandial injectable insulin (regular human insulin or insulin lispro) plus insulin glargine with respect to HbA1c,assess the impact of practice inhalations on inspiratory flow parameters (peak inspiratory flow rate [IFR] and total inspired volume [TIV]) achieved by patients using the insulin inhaler following training with the DFU,,2003-04,COMPLETED,INTERVENTIONAL,['PHASE2']
11738,NCT02871089,Area under the meal stimulated C-peptide curve (AUC) during a mixed meal tolerance test (MMTT),Lipid profile,Qualitative Human Factor Assessment,2017-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
11739,NCT02666430,Change in Hemoglobin A1c (HbA1c) From Baseline,Change From Baseline in Cross-Reactive Insulin Antibody - Lantus Assay,,2015-12,COMPLETED,INTERVENTIONAL,['PHASE3']
11740,NCT00721019,Total body insulin sensitivity,Glycerol turnover and free fatty acid concentrations,,2008-07,COMPLETED,INTERVENTIONAL,['NA']
11741,NCT05298163,Albuminuria,Calcium level,,2022-04,UNKNOWN,INTERVENTIONAL,['NA']
11742,NCT01019642,"Insulin resistance, measured by HOMA-IR index",Serum 25-OH-vitamin D3 levels,,2008-03,COMPLETED,INTERVENTIONAL,['PHASE3']
11743,NCT04027023,impact of a temporary personalized poly-pharmaceutical treatment on the disease stage in patients with type 2 diabetes,Electrolytic balance,,2019-10-30,UNKNOWN,INTERVENTIONAL,['PHASE4']
11744,NCT05180604,The Patient Health Engagement score after intervention at 6 months,"The change Trajectory of Cholesterol level from baseline to after the intervention at 3, 6 and 12 months",,2019-08-01,COMPLETED,INTERVENTIONAL,['NA']
11745,NCT02705274,Proportion of visual acuity improvement using Snellen chart or equivalent from baseline and 1 year,Proportion of eyes Need for Vitrectomy,,2016-02,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
11746,NCT00099320,Change from Baseline to Week 16 in fasting serum glucose (FSG) and glucose,Changes in lipids between Baseline and Week 16,,2004-05,COMPLETED,INTERVENTIONAL,['PHASE3']
11747,NCT02027740,Change in LDL-c,HbA1C,,2009-01,COMPLETED,INTERVENTIONAL,['NA']
11748,NCT02681718,Difference in Hemoglobin A1C (Text Message vs. Control),Percentage of participants who visited a physician due to a diabetes related follow-up,,2016-01,COMPLETED,INTERVENTIONAL,['NA']
11749,NCT05969106,Incremental Cost Efficiency Rate (ICER),,Glucose control at start of the study,2020-01-01,COMPLETED,OBSERVATIONAL,['NA']
11750,NCT05846191,Mean different in concentration of serum pentraxin-3 and high sensitive CRP levels in study groups.,,,2023-12-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
11751,NCT00980356,To assess whether monotherapy with Vildagliptin improve glycemic control in kidney transplanted patients with newly diagnosed NODAT as judged in OGTT 3 months after treatment start compared to placebo.,To assess differences in the change in HbA1c and fasting plasma glucose after 3 months after treatment start and to assess the safety and efficacy of Vildagliptin in renal transplanted patients.,,2009-09,COMPLETED,INTERVENTIONAL,['PHASE2']
11752,NCT02694263,HbA1c + weight loss,Flash Glucose Monitoring - MAGE,,2016-07,COMPLETED,INTERVENTIONAL,['PHASE4']
11753,NCT01730885,"Mean absolute relative deviation (MARD) from paired reference values of BGStar®, iBGStar® and comparator BG meter measurements at stable hypoglycaemic, euglycaemic and hyperglycaemic levels and overal",,,2012-11,COMPLETED,INTERVENTIONAL,['PHASE4']
11754,NCT00389415,Adverse events profile after 52 weeks of treatment,Change from baseline to endpoint in body weight at 52 weeks,,2006-10,COMPLETED,INTERVENTIONAL,['PHASE3']
11755,NCT02590822,Increase in circumferential PEDSR rate as measured by CMR at 12 weeks.,Exercise Questionnaire,,2015-10-02,RECRUITING,INTERVENTIONAL,['NA']
11756,NCT00380913,The Average Pain Score at target site.,Safety will be assessed through the collection of AEs and vital signs.,,2006-09,COMPLETED,INTERVENTIONAL,['PHASE4']
11757,NCT05420714,Average change in glycemic control 3 months after Pro-CGM use,Percentage of positive patient response to the Pro-CGM Questionnaire,,2022-08,WITHDRAWN,INTERVENTIONAL,['NA']
11758,NCT03665350,Change in blood glucose variability,Changes in Hemoglobin A1c (HbA1c).,,2018-11-08,TERMINATED,INTERVENTIONAL,['PHASE2']
11759,NCT04331444,"Difference between change in TIR (3.9-10 mmol/l) in percent, assessed via blinded CGM device, between CGM group (A) and SMBG group (C)",Difference between number of participants using CGM vs. not using CGM increasing 5 % or more in TIR,Evaluating which blood glucose measured by SMBG best reflect TIR,2020-08-01,COMPLETED,INTERVENTIONAL,['NA']
11760,NCT03532620,Change from baseline in hemoglobin A1c levels,Changes from baseline in carotid intima-media thickness,Incidence of adverse events (AEs),2018-08-09,UNKNOWN,INTERVENTIONAL,['PHASE4']
11761,NCT01515059,Glycaemic shift,Change in palatability via VAS,,2012-09,TERMINATED,OBSERVATIONAL,['NA']
11762,NCT04011397,Change in enjoyment,Change in systolic and diastolic blood pressure,,2016-03,COMPLETED,INTERVENTIONAL,['NA']
11763,NCT06180616,Body weight,FIB-4,,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
11764,NCT03146156,Neonatal adiposity comparison between intervention and usual care group,Maternal metabolic status,,2017-03-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
11765,NCT01104168,prevalence of diabetes,evaluate the impact of quality of care and glycemic control on clinical outcome in elderly subjects,,2010-05,COMPLETED,OBSERVATIONAL,['NA']
11766,NCT05812547,To evaluate the average change in blood glucose levels with the use the Lumen device,To evaluate the change in need for neonatal intensive care unit (NICU) admission,,2023-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
11767,NCT05770076,Changes in fasting plasma glucose (FPG) level,body mass index (BMI),,2023-02-01,COMPLETED,INTERVENTIONAL,['NA']
11768,NCT03784612,Change in dietary intake,Blood pressure,Change in perceived social support from family and friends for healthy eating habits,2019-01-15,COMPLETED,INTERVENTIONAL,['NA']
11769,NCT00411554,Change From Baseline in HbA1c at Week 12,Change From Baseline in 2 Hour Postprandial Glucose at Week 12,,2007-01,COMPLETED,INTERVENTIONAL,['PHASE3']
11770,NCT05920434,Pain severity,Vibration sense,The quality of life,2020-07-19,COMPLETED,INTERVENTIONAL,['NA']
11771,NCT05525572,Changes in Endothelial Progenitor Cell Colony Forming Units (EPC-CFUs),Incidence of Serious Adverse Events (SAEs),,2024-06-30,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11772,NCT05890807,Parodontitis based on clinical observation of the patient's oral cavity (direct method),D. Visible clinical signs associated with periodontitis on the photos taken. Plaque,Charlson score,2023-03-20,RECRUITING,INTERVENTIONAL,['NA']
11773,NCT04210609,Wound closure rate at 20 weeks,"Time to 50%, 75%, 100% wound closure",,2021-10-04,UNKNOWN,INTERVENTIONAL,['NA']
11774,NCT01601990,Change of HbAlc,HbA1c Responder Rate,,2009-12,COMPLETED,INTERVENTIONAL,['PHASE3']
11775,NCT00355823,,,,2006-08,COMPLETED,OBSERVATIONAL,['NA']
11776,NCT03430141,Nutrition Intervention,Chronic disease prevalence,,2016-10-31,COMPLETED,INTERVENTIONAL,['NA']
11777,NCT03196362,Remission rate,Adverse events,,2016-12-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
11778,NCT04277117,Change in Hemoglobin A1C (HbA1c),Medication underuse due to cost (2 items),,2022-12-05,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
11779,NCT01346527,Left ventricular strain,Maternal palmitate rate of appearance during hyperinsulinemia,,2011-04,COMPLETED,OBSERVATIONAL,['NA']
11780,NCT05110703,Examination of the effect of daily use of a prebiotic fiber meal replacement (PFMR) shake on quality of life [Time Frame: Baseline to 12 weeks],Changes from baseline on short-chain fatty acid synthesis from baseline after daily use of PFMR shakes. [Time Frame: Baseline to 12 weeks],,2021-10-11,COMPLETED,INTERVENTIONAL,['NA']
11781,NCT00790439,Level of Stimulated C-peptide at 90-minutes in Response to a Mixed-Meal Tolerance Test (MMTT),Incidence of Worsening Retinopathy,,2008-07,WITHDRAWN,INTERVENTIONAL,['PHASE2']
11782,NCT01690481,MRI brain volumes,Neuropsychological scores,,2006-12,COMPLETED,OBSERVATIONAL,['NA']
11783,NCT04450394,Change From Baseline in Hemoglobin A1c (HbA1c),Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) of LY3209590,,2020-07-01,COMPLETED,INTERVENTIONAL,['PHASE2']
11784,NCT04449692,Difference between study visits in time (min) in hypoglycemia (plasma glucose < 3.9 mmol/l) from 0-180 minutes post-intervention,Difference between study visits in incidence rate of vomiting from 0-180 minutes post-intervention,,2020-07-02,COMPLETED,INTERVENTIONAL,['PHASE2']
11785,NCT05252793,Healthy Lifestyle Behaviors Scale II Score Change,Self-Efficacy Questionnaire,,2022-01-01,COMPLETED,INTERVENTIONAL,['NA']
11786,NCT02689570,coronary artery calcifications,diastolic dysfunction,,2011-06,UNKNOWN,OBSERVATIONAL,['NA']
11787,NCT00699023,Incremental AUC after a fat-rich meal of cholesterol concentration in chylomicron and VLDL fractions,Concentration and Composition of different lipoprotein subclasses in the fasting condition.,,2008-06,COMPLETED,INTERVENTIONAL,['PHASE4']
11788,NCT03946631,Sensitivity of early postpartum overt diabetes screening by 2-hour glucose tolerance testing in postpartum women.,,,2019-08-20,TERMINATED,OBSERVATIONAL,['NA']
11789,NCT02723019,Number of Patients With at Least 1 Hospital Readmission Within 180 Days After Enrollment,Number of Outpatient Visits Over the Past 6 Months - Patient-reported,,2016-07-14,COMPLETED,INTERVENTIONAL,['NA']
11790,NCT02280863,"Count of Participants With no More Than One Meter Glucose Value <50 mg/dL and no Values <40 mg/dL, no More Than Two Episodes With Meter Glucose Values Remaining >300 mg/dL for More Than 1 Hour, and no Ketonemia, Seizures, or Loss of Consciousness","Percentage of Fingerstick Meter Glucose Value Tests >300 mg/dL, Adult Cohort - Integrated System Interface and Adolescent Cohort",,2014-07,COMPLETED,INTERVENTIONAL,['NA']
11791,NCT02905487,Blood levels of C- Reactive Protein in mother and her child,Blood level of C-peptide in mother,,2016-01,UNKNOWN,OBSERVATIONAL,['NA']
11792,NCT01832935,Number Of Hypoglycemic events,,,2011-07,COMPLETED,INTERVENTIONAL,['PHASE4']
11793,NCT00888719,Change in HbA1c before and after treatment,"Triglyceride, LDL-cholesterol and HDL-cholesterol change",,2009-02,COMPLETED,INTERVENTIONAL,['PHASE2']
11794,NCT00374907,Insulin Secretion Rate Area Under the Curve (AUC) During Intravenous (IV)-Oral Hyperglycemic Clamp - Percent Change From Baseline at Week 12,Insulin Secretion Rate AUC During IV Hyperglycemic Clamp - Percent Change From Baseline at Week 12,Marked Laboratory Abnormalities - During ST + LT Treatment Period,2006-09,COMPLETED,INTERVENTIONAL,['PHASE3']
11795,NCT01522807,The single dose pharmacokinetics of PF-05190457 in three formulations will be described by estimating parameter of Elimination of half-life (t ½ ) as data permit.,Changes in plasma glucose and insulin due to single doses of three formulations of PF-05190457 will be estimated.,,2011-09,COMPLETED,INTERVENTIONAL,['PHASE1']
11796,NCT01156779,Assessment of safety,Pharmacokinetics and Pharmacodynamics,,2010-07,COMPLETED,INTERVENTIONAL,['PHASE1']
11797,NCT03370484,Postprandial plasma GLP-1 area under the curve (mmol/L x 120 min).,Subjective ratings of appetite (au),,2017-10-01,COMPLETED,INTERVENTIONAL,['NA']
11798,NCT05193578,HbA1c (mmol/mol),Absolute change in systolic and diastolic blood pressure (mmHg),,2022-01-12,RECRUITING,INTERVENTIONAL,['PHASE2']
11799,NCT05998837,Biopsy changes in the expression and location of senescence markers by immunohistochemistry,Outcomes of blood presssure control,,2021-04-13,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
11800,NCT01342939,Incretin effect,Plasma glucagon response,,2011-01,COMPLETED,OBSERVATIONAL,['NA']
11801,NCT05510245,Fraction of unbound drug in plasma; Cu/C where Cu represents unbound concentration and C represents total concentration,Number of Participants With Treatment emergent Clinically Significant Abnormal ECG,,2022-08-29,TERMINATED,INTERVENTIONAL,['PHASE1']
11802,NCT05253521,The change in the frequency / absolute number of circulating ALDHhiSSChi granulocyte precursor cells between individuals of South Asian origins and White individuals of European origin,The change in the frequency / absolute number of circulating ALDHhiSSClo cells with primitive provascular progenitor cell phenotype between individuals of South Asian origins and White individuals of European origin,Changes in the concentration of serum inflammatory markers individuals of South Asian origins and White individuals of European origins,2022-01-08,COMPLETED,OBSERVATIONAL,['NA']
11803,NCT03183804,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,,,2015-12-29,COMPLETED,OBSERVATIONAL,['NA']
11804,NCT01654120,Change from baseline in HbA1c at six months,GlycoMark,,2011-12,COMPLETED,INTERVENTIONAL,['PHASE4']
11805,NCT00220337,"Number of Subjects With Urine Protein Status 'Positive +++' at Baseline, Categorized by Urine Protein Status at Last Visit",Change in Quality of Life From Visit 2 (Baseline) to Termination Visit,,2004-12-21,COMPLETED,INTERVENTIONAL,['PHASE3']
11806,NCT03178591,The average of systolic blood pressure at 6 month between DPP4 inhibitor (vildaglptin) group and SGLT2 inhibitors (Dapagliflozin) group.,,,2014-10,COMPLETED,INTERVENTIONAL,['PHASE4']
11807,NCT04183868,Change of myocardial metabolic rate of glucose,Change of lipid profile,,2016-04,COMPLETED,INTERVENTIONAL,['PHASE4']
11808,NCT03531944,Change in HbA1c level,Cost effectiveness analysis,,2018-06-06,COMPLETED,INTERVENTIONAL,['NA']
11809,NCT00687960,Post-Prandial Metabolism,,,2006-11,COMPLETED,INTERVENTIONAL,['NA']
11810,NCT06083116,"Steady-state pharmacokinetics parameters of Hydrochlorothiazide: Css, max",Adverse events,,2019-08-28,COMPLETED,INTERVENTIONAL,['PHASE1']
11811,NCT02881164,Satiety,,,2015-07,COMPLETED,INTERVENTIONAL,['NA']
11812,NCT05766215,Body Mass Index,Adherence to diabetes treatment,Demographical information,2023-09-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
11813,NCT00160056,,,,2005-04,COMPLETED,INTERVENTIONAL,['NA']
11814,NCT05319496,Change in HbA1c,Hospital admissions,,2022-10-05,COMPLETED,INTERVENTIONAL,['NA']
11815,NCT01410097,Short Physical Performance Battery (SPPB) Score,Modified Mini-Mental Status Exam (3MS),,2009-09,COMPLETED,INTERVENTIONAL,['NA']
11816,NCT01122108,"Patient Acceptability of Colesevelam HCl Powder for Oral Suspension vs. Generic Cholestyramine Via the Bile Acid Sequestrant Acceptability (BASA) Scale, Based Upon an Anticipated Equivalent Cholesterol Lowering Doses of Each Comparator Drug.",,Weighted vs. Unweighted Composite BASA Scale Scores,2010-04,COMPLETED,INTERVENTIONAL,['PHASE4']
11817,NCT03838380,hemoglobin A1c levels,Mode of delivery,,2017-02-01,COMPLETED,INTERVENTIONAL,['NA']
11818,NCT00437008,A high-AGE meal causes a more pronounced postprandial endothelial dysfunction comparing to a low-AGE meal in people with type 2 diabetes mellitus.,To investigate whether treatment with Benfotiamine 1050mg/day for 3 days has a protective effect on endothelial function after a high-AGE meal,,2004-11,COMPLETED,INTERVENTIONAL,['PHASE4']
11819,NCT05872620,Mean Percent Change from Baseline in Body Weight,Mean Change from Baseline in Short Form 36 Version 2 Health Survey Acute Form (SF-36v2) Domain Scores,,2023-06-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
11820,NCT03646812,Insulin,,,2018-08-10,COMPLETED,INTERVENTIONAL,['NA']
11821,NCT01175473,Change From Baseline in Area Under the Plasma Glucose Concentration Curve From Time 0.5 Hours to 4.5 Hours (GLU-AUC0:30-4:30h) at Day 28,Percentages of Patients by Ranges of Oxyntomodulin Levels,,2010-08,COMPLETED,INTERVENTIONAL,['PHASE2']
11822,NCT03470415,epicardial fat thickness measurement,Electrocardiogram,,2018-05,UNKNOWN,OBSERVATIONAL,['NA']
11823,NCT03073577,Serious adverse event morbidity,Beta-2 score,,2017-02-17,RECRUITING,INTERVENTIONAL,['PHASE1']
11824,NCT01841229,Glycated hemoglobin (HbA1c),Homeostasis model assessment of insulin resistance (HOMA-IR),,2012-10,UNKNOWN,OBSERVATIONAL,['NA']
11825,NCT05631431,primary objective,,,2021-10-15,RECRUITING,INTERVENTIONAL,['PHASE2']
11826,NCT00297063,HbA1c change from baseline at Week 28.,"Efficacy variables (changes from baseline in FPG, fasting insulin, HOMA-IR and HOMA-beta) at stipulated date in each treatment group.",,2006-01-11,COMPLETED,INTERVENTIONAL,['PHASE3']
11827,NCT05994651,The effect of using the tidal model on the psychological well-being of individuals with diabetes will be evaluated.,,,2023-07-10,COMPLETED,INTERVENTIONAL,['NA']
11828,NCT05234086,Proportion of patients with completely closed ulcers,,,2020-01-02,UNKNOWN,INTERVENTIONAL,['PHASE2']
11829,NCT02391558,"Comparison between examination techniques on the detection of morphological changes in the retina (such as vessels morphology, vascular ischemia, retinal neovascularization, choroidal neovascularization, and other vascular abnormalities).",,,2015-09,COMPLETED,OBSERVATIONAL,['NA']
11830,NCT03987633,Ethnic disparities in treatment failure,Identification of candidate genetic variants associated with observed disparities in treatment failure.,,2021-02-01,RECRUITING,OBSERVATIONAL,['NA']
11831,NCT04432025,Proportion of patients reaching end point for glycemic control,Change in quality of life,,2021-04-01,RECRUITING,INTERVENTIONAL,['NA']
11832,NCT03888053,Presence of anti-BB-101 antibodies,To evaluate plasma concentration of BB-101,,2018-03-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
11833,NCT01447940,HbA1c measured at 12 months in Meos ePoral group versus conventional care group. Non-inferiority level is defined at a 0.15% threshold for an expected HbA1c of 8.5% at 12 months,"Qualitative analysis by semi-structured interviews, then quantitative survey by questionnaire",,2012-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
11834,NCT05845190,homocystiene,cholestrol,,2022-04-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
11835,NCT01756716,Frequency and nature of treatment-emergent adverse events and serious adverse events.,Plasma concentrations of MT-3995 and its major metabolite,,2012-12,COMPLETED,INTERVENTIONAL,['PHASE2']
11836,NCT02057211,∆-change of C-peptide Area Under the Curve (AUC) (0-120 min) for a mixed meal tolerance test at two year follow-up when compared to pre-treatment values at enrolment.,,,2014-04,TERMINATED,INTERVENTIONAL,['PHASE2']
11837,NCT01483352,Percentage of Participants Categorized by Ability of the Port to Deliver Insulin Intraperitonally,Design Validation Participant Questionnaire - Percentage of Participants With a Positive Response,,2011-11,COMPLETED,INTERVENTIONAL,['NA']
11838,NCT04620265,Change from baseline spatial and temporal gait parameters at 3 months,,,2020-03-01,COMPLETED,INTERVENTIONAL,['NA']
11839,NCT03617146,Diabetes distress score,"Self-care behaviors (medication adherence, dietary practices, and physical activity behaviors)",,2018-06-15,TERMINATED,INTERVENTIONAL,['NA']
11840,NCT01026103,Proportion of Patients With an Uneventful Creation of a Functional Staple Line,Incidence of Serosal Tearing,,2010-01,COMPLETED,INTERVENTIONAL,['NA']
11841,NCT03960424,Hemoglobin A1C,Diabetes Quality of life,,2019-09-30,COMPLETED,INTERVENTIONAL,['NA']
11842,NCT03054454,Nights spent in hospital with a diabetes-related foot problem.,number of below knee amputations attributed to diabetic foot disease,,2017-04,UNKNOWN,INTERVENTIONAL,['NA']
11843,NCT05592860,HbA1c,Change in blood pressure,,2021-07-10,COMPLETED,INTERVENTIONAL,['NA']
11844,NCT02451722,Reduction of Peak Pressure,Comfort of wear,,2015-05,COMPLETED,INTERVENTIONAL,['NA']
11845,NCT03842475,Diabetes remission (complete),Change in ectopic fat,Changes in gut microbiome,2018-10-01,RECRUITING,OBSERVATIONAL,['NA']
11846,NCT00394407,blood glucose control,inflammatory markers,,2005-09,COMPLETED,INTERVENTIONAL,['PHASE4']
11847,NCT04717050,Change in Metabolic Dysregulation (MetD) After Completion of Phase 1 Progressive Combine Training (PCT) -metabolic syndrome (MSY),Metabolic Dysregulation (MetD) Status During 4 month follow up period - metabolic syndrome (MSY),,2021-08-12,RECRUITING,INTERVENTIONAL,['NA']
11848,NCT01632007,Glycosylated hemoglobin (HbA1c),,,2012-05-01,COMPLETED,INTERVENTIONAL,['PHASE3']
11849,NCT05342012,Pixel wise quantification of fat fraction will be performed from fat and water maps.,Biomarkers - cGMP,,2022-06-30,COMPLETED,INTERVENTIONAL,['NA']
11850,NCT00614939,Absolute Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) Level to Week 12 Last Observation Carried Forward (LOCF),Absolute Change From Baseline in Fasting Plasma Glucose (FPG) to Week 52 - Moderate Renal Impairment Subgroup,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE3']
11851,NCT03659461,change in blood insulin response to sitagliptin,,,2017-10-01,COMPLETED,INTERVENTIONAL,['NA']
11852,NCT03541096,Difference in brown adipose tissue (BAT) activity after cooling between Winter Swimmers (WS) and No-Winter Swimmers (NWS).,Difference in glycemic control after winter swimming,,2018-11-07,UNKNOWN,INTERVENTIONAL,['NA']
11853,NCT02411006,Medication refills,LDL cholesterol,,2014-11,COMPLETED,INTERVENTIONAL,['NA']
11854,NCT01551446,Change in renal perfusion,Change in total body water,,2012-04-30,WITHDRAWN,INTERVENTIONAL,['PHASE1']
11855,NCT04123587,the list of previously found candidate variants which are observed in the slufonylurea-dependent patients but not in the non-dependent patients,,,2019-09-10,COMPLETED,INTERVENTIONAL,['PHASE4']
11856,NCT02630706,Percentage of Participants Discontinuing Study Treatment Due to an AE (Including Rescue Approach) (China Subpopulation),Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach (China Subpopulation),,2015-12-16,COMPLETED,INTERVENTIONAL,['PHASE3']
11857,NCT02231684,Area under the semaglutide plasma concentration curve,Number of treatment emergent adverse events (TEAEs),,2014-09,COMPLETED,INTERVENTIONAL,['PHASE1']
11858,NCT03037190,Preservation of beta cells function,Prevention of Celiac DIsease,,2015-12,UNKNOWN,INTERVENTIONAL,['NA']
11859,NCT02211742,postprandial glucose homeostasis,,,2014-08,COMPLETED,INTERVENTIONAL,['PHASE4']
11860,NCT06311019,Change in Haemoglobin A1c,Fraction of patients with increased number of bolus insulin per day,Diabetes Treatment Satisfaction Questionnaire (DTSQ),2024-02-27,RECRUITING,INTERVENTIONAL,['NA']
11861,NCT06235086,Changes in glycosylated hemoglobin (HbA1c) from baseline at 28 weeks of treatment,The occurrence of TG103 anti-drug antibodies (ADA) and neutralizing antibody (NAb).,,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
11862,NCT01970033,Change From Baseline in HbA1c (Hemoglobin A1C) at Week24,"Change From Baseline in Body Weight at Week 4,8,12、24、38、52",,2012-12,UNKNOWN,INTERVENTIONAL,['PHASE3']
11863,NCT04276428,Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,Pharmacodynamics (PD): Change from Baseline in Fasting Plasma Glucose,,2020-02-28,COMPLETED,INTERVENTIONAL,['PHASE1']
11864,NCT04763746,"Train Lifelight algorithms on a more diverse population, including patients with Fitzpatrick scale 1, 4, 5 and 6 skin tones.",,,2021-06-01,COMPLETED,OBSERVATIONAL,['NA']
11865,NCT05033275,Babies with sacral agenesis identified with screening of asymptomatic babies with a spinal ultrasound,,,2021-05-01,RECRUITING,OBSERVATIONAL,['NA']
11866,NCT05885828,Blood glucose profile,Changes in lipid metabolism,,2023-07-17,RECRUITING,INTERVENTIONAL,['NA']
11867,NCT03624023,Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs),Change of Wound Volume for Individual Subject Measured by 3D Camera and Analysis Software up to 12 Weeks.,,2019-12-19,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11868,NCT04419337,HbA1C,insulin resistance,,2019-09-15,RECRUITING,INTERVENTIONAL,['PHASE2']
11869,NCT02791204,Assessment of lower extremity skeletal muscle perfusion in healthy control subjects compared to patients with peripheral arterial disease and diabetes using quantitative SPECT/CT imaging.,,,2016-05,RECRUITING,OBSERVATIONAL,['NA']
11870,NCT04298424,HbA1C,Self-Efficacy Score,,2020-02-14,UNKNOWN,INTERVENTIONAL,['NA']
11871,NCT00726674,Decrease in HbA1c level,Safety measures,,2008-08,COMPLETED,OBSERVATIONAL,['NA']
11872,NCT06051058,To determine the effect of the Care Transitions App on post-discharge adverse events,To determine the effect of the Care Transitions App on the 30-day readmission rate,,2024-08,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
11873,NCT00950599,Change From Baseline in A1C at Week 12 in the 0-40 mg Cohort,"Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths and Discontinuations During the Follow-up Period in the 0 & 100 mg Cohort",,2003-05,COMPLETED,INTERVENTIONAL,['PHASE2']
11874,NCT00391027,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26,Change From Baseline in Urinary Free 8-iso Prostaglandin F2-alpha (α) in a Subset of Subjects,,2006-12,COMPLETED,INTERVENTIONAL,['PHASE4']
11875,NCT04375943,"E velocity, A velocity,E' velocity",,,2018-04-01,COMPLETED,OBSERVATIONAL,['NA']
11876,NCT04399434,glucolipid metabolism and insulin sensitivity in pregnant women,,,2019-01-01,UNKNOWN,OBSERVATIONAL,['NA']
11877,NCT04018326,Final UCVA,,,2013-05-01,COMPLETED,OBSERVATIONAL,['NA']
11878,NCT00810589,"Duration of action, time from onset of action until end of action","GIRmax, maximum glucose infusion AUCGIR,0-32h, AUCGIR,0-12h, AUCGIR,12-32h, tinf=0, Cmax,ins, tmax,ins, AUCins,0-24h AUCins,0-∞ AUCins,0-12h AUCins,12-24h",,2008-11,COMPLETED,INTERVENTIONAL,['PHASE1']
11879,NCT00814372,Change in HbA1c from baseline and compared to placebo,Change in fasting plasma glucose (FPG) from baseline and vs. placebo,,2008-12,TERMINATED,INTERVENTIONAL,['PHASE2']
11880,NCT01453842,Plasma GLP-1,Plasma paracetamol,,2011-03,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
11881,NCT00680849,"Food Frequency Questionnaire for Fruits, Vegetables and percent calories from fat (FFQ) by Kristal and colleagues","Lipids, weight loss",,2003-12,COMPLETED,OBSERVATIONAL,['NA']
11882,NCT03331614,Reduction in Subjective Pain,Quality of Life,,2017-10-15,UNKNOWN,INTERVENTIONAL,['NA']
11883,NCT06187285,Mean blood glucose concentration,Glycated hemoglobin,,2024-01-01,RECRUITING,INTERVENTIONAL,['NA']
11884,NCT01508923,24-hour glucose profiles after three fixed meals,Adverse events,,2001-05,COMPLETED,INTERVENTIONAL,['PHASE2']
11885,NCT02284893,Mean Change in HbA1c,Mean Change in Fasting Plasma Glucose (FPG),,2014-09-09,COMPLETED,INTERVENTIONAL,['PHASE3']
11886,NCT01147627,the Comparison Between Treatment Groups of the Changes From Baseline in HbA1c at 48 Weeks,Safety and Tolerability in Different Groups,,2010-08,COMPLETED,INTERVENTIONAL,['NA']
11887,NCT04745572,Changes in QUICKI index,Diet Intake and Physical Activity Monitoring,,2021-05-14,COMPLETED,INTERVENTIONAL,['NA']
11888,NCT04957914,Incidence of Documented Hypoglycemia,,,2021-07-14,COMPLETED,INTERVENTIONAL,['PHASE1']
11889,NCT05243589,"WHO Quality of Life Scale (WHOQOL BREF)( assessing change in quality of life at baseline, 4th and 6th week of intervention.",,,2021-02-26,COMPLETED,INTERVENTIONAL,['NA']
11890,NCT01481779,Hemoglobin A1c (HbA1c) at 26 Weeks,Rapid Assessment of Physical Activity (RAPA),,2012-01,COMPLETED,INTERVENTIONAL,['PHASE3']
11891,NCT04790760,Difference in time-matched glucose levels between the right arm and the left arm,Difference in time below range between the right arm and the left arm,Change in bone mass,2021-03,UNKNOWN,INTERVENTIONAL,['NA']
11892,NCT03083600,Plasma Glycated Haemoglobin (HbA1c) (mmol/mol),Blood pressure (mmHg),,2017-05-22,TERMINATED,INTERVENTIONAL,['NA']
11893,NCT00462371,quality of life,impact of disease,,2002-01,COMPLETED,INTERVENTIONAL,['PHASE4']
11894,NCT01847937,Increase in magnetic resonance signal intensity of segmented nerves,Correlation of magnetic resoance signal intensity value and nerve conduction thresholds,,2013-05,COMPLETED,OBSERVATIONAL,['NA']
11895,NCT01871415,Change in HbA1c,Safety: Incidence of adverse events,,2013-05,COMPLETED,INTERVENTIONAL,['PHASE3']
11896,NCT05046483,Change of cardiac function,"Incidence of further cardiovascular diseases (CVD) and STEMI-related complications, new onset of prediabetes and diabetes mellitus and associated comorbidities",,2018-12-30,RECRUITING,OBSERVATIONAL,['NA']
11897,NCT02854111,The correct diagnosis of diabetes mellitus,The correct diagnosis of impaired glucose tolerance,,2013-07,COMPLETED,INTERVENTIONAL,['NA']
11898,NCT05611112,Mental health - Depression,Health literacy,,2022-11-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
11899,NCT00418288,The acute effect of GLP-1 on glucose uptake in the heart,The acute effect of GLP-1 on lumped constant in the brain,,2007-01,COMPLETED,INTERVENTIONAL,['NA']
11900,NCT03120871,Insulin sensitivity (Si),Urinary follicle stimulating hormone (FSH),,2017-05-12,COMPLETED,OBSERVATIONAL,['NA']
11901,NCT01011062,insulin sensitivity measured as glucose disposal during clamp,plasma adipokines and their expressions in SAT,,2004-01,COMPLETED,INTERVENTIONAL,['NA']
11902,NCT00543556,,,,2001-10,TERMINATED,INTERVENTIONAL,['PHASE2']
11903,NCT04843527,Impact on time above 180 mg/dL,,,2021-04-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
11904,NCT00622960,body weight,"glycemic control (glucose, insulin, and HbA1c)",,2004-04,COMPLETED,INTERVENTIONAL,['PHASE1']
11905,NCT04371497,differential HbA1c before and after insulin switch,Continuous Glucose Monitoring before and after insulin switch,,2011-06-01,COMPLETED,OBSERVATIONAL,['NA']
11906,NCT00641056,Change in HbA1c From Baseline to Week 26,Assessment on Event Rate of Treatment-emergent Hypoglycemic Episodes,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE3']
11907,NCT02378675,Difference of adipocytokines between women with GDM and women with normal glucose tolerance.,,,2012-08,COMPLETED,OBSERVATIONAL,['NA']
11908,NCT01131182,Proportion of Participants With at Least One Symptomatic Hypoglycemic Event,Proportion of Participants With at Least One Symptomatic or Asymptomatic Hypoglycemic Event,,2010-06-13,COMPLETED,INTERVENTIONAL,['PHASE4']
11909,NCT01724814,Incidence and severity of treatment emergent adverse events,Peak Plasma Concentration(Cmax) of HM12460A following a single dose in Parts 1-3,,2012-12-20,COMPLETED,INTERVENTIONAL,['PHASE1']
11910,NCT01086293,Number of participants hospitalized with a diagnosis of acute liver failure,Hospitalizations with acute liver injury,,2010-01,COMPLETED,OBSERVATIONAL,['NA']
11911,NCT03636867,Incidence of amputation,Incidence of revascularization of peripheral arteries,Incidence of major cardio and cerebrovascular adverse events (MACCE),2018-08-07,COMPLETED,OBSERVATIONAL,['NA']
11912,NCT06257082,Change in Eye Health Literacy as measured by Compliance with Annual Diabetic Eye Exams Survey (CADEES),Change in Trust in Healthcare as measured by Trust in the Health Care Team (T-HCT) scale score,,2024-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
11913,NCT02196571,"Number of pregnant women with complications during pregnancy, labour and delivery",Weight gain in pregnancy,Physical Activity in Pregnancy,2014-07,COMPLETED,INTERVENTIONAL,['NA']
11914,NCT02344186,Changes in unfolded protein response markers,Beta cell function,,2014-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4']
11915,NCT06053047,Relative risk reduction in the incidence of new Diabetic Foot Ulcers (DFUs),Relative risk reduction in resource utilization,Healthcare Provider acceptance of Bluedrop Monitoring System (BMS),2024-01-22,RECRUITING,INTERVENTIONAL,['NA']
11916,NCT05413239,Time in Range (TIR),Attitudes toward diabetes device use,Diabetes incorporation/identity,2022-07-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
11917,NCT02244164,Volumetric measurement of the pancreas,Quantitative response to secretin,Lipasemia,2014-10,TERMINATED,INTERVENTIONAL,['NA']
11918,NCT02607280,Change From Baseline in Average Daily Pain Score (ADPS) at Each Week,,,2015-12,COMPLETED,INTERVENTIONAL,['PHASE3']
11919,NCT00423059,Factor VIII,complication rate,,2006-12,COMPLETED,INTERVENTIONAL,['NA']
11920,NCT01264016,Percent of Venous Blood Glucose (BG) Results Within +/- 5 to 20 mg/dL (<75 mg/dL) or Within +/- 5% to 20% (>=75 mg/dL) of Laboratory Glucose Method,Number of Subjects Rated as<=3 Performing Basic Meter Tasks (Labeling Comprehension),,2010-11,COMPLETED,INTERVENTIONAL,['NA']
11921,NCT00432887,glucose tolerance,plasma caffeine concentration,,2004-07,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
11922,NCT04221152,"Adverse events, Adverse drug reactions, and Presence/absence of the use of rescue treatment drugs",Postprandial glucose for 2 hours over time,,2020-02-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
11923,NCT03059056,Area under the curve,,,2017-02-02,COMPLETED,INTERVENTIONAL,['PHASE1']
11924,NCT01781975,Area Under the Stimulated C-peptide Curve (AUC) Mean Over the First 2 Hours of a 4 Hour Mixed Meal Tolerance Test at the 1 Year Visit,Number of Adverse Events,,2014-01,COMPLETED,INTERVENTIONAL,['PHASE2']
11925,NCT00612599,Area under the serum glucose concentration profile during 24 hours,Hypoglycaemic episodes,,2003-09,COMPLETED,INTERVENTIONAL,['PHASE3']
11926,NCT01105455,Serum glucose concentration 1hr after glucose challenge test,Acceptability of study foods,,2010-03,COMPLETED,INTERVENTIONAL,['NA']
11927,NCT05806294,Blood pressure,Changes in resting energy expenditure,Changes in hospital admissions rates for ischemic stroke events,2022-11-17,RECRUITING,INTERVENTIONAL,['NA']
11928,NCT05713396,AV,TPF/FT,,2017-01-01,COMPLETED,INTERVENTIONAL,['PHASE4']
11929,NCT04838600,"Incidence of clean wound bed at End of Treatment, as assessed by investigator","Relative change in devitalized tissue and wound size at End of Treatment, compared to Baseline, assessed by planimetry",,2021-06-07,TERMINATED,OBSERVATIONAL,['NA']
11930,NCT00870402,Reduction of albuminuria,Reduction of diastolic disfunction,,2009-03,UNKNOWN,INTERVENTIONAL,['PHASE4']
11931,NCT04805996,HbA1c,Diabetes complications follow up,,2021-03-23,COMPLETED,INTERVENTIONAL,['NA']
11932,NCT00500097,"Sensitivity, specificity, kappa coefficient",,,2005-05,COMPLETED,INTERVENTIONAL,['NA']
11933,NCT03637075,Effects of nasal insulin vs. placebo on the insulin sensitivity of the human brain as well as effects on regional availability of dopamine receptors.,Effects of nasal insulin vs. placebo on changes in autonomic nervous system,,2017-02-20,RECRUITING,INTERVENTIONAL,['NA']
11934,NCT03412253,Cure of type II DM.,,,2013-11-01,SUSPENDED,INTERVENTIONAL,['NA']
11935,NCT02614625,Sensitivity as the proportion of anatomical structures that are detectable with the two instruments,Corneal sublayer thickness and retinal sublayer thickness obtained with the two study instruments,,2014-12,UNKNOWN,OBSERVATIONAL,['NA']
11936,NCT02386943,β-cell function (measurement of insulin and c-peptide during the clamp study),Incretin effect (measurement of active GLP-1 during the clamp study),,2013-12,UNKNOWN,INTERVENTIONAL,['PHASE4']
11937,NCT02091193,Change in Endothelial Function with Krill Oil Supplementation as Compared with Baseline and Placebo,"Change in Lipid Profile (HDL, LDL, Total Cholesterol), Glucose, Hemoglobin A1C with Krill Oil Supplementation Compared with Baseline and Placebo","Effects of Longer Term Krill Oil Supplementation compared to Baseline on Endothelial function, lipid profile, Hemoglobin A1C, glucose, c-peptide and total antioxidant capacity.",2012-03,COMPLETED,OBSERVATIONAL,['NA']
11938,NCT03182231,Pancreatic uptake of 68Ga-NODAGA-exendin-4,Beta cell function,,2016-10-07,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
11939,NCT04126603,Gene Expression of CD34+ Endothelial Progenitor Cell number,Biochemistry: LDL over HDl Ratio,,2019-08-01,COMPLETED,INTERVENTIONAL,['PHASE4']
11940,NCT00295256,"Outcomes measures are mean fasting glucose levels, mean systolic pressure and mean diastolic pressure",,,2006-02,COMPLETED,INTERVENTIONAL,['NA']
11941,NCT03285750,GPR120 expression in adipose tissue,,,2013-08,COMPLETED,OBSERVATIONAL,['NA']
11942,NCT02414217,Change in Objective Diabetes Numeracy from Baseline to ≈6 weeks,Change in Glycemic Control from Baseline to ≈3 months,,2015-07,COMPLETED,INTERVENTIONAL,['NA']
11943,NCT01181882,Platelet function,Lysophospholipids,,2010-08,COMPLETED,INTERVENTIONAL,['PHASE2']
11944,NCT00402012,Change in skeletal muscle mitochondrial number (electron microscopy + qPCR of mtDNA) and mitochondrial gene expression in T2DM patients treated with pioglitazone (vs. placebo),intra hepatic and intra myocellular lipid by MRS; mitochondrial content by MRS (ATP max) post weight loss period,,2006-11,COMPLETED,INTERVENTIONAL,['PHASE4']
11945,NCT05724134,Serum C-peptide (relative/change) (units: fold difference and/or ∆ µIU/mL relative to previous time points),Plasma glucose kinetics: endogenous glucose production (units: mg/kg/min),Serum or plasma growth hormone (relative/change) (units: fold difference and/or ∆ng/mL relative to previous time points),2023-08-29,RECRUITING,INTERVENTIONAL,['PHASE1']
11946,NCT00875108,The frequency of occurrence of hypoglycemia measured quarterly over one year.,"Changes in total daily:Prandial insulin dose, insulin dose, body weight, insulin antibody titers, the effects of insulin antibodies on glycemic control, individual and group mean %HbA1C measured quarterly and over one year.",,2007-07,COMPLETED,INTERVENTIONAL,['PHASE3']
11947,NCT02660593,Blood Sugar level,,,2016-03,UNKNOWN,INTERVENTIONAL,['NA']
11948,NCT02589028,Area under the curve (AUC) of plasma glucose level after breakfast,Area under the curve of plasma glucagon level after breakfast,,2015-10,COMPLETED,INTERVENTIONAL,['NA']
11949,NCT02828995,Diabetes Medication Adherence,Diabetes Patient Weight (in Pounds),,2016-07-08,COMPLETED,OBSERVATIONAL,['NA']
11950,NCT00525629,Insulin Resistance,,,2007-02,COMPLETED,INTERVENTIONAL,['NA']
11951,NCT05648721,Patient compliance,Patients' satisfaction from the monitoring protocol,,2023-05-18,RECRUITING,INTERVENTIONAL,['NA']
11952,NCT01469143,Area under the serum insulin aspart concentration-time curve,Time to maximum observed serum insulin aspart concentration,,2011-11,COMPLETED,INTERVENTIONAL,['PHASE1']
11953,NCT04601311,diabetes distress,diabetes distress,Proportion of participants with one or more serious adverse events in the intervention period,2020-11-11,UNKNOWN,INTERVENTIONAL,['NA']
11954,NCT03041844,Change in wound size,Microcirculatory blood flow index change,,2017-01,UNKNOWN,INTERVENTIONAL,['NA']
11955,NCT00237952,"The primary end point is an increase in serum creatinine to 1.5 times the base-line value, measured on two occasions one month apart, or the need for hemodialysis during the longitudinal observation period.",A secondary end point is a temporal change in the creatinine clearance or glomerular filtration rate during the follow-up period.,,2005-08,COMPLETED,INTERVENTIONAL,['NA']
11956,NCT05380817,Percentage of underrepresented minority participants enrolled,Number of patient reported device related issues,,2022-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
11957,NCT00147342,,,,2005-05,COMPLETED,OBSERVATIONAL,['NA']
11958,NCT01615978,Adverse events,24-hour profiles of plasma glucose,,2003-12,COMPLETED,INTERVENTIONAL,['PHASE1']
11959,NCT03154060,Mean Absolute Relative Difference,Precision Absolute Relative Deviation,,2017-05-19,COMPLETED,INTERVENTIONAL,['NA']
11960,NCT03950505,A degree of liver fibrosis,Clinical glucometabolic parameters :Anthropometric parameters,,2020-05-29,UNKNOWN,INTERVENTIONAL,['PHASE4']
11961,NCT02337218,Gait Test (LegSys System),,,2014-11,COMPLETED,INTERVENTIONAL,['NA']
11962,NCT00571818,Evaluate insulin sensitivity/glucose effectiveness,,,2000-11-01,COMPLETED,INTERVENTIONAL,['NA']
11963,NCT02989740,The per patient incidence of the target lesion(s) related composite MACE,"The incidence of MACE (Cardiac death, MI, any clinically driven-revascularization or hospitalization due to unstable or progressive angina)",,2015-03-26,COMPLETED,OBSERVATIONAL,['NA']
11964,NCT05657769,HbA1C Changes,Lab outcome VI (triglyceride),,2022-11-12,RECRUITING,INTERVENTIONAL,['NA']
11965,NCT03625856,HbA1c changes,Depression score changes,,2018-11-30,COMPLETED,INTERVENTIONAL,['NA']
11966,NCT01925989,Sleep Respiratory Quotient (RQ) in Type 1 Diabetes Mellitus (T1DM),"Change in RQ, Pre-breakfast to Post-breakfast Meal, in T1DM",,2013-11,COMPLETED,INTERVENTIONAL,['PHASE1']
11967,NCT01065909,,,,2009-05,COMPLETED,OBSERVATIONAL,['NA']
11968,NCT00679939,Adjusted Percent Change in Femoral Neck (FN) Bone Mineral Density (BMD) Via Dual-energy X-ray Absorptiometry (DXA) From Week 52 +10 Days to Week 76+10 Days,Percent Change in Sex Hormone Binding Globulin (SHBG) From Week 52 to Week 76,Percent Change in Free Estradiol From Week 52 to Week 76,2008-04-21,COMPLETED,INTERVENTIONAL,['PHASE4']
11969,NCT01580852,Glucose Levels,HbA1c levels,,2012-05,COMPLETED,INTERVENTIONAL,['NA']
11970,NCT01483560,Change in Averaged Mean Far Wall Common Carotid Artery Intima-media Thickness (cIMT),Change in Endothelial Function,,2011-12,COMPLETED,INTERVENTIONAL,['PHASE3']
11971,NCT01038518,"5-year change in prevalence of biomarkers of chronic diseases (e.g. diabetes, asthma, allergy) and micronutrient status (e.g. vitamin D status).",significant interaction (on a additive scale) between Vitamin D status and genetic variants in the Vitamin D receptor in relation to selected chronic disease biomarkers,,2010-11,COMPLETED,OBSERVATIONAL,['NA']
11972,NCT04581447,Proportion of patients with partial or complete T2D remission criteria,Level of glicentin,,2021-01-07,RECRUITING,INTERVENTIONAL,['PHASE3']
11973,NCT04722354,Insulin sensitivity,,,2021-03-08,RECRUITING,INTERVENTIONAL,['PHASE2']
11974,NCT02352974,Number of Subjects With Injection Site Reactions Month 32,"Mean IDAA1c Values, Month 43",,2015-01,COMPLETED,INTERVENTIONAL,['PHASE1']
11975,NCT05066893,Change in HbA1c,,,2020-11-05,RECRUITING,INTERVENTIONAL,['NA']
11976,NCT06243536,Eating Attitude Test (EAT-26) questionnaire score,"Concentration of incretin hormones (GLP-1, GIP)",,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
11977,NCT02371239,Mean 24 hour glucose concentration,Homeostatic model assessment 2 (HOMA2),,2015-02,COMPLETED,INTERVENTIONAL,['NA']
11978,NCT05662657,To evaluate the prevalence of post-traumatic stress disorder (PTSD) in adult with Type 1 Diabetes,To evaluate whether there is a correlation between PTSD and the patient participation to a therapeutic education program,,2022-11-30,RECRUITING,OBSERVATIONAL,['NA']
11979,NCT02968628,Lower Margin Amplitude on aEEG,Bandwidth on aEEG,,2016-09-01,COMPLETED,OBSERVATIONAL,['NA']
11980,NCT03521362,Change from Baseline HbA1c at 6 months and 12 months,"Unified theory of acceptance and use of technology (UTAUT) Vantakesh, Morris, et al., 2003",,2019-01-01,COMPLETED,INTERVENTIONAL,['NA']
11981,NCT01725672,AUC(0-t) and AUC(0-inf) for metformin and glimepiride,Number of subjects with adverse events (AE)s,,2012-09-27,TERMINATED,INTERVENTIONAL,['PHASE1']
11982,NCT06305143,improvement of visual acuity,,,2024-04-01,RECRUITING,INTERVENTIONAL,['PHASE4']
11983,NCT02304627,Area under the serum insulin 338 concentration-time curve,Maximum observed plasma capric acid concentration,,2014-11-24,COMPLETED,INTERVENTIONAL,['PHASE1']
11984,NCT04369313,Number of infants with neonatal hyperbilirubinemia,neonatal initial blood glucose levels,,2019-09-01,UNKNOWN,INTERVENTIONAL,['NA']
11985,NCT05098470,Contribution of gluconeogenesis (GNG) to endogenous glucose production (EGP),Glucokinase activity,,2022-03-07,RECRUITING,INTERVENTIONAL,['PHASE3']
11986,NCT05596773,Occurrence of clinically relevant events (number),,Adherence to clinical algorithms provided via the eHealth application,2023-02-22,RECRUITING,OBSERVATIONAL,['NA']
11987,NCT06032221,Device Feasibility - Patient feedback on device use,,,2023-07-14,RECRUITING,INTERVENTIONAL,['NA']
11988,NCT03938233,Total cardiovascular risk,Body mass index (BMI),Smoking,2020-03-01,UNKNOWN,INTERVENTIONAL,['NA']
11989,NCT00432679,Change From Baseline in Glycosylated Hemoglobin (HbA1c) After 16 Weeks of Treatment in Rosiglitazone Group and Placebo Group,Percentage of Participants With Changes in HbA1c and FPG Meeting Specified Criteria After 16 Weeks of Treatment,,2006-05-24,COMPLETED,INTERVENTIONAL,['PHASE3']
11990,NCT02440217,Myocardial metabolic responses to stress in humans,,,2015-05,UNKNOWN,OBSERVATIONAL,['NA']
11991,NCT03495765,The primary endpoint for the study will be the mean change in best-corrected visual acuity (BCVA) from baseline to the mean level at Month 12.,,,2011-03,COMPLETED,INTERVENTIONAL,['PHASE3']
11992,NCT01255085,Energy Intake,Subjective Appetite,,2008-05,COMPLETED,INTERVENTIONAL,['NA']
11993,NCT00024583,,,,2001-09,COMPLETED,OBSERVATIONAL,['NA']
11994,NCT01220336,"Composite clinical outcome measure- improvement in either HgA1C, SBP, or LDL","Composite clinical outcome measure- improvement in either HgA1C, SBP, or LDL",,2011-04,COMPLETED,INTERVENTIONAL,['NA']
11995,NCT03406663,Proportion of patients achieving fasting SMPG ≤ 5.6 mmol/L without hypoglycemia at 12 weeks,Health care professionals' satisfaction to the insulin titration methods (evaluated by prespecirfied questionnaire: health care provider treatment satisfaction questionnaire),,2017-10-01,COMPLETED,INTERVENTIONAL,['NA']
11996,NCT00377442,AUC0-6h of plasma glucose from pre-dose to 6h post-dose.,"AEs, laboratory parameters.",,2006-08,COMPLETED,INTERVENTIONAL,['PHASE1']
11997,NCT01135914,Mean Change From Baseline in Best Corrected Visual Acuity- (BCVA) at Month 12,Time Trade-Off Questionnaire - 25 (TTO) Composite Score at Month 12,,2010-07,COMPLETED,INTERVENTIONAL,['PHASE3']
11998,NCT01441323,insulin sensitivity,adiposity,,2007-06,COMPLETED,INTERVENTIONAL,['NA']
11999,NCT02840630,Change in Glycated Hemoglobin (HbA1c),Change in Vitamin D,,2016-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
12000,NCT02739984,Percent Change From Baseline in LDL-C at Week 12,Percent Change From Baseline in VLDL-C at Week 12,,2016-05-17,COMPLETED,INTERVENTIONAL,['PHASE3']
12001,NCT01276743,• Difference of distribution of PTPN22 C1858T alleles between patients and controls of Greek origin,• The association between the PTPN22 C1858T polymorphism among patients and presence of autoantibodies,,2010-02,COMPLETED,OBSERVATIONAL,['NA']
12002,NCT01754259,Change in Post-exercise Coronary Vasodilator Reserve,Change in LV Diastolic Function,,2013-04,COMPLETED,INTERVENTIONAL,['PHASE3']
12003,NCT01595789,LVEF,Diastolic heart function (E/E*),,2012-05,COMPLETED,INTERVENTIONAL,['PHASE4']
12004,NCT04261933,Change in HbA1c,Patient completed the study under treatment with semaglutide (yes/no),,2020-02-13,COMPLETED,OBSERVATIONAL,['NA']
12005,NCT01125969,Hemoglobin A1c,Cost-effectiveness of change in Hemoglobin A1c,,2011-03,COMPLETED,INTERVENTIONAL,['NA']
12006,NCT01280409,Weight Change,Satisfaction With Medication as Assessed by a 5-point Likert Scale,,2011-01,COMPLETED,INTERVENTIONAL,['PHASE4']
12007,NCT03957811,Effect of whole body vibration on TcPO2 levels,,,2017-04-04,UNKNOWN,INTERVENTIONAL,['PHASE3']
12008,NCT01348672,"Topographic distribution of retinal / ON oxygen saturation disturbance, vascular dysfunction and change in morphometric parameters",,,2012-03,UNKNOWN,OBSERVATIONAL,['NA']
12009,NCT00315133,C-peptide levels,Quality of Life,,2003-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12010,NCT00989534,,,,2003-01,COMPLETED,INTERVENTIONAL,['NA']
12011,NCT04314622,Immunogenicity Tests,PK: Tmax of Supaglutide,,2020-04-14,COMPLETED,INTERVENTIONAL,['PHASE2']
12012,NCT03338153,Major adverse cardiac event,target lesion revascularization,,2007-10,COMPLETED,OBSERVATIONAL,['NA']
12013,NCT02526615,insulin sensitivity in skeletal muscle,insulin stimulated intestinal glucose uptake,,2000-10,COMPLETED,INTERVENTIONAL,['PHASE4']
12014,NCT03168295,Change in Endogenous Glucose Production (EGP),Change in Fasting Plasma Insulin,,2016-10,COMPLETED,INTERVENTIONAL,['PHASE4']
12015,NCT06068686,NT-proBNP Concentration (pg/ml),Fasting blood glucose (mg/dl),,2022-10-01,RECRUITING,INTERVENTIONAL,['NA']
12016,NCT05570734,Psychological Distress - Anxiety,,,2023-02-27,RECRUITING,INTERVENTIONAL,['NA']
12017,NCT00366379,Percentage of patients at each dose who achieve FPG <100mg/dL.,"AEs, laboratory parameters.",,2006-07,COMPLETED,INTERVENTIONAL,['PHASE2']
12018,NCT02039986,Change from baseline in insulin secretion capacity at 16 weeks,Composite change from baseline in relationships of insulin secretion and protein and interleukin levels at 16 weeks,,2014-01-06,COMPLETED,OBSERVATIONAL,['NA']
12019,NCT05359432,Serum triglycerides,,,2020-07-01,COMPLETED,INTERVENTIONAL,['PHASE4']
12020,NCT00822367,"To determine the nutritional supplements glycemic response in patients with DM, defined as the maximum glucose excursion, area under the curve, and 2 and 3 hour BG levels fol",,,2006-05,COMPLETED,INTERVENTIONAL,['NA']
12021,NCT00737880,Pancreas graft survival,Exogenous insulin requirement,,2001-07,COMPLETED,INTERVENTIONAL,['PHASE4']
12022,NCT01399489,Change from Baseline in Arterial stiffness (pulse wave velocity),Change in Resting blood pressure after 16 weeks of training,,2009-09,COMPLETED,INTERVENTIONAL,['NA']
12023,NCT00402909,Change from baseline in hemoglobin (Hb)_A1c,Proportion of patients achieving reduction in HbA1c of 0.5%,,2006-11,COMPLETED,INTERVENTIONAL,['PHASE4']
12024,NCT04909983,Response rate of active treatment versus standard of care,Time to resolution of Irritative contact dermatitis,,2021-05-19,TERMINATED,INTERVENTIONAL,['NA']
12025,NCT01056367,Pulse wave velocity,Pulse wave analysis,,2009-06,COMPLETED,OBSERVATIONAL,['NA']
12026,NCT01163721,Change From Baseline in Fasting Serum Glucose at Week 12,,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE2']
12027,NCT05958706,Substrate-specific JVO2 of ventricular myocardial mitochondrial oxidative capacity,Longitudinal Substrate-specific JVO2,,2021-12-01,RECRUITING,OBSERVATIONAL,['NA']
12028,NCT01533688,Measure the % of Participants With Effective (How Well the Colon is Cleansed Using the Validated Boston Bowel Preparation Scale) for Various Bowel Preparations for Colonoscopy.,Measure of Patients Who Develop (Tolerance)Side Effects of Taking Bowel Preparations.,,2011-10,COMPLETED,INTERVENTIONAL,['NA']
12029,NCT00699413,Body Mass Index,Hunger,,2008-02,TERMINATED,INTERVENTIONAL,['PHASE4']
12030,NCT02328040,"Blood Glucose Measures in Subjects Treated With Sitagliptin, Compared to the Placebo","Measure of Glucagon Concentration in Subjects Treated With Sitagliptin, Compared to Placebo",,2014-09,COMPLETED,INTERVENTIONAL,['PHASE1']
12031,NCT01069341,Adverse Event (AE),Mean Change in Intraocular Pressure (IOP),,2007-07,COMPLETED,INTERVENTIONAL,['PHASE1']
12032,NCT04065724,Ulcer area,Participant satisfaction measured by Numeric Rating Scale(NRS),,2013-02,COMPLETED,INTERVENTIONAL,['NA']
12033,NCT00991575,Fatal and non fatal cardiovascular disease (CVD) and stroke,Vessel area stenosis,,2009-04-01,COMPLETED,OBSERVATIONAL,['NA']
12034,NCT00554697,Diabetes Mellitus Type II and Tissue Oxygenation,,,2007-11,TERMINATED,OBSERVATIONAL,['NA']
12035,NCT05453838,Blood glucose - Product A versus Product B,GL new product,,2022-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
12036,NCT00826774,Weight,Homeostasis model assessment of insulin resistance (HOMA-IR),,2008-01,COMPLETED,INTERVENTIONAL,['PHASE3']
12037,NCT04254380,Treatment developed AIAs or important increase in AIA titers,Percentage of subjects who achieve an HbA1c of ≤ 7.0% at visit Week 26,,2019-12-04,WITHDRAWN,INTERVENTIONAL,['PHASE3']
12038,NCT00411892,HbA1c change from baseline,Change in body weight,,2006-11-29,TERMINATED,INTERVENTIONAL,['PHASE3']
12039,NCT01970566,"Compare the rate of change in fat mass in intense exercise/moderate diet restriction, topiramate-phentermine and cognitive behavior therapy","Compare the change in quality-of-life in response to intense exercise/moderate diet restriction, topiramate-phentermine and cognitive behavioral therapy",,2013-11,WITHDRAWN,INTERVENTIONAL,['NA']
12040,NCT01519505,Incident cases of type 2 diabetes,Cost-effectiveness,,2005-03,UNKNOWN,INTERVENTIONAL,['NA']
12041,NCT06147310,Ridge horizontal width,Inflammatory proliferative remodelling,,2024-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
12042,NCT01049633,,,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA']
12043,NCT04077216,trans-meal blood glucose,,,2018-09-01,COMPLETED,INTERVENTIONAL,['NA']
12044,NCT06326047,Change in Glycated haemoglobin (HbA1c),Number of adverse events,,2024-03-18,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
12045,NCT04476433,Change of Perceived level of disease threat (Baseline-Pre-Post),Change Psychological well-being (Baseline-Pre-Post),Exocrine pancreatic test ( Baseline-Pre-Post),2019-02-04,COMPLETED,INTERVENTIONAL,['NA']
12046,NCT03133819,Peripheral arterial occlusive disease,"Major cardiac events ( myocardial infarction, strokes and cardiac related death)",,2016-11,UNKNOWN,INTERVENTIONAL,['NA']
12047,NCT05952999,Patient Perception of Digital Care at discharge,Number of participants with Hospital Acquired Infections,Clinical Sustainability Assessment Tool,2023-08-15,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
12048,NCT04610749,Retinal metabolism,Depressive symptoms,,2020-11-25,COMPLETED,OBSERVATIONAL,['NA']
12049,NCT01548235,Incidence of SADR (serious adverse drug reactions) including major hypoglycaemia,"Overall, daytime and nocturnal frequency of hypoglycaemic events",,2006-02,COMPLETED,OBSERVATIONAL,['NA']
12050,NCT03152552,Change From Baseline in N-terminal Pro B-type Natriuretic Peptide (NT-proBNP) at Week 12,Change From Baseline in Bone Mineral Density (BMD) at Weeks 12 and 36,,2017-07-25,TERMINATED,INTERVENTIONAL,['PHASE2']
12051,NCT04947163,Audit of Diabetes Dependent Quality of Life:,30sec sit-to-stand (30secSTS),,2021-07-01,COMPLETED,INTERVENTIONAL,['NA']
12052,NCT03344549,Know the renal function,Adherence to treatment,,2017-12-28,COMPLETED,INTERVENTIONAL,['NA']
12053,NCT01661192,Safety and tolerability of the AAT in terms of laboratory values,Daily insulin dose adjusted to body weight,,2013-01,COMPLETED,INTERVENTIONAL,['PHASE2']
12054,NCT05454709,Time in range,AP related parameters - algorithm,,2023-12-29,WITHDRAWN,INTERVENTIONAL,['PHASE2']
12055,NCT01640210,weight of the insulin pump (JewelPUMP and usual pump),acceptability,,2011-11,COMPLETED,INTERVENTIONAL,['NA']
12056,NCT00907608,Death,"Number of hospital admissions, total number of days of hospital stay and attendance at the Accident and Emergency Department",,2007-12,TERMINATED,INTERVENTIONAL,['NA']
12057,NCT01156116,Change From Baseline in Area Under the Curve (AUC) Glucose at Week 2,Change From Baseline in 24-hr Diastolic Blood Pressure (mmHg) at Week 2,,2009-10,COMPLETED,INTERVENTIONAL,['NA']
12058,NCT03731533,Weight,Minutes per day of exercise,,2018-12-01,WITHDRAWN,INTERVENTIONAL,['NA']
12059,NCT05270148,Body composition: Fatmass and Fat-free mass.,Self-reported quality of life,,2022-03-10,RECRUITING,INTERVENTIONAL,['NA']
12060,NCT05875259,"Cmax,ss",,,2023-05-13,COMPLETED,INTERVENTIONAL,['PHASE1']
12061,NCT01980017,Percentage of Participants Who Self Report of Not Smoking (Even a Puff) in the Last 7 Days + CO <10ppm,Cost-effectiveness of Smoking Cessation Interventions.,Implementation Costs - Clinic,2013-07,COMPLETED,INTERVENTIONAL,['NA']
12062,NCT05449678,Time in range (TIR),Adherence,,2022-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
12063,NCT03223129,Glucose kinetics,Metabolomics,,2018-01-09,COMPLETED,INTERVENTIONAL,['NA']
12064,NCT05683106,Change from Baseline Pre-ulcerative lesions and ulcers at 12 and 24 weeks,Change from Baseline Comfort at 12 weeks,,2023-09-06,RECRUITING,INTERVENTIONAL,['NA']
12065,NCT05403502,Adverse drug reactions,CGM hypoglycemia outcomes: Rate of hypoglycemia events,Patient Reported Outcomes: ITSQ,2022-08-31,COMPLETED,INTERVENTIONAL,['NA']
12066,NCT01557634,Time in target,Glucose variability,,2012-12,UNKNOWN,INTERVENTIONAL,['PHASE2']
12067,NCT05816577,Bristol Stool Chart,Microbiome composition,Fasting blood short chain fatty acids,2023-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
12068,NCT03029546,Concentration of advanced glycation end products in maternal serum following the glucose load,,,2015-11,COMPLETED,OBSERVATIONAL,['NA']
12069,NCT01545401,Change in the proportion of patients achieving glycaemic and BP control,Other secondary outcome measures,,2012-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
12070,NCT04902326,Change in hemoglobin A1C from baseline to 12 months,Proportion of days covered by Metformin,,2021-09-16,COMPLETED,INTERVENTIONAL,['NA']
12071,NCT00574639,Change in Epinephrine Levels,,,2007-07,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
12072,NCT04857957,CNTX-6016 Pharmacokinetics - tmax,,CNTX-6016 Efficacy - PDN Cohort,2021-04-14,COMPLETED,INTERVENTIONAL,['PHASE1']
12073,NCT01334125,Baseline Adjusted Hemoglobin A1c Over Time,"Number of Participants With Minor, Major, and Nocturnal Hypoglycemia",,2011-02,COMPLETED,INTERVENTIONAL,['PHASE3']
12074,NCT01455896,"time to first occurrence of any event included in the MACE cardiovascular composite endpoint (CV death, non fatal MI, non fatal stroke, or hospitalization for unstable angina),",,,2013-03,COMPLETED,INTERVENTIONAL,['PHASE3']
12075,NCT00270855,Glucose Effectiveness (Sg) Between Groups,Ratio of Total Cholesterol to High Density Lipoprotein Cholesterol (TC:HDL) Between Groups,Resting Metabolic Rate Between Groups,2008-05,COMPLETED,INTERVENTIONAL,['NA']
12076,NCT02812303,Difference in differences in Blood pressure (BP) goal achievement over the follow-up period comparing PHC and non-PHC practices,Difference in differences in proportion of patients completing colorectal cancer screening over the follow-up period comparing PHC and non-PHC practices,,2014-07,COMPLETED,OBSERVATIONAL,['NA']
12077,NCT01069965,Change from Baseline in Glycosylated Hemoglobin at Week 13,Cardiovascular and metabolic biomarkers at Baseline and 13 weeks,,2010-10,TERMINATED,INTERVENTIONAL,['PHASE2']
12078,NCT03465878,Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Curve (AUC) Following Each Treatment Arm for Each Study Part,Glucodynamics (GD): Area Under the Baseline Subtracted Glucose Concentration Versus Time Curve Following Each Treatment Arm for Each Study Part,,2018-03-26,COMPLETED,INTERVENTIONAL,['PHASE1']
12079,NCT01571661,urine glucose concentrations in subjects with type 2 diabetes mellitus following a 50g oral glucose challenge.,,,2004-09,COMPLETED,INTERVENTIONAL,['PHASE1']
12080,NCT02429258,Change in 24-hour Mean Weighted Glucose (MWG) From Baseline to End of Treatment (Week 4) Using the Continuous Glucose Monitoring (CGM) System,Change in Static Insulin Secretion Rate (10^-9 Min^-1) From Baseline to Week 4 - ITT Population,,2015-05,COMPLETED,INTERVENTIONAL,['PHASE4']
12081,NCT00909597,Absolute change from baseline in HbA1c,Adverse events; laboratory parameters; cardiovascular events,,2009-05,COMPLETED,INTERVENTIONAL,['PHASE3']
12082,NCT05553509,Clinical Outcomes Following Surgical Debridement of Diabetic Foot Infection With Borderline Vascularity,Clinical Outcomes Following Surgical Debridement of Diabetic Foot Infection With Borderline Vascularity,,2023-01-01,RECRUITING,OBSERVATIONAL,['NA']
12083,NCT01365793,the Number of Participants With Glasgow Coma Score (GCS) < 14 Within the First 24 Hours of Treatment for Diabetic Ketoacidosis (DKA),Intelligence Quotient (IQ) Testing,,2010-11,COMPLETED,INTERVENTIONAL,['PHASE3']
12084,NCT02763150,Incidence of Gestational Diabetes Mellitus,Minutes per week of moderate physical activity,,2017-12-15,COMPLETED,INTERVENTIONAL,['NA']
12085,NCT02974244,Changes from baseline in weight (kg),Frequency of diarrhea and constipation,,2014-10-28,COMPLETED,OBSERVATIONAL,['NA']
12086,NCT03481829,Infant BMI,Child BMI,,2022-04-14,RECRUITING,OBSERVATIONAL,['NA']
12087,NCT01307072,Preoperative status,Postoperative status,,2008-09,COMPLETED,OBSERVATIONAL,['NA']
12088,NCT03467932,Change From Baseline of HbA1C (Glycated Hemoglobin),Change Over Time in Hb1Ac,,2018-05-29,COMPLETED,INTERVENTIONAL,['PHASE2']
12089,NCT03203694,Plasma insulin,,,2017-12-04,COMPLETED,INTERVENTIONAL,['NA']
12090,NCT04226105,Immunogenicity,Achievement of Glycated Hemoglobin < 7%,,2020-01-20,UNKNOWN,INTERVENTIONAL,['PHASE3']
12091,NCT02333734,Oral Glucose tolerance test (OGTT),Physical fitness,blood flow,2014-07,COMPLETED,INTERVENTIONAL,['NA']
12092,NCT01453049,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24,Change From Baseline in Electrocardiogram (ECG) Data at Week 24/EW,,2010-04,TERMINATED,INTERVENTIONAL,['PHASE3']
12093,NCT02914496,HbA1c,The Summary of Self-Care Activities,,2016-10-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
12094,NCT01657227,Change in Glycosylated hemoglobin (HbA1c),Change in Morisky Compliance Scale,Resource utilization and costs,2013-01,COMPLETED,INTERVENTIONAL,['NA']
12095,NCT03222726,kidney endpoint,Retinal progression,,2021-04-06,UNKNOWN,INTERVENTIONAL,['NA']
12096,NCT00795275,Change in Insulin Secretion,"Baseline and Change in Hormones, Substrates and Insulin Action: Glycerol",,2008-01,COMPLETED,INTERVENTIONAL,['NA']
12097,NCT01627210,Evaluate the Dexcom G4 system utility and usability during home use.,,,2012-05,COMPLETED,OBSERVATIONAL,['NA']
12098,NCT00493012,Change in Body Weight From Baseline to 12 Months,Change in Hb A1c From Baseline to 12 Months,,2006-01,COMPLETED,INTERVENTIONAL,['NA']
12099,NCT01292993,Plasma concentration of LX4211 and metformin after concurrent single-dose administration,Glucose-dependent insulinotropic peptide,,2011-02,COMPLETED,INTERVENTIONAL,['PHASE1']
12100,NCT02941367,Percentage of patients with at least 1 documented symptomatic hypoglycemia event (plasma glucose ≤70 mg/dL; 3.9 mmol/L),"Percentage of patients with HbA1c <7%, no weight gain and no documented symptomatic hypoglycemia (plasma glucose ≤70 mg/dL; 3.9 mmol/L)",,2017-02-23,COMPLETED,INTERVENTIONAL,['PHASE4']
12101,NCT05669560,Change of HbA1C measured in percentage.,Change in Clinical attachment levels(mm).,,2023-01-20,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1']
12102,NCT05319600,Change from Baseline in Physical Activity,Change in insulin requirements,,2022-03-23,COMPLETED,INTERVENTIONAL,['NA']
12103,NCT03483467,The primary outcome is wound healing (defined as full epithelialisation without drainage maintained for 2 weeks) within 12 weeks of starting study treatment.,Effectiveness of participant blind,,2018-03-11,COMPLETED,INTERVENTIONAL,['NA']
12104,NCT00960076,Change in HbA1c Level From Baseline to Week 18 (LOCF),Percent of Subjects Reaching Goal (HbA1c <7%) at Week 18 (LOCF) - Percent of Subjects (1),,2009-08,COMPLETED,INTERVENTIONAL,['PHASE3']
12105,NCT03361878,Metformin AUC,Lactate,,2014-05-04,COMPLETED,INTERVENTIONAL,['PHASE4']
12106,NCT01490099,"Cmax, maximum serum insulin detemir concentration",Adverse events,,2006-08,COMPLETED,INTERVENTIONAL,['PHASE1']
12107,NCT01590771,Number of Participants Who Discontinued Study Drug Due to an Adverse Event,Change From Baseline in FPG Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea Alone,,2012-07-09,COMPLETED,INTERVENTIONAL,['PHASE3']
12108,NCT04769375,Evaluation of pelvic girdle questionnaire,,,2021-04-01,COMPLETED,OBSERVATIONAL,['NA']
12109,NCT01829555,change from baseline in number of self-monitoring of blood glucose tests conducted,change from baseline in hemoglobin A1c levels,,2013-02,COMPLETED,INTERVENTIONAL,['NA']
12110,NCT01107132,,,,2010-05,UNKNOWN,OBSERVATIONAL,['NA']
12111,NCT05958368,Fasting Blood Glucose,Glycated Albumin,Insulin,2023-10-10,RECRUITING,INTERVENTIONAL,['NA']
12112,NCT01717911,The primary outcome was the comparison of A1C change.,Beta-cell function and insulin sensitivity and the proportion of subjects who reached the treatment target (A1C <7.0% or <6.5% at 6 months).,,2010-09,UNKNOWN,INTERVENTIONAL,['PHASE4']
12113,NCT03851549,System Use Evaluation,,,2019-03-12,UNKNOWN,INTERVENTIONAL,['NA']
12114,NCT02125682,effect on HDL function,,,2012-01,COMPLETED,INTERVENTIONAL,['PHASE4']
12115,NCT04108884,Prevalence of Atrial Fibrillation,Compliance of patients using the app,,2019-10-22,RECRUITING,INTERVENTIONAL,['NA']
12116,NCT04623320,Correlation of the 13C breath test with the golden standard,,,2020-10-27,UNKNOWN,OBSERVATIONAL,['NA']
12117,NCT02295696,HbA1c,Self-management,,2014-11,UNKNOWN,INTERVENTIONAL,['NA']
12118,NCT03526237,Change in BMI,Change in Diet and exercise Behaviors,,2015-04-24,COMPLETED,INTERVENTIONAL,['NA']
12119,NCT01414660,interleukin 7,metabolic parameters,,2010-06-09,COMPLETED,OBSERVATIONAL,['NA']
12120,NCT00412165,"To evaluate the effect, at 12 months, of the 3 intensities of the PACEi-DP intervention on Body Mass Index (BMI) among male & female adolescents.",behavioral measures of diet and physical activity.,,2006-02,COMPLETED,INTERVENTIONAL,['NA']
12121,NCT00985179,health behavior (physical activity & fruits and vegetables),perceived occupational efficiency,,2009-10,COMPLETED,INTERVENTIONAL,['NA']
12122,NCT05203640,Blood glucose,carbohydrate supplementation,,2022-04-01,RECRUITING,INTERVENTIONAL,['NA']
12123,NCT04791618,Life Simple 7(LS7 the metrics for defining ideal cardiovascular health) score at 6-month follow-up,Change in Tobacco Use,Change in Carotid Intima Media Thickness (CIMT),2017-05-01,UNKNOWN,INTERVENTIONAL,['NA']
12124,NCT03239119,Change in HbA1c from Baseline to Week 30,Change in 7-SMBG from Baseline to Week 16，Week 24 and Week 30,,2017-11-30,UNKNOWN,INTERVENTIONAL,['PHASE3']
12125,NCT03682237,Time in normoglycemia,Urinary albumin/excretion rate,,2018-10-01,COMPLETED,INTERVENTIONAL,['NA']
12126,NCT01427660,Changes in decisional conflict,Medication adherence and intensification,,2011-09,COMPLETED,INTERVENTIONAL,['NA']
12127,NCT04647175,Blood glucose total area under the curve (tAUC),Microbiomics,,2020-11-23,UNKNOWN,INTERVENTIONAL,['NA']
12128,NCT04911582,Area under the curve for glucose,Area under the curve for GIP (Glucose-dependent insulinotropic polypeptide),,2021-05-25,COMPLETED,INTERVENTIONAL,['NA']
12129,NCT00950534,The percentage of patients achieving glycosylated haemoglobin (HbA1c) levels < or = 7.0%,Mean change in body weight,,2009-07,TERMINATED,INTERVENTIONAL,['PHASE4']
12130,NCT04187521,Peak blood glucose following test meal (CGM),Total caloric intake on the days of test meals,,2020-02-10,RECRUITING,INTERVENTIONAL,['NA']
12131,NCT04228341,Glucose,Insulin,,2019-02-13,COMPLETED,INTERVENTIONAL,['NA']
12132,NCT04782999,Insulin secretion during iv stimulation,Alpha cell function,,2015-01,COMPLETED,INTERVENTIONAL,['NA']
12133,NCT06211270,Integration,Body Mass Index,,2023-11-17,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
12134,NCT00949286,Death from any cause,Myocardial infarction (non-fatal and fatal),,2010-01,COMPLETED,OBSERVATIONAL,['NA']
12135,NCT00332826,The primary safety outcome will be measurements of post bronchodilator FEV1 throughout the treatment period,,,2006-06,TERMINATED,INTERVENTIONAL,['PHASE3']
12136,NCT03610984,Effects of structured education on β-cell endocrine function progression of T1D patients.,Effects of structured education on metabolic control.,,2016-10-01,COMPLETED,OBSERVATIONAL,['NA']
12137,NCT04722289,"Change from baseline, use of healthcare services (diabetes controls at the ophthalmologist )",,,2017-12-01,COMPLETED,INTERVENTIONAL,['NA']
12138,NCT00878293,Average daily pain intensity,"Quality of life Neuropathic pain scale Amount and first time of Rescue medication Adverse events, ECG, Laboratory values",,2009-04,COMPLETED,INTERVENTIONAL,['PHASE2']
12139,NCT01627509,,,,2012-05,UNKNOWN,OBSERVATIONAL,['NA']
12140,NCT00134160,All cause mortality,Serious adverse events other than primary outcome events,,2005-08,COMPLETED,INTERVENTIONAL,['PHASE4']
12141,NCT04126551,Mitochondrial DNA methylation,Mitochondrial Function,,2019-07-23,RECRUITING,OBSERVATIONAL,['NA']
12142,NCT05319301,Change in oxytocin concentration,Alexithymia assessment,,2022-04-01,UNKNOWN,INTERVENTIONAL,['NA']
12143,NCT00885378,Mean Hemoglobin A1C (A1c) and Change From Baseline to Week 12,Percentage of Participants Achieving a Therapeutic Glycemic Response (A1C <= 6.5%) at Week 12,Participants Experiencing Changes From Baseline in Urinalysis Parameters That Met the Marked Abnormality Criteria,2009-05,COMPLETED,INTERVENTIONAL,['PHASE3']
12144,NCT01629251,Primary efficacy endpoint,Secondary efficacy endpoints,,2011-04,COMPLETED,INTERVENTIONAL,['PHASE2']
12145,NCT04183543,Change in baseline fasting blood glucose level at 17 weeks.,Change in baseline blood pressure at 17 weeks.,,2020-01-30,UNKNOWN,INTERVENTIONAL,['NA']
12146,NCT02394886,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,Wound size and depth measurement,,2014-11,COMPLETED,INTERVENTIONAL,['PHASE1']
12147,NCT03851432,Change in Hemoglobin A1c (HbA1c) From Baseline to Week 24 (Core period),Percentage of Patients Who Have Received Rescue Therapy at Week 24 (Core period) and Week 52 (Extension period),,2019-06-30,UNKNOWN,INTERVENTIONAL,['PHASE3']
12148,NCT04097691,Injection of subcutaneous glucose 10% in small shots is effective in improving neuropathic signs using the Michigan Neuropathy Screening Instrument (MNSI),,,2019-07-14,COMPLETED,OBSERVATIONAL,['NA']
12149,NCT02438189,Comparison of percent time in range overnight between the two treatment arms,Change in HbA1c from clinical baseline to study completion,,2015-06,COMPLETED,INTERVENTIONAL,['PHASE2']
12150,NCT04991350,Change in vascular density of the deep retinal capillary plexus,Change of severity of diabetic retinopathy,,2021-11-26,TERMINATED,INTERVENTIONAL,['PHASE4']
12151,NCT06326034,Quality of Life Assessment tool,,,2022-05-01,COMPLETED,INTERVENTIONAL,['PHASE4']
12152,NCT00491322,Fibroblast Growth Factor 23 (FGF23) After 12 Weeks of Weekly Ergocalciferol 50000 Units,,,2006-05,COMPLETED,INTERVENTIONAL,['NA']
12153,NCT05460884,Changes in maximal incremental plasma glucose level (iCmax) between baseline and endpoint within intervention groups vs. control.,Changes in plasma insulin levels between baseline and endpoint within the intervention group vs. control,,2020-09-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
12154,NCT01638585,Duration of survival without major amputation in urokinase group compared to group with standard therapy,new lesions on the contralateral leg,,2011-06,TERMINATED,INTERVENTIONAL,['PHASE3']
12155,NCT01170832,Heart rate (HR) Variability Studies,Positron Emission Tomography (PET) scan,,2010-05,COMPLETED,OBSERVATIONAL,['NA']
12156,NCT01376557,Change From Baseline in HbA1c to Week 12,Change From Baseline in Triglycerides at Week 12,,2011-06,COMPLETED,INTERVENTIONAL,['PHASE2']
12157,NCT00709917,HbA1C,FBG,,2007-03,COMPLETED,OBSERVATIONAL,['NA']
12158,NCT05524909,"Changes in Moderate to Vigorous Physical Activity Minutes between baseline and Immediate post-intervention, between baseline and 12-month post-intervention, and between baseline and 6-month follow-up","Changes in five activity indicators (steps, 'sedentary minutes', 'lightly active minutes', calories burn, and sleep time)",,2022-11-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
12159,NCT00320879,urinary albumin excretion rate,genotypes with possible implications for the risk of cardiovascular disease,,2003-09,COMPLETED,INTERVENTIONAL,['PHASE4']
12160,NCT01295229,Feasibility,Efficacy and Mechanisms,,2011-05,COMPLETED,INTERVENTIONAL,['NA']
12161,NCT00412178,HbA1c,Compliance,,2004-12,TERMINATED,INTERVENTIONAL,['NA']
12162,NCT02026310,"24 weeks after treatment, HbA1c values' change compared with baseline",hypoglycemia events,,2014-01,COMPLETED,INTERVENTIONAL,['NA']
12163,NCT01291875,Changes in HbA1c and serum inflammatory markers of inflammation after periodontal intervention,,,2011-02,COMPLETED,INTERVENTIONAL,['NA']
12164,NCT06332690,Modification of inflammatory biomarkers on OCT and perfusion density parameters on OCT-A at 4 months after surgery (Change measure),"Initial clinical characteristics in patients with a gain in BCVA (Best Corrected Visual Acuity) of ≥ 5, ≥ 10, and ≥ 15 ETDRS (Early Treatment Diabetic Retinopathy Study) letters.",,2023-10-17,RECRUITING,OBSERVATIONAL,['NA']
12165,NCT00324675,Proteinuria,HbA1c,,2006-08,COMPLETED,INTERVENTIONAL,['NA']
12166,NCT05699408,Change in HbA1c,Change in scores of diabetes treatment satisfaction questionnaire status version (DTSQs),,2023-03-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
12167,NCT02496780,post-prandial protein turnover,,,2015-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
12168,NCT01677936,Postprandial Glucose Levels,Systolic Blood Pressure,,2012-06,COMPLETED,INTERVENTIONAL,['PHASE4']
12169,NCT03953092,Adverse events will be evaluated,maximum plasma concentration (Cmax),,2019-05-01,COMPLETED,INTERVENTIONAL,['PHASE1']
12170,NCT02836015,Hemoglobin A1c,BMI,,2016-05-13,COMPLETED,INTERVENTIONAL,['NA']
12171,NCT02797392,Change in proportion of citizens at increased risk of lifestyle related disease from baseline to the 12 weeks follow up,GP reported Personal belief,,2016-09,COMPLETED,INTERVENTIONAL,['NA']
12172,NCT00570310,Daily Evening Patient Reported Pain Intensity Scores,'Time to Efficacy Failure' During the Randomized Withdrawal Portion of the Study,,2007-12,COMPLETED,INTERVENTIONAL,['PHASE1']
12173,NCT00497133,,,,2007-07,COMPLETED,OBSERVATIONAL,['NA']
12174,NCT02082301,Primary outcome: sensitivity of immediate post partum screen,Secondary outcome: physiology,,2012-10,COMPLETED,OBSERVATIONAL,['NA']
12175,NCT00938158,"The primary objective is to characterize the PK of albiglutide in subjects with type 2 diabetes and varying degrees of renal impairment, including subjects requiring hemodialysis, and in age, gender and BMI-matched subjects.","To assess the safety and tolerability of a single dose of albiglutide in subjects with varying degrees of renal impairment and in age, gender and BMI-matched subjects with normal renal function",,2009-08-05,COMPLETED,INTERVENTIONAL,['PHASE1']
12176,NCT01324388,"Mean, 24-hour Blood Pressure (Collected by Ambulatory Blood Pressure Monitoring [ABPM]) in Response to Co-administration of LY2189265 and Metoprolol","Pharmacokinetics, Maximum Concentration (Cmax) of Metoprolol When Administered With LY2189265",,2011-03,COMPLETED,INTERVENTIONAL,['PHASE1']
12177,NCT03606694,First phase of insulin secretion,Blood pressure,,2019-10-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
12178,NCT05689684,change in levels of postprandial blood glucose,body weight,,2022-11-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
12179,NCT03130101,Time in interstitial glucose target range (CGM analysis),,,2017-04-03,COMPLETED,INTERVENTIONAL,['NA']
12180,NCT03232333,Percentage of Participants,,Short Form - 36: Bodily Pain,2017-07-21,COMPLETED,OBSERVATIONAL,['NA']
12181,NCT03036254,Change in Cognitive outcome,IADL questionnaire,,2017-10-08,RECRUITING,INTERVENTIONAL,['NA']
12182,NCT00263276,Mean change from baseline in HbA1c compared to placebo.,"Mean change from baseline in fasting plasma glucose, evaluate proportion of subjects who achieve a therapeutic response (HbA1c <7%); change from baseline in urinary glucose excretion",,2005-12,COMPLETED,INTERVENTIONAL,['PHASE2']
12183,NCT02727231,Time spent in the target glucose range (3.9 to 10.0 mmol/l) based on subcutaneous glucose monitoring,Utility Evaluation,Accuracy of CGM,2016-03,COMPLETED,INTERVENTIONAL,['NA']
12184,NCT03579615,Time spent in the target glucose range,AUC of glucose below 3.0mmol/l (54mg/dl),,2020-12-23,COMPLETED,INTERVENTIONAL,['NA']
12185,NCT01617603,Difference in Insulin Resistance (HOMA) Between Treatments After 12 Weeks of Product Intake,Oxidative Stress After 12 Weeks of Product Intake,,2009-04,COMPLETED,INTERVENTIONAL,['NA']
12186,NCT00605774,catecholamine levels,,,na,WITHDRAWN,INTERVENTIONAL,['NA']
12187,NCT03793023,Change in HbA1c,Safety Outcome,,2016-01,UNKNOWN,OBSERVATIONAL,['NA']
12188,NCT05421845,incidence of gestational diabetes mellitus,maternal physical activity information,,2022-07,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
12189,NCT01315171,Cognitive function tests,Brain activity,,2012-01,COMPLETED,INTERVENTIONAL,['NA']
12190,NCT02411253,"AUC (T0-T120) of serum C-peptide, determined after a mixed meal tolerance test at month 12, compared to baseline.",Adverse event.,,2015-06,COMPLETED,INTERVENTIONAL,['PHASE2']
12191,NCT04362241,To measure the effect of 0.4mg dexamethasone intracanalicular insert in preventing PME in diabetic patients undergoing cataract surgery when compared to topical prednisolone acetate 1% as measure.,Rescue Therapy,,2020-08-07,UNKNOWN,INTERVENTIONAL,['PHASE4']
12192,NCT05347836,To compare the levels of monocyte soluble activation markers among children with T1DM and healthy controls,,,2022-07-01,UNKNOWN,OBSERVATIONAL,['NA']
12193,NCT05717608,fructose on glucose metabolism,changes in (postprandial )plasma metabolites,,2023-02-05,RECRUITING,INTERVENTIONAL,['NA']
12194,NCT02925676,Number of adverse events,User experience in an everyday context based on interview,,2016-10-05,TERMINATED,INTERVENTIONAL,['NA']
12195,NCT03278483,Toxicity (liver function),,,2019-02-28,COMPLETED,INTERVENTIONAL,['PHASE4']
12196,NCT01196104,Change in HbA1c (%) From Baseline to Week 16,Week 20 (Follow-up) Change From Baseline in Forced Vital Capacity,,2010-09,TERMINATED,INTERVENTIONAL,['PHASE3']
12197,NCT02964585,Gene Expression and Function Change of CD34+ Endothelial Progenitor Cells (Cell Proliferation),eGFR,,2016-11,COMPLETED,INTERVENTIONAL,['PHASE4']
12198,NCT03895515,Change in percentage of time spent in glycaemic target range (TIR),Change in Glycated Haemoglobin A1c (HbA1c),,2020-01-03,COMPLETED,OBSERVATIONAL,['NA']
12199,NCT04630925,"Glucose time in range (3,9-10 mmol/l) (% pr day)",Time with active isCGM,,2021-01-04,TERMINATED,INTERVENTIONAL,['NA']
12200,NCT03553862,Incidence of hypoglycaemia,"Work Productivity and Activity Impairment questionnaire, General Health version (WPAI-GH)",,2018-05-11,COMPLETED,INTERVENTIONAL,['NA']
12201,NCT00891124,"Proportion of achievement patients in treatment target goal on glycemic control, hypertension and hyperlipidemia according to ADA 2008 guideline",The treatment goal of risk factors is based on ADA guideline.,,2009-05,COMPLETED,OBSERVATIONAL,['NA']
12202,NCT03415074,CKD progression,Occurence of the adverse events,,2019-10-01,UNKNOWN,INTERVENTIONAL,['NA']
12203,NCT00853151,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 6-Month Endpoint,Change From Baseline in Homeostatic Model Assessment (HOMA) at 3-Week and 6-Month Endpoints,,2009-02,COMPLETED,INTERVENTIONAL,['PHASE1']
12204,NCT03895996,"The incidence and severity of local i.v.-site reactions,",Changes from baseline in HbA1c,,2019-06-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12205,NCT00099333,Change in HbA1c (glycosylated hemoglobin) from Baseline to Week 16,,,2004-02,COMPLETED,INTERVENTIONAL,['PHASE2']
12206,NCT06080425,body weight measured at the five post-baseline follow-up points,Diabetes Distress,,2023-09-01,RECRUITING,INTERVENTIONAL,['NA']
12207,NCT02714972,Comparison of percent time in range overnight between the two treatment arms,"Amount of total (manual, automatic, combined) and insulin boluses",,2016-05,COMPLETED,INTERVENTIONAL,['PHASE2']
12208,NCT00036504,,,,2001-08,COMPLETED,INTERVENTIONAL,['PHASE4']
12209,NCT01456130,Number of Participants With Treatment Emergent Adverse Events (TEAEs),Change From Baseline in Fasting Glucose,,2011-11,COMPLETED,INTERVENTIONAL,['PHASE3']
12210,NCT02954822,"AUCτ,ss for Evogliptin and Glimepiride",,,2016-11-14,COMPLETED,INTERVENTIONAL,['PHASE1']
12211,NCT03294265,Glycated hemoglobin,Foot care,,2016-08-01,UNKNOWN,INTERVENTIONAL,['NA']
12212,NCT03604198,Long-term safety of relacorilant,,Long-term benefit of relacorilant,2018-05-07,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE2']
12213,NCT04132531,Change in the frequency of circulating cells with aldehyde dehydrogenase activity.,Change in the frequency of circulating cells with aldehyde dehydrogenase activity and cell surface marker expression.,Changes in the concentration of oxidative stress and inflammatory markers,2018-05-01,COMPLETED,OBSERVATIONAL,['NA']
12214,NCT05645068,coefficient of variation of the superficial retinal capillary plexus,,,2023-02-28,RECRUITING,INTERVENTIONAL,['NA']
12215,NCT02606617,Change of control rate of blood glucose(%),Change of clinic blood pressure and 24h mean blood pressure(mmHg).,,2015-12,UNKNOWN,INTERVENTIONAL,['PHASE4']
12216,NCT03766802,Glycated Hemoglobin (HbA1c),Accelerometer,Triglyceride,2018-02-05,UNKNOWN,INTERVENTIONAL,['NA']
12217,NCT03143764,examine cycling distance,examine changes in cardiorespiratory fitness,,2014-09-01,COMPLETED,INTERVENTIONAL,['NA']
12218,NCT04721158,More Frequent Glycemic Control Monitoring,,,2021-01-17,COMPLETED,INTERVENTIONAL,['NA']
12219,NCT04145479,postprandial triglyceride,,,2021-03-01,UNKNOWN,INTERVENTIONAL,['NA']
12220,NCT03754036,Insulin sensitivity,Physical activity level,,2019-01-05,COMPLETED,INTERVENTIONAL,['NA']
12221,NCT01319240,The area under liraglutide concentration-time curve,Number of hypoglycaemic episodes,,2011-03,COMPLETED,INTERVENTIONAL,['PHASE1']
12222,NCT02109315,Endothelial dysfunction (Flow mediated dilation): Endothelial function is assessed measuring flow-mediated vasodilation (FMD) of the brachial artery.,Oxidative stress markers,,2014-05,WITHDRAWN,INTERVENTIONAL,['PHASE1']
12223,NCT03608163,Difference in peak epinephrine levels between first and third hypoglycemic episodes,Symptoms of low blood sugar (hypoglycemia),,2018-08-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4']
12224,NCT04835194,The correlation between clinical phenotypes and combined endpoint,"Time to first cardiovascular mortality in patients with heart failure with preserved ejection fraction and concurrent hypertension, diabetes.","The correlation between simultaneous risk factor control (HbA1c (%), and LDL-c (mmol/L), and blood pressure (mmHg)) and mortality in patients with diabetes, hypertension and heart failure with preserved ejection fraction",2020-12-01,COMPLETED,OBSERVATIONAL,['NA']
12225,NCT02620878,Percentage of Time Spent in Target Range (70-180 mg/dl or 3.9-10.0 mmol/L),Percentage of Time Artificial Pancreas is Active,,2015-07,COMPLETED,INTERVENTIONAL,['NA']
12226,NCT02349516,To explore the effect of Squalamine Lactate eye drops on Best Corrected Visual Acuity in subjects with diabetic macular edema,"To assess the safety and tolerability of Squalamine Eye Drops, measured by ophthalmic examination, the recording and evaluation of clinical AEs",,2015-02,WITHDRAWN,INTERVENTIONAL,['PHASE2']
12227,NCT00155142,,,,2004-09,UNKNOWN,OBSERVATIONAL,['NA']
12228,NCT03333772,Acceptability,Change from baseline in Glycated hemoglobin (HbA1C) at post-intervention,,2017-11-15,COMPLETED,INTERVENTIONAL,['NA']
12229,NCT03087253,Prevalence of diabetes mellitus,Incidence of severe morbidities and causes of mortality,,2018-02-27,RECRUITING,OBSERVATIONAL,['NA']
12230,NCT01945138,Study Period: Serum BG Standard Deviation,Day 28 Follow-Up: C-Peptide,,2014-02,COMPLETED,INTERVENTIONAL,['NA']
12231,NCT06152588,Change in HbA1c (mmol/mol),Use of antidiabetic medication,Dietary fibers (gram),2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
12232,NCT00627744,Improvement in beta-cell function measured by means of the insulinogenic index (ΔI30/ΔG30) obtained from an oral glucose tolerance test (OGTT),Improvement in incretin-independent beta-cell function measured as the Acute Insulin Response (ΔAIRG) during an intravenous glucose tolerance test.,,2008-05,COMPLETED,INTERVENTIONAL,['PHASE4']
12233,NCT02983214,Number of participants who suffer from bleeding events as defined by the Bleeding Academic Research Consortium (BARC) criteria during the entire follow-up period.,"Number of participants who suffer from the secondary safety end points which are palpitations, tachycardia, headache, diarrhea, urticaria, neoplasms, blood disorders, drug interruption.",,2016-11,COMPLETED,INTERVENTIONAL,['PHASE4']
12234,NCT02927561,To compare the sensitivity and specificity of automated grading system versus human grading in detecting diabetic retinopathy,,,2015-06,COMPLETED,OBSERVATIONAL,['NA']
12235,NCT06221241,Change of the Average Daily Pain Score (ADPS) from baseline to Week 12. [ADPS is the weekly average pain score based on the 11-point numeric rating scale (NRS)],Adverse Events,,2024-03-02,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
12236,NCT04136951,To learn if using PREVENT tool results in high nurses' system usability perception measured by the System Usability Scale (SUS).,,,2023-02-01,COMPLETED,INTERVENTIONAL,['NA']
12237,NCT01073826,Glucagon like peptide- 1 (GLP-1),,,2010-02,COMPLETED,INTERVENTIONAL,['NA']
12238,NCT00887302,Metabolics of RYGB with Gastrostomy - Glucose,,,2009-03-25,COMPLETED,OBSERVATIONAL,['NA']
12239,NCT04835636,HbA1c,Weight change,,2016-01-01,COMPLETED,OBSERVATIONAL,['NA']
12240,NCT03172598,Efficacy as measured by reduction in pain using a numerical rating scale.,Plasma concentration of MT-8554,,2017-07-25,COMPLETED,INTERVENTIONAL,['PHASE2']
12241,NCT04395378,Glucose concentration (mmol/L),Plasma albumin concentration (g/dL),Glucose concentration from the pilots log books for the previous 6 months,2019-12-05,SUSPENDED,OBSERVATIONAL,['NA']
12242,NCT03713502,Prevalence of pre-diabetes,,,2019-05-01,UNKNOWN,OBSERVATIONAL,['NA']
12243,NCT00378508,C-peptide Area Under the Curve (AUC) Response to a Mixed Meal Tolerance Test (MMTT) at Baseline,Baseline Hemoglobin A1c,,2006-09,COMPLETED,INTERVENTIONAL,['PHASE2']
12244,NCT03363386,Change in fasting blood glucose level,,,2016-12,COMPLETED,INTERVENTIONAL,['NA']
12245,NCT00600483,Number of Participants With Surgical Wound Infections From Surgery Through Post-operative Day 90,Rehospitalization for Sternal Wound Infection,,2007-12,COMPLETED,INTERVENTIONAL,['PHASE3']
12246,NCT00347542,Oral Glucose Insulin Sensitivity (OGIS),Blood Pressure,,2006-07,COMPLETED,INTERVENTIONAL,['NA']
12247,NCT04723628,Glycemic Control,Perceived Diabetes Self-Management Scale (PDSMS),,2019-01-01,COMPLETED,INTERVENTIONAL,['NA']
12248,NCT04208230,Association between Type 2 diabetes status and marrow fat at the distal tibia,,,2017-01-03,COMPLETED,OBSERVATIONAL,['NA']
12249,NCT01289145,Self-reported physical activity frequency and duration,Social Cognition,,2011-02,COMPLETED,INTERVENTIONAL,['NA']
12250,NCT01441232,Change from baseline in gut hormones,Change from baseline in urinary glucose excretion,,2011-10,COMPLETED,INTERVENTIONAL,['PHASE1']
12251,NCT05482321,Primary outcome 4,Secondary outcome 6,,2023-02-27,RECRUITING,OBSERVATIONAL,['NA']
12252,NCT01940614,Overall diagnostic accuracy,Predictive value of absent bright spot in posterior pituitary enlargement,,2013-07,COMPLETED,OBSERVATIONAL,['NA']
12253,NCT04545151,Area under the stimulated C-peptide response curve,Continous glucose monitoring (CGM),Quality of life: HypoFear questionnaire,2021-02-08,RECRUITING,INTERVENTIONAL,['PHASE2']
12254,NCT04702048,Mean change in photoreceptor cell spacing,Proportion of participants who receive intravitreal aflibercept,,2021-02-01,WITHDRAWN,INTERVENTIONAL,['PHASE4']
12255,NCT02292433,Accumulation Ratio (Rac) on Day 7 for PF-04937319,Change From Baseline in Pre-Meal C-Peptide at Day 7,,2015-01,COMPLETED,INTERVENTIONAL,['PHASE1']
12256,NCT02076945,Duration of analgesia,,,2014-02,COMPLETED,INTERVENTIONAL,['NA']
12257,NCT04172077,"Examine the effects of patients' attachment styles (secure, mixed and fearful) on their type one diabetes management represented by A1C level",b)Compare diabetes management self-efficacy and attachment style in parents,,2019-09-18,COMPLETED,OBSERVATIONAL,['NA']
12258,NCT04339296,Self-reported Medication Adherence,,,2019-03-01,COMPLETED,INTERVENTIONAL,['NA']
12259,NCT02844517,The primary outcome is a qualitative assessment of the system's suitability for use in a large-scale in-home clinical trial based on the results of the Technology Acceptance questionnaire and feedback from clinical staff.,,,2016-11,COMPLETED,INTERVENTIONAL,['NA']
12260,NCT02961179,Change from baseline to 6 weeks in insulin sensitivity between high dairy and dietary counselling phases,Change from baseline to 6 weeks in metabolomics profiles between high dairy and dietary counselling phases,,2017-01,COMPLETED,INTERVENTIONAL,['NA']
12261,NCT04709419,Change in Tissue Oxygenation,Number of Participants with Complete Wound Closure,Number of Patients with Maintained Wound Closure,2022-10-27,TERMINATED,INTERVENTIONAL,['NA']
12262,NCT02967237,Mean change from baseline in HbA1c,Number of adverse events,,2016-01-04,COMPLETED,INTERVENTIONAL,['PHASE4']
12263,NCT00665808,treatment satisfaction (DTSQs and DTSQc),Pregnancy,,2007-10,COMPLETED,OBSERVATIONAL,['NA']
12264,NCT03012113,The effect of Mirabegron treatment on BAT activity measured by MRI in South Asians compared with white Caucasians.,The effect of Mirabegron treatment on sympathetic output in South Asian and white Caucasian individuals.,,2016-06,UNKNOWN,INTERVENTIONAL,['PHASE4']
12265,NCT00420511,Preservation of Beta-cell Function Measured by Area-under-the-curve (C-peptide/Glucose)/HOMA-IR,Proportion of Patients Achieving Sustained Normoglycemia Off Medication at 1-week Post-insulin Therapy,,2007-01,COMPLETED,INTERVENTIONAL,['PHASE2']
12266,NCT03881657,Blood pressure,Life functioning,,2015-11-24,COMPLETED,INTERVENTIONAL,['NA']
12267,NCT05568134,"Agreement between plasma glucose, CGM measured glucose using the Dexcom G7, and GTT@home glucose",Perceived benefits and burdens of CGM use,,2023-07-17,RECRUITING,OBSERVATIONAL,['NA']
12268,NCT04964752,the percentage of MARD (Mean Absolute Relative Difference),Sensor Stability,,2021-07-30,UNKNOWN,INTERVENTIONAL,['NA']
12269,NCT01262586,Change in Glycemic profiles between vildagliptin and glimepiride,Glucose Fluctuation before and during treatment,,2010-11,COMPLETED,INTERVENTIONAL,['PHASE3']
12270,NCT05826054,Maximum tolerated dose (MTD),,,2023-12-01,RECRUITING,INTERVENTIONAL,['PHASE1']
12271,NCT04917926,Glycaemic control,Level of physical activity,Frequency of health service utilisation,2021-06-21,RECRUITING,INTERVENTIONAL,['NA']
12272,NCT00334503,,,,na,COMPLETED,INTERVENTIONAL,['PHASE3']
12273,NCT06010992,Glycemic control,Serum levels of asprosin,,2023-10-01,RECRUITING,INTERVENTIONAL,['PHASE2']
12274,NCT00822211,Change from baseline in HbA1c after 24 weeks,Change from baseline in fasting plasma glucose at 24 weeks,,2008-12,COMPLETED,INTERVENTIONAL,['PHASE3']
12275,NCT01102699,CPC mobilization after a single G-CSF dose,,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE4']
12276,NCT02145988,Resting ankle-brachial index (ABI),Adverse events,,2015-06-03,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
12277,NCT00975052,Weighted average active GLP-1 (glucagonlike peptide-1) concentrations,,,2006-01,COMPLETED,INTERVENTIONAL,['PHASE1']
12278,NCT01182948,Change in haemoglobin A1c (HbA1c) levels,"Changes in expression in the muscle of some genes involved in ATP production, mitochondrial biogenesis and substrate utilization",,2009-01,COMPLETED,INTERVENTIONAL,['NA']
12279,NCT05666791,Self-efficacy,,,2022-12-21,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
12280,NCT00997152,Change in Fasting Plasma Glucose (FPG) levels,"Safety (biochemistry, hematology, urinalysis and adrenal-related markers) and tolerability (adverse events)",,2009-09,TERMINATED,INTERVENTIONAL,['PHASE2']
12281,NCT02681809,Number of Subjects With Total PVD by the Month 3 Visit,Number of Subjects With Ocular Treatment-emergent Adverse Events in the Study Eye,,2015-12,TERMINATED,INTERVENTIONAL,['PHASE2']
12282,NCT01337947,arterial vascular stiffness,nitric oxide dependent vasodilation,,2011-04,COMPLETED,OBSERVATIONAL,['NA']
12283,NCT04281186,Retinal sensitivity,Diabetes Specific Dementia Risk Score.,,2020-11-16,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
12284,NCT01908816,Number of Participants With Adverse Events as a Measure of Safety and Tolerability,Ranibizumab Injection,,2013-09-26,COMPLETED,INTERVENTIONAL,['PHASE3']
12285,NCT00979719,physical activity,"social-cognitive predictors of behavior (self-efficacy, action control etc.)",,2009-10,COMPLETED,INTERVENTIONAL,['NA']
12286,NCT02730754,Depressive symptoms measured with Patient Health Questionnaire-9,Diabetes distress measured with Problem Areas in Diabetes Scale (PAID-5),Health care utilisation/hospitalisation,2016-04,COMPLETED,OBSERVATIONAL,['NA']
12287,NCT01586065,Number of High Glucose Correction Doses Administered.,Pre- and Post-meal (2-3 Hour) Glucose Levels,,2012-02,COMPLETED,INTERVENTIONAL,['NA']
12288,NCT04345497,HbA1c Level,Hyperglycemic Episodes,,2020-08-26,COMPLETED,INTERVENTIONAL,['NA']
12289,NCT02936115,Proportion of Patients that achieve a 50% or greater reduction in wound size by 8 weeks,Number of patients with worsening of index wound defined by ≥ 50% increase in wound size,,2016-07,TERMINATED,INTERVENTIONAL,['PHASE4']
12290,NCT05463289,Proportion screened for diabetic retinopathy,Diagnostic Accuracy,,2022-07-11,RECRUITING,INTERVENTIONAL,['NA']
12291,NCT00120536,Change from baseline in HbA1c at 24 weeks,Change from baseline in HbA1c at 24 weeks for patients with high baseline HbA1c vs. low baseline HbA1c,,2005-06,COMPLETED,INTERVENTIONAL,['PHASE3']
12292,NCT04953442,Percentage of participants that are satisfied with participation in the study,Average of minutes of sleep per night,Autonomous motivation for physical activity as assessed using Behavioural Regulation in Exercise Questionnaire-2 (BREQ-2),2021-04-15,RECRUITING,INTERVENTIONAL,['NA']
12293,NCT02459899,Change From Baseline in Hemoglobin A1C (A1C) at Week 12,Change From Baseline to Week 12 in Fasting Plasma Glucose,,2015-07,COMPLETED,INTERVENTIONAL,['PHASE2']
12294,NCT05780151,Query rate,,,2023-07-10,RECRUITING,INTERVENTIONAL,['PHASE4']
12295,NCT01945242,Number of Participants Reporting One or More Serious Adverse Drug Reactions,Change From Baseline in Fasting Insulin,,2011-03,COMPLETED,OBSERVATIONAL,['NA']
12296,NCT04017221,Incidence rate of lower extremity amputation,Incidence rate of Fournier's gangrene,,2018-10-01,COMPLETED,OBSERVATIONAL,['NA']
12297,NCT01718080,Overweight and Lean Children Sugar Metabolism Before and During Puberty,,,2012-10,COMPLETED,OBSERVATIONAL,['NA']
12298,NCT02663713,platelet reactivity measured in P2Y12 reaction units (PRU) at the end of the 2 study periods (pre-crossover and post-crossover).,"• VerifyNow P2Y12 assay % inhibition, using the TRAP-induced (BASE channel) response at the end of the 2 study periods",,2017-01,COMPLETED,INTERVENTIONAL,['PHASE4']
12299,NCT00107107,To examine the long-term effect of subcutaneously (SC) injected pramlintide on body weight,To examine the effects of long term pramlintide treatment on HbA1c in subjects with type 1 diabetes completing protocol 137-150.,,2002-11,COMPLETED,INTERVENTIONAL,['PHASE3']
12300,NCT00603239,Change in Glycosylated Hemoglobin (HbA1c),Change in Euroqol - 5 Domain Quality of Life (EQ-5D) Score,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE3']
12301,NCT04744636,Guanylate triphosphate cyclohydrolase (GTP-CH) investigations,Blood pressure supine,,2017-04-03,COMPLETED,INTERVENTIONAL,['PHASE1']
12302,NCT00476788,Mean Glycated Hemoglobin (A1c),Number of Reported Adverse Events,,2007-04,COMPLETED,INTERVENTIONAL,['NA']
12303,NCT00201110,A1C,Lipid panel,,2004-07,COMPLETED,INTERVENTIONAL,['NA']
12304,NCT05113693,"Cmax of CKD-501, D759, H053",,,2021-11-25,COMPLETED,INTERVENTIONAL,['PHASE1']
12305,NCT05870202,Acceptability,Change in HbA1c,,2023-03-07,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
12306,NCT01545388,Number of Participants Who Discontinued Study Drug Due to an Adverse Event,Change From Baseline to Week 24 in Fasting Plasma Glucose (FPG),,2012-02-23,COMPLETED,INTERVENTIONAL,['PHASE3']
12307,NCT01730196,Weight change,hemoglobin A1C,waist circumference,2009-09,COMPLETED,INTERVENTIONAL,['NA']
12308,NCT00580294,Brief Pain Inventory,,,2007-11,COMPLETED,INTERVENTIONAL,['NA']
12309,NCT01435980,Clinical events,Blood testing,,2008-02,UNKNOWN,INTERVENTIONAL,['PHASE4']
12310,NCT02659007,change in 10 meter walk,,,2014-09,COMPLETED,INTERVENTIONAL,['PHASE1']
12311,NCT03544242,96 Hours Post Operative Blood Samples Serum Glucose Levels,,,2017-05-07,TERMINATED,INTERVENTIONAL,['PHASE2']
12312,NCT00145353,Meal-regulated insulin time two peaks after the two intervention periods,,,2004-11,UNKNOWN,INTERVENTIONAL,['PHASE4']
12313,NCT01102530,,,,2009-01,COMPLETED,OBSERVATIONAL,['NA']
12314,NCT00477022,"Foot ulcer surface area was estimated stereologically, based on Cavalieri's principle before and after intervention, at pre treatment and post treatment",,,2006-02,COMPLETED,INTERVENTIONAL,['NA']
12315,NCT01206712,Investigation of ß-cell function via comparison of AUC0-300 minutes of intact Proinsulin in T2DM patients treated with LANTUS + Metformin (MET) vs. T2DM patients treated with Sulfonylurea (SU) + Metformin,"Investigation of insulin, intact proinsulin, glucose and PAI-1 levels over a 5 h period after uptake of a standardized meal comparing four different population groups",,2009-11,COMPLETED,OBSERVATIONAL,['NA']
12316,NCT02313363,change of HbA1c,change of the scores of Summary of Diabetes Self-Care Activities (SDSCA),number of events of hypoglycemia,2013-12,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
12317,NCT06277362,Safety Composite,Rutherford class,,2020-01-31,RECRUITING,OBSERVATIONAL,['NA']
12318,NCT05115175,Feasibility of the Scaled Mindfulness-Based Intervention as Assessed by Participant Feedback,,,2019-07-14,COMPLETED,INTERVENTIONAL,['NA']
12319,NCT01619345,Anatomical location (stomach or proximal small bowel) of tablet at complete tablet erosion (CTE),Time to CTE,,2012-06,COMPLETED,INTERVENTIONAL,['PHASE1']
12320,NCT00607945,Difference in change in body weight of the intervention groups,Nutrition knowledge,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE1']
12321,NCT00472342,Improvements of adipokine levels,Prevention of diabetes,,2007-03,UNKNOWN,INTERVENTIONAL,['NA']
12322,NCT04222660,Change in cornea nerve density,Determination of tibial nerve conduction velocity,,2021-06-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
12323,NCT05643144,Level of Situation Awareness (Aim 2),Glucose variability (Aim 1),,2023-03-20,RECRUITING,INTERVENTIONAL,['NA']
12324,NCT06325111,Identification of oral microbiome characteristics associated to T1D glycaemic control,,,2023-05-29,RECRUITING,OBSERVATIONAL,['NA']
12325,NCT01334203,The primary efficacy endpoint is the change from baseline in exercise treadmill duration in the peak ETT at week 12 or last visit.,Change from baseline in exercise treadmill duration in the trough ETT at week 12,,2011-05,WITHDRAWN,INTERVENTIONAL,['PHASE4']
12326,NCT06218342,Liver stiffness measurement (LSM),Body weight,,2024-02-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
12327,NCT05147818,Identify risk factors for Acute kidney injury in diabetic patients,,,2021-12-01,UNKNOWN,OBSERVATIONAL,['NA']
12328,NCT00479973,"The primary objective measures will consist of fasting blood glucose, insulin and HA1C.","Total-C, TG, HDL, LDL, BP, weight, BMI, waist/hip ratio, self-monitoring blood glucose, HOMA-IR, AST, ALT, total protein, albumin, alk phos, total/direct bilirubin, creatinine, BUN, PT, PTT, fibrinogen, adverse effects, Diabetes-39, SF-36",,2007-09,UNKNOWN,INTERVENTIONAL,['PHASE2']
12329,NCT03452657,Proportion of eyes with a ≥ 2-step improvement in the ETDRS Diabetic Retinopathy Severity Scale (DRSS) score,Proportion of eyes that meet the protocol-defined failure criteria,,2018-04,UNKNOWN,INTERVENTIONAL,['PHASE3']
12330,NCT00683878,Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF]),Adjusted Mean Change From Baseline in Total Body Weight (kg) Among Subjects With Baseline Body Mass Index (BMI) ≥ 27 kg/m^2 at Week 24 (Last Observation Carried Forward [LOCF]),,2008-07,COMPLETED,INTERVENTIONAL,['PHASE3']
12331,NCT06140303,Incidence of index ulcers closed,Time to closure,,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
12332,NCT00435565,,,,na,COMPLETED,OBSERVATIONAL,['NA']
12333,NCT04235439,GIRmax,Safety and Local Tolerability,,2019-04-23,COMPLETED,INTERVENTIONAL,['PHASE1']
12334,NCT01084928,body weight,Percent of Total Calories from Fat,,2010-04,COMPLETED,INTERVENTIONAL,['NA']
12335,NCT05816733,Rate of atrial fibrillation recurrence,Cardiovascular complex adverse events,,2023-09-01,RECRUITING,INTERVENTIONAL,['PHASE4']
12336,NCT02744976,Percentage plaque volume change over 24 months,Plaque volume change in metformin vs non-metformin treated patients over 24 months,,2016-02,COMPLETED,INTERVENTIONAL,['PHASE4']
12337,NCT05677334,Time percentage (% TIR) in the range of 3.9~10.0 mmol/L blood glucose,time above range (TAR),,2023-03-01,RECRUITING,INTERVENTIONAL,['PHASE4']
12338,NCT00837941,analgesic efficacy measured by patients self reported pain level after single dose administration,The onset of analgesic efficacy following single dose of pregabalin and duloxetine hydrochloride versus placebo,,2009-04,WITHDRAWN,INTERVENTIONAL,['PHASE2']
12339,NCT02928250,effect on on urinary albumin excretion (UAE),"total antioxidant capacity (TAC), malondialdhyde (MDA).",,2015-08,COMPLETED,INTERVENTIONAL,['NA']
12340,NCT06115265,Weight in kg,CAC scores,,2023-09-05,RECRUITING,INTERVENTIONAL,['NA']
12341,NCT03987412,The risk of gestational diabetes mellitus (GDM),Satisfaction of prenatal medical care; questionnaires,,2019-08-16,UNKNOWN,INTERVENTIONAL,['NA']
12342,NCT06136013,"Changes in 24-hour area under cover (AUC) glucose from baseline to 1, 2, and 3 months",Quantify the differences in the number of responders and low-responders for glycemic control and other health-related outcomes for individuals with T2DM and age-matched overweight/obese older adults.,,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
12343,NCT02755831,Number of Participants With Adverse Pregnancy Outcomes,Hospital Costs at Time of Delivery,,2017-02-20,COMPLETED,INTERVENTIONAL,['NA']
12344,NCT04027712,b amyloid predicts cardiovascular mortality in diabetic with coronary artery,,,2014-01-01,UNKNOWN,OBSERVATIONAL,['NA']
12345,NCT00150410,Glycosylated hemoglobin,insufficient clinical response.,,2003-01,COMPLETED,INTERVENTIONAL,['PHASE3']
12346,NCT02087215,number of the participants with complete epithelization of diabetic foot ulcer,number of participants in whom local infective complications develop in diabetic foot ulcer patients,improvement of inflammatory parameters in diabetic foot ulcers,2014-01,UNKNOWN,INTERVENTIONAL,['PHASE1']
12347,NCT04559815,Change in Glycated haemoglobin (HbA1c),"Diabetes Treatment Satisfaction Questionnaire, status (DTSQs), change in absolute treatment satisfaction",,2020-11-08,COMPLETED,OBSERVATIONAL,['NA']
12348,NCT04225507,Change from baseline 2-hour glucose levels at 6 months,Change from baseline morning blood pressure at 6 months,,2021-04-13,RECRUITING,INTERVENTIONAL,['NA']
12349,NCT03802825,Percent of Participants With A1C < 8%,Mean A1C Change,,2019-03-01,COMPLETED,INTERVENTIONAL,['NA']
12350,NCT06040463,Change in A1c,CHW Support Adherence,,2023-10-23,RECRUITING,INTERVENTIONAL,['NA']
12351,NCT01298375,Euglycemic-hyperinsulinemic clamp for measurement of insulin sensitivity and metabolic flexibility,Evaluating mitochondrial function through measurement of phosphocreatine (PCr) recovery by phosphorus magnetic resonance spectroscopy (31P-MRS) within the skeletal muscle,,2011-03,RECRUITING,OBSERVATIONAL,['NA']
12352,NCT02645799,%NIH volume,Definite or probable ARC defined stent thrombosis,,2016-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
12353,NCT01330563,CKD-501 AUC,CKD-501 Tmax,,2011-03,COMPLETED,INTERVENTIONAL,['PHASE1']
12354,NCT01086306,To compare the incidence of hospitalizations with infections associated with T Lymphocyte dysfunction,Inpatient diagnoses of respiratory tract infections,,2010-01,COMPLETED,OBSERVATIONAL,['NA']
12355,NCT04041167,Number of participants with functional independence,Number of participants with recurrence,,2018-08-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
12356,NCT03738449,Area under the plasma concentration of Metformin-time curve from time zero to time of last measurable concentration,Apparent volume of distribution of Metformin,,2019-01-08,COMPLETED,INTERVENTIONAL,['PHASE1']
12357,NCT01247753,Change in body weight,Change in physical activity,,2011-03-01,COMPLETED,INTERVENTIONAL,['NA']
12358,NCT04230889,Interstitial Glucose Response,Postprandial Glucose,Medications,2017-02-06,COMPLETED,INTERVENTIONAL,['NA']
12359,NCT00106457,,,,2005-02,COMPLETED,OBSERVATIONAL,['NA']
12360,NCT03217591,Percent Change From Baseline in Urine Albumin Creatinine Ratio (UACR) Over Weeks 8 and 12,,,2017-08-01,COMPLETED,INTERVENTIONAL,['PHASE2']
12361,NCT02601482,Glycemic control,HOMA-2 insulin resistance index,,2015-10,UNKNOWN,INTERVENTIONAL,['NA']
12362,NCT00438503,"Effect og glucose in dialysis water on blood pressure, plasma glucose and hormones in plasma",Relationship between changes in blood pressure and and changes in hormones,,2006-05,COMPLETED,INTERVENTIONAL,['PHASE4']
12363,NCT06323174,Change in glycated haemoglobin (HbA1c),"Number of severe hypoglycaemic episodes (level 3): hypoglycaemia associated with severe cognitive impairment requiring external assistance for recovery, with no specific glucose threshold",,2024-03-19,RECRUITING,INTERVENTIONAL,['PHASE3']
12364,NCT00286455,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26.,Change From Baseline in Glucagon (Week 26).,,2006-02,COMPLETED,INTERVENTIONAL,['PHASE3']
12365,NCT01107314,,,,2010-02,COMPLETED,OBSERVATIONAL,['NA']
12366,NCT00432835,Symptom of Gastric Emptying Time (GET) Associated With Gastroparesis,,,2005-08,COMPLETED,INTERVENTIONAL,['PHASE3']
12367,NCT03069196,"Progression of Micro-vascular, Macro-Vascular and Pulmonary Complications.",Association of Risk factors with prevalence of complications.,,2016-06-10,UNKNOWN,OBSERVATIONAL,['NA']
12368,NCT04869098,Glycaemic response,respiratory quotient,,2021-04-27,RECRUITING,INTERVENTIONAL,['NA']
12369,NCT03749889,Birth Outcome Questionnaire,,,2018-09-04,TERMINATED,INTERVENTIONAL,['NA']
12370,NCT03203278,Glycaemic control,Glycaemic control,,2017-11-06,COMPLETED,INTERVENTIONAL,['NA']
12371,NCT02383784,Body fat content determined by tetrapolar bioelectrical impedance .,,,2007-03,COMPLETED,INTERVENTIONAL,['NA']
12372,NCT00577824,Change in Glycosylated Hemoglobin (HbA1c) From Baseline to Week 24,"Change in 1,5-anhydroglucitol",,2008-01,COMPLETED,INTERVENTIONAL,['PHASE3']
12373,NCT00789945,To determine the changes in A1C.,To determine changes in postprandial glucose excursion during the meal's 5 hour postprandial period.,,2008-12,COMPLETED,INTERVENTIONAL,['NA']
12374,NCT05461274,Rate of patients who remain in diabetic neuropathy clinical trial to trial completion,,,2024-08,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
12375,NCT02604875,measurement of copeptin values in mmol/l within 24 hours to assess the amount of release in a day curve.,,,2015-11,COMPLETED,OBSERVATIONAL,['NA']
12376,NCT01164501,HbA1c Change From Baseline in Patients With Moderate Renal Impairment,,Hypoglycaemic Events,2010-07,COMPLETED,INTERVENTIONAL,['PHASE3']
12377,NCT04739124,"Correlation between appropriation factors, intention to use, Freestyle Libre use and glycemic control",,,2021-06-10,COMPLETED,OBSERVATIONAL,['NA']
12378,NCT01999322,Number of Microscopically Confirmed Episodes of Infusion Set Occlusions,Number of Premature Infusion Set Changes,,2013-11-19,COMPLETED,INTERVENTIONAL,['PHASE3']
12379,NCT00704795,"Glucagon responses (as assessed by area under curve (AUC)) during 50-g oral glucose tolerance test (OGTT) and isoglycemic iv glucose infusion, respectively.",GI-mediated glucose tolerance as assessed by the amount of glucose ingested as compared to the amount of glucose needed to mimic the OGTT curve during the iv glucose infusion.,,2008-06,UNKNOWN,OBSERVATIONAL,['NA']
12380,NCT05211375,Complete remission rate of type 2 diabetes,Late complication rate,,2022-01-03,RECRUITING,INTERVENTIONAL,['PHASE3']
12381,NCT02442544,Glycemic control (serum hemoglobin A1c),Glycemic control (as measured by serum hemoglobin A1c),Change in gut permeability (quantification of specific sugars in urine),2015-09,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
12382,NCT05530369,Neuropathy,Mean glucose (mg/dl),,2014-09-01,COMPLETED,OBSERVATIONAL,['NA']
12383,NCT03650023,Glucose levels,The areas under the curve (AUC) of glucose,,2018-05-09,COMPLETED,INTERVENTIONAL,['NA']
12384,NCT00453375,"The primary endpoint in this study is safety.Safety parameters include: stimulated C-peptide response levels, opthalmologic examination, laboratory assessments, 24-hr urine protein, allergic reactions and adverse events including hypoglycemia.","The secondary endpoints are pharmacodynamic parameters. Parameters include plasmid levels and insulin mRNA levels in blood and urine, Stimulated C-peptide response and Immunological response.",,2006-10,COMPLETED,INTERVENTIONAL,['PHASE1']
12385,NCT02548767,Change of de novo lipogenesis: palmitate tracer-to-tracee ratios by gas chromatography-mass spectrometry.,Change of Very low density lipoprotein (VLDL)-triglyceride (TG) kinetics,Change of blood levels of uric acid,2016-02,COMPLETED,INTERVENTIONAL,['NA']
12386,NCT00530881,postprandial blood glucose,"fasting blood glucose, HbA1c, safety",,2006-04,COMPLETED,INTERVENTIONAL,['PHASE2']
12387,NCT04602039,This project aimed to examine changes in insulin resistance in participants using dairy colostrum as a food supplement,This project aimed to examine changes in inflammatory markers in participants using dairy colostrum as a food supplement,,2016-07-21,COMPLETED,INTERVENTIONAL,['NA']
12388,NCT01116180,Cognitive function and brain cortical activity assessed by EEG,Cardiac conduction evaluated by a three channel digital Holter Monitor.,,2010-04,COMPLETED,INTERVENTIONAL,['NA']
12389,NCT02595606,ocular surface disease index,corneal fluorescein staining assessment,,2015-09,UNKNOWN,INTERVENTIONAL,['PHASE4']
12390,NCT02397265,Percentage of Time in Target Range Over 24 Hour,,,2014-12-03,COMPLETED,INTERVENTIONAL,['NA']
12391,NCT06333080,Time-in-Range (TIR),Treatment-Related Impact Measure for Diabetes (TRIM-D),,2024-05-01,RECRUITING,OBSERVATIONAL,['NA']
12392,NCT02100488,Intra-subject postprandial glycemic variability,CV_AUC-PG_3-8h,Time into range,2014-03,COMPLETED,INTERVENTIONAL,['NA']
12393,NCT00553488,"Area Under Curve (AUC) of the blood glucose (BG) profile after the meal, with and without baseline correction.",Time to BGmax (tBGmax),,2007-09,COMPLETED,INTERVENTIONAL,['PHASE2']
12394,NCT02210000,Percentage of Responders Based on the Fullness/Early Satiety Subscale (Responders) as Assessed by Gastrointestinal Cardinal Symptom Index-Daily Diary (GCSI-DD) at Week 12,Trough Plasma Concentration of Camicinal on Day 28 and Day 84,,2014-08-27,COMPLETED,INTERVENTIONAL,['PHASE2']
12395,NCT05461716,Detection of hypoglycaemic events,Registry of hypoglycaemia events in patients with T2DM treated with insulin and insulin secretagogues,,2022-01-01,RECRUITING,OBSERVATIONAL,['NA']
12396,NCT03452085,xerostomia,patients preference for treatment AS or TT,,2017-09-23,COMPLETED,INTERVENTIONAL,['NA']
12397,NCT06332378,Hemoglobin A1C,,,2024-04-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
12398,NCT05241522,Standard uptake value in the kidney,,,2021-08-06,RECRUITING,INTERVENTIONAL,['PHASE1']
12399,NCT03784443,Number of Lucentis Injections received in the study eye,Number of focal laser treatments,,2019-09-01,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
12400,NCT05553093,Brain function,"Inflammation factors, including adiponectin,leptin,IL-1,IL-6,IL-18,TNF-α,ghrelin,asprosin.",,2022-03-15,RECRUITING,INTERVENTIONAL,['PHASE4']
12401,NCT02233491,Glucose metabolism,Hospitalization,,2015-08,COMPLETED,INTERVENTIONAL,['NA']
12402,NCT05495451,Feasibility of an intensive multidisciplinary program based on lifestyle changes in patients diagnosed with type 2 diabetes.,"Evolution of the HOMA-IR between the start of the program, the middle of the intervention (3 months) and the end of the intervention (6 months).",,2022-01-21,COMPLETED,INTERVENTIONAL,['NA']
12403,NCT01530178,Better Targeted Blood Glucose Levels,,,2011-11,COMPLETED,INTERVENTIONAL,['PHASE4']
12404,NCT04607096,Change in first phase insulin secretion.,Change in subcutaneous adipose tissue.,Change in insuin clearance.,2021-04-08,UNKNOWN,INTERVENTIONAL,['NA']
12405,NCT01724060,Change in Energy Intake From Baseline,Change in Macronutrient Composition From Baseline,,2012-09,COMPLETED,OBSERVATIONAL,['NA']
12406,NCT01822925,Change in Clinic Visit Pain Score at the 12 Week Visit Compared to Baseline as Assessed by the 11-point Likert Numerical Rating Scale (NRS),Average Weekly Rescue Medication Use,,2013-11,COMPLETED,INTERVENTIONAL,['PHASE2']
12407,NCT02942056,Type 2 DM control,obesity,,2017-01,WITHDRAWN,INTERVENTIONAL,['PHASE2']
12408,NCT03443713,Percent of Time With Sensed Glucose Less Than 70 mg/dl,Mean Sensed Glucose,,2018-07-18,COMPLETED,INTERVENTIONAL,['NA']
12409,NCT01179555,Pt. 1 Dilated Fundus Exam (DFE),Pt. 2 Appointment Adherence Characteristics,Pt. 2 Cost-effectiveness,2010-10,COMPLETED,INTERVENTIONAL,['NA']
12410,NCT00086515,Change From Baseline in Hemoglobin A1C (A1C) at Week 24,Change From Baseline in 2-hour Post-meal Glucose (PMG) at Week 24,,2004-06-30,COMPLETED,INTERVENTIONAL,['PHASE3']
12411,NCT02795910,Systolic blood pressure,Ischemic heart disease treatment,,2017-04-01,UNKNOWN,INTERVENTIONAL,['NA']
12412,NCT02995863,Presence of diabetic foot ulcer,Toe - Brachial Index (TBI),,2016-12-10,COMPLETED,INTERVENTIONAL,['NA']
12413,NCT05642377,Pharmacokinetic Assessment by Apparent Volume of Distribution of HGR4113,Pharmacodynamic Assessment by Change in Plasma C-peptide,,2022-11-22,RECRUITING,INTERVENTIONAL,['PHASE1']
12414,NCT02463682,"Safety and efficacy of the system, as assessed by the composite outcome of time in range for glucose levels of 70-180 mg/dL and time < 70 mg/dL.",Failure analysis of the devices/connectivity issues that may occur.,,2015-05,COMPLETED,INTERVENTIONAL,['NA']
12415,NCT00740012,Glucose (continuous glucose monitoring),"Hormones (norepinephrine, cortisol, glucagon, growth hormone, prolactin), Pulse, Blood glucose",,2007-03,COMPLETED,INTERVENTIONAL,['NA']
12416,NCT01871558,Percentage of Patients Who Reported at Least One Symptomatic Hypoglycemic Event During the 24 Week Randomized Period in Both Treatment Arms,Percent of Participants That Reach Therapeutic Goal (HbA1c ≤ 7%) at Week 24 Without Any Hypoglycaemic Episode (Symptomatic or Not) and Without Any Weight Gain (Variation ≥3% Compared to Baseline),,2013-06,COMPLETED,INTERVENTIONAL,['PHASE3']
12417,NCT04068805,Change in self-reported HbA1C level,Change in positive affect [Patient-Reported Outcomes Measurement Information Systems - Positive Affect Subscale(PROMIS)],,2020-08-31,TERMINATED,INTERVENTIONAL,['NA']
12418,NCT02453711,Relative Change in Body Weight (%),Anti-semaglutide Antibodies During and After Treatment,,2015-10-01,COMPLETED,INTERVENTIONAL,['PHASE2']
12419,NCT05076656,Changes in HOMA-IR,Changes in glucose metabolism,,2019-06-10,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
12420,NCT01430221,Severity of depressive symptoms,Changes in inflammation,,2011-05,COMPLETED,INTERVENTIONAL,['NA']
12421,NCT02066155,Hemoglobin A1C,BMI,Diabetes-related distress,2013-01,COMPLETED,INTERVENTIONAL,['NA']
12422,NCT01268995,90 days OGTT,Hypoglycemia,,2009-09,TERMINATED,INTERVENTIONAL,['PHASE2']
12423,NCT05885659,Variability of glycemic levels,Anthropometric data,,2023-09-01,RECRUITING,INTERVENTIONAL,['NA']
12424,NCT04166032,Mean Absolute Relative Difference (MARD) of Glucose Values Between the ANICGM and FDA-approved Glucose Monitoring Device,,,2019-11-06,COMPLETED,INTERVENTIONAL,['NA']
12425,NCT01790412,prevention gestational diabetes,Maternal weight gain,Other pregnancy outcomes,2009-02,COMPLETED,INTERVENTIONAL,['NA']
12426,NCT00757601,Number of Participants Who Discontinued Treatment Due to an AE,Mean Area Under The Plasma Concentration Curve From Time Zero to 24 Hours (AUC[0-24]) After Single Dose MK1006,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE1']
12427,NCT03156179,fractional calcium absorption,Estimated calcium retention,,2015-09-01,COMPLETED,OBSERVATIONAL,['NA']
12428,NCT03974464,Show that the negativity of S-100b protein and copeptin eliminates stroke in the face of vertigo,,,2016-05-01,COMPLETED,OBSERVATIONAL,['NA']
12429,NCT02733315,Weekly self-monitoring of blood glucose times as determined by medical chart review,fasting plasma glucose as determined by medical chart review,,2014-01,COMPLETED,INTERVENTIONAL,['NA']
12430,NCT00700908,Change in HbA1c,Change in adherence to SMBG frequency,,2007-06,COMPLETED,INTERVENTIONAL,['NA']
12431,NCT02027571,The primary outcome measure is restoration of normal glucose regulation,Glucose normalization,Incident prediabetes in observational cohort,2013-10,COMPLETED,INTERVENTIONAL,['NA']
12432,NCT01326117,improvement in Gastric Emptying Study residual tracer amount,,,2011-04,WITHDRAWN,INTERVENTIONAL,['PHASE4']
12433,NCT02156037,HbA1c,Depression,,2009-07,COMPLETED,INTERVENTIONAL,['NA']
12434,NCT02497313,Glucagon-like peptide-1 (GLP-1): Incremental and total area under the Concentration-Time Curve,Appetite as assessed by Visual analog scale score,,2015-07,COMPLETED,INTERVENTIONAL,['NA']
12435,NCT00263835,Change in hemoglobin A1c.,"Change in blood pressure, cholesterol, and weight.",,2004-10,COMPLETED,INTERVENTIONAL,['PHASE2']
12436,NCT01707160,Area under the Curve,Adverse events,,1995-11,COMPLETED,INTERVENTIONAL,['PHASE1']
12437,NCT03269058,Change from baseline the Fractional Catabolic Rate of HDL 'Apo A1,,,2017-12-20,COMPLETED,INTERVENTIONAL,['PHASE4']
12438,NCT05994586,Discomfort related to metformin side effects,HbA1c level,,2023-05-25,RECRUITING,INTERVENTIONAL,['NA']
12439,NCT05700877,Rates of a composite cardiovascular endpoint,Cost-effectiveness,Cardiovascular risk markers 4,2023-01-26,RECRUITING,INTERVENTIONAL,['PHASE4']
12440,NCT04890886,Assessment of the distribution of adipose tissue,Thermal assessment,,2021-06-01,UNKNOWN,OBSERVATIONAL,['NA']
12441,NCT03547440,Metabolic control,Akkermansia muciniphila quantification in stool,Metabolic control 2,2015-03-18,UNKNOWN,OBSERVATIONAL,['NA']
12442,NCT00985881,Gait variability,,,2007-04-01,COMPLETED,INTERVENTIONAL,['NA']
12443,NCT02148978,glucose tolerance after treatment with Saxagliptin,,,2014-03,UNKNOWN,INTERVENTIONAL,['NA']
12444,NCT04981067,Median effective anesthetic concentration 90 (MEAC 90),Any adverse events,,2021-08-24,RECRUITING,INTERVENTIONAL,['NA']
12445,NCT01636349,muscular adaptations,glycaemic control,,2011-11,COMPLETED,INTERVENTIONAL,['NA']
12446,NCT04637841,Evaluation of relaxation time,Evaluation of skin temperature,,2021-02-01,COMPLETED,INTERVENTIONAL,['NA']
12447,NCT00672919,Change from Baseline in Triglyceride Levels,Change from Baseline in C-reactive Protein,,2003-11,COMPLETED,INTERVENTIONAL,['PHASE4']
12448,NCT04185454,Osteocalcin ratio,Lipid profil 2,,2018-09-01,COMPLETED,INTERVENTIONAL,['NA']
12449,NCT04645732,"EQ-5D-5L, the descriptive index",Mortality,Vigorous Intermittent Lifestyle Physical Activity (VILPA): Time spent on VILPA intensity activities,2021-11-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
12450,NCT02960373,Glycemic index (GI),,,2016-11,UNKNOWN,INTERVENTIONAL,['NA']
12451,NCT04463082,Change in collapsibility index pre- and post-hydration,Correlation to body surface area,,2020-09-01,COMPLETED,INTERVENTIONAL,['NA']
12452,NCT05047237,Point estimates of Feasibility Measures: Time,Implementation Metric- Value,,2021-10-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
12453,NCT01316016,,,,2009-04,COMPLETED,INTERVENTIONAL,['NA']
12454,NCT02359214,Pulsewave Velocity,Systolic Blood Pressure,Plasma Angiotensin II,2014-04,COMPLETED,INTERVENTIONAL,['NA']
12455,NCT00737022,Macular appearance,Post-operation best-corrected visual acuity,,2005-05,COMPLETED,OBSERVATIONAL,['NA']
12456,NCT04604223,Difference in the incidence at 4 weeks of a composite outcome comprised of:,Incidence at 4 weeks of a composite of extrapulmonary disease comprised of :,,2021-01-18,UNKNOWN,INTERVENTIONAL,['PHASE4']
12457,NCT02647905,CGM Relative Difference to Laboratory Reference Reported as MARD,,CGM System Agreement With Reference Control,2016-01,COMPLETED,INTERVENTIONAL,['NA']
12458,NCT03627715,The Change in Albumin/Creatinine Ratio with Adjunct use of Propagermanium Compared to Placebo in Participants with DKD who are Receiving Irbesartan,The Effect of Treatment with Propagermanium on Measures of Proteinuria as measured by ACR,,2018-11-06,COMPLETED,INTERVENTIONAL,['PHASE2']
12459,NCT00621140,HbA1c Change From Baseline at Week 24,Adjusted Means for 2h Post Prandial Blood Glucose (PPG) Change From Baseline at Week 24,,2008-02,COMPLETED,INTERVENTIONAL,['PHASE3']
12460,NCT06057805,CGM metric of mean glucose compared to OGTT result,CGM variability measure MAGE will be compared to fructosamine test,Tolerability to dexcom adhesive,2024-02-06,RECRUITING,INTERVENTIONAL,['NA']
12461,NCT02641743,plasma glucose concentration,plasma free fatty acid concentration,,2009-01,COMPLETED,INTERVENTIONAL,['NA']
12462,NCT05968924,Adherence to use of SmartMat,Use of health care facilities,,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
12463,NCT05951569,Measure of Loop Safety by Self-Report of Hospitalization Events,,HbA1c,2023-06-20,COMPLETED,OBSERVATIONAL,['NA']
12464,NCT00032487,Primary Major Macrovascular Events,Secondary Endpoint,,2000-12-01,COMPLETED,INTERVENTIONAL,['PHASE3']
12465,NCT03369834,strength capacities,blood flow,,2018-02-01,COMPLETED,INTERVENTIONAL,['NA']
12466,NCT02486172,Glycaemic control,Body weight,Sustainability of the program,2015-07,UNKNOWN,INTERVENTIONAL,['NA']
12467,NCT00271284,Efficacy data : fasting blood glucose concentration,Tolerance data : undesirable events including episodes of hypoglycaemia,,2005-10,COMPLETED,INTERVENTIONAL,['PHASE3']
12468,NCT02985242,"Microaneurysm formation rate over 12 months, i.e. number of newly developed microaneurysms within 12 months",Change in ambulatory blood pressure,,2017-06-12,TERMINATED,INTERVENTIONAL,['PHASE4']
12469,NCT04370600,Bicarbonate concentration,,,2020-06,UNKNOWN,INTERVENTIONAL,['PHASE1']
12470,NCT00946257,Safety and tolerability after a single dose of otelixizumab in T1DM patients,,,2009-07-08,COMPLETED,INTERVENTIONAL,['PHASE1']
12471,NCT03961516,Pancreatic Fat and Glycemic measures,Pancreatic Fat by Modulator Status,,2019-05-01,COMPLETED,OBSERVATIONAL,['NA']
12472,NCT06296485,Hypoglycemia aggregate outcome,Hypoglycemia Distress,Caregiver Action,2024-03-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
12473,NCT02245633,ADAMTS13 levels in diabetic hemodialysis patients,VWF levels in diabetic hemodialysis patients,miRNA expression in plasma from diabetic hemodialysis patients,2014-09,UNKNOWN,OBSERVATIONAL,['NA']
12474,NCT06006312,the prevalence of pancreatic exocrine insufficiency,Insulin level,,2023-08,RECRUITING,OBSERVATIONAL,['NA']
12475,NCT05072990,"Changes from Baseline Body Mass Index at 3 months, 6 months",Changes from Diastolic Blood Pressure at 6 months,,2021-10-27,COMPLETED,OBSERVATIONAL,['NA']
12476,NCT02811289,whole body organ glucose partitioning,Electrocardiogram,,2016-08-05,COMPLETED,INTERVENTIONAL,['NA']
12477,NCT01341067,Change in HgbA1c,Change in Basal Insulin Dose From Baseline Values,,2011-04,COMPLETED,OBSERVATIONAL,['NA']
12478,NCT03769675,Positive Pain,Extensor Digitorum Brevis Muscle Nerve Conduction,,2018-11-20,COMPLETED,INTERVENTIONAL,['NA']
12479,NCT01726114,Performance of the test device in comparison to the reference device,,,2012-06,COMPLETED,INTERVENTIONAL,['NA']
12480,NCT05749029,Change in Diabetes Distress Scale (DDS) scores from baseline (week 0) to post-intervention (week 4).,Change in Compassionate Engagement and Action Scale (CEAS) scores at baseline (week 0) to follow-up (week 8).,,2023-05-01,COMPLETED,INTERVENTIONAL,['NA']
12481,NCT01180972,"Assess the built environment for energy requirements of movement, nutrition options, suitability for outdoor physical activity, and for children's actual physical activity and energy expenditure within those environments.",Assess the impact of children's social environment on movement and nutrition choices within the built environment.,"Conduct a quantitative assessment of children's fitness, obesity, and indicators of metabolic health.",2010-08,COMPLETED,OBSERVATIONAL,['NA']
12482,NCT01461616,Growth Hormone(ng/ml),"insulin concentration (mmol/L) after a single injection of either NPH insulin, insulin Detemir or insulin glargine",,2012-02,COMPLETED,INTERVENTIONAL,['PHASE3']
12483,NCT00393718,Glycosylated Haemoglobin A1c (HbA1c) After 24 Weeks of Treatment,Hypoglycaemic Episodes,,2006-11,COMPLETED,INTERVENTIONAL,['PHASE3']
12484,NCT00813410,glucose concentration at the subcutaneous insulin delivery site,,,2007-02,COMPLETED,INTERVENTIONAL,['NA']
12485,NCT00770640,Change of total daily Insulin Dose.,Change from Baseline in intact Parathyroid Hormone.,,2008-08,COMPLETED,INTERVENTIONAL,['PHASE2']
12486,NCT00744458,Percentage of patients with regular follow-up one year after the treatment was started,Treatment response of patients with arterial hypertension (blood pressure),,2008-08,COMPLETED,INTERVENTIONAL,['NA']
12487,NCT05689372,Number (incidence) of adverse events (AEs),Dose of Ozempic,,2024-06-30,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
12488,NCT03654586,Total calories purchased in last two weeks of study,Newest vital sign measure,,2018-07-30,TERMINATED,INTERVENTIONAL,['NA']
12489,NCT00770939,Percentage of patients with a 50% reduction of wound area after 4 and 8 weeks,Granulation rate,,2008-07,COMPLETED,INTERVENTIONAL,['PHASE4']
12490,NCT01006889,Hepatic Steatosis,Change in Anthropometric Variables (BMI).,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE4']
12491,NCT02380339,Reduction of fear of hypoglycemia in type 1 diabetic patients as measured by reduction of 2 point on the HFS-W). pre-treatment and after two months post completion of treatment.,,,2018-03-01,UNKNOWN,INTERVENTIONAL,['NA']
12492,NCT05830994,Changes in gastric emptying,Incidence of Treatment-Emergent Adverse Events rated by the ASGE lexicon for adverse events,,2023-04-12,RECRUITING,INTERVENTIONAL,['NA']
12493,NCT01578460,Offspring Birth Weight,Shoulder Dystocia (neonatal),,2012-05,COMPLETED,INTERVENTIONAL,['NA']
12494,NCT00111800,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12,Descriptive Statistics of Dipeptidyl Peptidase-IV (DPP-IV) Inhibition Performed as Part of the Population PK,,2005-04-28,COMPLETED,INTERVENTIONAL,['PHASE2']
12495,NCT00837512,Onset Time (Tmax),,,2008-09,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
12496,NCT04923386,Change in AUC glucose level above expected baseline,Change in fasting blood glucose levels above expected baseline,,2021-06-15,COMPLETED,OBSERVATIONAL,['NA']
12497,NCT00781495,To detect an association between insulin-induced weight gain and physical activity levels,To assess the relationship between insulin-induced weight gain and cardiovascular risk profile,,2008-12,UNKNOWN,OBSERVATIONAL,['NA']
12498,NCT03242252,Change From Baseline in HbA1c at Week 26,Percentage of Participants With Treatment-emergent Adverse Events (TEAEs),Percentage of Participants With Hypoglycemic Events,2017-08-16,COMPLETED,INTERVENTIONAL,['PHASE3']
12499,NCT04825366,Change in the Gold score,Number of severe hypoglycemia,,2021-08-03,RECRUITING,INTERVENTIONAL,['NA']
12500,NCT01472640,"Change in Left ventricular function from visit 1 to week 24, measured by Ecco",left ventricular diastolic function,,2011-11,COMPLETED,INTERVENTIONAL,['NA']
12501,NCT03218735,Number of children with birthweight above 4500 grams,Number of children admitted to NICU,,2017-07-12,WITHDRAWN,INTERVENTIONAL,['NA']
12502,NCT01068717,"Time to Achieve the Observed Maximum Plasma Concentration (Tmax) for Saxagliptin and Metformin, Tablets and FDC, Administered to Participants in the Fasted and Fed States","Number of Participants With Clinically Significant Abnormalities in Body Temperature, Blood Pressure, or Heart Rate",,2010-03,COMPLETED,INTERVENTIONAL,['PHASE1']
12503,NCT02709577,Change in HbA1c Values From Baseline Measurement,Absolute Weight Change,,2007-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12504,NCT05577104,the time to STSG surgery,the wound neutrophil extracellular traps (NETs) formation,,2022-05-01,RECRUITING,INTERVENTIONAL,['NA']
12505,NCT02865525,Number of events 'hospitalization and death' for 2 patient groups defined through the questionnaire QUILAM score,Number of events 'hospitalization and death' for 2 patient groups separate with different cut off,,2013-03,COMPLETED,OBSERVATIONAL,['NA']
12506,NCT04136730,Glycated Haemoglobin concentration (mmol/mol),Short performance physical battery test,Quality of life score,2019-08-01,COMPLETED,INTERVENTIONAL,['NA']
12507,NCT05893576,Calculate the ratio of bioavailability between the new formulation and original formulation of HRS9531 according to the equation F (relative bioavailability) =AUCT·DR/AUCR·DT×100%,Incidence and severity of adverse events,,2023-05-15,COMPLETED,INTERVENTIONAL,['PHASE1']
12508,NCT01930110,The number of patients experiencing exercise-induced hypoglycemia requiring dextrose infusion (< 3.3 mmol/L symptomatic or < 3.0 mmol/L regardless of symptoms).,The amount of dextrose infused,,2014-04,COMPLETED,INTERVENTIONAL,['PHASE2']
12509,NCT04213651,Correlation of Microbiome to Disease via Relative Abundance Found in Microbiome Sequencing,,,2020-03-02,UNKNOWN,OBSERVATIONAL,['NA']
12510,NCT03430310,Pancreas lipid,Insulin secretion,,2018-10-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
12511,NCT01526980,Glucose average in 24-hour blood glucose profiles,Adverse events,,2002-05,COMPLETED,INTERVENTIONAL,['PHASE2']
12512,NCT00959101,AUC0-t and Cmax (after repaglinide 2.0 mg and metformin 500 mg as co-administered tablets and combination tablet dosing under fed state),Repaglinide AUC(0-24 & 0-∞) and Cmax after combination tablet (repaglinide 1.0 mg/metformin 500 mg) during fed state,,2009-08,COMPLETED,INTERVENTIONAL,['PHASE1']
12513,NCT05632601,Satisfaction Questionnaire,,,2023-04-26,RECRUITING,INTERVENTIONAL,['NA']
12514,NCT04758858,Percentage of time-in-target (range of 4-10 mmol/L),Self-reported symptoms,,2021-03,WITHDRAWN,INTERVENTIONAL,['NA']
12515,NCT01162876,Pharmacodynamics,Safety issues,,2010-07,COMPLETED,INTERVENTIONAL,['PHASE3']
12516,NCT01821053,preeclampsia,light for gestational age,,2013-06,COMPLETED,OBSERVATIONAL,['NA']
12517,NCT02266758,Number of Cesarean Section Deliveries,Number of Infant Bone Fractures or Nerve Palsies associated with delivery,Number of pregnant women with anxiety or depression,2014-06-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
12518,NCT03112343,the proportion of patients who reach his/her optimal insulin dose within 12 weeks of enrolling in the study without severe hypoglycemia or unscheduled clinic visits.,the number of self-monitoring blood glucose measurements,,2017-09-26,COMPLETED,INTERVENTIONAL,['NA']
12519,NCT03166852,Frequency of training,Interview,,2016-04-27,COMPLETED,INTERVENTIONAL,['NA']
12520,NCT02864160,Change in Patient Hemoglobin A1C from Baseline to 6 Months,Change in Health Coach Interpersonal Communication from Baseline to 6 Months as Assessed by the RIAS,Change in Program Reach to End of Year 5,2014-09,COMPLETED,INTERVENTIONAL,['NA']
12521,NCT02719132,Composite endpoint including quality of life score,Proportion of patients,laboratory values changes,2016-07,WITHDRAWN,INTERVENTIONAL,['PHASE4']
12522,NCT01628289,Retinopathy profile in the two groups,Subjects' attendance of the screening,,2009-02,COMPLETED,INTERVENTIONAL,['NA']
12523,NCT02748239,A1c values,Depression,,2013-02,COMPLETED,INTERVENTIONAL,['NA']
12524,NCT00541437,,,,2006-05,COMPLETED,OBSERVATIONAL,['NA']
12525,NCT05198765,Change in weight trajectory during 18-month post-intervention follow-up period,Intentions to engage in weight loss,,2023-04-19,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
12526,NCT04833062,Addition of the UAPI to the CPR,,,2022-01-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
12527,NCT00848757,Change in Blood Pressure,Physical Activity Levels (Self-reported),,2009-03,COMPLETED,INTERVENTIONAL,['NA']
12528,NCT02903199,Postprandial capillary glucose,24 h Interstitial Glucose,,2015-07,UNKNOWN,INTERVENTIONAL,['NA']
12529,NCT02821052,Incidence of AEs (adverse event),Change in Glycosylated haemoglobin A1c (HbA1c),,2016-07-01,COMPLETED,OBSERVATIONAL,['NA']
12530,NCT02932826,Number of Participants with Adverse events as a Measure of Safety and Tolerability,Autoimmune Status,,2016-10,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12531,NCT00420095,Glycosylated Hemoglobin (HbA1c) Value at 12 Week Endpoint,Hypoglycemia Rate Per Participant Per 30 Days,,2007-01,COMPLETED,INTERVENTIONAL,['PHASE4']
12532,NCT03916640,AUCIns 0-8h,Safety and tolerability (Adverse Events recording),,2019-01-04,COMPLETED,INTERVENTIONAL,['PHASE1']
12533,NCT04511325,The effects of daily white potato versus white rice consumption for 12 weeks (each intervention for 12 weeks with a 2-week washout period) on pulse wave velocity (PWV) in individuals with type 2 diabetes mellitus.,The effects of daily white potato versus white rice consumption for 12 weeks (each intervention for 12 weeks with a 2-week washout period) on waist-to-hip ratio in individuals with type 2 diabetes mellitus.,,2019-04-27,COMPLETED,INTERVENTIONAL,['NA']
12534,NCT00432276,Change From Baseline in Glycosylated Hemoglobin (HbA1c),Change From Baseline in Mean HDL Particle Size,,2007-01,COMPLETED,INTERVENTIONAL,['PHASE3']
12535,NCT02427802,Clinical Cure (Resolution of All Clinical Signs and Symptoms of Infection),Ulcer Closure (Percent of Patients With Target Ulcer Closure),,2015-05,COMPLETED,INTERVENTIONAL,['PHASE3']
12536,NCT02844803,Change of serum glucose level after 8 weeks from baseline,,,2016-07,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
12537,NCT00869609,Change in Weight,Change in Waist Circumference,,2009-03,COMPLETED,INTERVENTIONAL,['NA']
12538,NCT05884957,ِAssessments of endothelial nitric oxide synthase In diabetes mellitus,Tadalafil 5milligram (tablets) therapy in diabetic patients,,2023-06-01,COMPLETED,INTERVENTIONAL,['NA']
12539,NCT05380232,All-cause mortality,Major adverse cardiovascular events (MACE),,2006-03,COMPLETED,OBSERVATIONAL,['NA']
12540,NCT01695278,Change in hemoglobin A1c,Task related self-efficacy for initiating and maintaining diabetes self-management,Diabetes self-management behaviors,2012-09,COMPLETED,INTERVENTIONAL,['PHASE3']
12541,NCT03851627,Liver fat,diabetes management satisfaction questionnaire,amount of pancreatic fat,2022-01-25,RECRUITING,INTERVENTIONAL,['PHASE4']
12542,NCT00959348,To investigate the ICS effect on the risk of DM/IGT/insulin resistance,To study the dose response relationship and effect modifying factors if risk is present,,2007-08,COMPLETED,OBSERVATIONAL,['NA']
12543,NCT00562029,Measure: Resolution of Type 2 Diabetes Mellitus,Measure: Safety and efficacy of duodenal-jejunal bypass,,2007-11,COMPLETED,INTERVENTIONAL,['NA']
12544,NCT01304537,Safety and Tolerability,Efficacy,,2011-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12545,NCT04786418,"Changes in liver fat >5 percent, determined by MRI, from baseline to after 12 months of intervention.","Multi organs pancreas, spleen and kidney fat content",,2021-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
12546,NCT03182426,Rate of Serious Adverse Event/Medical Event of Special Interest,T-cell phenotyping,,2017-08-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12547,NCT01292590,Change in insulin requirements,,,2010-09,COMPLETED,INTERVENTIONAL,['NA']
12548,NCT04764279,Partial Remission of Diabetes,Reduction in Visceral Adiposity,,2021-06,UNKNOWN,INTERVENTIONAL,['NA']
12549,NCT04020068,Improvement of patient care,,,2019-04-08,UNKNOWN,OBSERVATIONAL,['NA']
12550,NCT01396564,Short-term comparison of metformin and pioglitazone in pediatric patients with T2D,Comparison of long-term effects of metformin vs pioglitazone,,2005-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12551,NCT01374178,Pharmacokinetics: Area Under the Concentration-Time Curve (AUC),Number of Participants With Clinically Significant Effects,,2011-06,COMPLETED,INTERVENTIONAL,['PHASE1']
12552,NCT04466007,Complication rate after treatment administration,% amputations,VascuQol-6 questionnaire,2021-01-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
12553,NCT03557138,Kinetic behavior of glucose reabsorption,positron emission tomography (PET),,2017-02-22,UNKNOWN,INTERVENTIONAL,['NA']
12554,NCT00662519,Number of participants with adverse events,Increase T regulatory cells (Treg) from the bone marrow,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE1']
12555,NCT00005760,,,,2000-05,COMPLETED,OBSERVATIONAL,['NA']
12556,NCT02737657,Percentage of Participants With at Least one Episode of Hypoglycaemia,Relationship of Volume Depletion Events With Number of Fasting Days,,2016-04,COMPLETED,OBSERVATIONAL,['NA']
12557,NCT05140564,HbA1c,,,2022-01-18,COMPLETED,INTERVENTIONAL,['NA']
12558,NCT01288326,Percentage of participants reaching the treatment target of a HbA1c (glycosylated haemoglobin A1c) decrease of at least 1%,Frequency of hypoglycaemic episodes (frequency of episodes with low blood sugar),,2011-02,COMPLETED,OBSERVATIONAL,['NA']
12559,NCT04160078,Number of Participants With PSS Score Indicating High Stress,Blood Pressure,,2019-12-18,COMPLETED,INTERVENTIONAL,['NA']
12560,NCT02029846,Time to Achieve Glycemic Target (HbA1c <7.5%).,Overall Hypoglycemia Measured by Glucose Meter,Diabetes Quality of Life,2013-04,TERMINATED,INTERVENTIONAL,['PHASE4']
12561,NCT05415878,Offloading adherence,Cumulative plantar tissue stress,Correlates of joint pain,2022-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
12562,NCT01270191,The time of monotherapy failure and monotherapy failure rate,"Comparison of A1C change, the proportion of subjects who reached the treatment target",,2010-11,UNKNOWN,INTERVENTIONAL,['PHASE4']
12563,NCT05005741,haemoglobin A1c(HbA1c),Homeostasis model assessment for β cell(HOMA-β),,2021-05-01,RECRUITING,INTERVENTIONAL,['PHASE4']
12564,NCT05359796,the development or progression of diabetic retinopathy,the changes of carotid intima-media thickness(IMT),,2022-05-01,RECRUITING,OBSERVATIONAL,['NA']
12565,NCT05388721,Environmental contaminants 2,,,2022-05-01,RECRUITING,OBSERVATIONAL,['NA']
12566,NCT00446251,The Number of Subjects Who Experience a Decrease in Their Panel of Reactive Antibodies (PRA) at 6 Months Post Rituximab Infusion.,The Number of Subjects With a Negative Crossmatch at the Time of Transplant.,,2006-12,COMPLETED,INTERVENTIONAL,['PHASE2']
12567,NCT03327896,Provider Ranking as Assessed by Health Care Quality Metrics,Colorectal Cancer Screening (Patient level),,2017-01-15,UNKNOWN,OBSERVATIONAL,['NA']
12568,NCT00707460,Pilot Study: no formal primary outcome measure. There is no noted safety issue for this study; although adverse/side effects and/or symptoms will be closely monitored by the RPN and community research staff.,"Future dietary intervention feasibility will be assessed by 24-hour recalls/ diet records, appointment attendance, participant and community staff feedback, and questionnaire completion.",,2008-05,COMPLETED,INTERVENTIONAL,['PHASE1']
12569,NCT03137966,Healing,Improvement of ulcer,,2022-12-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
12570,NCT03966911,Percentage of Readings Within 20% Agreement,,,2019-06-14,COMPLETED,INTERVENTIONAL,['NA']
12571,NCT00486187,Change in adiponectin level in the rosiglitazone vs. metformin/sulfonylurea arms,"Secondary end-points include changes in leptin, resistin, hs-CRP, IL-6, MMP-9, ICAM-1, insulin sensitivity (as estimated by the HOMA technique), HbA1c, and lipid levels in the rosiglitazone vs. metformin/sulfonylurea arms",,2006-04,COMPLETED,INTERVENTIONAL,['NA']
12572,NCT01469481,radioactivity t1/2,,,2011-11,COMPLETED,INTERVENTIONAL,['PHASE1']
12573,NCT02232971,Maximum plasma glucose response,Duration of hyperglycemic effect of glucagon,Plasma triglycerides,2014-09,UNKNOWN,INTERVENTIONAL,['PHASE4']
12574,NCT04143945,Intensity of Injection Site Pain,,,2019-10-28,COMPLETED,INTERVENTIONAL,['PHASE2']
12575,NCT04450810,Clinical attachment level,,,2014-06-01,COMPLETED,OBSERVATIONAL,['NA']
12576,NCT03938441,Number of hypoglycemic events,,,2019-07-31,TERMINATED,INTERVENTIONAL,['NA']
12577,NCT06305377,Glucometric data,,,2024-03-11,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
12578,NCT05105321,Rate of composite cardiometabolic endpoints,Changes of body mass index,,2021-12,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
12579,NCT03455101,Glycemia control status of Turkish adult patients with diabetes mellitus,Weight control status of Turkish adult patients with diabetes mellitus.,,2017-04-01,COMPLETED,OBSERVATIONAL,['NA']
12580,NCT00929201,Plasma Area Under the Curve (AUC(0 to Infinity)) for Metformin,Peak Plasma Concentration (Cmax) of Metformin,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE1']
12581,NCT03543644,75g OGTT derived plasma glucose iAUC,75g OGTT derived Matsuda whole body insulin sensitivity index [Matsuda ISI OGTT],Urinary and blood proteomic panel,2018-05-31,COMPLETED,INTERVENTIONAL,['NA']
12582,NCT03490253,Physical Activity,Patient Health Questionnaire-8 (PHQ-8),,2020-02-05,COMPLETED,INTERVENTIONAL,['NA']
12583,NCT00808795,"Incidence of CIN, defined as increase in serum creatinine concentration>=0.5mg/dL(44.2micromol/L) or >=25% above baseline.",Change in Glomerular filtration rate(GFR),,2006-04,COMPLETED,INTERVENTIONAL,['PHASE3']
12584,NCT03293082,Glucose variability,HbA1c,,2017-09-30,COMPLETED,OBSERVATIONAL,['NA']
12585,NCT04972539,Cmax,,,2020-08-01,COMPLETED,INTERVENTIONAL,['PHASE1']
12586,NCT02362607,Blood Glucose Control Status Measured by HbA1c,Patient Satisfaction Measured by Questionnaire,,2015-02,COMPLETED,INTERVENTIONAL,['NA']
12587,NCT03818581,Subjective Total Sleep Time,Insomnia Severity Index,,2019-03-15,COMPLETED,INTERVENTIONAL,['PHASE4']
12588,NCT04656236,Differences in lipolysis rate,"Differences in circulating concentrations of 3-hydroxybutyrate, glucose, free fatty acids, insulin, glucagon and C-peptide",,2021-01-01,COMPLETED,INTERVENTIONAL,['NA']
12589,NCT01017302,Safety and Tolerability of various doses of RO5095932,"Pharmacodynamics: glucose, insulin, C-peptide",,2009-12,COMPLETED,INTERVENTIONAL,['PHASE1']
12590,NCT00160927,,,,2003-01,UNKNOWN,OBSERVATIONAL,['NA']
12591,NCT02702375,Gout,,,2015-09,UNKNOWN,OBSERVATIONAL,['NA']
12592,NCT04214704,Percentage reduction in HbA1c,Subjective assessment of probability of using Genteel for SMBG,,2020-02-04,COMPLETED,INTERVENTIONAL,['NA']
12593,NCT05544214,"Cmax of CKD-371, D745+D759",,,2022-10-21,COMPLETED,INTERVENTIONAL,['PHASE1']
12594,NCT02088658,Hemoglobin A1c,Resource Utilization & Cost,,2013-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
12595,NCT00421850,Metabolic Outcomes (Systolic Blood Pressure),Satisfaction (Provider and Health Team),,2001-07,COMPLETED,INTERVENTIONAL,['NA']
12596,NCT01357889,Maximum Observed Plasma Concentration (Cmax) of Albiglutide in the BE Phase,Number of Participants With a Change From Baseline of Clinical Concern in Electrocardiogram (ECG) Values by Any On-therapy Visit,,2011-07,COMPLETED,INTERVENTIONAL,['PHASE2']
12597,NCT03984929,Patient Activation,,,2019-06-01,COMPLETED,INTERVENTIONAL,['NA']
12598,NCT05988346,normalization of LV diastolic dysfunction,,,2016-01-01,COMPLETED,OBSERVATIONAL,['NA']
12599,NCT06082973,Number of Level 1 (<70 mg/dL) and Level 2 (<54 mg/dL) hypoglycemic events,Total number of carbohydrates ingested,,2023-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
12600,NCT04049110,Mean Amplitude of Glucose Excursions (MAGE) after physical exercise,"Area under the curve for glucagon before, during and after physical exercise","Area under the curve for somatostatin before, during and after physical exercise",2020-08-25,COMPLETED,INTERVENTIONAL,['PHASE3']
12601,NCT00338923,Safety,Time to Heal & Rate of Healing,,2006-06,COMPLETED,INTERVENTIONAL,['PHASE1']
12602,NCT02608177,Glucose Time in Range,Biomarkers of Albuminuria,,2015-11,COMPLETED,INTERVENTIONAL,['NA']
12603,NCT02097069,Insulin resistance level evaluated by homeostasis model assessment of insulin resistance (HOMA-IR),insulin therapy requirements,,2014-04,UNKNOWN,INTERVENTIONAL,['NA']
12604,NCT01805414,Relative change in Blood sugar,,,2012-09,COMPLETED,INTERVENTIONAL,['NA']
12605,NCT02982408,Adipose tissue expandability,Epigenetics,,2016-08,COMPLETED,INTERVENTIONAL,['NA']
12606,NCT02926937,Change From Baseline in Hemoglobin A1c (HbA1c) at Week 26 (Sotagliflozin 400 mg Versus Placebo),Change From Baseline in HbA1c at Week 26 (Sotagliflozin 200 mg Versus Placebo),Percentage of Participants With Hypoglycemic Events (Sotagliflozin 200 mg Versus Placebo),2016-11-11,COMPLETED,INTERVENTIONAL,['PHASE3']
12607,NCT06238778,hypoglycemia percentage of time,blood chemistry values,,2024-01-23,RECRUITING,INTERVENTIONAL,['PHASE2']
12608,NCT03703440,Hemaglobin A1c (HbA1c),Cost effectiveness (self-efficacy),,2019-11-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
12609,NCT05560256,Building Capacity in Human-Centered Design: Developing a Diabetes mHealth Application for and with Kenyan Adolescents,,,2019-10-01,COMPLETED,INTERVENTIONAL,['NA']
12610,NCT02778269,Number of power-line interference on the ECG,"Number of congruences concerning identified arrhythmias of this validation study and the previous study ""Predicting Hypoglycaemia and Arrhythmias in the vulnerable Patient with Diabetes and Chronic Kidney Disease"".",,2016-06,COMPLETED,INTERVENTIONAL,['NA']
12611,NCT06150495,"Retinal vessel density (VD, %)",,,2019-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
12612,NCT00361868,HbA1c/TG,Lipid and glycemic parameters.,,2006-06,TERMINATED,INTERVENTIONAL,['PHASE3']
12613,NCT03906201,Changes in glycosylated hemoglobin (A1C) after 90 days of intervention with betaecdysterone and placebo,Blood pressure,,2019-02-06,UNKNOWN,INTERVENTIONAL,['NA']
12614,NCT00604253,HbA1c,Insulin antibodies,,2003-12,COMPLETED,INTERVENTIONAL,['PHASE3']
12615,NCT05097339,Change in ketone concentration during and after morning Aerobic and Symptom Limited Maximal Exercise Test,,,2019-05-10,COMPLETED,OBSERVATIONAL,['NA']
12616,NCT02592421,Change in Endogenous Glucose Production (EGP),Change in Glucagon During EGP Measurement,,2015-10-23,COMPLETED,INTERVENTIONAL,['PHASE3']
12617,NCT03574558,Number of hypoglycemic below 54 mg/dl,,,2018-08-01,COMPLETED,INTERVENTIONAL,['NA']
12618,NCT02390973,Type 2 diabetes remission rate,Dislipidemia remission,Long-term complications,2015-03,UNKNOWN,INTERVENTIONAL,['NA']
12619,NCT01379690,Hip Fracture,,,2011-04,COMPLETED,OBSERVATIONAL,['NA']
12620,NCT00761540,AUC 0-24h (last dosing day): Area under the plasma liraglutide curve from 0 to 24 hours after last dosing.,Hypoglycaemic events,,2008-10,COMPLETED,INTERVENTIONAL,['PHASE1']
12621,NCT02688920,"Thickness of the duodenal mucosa using OCT, and EUS if possible","Thickness of the duodenal submucosa using OCT if possible, and EUS","Thickness of the duodenal muscularis using OCT if possible, and EUS",2016-03,COMPLETED,OBSERVATIONAL,['NA']
12622,NCT03288571,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability],Evaluation of the preliminary efficacy of the injection on kidney's protein to creatinine ratio,,2019-11,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12623,NCT02341664,"Lipid-lowering therapy use among a contemporary, nationally representative, community-based sample of adult patients receiving primary and subspecialty care in the US.",,,2015-05,COMPLETED,OBSERVATIONAL,['NA']
12624,NCT01572610,Adverse Event collection and assessment,,,2012-02,TERMINATED,INTERVENTIONAL,['PHASE2']
12625,NCT00475202,,,,na,UNKNOWN,OBSERVATIONAL,['NA']
12626,NCT06229379,Students' scores in the medical history acquisition exam,,,2023-09-01,RECRUITING,INTERVENTIONAL,['NA']
12627,NCT02957721,Change in A1C,Blood Pressure (BP),,2017-11-01,COMPLETED,INTERVENTIONAL,['NA']
12628,NCT00644748,Change from baseline Mean Pain Score,Global Change Impression from the Physician's Point of View,,2003-05,COMPLETED,INTERVENTIONAL,['PHASE4']
12629,NCT05794009,Glycated Hemoglobin (HbA1C),Depression,,2022-06-01,RECRUITING,INTERVENTIONAL,['NA']
12630,NCT04691973,Change of long-term blood glucose concentration measured as glycated hemoglobin at one year,Insulin secretion,"Change of long-term blood glucose concentration measured as glycated hemoglobin in participants with and without Mild Obesity-related Diabetes, respectively.",2017-01-01,UNKNOWN,OBSERVATIONAL,['NA']
12631,NCT02423993,HbA1c,Quality of Life (SF36 Questionnaire),,2009-10,COMPLETED,INTERVENTIONAL,['NA']
12632,NCT01419535,Change in Insulin Sensitivity Index,Adipose-tissue Insulin Sensitivity Index (Adipo-SI),,2011-11-29,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12633,NCT02419612,Change From Baseline in Hemoglobin A1c (HbA1c) at Week 52,Time to Treatment Intensification During the 156-Week Short-term Plus Long-Term Treatment Period.,,2015-08-14,COMPLETED,INTERVENTIONAL,['PHASE3']
12634,NCT05360147,Changes in cognitive function from baseline to 12 weeks,Changes of metabolic parameters from baseline to 12 weeks,,2021-01-20,COMPLETED,INTERVENTIONAL,['PHASE3']
12635,NCT01208012,The difference in increase of retinal blood flow after flicker stimulation of retinal endothelial cells,Safety evaluation,,2010-04,COMPLETED,INTERVENTIONAL,['PHASE4']
12636,NCT04776811,Mean absolute relative difference (MARD),"Correlation between CGM metrics, HbA1c and fructosamine",,2021-03-01,COMPLETED,OBSERVATIONAL,['NA']
12637,NCT01875224,Decreased insulin resistance,,,2013-08,UNKNOWN,INTERVENTIONAL,['PHASE4']
12638,NCT05279729,Long term diabetes improvement via A1c,mhealthy app preference assessed by questionnaire,,2022-08-01,RECRUITING,INTERVENTIONAL,['NA']
12639,NCT01972412,Telephone Support for self-monitoring of persons with diabetes mellitus using the Chronic Care Model,,,2013-04,UNKNOWN,INTERVENTIONAL,['NA']
12640,NCT01398670,Change in HbA1c,Correlation of the immunogenicity with hypoglycemia,,2012-02,WITHDRAWN,INTERVENTIONAL,['PHASE3']
12641,NCT04946188,Validation of predictive model for determining blood glucose levels,,,2020-07-21,COMPLETED,INTERVENTIONAL,['NA']
12642,NCT04858386,Excessive Fetal Growth,Adverse Pregnancy Outcomes,,2017-11-01,TERMINATED,OBSERVATIONAL,['NA']
12643,NCT04456192,C-reactive protein concentration (CRP) [mg/l],"Resting SBP [mmHg], Resting DBP [mmHg], Exercise SBP [mmHg], Exercise DBP [mmHg]",,2013-01-01,COMPLETED,INTERVENTIONAL,['NA']
12644,NCT05819749,Acceptability of intervention,Diabetes medication adherence,,2023-05-01,RECRUITING,INTERVENTIONAL,['NA']
12645,NCT03845465,Glycemic Control (HbA1c),Diabetes-Related Quality of Life,,2019-12-17,COMPLETED,INTERVENTIONAL,['NA']
12646,NCT03316690,Change in postprandial glycemic control as assessed by mean blood glucose concentration during a 4 hour mixed-meal tolerance test,Training rate of perceived exertion,,2017-10-20,COMPLETED,INTERVENTIONAL,['NA']
12647,NCT03547427,Relative glucagon counterregulation (GCR) response,Rate of gastric emptying,,2018-05-20,TERMINATED,INTERVENTIONAL,['NA']
12648,NCT05658770,MAGE,quality of life (self-reported questionnaire),,2023-09-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
12649,NCT01536808,Telomere shortening,Cardiovascular events,,2009-04,COMPLETED,INTERVENTIONAL,['NA']
12650,NCT03285386,Time constant for muscle deoxygenation kinetics (assessed by near-infrared spectroscopy),Time constant for heart rate kinetics,,2018-01-01,COMPLETED,INTERVENTIONAL,['NA']
12651,NCT02024971,Number of Participants With Adverse Drug Reactions,Change From Baseline in Fasting Insulin,,2010-07,COMPLETED,OBSERVATIONAL,['NA']
12652,NCT00719251,Quality of life with the EQ-5D.,"Sociodemographic data like gender and age, were recorded. Additionally clinical history, deformities, alcohol dependence or smoking history, previous and present pharmacologic treatment and corticosteroids were included.",,2004-03,COMPLETED,INTERVENTIONAL,['NA']
12653,NCT01033500,Achieve and consistently maintain insulin independence in simultaneous islet-kidney transplant recipients for one year.,,,2010-07,WITHDRAWN,INTERVENTIONAL,['NA']
12654,NCT02254291,Number of Treatment Emergent Adverse Events (TEAEs),Change in Glycosylated Haemoglobin A1c (HbA1c),,2014-10-02,COMPLETED,INTERVENTIONAL,['PHASE3']
12655,NCT04148482,Hunger perception before and after test meals consumption using visual analogue scales,Appetite satiety hormones levels by immunoassay kits,,2021-06-17,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
12656,NCT05262595,"AUC (NNC0471-0119,0-30min,basal-corrected)/AUC (NNC0471-0119,0-t,basal-corrected)","GIRmax,basal-corrected: Maximum observed basal-corrected GIR",,2022-03-03,COMPLETED,INTERVENTIONAL,['PHASE1']
12657,NCT06243172,"Cortisol oscillations (amplitude, peak, mesor, phase, period length (TAU))","Glucagon-like peptide-1 (GLP-1) oscillations (amplitude, peak, mesor, phase, period length (TAU))",Cardiovascular autonomic neuropathy,2024-02-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
12658,NCT00940251,antidiabetic activity,"Improvement in metabolic, insulin level, HbA1c,kidney and lipid profile",,2008-09,COMPLETED,INTERVENTIONAL,['PHASE2']
12659,NCT02545140,Chronic disease risk factor - Body mass index (BMI),Chronic disease risk factor - total cholesterol,Risk tool refinement,2015-10,COMPLETED,OBSERVATIONAL,['NA']
12660,NCT02215200,Change in Area Under the Stimulated C-peptide Curve From Baseline to 12 Months.,,,2014-12,COMPLETED,INTERVENTIONAL,['PHASE2']
12661,NCT01681550,Death,Macrovasular complications,,2012-10,UNKNOWN,INTERVENTIONAL,['NA']
12662,NCT02682056,Glucose Level,Pain Level Assessed by Pain Visual Analog Scale (VAS),,2017-12-21,COMPLETED,INTERVENTIONAL,['NA']
12663,NCT00235469,"To investigate the efficacy of 200, 400, and 600 mg/day of lacosamide compared with placebo in reducing pain in subjects with painful distal diabetic neuropathy.","To investigate the effect of lacosamide on subjects' perception of pain, sleep, activity, quality of life, as well as to investigate the pharmacokinetics and safety of lacosamide.",,2004-04,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
12664,NCT04590872,Number of successful manufactured products,Change in blood glucose levels,,2022-06-16,RECRUITING,INTERVENTIONAL,['PHASE1']
12665,NCT03020069,Change in Score of Diabetes Empowerment Scale Short Form (DES-SF) From Baseline to 3 Months,,,2015-11,COMPLETED,INTERVENTIONAL,['NA']
12666,NCT01944449,Fasting circulating levels of HbA1c,Body Weight,,2013-09,COMPLETED,INTERVENTIONAL,['NA']
12667,NCT01758757,Incidence of retinal breaks,Incidence of neovascular glaucoma,,2007-09,COMPLETED,INTERVENTIONAL,['NA']
12668,NCT00324363,To test the hypothesis that exenatide (before morning and evening meals) produces a greater decrease in HbA1c than placebo in patients with type 2 diabetes and inadequate glycemic control taking metformin alone or metformin and sulfonylureas.,To compare exenatide and placebo groups with respect to: *safety and tolerability; *proportion of patients achieving HbA1c<=7%; *body weight; *incidence and rate of hypoglycemic events; *glucose measurements,,2006-01,COMPLETED,INTERVENTIONAL,['PHASE3']
12669,NCT02969954,Self-efficacy for diabetes management,,,2016-11,COMPLETED,INTERVENTIONAL,['NA']
12670,NCT00991055,The change from baseline in HbA1Cand FPG,Insulin resistance (HOMA-IR index),,2008-05,UNKNOWN,INTERVENTIONAL,['PHASE4']
12671,NCT00108459,,,,2004-09,COMPLETED,INTERVENTIONAL,['PHASE3']
12672,NCT00696605,,,,2008-07,COMPLETED,OBSERVATIONAL,['NA']
12673,NCT05906199,Changes in carotid IMT,,,2021-07-28,RECRUITING,INTERVENTIONAL,['PHASE4']
12674,NCT04315688,Change in laboratory measured HbA1c (mmol/mol),"Reason(s) for discontinuing treatment with Tresiba® during the treatment period, if applicable (according to pre-specified response options)",,2020-03-30,COMPLETED,OBSERVATIONAL,['NA']
12675,NCT01436916,Change in insulin sensitivity using OGIS (oral glucose insulin sensitivity index),Change in fasting and post prandial blood glucose,,2011-09,COMPLETED,INTERVENTIONAL,['PHASE4']
12676,NCT03542929,Changes in lactate levels,Borg's Rating of Perceived Exertion Scale (RPE) or Modified Borg Scale,,2017-11-20,COMPLETED,INTERVENTIONAL,['NA']
12677,NCT02637609,Measuring patients' priorities for barriers and facilitators for diabetes self-management using Best-Worst Scaling,,Self-reported difficulty in understanding and answering the survey questions,2013-07,UNKNOWN,OBSERVATIONAL,['NA']
12678,NCT03430856,Change From Baseline in HbA1c at 24 Weeks (Part 1),CGM,Participants Achieving HbA1c < 7% Without Reported Clinically Significant or Severe Hypoglycemic Event Between End of Week 8 and Week 24,2017-12-26,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
12679,NCT05350553,Methylglyoxal Evaluation,Neuropathy Status using the Michigan Neuropathy Screening Index,,2022-05-02,UNKNOWN,OBSERVATIONAL,['NA']
12680,NCT02923960,Plasma Glucose Concentration,Serum Insulin Concentration,,2016-10,COMPLETED,INTERVENTIONAL,['NA']
12681,NCT00328965,To investigate the clinical effectiveness of lacidipine on elevated systolic blood pressure (SBP) in Korean patients aged 35 to 75 years.,To investigate the clinical effectiveness of lacidipine on elevated diastolic blood pressure and endothelial function by flow-medicated vasodilation and measurement of markers of inflammation in Korean patients aged 35 to 75 years with type 2 diabetes.,,2004-11,COMPLETED,INTERVENTIONAL,['PHASE4']
12682,NCT01879501,Vision-related quality of life,"Perceived self-efficacy, emotional well being, and vision-specific distress",,2013-01,UNKNOWN,INTERVENTIONAL,['NA']
12683,NCT00228579,Visceral adipose tissue volume,Insulin sensitivity,,2003-06,COMPLETED,OBSERVATIONAL,['NA']
12684,NCT04161976,PK: Maximum Observed Insulin Lispro Concentration (Cmax),Duration Until Catheter Failure,,2019-12-27,COMPLETED,INTERVENTIONAL,['PHASE1']
12685,NCT03426566,Abnormal Plantar Pressure Distribution,BMI,,2012-09,COMPLETED,OBSERVATIONAL,['NA']
12686,NCT05011292,Percentage of parents who report that they do not give their young children fruit juice,Percentage of parents who viewed an intervention video report that they enjoyed it or learned something from it,,2021-08-10,COMPLETED,INTERVENTIONAL,['NA']
12687,NCT06289920,Cmax,,,2024-03,RECRUITING,INTERVENTIONAL,['PHASE1']
12688,NCT00546741,To determine the effect of metformin on the exposure of dapagliflozin and the effect of dapagliflozin on the exposure of metformin in healthy subjects after a single dose of each treatment,To assess the safety and tolerability of dapagliflozin when administered alone or with metformin after a single dose of each treatment,,2007-11,COMPLETED,INTERVENTIONAL,['PHASE1']
12689,NCT04115579,Postprandial glucose,Postprandial insulin,,2019-02-20,COMPLETED,INTERVENTIONAL,['NA']
12690,NCT03003793,Insulin Sensitivity Difference Between Patients With Atopic Dermatitis and Controls,,,2015-11,COMPLETED,OBSERVATIONAL,['NA']
12691,NCT03221205,Strain,Mean value of arterial pressure,,2014-10-15,COMPLETED,INTERVENTIONAL,['NA']
12692,NCT04965935,Systolic blood pressure,Adverse Events (AEs),,2021-07-15,RECRUITING,INTERVENTIONAL,['PHASE3']
12693,NCT03693560,Change in Adiponectin level.,Percent Change in (total cholesterol / High-density lipoprotein (HDL) cholesterol) for each patient before and after 3 months combination treatment for each group .,,2018-10-08,COMPLETED,INTERVENTIONAL,['PHASE4']
12694,NCT06071559,"Blood tests for extracellular vesicles comparing two years after surgery with baseline (below referred to as ""changes in"").",,,2015-01-01,COMPLETED,INTERVENTIONAL,['NA']
12695,NCT05488210,Muscle mass (%),Sensory perception,,2022-07-01,UNKNOWN,OBSERVATIONAL,['NA']
12696,NCT01382459,,,,2011-07,UNKNOWN,OBSERVATIONAL,['NA']
12697,NCT02040441,Albuminuria,Slope of estimated GFR,,2014-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
12698,NCT05708820,HbA1c,Awareness of hypoglycemia,,2022-12-14,RECRUITING,INTERVENTIONAL,['NA']
12699,NCT02707406,Incidence of adverse events collected throughout the trial compared between the two groups,Difference in score of quality of life assessment determined by Cardiff Wound Impact Schedule (CWIS),,2016-02,COMPLETED,INTERVENTIONAL,['NA']
12700,NCT03012529,Amputation-Free Survival,First occurrence of ipsilateral amputation related to index osteomyelitis,,2018-01-22,RECRUITING,INTERVENTIONAL,['PHASE4']
12701,NCT02156843,Time to composite endpoint of >=50% SCr increase from baseline or ESRD,Time to the composite endpoint >=100% SCr increase or ESRD,Change in SCr,2014-06,TERMINATED,INTERVENTIONAL,['PHASE3']
12702,NCT01407315,Accuracy of the GlucoMenDay,Safety of the GlucoMenDay System,,2010-11,COMPLETED,INTERVENTIONAL,['PHASE1']
12703,NCT01117103,Proportion of subjects who discontinue Glucophage XR treatment prematurely (< 12 weeks) due to side effects,Change in glycosylated haemoglobin (HbA1c) levels from baseline after 12 weeks,,2008-01,COMPLETED,OBSERVATIONAL,['NA']
12704,NCT05754008,Differences between study arms in HbA1c change 6-months following enrollment,Participant-reported measures: Diabetes stigma,,2023-03-31,RECRUITING,INTERVENTIONAL,['NA']
12705,NCT06260722,Change from Baseline in Hemoglobin A1c (HbA1c) (%),Change from Baseline in Systolic Blood Pressure (SBP),,2024-02-21,RECRUITING,INTERVENTIONAL,['PHASE3']
12706,NCT05273840,the proportions of participants regressing back to normal glucose level,body weight,changes in triglyceride level (blood lipids),2021-06-11,RECRUITING,INTERVENTIONAL,['NA']
12707,NCT00655200,Safety profile of Insulin Detemir among Filipino patients,,,2008-02,COMPLETED,OBSERVATIONAL,['NA']
12708,NCT01136902,Vessel caliber,Blood glucose level,,2009-08,COMPLETED,OBSERVATIONAL,['NA']
12709,NCT02605148,Change in glucose metabolism,Incidence of Treatment-Emergent Adverse Events,,2015-12,UNKNOWN,INTERVENTIONAL,['NA']
12710,NCT04725890,Device- or Procedure-related SAE Rate,Changes in blood pressure,Procedure time,2021-02-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
12711,NCT03410537,Ankle-brachial index,Fasting serum insulin,,2017-01,UNKNOWN,INTERVENTIONAL,['NA']
12712,NCT03576300,Tear cytokines levels,Clinical correlations of the tear cytokines,,2018-02-01,COMPLETED,OBSERVATIONAL,['NA']
12713,NCT03909451,Adverse events (AEs),Assessment of PD parameter: urinary glucose excretion (UGE),,2019-04-28,COMPLETED,INTERVENTIONAL,['PHASE1']
12714,NCT05494450,evaluate the safety and performance of Exufiber Ag+ in medium to high exuding chronic wounds,,,2022-01-01,TERMINATED,INTERVENTIONAL,['NA']
12715,NCT00384085,Percentage of Patients Achieving Glycosylated Hemoglobin A1c (HbA1c) < 7.0% at Week 60 (Lantus/Apidra-3 Versus Novolog Mix 70/30 - ITT Population With All Sites) (Sensitivity Analysis),Adjusted Hypoglycemic Event Rates (Event/Patient-year),,2006-05,COMPLETED,INTERVENTIONAL,['PHASE4']
12716,NCT04529590,Rate of cardiovascular death,Rate of all-cause death,,2020-10-01,COMPLETED,OBSERVATIONAL,['NA']
12717,NCT01885234,glycated hemoglobin,HOMA,First ventilatory threshold,2011-12,COMPLETED,INTERVENTIONAL,['NA']
12718,NCT06061237,Functional reach test,Muscle mass,,2022-09-19,COMPLETED,INTERVENTIONAL,['NA']
12719,NCT04992325,"The measurements of corneal features in patients with type 2 diabetes mellitus, using anterior segment-optical coherence tomography",,,2020-07-01,COMPLETED,OBSERVATIONAL,['NA']
12720,NCT02428998,All adverse events occurring up to 24 weeks time after taking the Investigational product,Baseline by 24 weeks after the change in quality of life measures ingestion of Investigational product,variation of biological age,2014-09,COMPLETED,INTERVENTIONAL,['NA']
12721,NCT01238380,Identification of patients with monogenic diabetes,To develop a health economic model of the care pathway leading to testing of monogenic diabetes.,,2010-12,COMPLETED,OBSERVATIONAL,['NA']
12722,NCT04945109,Changes in glycemic control,questionnaire 4,,2021-10-19,COMPLETED,INTERVENTIONAL,['NA']
12723,NCT01809184,Number of adverse events (AEs),Area under the glucose infusion rate (GIR)-time curve,,2013-03-04,COMPLETED,INTERVENTIONAL,['PHASE1']
12724,NCT05395806,Change in fatigue level,Change in cardiovascular risk level,,2021-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
12725,NCT01875783,Rates of Retina Care Referral for Patients With Diabetic Macular Edema,Rates of Retinal Treatment Over 1 Year for Patients With DME,,2014-03-17,COMPLETED,INTERVENTIONAL,['NA']
12726,NCT01028404,Number and severity of adverse events for trial part 2,Area under the glucose infusion rate-time curve after a single dose,,2009-11,COMPLETED,INTERVENTIONAL,['PHASE1']
12727,NCT00544206,mean glucose level,"fasting capillary blood glucose level;percentage change from baseline in the dose and amount of antihyperglycemic medication(s), including insulin",,2007-10,COMPLETED,INTERVENTIONAL,['PHASE2']
12728,NCT03592667,Ambulatory arterial stiffness index,Glomerular filtration rate,,2019-02-14,UNKNOWN,INTERVENTIONAL,['PHASE4']
12729,NCT01274663,Single dose pharmacokinetics of PF-05175157,Exploratory pharmacodynamic biomarkers,,2010-11,COMPLETED,INTERVENTIONAL,['PHASE1']
12730,NCT05117424,Coronary lesion severity,Cardiovascular events,Lipoprotein function assessment,2018-11-01,RECRUITING,OBSERVATIONAL,['NA']
12731,NCT02199769,Resulted Diabetes Screening Test,Diabetes Diagnosis,,2014-07-01,COMPLETED,INTERVENTIONAL,['NA']
12732,NCT01399892,incidence of hypoglycemia after fiber supplementation,,,2008-09,COMPLETED,INTERVENTIONAL,['NA']
12733,NCT02356835,Percent change in total wound size,Wound pain,,2015-02,COMPLETED,INTERVENTIONAL,['NA']
12734,NCT02000817,Number of Participants With Abnormal Vital Sign Results,Number of Participants With Anti-drug Antibody Binding,,2014-03-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12735,NCT00734669,Number of hypoglycemic events,"Secretion of hormones increasing blood glucose, effect of exercise on hypoglycemic events, postprandial glucose excursions, heart rate and forearm blood flow at hypoglycemia",,2008-07,COMPLETED,OBSERVATIONAL,['NA']
12736,NCT00341614,Total kcal and fat kcal at 3 months,Bone-mineral density at 3 months,,2006-06,COMPLETED,INTERVENTIONAL,['PHASE1']
12737,NCT03760640,Percentage of Time With Sensor Glucose Values Between 70 and 180 Milligrams Per Deciliter (mg/dL) (24-Hour),Total Daily Insulin Dose,,2019-02-18,COMPLETED,INTERVENTIONAL,['PHASE2']
12738,NCT00336310,Change of postprandial plasma glucose (PPG) at 12 weeks,change of liver and renal function test,,2006-07,UNKNOWN,INTERVENTIONAL,['PHASE4']
12739,NCT01935765,Compare the prevalence of sleep apnea syndrome by polysomnography between type 1 diabetic patients and healthy volunteers,Precise clinical symptoms in DT1 patients with Sleep apnea syndrome,,2013-09,COMPLETED,INTERVENTIONAL,['NA']
12740,NCT02624804,Treatment related adverse events,Number of patients unable to complete therapy,,2017-06-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
12741,NCT02816710,Intraoperative Bleeding,Need for Reoperation,,2016-07,COMPLETED,INTERVENTIONAL,['PHASE4']
12742,NCT00380822,,,,na,COMPLETED,INTERVENTIONAL,['PHASE3']
12743,NCT05760677,The recovery of menstrual cycle,The changes in body weight,,2022-10-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE1']
12744,NCT02139878,Blood Pressure,Glucose,,2014-05,COMPLETED,INTERVENTIONAL,['NA']
12745,NCT00662714,HbA1c,,,2001-09,COMPLETED,INTERVENTIONAL,['PHASE3']
12746,NCT00391209,Demonstrate that a simple approach for adding AIR® Inhaled Insulin to oral antihyperglycemic medication can achieve glycemic control similar to a more aggressive approach.,"Patient reported outcome from ""Expectations About Insulin Therapy Questionnaire""",,2006-10,COMPLETED,INTERVENTIONAL,['PHASE3']
12747,NCT03420781,Percentage of Participants Meeting the Vomiting Responder Criterion During Each of the Last 6 Weeks of the First 12-weeks of the Treatment Period,Number of Participants With Anti-relamorelin Antibody Testing Results,,2018-01-24,TERMINATED,INTERVENTIONAL,['PHASE3']
12748,NCT02189005,Safety of Dietary Supplement PreCrea 600 mg twice-daily,Efficacy of Dietary Supplement PreCrea 600 mg twice-daily in lowering Fasting Plasma Glucose (FPG),Safety of Dietary Supplement PreCrea 600 mg twice-daily with Liver Function,2013-11,COMPLETED,INTERVENTIONAL,['PHASE3']
12749,NCT00273572,Parameters of the metabolic syndrome,Attainment of weight reduction and physical activity targets,,2004-12,COMPLETED,INTERVENTIONAL,['NA']
12750,NCT01242215,Change from baseline in HbA1c,"Safety as reflected by adverse events, routine safety laboratories, vital signs, physical examinations and 12-lead electrocardiograms (ECGs)",,2010-09-17,COMPLETED,INTERVENTIONAL,['PHASE3']
12751,NCT02650830,bile acid profile,,,2015-09-12,COMPLETED,OBSERVATIONAL,['NA']
12752,NCT05571865,Primary Outcome Measure-II,Secondary Outcome Measure-I,,2023-07,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
12753,NCT00313937,Difference of change of blood glucose between patients on Insulin glargine and NPH insulin.,,,2001-11,COMPLETED,INTERVENTIONAL,['PHASE4']
12754,NCT05494775,Visual acuity,Central subfield thickness,,2019-02-01,RECRUITING,INTERVENTIONAL,['NA']
12755,NCT03021746,Change in A1C Blood Glucose level,,,2016-03,COMPLETED,INTERVENTIONAL,['NA']
12756,NCT02444364,Change in Bone Turnover,,,2015-05,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1']
12757,NCT01207284,Peak pressure at lateral forefoot,Activities-Specific Balance Confidence Scale (ABC),,2010-08,COMPLETED,INTERVENTIONAL,['PHASE1']
12758,NCT01538511,Area under the plasma insulin concentration curve from 0 to 24 hours,Frequency of adverse events,,2006-06-05,COMPLETED,INTERVENTIONAL,['PHASE1']
12759,NCT00472875,Glucose threshold for development of symptoms and cognitive impairment due to hypoglycaemia,Improvement in counter regulatory hormone response to hypoglycaemia,,2007-05,UNKNOWN,INTERVENTIONAL,['PHASE4']
12760,NCT01308164,Time spent in the normal range,Number of recommendations for changes in setting per patient and per iPRO wear,,2011-03,COMPLETED,INTERVENTIONAL,['NA']
12761,NCT00877526,"Percentage of diabetic patients having dyslipidemia and hypertension, cardiovascular complications, peripheral vascular disease, diabetic nephropathy and diabetic eye complications, respectively","Minimum duration of diabetes associated with 10% incidence of diabetic complications (CVD, Nephropathy and retinopathy)",,2009-05,COMPLETED,OBSERVATIONAL,['NA']
12762,NCT04957589,Muscle Protein Breakdown (MPB) (3MH),Skeletal Muscle & Creatine Pool Assessment (D3-C),,2020-01-01,COMPLETED,INTERVENTIONAL,['NA']
12763,NCT02384109,Uptake of evidence-based diabetes prevention (lifestyle change or metformin),Change in systolic blood pressure,,2015-06,COMPLETED,INTERVENTIONAL,['NA']
12764,NCT00865397,Change in HbA1c,Change in waist and hip circumference,,2009-02,COMPLETED,OBSERVATIONAL,['NA']
12765,NCT01022411,fasting glucose,HbA1c,,2009-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
12766,NCT00973960,The primary efficacy endpoint is an assessment of glycemic control at week 24 or last assessment measured via HbA1c.,The safety endpoint will be the incidence and severity of anticipated and unanticipated adverse events (device and non-device related).,,2009-09,COMPLETED,OBSERVATIONAL,['NA']
12767,NCT04419948,Incremental Area Under the Serum Concentration Versus Time Curve (AUC) of Triglycerides,Incremental Area Under the Plasma Concentration Versus Time Curve (AUC) of Protein Carbonyls,,2019-05-16,UNKNOWN,INTERVENTIONAL,['NA']
12768,NCT01474473,Kinetics of Evolution of wound size within 60 days,Pain experienced during time,,2011-08,COMPLETED,INTERVENTIONAL,['NA']
12769,NCT05937737,Total Reactive Antioxidant Potential (TRAP),,,2020-04-20,COMPLETED,INTERVENTIONAL,['NA']
12770,NCT01121315,"Composite end-point consisting of Cardiovascular Disease, elective coronary revascularisation and mortality",Number of consultations in primary care. Number of hospitalisations,,2010-05,COMPLETED,OBSERVATIONAL,['NA']
12771,NCT00400036,Insulin signaling in skeletal muscle at 4 weeks,glucose tolerance at 4 weeks,,2004-02,COMPLETED,INTERVENTIONAL,['PHASE2']
12772,NCT00283777,"Insulin Senstivity, glycated hemoglobin","weight, body composition",,1998-08,COMPLETED,INTERVENTIONAL,['PHASE4']
12773,NCT02699541,"Participants' diabetes self-Management activities: diet habits, physical activity and medications Management",Diabetes Self-Management Self-Efficacy.,,2016-04,COMPLETED,INTERVENTIONAL,['NA']
12774,NCT01571310,Postprandial Glucose Response,Postprandial Free Fatty Acids Response,,2012-07,COMPLETED,INTERVENTIONAL,['NA']
12775,NCT03644134,Change in HbA1c,,,2013-09-26,COMPLETED,INTERVENTIONAL,['NA']
12776,NCT05754281,Mean absolute relative difference (MARD),,,2023-02-03,RECRUITING,OBSERVATIONAL,['NA']
12777,NCT00135109,"To investigate the efficacy of 200, 400, and 600mg/day of lacosamide compared with placebo in reducing pain in subjects with painful distal diabetic neuropathy.","To investigate the effect of lacosamide on subjects' perception of pain, sleep, activity, and quality of life, as well as to investigate the pharmacokinetics and safety of lacosamide.",,2004-10,COMPLETED,INTERVENTIONAL,['PHASE3']
12778,NCT02694172,Fecal microbiota profile,Plasma HDL cholesterol,,2007-09,COMPLETED,INTERVENTIONAL,['NA']
12779,NCT04440449,Frailty Scale Using Fried's Phenotype Method Based on Five Frailty Characteristics,SPPB Chair Stands,,2019-07-15,COMPLETED,INTERVENTIONAL,['NA']
12780,NCT04794478,Dexcom Continuous Glucose Monitoring System Performance,System Related Adverse Device Effects,,2021-02-19,COMPLETED,INTERVENTIONAL,['NA']
12781,NCT02167620,"Improvement in HbA1C derived from Oral glucose tolerance test (Matsuda, index of insulin sensitivity; area under glucose curve; insulin secretion sensitivity index-2 (ISSI-2))",Improvements in hippocampal volume,,2014-06,COMPLETED,INTERVENTIONAL,['PHASE4']
12782,NCT04271228,HbA1c,Total daily consumed carbohydrates,"Time required to review insulin pump and sensor data, make and send recommendations or length of visit",2020-02-15,COMPLETED,INTERVENTIONAL,['NA']
12783,NCT03941652,Basic version of the eMOM GDM application has developed,Usability of professional eMOM GDM application,Nutrition dataset,2019-05-27,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
12784,NCT01050465,seeking information using MedlinePlus,,,2009-05,COMPLETED,INTERVENTIONAL,['NA']
12785,NCT03214107,Percentage of time of capillary glucose levels spent between 4-10 mmol/L,Mean glucose levels,,2017-08-03,COMPLETED,INTERVENTIONAL,['NA']
12786,NCT04902235,Change in oxytocin concentration,Alexithymia assessment,,2021-07-06,COMPLETED,INTERVENTIONAL,['PHASE4']
12787,NCT04049500,Usability will be assessed using a 5-point Likert scale,,,2021-09,WITHDRAWN,OBSERVATIONAL,['NA']
12788,NCT01022112,Change in Hemoglobin A1c (A1C) From Baseline (NGSP Value),Safety and Tolerability,,2009-11,COMPLETED,INTERVENTIONAL,['PHASE2']
12789,NCT01242059,Energy Intake,Subjective Appetite,,2009-01,COMPLETED,INTERVENTIONAL,['NA']
12790,NCT01991197,The Change in the Psoriasis Area and Severity Index (PASI) From Baseline to 16 Weeks in Psoriasis Patients With Type 2 Diabetes Treated With Sitagliptin Compared to Patients Treated With Gliclazide.,The Effects of Treatment With Sitagliptin and Treatment With Gliclazide on the Change in Serum Leptin From Baseline to 16 Weeks.,The Effect of Treatment With Sitagliptin and With Gliclazide From Baseline to 16 Weeks on the Change in Dipeptidyl Peptidase-4 Levels in the Skin (in a Sub-group of Participants Willing to Undergo Skin Biopsies).,2014-04,COMPLETED,INTERVENTIONAL,['PHASE2']
12791,NCT04562714,Time in Range (TIR),Mean number of glucose checks,Exploratory analysis 4: Frequency of glucose testing,2020-09-08,COMPLETED,INTERVENTIONAL,['NA']
12792,NCT00302055,Weight Loss,Rate of Community Program Participation,,2006-03,COMPLETED,INTERVENTIONAL,['NA']
12793,NCT03918525,Type 2 diabetes,Dyslipidemia,,2017-02-20,COMPLETED,OBSERVATIONAL,['NA']
12794,NCT01951768,Clinical Cure,Pathogen Eradication,,2013-09,COMPLETED,INTERVENTIONAL,['PHASE4']
12795,NCT00954109,Blood Flow in Response to Oral Glucose Tolerance Tests,,,2009-08,COMPLETED,INTERVENTIONAL,['NA']
12796,NCT04433598,Glycemic control,Health literacy (HL),,2019-06-09,COMPLETED,INTERVENTIONAL,['NA']
12797,NCT00190320,reduction of neonatal traumatism risk,reduction of maternal morbidity and caesarean,,2005-02,COMPLETED,INTERVENTIONAL,['PHASE4']
12798,NCT02794506,Change of glycosylated hemoglobin (HbA1c),Change of serum N- epsilon (carboxymethyl) lysine level,,2014-06,COMPLETED,INTERVENTIONAL,['PHASE4']
12799,NCT05639088,Attendance at clinic visits,Change in Quality of Life,Transition Status,2023-08-24,RECRUITING,INTERVENTIONAL,['NA']
12800,NCT02838693,Changes in insulin sensitivity in Asian populations with normal glucose tolerance and prediabetes over 3 years. Data will be presented at the end of 5.5years.,To discover and/or validate biomarkers that predict which subjects will progress from NGT to prediabetes and/or from prediabetes to diabetes. Data will be presented at the end of 5.5years.,,2016-03,UNKNOWN,OBSERVATIONAL,['NA']
12801,NCT06143423,Severity of serious adverse events (SAEs),Anti-Drug Antibody (ADA),,2023-05-24,RECRUITING,INTERVENTIONAL,['PHASE1']
12802,NCT00119054,Blood Pressure and Hemaglobin A1c,Knowledge Compliance Self-efficacy Quality of life Satisfaction with care,,2005-09,COMPLETED,INTERVENTIONAL,['NA']
12803,NCT02439177,User Performance of blood glucose monitoring system indicated by patient,,,2015-05,TERMINATED,INTERVENTIONAL,['NA']
12804,NCT02559180,Mean Absolute Change on Central Foveal Thickness,Mean Change on Visual Acuity Score,Number of Participants That Gained or Lost Letters of Visual Acuity.,2015-10,COMPLETED,INTERVENTIONAL,['PHASE4']
12805,NCT06117098,Change and ceiling and floor effect in outcomes,Antropometric measures,,2023-05-02,RECRUITING,INTERVENTIONAL,['NA']
12806,NCT06079450,Hypoglycemic Confidence Scale,hospitalization rate,,2022-06-10,COMPLETED,OBSERVATIONAL,['NA']
12807,NCT04149951,Glycated Hemoglobin (HbA1c),Fullness,Dose response analysis,2020-06-03,COMPLETED,INTERVENTIONAL,['NA']
12808,NCT02090673,The proportion of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) in patients who are treated with Exenatide for type 2 diabetes mellitus,Change from baseline to endpoint in subjective measures include improvement of main indication,,2009-02,COMPLETED,OBSERVATIONAL,['NA']
12809,NCT01726075,"Changes in the Implicit Time assessed by mfERG (IT-mfERG) at month 6, 12, 18 and 24",DR severity assessed by ETDRS scale CFP - 30º/35º-7 fields at month 24,"ophthalmological examination: Refractive Error, Slit Lamp Exam, Ophthalmoscopy (Vitreous, Retina, Macula, Choroid, Optic Nerve), Intra-Ocular Pressure (IOP) Measurement at month 24",2013-02,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
12810,NCT00944697,Short Form McGill Pain Score.,,,2009-07,COMPLETED,INTERVENTIONAL,['PHASE2']
12811,NCT04976283,Change in radiologic liver parameters,Change in Lipid profile,Change in Systolic and Diastolic blood pressure,2021-09-15,UNKNOWN,INTERVENTIONAL,['PHASE4']
12812,NCT01369602,Amount of drug excreted (Ae),,,2011-07,COMPLETED,INTERVENTIONAL,['PHASE1']
12813,NCT01965639,Mortality,Change in patient-reported outcomes,,2013-04,COMPLETED,INTERVENTIONAL,['NA']
12814,NCT04224428,Percent change in urinary albumin creatinine ratio (UACR),Urinary monocyte chemoattractant protein-1 (MCP-1),,2020-01-01,COMPLETED,INTERVENTIONAL,['PHASE3']
12815,NCT03771053,Change from Baseline coronary plaque volume percentage(PAV) at 12 months,Inflammation marker,,2018-01-01,UNKNOWN,INTERVENTIONAL,['NA']
12816,NCT01876485,Change in Diabetes Specific Quality of Life,,,2015-07-13,COMPLETED,INTERVENTIONAL,['NA']
12817,NCT05299918,Cardiac Autonomic Neuropathy assesed by Othostatic BP change,,,2014-07-15,COMPLETED,OBSERVATIONAL,['NA']
12818,NCT00004984,Rate of Type 1 Diabetes Per Year,,,1994-02,COMPLETED,INTERVENTIONAL,['PHASE3']
12819,NCT04711980,Changes in total score on the Michigan Diabetic Neuropathy Score (MDNS) of Scale,Changes in total score on the Clinical Symptoms Score of Scale,,2021-06,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
12820,NCT01870557,Bone Mineral Density (t-score),Lifestyle and Medical history,urine creatinine albumin ratio,2013-03,COMPLETED,OBSERVATIONAL,['NA']
12821,NCT00774800,Area Under the Insulin Concentration-time Curve for the First Hour (AUC0-60),Area Under the Blood Glucose Time-Concentration Curve Blood Glucose (AUC[BG]),,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2']
12822,NCT00123604,Flow Mediated Dilation,,,2004-06,COMPLETED,INTERVENTIONAL,['PHASE4']
12823,NCT05932251,glucose-disposition-index,Neonatal body length,,2023-06-19,RECRUITING,OBSERVATIONAL,['NA']
12824,NCT02189694,Percentage of time of glucose levels spent below 4.0 mmol/L.,Hypoglycemic risk assessed by the number of patients experiencing at least one hypoglycemic event (> 15 minutes) below 3.1 mmol/L,,2014-06,COMPLETED,INTERVENTIONAL,['PHASE2']
12825,NCT00425490,C-peptide total and incremental area under the curve.,,,2007-01,COMPLETED,INTERVENTIONAL,['PHASE3']
12826,NCT02091362,Change From Baseline to 6 Weeks in Mean 24-Hour Systolic Blood Pressure,Population Pharmacokinetics: Apparent Volume of Distribution of LY2409021,,2014-03,COMPLETED,INTERVENTIONAL,['PHASE2']
12827,NCT04629586,Gather longitudinal data from individuals living with type 1 diabetes.,,,2018-12-13,RECRUITING,OBSERVATIONAL,['NA']
12828,NCT06196996,insulin,Dose of exogenous insulin,,2021-09-14,RECRUITING,INTERVENTIONAL,['NA']
12829,NCT01792518,HbA1c Change From Baseline After 24 Weeks Double-blind Randomized Treatment,The Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) After 24 Weeks of Treatment,,2013-02,COMPLETED,INTERVENTIONAL,['PHASE3']
12830,NCT05797935,To assess and estimate the difference in pancreatic fat content in the patients of Type 2 Diabetes Mellitus at baseline and after taking dapagliflozin for 24 weeks,To estimate the correlation between two advanced MR techniques commonly used for quantification of pancreatic fat(PDFF and MR Spectroscopy),,2021-08-01,COMPLETED,INTERVENTIONAL,['PHASE4']
12831,NCT04361799,The proportion of time spent in the target glucose range from 5.6 to 10.0 mmol/L based on sensor glucose levels during the time from hospital admission for elective surgery until discharge.,Total daily insulin requirements,Proportion when closed-loop was active,2020-09-25,COMPLETED,INTERVENTIONAL,['NA']
12832,NCT00674271,Plaque burden in carotid arteries,Genotyping genes for pattern recognition molecules,,2008-05,UNKNOWN,OBSERVATIONAL,['NA']
12833,NCT01770483,"Sustained Viral Response,",Normalization of Alanine Transferase Test,,2011-07,COMPLETED,INTERVENTIONAL,['PHASE4']
12834,NCT00208598,,,,2003-01,COMPLETED,OBSERVATIONAL,['NA']
12835,NCT00184639,Fasting plasma glucose,Hypoglycaemia,,2004-08-16,COMPLETED,INTERVENTIONAL,['PHASE3']
12836,NCT02612402,increase in daily physical activity,glycemic control,,2014-07,UNKNOWN,INTERVENTIONAL,['NA']
12837,NCT00290043,"Outcome measures: Post-prandial glucose and insulin concentrations. Outcome: In T1DM, insulin glulisine provides a better mimic of the physiological postprandial glucose disposal than RHI.",,,2001-12,COMPLETED,INTERVENTIONAL,['PHASE1']
12838,NCT03321032,Target lesion failure at 2-years follow-up,Non-target lesion revascularization,,2017-12-19,UNKNOWN,INTERVENTIONAL,['PHASE4']
12839,NCT00994357,Prevalence of LGA in children of diabetic women.,The occurrence of low grade inflammation and endothelial dysfunction in pregnant women with diabetes.,,2009-02,COMPLETED,INTERVENTIONAL,['NA']
12840,NCT02443922,Beta Cell Function as measured by the arginine stimulation test in response to two therapies for type 2 diabetes mellitus,,,2015-06,UNKNOWN,INTERVENTIONAL,['NA']
12841,NCT05214235,Visual Analogue Scale (VAS) at 1 Year after Surgery,Number of Participants with Spinal Fusion at 1 Year after Surgery,,2022-02-07,RECRUITING,OBSERVATIONAL,['NA']
12842,NCT00464880,To investigate whether renin-inhibition using aliskiren 300 mg daily could be a treatment alternative to the angiotensin II receptor antagonist irbesartan 300 mg with an equivalent potential for reno-protection,"To investigate whether aliskiren, irbesartan or the combination reduce biomarkers of inflammation and cardiovascular risk",,2005-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12843,NCT04042207,"Percentage of CGM time in glucose range 70-180 mg/dl, during 24 hours periods for the third and fourth week for each treatment period","Percentage of CGM time in glucose range 70-180 mg/dl, during 24 hours periods",,2019-09-03,COMPLETED,INTERVENTIONAL,['NA']
12844,NCT04617795,Hypoglycemia,Change in Hemoglobin A1c (HbA1c),,2020-11-23,COMPLETED,INTERVENTIONAL,['NA']
12845,NCT00818779,Plasminogen Activator Inhibitor 1,Serum Level of Nitric Oxide,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE4']
12846,NCT05742685,Diabetes medication adherence,Glycemic control,,2023-08-23,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
12847,NCT05174806,Proportion of patients with adverse events,Proportion of subjects undergoing lower-extremity amputation,,2022-06-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
12848,NCT06118008,Temperature,Pharmacodynamics (PD): HbA1c,,2023-05-30,RECRUITING,INTERVENTIONAL,['PHASE2']
12849,NCT00826007,Hypoglycemia Incidence,,,2009-01,COMPLETED,OBSERVATIONAL,['NA']
12850,NCT00024921,,,,na,COMPLETED,OBSERVATIONAL,['NA']
12851,NCT00395031,"Reduced Glucose, Cholesterol and Lipid Levels",Improvement in quality of life & Positive and Negative Symptoms,,2003-09,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
12852,NCT03228602,Latency of the gustatory evoked potential,,,2016-07-11,TERMINATED,INTERVENTIONAL,['NA']
12853,NCT02005432,fluorescein angiography leakage area,,,2012-02,UNKNOWN,INTERVENTIONAL,['PHASE4']
12854,NCT00138580,Change from baseline in HbA1c at 52 weeks,Change from baseline in HOMA IR at 52 weeks,,2004-11,COMPLETED,INTERVENTIONAL,['PHASE3']
12855,NCT01783717,Insulin sensitivity.,waistline/hipline ratio,,2012-12,UNKNOWN,INTERVENTIONAL,['NA']
12856,NCT02419898,Recruitment feasibility,Acceptability of the data collection procedures to participants.,,2013-04,UNKNOWN,OBSERVATIONAL,['NA']
12857,NCT02278926,Glucose control,Glucose control,,2012-01,COMPLETED,OBSERVATIONAL,['NA']
12858,NCT03531294,Incidence of Adverse Events for diabetic retinopathy subjects who receive intravitreal Aflibercept,Cytokine Levels,,2018-05-23,COMPLETED,INTERVENTIONAL,['PHASE2']
12859,NCT02606357,Change from baseline in HbA1c,- Time to reach control,,2015-11-22,COMPLETED,INTERVENTIONAL,['PHASE4']
12860,NCT02009410,Recovery rate of 13CO2 (carbon dioxide with stable isotope of carbon),Change in clinical global impression of disease symptoms,routine safety laboratory,2013-11,WITHDRAWN,INTERVENTIONAL,['PHASE4']
12861,NCT01490372,Metabolic syndrome,Inflammatory markers,,2011-08,COMPLETED,OBSERVATIONAL,['NA']
12862,NCT00178633,Change in Weight,Change in Left Ventricular Mass,,2004-05,COMPLETED,OBSERVATIONAL,['NA']
12863,NCT05047471,risk factors of albuminuria: Increase in Low density lipoprotein cholesterol (LDL-C),OR of the incidence of the adverse events,MD the Percentage change from baseline of other laboratory test parameters of interest,2021-12-25,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
12864,NCT01284465,HbA1c,Risk factors for co-morbidity and daily self-management behaviors,,2011-01,COMPLETED,INTERVENTIONAL,['NA']
12865,NCT04711382,Time in Range,Coefficient of variation,,2018-01-29,COMPLETED,OBSERVATIONAL,['NA']
12866,NCT02328326,"Change in Cardiac Event 5-year Risk Score, as Measured by UKPDS Risk Engine",Change in Diabetes Self-Management Behavior - Check Feet,Change in Supporter Distress About Patient Participant's Diabetes,2016-11-16,COMPLETED,INTERVENTIONAL,['NA']
12867,NCT03227094,Predictive value (positive and negative),Cost evaluation of methods,,2017-11-13,COMPLETED,INTERVENTIONAL,['NA']
12868,NCT04587297,number of meals,,,2020-12-08,COMPLETED,OBSERVATIONAL,['NA']
12869,NCT04344210,Variation in HbA1c levels,Comparison of sleep pattern changes between groups,,2020-04-17,COMPLETED,INTERVENTIONAL,['NA']
12870,NCT06115304,Appetite regulating hormones measured by specific immunoassays,,Peptidomicsmeasured in blood and cerebrospinalfluid using mass spectrometry,2023-10-05,RECRUITING,INTERVENTIONAL,['NA']
12871,NCT02973100,Change From Baseline in Hemoglobin A1c (HbA1c),"Pharmacokinetics: Area Under the Concentration-Time Curve at Steady State From Time Zero to 168 Hours (AUC[0-168], ss) of Dulaglutide",,2016-12,COMPLETED,INTERVENTIONAL,['PHASE2']
12872,NCT05500352,"Change in the global work during hypoglycemia in individuals with type 1 diabetes, type 2 diabetes, and without diabetes, respectively.","Change in mechanical dyssynchrony during hyperglycemia in individuals with type 1 diabetes, type 2 diabetes and without diabetes, respectively.",,2022-07-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
12873,NCT04141111,Glycemic control,Therapeutic changes,,2015-03-22,COMPLETED,INTERVENTIONAL,['NA']
12874,NCT01073566,Mean Daily Blood Glucose,Self-reported Hypoglycemic Episodes,,2010-01,COMPLETED,INTERVENTIONAL,['PHASE2']
12875,NCT03754465,Proportions of subjects who achieved complete wound closure,Durability of complete wound closure,,2019-05-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
12876,NCT03576430,Change in Hemoglobin A1C,Diabetes treatment satisfaction questionnaire (DTSQ),resting pulse rate,2018-05-31,UNKNOWN,INTERVENTIONAL,['NA']
12877,NCT05279326,"Change in glycaemic management, to be assessed by blood analysis","Change in the participants' satisfaction, to be assessed by questionnaire",,2023-12,RECRUITING,INTERVENTIONAL,['NA']
12878,NCT01801150,Glycemic control,To determine additional effects of CPAP on insulin resistance in patients with type 2 diabetes and SAHS.,Influence of body distribution and activity on metabolic control,2011-10,COMPLETED,INTERVENTIONAL,['PHASE4']
12879,NCT03913962,Maximal lipid oxidation rate during submaximal incremental exercise,Blood sample calprotectin,,2019-05-02,RECRUITING,INTERVENTIONAL,['NA']
12880,NCT02548494,Blood glucose,Urinalysis for levels of ketones & glucosuria,Hypoglycemic events,2015-11,TERMINATED,INTERVENTIONAL,['NA']
12881,NCT02335931,Disease progression in the previously affected foot,Altered levels of bone resorption markers,Diabetes regulation,2014-09,COMPLETED,OBSERVATIONAL,['NA']
12882,NCT02036138,To assess the efficacy of intensive medical therapy alone versus medical therapy combines with LRYGB or LSG in controlling type 2 DM in non-morbid obese patients (BMI 30-34.9),To assess the safety of intensive medical therapy alone versus medical therapy combines with LRYGB or LSG in diabetic non-morbid obese patients (BMI 30-34.9).,,2015-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
12883,NCT00808860,HbA1C (glycosylated hemoglobin),"body weight (BMI, hip-weight ratio)",,2008-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12884,NCT02981121,Cumulative incidence of Diabetes Mellitus after randomization,Change on HOMA2%B,,2016-11,UNKNOWN,INTERVENTIONAL,['PHASE4']
12885,NCT05848180,The Falls Efficacy Scale International (FES-I),,,2023-05-05,COMPLETED,INTERVENTIONAL,['NA']
12886,NCT02482675,Vascular Endothelial Function,Arachidonic Acid,,2015-06,COMPLETED,INTERVENTIONAL,['NA']
12887,NCT05081765,correlation between glucose level and C through.olaparib in the blood of the patients with ovarian cancer,,,2021-09-20,UNKNOWN,OBSERVATIONAL,['NA']
12888,NCT01707147,Percentage of Patients With Incidence of Adverse Events Who Had Taken at Least One Dose of Trajenta,Change From Baseline After 24 Weeks in Fasting Plasma Glucose (FPG),,2012-11-16,COMPLETED,OBSERVATIONAL,['NA']
12889,NCT02718326,Percentage of Participants With a ≥ 2-step Change at Week 52 in Diabetic Retinopathy Severity Scale (DRSS) From Baseline,Area Under the Curve (AUC) for Change From Baseline in Best Corrected Visual Acuity (BCVA) at Week 52,,2016-03-29,COMPLETED,INTERVENTIONAL,['PHASE3']
12890,NCT01282060,Link between HbA1c level and the overall mortality rate at 5 years.,Role of other cardiovascular risk factors,,2009-03,UNKNOWN,OBSERVATIONAL,['NA']
12891,NCT00846898,HbA1c,"Plasma glucose concentration Plasma lipid profiles (HDL, LDL, Triglycerides and total cholesterol) systolic and diastolic blood pressures. Body Mass Index. Waist circumference. Total calorie intake.",,2008-03,COMPLETED,INTERVENTIONAL,['PHASE2']
12892,NCT00845858,The Primary Efficacy Endpoint is the Change From Baseline to Week 4 of the Treatment Period in the Modified Gastroparesis Cardinal Symptom Index-Daily Diary (mGCSI-DD) Total Score.,,The Pre-specified Endpoint is the Change From Baseline to Week 4 of the Treatment Period in the Modified Gastroparesis Cardinal Symptom Index-Daily Diary (mGCSI-DD) Total Score by Gender.,2009-04,COMPLETED,INTERVENTIONAL,['PHASE2']
12893,NCT06049550,renal failure,,,2023-10-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
12894,NCT01064414,Change in HbA1c From Baseline to Week 26,Change in Fasting Plasma Glucose (FPG) From Baseline to Week 26,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE3']
12895,NCT02688933,Percentage of Time of Mean Glucose Concentration Within the Target Range of 70-180 mg/dL as Obtained From CGM,Coefficient of Variation (CV%) in Mean CGM Glucose,Change From Baseline in Daily Insulin Dose at Week 16,2016-05-05,COMPLETED,INTERVENTIONAL,['PHASE4']
12896,NCT06094231,Changes in HbA1c,Time in range,,2023-09-25,RECRUITING,INTERVENTIONAL,['NA']
12897,NCT05545722,diabetes self-management skill scale,Diabetes strengthening scale,,2021-04-01,COMPLETED,INTERVENTIONAL,['NA']
12898,NCT06228911,low blood glucose,,,2020-01-15,COMPLETED,INTERVENTIONAL,['NA']
12899,NCT02135328,"Acceptability and effectiveness of radio stories, a health communication intervention that addresses family eating behaviors and physical activity among immigrant Somali, Latino, and Hmong families",,,2012-09,COMPLETED,INTERVENTIONAL,['NA']
12900,NCT04094649,"Change in blood glucose Area Under the Curve (AUC, mg/dL ● hours) from baseline to 3 hours after an Oral Glucose Tolerance Test (OGTT) with Ultrasonic Vagus Nervous Stimulation (uVNS).hyperglycemia",Change in whole blood lipospolysaccharide-induced TNF-Alpha (pg/mL) production from base line to 4 hours post stimulation.,,2019-08-01,SUSPENDED,INTERVENTIONAL,['NA']
12901,NCT02595580,difference between Glucopred and the reference method,,,2016-01,TERMINATED,INTERVENTIONAL,['NA']
12902,NCT02852759,Change of Glucose Tolerance measured by OGTT,Change of glucose infusion rate by hyperinsulinemic euglycemic clamp,,2016-07,COMPLETED,INTERVENTIONAL,['NA']
12903,NCT05317130,Incidence of sports injuries and illnesses 4 years following study start,Health literacy 12 months following study start.,,2022-09-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
12904,NCT01173094,Occlusion of the below-knee artery or bypass,Restenosis measured by Duplex Ultrasound or CTA,,2010-08,UNKNOWN,INTERVENTIONAL,['PHASE4']
12905,NCT03182322,The activation of an immune response (antibody or CD4+ T cell) against insulin.,,Transcriptome of peripheral blood cell populations,2018-05-25,COMPLETED,INTERVENTIONAL,['PHASE2']
12906,NCT04936633,Changes in glycemic control measured by HbA1c,Changes in anxiety assessed by questionnaires,,2021-06-30,COMPLETED,INTERVENTIONAL,['NA']
12907,NCT06245369,Change in Healthy Eating Index,Change in Body weight,,2024-04-01,RECRUITING,INTERVENTIONAL,['NA']
12908,NCT02113332,Change in HbA1c from baseline to week 24.,Change in blood lipid levels from baseline to week 24,,2013-01,COMPLETED,INTERVENTIONAL,['PHASE2']
12909,NCT02921906,Insulin levels,Paracetamol levels,,2016-06,COMPLETED,INTERVENTIONAL,['NA']
12910,NCT04256304,The Diabetes Management Self-Efficacy Scale for Patients with Type 2 Diabetes Mellitus,,Health Literacy Scale for Turkish Diabetic Patients,2018-12-28,COMPLETED,INTERVENTIONAL,['NA']
12911,NCT02710370,Change from baseline (time of operation) in metabolite profile.,Generation of intestinal organoids from Roux limb biopsies.,,2016-02,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
12912,NCT00004407,,,,1998-02,TERMINATED,INTERVENTIONAL,['NA']
12913,NCT05695417,Safety and Tolerability,Diabetic Retinopathy Severity Scale (DRSS) changes,,2023-01-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
12914,NCT00729456,Ulcer recurrence.,Amputation. Quality of life. Mood. Well-being. Compliance.,,2003-04,COMPLETED,INTERVENTIONAL,['NA']
12915,NCT01812291,Depressive Mood - Hamilton Rating Scale for Depression (HAMD),Diabetes Self-Care Behavior - The Diabetes Self-Management Questionnaire (DSMQ),Major Depressive Disorder,2012-02,COMPLETED,INTERVENTIONAL,['NA']
12916,NCT06021691,delayed language development in children,,,2023-02-01,RECRUITING,OBSERVATIONAL,['NA']
12917,NCT04463160,"The impact of the ""Say No to Diabetes"" intervention on the incidence of type 2 diabetes",HbA1c assay for the diagnosis of glucose intolerance and prediabetes compared to HGPO,,2019-07-18,RECRUITING,INTERVENTIONAL,['NA']
12918,NCT01507285,Area under the Curve,Adverse events,,1999-08,COMPLETED,INTERVENTIONAL,['PHASE1']
12919,NCT05372471,HbA1c change,Hypoglycemia level 1 and 2,,2020-10-01,COMPLETED,INTERVENTIONAL,['NA']
12920,NCT04436666,pain relief,,,2020-07-15,COMPLETED,INTERVENTIONAL,['NA']
12921,NCT05000840,HcA1c at 6 months for participants with HbA1c < 7.5%,Changes in HbA1c over time- Patient-Reported Variable #4,,2021-10-20,RECRUITING,OBSERVATIONAL,['NA']
12922,NCT02093234,Change From Baseline in the Unmet Behaviors/Goals That Were Not Achieved at Year 1,Change in Medication Adherence,,2014-04,COMPLETED,INTERVENTIONAL,['NA']
12923,NCT02079415,Congenital malformations,Length of hospital stay,Admission to neonatal intensive care unit,2011-01,COMPLETED,OBSERVATIONAL,['NA']
12924,NCT02575001,Significant between group differences in metabolic control,Significant differences in psychological scores between groups,,2015-07,COMPLETED,OBSERVATIONAL,['NA']
12925,NCT06292871,Satisfaction levels,Proportion of participants with optimal blood glucose control,Proportion of participants delivering healthy live birth,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
12926,NCT01296308,Neuropathy-related Quality of Life (QOL-DN),Waist-to-Hip Ratio (WHR) and Body Mass Index (BMI),,2011-03,COMPLETED,OBSERVATIONAL,['NA']
12927,NCT02908152,Hepatic steatosis,AST,,2017-02-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
12928,NCT03351530,"The change of hs-CRP between diabetes mellitus patients, periodontal disease patients and healthy people after receiving periodontal therapy and using mouthwash",,,2017-05-18,UNKNOWN,OBSERVATIONAL,['NA']
12929,NCT01022645,Glucose tolerance at 12 months postpartum.,,,2009-11,COMPLETED,OBSERVATIONAL,['NA']
12930,NCT01316783,Metabolic disorders,,,2011-05-06,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
12931,NCT00567905,Homeostasis model assessment for insulin resistance (HOMA-IR) was used as the major outcome measurement.,"HbA1C, blood sugar, creatinine, aminotransferases aspartate, aminotransferases alanine, uric acid, and plasma lipoproteins (triglyceride, cholesterol, cholesterol-HDL (HDL) and cholesterol-LDL (LDL)) cholesterol; BMI,WC---.",,2007-09,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
12932,NCT00646438,The purpose of this study is to see how safe and effective strict glucose control is when extended beyond 3 days and hospital discharge for one year.,Another purpose is to see how well patients can comply with the daily management of intensive glucose control for one-year as well as the study follow-up schedule.,,2009-03,UNKNOWN,INTERVENTIONAL,['NA']
12933,NCT02009813,Insulin sensitivity,Hypoxia and inflammatory markers,,2013-03,COMPLETED,INTERVENTIONAL,['NA']
12934,NCT04055090,Long-term Safety for Engensis Versus Placebo,Subgroup Analysis of the Change in the Average 24-hour Pain Score From Baseline (Day 0 of Study VMDN-003) to Day 365 for Engensis Versus Placebo for Subjects Without Gabapentin and/or Pregabalin Use at Baseline,,2019-02-04,COMPLETED,INTERVENTIONAL,['PHASE3']
12935,NCT05040412,Intubation time,Intubation difficulty,,2020-01-25,COMPLETED,INTERVENTIONAL,['NA']
12936,NCT00631007,Change From Baseline in Hemoglobin A1c (HBA1c) at Week 24 With Last Observation Carried Forward,Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24 With Last Observation Carried Forward.,,2008-02,COMPLETED,INTERVENTIONAL,['PHASE2']
12937,NCT05609175,Area under the receiver operator characteristics curve (AUROC) in detecting nocturnal level 1 hypoglycemia based on motion data obtained by radar signals,"AUROC in classifying motion patterns according to thermal camera measurements based on motion data, physiological data, and Artificial Intelligence",,2023-02-14,RECRUITING,OBSERVATIONAL,['NA']
12938,NCT02387164,Type 1 Diabetes Status Overall,Change From Baseline in GADA Month 24,,2015-03-09,TERMINATED,INTERVENTIONAL,['PHASE2']
12939,NCT00460941,Percentage of patients withdrawn because of gastrointestinal effects,"Mean changes in 24h blood glucose Area Under the Curve (AUC), Fasting Plasma Glucose (FPG), fructosamine, Hemoglobin A1c (HbA1c), body weight, Adverse Events (AEs), laboratory parameters.",,2007-04,COMPLETED,INTERVENTIONAL,['PHASE2']
12940,NCT01323114,Hemoglobin A1C,,,2011-04,UNKNOWN,INTERVENTIONAL,['NA']
12941,NCT00763022,Change in Baseline in Glycosylated hemoglobin.,Urinary albumin/creatinine ratio.,,2003-11,COMPLETED,INTERVENTIONAL,['PHASE3']
12942,NCT00691249,Post-Prandial metabolism,Satiety,,2008-05,COMPLETED,INTERVENTIONAL,['NA']
12943,NCT04174508,Average annual number of new cases of diabetes according to World Health Organization (WHO) criteria,,,2020-03-24,RECRUITING,OBSERVATIONAL,['NA']
12944,NCT04871438,HbA1c,Glucose Monitoring Satisfaction Score (GMSS),Exercise duration,2021-11-10,RECRUITING,INTERVENTIONAL,['NA']
12945,NCT00789282,A higher proportion of patients with type 2 diabetes enrolled in the 'enhanced care' arm compared with the patients enrolled 'usual' care' arm will achieve an absolute reduction in their HbaA1c of 1.0% or greater during the study period.,A higher proportion of patients with type 2 diabetes in the 'enhanced care' arm compared with the patients enrolled in 'usual care' arm will achieve a 10% or greater reduction in HbA1c values during the study period.,,2008-02,TERMINATED,INTERVENTIONAL,['NA']
12946,NCT03457818,Change in Cortical Porosity (Ct.Po) (%) by High Resolution Peripheral Quantitative Computed Tomography (HR-pQCT) Imaging From Baseline to 6 and 12 Months.,"Change in Dual-energy X-ray Absorptiometry (DXA) (gm/cm2) at Lumbar Spine, Femoral Neck, Total Hip and Radius From Baseline to 6 and 12 Months.",Change in Skin Autofluorescence (SAF) (Unitless) From Baseline to 6 and 12 Months.,2018-11-07,TERMINATED,INTERVENTIONAL,['PHASE2']
12947,NCT00948493,,,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA']
12948,NCT05352230,Compliance,Time in Range (TIR) of 70 to 180 mg/dL,,2023-04-15,RECRUITING,INTERVENTIONAL,['PHASE1']
12949,NCT03847753,Risk of Cancers,,,2000-01-01,COMPLETED,OBSERVATIONAL,['NA']
12950,NCT03278704,Change in fibre-type specific satellite cell content,Change in glycaemic control,,2017-12-06,TERMINATED,INTERVENTIONAL,['NA']
12951,NCT03739099,Percent of time spent in the 70-180 mg/dl glucose range assessed on daily CGM data,Score of the Artificial Pancreas Acceptance Questionnaire,,2018-11-05,UNKNOWN,INTERVENTIONAL,['NA']
12952,NCT04921306,insulin-stimulated fluorodeoxyglucose (18F-FDG) uptake in quadriceps muscle.,insulin-stimulated 18F-FDG uptake in BAT,skeletal muscle GLUT4 translocation,2021-09-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
12953,NCT05598203,Change in diabetic retinopathy and baseline diabetic kidney disease at 12 months,Change in baseline blood pressure at 12 months,Change in baseline adherence to recommendations at 12 months,2022-09-06,RECRUITING,INTERVENTIONAL,['NA']
12954,NCT00221234,Physical Activity Behaviour,"HbA1c, CRP, lipid concentrations, fasting blood glucose, insulin, health related quality of life, psychosocial predictors of physical activity.",,2005-09,COMPLETED,INTERVENTIONAL,['PHASE2']
12955,NCT00895986,Improved frequency of recommended self-care behaviors (Self-Care Inventory-R),"Major mediating/moderating variables include Problem Areas in Diabetes, Brief Symptom Inventory, Coping Styles, and Confidence in Diabetes",,2008-12,COMPLETED,INTERVENTIONAL,['NA']
12956,NCT01539811,Wound Healing,,,2012-02,TERMINATED,INTERVENTIONAL,['NA']
12957,NCT02731859,Weight reduction,Reduction of daily caloric intake,,2014-01,UNKNOWN,OBSERVATIONAL,['NA']
12958,NCT04129528,Stimulated C-peptide AUC by mixed meal tolerance test (MMTT).,Stimulated C-peptide AUC by MMTT.,,2019-11-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
12959,NCT00799448,HbA1c,Adverse events,,2003-09-16,TERMINATED,INTERVENTIONAL,['PHASE4']
12960,NCT00782847,deterioration of kidney function in diabetic nephropathy,HbA1c,,2004-07,COMPLETED,INTERVENTIONAL,['PHASE3']
12961,NCT03659799,Decrease in plasma glucose levels during exercise,Total amount of carbohydrates needed to treat hypoglycemic events,,2019-04-12,COMPLETED,INTERVENTIONAL,['PHASE4']
12962,NCT03243383,Incidence of initial hospital readmission,Change in A1c level,,2017-09-07,COMPLETED,INTERVENTIONAL,['NA']
12963,NCT03372018,Body Weight,Beck Depression Inventory,,2018-08-07,COMPLETED,INTERVENTIONAL,['NA']
12964,NCT01717937,Measurement of to be determined physical characteristics of retinovascular structures seen on phase variance optical coherence tomography (PV-OCT) and fluorescein angiography(FA).,Changes over time in the to be determined measured physical characteristics of retinovascular structures seen on PV-OCT and FA.,,2013-02,TERMINATED,OBSERVATIONAL,['NA']
12965,NCT05083559,Percent of Time With Sensed Glucose Between 70-180 mg/dl,Mean Amount of Insulin Delivered Per Day (in Units),,2021-12-08,COMPLETED,INTERVENTIONAL,['NA']
12966,NCT03650127,Coronary heart disease/Type 2 diabetes/Venous thromboembolism diagnosis,,,2018-02-02,UNKNOWN,OBSERVATIONAL,['NA']
12967,NCT00976729,"Safety and tolerability of NOX-E36 by means of adverse events, vital signs, laboratory parameters, 12-lead ECG and immunogenicity assessment",Pharmacodynamic profile,,2009-05,COMPLETED,INTERVENTIONAL,['PHASE1']
12968,NCT03492580,Number of Participants with Below Knee Lower Extremity Amputation Events,,,2018-02-22,COMPLETED,OBSERVATIONAL,['NA']
12969,NCT04988581,Phase 2,The secondary outcomes,,2021-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
12970,NCT04053959,Proportion of time in target range,Total insulin dose,,2019-09-27,COMPLETED,INTERVENTIONAL,['PHASE4']
12971,NCT02036372,Median glucose,Glucose,,2014-01,COMPLETED,INTERVENTIONAL,['NA']
12972,NCT06261944,Dichotomised diabetes risk status,Sensitivity and specificity,,2024-03-13,RECRUITING,INTERVENTIONAL,['NA']
12973,NCT02424500,Reduction in HbA1C,Comparison Percent Reduction HbA1c w/out Hypoglycemia,,2015-01,COMPLETED,INTERVENTIONAL,['NA']
12974,NCT03259789,Change From Baseline in HbA1c at Week 24 for High Glycemic Group,Change in HbA1c Over Time Among Subjects Who Have Baseline HbA1c of > 10.5% and ≤ 12.0%,,2017-11-28,COMPLETED,INTERVENTIONAL,['PHASE3']
12975,NCT03717688,GLP-1,Glucagon,GIP,2018-05-17,COMPLETED,INTERVENTIONAL,['PHASE4']
12976,NCT02034266,Change in corneal nerve fibre length,R-R interval,Serum fatty acid profile,2014-01,COMPLETED,INTERVENTIONAL,['PHASE2']
12977,NCT01382498,high sensitivity CRP and Endothelin-1 serum levels,,,2009-11,UNKNOWN,INTERVENTIONAL,['PHASE4']
12978,NCT00446992,LDL,,,2006-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
12979,NCT04579341,glycemic control,,,2018-01-21,UNKNOWN,INTERVENTIONAL,['NA']
12980,NCT04598893,"Incidence of adverse events (AEs), serious adverse events (SAEs) and adverse events of special interest (AESIs), including infections and malignancies",HbA1c,,2020-10-26,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
12981,NCT00005489,,,,1998-01,COMPLETED,OBSERVATIONAL,['NA']
12982,NCT02004327,Maximum Concentration of DW1029M in plasma,Apparent volume of distribution of DW1029M in Plasma,,2013-12,COMPLETED,INTERVENTIONAL,['PHASE1']
12983,NCT02597400,The primary pharmacokinetics parameters of Cmax To assess the potential pharmacokinetic interaction between HMS5552 and metformin in subjects with T2DM,"Pharmacodynamic responses (serum levels) of glucose, insulin and C-peptide will be evaluated.",,2015-10,COMPLETED,INTERVENTIONAL,['PHASE1']
12984,NCT05717127,Pancreatic beta-cell function,Fasting glucose,Satiety,2021-09-01,RECRUITING,INTERVENTIONAL,['NA']
12985,NCT05483803,Sub-study 2: Changes on caregiver's positive mood,Behavioral outcome: Usability,,2022-10-01,COMPLETED,INTERVENTIONAL,['NA']
12986,NCT02505451,Regional longitudinal strain,,,2015-07,COMPLETED,INTERVENTIONAL,['NA']
12987,NCT03281486,Relief from drymouth using VAS scoring,,,2018-01-28,COMPLETED,INTERVENTIONAL,['NA']
12988,NCT05605821,Evaluation of the association between diabetic disease control and the degree of hepatic fibrosis,Percentage of patients at risk of severe fibrosis in a population of type 2 diabetics followed in a tertiary diabetes service.,,2024-01-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
12989,NCT05280184,Change in daily insulin Bolus score,,,2023-01-01,RECRUITING,INTERVENTIONAL,['NA']
12990,NCT00869362,Hemoglobin A1c,Average Intervention Effect Over 12 Months After Hospital Discharge,,2009-03,COMPLETED,INTERVENTIONAL,['NA']
12991,NCT00831194,"Self reported stress, weight loss, and salivary alpha amylase.","Positive correlation between levels of salivary alpha amylase (sAA) and weight loss, BMI and levels of sAA, levels of sAA and maladaptive coping.",,2009-03,COMPLETED,INTERVENTIONAL,['NA']
12992,NCT04707508,Serum glycosylated hemoglobin A1c,Blood pressure,,2017-12-01,COMPLETED,INTERVENTIONAL,['PHASE4']
12993,NCT01937845,Weight loss of 7% body weight,,,2006-08,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
12994,NCT01554358,cardimetablic risk,approximately 40 SNPs,,2009-08,UNKNOWN,INTERVENTIONAL,['NA']
12995,NCT03377127,Hemoglobin A1c at 12 Months,No-show,,2018-02-19,COMPLETED,INTERVENTIONAL,['NA']
12996,NCT03660345,BCVA,,,2018-09-04,COMPLETED,INTERVENTIONAL,['PHASE3']
12997,NCT02284009,Mean Change From Baseline in Time Normalized Stimulated (From Mixed Meal Tolerance Test [MMTT]) 2-hour Plasma C-peptide Area Under the Curve (AUC) at Week 52,Population Estimates of PK Parameters: First-order Absorption Rate Constant [Ka],,2014-10-10,COMPLETED,INTERVENTIONAL,['PHASE2']
12998,NCT01582230,"Change from baseline in glycosylated hemoglobin (HbA1c) at study endpoint, assessed in Chinese study population",Percentage of patients meeting responder criteria after 24 weeks treatment on Chinese population,,2012-04,COMPLETED,INTERVENTIONAL,['PHASE3']
12999,NCT05650229,Change in 30 Second Site-to-Stand Test.,Change from baseline in Glycated haemoglobin (HbA1c) for subjects with diabetes,,2022-12-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
13000,NCT00143949,"To obtain two percutaneous renal biopsies from each patient, five years apart.",To evaluate retinal lesions in RASS cohort to determine relationship to the histologic changes of DN and the effects of RAS inhibition and/or systemic blood pressure.,,1997-03,COMPLETED,INTERVENTIONAL,['PHASE2']
13001,NCT03135327,Tear film thickness,Conjunctival blood flow velocity by functional slit-lamp (FSLB),,2007-01-01,RECRUITING,INTERVENTIONAL,['NA']
13002,NCT01921491,Proportion of ulcers achieving 100% epithelialization in the dHACM group vs other commercially available product and control.,Cost effectiveness of each treatment modality.,,2013-08,COMPLETED,INTERVENTIONAL,['NA']
13003,NCT01616784,The change in HbA1c after 2 years in those participants whose baseline HbA1c was at or above 7.5% (58mmol/mol).,Quality of adjusted life years,,2011-11,COMPLETED,INTERVENTIONAL,['PHASE3']
13004,NCT03485586,the visual quality of the eye after surgery,,,2018-04-03,UNKNOWN,OBSERVATIONAL,['NA']
13005,NCT02366377,The number of volunteers with adverse events as a measure of safety and tolerability,Proportion of Participants Achieving Glycemic Response Defined as HbA1c <7%,,2015-02,UNKNOWN,INTERVENTIONAL,['PHASE1']
13006,NCT02021695,DNA methylation and gene expression in blood monocytes and lymphocytes,,,2013-09,COMPLETED,OBSERVATIONAL,['NA']
13007,NCT02039258,Plasma concentration of metformin following the single dose of CANA/MET XR FDC after fed and fasted conditions,Percentage of participants with adverse events as a measure of safety and tolerability,,2014-01,COMPLETED,INTERVENTIONAL,['PHASE1']
13008,NCT05680155,Change from baseline in HbA1c,Pharmacokinetics: plasma trough level of XW003,,2022-12-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
13009,NCT02845219,Area under the levonorgestrel plasma concentration-time curve during a dosing interval (0-24 hours) at steady state,Maximum observed levonorgestrel plasma concentration during a dosing interval 0-24 hours) at steady state,,2016-07,COMPLETED,INTERVENTIONAL,['PHASE1']
13010,NCT00243984,"BMI on days 1, 84, 168, and 175.","C reactive protein on days 1, 84, and 168.",,2005-03,SUSPENDED,INTERVENTIONAL,['PHASE3']
13011,NCT00232375,The primary endpoint was insulin-dependency (IDDM: integrated C-peptide values [sigma C-peptide] <4 ng/ml).,,,1996-01,COMPLETED,INTERVENTIONAL,['NA']
13012,NCT03326206,Change in hemoglobin A1c,Change in counseling / behavioral services,Change in self-report coping,2013-11-01,COMPLETED,OBSERVATIONAL,['NA']
13013,NCT00813657,,,,2000-01,COMPLETED,INTERVENTIONAL,['PHASE4']
13014,NCT01588093,Difference in MD (microdialysate) IGF-1 over time (expressed as AUC or peak microdialysate IGF-I) between saline and IGF-I injection.,,,2011-04,COMPLETED,INTERVENTIONAL,['NA']
13015,NCT02008682,Change From Baseline in Glycosylated Haemoglobin (HbA1c),Number of Confirmed Hypoglycaemic Episodes,,2013-12,COMPLETED,INTERVENTIONAL,['PHASE4']
13016,NCT03049839,Reduction of body weight average at year-end structured intervention compared with the baseline.,Reduced of waist circumference average at year-end structured intervention program compared with baseline.,,2017-08-01,UNKNOWN,INTERVENTIONAL,['NA']
13017,NCT00157638,"Symptom improvement (constipation, pain)",Health services utilization,,2004-02,COMPLETED,INTERVENTIONAL,['PHASE4']
13018,NCT02025907,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26,Change From Baseline in Systolic Blood Pressure (SBP) at Week 26,,2014-02,COMPLETED,INTERVENTIONAL,['PHASE4']
13019,NCT05902468,Glycemic control,Serum asprosin,,2023-06-28,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
13020,NCT04767750,"Measurement of the gene expression levels of LncRNA H19 & IGF-1R mRNA, normalized to the housekeeping gene GAPDH expression level, in HCC and T2DM in comparison with healthy controls using Real-Time Quantitative PCR (by the 2^-ΔΔCT method).",,,2020-01-01,COMPLETED,OBSERVATIONAL,['NA']
13021,NCT05022316,diabetes control,completion of medication adherence documentation,,2022-09-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
13022,NCT02443415,Acute change in brain morphology,Change in neurocognitive assessment,,2015-02,COMPLETED,OBSERVATIONAL,['NA']
13023,NCT03448029,Outcome Quality after Revascularization: Re-Intervention,,,2018-01-01,RECRUITING,OBSERVATIONAL,['NA']
13024,NCT00460304,The mean ICR from Vist 3a-e and 4a-e will be compared. Percentage reduction of ICR will be calculated. From these the mean ICR will be calculated.,The mean post-meal glucose from the four hour period after beginning a meal will be averaged for each bolus wave form. Then the three wave form mean glucose results will be compared.,,2007-09,COMPLETED,INTERVENTIONAL,['NA']
13025,NCT03839667,change in HbA1C level (%),cardiovascular risk,,2019-01-07,COMPLETED,INTERVENTIONAL,['NA']
13026,NCT02929953,prematurity prevalence among T1D patients,Medications exposure in premature who developed T1DM compared with prematures who did not develop diabetes,,2014-01,COMPLETED,OBSERVATIONAL,['NA']
13027,NCT02540642,To compare the change in HbA1c levels (%) with vitamin B12 supplementation in poorly controlled type 2 diabetic patients,To compare the change in serum homocysteine level (micromol/L) with vitamin B12 supplementation in poorly controlled type 2 diabetic patients,,2010-10,COMPLETED,INTERVENTIONAL,['NA']
13028,NCT00952198,Characterize the pharmacokinetics (PK) of the study drug and metabolites in terms of plasma concentrations.,Characterize the pharmacodynamic (PD) activity of the study drug on biomarkers.,,2009-08,COMPLETED,INTERVENTIONAL,['PHASE1']
13029,NCT04520971,time in range,number with composite neonatal outcome,,2021-01-15,COMPLETED,INTERVENTIONAL,['NA']
13030,NCT05477134,The difference in arginine availability,The difference in insulin sensitivity and the effect of intravenous arginine bolus on insulin sensitivity,,2023-02-06,RECRUITING,INTERVENTIONAL,['NA']
13031,NCT00552409,Change in Urine Albumin Excretion,,,2007-12,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
13032,NCT00471549,Relative reduction in circulating osteoprotegerin levels,Relative reduction in adhesion molecules (ICAM and VCAM),,1991-06,COMPLETED,INTERVENTIONAL,['PHASE4']
13033,NCT00854347,Prevalence of diabetes and prediabetes.,Evaluate insulin needs capacity to predict subsequent diagnosis of diabetes and prediabetes,,2005-11,COMPLETED,OBSERVATIONAL,['NA']
13034,NCT04993326,Type 2 Glycemic Control - HbA1c of 7% or less,"Understand of COVID-19 Risks, Protection and Prevention",,2022-01-10,WITHDRAWN,INTERVENTIONAL,['NA']
13035,NCT02146157,Change from Baseline in fasting blood glucose,Change from Baseline in waist-to-hip ratio,,2013-02,COMPLETED,INTERVENTIONAL,['NA']
13036,NCT05339841,Long-term CV clinical outcome at 7 years follow-up,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) - history of vaccination (questionnaire),Ancillary study of UO-14 (IRCCS San Raffaele Roma): mean corpuscular hemoglobin (MCH) in the CV-PREVITAL Exercise sub-study cohort,2022-06-10,RECRUITING,INTERVENTIONAL,['NA']
13037,NCT00399620,,,,2008-03,UNKNOWN,INTERVENTIONAL,['NA']
13038,NCT05179798,Percentage of postprandial capillary glucose values above target (>7.0 mmol/L),Patient satisfaction evaluated through a questionnaire,,2022-01-12,RECRUITING,INTERVENTIONAL,['NA']
13039,NCT03596450,Number of Participants With Glycosylated Haemoglobin (HbA1c) Less Than 7.0 Percentage (%) (53 Millimoles Per Mole [mmol/Mol]) at Year 1 (Yes/No),Percentage of Medication Possession Ratio (MPR) for Study Drug Medication Adherence For The Two Years of The Study,,2018-07-13,COMPLETED,INTERVENTIONAL,['PHASE4']
13040,NCT00708981,Delay in development in end-stage renal failure in subjects with Advanced Diabetic Nephropathy (CKD stages 3 and 4),,,2007-05,COMPLETED,INTERVENTIONAL,['NA']
13041,NCT00099918,Change from baseline in HbA1c at 24 weeks,Change from baseline in HbA1c at 24 weeks for patients with high baseline HbA1c vs. low baseline HbA1c,,2004-05,COMPLETED,INTERVENTIONAL,['PHASE3']
13042,NCT00392678,Change in HbA1c Baseline to End of Trial in TINSAL-T2D Stage 1,"Change in Insulin, C-peptide, Homeostasis Model [HOMA] Index",,2006-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
13043,NCT03177096,Evolution of Peds QL questionnaire results,Evolution of WHO-5 and felt questionnaire,,2016-09-20,COMPLETED,INTERVENTIONAL,['NA']
13044,NCT03710811,Circulating immunity cell profiles,skeletal muscle parameter,fasting blood glucose,2017-09-01,UNKNOWN,OBSERVATIONAL,['NA']
13045,NCT04687215,Vascular improvement on lower extremities with the Doppler Flowmetry,Vascular improvement on lower extremities by performing the flow mediated arterial dilation test,,2022-01-27,RECRUITING,OBSERVATIONAL,['NA']
13046,NCT04205617,Change in Hemoglobin A1c,Change in diastolic blood pressure,,2019-12-14,COMPLETED,INTERVENTIONAL,['NA']
13047,NCT00094796,Peak VO(2) after 3 months of rosiglitazone therapy compared with baseline VO(2) max.,,,2004-10-20,COMPLETED,INTERVENTIONAL,['PHASE2']
13048,NCT00278057,,,,2003-05,COMPLETED,INTERVENTIONAL,['PHASE4']
13049,NCT03654651,Fasting Plasma Glucose,Microbiota Alpha-diversity,,2018-10-01,COMPLETED,INTERVENTIONAL,['PHASE2']
13050,NCT04918004,Hba1c mmol/mol,,,2018-01-01,COMPLETED,INTERVENTIONAL,['NA']
13051,NCT00464555,Proportion of participants with insulin independence,Quality of life measures,,2006-12,COMPLETED,INTERVENTIONAL,['PHASE2']
13052,NCT01932671,Combined endpoint of cardiovascular events,All cause mortality,,2012-08,UNKNOWN,OBSERVATIONAL,['NA']
13053,NCT01109927,Glucagon stimulated C-peptide,,,1995-02,COMPLETED,INTERVENTIONAL,['PHASE4']
13054,NCT05073692,Incidence of 3-point Major Adverse Cardiovascular Events (MACE),,,2021-07-01,RECRUITING,OBSERVATIONAL,['NA']
13055,NCT01375686,"Validation of SCOUT DS algorithm, ROC performance equivalent to FPG, A1c for detection abnormal glucose tolerance.",,,2011-06,COMPLETED,OBSERVATIONAL,['NA']
13056,NCT02621736,Change of copeptin at baseline and after 28 days during routine desmopressin therapy,,,2016-01-01,COMPLETED,OBSERVATIONAL,['NA']
13057,NCT01459120,Absolute number of clients newly tested HIV-positive who enrolled into HIV/AIDS care,Absolute number of clients with a positive Tuberculosis-screening who return their sputum-bottles and who have at least one AFB-positive smear.,,2011-10,COMPLETED,INTERVENTIONAL,['NA']
13058,NCT02846831,Percentage of time of glucose levels spent between 3.9 and 10 mmol/L.,Number of patients calling for technical issues related to the closed-loop system,,2019-01-24,COMPLETED,INTERVENTIONAL,['PHASE2']
13059,NCT05355038,effect of lifestyle modification among GDM on pregnancy outcome,,,2020-11-11,COMPLETED,INTERVENTIONAL,['NA']
13060,NCT05787873,Cmax of SIPS-2209-1,Vd/F of SIPS-2209-1,,2022-08-30,COMPLETED,INTERVENTIONAL,['PHASE1']
13061,NCT04211220,Percentage of time spent in 70-180mg/dl (time in range) in the last month of each period of the study (without and then with IRTA©),Type of advice given by the IRTA system that is more often asked,,2020-01-09,COMPLETED,INTERVENTIONAL,['NA']
13062,NCT00876928,Percent of Subjects Who Develop Diabetes,Disposition Index,,2009-03,COMPLETED,INTERVENTIONAL,['NA']
13063,NCT03336411,"Body weight, percent change",Weight regain,Self-efficacy,2017-12-12,COMPLETED,INTERVENTIONAL,['NA']
13064,NCT00136916,Summary of ≥ 20 % Decliners in DLco,Insulin Antibodies,,2002-06,TERMINATED,INTERVENTIONAL,['PHASE3']
13065,NCT01014949,Coronary Flow Reserve and Index of Microvascular Resistance values,,,2008-07,COMPLETED,INTERVENTIONAL,['NA']
13066,NCT01620463,Adverse events,24-hour glucagon profile in plasma,,2002-12,COMPLETED,INTERVENTIONAL,['PHASE1']
13067,NCT00978263,Change From Baseline in Glycosylated Hemoglobin at month 6,Change From Baseline in Body Weight (month 12),,2009-02,COMPLETED,INTERVENTIONAL,['NA']
13068,NCT00360334,Percent of Patients Who Achieved HbA1c ≤ 7.4% With Minimal Weight Gain (≤ 1kg),Severe Hypoglycemic Rate Per 30 Days,,2006-06,COMPLETED,INTERVENTIONAL,['PHASE3']
13069,NCT06120322,"To identify the factors contributing to chronic inflammation within the intestine and in peripheral organs, in particular focusing on biopsies markers","Taking advantage of the measurements collected in Outcome 1, the investigators will use a machine learning-based multi-omics approach to easily recognize patient differences, stratification and characterization",,2023-11-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
13070,NCT05172622,The evaluation of the number of adverse events and the number and percentage of subjects,,,2020-11-24,UNKNOWN,INTERVENTIONAL,['PHASE1']
13071,NCT05974020,Plantar Pressure Distribution,Foot Posture,,2023-08-04,COMPLETED,INTERVENTIONAL,['NA']
13072,NCT06103799,Peri-implant bone resorption,Patient satisfaction,,2023-01-01,COMPLETED,INTERVENTIONAL,['NA']
13073,NCT05120544,Change in HbA1c,Change in hypertension knowledge,,2022-04-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
13074,NCT04838145,Insulin secretion,Presence of enterovirus,,2018-08-30,COMPLETED,INTERVENTIONAL,['PHASE2']
13075,NCT02074423,"Blood glucose incremental Area Under the Curve between 0 and 120 minutes after consumption of a standard meal, compared between MealShape and the placebo",Insulin incremental Area under the Curve between 0 and 60 minutes compared between MealShape and Placebo after consumption of a standard meal,,2013-03,COMPLETED,INTERVENTIONAL,['NA']
13076,NCT02580266,Cellular phenotype,,,2015-09,WITHDRAWN,OBSERVATIONAL,['NA']
13077,NCT03423862,Predicting the honeymoon period,Establishing the relationship between baseline inflammation and other measures,,2017-10-01,COMPLETED,OBSERVATIONAL,['NA']
13078,NCT01017965,HbA1c in %,Quality of life assessed through questionnaire,,2009-11,TERMINATED,OBSERVATIONAL,['NA']
13079,NCT01488136,Adrenaline response(pmol/L) at 2.5mmol/L of glucose,"Glucose Thresholds (calculated when counter-regulatory hormone release is greater than 2SD of hormone level at euglycaemia 4.0mmol/L blood sugar) of each of the counter-regulatory hormones (adrenaline, noradrenalin, glucagon)",Symptom scores and Cognitive function scores at 2.5mmol/L,2012-01,COMPLETED,INTERVENTIONAL,['PHASE4']
13080,NCT03918148,Urinary albumin to creatinine ratio excretion,estimated Glomerular filtration rate (eGFR),Lipid profile,2018-01-15,RECRUITING,OBSERVATIONAL,['NA']
13081,NCT03091712,Change in HbA1c,Proportion of accepted MIDS recommended insulin degludec doses,,2017-05-05,COMPLETED,INTERVENTIONAL,['NA']
13082,NCT02359461,Changes from Baseline in endothelial function of the large vessels by FMD (Flow Mediated Dilatation),Assessment of microalbuminuria levels of 24 hours,,2014-11,COMPLETED,INTERVENTIONAL,['NA']
13083,NCT01497938,The Event Area Under the Curve (AUC) Was Used to Demonstrate the Reduction of Nocturnal Hypoglycemia With the Low Glucose Suspend (LGS) Feature (LGS ON),,,2011-12,COMPLETED,INTERVENTIONAL,['PHASE3']
13084,NCT00724087,Total energy expenditure,Glycerol turnover and free fatty acid concentration,,2008-07,COMPLETED,INTERVENTIONAL,['NA']
13085,NCT00328627,Change From Baseline to Week 26 in HbA1c,Change From Baseline to Week 26 in Mean HDL Particle Size,,2006-05,COMPLETED,INTERVENTIONAL,['PHASE3']
13086,NCT04866212,academic achievement,,,2020-04-30,UNKNOWN,OBSERVATIONAL,['NA']
13087,NCT01471808,the remission rate after short intensive therapy in newly diagnosed type 2 diabetic patients,the effects of different interventions on the remission rate in newly-diagnosed type 2 diabetic patients,,2011-10,UNKNOWN,INTERVENTIONAL,['PHASE4']
13088,NCT02236364,Photographic Images of the eye,,,2014-08,TERMINATED,INTERVENTIONAL,['NA']
13089,NCT00660374,HbA1c,HbA1c,,2008-02,COMPLETED,INTERVENTIONAL,['PHASE2']
13090,NCT06025721,Treatment Engagement Measured by Sessions Attended,Cardiovascular health (AHA Life's Essential 8),,2024-01-05,RECRUITING,INTERVENTIONAL,['NA']
13091,NCT01206322,Perfusion Outcome: Right Insular Cortex Perfusion (ml/100g/Min/mmHg),,,2010-05,COMPLETED,INTERVENTIONAL,['PHASE2']
13092,NCT05785832,HbA1c,Coefficient of variation,Other device malfunctions/device issues,2023-06-01,RECRUITING,INTERVENTIONAL,['NA']
13093,NCT04497792,HbA1C level,,,2016-11,COMPLETED,INTERVENTIONAL,['PHASE4']
13094,NCT03890003,Continuous Glucose Monitor (CGM) Measured Percentage of Time <70 mg/dL,,,2019-03-28,COMPLETED,INTERVENTIONAL,['NA']
13095,NCT02736084,Intervention Acceptability,Changes in MOS SAS Scores,,2013-08,COMPLETED,INTERVENTIONAL,['NA']
13096,NCT03536377,change in Hba1C,change in blood pressure medication,,2019-02-11,UNKNOWN,INTERVENTIONAL,['NA']
13097,NCT00737152,To determine cardiovascular side effects such as coronary artery disease (CAD) and congestive heart failure (CHF) in patients treated with RAS 130 along with diet and exercise.,To determine the effect of RAS 130 on reduction of blood glucose level with or without diet and exercise,,2011-07,UNKNOWN,INTERVENTIONAL,['PHASE2']
13098,NCT05631561,The changes of Hba1c from baseline at 6 months post procedure,Quality of life assessment (EQ-5D-5L) at pre-procedure and 6 months post procedure,,2022-12-27,RECRUITING,INTERVENTIONAL,['NA']
13099,NCT03096002,independent bouts of physical activity,independent bouts of physical activity,dietary adherence,2017-06-12,UNKNOWN,OBSERVATIONAL,['NA']
13100,NCT00246623,Proportion of patients with type 2 diabetes (A1C 7.5-10% on >= 2 oral agents) in each study arm (Exubera dosage adjusted 'once weekly' or 'twice weekly') that attain an A1C of <=7% with forced dose titration of Exubera at 6 months.,"Secondary endpoints include change in A1C, fasting and 2 hr PP glucose, 24-hr mean glucose measured by continuous glucose monitoring, weight, lipids, and markers of oxidative stress. Hypoglycemia will also be assessed.",,2005-11,COMPLETED,INTERVENTIONAL,['PHASE3']
13101,NCT04560296,Change in Self-care ability of Chronic disease,HbA1c,,2020-09-15,UNKNOWN,INTERVENTIONAL,['NA']
13102,NCT02221284,Percentage of Participants Who Had One or More Adverse Reactions,Change From Baseline in Laboratory Test Values (Homeostasis Model Assessment of Beta-cell Function [HOMA-β]),,2014-06-30,COMPLETED,OBSERVATIONAL,['NA']
13103,NCT00575783,,,,2005-08,COMPLETED,OBSERVATIONAL,['NA']
13104,NCT03378895,Individualized Prevention Program participation rate,Variation of the risk score in at least one of the three behavioral domains; The risk score will be calculated from the results reported on a self-administered questionnaire,,2017-12-01,COMPLETED,INTERVENTIONAL,['NA']
13105,NCT00469586,HbA1c change from baseline,Hypoglycaemia,,2007-04-26,TERMINATED,INTERVENTIONAL,['PHASE3']
13106,NCT04575181,Change in flow mediated dilation,"Number of clinically significant hypoglycaemic episodes s (level 2) ((below 3.0 mmol/L (54 mg/dL), confirmed by BG meter)",,2020-10-21,COMPLETED,INTERVENTIONAL,['PHASE1']
13107,NCT00331370,"Primary outcome would be abnormal retinal geometry defined as the composite outcome of a) abnormal arteriolar length: diameter, b) narrowed branching angles, or c) disturbed junction exponents.",,,2006-05,UNKNOWN,INTERVENTIONAL,['NA']
13108,NCT02248857,Prescription Understanding,Medication Adherence: Pharmacy Records,Changes in Low-density Lipoprotein Cholesterol (LDL),2014-12,COMPLETED,INTERVENTIONAL,['NA']
13109,NCT01041365,Insulin Sensitivity,Vascular Function,,2009-12,COMPLETED,OBSERVATIONAL,['NA']
13110,NCT03940937,Oxygen consumption (VO2; mL/kg/min),,,2019-05,UNKNOWN,OBSERVATIONAL,['NA']
13111,NCT02459834,Plasma glucose iAUC,Mean plasma glucose and insulin responses,,2015-11,COMPLETED,INTERVENTIONAL,['NA']
13112,NCT01928550,Total retinal blood flow & visual acuity,"Macular ischemic areas and microaneurysms, as identified by FA vs. OCT",,2013-08,COMPLETED,OBSERVATIONAL,['NA']
13113,NCT01855282,Change in BMI,Change in Waist Circumference,Change in fasting blood glucose,2010-04,COMPLETED,INTERVENTIONAL,['NA']
13114,NCT03209089,clinical characteristics of T2DM patients managed by GPs,,,2017-08-07,COMPLETED,OBSERVATIONAL,['NA']
13115,NCT01901952,Hemoglobin A1c,Medications,,2012-03,COMPLETED,INTERVENTIONAL,['NA']
13116,NCT00333554,"At least a 20% reduction in the level of the major inflammatory cytokine, IL1-beta, achieved in the plasma of the treatment group",95% of families will continue to attend follow-up visits,,2006-06,COMPLETED,INTERVENTIONAL,['NA']
13117,NCT00688363,Haemoglobin A1c after one year,the number of serious hypoglycaemic episodes (hypoglycaemic episodes when the patient needs help from other people),,2003-02,COMPLETED,INTERVENTIONAL,['PHASE4']
13118,NCT04082351,HbA1c,,,2016-07-03,COMPLETED,INTERVENTIONAL,['NA']
13119,NCT05237895,Detection of diagnostic value of serum endocan levels in patient with gestational diabetes,,,2022-03-03,COMPLETED,INTERVENTIONAL,['NA']
13120,NCT03225209,Change in Glycemic control,Change in Physical activity,,2018-01-31,COMPLETED,INTERVENTIONAL,['PHASE2']
13121,NCT02032108,between groups difference in glycated haemoglobin (HbA1c),endpoint versus baseline differences in glycated hemoglobin,,2013-03,COMPLETED,INTERVENTIONAL,['NA']
13122,NCT01129297,Study the influence of phenotypic characteristics on gene expression of tissues involved in glucose metabolism,Genotype-Phenotype correlation,,2006-06-13,RECRUITING,OBSERVATIONAL,['NA']
13123,NCT02288351,Elevated Glut-1 gene and protein expression levels,Glut-1 level change in fasting glucose,,2014-11,WITHDRAWN,INTERVENTIONAL,['NA']
13124,NCT03768245,Mean Change From Baseline In Power At 12 Weeks,,,2016-07-01,COMPLETED,INTERVENTIONAL,['NA']
13125,NCT02474147,Functional brain imaging of reward circuitry,Serum concentrations of oxidative stress markers,,2015-08,COMPLETED,INTERVENTIONAL,['NA']
13126,NCT01206725,Early diastolic tissue velocity (e'),Early diastolic tissue velocity (e'),,2010-09,COMPLETED,INTERVENTIONAL,['NA']
13127,NCT02317796,Change in PPG AUC0-3h in a MMTT between Days 1 and 29.,Differences between placebo and MLR-1023 dose groups in PPG AUC0-3h Days 1 and 29.,,2014-12,COMPLETED,INTERVENTIONAL,['PHASE2']
13128,NCT02172716,Change from baseline in the expression on mDCs,"periodontal probing depth, periodontal attachment level, bleeding on probing, visible plaque and gingival bleeding.",,2014-05,COMPLETED,INTERVENTIONAL,['NA']
13129,NCT01455857,Change in HbA1c,,,2013-03,COMPLETED,INTERVENTIONAL,['PHASE3']
13130,NCT05951660,Changes from baseline to follow up in the total score of Changes in Sexual Function Questionnaire-14 (CSFQ-14),Changes from baseline to follow up in shared decision making,,2023-08-24,RECRUITING,INTERVENTIONAL,['NA']
13131,NCT04152811,Change in Hemoglobin A1c over 4.5 months,Change in Health Related Quality of Life over 4.5 months using SF-12 Survey,,2019-07-05,COMPLETED,INTERVENTIONAL,['NA']
13132,NCT04116203,Plasma Triglycerides and apoB-lipoprotein remnants in non-fasting and fasted state,"Plasma hormones, testosterone, SHBG, Estrogen",,2016-06-30,SUSPENDED,INTERVENTIONAL,['PHASE1']
13133,NCT03120299,Change in blood metabolomics profile of lipid species from baseline,Pharmacogenomics analysis,,2017-05-01,COMPLETED,INTERVENTIONAL,['PHASE4']
13134,NCT03582878,Pancreas graft survival,Kidney graft survival,,2004-01-01,COMPLETED,INTERVENTIONAL,['PHASE4']
13135,NCT02728453,change in left ventricular mass,change in body fat mass,number of participants with lower urinary tract infections or genital fungal infections,2016-04-27,TERMINATED,INTERVENTIONAL,['PHASE4']
13136,NCT04635670,Change in albuminuria based on urinary albumin-creatinine ratio (UACR),Change in autonomous neuropathy evaluated by VagusTM,Change in Gut microbiome characterization assessed by 16S RNA sequencing,2020-06-29,COMPLETED,INTERVENTIONAL,['NA']
13137,NCT02641522,Percent Change From Baseline in IL-6 Stimulated Intracellular p-STAT3 at Week 12,,Adverse Event Monitoring,2016-03-08,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
13138,NCT02949687,"glycated hemoglobin(HbA1c) level of 6.0% or less, without the use of diabetes medications",,,2016-09-20,WITHDRAWN,INTERVENTIONAL,['NA']
13139,NCT00172757,,,,2002-01,UNKNOWN,OBSERVATIONAL,['NA']
13140,NCT02843503,Mean Absolute Relative Difference (MARD),Glucose content (mg/dL) of capillary reference samples.,,2016-07,COMPLETED,INTERVENTIONAL,['NA']
13141,NCT00467168,Lipids including triglyceride and cholesterol in four subfractions of ppTRLs.,Lipids lipoproteins in the postprandial plasma,,1998-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13142,NCT03248466,hospital stay,Transcutaneous oxygen partial pressure,,2017-08-30,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
13143,NCT02179385,Clinical composite,Change in Self Efficacy Score,Change in Quality of life score,2014-06,UNKNOWN,INTERVENTIONAL,['NA']
13144,NCT03285308,Percentage of Participants Meeting the Vomiting Responder Criterion During Each of the Last 6 Weeks of the 12-week Treatment Period,Number of Participants With Anti-relamorelin Antibody Testing Results by Visit,,2017-09-29,TERMINATED,INTERVENTIONAL,['PHASE3']
13145,NCT03800680,Change in HbA1c levels at Month 12,Incremental cost-effectiveness ratios based on QALY at Month 12,,2019-10-19,COMPLETED,INTERVENTIONAL,['NA']
13146,NCT05108350,Pharmacokinetics parameters of SHR3824 and Metformin in the fasted and fed state: AUC0-inf (if applicable),The incidence and severity of adverse events/serious adverse events,,2021-11-09,UNKNOWN,INTERVENTIONAL,['PHASE1']
13147,NCT04568382,Pilot acceptability),Anxiety Symptoms,,2020-10-12,COMPLETED,INTERVENTIONAL,['NA']
13148,NCT02043054,Change in peak early diastolic strain rate measured by cardiac MRI,Composite 7 point glucose profile,,2013-12-16,COMPLETED,INTERVENTIONAL,['PHASE3']
13149,NCT04445714,To assess the safety of fixed dose combination of dapagliflozin + saxagliptin in Indian Type 2 Diabetes Mellitus (T2D) patients,To assess the efficacy of fixed dose combination of dapagliflozin + saxagliptin in Indian Type 2 Diabetes Mellitus (T2D) patients,,2021-04-07,COMPLETED,INTERVENTIONAL,['PHASE4']
13150,NCT00715780,Incidence of major hypoglycaemic episodes,Percentage of patients reaching the target of HbA1c less than 6.5%,,2008-06,COMPLETED,OBSERVATIONAL,['NA']
13151,NCT02168348,Percentage of healed lesions,Number of malnourished patients according to HAS 2003 and 2007 criteria,Number of malnourished patients at 12 and 24 weeks,2013-11-26,COMPLETED,OBSERVATIONAL,['NA']
13152,NCT04977908,Time in target glucose range,"Total, basal, and bolus insulin dose",Human Factor assessment,2021-08-31,COMPLETED,INTERVENTIONAL,['NA']
13153,NCT01879579,Percentage of Subjects Who Reach Optimal Long-acting Insulin Dose,Incidence of Hypoglycemia,Qualitative Patient Satisfaction Interview,2013-06,COMPLETED,INTERVENTIONAL,['NA']
13154,NCT02015988,Percentage change from baseline in triglycerides (TG) at week 12,Percentage changes from baseline in uric acid at week 52,Number of adverse events (AE) caused discontinuations of investigational products,2014-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
13155,NCT01334606,Glycemic Control as Measured by Percent (%) Absolute Change in Fructosamine,,,2011-03,TERMINATED,INTERVENTIONAL,['NA']
13156,NCT03653091,Change in Hemoglobin A1c (HbA1c),,,2018-09-28,COMPLETED,INTERVENTIONAL,['NA']
13157,NCT01071967,All-cause mortality,Weight control,,2002-04,UNKNOWN,INTERVENTIONAL,['NA']
13158,NCT00574665,Endothelial function and fibrinolytic balance,,,2006-10,COMPLETED,INTERVENTIONAL,['NA']
13159,NCT02858648,Change in Glycemic control as assessed by HbA1c levels,Change in Self-efficacy for diabetes as assessed by the Self-efficacy for diabetes measure,,2013-01,COMPLETED,INTERVENTIONAL,['NA']
13160,NCT01310556,Frequency of unknown glucose metabolism disorders in patients with coronary artery disease,Fasting and 120 minute glucose levels have relation with vessels' stenosis.,,2009-06,COMPLETED,OBSERVATIONAL,['NA']
13161,NCT01062763,Change of Diastolic Blood Pressure,Adverse Effects,,2010-03,COMPLETED,INTERVENTIONAL,['PHASE3']
13162,NCT03542084,Glycemic Control,A1c testing frequency,,2018-09-04,COMPLETED,INTERVENTIONAL,['NA']
13163,NCT00490165,,,,2007-03,COMPLETED,OBSERVATIONAL,['NA']
13164,NCT01889628,Glycaemic response,,,2013-06,COMPLETED,INTERVENTIONAL,['NA']
13165,NCT03860558,Spermatozoa concentration,RNA Sequencing,,2018-05-01,RECRUITING,INTERVENTIONAL,['NA']
13166,NCT02500979,Efficacy of Pramlintide by Measurement of 24-hour Tissue Mean Weighted Glucose (MWG) Obtained With Continuous Glucose Monitoring (CGM),Pharmacokinetics of Insulin as Demonstrated by the Time to the Maximum Plasma Insulin Concentration,,2015-08-17,COMPLETED,INTERVENTIONAL,['PHASE1']
13167,NCT02221466,Peripheral arterial tonometry (PAT),Nitric oxide and cytokine expression,,2014-02,COMPLETED,OBSERVATIONAL,['NA']
13168,NCT04285554,Rate of Serious Adverse Device Effects,Adverse Event rate 365 days,,2020-07-28,COMPLETED,INTERVENTIONAL,['NA']
13169,NCT01424319,The change from baseline to each post-baseline visit in log-transformed UACR (urinary albumin to creatinine ratio),The proportion of subjects who achieve various percent of reduction in UACR (Urinary Albumin to Creatinine Ratio) from baseline to final,,2011-08,COMPLETED,INTERVENTIONAL,['PHASE2']
13170,NCT05138432,Change in Hemoglobin A1c,Change in HDL cholesterol,,2021-11-29,RECRUITING,INTERVENTIONAL,['NA']
13171,NCT03877523,Change in macrophages activation after 30-days Cocarnit administration,,,2018-10-03,COMPLETED,INTERVENTIONAL,['NA']
13172,NCT02315235,Changes in pain for a week after the procedure,The evaluation of changes in the specific neuro-sensory system,The secondary effect of the procedure for the peripheral nerves and blood vessels,2014-05,WITHDRAWN,INTERVENTIONAL,['NA']
13173,NCT04927377,Glycemic Management,Health Technology Usability,,2022-10-31,RECRUITING,INTERVENTIONAL,['NA']
13174,NCT00005133,,,,1988-06,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
13175,NCT00792935,Number of Participants Who Experienced One or More Episodes of Hypoglycemia (Symptomatic or Asymptomatic),,,2009-01,COMPLETED,INTERVENTIONAL,['PHASE2']
13176,NCT06217614,Changes in subjective dry mouth score,Salivary Nitric oxide levels,,2022-08-01,COMPLETED,INTERVENTIONAL,['NA']
13177,NCT00755833,Change in HbA1c,Number of ADRs (adverse drug reaction),,2008-09,COMPLETED,OBSERVATIONAL,['NA']
13178,NCT04603937,Non-inferiority of KSI-301 to Aflibercept measured by changes in BCVA.,Safety and Tolerability of KSI-301 mg compared to aflibercept 2 mg measured by the number of ocular and systemic adverse events.,,2020-09-30,TERMINATED,INTERVENTIONAL,['PHASE3']
13179,NCT02140645,Binary EMR Characteristic: Pancreatitis,,,2014-05,COMPLETED,OBSERVATIONAL,['NA']
13180,NCT01588795,proteinuria/creatininuria ratio,Evaluate the outcome of specific kidney injury markers,,2012-04,COMPLETED,INTERVENTIONAL,['PHASE4']
13181,NCT01065155,"Cardiovascular target organ damage (renal, cardiac and vascular) and new cardiovascular events",,,2010-02,COMPLETED,OBSERVATIONAL,['NA']
13182,NCT01906333,Change in IntraMyoCellularLipid (IMCL)content,Change in substrate metabolism,,2013-05,COMPLETED,INTERVENTIONAL,['NA']
13183,NCT03665090,Prevalence and incidence rate of diabetic eye disease,Visual impairment,,2016-01-01,UNKNOWN,OBSERVATIONAL,['NA']
13184,NCT04278664,"HbA1c, maternal glycemic control",,,2015-07,TERMINATED,OBSERVATIONAL,['NA']
13185,NCT01213277,Primary endpoint is to see whether they are fast glycators,A secondary endpoint includes adverse events such as unplanned hospitalizations for any cause that last more than 24 hours,,2010-10,SUSPENDED,INTERVENTIONAL,['NA']
13186,NCT05574699,Change in the number of social needs identified during the visit,Change in the number of hospitalization events and emergency department (ED) visits between intervention and control arms,,2023-04-30,RECRUITING,INTERVENTIONAL,['NA']
13187,NCT01269047,"Post-prandial Blood Glucose Concentration in Both Pramlintide and Exenatide Treated Groups in Acute and Chronic Setting, Compared to Insulin Monotherapy in Type 1 Diabetes Mellitus.",Difference in HbA1C Between the Treatment and the Control Groups,,2009-08,COMPLETED,INTERVENTIONAL,['PHASE4']
13188,NCT01185743,gene expression profiling,,,2010-07,COMPLETED,INTERVENTIONAL,['PHASE4']
13189,NCT06097689,Changes in spectral fingerprints measured by the Lab Demo 1.0 at fluctuations of venous blood glucose levels,Oxygen saturation,,2023-11-24,RECRUITING,INTERVENTIONAL,['NA']
13190,NCT03063138,Wound volume,,,2015-08-01,COMPLETED,OBSERVATIONAL,['NA']
13191,NCT02514850,Area under the glucose infusion rate curve (AUCGIR) 12-30h (mg/kg),Local tolerability,,2015-07,COMPLETED,INTERVENTIONAL,['PHASE1']
13192,NCT00643435,"Resident physician use of self-efficacy enhancing patient interviewing techniques, assessment via coding of audio recordings from standardized patient encounters",,,2006-02,COMPLETED,INTERVENTIONAL,['NA']
13193,NCT00341406,adipose cell size distribution,,,2003-09-04,COMPLETED,OBSERVATIONAL,['NA']
13194,NCT00250731,diabetes regimen adherence,diabetes self-efficacy,,2006-01,COMPLETED,INTERVENTIONAL,['PHASE1']
13195,NCT00818571,Measure: pharmacokinetics of vildagliptin and its metabolites,"Measure: safety assessments will include vital signs, electrocardiograms and adverse events",,2008-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13196,NCT02399423,Change in adipose cell function after gaining 7% body weight and after losing 7% body weight,Change in cognition after gaining 7% body weight and after losing 7% of body weight,,2015-03-11,COMPLETED,INTERVENTIONAL,['NA']
13197,NCT01982019,Serum 26RFa levels,score of satiety,,2014-02-04,UNKNOWN,INTERVENTIONAL,['NA']
13198,NCT05083767,Fasting Blood Sugar,,,2019-04-03,COMPLETED,INTERVENTIONAL,['NA']
13199,NCT01963559,Cutaneous blood flow,Effect of neuropathy on PIV impairment,,2012-04,COMPLETED,INTERVENTIONAL,['NA']
13200,NCT00050479,,,,2002-12,COMPLETED,INTERVENTIONAL,['PHASE3']
13201,NCT01883024,"Patient agreement with the IPRA© advices: global rate of agreement, according to advice subtypes, according to blood glucose levels, according to the situations (pre or post-meal, bedtime)",Assessment of patient satisfaction,,2013-06,COMPLETED,INTERVENTIONAL,['NA']
13202,NCT02598544,Adipose tissue inflammation,Concomitant medication,,2013-05,COMPLETED,INTERVENTIONAL,['NA']
13203,NCT01179815,Mortality,Diabetes related influence on quality of Life,,2010-01,RECRUITING,OBSERVATIONAL,['NA']
13204,NCT00171574,Change from baseline in urine protein excretion after 20 weeks,Change from baseline in diastolic blood pressure after 20 weeks,,2004-11,COMPLETED,INTERVENTIONAL,['PHASE4']
13205,NCT01793168,"To accelerate research into rare disorders by connecting individuals who are interested in research and who have been diagnosed with a rare disorder (or a disorder of unknown prevalence, or who are undiagnosed) with researchers who study rare diseases.",,,2010-07,RECRUITING,OBSERVATIONAL,['NA']
13206,NCT00005137,,,,1992-07,COMPLETED,INTERVENTIONAL,['NA']
13207,NCT03545178,Hypoglycemia prediction (for Substudy B),Change of mean amplitude of glucose excursion (MAGE) day 0-3 compared to day 4-28 and day 0-7 compared to day 8-28 prior to consultation (for Substudy A),Change of mean of daily differences (MODD) day 0-3 compared to day 4-28 and day 0-7 compared to day 8-28 prior to consultation (for Substudy A),2018-04-01,COMPLETED,OBSERVATIONAL,['NA']
13208,NCT04167553,adverse events (AEs):,,,2019-08-30,COMPLETED,INTERVENTIONAL,['PHASE1']
13209,NCT04897945,Weight change,Health-related quality of life,,2021-10-12,RECRUITING,INTERVENTIONAL,['NA']
13210,NCT05015283,"One year after operation, the complete remission rate of type 2 diabetes mellitus [HbA1c < 6%, fasting plasma glucose < 5.6 mmol/L, no need to use any hypoglycemic drugs]",Dumping syndrome and hypoglycemia symptoms,,2022-02-01,RECRUITING,INTERVENTIONAL,['NA']
13211,NCT01941277,A decrease in Insulin Resistance (IR) as measured by a change in IR.,,,2014-08,TERMINATED,INTERVENTIONAL,['NA']
13212,NCT03216226,Percentage of Patients With ADA,Pharmacodynamics - An Increase in the Plasma Glucose Concentration of ≥20 mg/dL Within 30 Minutes After Treatment,,2017-06-28,COMPLETED,INTERVENTIONAL,['PHASE3']
13213,NCT02675608,Change in HAI titer from day 0 to day 30 (+/- 4 days),Inflammatory Soluble Factor and Cellular Analysis additional measurements,,2015-08,COMPLETED,OBSERVATIONAL,['NA']
13214,NCT00110851,Effect on HbA1c levels,Effect on lipid levels,,2005-04,COMPLETED,INTERVENTIONAL,['PHASE2']
13215,NCT05950516,Change in HbA1c,Percentage of Participants That Achieved Body Weight Loss ≥5%,,2023-07-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
13216,NCT04161846,Post Training Presentation Delivery Skills,Change in Physical Activity,Adherence,2019-08-08,COMPLETED,INTERVENTIONAL,['NA']
13217,NCT03156985,Incidence of adverse events,,The incidence of interested adverse events,2017-08-16,COMPLETED,OBSERVATIONAL,['NA']
13218,NCT02167061,Maximum of concentration (Cmax) of Evogliptin and Metformin,Time prior to the first measurable concentration (tlag) of Metformin (only in Part 2 trial),,2014-07,COMPLETED,INTERVENTIONAL,['PHASE1']
13219,NCT03554200,effect of Empagliflozin 10mg qd versus placebo on cardiac output in patients with acute heart failure,Effect of Empagliflozin 10 mg daily on Left ventricular diastolic function,,2018-06-11,TERMINATED,INTERVENTIONAL,['PHASE2']
13220,NCT00920881,,,,2005-11,COMPLETED,OBSERVATIONAL,['NA']
13221,NCT00677599,"Change in cardiovascular disease risk indictaors - including carotid intima-media thickness (CIMT), total plaque volume (TPV) (at the carotid bifurcation), pulse wave velocity (PWV) and biomarkers of risk in blood samples .",,,2008-05,COMPLETED,INTERVENTIONAL,['NA']
13222,NCT01236404,Safety/Tolerability,Pharmacodynamic Response,,2010-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13223,NCT01145092,Insulin Sensitivity,skeletal muscle lipid content,,2006-02,COMPLETED,INTERVENTIONAL,['NA']
13224,NCT00566358,"Changes in the secretion pattern of incretins, insulin and glucagon after intervention, as measured by standardized mixed meal tolerance test",Regression of carotid intima-media thickness,,2006-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13225,NCT02938572,The ratio of suppression of endogenous glucose production relative to total glucose lowering effect,Number of treatment emergent adverse events,,2016-10-19,COMPLETED,INTERVENTIONAL,['PHASE1']
13226,NCT05495386,To collect continuous glucose monitoring (CGM) data to develop a hypoglycaemia notification algorithm.,To evaluate the surgeon satisfaction of H02 in participants with type 1 diabetes.,,2022-09-01,WITHDRAWN,INTERVENTIONAL,['NA']
13227,NCT01407276,Apparent Terminal Half-life (t1/2) of Omarigliptin,Number of Participants Withdrawn From Study,,2011-08-08,COMPLETED,INTERVENTIONAL,['PHASE1']
13228,NCT00289237,Incidence of CHD and other lifestyle related diseases after ten years,"Changes in lifestyle and biological markers after one, three and five years",,1999-03,COMPLETED,INTERVENTIONAL,['NA']
13229,NCT02456064,HbA1c,,,2015-05,COMPLETED,INTERVENTIONAL,['NA']
13230,NCT05706506,Change from Baseline in Hemoglobin A1c (HbA1c),Change from Baseline in Weight,,2023-03-08,COMPLETED,INTERVENTIONAL,['PHASE4']
13231,NCT00005539,,,,1999-02,COMPLETED,OBSERVATIONAL,['NA']
13232,NCT01955694,The percentage of subjects with a relative decrease in N-terminal prohormone B-type natriuretic peptide of more than 30% from baseline to Visit 10,Change in serum potassium,,2013-11-11,COMPLETED,INTERVENTIONAL,['PHASE2']
13233,NCT00079638,Mean percent change in LDL-C from Baseline to Week 12,,,2004-04,COMPLETED,INTERVENTIONAL,['PHASE4']
13234,NCT01280929,Regression of neovascularization,Need for vitrectomy due to occurrence of vitreous hemorrhage or retinal detachment relative to the three treatment arms.,,2010-09,COMPLETED,INTERVENTIONAL,['PHASE2']
13235,NCT02040246,HbA1c change from baseline,,,2009-02,COMPLETED,INTERVENTIONAL,['PHASE4']
13236,NCT00397553,HbA1c,Post-prandial glycemia (2 hour after breakfast),,2005-01,COMPLETED,INTERVENTIONAL,['PHASE3']
13237,NCT05218304,"To know the prevalence of the main risk factors chronic diseases (obesity, diabetes, high blood pressure, high cholesterol and kidney failure) in the adult population of New Caledonia aged 18 to 64 using the WHO STEPS survey method.",Seroprevalence of infectious diseases,,2021-07-26,SUSPENDED,INTERVENTIONAL,['NA']
13238,NCT01176097,To investigate the safety and tolerability of AZD5658 following oral administration of single ascending doses and to estimate the maximum tolerated dose (MTD).,Effect of fasting on the pharmacokinetics and explore the pharmacodynamics of AZD5658.,,2010-07,COMPLETED,INTERVENTIONAL,['PHASE1']
13239,NCT02940275,Perfused small vessel density of sublingual small vessels measured by Cytocam,Total small vessel density of sublingual small vessels measured by Cytocam,,2016-10-17,COMPLETED,OBSERVATIONAL,['NA']
13240,NCT03947333,Change in Patient Activation at 3 Months,System Usage Data for My Diabetes Care - Utilization of Embedded Features and Functionality (Intervention Group Only),,2020-03-09,COMPLETED,INTERVENTIONAL,['NA']
13241,NCT02343926,Change from baseline in HbA1c,Number of serious adverse events,,2014-12,COMPLETED,INTERVENTIONAL,['PHASE3']
13242,NCT05919706,SF-36,,,2022-10-06,COMPLETED,INTERVENTIONAL,['NA']
13243,NCT01298726,GLYCATED HEMOGLOBIN (A1C) LEVELS,DIASTOLIC BLOOD PRESSURE LEVELS,,2010-01,COMPLETED,INTERVENTIONAL,['NA']
13244,NCT04238936,Interleukin-1 (IL-1) receptor antagonist,,,2020-01-20,COMPLETED,OBSERVATIONAL,['NA']
13245,NCT01844050,Change from Baseline Total score of diabetes symptoms at 4 weeks,Change from Baseline blood glucose at 2 hours after meal at 4 weeks,,2008-09,COMPLETED,INTERVENTIONAL,['NA']
13246,NCT02132637,Percentage of Participants With Clinically Significant Hypoglycemia,Beta Cell Function,,2014-05,COMPLETED,INTERVENTIONAL,['PHASE3']
13247,NCT01422668,Glycemic Index of Khalas dates with and without coffee,,,2010-03,COMPLETED,INTERVENTIONAL,['PHASE3']
13248,NCT02770235,erectile dysfunction and AGE levels,,,2014-03-17,COMPLETED,INTERVENTIONAL,['NA']
13249,NCT04406402,High asymmetric dimethylarginine (ADMA) change,Glycated hemoglobin (HbA1c) change,,2006-12-05,COMPLETED,INTERVENTIONAL,['NA']
13250,NCT05014204,Primary Safety Endpoint,Changes in glucose-lowering medication usage,Procedural Time,2021-10-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
13251,NCT01361971,Insulin sensitivity,Hypoxia and inflammatory markers,,2011-04,COMPLETED,INTERVENTIONAL,['NA']
13252,NCT02868983,PROMIS-29 v2,Asthma Symptom Utility Index,Covid-19 patient measures,2016-04,UNKNOWN,INTERVENTIONAL,['NA']
13253,NCT02956044,AUC0-inf (Area Under the Plasma Concentration-time Curve From Time 0 to Infinity),Urinary Glucose Excretion up to 0-72 hr,,2016-11,COMPLETED,INTERVENTIONAL,['PHASE1']
13254,NCT01672255,Change in Catecholamines,,,2012-10,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
13255,NCT02264288,"Safety (adverse events [type, frequency, and severity of AEs, and relationship of AEs to study drug], laboratory abnormalities, and hospitalizations",Leg rest pain score,,2014-10-23,TERMINATED,INTERVENTIONAL,['PHASE2']
13256,NCT02735369,The effect of OC-10X 2% on regression/inhibition of neovascularization in PDR patients as measured by regression of total area of neovascularization (NVD+NVE) from baseline compared to Visit 6 (Week 24) for OC-10X 2% vs. Placebo.,Number of patients requiring pars plana vitrectomy surgery due to traction retinal detachment at the end of the study.,Evaluation of systemic exposure as measured by bioanalytic methods.,2014-12,TERMINATED,INTERVENTIONAL,['PHASE2']
13257,NCT02931630,Postprandial triglyceride response,Microbiota,,2016-05,COMPLETED,INTERVENTIONAL,['NA']
13258,NCT04141423,Anti-insulin Tregopil antibodies,PD Endpoints - CGM profile,,2019-10-28,TERMINATED,INTERVENTIONAL,['PHASE1']
13259,NCT01451918,Examine the effect of resveratrol on ApoB 100 and ApoB 48 production in humans,Assess the change in insulin sensitivity with resveratrol treatment,,2011-10,COMPLETED,INTERVENTIONAL,['PHASE2']
13260,NCT01719029,Glucose area-under-the-curve,Infant Adiposity,,2007-08,COMPLETED,INTERVENTIONAL,['NA']
13261,NCT01223612,Functional and anatomical change in the retina,OCT macular thickness,,2010-10,COMPLETED,INTERVENTIONAL,['PHASE4']
13262,NCT06074913,Temperature of the back of the hand,2-hour postprandial blood glucose (2hPG),,2023-07-07,RECRUITING,INTERVENTIONAL,['NA']
13263,NCT02857764,Incidence of Below-Knee Lower Extremity Amputation in Canagliflozin New Users Versus non-SGLT2i Aha New Users,,,2016-02-15,COMPLETED,OBSERVATIONAL,['NA']
13264,NCT02363803,Change in Spontaneous Pain at 60-120 Minutes After Lidocaine Infusion Initiated (Assessed on 0-10 NRS),Change in Spontaneous Pain Intensity as a Function of Baseline HPT,,2015-02,COMPLETED,INTERVENTIONAL,['NA']
13265,NCT00090519,Occurrence of Sustained Moderate Visual Loss (SMVL) in a Diabetic Retinopathy (DR) Study Eye,Number of Participants With Adverse Events,,2004-02,COMPLETED,INTERVENTIONAL,['PHASE3']
13266,NCT04914559,Area under the blood glucose curve,Insulinogenic index,,2021-05-17,COMPLETED,INTERVENTIONAL,['NA']
13267,NCT04767789,Glycated Hemoglobin A1c (HbA1c),Gastrointestinal Symptoms,Fecal calprotectin,2021-05-12,COMPLETED,INTERVENTIONAL,['NA']
13268,NCT01992588,CSII bolus related baseline corrected area under the serum insulin aspart concentration-time curve,CSII bolus related baseline corrected area under the glucose infusion rate curve,,2013-11,COMPLETED,INTERVENTIONAL,['PHASE1']
13269,NCT00192803,ACE and ACE2 activities in monocytes,,,na,UNKNOWN,INTERVENTIONAL,['PHASE4']
13270,NCT04645875,Glycaemia,,,2020-11-19,UNKNOWN,INTERVENTIONAL,['NA']
13271,NCT04189848,Intensity of Injection Site Pain,,,2019-12-03,COMPLETED,INTERVENTIONAL,['PHASE4']
13272,NCT00231647,Percent change in body weight from baseline to Week 16.,"Changes in body weight, body mass index,anthropometric measurements (waste and hip circumference and their ratio),fasting blood glucose and lipid profile from baseline to Week 16; safety evaluations including incidence of adverse events during the study.",,2004-02,COMPLETED,INTERVENTIONAL,['PHASE2']
13273,NCT01154478,incremental AUC after a test meal of triglycerides concentration in chylomicrons and VLDL fraction,endothelial function,,2010-01,COMPLETED,INTERVENTIONAL,['NA']
13274,NCT05037045,Change from baseline serum lipids at 6 month,incidence and severity of possible adverse reaction within 6 month after GLP-1 RA treatment,,2019-01-10,RECRUITING,INTERVENTIONAL,['NA']
13275,NCT01202474,Percentage of patients achieving HbA1c level < 8% (in patients 6-12 year-old) and HbA1c level < 7.5 % (in patients 13-17 year-old),Change in daily dose of glargine and glulisine,,2011-05,COMPLETED,INTERVENTIONAL,['PHASE4']
13276,NCT05847907,Complications,Implant stability quotient (ISQ),,2023-04-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
13277,NCT04288362,Change in HbA1c levels,"Change in healthcare cost in terms of total healthcare cost of polyclinic, emergency department, hospital admissions and specialist outpatient clinic visits",Change in Diabetes Retinal Photography rates,2019-03-25,COMPLETED,INTERVENTIONAL,['NA']
13278,NCT03718832,HbA1c,Healthy behaviors observed in paid claims HEDIS measures,Heterogeneity: HbA1c by causal tree,2019-04-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
13279,NCT01346254,Oral glucose tolerance test (OGTT),Lipid profiles,,2009-12,COMPLETED,INTERVENTIONAL,['PHASE2']
13280,NCT01563419,the time spent to complete dialing up insulin pens,the recommendation for the use of a magnifier,,2011-10,COMPLETED,INTERVENTIONAL,['NA']
13281,NCT03864510,Genetic factors associated with advanced liver disease (fibrosis >2),Number of patients that develop symptoms of end-stage liver disease,,2019-04-01,COMPLETED,OBSERVATIONAL,['NA']
13282,NCT04772729,Glycaemia difference in time in range (TIR) 70-180mg/dl,Difference in the basal rate of insulin,,2021-03-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
13283,NCT05323162,Preservation of residual beta cell insulin secretion capacity,Dietary intake,,2022-04,UNKNOWN,INTERVENTIONAL,['NA']
13284,NCT05789810,Fear Severity,,,2022-09-10,COMPLETED,INTERVENTIONAL,['NA']
13285,NCT02682901,Change in Hands ESC From Baseline to Endpoint After 24 Weeks of Intervention With Bromocriptine QR vs Placebo,,,2015-10-05,COMPLETED,INTERVENTIONAL,['PHASE4']
13286,NCT04457752,Complete Wound Closure,Changes in bacterial Load,,2020-09-01,RECRUITING,INTERVENTIONAL,['PHASE4']
13287,NCT02003898,Mean Change in A1C From Baseline to 1 Year,"Mean Change in A1C From Baseline to 1 Year, Baseline A1c > 9%",,2013-11-26,COMPLETED,INTERVENTIONAL,['NA']
13288,NCT05986097,HbA1c change,Change in insulin resistance,,2023-08-02,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13289,NCT05214547,Change from 4 weeks Shoulder Pain at 6 weeks,Change from 4 weeks Shoulder Function at 6 weeks,Change from baseline Shoulder Muscle Tone at 6 weeks,2022-02-25,UNKNOWN,INTERVENTIONAL,['NA']
13290,NCT01195454,The area under the body weight standardized glucose infusion rate curve (GIR) within 36 hours (GIR-AUC0-36),"Maximum insulin concentration INS-Cmax, and time to Cmax (INS-Tmax)",,2010-08,COMPLETED,INTERVENTIONAL,['PHASE1']
13291,NCT02565862,Area Under the Curve (AUC),adverse events,,2016-01,COMPLETED,INTERVENTIONAL,['PHASE1']
13292,NCT01881347,Change from baseline in Brachial artery flow mediated dilation,Change from Baseline in Reactive hyperemia,Change from Baseline in Endothelial cell protein expression,2013-01-01,COMPLETED,INTERVENTIONAL,['NA']
13293,NCT04829084,Increased number of DR patients at REMEH for eye screening,,,2021-02-26,COMPLETED,INTERVENTIONAL,['NA']
13294,NCT00383578,Change from baseline in HbA1c,Change from baseline in body weight,,2006-09,COMPLETED,INTERVENTIONAL,['PHASE3']
13295,NCT01238224,"Capillary recruitment, muscle glucose uptake and circulating glucose levels following a meal",Vascular function and circulating biomarkers.,,2009-11,TERMINATED,INTERVENTIONAL,['PHASE1']
13296,NCT02012166,Post-infusion Incremental Glucose Area Under the Plasma Concentration Versus Time Curve [AUC0-240 min] Study Part 2,Number of Participants Who Discontinued Study Treatment Due To AEs,,2005-07,COMPLETED,INTERVENTIONAL,['PHASE1']
13297,NCT05054283,Prolonged Length of hospital,,,2021-10-01,UNKNOWN,OBSERVATIONAL,['NA']
13298,NCT01572415,Comparison of SCOUT DS to Random Capillary Glucose,,,2011-09,COMPLETED,OBSERVATIONAL,['NA']
13299,NCT00311077,To evaluate the serum insulin glulisine concentration and insulin lispro concentration,Adverse events collection,,2004-04,COMPLETED,INTERVENTIONAL,['PHASE1']
13300,NCT00863967,Cardiovascular events,Disease activity score,,2003-10,UNKNOWN,OBSERVATIONAL,['NA']
13301,NCT01595269,Changes in A1C,Changes in Diabetes self-care activities,,2007-04,COMPLETED,INTERVENTIONAL,['NA']
13302,NCT05402358,The RAND 36-item Health Survey 1.0,Focus group and individual interviews with health professional participants,,2020-06-01,COMPLETED,OBSERVATIONAL,['NA']
13303,NCT03434860,HOMA-IR,cytokines levels,,2016-01-15,COMPLETED,INTERVENTIONAL,['NA']
13304,NCT02880267,"Proportion of blood glucose values, compared between CGM and a lab glucose analyzer that are matched relative to a proportion of blood glucose values, compared between CGM and a lab glucose analyzer matched to an accuracy measurement of %20/20 mg/dL",,,2016-05,COMPLETED,INTERVENTIONAL,['NA']
13305,NCT01269008,Better meal and post meal sugars on the closed loop device using the study medications.,,,2010-12,COMPLETED,INTERVENTIONAL,['PHASE1']
13306,NCT01583790,Weightloss of patients,Improvement of co-morbidities after surgery,,2012-01,UNKNOWN,OBSERVATIONAL,['NA']
13307,NCT04805541,Number of subject eyes whose EyeCheckup results match the reading center grading for identifying vision threatening diabetic eye disease (severe NPDR or PDR or surrogate markers for CSME).,,,2022-02-01,RECRUITING,OBSERVATIONAL,['NA']
13308,NCT00146484,* Hemoglobin A1c over the first 24 months of diabetes,* Family Functioning (Family Environment Scale)over the first 24 months of diabetes,,1996-04,COMPLETED,INTERVENTIONAL,['PHASE2']
13309,NCT02922179,serious hypoglycemic events,Serious cardiac events,A1C control,2011-01-01,COMPLETED,OBSERVATIONAL,['NA']
13310,NCT01272232,Proportion of Subjects Losing More Than 10% of Baseline Body Weight,Incidence of Hypoglycaemic Episodes,,2011-06-01,COMPLETED,INTERVENTIONAL,['PHASE3']
13311,NCT06137963,Change in percent of body weight before and after a 6 month intervention period.,Postoperative length of stay,,2024-01-24,WITHDRAWN,INTERVENTIONAL,['NA']
13312,NCT00677937,Reduction in incidence of diabetes at 3 years,"change in hba1c, fasting and post glucose levels, cardiovascular risk (framingham), presence of MetS (NCEP ATP III)",,2009-05,COMPLETED,INTERVENTIONAL,['NA']
13313,NCT01209312,Blood glucose area under the curve,,,2009-12,COMPLETED,INTERVENTIONAL,['NA']
13314,NCT04595968,Frequency of all device related Serious Adverse Events,Frequency of hypoglycemic episodes,,2021-05-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
13315,NCT03315143,"Number of Total Occurrences of Cardiovascular (CV) Death, Hospitalizations for Heart Failure (HHF) and Urgent Visits for Heart Failure (HF)","Total Number of Occurrences of CV Death, Non-fatal Myocardial Infarction and Non-fatal Stroke",,2017-12-19,TERMINATED,INTERVENTIONAL,['PHASE3']
13316,NCT04801121,Placental pathology,,,2020-11-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
13317,NCT03772600,Difference in time in range (70-180 mg/dL) between the control and experimental group,Between group difference in number of patients having allergic reactions to the sensors,Number of patients who stop using the Dexcom G6® CGM and the reason to stop,2019-01-29,COMPLETED,INTERVENTIONAL,['NA']
13318,NCT01247649,Correlation between continuous glucose measurements using study device and YSI(yellow springs instrument),,,2010-11,TERMINATED,INTERVENTIONAL,['NA']
13319,NCT00901979,Effect of LCQ on measures of glucose control,Safety and tolerability,,2009-04,COMPLETED,INTERVENTIONAL,['PHASE2']
13320,NCT04796649,Incidence of complete (100%) wound closure,Time to complete (100%) wound closure,,2022-05-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
13321,NCT00841503,determine glucose-lowering potential of the buckwheat bioactive compound during acute phase testing in volunteers with Type 2 diabetes,determine bioavailability of buckwheat bioactive compounds,,2008-09,COMPLETED,OBSERVATIONAL,['NA']
13322,NCT05536232,Peptide C evolution,Circulating rate of cytokines,,2022-10-17,RECRUITING,INTERVENTIONAL,['NA']
13323,NCT00680745,Adjusted Mean Change in HbA1c Levels,Adjusted Mean Change in Fasting Plasma Glucose (FPG),,2008-04,COMPLETED,INTERVENTIONAL,['PHASE3']
13324,NCT04646408,Educational,,,2020-10-01,UNKNOWN,OBSERVATIONAL,['NA']
13325,NCT01243138,"Prevalence of cardiovascular (CV) risk factors such as obesity, smoking, dyslipidemia, diabetes mellitus and hypertension","Ascertain the most commonly used medications in those that have been previously diagnosed as diabetic, hypertensive or dyslipidaemic.",,2011-07,COMPLETED,OBSERVATIONAL,['NA']
13326,NCT04765254,Investigation of bad prognosis cause for covid-19 diabetic patients,,,2021-02-20,UNKNOWN,OBSERVATIONAL,['NA']
13327,NCT03447301,HbA1c (glycated hemoglobin),Weight,,2018-02-25,UNKNOWN,INTERVENTIONAL,['NA']
13328,NCT04129021,Visualization of a structure of interest and measuring the short-term and long-term reproducibility of the data collected compared to routine systems,,,2019-07-15,UNKNOWN,INTERVENTIONAL,['NA']
13329,NCT05190744,Change in urine osmolality,Change in urine output,,2022-09-01,RECRUITING,INTERVENTIONAL,['PHASE2']
13330,NCT00511602,HbA1c change from baseline (week 2) to end of treatment (week 12),"Safety variables included adverse events (AEs), clinical laboratory tests, vital signs and physical examinations",,2003-12,COMPLETED,INTERVENTIONAL,['PHASE2']
13331,NCT00486109,Glycosylated albumin levels,"Participants' satisfaction evaluated with standard quality of life questionnaires and adverse events related to the study device including incidents of erythema > 2cm diameter, incidence of induration > 1cm dimater and incidence of suppuration.",,2006-10,COMPLETED,INTERVENTIONAL,['NA']
13332,NCT03063580,Area under the concentration-time curve from 0 to infinity (AUC0 ∞),Total 24-hour UGE (urinary glucose excretion),,2017-02-27,COMPLETED,INTERVENTIONAL,['PHASE1']
13333,NCT00961974,"Glycemic control, assessed by hemoglobin A1c","Frequency of hospitalizations, emergency department visits, and episodes of severe hypoglycemia",,2002-04,COMPLETED,INTERVENTIONAL,['NA']
13334,NCT05480228,The frequency (i.e. number of participants) with treatment emergent adverse events (TEAEs) reported in the time period defined by first administration of IP until 7 days after the last dose of IP.,Occurrence of 50% reduction of WAP from Baseline to Week 13.,To assess the effect of NRD135S.E1 in comparison to placebo with respect to the actigraphy step count.,2022-09-21,RECRUITING,INTERVENTIONAL,['PHASE2']
13335,NCT01196325,Quantitative inner retinal blood flow,Mean angle opening distance and trabecular-iris spur area,,2009-07,UNKNOWN,OBSERVATIONAL,['NA']
13336,NCT03406975,Percentage of Excess Weight Loss (EWL),Change in Eating Behaviors,,2017-12-20,COMPLETED,INTERVENTIONAL,['NA']
13337,NCT02285218,new hepatokines,,,2014-04,UNKNOWN,OBSERVATIONAL,['NA']
13338,NCT06011798,Mean change from baseline in BCVA by ETDRS letter,Assess safety outcome - TEAE,,2023-08-23,RECRUITING,INTERVENTIONAL,['PHASE2']
13339,NCT01749176,HbA1c,,,2012-10,COMPLETED,INTERVENTIONAL,['NA']
13340,NCT04118257,Change in glucose iAUC,Change in serum fructosamine,,2017-02-10,COMPLETED,INTERVENTIONAL,['NA']
13341,NCT05464524,"Established the role of tested environmental factors and lifestyle choices on the incidence, recurrence, and severity of diabetic foot ulcers in adults living with diabetes in England.",Established changes to DFU status and quality of life over the 12 week follow up period.,,2023-10-19,RECRUITING,OBSERVATIONAL,['NA']
13342,NCT03073330,Incidence of gestational diabetes diagnosed on each screening test of each arm.,Apgar score,,2016-06,UNKNOWN,INTERVENTIONAL,['NA']
13343,NCT05328726,Dose limiting toxicity,Glycosylated Hemoglobin,,2022-03-08,COMPLETED,INTERVENTIONAL,['PHASE1']
13344,NCT02727790,"Number of participants with hypoglycemia, and/ or adverse events that are related to treatment",Changes in mean interstitial glucose levels measured by CGM,,2014-07,COMPLETED,INTERVENTIONAL,['NA']
13345,NCT01323075,The duration of sensory block in minutes.,"Occurrence of neurological complications, yes/no",,2011-05,COMPLETED,OBSERVATIONAL,['NA']
13346,NCT02052817,Change from baseline measured wound area,,,2013-12,UNKNOWN,INTERVENTIONAL,['NA']
13347,NCT00885638,Glucagon-like Peptide-1 Secretion After Meal Ingestion,Insulin Secretion After Ingestion of Meal,,2009-08,COMPLETED,INTERVENTIONAL,['PHASE4']
13348,NCT06265935,SF-36 Quality of Life Scale:,Visual Similarity Scale for Fatigue,,2024-03-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
13349,NCT06327737,Prediction of cerebral edema with Integrated Pulmonary Index,,,2020-12-15,COMPLETED,OBSERVATIONAL,['NA']
13350,NCT00005347,,,,1992-02,COMPLETED,OBSERVATIONAL,['NA']
13351,NCT05530486,Change in complete ulcer healing,,,2023-06-30,RECRUITING,INTERVENTIONAL,['NA']
13352,NCT02055755,Questionnaire relevant to wound healing,Develop new parameters for clinical decision support based on data collected in this study.,,2013-04,WITHDRAWN,OBSERVATIONAL,['NA']
13353,NCT01198730,Diabetes,Mortality,,2009-04,RECRUITING,OBSERVATIONAL,['NA']
13354,NCT02803892,Change from Baseline C-peptide after the MMTT,Adverse Events (AEs) and Serious Adverse Events (SAEs),,2016-05,COMPLETED,INTERVENTIONAL,['PHASE2']
13355,NCT00315991,Accuracy of blood glucose level estimation,,,2006-04,COMPLETED,INTERVENTIONAL,['NA']
13356,NCT02171130,Percentage of Participants Awakening or Returning to a Normal Status Within 30 Minutes Following Studied Drug of Administration,Percentage of Participants With Adverse Events (AEs) Reported Through the Nasal Score Questionnaire,Number of Participants With Treatment-Emergent Glucagon Anti-Drug Antibodies (ADA),2014-05,COMPLETED,INTERVENTIONAL,['PHASE3']
13357,NCT01358994,,,,2011-01,COMPLETED,OBSERVATIONAL,['NA']
13358,NCT02627027,Cmax of Lobeglitazone Metformin,Vd/F of Metformin,,2015-08,COMPLETED,INTERVENTIONAL,['PHASE1']
13359,NCT01114750,Pharmacokinetic variable: insulin,,,2010-04,SUSPENDED,INTERVENTIONAL,['PHASE1']
13360,NCT01785667,Incidence of diabetic retinopathy and proliferative diabetic retinopathy,Vessel diameters as a predictor of diabetic retinopathy and proliferative diabetic retinopathy,Fractal dimensions as a predictor of diabetic retinopathy and proliferative diabetic retinopathy,2011-01,COMPLETED,OBSERVATIONAL,['NA']
13361,NCT05892848,"level of serum ostecalcin, sclerostin in patients with type 1 diabetes ann d their age and sex matched control",,,2023-06-10,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
13362,NCT00330473,To assess blood sugar control as measured by HbA1c,To assess patient-reported outcomes based on the DTSQ Questionnaire,,2006-06,COMPLETED,INTERVENTIONAL,['PHASE3']
13363,NCT01791465,Serum Interleukin 6 (IL-6) at Levels at Baseline and 16 Weeks,Waist to Hip Ratio at Baseline and 16 Weeks,"Peripheral Endothelial Tonography, as Measured by the Non-invasive EndoPAT System Using the LnRHI (Natural Log of Reactive Hyperemia Index), at Baseline and 16 Weeks",2013-03,TERMINATED,INTERVENTIONAL,['PHASE4']
13364,NCT04937816,Incidence Rate of Lower Limb Amputation (LLA),Incidence Rate of Adverse Events Related to Amputation,,2021-06-01,COMPLETED,OBSERVATIONAL,['NA']
13365,NCT04917965,Coagulation Index,,,2021-08-01,UNKNOWN,OBSERVATIONAL,['NA']
13366,NCT01790711,The Efficiency of FMT on T2DM,Durability,,2012-10,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
13367,NCT01739712,Academic performance,,,2012-10,COMPLETED,INTERVENTIONAL,['NA']
13368,NCT05502016,"Glycemic control, measured by change in mean HbA1c (%) from baseline",,,2023-06-30,RECRUITING,INTERVENTIONAL,['NA']
13369,NCT00463671,The aim of the present study was to investigate whether changes in oxidative stress and NO bioavailability are responsible for the different effects of HBOT on tissue oxygenation in diabetic patients suffering from foot ulcers.,,,2003-12,COMPLETED,INTERVENTIONAL,['NA']
13370,NCT00318032,"To contribute to the ADDITION-Europe study, to assess screening and intensive treatment on 5 year cardiovascular outcomes",To assess the economic and psychological cost of screening,,2004-08,UNKNOWN,INTERVENTIONAL,['NA']
13371,NCT05541120,Percentage of participants in each group who have HbA1c < 7%,Mean change in PAM-13 at 9 months,,2022-10-18,WITHDRAWN,INTERVENTIONAL,['NA']
13372,NCT00462046,LDL-c,Blood pressure,,2005-04,COMPLETED,INTERVENTIONAL,['PHASE3']
13373,NCT05096078,Blood count test 8,WMS Number Range Test,,2020-10-16,UNKNOWN,INTERVENTIONAL,['NA']
13374,NCT04948112,Average percent time in glucose range,Neonatal hypoglycemia,Perceived benefit questionnaire (GMS),2021-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
13375,NCT02120976,Plasma glucose,,,2014-04,TERMINATED,INTERVENTIONAL,['PHASE1']
13376,NCT05634174,Free Fatty Acid measured Catecholamine Sensitivity,IL-6 Adipokine Gene Expression,ADRB3 Signaling Pathway,2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
13377,NCT03945656,Clinically significant hypoglycaemia (Double dose): Clinically significant hypoglycaemia (Plasma glucose [PG] less than 3.0 mmol/L [54 mg/dL]) after 2 times the individualised optimal basal dose of insulin,"Clinically significant hypoglycaemia (Triple dose) - Clinically significant hypoglycaemia [PG less than 3.0 mmol/L (54 mg/dL)], after 3 times the individualised optimal basal dose of insulin",,2019-05-07,COMPLETED,INTERVENTIONAL,['PHASE1']
13378,NCT04176120,Complete wound healing,Patient-reported mobility,,2020-07-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
13379,NCT00815932,Changes in the Latency of P300,Changes in Pain Thresholds for Tactile and Thermal Stimuli will be calculated as the difference between ratings obtained form pain threshold measurements before- and after tDCS,,2016-09,WITHDRAWN,INTERVENTIONAL,['NA']
13380,NCT04368741,Glycated albumin level,,,2019-10-15,UNKNOWN,INTERVENTIONAL,['NA']
13381,NCT00099853,Change from baseline in HbA1c after 24 weeks,Change from baseline in HbA1c at 24 weeks for patients with high baseline HbA1c vs low baseline HbA1c,,2004-05,COMPLETED,INTERVENTIONAL,['PHASE3']
13382,NCT04200625,Epicardial Fat thickness,,,2019-09-24,COMPLETED,OBSERVATIONAL,['NA']
13383,NCT04436796,Non-inferiority for CGM Time <54 mg/dL,Basal: Bolus Insulin Ratio,Any Adverse Event Rate Per 100 Person-years,2020-08-05,COMPLETED,INTERVENTIONAL,['NA']
13384,NCT03200535,Enrollment in Diabetes Prevention or Weight Management Class (Online),Enrollment in Diabetes Prevention or Weight Management Class (in Person),,2017-06-26,COMPLETED,INTERVENTIONAL,['NA']
13385,NCT04817644,"Area under the salcaprozate sodium (SNAC) milk concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,SNAC,D10,milk)","Time to maximum SNAC metabolite E1247 plasma concentration during a dosing interval after the 10th dosing (tmax,E1247,D10,plasma)",,2021-09-10,COMPLETED,INTERVENTIONAL,['PHASE1']
13386,NCT05029076,"Adverse Event, Serious Adverse Event and Drug Combination",The Number of participants with abnormal laboratory examinations,,2019-05-21,COMPLETED,INTERVENTIONAL,['PHASE1']
13387,NCT04395521,The efficacy of the study intervention on participants' foot self-care adherence.,The efficacy of the study intervention on participants' quality of life.,,2021-02-16,COMPLETED,INTERVENTIONAL,['NA']
13388,NCT01550328,Determine Device Bias,,,2012-04,TERMINATED,OBSERVATIONAL,['NA']
13389,NCT00831389,Incidence of Nocturnal Hypoglycemia Following Exercise,Percentage of Time Plasma Glucose (PG) is Below the Euglycemic Range.,,2009-01,COMPLETED,INTERVENTIONAL,['NA']
13390,NCT03696797,Change in FSIGTT DI (Frequently sampled intravenous glucose tolerance test),Number of participants that converted from pre-diabetes to normal glucose tolerance,,2019-05-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
13391,NCT05491746,Visual acuity at distance,Contrast sensitivity,,2022-07-01,COMPLETED,INTERVENTIONAL,['NA']
13392,NCT04328233,Change in fasting glucose concentration,Duration of eating period,,2019-10-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
13393,NCT00476658,,,,2007-01,COMPLETED,OBSERVATIONAL,['NA']
13394,NCT05571436,Diabetes self-management behavior,Self-efficacy related to diabetes self-management,,2022-10-17,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
13395,NCT01169779,Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24,Percentage of Patients Requiring Rescue Therapy During Main 24-Week Period,Number of Patients With Symptomatic Hypoglycemia and Severe Symptomatic Hypoglycemia,2010-07,COMPLETED,INTERVENTIONAL,['PHASE3']
13396,NCT03305939,"Proportion of women with a change of glycaemic category, at or prior to final visit",Change in dietary habits as assessed by Intake 24 (a 24-hour recall questionnaire),,2017-08-01,COMPLETED,INTERVENTIONAL,['NA']
13397,NCT06114134,Hemoglobin A1C (HbA1C),Antropometric Indices,,2023-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
13398,NCT04001725,Metformin in preventing precocious (14 days) dexamethasone-induced diabetes,Amino acid profile,,2019-10-15,UNKNOWN,INTERVENTIONAL,['PHASE2']
13399,NCT00220831,A combination of CVD mortality non fatal MI and Stoke at a 4 year follow up.,"etc…), all cause mortality, heart failure, at a 4 year follow up.",,2005-04,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
13400,NCT00065130,Postprandial glycemic control,Adverse events,,2000-04,COMPLETED,INTERVENTIONAL,['PHASE3']
13401,NCT01437072,HbA1c (Glycosylated Haemoglobin) level,The presence of retinopathy,,2010-11,COMPLETED,OBSERVATIONAL,['NA']
13402,NCT02756442,Respiratory Disturbance Index,Air flow debit associated to micro awaking during sleep,,2016-04,UNKNOWN,INTERVENTIONAL,['NA']
13403,NCT00288392,- Time to healing,Safety,,2005-06,COMPLETED,INTERVENTIONAL,['PHASE2']
13404,NCT02062047,Changes in clinical attachment level (CAL) in sites with initial PD ≥7mm from baseline to 12 months.,Changes in the levels of osteoprotegerin (OPG) in gingival crevicular fluid,,2007-12,COMPLETED,INTERVENTIONAL,['PHASE4']
13405,NCT05417646,Urinary glucose excretion,Renal threshold of glucose excretion,,2022-06-22,COMPLETED,INTERVENTIONAL,['NA']
13406,NCT01320345,Occurrence of clinical significant retinopathy progression.,Frequency of foot ulcer and non-traumatic amputation.,Quality of Life questionnaire,2016-11-03,RECRUITING,INTERVENTIONAL,['PHASE3']
13407,NCT01308437,Change in HbAlc from baseline to 6 months of treatment between Wosulin arm and Novolin arm(as surrogate indicator of change in insulin antibodies titers between the two treatment arms).,"Correlation of the immunogenicity with hypoglycemia, local allergic reactions and systemic allergic reactions will be evaluated.",,2011-03,TERMINATED,INTERVENTIONAL,['PHASE3']
13408,NCT03749642,Change of the average daily pain score based on the 11-point Numeric Rating Scale (NRS).,Frequency of adverse events,,2018-11-22,COMPLETED,INTERVENTIONAL,['PHASE2']
13409,NCT04254016,Variation of mitral E' velocity,Variation of lipid profile.,,2016-11-01,COMPLETED,INTERVENTIONAL,['PHASE4']
13410,NCT04238702,Effective Renal Plasma Flow (ERPF),Vascular function,,2020-11-04,COMPLETED,INTERVENTIONAL,['PHASE4']
13411,NCT00100204,,,,2004-12-21,COMPLETED,OBSERVATIONAL,['NA']
13412,NCT01175408,The primary endpoint is the A1c level or the change in A1c level,A secondary endpoint includes adverse events such as unplanned hospitalizations for any cause that last more than 24 hours,,2010-09,COMPLETED,INTERVENTIONAL,['NA']
13413,NCT04834648,Primary Outcome,,,2021-03-15,COMPLETED,INTERVENTIONAL,['NA']
13414,NCT06013826,Fear,,,2022-02-17,COMPLETED,INTERVENTIONAL,['NA']
13415,NCT05854862,TIR,Incidence of hypoglycemia,,2013-08-01,RECRUITING,OBSERVATIONAL,['NA']
13416,NCT02690168,Percent Enrichment of Bicarbonate as Measured by Magnetic Resonance Spectroscopy (MRS),Change in Leptin Levels,,2016-02,COMPLETED,OBSERVATIONAL,['NA']
13417,NCT00279266,Daily pain evaluations on a visual analog pain scale,Changes in sleep disturbance in secondary to pain as rated by a visual analog scale,,2006-01,WITHDRAWN,INTERVENTIONAL,['NA']
13418,NCT06098040,time in range,PAT plasma antioxidant capacity,,2023-09-22,RECRUITING,INTERVENTIONAL,['NA']
13419,NCT01524159,fibrinogen,Creatinine,,2011-06,COMPLETED,INTERVENTIONAL,['NA']
13420,NCT01584232,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks,Percentage of Participants With Hypoglycemic Episodes,,2012-04,COMPLETED,INTERVENTIONAL,['PHASE3']
13421,NCT01420497,"glycemic values,",urinary excretion rate,,2008-08,COMPLETED,INTERVENTIONAL,['NA']
13422,NCT05161741,Change from baseline in fasting plasma glucose to the last- observation on treatment,,,2021-01-01,COMPLETED,INTERVENTIONAL,['PHASE4']
13423,NCT01970163,Effect of DermACELL on the proportion of chronic wounds of the lower extremity that have healed.,Proportion of wounds closed at 12 weeks and weekly thereafter for up to 24 weeks,"Incidence of treatment-emergent adverse events (AE), changes in vital signs, ankle-brachial index (ABI) and physical examination findings.",2013-10,COMPLETED,INTERVENTIONAL,['NA']
13424,NCT03369626,Level of engagement with the assigned mobile app,Change in self-reported diabetes medication type or dose,,2017-07-26,COMPLETED,INTERVENTIONAL,['NA']
13425,NCT02798198,The correlation between the pulmonary function and the renal hemodynamics in 37 T2DM patients without DKD,"The albumin excrete rate (AER), urinary albumin/creatinine ratio (UACR)in the healthy people and T2DM patients and comparing the differences between the two groups",,2015-09,COMPLETED,OBSERVATIONAL,['NA']
13426,NCT03171623,Safety and tolerability of single dose of SY-004,C-peptide secretion following single dose of SY-004,,2017-04-05,COMPLETED,INTERVENTIONAL,['PHASE1']
13427,NCT02247635,"Reduction in the prevalence of metabolic syndrome (obesity, diabetes, hypertension, dyslipidemia)",Reduction of hypercholesterolemia,,2008-11,COMPLETED,INTERVENTIONAL,['NA']
13428,NCT00368134,Change in HbA1c after 12 weeks,Safety Profile after 12 weeks treatment,,2006-08,COMPLETED,INTERVENTIONAL,['PHASE3']
13429,NCT03545802,Compliance over the course of the training programme,change in glycaemic control,,2017-05-20,COMPLETED,INTERVENTIONAL,['NA']
13430,NCT04081792,Number of Participants with a clinical and microbiological remission of treated infection at 2 months,Statistical evaluation of risk factors for failure of remission,,2019-09-04,RECRUITING,INTERVENTIONAL,['NA']
13431,NCT03844789,Continuous Glucose Monitor (CGM)-Measured Percent Time in Range 70-180mg/dL Over 16 Week Trial Period,Continuous Glucose Monitor (CGM)-Measured Glucose Variability Percentage Measured With the Coefficient of Variation (CV) Over 12 Week Trial Extension Period,Body Mass Index (BMI) at Conclusion of 12 Week Trial Extension Period,2019-06-06,COMPLETED,INTERVENTIONAL,['NA']
13432,NCT00554450,Iohexol PK blood & urine samples for GFR assessment,"The following urine/serum safety parameters will be assessed: sodium, potassium, magnesium, phosphorus, calcium, and total protein (urine only)",,2006-03,COMPLETED,INTERVENTIONAL,['PHASE1']
13433,NCT03804983,change between Percent Time in Range at home pre/post intervention at home,Change in Total amount of carbohydrates corresponding to hypoglycemia treatment at camp,,2019-01-15,COMPLETED,INTERVENTIONAL,['NA']
13434,NCT04578431,Blood from mother,,,2020-11-01,COMPLETED,INTERVENTIONAL,['NA']
13435,NCT05301478,Plantar pressure,,,2022-03-01,RECRUITING,INTERVENTIONAL,['NA']
13436,NCT04352907,Continous Glucose Sensor values (CGM),Vasopressor Use,,2020-11-06,RECRUITING,OBSERVATIONAL,['NA']
13437,NCT03176524,Assessments of local tolerability at injection site,Time to plasma glucose increase of ≥20 mg/dL from baseline,,2017-06-06,COMPLETED,INTERVENTIONAL,['PHASE1']
13438,NCT01310491,HbA1c change over time (participants with T2DM only),Satisfaction and usability of the technology and equipments.,,2011-02,COMPLETED,INTERVENTIONAL,['NA']
13439,NCT02926950,Change From Baseline in Hemoglobin A1c (HbA1c) at Week 26,Percentage of Participants With HbA1c <7.0% at Week 26,Percentage of Participants With Hypoglycemic Events,2016-11,COMPLETED,INTERVENTIONAL,['PHASE3']
13440,NCT04227769,Change in insulin concentration in blood during the cephalic phase of insulin secretion in obese patients with type 2 diabetes,Change in autonomic function,,2020-01-13,RECRUITING,INTERVENTIONAL,['PHASE2']
13441,NCT04173117,Recruitment and retention rates,The number of participants who experience any Major Adverse Cardiovascular Events (MACE),,2020-02-28,TERMINATED,INTERVENTIONAL,['NA']
13442,NCT01982630,Accumulation Ratio of the Area Under the Concentration-time Curve From 0 to 24 Hours (AUC0-24hr) of MK-8521 for Type 2 Diabetes Mellitus (T2DM) and Non-Diabetic Overweight/Obese Participants in Part 2,Apparent Terminal Half Life (t1/2) of MK-8521 on Day 14 for Non-Diabetic Overweight/Obese Participants in Part 2,,2013-11-07,COMPLETED,INTERVENTIONAL,['PHASE1']
13443,NCT03771261,Change from Baseline Body weight at 4 months,Change from Baseline Insulin Sensitivity at 4 months,,2018-06-15,COMPLETED,INTERVENTIONAL,['NA']
13444,NCT01400295,Contrast-Induced Nephropathy,An early abnormal increase in serum cystatin C,,2010-12,COMPLETED,OBSERVATIONAL,['NA']
13445,NCT05832996,The efficacy of cooled versus room temperature artificial tears in reducing post intravitreal injection ocular discomfort as measured by pain scale survey.,,,2022-03-01,COMPLETED,INTERVENTIONAL,['PHASE4']
13446,NCT02014207,blood glucose,food intake,subjective appetite,na,COMPLETED,INTERVENTIONAL,['NA']
13447,NCT01688778,Changes in HbA1c,Use of medication,Number of visits at GP,2012-06,COMPLETED,INTERVENTIONAL,['NA']
13448,NCT02487888,Glucose levels for patients being treated for T2DM,Urine drug screen results,,2014-09,UNKNOWN,INTERVENTIONAL,['NA']
13449,NCT02669732,First-phase and Second-phase secretion C-peptide,plasma concentration of DS-8500a,,2016-01,COMPLETED,INTERVENTIONAL,['NA']
13450,NCT03391349,"mRNA expression of L-plastin,lipocalin and adiponection","Quantify the levels of L-plastin, lipocalin and adiponectin",,2016-10-20,COMPLETED,OBSERVATIONAL,['NA']
13451,NCT02330406,Change in glycated hemoglobin,Change in fatty acid fraction,,2015-04,COMPLETED,INTERVENTIONAL,['PHASE4']
13452,NCT00512707,Change From Baseline in Erectile Function Domain Score of the International Index of Erectile Function (IIEF),Change From Baseline in Positive Affects Ratio (PAR) of Derogatis Affects Balance Scale (DABS),Change From Baseline in Sex Hormone Binding Globulin (SHBG),2006-11,COMPLETED,INTERVENTIONAL,['PHASE4']
13453,NCT04424888,2-hour Interstitial Glucose Area Under the Curve (AUC),CGM-Smartphone Usability Feedback,,2018-03-15,COMPLETED,INTERVENTIONAL,['NA']
13454,NCT03207841,"Change in HDL, LDL, total cholesterol and triglycerides",Change in Spinal Cord Injury-Quality of Life (SCI-QOL) Score,,2017-11-01,COMPLETED,INTERVENTIONAL,['NA']
13455,NCT02076347,Percentage of patients in each arm who obtain monitoring of vitamin B12 as recommended,Percentage of patients with newly identified vitamin B12 deficiency who have prior evidence of neuropathy upon chart review,,2014-02,COMPLETED,INTERVENTIONAL,['NA']
13456,NCT01076218,,,,2008-04,COMPLETED,OBSERVATIONAL,['NA']
13457,NCT04455880,Prediction and differentiation of GDM and prognosis with Shear wave elastography velocity cut-offs,,,2019-05-15,COMPLETED,INTERVENTIONAL,['NA']
13458,NCT02623452,(Part B) PK: AUC of Insulin Lispro,(Part B) PD: AUC of Glucose Following a Meal,,2018-01,WITHDRAWN,INTERVENTIONAL,['PHASE1']
13459,NCT01928381,"Brief Pain Index - Item 5, Average Daily Pain Score (Range 0-10) Higher Values Indicate Worse Pain",,,2013-11,COMPLETED,INTERVENTIONAL,['PHASE2']
13460,NCT00964418,Area under the glucose infusion rate curve during one dosing interval at steady state (for NN1250),Area under the NN1250 concentration-time curve during one dosing interval at steady state,,2009-08,COMPLETED,INTERVENTIONAL,['PHASE1']
13461,NCT03982693,Prevention of major cardiovascular endpoints,Changes in PAD Quality of Life,,2019-03-19,RECRUITING,INTERVENTIONAL,['PHASE3']
13462,NCT00024518,C-Peptide Level,Hemoglobin A1C,,2001-09,COMPLETED,INTERVENTIONAL,['PHASE2']
13463,NCT03557892,HbA1c,Local Reactions,,2018-04-01,COMPLETED,INTERVENTIONAL,['NA']
13464,NCT01316861,Glycosylated hemoglobin (HbA1c),Safety will be evaluated by the Adverse events occurence,,2012-09,COMPLETED,INTERVENTIONAL,['PHASE3']
13465,NCT03732690,Post meal tolerance test glycemic excursion (area under the curve),Adipose tissue gene expression modifications,,2018-12-05,COMPLETED,INTERVENTIONAL,['NA']
13466,NCT04809285,Percentage of Time in Range,,,2021-04-06,COMPLETED,INTERVENTIONAL,['NA']
13467,NCT02599805,Comparative change in ulcer surface area,,,2015-12,UNKNOWN,INTERVENTIONAL,['PHASE3']
13468,NCT01640223,Percentage of data collected,,,2012-03,COMPLETED,INTERVENTIONAL,['NA']
13469,NCT00097955,Change from baseline in urinary albumin creatinine ratio after 24 weeks,Change from baseline in urinary albumin excretion rate after 24 weeks,,2004-10,COMPLETED,INTERVENTIONAL,['PHASE2']
13470,NCT01497912,Fibrin network permeability,skin microvascular reactivity,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE4']
13471,NCT00495235,Prevalence Rate of Insulin Resistance,,,2005-10,COMPLETED,OBSERVATIONAL,['NA']
13472,NCT04149392,Frequency of diabetes medication changes that take place at the follow up visit,Mortality rate,,2019-12-16,WITHDRAWN,INTERVENTIONAL,['NA']
13473,NCT01475422,HbA1c,Diabetes Attitude Questionnaire - ATT-19,,2011-09,UNKNOWN,INTERVENTIONAL,['NA']
13474,NCT03777722,Change in depression,Light exposure using the Daysimeter,,2018-11-01,RECRUITING,INTERVENTIONAL,['NA']
13475,NCT01136798,Total Amount of Slow Wave Activity,Mean 24-h Blood Glucose Levels,,2010-06-01,COMPLETED,INTERVENTIONAL,['NA']
13476,NCT01373489,Hemoglobin A1c (HbA1c) at 6 Months Post Randomization,,,2011-07,COMPLETED,INTERVENTIONAL,['NA']
13477,NCT04340648,Performance and accuracy in pulse monitoring,,,2019-06-03,COMPLETED,INTERVENTIONAL,['NA']
13478,NCT05922852,urinary protein changes,,,2023-03-01,RECRUITING,OBSERVATIONAL,['NA']
13479,NCT04364685,HbA1c,Quality of life-39,,2017-01-25,COMPLETED,INTERVENTIONAL,['NA']
13480,NCT05514080,Glucose outcomes: percentage of time spent in specific glucose ranges (ex: 3.9-10.0 mmol/L),,,2019-12-06,COMPLETED,INTERVENTIONAL,['NA']
13481,NCT00458081,Relative change in the microalbuminuria level.,Safety (including neuropsychiatric events) and Laboratory assessments.,,2007-03,TERMINATED,INTERVENTIONAL,['PHASE3']
13482,NCT05188014,Blood glucose,percent of time in hyperglycemia,Carbohydrate supplementation,2022-03-15,RECRUITING,INTERVENTIONAL,['NA']
13483,NCT02278068,Primary Safety Outcome as assessed by Incidence of serious adverse device effects,Adverse Event Rate,,2014-10,COMPLETED,INTERVENTIONAL,['NA']
13484,NCT01513746,Blood Glucose Values,Ecological Momentary Assessment of Emotional and Behavioral Outcomes,,2011-12,COMPLETED,OBSERVATIONAL,['NA']
13485,NCT02426138,Healthy Eating Index 2010 Score,Diabetes Distress Scale,Total Cholesterol,2015-04-01,COMPLETED,INTERVENTIONAL,['NA']
13486,NCT00233649,,,,2004-05,COMPLETED,OBSERVATIONAL,['NA']
13487,NCT03607617,SDH data adoption,DM Key tests,,2018-09-03,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
13488,NCT05391854,Glycated haemoglobin (HbA1c),SF-12 (Short-fom 12),,2022-06-21,COMPLETED,INTERVENTIONAL,['NA']
13489,NCT03941132,"Rate, frequency and severity of all adverse events including; hypoglycemic episodes; injection reactions; hypersensitivity reactions; evidence of infection and posterior leukoencephalopathy syndrome.",Glycaemic variability in continuous glucose monitoring and hypoglycaemia rates.,,2021-01-04,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
13490,NCT00850135,Correlation Between Glucose AUC and Birth Weight.,"Pregnancy and Delivery Characteristics for Participants With AUC-130 <= 22,000 and AUC-130 > 22,000",,2009-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13491,NCT01053026,1. Vascular function testing,"Circulating biomarkers including hs-CRP, adiponectin, myostatin, MMP, etc",,2009-12,COMPLETED,OBSERVATIONAL,['NA']
13492,NCT01160887,glucose,,,2010-06,COMPLETED,OBSERVATIONAL,['NA']
13493,NCT04632277,Serum Cholesterol,Serum Creatinine.,Body mass index,2020-08-25,COMPLETED,INTERVENTIONAL,['NA']
13494,NCT00569400,Change of human insulin antibodies,Frequency of adverse events,,2003-05-01,COMPLETED,INTERVENTIONAL,['PHASE3']
13495,NCT02525263,"Serial Estimation of Glomerular Filtration Rate (GFR) Through 6 Months Following the Final Cell Implantation, as Measured by Serial Serum Creatinine.",Renal-specific Laboratory Assessments Through 12 Months Following the Last NKA Implantation Under This Protocol.,Evaluation of Renal Structure Over Time as Measured by Imaging Modalities.,2016-07,TERMINATED,INTERVENTIONAL,['PHASE2']
13496,NCT01220856,The Percentage of Insulin-independent Patients Following Single Infusion Islet Cell Transplantation at Day 75 +/- 5,,Change From Pre-transplant in Cytokine Levels - IL-6,2010-07-28,COMPLETED,INTERVENTIONAL,['PHASE2']
13497,NCT01545492,difference in 'change in z score for weight' at 12 m(+/- 2m),differences in DNA methylation,,2012-01,UNKNOWN,OBSERVATIONAL,['NA']
13498,NCT05482958,Glycemic control amongst people with established T2DM.,Change in glycemic control.,,2022-07-29,RECRUITING,OBSERVATIONAL,['NA']
13499,NCT02343471,Effect on apolipoprotein B48 of whey protein as pre-meal after a high-fat meal in healthy subjects and subjects with type 2 diabetes measured as incremental Area Under the Curve (iAUC -15 - 360 min).,Gastric inhibitory peptide (GIP) responses measured as incremental Area Under the Curve (AUC -15 - 360 min).,Responses of satiety visual analog scale (VAS) measured as incremental Area Under the Curve (AUC -15 - 360 min),2015-03,COMPLETED,INTERVENTIONAL,['NA']
13500,NCT01582243,Mean Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24,The Percentage of Patients Achieving the Two Glycemic Goals After 12- and 24-week Treatment,,2013-04,COMPLETED,INTERVENTIONAL,['PHASE4']
13501,NCT02489773,Compare the Pearson Correlation of Glycated Albumin (GA) and Fructosamine Within All Subjects With the Performance Goal of 0.8,"Kendall Correlation Analysis of Changes in GA, HbA1c, and 7-day Interval MBG in the First 3 Months in Group 1",,2015-06,COMPLETED,OBSERVATIONAL,['NA']
13502,NCT05788965,"Feasibility, safety, tolerability",,,2023-04-30,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
13503,NCT04601519,Objective sleep fragmentation,Sleep fragmentation by subgroups,,2021-07-01,UNKNOWN,OBSERVATIONAL,['NA']
13504,NCT04554810,Knowledge about chronic medications scores,,,2015-05-10,COMPLETED,INTERVENTIONAL,['NA']
13505,NCT05654727,BDNF,,,2021-07-01,COMPLETED,OBSERVATIONAL,['NA']
13506,NCT06143267,Total glucagon response,Food intake,,2022-12-06,RECRUITING,INTERVENTIONAL,['NA']
13507,NCT03774186,Fear of Hypoglycemia Score,Fetal Outcomes: Number of Participants With Neonatal Hypoglycemia Infants,,2019-03-21,COMPLETED,INTERVENTIONAL,['NA']
13508,NCT04051866,Glycated Hemoglobin A (HbA1c),Gingival Probing bleeding,,2022-12-02,WITHDRAWN,INTERVENTIONAL,['NA']
13509,NCT00978627,Extension Trial (Primary Endpoint): Rate of Treatment Emergent Adverse Events (AEs),Extension Trial (Secondary Endpoint): Change in Fasting Plasma Glucose (FPG) After 52 Weeks of Treatment,,2009-08,COMPLETED,INTERVENTIONAL,['PHASE3']
13510,NCT00325559,Paired difference in the time to complete a time trial corresponding to 5 km cycling between euglycaemia and hyperglycaemia,Pretest diary data,,2006-06,COMPLETED,INTERVENTIONAL,['NA']
13511,NCT00464776,Investigate the antiproteinuric effect of increasing doses of Aliskiren compared to matching placebo.,To investigate whether there is a change in biomarkers of inflammation and cardiovascular risk.,,2005-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13512,NCT01671735,weight loss,,,2012-09,WITHDRAWN,INTERVENTIONAL,['NA']
13513,NCT01547897,Effect of NOX-E36 on albuminuria as measured by ACR (albumin to creatinine ratio; mg/g),Effect of NOX-E36 on eGFR,,2012-03,COMPLETED,INTERVENTIONAL,['PHASE2']
13514,NCT05136287,Weight loss,Number of participants experiencing adverse events,,2022-02-01,COMPLETED,OBSERVATIONAL,['NA']
13515,NCT00205738,Effects of olanzapine/risperidone/haloperidol on glucose regulation.,Explore Treatment-related effects on glucose effectiveness.,,2000-07,COMPLETED,INTERVENTIONAL,['NA']
13516,NCT00873223,Insulin detemir pharmacokinetics with and without liraglutide administration,Pharmacokinetics of liraglutide with and without insulin detemir,,2009-03,COMPLETED,INTERVENTIONAL,['PHASE1']
13517,NCT04013581,Change of HbA1c,Change of liver enzymes,,2019-08-05,COMPLETED,INTERVENTIONAL,['PHASE4']
13518,NCT02327039,"Change from baseline in reverse cholesterol transport, measured as cholesterol efflux capacity of patient's plasma",Safety as measured by monitoring of adverse events,Exploratory analyses - changes from baseline in impedance cardiography analysis,2015-03,COMPLETED,INTERVENTIONAL,['PHASE4']
13519,NCT01363336,General evaluation of patient concerning efficacy of AdalatCR treatment in real practice,Overall evaluation,,2009-11,COMPLETED,OBSERVATIONAL,['NA']
13520,NCT04040595,Mean adipocyte size (µm2) assessed using Image J software.,"Adipose tissue expression of genes that are determinants of adipose inflammation (IL-1beta, IL-6, and 8, TNFalpha, MCP-1/CCL2).",,2019-03-07,COMPLETED,INTERVENTIONAL,['NA']
13521,NCT01976689,Left ventricular hypertrophy,,,2012-03,COMPLETED,OBSERVATIONAL,['NA']
13522,NCT02417090,Metabolic late effects,,,2015-05,COMPLETED,OBSERVATIONAL,['NA']
13523,NCT01929018,Timed Up-and-Go Test,World Health Organization Disability Assessment Scale,,2013-10-09,COMPLETED,INTERVENTIONAL,['NA']
13524,NCT05015504,estimated hemoglobin A1c levels,body weight,,2022-02-10,RECRUITING,INTERVENTIONAL,['NA']
13525,NCT03483129,Percentage of eligible patients recruited into the study assessed by study attendance and surgery patient records,Change in the urinary concentration of metabolites of high health importance assessed by FIE-MS,,2018-04-25,COMPLETED,INTERVENTIONAL,['NA']
13526,NCT04097600,"AUC0-24h,sema,SS; area under the semaglutide plasma concentration-time curve during a dosing interval at steady state","t½,sema,SS; terminal half-life of semaglutide at steady state",,2019-09-30,COMPLETED,INTERVENTIONAL,['PHASE1']
13527,NCT06024590,The primary endpoint is the percentage of index ulcers healed at 12 weeks,Wound complication rate,,2023-10-03,RECRUITING,INTERVENTIONAL,['PHASE4']
13528,NCT02158442,"Efficacy of Timentin Delivered by PILP Procedure (Treatment Group) Versus Intravenous Delivery (Control Group) at Reducing Microbiological Load in Subjects With Diabetes, and Significant Wound Infection of the Lower Limb.",,,2013-10,COMPLETED,INTERVENTIONAL,['PHASE2']
13529,NCT03162926,Incidence of all adverse events reported for subjects,,,2017-07-05,COMPLETED,INTERVENTIONAL,['PHASE1']
13530,NCT02265276,Change in the NAFLD fibrosis score,Change in HbA1c,,2014-10,UNKNOWN,INTERVENTIONAL,['PHASE3']
13531,NCT05785780,Up-to-date CRC screening,Rate of CRC Screening Uptake by Glucose Control (Controlled vs. Uncontrolled) Among Participants with Type 2 Diabetes,Implementation Fidelity,2022-11-01,RECRUITING,INTERVENTIONAL,['NA']
13532,NCT00214253,post-transplant islet function,Suitability of cadaver donor pancreases for islet transplantation,,2002-02,COMPLETED,INTERVENTIONAL,['PHASE1']
13533,NCT00159679,Nerve conduction measurements; Pain scores from patient diaries,Proportion of patients with at least a 50% reduction in pain scores; Short-Form McGill Pain Questionnaire; Sleep interference scores from patient diaries; Clinical Global Impression of Change; Patient Global Impression of Change,,2004-09,COMPLETED,INTERVENTIONAL,['PHASE4']
13534,NCT05174390,Number of participants with the diagnosis of atrial fibrillation,Patient-reported symptoms (descriptive category variables) of atrial fibrillation using a questionnaire in a digital application,,2021-09-20,UNKNOWN,OBSERVATIONAL,['NA']
13535,NCT05980754,biochemical parameters including level of insulin,pancreatic fat content,,2024-05-20,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
13536,NCT04407650,Glycaemic control,Biomedical neonatal outcomes,,2021-07-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
13537,NCT00660790,Change of Intima Media Thickness (IMT),,,2008-04,COMPLETED,OBSERVATIONAL,['NA']
13538,NCT01108263,Overall Decrease in Wound Size,Decreased Peak Plantar Pressures in Both the Static and Dynamic Phases of Gait as Compared to Pre-operative Pressure Values.,,2010-06,TERMINATED,INTERVENTIONAL,['PHASE4']
13539,NCT02772497,Proportion of visual acuity improvement using Snellen chart or equivalent,Number of eyes with retinal toxicity after ziv aflibercept treatment,,2016-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
13540,NCT04486547,Change from baseline social motivation level of adolescents at 6 months,,,2018-10-15,COMPLETED,INTERVENTIONAL,['NA']
13541,NCT04336969,Change in rise of HbA1c,Change in education exposure to safe exercise strategies,"T1D Patients receiving 4T education and care monitored on a step-down cadence in study 2, will achieve an HBA1c non-inferior to weekly review",2020-06-18,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
13542,NCT00233298,"Differences in response among healthy, healthy obese, pre-diabetic or 3 diabetes",,,2005-05-26,COMPLETED,OBSERVATIONAL,['NA']
13543,NCT03378024,The correlation of changes of albuminuria and the outcome of PAD,,,2016-12-01,UNKNOWN,OBSERVATIONAL,['NA']
13544,NCT00605280,Number of Participants With Greater Than or Equal to ≥10 Letter (or 2 Line) Improvement in Vision at 1 Year,Number of Participants Requiring Focal or Grid Laser Treatment During Year 2,,2005-09,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
13545,NCT04234334,Plasma Zeaxanthin,Plasma glucose,,2020-01-13,COMPLETED,INTERVENTIONAL,['NA']
13546,NCT00850161,The primary endpoint is to determine whether intranasal administration of Nasulin™ will stimulate glucose disposal and suppress endogenous glucose production.,,,2009-07,WITHDRAWN,INTERVENTIONAL,['PHASE2']
13547,NCT03444467,Number of treatment emergent adverse events (TEAEs),Change from baseline in Activated Partial Thromboplastin time (APTT),,2018-02-05,COMPLETED,INTERVENTIONAL,['PHASE1']
13548,NCT01029392,Change in Hemoglobin A1c,Change in Insulin Requirements,,2009-11,COMPLETED,INTERVENTIONAL,['PHASE3']
13549,NCT00179400,Whole body in vivo glucose turnover,,,2000-12,COMPLETED,INTERVENTIONAL,['PHASE4']
13550,NCT05443204,MFG discharge - hypoglycaemic events,Postprandial glucose intersticial monitoringdiabetes specific supplement,,2022-07-07,RECRUITING,INTERVENTIONAL,['NA']
13551,NCT03084900,HbA1c value,DKA,,2017-07-27,COMPLETED,INTERVENTIONAL,['NA']
13552,NCT00000539,,,,1992-09,COMPLETED,INTERVENTIONAL,['PHASE3']
13553,NCT00641719,Number of Participants Who Experienced an Adverse Event (AE),Change From Baseline to One Year Endpoint in Beck Depression Inventory-II (BDI-II) Total Score,,2008-03,COMPLETED,INTERVENTIONAL,['PHASE3']
13554,NCT00726713,Change From Baseline in Vibration Perception Threshold (VPT) at 24 Weeks,(Exploratory) Change From Baseline in Levels Potential Antioxidant (PAO) at Week 24,,2008-06,COMPLETED,INTERVENTIONAL,['PHASE4']
13555,NCT03258840,HbA1c,Serum Lpa,,2013-01,COMPLETED,INTERVENTIONAL,['NA']
13556,NCT03133156,Changes in human adipose tissue characteristics following exercise training.,,,2017-06-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
13557,NCT03383627,Mean HbA1c,Determination of Serum Fructosamine,,2017-11-30,COMPLETED,INTERVENTIONAL,['NA']
13558,NCT01729299,post-prandial insulin secretion,gastric emptying,,2013-04,UNKNOWN,INTERVENTIONAL,['NA']
13559,NCT03513055,the relationship between SDBG and injection score,the relation between insulin antibodies and glucose excursions,,2018-05-07,UNKNOWN,INTERVENTIONAL,['NA']
13560,NCT05950477,"In 100 subjects with type 1 diabetes it will be evaluated the relationship between time in range, assessed though continuous glucose monitoring, and the score of the depression questionnaire CES-D",,,2023-06-12,RECRUITING,OBSERVATIONAL,['NA']
13561,NCT00173134,,,,2005-05,UNKNOWN,OBSERVATIONAL,['NA']
13562,NCT01514292,CGM Relative Differences to Laboratory Reference,,,2011-12,COMPLETED,INTERVENTIONAL,['NA']
13563,NCT01079234,Extension Trial (Primary Endpoint): Rate of Nocturnal Confirmed Hypoglycaemic Episodes,Extension Trial (Secondary Endpoint): Change in Fasting Plasma Glucose (FPG) After 52 Weeks of Treatment,,2010-03,COMPLETED,INTERVENTIONAL,['PHASE3']
13564,NCT01590797,Number of Participants Discontinuing Study Medication Due to an AE,Change From Baseline in 2-Hour Post Meal Glucose Levels at Week 24 in Participants Receiving Insulin Alone or in Combination With Metformin,,2012-07-10,COMPLETED,INTERVENTIONAL,['PHASE3']
13565,NCT05759897,Mean Change From Baseline in HbA1c at Week 16,"A summary of adverse events, including serious adverse events (SAEs), and Hypoglycemic Event[",,2023-02-28,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
13566,NCT00693537,,,,na,COMPLETED,INTERVENTIONAL,['PHASE4']
13567,NCT00049907,,,,2002-09,COMPLETED,OBSERVATIONAL,['NA']
13568,NCT01431430,Patient death,Renal lithiasis,,2012-01-06,COMPLETED,INTERVENTIONAL,['PHASE4']
13569,NCT02321878,Number of AEs (adverse events),Change in HbA1c (glycosylated haemoglobin),,2014-12-15,COMPLETED,OBSERVATIONAL,['NA']
13570,NCT05541484,Ketone levels measured in blood and breath in persons with T1D in persons with T1D,Ketone levels in persons with T1D during usual care versus usual care plus SGLT2i treatment,Ketone levels in persons with T1D undergoing insulin withdrawal,2022-10-14,RECRUITING,INTERVENTIONAL,['PHASE4']
13571,NCT01765517,effects of probiotics on endotoxin levels in patients with T2DM,effects of probiotics on gut microflora,Effects of probiotics on insulin resistance,2013-10,COMPLETED,INTERVENTIONAL,['NA']
13572,NCT00288132,Hemoglobin A1c,Waist Circumference,,2005-09,COMPLETED,INTERVENTIONAL,['NA']
13573,NCT01383772,Risk of failing visual field criteria to hold a driving licence.,Visual field assessment prior to planned pan retinal photocoagulation,,2012-06,COMPLETED,INTERVENTIONAL,['NA']
13574,NCT04318184,"""Change"" is being assessed for Triglyceride","""Change"" is being assessed for BMI",,2018-01-02,COMPLETED,INTERVENTIONAL,['NA']
13575,NCT00268541,Adipose tissue gene expression at 8 weeks,Body composition/adiposity at 8 weeks,,2004-09,COMPLETED,INTERVENTIONAL,['NA']
13576,NCT05525884,Diagnosis of significant hepatic fibrosis,High HOMA-IR,,2017-01-01,RECRUITING,OBSERVATIONAL,['NA']
13577,NCT00742521,catecholamine measures,,,2001-03,COMPLETED,INTERVENTIONAL,['NA']
13578,NCT01500590,change of estimated GFR calculated by MDRD equation and onset of microalbuminuria,,,2011-11,UNKNOWN,INTERVENTIONAL,['PHASE4']
13579,NCT03975309,Montreal Cognitive Assessments (MoCA),Number Span Test (Forward/Backward),,2019-09-09,COMPLETED,OBSERVATIONAL,['NA']
13580,NCT03312582,Peri-implant prpbing depth,,,2015-03-15,COMPLETED,INTERVENTIONAL,['PHASE4']
13581,NCT05705271,Number of participants with hyperkalemia events,Change in urine albumin-to-creatinine ratio (UACR) from baseline to 4 months,,2023-02-08,RECRUITING,INTERVENTIONAL,['PHASE4']
13582,NCT05095922,Blood pressure,,,2023-03-28,RECRUITING,INTERVENTIONAL,['PHASE4']
13583,NCT00518167,Diabetes incidence,CVD incidence,,1993-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
13584,NCT00873405,"Weight loss, BMI reduction and waist circumference reduction","Glucose homeostasis, metabolic control.",,2006-06,UNKNOWN,INTERVENTIONAL,['NA']
13585,NCT02816073,Regression of neovascularization,Retreatment rate,,2012-12,COMPLETED,INTERVENTIONAL,['NA']
13586,NCT01565317,Change in Sural nerve conduction velocity,Change in Sural Nerve Amplitude potential,,2012-04,COMPLETED,INTERVENTIONAL,['NA']
13587,NCT00839865,The primary objective is to determine the effect of this ointment on the incidence of complete wound closure.,"Secondary objectives include: evaluating the acceleration of ulcer closure or facilitation of surgical closure, reduction of ulcer surface area over time, reduction in complications, the quality of life and it's safety.",,2008-11,UNKNOWN,INTERVENTIONAL,['PHASE2']
13588,NCT00005146,,,,1979-05,COMPLETED,OBSERVATIONAL,['NA']
13589,NCT01823367,Changes in weight,Changes in diet,,2012-12,COMPLETED,INTERVENTIONAL,['NA']
13590,NCT01572649,GLU-AUC 0:30-4:30h: area under the plasma glucose concentration time profile from time of the standardized breakfast start (30 min after IMP injection and pre-meal plasma glucose) until 4 hours later subtracting the pre-meal value,"Area under the concentration time profile from time of standardized breakfast start (30 min after IMP injection) until 4 hours later for insulin, C-peptide and glucagon",,2012-05,COMPLETED,INTERVENTIONAL,['PHASE1']
13591,NCT00431977,Cardiac death,All-caused death,,2006-11,COMPLETED,INTERVENTIONAL,['NA']
13592,NCT03130426,The first occurrence of diabetes relapse,Glycated hemoglobin (HbA1C),,2017-06-27,COMPLETED,INTERVENTIONAL,['PHASE3']
13593,NCT04678557,Cohort 2: The Change in AUC (Area Under Curve) From Baseline to Week 26 in C-peptide During 4-hour MMTT,,,2019-06-25,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13594,NCT01020955,Insulin sensitivity,body composition,,2009-10,COMPLETED,INTERVENTIONAL,['PHASE3']
13595,NCT03400618,The difference in mean glucose level,Hypoglycemia confidence score,Ketoacidosis,2018-03-01,COMPLETED,INTERVENTIONAL,['NA']
13596,NCT05487534,Glucose variability and insulin resistance (CGMS - 10 days),Attentional Cueing Procedure,,2023-04-26,RECRUITING,OBSERVATIONAL,['NA']
13597,NCT01125553,Maximum observed serum insulin aspart concentration,Time to maximum observed serum insulin aspart concentration,,2010-05,COMPLETED,INTERVENTIONAL,['PHASE1']
13598,NCT02362737,Change help-seeking behaviors (Medication adherence and doctor/ER visits).,Change HbA1c.,,2015-01,UNKNOWN,INTERVENTIONAL,['NA']
13599,NCT00241085,Change from baseline in urinary protein excretion after 30 weeks,"Change from baseline in circulating markers of blood vessel inflammation, insulin resistance, serum creatinine, diabetic control, and proportion of patients who return to normalization of protein excretion after 30 weeks",,2002-11,COMPLETED,INTERVENTIONAL,['PHASE4']
13600,NCT05597202,Difference in coronary 68Ga-Dotatate uptake after treatment.,Difference in bone marrow aspirates after treatment.,,2023-01-01,RECRUITING,INTERVENTIONAL,['PHASE4']
13601,NCT01886989,Blood pressure (mm Hg),Inflammation,,2012-01,COMPLETED,INTERVENTIONAL,['NA']
13602,NCT05756829,Change from Baseline HbA1c at 6 months,,,2023-05-10,RECRUITING,INTERVENTIONAL,['NA']
13603,NCT00874159,Percentage of diabetic patients having diabetic eye complications,"Minimum duration of diabetes associated with 10% incidence of diabetic complications (CVD, nephropathy and retinopathy)",,2009-04,COMPLETED,OBSERVATIONAL,['NA']
13604,NCT01045005,Doppler Blood flow velocity waveforms measured at rest and after administration of oxygen and carbon dioxide,Radial Artery pressure waveforms,,2006-01,WITHDRAWN,INTERVENTIONAL,['NA']
13605,NCT01965496,To assess HbA1C levels after 14 weeks continuous treatment,To assess Fasting blood glucose levels,To assess the body weights after the treatment,2012-03,COMPLETED,INTERVENTIONAL,['PHASE1']
13606,NCT04413578,HbA1c Range,Healthcare Cost,,2018-12-01,COMPLETED,INTERVENTIONAL,['PHASE4']
13607,NCT03782649,Generation and validation of prediction models - Consensus Error Grid,Safety evaluation: paucity of adverse events,,2018-11-29,COMPLETED,INTERVENTIONAL,['NA']
13608,NCT03015220,Number of Treatment-emergent Adverse Events (TEAEs),Diabetes Therapy-Related Quality of Life (DTR-QoL): Total Score and Scores for the 4 Domains,,2017-01-10,COMPLETED,INTERVENTIONAL,['PHASE3']
13609,NCT05073302,Rate of inflammation in the DL implant site,Cellular composition demonstrated by immunohistochemistry,,2022-03-22,RECRUITING,INTERVENTIONAL,['PHASE1']
13610,NCT06241664,Sensitivity and Specificity,,,2024-01-31,RECRUITING,INTERVENTIONAL,['NA']
13611,NCT02963766,Change From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses) at Week 26,PK: Area Under the Concentration Time Curve Over a 1-week Interval of Dulaglutide at Steady-State [AUC(0-168)ss],,2016-12-29,COMPLETED,INTERVENTIONAL,['PHASE3']
13612,NCT02036515,Percentage of Participants Discontinuing Study Treatment Due to an AE,Change From Baseline in EQ-5D-3L Score at Week 52,,2014-03-12,COMPLETED,INTERVENTIONAL,['PHASE3']
13613,NCT02470806,Percentage Change in Ulcer Area From Baseline to the End of the Treatment Period,Percentage Change in Target Ulcer Depth and Volume Following Treatment With Either PICO or tNPWT From Baseline Over the 12-week Treatment Period,,2015-07-02,COMPLETED,INTERVENTIONAL,['NA']
13614,NCT04866667,New-onset cardiovascular events,Microvascular complications,,2021-05-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
13615,NCT04977583,Connection to New Resources,Hemoglobin A1c (HbA1c),,2022-05-02,COMPLETED,INTERVENTIONAL,['NA']
13616,NCT05990530,Residual β-Cell function (RBCF),Quality of life score,,2023-02-22,RECRUITING,INTERVENTIONAL,['PHASE2']
13617,NCT04143737,Change in average daily steps- measured by Pedometer,Change in Leadership self-efficacy scale,,2016-03-07,COMPLETED,INTERVENTIONAL,['NA']
13618,NCT00687063,Weight change from baseline,Insulin dose and frequency at the end of the study,,2008-04,COMPLETED,OBSERVATIONAL,['NA']
13619,NCT01511692,The energy intake at a standardised buffet meal with a preload paradigm quantified using Foodworks 2.10,Adverse events,,2005-11,COMPLETED,INTERVENTIONAL,['PHASE1']
13620,NCT04090008,Percent reduction in the ulcer size,,,2017-08-01,COMPLETED,INTERVENTIONAL,['NA']
13621,NCT02072902,Hazard ratios for all-site and site specific cancer,,,2012-03,COMPLETED,OBSERVATIONAL,['NA']
13622,NCT01193387,Maximum observed Insulin Degludec concentration,Area under the Insulin Degludec concentration-time curve,,2010-08,COMPLETED,INTERVENTIONAL,['PHASE1']
13623,NCT01869881,ACR(Urine Albumin/Creatinine ratio),PCR(Protein to Creatinine ratio in Urine),,2013-02-01,COMPLETED,INTERVENTIONAL,['PHASE4']
13624,NCT00508014,"Mean change in blood pressure, glycated hemoglobin, and LDL-cholesterol between baseline and follow-up","Use of aspirin, ACE inhibiters/ARBs (diabetic patients), pneumonia vaccine updated, diabetic foot exam, diabetic microalbumuria check, retinal exam, smoking cessation counseling, dental visit, and self management goal",,2006-12,COMPLETED,INTERVENTIONAL,['NA']
13625,NCT00171561,Blood measures of hypertension after 24 weeks,Change in serum markers of endothelial function and oxidative stress after 24 weeks,,2003-03,COMPLETED,INTERVENTIONAL,['PHASE4']
13626,NCT00324350,Number of Participants With at Least One Fall,Number of Participants With > 2 cm of Height Loss,,2003-10,COMPLETED,INTERVENTIONAL,['PHASE3']
13627,NCT01246687,Change from Baseline in Dietary KAB Score at 12 months,Change from Baseline in blood biomarkers at 12 months,,2010-03,COMPLETED,INTERVENTIONAL,['NA']
13628,NCT03364868,The development of diabetes,Abnormal glucose tolerance (AGT) defined by dysglycemia or diabetes.,,2018-02-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
13629,NCT01963546,Stress Indicators,Vital Signs,,2014-03,UNKNOWN,INTERVENTIONAL,['NA']
13630,NCT02206152,Difference in Epinephrine Secretion During the Morning Episodes of Hypoglycemia on Days One and Two Under the Two Treatment Conditions,,,2015-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13631,NCT02986256,Number of hospitalization days related to diabetic foot ulcers after one year of follow-up,Patient satisfaction score,,2017-01-04,COMPLETED,INTERVENTIONAL,['NA']
13632,NCT03416855,Percentage of patients with AEs at week 26,Changes from baseline in PPBG/PPPG after 26 weeks treatment,,2018-01-31,COMPLETED,OBSERVATIONAL,['NA']
13633,NCT03858062,Time in target,Glucose measurement performance,Glucagon dose,2019-03-10,COMPLETED,INTERVENTIONAL,['NA']
13634,NCT02665455,Point Accuracy Determined as % Within Consensus Error Grid Zone A,,,2016-01,COMPLETED,INTERVENTIONAL,['NA']
13635,NCT06236581,Change from baseline on percent time in range from continuous glucose monitor at post-intervention,,,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
13636,NCT04917692,Number of episodes of diabetic ketoacidosis per patient,Number of episodes of hypoglycemia per patient,,2021-07,WITHDRAWN,INTERVENTIONAL,['PHASE4']
13637,NCT01464320,Change in glomerular filtration rate,Change in urinary albumin excretion,,2011-11,COMPLETED,INTERVENTIONAL,['PHASE1']
13638,NCT01580813,Evaluate the Impact of Acipimox on Exercise Parameters in People With Type 2 Diabetes: Peak VO2,Triglycerides,,2011-06,COMPLETED,INTERVENTIONAL,['NA']
13639,NCT04657939,Change in myocardial perfusion after treatment,Peripheral endothelial function,,2020-12-01,COMPLETED,INTERVENTIONAL,['PHASE4']
13640,NCT03684642,Change From Baseline to Week 56 in HbA1c,Number of Hypoglycemic Events (Documented Symptomatic Hypoglycemia <3.0 mmol/L [<54 mg/dL] and Severe Hypoglycemia) Per Participant-Year,,2018-09-26,TERMINATED,INTERVENTIONAL,['PHASE3']
13641,NCT03060577,Percentage Change in LDL-C From Baseline of the ORION-1 Study to Day 210 in ORION-3 (Inclisiran Arm),"Number of Participants Reaching on Treatment LDL-C Levels of <25 mg/dL, <50 mg/dL, <70 mg/dL, and <100 mg/dL (Inclisiran Arm)",,2017-04-27,COMPLETED,INTERVENTIONAL,['PHASE2']
13642,NCT01167959,Changes in gut hormones,,,2009-06,COMPLETED,OBSERVATIONAL,['NA']
13643,NCT04359771,Change in the Best Corrected Visual Acuity (BCVA),,,2018-01-22,COMPLETED,INTERVENTIONAL,['PHASE4']
13644,NCT03849261,AUClast of Metformin,CL/F of Metformin,,2019-01-14,UNKNOWN,INTERVENTIONAL,['PHASE1']
13645,NCT05680129,Change from baseline in HbA1c,Pharmacokinetics: plasma trough level of XW003,,2023-01-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
13646,NCT02700477,Post prandial blood sugar levels,Glycosylated haemoglobin (HbA1C)(%),,2013-07,COMPLETED,INTERVENTIONAL,['PHASE4']
13647,NCT02052037,Glycemic Index,Physical Activity,,2014-01,COMPLETED,INTERVENTIONAL,['NA']
13648,NCT00957957,Change from baseline in PYY (Peptide YY) measured by ELISA 4 weeks after RYGBP,Change from baseline in PYY measured by dMS 4 weeks after RYGBP,,2010-02,COMPLETED,OBSERVATIONAL,['NA']
13649,NCT04023344,Antibody Response,Treatment Satisfaction,,2018-03-14,COMPLETED,INTERVENTIONAL,['PHASE3']
13650,NCT05369585,Evolution of energy metabolism (energy expenditure),"Evolution of metabolomics (amino acids, fatty acids and acylcarnitine species)",,2022-04-25,COMPLETED,INTERVENTIONAL,['NA']
13651,NCT06228313,VivaChek Ino glucose concentration,,,2022-06-01,COMPLETED,OBSERVATIONAL,['NA']
13652,NCT02311504,presence of diabetic retinopathy,,,2014-01,COMPLETED,OBSERVATIONAL,['NA']
13653,NCT00449839,Absorbed Insulin Aspart,,,2007-04,COMPLETED,INTERVENTIONAL,['PHASE4']
13654,NCT03737942,neuromuscular monitoring,,,2018-11-15,UNKNOWN,OBSERVATIONAL,['NA']
13655,NCT02011100,chronic systemic inflammation,level of glucose intolerance,muscle carnosine content,2013-12,COMPLETED,INTERVENTIONAL,['NA']
13656,NCT02616666,Proportion of patients achieving clinical success as measured by a 4-item composite endpoint.,"To assess differences between dapagliflozin and SOC in the healthcare resource utilization up to 52 weeks following randomization and separately, up to 104 weeks following randomization",,2016-08-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4']
13657,NCT01318070,Change From Baseline in Glycosylated Hemoglobin (Week 12).,Change From Baseline in Blood Glucose Measured by the Meal Tolerance Test (Week 12).,,2007-11,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
13658,NCT00164658,Change in stage of adoption of health behaviors and referral for additional screening and follow up for high risk participants at 6 month post evaluation,Primary care physicians' provision of preventive services in response to family medical history.,,2005-09,COMPLETED,INTERVENTIONAL,['PHASE1']
13659,NCT05335083,Mean 24 hour glucose difference between the CPAP on and CPAP off conditions,Insulin sensitivity,,2023-01-31,RECRUITING,INTERVENTIONAL,['NA']
13660,NCT04272359,Long-term diabetes complications,Insulin parameters after shift to new-generation hypoglycaemic therapeutic regimens,,2019-05-06,UNKNOWN,OBSERVATIONAL,['NA']
13661,NCT01067092,% of persons with blood pressure less than 130/80,Summary of Diabetes Self-Care Activities,,2005-05,COMPLETED,INTERVENTIONAL,['NA']
13662,NCT01053936,To assess a trend in mean change from baseline to Day 29 in eGFR (as estimated by the 4-component MDRD formula) with increasing doses of bardoxolone methyl (amorphous dispersion) in patients with Type 2 diabetes and CKD (eGFR 15-45 mL/min/1.73m2).,To assess a trend in mean change from baseline to Day 85 in eGFR (as estimated by the 4-component MDRD formula with increasing doses of bardoxolone methyl (amorphous dispersion) in patients with Type 2 diabetes and CKD (eGFR 15-45 mL/min/1.73m2),,2010-01-31,COMPLETED,INTERVENTIONAL,['PHASE2']
13663,NCT02025751,"Gastroparesis Symptom Assessment (GSA), a Patient Reported Outcome Measure",,,2014-04,COMPLETED,INTERVENTIONAL,['PHASE3']
13664,NCT02370719,Change in HbA1c from baseline to 12 months,Summary of Diabetes Self-Care Activities,,2015-06-28,TERMINATED,INTERVENTIONAL,['NA']
13665,NCT01475201,change in arterial stiffness,change in diastolic blood pressure,,2012-02,COMPLETED,INTERVENTIONAL,['NA']
13666,NCT05679037,The change in carotid artery intima-media thickness (CIMT),Fast blood glucose measuremt,,2023-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
13667,NCT05476627,Number of Participants with all cause death,Advanced Intelligence Assessment with Mini-Mental State Examination (MMSE),,2022-07-01,RECRUITING,OBSERVATIONAL,['NA']
13668,NCT01911663,change from baseline in glucose,change from baseline in C-peptide,,2011-11,COMPLETED,INTERVENTIONAL,['PHASE4']
13669,NCT00355849,"To compare in patients who at study entry have type 2 diabetes not optimally controlled by one or more oral antihyperglycemic medications plus once daily insulin glargine, a regimen that may include mealtime AIR Insulin.",To assess rate and incidence of hypoglycemia,,2006-08,COMPLETED,INTERVENTIONAL,['PHASE3']
13670,NCT04922294,Implementation preferences,,,2020-07-20,COMPLETED,OBSERVATIONAL,['NA']
13671,NCT03339453,Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia,PK: Time to Maximum Concentration (Tmax) of Baseline Adjusted Glucagon,,2017-11-10,COMPLETED,INTERVENTIONAL,['PHASE1']
13672,NCT01956773,Number of Participants With Uptake of Genetic Counseling for Those at Risk of Hereditary Conditions at 1 Year,Number of Providers Who Were Successfully Using MeTree in Their Clinical Work Flow,,2014-04-11,COMPLETED,INTERVENTIONAL,['NA']
13673,NCT02687893,Mean duration of time with sensed glucose less than 70 mg/dl post-exercise,Mean duration of time with capillary blood glucose > 180 mg/dl,,2016-02,COMPLETED,INTERVENTIONAL,['NA']
13674,NCT03761719,Neurocognitive test domain scores,,,2018-07-30,COMPLETED,OBSERVATIONAL,['NA']
13675,NCT04266054,Glycemic control as measured by hemoglobin A1c. Hemoglobin A1c will be measured from whole blood samples obtained and analyzed in a blinded fashion.,triglycerides will be measured from the same blood sample used to derive the outcome measure.,,2019-12-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
13676,NCT02181621,Within-patient Change From Baseline in Log^10 Biofilm-protected Bacteria Count (Colony Forming Units [Cfu]/Gram[g]),Presence of Biofilm by Clinical Judgment Versus Presence of Biofilm by Laboratory Test,,2014-08,TERMINATED,INTERVENTIONAL,['NA']
13677,NCT00179374,Metabolic control (measured by HbA1c),Cost evaluations,,2003-07,COMPLETED,INTERVENTIONAL,['NA']
13678,NCT04706637,Change of 24 hour urine creatinine,Adverse events,,2021-02-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
13679,NCT05477368,To determine the feasibility of conducting such an RCT: Retention as measured by the number of participants that complete the study,Self-reported blood pressure (systolic and diastolic),Viability of methods,2022-09-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
13680,NCT01123083,Change From Baseline in 2 Hour Mixed Meal-stimulated C-peptide Area Under Curve (AUC) (Normalized for 120-minute Time Interval) at Month 12,"Composite Rank Sum: C-Peptide AUC, HbA1c and Exogenous Insulin Use at 6 and 12 Months",,2010-05-17,COMPLETED,INTERVENTIONAL,['PHASE3']
13681,NCT01507389,Area under the Curve (0-infinity),Adverse events,,2006-03,COMPLETED,INTERVENTIONAL,['PHASE1']
13682,NCT05393284,Improvement in Diabetic Retinopathy Severity Scale (DRSS) score,Safety and tolerability,,2022-08-16,RECRUITING,INTERVENTIONAL,['PHASE2']
13683,NCT00513201,Glycemic control in lyspro vs regular insulin in cirrhotic patients,Tolerance to treatment and reduced postprandial hypoglycemia episodes,,na,COMPLETED,INTERVENTIONAL,['PHASE4']
13684,NCT00270842,Gait and Balance Measures,Fall Self Efficacy,,2006-01,COMPLETED,INTERVENTIONAL,['NA']
13685,NCT05260021,Change From Baseline in Hemoglobin A1c (HbA1c),Change From Baseline PedsQL (3.2) Diabetic Module,,2022-04-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
13686,NCT04731142,Number of Participants With Hospital Admissions,Change in Systolic Blood Pressure,,2021-06-01,COMPLETED,INTERVENTIONAL,['NA']
13687,NCT04018833,Functional change,,,2012-01-01,COMPLETED,OBSERVATIONAL,['NA']
13688,NCT01497535,Maximum glucose infusion rate (GIRmax),Adverse events,,2004-05-27,COMPLETED,INTERVENTIONAL,['PHASE1']
13689,NCT03062475,GDM,pre-eclampsia,,2019-05-01,UNKNOWN,INTERVENTIONAL,['NA']
13690,NCT02783677,Digital infrared thermal imaging (DITI),,,2013-01,UNKNOWN,OBSERVATIONAL,['NA']
13691,NCT04051294,Insulin level,Blood pressure,,2019-01-03,COMPLETED,INTERVENTIONAL,['NA']
13692,NCT02594397,the score of GCSI,motilin concentrations,,2015-12,UNKNOWN,INTERVENTIONAL,['NA']
13693,NCT05026723,Bodyweight at Month 6,Diabetes Distress Score as assessed by PAID-11 at Month 18,C-Reactive Protein (CRP) at Month 6,2021-10-04,RECRUITING,INTERVENTIONAL,['NA']
13694,NCT05508061,Percentage of time the glucose level is above 10 mmol/l for the study participants,AP-related parameters: algorithm activity,,2022-10-19,COMPLETED,INTERVENTIONAL,['NA']
13695,NCT02935855,Efficacy on coagulation parameters,Safety and tolerability parameters,,2015-09,COMPLETED,INTERVENTIONAL,['PHASE4']
13696,NCT06091501,The between group differences for change in Perceived competence in Diabetes (PCS-5),The between group differences for change in physical activity,,2023-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
13697,NCT04746599,Pain reduction,Limb salvage,,2021-01-01,UNKNOWN,INTERVENTIONAL,['NA']
13698,NCT01778738,Beta-cell function,Vitamin and mineral deficiencies,,2013-01,COMPLETED,INTERVENTIONAL,['NA']
13699,NCT00823381,global skeletal muscle gene expression profile,safety and tolerability,,2009-01,COMPLETED,INTERVENTIONAL,['NA']
13700,NCT00668850,"To compare the efficacy of Generex Oral-lyn™ RapidMist™ System and standard regular human insulin therapy as measured by HbA1c, in type-1 diabetes mellitus subjects on BID NPH intermediate acting insulin therapy","To evaluate the safety, tolerability, and satisfaction with Generex Oral-lyn™ therapy when administered by the RapidMist™ Diabetes Management System",,2008-04,UNKNOWN,INTERVENTIONAL,['PHASE3']
13701,NCT03945747,Change in estimated insulin sensitivity,Change in DXA scan,,2019-08-14,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
13702,NCT01412554,Exploring Insulin Sensitivity After 10-20 Years of Follow-up,Ultrasound Abdomen,,2011-08,COMPLETED,OBSERVATIONAL,['NA']
13703,NCT01907958,Stabilisation or improvement of urine albumin excretion status by at least one stage,Microalbuminuria (or further stages of CKD) after 12 months,"Demographics, medical history and medication Diabetes and hypertension status Blood pressure measurements",2013-04,UNKNOWN,OBSERVATIONAL,['NA']
13704,NCT03844217,"Change in Copeptin value (pmol/l), after intake of Macimorelin of 0.5mg/kg body weight",Change in Follicle-stimulating hormone value(FSH) (IU/mL),,2019-03-07,COMPLETED,INTERVENTIONAL,['NA']
13705,NCT04789148,Dot-probe task - anxious behavior between low dose oxytocin and placebo,Socioemotional functioning - Emotion recognition task between all three interventions,,2023-06,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
13706,NCT03912363,Neonatal blood glucose value,Incidence of composite neonatal outcome,,2019-11-01,RECRUITING,INTERVENTIONAL,['NA']
13707,NCT04621396,Type 2 Diabetes,,,2013-09,RECRUITING,OBSERVATIONAL,['NA']
13708,NCT03724981,Participant Preference Between 2 Injection Devices Based on Global Preference Item,Participant Preference Between 2 Injection Devices Based on Ease of Use,,2018-10-18,COMPLETED,INTERVENTIONAL,['PHASE4']
13709,NCT03482596,Glucose incremental Area Under the Curve (iAUC),Intervention perception,,2018-02-21,COMPLETED,INTERVENTIONAL,['NA']
13710,NCT05765097,TIR,mean BG,,2022-09-28,COMPLETED,INTERVENTIONAL,['NA']
13711,NCT02062034,Oxidative Stress markers,Progression and regression of non-proliferative diabetic retinopathy,Security profile,2011-02,COMPLETED,INTERVENTIONAL,['PHASE2']
13712,NCT01614496,Time spent with glucose in the target range,,,na,COMPLETED,INTERVENTIONAL,['NA']
13713,NCT03300934,Time spent in glucose target (%) (3.9 - 10 mmol/l),User experience after the 4 week treatment,,2017-07-01,COMPLETED,INTERVENTIONAL,['NA']
13714,NCT03166124,Pharmacokinetics: Insulin Lispro Area Under the Concentration Versus Time Curve (AUC) for Each Treatment Arm,Total Amount of Glucose Infused (Gtot) Over Duration of Clamp for Each Treatment Arm,,2017-05-24,COMPLETED,INTERVENTIONAL,['PHASE1']
13715,NCT00403195,,,,2006-11,COMPLETED,OBSERVATIONAL,['NA']
13716,NCT05104333,Neutralizing antibody level,Adverse events following vaccination,,2021-11,UNKNOWN,INTERVENTIONAL,['PHASE4']
13717,NCT03931759,The measurement of heart rate variability in laparoscopic surgeries,,,2019-06,UNKNOWN,INTERVENTIONAL,['NA']
13718,NCT05414968,Change from Baseline Pain Assessment,,,2023-03-22,RECRUITING,INTERVENTIONAL,['NA']
13719,NCT02132442,Change in hepatic triglyceride content (HTGC),Hemoglobin A1c,,2014-03,COMPLETED,INTERVENTIONAL,['PHASE3']
13720,NCT00940082,"the gender, height, weight, blood pressure, course of the disease of each patient was recorded","Left ventricular mass index (LVMI), relative wall thickness (RWT) were calculated and High-sensitive C-reactive protein (HsCRP), homocysteine and TNF-α were detected",,2007-06,UNKNOWN,OBSERVATIONAL,['NA']
13721,NCT00704574,"Incidence of serious adverse drug reactions, including major hypoglycaemic events",Variability in FPG (Fasting Plasma Glucose),,2008-01,COMPLETED,OBSERVATIONAL,['NA']
13722,NCT05977205,Glycemic control,Fear of COVID-19 infection,,2020-05-02,COMPLETED,OBSERVATIONAL,['NA']
13723,NCT01336023,Mean Change From Baseline in HbA1c (Glycosylated Haemoglobin) at Week 26.,Mean Actual Daily Insulin Dose,,2011-05-23,COMPLETED,INTERVENTIONAL,['PHASE3']
13724,NCT05390307,Weight,Weight change,,2023-04-01,COMPLETED,INTERVENTIONAL,['NA']
13725,NCT05430204,Number of fetal or neonatal deaths,Number of participants who formula fed their babies,,2023-03-07,RECRUITING,INTERVENTIONAL,['NA']
13726,NCT01563120,glycemic control,,,2012-01,COMPLETED,INTERVENTIONAL,['PHASE4']
13727,NCT04811989,General foot health,Representations about diabetic foot,Sociodemographic data,2021-03-08,COMPLETED,INTERVENTIONAL,['NA']
13728,NCT04860908,Presence of anti COVID 19 antibodies in maternal and cord blood,,,2021-04-26,UNKNOWN,OBSERVATIONAL,['NA']
13729,NCT03396484,DQ8 Antigen Presentation,,,2020-09,WITHDRAWN,INTERVENTIONAL,['PHASE2']
13730,NCT05166512,Change from baseline in body weight (kilograms (kg) and percent of baseline bodyweight),Change from baseline in food security status over the past 30 days using the 10-item United States Department of Agriculture (USDA) adult food security survey module,Program satisfaction among DPP Cooks participants (qualitative),2022-02-02,COMPLETED,INTERVENTIONAL,['NA']
13731,NCT03258281,Change From Baseline in Adenosine Diphosphate (ADP) Stimulated P-selectin Expression,Change in ADP-stimulated Cluster of Differentiation (CD)-147 MFI,,2018-05-01,TERMINATED,INTERVENTIONAL,['PHASE4']
13732,NCT03367390,Number of Participants Who Show a Resumption of Auto Mode Following Restored Continuous Glucose Monitoring (CGM) Connectivity,,,2017-11-08,COMPLETED,INTERVENTIONAL,['PHASE1']
13733,NCT00043797,,,,na,UNKNOWN,INTERVENTIONAL,['PHASE2']
13734,NCT02068443,Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) National Glycohemoglobin Standardization Program (NGSP) at the End of Treatment (EOT) Period,Number of Participants Who Had Clinically Relevant Changes in 12-Lead Electrocardiogram (ECG) Findings,,2014-02,COMPLETED,INTERVENTIONAL,['PHASE3']
13735,NCT02554851,The proportion of participants with 100% healing at the end of follow-up,,,2017-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
13736,NCT05492448,Changes in ratio of forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC).,Changes in scores of modified Bristol stool form scale.,,2022-09-19,RECRUITING,INTERVENTIONAL,['NA']
13737,NCT05730634,DOTATATE coronary arteries,Change in splenic/bone marrow DOTATATE signal,,2019-06-01,COMPLETED,INTERVENTIONAL,['NA']
13738,NCT03523143,TESGO composite outcome,The growth and development of the offspring,,2018-06-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
13739,NCT00264914,"Safety : Physical examination, vital signs, adverse events, electrocardiogram, hematology, serum chemistry",Serum sodium,,2005-07,COMPLETED,INTERVENTIONAL,['PHASE3']
13740,NCT01876849,"Long-term safety of twice-daily exenatide treatment, as defined by the occurrence of adverse events.",,,2003-12,COMPLETED,INTERVENTIONAL,['PHASE3']
13741,NCT03078049,Total costs,Index medication dose increase,,2017-03-31,COMPLETED,OBSERVATIONAL,['NA']
13742,NCT04335656,Change in composite inflammatory index after probiotic supplementation,scRNA-seq analyses of peripheral blood mononuclear cells,,2021-04-01,RECRUITING,INTERVENTIONAL,['PHASE2']
13743,NCT04120571,Blood glucose (CGM),Blood glucose (OGTT),,2019-04-01,UNKNOWN,INTERVENTIONAL,['NA']
13744,NCT05403853,Performance of the LumiraDx POC HbA1c assay when compared to a current CE marked reference method in patients being assessed for diagnosis or monitored for diabetes.,,,2022-04-19,COMPLETED,INTERVENTIONAL,['NA']
13745,NCT00687479,Insulin action measures,infant gestational age,,2006-01,COMPLETED,OBSERVATIONAL,['NA']
13746,NCT00353561,Mycological cure on the 15th day of therapy and defined as the absence of Candida growth on fungal culture of high vaginal swab,"Relief in clinical symptoms and signs of vulvovaginal candidiasis including vaginal discharge, pruritus, burning sensation and vaginal congestion",,2004-06,COMPLETED,INTERVENTIONAL,['PHASE3']
13747,NCT01977417,Aim 1: Vascular Endothelial Function in Obese Prediabetic Adults Before and After 1 Month of Salsalate or Placebo.,,,2012-11,TERMINATED,INTERVENTIONAL,['PHASE2']
13748,NCT00829569,insulin sensitivity,oxidative stress,,2004-01,COMPLETED,INTERVENTIONAL,['NA']
13749,NCT01836796,HbA1c,Urine albumine excretion rate,,2012-05,COMPLETED,INTERVENTIONAL,['NA']
13750,NCT00805922,Mean blood glucose parameters of diabetic patients,"Minimum duration of diabetes associated with 10% incidence of diabetic complications (CVD, Nephropathy and retinopathy)",,2008-12,COMPLETED,OBSERVATIONAL,['NA']
13751,NCT06055829,Glucose level,,,2022-10-24,COMPLETED,OBSERVATIONAL,['NA']
13752,NCT04387045,Salivary Tumor Necrosis Factor alpha,Depression,,2017-05-02,COMPLETED,INTERVENTIONAL,['NA']
13753,NCT01143948,optimal glycemic control in inpatient cirrhotics,Incidence of hypoglycemic episodes,,2011-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
13754,NCT03958539,The incidence of new ulcer in patients with high-risk diabetic feet is our primary outcome measure,Need for debridement of callus,,2019-08-05,UNKNOWN,INTERVENTIONAL,['NA']
13755,NCT05719961,Time to maximum concentration （Part II）,Incidence and severity of adverse events (AEs)（Part II）,,2023-01-05,RECRUITING,INTERVENTIONAL,['PHASE1']
13756,NCT01999218,Percentage of Participants Discontinuing Study Treatment Due to an AE Up to Week 104,Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Week 52 Excluding Rescue Approach,,2013-12-16,COMPLETED,INTERVENTIONAL,['PHASE3']
13757,NCT00599040,Insulin Sensitivity,,,2005-09,COMPLETED,INTERVENTIONAL,['PHASE4']
13758,NCT00799695,"a change in the proportion of diabetic patients who acted as a result of the phone contact, and obtained a retina eye exam.",,,2008-01,COMPLETED,INTERVENTIONAL,['NA']
13759,NCT01106625,Change in HbA1c From Baseline to Week 26,Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 26,,2010-05,COMPLETED,INTERVENTIONAL,['PHASE3']
13760,NCT05244200,Fasting plasma glucose (FPG),Body Weight.,,2022-01-20,UNKNOWN,INTERVENTIONAL,['NA']
13761,NCT04424290,Multiple dosing (MD) part: Number of patients with drug related adverse events (AEs) from drug administration till end of study (EOS),MD part: Number of patients with ocular AEs at EOS,,2020-06-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13762,NCT01511185,AUC (area under the curve) of Insulin Secretion Rate (ISR) over the 90-216 mg/dL glucose interval,Adverse events,,2001-02,COMPLETED,INTERVENTIONAL,['PHASE1']
13763,NCT05232708,"Cmax,sema,0.5mg: maximum observed semaglutide concentration-time after single dose of s.c. semaglutide 0.5 mg administration",,,2022-01-19,COMPLETED,INTERVENTIONAL,['PHASE1']
13764,NCT00005374,,,,1994-01,COMPLETED,OBSERVATIONAL,['NA']
13765,NCT01858597,The Concentration of Serum FGF19,Expression of FGF19 in Term Placenta,,2013-03,COMPLETED,INTERVENTIONAL,['NA']
13766,NCT04830462,OGTT (oral glucose tolerance test),Changes in body composition,,2021-04-15,COMPLETED,INTERVENTIONAL,['PHASE4']
13767,NCT03814694,Change in glycated hemoglobin (HbA1c) during 6 weeks of hypo-energetic CRHP diet compared with hypo-energetic CD diet.,Change in fasting plasma triglycerides during 6 weeks of hypo-energetic CRHP diet compared with hypo-energetic CD diet.,Change in health-related quality of life (HRQoL) after 6 weeks of hypo-energetic CRHP diet compared with hypo-energetic CD diet.,2019-01-29,COMPLETED,INTERVENTIONAL,['NA']
13768,NCT02806973,PD: Baseline-Adjusted Glucose Maximum Concentration (BGmax),,PK: Area Under the Curve Extrapolated to Infinity (AUC[0-inf]) of Glucagon,2015-01,COMPLETED,INTERVENTIONAL,['PHASE1']
13769,NCT01229891,Serum 25-hydroxyvitamin D,Serum High Density Lipoprotein (HDL),,2009-10,COMPLETED,INTERVENTIONAL,['PHASE2']
13770,NCT00245206,"Change in LDL cholesterol, HDL cholesterol, and triglycerides",,,2005-08,COMPLETED,INTERVENTIONAL,['PHASE4']
13771,NCT02984709,Glycemic Control (A1C),Self Care Inventory,,2016-10,COMPLETED,INTERVENTIONAL,['NA']
13772,NCT02447185,intraoperative bleeding,the change of inflammatory factors in vitreous body,,2015-06,UNKNOWN,INTERVENTIONAL,['PHASE3']
13773,NCT06188481,Change from baseline in HbA1c in %,Change from baseline in well-being,,2024-01-23,RECRUITING,INTERVENTIONAL,['NA']
13774,NCT02630524,Adherence to prescribed macronutrient composition as measured by multiple pass 24 hour dietary recall,,,2016-08,COMPLETED,INTERVENTIONAL,['NA']
13775,NCT02914730,Number of Missed Insulin Doses,,,2016-09,COMPLETED,OBSERVATIONAL,['NA']
13776,NCT03554590,glycemic control,glucose variability: incidence of hypoglycaemia,,2016-12,UNKNOWN,INTERVENTIONAL,['NA']
13777,NCT03284216,Exercise-induced change in blood glucose control.,Hyperglycemia-induced change in cognitive function.,,2017-08-01,COMPLETED,INTERVENTIONAL,['NA']
13778,NCT02040012,"To investigate the number of adverse events of single and multiple ascending doses AZP-531 in healthy volunteers, in overweight/obese volunteers, in patients with type 2 diabetes mellitus.",To determine the plasma pharmacokinetic (PK) profile of AZP-531 after single and multiple doses,To obtain exploratory data on the effects of AZP-531 on the pharmacodynamic (PD) markers,2013-07,UNKNOWN,INTERVENTIONAL,['PHASE1']
13779,NCT01452815,Change from baseline in symptoms associated with diabetic gastroparesis,Clinical Chemistry and Hematology Parameters,,2011-09,COMPLETED,INTERVENTIONAL,['PHASE2']
13780,NCT04374864,Area under the curve,,,2020-03-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
13781,NCT03194009,Physical Activity,Cost-utility of Metformin. Measured using cost per QALYS,,2017-08-10,UNKNOWN,INTERVENTIONAL,['NA']
13782,NCT02830113,Insulin sensitivity,Inflammation,,2014-12,COMPLETED,INTERVENTIONAL,['NA']
13783,NCT06019624,Change in Food Security,Change in Emergency Room Utilization,,2023-09-13,RECRUITING,INTERVENTIONAL,['NA']
13784,NCT05761301,Part B: Frequency of Adverse Events,Part B: Plasma Concentrations of ALN-KHK and Potential Major Metabolite(s),,2023-03-10,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13785,NCT05261841,Change from Baseline HbA1c at 6 and 12 months,,,2021-06-26,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
13786,NCT04862858,"Percentage of individuals who initiate guideline-based SGLT2i or GLP-1 RA medications with cardiovascular benefit, excluding combination products, based on administrative claims data","Percentage of individuals who initiate guideline-based SGLT2i or GLP-1 RA medications with cardiovascular benefit, including combination products, based on administrative claims data",,2021-08-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
13787,NCT00400491,glycated hemoglobin,insulin sensitivity,,2006-06,COMPLETED,INTERVENTIONAL,['PHASE2']
13788,NCT06010433,Primary Outcomes,Secondary Outcome,,2023-09-22,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
13789,NCT04511312,Days at Home at 30 Days after surgery (DAH-30),Quality of Recovery QoR-15 measuring quality of recovery on Day 1 only,,2021-05-01,RECRUITING,OBSERVATIONAL,['NA']
13790,NCT04057248,HbA1C Value at 3 Months From Subject Start of Study Compared to Baseline,Triglycerides Value at 3 Months From Subject Start of Study,,2018-07-09,COMPLETED,INTERVENTIONAL,['NA']
13791,NCT04523064,Acute kidney injury,Myocardial Infarction Type 5,,2020-09-22,RECRUITING,INTERVENTIONAL,['PHASE4']
13792,NCT03188757,prolonged reaction time,,,2017-07-13,COMPLETED,INTERVENTIONAL,['NA']
13793,NCT03340311,Glucose log completeness,Patient satisfaction,,2017-11-01,COMPLETED,INTERVENTIONAL,['NA']
13794,NCT04831723,Normal range of capillary blood glucose in newborns at day 5 of life,Validation of laboratory procedures,,2021-07-09,COMPLETED,OBSERVATIONAL,['NA']
13795,NCT06124560,Area under the plasma concentration versus time curve (AUC) 0-inf (Metformin only),Number of participants with adverse events (AEs),,2022-10-28,COMPLETED,INTERVENTIONAL,['PHASE1']
13796,NCT00756041,Weight.,"Change from Baseline in quality of life index as assessed by the Short-Form, 36-Item Health Survey.",,2005-09,TERMINATED,INTERVENTIONAL,['PHASE2']
13797,NCT01865305,Maximum glucose infusion rate divided by the average glucose infusion rate (for subjects with type 2 diabetes),Area under the serum insulin degludec concentration curve,,2006-09,COMPLETED,INTERVENTIONAL,['PHASE1']
13798,NCT01916096,Blood Volume Measurements,,,2012-02,COMPLETED,OBSERVATIONAL,['NA']
13799,NCT04270604,"Establishment of a diverse bank of biological samples, stem cell lines, derivatives, and associated information.",,,2012-02-06,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
13800,NCT04533152,DFU risk score,Survival without major microvascular events (MICE),,2021-11-24,RECRUITING,OBSERVATIONAL,['NA']
13801,NCT03022344,Progression of contrast enhanced cardiac CT in relation to baseline and follow-up cardiovascular risk factors and biomarkers.,Blood pressure (mmHg),,2014-11,UNKNOWN,INTERVENTIONAL,['NA']
13802,NCT05355285,Change in anterior cingulate cortex glutamate concentration from Baseline Euglycemia to Hyperglycemia,Change in plasma insulin concentration from Baseline Euglycemia to Hyperinsulinemic Euglycemia,Self Referential Emotional Task (SRET) response time,2011-01,COMPLETED,INTERVENTIONAL,['NA']
13803,NCT01365013,Incidence of Diabetes,Implementation of the program,,2011-06,COMPLETED,INTERVENTIONAL,['PHASE4']
13804,NCT00260130,"satiation and satiety on liquid verses solid foods with concurrent measurements of appetite, dietary intake, energy expenditure and body weight/composition.",cephalic phase testing at week 8,,2005-02,COMPLETED,INTERVENTIONAL,['NA']
13805,NCT01691755,Change from baseline in hemoglobin HbA1c,Safety: incidence of adverse events,,2012-11,COMPLETED,INTERVENTIONAL,['PHASE3']
13806,NCT01606007,Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24,Adjusted Mean Change From Baseline in Body Weight at Week 24,,2012-07,COMPLETED,INTERVENTIONAL,['PHASE3']
13807,NCT01297049,Blood glucose control with changes in Glycated hemoglobin (HbA1c) values,Audit of Diabetes Dependence Quality of Life (ADDQoL-19),,2010-04,COMPLETED,INTERVENTIONAL,['NA']
13808,NCT05996601,Medication adherence of participants using a 4-item medication adherence scale,,,2023-08-28,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
13809,NCT03997526,Complete healing,Minor amputation - contralateral limb,,2020-07-15,TERMINATED,OBSERVATIONAL,['NA']
13810,NCT00564070,Depression on the CGI at Acute Outcome,Glucose Control,Glucose Control Over Follow up,2007-06,COMPLETED,INTERVENTIONAL,['NA']
13811,NCT03925714,Number of patients with improved insulin resistance,,,2019-04-01,RECRUITING,INTERVENTIONAL,['PHASE3']
13812,NCT06033872,a. To compare the first incidence rate of hypoglycemia or severe hypoglycemia between intervention and control groups in Ramadan,"Healthcare utilizations costs - Medical services, drugs and devices utilized, outpatient and inpatient visits, cost of intervention sessions, telemonitoring and equipment, indirect costs related to health care utilisation, and caregiver costs.",,2021-01-25,COMPLETED,INTERVENTIONAL,['NA']
13813,NCT05092945,Brown Adipose Tissue (BAT) Glucose uptake,Changes in insulin level and secretion,,2021-05-18,RECRUITING,INTERVENTIONAL,['NA']
13814,NCT03878277,Renal Perfusion,Tubular Injury Markers,,2019-07-01,COMPLETED,INTERVENTIONAL,['PHASE2']
13815,NCT02658591,Change in gut hormone levels measured in the blood,Ad libitum food (pizza meal) intake as measured by the amount of pizza (in grams) consumed during the 20 minute period,,2016-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
13816,NCT01803711,Hospital Anxiety and Depression Scale,Leeds Sleep Evaluation Questionnaire (LSEQ),,2013-02,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
13817,NCT05261867,"Composite of cardiovascular death, recurrent AMI, and hospitalization for HF (MACE).",Any coronary revascularization,,2017-01,RECRUITING,OBSERVATIONAL,['NA']
13818,NCT02571608,Recruitment rate,Length of Hospital Stay,,2022-01-01,WITHDRAWN,INTERVENTIONAL,['PHASE4']
13819,NCT05874323,correlation of RAGE gene polymorphism rs1800625 with the incidence of type I diabetes,"the relation between MiRNA-34, MiRNA-146, to TID severity and activity.",,2023-01-01,COMPLETED,INTERVENTIONAL,['NA']
13820,NCT00837122,A,,,2009-02-03,RECRUITING,OBSERVATIONAL,['NA']
13821,NCT01270633,Percent of study ulcers healed,Cost of Treatment,,2010-12,TERMINATED,INTERVENTIONAL,['NA']
13822,NCT04972890,Changes in microRNA 126 expression after stem cells injection,Number of participants with side effects after intracavernosal injection,,2020-10-27,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
13823,NCT05628168,Effect of Neurodynamic Mobilization Techniques in Patients With Diabetic Neuropathy,,,2021-12-05,COMPLETED,INTERVENTIONAL,['NA']
13824,NCT02194608,Change from baseline in body mass index,Number of severe/symptomatic hypoglycemic episodes,,2011-12,COMPLETED,INTERVENTIONAL,['NA']
13825,NCT02786823,HbA1c,Serum C reactive protein (CRP),,2017-05-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
13826,NCT05540704,Feasibility as measured by participant attrition less than 20%,Change in NIH PROMIS Scale - Anxiety,,2023-04-04,RECRUITING,INTERVENTIONAL,['NA']
13827,NCT01625507,Change in Nutrient Intake,Change in Waist Circumference,,2012-10,COMPLETED,INTERVENTIONAL,['PHASE2']
13828,NCT04641650,Difference between estimated Hba1c (or Glucose Management Index (GMI)) with FreeStyle Libre Pro sensor and laboratory Hba1c,Glucose total coefficient of variation (CV),,2021-07-21,UNKNOWN,OBSERVATIONAL,['NA']
13829,NCT04716244,Identification of four consistent themes on thematic qualitative analysis,,,2021-01-20,RECRUITING,OBSERVATIONAL,['NA']
13830,NCT05766449,"Risk factors of chronic hepatitis B patients with non-alcoholic fatty liver disease progressing to cirrhosis, liver cancer or liver failure","Incidence of cirrhosis, cancer and liver failure in patients with chronic hepatitis B and non-alcoholic fatty liver disease",,2022-06-01,RECRUITING,OBSERVATIONAL,['NA']
13831,NCT01159600,HbA1c Change From Baseline,Mean Daily Plasma Glucose (MDG) Change From Baseline,Confirmed Hypoglycaemic Adverse Events,2010-07,COMPLETED,INTERVENTIONAL,['PHASE3']
13832,NCT02371759,Electrocardiogram at 20 Minutes,Local Postoperative Complications,,2013-06,COMPLETED,INTERVENTIONAL,['PHASE3']
13833,NCT03175315,Changes in Glycemic Control Measured by A1c,Depressive symptoms,,2017-05-02,COMPLETED,INTERVENTIONAL,['NA']
13834,NCT01062529,Plasma levels of glucose,Serum levels of free fatty acids (FFA),,2009-10,COMPLETED,INTERVENTIONAL,['NA']
13835,NCT01755442,Mean 24-hour systolic blood pressure,Safety end points will include ECGs.,,2012-11,TERMINATED,INTERVENTIONAL,['PHASE1']
13836,NCT02511067,Anatomic Retinal Changes,Rescue Therapy,,2016-10-01,WITHDRAWN,INTERVENTIONAL,['PHASE2']
13837,NCT01933672,Change From Baseline in Weighted Mean Daily Glucose (WMDG) at Day 14,Plasma PF-04937319 Time for Cmax (Tmax) on Day 14,,2013-10,COMPLETED,INTERVENTIONAL,['PHASE1']
13838,NCT05272670,Foot Care Self-Efficacy Scale,Health promotion satisfaction,,2022-02-15,RECRUITING,INTERVENTIONAL,['NA']
13839,NCT02720393,Change in hemoglobin A1c,Change in insulin signaling pathway,Change in fecal calprotectin,2016-02,COMPLETED,INTERVENTIONAL,['NA']
13840,NCT00207389,GIP area under the curve after OGTT,Other GI peptides and hormones after OGTT,,2004-03,TERMINATED,OBSERVATIONAL,['NA']
13841,NCT02612493,Insulin dosage,Change in lipids,,2006-01,COMPLETED,OBSERVATIONAL,['NA']
13842,NCT00330265,Percent of subjects achieving complete or (100%) study wound closure by week 12 after initial treatment,,,2006-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
13843,NCT01143870,Change in Percent of Glycosylated Hemoglobin 6 Months Following Enrollment,Change in Hemoglobin A1C Over 12 Months From Enrollment,,2010-04,COMPLETED,INTERVENTIONAL,['NA']
13844,NCT03157414,Weighted mean glucose,Renal function,Urinary glucose excretion,2016-11-07,COMPLETED,INTERVENTIONAL,['PHASE4']
13845,NCT01474525,"Mean blood glucose, based on the highest post-prandial blood glucose reading for each day, by trimester","Provider usage: number of logins onto the system, average amount of time spent on the system per week",,2010-01,UNKNOWN,INTERVENTIONAL,['NA']
13846,NCT03071068,"Incidence of acute (up to the 7-day follow-up visit) ocular (serious) adverse events ([S]AEs) in the study eye, after each injection and across injections per subject","Mean change from baseline in CST, by study visit, based on spectral domain optical coherence tomography (SD-OCT), as assessed by the central reading centre (CRC)",,2016-12-22,COMPLETED,INTERVENTIONAL,['PHASE2']
13847,NCT00972322,Number of Participants Discontinuing Study Drug Due to an AE,,,2009-08-24,COMPLETED,INTERVENTIONAL,['PHASE1']
13848,NCT01869348,Change in Physical Activity From Baseline to 12 Weeks,Change in Weight From Baseline to 12 Weeks,Acceptability,2014-06,COMPLETED,INTERVENTIONAL,['NA']
13849,NCT03671161,Number of ketoacidosis episodes,Any changes in Weight,,2016-01-01,COMPLETED,INTERVENTIONAL,['NA']
13850,NCT03042039,Total number of hospital admissions per participant measured at end of study (at approx 12 months),Change in Disease specific health status measurement (6) as measured with BMI of all patients with chronic heart failure between start and end of study (12 months),,2015-01-01,UNKNOWN,OBSERVATIONAL,['NA']
13851,NCT01152372,"Glucose (labeled and unlabeled), insulin and c-peptide will be measured to calculate insulin sensitivity, endogenous glucose production and insulin secretion",Characterize the patterns of intermediate metabolites in healthy subjects and subjects with type 2 diabetes mellitus,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE1']
13852,NCT00467246,Reduction of recurrence of ketoacidosis and hyperglycaemia.,To investigate time to treatment in patients presenting with a hyperglycaemic emergency,,na,WITHDRAWN,INTERVENTIONAL,['NA']
13853,NCT03835195,Differences in HbA1C value after the intervention,Difference in the body mass index after the intervention,,2018-06-01,COMPLETED,INTERVENTIONAL,['NA']
13854,NCT01608607,Body weight,,,2012-05,UNKNOWN,OBSERVATIONAL,['NA']
13855,NCT02345239,Mean post-prandial glucose excursion,Postprandial glucose excursion,,2015-02,UNKNOWN,INTERVENTIONAL,['PHASE3']
13856,NCT01513798,Fat mass,Substrate utilization during submaximal exercise,,2012-01,COMPLETED,INTERVENTIONAL,['NA']
13857,NCT05488197,Uterine artery Doppler ultrasonography in gestational diabetes mellitus,Prediction of GDM with uterine artery pulsatility index cut-offs,,2021-06-10,COMPLETED,OBSERVATIONAL,['NA']
13858,NCT02151695,Percentage of patients with regression of retinal neovascularization between baseline and 12th month.,,,2015-05,COMPLETED,INTERVENTIONAL,['PHASE2']
13859,NCT03423108,HbA1c,Lower body maximal muscle strength,,2018-09-10,UNKNOWN,INTERVENTIONAL,['NA']
13860,NCT02620332,Assessment of MultiPepT1De safety profile,Assessment of T lymphocyte immune response to islet cell antigens,,2015-10-20,COMPLETED,INTERVENTIONAL,['PHASE1']
13861,NCT01340911,Number of participants with adverse events and incidence of adverse events will be used as a measure of safety and tolerability of multiple doses of SRT3025 in healthy male subjects.,Plasma levels of SRT3025 may be compared to the number and types of adverse events experienced by subjects receiving multiple doses of SRT3025 to assess any relationship between plasma SRT3025 levels and adverse events.,,2011-06-03,COMPLETED,INTERVENTIONAL,['PHASE1']
13862,NCT05204706,Number of women withdrawn or loss to follow up,Number of women randomised,Length of stay at the hospital ward,2022-01-24,RECRUITING,INTERVENTIONAL,['NA']
13863,NCT01511172,Fasting plasma/serum glucose,Other adverse events,,2002-08,COMPLETED,INTERVENTIONAL,['PHASE2']
13864,NCT04474795,Staff - Self-efficacy to Provide Diabetes Education Questionnaire (Newly Developed),Staff - Intention to Recommend Diabetes Prevention Activities Questionnaire (Newly Developed),Staff-Provider Teaching Motivation Questionnaire Intrinsic Motivation Subscale,2020-06-18,COMPLETED,INTERVENTIONAL,['NA']
13865,NCT04858854,Fasting serum glucose,Fasting insulin,,2021-10-10,COMPLETED,INTERVENTIONAL,['NA']
13866,NCT00005399,Incident coronary heart disease and stroke events,all-cause and cause-specific mortality,,1996-08,COMPLETED,OBSERVATIONAL,['NA']
13867,NCT00563043,changes in ERG implicit time,,,2007-10,UNKNOWN,INTERVENTIONAL,['PHASE4']
13868,NCT01364675,Cardiovascular Events,Incidence of Individual Cardiovascular Disease,,2012-01,UNKNOWN,INTERVENTIONAL,['NA']
13869,NCT00682448,Weight Gain,Hemoglobin A1C,,2007-08,COMPLETED,INTERVENTIONAL,['PHASE4']
13870,NCT00615121,Discover novel gene expression pattern in peripheral arterial disease,,,2004-06,COMPLETED,OBSERVATIONAL,['NA']
13871,NCT05226897,HbA1c,C-peptide,,2021-07-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
13872,NCT03438617,Change from Baseline HbA1c at 12 and 18 months,Change from Baseline Depression at 12 and 18 months,,2017-03-08,COMPLETED,INTERVENTIONAL,['NA']
13873,NCT04452331,Contextualization of Care,hospital admission rate,,2021-10-05,RECRUITING,INTERVENTIONAL,['NA']
13874,NCT02557022,Body weight analysis,,,2014-09,UNKNOWN,OBSERVATIONAL,['NA']
13875,NCT00614341,Pain reduction in diabetic patients with chronic diabetic neuropathy,Improvement in sensation and overall foot condition,,2006-05,COMPLETED,INTERVENTIONAL,['PHASE4']
13876,NCT06240910,Berge balance scale,Functional reach test,Michigan neuropathy screening instrument questionnaire,2023-07-17,RECRUITING,INTERVENTIONAL,['NA']
13877,NCT03059069,changes in Hamilton Depression Rating Scale (HDRS),changes in Mini-mental state examination (MMSE) score,,2016-06-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
13878,NCT01157611,change of the blood glucose,satisfaction score,,2010-07,COMPLETED,INTERVENTIONAL,['NA']
13879,NCT00982228,Extension Trial (Primary Endpoint): Cross-reacting Antibodies to Human Insulin,Main Trial (Secondary Endpoint): Mean of 9-point Self Measured Plasma Glucose Profile (SMPG) at Week 52,,2009-09-01,COMPLETED,INTERVENTIONAL,['PHASE3']
13880,NCT01970046,Change From Baseline in HbA1c (Hemoglobin A1C) at Week24,"Change From Baseline in Body Weight at Week 4,8,12、24、38、52",,2013-04,UNKNOWN,INTERVENTIONAL,['PHASE3']
13881,NCT00993018,Average pain intensity,Number of patients with adverse events,,2009-11,TERMINATED,INTERVENTIONAL,['PHASE2']
13882,NCT05110846,Change in hemoglobin A1c (HbA1c),Fasting plasma glucose,,2022-02-22,UNKNOWN,INTERVENTIONAL,['PHASE2']
13883,NCT04509245,Change in insulin sensitivity,Change in öiver fat,,2018-10-01,COMPLETED,INTERVENTIONAL,['NA']
13884,NCT00574808,Quality of care process index = ∑ of recommended services received by patient/ ∑ of the recommended services for which the patient was eligible,Quality of care outcome index = ∑ of recommended targets reached / ∑ of the number of targets for which the patient is eligible based on the number of conditions suffered by the patient,,2007-04,COMPLETED,INTERVENTIONAL,['PHASE1']
13885,NCT00910780,Changes in per cent of body fat,Psychiatric safety and tolerability,,2009-11,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
13886,NCT05912647,Change in mean hemoglobin A1c score,Mean scores on the Adherence to Refills and Medications Scale for Diabetes,,2024-02-03,RECRUITING,INTERVENTIONAL,['NA']
13887,NCT06060483,major adverse cardiovascular events,,,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
13888,NCT00965549,Glycosylated Haemoglobin (HbA1c),"Hypoglycaemia (total, severe and nocturnal)",,2009-07,COMPLETED,INTERVENTIONAL,['PHASE4']
13889,NCT00958711,Bacterial Burden,Ease of Dressing Use,,2009-01,TERMINATED,INTERVENTIONAL,['NA']
13890,NCT00381186,insulin resistance,exercise change,,1999-02,COMPLETED,INTERVENTIONAL,['NA']
13891,NCT03202563,Changes from baseline MAGE(Mean amplitude of glycemic excursion) at week 12,Changes from baseline Nitrotyrosine at week 12,Changes of baseline Body weight at week 13,2017-08-09,COMPLETED,INTERVENTIONAL,['PHASE4']
13892,NCT03228732,Change in the level of catecholamines in plasma,,,2017-12-19,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
13893,NCT05526131,val66met polymorphism of BDNF gene,,,2021-02-17,COMPLETED,INTERVENTIONAL,['NA']
13894,NCT03782805,Change from Baseline TNF-alpha at 6 months,Change from Baseline Parathyroid hormone (PTH) at 6 months,,2018-05-09,COMPLETED,INTERVENTIONAL,['NA']
13895,NCT00849849,Determine best way to assess glucose disorder prevalence in women with prior GDM,"Investigate if cardiometabolic markers-lipid profile and blood pressure anthropometric markers such as BMI [BMI, absolute body weight]; visceral adiposity as assessed by abdominal girth are associated with an increased diabetes risk",,2011-07,COMPLETED,OBSERVATIONAL,['NA']
13896,NCT05727579,To investigate the modifying effect of sodium intake on Ertugliflozin on blood pressure,To investigate the effect of Ertugliflozin on the hypertensive effects of high dietary sodium intake,Biomarkers,2023-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
13897,NCT03563638,Serum PTX3 levels in early pregnancy,,,2015-10-01,COMPLETED,OBSERVATIONAL,['NA']
13898,NCT04258904,Incidence of dermatological complications,Trans Epidermal Water Loss (TEWL):,,2020-03-10,COMPLETED,INTERVENTIONAL,['NA']
13899,NCT02478554,Detection of fetal growth abnormalities,,,2015-08,WITHDRAWN,INTERVENTIONAL,['NA']
13900,NCT01889277,Plasma concentrations of MT-3995 and its major metabolite,Change from baseline in Urine albumin-to-creatinine ratio (UACR) and blood pressure,,2013-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13901,NCT00000151,,,,1979-12,COMPLETED,INTERVENTIONAL,['PHASE3']
13902,NCT03025607,Change in Autonomous Motivation to Prevent T2DM,Change in psychosocial measures,,2017-05-03,COMPLETED,INTERVENTIONAL,['NA']
13903,NCT01349855,"Safety in terms of adverse and serious adverse events, vital signs, ECG, safety laboratory",Pharmacokinetic parameter : AUC,,2011-03,COMPLETED,INTERVENTIONAL,['PHASE1']
13904,NCT00786487,Insulin Sensitivity as Measured by Hyperinsulinemic Euglycemic Clamp at a Single Time Point (6 Hrs) After Intralipid or Glycerol Infusion,,,2009-01,COMPLETED,INTERVENTIONAL,['NA']
13905,NCT03371355,Percent Change From Baseline in Fasting Triglycerides Level at the Primary Analysis Time Point,Number of Participants With Treatment-emergent Adverse Events (TEAEs),,2017-12-21,COMPLETED,INTERVENTIONAL,['PHASE2']
13906,NCT02180555,Glucose metabolism disturbance,Patient characteristics predicting adverse outcome,,2012-02,UNKNOWN,OBSERVATIONAL,['NA']
13907,NCT01947036,Identify shared defects in T and B cell function by disease classification,,,2014-01,TERMINATED,OBSERVATIONAL,['NA']
13908,NCT02019186,endothelial function,Endothelial progenitor cells,,2013-12,COMPLETED,INTERVENTIONAL,['PHASE4']
13909,NCT00406458,"Visual analog scale for pain intensity (VASPI), Nerve Conduction Velocity (NCV), Total Neuropathy Score (TNS), Epidermal Nerve Fiber Density (ENFD) & Epidermal Nerve Fiber Density Regeneration (ENFDR)",Safety,,2006-11,COMPLETED,INTERVENTIONAL,['PHASE2']
13910,NCT00328536,"Postprandial (2, 4 and 6 hours) flow-mediated vasodilation after a 6-week treatment with Omacor",Baseline flow-mediated vasodilation after a 6-week treatment with Omacor,,2007-04,COMPLETED,INTERVENTIONAL,['PHASE4']
13911,NCT02131675,C-peptide level,Duration of diabetes,,2012-10,COMPLETED,OBSERVATIONAL,['NA']
13912,NCT03908125,Time in Range,,,2019-03-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
13913,NCT00886392,"Thickening measured by optical coherence tomography in 3 zones: central subfield (when field 1 was thickened), inner ring (when any of fields 2, 3, 4 or 5 was thickened), and inner ring or outer ring (when any of fields 6, 7, 8, or 9 was thickened)","Severity level: adaptation of International clinical diabetic macular edema severity scale to fields of the OCT; mild if thickening exclusively involved outer-ring, moderate if was in inner-ring without involvement field 1, and severe if was in field 1",,2006-06,COMPLETED,OBSERVATIONAL,['NA']
13914,NCT01813929,Flow-mediated Brachial Artery Dilation,Cardiac Function,Mitochondrial Oxidant Generation,2011-06,COMPLETED,INTERVENTIONAL,['PHASE4']
13915,NCT00961207,Reduction in albuminuria/proteinuria,"Safety of Triple RAAS inhibition with ACE-I, ARB and DRI",,2009-08,TERMINATED,INTERVENTIONAL,['PHASE4']
13916,NCT03504566,Strongest albuminuria-lowering effect.,Effect on glycocalyx.,,2017-11-15,WITHDRAWN,INTERVENTIONAL,['PHASE4']
13917,NCT06097351,Statistical analysis and target gene prediction of misexpressed mirnas and enrichment pathway analysis,,,2020-06-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
13918,NCT06089655,The change of blood glucose level from diet consulting,,,2023-09-01,RECRUITING,INTERVENTIONAL,['NA']
13919,NCT00316758,"AEs, laboratory parameters, ECG.","Mean change from original baseline in HbA1c, FPG, lipid profile.",,2006-02,COMPLETED,INTERVENTIONAL,['PHASE2']
13920,NCT01153048,"compare the improvement of HbA1c 1 year after an intervention led by peer educators, versus a conventional care in health centre","Study the evolution of bio clinical parameters: fasting glucose, weight, BMI, blood pressure, waist size",,2010-06,COMPLETED,INTERVENTIONAL,['PHASE1']
13921,NCT04184440,changes of OGTT,changes of short chain fatty acids,,2020-03,UNKNOWN,INTERVENTIONAL,['NA']
13922,NCT04712266,hyperglycemic excursions,,,2020-09-15,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
13923,NCT02488733,Rate of patients achieving diabetes resolution,"Renal (onset of nephropathy or microalbuminuria), cardiovascular (defined as the occurrence of myocardial infarction, congestive heart failure or stroke), and ocular damage (development of diabetic retinopathy), and diabetes-related peripheral neuropathy",,2015-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
13924,NCT00383110,Health Care System Distrust Scale,LDL-cholesterol,,2004-11,COMPLETED,OBSERVATIONAL,['NA']
13925,NCT04812782,Change of Endothelial function from pre meal to post meal period,Gastric emptying rate,,2018-02-12,COMPLETED,INTERVENTIONAL,['NA']
13926,NCT00011141,,,,na,COMPLETED,INTERVENTIONAL,['NA']
13927,NCT01120912,Adverse events occurrence,Evaluate the glucose lowering effect of Oshadi Oral Insulin,,2010-10,COMPLETED,INTERVENTIONAL,['PHASE1']
13928,NCT03081676,Insulin secretion,Amount glucose used to maintain the glucose clamp,,2017-03-08,COMPLETED,INTERVENTIONAL,['NA']
13929,NCT00271739,Serum Lipids Levels; Low-density Lipoprotein (LDL)-Cholesterol,,,2000-12,COMPLETED,INTERVENTIONAL,['NA']
13930,NCT01959529,"Time From Randomisation to First Occurrence of a Major Adverse Cardiovascular Event (MACE): Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke",Change in Glycosylated Haemoglobin (HbA1c),,2013-10-29,COMPLETED,INTERVENTIONAL,['PHASE3']
13931,NCT03998267,Difference in mean HbA1c,Lipids,Exploratory outcome,2019-08-22,UNKNOWN,INTERVENTIONAL,['NA']
13932,NCT00568984,HbA1c,Adverse events,,2002-11-21,COMPLETED,INTERVENTIONAL,['PHASE4']
13933,NCT01600690,Change in EPC levels,Change in hsCRP,,2012-05,COMPLETED,INTERVENTIONAL,['PHASE4']
13934,NCT00122447,AIM 1: Change in Flow Mediated Dilation (FMD) (%),AIM 1: Change in hsCRP (High Sensitivity C-reactive Peptide) Level,AIM 2: Difference in FMD (Measure of Endothelial Function),2005-05,COMPLETED,INTERVENTIONAL,['NA']
13935,NCT06241976,Postprandial glycaemic response,Knowledge and perception of vitamin D,C-reactive protein (CRP),2023-12-12,RECRUITING,INTERVENTIONAL,['NA']
13936,NCT04674254,Change in vascular density of the retinal capillary plexuses,Change in orbital blood flow,,2021-03-30,COMPLETED,INTERVENTIONAL,['PHASE4']
13937,NCT00444392,Brachial artery flow mediated dilation,Inflammatory Markers,,2007-03,COMPLETED,INTERVENTIONAL,['PHASE3']
13938,NCT01737957,Macular thickness change,Adverse events,"Regression of neovessels, change over time",2012-11,UNKNOWN,INTERVENTIONAL,['NA']
13939,NCT04377399,Microcirculation,Neuropathic symptom score,,2018-01-10,COMPLETED,INTERVENTIONAL,['PHASE4']
13940,NCT00718614,choroidal blood flow,heart rate variability,,2007-06,TERMINATED,INTERVENTIONAL,['NA']
13941,NCT00817622,Changes in leptin and adiponectin after 12 Weeks,,,2007-01,COMPLETED,INTERVENTIONAL,['PHASE4']
13942,NCT01959334,Number of Participants With At Least One Adverse Event,,,2013-09,COMPLETED,INTERVENTIONAL,['PHASE3']
13943,NCT03228004,Frequency of data upload,,,2017-07-26,COMPLETED,INTERVENTIONAL,['PHASE1']
13944,NCT05305352,Asses change in NFk,,,2024-01,SUSPENDED,INTERVENTIONAL,['NA']
13945,NCT03935191,Dexcom G6 CGM Accuracy,Dexcom G6 CGM Safety,,2019-05-01,UNKNOWN,OBSERVATIONAL,['NA']
13946,NCT00339482,To investigate the determinants of type 2 diabetes and its complications.,,,1976-09-03,COMPLETED,OBSERVATIONAL,['NA']
13947,NCT02591849,Concentration of glucagon during fasting glycemia and during hyperglycemic conditions measured in picomoles per liter,Insulin sensitivity index,,2014-10,COMPLETED,INTERVENTIONAL,['NA']
13948,NCT06054659,Time to DFU healing,Relationship of glycemic variability and the likelihood of healing,,2024-02-20,RECRUITING,INTERVENTIONAL,['NA']
13949,NCT01231984,Glycemic Control as Measured by HbA1c (4 mm vs. 12.7 mm),"Number of Serious, Unexplained Hyperglycemic Events, Reported as Number of Events by Needle.",,2010-10,COMPLETED,INTERVENTIONAL,['NA']
13950,NCT02864654,Serious adverse reactions,Quality of life monitoring - 2,,2016-07,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
13951,NCT00348712,Treatment difference in HbA1c,Hypoglycaemia,,2006-10-30,TERMINATED,INTERVENTIONAL,['PHASE3']
13952,NCT03328975,Can diabetic patients maintain their blood glucose in a normal range after receiving a corticosteroid injection?,,,2017-11-01,WITHDRAWN,INTERVENTIONAL,['NA']
13953,NCT05491577,Results of the FAAM-F questionnaire at Month 24,K. Sanders Classification of the Charcot Foot,Front view X-ray of the ankle(s) under loading,2023-01-23,RECRUITING,OBSERVATIONAL,['NA']
13954,NCT00001310,,,,1992-03-05,TERMINATED,OBSERVATIONAL,['NA']
13955,NCT03591354,Time in Target Range,BMI,Any Adverse Event Rate Per 100 Person-years From Months 4-12,2019-01-17,COMPLETED,INTERVENTIONAL,['NA']
13956,NCT03450863,Change in Glycated Haemoglobin (HbA1c),Change in fasting plasma glucose (FPG),,2018-03-22,COMPLETED,OBSERVATIONAL,['NA']
13957,NCT01350388,Change in Urinary Concentrations of Transforming Growth Factor-beta1 (TGF-beta1) From Baseline to 24 Weeks,Change in High Sensitivity C-Reactive Protein (hsCRP) Concentration in Plasma From Baseline to 24 Weeks,,2011-05,COMPLETED,INTERVENTIONAL,['NA']
13958,NCT02070926,Time to major adverse events,,,2006-01,COMPLETED,OBSERVATIONAL,['NA']
13959,NCT02605772,redunction of Hemoglobin A1c (HbA1c) Levels (%) in two groups respectively after three months intervention,Difference of Homeostasis model assessment of insulin resistance (HOMA-IR) and Homeostasis model assessment beta cell function index (HOMA-β) between two groups after three months intervention,,2015-12,UNKNOWN,INTERVENTIONAL,['PHASE4']
13960,NCT00549536,To evaluate the difference in 24h blood pressure measurement and insulin sensitivity between the treatment and the control group.,To evaluate differences in the transmembrane sodium/hydrogen exchanger activity between the active treatment and the control group.,,2007-01,COMPLETED,INTERVENTIONAL,['PHASE4']
13961,NCT02494375,Association between HbA1c and sleep characteristics,Body composition (BMI fat and lean mass percentage),,2015-06-28,UNKNOWN,INTERVENTIONAL,['NA']
13962,NCT03509532,MACE,,,2017-01,UNKNOWN,OBSERVATIONAL,['NA']
13963,NCT04268212,incremental area under the curve,,,2016-04-15,COMPLETED,INTERVENTIONAL,['NA']
13964,NCT00853424,"Composite outcome consisting of progression of DR, development of significant ME, or moderate visual loss in patients who have significant ME at randomization.",,,2009-12,WITHDRAWN,INTERVENTIONAL,['PHASE3']
13965,NCT04612257,Time in range,Total insulin delivery,,2019-06-18,TERMINATED,INTERVENTIONAL,['NA']
13966,NCT05074342,The provision of a DRS status list to primary health care settings will increase the rate of annual DR screening in patients with type 1 or type 2 diabetes who have attended the centres.,,,2022-02-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
13967,NCT02004964,eligibility for islet transplantation,,,2009-04,COMPLETED,OBSERVATIONAL,['NA']
13968,NCT05238987,Change in insulinogenic index,Change in insulin clearance rate,,2020-10-10,COMPLETED,INTERVENTIONAL,['NA']
13969,NCT05729334,Repeatability of Clinicgram Euclides in the automatic calculation of skin lesion areas between two measurements performed by the same investigator.,Usability of the investigational software Clinicgram Euclides.,,2022-11-28,COMPLETED,INTERVENTIONAL,['NA']
13970,NCT05402579,Identification of genomic variants associated with an increased risk of SGLT2 inhibitor-associated DKA,,,2022-07-29,RECRUITING,OBSERVATIONAL,['NA']
13971,NCT00242372,Absolute change from baseline to end of randomized treatment period in glycosylated hemoglobin A1c (HbA1c),To validate the Work Productivity and Activity Impairment-Diabetes Questionnaire (WPAI-Diabetes) and the Diabetes Productivity Impairment Questionnaire (DPIQ) in patients with type 2 diabetes and to explore the effects of tesaglitazar (0.5 mg) on pati,,2004-08,TERMINATED,INTERVENTIONAL,['PHASE3']
13972,NCT06224790,15% improvement in eGFR,Safety - Adverse Effects of Drugs,,2024-03-10,RECRUITING,INTERVENTIONAL,['PHASE4']
13973,NCT00264940,,,,na,UNKNOWN,OBSERVATIONAL,['NA']
13974,NCT04729296,The primary outcome is the elapsed time from random treatment assignment to the development of diabetes (T1D) or time of last contact among those randomized,,,2021-07-01,WITHDRAWN,INTERVENTIONAL,['PHASE2']
13975,NCT00428571,Diabetic control as assessed by HbA1c,Utilization of resources and productivity losses,,2007-05,TERMINATED,INTERVENTIONAL,['NA']
13976,NCT05933460,Diastolic Blood pressure,Continuous glucose monitoring statistic data,,2022-03-01,COMPLETED,INTERVENTIONAL,['NA']
13977,NCT06092827,Satisfaction towards physical activity intervention,Questionnaire on motivation to practice physical activity,Hemoglobin (safety parameter),2023-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
13978,NCT05003908,Safety (adverse events),Efficacy: Insulin dose reduction,,2022-02-01,RECRUITING,INTERVENTIONAL,['PHASE1']
13979,NCT05527535,Efficiency of AI in diabetic retinopathy screening,Satisfaction of patients and health care personnel in AI-based screening,,2022-10-03,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
13980,NCT00284609,Change in HgbA1c (Glycemic control),Body mass index,,2006-08,COMPLETED,INTERVENTIONAL,['NA']
13981,NCT00454597,"To compare the Blood levels of of glucose, curve of tolerance wing glucose, hemoglobin glycosylated, insulin, triglyceride, cholesterol, HDL, LDL, leptin and Adiponectin before and after the procedure","To evaluate the metabolic conditions of the subjects of both groups to the 15 days and the month, 6, 12 and 24 months later to the procedure",,2007-02,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
13982,NCT02956577,Changes in Global Longitudinal Strain (GLS) stratified by Coronary Artery Calcium Score (CAC) in patients with diabetes during one year of follow-up,Changes in GLS in patients with long-term diabetes and no macrovascular disease,LA function stratified by micro- and macrovascular status,2016-03-16,COMPLETED,OBSERVATIONAL,['NA']
13983,NCT00496457,Effect of TRO19622 versus Placebo on the mean 24h neuropathic pain score on the Likert numerical rating scale.,Adverse events,,2007-05,COMPLETED,INTERVENTIONAL,['PHASE2']
13984,NCT02218931,"Composite fetal outcomes: stillbirth, small for gestational age or admission to neonatal intensive care unit",Development of a cohort for medium and long term follow up of mothers and babies after birth through applications to other grant giving bodies.,,2014-09-12,COMPLETED,INTERVENTIONAL,['NA']
13985,NCT03333642,Remission of type 2 Diabetes at 24 months,Control of type 2 diabetes,Measurement of surgical adverse events,2017-11-27,UNKNOWN,INTERVENTIONAL,['NA']
13986,NCT00334841,,,,2006-07,UNKNOWN,OBSERVATIONAL,['NA']
13987,NCT04743479,Hazard ratio (HR),Diagnostic yield,,2020-12-01,RECRUITING,OBSERVATIONAL,['NA']
13988,NCT01879228,Change in Second-phase Insulin Response Derived From the Glucose-potentiated Arginine Test as a Measure of β-cell Sensitivity to Glucose at Baseline and at 6 Months,,,2013-06,COMPLETED,INTERVENTIONAL,['NA']
13989,NCT00960674,HbA1c,Quality of life by SF-36,,2007-08,COMPLETED,INTERVENTIONAL,['PHASE3']
13990,NCT02378909,Improvement in ulcer size at monthly intervals up to 12 months follow up.,Proportion of wounds healed at monthly intervals up to 12 months followup,,2015-04,UNKNOWN,INTERVENTIONAL,['PHASE1']
13991,NCT05146401,Gestational diabetes mellitus,,,2012-08-01,COMPLETED,OBSERVATIONAL,['NA']
13992,NCT05937321,Time in Range,Diabetes Distress Scale for Partners of Adults with Type 1 Diabetes,World Health Organisation-Five Well-Being Index,2023-11-02,RECRUITING,INTERVENTIONAL,['NA']
13993,NCT03594591,Changes in arterial wall microcirculation (vasa-vasorum density),Changes in retinal microcirculation (Foveal Avascular Area),,2018-01-02,UNKNOWN,OBSERVATIONAL,['NA']
13994,NCT00115973,HbA1c,Frequency of hypoglycemic events,,2005-06,COMPLETED,INTERVENTIONAL,['PHASE1']
13995,NCT04800471,Change in hyperglycemia,Change in Glucose Variability,,2021-08-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
13996,NCT02068300,"The correlation between 1,5-anhydro-D-glucitol and Modified Hypoglycemic score","The relation between glycemic variability indices such as MAGE of continuous glucose monitoring system and 1,5-AG in insulin using patients.","The plasma 1,5-anhydro-D-glucitol level may be a useful marker of daily glucose excursion in diabetes patients",2013-10,COMPLETED,OBSERVATIONAL,['NA']
13997,NCT03837119,urinary tract infection,,,2018-04-04,COMPLETED,OBSERVATIONAL,['NA']
13998,NCT02588898,Polyneuropathy grade estimated using a score including a combination of data from questionnaire and electrophysiology investigations,Plasma cobalamin levels,,2009-09,COMPLETED,OBSERVATIONAL,['NA']
13999,NCT00780195,catecholamines,,,1998-07,COMPLETED,INTERVENTIONAL,['NA']
14000,NCT03386864,mitochondrial oxygen flux,,,2016-04,COMPLETED,OBSERVATIONAL,['NA']
14001,NCT04485845,estimation of metabolic syndrome deterioration,reduce nephropathic impairement,,2019-11-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
14002,NCT01917227,HbA1c,,,2013-07,COMPLETED,INTERVENTIONAL,['NA']
14003,NCT04759144,Time in target (3.9 to 10.0mmol/L) (70 to 180 mg/dL),Human factors assessment,,2021-03-12,COMPLETED,INTERVENTIONAL,['NA']
14004,NCT00499954,,,,2006-02,COMPLETED,OBSERVATIONAL,['NA']
14005,NCT05208827,Gestational diabetes,Weight gain during pregnancy,,2022-01-01,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
14006,NCT04101045,Fractional hepatic DNL,,,2019-11-21,TERMINATED,INTERVENTIONAL,['NA']
14007,NCT01727817,Effect size of Control-to-Range (CTR) vs. Continuous Glucose Monitor (CGM)-augmented insulin pump treatment in an outpatient setting.,Time spent in target range,Reliability of inter-device connections between DiAs and the CGM and between DiAs and the insulin pump.,2013-01,COMPLETED,INTERVENTIONAL,['NA']
14008,NCT03393208,Maximum Observed Plasma Concentration (Cmax) of Metformin (GIR Tablet Active Ingredient),"Number of Participants With Clinically Significant Abnormalities in Vital Signs, Laboratory Parameters, Physical Examination Findings and 12-lead Electrocardiogram (ECG) Findings",,2018-01-10,COMPLETED,INTERVENTIONAL,['PHASE1']
14009,NCT03017482,percent of time patients are on the closed loop system,Percent time in range,Diabetic Ketoacidosis,2017-07-15,COMPLETED,OBSERVATIONAL,['NA']
14010,NCT00552227,The primary efficacy measure is the ratio of urinary isoprostane to creatinine as measured by gas chromatography/mass spectrometry (GC/MS) in the two consecutive 12-hour urine samples obtained prior to both Visit 2 (baseline) and Visit 3 (endpoint).,The ratio of urinary albumin to creatinine,,2002-09,COMPLETED,INTERVENTIONAL,['PHASE1']
14011,NCT01919684,Safety and tolerability of single oral doses of LGD-6972 in healthy subjects and in subjects with T2DM.,The effect of food on the bioavailability and PK profile of LGD-6972 and its potential metabolites after a single oral 40 mg dose in healthy subjects.,,2013-11,COMPLETED,INTERVENTIONAL,['PHASE1']
14012,NCT02656069,Hypoglycemia Rescue: Alternate Glucose Response Definition,Global Assessment of Hypoglycemia,,2017-03-15,COMPLETED,INTERVENTIONAL,['PHASE3']
14013,NCT02438670,Time spent in safe blood glucose range,Glucose level extremes and need for outside intervention,,2015-05,COMPLETED,INTERVENTIONAL,['NA']
14014,NCT05089617,Adverse events will be evaluated,maximum plasma concentration (Cmax),,2022-01-09,COMPLETED,INTERVENTIONAL,['PHASE1']
14015,NCT02318797,Change in Health Status ( SF-12v2™): Mental Health Sub-scale,Change in Lab Monitoring - EKG,,2013-10,COMPLETED,INTERVENTIONAL,['NA']
14016,NCT02510885,Number of Participants With Image Quality Sensitive Enough to Identify Specific New Vessel Morphology,,,2015-07,TERMINATED,INTERVENTIONAL,['NA']
14017,NCT02137070,Change in BOLD fMRI signal,,,2014-08,COMPLETED,OBSERVATIONAL,['NA']
14018,NCT01234649,Insulin Secretion-Sensitivity Index (IS-SI),Alanine Aminotransferase /Aspartate Aminotransferase (ALT/AST) Ratio,,2011-08-11,COMPLETED,INTERVENTIONAL,['PHASE3']
14019,NCT00701051,Skeletal Muscle Capillarization (Pre/Post Intervention),Body Composition (%Fat),,2006-10,COMPLETED,INTERVENTIONAL,['NA']
14020,NCT03835208,mean amplitude of glucose excursions (MAGE),C-peptide,3-hydroxy-butyrate,2019-02-25,UNKNOWN,INTERVENTIONAL,['NA']
14021,NCT04233658,Change of HbA1c-level from baseline to week 12,,,2020-05,UNKNOWN,INTERVENTIONAL,['PHASE3']
14022,NCT00698698,,,,2009-01,UNKNOWN,OBSERVATIONAL,['NA']
14023,NCT03018665,Time of Maintaining Diabetes Remission,The Incidence of Diabetic Nephropathy,,2017-02,UNKNOWN,INTERVENTIONAL,['PHASE4']
14024,NCT02235194,Area under the curve for Glucose,Gut peptide hormones,,2014-08,COMPLETED,INTERVENTIONAL,['NA']
14025,NCT04012775,Antibody Response,Change in total basal insulin dose (U) from baseline,,2017-04-20,COMPLETED,INTERVENTIONAL,['PHASE3']
14026,NCT03094910,Heart rate variability (HRV),,,2017-01-01,COMPLETED,INTERVENTIONAL,['NA']
14027,NCT06067178,Change in systolic blood pressure (mmHg),,Costs per attained blood pressure target among individuals in the health dialogue group vs. the opportunistic screening group,2023-12-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
14028,NCT03585738,Weight gain in pregnancy,,,2022-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
14029,NCT03849495,Cmax of Empagliflozin,Vd/F of Empagliflozin,,2019-02-19,UNKNOWN,INTERVENTIONAL,['PHASE1']
14030,NCT04915339,Episodic memory performances,Client satisfaction questionnaire,,2021-06,UNKNOWN,INTERVENTIONAL,['NA']
14031,NCT02539355,Change in adipose tissue macrophage cell surface expression of metabolic activation marker ABCA1 as measured by relative mean fluorescence intensity (rMFI),Change in fasting plasma total adiponectin assessed by ELISA,Changes in gut microbiota assessed by stool sample analysis,2015-08,COMPLETED,INTERVENTIONAL,['NA']
14032,NCT04988321,Change in bodily and emotional perception of pain (BEEP) score,Change in corticospinal excitability (CE),,2021-09-03,COMPLETED,INTERVENTIONAL,['NA']
14033,NCT04588896,1-hour glucose from OGTT,Socio-cognitive measures,,2020-12-01,UNKNOWN,INTERVENTIONAL,['NA']
14034,NCT00952445,,,,2003-12,COMPLETED,INTERVENTIONAL,['PHASE2']
14035,NCT00311064,too large infants (> 2 standard deviation [SD]),induction of labour,,2006-03,WITHDRAWN,INTERVENTIONAL,['PHASE1']
14036,NCT01671969,Urinary albumin excretion,,,2012-03,COMPLETED,INTERVENTIONAL,['NA']
14037,NCT03555591,Number of Participants Who Had One or More Adverse Drug Reactions,Percentage of Participants Achieving Good Glycemic Control (Reduction in HbA1c Values < 6.0 Percent),,2016-05-01,COMPLETED,OBSERVATIONAL,['NA']
14038,NCT05790421,Toe Strength Dynamometer,,,2022-04-02,COMPLETED,INTERVENTIONAL,['NA']
14039,NCT04735835,Glucose and HbA1c,Covid-19 symptom assessment,Hip Circumference (in sub-cohort),2020-07-20,RECRUITING,INTERVENTIONAL,['NA']
14040,NCT01779141,Percent of Sensor Glucose Values in 70-140 mg/dL,Unhealthy Babies,,2013-05,COMPLETED,OBSERVATIONAL,['NA']
14041,NCT04654390,Change from Visit 2(Randomization) in HbA1c level at Week 24 after administation of the IP,"Proportions of subjects who achieved HbA1c level < 7% at Weeks 6, 12, 18, and 24 after administration of the IP",,2020-12-30,COMPLETED,INTERVENTIONAL,['PHASE3']
14042,NCT04231838,Change in Metabolic Syndrome Prevalence,Change in Waist Circumference,,2021-09-27,RECRUITING,INTERVENTIONAL,['NA']
14043,NCT02122874,Serum glucose levels (mg/dl),Homeostasis model assessment (HOMA),,2013-01,COMPLETED,INTERVENTIONAL,['PHASE3']
14044,NCT03766750,Reduction of glycated hemoglobin levels measured between the first visit and the last visit.,Incidence and severity of adverse events recorded during the study.,,2021-12,WITHDRAWN,INTERVENTIONAL,['PHASE3']
14045,NCT05248334,Visual acuity,The number of pars plana vitrectomy,,2022-04-10,RECRUITING,INTERVENTIONAL,['PHASE1']
14046,NCT02232126,30-day Hospital Readmission,30-day Readmission Among Intervention Participants,,2011-02,COMPLETED,INTERVENTIONAL,['NA']
14047,NCT03074214,Major adverse cardiovascular events (MACE),myocardial infarct size,,2017-03-06,UNKNOWN,OBSERVATIONAL,['NA']
14048,NCT02039141,"Change in Quality of Life Measured at Baseline, 3-months, 6-months, and 12-months",Change in Social support from family and friends on healthy eating and exercise.,Initial incremental cost effectiveness of intervention vs. standard care,2012-04,COMPLETED,INTERVENTIONAL,['NA']
14049,NCT03102801,"Measurement of endothelial microparticles (composite number of CD105, CD106, CD142, CD54, CD62 & CD31) following hypoglycemic event",,,2017-03-01,COMPLETED,INTERVENTIONAL,['NA']
14050,NCT00707629,Ease of Injections versus Insulin pump Therapy,,,2005-08,COMPLETED,OBSERVATIONAL,['NA']
14051,NCT02379468,Time to complete wound healing within 12 weeks before the end of treatment duration.,To identify adverse events associated with the application of Pedyphar® ointment.,,2013-04,COMPLETED,INTERVENTIONAL,['PHASE3']
14052,NCT05576116,Patients achieving normoglycemia,Proportion of participants with morbid obesity post PAK,,2022-09-23,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
14053,NCT03501511,Hypoglycemia,Number of successful fasting days,,2018-04-07,COMPLETED,INTERVENTIONAL,['NA']
14054,NCT00134550,Recurrence rate of foot ulcers (during 26 weeks of study),Cost of DFU treatment from debut to healing (IDUS substudy),,2005-02,COMPLETED,INTERVENTIONAL,['PHASE2']
14055,NCT00536744,The Primary Variable for Effectiveness of the dermaPACE Device Will be Assessed by Comparing the Incidence of Complete Wound Closure of the dermaPACE and Control Groups 12 Weeks Post Initial Application.,"Time to Wound Closure, Wound Closure Area and Volume Between Active and Control 12 Weeks Post Initial Application, Subject Pain Assessment Between Active and Control 24 Weeks Post Initial Application",,2007-10,COMPLETED,INTERVENTIONAL,['PHASE3']
14056,NCT01796834,HbA1C Blood Test,Blood Pressure,patient evaluation of MBSR intervention,2012-08,COMPLETED,INTERVENTIONAL,['NA']
14057,NCT01941329,Regression of neovascularization,Adverse events related to the treatments,,2014-04,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
14058,NCT00252720,Number of Participants With a 3-step or Greater Increase in Early Treatment of Diabetic Retinopathy Study (EDTRS) Severity Scale,Rate of Change in Urinary Albumin Excretion Rate (UAER).,,2001-08,COMPLETED,INTERVENTIONAL,['PHASE3']
14059,NCT00315718,HbA1c values,Blood pressure (systolic/diastolic),,2002-06,COMPLETED,INTERVENTIONAL,['PHASE3']
14060,NCT00398944,Patients who underwent the recommended procedures during the last 12 months,,,2006-11,COMPLETED,INTERVENTIONAL,['NA']
14061,NCT00494767,Body fat and fat-free mass as determined by a new investigational MR technique compared to 4C Model methodologies.,"Drug levels in blood over time (Day 42 PK parameters are AUC, Cmax, tmax)",,2006-09-29,COMPLETED,INTERVENTIONAL,['PHASE1']
14062,NCT03745885,Pharmacokinetic: t½ of Supaglutide,,,2018-12-04,COMPLETED,INTERVENTIONAL,['PHASE1']
14063,NCT03399357,Humoral immune response measure,,,2017-05-31,UNKNOWN,OBSERVATIONAL,['NA']
14064,NCT03202732,HbA1c,Mortality,,2017-10-09,COMPLETED,INTERVENTIONAL,['NA']
14065,NCT03598400,Severe hypoglycaemia,area under the curve of episodes of hypoglycaemia and hyperglycaemia,,2018-08-01,COMPLETED,INTERVENTIONAL,['NA']
14066,NCT01515228,In-segment late luminal loss,Stent thrombosis (by ARC definition),,2012-01,COMPLETED,INTERVENTIONAL,['PHASE4']
14067,NCT02303405,Hemoglobin A1c,Adverse Events,,2014-11,TERMINATED,INTERVENTIONAL,['PHASE2']
14068,NCT03871621,Left ventricular mass index,Plasma biomarker: fatty acid binding protein 4 (FABP-4),,2019-04-01,COMPLETED,INTERVENTIONAL,['PHASE4']
14069,NCT00027287,,,,2001-11,COMPLETED,INTERVENTIONAL,['PHASE1']
14070,NCT05767450,Glycemic control by Time-in-Range (TIR) monitoring,Measurement by flow cytometry of differences in the percentages of innate lymphoid cells,,2022-12-16,RECRUITING,INTERVENTIONAL,['NA']
14071,NCT03642184,eGFR,Adverse events,,2018-07-14,TERMINATED,INTERVENTIONAL,['PHASE4']
14072,NCT05662267,"Graft failure defined by death-uncensored graft survival, i.e. the return to dialysis or death",Death-censored graft survival,,2020-03-10,RECRUITING,OBSERVATIONAL,['NA']
14073,NCT04429503,Change From Baseline in Best Corrected Visual Acuity (BCVA) (Early Treatment Diabetic Retinopathy Study [ETDRS] Letter Score) in the Study Eye at Week 48,Safety Assessed by Serious Adverse Events (SAEs) Through Week 156,,2020-06-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
14074,NCT04429958,BMI in offspring,Adiposity offsping skin folds,,2021-01-25,COMPLETED,OBSERVATIONAL,['NA']
14075,NCT05270343,Residual β-Cell function (RBCF),Daily Insulin Dosage,,2022-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
14076,NCT05944731,Impact of continuous and intermittent CGM used on blood glucose levels in comparison to standard of care in people living with type 1 diabetes,Cost of continuous and intermittent CGM from a user and provider perspective,,2024-02-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
14077,NCT02226822,Classes of diabetic medications at baseline and changes up to 3 years,Treatment choice,,2014-09-20,COMPLETED,OBSERVATIONAL,['NA']
14078,NCT05258240,Single leg standing test,,,2021-03-01,COMPLETED,INTERVENTIONAL,['NA']
14079,NCT03983733,Hunger and appetite assessment,Covid-19 symptom assessment,Gut microbiome species richness,2019-06-10,COMPLETED,INTERVENTIONAL,['NA']
14080,NCT02143440,When the glucose level decreased to about 10 mmol/L,,,2012-03,UNKNOWN,INTERVENTIONAL,['NA']
14081,NCT03260452,Number of pro-inflammatory macrophages derived from human adipose tissue in mice transplanted with adipose tissue-hematopoietic stem cells .,Comparison of the metabolic profile of the transplanted mice evaluated by the grafted mice's oral glucose tolerance test.,,2018-06-28,COMPLETED,INTERVENTIONAL,['NA']
14082,NCT03811132,HbA1c,Marker of inflammation #4: interleukin-1 receptor antagonist (IL-1Ra),Fear of diabetes complications,2018-07-01,COMPLETED,OBSERVATIONAL,['NA']
14083,NCT02610179,The serum glucose levels will be measured in response to oral glucose challenge and compared between Twizzlers and glucola beverage.,Cost-effectiveness,,2015-04,RECRUITING,INTERVENTIONAL,['NA']
14084,NCT02344732,Mean corneal epithelial wound healing time (in days),Duration of diabetes mellitus (measured in years) and its influence on wound healing time,,2013-10,COMPLETED,INTERVENTIONAL,['NA']
14085,NCT04403789,Change from Baseline Fasting Plasma Glucose (mmol/L) at 12 Weeks,Change from Baseline Physical Activity (AX3 Device) at 12 Weeks and 16 weeks,,2021-03-28,COMPLETED,INTERVENTIONAL,['NA']
14086,NCT01242228,Change from baseline in HbA1c,"Safety as reflected by adverse events, routine safety laboratories, vital signs, physical examinations and 12-lead electrocardiograms (ECGs)",,2010-10-21,COMPLETED,INTERVENTIONAL,['PHASE3']
14087,NCT00979823,Number of risky prescribing events,"Secondary analyses will evaluate the actual use of the tool by residents, direct costs of the program, and resident satisfaction.",,2010-09,COMPLETED,INTERVENTIONAL,['NA']
14088,NCT00017953,First Occurrence of a Severe Cardiovascular Event,First Occurrence of Major Clinical Events,,2001-06,COMPLETED,INTERVENTIONAL,['NA']
14089,NCT04807452,Toronto Clinical Neuropathy Scoring System,,Berg Balance Scale,2020-03-30,COMPLETED,INTERVENTIONAL,['NA']
14090,NCT03290144,Change in FEV1,Change in Body Mass Index (BMI),,2015-02-02,UNKNOWN,OBSERVATIONAL,['NA']
14091,NCT01541735,Total Insulin Secretion,Glycated Hemoglobin A1C,,2012-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
14092,NCT02763007,Proportion of subjects achieving HbA1c <7% after 36 month treatment,change of HOMA-beta(homeostasis model assessment of beta cell) from baseline to 36 month,,2016-05-18,TERMINATED,INTERVENTIONAL,['PHASE4']
14093,NCT04469855,Number of adverse events (AEs),Change in patient-reported outcomes (PROs) using the Diabetes Therapy-Related QOL (DTR-QOL) questionnaire - satisfaction with treatment,,2020-07-27,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
14094,NCT04065581,AUC (plasma metformin),Frequency of TEAE (treatment-emergent adverse event）,,2019-10-14,COMPLETED,INTERVENTIONAL,['PHASE1']
14095,NCT03990844,Change in insulin response,Change in satiety rating,,2019-01-12,COMPLETED,INTERVENTIONAL,['NA']
14096,NCT02738671,Functional MRI of the brain tracking testing.,Change from baseline Functional magnetic resonance imagine,,2016-01,COMPLETED,OBSERVATIONAL,['NA']
14097,NCT03376698,Change in serum high-sensitivity CRP (mg/dl),Change in plasma myeloperoxidase level (ng/ml),Concentration of colhicine in white blood cell (ng/1*10^9 cells),2017-06-15,COMPLETED,INTERVENTIONAL,['PHASE2']
14098,NCT03734367,Change in the emotional skills of adolescents with type 1 diabetes that will be related to a glycosylated index between normal values,,,2019-01,UNKNOWN,INTERVENTIONAL,['NA']
14099,NCT05603130,Effectiveness of patients with COVID-19 who have developed de novo diabetes.,Demographic characteristics of diabetic patients,,2022-03-23,COMPLETED,OBSERVATIONAL,['NA']
14100,NCT00698789,"Safety and tolerability as determined by monitoring of AEs, vital signs, ECGs, physical examinations, and clinical laboratory blood and urine parameters.",Change from Baseline in fasting plasma glucose and population pharmacokinetics of INCB019602 in type 2 diabetic patients.,,2008-05,TERMINATED,INTERVENTIONAL,['PHASE2']
14101,NCT04196231,Proportions of patients with significant HbA1c change,Diabetes treatment satisfaction,,2019-11-27,COMPLETED,INTERVENTIONAL,['PHASE4']
14102,NCT00331851,HbA1c,Glycaemic control,,2006-05,COMPLETED,INTERVENTIONAL,['PHASE3']
14103,NCT00830011,Pain intensity score (NRS),pain-related disability (MPI) and emotional functioning,,2004-09,COMPLETED,INTERVENTIONAL,['NA']
14104,NCT01375660,Oral Glucose Insulin Sensitivity (OGIS),Incident Diabetes,,2011-05,COMPLETED,INTERVENTIONAL,['NA']
14105,NCT01236053,Number of Renal Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin,,,2010-06,COMPLETED,OBSERVATIONAL,['NA']
14106,NCT00887094,Reduction of the prevalence of hyperglycemic peaks during a 24-h period after a bout of aerobic or aerobic/resistance exercise in type 2 diabetes patients on metformin/diet therapy.,,,2009-06,COMPLETED,INTERVENTIONAL,['NA']
14107,NCT03851055,Fasting blood glucose mg/dl,fructosamine mg/dl,,2017-08-01,COMPLETED,INTERVENTIONAL,['PHASE3']
14108,NCT02089477,The primary outcome is amount of time duing interval walking (in minuts) with InterWalk per week after 3 month,VO2-peek test in the InterWalk Application,,2014-03,COMPLETED,INTERVENTIONAL,['NA']
14109,NCT03561571,after breakfast thromboxane B2 concentration,post prandial lipidomic composition of triglyceride rich lipoproteins,,2018-10-15,COMPLETED,INTERVENTIONAL,['NA']
14110,NCT06212778,Fatigue,,,2023-09-26,RECRUITING,OBSERVATIONAL,['NA']
14111,NCT05404789,Time of data entry completion during Emergency Scenario,,,2021-09-27,COMPLETED,INTERVENTIONAL,['NA']
14112,NCT00887874,"Percentage of diabetic patients having dyslipidemia and hypertension, cardiovascular complications, peripheral vascular disease, diabetic nephropathy and diabetic eye complications, respectively","Minimum duration of diabetes associated with 10% incidence of diabetic complications (CVD, Nephropathy and retinopathy)",,2009-05,COMPLETED,OBSERVATIONAL,['NA']
14113,NCT04883372,glycated hemoglobin,Time spent below target (TBR),,2021-05-22,COMPLETED,OBSERVATIONAL,['NA']
14114,NCT05129345,Aim 3: Number of strategies modified in the self-management support and education,,,2022-06-07,RECRUITING,OBSERVATIONAL,['NA']
14115,NCT06058338,Hemoglobin A1c,Program satisfaction,Program feasibility,2023-05-31,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
14116,NCT01587638,Rate of New Onset Diabetes (NOD),,,2009-04,COMPLETED,OBSERVATIONAL,['NA']
14117,NCT00071448,HbA1c (glycosylated haemoglobin A1c),FPG (fasting plasma glucose),,2002-06,COMPLETED,INTERVENTIONAL,['PHASE3']
14118,NCT05228860,HgbA1c,Food Assistance Programs,,2023-09-18,RECRUITING,INTERVENTIONAL,['NA']
14119,NCT02684331,On CMR; passive atrial emptying fraction (%) as a measure for cardiac diastolic function,Echocardiography,,2016-01,COMPLETED,OBSERVATIONAL,['NA']
14120,NCT05364723,distribution of diabetic retinopathy in eastern morocco,,,2022-05-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
14121,NCT00456105,Glycemic control,Readmission,,2006-07,TERMINATED,INTERVENTIONAL,['NA']
14122,NCT05220917,Hospitalization for Heart Failure (HHF) Hospitalization for Heart Failure (HHF),Coronary revascularization,Switching patterns,2021-08-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
14123,NCT00309608,HbA1c Change From Baseline at Week 12,Fasting Blood Plasma Glucose Level (FPG) Change From Baseline at Week 12,,2006-04,COMPLETED,INTERVENTIONAL,['PHASE2']
14124,NCT00534547,Treatment success based on patients' glycemic control,"Physiologic Measurements, Comorbidity improvement, Improvement in QOL",,na,WITHDRAWN,INTERVENTIONAL,['NA']
14125,NCT03503747,Quantification of the number of participants with high-risk genetic markers for the development of type 1 diabetes.,,,2018-04-25,COMPLETED,OBSERVATIONAL,['NA']
14126,NCT02923063,Quadriceps muscle work efficiency,Perceived Stress (NIH),Walking economy during 6 minute walk,2020-01-16,RECRUITING,INTERVENTIONAL,['PHASE2']
14127,NCT05973734,Number of patients who receive Treg infusions (Arm1) or Donor Derived Vertebral Bone Marrow (Arm2) and islet transplantation (feasibility),Quality of life (QOL) assessment,,2023-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
14128,NCT00336674,Diagnosis of Diabetes AT 5 years according to American Diabetes Association / World Health Organization (ADA/WHO) criteria.,Immune function,,2006-12,COMPLETED,INTERVENTIONAL,['PHASE2']
14129,NCT06143566,Oxygen uptake during peak exercise (Peak VO2),Urine albumin to creatinine ratio,Medication Adherence,2024-03-11,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14130,NCT03341429,%WL,HRQoL,,2018-08-22,COMPLETED,INTERVENTIONAL,['PHASE4']
14131,NCT05638880,Reduction of albuminuria,,,2022-12-20,RECRUITING,INTERVENTIONAL,['PHASE2']
14132,NCT05260983,Phenomenological Body Shame Scale - Revised,Short-form State-Trait Anxiety Inventory,1-item Expected Diabetes Prevention Self-Efficacy Scale,2021-08-28,COMPLETED,INTERVENTIONAL,['NA']
14133,NCT01252082,Metabolic control,periodontal improvement after scaling and rootplaning,,2007-06,COMPLETED,INTERVENTIONAL,['PHASE2']
14134,NCT00530309,Plasma concentrations and PD parameters over time and at the end of study,Other metabolic parameters at the end of study,,2007-08-01,COMPLETED,INTERVENTIONAL,['PHASE1']
14135,NCT05099887,Percent of Wound closure,,,2021-12-01,UNKNOWN,INTERVENTIONAL,['NA']
14136,NCT00413335,Mean Percent Change From Baseline in Hepatic Fat Fraction (HFF),Mean Percent Change From Baseline in Adiponectin,,2005-11,COMPLETED,INTERVENTIONAL,['NA']
14137,NCT00422630,Change in insulin sensitivity over time,Diet satisfaction,,2007-10,COMPLETED,INTERVENTIONAL,['NA']
14138,NCT04637217,Correlation between neurodegeneration and retinal vessels characteristics,Correlation between choroidal parameters and diabetes control,,2018-07-01,COMPLETED,OBSERVATIONAL,['NA']
14139,NCT00593255,2-hours postprandial plasma glucose (PPPG),Hypoglycaemic episodes,,2004-07,COMPLETED,INTERVENTIONAL,['PHASE4']
14140,NCT04378972,pro-inflammatory cytokines analysis,,,2019-09-16,COMPLETED,OBSERVATIONAL,['NA']
14141,NCT00536796,Cholesterol levels,,,2007-09,COMPLETED,OBSERVATIONAL,['NA']
14142,NCT05695573,Determine the urinary exosomal UMODmRNA gene expression,,,2019-07-05,COMPLETED,OBSERVATIONAL,['NA']
14143,NCT06160934,Client Satisfaction Questionnaire,Time in Range,,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
14144,NCT03332927,Insulin sensitivity index (IV-SI) from short (40 min) IVGTT.,Vertical Auto-Profile (VAP) analysis of cholesterol carried by lipoproteins and lipoprotein subfractions.,,2017-10-25,COMPLETED,INTERVENTIONAL,['NA']
14145,NCT06086067,Time spent at each glucose range,Progesterone,,2023-09-15,COMPLETED,INTERVENTIONAL,['NA']
14146,NCT06329375,Food insecurity at 30-days post initial discharge,Hospitalization,,2024-03-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
14147,NCT03608358,Mean change from baseline in HbA1c at Week 24,Percent of subjects achieving a therapeutic glycaemic response of HbA1c <7.0% at Week 24,,2019-02-27,TERMINATED,INTERVENTIONAL,['PHASE3']
14148,NCT06208189,Prevalence of hypoglycemia,Session rating of perceived exertion,,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
14149,NCT01407003,"Safety and tolerability of single and multiple dose(s) of LIK066: number of patients with adverse events and changes from baseline in vital signs, ECG and clinical labs (blood chemistry, hematology and urinalysis).",Change in fasting and post-challenge plasma glucose after a single dose and 2 weeks of treatment,,2011-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14150,NCT04113239,Genotypes of participants,Food frequency questionnaire,,2019-11-27,COMPLETED,OBSERVATIONAL,['NA']
14151,NCT02742987,Flow-mediated Dilation of the Brachial Artery,Number of Patients With Platelet Reactivity >256 P2Y12 Reaction Units,,2014-03,COMPLETED,INTERVENTIONAL,['PHASE4']
14152,NCT03032991,Electroencephalography (EEG),Metabolomic,Physical Activity,2016-01,UNKNOWN,OBSERVATIONAL,['NA']
14153,NCT03958760,Triglyceride (TG) (mmol/L),The proportion of re-hospitalization,,2021-02-28,COMPLETED,OBSERVATIONAL,['NA']
14154,NCT00099931,Change from baseline in HbA1c at 24 weeks,Patients with endpoint <7% after 24 weeks,,2004-05,COMPLETED,INTERVENTIONAL,['PHASE3']
14155,NCT02817360,Number of patients with an unplanned cardiac hospitalization or death due to a cardiac event,,Change of kidney function,2016-02,RECRUITING,INTERVENTIONAL,['PHASE4']
14156,NCT01593137,"assess the effect of treatment with liraglutide compared to glimepiride, as add-on to metformin, for one year on circulating levels of EPCs in patients with type 2 diabetes poorly controlled.","Safety parameters of glycaemic control: HbA1c, FPG",,2012-05,WITHDRAWN,INTERVENTIONAL,['PHASE4']
14157,NCT00171600,"Change from baseline in urine albumin excretion rate from collected urine samples, after 16 and 20 weeks",Change from baseline in kidney function after 16 and 20 weeks,,2005-07,TERMINATED,INTERVENTIONAL,['PHASE4']
14158,NCT01178957,Very-Low-Density-Lipoprotein-Triglyceride(VLDL-TG) secretion,,,2012-04,COMPLETED,OBSERVATIONAL,['NA']
14159,NCT01652911,To assess the safety of the Sernova Cell Pouch™ in adult participants with Type-1 diabetes receiving islet transplantation for the first time.,To obtain preliminary data on the efficacy of the Cell Pouch™.,,2012-06,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14160,NCT00545584,Hemoglobin A1c Measurement,Fasting Plasma Glucose (FPG) Measurement,,2007-04-01,COMPLETED,INTERVENTIONAL,['PHASE3']
14161,NCT03260868,Change From Baseline in Glycated Hemoglobin A1c (HbA1c) to Week 24,"Number of Participants With At Least One Hypoglycemic Events (Any, Severe Documented Symptomatic, Probable Symptomatic, Asymptomatic, Pseudo-hypoglycemia: Any Time of the Day) During 24 Week Treatment Period",,2017-09-19,TERMINATED,INTERVENTIONAL,['PHASE4']
14162,NCT03529188,HFS-Parent score,HbA1C,,2018-08-03,UNKNOWN,OBSERVATIONAL,['NA']
14163,NCT04057417,Major adverse cardiovascular events,Cardiovascular disease-related risk factors,Trail counts,2018-01-05,UNKNOWN,INTERVENTIONAL,['NA']
14164,NCT03748251,Continuous glucose sensor data,Content of carbohydrates,Content of amino acids,2018-02-14,COMPLETED,INTERVENTIONAL,['NA']
14165,NCT04038125,Evaluate re perfusion following Ozurdex use.,,,2019-08-22,UNKNOWN,INTERVENTIONAL,['PHASE4']
14166,NCT02337972,Change of conjunctival flora and bacterial resistance,,,2015-01,UNKNOWN,INTERVENTIONAL,['NA']
14167,NCT04973111,Change in insulin secretion rate and ambient glucose levels,Change in blood glucose levels at each level of glucose infusion,,2021-07-12,COMPLETED,INTERVENTIONAL,['PHASE1']
14168,NCT00672386,Mean change in HbA1c from baseline to week 12,Changes in insulin sensitivity and beta cell function (homeostatic model assessment 2 - HOMA-2 and MMTT); Changes in GLP-1 (glucagon-like peptide 1) and PYY (peptide tyrosine tyrozine) levels in the MMTT; Changes in insulin and glucagon,,2007-12,COMPLETED,INTERVENTIONAL,['PHASE2']
14169,NCT01686932,Hypoglycemic Profile of Vildagliptin Compared to Sitagliptin Over 4 Days After 8 Weeks of Treatment in Period 1 & 2,Number of Occurrence of Pre-defined ECG Findings During 4 Days of Continuous ECG Monitoring at Baseline and in the 8th Week of Periods 1 and 2,,2012-11,COMPLETED,INTERVENTIONAL,['PHASE4']
14170,NCT06161844,Change from baseline to week 32 in glycosylated haemoglobin (HbA1c),Incidence and severity of adverse events,,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
14171,NCT03065140,Non-invasive 1H Magnetic Resonance Spectroscopy of vastus lateralis,Saturated and unsaturated lipid pool turnover examined by stable isotopes,,2016-09,COMPLETED,INTERVENTIONAL,['NA']
14172,NCT01385865,Blood glucose change with meal tolerance test,"Lipid profile (triglyceride, total cholesterol, low-density lipoprotein cholesterol, very-low-density lipoprotein cholesterol, high-density lipoprotein cholesterol)",,2011-01,COMPLETED,INTERVENTIONAL,['NA']
14173,NCT02328911,Change in self-reported pain.,Change in quality of life.,,2015-01,WITHDRAWN,INTERVENTIONAL,['PHASE2']
14174,NCT03952819,change from levels of serum sclerostin of control group,,,2017-09-14,COMPLETED,OBSERVATIONAL,['NA']
14175,NCT06183476,Sleep,Glucose levels,,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
14176,NCT05956743,Pittsburgh Sleep Quality Index,,,2023-06-01,COMPLETED,INTERVENTIONAL,['NA']
14177,NCT05143411,Change in glucose levels,Change in glycemic variability,,2021-10-08,COMPLETED,INTERVENTIONAL,['NA']
14178,NCT03533738,Insulin response,,,2017-10-12,COMPLETED,INTERVENTIONAL,['NA']
14179,NCT06025292,Whole Body Protein Balance,,,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
14180,NCT04007926,Whole-body Insulin sensitivity,Waist circumference,,2021-08,SUSPENDED,INTERVENTIONAL,['NA']
14181,NCT00845130,Quantify the Effect of Chronic Hyperglycemia on Cellular Uptake of Vitamin C Across the Blood-brain Barrier,,,2009-09,COMPLETED,INTERVENTIONAL,['NA']
14182,NCT00774553,"Safety variables (AE, BP, pulse, plasma glucose, laboratory variables, weight and ECG)",Pharmacodynamic variables,,2008-10,COMPLETED,INTERVENTIONAL,['PHASE1']
14183,NCT06124573,Area under the plasma concentration versus time curve (AUC) 0-inf (Metformin only),Number of participants with adverse events (AEs),,2022-11-07,COMPLETED,INTERVENTIONAL,['PHASE1']
14184,NCT01918488,24-hour urinary sodium excretion induced by amiloride,Office blood pressure measurements,,2013-10,UNKNOWN,INTERVENTIONAL,['NA']
14185,NCT05492890,Maternal outcome,Neonatal outcomes,,2022-08,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
14186,NCT03272854,Graft Failure,Non-Cardiovascular Mortality,Venous Thrombosis,2001-08,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
14187,NCT05219409,Rate of new diagnoses of Type 1 Diabetes Mellitus per year,Number of participants with adverse effects on Sitagliptin,Monitor Stage 2 patients with a CGM system (continuous blood glucose detection),2023-07,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
14188,NCT03196154,HbA1C,Cardiovascular risk estimation,,2017-08-01,COMPLETED,OBSERVATIONAL,['NA']
14189,NCT04585139,HbA1c,,,2020-10-06,COMPLETED,INTERVENTIONAL,['NA']
14190,NCT02109094,Plasma Leptin Level,,,2014-02,COMPLETED,OBSERVATIONAL,['NA']
14191,NCT05285085,Statin use on primary prevention,High dose statin use on patients with unknown diagnosis,,2021-11-19,COMPLETED,OBSERVATIONAL,['NA']
14192,NCT03136471,Glycemic Control (HbA1c) for Telehealth visits for COVID-19 patients,,,2017-01,COMPLETED,OBSERVATIONAL,['NA']
14193,NCT05169502,Genome wide expression profile of circulating cells in blood samples from each cohort group,,,2021-12-08,RECRUITING,OBSERVATIONAL,['NA']
14194,NCT01916174,Maximum observed plasma liraglutide concentration after single dose,Terminal elimination half-life of liraglutide after single dose,,2013-08,COMPLETED,INTERVENTIONAL,['PHASE1']
14195,NCT00706420,Percent of subjects who have achieved insulin independence post transplant.,HgAlc</= 6.5%,,2004-04-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
14196,NCT06292026,time to wound closure,,,2022-03-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
14197,NCT05337306,Health Literacy Questionnaire Subscale 2: having sufficient information to manage my health,Perceived Diabetes Self-Management Scale score,,2023-04-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
14198,NCT00706511,Polysomnography - Sleep Efficiency,IVGTT (Intravenous Tolerance Test) - Disposition Index (DI),,2007-12,COMPLETED,INTERVENTIONAL,['NA']
14199,NCT01059669,Peak enzyme Concentration IE,peak amylase,Rosemont score US,2009-08,UNKNOWN,OBSERVATIONAL,['NA']
14200,NCT04851223,Changes in BCAA and its derivatives,,,2021-03-22,RECRUITING,OBSERVATIONAL,['NA']
14201,NCT00541515,Blood glucose levels,,,2007-10,COMPLETED,INTERVENTIONAL,['NA']
14202,NCT02910674,"Percent of Participants Responding 'YES' on the Question ""Did You Successfully Obtain Measurement Result Using the Dario™ BGMS?""",,,2016-07,COMPLETED,INTERVENTIONAL,['NA']
14203,NCT00428207,Glycemic Stability,Frequency of Catheter Change,,2007-02,TERMINATED,INTERVENTIONAL,['NA']
14204,NCT05016375,Explore bathing and spa behaviour by applying the social-ecological model to interpretivist thematic analysis.,Explore how passive heating might impact physical activity by applying the social-ecological model to interpretivist thematic analysis.,,2022-06-28,COMPLETED,OBSERVATIONAL,['NA']
14205,NCT01622777,Nerve growth factor,,,2010-02,COMPLETED,INTERVENTIONAL,['PHASE2']
14206,NCT04945551,Gene expression will be quantitatively determined at cellular resolution using single nuclei sequencing,Cardiorespiratory fitness,,2021-02-20,UNKNOWN,INTERVENTIONAL,['NA']
14207,NCT05286450,Distribution of Participants Responses as Regards DSMQ Health Care Use Domain,,,2022-03-15,COMPLETED,OBSERVATIONAL,['NA']
14208,NCT05197920,diabetes mellitus (DM) following a qualifying episode of acute pancreatitis (AP),Fecal Elastase,,2022-01-14,RECRUITING,OBSERVATIONAL,['NA']
14209,NCT02054650,Change in low back pain severity,Change in biomarker concentrations,,2014-05,TERMINATED,INTERVENTIONAL,['NA']
14210,NCT02243072,Metabolic Control: Hemoglobin A1c (HbA1c),"Regimen Adherence: Diabetes Management Scale (DMS), Glucose Meter Downloads",,2014-12,COMPLETED,INTERVENTIONAL,['NA']
14211,NCT03815305,Change in SRRC,,,2018-07-30,UNKNOWN,INTERVENTIONAL,['PHASE4']
14212,NCT05188703,Number of participants who completed a follow-up eye exam 12+ months after baseline eye exam,,,2022-07-25,RECRUITING,INTERVENTIONAL,['NA']
14213,NCT06020235,Efficacy,Pharmacokinetics,Wound healing,2024-12,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
14214,NCT00794430,Investigate the safety and tolerability of V3381 in patients with diabetic neuropathic pain at doses of up to 400 mg bid,Determine the efficacy of V3381 in the treatment of diabetic peripheral neuropathic pain at does of up to 400 mg bid,,2008-12,COMPLETED,INTERVENTIONAL,['PHASE2']
14215,NCT03967639,Smoking habits of patients undergoing cardiac surgery,,,2019-02-01,UNKNOWN,OBSERVATIONAL,['NA']
14216,NCT03728296,Occurrence of treatment related adverse events as assessed by CTCAE v4.0,,,2019-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
14217,NCT05769127,Change in body weight for DPP participants,change in liver elastography in DPP participants,,2023-04-26,RECRUITING,INTERVENTIONAL,['NA']
14218,NCT03960333,circulating CD4+T cells in Type 2 Diabetic pre/post Metformin,,,2019-04-25,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
14219,NCT06180837,Insulin Sensitivity,Cardiac Event Risk Test 1 (CERT 1),,2023-12,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
14220,NCT05341063,Health Literacy Scale,,,2021-10-10,COMPLETED,INTERVENTIONAL,['NA']
14221,NCT02745470,Whole brain connectivity,intake of food in the buffet,,2016-02,COMPLETED,INTERVENTIONAL,['NA']
14222,NCT00897169,"Beta-cell function index estimated by a model-based analysis fit to the complete OGTT C-peptide and glucose profiles (12 time points), and including diabetes progression (as assessed by the glucose concentration 2 hours after an oral glucose load)",Evaluation of comparability of OGTT and clamp data based on modelling data of insulin sensitivity from steady-state clamp insulin and glucose concentrations and OGTT insulin and glucose profiles (12 time points),,2009-06,COMPLETED,INTERVENTIONAL,['PHASE1']
14223,NCT02313220,Body weight (kg),Body weight (%),"Adverse events /serious adverse events, vital signs and collection of clinical chemistry/haematology parameters.",2014-12,COMPLETED,INTERVENTIONAL,['PHASE2']
14224,NCT01474018,Change in A1c,Total Daily Insulin Dose,,2011-11,COMPLETED,INTERVENTIONAL,['PHASE4']
14225,NCT02041234,number of subjects achieving LDL level of <100mg/dl without lipid lowering medication,Weight loss,,2014-02,COMPLETED,INTERVENTIONAL,['PHASE4']
14226,NCT01267175,Usability of the X54 Insulin Pump Meets Expectations,Usability of the Training Material Meets Expectations,,2009-01,COMPLETED,INTERVENTIONAL,['PHASE4']
14227,NCT01602003,Change of HbAlc,HbA1c Responder Rate,,2009-12,COMPLETED,INTERVENTIONAL,['PHASE3']
14228,NCT03611322,"Cmax,sema,Week5: the maximum plasma semaglutide concentration after first maintenance dose of subcutaneous semaglutide 1 mg administration following a four week escalation period",Number of site-initiated technical complaints with or without co-reported adverse events,,2018-08-08,COMPLETED,INTERVENTIONAL,['PHASE1']
14229,NCT02441023,Metabolic control,Body mass index (BMI),,2013-03,COMPLETED,INTERVENTIONAL,['NA']
14230,NCT02505321,Level of Circulatory Lipids following Triglyceride stimulation test (OTTT) (mmol/L),Incremental Area under the Curve NEFA levels (µmol/L),,2015-05-29,COMPLETED,INTERVENTIONAL,['NA']
14231,NCT03809858,Number of missed meal boluses,Diabetes Distress Scale (DDS) Scores,,2019-05-29,COMPLETED,INTERVENTIONAL,['NA']
14232,NCT04161430,Change from baseline in HbA1c (%) compared to placebo comparator at week 24,"Change from baseline in fasting plasma glucose/2-hour postprandial plasma glucose/body weight at week 12,week 24",,2020-01-02,COMPLETED,INTERVENTIONAL,['PHASE3']
14233,NCT01831921,Hemoglobin A1c,Triglycerides,Homeostasis Model of Insulin Resistance (HOMA IR),2014-01,COMPLETED,INTERVENTIONAL,['NA']
14234,NCT02158741,Summary of Diabetes Self-Care Activities,SF12v2,Health Assessment forms,2014-09,COMPLETED,INTERVENTIONAL,['NA']
14235,NCT00007696,,,,1998-04,COMPLETED,OBSERVATIONAL,['NA']
14236,NCT04088201,Interstitial fluid glucose readings,Acceptablility of sensor,,2019-09-26,UNKNOWN,INTERVENTIONAL,['NA']
14237,NCT00324207,,,,2006-02,COMPLETED,OBSERVATIONAL,['NA']
14238,NCT00363233,Total cholesterol at 3 months,LDL and triglycerides at 3 months; Blood glucose and HbA1C at 3 months,,2006-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
14239,NCT02647515,intraocular pressure,,,2013-01,COMPLETED,INTERVENTIONAL,['PHASE4']
14240,NCT02691234,"To assess initial closure rate of the wound 4 weeks after the last treatment session, as compared to the control group receiving conventional standard of care.",,,2016-04,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14241,NCT02034513,Number of Treatment Emergent Severe or BG (Blood Glucose) Confirmed Symptomatic Hypoglycaemic Episodes During the Maintenance Period,FPG (Fasting Plasma Glucose),,2014-01-05,COMPLETED,INTERVENTIONAL,['PHASE3']
14242,NCT01836172,Flow-mediated dilation (FMD),Systolic and Diastolic Blood Pressure,"Serum Lipids (LDL, HDL and TG)",2013-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
14243,NCT06069258,Movement behaviour,Adverse events,,2023-10-20,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
14244,NCT03042325,Percentage of Participants with Glycosylated Hemoglobin < 7.0%,,,2017-07-30,WITHDRAWN,INTERVENTIONAL,['PHASE4']
14245,NCT01076608,,,,2003-09,COMPLETED,OBSERVATIONAL,['NA']
14246,NCT03118739,Urinary Albumin to Creatinine Ratio (UACR),MRI Variables - LV Mass,Baseline Flow Mediated Dilatation (Reactive Hyperemia),2017-05-18,COMPLETED,INTERVENTIONAL,['PHASE2']
14247,NCT02196272,Medication adherence,Contacts with health services,,2014-07,UNKNOWN,INTERVENTIONAL,['NA']
14248,NCT06028399,Quality of life for disease-specific patient reported outcomes,,,2023-07-15,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
14249,NCT03365180,Accuracy of estimate 2,Time spent in normoglycemia,,2018-01-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
14250,NCT01040819,Plasma 15-epi-lipoxin A4,,,2010-02,COMPLETED,INTERVENTIONAL,['PHASE4']
14251,NCT05222815,Change in Diabetes Distress,,,2022-08-29,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
14252,NCT04372810,Tibiotarsal joint range of motion,Static balance,,2017-08-09,COMPLETED,INTERVENTIONAL,['NA']
14253,NCT02637037,Observed Maximum Plasma Concentration [Cmax] Under Fasted or Fed State,Apparent Volume of Distribution During the Terminal Phase After Extravascular Administration [Vz/F],,2015-12-21,COMPLETED,INTERVENTIONAL,['PHASE1']
14254,NCT02307968,leaking,,,2014-10,COMPLETED,OBSERVATIONAL,['NA']
14255,NCT01772173,Area under the Curve of algorithm,,,2013-02-01,COMPLETED,OBSERVATIONAL,['NA']
14256,NCT02147925,Intrahepatic lipids (IHL),Change in hemoglobin A1c(HbA1c),,2014-08,COMPLETED,INTERVENTIONAL,['PHASE4']
14257,NCT05181449,To compare the percentage of patients in the TPT and Usual Care groups who have a HbA1c less than 6.5 and are not on any glucose lowering medications (excluding Metformin up to 2000 mg/day) at 12 months (360 days).,To compare the percentage of patients in the TPT and Usual Care groups who have a HbA1c less than at 6.5 and are not on any glucose lowering medications at 12 months (360 days).,,2022-02-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
14258,NCT02011620,Improvement in endothelial function as measured by laser doppler imaging.,Improvement in bone metabolism,,2014-10,WITHDRAWN,INTERVENTIONAL,['PHASE4']
14259,NCT05787457,Metabolic phenotype of type 2 diabetes mellitus across groups,Genetic Differences,,2014-07-31,TERMINATED,OBSERVATIONAL,['NA']
14260,NCT01291160,Number of 100% Wound Closure,,,2009-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
14261,NCT03842267,Changes from baseline HbA1c at week 24,,,2019-05-13,COMPLETED,INTERVENTIONAL,['PHASE3']
14262,NCT06071325,Types and Amount of Diabetes Waste,,,2023-09-19,RECRUITING,OBSERVATIONAL,['NA']
14263,NCT05769335,Glucose area under curve (AUC) after 3 meals,Change in fat mass,,2023-03-15,RECRUITING,INTERVENTIONAL,['NA']
14264,NCT05376969,"Changes from baseline in Adverse events (AEs) and adverse events of special interest (AESIs)* at Weeks 6, 12, 18, 24, 38, and 52 after administration of the IP","Proportion of subjects achieving HbA1c target of < 7% at Weeks 6, 12, 18, 24, 38, and 52 after administration of the IP",,2021-05-25,COMPLETED,INTERVENTIONAL,['PHASE3']
14265,NCT01514487,"Cmax, maximum concentration",Adverse events,,2005-01-13,COMPLETED,INTERVENTIONAL,['PHASE1']
14266,NCT00428727,Ulcer reduction percentage,Presence of adverse events related to the application of the patches,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE3']
14267,NCT00515723,Clamp Derived Insulin Sensitivity (mg/kg/Min),,,2001-09,COMPLETED,INTERVENTIONAL,['NA']
14268,NCT02008435,Percent body weight loss,Exercise stress test (EST),Habit formation indices of fat grams and calorie tracking,2013-04,COMPLETED,INTERVENTIONAL,['NA']
14269,NCT04938388,HbA1c < 7.0%,Number of participants with treatment-related adverse events assessed by research physician classified according to Good Clinical Practice guidelines,,2022-01-29,TERMINATED,INTERVENTIONAL,['PHASE4']
14270,NCT02308293,"Plasma level of adrenaline in response to hypoglycemia (Adrenaline, measured in arterial plasma)",Brain lactate accumulation measured with 1H-MRS,"Plasma insulin concentration (Insulin levels, measured in arterial plasma)",2015-01,COMPLETED,INTERVENTIONAL,['NA']
14271,NCT02965443,Percentage of subjects achieving a HbA1c ≤ 7.5% and having a reversal from a BBIT to a BOT regimen,changes in fear of hypoglycemia between groups,changes in clinical chemistry/haematology parameters between groups,2018-02-02,TERMINATED,INTERVENTIONAL,['PHASE4']
14272,NCT01590433,Change in Body Weight,,,2012-03,COMPLETED,INTERVENTIONAL,['PHASE4']
14273,NCT04131608,Iron deficiency detected by Hemoglobin level in g/dl HBA1C level in diabetic patients,,,2021-02-01,UNKNOWN,OBSERVATIONAL,['NA']
14274,NCT03502083,Forearm bloodflow ratio with GLP-1,,,2015-12-01,COMPLETED,INTERVENTIONAL,['NA']
14275,NCT00265746,Incidence of type 2 diabetes mellitus.,Incidence of IGT,,2005-11,WITHDRAWN,INTERVENTIONAL,['PHASE4']
14276,NCT01719640,microvascular complications,The incidence and severity of adverse events related to the stem cell infusion procedure,,2011-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14277,NCT03296436,complete ulcer closure,recurrent ulcer-related complications,,2020-01,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1']
14278,NCT00173628,,,,1990-01,UNKNOWN,OBSERVATIONAL,['NA']
14279,NCT01418703,Hypoglycemic Events,Mean Glucose,,2009-10,COMPLETED,INTERVENTIONAL,['NA']
14280,NCT00612014,Change from baseline in the mean Gastroparesis Cardinal Symptom Index score (24 hour recall version) across the four days of dosing. Baseline is the average of the scores collected across the 4 days just prior to admission for dosing.,Cumulative GSA score after each dosing event and after all dosing events,,2007-10,COMPLETED,INTERVENTIONAL,['PHASE2']
14281,NCT05426525,Insulin-stimulated glucose disposal,Skeletal muscle energetic stress,,2022-10-13,RECRUITING,INTERVENTIONAL,['PHASE4']
14282,NCT00872456,"Composite of major CVD events (non fatal MI, Stroke and CVD death)",Revascularization procedures,,2005-03,COMPLETED,OBSERVATIONAL,['NA']
14283,NCT02038517,Relationship of insulin secretion and sensitivity with the development of abnormalities of glucose metabolism after OLT,Relationship of insulin secretion and sensitivity with the development of the metabolic syndrome after OLT,Morbidity and mortality after OLT,2013-06,RECRUITING,OBSERVATIONAL,['NA']
14284,NCT03820349,MRI outcome,Cognitive function,,2018-05-07,COMPLETED,OBSERVATIONAL,['NA']
14285,NCT02673866,Change in weekly Average Daily Pain Score (ADPS),Rescue medication usage,,2016-02,WITHDRAWN,INTERVENTIONAL,['PHASE2']
14286,NCT04583839,Postpartum weight retention,Diabetes risk perception,Participant adherence with navigation,2020-12-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
14287,NCT03361631,To evaluate the occurrence of clinical adverse event (tolerance) to intracavernous injection of autologous MSC in patients 18 to 50 years of age with complicated type 1 diabetes mellitus with erectile dysfunction refractory to oral treatment.,Evaluation of the feasibility of the autologous MSC intracavernous injection protocol by the Injection rate actually achieved,,2018-06-30,UNKNOWN,INTERVENTIONAL,['PHASE1']
14288,NCT02002611,Assess Cmax of R-warfarin,Assess Vd/F of R-warfarin,,2013-12,COMPLETED,INTERVENTIONAL,['PHASE1']
14289,NCT04942119,Lifestyle adherence,Side effects or complications,,2021-05-01,UNKNOWN,INTERVENTIONAL,['NA']
14290,NCT02791035,Correlation between change of HbA1c and urinary glucose excretion,Percentage of subjects achieving the target HbA1c(<6.5%),,2016-06,COMPLETED,INTERVENTIONAL,['PHASE4']
14291,NCT04630795,Plantar skin perfusion before and after use.,Plantar Pressure during walking,,2023-09-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
14292,NCT03439072,Number of Subjects With a Positive Glucose Response,Glucagon Preparation and Administration Time,,2018-01-23,COMPLETED,INTERVENTIONAL,['PHASE3']
14293,NCT01018173,Time to cardiovascular composite primary endpoints,"Metabolic and renal function parameters: HbA1c, fasting plasma glucose, body weight, lipid profile, albumin/creatinine ratio (ACR), albuminuria, glomerular filtration rate (GFR)",,2010-01,COMPLETED,INTERVENTIONAL,['PHASE3']
14294,NCT03912623,HbA1c evolution,Subgroup analysis,,2019-09-13,UNKNOWN,INTERVENTIONAL,['NA']
14295,NCT01454973,,,,2011-10,COMPLETED,OBSERVATIONAL,['NA']
14296,NCT06327503,opiorphin levels in saliva,unstimulated saliva flow,,2024-04-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
14297,NCT03104738,"Pre-operative Fasting Blood Glucose, as Measured by Standardized Point of Care Capillary Blood Glucose (CBG) Device in the Pre-op Holding Area.",Mean 24-hour Glucose Postoperatively,,2013-11-20,COMPLETED,INTERVENTIONAL,['NA']
14298,NCT02043886,Catecholamines,,,2007-06,COMPLETED,INTERVENTIONAL,['PHASE2']
14299,NCT05210517,Fractional uric acid excretion,urinary glucose levels,,2020-10-01,COMPLETED,INTERVENTIONAL,['PHASE4']
14300,NCT03912961,Number of subjects where the image readout by retina specialists match the readouts by EyeStar AI system for identifying diabetic eye disease,Number of subjects with ocular diseases other than diabetic retinopathy between the readout by the EyeStar AI system and those by the retina specialists,,2019-01-21,COMPLETED,OBSERVATIONAL,['NA']
14301,NCT03671915,"The time spent of the glucose level drop in below 70 mg/dl over the 72-h, as recorded by continuous subcutaneous glucose monitoring (CGM).","Subject's perception in terms of life-style change, satisfaction and diabetes management",,2019-05-06,COMPLETED,INTERVENTIONAL,['NA']
14302,NCT03981328,LGA newborns,Health-related quality of life,,2020-08-26,RECRUITING,INTERVENTIONAL,['NA']
14303,NCT05100576,Change of HbA1c level,Difference in the decisions between the two type of visits,,2021-07-01,UNKNOWN,INTERVENTIONAL,['NA']
14304,NCT04878406,Number of treatment emergent adverse events (TEAEs),"Cmax,semaglutide,SD: Maximum plasma concentration of semaglutide upon a single-dose",,2021-05-18,COMPLETED,INTERVENTIONAL,['PHASE1']
14305,NCT04308590,Rate of safety based TEAEs,Proportion of patients with normalization of the mean SBP,,2020-07-27,RECRUITING,INTERVENTIONAL,['PHASE3']
14306,NCT03829891,Changes of blood sugar variation .,Inflammatory factors (hs-CRP) change,Safety Outcome Measure: Serious adverse event,2018-08-07,COMPLETED,INTERVENTIONAL,['NA']
14307,NCT06192693,Hba1c change from baseline to 6 months post randomization,Evaluate quality of life,,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
14308,NCT03713268,Estimate of subretinal fluid volume before and after surgery for retinal detachment based on surgical view versus based on OCT output,,,2018-09-30,RECRUITING,OBSERVATIONAL,['NA']
14309,NCT04903743,duration of postoperative analgesia,,,2021-01-10,UNKNOWN,INTERVENTIONAL,['NA']
14310,NCT01386099,Beta-cell function,Body weight,,2011-05,COMPLETED,INTERVENTIONAL,['PHASE2']
14311,NCT00128154,Increase in insulin sensitivity,weight and/or body composition,,2004-01,COMPLETED,INTERVENTIONAL,['NA']
14312,NCT01396161,Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs),Urinary Recovery,,2011-07,COMPLETED,INTERVENTIONAL,['PHASE1']
14313,NCT00707590,"AEs, vital signs, ECG and clinical laboratory test results",DPP-4 inhibition and incretin response,,2008-08,TERMINATED,INTERVENTIONAL,['PHASE1']
14314,NCT00605839,Quality of Parent-child Relationship,,,2008-01,COMPLETED,INTERVENTIONAL,['NA']
14315,NCT06072573,"Change in pain level on the Numeric Rating Scale (NRS, 0-10) between baseline and at treatment week 14 (end of first treatment phase) in comparison of study arm 1 (verum) and study arm 2 (placebo)","Number of patients with rescue medication over the course of the clinical trial and within periods: until treatment week ≤5, ≤11 and ≤14",Number and severity of adverse events (AE),2023-11-02,RECRUITING,INTERVENTIONAL,['PHASE3']
14316,NCT01377961,A1C,"For Arm 1 :AUCglucose,Plasma Lipids concentrations,BMI,Plasma lycopene and isoflavones concentration,EPCs count and function,Chlamydia Trachomatis titers in serum",,2010-09,WITHDRAWN,INTERVENTIONAL,['NA']
14317,NCT02219646,Endothelin-1,Flow Mediated Dilation,carotid Intima Media Thickness,2010-03,COMPLETED,INTERVENTIONAL,['PHASE2']
14318,NCT01572740,Change in Glycosylated Haemoglobin (HbA1c) From Baseline to Week 16,Number of Confirmed Hypoglycaemic Episodes,,2012-04-05,COMPLETED,INTERVENTIONAL,['PHASE3']
14319,NCT00829296,Change in Central Systolic Blood Pressure (SBP),Change in Pulse Pressure Amplification,,2009-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
14320,NCT03989063,Change in balance performance,Change in patient's self-reported outcomes,,2019-10-01,RECRUITING,INTERVENTIONAL,['NA']
14321,NCT05569525,Glycated hemoglobin (HbA1c),Glucose coefficient of variability (CV),,2022-11-06,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
14322,NCT02854423,major cardiac adverse events,Rate of target-vessel revascularization (TVR) in all participants,,2007-01,COMPLETED,OBSERVATIONAL,['NA']
14323,NCT03963219,"% Time blood glucose in target, day time assess by device",,,2019-08-22,UNKNOWN,INTERVENTIONAL,['NA']
14324,NCT02328521,Neointimal area,number of major adverse cardiovascular events,,2014-12,UNKNOWN,INTERVENTIONAL,['PHASE4']
14325,NCT05344066,Number of stillbirths,The acceptability of the dietary interventions will be explored qualitatively,Mode of delivery,2022-11-24,RECRUITING,INTERVENTIONAL,['NA']
14326,NCT01506869,number of participants who develop cancer during follow-up,,,2011-05,UNKNOWN,OBSERVATIONAL,['NA']
14327,NCT02620917,Number of Patients With Glycated Hemoglobin on Target,"Number of Patients With HbA1c on Target Using Advanced Pump's Functions, CGM and CHO Counting",,2015-11-01,COMPLETED,OBSERVATIONAL,['NA']
14328,NCT04937296,HBA1c (Glycated hemoglobin),Triglyceride-glucose index,,2022-01-12,COMPLETED,INTERVENTIONAL,['NA']
14329,NCT05018416,Procedural and investigational product-related treatment-emergent adverse events (TEAEs) obtained through 18 months after the last REACT injection.,,,2021-07-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
14330,NCT04283617,Intracerebral concentrations of glucose between T2DM patients,Multitasking Test (MTT),,2021-10-12,WITHDRAWN,INTERVENTIONAL,['NA']
14331,NCT02126358,LDL-C change rate,LDL-C change rate,,2014-05,COMPLETED,INTERVENTIONAL,['PHASE3']
14332,NCT06239129,Effect of medications or conditions on kidney function decline,Adverse health events associated to laboratory abnormalities,,2006-01-01,COMPLETED,OBSERVATIONAL,['NA']
14333,NCT02223065,Dapagliflozin AUC From Time 0 Extrapolated to Infinite Time (AUC[0-inf]),,,2014-09,COMPLETED,INTERVENTIONAL,['PHASE1']
14334,NCT05974592,Foot Care Behavior Scale (USAS),Diabetic Foot Evaluation Form (DADF),,2023-09-01,RECRUITING,INTERVENTIONAL,['NA']
14335,NCT04689984,Improvement in Brief Pain inventory at week 8,,,2020-11-03,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
14336,NCT04620668,Changes in stress as measured by the Perceived Stress Scale (PSS-10),Changes in life satisfaction as measured by the Satisfaction with Life Scale,,2021-10-01,COMPLETED,INTERVENTIONAL,['NA']
14337,NCT04874012,HbA1c,Body mass index (BMI),,2021-06-12,RECRUITING,INTERVENTIONAL,['PHASE2']
14338,NCT02816762,Change form baseline in albuminuria levels,To identify the CPAP-responder subgroup of OSA patients with diabetic nephropathy,,2016-06,COMPLETED,INTERVENTIONAL,['PHASE4']
14339,NCT01198678,Evaluate capability to follow glucose concentration changes over 15 consecutive days,,,2010-11,COMPLETED,INTERVENTIONAL,['PHASE1']
14340,NCT01868581,Maximum serum insulin degludec concentration (Cmax) (for IDegAsp),,,2008-05,COMPLETED,INTERVENTIONAL,['PHASE1']
14341,NCT03613805,device accuracy,changes in fear of hypoglycaemia,,2018-03-14,COMPLETED,INTERVENTIONAL,['NA']
14342,NCT04283318,change of 2h glucose levels,Changes in body composition,,2018-06-13,COMPLETED,INTERVENTIONAL,['NA']
14343,NCT04622722,2-hour postprandial glucose,Gastrointestinal tolerance,,2018-08-22,COMPLETED,INTERVENTIONAL,['NA']
14344,NCT03937050,Mean fasting blood sugar (women with GDM),Adverse perinatal outcomes (composite measure),,2021-05-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
14345,NCT00437164,changes in fluid related parameters as measured by hematocrit and hemoglobin levels and body weight,"safety/tolerability, as measured by adverse events, clinical laboratory, edema & glycemic measures, ophthalmic assessments; & changes in weight, waist & hip circumference",,2006-09,TERMINATED,INTERVENTIONAL,['PHASE2']
14346,NCT01742624,"Incidence of efficacy failure (treated-BCAR, biopsy-confirmed acute rejection, graft loss rate, death, or follow-up failure)","Safety assessed by the incidence of adverse events, physical exam, and labo-tests",,2012-04,COMPLETED,INTERVENTIONAL,['PHASE4']
14347,NCT05116410,"Incidence of adverse event (AE), serious adverse event (SAE), AE leading to study discontinuation, AE severity and relation with study drug",Weight change,,2021-11-01,UNKNOWN,INTERVENTIONAL,['PHASE1']
14348,NCT01627184,Glycemic Control during Exercise,System Utility and Usability,,2012-05,COMPLETED,OBSERVATIONAL,['NA']
14349,NCT02710799,Number of consultations authorized,Usage of TelessaúdeRS teleconsultations,,2015-06,COMPLETED,INTERVENTIONAL,['NA']
14350,NCT05013294,Glycated hemoglobin,Waist-hip ratio,,2021-08-23,COMPLETED,INTERVENTIONAL,['NA']
14351,NCT03399565,HDL-C,,,2016-01-18,UNKNOWN,OBSERVATIONAL,['NA']
14352,NCT06013865,Discontinuation of Empagliflozin,Blood Pressure,,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
14353,NCT05583877,Process Evaluation,Change in HbA1c Percentage,,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
14354,NCT01076647,Change in Glycosylated Haemoglobin (HbA1c),Change in Body Weight,,2010-03,COMPLETED,INTERVENTIONAL,['PHASE3']
14355,NCT01315808,Study the rate of change of HbA1c in normal population with known risk factors of diabetes,Diabetes prediction model based on the rate of change in HbA1c,,2011-03,TERMINATED,OBSERVATIONAL,['NA']
14356,NCT00272012,Change in HbA1c.,Adverse events.,,2004-07,COMPLETED,INTERVENTIONAL,['PHASE3']
14357,NCT02848261,Pediatric Quality of Life Inventory,General and diabetes-specific technology use,,2016-08-15,COMPLETED,INTERVENTIONAL,['NA']
14358,NCT05714852,Change in blood glucose,Change in waist circumference,,2023-02-15,RECRUITING,INTERVENTIONAL,['NA']
14359,NCT00608816,catecholamine levels,,,na,WITHDRAWN,INTERVENTIONAL,['NA']
14360,NCT05452551,Logarithmic decrement,,,2021-07-06,COMPLETED,OBSERVATIONAL,['NA']
14361,NCT00013286,,,,1999-10,COMPLETED,OBSERVATIONAL,['NA']
14362,NCT01168258,Genotype frequency of SNP in the study genes of DME participants and control participants.,"Secondary outcomes are ophthalmic measurements, including visual acuity, FA and OCT data, to investigate associations between detected genetic polymorphisms and response to conventional diabetic retinopathy treatment.",,2010-07-07,TERMINATED,OBSERVATIONAL,['NA']
14363,NCT05635266,Biospecimen & Clinical Data Collection,,,2021-10-26,RECRUITING,OBSERVATIONAL,['NA']
14364,NCT01606371,Number of participants with one or more drug related adverse events (AEs) or any serious AEs,Glucose excursion after meals,,2007-05,COMPLETED,INTERVENTIONAL,['PHASE1']
14365,NCT02352298,Dario Blood Glucose Monitoring System Accuracy at High Altitude (ISO 15197:2003),,,2015-02,COMPLETED,INTERVENTIONAL,['NA']
14366,NCT01913145,Usability and HbA1c Method Comparison Study Using Lay-Person Micro-Blood Specimens,,,2012-05,COMPLETED,INTERVENTIONAL,['PHASE1']
14367,NCT01472406,% of time within zone [80-140] mg/dL except 5 hours post-prandial and during exercise and 3 hours post-exercise,% of time within zone [70-150] mg/dL during the 3 hours following exercise,,2011-11,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
14368,NCT01980459,The magnesium cellular levels will provide a stronger correlation with antiinflammatory indicators compared to the circulating serum levels of magnesium.,Magnesium supplementation will lower parameters of inflammation in hypomagnesemic diabetic patients.,,2013-10,COMPLETED,INTERVENTIONAL,['PHASE1']
14369,NCT03227484,effect of treatment with 25 mg empagliflozin daily versus placebo on regional brain insulin sensitivity,effect of treatment with empagliflozin versus placebo on energy expenditure,,2017-06-09,COMPLETED,INTERVENTIONAL,['PHASE2']
14370,NCT05262946,Cumulative Somatosensory Impairment Index,Validated Spanish version of Short-Form Late-Life Function and Disability Instrument,,2016-01-01,COMPLETED,INTERVENTIONAL,['NA']
14371,NCT05155410,Glucose Control: Change in Fructosamine,Waist circumference,Cravings,2022-02-15,COMPLETED,INTERVENTIONAL,['NA']
14372,NCT03806166,Definitive treatment failure (infection recurrence),Quality of life measured by EuroQol 5 Dimensions 5 Levels Score and EuroQol Visual Analogue Score,,2019-02-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
14373,NCT00254085,Blood glucose fluctuations,number of hypoglycemia,,2005-03,UNKNOWN,INTERVENTIONAL,['PHASE4']
14374,NCT01224366,HbA1c reduction,Incidence of hypoglycemia and severe hypoglycemia (overall and subpopulations),,2010-09,COMPLETED,INTERVENTIONAL,['PHASE3']
14375,NCT05670548,Serum metabolomics,,,2023-01-01,RECRUITING,OBSERVATIONAL,['NA']
14376,NCT04055064,Change in dietary intake of nutrients,Change in Ankle Brachial Index(ABI),,2017-05-23,COMPLETED,INTERVENTIONAL,['NA']
14377,NCT00569556,"Combined outcome of BP<130/80 mmHG, HgbA1C<8%, and LDL<100mg/dl at 1 year; the primary analysis will compare the intervention to usual care with respect to the percentage of diabetic individuals achieving all three therapeutic goals",Safety of the intervention (occurence of adverse events over the course of the trial),,2006-09,COMPLETED,INTERVENTIONAL,['NA']
14378,NCT03912012,"Glomerular hyper filtration (Glomerular filtration > 135 mL/min/1,73 m2)",trabecular microarchitecture,,2019-07-09,COMPLETED,INTERVENTIONAL,['NA']
14379,NCT02542735,Metabolic syndrome incidence,Risk of metabolic syndrome according to each of the measured SNP,,2015-11,COMPLETED,OBSERVATIONAL,['NA']
14380,NCT00813280,glucose levels,type of insulin treatment,,2008-06,COMPLETED,OBSERVATIONAL,['NA']
14381,NCT00576368,"Glycemic status (Fasting Blood Glucose, Fasting Plasma Glucose, and HbA1C as done in routine medical practice)",,,2003-06,COMPLETED,INTERVENTIONAL,['PHASE4']
14382,NCT03998475,Program acceptability - provider,Change in transition readiness,Change in problem solving,2019-07-11,COMPLETED,INTERVENTIONAL,['NA']
14383,NCT03723785,"AUCI287,0-840h,SD: Area under the serum insulin 287 concentration-time curve after a single dose",Positive cross-reactive anti-human insulin antibodies,,2018-11-09,COMPLETED,INTERVENTIONAL,['PHASE1']
14384,NCT01756274,Percent of Blood Glucose Results Within +/-15 mg/dL(<75 mg/dL) and Within +/-20% (>=75 mg/dL) of the Reference Instrument BG Value,Percent of BG Results (Per Population) Within +/-15 mg/dL (<100 mg/dL)and Within +/-15% (>=100 mg/dL) of the Reference Instrument BG Value,"Number of Blood Samples From Babies in the Neonatal Intensive Care Unit (NICU) That Produced Meter Results Beyond What Random Chance Would Predict (i.e., Outside 95% Limits for Studentized Residuals)",2012-12,COMPLETED,INTERVENTIONAL,['NA']
14385,NCT05224986,Mean Amplitude of Glycemic Excursion and Standard Deviation of Mean Glucose,"Endothelial cell oxidative stress (sub-set, n≤10)",,2022-01-19,RECRUITING,INTERVENTIONAL,['NA']
14386,NCT05908812,Differences in glycated hemoglobin and/or insulin resistance in diabetic patients with non-sarcopenic obesity vs patients with sarcopenic obesity,,,2023-02-01,RECRUITING,OBSERVATIONAL,['NA']
14387,NCT02631902,Health-Related Quality of Life,Body Mass Index,,2015-10,COMPLETED,INTERVENTIONAL,['NA']
14388,NCT01920256,Change in baseline A1C (glycated hemoglobin) at 12 months,Change in baseline insulin satisfaction at 12 months,Cost,2013-08,COMPLETED,INTERVENTIONAL,['NA']
14389,NCT06111833,Genetic testing for evaluate the different types of MODY,Sudomotor function,,2023-05-22,RECRUITING,OBSERVATIONAL,['NA']
14390,NCT02910518,Assessment of PK parameter: area under the concentration time curve,Number of patients with treatment emergent adverse events,,2017-02-17,COMPLETED,INTERVENTIONAL,['PHASE1']
14391,NCT01699932,Change in HbA1c,Hypoglycemia,,2012-09,COMPLETED,INTERVENTIONAL,['PHASE3']
14392,NCT01396187,Number of Participants With Blood Glucose Abnormalities,Average Plasma Concentration (Cav) of PF-05231023 at Steady State,,2011-07,COMPLETED,INTERVENTIONAL,['PHASE1']
14393,NCT03696368,GDM Diagnosis,,,2019-01-04,RECRUITING,OBSERVATIONAL,['NA']
14394,NCT02170870,Mean Intestinal Chemosensitivity to Lipids Perfusion,Rate of Gastric Emptying (GE t 1/2) in Patients With Diabetes Mellitus (DM) or Non-ulcer Dyspepsia (NUD) Compared to Placebo,,2014-06,COMPLETED,INTERVENTIONAL,['PHASE2']
14395,NCT01605149,,,,2012-07,COMPLETED,OBSERVATIONAL,['NA']
14396,NCT00690456,Change from baseline in HbA1c,Percent change from baseline in HDL-C and Triglycerides,,2008-05,TERMINATED,INTERVENTIONAL,['PHASE3']
14397,NCT02178176,Adherence to oral hypoglycemic agents: Medication Event Monitoring System,,,2013-09,COMPLETED,INTERVENTIONAL,['NA']
14398,NCT00509236,Number of Participants With Clinical Adverse Events,Change From Baseline in Hemoglobin A1c for Sitagliptin Versus Glipizide Treatment,,2007-10-19,COMPLETED,INTERVENTIONAL,['PHASE3']
14399,NCT01906099,Fasting blood glucose (mg/dl),Triglyceride (mg/dl),,2012-09,COMPLETED,INTERVENTIONAL,['NA']
14400,NCT04100473,Primary Pharmacodynamic Endpoint - PD 2,Secondary Pharmacodynamic Endpoint - PD3,,2018-04-23,COMPLETED,INTERVENTIONAL,['PHASE2']
14401,NCT02796079,Area of diabetic foot ulcers,Walking distance (treadmill) if possible,,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE1']
14402,NCT02532829,Plasma GLP-1 and P-YY measurements by ELISA in participants treated by different bariatric and metabolic surgical techniques.,Plasma insulin levels in participants treated by different bariatric and metabolic surgical techniques.,"Plasma Liver Function Tests (SGOT, SGPT and GGT levels) in participants treated by different bariatric and metabolic surgical techniques.",2015-09,UNKNOWN,OBSERVATIONAL,['NA']
14403,NCT05731544,Change in HbA1c,To assess the effect on HbA1c,,2022-08-17,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14404,NCT05662475,Sirtuin 1 concentration in GCF,,,2021-11-15,COMPLETED,INTERVENTIONAL,['NA']
14405,NCT01006018,Insulin Secretion,,,2011-07,TERMINATED,INTERVENTIONAL,['NA']
14406,NCT03329261,Major Cardiovascular Events (MACE),Incidence of Adverse Events,,2017-12-07,COMPLETED,INTERVENTIONAL,['PHASE4']
14407,NCT02673762,A multi marker test score based on a pre-specified model is measured in each patient. The test score is on a scale of 0 to 1.0 and relates to the probability of disease.,Housekeeping gene Ct values on PCR analysis will be measured in individual patients,,2016-01,UNKNOWN,OBSERVATIONAL,['NA']
14408,NCT05165758,Compare the levels of quality of life in diabetic subjects with and without foot ulcer,"Compare the quality of life levels according to the type of antidiabetic treatment, in diabetic subjects with and without foot ulcer",,2022-01-21,COMPLETED,OBSERVATIONAL,['NA']
14409,NCT00609154,Insulin Biosynthesis Rate,,,2010-08-12,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14410,NCT05899166,Decline in Beta-cell Function,"Qualitative patient perspectives, interview - child",Study termination for dyslipidemia,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
14411,NCT03409523,Compliance with Choosing Wisely guidelines measured by number of reductions of medications,Usability measured by module user testing with direct observation and semi structured interviews,,2018-01-08,COMPLETED,OBSERVATIONAL,['NA']
14412,NCT02471963,Effect of empagliflozin after 6 weeks of treatment on macrocirculation,Biomarkers,,2014-12,COMPLETED,INTERVENTIONAL,['PHASE3']
14413,NCT02898493,Internal Consistency (IC) assessed as Cronbach's Alpha Value,Test-retest Reliability,,2016-09,UNKNOWN,OBSERVATIONAL,['NA']
14414,NCT04180813,Proportion of T2DM patients with high medication adherence at Week 24,Patient satisfaction by Diabetes Treatment Satisfaction Questionnaire (DTSQ) among linagliptin and acarbose initiators. The DTSQ would be completed at routine physician visits since initiation of the drug,,2020-03-04,TERMINATED,OBSERVATIONAL,['NA']
14415,NCT04289727,Change in bone mineral density by Dual X-ray Absorptometry (DXA),,,2020-01-01,RECRUITING,OBSERVATIONAL,['NA']
14416,NCT00490178,,,,2007-03,COMPLETED,INTERVENTIONAL,['PHASE3']
14417,NCT00805974,Ambulatory blood pressure monitoring on 24 hours,Glycemic measurements on 24h (D0-D1).,,2005-10,TERMINATED,INTERVENTIONAL,['NA']
14418,NCT00566592,Rate of glucose recovery from hypoglycemia.,Hormone and substrate concentrations,,2005-01,COMPLETED,INTERVENTIONAL,['NA']
14419,NCT01869608,Diagnosis of abnormal glucose tolerance,Patient's satisfaction,,2014-04,COMPLETED,INTERVENTIONAL,['NA']
14420,NCT02274844,Change in Low-Density Lipoprotein (LDL) Cholesterol,Change in Diabetes Medication Counts,Change in Medication Beliefs- Concerns (Concerns About the Negative Effects of Medications),2016-04,COMPLETED,INTERVENTIONAL,['NA']
14421,NCT04593992,Neuropathy symptom score,,,2020-10-20,COMPLETED,INTERVENTIONAL,['NA']
14422,NCT06305416,Changes in Central Subfield Thickness (CST) from Baseline,Evaluation and comparison of safety between reference vs. test drug.,,2024-03-20,RECRUITING,INTERVENTIONAL,['PHASE3']
14423,NCT01926938,"markers of endothelial activation, coagulation and inflammation",,,2003-05,COMPLETED,OBSERVATIONAL,['NA']
14424,NCT05071235,Quality of life (QoL) follow up,Change in visual analogue scale (VAS),,2019-08-27,COMPLETED,INTERVENTIONAL,['NA']
14425,NCT04074148,glycated haemoglobin (HbA1c) percent,,,2019-10-25,COMPLETED,INTERVENTIONAL,['NA']
14426,NCT04847414,change in BMI,HOMA-IR,,2021-04-10,UNKNOWN,OBSERVATIONAL,['NA']
14427,NCT00005669,Changes in Body Weight as Determined by Body Mass Index-standard Deviation Score (BMI-SDS).,Change in Body Fat by Bod Pod,,2000-05,COMPLETED,INTERVENTIONAL,['PHASE2']
14428,NCT03062774,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability],Determine PB-119 blood concentration,,2014-11-15,COMPLETED,INTERVENTIONAL,['PHASE1']
14429,NCT01702051,Beta cell function,Incidence of complications after pancreatic surgery,Incidence of each individual postoperative complication,2012-02,RECRUITING,OBSERVATIONAL,['NA']
14430,NCT04182503,Incidence of gestational hypertension,,,2019-08-12,UNKNOWN,OBSERVATIONAL,['NA']
14431,NCT01176149,Improvement of metabolic control,Percentage of patients reaching target HbA1c (i.e. <7.0%),,2007-03,COMPLETED,INTERVENTIONAL,['PHASE3']
14432,NCT02803918,Number of patients with anti-lixisenatide antibodies,Assessment of pharmacodynamic parameter: plasma glucose AUC-0-4.5 hours,,2017-05-17,COMPLETED,INTERVENTIONAL,['PHASE1']
14433,NCT03291171,Change in self-reported sedentary behaviour,change in coping planning,,2017-10-15,COMPLETED,INTERVENTIONAL,['NA']
14434,NCT01398267,"Glomerular filtration rate (mGFR), measured as iohexol clearance",High density lipoprotein-cholesterol (HDL-C) blood levels,,2011-08,COMPLETED,INTERVENTIONAL,['PHASE1']
14435,NCT01350219,Autoimmune control,Analysis of islet beta cell function,,2010-09,UNKNOWN,INTERVENTIONAL,['PHASE2']
14436,NCT01765270,Troponin I (TnI) Area Under the Curve (AUC),Need for Antiarrhythmic Therapy,,2013-03,TERMINATED,INTERVENTIONAL,['PHASE4']
14437,NCT02563834,Myocardial Fatty Acid Uptake Rate,Myocardial Perfusion Rate,,2007-01,COMPLETED,INTERVENTIONAL,['NA']
14438,NCT00651196,histomorphometry measurements,Bone mineral density,,2008-01,COMPLETED,OBSERVATIONAL,['NA']
14439,NCT05689099,"Cmax,sema,0.5mg: maximum observed semaglutide concentration-time after single dose of subcutaneous semaglutide 0.5 mg administration",,,2023-01-17,COMPLETED,INTERVENTIONAL,['PHASE1']
14440,NCT02128854,Diet Score on the Rapid Eating and Activity Assessment for Participants,Quality of Life Using the Medical Outcomes Study Short Form,,2014-08-14,COMPLETED,INTERVENTIONAL,['NA']
14441,NCT00729040,Total steps,content of posts (qualitative),,2008-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14442,NCT05551988,Predictors of amputation in diabetic foot ulcer patient,Antibiotic resistance level,,2021-06-01,COMPLETED,OBSERVATIONAL,['NA']
14443,NCT05362071,Glycaemic control,Subjective perception of well-being,,2022-05-02,COMPLETED,INTERVENTIONAL,['NA']
14444,NCT02172092,Extracellular volume,Distribution of strong and weak acids,,2014-08,COMPLETED,INTERVENTIONAL,['NA']
14445,NCT02343107,dietary score (International Diet Quality Index),Blood pressure,,2014-03,COMPLETED,INTERVENTIONAL,['NA']
14446,NCT05435196,The glycosylated hemoglobin A1c,The Visual Analog Scale,,2022-04-01,RECRUITING,INTERVENTIONAL,['NA']
14447,NCT03991026,Change in Body mass index (kg/m^2),Change in Blood pressure (mmHg),,2019-06-18,COMPLETED,INTERVENTIONAL,['NA']
14448,NCT00738023,Changes in Systolic Blood Pressure During Initial Intralipid Infusion,Changes in Systolic Blood Pressure During Intralipid Infusion Post-rosiglitazone Intervention,,2004-03,COMPLETED,INTERVENTIONAL,['PHASE4']
14449,NCT02496156,Continuous Glucose Monitor Use Profile or Insulin Pump Use Profile,SURE Test,,2015-02,COMPLETED,INTERVENTIONAL,['NA']
14450,NCT02358109,The Incremental Cost Effectiveness Ratio (ICER),Quality Adjusted Life Years (QALYs),Hemogram profile,2014-01,COMPLETED,INTERVENTIONAL,['NA']
14451,NCT04913909,Change in blood fructosamine levels in Type 2 diabetic patients an Oral probiotic use,,,2015-09-10,COMPLETED,INTERVENTIONAL,['NA']
14452,NCT03022058,Presence of significant qEEG hypoglycaemia indicators when comparing normo- and hypoglycaemic EEG as measured by the EarEEG systems for subjects where hypoglycaemia-induced changes have been observed in the scalp EEG (visit 4),,,2017-06-22,COMPLETED,INTERVENTIONAL,['NA']
14453,NCT03285594,Change From Baseline in Hemoglobin A1c (HbA1c) at Week 18,Percentage of Participants With Adverse Events (AEs),Percentage of Participants With Hypoglycemic Events,2017-09-15,COMPLETED,INTERVENTIONAL,['PHASE3']
14454,NCT06092476,Efficacy endpoint 2,Mechanistic: Change in Cystatin Value,,2023-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
14455,NCT02413086,Grades of wound healing,SF-36,,2015-04,UNKNOWN,INTERVENTIONAL,['NA']
14456,NCT00455988,,,,2006-09,UNKNOWN,OBSERVATIONAL,['NA']
14457,NCT01858233,The IBEP Study,The IBEP Study,,2012-11,COMPLETED,INTERVENTIONAL,['NA']
14458,NCT02084498,Change in HbA1c,Frequency of serious hypoglycemic events,Treatment Satisfaction,2012-09,COMPLETED,INTERVENTIONAL,['NA']
14459,NCT00138671,Change From Baseline in Post-Bronchodilator Carbon Monoxide Diffusion Capacity (DLco),Severe Hypoglcyemic Event Rates,,2003-01,TERMINATED,INTERVENTIONAL,['PHASE3']
14460,NCT05461495,BMI,,,2023-02-01,RECRUITING,INTERVENTIONAL,['NA']
14461,NCT00501462,drug & metabolite plasma levels,"Safety and tolerability parameters, including AEs and clinically relevant changes in vital signs (heart rate and blood pressure), ECGs, urine electrolytes, and clinical laboratory assessments (clinical chemistry, hematology, and urinalysis).",,2007-07,COMPLETED,INTERVENTIONAL,['PHASE1']
14462,NCT04517201,Fasting plasma glucose of T2D patients,Total insulin dose,,2020-11-04,UNKNOWN,INTERVENTIONAL,['NA']
14463,NCT05881200,Change in insulin resistance,,,2023-06-01,RECRUITING,INTERVENTIONAL,['NA']
14464,NCT01835678,effect of linagliptin compared to placebo on basal production and release of nitric oxide (NO) from renal vasculature,determine the relationship between changes of renal endothelial function with metabolic changes and changes of isoprostanes,,2012-10,COMPLETED,INTERVENTIONAL,['PHASE3']
14465,NCT04636307,Presence of ischemia,,,2021-09-22,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
14466,NCT03317028,The HbA1c treatment effect among CS02 groups and the Placebo group,,,2017-10-10,COMPLETED,INTERVENTIONAL,['PHASE2']
14467,NCT00433758,Clarke Error Grid,,,2006-12,UNKNOWN,INTERVENTIONAL,['NA']
14468,NCT03025399,"the changes of degree of retinal microvascular lesions before and after treatment (no, mild non proliferative phase, moderate non proliferative phase, severe non proliferative phase, proliferative phase)",Change of Vision (analysis of visual acuity before and after medication using EDTRS international visual acuity chart),,2017-02,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
14469,NCT00359112,Change in HbA1c level from baseline following 52 weeks of treatment.,Diabetes treatment satisfaction.,,2004-02,COMPLETED,INTERVENTIONAL,['PHASE3']
14470,NCT02568514,Change in inpatient mortality,Change in Hospital Consumer Assessment of Healthcare Providers and Systems (HCAPs) scores,,2016-08,WITHDRAWN,INTERVENTIONAL,['NA']
14471,NCT04341571,First phase of insuline secretion,Incidence of treatment-Emergent Adverse Events,,2019-10-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
14472,NCT05970237,Target blood glucose achievement rate,,,2023-07-26,RECRUITING,OBSERVATIONAL,['NA']
14473,NCT00831519,oxidative stress,,,2009-01,COMPLETED,OBSERVATIONAL,['NA']
14474,NCT03172260,HbA1c,Kidney function,,2017-02-08,COMPLETED,OBSERVATIONAL,['NA']
14475,NCT01866462,Metformin Tolerance,Weight Loss,,2013-05,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
14476,NCT00811889,To determine the safety and tolerability of bardoxolone methyl when administered for 12 months (52 weeks)following randomization to type 2 diabetic patients with CKD (eGFR 20 - 45 mL/min/1.73m2).,To determine the change in eGFR from baseline in patients with type 2 diabetes and CKD (baseline eGFR = 20 - 45 mL/min/1.73m2) after receiving bardoxolone methyl for 12 months (52 weeks) following randomization.,,2009-04-30,COMPLETED,INTERVENTIONAL,['PHASE2']
14477,NCT04838561,"INsulin delivery Systems: Perceptions, Ideas, Reflections and Expectations Questionnaire Post Intervention (Youth and Parent Versions)",Estimated HbA1c (%),"INsulin delivery Systems: Perceptions, Ideas, Reflections and Expectations Questionnaire (Baseline and Post Intervention)",2021-03-15,COMPLETED,OBSERVATIONAL,['NA']
14478,NCT05177094,Change From Baseline in Average Pain Intensity as Measured by the Numeric Rating Scale (NRS),Change From Baseline on the EuroQuality of Life Five Dimensions (5D) Five Level (5L) Questionnaire (EQ-5D-5L) Health State Index (United States Algorithm),,2022-01-26,COMPLETED,INTERVENTIONAL,['PHASE2']
14479,NCT05228067,Change in dopamine-dependent cognitive function,Food choice,,2021-11-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
14480,NCT03782441,Safety evaluation: paucity of adverse events,Device usability,,2019-11-05,COMPLETED,INTERVENTIONAL,['NA']
14481,NCT03326232,Mean blood glucose (mg/dL),Respiratory distress syndrome,,2017-11-13,UNKNOWN,INTERVENTIONAL,['NA']
14482,NCT06304844,Determine the number of participant with eGFR<60 ml/min/1.73 m2 or albuminuria (urinary albumin-to-creatinine ratio (ACR) ⩾3 mg/mmol) in patients with type 2 DM and MAFLD,,,2024-04-20,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
14483,NCT00543517,,,,2003-02,TERMINATED,INTERVENTIONAL,['PHASE3']
14484,NCT01328717,Percent of Fingerstick Blood Glucose (BG) Results Within +/-20%(>=75 mg/dL) and Within +/- 15mg/dL (<75 mg/dL) of Laboratory Glucose Method,Number of Subjects Rated as<=3 Performing Basic Meter Tasks (Labeling Evaluation),,2010-12,COMPLETED,INTERVENTIONAL,['NA']
14485,NCT01691846,Change from baseline in hemoglobin HbA1c,Safety: incidence of adverse events,,2012-10,COMPLETED,INTERVENTIONAL,['PHASE3']
14486,NCT03437525,Change from Baseline HbA1c at 6 and 12 months,Change from Baseline Insulin Attitudes at 6 and 12 months,,2017-03-08,COMPLETED,INTERVENTIONAL,['NA']
14487,NCT00489645,• To examine the influence of acute glycaemia (normoglycaemia and hyperglycaemia) on gastric emptying kinetics in patients with type 1 diabetes and non diabetic subjects when treated with subcutaneous (SC) injections of pramlintide.,"• Gastric peristalsis derived from high-resolution scintigraphy by means of Fast Fourier Transform (FFT) analysis. • Effects on gastric emptying and on the rate of appearance of ingested glucose appearance, postprandial glucose sequestration, endoge",,2005-01,COMPLETED,INTERVENTIONAL,['NA']
14488,NCT04894461,Pain assessment measured with the Neuropathy Pain Scale (NPS),Serum Albumin levels,,2021-11-01,UNKNOWN,INTERVENTIONAL,['NA']
14489,NCT01158040,Neonatal hypoglycemia (neonatal capillary blood glucose lowers then 40 mg/dL),Mean maternal blood glucose during labor,,2010-08,UNKNOWN,OBSERVATIONAL,['NA']
14490,NCT01285076,Number of Participants With Hypoglycemic Episodes,Self-reported Barrier Questionnaire,,2011-01,COMPLETED,OBSERVATIONAL,['NA']
14491,NCT00813475,All-cause mortality (including in-hospital and up to 12 months post discharge) or re-admission to hospital,Total # of in-hospital days during 1 year follow-up.The rate of any major clinical events during 1 year follow-up. Hypoglycemic events during index hospital stay,,2009-01,UNKNOWN,INTERVENTIONAL,['NA']
14492,NCT01606085,Diabetes health related quality of life measures,Diabetes (DM) self efficacy,,2009-09,COMPLETED,INTERVENTIONAL,['NA']
14493,NCT00419302,Glycemic response to a meal challenge,Safety variables,,2003-10,COMPLETED,INTERVENTIONAL,['PHASE2']
14494,NCT03151343,Invasive hemodynamics,Daily activity,,2017-03-29,COMPLETED,INTERVENTIONAL,['PHASE3']
14495,NCT00562133,the postprandial time course of nitrotyrosine after injection of insulin glulisine compared with regular human insulin,"postprandial time course of blood glucose, insulin, intact proinsulin, ADMA, MMP-9, FFA, ox-LDL, per ox Status, IL-18, postprandial time course of microvascular blood circulation measured with laserdopplerflux at 37 °C and 44 C",,2006-12,COMPLETED,INTERVENTIONAL,['PHASE3']
14496,NCT01275794,To assess frequency of target levels of HbA1c ≤ 7% in patients with T2D during OAD monotherapy,To compare the results of OAD monotherapy in different groups of patients,,2010-12,COMPLETED,OBSERVATIONAL,['NA']
14497,NCT02451631,Change in HbA1c (%),Change in FBG(Fasting Blood Glucose),,2015-04,UNKNOWN,INTERVENTIONAL,['NA']
14498,NCT00477581,Effect of Exenatide on postprandial glucose,"Assessment of effect of exenatide to the effect of sitagliptin the acetaminophen absorption test, and 6-point self-monitored blood glucose (SMBG) profiles",,2007-05,COMPLETED,INTERVENTIONAL,['PHASE4']
14499,NCT00360893,,,,1994-04,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
14500,NCT06330727,Fasting triglycerides (mmol/L),Standard deviation of heart rate variability (SDNN),,2024-02-05,RECRUITING,INTERVENTIONAL,['NA']
14501,NCT01411930,Insulin sensitivity,Hepatic glucose production,,2009-03,COMPLETED,INTERVENTIONAL,['PHASE4']
14502,NCT03676595,Change of Berg Balance Scale (BBS) score,Change of Unipedal Stance Test (UST) time,,2013-11-20,COMPLETED,INTERVENTIONAL,['NA']
14503,NCT03179423,Safety and tolerability of GNbAC1 in patients with recent onset type 1 diabetes: Serious Adverse Events (SAE) and Adverse Events (AE),,,2017-06-14,COMPLETED,INTERVENTIONAL,['PHASE2']
14504,NCT02059538,Look for differences in gut microbiota signatures using metagenomic approach in the 8 different groups,Establish differences in fecal metabolomic signatures using 1H nuclear magnetic resonance (NMR) spectroscopy and Ultra-high Performance Liquid Chromatography Mass Spectrometry ((UPLC-MS) on fecal samples) in the 8 different groups (cf above mentioned),Look for statistical association between gut derived signatures and lifestyle factors such as environment and diet (using data obtained from environment questionnaires and the results of both FFQ and Three day 24h diet recall),2013-06,UNKNOWN,INTERVENTIONAL,['NA']
14505,NCT00330200,Evaluate the effects on hemoglobin A1c (HbA1c),Assess the effects of ISIS 113715 on insulin suppression of local rates of lipolysis (microdialysis),,2005-11-01,TERMINATED,INTERVENTIONAL,['PHASE2']
14506,NCT05218915,Glycemic variability,Diabetes Treatment Satisfaction,,2022-01-28,RECRUITING,INTERVENTIONAL,['PHASE4']
14507,NCT05465317,"Composite outcome including: 40% decline in estimated glomerular filtration rate (eGFR), incident end-stage kidney disease (ESKD), all-cause mortality",Genital Mycotic infection,,2022-08-08,COMPLETED,OBSERVATIONAL,['NA']
14508,NCT00938119,"MACE (clinically driven TLR, cardiac death, MI, ST) at 12 months","ARC (probable + definite) ST at 1-day, and 1 and 12 months",,2009-08,TERMINATED,OBSERVATIONAL,['NA']
14509,NCT06046417,Percentage of time of glucose levels spent in the target range (3.9-10.0 mmol/L).,Thematic interview analysis,Safety Endpoints,2023-11-30,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
14510,NCT00700960,HbA1c,,,2007-06,COMPLETED,OBSERVATIONAL,['NA']
14511,NCT02823808,Cumulative treatment failure (HbA1c≥7.0%) rate for glycemic control,Change in glucagon,,2017-07,UNKNOWN,INTERVENTIONAL,['PHASE4']
14512,NCT01380873,△Cmax of plasma glucose,,,2010-01,COMPLETED,INTERVENTIONAL,['PHASE1']
14513,NCT01345435,Changes in Hemoglobin A1c,Medication compliance,,2011-01,COMPLETED,INTERVENTIONAL,['NA']
14514,NCT02846779,Insulin Persistence,Number of Hospitalizations,,2016-07,COMPLETED,INTERVENTIONAL,['NA']
14515,NCT02906917,Change in HbA1c (%) - Week 26,Incidence of TEAEs,,2016-09-20,COMPLETED,INTERVENTIONAL,['PHASE3']
14516,NCT01685879,Blood Glucose response,Appetite Response,,2012-10,COMPLETED,INTERVENTIONAL,['NA']
14517,NCT00273104,Improvement of co-morbidities,Safety issues,,2005-12,COMPLETED,INTERVENTIONAL,['NA']
14518,NCT04695158,Physical Activity Level for Group III,The levels of Routine Blood Samples for Group III,,2021-01-06,UNKNOWN,OBSERVATIONAL,['NA']
14519,NCT00832741,blood glucose,gastric emptying,,2008-05,COMPLETED,OBSERVATIONAL,['NA']
14520,NCT03196336,hospitalization,"severe evolving complication (ischemic or proliferative retinopathy, severe renal insufficiency, severe hypoglycemia, coronaropathy or evolving foot lesion)",,2015-03,COMPLETED,INTERVENTIONAL,['NA']
14521,NCT00674596,,,,2006-01,COMPLETED,INTERVENTIONAL,['PHASE4']
14522,NCT00570466,Dietary intake of servings of fruit and vegetables as measured by three 24-hour dietary recalls; and minutes of moderate to vigorous physical activity as measured by 5 days of accelerometry.,"Height, weight, waist circumference, propylthiouracil (PROP) sensitivity status and nutrition and physical activity psychosocial questionnaires.",,2008-01,COMPLETED,INTERVENTIONAL,['NA']
14523,NCT04403217,Changes in fasting insulin (μU/mL) levels from baseline to visit 2 and 3,Changes in waist perimeter (cm) from baseline to visit 2 and 3,,2019-04-01,UNKNOWN,INTERVENTIONAL,['NA']
14524,NCT02324309,Post-breakfast glucose exposure (AUC),Injection site toleration (VAS and severity scales),,2014-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14525,NCT04529824,Diabetes Status,Fitbit-derived sedentary time,Healthcare medical costs,2019-04-01,COMPLETED,OBSERVATIONAL,['NA']
14526,NCT04678895,Change in Numeric Rating Scale for Pain,Ratio of Pre-treatment Expectations Compared to Change in Numeric Rating Scale,,2020-12-22,RECRUITING,INTERVENTIONAL,['PHASE2']
14527,NCT01552213,Number of Patients With a Diagnosis of Gestational Diabetes at 26 Weeks Gestation.,Number of Participants With Intrauterine Fetal Demise,,2012-03,COMPLETED,INTERVENTIONAL,['NA']
14528,NCT00323414,Number of Participants With Improvement of >= 2 Points in NAFLD Activity Score (NAS),HbA1C Levels,,2006-04,COMPLETED,INTERVENTIONAL,['PHASE2']
14529,NCT00941161,"fasting glucose, HbA1c","total cholesterol, C-LDL, C-HDL, triglycerides, VLDL, insulin",,2009-02,COMPLETED,INTERVENTIONAL,['PHASE4']
14530,NCT04412798,Capillary glycaemic responses,Systolic/diastolic blood pressure,,2020-05-01,UNKNOWN,INTERVENTIONAL,['NA']
14531,NCT03890172,Change of ulcer size,time of wound healing,,2019-07-30,UNKNOWN,OBSERVATIONAL,['NA']
14532,NCT00946517,Parenting styles,Adherence to therapy,,2009-07,TERMINATED,OBSERVATIONAL,['NA']
14533,NCT01420692,"The Changes in the Peripheral Blood Levels of TNF-α, IL-6, MCP-1, sICAM-1, sVCAM-1, vWF, E-selectin, P-selectin, Endothelin-1, PAI-1, tPA and HMW Adiponectin at 12th and 24th weeks compared to the baseline level, as Measures of Inflam. and Coagulation","Calculation of Body-mass Index, Body Fat Mass, Level of Insulin Resistance and the Insulin Secretion Capacity of Pancreatic Beta Islet Cells as Measures to Identify the Effects of Gliclazide and Insulin Detemir Treatments on Diabetes Progression",,2010-06,COMPLETED,INTERVENTIONAL,['NA']
14534,NCT01452451,Number of subjects with adverse events as a measure of safety and tolerability,The pharmacodynamics in repeat-dose,,2011-12,COMPLETED,INTERVENTIONAL,['PHASE2']
14535,NCT01620489,Estimated Mean From the Statistical Model and Standard Deviation From Observed Data For Change From Baseline to Week 26 in HbA1c (%) (Glycosylated Haemoglobin),Estimated Mean Ratio to Baseline and Observed Coefficient of Variation in Renal Function-estimated Glomerular Filtration Rate (eGFR) (to Check How Well the Kidneys Are Functioning Using Modification of Diet in Renal Disease (MDRD) Formula),,2012-06-14,COMPLETED,INTERVENTIONAL,['PHASE3']
14536,NCT00534183,Study of metabolic profile,Study of obesity and diabetes,,2006-06,COMPLETED,INTERVENTIONAL,['NA']
14537,NCT05031572,To investigate whether IF is better than DCR in terms of metabolic improvement through the study (change in the secretory pattern of insulin after crossing arm),variability on biliary acids (BA) after weight loss,,2021-08-01,COMPLETED,INTERVENTIONAL,['NA']
14538,NCT02583061,Glucose tolerance status,,,2003-09,RECRUITING,OBSERVATIONAL,['NA']
14539,NCT00154401,HbA1c,Safety and tolerability,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE2']
14540,NCT01373346,Operation Related Mortality,Albumin : Good Response Group,,2010-02,COMPLETED,INTERVENTIONAL,['NA']
14541,NCT00770367,Asymmetric Dimethylarginine (ADMA) Level,NOx f2-isoprostanes,,2008-10,COMPLETED,INTERVENTIONAL,['PHASE4']
14542,NCT00372060,Change From Baseline in Hemoglobin A1c (HbA1c ) at Week 12,Change From Baseline in Fasting Plasma Glucose at Week 12,Change From Baseline in Hemoglobin A1c (HbA1c ) at Week 52,2006-08-21,COMPLETED,INTERVENTIONAL,['PHASE3']
14543,NCT01638780,"insulin sensitivity (overall, muscle- and liver specific)",heart function,,2012-05,UNKNOWN,INTERVENTIONAL,['NA']
14544,NCT00065650,HbA1C,Lipids,,2003-07,COMPLETED,INTERVENTIONAL,['PHASE2']
14545,NCT03217175,Number of Subjects With Plasma Glucose < 60 mg/dl,Time From Exercise Start to Plasma Glucose < 60 mg/dl,,2017-08-18,TERMINATED,INTERVENTIONAL,['NA']
14546,NCT03601494,visual analog scale of pain,Nerve conduction velocity,,2017-02-01,COMPLETED,INTERVENTIONAL,['NA']
14547,NCT03794960,Treatment Effect,Immunologic,,2019-12-14,WITHDRAWN,INTERVENTIONAL,['PHASE2']
14548,NCT01586897,"Medication Safety Monitoring - ACE/ARB, Thiazide",,,2012-05,COMPLETED,INTERVENTIONAL,['NA']
14549,NCT05176847,Change in body weight,Change in minutes a week of moderate to vigorous physical activity (MVPA),,2022-03-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
14550,NCT05570435,3h-iAUC of PPGR,iCmax of PPIR,additional endpoints slopes derived from PPGR,2022-11-16,COMPLETED,INTERVENTIONAL,['NA']
14551,NCT00267683,HbA1c,Percentage of subjects achieving the treatment target of HbA1c value < 6.5%,,2005-12,TERMINATED,INTERVENTIONAL,['PHASE3']
14552,NCT00678080,The Number of Participants Who Achieved a Hemoglobin A1C <7%,Number of Participants With Newborns Who Needed Neonatal Dextrose,,2008-09,COMPLETED,INTERVENTIONAL,['NA']
14553,NCT05268926,urinary albumin/creatinine ratio,number of SAE's and AE's,,2022-02-03,TERMINATED,INTERVENTIONAL,['PHASE2']
14554,NCT01862120,Treg response following the induction cure period,Treg response during the maintenance period compare to the baseline,,2013-06-27,COMPLETED,INTERVENTIONAL,['PHASE2']
14555,NCT03949504,Concentration of glucose in plasma,,,2019-01-09,COMPLETED,OBSERVATIONAL,['NA']
14556,NCT02147496,Food intake,Appetite hormones,Subjective Appetite,2011-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14557,NCT01127269,Percentage of patients with Glycosylated Haemoglobin (HbA1c) <7% with no severe documented nocturnal hypoglycemia episode.,Hypoglycemic episodes,,2010-05,COMPLETED,INTERVENTIONAL,['PHASE4']
14558,NCT01028963,Subject incidence of adverse events,Effect on fasting plasma glucose concentration,,2010-01,COMPLETED,INTERVENTIONAL,['PHASE2']
14559,NCT02094521,Area under the NNC0113-0987 plasma concentration time curve,Maximum observed NNC0113-0987 plasma concentration,,2014-03,COMPLETED,INTERVENTIONAL,['PHASE1']
14560,NCT03865342,Change in weight,Change in hemoglobin A1c,Change in quality of life,2016-09,COMPLETED,INTERVENTIONAL,['NA']
14561,NCT01363284,Prediction of duloxetine pain relief efficacy by pre-treatment extent of the CPM response,Treatment-related increase in CPM response,,2010-06,COMPLETED,INTERVENTIONAL,['NA']
14562,NCT02293720,Measure the incidence of device related serious adverse events requiring an early removal,,,2015-04,WITHDRAWN,INTERVENTIONAL,['NA']
14563,NCT06037512,Analysis of system accuracy based on DIN EN ISO 15197,,,2023-04-13,COMPLETED,INTERVENTIONAL,['NA']
14564,NCT03791567,,,,na,APPROVED_FOR_MARKETING,EXPANDED_ACCESS,['NA']
14565,NCT02640768,Composite performance score computed as the sum of the performance scores of all 5 domains of appropriateness and efficacy in both the intervention and the control wards,discharge condition in the intervention and control wards,,2012-01,COMPLETED,INTERVENTIONAL,['NA']
14566,NCT00035542,,,,2001-12,COMPLETED,INTERVENTIONAL,['PHASE3']
14567,NCT04118374,Change in endothelial function - diet 2,,,2019-03-29,RECRUITING,INTERVENTIONAL,['NA']
14568,NCT02963662,The levels of adipokines and inflammatory cytokines in the fasting state at preoperation in patients with BMI ≥35 kg/m2 or BMI ≥28 kg/m2 and T2D or metabolic syndrome.,"The adipokines and inflammatory cytokines levels in the fasting state at 1 month, 3 months, 6 months and 12 months after surgery",,2015-10,COMPLETED,INTERVENTIONAL,['NA']
14569,NCT05809817,Metabolic control,,,2023-03-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
14570,NCT02605564,Area Under the Curve (AUC) of C-peptide on mixed meal tolerance test,,,2016-01-19,TERMINATED,INTERVENTIONAL,['NA']
14571,NCT03919617,Rate of Resting Energy Expenditure (REE),,,2019-07-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14572,NCT03188094,probability of eligible patients at a practice site to lose 5% or more of their body weight six months following the index office visit.,improved blood pressure following the index office visit,,2018-12-17,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
14573,NCT00457470,Change of retinal thickness at Day 15 or Day 25 depending on dosing regimen,; Proportion of eyes experiencing an improvement in the degree of retinopathy at Day 28,,2007-06,WITHDRAWN,INTERVENTIONAL,['PHASE2']
14574,NCT01434030,Desire to Receive Advice From Personal Glucose Advisory System (PGASystem),Willingness to Follow PGASystem Advice,,2010-04,COMPLETED,INTERVENTIONAL,['NA']
14575,NCT01917656,Change in Fructosamine From Start of Ramadan to End of Ramadan,"Number of Treatment Emergent Adverse Events (TEAEs) During Ramadan (Fasting), Based on Each Subject's Individual Fasting Period.",,2014-01-09,COMPLETED,INTERVENTIONAL,['PHASE4']
14576,NCT02421510,Change From Baseline in A1C at Week 24,Percent Change From Baseline in Body Weight at Week 24,,2015-05,COMPLETED,INTERVENTIONAL,['PHASE3']
14577,NCT02642159,Percent Change From Baseline in Non-HDL-C at Week 24: ITT- Intent to Prescribe Fenofibrate Stratum,Absolute Change From Baseline in Number of Glucose-Lowering Treatments at Week 12 and 24 : Overall ITT Analysis,,2016-03-15,COMPLETED,INTERVENTIONAL,['PHASE4']
14578,NCT04265469,Foot Self-care Behavior,,,2016-02-10,COMPLETED,INTERVENTIONAL,['NA']
14579,NCT02773368,Change in HbA1c (Glycosylated Haemoglobin),Change From Baseline in Patient Reported Outcomes (PROs) After 26 Weeks: Summary Scores of Treatment Related Impact Measure for Diabetes (TRIM-D),,2016-05-23,COMPLETED,INTERVENTIONAL,['PHASE3']
14580,NCT03232437,Precision (as measured by %CV) of HbA1c measurements,,,2017-06-14,COMPLETED,OBSERVATIONAL,['NA']
14581,NCT00501930,"Clinical laboratory tests, ECGs, adverse events",clinical lab tests,,2007-04,COMPLETED,INTERVENTIONAL,['PHASE1']
14582,NCT00379769,"Independent Re-adjudication Outcome: Number of Participants With an Event of Stroke (Fatal and Non-fatal), Based on Contemporary Endpoint Definitions",Number of Participants With the Indicated Serious Adverse Event: Observational Follow-up,,2001-04,COMPLETED,INTERVENTIONAL,['PHASE3']
14583,NCT00629213,Incidence of newly diagnosed type 2 diabetes,newly diagnosed hypertension,,na,COMPLETED,INTERVENTIONAL,['PHASE3']
14584,NCT00354536,blood plasma levels of GSK716155,blood plasma levels of GSK716155,,2006-02,COMPLETED,INTERVENTIONAL,['PHASE2']
14585,NCT02023918,Insulin Sensitivity,Lipolysis,,2014-01,COMPLETED,INTERVENTIONAL,['PHASE2']
14586,NCT05915949,HbA1c,Fib-4,Adverse events,2022-01-01,RECRUITING,INTERVENTIONAL,['PHASE4']
14587,NCT02064309,"Safety of device, as evaluated by incidence of adverse events or serious adverse events judged probable or highly probable related to the device","8. Number of patients with non-fasting c-peptide concentrations >0.003 nmol/l at 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 and 26 weeks post-transplantation; i.e. Kaplan-Meier analysis of survival time for islet grafts.",7. Score in diabetes treatment satisfaction questionnaire in transplanted patients at 12 and 26 weeks post-transplantation when compared to before transplantation and 6 months after explantation.,2014-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14588,NCT02849288,Assessment of safety outcomes and serious adverse events and device related adverse effects.,System functionality as evidenced by the availability of CGM data,,2016-07,COMPLETED,INTERVENTIONAL,['PHASE1']
14589,NCT00900887,"ocular topic antiinflammatory therapy (ketorolac, nepafenac or placebo) applied 3 times a day in the treated eye for a week after selective photocoagulation",visual capacity under subjective refractive correction measured in decimal equivalent,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE2']
14590,NCT04061746,12 month Change in C-peptide area under the curve after a 2-hour MMTT,Change in 24-hour insulin dose per kilogram between baseline and 1 year measurements,Changes in serum cytokine levels after treatment,2020-02-27,RECRUITING,INTERVENTIONAL,['PHASE1']
14591,NCT02503527,Blood glucose variability (within patient standard deviation of blood glucose values per day),"Gastro-intestinal intolerance (AEs, complications)",,2015-08,TERMINATED,INTERVENTIONAL,['NA']
14592,NCT04119947,The Safety and tolerance of SY-009，Collecting Number of subjects with adverse events as assessed by CTCAE V5.0,C-peptide secretion following single dose of SY-009,,2019-03-01,COMPLETED,INTERVENTIONAL,['PHASE1']
14593,NCT05293587,Participant satisfaction,Change in Aerobic Fitness from Baseline at 8 weeks,Structured Assessment of FEeasibility,2021-09-13,COMPLETED,INTERVENTIONAL,['NA']
14594,NCT01106690,Change in HbA1c From Baseline to Week 26,Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 26,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE3']
14595,NCT01843387,The primary objective of the study is to assess the safety and tolerability of MPC therapy,Exploratory assessment of the efficacy of MPC therapy,,2013-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14596,NCT05325294,Primary Effectiveness Endpoint for Age 7-17 - Percent of Time in Range (TIR 70-180 mg/dL),Secondary Effectiveness Endpoint 2 for Age 7-17 - Percent of Time in Range (TIR 70-180 mg/dL),,2022-05-05,COMPLETED,INTERVENTIONAL,['NA']
14597,NCT04569396,Fatty Liver Index,,,2016-01-12,COMPLETED,OBSERVATIONAL,['NA']
14598,NCT04448496,Mean change of best corrected visual acuity,Changes of total area (mm^2)of nonperfusion within the ETDRS grid using fluorescein angiography and optical coherence tomography angiography,,2020-06-22,UNKNOWN,INTERVENTIONAL,['PHASE4']
14599,NCT02227745,efficiency in visual function with dorzolamide after photocoagulation,,,2014-01,UNKNOWN,OBSERVATIONAL,['NA']
14600,NCT02809911,Lower Extremity - Pain Sensitivity to Various Experimentally Induced Pain Stimuli,,,2016-06,COMPLETED,INTERVENTIONAL,['NA']
14601,NCT00803296,Incretin effect,Insulin resistance,,2006-01,COMPLETED,OBSERVATIONAL,['NA']
14602,NCT05473494,Diabetic Foot Care Self-Efficacy Scale,Foot Care Behavıor Scale,,2022-01-01,RECRUITING,INTERVENTIONAL,['NA']
14603,NCT04089202,Glycemic control based on A1c,Cost effectiveness analysis (CEA),,2020-02-03,TERMINATED,INTERVENTIONAL,['NA']
14604,NCT05454176,Cost analysis of CGM,,,2022-08-15,RECRUITING,INTERVENTIONAL,['PHASE4']
14605,NCT03067012,"micronutrients' deficiency (iron, folate, vitamin B12)",Remission rates of co-morbidities,,2015-09-01,COMPLETED,INTERVENTIONAL,['NA']
14606,NCT01542424,HbA1c (glycosylated haemoglobin),Incidence of adverse events,,2006-03,COMPLETED,OBSERVATIONAL,['NA']
14607,NCT05124808,Number of participants with composite neonatal morbidity,Infant adiposity,,2022-03-01,RECRUITING,INTERVENTIONAL,['NA']
14608,NCT04311164,Glycated Hemoglobin A1c (HbA1c),"Educational, time and risk preferences",,2020-05-15,COMPLETED,OBSERVATIONAL,['NA']
14609,NCT05152277,Number of Adverse Events,Glucose concentration,,2021-12-06,COMPLETED,INTERVENTIONAL,['PHASE1']
14610,NCT03339336,Change from Randomization in Weekly Mean ADP Score,Maximum Observed Concentration (Cmax) at Steady State,,2018-05-31,TERMINATED,INTERVENTIONAL,['PHASE2']
14611,NCT04674332,time needed to achieve glycemic control,,,2019-09-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
14612,NCT05594446,Collection of anthropometric measurements of the foot : European shoe size,,,2022-09-09,COMPLETED,OBSERVATIONAL,['NA']
14613,NCT02245659,Average nightly hours of CPAP use,Maternal glucose levels,,2015-03,COMPLETED,INTERVENTIONAL,['NA']
14614,NCT04243200,Repeat ambulance calls and attendances for hypoglycaemia within 14 days.,"To assess whether the ""Hypos can strike twice"" intervention can reduce repeat ambulance calls and attendance for hypoglycaemia within 30 and 90 days.",,2020-09-14,COMPLETED,OBSERVATIONAL,['NA']
14615,NCT00276250,The Number of Insulin-independent Subjects at Day 75 (± 5 Days) Following the First Islet Cell Transplantation,"Number of Subjects With Normal Renal Function, as Measured by Serum Creatinine Levels",,2005-12,COMPLETED,INTERVENTIONAL,['PHASE2']
14616,NCT01986231,Assess Difference in Hepatic Glycogen Measured in the Fasting State Before vs. After Repeated Glucagon Administration,Assess Difference in Hepatic Glycogen Measured in the Fed State Before vs. After Repeated Glucagon Administration,,2011-01,COMPLETED,INTERVENTIONAL,['NA']
14617,NCT05542420,The proportion of patients prescribed cardiovascular disease (CVD) medications,,,2022-10-19,COMPLETED,OBSERVATIONAL,['NA']
14618,NCT05831384,Overall diabetes distress score,"The The patient's glycated haemoglobin (Hba1c) result, expressed as a %, taken during the standard check-up on the day of admission to hospital result (Hba1c)",,2023-05-11,COMPLETED,OBSERVATIONAL,['NA']
14619,NCT03221868,Change in HbA1c,Change in QoL,,2016-08,COMPLETED,INTERVENTIONAL,['NA']
14620,NCT04026165,eGFRcr Slope,eGFRcys Slope,,2019-07-24,COMPLETED,INTERVENTIONAL,['PHASE2']
14621,NCT04238208,Outcome 2 Patient Global Impression of Change score,,,2019-01-10,COMPLETED,INTERVENTIONAL,['PHASE4']
14622,NCT05641753,Change in Light Transmission Aggregation (LTA) from Baseline,Percent Change in CD8 Cell Population from Baseline,,2022-12-06,RECRUITING,INTERVENTIONAL,['PHASE4']
14623,NCT03222791,Mean change in Glucose Tolerance Test from the baseline level,Change in HOMA-IR from baseline,Patients compliance evaluation using a compliance questionnaire,2017-02-01,COMPLETED,INTERVENTIONAL,['NA']
14624,NCT06273657,HbA1c,Diabetes Treatment Satisfaction,,2024-02-07,RECRUITING,INTERVENTIONAL,['NA']
14625,NCT01603329,Medication Adherence,Demographic Controls for Patients,,2012-06,COMPLETED,INTERVENTIONAL,['NA']
14626,NCT01319487,change from baseline of central retinal thickness as determined by logOCT,Change in macular volume and retinal thickness from baseline to Week 12 and Week 24,,2011-05,COMPLETED,INTERVENTIONAL,['PHASE2']
14627,NCT05659043,Qualitative and Quantitative Mapping ApoA-I Glycation Modification Profiles,Individual ApoA-I Glycation Profiles Variability and Cardiovascular Events,,2017-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
14628,NCT01409213,Change From Baseline for Mean Fasting Blood Glucose (FBG),,,2009-08,COMPLETED,OBSERVATIONAL,['NA']
14629,NCT01858896,Change in Flow mediated dilation (FMD),,,2013-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
14630,NCT01220349,Measurement of the alteration of left ventricular myocardial strain (≤ 18% in absolute value) by echocardiography and the relationship to micro-angiopathy.,"Analyses of this association (alteration of myocardial strain and micro-angiopathy) in relation with the duration of diabetes, and other co-factors such as dyslipidemia, unstable diabetes, and coexisting macro-angiopathy.",,2011-01,COMPLETED,INTERVENTIONAL,['NA']
14631,NCT02685384,Change of health insurance status,Change of Medicaid expenditures,,2012-01,COMPLETED,OBSERVATIONAL,['NA']
14632,NCT01404676,Change in mean amplitude of glycemic excursion(MAGE) for 12 weeks(12weeks - 0 week).,Change from baseline in oxidative stress markers and inflammatory markers at 12 weeks. Change from baseline in endothelial cell function at 12 weeks.,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE4']
14633,NCT02958995,Hazard Ratio for Risk of 10 Common Cancers Associated With Diabetes,,,1997-01-01,COMPLETED,OBSERVATIONAL,['NA']
14634,NCT01005264,Decrease in ulcer size,Complete healing rate at the end of the study,,2008-02,COMPLETED,INTERVENTIONAL,['PHASE3']
14635,NCT02919839,blood glucose,,,2016-09,UNKNOWN,OBSERVATIONAL,['NA']
14636,NCT03322631,Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,Pharmacodynamics (PD): Change From Baseline to 8 Weeks in Fasting Plasma Glucose,,2017-11-15,COMPLETED,INTERVENTIONAL,['PHASE1']
14637,NCT05696015,"Change from baseline discharge telehealth orientation and application of the Diabetes Self-Care Activity Questionnaire (QAD) at within 72 hours after discharge, 10 days after and within 30 days after discharge",,,2023-03-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
14638,NCT02538120,Neurovascular microcirculatory response,,,2012-05,COMPLETED,INTERVENTIONAL,['NA']
14639,NCT04304560,Diastolic Function,Galectin -3,,2020-03,UNKNOWN,INTERVENTIONAL,['PHASE2']
14640,NCT03376607,Change in HbA1c,Alcohol intake per week,The differences the HBCPs note from patient to patient,2019-01-11,UNKNOWN,INTERVENTIONAL,['NA']
14641,NCT06059287,Extra-cellular volume fraction,Native T2 mapping,,2023-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
14642,NCT05992415,Adherence to Follow-up Eye Care,,,2024-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
14643,NCT00346996,Severe hypoglycaemia,hypoglycaemia during daytime,,2007-05,COMPLETED,INTERVENTIONAL,['PHASE4']
14644,NCT04060745,Changes in glucose metabolism between non-activated and cold-activated BAT,Changes in metabolic profiles in cold versus thermoneutral conditions,,2019-08-01,UNKNOWN,INTERVENTIONAL,['NA']
14645,NCT05128747,Evaluate the effectiveness of one of the most common dietary approches;DASH diet in controlling lipid profile in diabetic patients.,,,2022-03-01,UNKNOWN,INTERVENTIONAL,['NA']
14646,NCT00627783,"Death from all causes, non-fatal myocardial infarction, non-fatal stroke, or heart failure requiring hospitalization or emergency service intervention, measured after a minimum follow-up of 2 years",Unstable angina requiring hospitalization Coronary events Coronary revascularization,,2000-12,TERMINATED,INTERVENTIONAL,['NA']
14647,NCT00262977,Patient reported aspirin use daily or every other day.,,,2004-09,COMPLETED,INTERVENTIONAL,['NA']
14648,NCT00811044,Genes affecting the development of Type 2 diabetes will be identified,Any differences between genetic groups in the metabolism of glucose/sugar will be studied to the extent that the data allow,,2000-10,WITHDRAWN,OBSERVATIONAL,['NA']
14649,NCT06243939,Quality of Life Scale,,,2023-06-06,RECRUITING,INTERVENTIONAL,['NA']
14650,NCT02328508,wound healing,glycemic control,,2011-06,COMPLETED,INTERVENTIONAL,['PHASE1']
14651,NCT03971838,Enrollment and participation rates in a diabetes prevention intervention,BMI,,2019-06-01,COMPLETED,INTERVENTIONAL,['NA']
14652,NCT02251067,Change from baseline in albuminuria,Change from baseline in eGFR,,2014-09,COMPLETED,INTERVENTIONAL,['PHASE2']
14653,NCT04232631,Evaluating the effectiveness of 3 devices to measure perfusion to predict wound healing,,,2021-04-28,RECRUITING,OBSERVATIONAL,['NA']
14654,NCT01620450,Maximum insulin aspart concentration (Cmax IAsp),Adverse events,,2004-11-20,COMPLETED,INTERVENTIONAL,['PHASE1']
14655,NCT01215994,,,,2009-03,UNKNOWN,OBSERVATIONAL,['NA']
14656,NCT00775840,The change from Baseline in N-terminal pro-B-type Natriuretic Peptide biomarker.,"Progression of preserved (Left Ventricular Ejection Fraction greater than or equal to 45%) to impaired systolic dysfunction (Left Ventricular Ejection Fraction less than 45%), based on echocardiographic results.",,2008-01,COMPLETED,INTERVENTIONAL,['PHASE3']
14657,NCT01666938,level of physical activity,Metabolic Control,,2012-04,COMPLETED,INTERVENTIONAL,['NA']
14658,NCT01884792,Blood sugar area under the curve,Accelerometer counts,,2013-03,COMPLETED,INTERVENTIONAL,['NA']
14659,NCT03444584,Percent Change From Baseline to Day 28 in Plasma Glucose AUC0-4hrs as Measured by MMTT,Change From Baseline in the Percentage of 24-hrs Glucose Readings That Falls Within Clinically Significant Hypoglycemic Range to the End of Each Dosing as Measured by CGM,,2018-05-08,COMPLETED,INTERVENTIONAL,['PHASE2']
14660,NCT01270789,Preservation of beta-cell function measured by Insulin Secretion-Sensitivity Index-2 (ISSI-2),Glycemic Control,,2011-01,COMPLETED,INTERVENTIONAL,['PHASE3']
14661,NCT05601349,Rate of patients who received comprehensive Rehabilitation,,,2020-01-01,COMPLETED,INTERVENTIONAL,['NA']
14662,NCT05335889,Proportion of participants who are fully compliant with eButton use,,,2022-07-18,COMPLETED,OBSERVATIONAL,['NA']
14663,NCT03881956,Pre-test and post-test scores,Postpartum characteristics of neonates,,2015-01-01,COMPLETED,INTERVENTIONAL,['NA']
14664,NCT00617916,,,,2006-03,COMPLETED,OBSERVATIONAL,['NA']
14665,NCT01812590,Pancreatic endocrine function,,,2013-01,COMPLETED,INTERVENTIONAL,['NA']
14666,NCT05754567,Childhood executive function,Significant associations between maternal pre-existing diabetes and ADHD (Attention Deficit Hyperactivity Disorder),Maternal CGM (Continuous Glucose Monitor) percentage time in target,2023-09-07,RECRUITING,OBSERVATIONAL,['NA']
14667,NCT01131091,The primary objective is to determine the effect of renal insufficiency on the pharmacokinetics of a single 400 mg dose of SK 0403.,The secondary objective is to determine the safety and tolerability of a single 400 mg dose of SK 0403 in subjects with renal insufficiency.,,2010-05,COMPLETED,INTERVENTIONAL,['PHASE1']
14668,NCT04420936,Change in body weight,Change in blood pressure,,2021-09-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
14669,NCT02673203,Glucose Nadir,Nutirion Intake: Protein,,2016-02,COMPLETED,INTERVENTIONAL,['NA']
14670,NCT02908087,Serum C-peptide AUC,Insulin dose,,2016-03,COMPLETED,INTERVENTIONAL,['PHASE2']
14671,NCT05166525,90-day hospitalization for any cause,"90-day composite of hospitalization for any cause, emergency department visit for any cause or all-cause death",,2020-04-27,COMPLETED,INTERVENTIONAL,['NA']
14672,NCT04806685,Hemoglobin A1c,Insomnia Severity Index,,2021-03-15,COMPLETED,INTERVENTIONAL,['NA']
14673,NCT00058968,Reduction in average pain severity as measured by an 11-point Likert scale.,Dynamic Allodynia measure to elicit the pain severity to a normally non-painful stimulus.,,2002-10,COMPLETED,INTERVENTIONAL,['PHASE3']
14674,NCT01401127,Glucose excursion,Comparison between the two groups of levels of cortisol,,2011-01,COMPLETED,OBSERVATIONAL,['NA']
14675,NCT04637880,25- Hydroxyvitamin D and relation to development of preeclampsia,25 Hydroxyvitamin D in newborn,,2012-07,COMPLETED,OBSERVATIONAL,['NA']
14676,NCT05588583,Wound progress of the total effect of treatment using Mepilex Up,Evaluation of all reported adverse events and device deficiencies,,2022-10-31,RECRUITING,INTERVENTIONAL,['NA']
14677,NCT01233622,HbA1c Reduction,Responder Rate,,2010-10,COMPLETED,INTERVENTIONAL,['PHASE3']
14678,NCT04132089,20 participants baseline diabetes self-management score will be measured at baseline and after the utilization (9 weeks) of the mHealth application capABILITY.,Participants who receive a Spark trigger message will login and use capABILITY quicker (time measured in seconds) than those participants who receive Facilitator trigger message.,,2015-01-01,COMPLETED,INTERVENTIONAL,['NA']
14679,NCT02620592,"Safety and tolerability assessed by monitoring adverse events, clinical, laboratory, electrocardiogram, and vital signs examinations.",Glucagon,,2014-10,COMPLETED,INTERVENTIONAL,['PHASE1']
14680,NCT01674348,Change in HbA1c from baseline,Number of subjects with adverse events,"Pharmacokinetic profile (Cmax, Tmax and AUC)",2011-04,TERMINATED,INTERVENTIONAL,['PHASE2']
14681,NCT00834262,Number of all hypoglycaemic episodes,"Average post-breakfast (2h), post-lunch (2h), post-dinner (2h) blood glucose level",,2009-04,COMPLETED,OBSERVATIONAL,['NA']
14682,NCT02215642,Disease-specific survival,Overall survival,Disease-free survival,2009-01,UNKNOWN,OBSERVATIONAL,['NA']
14683,NCT00175721,Health care utilization and patient/provider satisfaction (5 years),Patient outcomes (5 years),,2005-12,COMPLETED,INTERVENTIONAL,['NA']
14684,NCT02547311,Cost effectiveness,,,2012-10,COMPLETED,INTERVENTIONAL,['NA']
14685,NCT01135771,demonstrate the accuracy of the OptiScanner in measuring blood glucose levels in otherwise healthy diabetic subjects when compared to blood glucose levels simultaneously measured on the YSI,The secondary objective of the study is to demonstrate a blood glucose measurement range of 60 to 500 mg/dL at the hematocrit levels referenced as normal,,2009-11,COMPLETED,INTERVENTIONAL,['PHASE1']
14686,NCT00221208,Muscular strength,"Fasting blood glucose, insulin, lipid concentrations, C-reactive protein, body composition (DEXA), exercise adherence, behaviour change, psychosocial predictors of resistance training, quality of life.",,2005-04,COMPLETED,INTERVENTIONAL,['PHASE1']
14687,NCT00529165,HbA1c,Quality of Life,,2007-07,COMPLETED,INTERVENTIONAL,['NA']
14688,NCT01560676,BMI,Physical activity,,2009-09,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
14689,NCT01970319,Left ventricle mass,RAAS activity,,2013-10,COMPLETED,OBSERVATIONAL,['NA']
14690,NCT05593653,Insomnia Severity Index Score,Fasting Plasma Glucose,,2023-01-06,RECRUITING,INTERVENTIONAL,['PHASE4']
14691,NCT00895440,Identify patients with peripheral neuropathy with the Neuropad indicator test,,,2009-07,COMPLETED,OBSERVATIONAL,['NA']
14692,NCT02435277,Change in HbA1c Levels in Patient Receiving the Various Doses of Leucine and Metformin Combinations,Change in Fasting Plasma Glucose,,2014-10,COMPLETED,INTERVENTIONAL,['PHASE2']
14693,NCT03490773,Difference in immune function in Cpeptide negative and positive,Difference in HLA type in Cpeptide negative and positive groups,,2014-11-01,COMPLETED,OBSERVATIONAL,['NA']
14694,NCT00389636,Time to complete wound healing within 12 weeks,Excess pain,,2006-09,UNKNOWN,INTERVENTIONAL,['NA']
14695,NCT01464346,"Mean Daily Agreement (Percent of Sensor Values Within 30% of Reference Value) With Minimum Calibration, Combined Abdomen and Buttock Insertion Sites","Mean Daily Agreement (Percent of Sensor Values Within 30% of Reference Value) With 3-4 Calibrations Per Day, Combined Abdomen and Buttock Insertion","Mean Absolute Relative Difference (MARD) Between Sensor and YSI for Buttock Insertion Site, With Calibration Every 12 Hours",2011-11,COMPLETED,INTERVENTIONAL,['NA']
14696,NCT01458158,Association of matrix metalloproteinases with atherosclerosis in patients with chronic kidney disease,Matrix metalloproteinases and atherosclerosis associated with pro-inflammatory and oxidative stress markers in chronic kidney disease,,2011-10,UNKNOWN,OBSERVATIONAL,['NA']
14697,NCT01199848,Postprandial Insulin Levels for 6 Hours,Strawberry Dose-response Effect on Postprandial Oxidative Stress (Ox-LDL) in Insulin-resistant Men and Women in an Acute Postprandial Paradigm,,2010-09-15,COMPLETED,INTERVENTIONAL,['NA']
14698,NCT00500955,The primary efficacy endpoint was percent change from baseline in ACR after 32 weeks of treatment.,"Secondary efficacy endpoints included change from baseline (visit 3) at week 32 (visit 7) in the following: serum TGF, creatinine clearance (calculated), PAI-1, CRP, IL-6, vWF, sVCAM, fibrinogen, TNF alpha, ET-1, heart rate and blood pressure",,2000-04,COMPLETED,INTERVENTIONAL,['PHASE3']
14699,NCT02191644,Lp-PLA2 Activity in PBMC,PBMC metabolites,LDL particle size,2013-01,COMPLETED,INTERVENTIONAL,['PHASE2']
14700,NCT01887067,Change in office systolic & diastolic blood pressure from baseline to 6 months,Change in glucose metabolism,,2013-06,TERMINATED,INTERVENTIONAL,['NA']
14701,NCT05547594,Changes in Short Physical Performance Battery (SPPB) at different time points from baseline to 1 year after surgery,Changes in Patient Health Questionnaire-9 (PHQ-9) at different time points from baseline to 1 year after surgery,Postsurgical complications,2023-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
14702,NCT01601704,Percentage of Participants With a Confirmed Occurrence of Major Adverse Cardiovascular Event (MACE),Percentage of Participants With a Confirmed Occurrence of Stroke (Nonfatal or Fatal),,2012-06,TERMINATED,INTERVENTIONAL,['PHASE3']
14703,NCT00760448,"Baseline-adjusted hypoglycaemic symptoms score at nadir plasma glucose concentration based on the Edinburgh Hypoglycaemia Scale: autonomic symptoms, neuroglycopenic symptoms and general malaise",,,2004-04,COMPLETED,INTERVENTIONAL,['PHASE1']
14704,NCT00513643,AUC GIR 360-720 min,"PD endpoints like GIR max, t max/GIR, AUC GIR 0-120 min, AUC GIR 0-720 min, t >2/GIR, early and late t 50%/GIR",,2002-04,COMPLETED,INTERVENTIONAL,['PHASE1']
14705,NCT02653209,On treatment HbA1c in patients with an eGFR <90 mls/min/1.73m2 compared to patients with an eGFR >90 mls/min/1.73m2.,HbA1c on therapy against predefined test of gender heterogeneity,,2016-11-01,COMPLETED,INTERVENTIONAL,['PHASE4']
14706,NCT04726631,the percentage of maternal glycosylated Hemoglobin,,,2015-01-01,COMPLETED,INTERVENTIONAL,['NA']
14707,NCT01461434,Time to first diagnosis of atrial fibrillation,Stroke,,2011-11,UNKNOWN,INTERVENTIONAL,['PHASE4']
14708,NCT02786953,Sleep Duration: 3 Months,Adherence (Self Care Inventory) Teen,,2017-10-19,COMPLETED,INTERVENTIONAL,['NA']
14709,NCT02577874,Blood sugar response measured by 7 finger prick blood samples,,,2015-06,UNKNOWN,OBSERVATIONAL,['NA']
14710,NCT00858676,"sudden cardiac death, fatal or non-fatal myocardial infarction, coronary revascularization, admission due to heart failure, fatal or non-fatal stroke",,,2009-04,UNKNOWN,INTERVENTIONAL,['PHASE4']
14711,NCT06295289,TIR,MBG,postoperative infection,2023-10-16,RECRUITING,INTERVENTIONAL,['NA']
14712,NCT00529594,The group taking the etoricoxib feel less pain then the group taking placebo,,,2006-08,COMPLETED,INTERVENTIONAL,['NA']
14713,NCT01729546,Evaluation of System Accuracy according to ISO 15197,,,2012-11,COMPLETED,INTERVENTIONAL,['NA']
14714,NCT04310137,Change in walking behavior (step timing),Waist circumference,,2021-05-01,UNKNOWN,INTERVENTIONAL,['NA']
14715,NCT01197963,Serial Postoperative HgA1c levels,Serial Postoperative Lipid Profiles levels,,2010-09,TERMINATED,INTERVENTIONAL,['NA']
14716,NCT01726816,A/C ratio,P/C ratio,c-peptide,2012-10,COMPLETED,INTERVENTIONAL,['PHASE2']
14717,NCT02790931,Fast gait speed,EQ-5D score of the quality of life,,2016-08,COMPLETED,INTERVENTIONAL,['NA']
14718,NCT00942318,HbA1c,"self monitoring blood glucose measurements (frequency, mean and standard deviation, number of hypoglycaemic and hyperglycaemic events)",,2009-03,COMPLETED,INTERVENTIONAL,['PHASE4']
14719,NCT06182891,Evaluation of the biomarkers of the epithelial-mesenchymal transition process,Evaluation of adverse event,,2021-10-30,COMPLETED,INTERVENTIONAL,['NA']
14720,NCT04984421,Change in fidelity (R) assessed by questionnaire to parents,Change in parents' risk of type 2 diabetes assessed by FINDRISC questionnaire,,2021-09-01,RECRUITING,INTERVENTIONAL,['NA']
14721,NCT03182569,Comfort measured by a visual analogue scale for pain,Metabolic stability according to lab determinations,,2016-12-11,COMPLETED,INTERVENTIONAL,['NA']
14722,NCT00132132,Percentage of Participants With BMI Reduction,,,2005-08,COMPLETED,INTERVENTIONAL,['NA']
14723,NCT06117137,Number of participants with tight controlled diabetes melitus,Number of participant with changing in inflammatory biomarkers,,2023-11-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
14724,NCT02018497,"Relationship between blood pressure group, adaptability group and comorbidities","Relationship between adaptability group, habits and anthropometric, metabolic, endocrine, Electrocardiogram, Holter, ambulatory blood pressure monitoring (ABPM)",Description of the blood pressure hemodynamic profile at a medical office and their prognostic implications.,1995-01,RECRUITING,OBSERVATIONAL,['NA']
14725,NCT00786890,"Cardiovascular risk factors: anthroprometric parameters, blood pressure and lipid profiles",,,2008-11,UNKNOWN,OBSERVATIONAL,['NA']
14726,NCT02743598,Neurocognitive performance- change in domain averages on a standard neuropsychological profile,Change from baseline serum LDL,,2016-09,TERMINATED,INTERVENTIONAL,['PHASE4']
14727,NCT00946504,Bioequivalence based on AUC and Cmax,,,1992-10,COMPLETED,INTERVENTIONAL,['PHASE1']
14728,NCT02325531,"Rate Ratio of the Percent of the Clinics' Patients ""Indicated"" for ACE/ARB With Guideline-appropriate Prescription for ACE/ARBs",Rate Ratio of the Change in the Percent of the Clinic's 'Indicated' Patients With Correct Intensity Statin Prescribing,,2014-09,COMPLETED,INTERVENTIONAL,['NA']
14729,NCT04070963,Diabetes incidence,Association of HbA1C levels with post operative complications,,2019-05-01,UNKNOWN,OBSERVATIONAL,['NA']
14730,NCT01800851,Energy expenditure,Insulin resistance,,2008-01,COMPLETED,INTERVENTIONAL,['NA']
14731,NCT04885621,hemoglobin A1C levels,Weight/BMI,,2021-05-01,COMPLETED,OBSERVATIONAL,['NA']
14732,NCT01681160,change from baseline in BATES-JENSEN WOUND ASSESSMENT score at 3days and change from baseline in BATES-JENSEN WOUND ASSESSMENT score at 6 days,,,2009-01,COMPLETED,INTERVENTIONAL,['NA']
14733,NCT01076829,The protocol is designed to study the effect of spice on MDA production in hamburg meat,,,2009-07,COMPLETED,INTERVENTIONAL,['NA']
14734,NCT00718198,Mean Inpatient Glucose,Percent of patient-days with severe hypoglycemia,,2006-03,COMPLETED,OBSERVATIONAL,['NA']
14735,NCT06180811,Emergency Room Visit,Cost-Related Medication Underuse,,2024-01,RECRUITING,INTERVENTIONAL,['NA']
14736,NCT00541606,"Primary outcomes included the achievement of targets for A1c (< or = 7%), LDL cholesterol (< or = 100 mg/dL) and blood pressure (< or = 130/80), changes in quality of life as measured by the SF-36 Health Survey, and patient satisfaction.",Secondary outcomes included diabetes-related hospitalizations and acute care visits during the study period for both the intervention and control groups.,,2000-09,COMPLETED,INTERVENTIONAL,['NA']
14737,NCT03447340,Healthy food intake,Diastolic Blood pressure,,2016-11-09,COMPLETED,INTERVENTIONAL,['NA']
14738,NCT01891786,Coronary heart disease 10 year risk,Impact of receiving genetic results,,2013-07,COMPLETED,INTERVENTIONAL,['NA']
14739,NCT03513874,Change in C-peptide,Adverse effects,,2017-08-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
14740,NCT01564459,Percentage of Participants Who Were Discontinued Form the Study Due to an AE,Change in Pain Intensity Scores - All Responders,,2012-03-26,COMPLETED,INTERVENTIONAL,['PHASE2']
14741,NCT03380338,Change in capillary recruitment,Changes in continous cardiovascular monitoring,,2016-05-11,COMPLETED,INTERVENTIONAL,['NA']
14742,NCT04678661,Change From Baseline in Glycemic Control at 3 Months,Number of Participants Who Experienced Severe Hypoglycemic Events.,Type of Escalation of Care,2021-02-15,TERMINATED,INTERVENTIONAL,['NA']
14743,NCT05378295,Peripheral insulin sensitivity,body weight,,2021-11-05,RECRUITING,INTERVENTIONAL,['NA']
14744,NCT05566197,Body Fat Percentage,,,2022-07-15,RECRUITING,INTERVENTIONAL,['NA']
14745,NCT00895427,,,,2009-02,COMPLETED,OBSERVATIONAL,['NA']
14746,NCT05545657,Baseline brain functional MRI scan,Longitudinal changes of brain functional MRI scan,,2022-10-18,RECRUITING,OBSERVATIONAL,['NA']
14747,NCT00110435,Percent reduction in LDL-C from baseline after 6 weeks of treatment,Percent of patients attaining LDL-C <70 mg/dl after 6 weeks of treatment,,2005-05,COMPLETED,INTERVENTIONAL,['PHASE3']
14748,NCT05156021,Changes in Intraocular Pressure from baseline to 12 months after surgery,Changes in Ocular and Systemic Adverse Events from baseline to 12 months after surgery,,2021-12-12,COMPLETED,INTERVENTIONAL,['NA']
14749,NCT01073137,Otoacoustic emissions change with blood sugar levels,,,2006-06,UNKNOWN,OBSERVATIONAL,['NA']
14750,NCT05730582,Cost effectiveness as measured by cost per case found,,,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
14751,NCT06131918,Objective improvement in Diabetic Neuropathy,Levels of Superoxide dismutase and Glutathione peroxidase,,2023-01-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
14752,NCT02053584,BGMS Accuracy Assessment When Used by Layperson,Evaluation of the Ease of Use of the Dario BGMS by the Lay-person,,2013-06,COMPLETED,INTERVENTIONAL,['NA']
14753,NCT02169999,Patients' change in knowledge about diabetes and its treatments,Patients' Change in Decisional Conflict Scores,,2011-06,COMPLETED,INTERVENTIONAL,['NA']
14754,NCT02657018,Change from baseline daily physical activity at 24 weeks,Adherence to the intervention,Perceived acceptance of intervention,2016-08,COMPLETED,INTERVENTIONAL,['NA']
14755,NCT03298009,Change to be observed with canagliflozin on whole-body partitioning.,plasma NEFA turnover,body composition,2017-11-01,WITHDRAWN,INTERVENTIONAL,['NA']
14756,NCT03406910,Risk for Type 2 Diabetes (T2D) in subjects who consume different frequencies/amounts of eggs and meat.,,,2015-02-13,COMPLETED,OBSERVATIONAL,['NA']
14757,NCT03499223,Change from baseline in BCVA,Withdrawal from repeat study treatment and reason for withdrawal,,2018-04-20,COMPLETED,INTERVENTIONAL,['PHASE2']
14758,NCT02234947,Ultrasound of Pancreatic volume,Blood Test will be done for pancreatic function and diabetes markers,,2013-11,COMPLETED,OBSERVATIONAL,['NA']
14759,NCT03231839,change in glucose metabolism,body composition,,2009-02-01,COMPLETED,INTERVENTIONAL,['NA']
14760,NCT02960659,Change in Absolute Gluconeogenesis From Baseline to 12 Weeks,Change in Palmitate Turnover From Baseline to 12 Weeks,,2017-05-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14761,NCT03084822,Physical activity self-efficacy (using Self-Efficacy and Exercise Habits Survey),Cardiovascular health knowledge,,2016-03,COMPLETED,INTERVENTIONAL,['NA']
14762,NCT00252733,Number of Participants With a 2-step or Greater Increase in Early Treatment Diabetic Retinopathy Study (ETDRS) Severity Scale.,Rate of Change in Urinary Albumin Excretion Rate (UAER).,,2001-06,COMPLETED,INTERVENTIONAL,['PHASE3']
14763,NCT03943940,Adverse events,Insulin dose and drug dosage,,2019-04-24,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14764,NCT03066570,"Quality of Life as measured with Norfolk Quality of Life Questionnaire, Diabetic Neuropathy Version (Norfolk-QOL-DN)",,,2017-06-01,COMPLETED,INTERVENTIONAL,['NA']
14765,NCT00688974,Glucose control,Diabetes remission,,2004-05,COMPLETED,OBSERVATIONAL,['NA']
14766,NCT03869931,Triglyceride concentration following 30 days of fenofibrate treatment,Change in ETDRS scale following 30 days of fenofibrate treatment,,2019-03-08,UNKNOWN,INTERVENTIONAL,['PHASE3']
14767,NCT03862963,Usage of diabetes medications,Waist circumference,,2006-06-01,COMPLETED,INTERVENTIONAL,['NA']
14768,NCT00172796,,,,2005-04,UNKNOWN,OBSERVATIONAL,['NA']
14769,NCT03188484,Atrial fibrillation (AF) diagnosis,,,2016-05,COMPLETED,OBSERVATIONAL,['NA']
14770,NCT03039075,Changes of HbA1c,"Changes of LDL, HDL, TG, TC",,2016-11,COMPLETED,INTERVENTIONAL,['PHASE4']
14771,NCT05620225,Comparison of therapy-related AEs between the 2 Study arms,Neurological Exam - percentage of treatment arm with a change in neurological status,,2022-12-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
14772,NCT01237522,Renal clearance of metformin,,,2010-08,COMPLETED,INTERVENTIONAL,['PHASE4']
14773,NCT05930210,The ulcer complete closure rate,The proportion of subjects with complete ulcer closure,,2023-05-30,RECRUITING,INTERVENTIONAL,['PHASE3']
14774,NCT02096705,Adjusted Mean Change in HbA1c From Baseline to Week 24,Adjusted Mean Change in Absolute Calculated Mean Total Daily Dose of Insulin (TDDI) From Baseline to Week 24,,2014-03-31,COMPLETED,INTERVENTIONAL,['PHASE3']
14775,NCT01803126,To study the role of biofilm in the hardening of the arteries. The study will evaluate the hardening of the arteries found in legs that have been amputated because of vascular disease and/or diabetes.,,,2012-06,COMPLETED,OBSERVATIONAL,['NA']
14776,NCT03316508,Change of Copeptin concentrations,Complexity of procedures,,2017-06-14,COMPLETED,OBSERVATIONAL,['NA']
14777,NCT03973931,Medication adherence,Healthcare utilization costs (Costs),,2019-07-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
14778,NCT05973799,Glucose infusion rate,Peripheral glucose uptake,Growth Hormone,2019-10-10,RECRUITING,INTERVENTIONAL,['NA']
14779,NCT00828425,evolution of diabetic retinopathy,concomitant medication,,2008-12,COMPLETED,OBSERVATIONAL,['NA']
14780,NCT02139254,Number of women with gestational diabetes,Delivery Mode,,2013-08,COMPLETED,OBSERVATIONAL,['NA']
14781,NCT05256706,Changes in prescriptions of participants with type 2 diabetes (T2D) in concordance with SSCVD results over a 6-month period,Change in medication possession ratio,,2022-02-03,COMPLETED,INTERVENTIONAL,['NA']
14782,NCT00489190,Dynamics compared with the initial level of glycemia and insulin dosages.,"Evaluation of frequency of glycemia episodes. Also undesirable events, Influence on indexes of general clinical analysis of blood and biochemical analysis of blood.",,2005-08,COMPLETED,INTERVENTIONAL,['PHASE4']
14783,NCT05228561,The effect of mobile application supported diabetes education on blood sugar,,,2022-03-15,UNKNOWN,INTERVENTIONAL,['NA']
14784,NCT00071526,"Plasma, neutrophil and RBC Vitamin C concentrates",Determine the renal threshold and relative bioavailability for vitamin C,,2006-04-11,RECRUITING,OBSERVATIONAL,['NA']
14785,NCT02345057,Change from baseline in urinary albumin to creatine ratio (UACR),Change in serum potassium,,2015-01,COMPLETED,INTERVENTIONAL,['PHASE2']
14786,NCT00853619,Compliance with guideline,Patient outcomes,,2008-03,UNKNOWN,INTERVENTIONAL,['NA']
14787,NCT00351767,Skin re-epithelialization without drainage or dressing requirements,Number of debridements performed,,2006-01,COMPLETED,INTERVENTIONAL,['PHASE2']
14788,NCT01503008,Self-efficacy,Device-related and -unrelated adverse events,,2012-02,WITHDRAWN,INTERVENTIONAL,['NA']
14789,NCT01731808,feasibility of an intensive nurse led education program,,,2010-10,COMPLETED,INTERVENTIONAL,['NA']
14790,NCT06076720,Comparison of changes in the Low Vision Quality-of-Life Questionnaire (LVQOL) scores at different time points,Comparison of changes in visual scanning test at different time points,,2023-10-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
14791,NCT00301249,,,,1999-10,COMPLETED,OBSERVATIONAL,['NA']
14792,NCT04067999,Change in Glycated Haemoglobin A1c (HbA1c) (measured in mmol/mol),Patient completed the study under treatment with semaglutide (yes/no),,2019-08-05,COMPLETED,OBSERVATIONAL,['NA']
14793,NCT02633722,Postprandial glucose response to meal test,Glycaemic response over 1 week by continuous glucose monitoring,,2016-01,COMPLETED,INTERVENTIONAL,['NA']
14794,NCT02361931,Number of participants with the reduction of wound area by 75%$ or more,Recurrence of closed wounds,,2016-03-21,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14795,NCT02280486,Proportion of subjects achieving glycemic response defined as Glycosylated hemoglobin (HbA1c) < 7.0%,"Safety and tolerability of saxagliptin vs. glimepiride measured by adverse events, serious adverse events (SAEs); laboratory assessments (biochemistry, lipids, blood and urine routine tests",,2015-01,COMPLETED,INTERVENTIONAL,['PHASE4']
14796,NCT03813927,Wound healing,Vitamin D blod level status,,2016-04-01,COMPLETED,INTERVENTIONAL,['NA']
14797,NCT05063253,Changes in glycosylated hemoglobin (HbA1c) from baseline to week 20,The occurrence of TG103 anti-drug antibodies (ADA) and neutralizing antibody (Nab).,,2021-10,UNKNOWN,INTERVENTIONAL,['PHASE2']
14798,NCT01640873,Fasting Plasma Glucose (FPG),Change From Baseline at 2 Hours Oral Glucose Tolerance Test,,2012-09-19,COMPLETED,INTERVENTIONAL,['PHASE1']
14799,NCT05226416,hospitalization for any cause,rate of demand for medical care,,2022-02-21,COMPLETED,OBSERVATIONAL,['NA']
14800,NCT04689685,Accuracy of the RADAR model: Diagnostic accuracy of wearable based physiological data in detecting dysglycemia (glucose > 13.9mmol/L and glucose < 3.9 mmol/L) quantified as the area under the receiver operator characteristics curve (AUC-ROC),24. Analysis of user requirements for smartwatch based dysglycemia warning systems,,2021-02-19,COMPLETED,OBSERVATIONAL,['NA']
14801,NCT03793855,GC,DQ,ADD,2019-05-06,COMPLETED,INTERVENTIONAL,['NA']
14802,NCT01194882,Change in glycosylated hemoglobin (HbA1c),Antibody assessments (anti-Insulin antibodies),,2010-11-16,COMPLETED,INTERVENTIONAL,['PHASE3']
14803,NCT02737527,Difference in Procedure time (I1),A 5-pointed Likert satisfaction scale related to the procedure,,2016-04,UNKNOWN,INTERVENTIONAL,['NA']
14804,NCT05023993,Feasibility of a nutrition and exercise program in childhood cancer survivors (CCS),,,2022-06-23,RECRUITING,INTERVENTIONAL,['NA']
14805,NCT01452113,plasma glucagon concentration,GIP,,2010-10,COMPLETED,INTERVENTIONAL,['PHASE2']
14806,NCT06268145,ECC5004 PK parameters: tmax,ECC5004 PK parameters: AUC(extr),,2024-02-06,RECRUITING,INTERVENTIONAL,['PHASE1']
14807,NCT01755351,The influence of diabetes distress on treatment sdherence,,,2011-12,COMPLETED,OBSERVATIONAL,['NA']
14808,NCT01174303,Area under the Glucose Infusion Rate curve (only for NN5401),Area under the glucose infusion rate curve (only for biphasic insulin aspart 30),,2010-08,COMPLETED,INTERVENTIONAL,['PHASE1']
14809,NCT00381992,"The prevalence of hepatitis B, hepatitis C, hypertension, hyperlipidemia, diabetes and obesity, HIV, N. gonorrhoeae, and C. trachomatis",,,2005-09,COMPLETED,OBSERVATIONAL,['NA']
14810,NCT01316341,Fasting Plasma Glucose (FPG) Change From Baseline,"Clinical Relevant Abnormalities for Protocol-Specified Significant Adverse Events, Hypoglycaemic Events, Vital Signs, Blood Chemistry, Rescue Therapy, Body Weight and Waist Circumference",,2011-03,COMPLETED,INTERVENTIONAL,['PHASE1']
14811,NCT03219320,Numeric Rating Scale (NRS) Average Pain Intensity,Numeric Rating Scale (NRS) Average Pain Intensity in Patients Who Did Not Use a Concomitant Medication at Baseline,,2017-06-27,COMPLETED,INTERVENTIONAL,['PHASE2']
14812,NCT00612625,insulin secretion rate (ISR) were derived by deconvolution of c-peptide. ISR is expressed as pmol/kg/min,The calculated ISR values was plotted against the ambient plasma glucose. The slopes of this linear relationships were calculated by cross-correlation analysis and is and estimation of beta-cell responsiveness (pmol/kg/min)/mmol/l,,2004-02,COMPLETED,INTERVENTIONAL,['NA']
14813,NCT04689958,Improvement in Brief Pain inventory at week 8,,,2020-11-03,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
14814,NCT04235959,Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration.,PK: Cmax of Tirzepatide (Cohort 2),,2020-10-21,COMPLETED,INTERVENTIONAL,['PHASE1']
14815,NCT05272059,Number of participants with Adverse events (AEs) and Serious Adverse events (SAEs),Time to Reach Maximum Blood Concentrations (Tmax) of MHS552,,2023-09-01,WITHDRAWN,INTERVENTIONAL,['PHASE1']
14816,NCT00718874,decreased insulin secretion,decreased markers of inflammation; decreased estradiol concentration,,2008-06,COMPLETED,INTERVENTIONAL,['NA']
14817,NCT00472953,To evaluate pulmonary safety comparing inhaled insulin to subcutaneous injections,Preprandial Insulin Doses,,2007-05-15,TERMINATED,INTERVENTIONAL,['PHASE3']
14818,NCT03658512,Glycemic control (HbA1C),,Nasal and skin swab,2018-08-13,RECRUITING,OBSERVATIONAL,['NA']
14819,NCT00332085,Hemoglobin A1c,Oral Glucose Tolerance Test,,2006-01,TERMINATED,INTERVENTIONAL,['PHASE1']
14820,NCT00454233,"Safety and tolerability (adverse events; biochemical, hematological and urine analysis tests; vital signs, 12-lead ECG, physical examination)","Efficacy and pharmacodynamics (change in HbA1c and fasting plasma glucose; change in urinary glucose excretion; plasma levels of YM543; C-peptide, insulin, fructosamine, non-esterified fatty acids, triglyceride, cholesterol-panel)",,2007-02,COMPLETED,INTERVENTIONAL,['PHASE2']
14821,NCT03784703,leptin (ng/mL),Triglycerides,,2018-01-01,COMPLETED,INTERVENTIONAL,['PHASE4']
14822,NCT03593135,HbA1c (Glycosylated Hemoglobin),fasting lipid profile,,2017-07-15,COMPLETED,INTERVENTIONAL,['NA']
14823,NCT03769870,"AUCτ,ss(Area under the concentration-time curve at steady state)",,,2019-01-11,COMPLETED,INTERVENTIONAL,['PHASE1']
14824,NCT06065098,Fidelity summary score,Sustainability (Participants),Difference in quality of life (QoL),2023-11-18,RECRUITING,INTERVENTIONAL,['NA']
14825,NCT04369664,Change in platelet activity (LTA) before and after cholesterol reduction,,,2020-08-12,COMPLETED,INTERVENTIONAL,['PHASE4']
14826,NCT00005380,,,,1993-09,COMPLETED,OBSERVATIONAL,['NA']
14827,NCT02189395,difference in glycemic control between treatment groups as measured by the mean daily blood glucose,number of hypoglycemic events,,2013-04,TERMINATED,INTERVENTIONAL,['PHASE4']
14828,NCT01736930,Mornings With Urine Ketones Characterized as Moderate or Large - Algorithm 3,Percentage of Sensor Glucose Values 71 to 180 mg/dL - Algorithm 3,,2012-01,COMPLETED,INTERVENTIONAL,['PHASE2']
14829,NCT05791188,Serum chloride,,,2023-05,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
14830,NCT02099409,Time spent in normal glucose range ( mg/dl),time spent in high glucose range (>180mg/dl),,2014-01,COMPLETED,INTERVENTIONAL,['NA']
14831,NCT01648296,The Primary Endpoint is to Determine if PET/CT Measurements of Myocardial FA Metabolism Performed With [18F]FluorbetaOx Correlated With Those Performed With [11C]Palmitate and Calculation of Human Dosimetry.,To Determine Human Dosimetry Based on the Human Biodistribution of [18F](+/-)NOS in Both Normal Healthy Volunteers and Dilated Non-ischemic Cardiomyopathy Patients.,,2012-09-13,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
14832,NCT05309850,Incidence of type 2 diabetes,,,2022-04-05,RECRUITING,INTERVENTIONAL,['NA']
14833,NCT02869659,Chang in Epigengene score (and related individual transcriptional and methylation measures),change in homeostatic model assessment (HOMA) estimates of insulin resistance,,2016-11-01,COMPLETED,INTERVENTIONAL,['NA']
14834,NCT00501592,Insulin Resistance and Glucose Homeostasis,Hepatocellular Function,,2007-07,COMPLETED,INTERVENTIONAL,['PHASE2']
14835,NCT05760456,Change from Baseline at Week 12 in Hemoglobin A1c (HbA1c),Safety assessments,,2023-03-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
14836,NCT03479866,Hunger and appetite assessment,,Carotid plaque,2018-06-04,UNKNOWN,INTERVENTIONAL,['NA']
14837,NCT03864562,Gastric emptying rate,Recruitment rate,,2019-03-01,COMPLETED,OBSERVATIONAL,['NA']
14838,NCT04200313,HbA1c,Other Secondary Efficacy Endpoint: Mean Participant-reported Grams of Carbohydrate Taken Specifically to Prevent or Treat Hypoglycemic Events Per 24 Hours,Safety Outcome Measure: Worsening of HbA1c by >0.5%,2020-03-31,COMPLETED,INTERVENTIONAL,['NA']
14839,NCT00624364,HbA1c,Adverse events,,2004-05,COMPLETED,INTERVENTIONAL,['PHASE4']
14840,NCT00123136,improve quality of life,"serial changes in EDX, QST, autonomic functions, biopsy",,2005-08,UNKNOWN,INTERVENTIONAL,['PHASE4']
14841,NCT04243174,"Feasibility of mobile phone text messaging intervention for people with T2DM: Number of Participants recruited, completed the study, dropped out",Self-report questionnaire (International Physical Activity Questionnaire - IPAQ),,2020-01-23,COMPLETED,INTERVENTIONAL,['NA']
14842,NCT03925519,"Analysis of blood sugar, glycated hemoglobin (HbA1c)",Analysis of Nitric Oxide,,2013-01-25,COMPLETED,OBSERVATIONAL,['NA']
14843,NCT05668442,Adverse events,Questionnaires,,2020-11-21,COMPLETED,OBSERVATIONAL,['NA']
14844,NCT02623465,(Part B) PK: AUC of Insulin Lispro Glucose Following a Mixed Meal,(Part B) PD: AUC of Glucose Following a Meal,,2018-01,WITHDRAWN,INTERVENTIONAL,['PHASE1']
14845,NCT00676819,Glucose infusion rate,"Cmax,ins: the maximal serum insulin (or serum insulin aspart) concentration",,2002-01-10,COMPLETED,INTERVENTIONAL,['PHASE4']
14846,NCT03182972,Medication reconciliation: Percentage unreconciled medications,,,2016-08-02,COMPLETED,INTERVENTIONAL,['NA']
14847,NCT02409238,Primary cognitive endpoint (Neuropsychological Performance),Secondary adherence endpoints Fasting Lipids,,2015-03-11,TERMINATED,INTERVENTIONAL,['PHASE4']
14848,NCT03131687,Change From Baseline to Week 26 in Hemoglobin A1c (HbA1c) Bayesian Dose Response,Pharmacokinetics (PK): Model Predicted Concentration at Steady State (Css) of Tirzepatide,,2017-05-24,COMPLETED,INTERVENTIONAL,['PHASE2']
14849,NCT02996539,Association between HRV and renal function (eGFR and UACR),Clinical characteristics of patients,,2013-02,COMPLETED,OBSERVATIONAL,['NA']
14850,NCT00129259,Change in Mean C-peptide Area Under the Curve (AUC) Response to a Mixed Meal Tolerance Test (MMTT),Change in Average Total Insulin Dose Per Body Weight,,2005-09,COMPLETED,INTERVENTIONAL,['PHASE2']
14851,NCT03816280,Central venous oxygen saturation,,,2019-02-01,UNKNOWN,OBSERVATIONAL,['NA']
14852,NCT04420845,Change in mean HbA1c (NGSP%) from baseline to 12 weeks post-intervention,Change in diabetes-related quality of life from baseline to 12 weeks post-intervention,,2022-03-25,WITHDRAWN,INTERVENTIONAL,['NA']
14853,NCT05346679,BMI,,,2021-03-01,COMPLETED,OBSERVATIONAL,['NA']
14854,NCT04134143,Number of participants with adverse events through study completion,,,2019-11-07,TERMINATED,INTERVENTIONAL,['PHASE1']
14855,NCT03046927,Residual beta-cell function (RBCF),Duration of Partial Clinical Remission (PCR),,2017-10-19,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
14856,NCT00085969,Change in HbA1c (glycosylated hemoglobin) from Baseline to Day 28,Change in postprandial blood glucose concentrations from Baseline to Day 28,,2003-09,COMPLETED,INTERVENTIONAL,['PHASE2']
14857,NCT01060241,The primary endpoint is the A1c level or the change in A1c level,"The secondary endpoints include severe hypoglycemia defined as requiring external aid, hospital admissions for any CVD related intervention, and adverse events such as unplanned hospitalizations for any cause that last more than 24 hours",,2010-02,SUSPENDED,INTERVENTIONAL,['NA']
14858,NCT00847327,Glycemic variability,Hemoglobin A1C,,2008-04,COMPLETED,INTERVENTIONAL,['NA']
14859,NCT05344859,Change in Hemoglobin A1C level between screening and 6 months,,,2023-05-15,RECRUITING,INTERVENTIONAL,['NA']
14860,NCT06242548,Ketonemia variation among groups over time during mountains outings,weight measurements for each of the 4 mountains outings,,2023-06-02,COMPLETED,INTERVENTIONAL,['NA']
14861,NCT00827853,Rate of binary restenosis as determined by duplex ultrasound.,Resting ankle-brachial index,,2008-11,COMPLETED,INTERVENTIONAL,['NA']
14862,NCT03061214,Change in HbA1c,Occurence of Cross Reacting Antibodies With in Vitro Neutralising Effect to Endogenous GLP-1 (Yes/no),,2017-08-28,COMPLETED,INTERVENTIONAL,['PHASE3']
14863,NCT03281083,Liver fat content,Abdominal fat,,2014-03-28,TERMINATED,INTERVENTIONAL,['PHASE2']
14864,NCT01081834,Change in HbA1c From Baseline to Week 26 (High Glycemic Substudy),Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 26 (High Glycemic Substudy),,2010-03,COMPLETED,INTERVENTIONAL,['PHASE3']
14865,NCT04102657,Difference in body-fat percentage before and after 12-14 days of designated diet,Time below range (Interstitial BG <70 mg/dL) between designated diet groups,,2019-09-20,UNKNOWN,INTERVENTIONAL,['NA']
14866,NCT01135927,Area under the NN1250 GIR (glucose infusion rate) curve,Area under the serum insulin detemir concentration-time curve,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE1']
14867,NCT04074954,Amount of activity conducted by the patient after receiving surgery,,,2023-03-23,WITHDRAWN,OBSERVATIONAL,['NA']
14868,NCT02643771,Percentage of bleeding on probing,Clinical attachment level (mm),,2013-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
14869,NCT01642108,HbA1c,Glucagon secretion,,2012-07,UNKNOWN,INTERVENTIONAL,['NA']
14870,NCT02462785,Change in Carbohydrate Counting Accuracy Measured Using a Standardized Meal & Snack Tray Test at Baseline and 3-months Post-Education,Change in Carbohydrate Counting Knowledge Tested Using the PedCarbQuiz (PCQ) at Baseline and 3-months Post-Education,,2014-07,COMPLETED,INTERVENTIONAL,['NA']
14871,NCT01221467,Primary Efficacy Outcome,Secondary outcomes,,2012-06,COMPLETED,INTERVENTIONAL,['PHASE2']
14872,NCT00434954,Incidence of Hypoglycemia (Percentage of Participants With at Least One Hypoglycemic Episode),Patient Reported Outcomes: Quality of Life (SF-12),,2007-02,COMPLETED,INTERVENTIONAL,['PHASE3']
14873,NCT04564391,change of fasting insulin sensitivity in mixed-meal test,change of urea concentration in serum(mmol/l),change in uric Acid concentration in Serum (µmol/l),2020-09-21,RECRUITING,INTERVENTIONAL,['NA']
14874,NCT04000789,Conjunctival Goblet Cell Density,,,2019-07,UNKNOWN,INTERVENTIONAL,['NA']
14875,NCT03273881,Neonatal hypoglycemia,NICU admission,,2017-10-31,RECRUITING,INTERVENTIONAL,['NA']
14876,NCT01386801,,,,2009-12,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
14877,NCT05683990,"Number of Clinically Significant Abnormal Results From Laboratory measurements, including hematology, clinical chemistry, metabolic status parameters (fasting C-peptide, HbA1c, fasting glucose) and urine analysis",Variables that indicate effects on the immune system,,2023-11-14,RECRUITING,INTERVENTIONAL,['PHASE2']
14878,NCT04628481,Change from baseline in HbA1c,Estimated Glucose Disposal Rate (eGDR),,2020-12-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
14879,NCT04929379,Baseline-adjusted levels of serum biomarkers of increased ESKD risk at the end of the drug wash-out period,Levels of serum biomarkers of increased ESKD risk at the end of treatment,,2022-01-04,RECRUITING,INTERVENTIONAL,['PHASE2']
14880,NCT02544568,Maximum plasma concentration [Cmax] of glucose and triglycerides,Maximum plasma concentration [Cmax] of glucagon,,2009-11,COMPLETED,INTERVENTIONAL,['NA']
14881,NCT02334137,Change from Baseline in Patient Knowledge about Diabetes at 3 months (via multiple-choice surveys),Change from Baseline in Patient Knowledge about Diabetes Immediately after using Educational Services (via multiple-choice surveys),,2014-11,COMPLETED,OBSERVATIONAL,['NA']
14882,NCT04564846,Difference in Area Under the Curve (AUC(0-16)) of endogenous glucose production between placebo and ORMD-0801,Mean changes in ketones from baseline to Day 29 of the treatment period.,,2020-11-23,COMPLETED,INTERVENTIONAL,['PHASE2']
14883,NCT03343730,Rate of Diabetic Retinopathy Detection,,,2018-02-27,UNKNOWN,INTERVENTIONAL,['NA']
14884,NCT00169624,Flow dependent and independent Brachial artery vasoreactivity assessed using Doppler technology at 3 month vs baseline,Myocardial perfusion improvement following improved vasoreactivity assessed using myocardial perfusion imaging at 3 month vs baseline,,2005-10,TERMINATED,INTERVENTIONAL,['PHASE3']
14885,NCT00312104,HbA1c,Hypoglycaemia,,2002-04,COMPLETED,INTERVENTIONAL,['PHASE3']
14886,NCT00501072,Clinical effectiveness: percentage of time spent in euglycaemia,"Incidence of hypoglycaemia; Number of SMBG performed, Number of adjustments of insulin therapy, Patient satisfaction, agreement of paired SMBG and RT-CGMS measurements.",,2007-11,COMPLETED,INTERVENTIONAL,['NA']
14887,NCT02742597,Evaluation of Intervention Effectiveness - Change in Patient-Centredness,Evaluation of Intervention Effectiveness - Change in Demographics,,2016-01-12,COMPLETED,INTERVENTIONAL,['NA']
14888,NCT04160988,Specificity,Percentage of Participant Images With Insufficient Quality as Judged by VeriSee DR,,2019-12-16,COMPLETED,OBSERVATIONAL,['NA']
14889,NCT03135535,Change in Skin Perfusion From Baseline to 4 Weeks,Change in Stride Velocity From Baseline to 4-week,,2017-05-02,COMPLETED,INTERVENTIONAL,['PHASE2']
14890,NCT01112709,Muscular Strength,Body Composition,,2011-01,COMPLETED,INTERVENTIONAL,['PHASE2']
14891,NCT02476760,Hospitalization for acute pancreatitis,,,2014-03,COMPLETED,OBSERVATIONAL,['NA']
14892,NCT05505773,To evaluate the systemic metabolic rate of diabetic patients before and after bariatric gastric bypass surgery using the Breezing® device.,,,2017-01-06,COMPLETED,OBSERVATIONAL,['NA']
14893,NCT05237128,Change in HbA1c,Change in HbA1c,,2022-03-22,RECRUITING,INTERVENTIONAL,['NA']
14894,NCT03835312,Concentration of serum C-peptide,Occurrence of graft versus host disease,,2019-02-20,RECRUITING,INTERVENTIONAL,['NA']
14895,NCT03609294,AUClast,,,2018-07-18,COMPLETED,INTERVENTIONAL,['PHASE1']
14896,NCT02034045,Hospital admissions per patient,Cost Effectiveness,Trial Fidelity and Safety,2013-06,COMPLETED,INTERVENTIONAL,['NA']
14897,NCT01782261,Increase of regulatory FOXP3+ T cells,Immunophenotyping,,2012-02,COMPLETED,INTERVENTIONAL,['PHASE2']
14898,NCT06002048,Montreal Cognitive Assessment (MoCA),,,2023-07-19,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
14899,NCT01680978,Cardiac energetics: Change in PCr/ATP ratio using phosphorus magnetic resonance spectroscopy (MRS),Change in cardiac/hepatic triglyceride content assessed my MRS,,2012-10,COMPLETED,INTERVENTIONAL,['PHASE2']
14900,NCT06147583,Sensitivity,False positive per day,,2023-12,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
14901,NCT02930044,Duration of intravenous insulin infusion,Incidence of low serum glucose (hypoglycemia) within 24 hours,,2016-10,COMPLETED,INTERVENTIONAL,['NA']
14902,NCT01277432,Depression and psychological well-being,Quality of life,,2010-07,COMPLETED,OBSERVATIONAL,['NA']
14903,NCT03709108,Safety and feasibility of the SI-informed bolus calculator: Low Blood Glucose Index,,,2018-11-19,COMPLETED,INTERVENTIONAL,['NA']
14904,NCT00857558,changes in HbA1C from baseline,adverse event,,2009-01,COMPLETED,INTERVENTIONAL,['PHASE2']
14905,NCT00781534,,,,2003-09,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
14906,NCT01578382,Martorell HYTILU and calciphylaxis show both decreased tissue protection mechanisms against tissue calcification,Martorell hypertensive ischemic leg ulcer and calciphylaxis are both characterized by non-infectious inflammation,,2011-09,COMPLETED,OBSERVATIONAL,['NA']
14907,NCT03997396,Changes in Gesell developmental scale test results within 6 months of age,Changes in percentage of RBC width distribution(RDW%),,2019-06-01,RECRUITING,OBSERVATIONAL,['NA']
14908,NCT05773677,incidence of maternal obstetric complications:,differences in early or late enrollment of patients,,2022-10-10,RECRUITING,INTERVENTIONAL,['NA']
14909,NCT00134264,The time to first occurrence of a major cardiovascular disease event,Various composites of major cardiovascular disease events and other lipid parameters,,2004-07,TERMINATED,INTERVENTIONAL,['PHASE3']
14910,NCT01468675,Number of Subjects Who Discussed Disease Risk With Primary Care Provider,,,2013-02,COMPLETED,INTERVENTIONAL,['NA']
14911,NCT01517490,"Changes in visual acuity, diabetic retinopathy grading and OCT",,,2011-08,UNKNOWN,OBSERVATIONAL,['NA']
14912,NCT02635646,Individual Insulin Resistance and Insulin Secretion,2h OGTT Glucose,,2015-10,COMPLETED,INTERVENTIONAL,['NA']
14913,NCT03449251,Sub-study 5: Change in hand vein diameter after relaxin infusion in healthy participants,Sub-study 4: Change in glucose homeostasis after combined infusion of relaxin and apelin (TNF alpha),,2018-03-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
14914,NCT05846802,Measure of symptom severity of gastroparesis and functional dyspepsia using the change in total score from the Patient Assessment of Upper Gastrointestinal Disorders Symptoms (PAGI SYM) from baseline to 48 weeks.,"Changes in gastric emptying, as measured by gastric emptying scintigraphy (GES) at baseline and 48 weeks",Presence or absence of Carnett's sign for abdominal wall pain at baseline.,2024-05-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
14915,NCT04057677,Mitochondrial Respiration,Physical function,,2019-12-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
14916,NCT05543850,Time in range,Satisfaction,Glucagon dose,2022-10-28,COMPLETED,INTERVENTIONAL,['NA']
14917,NCT06170905,Postprandial glucose excursion,Glicentin course,,2024-02-01,RECRUITING,INTERVENTIONAL,['NA']
14918,NCT04079881,AUC Postprandial Glucagon,AUC Postprandial Glucose,,2020-02-13,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14919,NCT01048268,The difference in glucagon secretion quantified as the difference in plasma glucagon concentration and incremental baseline-subtracted area under the curve (AUC) for plasma glucagon,The difference between the amount of infused glucose and the insulin responses,,2009-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
14920,NCT06310356,a composite of pregnancy outcomes,day glucose time in range >180mg/dl,,2024-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
14921,NCT02435862,Observation of pharmacologic induction of PVD.,The secondary endpoints of this study is the observation of a complete stage 4 PVD to the equator including vitreopapillary release as seen by B-scan ultrasound and confirmed by OCT where possible by study day 90 as determined by the reading center.,,2015-02-01,COMPLETED,INTERVENTIONAL,['PHASE2']
14922,NCT01425359,Average Weekly Angina Frequency Over the Last 6 Weeks of Treatment,Patient's Global Impression of Change (PGIC) Scale Score,,2011-09,COMPLETED,INTERVENTIONAL,['PHASE4']
14923,NCT00072891,,,,na,COMPLETED,INTERVENTIONAL,['NA']
14924,NCT06137586,Total glucagon response,Difference in heart rate,,2022-08-10,RECRUITING,INTERVENTIONAL,['NA']
14925,NCT00997178,Change in Glycosylated Hemoglobin (HbA1c),Need for Diabetes Rescue Therapy,,2009-10,COMPLETED,INTERVENTIONAL,['PHASE3']
14926,NCT05946785,microvascular insulin-mediated dilation,endothelial cell insulin-stimulated eNOS phosphorylation,,2021-02-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
14927,NCT00013975,,,,2001-03,COMPLETED,OBSERVATIONAL,['NA']
14928,NCT03297762,CGM use,Hgb A1c,,2018-05-07,TERMINATED,INTERVENTIONAL,['NA']
14929,NCT03276312,Healing time,Quality of Life using the Short Form 36 (SF-36) questionnaire,,2015-04,COMPLETED,INTERVENTIONAL,['NA']
14930,NCT00105755,Reduce the risk for lower extremity ulceration and amputation in veterans at high risk for these complications.; Incidence of diabetic foot ulcers over 18 months. Incidence of foot infections over 18 months. Incidence of Charcot fractures.,Improve quality of life. Health Related Quality of Life (change over 18 months),,2003-01,COMPLETED,INTERVENTIONAL,['NA']
14931,NCT01720303,Change in HbA1c,Change in body weight,,2002-09-19,COMPLETED,INTERVENTIONAL,['PHASE4']
14932,NCT05449795,Number of results from the Contour Next and Contour Plus Elite BGMSs reference values within ±20% of reference values,,,2022-11-29,COMPLETED,OBSERVATIONAL,['NA']
14933,NCT00987285,"Improvement in health behaviors (e.g., dietary patterns, physical activity, medication taking) and biologic outcomes (HbA1c, lipid ratio, blood pressure, and smoking status).","Diabetes-specific quality of life (Diabetes Distress Scale), patient activation (PAM scale), and perceived social-environmental support (the Chronic Illness Resources Survey) at 4- and 12-month follow-ups.",,2007-01,COMPLETED,INTERVENTIONAL,['NA']
14934,NCT00915486,Percentage reduction in ulcer surface area,"Changes in vital signs, body weight, physical examination and laboratory parameters",,2009-05,COMPLETED,INTERVENTIONAL,['PHASE2']
14935,NCT05145673,Variation of blood glucose maximum concentration,Antioxidant activity,,2016-01-19,COMPLETED,INTERVENTIONAL,['NA']
14936,NCT00313313,Change From Baseline in Hemoglobin A1c (A1C) at Week 24,Changes From Baseline in Postprandial Glucose (PPG) Area Under the Curve (AUC) Response to an Oral Glucose Tolerance Test (OGTT) at Week 24,,2006-04,COMPLETED,INTERVENTIONAL,['PHASE3']
14937,NCT01599442,duration of survival without major amputation,total mortality,,2010-06,TERMINATED,OBSERVATIONAL,['NA']
14938,NCT03225339,Weight loss,Patient reported outcomes,Waist Circumference,2017-07-16,COMPLETED,INTERVENTIONAL,['NA']
14939,NCT01548222,Percentage of time CGM glucose is <70mg/dl,Weight gain,,2012-02,COMPLETED,OBSERVATIONAL,['NA']
14940,NCT05133973,Incidence and severity of device related adverse events (ADE),User satisfaction questionnaire score,,2022-10-10,RECRUITING,INTERVENTIONAL,['NA']
14941,NCT01495052,changes from baseline in insulin resistance Hematology index detection Hematology index detection Hematology index detection Hematology index detection Hematology index detection,changes from baseline in WHR,,2011-08,COMPLETED,INTERVENTIONAL,['NA']
14942,NCT04709120,death,Rate of cases of health status worsening occured during hospitalisation,,2020-10-01,COMPLETED,OBSERVATIONAL,['NA']
14943,NCT05566717,Primary Endpoint,,,2022-07-01,RECRUITING,OBSERVATIONAL,['NA']
14944,NCT01341587,Change in HbA1c,,,2011-04,TERMINATED,INTERVENTIONAL,['NA']
14945,NCT06135987,Number of patients with complete healed chronic wound (venous leg ulcer and Diabetic foot ulcer) at 12 weeks,Defectuosity of the device,,2022-06-24,RECRUITING,OBSERVATIONAL,['NA']
14946,NCT04521049,to classify renal responders to saxagliptin using tubular markers,,,2019-03-01,COMPLETED,INTERVENTIONAL,['PHASE4']
14947,NCT01271023,Overall frequency of hyperglycemia,Percent of subjects with a nadir blood glucose <=60 mg/dL following the breakfast with a meal bolus 30% more than the recommended bolus amount,,2011-03,COMPLETED,INTERVENTIONAL,['PHASE1']
14948,NCT01786408,Non-Inferiority of Analyte Levels,,,2013-03,WITHDRAWN,INTERVENTIONAL,['NA']
14949,NCT04999722,Change from Baseline Glycated hemoglobin at 12 months,Change from Baseline Diabetic nephropathy at 12 months,,2021-08-25,UNKNOWN,INTERVENTIONAL,['NA']
14950,NCT05737576,Area under the concentration-time curve (AUC0-0.5h),Incidence and severity of adverse events (AEs),,2023-03-20,COMPLETED,INTERVENTIONAL,['PHASE1']
14951,NCT05816057,The observed mean change in Glycosylated Haemoglobin A1c (HbA1c) values from baseline after 32 weeks of treatment.,Change From Baseline to Week 32 in Fasting Blood Lipids: Total Cholesterol、Low-density Lipoprotein (LDL) Cholesterol、 High-density Lipoprotein (HDL) Cholesterol 、Triglycerides (Ratio to Baseline).,,2022-07-25,COMPLETED,INTERVENTIONAL,['PHASE3']
14952,NCT01710540,"Cmax, Tmax, AUC0-t, AUC0-∞, AUC%_Extrap, Kel and t1/2",Safety profile,,2012-08,COMPLETED,INTERVENTIONAL,['PHASE2']
14953,NCT04201600,Aggregate Language Score,Instrumental Activities of Daily Living (IADL) total score,,2022-03-01,RECRUITING,OBSERVATIONAL,['NA']
14954,NCT04233229,Time in range (TIR),Body Weight,,2019-12-30,COMPLETED,INTERVENTIONAL,['NA']
14955,NCT02893306,Changes in insulin pancreatic reserve,Changes in insulin requirement,Number of patients with grade 3 through grade 5 adverse events (CTCAE v3.0),2012-03,UNKNOWN,INTERVENTIONAL,['PHASE2']
14956,NCT00838825,resource utilization,metabolic outcome,,2005-04,COMPLETED,INTERVENTIONAL,['PHASE2']
14957,NCT03648424,Composite Cardiovascular (CV) Outcome,,,2011-05-01,COMPLETED,OBSERVATIONAL,['NA']
14958,NCT00970099,insulin sensitivity and insulin signaling,,,2004-02,COMPLETED,INTERVENTIONAL,['PHASE1']
14959,NCT03234322,Difference of participant's physical activity at twelve months after the routine health check between the groups.,Acceptance of participants according to the application of a diabetes risk score for routine use in clinical practice.,Change on participant's individual diabetes risk.,2017-09-13,COMPLETED,INTERVENTIONAL,['NA']
14960,NCT01745900,Continuing validation of near infrared spectroscopy-based glucose meter algorithm,,,2012-12,UNKNOWN,OBSERVATIONAL,['NA']
14961,NCT02970344,Change in psychological distress,Assessing change in Physical Activity,,2017-04-20,COMPLETED,INTERVENTIONAL,['NA']
14962,NCT01235260,The number and rate of deaths from cancer in patients who have used becaplermin and patients who have not used not used becaplermin.,The number of becaplermin doses associated with risk of incident cancer and/or cancer death.,,2010-03,COMPLETED,OBSERVATIONAL,['NA']
14963,NCT00939939,incremental area under the triglyceride curve (iAUC-TG),hs-CRP,,2010-03,TERMINATED,INTERVENTIONAL,['PHASE4']
14964,NCT01501032,Percent of subjects with a peak blood glucose >400 mg/dL following the breakfast with a meal bolus 30% more than the recommended bolus amount,Percent of subjects with a nadir blood glucose <=60 mg/dL following the breakfast with a meal bolus 30% more than the recommended bolus amount,,2013-10,WITHDRAWN,INTERVENTIONAL,['PHASE1']
14965,NCT03495102,Change in Hemoglobin A1c (HbA1c) From Baseline,Pharmacokinetic (PK): Area Under the Curve AUC (0-168)ss at Steady State,,2018-04-05,COMPLETED,INTERVENTIONAL,['PHASE3']
14966,NCT02725593,Adjusted Change From Baseline in Glycated Haemoglobin (HbA1c) at Week 24,Percentage of Participants With Baseline Glycated Haemoglobin (HbA1c) >= 7% Who Achieved HbA1c Level < 7% at Week 24,,2016-06-22,COMPLETED,INTERVENTIONAL,['PHASE3']
14967,NCT00795860,Insulin sensitivity,whole body and skeletal muscle oxidative capacity,,2003-06,COMPLETED,INTERVENTIONAL,['NA']
14968,NCT01358435,Mean AUC0-24h and Cmax,"PK endpts: AUC0-4h, AUC0-6h, AUC0-12h, AUC6-12h, AUC6-24h,tmax,and elimination rate constant. PD endpoints: AUCGIR0-4h, AUCGIR0-6h, AUCGIR0-12h,AUCGIR0-24h, AUCGIR6-12h, AUCGIR6-24h, GIRmax and tGIRmax Safety : AEs,haematology,biochem,phy exam",,2011-01,COMPLETED,INTERVENTIONAL,['PHASE1']
14969,NCT05545800,Amplitude of glycemic excursions,Percentage of adverse events,,2022-09-01,RECRUITING,INTERVENTIONAL,['PHASE3']
14970,NCT03018028,Change in HbA1c (Week 26),Change From Baseline in DTR-QOL: Sub-domains,,2017-01-10,COMPLETED,INTERVENTIONAL,['PHASE3']
14971,NCT04502212,Change From Baseline in Rate of Glucose Disappearance (Rd),Incidence of Adverse Device Effects (ADEs) With a Severity Score of 5: Treatment Emergent Adverse Events (TEAEs) by System Organ Class and Preferred Term,Change From Baseline in Inflammatory Biomarkers: Interleukin-6,2020-07-30,COMPLETED,INTERVENTIONAL,['NA']
14972,NCT03407989,estimated GFR decline ml/min/y,"Diabetes-specific health-related quality of life baseline measures, CKD stage, and eGFR decline.",,2014-01-01,UNKNOWN,OBSERVATIONAL,['NA']
14973,NCT04942756,Evaluate CGM by using FSL2 in preventing severe hyperglycemia peaks,,,2021-06-30,UNKNOWN,INTERVENTIONAL,['NA']
14974,NCT01969318,Change From Baseline in HbA1c (Hemoglobin A1C) at Week 12,"Change From Baseline in Body Weight at Week 4,8,12",,2012-03,COMPLETED,INTERVENTIONAL,['PHASE2']
14975,NCT05883072,Internet Speed,Analyzing Chat response generated by AI Chatbot,,2023-01-05,RECRUITING,OBSERVATIONAL,['NA']
14976,NCT01293669,Changes in fasting plasma glucose (FPG),Change in AUC insulin from Day 1 (Baseline) at Week 4,,2011-01,COMPLETED,INTERVENTIONAL,['PHASE2']
14977,NCT02750774,Gestational Diabetes Mellitus (GDM) occurrence,Neonatal Intensive Care Unit (NICU) admission,,2015-12,UNKNOWN,INTERVENTIONAL,['NA']
14978,NCT03244241,Difference in mean daily plasma glucose between the two groups,Number of post-discharge infections or re-admissions 1 month after discharge,,2017-04-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
14979,NCT06305195,deep breath test interpretation,Framingham risk score (FRS),,2023-08-23,RECRUITING,OBSERVATIONAL,['NA']
14980,NCT02669524,Difference in postprandial glucose excursions,Fibroblast growth factor-21,,2015-10,COMPLETED,INTERVENTIONAL,['NA']
14981,NCT00011206,,,,2001-01,COMPLETED,OBSERVATIONAL,['NA']
14982,NCT01102673,"PK Endpoints: AUC(0-inf), AUC(0-last), AUC(0-24), Cmax, Tmax, CL/F, Vz/F and half-life (t1/2), as the data permit.",none-see my comment,,2010-04,COMPLETED,INTERVENTIONAL,['PHASE1']
14983,NCT02875704,"Aqueous levels of oxidized adducts on protein (i.e. oxidative biomarker) in patients with stargardt disease, AMD, DR and controls",,,2017-01-03,TERMINATED,OBSERVATIONAL,['NA']
14984,NCT05667051,Percentage of bleeding on probing sites (BOP%),,,2022-04-05,COMPLETED,OBSERVATIONAL,['NA']
14985,NCT03782129,Mortality rate 5 years after DFU diagnosis,Risks factors correlated to mortality rate among DFU patients diagnosed in 2010,,2009-03,COMPLETED,OBSERVATIONAL,['NA']
14986,NCT01594801,Safety,,,2012-05,COMPLETED,INTERVENTIONAL,['NA']
14987,NCT02768935,level of expression markers,,,2017-10-30,COMPLETED,INTERVENTIONAL,['NA']
14988,NCT05039970,Number of Sessions Attended,Participants' game rating/Net Promoter Score or questionnaire.,Fitness tracker integration with the game.,2021-09-07,COMPLETED,INTERVENTIONAL,['NA']
14989,NCT05386849,Primary Efficacy Outcome,Time in desired control range,Glucose readings from CGM's versus from blood,2022-05-09,COMPLETED,INTERVENTIONAL,['NA']
14990,NCT04868851,Drop out,Parent survey on intervention acceptability (Here for Health),,2021-09-01,RECRUITING,INTERVENTIONAL,['NA']
14991,NCT02682342,change in mitochondrial network complexity of endothelial cells as measured by mitochondrial network fragment ratio,,,2016-03-09,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
14992,NCT00722917,Change from Baseline in Glycosylated Hemoglobin,Plasma concentrations of TAK-379 and its metabolite M-I via a sparse sampling population approach.,,2008-07,TERMINATED,INTERVENTIONAL,['PHASE2']
14993,NCT00779363,Device Functionality Evaluation,Percentage of body weight loss,,2004-06,COMPLETED,INTERVENTIONAL,['NA']
14994,NCT01771042,Change in whole-body norepinephrine kinetics,Change in muscle sympathetic nerve activity,Change in insulin sensitivity,2013-04,UNKNOWN,INTERVENTIONAL,['NA']
14995,NCT01468519,Change in total International Index of Erectile Function (IIEF) score from baseline to six months,Global assessment question on erectile function,,2012-01,COMPLETED,INTERVENTIONAL,['PHASE4']
14996,NCT06034548,Clinical outcomes - BP,Behavioral outcome - exercise; questions,,2018-08-27,COMPLETED,INTERVENTIONAL,['NA']
14997,NCT01257334,the change from baseline in HbA1c,,,2010-09,UNKNOWN,INTERVENTIONAL,['PHASE3']
14998,NCT05431296,Primary outcome: Percent time spent in glucose target range (3.9-10mmol/L),Audit of Diabetes Dependent Quality of Life questionnaire domain.,"Changes in care, measured by changes in diabetes medication usage.",2023-02-07,RECRUITING,INTERVENTIONAL,['NA']
14999,NCT04098562,Changes of Inflammation Marker at 3 Week,,,2019-10,UNKNOWN,INTERVENTIONAL,['PHASE2']
15000,NCT04864977,Percentage of Participants with Type 2 Diabetes Who Achieve Nadir Glucose in Range 70-125 milligram/deciliter (mg/dL),Percentage of Participants who successfully use Continuous Glucose Monitoring (CGM),,2021-08-16,WITHDRAWN,INTERVENTIONAL,['PHASE4']
15001,NCT04698122,Biological samples collection for establishment of the first National Microbiome Biobank,,,2021-05-27,COMPLETED,OBSERVATIONAL,['NA']
15002,NCT02462369,microalbuminuria improvement in T2DM treated with saxagliptin,incidence of hypoglycaemia of saxagliptin or glimepiride,,2015-06,UNKNOWN,INTERVENTIONAL,['PHASE4']
15003,NCT05145439,Transcutaneous Oxygen Pressure (TcPO2),Ankle Brachial Index (ABI),,2023-01-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
15004,NCT02026024,mean amplitude of glycaemic excursions (MAGE),,,2013-10,COMPLETED,OBSERVATIONAL,['NA']
15005,NCT02919397,Weight (kg),Sleep duration (average hours per night),,2016-10-01,COMPLETED,INTERVENTIONAL,['NA']
15006,NCT05407454,The Diabetes Quality of Life - Brief Clinical Inventory,,,2022-06-07,COMPLETED,OBSERVATIONAL,['NA']
15007,NCT03528811,"Coincidence rate of ""5 points test of Tongji university""",,,2016-08-01,UNKNOWN,INTERVENTIONAL,['PHASE1']
15008,NCT02596204,Change in Hemoglobin A1c,Change in Hemoglobin A1c,,2015-09,COMPLETED,INTERVENTIONAL,['NA']
15009,NCT03406000,Mean change in HbA1c,Number of hypoglycemic events per patient-year,,2018-01-22,COMPLETED,INTERVENTIONAL,['PHASE4']
15010,NCT01607190,CSME needing treatment either photocoagulation or ITV.,"Microaneurysm(MA) activity (number of MA, MA formation and MA disappearance rates and MA turnover)",,2012-11,COMPLETED,OBSERVATIONAL,['NA']
15011,NCT03760965,Change in hemoglobin A1c (HbA1c),Adverse events,,2018-11-27,TERMINATED,INTERVENTIONAL,['PHASE3']
15012,NCT00552994,In stent neointimal hyperplasia,Peri-stent remodeling - Edge response to Cypher Select plus and Xience V stent - Malapposition - Angiographic late lumen loss,,2007-08,COMPLETED,INTERVENTIONAL,['NA']
15013,NCT02106364,Change from Baseline in Hemoglobin A1c (HbA1c) at 26 Week Endpoint,Change from Baseline in Lipid Profile,,2015-02,WITHDRAWN,INTERVENTIONAL,['PHASE3']
15014,NCT02565706,Quantity of Fruit and Vegetable Intake,Response to Survey Items Assessing Knowledge of Area Farmers' Markets,,2014-07,COMPLETED,INTERVENTIONAL,['NA']
15015,NCT02415556,Verbal Memory Composite z Score,Weight (kg).,Cerebral Blood Flow on Magnetic Resonance Imaging (MRI).,2015-10-06,COMPLETED,INTERVENTIONAL,['PHASE2']
15016,NCT05347420,The quantitative Neuropad test,The visual Neuropad test,,2020-08-01,UNKNOWN,OBSERVATIONAL,['NA']
15017,NCT01467414,Area under the glucose infusion rate curve during one dosing interval at steady state,Maximum observed serum insulin degludec concentration at steady state,,2011-10,TERMINATED,INTERVENTIONAL,['PHASE1']
15018,NCT00502008,"Fasting and Post Prandial Blood Glucose, Glycosylated Hemoglobin",Serum Lipid levels,,2005-11,COMPLETED,INTERVENTIONAL,['NA']
15019,NCT03922932,Structural OCT Retinal Thickening Area,,,2017-08-30,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
15020,NCT00226902,Change in pulse wave velocity at the three different haemoglobin levels,,,2006-09,COMPLETED,INTERVENTIONAL,['NA']
15021,NCT01006590,Absolute Change From Baseline in HbA1c at Week 24,Change From Baseline to Week 24 in Beta-cell Function as Measured by Homeostasis Model Assessment-2-beta,,2009-10,COMPLETED,INTERVENTIONAL,['PHASE4']
15022,NCT01375803,Mean changes in blood HbA1c values from baseline to end of study,"Mean changes in total body fat, lean tissue and abdominal fat as determined by DEXA [distribution or absolute changes]",,2009-06,COMPLETED,INTERVENTIONAL,['NA']
15023,NCT06074731,Morphological changes using Swept Source Optical Coherence Tomography,,,2017-06-01,RECRUITING,OBSERVATIONAL,['NA']
15024,NCT01571622,Glucose response,"Insulin GLP-1, GIP and DPP4",,2012-04,COMPLETED,INTERVENTIONAL,['NA']
15025,NCT02617654,"The effect of 52 weeks of treatment with liraglutide 1.8 mg/day, compared to placebo, on stimulated C-peptide concentrations in patients with long-standing type 1 diabetes and residual insulin production",Change in QoL between after and prior to treatment with liraglutide,,2015-11,COMPLETED,INTERVENTIONAL,['PHASE2']
15026,NCT01065766,"Percentage of Participants With an Overall Efficacy Evaluation by the Investigator of Improved, Stable, or Worse at Week 24",,,2009-03,COMPLETED,OBSERVATIONAL,['NA']
15027,NCT03208686,Blood glucose levels,,,2019-04-01,UNKNOWN,INTERVENTIONAL,['NA']
15028,NCT00487240,Change in Hemoglobin A1c (HbA1c) From Baseline to Endpoint,Insulin Dose (Total and By Component [Basal and Bolus]),,2007-06,COMPLETED,INTERVENTIONAL,['PHASE3']
15029,NCT03737188,Analysis of system accuracy based on ISO 15197,,,2018-11-14,COMPLETED,INTERVENTIONAL,['NA']
15030,NCT00237549,"Amputations, non traumatic","Neuropathy, periphery and autonomy",,2001-01,COMPLETED,INTERVENTIONAL,['NA']
15031,NCT00118937,HbA1c - difference between final visit and baseline.,Extra blood- and urine-samples will be stored at -80 degrees Celsius for potential extra analyses after closure of the study. DNA will be stored for later pharmaco-genetic analysis.,,2003-12,COMPLETED,INTERVENTIONAL,['PHASE4']
15032,NCT05231642,Glucose AUC,PAI-1,,2021-11-30,COMPLETED,INTERVENTIONAL,['NA']
15033,NCT00372957,Glucose Weighted Mean AUCs at Baseline (Day -1) and Day 7,Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs),,2006-03-22,COMPLETED,INTERVENTIONAL,['PHASE2']
15034,NCT03785886,Change from Baseline Fasting Blood Glucose at 3 months,Time and Frequency of Adverse Reactions and Serious Adverse Events through the study completion,,2019-03,UNKNOWN,INTERVENTIONAL,['NA']
15035,NCT05394519,Achievement of greater than or equal to (≥) 5% weight reduction,"Number of severe hypoglycaemic episodes (level 3): hypoglycaemia associated with severe cognitive impairment requiring external assistance for recovery, with no specific glucose threshold",,2023-02-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
15036,NCT01739283,plasma glucagon area under curve values,"plasma gut hormones and nutrients (absolute, incremental and area under curve values)",glucose (g/kg body weight) needed to be infuse to keep clamp,2012-07,COMPLETED,INTERVENTIONAL,['NA']
15037,NCT00987662,Reduction of 24h BP and arterial stiffness in obese hypertensives,Drug specific effect on reduction in central fat deposition and the leptin to adiponectin ratio,,2012-01,WITHDRAWN,INTERVENTIONAL,['PHASE4']
15038,NCT02413385,Average steps per day,Body mass index,,2015-05,COMPLETED,INTERVENTIONAL,['NA']
15039,NCT05333185,Blood Glucose Levels,Regulating the Nutrition of Children according to their blood sugar level,,2023-05-01,RECRUITING,INTERVENTIONAL,['NA']
15040,NCT02127762,"Change from baseline in pain-related disability, as measured by the Brief Pain Inventory. Pain interference scale at 3-month post-intervention.","Change from baseline in glycemic control, as measured by blood levels of Hemoglobin A1c.",,2012-09,COMPLETED,INTERVENTIONAL,['NA']
15041,NCT00970593,Change From Baseline in Predose Fasting Glucose Levels at Day 15,,Plasma Concentration Versus Time Summary of Multiple Dose of OAP-189,2009-09-02,COMPLETED,INTERVENTIONAL,['PHASE1']
15042,NCT03590223,occurence of Major adverse cardiac events,mortality,,2017-12-29,COMPLETED,OBSERVATIONAL,['NA']
15043,NCT00121667,Baseline and Change From Baseline in Hemoglobin A1c (A1C) at Week 24,Baseline and Change From Baseline at Week 24 in Postprandial Glucose (PPG) Area Under the Curve (AUC),Confirmed Hypoglycemia During the ST + LT Treatment Period,2005-08,COMPLETED,INTERVENTIONAL,['PHASE3']
15044,NCT00658099,Change in weight,"The satisfaction of physicians who treat the subjects with either insulin detemir or NPH insulin by using 4 questions, which are included in CRF, at the final visit.",,2007-11,COMPLETED,OBSERVATIONAL,['NA']
15045,NCT02723968,Measurement of the sensitivity and the specificity of HOMA-%IR (homeostasis model assessment index of insulin resistance) for the diagnosis of diabetes mellitus in comparison to a continuous glucose monitoring system.,Correlation between IGTT and HbA1C dosage (glycated haemoglobin A1C).,,2009-09,COMPLETED,INTERVENTIONAL,['NA']
15046,NCT00143104,"To assess in patients with type 1 diabetes mellitus the effects, if any, on lung lining, fluid cell count and differential within subjects after 12 weeks of inhaled insulin therapy compared to 12 weeks of subcutaneous short-acting therapy.","(1) Albumin and fibrinogen concentrations, and airway appearance in the above subjects. (2) routine safety, tolerance, and efficacy in the above subjects.",,2004-12,COMPLETED,INTERVENTIONAL,['PHASE2']
15047,NCT02861261,HbA1c,"Inflammation markers (hs-CRP, TNF-alfa, IL-6, and IL-8 etc. in ng/ml)",,2016-08-18,UNKNOWN,INTERVENTIONAL,['PHASE3']
15048,NCT02076542,Change from baseline in diabetes-specific empowerment on the adapted Diabetes Empowerment Scale at the 2-week and 6-month follow-up,Change from baseline in self-care behaviors at the 2-week and 6-month follow-up,,2014-02,COMPLETED,INTERVENTIONAL,['NA']
15049,NCT04123093,Wound Surface Area,Adverse Events - Wound Care Subjects,,2019-08-09,TERMINATED,INTERVENTIONAL,['NA']
15050,NCT01933529,Insulin secretion,Inflammation,Clinical chemistry parameter,2013-10,UNKNOWN,INTERVENTIONAL,['PHASE2']
15051,NCT00793390,breast cancer,,,2008-11-17,COMPLETED,OBSERVATIONAL,['NA']
15052,NCT05413330,Change in diabetic retinopathy grade as a measurement of efficacy,No. of subjects with Adverse Events as a measurement of safety,,2020-09-12,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
15053,NCT04222348,Baby wellness,LBP profile and oxidativge stress as well as in lipid profile,,2016-10-26,UNKNOWN,INTERVENTIONAL,['PHASE3']
15054,NCT00422253,,,,2006-11,COMPLETED,INTERVENTIONAL,['NA']
15055,NCT05596747,Incidence and Severity of Hypoglycemia,PD: Change from Baseline in 7-Point Glucose,,2022-11-30,COMPLETED,INTERVENTIONAL,['PHASE1']
15056,NCT02706821,Fasting and postprandial plasma glucose,Monocyte chemoattractant protein-1 (MCP-1),,2014-02,COMPLETED,INTERVENTIONAL,['NA']
15057,NCT06256419,Genotype identification in patients with T2DM,Incidence and severity of possible adverse reaction within 6 month after GLP-1 RA treatment,,2024-01-01,RECRUITING,INTERVENTIONAL,['NA']
15058,NCT04592107,progression of chronic kidney disease,,,2017-12-12,COMPLETED,OBSERVATIONAL,['NA']
15059,NCT06088615,Accuracy of non-invasive glucose measurement in comparison to invasive glucose measurement,,,2023-11-08,RECRUITING,OBSERVATIONAL,['NA']
15060,NCT02117765,Primary Safety Endpoints (composite outcome measure),Exploratory (composite outcome measure),,2015-03,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
15061,NCT03198832,Probing depth change,Clinical Attachment Level,,2016-05-02,COMPLETED,INTERVENTIONAL,['NA']
15062,NCT02585505,Increase in glucagon stimulated C peptide level,,,2010-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
15063,NCT00327574,the three intervention arms,Cost outcomes: the total cost per intervention and cost per subjects,,2004-06,UNKNOWN,INTERVENTIONAL,['NA']
15064,NCT01206582,Gastric Emptying Half-time,Leukocyte and Platelet Counts,,2010-05,COMPLETED,INTERVENTIONAL,['PHASE2']
15065,NCT03528226,Change in percent flow-mediated dilation (FMD) values,Body composition (DEXA),,2019-11-12,RECRUITING,INTERVENTIONAL,['NA']
15066,NCT00821899,"Evaluate glycosylated hemoglobin 1,3,6, and 12 months after autologous bone marrow blood administration.","Evaluate GADab titers and treatment tolerance 1,3,6, and 12 months after autologous bone marrow blood administration.",,2009-01,COMPLETED,INTERVENTIONAL,['NA']
15067,NCT05135130,"Frequency of wound infection, gangrene, and amputation",,,2021-10-04,UNKNOWN,OBSERVATIONAL,['NA']
15068,NCT02242149,Evidence of improvement in glycemic control and improvement in liver steatosis,Changes of adipocytokines and cytokeratin-18,,2014-10-14,COMPLETED,INTERVENTIONAL,['PHASE3']
15069,NCT01768546,Change from Baseline Weight Measure at Week 16,Change from Baseline Weight Measure at Month 12,,2012-02,COMPLETED,INTERVENTIONAL,['NA']
15070,NCT04835493,HbA1c,Telehealth Acceptability,,2022-09-01,RECRUITING,INTERVENTIONAL,['NA']
15071,NCT02043405,Change in insulin sensitivity,Change in membrane localized diacylglycerol species,,2014-01,COMPLETED,INTERVENTIONAL,['NA']
15072,NCT00658021,Number of Participants With Post-Treatment Adverse Events of Special Interest (AESI) During Safety Follow-up Period,Percentage of Participants Discontinuing the Study Due to Failure to Maintain Glycemic Control Through Week 28,,2008-05-30,COMPLETED,INTERVENTIONAL,['PHASE3']
15073,NCT01206101,Proportion Of Insulin-independent Subjects After Receiving Only One (Single-Donor) Islet Cell Transplant,Glucose Level Variability And Hypoglycaemia Duration Derived From The Continuous Glucose Monitoring System (CGMS),,2012-03-21,TERMINATED,INTERVENTIONAL,['PHASE2']
15074,NCT01241695,postprandial blood glucose (iAUC) (0-240 min),daily compliance,,2010-11,COMPLETED,INTERVENTIONAL,['NA']
15075,NCT01548729,Metabolic efficiency at 1 year,Adverse events,,2012-02-25,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
15076,NCT04958980,Concentration of participants at increased risk for diabetes complications related to increased waist circumference,,,2021-08,UNKNOWN,INTERVENTIONAL,['NA']
15077,NCT03048747,Percentage of Subjects With Normalized Serum Sodium Concentration on the Day After Final IMP Administration,Change in Serum Sodium Concentration,,2017-03-02,COMPLETED,INTERVENTIONAL,['PHASE3']
15078,NCT04466904,To assess the number and incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] of IBI362 compared with placebo,Number of Participants With Anti-IBI362 Antibodies,,2020-09-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
15079,NCT02394314,Number of subjects with Adverse events as a measure of safety and tolerability of MEDI0382,Proportion of subjects with ADA to MEDI0382,,2015-02,COMPLETED,INTERVENTIONAL,['PHASE1']
15080,NCT06284681,Response to weight-neutral health coaching measurement,Change in Metabolic Syndrome Severity Score,Change in Metabolic Syndrome Severity Score,2024-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
15081,NCT05749679,Change in annual glomerular filtration rate (GFR) slope,change of Albuminuria,,2023-07,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
15082,NCT05271864,Oxygen Saturation,Heart rate,,2022-11-01,COMPLETED,OBSERVATIONAL,['NA']
15083,NCT04286399,Combined endpoint based on the first occurrence of cardiovascular death or major adverse cardiovascular event,,,2019-07-01,RECRUITING,INTERVENTIONAL,['PHASE4']
15084,NCT00287066,18F-labeled glucose uptake in muscle,Glucose turnover overnight Insulin pharmacokinetics,,2006-02,TERMINATED,INTERVENTIONAL,['PHASE3']
15085,NCT02006459,plasma Glucagon,"Satiety, hunger, appetite",,2013-09,COMPLETED,OBSERVATIONAL,['NA']
15086,NCT03248271,Nadir of diastolic blood pressure during the Tilt Table Test,Presence or absence of a positive Tilt Table Test (vasovagal syncope),,2017-10-01,WITHDRAWN,OBSERVATIONAL,['NA']
15087,NCT02629952,Improvement in Glucose Tolerance after 4 weeks of drinking blueberry tea.,Improvement in large artery stiffness after 4 weeks of drinking blueberry tea.,,2015-11,UNKNOWN,INTERVENTIONAL,['NA']
15088,NCT03807440,Number of Patients Per Type of Medical Specialty of Other Physicians Involved in Treatment Decision According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist,Time to Discontinuation of Type 2 Diabetes (T2D) Treatment According to Study Medication,,2019-08-26,COMPLETED,OBSERVATIONAL,['NA']
15089,NCT02882945,Test of allelic frequencies,Evaluation of serum CRP(C-reactive protein) levels,,2015-05,COMPLETED,OBSERVATIONAL,['NA']
15090,NCT03923205,AUC for postprandial glucose,Urine glucose concentration,,2019-03-07,UNKNOWN,INTERVENTIONAL,['NA']
15091,NCT02770885,Fluid intake in ml,Thirst perception,,2016-03,COMPLETED,INTERVENTIONAL,['PHASE2']
15092,NCT01724515,Mitochondrial Respiration,Phosphorylation of proteins,,2012-09,COMPLETED,INTERVENTIONAL,['NA']
15093,NCT04801485,the incidence of gestational diabetes,the perinatal outcomes-3,,2021-01-01,COMPLETED,INTERVENTIONAL,['NA']
15094,NCT03330756,glycaemic control,Cardiac / ventricular hypertrophy,,2017-10-23,UNKNOWN,INTERVENTIONAL,['NA']
15095,NCT03250533,Rate of ulcer healing - Digital photography,Bioimpedance,,2017-09-01,UNKNOWN,INTERVENTIONAL,['NA']
15096,NCT00609895,Compare % of subjects with glucose > or = to 56 mg/dL at any point of 8-point glucose profiles during 3 consecutive days,"To evaluate overall safety and tolerability based on adverse event reporting, laboratory tests, and clinical examinations",,2004-01,COMPLETED,INTERVENTIONAL,['PHASE4']
15097,NCT01774981,Part A and Part B: Number of Participants With One or More Treatment Emergent Adverse Events (AEs) or Any Serious AEs,Part B: Change From Baseline in Albuminuria Over Time,,2013-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
15098,NCT02538848,"Incidence, severity and causality of adverse events",,,2015-10,COMPLETED,INTERVENTIONAL,['PHASE1']
15099,NCT02453555,Change of Glycosylated Haemoglobin A1c (Glycosylated Haemoglobin A1c After 24 Weeks of Double-blind Treatment From Baseline),Change in HbA1c From Baseline at Week 52 (Empagliflozin 25 mg/Linagliptin 5 mg Versus All Placebo),,2015-05-14,COMPLETED,INTERVENTIONAL,['PHASE3']
15100,NCT00032864,,,,1997-01,COMPLETED,OBSERVATIONAL,['NA']
15101,NCT01463904,,,,2007-04,UNKNOWN,OBSERVATIONAL,['NA']
15102,NCT02612714,serum testosterone,sexual function evaluation,,2013-07,COMPLETED,INTERVENTIONAL,['PHASE4']
15103,NCT01530789,Percentage of patient using the system,satisfaction level of the telemedecin nurse,,2011-05,TERMINATED,OBSERVATIONAL,['NA']
15104,NCT03112538,between group difference of HbA1c changes from baseline to 6 months,Treatment satisfaction using Diabetes Treatment Satisfaction Questionnaire DTSQs,,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
15105,NCT02687776,myocardial injury in non-cardiac surgery (MINS),composite events composed of all-cause mortality and/or major adverse cardiac and cerebrovascular events (MACCE),,2016-02,UNKNOWN,OBSERVATIONAL,['NA']
15106,NCT02230501,HbA1c,antidiabetic medication,,2011-02,COMPLETED,INTERVENTIONAL,['NA']
15107,NCT01530165,Incidence of Type 2 Diabetes,The impact of city planning on prevalence of obesity and type 2 diabetes,,2011-12,UNKNOWN,INTERVENTIONAL,['NA']
15108,NCT01223547,Change in HbA1c,Weight,,2010-10,COMPLETED,INTERVENTIONAL,['NA']
15109,NCT02163278,Number of Participants With Adverse Events as a Measure of Safety and Tolerability,Pharmacodynamic parameters,,2014-06,COMPLETED,INTERVENTIONAL,['PHASE1']
15110,NCT01426737,Mean amplitude of glycemic excursion as described by Service et al. (1970) calculated from the glucose excursions of the CGMS profiles using MiniMedSolution Software (MedtronicMiniMed).,,,2011-04,UNKNOWN,INTERVENTIONAL,['PHASE4']
15111,NCT00532935,Change From Baseline in A1C at Week 32,Percent of Participants With A1C <7.0% at Week 32,,2008-01-26,COMPLETED,INTERVENTIONAL,['PHASE3']
15112,NCT05258292,Mean glucose levels during the late luteal phase,Total insulin delivery,,2022-05-02,RECRUITING,OBSERVATIONAL,['NA']
15113,NCT01354288,HbA1c 12 months after therapeutic education,Evolution of the parental and child quality of life 12 and 24 months after therapeutic education (evaluated by questionnaire),,2011-12-07,COMPLETED,INTERVENTIONAL,['NA']
15114,NCT00858351,Subjective Pain,Temperature,,2007-11,COMPLETED,INTERVENTIONAL,['NA']
15115,NCT01775878,glycosylated hemoglobin,blood pressure,,2009-05,COMPLETED,INTERVENTIONAL,['NA']
15116,NCT00022750,,,,2000-10,COMPLETED,INTERVENTIONAL,['NA']
15117,NCT05580705,Patient Satisfaction Level,,,2022-09-22,COMPLETED,INTERVENTIONAL,['NA']
15118,NCT01474889,Endogenous Glucose Production,Autonomic Symptom Response to Hypoglycemia,,2011-10,COMPLETED,INTERVENTIONAL,['NA']
15119,NCT04088981,Rate of glycemic control,Body weight,Endothelial function,2024-07,SUSPENDED,INTERVENTIONAL,['NA']
15120,NCT01602913,"Incidence of T2DM defined as having at least 2 diagnostic codes indicating T2DM after the index date, or 1 diagnostic code and 1 prescription of oral anti-diabetic medications or insulin (or Byetta and Victoza) after the index date",,,2011-12,COMPLETED,OBSERVATIONAL,['NA']
15121,NCT02382757,Long-term complications,Percentage of children lost to follow-up,,2011-09,TERMINATED,OBSERVATIONAL,['NA']
15122,NCT03786406,Diagnosed with carotid artery disease,High risk of CVD (above 20% over 10 years) according to the risk engine from the United Kingdom Prospective Diabetes Study (UKPDS),,2018-12-03,COMPLETED,OBSERVATIONAL,['NA']
15123,NCT00139516,,,,2001-09,COMPLETED,INTERVENTIONAL,['NA']
15124,NCT04216303,cause specific mortality from infection/sepsis,,,2019-09-12,WITHDRAWN,OBSERVATIONAL,['NA']
15125,NCT01936025,lowest dose of DXM,additive BG lowering effects,,2013-10,COMPLETED,INTERVENTIONAL,['PHASE2']
15126,NCT00297635,Magnitude of glucose excursions and fluctuations as indicated by the standard deviation between glucose tests to indicate relative glucose control and the mean daily glucose value over the 3 month period following the initiation of pump therapy,Whether use of the technology results in perceived improvement in the quality of care and improved satisfaction for all involved,,2006-03,WITHDRAWN,INTERVENTIONAL,['PHASE2']
15127,NCT01936935,Matsuda Insulin Sensitivity Index (MISI),Plasma high-sensitivity C-reactive protein (hs-CRP),Mean peak postprandial glucose,2012-09,COMPLETED,INTERVENTIONAL,['NA']
15128,NCT00457093,"In the time period 2400 to 0600 hours (the Basal Period) when post-meal food is least likely to affect the glucose level, detect the mean percentage pf time the glucose level is between 70-119 mg/dL","Establish the mean percentage of time spent in the glucose ranges of 40-70 mg/dL, 120-179 mg/dL, 180-240 mg/dL and >240 mg/dL in the Basal Period and for the entire day, and the average glucose for the entire 24 hour period.",,2006-10,COMPLETED,INTERVENTIONAL,['NA']
15129,NCT04982705,Percentage of subejcts with clinically significant change from baseline in safety laboratory test results,Apparent volume of distribution following oral administration (Vd/F),HbA1c level,2021-07-07,RECRUITING,INTERVENTIONAL,['PHASE1']
15130,NCT00276406,Ascending Colon Emptying Half-time (AC t1/2) Measured in Hours,QTc Interval Before and After Treatment,,2006-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
15131,NCT00238524,Investigate the efficacy of lacosamide compared with placebo in reducing pain in subjects with painful distal diabetic neuropathy will be determined by pain score ratings assessed in a patient's diary and at clinic visits.,"Investigate effect of lacosmide on subjects' perception of sleep, activity, quality of life, and safety, determined by rating scales assessed in a patient's diary and at the clinic visits.",,2003-12,COMPLETED,INTERVENTIONAL,['PHASE3']
15132,NCT01221090,HbA1c,Quality of Life (QOL),,2009-01,COMPLETED,INTERVENTIONAL,['PHASE4']
15133,NCT02410499,Change from Baseline in Urinary Albumin-to-Creatinine Ratio (UACR) at Day 85,Change from Baseline in Urinary Protein:Creatinine Ratio (UPCR) Over Time,,2015-05-20,WITHDRAWN,INTERVENTIONAL,['PHASE2']
15134,NCT03258853,Percentage of Time in Glucose Target Range (70-180 mg/dl) as Determined by Continuous Glucose Monitor (CGM) on Days 3-14,Number of Subjects With Time in Range (70-180 mg/dl) of 70% or Greater,,2021-08-26,COMPLETED,INTERVENTIONAL,['NA']
15135,NCT00139763,Will availability of inhaled insulin result in more type 2 diabetes patients choosing a treatment that involves insulin (if now on >2 OAs) or a more intensive insulin regimen (if now on OAs + glargine) compared to only standard therapies available,Determine both patient and MD reasons for treatment choices made. Determine if treatment choice is influenced by physician specialty or patient ethnicity. Determine how cost impacts patient treatment choice.,,2005-07,COMPLETED,INTERVENTIONAL,['PHASE3']
15136,NCT01536236,Visual Analog Scale (VAS),Short Form 36 (SF-36) Quality of Life Questionnaire,,2011-10,WITHDRAWN,INTERVENTIONAL,['NA']
15137,NCT01480843,"Change in Frequency of Hypoglycemia Episodes From Baseline, 5 Months, 8 Months",,,2011-06,COMPLETED,INTERVENTIONAL,['PHASE4']
15138,NCT05096325,Difference in the number of occlusion alarms generated by the new software algorithm compared to the currently implemented occlusion detection system.,Qualitative assessement of the state of the adhesive tapes after study completion,,2022-01-03,COMPLETED,OBSERVATIONAL,['NA']
15139,NCT01536665,Geometric mean glucagon concentration during hypoglycaemia (nadir glucose (target 2.5 mmol/L) ),Time from termination of insulin infusion at nadir to reach plasma glucose 4.0,,2012-02,COMPLETED,INTERVENTIONAL,['PHASE1']
15140,NCT01751321,glucose variability,,,2013-05,UNKNOWN,INTERVENTIONAL,['NA']
15141,NCT00348972,Safety / tolerability: hypoglycemia,Fasting supine levels of counterregulatory hormones,,2002-02,COMPLETED,INTERVENTIONAL,['PHASE1']
15142,NCT04591457,Anti-insulin antibodies (AIAs),Adverse events,,2020-10,UNKNOWN,INTERVENTIONAL,['PHASE2']
15143,NCT03244449,Whole-body glucose disposal,HOMA-IR (Homeostasis Model Assessment - Insulin Resistance),,2014-08-26,COMPLETED,OBSERVATIONAL,['NA']
15144,NCT03590561,Change in brain metabolites,Change in insulin secretion,,2018-06-13,COMPLETED,INTERVENTIONAL,['NA']
15145,NCT03164200,"Respiratory quotient (RQ, a measure of substrate oxidation)",,,2011-12-14,COMPLETED,INTERVENTIONAL,['NA']
15146,NCT01516320,Difference in insulin secretion between groups.,Difference in Body composition between groups,,2009-05-13,COMPLETED,INTERVENTIONAL,['NA']
15147,NCT06119204,Weight loss,EuroQol 5 Dimension 5 Level (EQ-5D),,2024-01-26,RECRUITING,INTERVENTIONAL,['NA']
15148,NCT01582139,Hypoglycemic Events,Time in Range,,2012-05,COMPLETED,INTERVENTIONAL,['NA']
15149,NCT03987191,Time Spent With CGM Glucose Levels >180mg/dl Between Two Groups,Work Productivity and Activity Impairment (WPAI:SHP Version 2 Questionnaire) Between Two Groups,,2020-01-10,COMPLETED,INTERVENTIONAL,['PHASE4']
15150,NCT05752045,Referable Diabetic Retinopathy screening sensitivity/specificity,Laterality determination algorithm accuracy for laterality assessment,,2023-06-28,RECRUITING,INTERVENTIONAL,['NA']
15151,NCT05641337,Compound adverse events,Incidence rate of complications of liver cirrhosis within six months,,2022-10-01,RECRUITING,INTERVENTIONAL,['PHASE3']
15152,NCT03980574,Hospital Readmission Rates,,Serological Assessment,2019-04-01,COMPLETED,INTERVENTIONAL,['NA']
15153,NCT01288144,Rate of screening,,,2007-07,COMPLETED,INTERVENTIONAL,['NA']
15154,NCT01938365,Deterioration of pancreatic islet function,"Insulin dosage, HbA1c levels and evaluation of chronic complications",,2012-01,UNKNOWN,OBSERVATIONAL,['NA']
15155,NCT03063515,First phase insulin response to IV glucose infusion,Glucose excursion after IV glucose infusion,,2017-04-19,COMPLETED,INTERVENTIONAL,['PHASE1']
15156,NCT00240370,Compare change from basline in HbA1c after 24 weeks and 50 weeks of treatment with muraglitazar + metformin vs. pioglitazone + metformin,hs-CRP from baseline to W24,,2003-10,COMPLETED,INTERVENTIONAL,['PHASE3']
15157,NCT01706289,,,,2009-03,UNKNOWN,OBSERVATIONAL,['NA']
15158,NCT03875729,The area under the time-concentration curve (AUC) of C-peptide after a mixed meal tolerance test (MMTT) at Week 78,Incidence and titers of anti-teplizumab antibodies after treatment courses,,2019-04-05,COMPLETED,INTERVENTIONAL,['PHASE3']
15159,NCT05396898,Difference in insulin secretion,Drug concentration/dose ratio,,2020-12-16,COMPLETED,INTERVENTIONAL,['PHASE4']
15160,NCT00458497,Oxygenation levels of blood in the feet will be compared between Holofiber and placebo socks at several time points using standard nonparametric t-test statistics.,,,2007-04,TERMINATED,INTERVENTIONAL,['NA']
15161,NCT03730480,Fingerstick Contour Next BGMS and Contour TV3 Results Compared to the Reference Analyzer,Subjects' Responses to 8 Statements Regarding Experience With Contour Next BGMS and Contour TV3 BGMS,,2018-09-06,COMPLETED,INTERVENTIONAL,['NA']
15162,NCT02081573,Acceptability Questionnaire.,Body Mass Index,,2013-01,COMPLETED,INTERVENTIONAL,['NA']
15163,NCT04258813,Diversity supplement primary outcome: 90-day postoperative cardiovascular complications,Provider-reported care coordination,PCP-reported care coordination,2021-06-14,RECRUITING,INTERVENTIONAL,['NA']
15164,NCT03294044,Success in clinical outcomes of primary disease Diabetes from baseline to 3 months,Quality of life (Euro-QoL),,2017-10-27,COMPLETED,INTERVENTIONAL,['NA']
15165,NCT02328235,Metabolic Flexibility measured ex vivo in skeletal muscle using radio labeled carbon isotopes,Intestinal Permeability using a 4 sugar probe test and mass spectrometry,,2013-01,COMPLETED,INTERVENTIONAL,['NA']
15166,NCT00726440,Comparison of HbA1c mean between the 3 groups,comparison of the sensors consumption in group 1 and 2 and the evolution in time of this consumption,,2008-02,COMPLETED,INTERVENTIONAL,['NA']
15167,NCT03512119,"Measure of 2 hours plasma glucose value (mmol/l) of OGTT, change from baseline at one year of Lumacaftor-Ivacaftor treatment",Number of cures of antibiotics IV and per os /year and interval between 2 cures (week),,2016-02-11,COMPLETED,OBSERVATIONAL,['NA']
15168,NCT03466866,number of incident diabetes-related ED visits and/or hospitalizations,Diabetes self-care behaviors,,2018-12-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
15169,NCT01026675,oral glucose challenge test plasma glucose value,oral glucose challenge test plasma glucose cut-off value,,2009-04,COMPLETED,OBSERVATIONAL,['NA']
15170,NCT02558296,Change in HbA1c From Baseline to Week 24,Change in Systolic Blood Pressure From Baseline to Week 24 in Subjects Hypertensive at Baseline,Proportion of Participants With Incidence of Hospitalization for Heart Failure,2015-10,COMPLETED,INTERVENTIONAL,['PHASE3']
15171,NCT00340132,24-hour metabolic rate,,,1983-01-01,COMPLETED,OBSERVATIONAL,['NA']
15172,NCT03504046,Percent time in glucose range 70-180 mg/dL,Connectivity Analysis (Number of Connection Errors Between devices),,2018-02-28,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
15173,NCT04623567,Change from Baseline Triglyceride at 12 weeks,Change from Baseline TCM Symptom Score at 12 weeks,Compositional and Functional Changes from Baseline Metabolites in blood and feces at 12 weeks,2021-12-22,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
15174,NCT04722991,DRSS improvement ≥2 steps at 48 weeks of treatment in the study eye,Frequency of treatment emergent adverse events,,2021-03-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
15175,NCT04078516,"Diagnostic value of CCM, PTT, AF and MRI",Validation of PainDETECT in diabetes,Exploratory measures,2019-08-12,COMPLETED,OBSERVATIONAL,['NA']
15176,NCT05418946,Variation in glycated hemoglobin (HbA1c) values (% -point) from baseline to 4 months from enrollment,Evaluation of albuminuria (mg/g creatinine),,2022-06,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
15177,NCT01283308,Diabetes Incidence,Program Acceptability,,2009-05,COMPLETED,INTERVENTIONAL,['NA']
15178,NCT03629912,Timed Up and Go (TUG) Test: Change in Dynamic Balance,Diastolic Blood Pressure,,2018-08-13,COMPLETED,INTERVENTIONAL,['NA']
15179,NCT00430742,"Body weight at 36 weeks, HbA1c at 36 weeks","Body weight at 24 and 52 weeks, HbA1c at 24 and 52 weeks",,2006-11,TERMINATED,INTERVENTIONAL,['PHASE3']
15180,NCT02531035,Percentage of Participants With A1C <7.0% at Week 24 and No Episode of Severe Hypoglycemia and No Episode of Diabetic Ketoacidosis (DKA) After Randomization,Percent Change From Baseline in Mean Daily Bolus Insulin Dose,,2015-09,COMPLETED,INTERVENTIONAL,['PHASE3']
15181,NCT05883098,Healing by 12 weeks,Infection rate,,2022-07-01,COMPLETED,INTERVENTIONAL,['NA']
15182,NCT00492700,improvement in steatosis,improvement in transaminase levels; improvement/less worsening in necrosis and inflammatory activity and /or fibrosis,,2003-01,COMPLETED,INTERVENTIONAL,['PHASE2']
15183,NCT03827902,Change in HbA1c,Cost of glycemic management during study,Frequency of hypoglycemic events,2019-07-09,WITHDRAWN,OBSERVATIONAL,['NA']
15184,NCT00491400,Brachial Artery Flow-mediated Dilation,Serum Lipids,,2005-09,TERMINATED,INTERVENTIONAL,['NA']
15185,NCT01840189,nocturnal hypoglycemic events,o Subjective health status,,2013-04-24,TERMINATED,INTERVENTIONAL,['PHASE2']
15186,NCT01594762,Number of Participants With Clinical Response,Number of Participants With Treatment-Emergent Adverse Events (TEAE),,2014-06,COMPLETED,INTERVENTIONAL,['PHASE3']
15187,NCT01232179,no leakage in widefield fluorescin angiography,,,2010-10,UNKNOWN,INTERVENTIONAL,['PHASE2']
15188,NCT03367351,Adherence to CGM,CGM Self-Efficacy,,2018-03-09,COMPLETED,INTERVENTIONAL,['NA']
15189,NCT01887691,change in continuous glucose profile,change in Sleep effectiveness biomarkers,,2012-10,TERMINATED,INTERVENTIONAL,['PHASE1']
15190,NCT05260879,Adoption of the recommended diet and exercise behavior,Reduction in number of participants with hyperglycemia,,2021-11-26,COMPLETED,INTERVENTIONAL,['NA']
15191,NCT04196348,Change in GIP dynamic profile,,,2019-03-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
15192,NCT05515939,Change in Hemoglobin A1c (HbA1c),Clinical Evaluation of Treatment,,2022-09-09,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
15193,NCT00539448,Evaluating the Glycemic control of the regimen : Change in A1C levels,Average daily dose : - For both insulin Glulisine & insulin Glargine. - FBG and PPBG if possible ?,,2007-04,COMPLETED,INTERVENTIONAL,['PHASE4']
15194,NCT02527265,Insulin Maximum Observed Concentration (Cmax),Assessment of Fumaryl Diketopiperazine (FDKP) Elimination Half-life (t1/2),,2017-09-28,COMPLETED,INTERVENTIONAL,['PHASE2']
15195,NCT02664064,% Weight Loss,HbA1c,Program engagement,2016-01,COMPLETED,INTERVENTIONAL,['NA']
15196,NCT05277805,Relational empowerment,,,2020-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
15197,NCT05970601,Effect of a single oral high-sodium chloride load or a partial substitution by potassium chloride on hypoxia-induced dilatation of brachial artery.,Effect of a single oral high-sodium chloride load or a partial substitution by potassium on systemic inflammation markers.,Effect of a single oral high-sodium chloride load or a partial substitution by potassium on metabolomics in stool.,2023-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
15198,NCT02198989,HbA1c,Insulin resistance measured as HOMA-IR,,2014-01,COMPLETED,INTERVENTIONAL,['NA']
15199,NCT02967224,Change in HbA1c (percentage %),Change in fasting plasma glucose,,2015-11-05,COMPLETED,INTERVENTIONAL,['PHASE4']
15200,NCT05737810,Attitudes regarding insulin icodec,,,2023-03-27,COMPLETED,OBSERVATIONAL,['NA']
15201,NCT04990427,Serious Adverse Events,UACR & UPCR,,2022-01-10,COMPLETED,INTERVENTIONAL,['PHASE1']
15202,NCT03155087,the incidence of T2DM,metformin efficacy----the decrease level of HbA1c,,2013-06,COMPLETED,OBSERVATIONAL,['NA']
15203,NCT03711383,Plasma acetate concentrations (microM),"Breath H2 using (Bedfont EC60 Gastrolyzer, Rochester, UK)",,2018-02-20,COMPLETED,INTERVENTIONAL,['NA']
15204,NCT00162240,compare change from baseline in HbA1c after 24 weeks of treatment with muraglitazar + metformin vs placebo + metformin,"change in FPG from basline to W24, proportion of subjects receiving therapeutic response at W24, percent change of fasting lipid levels from baseline to W11/12, change in hs-CRP from baseline to W24",,2003-06,COMPLETED,INTERVENTIONAL,['PHASE3']
15205,NCT02328118,"composite outcome including amotio retinae,vitreous hemorrhage within 12 months after vitrectomy",the change of inflammatory factors in vitreous body,,2015-02,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
15206,NCT05338463,Incidence of treatment-related Adverse Events associated with Fespixon cream,Time to complete ulcer healing,,2021-12-01,COMPLETED,INTERVENTIONAL,['PHASE4']
15207,NCT05426018,Changes of HbA1c compared with baseline at 12 weeks,Blood drug concentration level,,2022-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
15208,NCT00659165,Calories Consumed After Fast.,,,2008-04,COMPLETED,INTERVENTIONAL,['NA']
15209,NCT03292315,Homeostatic Model Assessment of Beta-Cell Function (HOMA-B),Glycated Hemoglobin (HbA1C),,2018-10-16,COMPLETED,INTERVENTIONAL,['PHASE4']
15210,NCT02061969,Mean Fasting Blood Glucose Level,Mortality,,2014-04-25,COMPLETED,INTERVENTIONAL,['PHASE4']
15211,NCT05543265,Rate of primary care provider visit attendance,Rate of patient-reported primary care visit attendance,,2022-11-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
15212,NCT05467514,To assess the effect of liraglutide on carotid intima media thickness in patients with type 1 diabetes mellitus.,"To assess the effect of liraglutide on cardiovascular risk factors, cardiometabolic markers. eGDR (Estimated glucose disposal rate)",,2022-07-01,COMPLETED,INTERVENTIONAL,['PHASE3']
15213,NCT04602650,Fecal Microbial Gene Sequencing,Neurological History Questionnaire,,2021-01-14,COMPLETED,OBSERVATIONAL,['NA']
15214,NCT04131257,Change in the incidence of diabetes among individuals with pre-diabetes,"Change in the ""Adoption at the clinic level""",,2019-12,UNKNOWN,INTERVENTIONAL,['NA']
15215,NCT02772887,Blood pressure,Placental growth factor (PlGF),,2016-08,TERMINATED,INTERVENTIONAL,['NA']
15216,NCT00396851,,,,2007-01,UNKNOWN,INTERVENTIONAL,['NA']
15217,NCT00401453,daily insulin requirements and glycemic control,"c-reactive protein, prostaglandin F2 alpha, cholesterol, HDL and LDL.",,2007-01,COMPLETED,INTERVENTIONAL,['PHASE3']
15218,NCT04811183,Evolution in the adherence,,,2021-06-04,UNKNOWN,OBSERVATIONAL,['NA']
15219,NCT05519501,Percent of subjects with study wound deemed closed at 12 weeks,,,2021-10-10,RECRUITING,INTERVENTIONAL,['NA']
15220,NCT02384889,Number of Participants with Dose Limiting Toxicities,,Changes in Serum Markers of Beta Cell Stress,2015-04,COMPLETED,INTERVENTIONAL,['PHASE1']
15221,NCT00592969,HbA1c,Adverse events,,2003-12-03,COMPLETED,INTERVENTIONAL,['PHASE4']
15222,NCT04741074,Kidney Transplant Eligibility,Receipt of Kidney Transplant,Proportion Experiencing Acute Pancreatitis Events,2021-07-23,TERMINATED,INTERVENTIONAL,['PHASE3']
15223,NCT02497170,Hemoglobin A1c,,,2015-09,COMPLETED,INTERVENTIONAL,['NA']
15224,NCT00105404,,,,2005-03-09,COMPLETED,INTERVENTIONAL,['PHASE3']
15225,NCT05691452,Changes of sit-to-stand transitions,Changes of 24-hour glucose levels assessed by continuous glucose monitors,,2023-01-24,RECRUITING,INTERVENTIONAL,['NA']
15226,NCT01335763,The change in HbA1c from baseline to week 26,Health economic evaluation,,2011-04,COMPLETED,INTERVENTIONAL,['NA']
15227,NCT05360056,Change in DTSQc scores,,,2022-04-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
15228,NCT03496298,Time to First Occurrence of Major Adverse Cardiovascular Events (MACE): Event Rate Per 100 Participant-years for First Occurrence of Major Cardiovascular (CV) Event - Non-Inferiority Analysis,Time to First Occurrence of Composite Renal Endpoint: Event Rate Per 100 Participant-years for First Occurrence of Composite Renal Endpoint,,2018-04-27,TERMINATED,INTERVENTIONAL,['PHASE3']
15229,NCT04073927,Intestinal inflammation,Kidney function,,2019-08-05,UNKNOWN,INTERVENTIONAL,['NA']
15230,NCT05400525,Changes in immune response,Dietary Habits,,2022-06-15,COMPLETED,INTERVENTIONAL,['NA']
15231,NCT01167231,"Safety, tolerability of acarbose and its effect on body weight, waist circumference and blood pressure","Effect of acarbose on HbA1c, fasting and postprandial glycemia and on lipid profile",,2007-05,COMPLETED,OBSERVATIONAL,['NA']
15232,NCT05543967,Longitudinal changes of odor-induced brain fMRI activation,Longitudinal changes of functional MRI scan,,2022-10-18,RECRUITING,OBSERVATIONAL,['NA']
15233,NCT05916729,Presence of Candida albicans after therapy at fourth reexamination,,,2021-05-01,RECRUITING,INTERVENTIONAL,['PHASE4']
15234,NCT03964428,hepicidin concentration,,,2018-09-01,COMPLETED,OBSERVATIONAL,['NA']
15235,NCT03348280,Renin production by monocytes,Renin production by monocyte media,,2017-09-01,RECRUITING,OBSERVATIONAL,['NA']
15236,NCT03360058,"Measure the effectiveness of an online training programme, practice implementation toolkit and face to face training for primary care staff",Training uptake,,2017-10-07,COMPLETED,INTERVENTIONAL,['NA']
15237,NCT04445181,Proportion of patients with CKD in a large T2D population,"Proportion of healthcare provider prescriptions of SGLT2i used to treat glycemia management, hypertension, heart failure, coronary artery disease, CKD or other condition",,2020-07-01,COMPLETED,OBSERVATIONAL,['NA']
15238,NCT03656744,Absolute Change in Liver Fat Content (LFC) as Measured by MRI-PDFF,Number of Participants Reporting an Adverse Events From Baseline Through Week 18,,2018-11-26,COMPLETED,INTERVENTIONAL,['PHASE2']
15239,NCT01786421,Determination of diurnal triglyceridemia depend on alcohol intake,Gender differences in diurnal triglyceridemia by alcohol consumption,,na,COMPLETED,OBSERVATIONAL,['NA']
15240,NCT05543434,Clinical attachment level gain,Radiographic Evaluation,,2022-12-01,RECRUITING,INTERVENTIONAL,['NA']
15241,NCT05933018,to evaluate presence of fatty liver in type 1 diabetes,presence of metabolic syndrome in type 1 Diabetes Mellitus,,2023-01-15,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
15242,NCT05564728,Qualitative perspective on a conversational agent/chatbot app usage experience among patients and carers at the end of the trial (1 month).,Usability of a conversational agent/chatbot among patients and carers at the end of the trial (1 month).,,2023-06-23,COMPLETED,OBSERVATIONAL,['NA']
15243,NCT02583438,gut microbiota,The change of inflammatory markers,,2015-10,UNKNOWN,INTERVENTIONAL,['PHASE4']
15244,NCT00813215,Incremental AUC og the triglyceride response,Gene expression of genes involved in lipid metabolism and inflammation,,2009-01,UNKNOWN,INTERVENTIONAL,['NA']
15245,NCT02119572,"Change from Baseline HbA1c at 6 months,12 months",cost,,na,UNKNOWN,INTERVENTIONAL,['NA']
15246,NCT02225457,Change from baseline in insulin sensitivity,Change from baseline in muscle and adipose tissue gene expression,,2013-12,UNKNOWN,INTERVENTIONAL,['NA']
15247,NCT01461577,Efficacy assessment of insulin glargine measured by changes of HbA1c levels from baseline,Number of patients with treatment-emergent adverse events,,2011-11,COMPLETED,INTERVENTIONAL,['PHASE4']
15248,NCT05801627,HbA1c change from baseline at week 24,eatic β-cell function change (calculated by HOMA-β ) from baseline at week 24 and week 52,,2020-05-06,COMPLETED,INTERVENTIONAL,['PHASE3']
15249,NCT03925909,Rate of change in microbiome,Rate of change in plasma glucose concentration,,2019-05-01,TERMINATED,INTERVENTIONAL,['NA']
15250,NCT05305794,Percentage of time spent within glycemic target range (0.70-1.80 g/l),,,2022-07-12,RECRUITING,INTERVENTIONAL,['PHASE3']
15251,NCT05501093,Bacterial composition,Gingival inflammation,,2019-03-11,RECRUITING,OBSERVATIONAL,['NA']
15252,NCT01272219,Proportion of Subjects With Onset of Type 2 Diabetes,Change From Baseline in Fasting Body Weight (%) (Re-randomised Subjects With No Pre-diabetes),,2011-06-01,COMPLETED,INTERVENTIONAL,['PHASE3']
15253,NCT05804565,Power Calculation for Definitive RTC,Patient-Reported Quality of Life,,2023-01-01,RECRUITING,INTERVENTIONAL,['NA']
15254,NCT06316544,admission to ICU,,,2023-03-01,RECRUITING,OBSERVATIONAL,['NA']
15255,NCT01881074,Local Inflammatory Markers,Systemic Inflammatory Markers,,2012-06,COMPLETED,OBSERVATIONAL,['NA']
15256,NCT03830840,"Success (evaluated by Yes/No format) recruiting and establishing an observational cohort of 1,000 Latino families with at least one family member living with type 2 diabetes by deploying the methods proven feasible by Mil Familias Operational Pilot.",National survey of children's health (NSCH) for all children and youth,Physical activity measured by two wearable physical activity monitors for 1 week,2019-02-01,COMPLETED,OBSERVATIONAL,['NA']
15257,NCT00005754,Progression of coronary artery calcification,,,1999-09,COMPLETED,OBSERVATIONAL,['NA']
15258,NCT03644238,Blood glucose,,,2017-08-21,COMPLETED,INTERVENTIONAL,['NA']
15259,NCT01002209,Time to complete healing of operative wounds,"HBO complications (confinement anxiety, barotrauma, oxygen convulsions)",,2019-10,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
15260,NCT05222633,Central subfield thickness,,,2022-01-01,UNKNOWN,OBSERVATIONAL,['NA']
15261,NCT02022254,Area under the R-warfarin plasma concentration-time curve,Incremental area under the INR (international normalised ratio) -curve,,2013-12-17,COMPLETED,INTERVENTIONAL,['PHASE1']
15262,NCT00322478,Patient Satisfaction,Standard Deviation of A1c and SMBG,,2006-04,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
15263,NCT05706298,Change in time in target glycaemic range,Change in carbohydrate intake,,2022-12-07,RECRUITING,INTERVENTIONAL,['NA']
15264,NCT05274009,Core temperature (AUC),Change in plasma volume,,2023-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
15265,NCT02783196,Clock Gene expression,Overall glycemia,,2016-07,UNKNOWN,INTERVENTIONAL,['NA']
15266,NCT04280315,TEWL,Sebum content in skin,,2020-02-18,COMPLETED,OBSERVATIONAL,['NA']
15267,NCT03583593,Time of healing,Insulin control,,2014-05-23,COMPLETED,INTERVENTIONAL,['PHASE2']
15268,NCT03817463,"Number of participants with myocardial infraction (MI), stroke, all cause mortality",Cost of care,,2019-04-15,COMPLETED,OBSERVATIONAL,['NA']
15269,NCT04666636,Change in glycohemoglobin,,,2020-12-07,RECRUITING,INTERVENTIONAL,['PHASE2']
15270,NCT00597545,Number of Participants With Improved Neuropsychometric Changes,,,2007-03,TERMINATED,INTERVENTIONAL,['NA']
15271,NCT06060392,Change in liver fat content,Change in LDL-cholesterol,,2023-10-30,RECRUITING,INTERVENTIONAL,['NA']
15272,NCT01433419,Adverse events,,,2012-01,COMPLETED,INTERVENTIONAL,['PHASE3']
15273,NCT05429229,Change from baseline in lipoperoxides levels in tear film at 30 days.,Change from baseline in tear secretion in mm with Schirmer I test at 30 days.,Change from baseline severity of dry eye symptoms according the punctuation in Ocular Surface Disease Index (OSDI) at 30 days,2021-11-01,RECRUITING,INTERVENTIONAL,['PHASE2']
15274,NCT02530840,Diabetes Control as Expressed by the Change in HbA1c %,,,2014-07,UNKNOWN,INTERVENTIONAL,['NA']
15275,NCT01772446,Compare the percentage of patients in the intervention group versus the control group who get a HbA1c below 7%,"Evaluate whether the intervention is more effective (reducing HbA1c below 7%) in patients with predictive risk index <1.5, or in patients with predictive risk index> 1.5.",,2013-06,COMPLETED,INTERVENTIONAL,['NA']
15276,NCT02325193,"average AUC/day in hypoglycaemic range < 70mg/dl (3,9mmo/l)",Number of PLGM activities,,2015-03,COMPLETED,OBSERVATIONAL,['NA']
15277,NCT02284425,Incidence and severity of treatment emergent adverse events (TEAEs),Concentration of REGN1193 in serum over time,,2014-10,TERMINATED,INTERVENTIONAL,['PHASE1']
15278,NCT00729898,"Incidence of serious adverse drug reactions, including major hypoglycaemic events",Weight changes,,2008-03,COMPLETED,OBSERVATIONAL,['NA']
15279,NCT01177709,Weight (wt) in Pounds (Lbs)..,Insulin Level,,2008-05,TERMINATED,INTERVENTIONAL,['NA']
15280,NCT06176495,Percentage change in glycemic control determined by HbA1C (in percent) in participants with diabetes pre and post intervention.,Assessment of Changes in Anxiety Screening score (in percentage pre and post intervention),,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
15281,NCT05852626,Number of patients who achieved individualized target HbA1c,Foot evaluation,,2023-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
15282,NCT03179332,AUCGIR(0-60min),Clinical safety laboratory,,2017-06-20,COMPLETED,INTERVENTIONAL,['PHASE1']
15283,NCT01861860,The incidence of MACE composite criteria among patients who received a TAXUS long stent deployed using IVUS according to the OPERA criteria according to the LPPR during a 12 months period after inclusion in the trial.,Medico-economics data at 12 months including,,2012-10,COMPLETED,INTERVENTIONAL,['NA']
15284,NCT03390322,Incidence of procedure related SAEs.,Change to HbA1c levels,,2017-07-28,RECRUITING,INTERVENTIONAL,['NA']
15285,NCT04469270,Efficacy of Engensis compared to Placebo on painful DPN in the feet and lower legs comparing the Average Daily Pain Score from the Day 0 Visit to the Day 180 Visit on the Brief Pain Inventory for Participants with Diabetic Peripheral Neuropathy,To evaluate the possibility of humoral responses to Engensis,"To determine whether IM administration of Engensis has the potential for improving quality of life, sensation, proprioception, and deep tendon reflexes by measuring the improvement in Bedside Sensory Testing at Day 180 compared to Baseline",2020-10-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
15286,NCT05254002,"Mean ratio of change from baseline to Day 180 in UACR for the combination therapy group, to finerenone alone",Total number of urosepsis and pyelonephritis events,,2022-06-23,RECRUITING,INTERVENTIONAL,['PHASE2']
15287,NCT01469559,Hypoglycemia monitoring,Short Form-36 (SF-36) Quality of life scale,,2011-08,COMPLETED,INTERVENTIONAL,['PHASE2']
15288,NCT01613755,Peak plasma concentration (Cmax) of metformin,,,2012-04,COMPLETED,INTERVENTIONAL,['PHASE4']
15289,NCT05502562,Change in Glycated haemoglobin A1c (HbA1c),HbA1c reduction greater than or equal to (>=) 1%-points and body weight reduction of greater than or equal to (>=) 3%,,2023-02-24,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
15290,NCT01609881,"Vitreous and anterior chamber levels of prostaglandins, other cytokines, and Acuvail",Secondary Outcome,,2012-03,WITHDRAWN,INTERVENTIONAL,['PHASE1']
15291,NCT05241262,Maximum tolerated dose (MTD) of NAC,Change in Brain glutathione (GSH) level,,2023-04,RECRUITING,INTERVENTIONAL,['PHASE1']
15292,NCT00608179,catecholamines,,,2002-08,COMPLETED,INTERVENTIONAL,['NA']
15293,NCT01434862,Percent of Blood glucose tests within target range of 70 to 180 mg/dl,Percent of Continuous Glucose Monitoring (CGM) System estimated blood glucose within target range of 70 to 180 mg/dl,,2011-02,TERMINATED,INTERVENTIONAL,['NA']
15294,NCT02939768,Mitochondrial superoxide dismutase (MnSOD) activity,,,2016-08,COMPLETED,INTERVENTIONAL,['NA']
15295,NCT02074540,Insulin adherence,,,2014-04,UNKNOWN,OBSERVATIONAL,['NA']
15296,NCT00069446,Incidence of clinically significant hypotension.,Percent reduction in total ulcer surface area.,,2003-08,COMPLETED,INTERVENTIONAL,['PHASE1']
15297,NCT05134987,"AUCPG,0.5-2h Area under the plasma glucose-time curve at steady concentrations",Number of adverse events,,2021-12-01,COMPLETED,INTERVENTIONAL,['PHASE1']
15298,NCT00321256,and 12 months following transplantation.,Morbidity and quality of life will also be assessed.,,2003-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
15299,NCT04991168,Number of missing and decayed teeth on the oral examination and clinical signs in diabetology.,,,2021-09-01,UNKNOWN,OBSERVATIONAL,['NA']
15300,NCT00142974,Reduction in weekly mean of a daily composite diabetic gastropathy dyspeptic symptom severity score throughout 6 weeks of treatment.,"Weekly mean severity of individual dyspeptic symptoms (nausea, vomiting, retching, epigastric/stomach, discomfort/pain, postprandial fullness, bloating, early satiety).",,2004-05,TERMINATED,INTERVENTIONAL,['PHASE2']
15301,NCT02218138,Homeostasis model assessment of insulin resistance,Center for Epidemiological Studies-Depression Scale,,2013-01,COMPLETED,INTERVENTIONAL,['NA']
15302,NCT03520153,Hepatic glucose fluxes (gluconeogenesis and glycogenolysis),Tumor necrosis factor alpha (TNF-alpha),Maturity-Onset Diabetes of Young (MODY) genetic testing,2018-08-07,WITHDRAWN,OBSERVATIONAL,['NA']
15303,NCT01704261,Percentage of Participants Who Discontinued From the Study Due to an AE,Percentage of Participants Attaining A1C Glycemic Goals of <7% and <6.5% at Week 24,,2012-10-18,COMPLETED,INTERVENTIONAL,['PHASE3']
15304,NCT05892341,Effectiveness of AQUACEL® Ag+ Extra™ and Cutimed® Sorbact® on wound management,Safety assesment,Quality of Life assesment,2022-12-05,COMPLETED,INTERVENTIONAL,['NA']
15305,NCT05585190,Insulin sensitivity (HOMA-IR),vascular endothelial function (superficial femoral and brachial arteries) and resilience to a high-glucose load,Acceptability Questionnaire,2023-02-06,RECRUITING,INTERVENTIONAL,['NA']
15306,NCT02999867,response to the dietary intervention by the change from baseline in insulin resistance at 30-day,response to the dietary intervention by the change from baseline in iron absorption at 30-day,,2017-03-01,COMPLETED,INTERVENTIONAL,['NA']
15307,NCT03758144,change in glycemic control,Gastrointestinal symptom questionnaire,change in weight,2018-11-01,UNKNOWN,INTERVENTIONAL,['NA']
15308,NCT06293417,major adverse cardiovascular events and diabetic microvascular events for 48 months,change in TC/HDL-C ratio at 48month from baseline,,2024-03-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
15309,NCT00707954,"Safety: Adverse Events, Adverse Drug Reactions",Pharmacodynamics- 1)Urinary Glucose Excretion; 2)Plasma Glucose Concentration; 3)Insulin Concentration in Serum; 4)Insulinogenic Index;and 5)Hemoglobin A1c and Glycoalbumin,,2008-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
15310,NCT00474838,Change of pancreatic beta cell function,Time to reach target goal of blood glucose level,,2007-04,COMPLETED,INTERVENTIONAL,['PHASE4']
15311,NCT02910089,Glycosylated Hemoglobin (HbA1c):,Patients Achieving HbA1c,,2016-10-20,COMPLETED,INTERVENTIONAL,['PHASE4']
15312,NCT01148862,The Primary Treatment Comparison is the Evaluation of the Severity (Milligrams Per Deciliter) of Induced Hypoglycemia.,,,2010-06,COMPLETED,INTERVENTIONAL,['NA']
15313,NCT00737763,The primary endpoint for this study will be the difference from baseline in the body's ability to respond to a Mixed Meal Tolerance Test at 12 months after enrollment.,,,2008-10,WITHDRAWN,INTERVENTIONAL,['PHASE2']
15314,NCT02169050,Oral Glucose Insulin Sensitivity (OGIS),Inflammatory markers in plasma,,2011-05,COMPLETED,OBSERVATIONAL,['NA']
15315,NCT01269580,post revascularization cardiovascualr mortality,post revascularization amputation,post revascularization restenosis,2009-02,UNKNOWN,OBSERVATIONAL,['NA']
15316,NCT00198146,"Area under the curve, Glucagon Stimulation Testing for c-peptide measurements at 0, +6min and +10min intervals over 2 years",Insulin requirements (units/kg/day),,2000-07,COMPLETED,INTERVENTIONAL,['PHASE2']
15317,NCT03313661,The level of fasting and post prandial BG level,,,2017-10-14,UNKNOWN,INTERVENTIONAL,['PHASE3']
15318,NCT04841291,The number of participants who believed in the practicality of the virtual simulation-based foot care education.,The participants' level of foot self-care efficacy to perform recommended diabetic foot self-care activities.,,2022-01-25,RECRUITING,INTERVENTIONAL,['NA']
15319,NCT04334109,"Change in mean HbA1c (NGSP%) from baseline to immediate post-intervention, 6 months post-intervention, 12 months post-intervention, and 18 months post-intervention","Change in diabetes-related quality of life from baseline to immediate post-intervention, 6 months post-intervention, and 12 months post-intervention",,2021-01-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
15320,NCT01531114,the superiority antiplatelet effect in terms of PR level of loading dose (LD) of Prasugrel (60 mg) versus LD of Ticagrelor (180 mg) in diabetic patients with STEMI undergoing primary PCI at 2 hours post drug administration.,PR level measured at 6 and 12 hours post study drugs administration.,,2013-05,COMPLETED,INTERVENTIONAL,['PHASE3']
15321,NCT04715776,"From baseline to 3 months after using dietary supplements (compare yourself with yourself), follow up for a total of 12 months",,,2018-12-10,UNKNOWN,INTERVENTIONAL,['NA']
15322,NCT01260337,Change in weight at 3 and 6 months,Change in HbA1C at 3 and 6 months,,2010-03,COMPLETED,INTERVENTIONAL,['NA']
15323,NCT04982575,Change in Glycated Haemoglobin (HbA1c): Cagrilintide 2.4 mg + Semaglutide 2.4 mg Versus Semaglutide 2.4 mg + Placebo (Cagrilintide),"Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (Below 3.0mmol/L (54mg/dL), Confirmed by BG Meter) or Severe Hypoglycaemic Episodes (Level 3)",,2021-08-02,COMPLETED,INTERVENTIONAL,['PHASE2']
15324,NCT04743778,Regimen Adherence,Diabetes Quality of Life,,2021-08-01,COMPLETED,INTERVENTIONAL,['NA']
15325,NCT06104969,Standard of Care Adherence,Change from baseline to later of Week 52 or Confirmation Visit in PROMIS Sleep Disturbance,,2023-06-15,RECRUITING,OBSERVATIONAL,['NA']
15326,NCT03673904,statistical significant elevation of high sensitive CRP in diabetics and prediabetes,,,2017-01-01,COMPLETED,OBSERVATIONAL,['NA']
15327,NCT01006057,Area under the insulin degludec concentration-time curve,Renal clearance of insulin degludec after single-dose,,2009-11,COMPLETED,INTERVENTIONAL,['PHASE1']
15328,NCT04387058,the cumulative incidence,,,2019-06-16,UNKNOWN,INTERVENTIONAL,['NA']
15329,NCT03702374,Changes in concentration of total antioxidant capacity (TAC) after intervention from baseline.,Diabetic retinopathy severity progress at the end of intervention from baseline,,2018-09-26,COMPLETED,INTERVENTIONAL,['PHASE3']
15330,NCT02681588,birthweight,,,2010-07,COMPLETED,INTERVENTIONAL,['NA']
15331,NCT02741674,Reoperation/Rehospitalization Rate,Composite Adverse Event,,2016-02,COMPLETED,OBSERVATIONAL,['NA']
15332,NCT01991093,Multiple electrode aggregometry in detection of clopidogrel resistance,,,2014-06,COMPLETED,OBSERVATIONAL,['NA']
15333,NCT03881540,Change in Glycated haemoglobin (A1C),Change in exercise minutes,,2014-06,COMPLETED,INTERVENTIONAL,['NA']
15334,NCT05471986,Sensitivity and Specificity of EyeCheckup to detect vision-threatening diabetic retinopathy,Negative Predictive Value,,2024-08-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
15335,NCT02268929,The mean HbA1c change by Generalized Estimating Equations (GEE) methods,Effects of integrated Personalized Diabetes Management (PDM) by means of Generalized Estimating Equations [GEE] methods,,2014-10-14,COMPLETED,INTERVENTIONAL,['NA']
15336,NCT04753294,Change in wound progress,Wear time,,2021-06-14,COMPLETED,INTERVENTIONAL,['NA']
15337,NCT03463629,Change in glucose level as indicated by HbA1c levels,Change in blood pressure,Glucose level as indicated by HbA1c levels,2018-03-21,COMPLETED,INTERVENTIONAL,['NA']
15338,NCT02477969,HbA1c,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,,2014-02-27,UNKNOWN,INTERVENTIONAL,['PHASE3']
15339,NCT03350984,Differences in the Mean Daily Blood Glucose Between a Basal-bolus Scheme and NPH Schemes of Insulin.,Number of Participants With Sustained Glycemic Control During Hospital Stay,,2017-11-02,COMPLETED,INTERVENTIONAL,['PHASE4']
15340,NCT02482584,Change in arterial stiffness measured by office carotid-femoral pulse wave velocity (cf-PWV) from start to end of 12 weeks intervention,Change from start to end of 13 weeks intervention in insulin sensitivity measured by hyperinsulinemic euglycemic clamp,,2015-04,UNKNOWN,INTERVENTIONAL,['NA']
15341,NCT04682795,Time In Range,Insulin dose,Insulin treatment compliance,2021-09-01,UNKNOWN,INTERVENTIONAL,['NA']
15342,NCT00428532,,,,2007-03,UNKNOWN,INTERVENTIONAL,['NA']
15343,NCT00960635,,,,2001-06,COMPLETED,INTERVENTIONAL,['PHASE2']
15344,NCT04617275,Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity,CFB in Body Weight at Week 12 (Non-diabetic Participants With Obesity),,2021-01-06,COMPLETED,INTERVENTIONAL,['PHASE2']
15345,NCT05525364,Variables of interests - Blood glucose and hyperglycemia data,,,2019-06-20,COMPLETED,OBSERVATIONAL,['NA']
15346,NCT02609633,Change From Baseline in Diabetes-Related Distress Among Parents/Caregivers According to the Problem Areas in Diabetes (PAID) Child and Teen (C&T) Parent Questionnaire Score at Month 6,Percentage of Participants With Overall Treatment Satisfaction With the Use of Accu-Chek® CONNECT Diabetes Management System According to a Questionnaire,,2015-12-28,COMPLETED,INTERVENTIONAL,['NA']
15347,NCT05186519,All non-traumatic amputate events,Length of stay in hospital,,2015-01-01,COMPLETED,OBSERVATIONAL,['NA']
15348,NCT05681533,Epicardial fat volume,,,2021-03-31,RECRUITING,OBSERVATIONAL,['NA']
15349,NCT06264427,Number of participants with obstructive sleep apnea,CPAP treatment effect on daytime sleepiness measured with the functional outcome of sleep questionnaire (FOSQ-10).,,2022-07-15,RECRUITING,INTERVENTIONAL,['NA']
15350,NCT01838083,Area under the serum insulin concentration curve within 24 hours (INS-AUC0-24) after dosing on Day 6,"Safety as measured by adverse events/serious adverse events, ohypoglycemia events, physical examinations, clinical laboratory, electrocardiograms, vital signs, injection site reactions and anti-insulin antibodies.",,2013-04,COMPLETED,INTERVENTIONAL,['PHASE1']
15351,NCT05102071,Occurrence of first hospitalization for congestive heart failure (HHF),All cause cost,,2021-11-01,WITHDRAWN,OBSERVATIONAL,['NA']
15352,NCT03022721,Development of diabetic complications,,,2016-09,RECRUITING,OBSERVATIONAL,['NA']
15353,NCT00795691,Change in Body Weight at month 12,Quality of life as assessed using the Diabetes Quality of Life Scale at month 12,,2004-05,COMPLETED,INTERVENTIONAL,['NA']
15354,NCT00948584,The primary objective was to compare the mean changes of A1C from baseline to end point between two groups.,Secondary objectives included the proportion of patients to achieve A1C level below 7.0%; incidence of hypoglycemic episodes; change in body weight; and insulin dose.,,2007-11,COMPLETED,INTERVENTIONAL,['NA']
15355,NCT02162407,Steady state glucose infusion rate (GIR) / interstitial insulin steady state concentration,Insulin concentration profiles,,1999-10,COMPLETED,INTERVENTIONAL,['PHASE1']
15356,NCT00440440,Mean absolute change in visceral adipose tissue mass in type 2 diabetic subjects with hypogonadism after 6 months of androgel therapy.,Mean absolute change in spine BMC and lumbar spine (L1-L4) BMD,,2009-08,WITHDRAWN,INTERVENTIONAL,['PHASE4']
15357,NCT05689658,Minutes of Moderate Physical activity,Glycemia,,2023-03-15,COMPLETED,INTERVENTIONAL,['NA']
15358,NCT02811055,Difference from baseline in Plasma aldosterone concentration,Difference from baseline in HOMA index,,2017-07-13,UNKNOWN,INTERVENTIONAL,['PHASE2']
15359,NCT05147194,Ratio of UACR levels at 6 months to baseline UACR,Ratio of UACR levels at 1 months to baseline UACR,,2022-01-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
15360,NCT00824395,,,,2006-01,WITHDRAWN,OBSERVATIONAL,['NA']
15361,NCT03222284,Device usability as assessed by the System Usability Scale (SUS),,,2017-07-17,UNKNOWN,INTERVENTIONAL,['NA']
15362,NCT01492166,Change in prandial glucose increment (PGI),Occurrence of Adverse Drug Reactions (ADR),,2006-11,COMPLETED,OBSERVATIONAL,['NA']
15363,NCT00878605,Hemoglobin A1C,,,2010-04-01,TERMINATED,INTERVENTIONAL,['PHASE2']
15364,NCT02889172,Beck Depression Inventory,Simplified Medication Adherence Questionnaire,,2015-02,TERMINATED,INTERVENTIONAL,['NA']
15365,NCT00812032,An exploratory study with three co-primary response variables which are directly related to platelet COX-1 inhibition: arachidonic acid-induced platelet aggregation in whole blood and PRP and in the Cone-and-Plate(let) Assay (CPA),"Indirectly COX-related platelet aggregation induced by collagen or ADP, and thromboxane metabolite excretion.",,2008-01,COMPLETED,INTERVENTIONAL,['PHASE4']
15366,NCT03368209,Calibration models for device predictive purposes,,,2015-12-04,TERMINATED,INTERVENTIONAL,['NA']
15367,NCT05894746,Amino acid metabolism,Fibrinogen,multiomics explorative analyses,2023-05-04,RECRUITING,INTERVENTIONAL,['NA']
15368,NCT00570154,,,,2007-11-27,COMPLETED,OBSERVATIONAL,['NA']
15369,NCT00358254,,,,2004-10,COMPLETED,OBSERVATIONAL,['NA']
15370,NCT05308836,Safety measure,Insulin dose,,2021-10-04,UNKNOWN,INTERVENTIONAL,['PHASE1']
15371,NCT01892319,"Proportion of pregnancies (Levemir® treatment), compared to pregnancies (other basal insulin treatment regimens), resulting in none of the following events: Major congenital malformations, Perinatal death, Neonatal death",Proportion with changes (progression/regression) of major congenital malformations,,2013-09-30,COMPLETED,OBSERVATIONAL,['NA']
15372,NCT02220036,Serum creatinine,high sensitive C-Reactive Protein,,2014-06,UNKNOWN,INTERVENTIONAL,['NA']
15373,NCT04707157,Change From Baseline in Average Pain Intensity as Measured by the Numeric Rating Scale (NRS),Change From Baseline on the EuroQuality of Life Five Dimensions (5D) Five Level (5L) Questionnaire (EQ-5D-5L) Health State Index (United States Algorithm),,2021-05-06,TERMINATED,INTERVENTIONAL,['PHASE2']
15374,NCT05645419,Number of Participants with myocardial infarction,,,2023-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
15375,NCT04625088,Time course change in plasma HISS levels,Time course change in Meal Induced Glycemia (MIG) scores (Molar Units),,2021-03-01,COMPLETED,INTERVENTIONAL,['NA']
15376,NCT04430946,Gut peptide hormone responses,Meal induced thermogenesis,,2020-08-25,RECRUITING,INTERVENTIONAL,['NA']
15377,NCT01223131,Absolute change of glycosylated hemoglobin (HbA1c),Anti-glargine and anti-human insulin antibody assessment,,2011-02,COMPLETED,INTERVENTIONAL,['PHASE3']
15378,NCT01545570,"pharmacokinetic parameters of GSK2374697, after ascending single or titrated multiple subcutaneous doses, in healthy subjects",dose proportionality of GSK2374697,,2011-11-07,COMPLETED,INTERVENTIONAL,['PHASE1']
15379,NCT02498119,"Composite measure of patient physical observations to include weight, height and BMI",The effect of LTB4 and LTC4 of eicosanoids,,2014-11,UNKNOWN,OBSERVATIONAL,['NA']
15380,NCT05409924,Safety analyses after multiple doses of ATR-258,PK analyses will be performed after PK of ATR-258 multiple dose,,2022-04-11,COMPLETED,INTERVENTIONAL,['PHASE1']
15381,NCT04259801,Number of treatment emergent adverse events (TEAE) in Part 2,The maximum concentration of semaglutide after administration of the 12th dose of semaglutide,,2020-02-17,COMPLETED,INTERVENTIONAL,['PHASE1']
15382,NCT05980026,change in UACR (mg/g creatinine) level,change in HbA1c(%),,2022-01-10,COMPLETED,INTERVENTIONAL,['NA']
15383,NCT05430061,Gastric half emptying time,Height and Weight,,2017-07-27,COMPLETED,INTERVENTIONAL,['NA']
15384,NCT01954459,Point accuracy of the continuous glucose monitor plus Insupatch (CGM+IP) by mean absolute relative difference (MARD) calculation of sensors with and without IP use.,,,2013-09,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1']
15385,NCT01277471,Change in Insulin Resistance,Oxidative stress markers and AGEs,,2010-12,COMPLETED,INTERVENTIONAL,['NA']
15386,NCT02303730,Change in liver fat content（%） measured by MRS,"Change in body weight,waist circumference and hip circumference",Incidence of adverse events（AEs）and Severe adverse events(SAEs),2015-03,COMPLETED,INTERVENTIONAL,['PHASE4']
15387,NCT00422955,Change in transcapillary escape rate of L125 albumin following 16 weeks treatment,"Change in plasma volume, pedal oedema, extracellular fluid volume following 16 weeks treatment.",,2003-11,COMPLETED,INTERVENTIONAL,['PHASE3']
15388,NCT01098539,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26,Plasma Concentrations (Conc.) of Albiglutide at Week 8 and Week 16,,2010-05,COMPLETED,INTERVENTIONAL,['PHASE3']
15389,NCT01478399,Pharmacokinetics,Safety/Tolerability,,2011-12,COMPLETED,INTERVENTIONAL,['PHASE1']
15390,NCT02002130,Compare the effect of oral GABA or oral GABA/GAD combination administration on pancreatic beta cell function by quantitative C-peptide secretion,Compare the effect of oral GABA or oral GABA/GAD administration on diabetes related autoantibodies,,2015-01,COMPLETED,INTERVENTIONAL,['PHASE1']
15391,NCT01901913,Area under the curve above 180 mg/dl (10 mmol/l),"Percentage of time spent above 180, 250, (10, 13.9 mmol/l)",,2013-10,COMPLETED,INTERVENTIONAL,['NA']
15392,NCT01626586,Diabetes-related Outcomes,Diabetes-related medical outcome data,,2012-05,COMPLETED,INTERVENTIONAL,['NA']
15393,NCT01993121,Changes from baseline in cardiovascular exercise performance,Changes from baseline in diastolic function will be measured,,2002-09,COMPLETED,INTERVENTIONAL,['NA']
15394,NCT06038968,assess functional outcomes by multifocal electroretinogram,visual acuity,,2022-09-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
15395,NCT00451620,The objective of this study is to determine whether GlucoNorm has a greater effect than Glyburide on insulin levels and postprandial glucose levels in elderly people with type 2 diabetes who are diet controlled.,,,2003-11,COMPLETED,INTERVENTIONAL,['PHASE2']
15396,NCT05198544,Evaluate Wound healing in Wagner 1 and 2 grade DFUs by wound size,Occurrence of adverse events through case report forms,Bacterial burden measured by Imaging,2023-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
15397,NCT05153564,"Area under the levonorgestrel plasma concentration time curve during a dosing interval (0 to 24 hours) at steady state (AUC0-24h,LN,SS)","Maximum observed paracetamol concentration following a standardised meal (Cmax,para)",,2021-12-13,COMPLETED,INTERVENTIONAL,['PHASE1']
15398,NCT04196140,Time in range 70-180 mg/dL,Body Mass Index (BMI) (kg/m2),Coefficient of variation,2019-12-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
15399,NCT01871324,the efficacy will be evaluated using Diabetes Quality of Life questionnaire before and after the program.,the efficacy will be evaluated using behavioral changes related to diabetes questionnaire before and after the program.,"the efficacy will be evaluated using HbA1c values, glucose levels before and after the program",2013-09,WITHDRAWN,INTERVENTIONAL,['NA']
15400,NCT00325429,Adverse events profile after 52 weeks of treatment,Change from baseline to endpoint in body weight at 52 weeks,,2006-04,COMPLETED,INTERVENTIONAL,['PHASE3']
15401,NCT02147041,composite of anthropometric measures,Quality of life evaluation,,2012-05,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
15402,NCT03530176,18F-Sodium Fluoride (18F-NaF) PET-CT Imaging to Identify Vulnerable Plaques in Patients With Diabetes,,,2015-01-01,COMPLETED,INTERVENTIONAL,['NA']
15403,NCT02586129,Change in HbA1c,,,2015-11-04,COMPLETED,INTERVENTIONAL,['PHASE3']
15404,NCT00425919,Fasting Plasma Glucose,"Mean changes of HbA1c, Fasting Insulin, HOMA-IR and QUICKI indices, Body weight, waist measurements, total cholesterol, LDL-C, HDL-C, total/HDL, apolipoprotein A-1 & B, triglycerides, free fatty acids, hs C-reactive protein, adiponectin, edema.",,2007-01,TERMINATED,INTERVENTIONAL,['PHASE2']
15405,NCT03898206,Postprandial glucose,Blood pressure,,2019-02-26,UNKNOWN,INTERVENTIONAL,['NA']
15406,NCT01174901,"Differentiation between serious secondary non-traumatic headache as opposed to benign, self-limiting non-traumatic headache by copeptin level measurement",Comparison of copeptin with other potential biomarkers in non-traumatic headache,,2010-10,COMPLETED,OBSERVATIONAL,['NA']
15407,NCT05081440,primary outcome,secondary outcome,,2021-12-01,UNKNOWN,OBSERVATIONAL,['NA']
15408,NCT04058951,Urine albumin creatinine ratio (UACR),,,2019-08-15,UNKNOWN,INTERVENTIONAL,['NA']
15409,NCT00909051,"Data collection on patients weight and waist circumference, fasting blood glucose, postprandial blood glucose (2h), HbA1C; exploratory analysis according to patient groups (concomitant cardiovascular disease groups, BMI)",,,2009-03-24,COMPLETED,OBSERVATIONAL,['NA']
15410,NCT03648307,Glucose tolerance,,,2008-07,COMPLETED,OBSERVATIONAL,['NA']
15411,NCT00738907,Pancreatic tracer binding as standardized uptake value (SUV) or binding potential (BPnd),,,2006-11,COMPLETED,OBSERVATIONAL,['NA']
15412,NCT04627272,Specificity,,,2020-12-01,UNKNOWN,INTERVENTIONAL,['NA']
15413,NCT01681173,Change of 2h-postprandial blood glucose from IGT to diabetes mellitus type 2 or normal glucose tolerance (NGT),Determination of gene expression in adipose tissue,,2010-05,COMPLETED,INTERVENTIONAL,['NA']
15414,NCT00090506,,,,2004-07,COMPLETED,INTERVENTIONAL,['PHASE1']
15415,NCT04873232,To evaluate the efficacy of IM administration of Engensis on pain in Participants with painful DPN in the feet and lower legs as compared to Placebo,To evaluate the safety of IM administration of Engensis in Participants with painful DPN in the feet and lower legs,,2021-05-17,RECRUITING,INTERVENTIONAL,['PHASE3']
15416,NCT01792323,tmax(GIR); time to maximum glucose infusion rate,"GIRmax, maximum glucose infusion rate","tmax(ins), time to maximum observed plasma insulin lispro concentration",2011-08,COMPLETED,INTERVENTIONAL,['PHASE1']
15417,NCT02204384,Area Under the Curve (AUC 0-180min) for glycemic and insulinemic responses,,,2014-08,COMPLETED,INTERVENTIONAL,['NA']
15418,NCT01470937,Progression of fasting glucose >140 mg/dL,,,1998-02,COMPLETED,INTERVENTIONAL,['PHASE4']
15419,NCT02575599,The Patient Activation Measure (PAM),Glycosylated haemoglobin (HbA1c),,2018-09-01,UNKNOWN,INTERVENTIONAL,['NA']
15420,NCT05659368,changing in insulin production,change in HbA1c,,2024-01-01,RECRUITING,INTERVENTIONAL,['PHASE2']
15421,NCT05173025,Angiotensin(1-7),HbA1c,,2018-01-01,RECRUITING,INTERVENTIONAL,['PHASE4']
15422,NCT00803920,Characterize glucose control using periodic CGM in subjects participating in protocol 2993LAR-105 at the International Diabetes Center study site.,,,2006-12,COMPLETED,OBSERVATIONAL,['NA']
15423,NCT01707979,near infrared spectroscopy,,,2012-09,COMPLETED,OBSERVATIONAL,['NA']
15424,NCT05541237,remission rate,blood lipid profile,,2022-08-17,RECRUITING,INTERVENTIONAL,['NA']
15425,NCT01089166,,,,na,COMPLETED,INTERVENTIONAL,['PHASE1']
15426,NCT05669599,Percent Change From Baseline to Week 52 in Body Weight,Percent Change From Baseline in Free Fatty Acids (FFA),,2023-01-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
15427,NCT00645268,The IIEF Erectile Function (EF) Domain score,Flow mediated brachial artery dilation (FMD) as an index of generalized endothelial function,,2002-12,COMPLETED,INTERVENTIONAL,['PHASE4']
15428,NCT03563456,Antioxydants,Personal history as independent factor,,2017-06-05,COMPLETED,INTERVENTIONAL,['NA']
15429,NCT05322122,Feasibility and performance measured by anastomosis success,Quality of life improvement,,2021-11-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
15430,NCT05341388,BDNF concentrations,36 item Short Form Survey (SF-36),,2021-03-01,TERMINATED,OBSERVATIONAL,['NA']
15431,NCT02249871,Area under the semaglutide plasma concentration time curve,Number of hypoglycaemic episodes,,2014-09-24,COMPLETED,INTERVENTIONAL,['PHASE1']
15432,NCT04592601,Weight Loss,Adverse Events,,2020-10-26,UNKNOWN,INTERVENTIONAL,['NA']
15433,NCT00282945,"This study will examine whether biomarkers of B-cell function measured early in the study (1, 3, and/or 6 months) will predict long-term changes in B-cell function (as represented by HOMA-B).",,,2006-01,TERMINATED,INTERVENTIONAL,['NA']
15434,NCT05054361,blood MAIT cells frequency,16 S sequencing in the Subjects stools,,2022-01-01,RECRUITING,OBSERVATIONAL,['NA']
15435,NCT01624259,Change From Baseline to 26 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c),Percent Change From Baseline in Lipid Parameters at 26 Weeks,,2012-06,COMPLETED,INTERVENTIONAL,['PHASE3']
15436,NCT04612933,Change from baseline of Time in Range (TiR),Change from baseline of time spent below target glucose range (TbR) level 2,Semi-structured interviews,2021-06-28,RECRUITING,INTERVENTIONAL,['NA']
15437,NCT03367455,Associations of serum potassium and KCNJ11 variants with incident diabetes as represented by odds ratio,,,2015-05,COMPLETED,OBSERVATIONAL,['NA']
15438,NCT05899439,Genetic risk of type 1 diabetes,,,2005-01-01,RECRUITING,OBSERVATIONAL,['NA']
15439,NCT04611737,height,Depression Anxiety Stress Scales,,2020-11-03,COMPLETED,INTERVENTIONAL,['NA']
15440,NCT02390245,Diagnostic Image Confirmation by Ophthalmologist,Adherence to Follow-up Ophthalmic Care.,,2014-09,COMPLETED,INTERVENTIONAL,['NA']
15441,NCT01871870,Verification of the Automation and Telemetry Components,Deviation From Target Blood Glucose,,2013-05,COMPLETED,INTERVENTIONAL,['PHASE2']
15442,NCT00989378,Amount of Slow Wave Activity determines insulin sensitivity.,,,2008-11,COMPLETED,OBSERVATIONAL,['NA']
15443,NCT05464407,Foot ulcer healing,Number of new foot ulcers,,2022-02-24,TERMINATED,INTERVENTIONAL,['NA']
15444,NCT05819151,Tongue image features,Symptom patterns,,2022-10-12,RECRUITING,OBSERVATIONAL,['NA']
15445,NCT04611152,Changes in BCVA to Assess Non-inferiority of KSI-301 to Aflibercept.,Safety and Tolerability of KSI-301 mg compared to aflibercept 2 mg measured by the number of ocular and systemic adverse events.,,2020-09-30,TERMINATED,INTERVENTIONAL,['PHASE3']
15446,NCT05579561,Change from baseline of triglycerides,Change in the microbiome,,2022-05-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
15447,NCT03973762,Se and Sp under investigation target 3,Se and Sp under investigation target 1/2/4/5,,2019-05-31,COMPLETED,INTERVENTIONAL,['NA']
15448,NCT01319734,improving the renal function,Vitamin C can improve the visual fields,,2011-02,UNKNOWN,INTERVENTIONAL,['PHASE1']
15449,NCT03407677,rotation of insulin injections,Accuracy of the ROTO track® injection log,glycaemic control,2018-08-27,COMPLETED,INTERVENTIONAL,['NA']
15450,NCT05563090,Tongue imaging device,Health Evaluation - Existing symptoms,,2022-09-17,RECRUITING,OBSERVATIONAL,['NA']
15451,NCT05349903,Postprandial plasma gut hormone response,Breath hydrogen (fermentability),,2021-11-10,COMPLETED,INTERVENTIONAL,['NA']
15452,NCT00662831,Number of Participants With Greater Than or Equal to 50 Percent Reduction in Ulcer Surface Area Including Intact Skin Healing,Transcutaneous Local Tissue Oxygenation (pO2),Number of Clinically Relevant Minor Hemorrhages and Trivial Hemorrhages,2008-04,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
15453,NCT01029639,"Questionnaires completed by subjects at baseline quarterly to assess ability to sense low blood sugar. Tracking incidences requiring outside assistance including paramedics, ER visits and hospitalizations due to low blood sugar incidences.",,,2007-01,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
15454,NCT02127047,Change in beta-cell function as derived from change in C-peptide and glucose levels during the mixed meal test,Change in fractalkine,,2013-11,COMPLETED,INTERVENTIONAL,['PHASE2']
15455,NCT02846545,Active Treatment Period: C-peptide Area Under the Concentration-time Curve (AUC) Calculated From a 4 Hour Mixed Meal Tolerance Test (MMTT) at Week 52,Titers of Antibodies to Golimumab,,2016-08-26,COMPLETED,INTERVENTIONAL,['PHASE2']
15456,NCT03421119,HbA1c,Liver enzymes,,2019-06-20,UNKNOWN,INTERVENTIONAL,['PHASE3']
15457,NCT04504045,Change from Baseline in Metabolic Rate of Midazolam (CYP3A4) at Week 12.,Change from Baseline in High Sensitivity C-Reactive Protein at Week 12.,,2020-09-01,TERMINATED,INTERVENTIONAL,['PHASE1']
15458,NCT02890745,"Urinary excretion of 8-oxo-7,8-dihydroguanosine (nmol/24h)","Plasma levels of iron, ferritin, transferrin and transferrin saturation",,2016-11,COMPLETED,INTERVENTIONAL,['PHASE2']
15459,NCT03108521,Glycosylated Hemoglobin A1c (HbA1c),Change in C-peptide,,2016-04-21,COMPLETED,INTERVENTIONAL,['PHASE4']
15460,NCT02898467,Neutrophile activation assessed by free DNA levels in atherothrombotic plaques,Atherothrombosis characterization assessed by histological analysis,Banking of biological samples,2016-10,UNKNOWN,OBSERVATIONAL,['NA']
15461,NCT00655863,Change From Baseline in Postprandial Incremental Area Under the Curve for Total Triglycerides at Week 16.,Change From Baseline in Endothelial Function Through Pulse Wave Tonometry,,2007-07,COMPLETED,INTERVENTIONAL,['PHASE3']
15462,NCT05624775,Change in cooking self-efficacy by the Nourishing the Community Through Culinary Medicine survey (NCCM),Change in Triglyceride,,2022-02-01,COMPLETED,INTERVENTIONAL,['NA']
15463,NCT02364323,percentage of patients attaining ≥ 3 pre-defined treatment targets from the following treatment targets: 1) BP <130/80 mm Hg 2) HbA1c <7% 3) Calculated LDL-cholesterol <2.6mmol/l 4) Fasting TG <2mmol/l 5) Use of ACEI or ARB,Patient behavior measured on the Summary of Diabetes Self-care Activities (SDSCA),,2015-02-17,COMPLETED,INTERVENTIONAL,['NA']
15464,NCT02563015,Lean mass,25(OH)D,,2016-03-07,TERMINATED,INTERVENTIONAL,['NA']
15465,NCT00640549,Changes in concentration of LDL subfractions LDL-5 and LDL-6 compared with screening (visit 1),Changes in size of LDL subfractions compared with screening (visit 1),,2003-03,TERMINATED,INTERVENTIONAL,['PHASE4']
15466,NCT02496000,Measure of the Mean Night Time Glucose Levels Based on Two Nights of Glucose Measurements.,The Effect of ORMD-0801 on the Percent Change in HbA1c,,2015-07-27,COMPLETED,INTERVENTIONAL,['PHASE2']
15467,NCT02216955,Disease-specific survival,Overall survival,Disease-free survival,2009-01,UNKNOWN,OBSERVATIONAL,['NA']
15468,NCT00847899,Glucose dynamics and insulin sensitivity,,,2009-01,COMPLETED,INTERVENTIONAL,['PHASE2']
15469,NCT03664726,Reinforcing Value of Food,Change in Working Memory Span,,2018-02-12,COMPLETED,INTERVENTIONAL,['NA']
15470,NCT05629117,Changes in Blood Pressure Level including Systolic blood pressure (SBP) and Diastolic blood pressure (DBP),Changes in Quality of Life,,2022-12-26,COMPLETED,INTERVENTIONAL,['NA']
15471,NCT00643773,Body Composition,Muscle characteristics,,2008-05,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
15472,NCT02320253,Percent Weight Change From Baseline,Depression Score: Change From Baseline.,Health Economics,2014-11,COMPLETED,INTERVENTIONAL,['NA']
15473,NCT01144091,The purpose of the study is to examine the potential renal protective effect of pentoxyphylline in high-risk patients undergoing angiography,The purpose of the study is to examine the potential renal protective effect of pentoxyphylline in patients with elevated base line creatinin level > 2 undergoing angiography,,2012-12,WITHDRAWN,INTERVENTIONAL,['NA']
15474,NCT04757233,Change in score on Summary of Diabetes Self-Care Activities Questionnaire (SDSCA),,,2018-02-01,COMPLETED,INTERVENTIONAL,['NA']
15475,NCT01593774,Change from baseline in weight at week eight,Changes from baseline in HOMA-IR values at week 8,,2012-05,COMPLETED,INTERVENTIONAL,['PHASE2']
15476,NCT00659295,"Incidence of Serious Adverse Reactions, Including Major Hypoglycaemic Events",,,2004-06,COMPLETED,OBSERVATIONAL,['NA']
15477,NCT04326166,Change in HbA1c,Change in FPG,,2020-03-25,UNKNOWN,OBSERVATIONAL,['NA']
15478,NCT00517283,To detect the mean difference in half gastric emptying time for a solid meal between any treatment and placebo,,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE1']
15479,NCT02028091,"Pulse wave arrival time difference between finger and toe, duration of diabetes",,,2012-09,COMPLETED,OBSERVATIONAL,['NA']
15480,NCT03095846,5. Difference in brown adipose tissue (BAT) activity after cooling between Winter Swimmers (WS) and No-Winter Swimmers (NWS).,Difference in resting energy expenditure after cooling versus no cooling,,2017-04-02,COMPLETED,INTERVENTIONAL,['NA']
15481,NCT02619487,glycemic control assessed by HbA1C level.,number of hospitalizations related to T1D,,2019-03,WITHDRAWN,INTERVENTIONAL,['NA']
15482,NCT00889226,Proportion of Patients Achieving LDL- C<100mg/dL,The Change of LDL-C,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE4']
15483,NCT01009021,Pain recorded using a Visual Analog Scale,,,2008-03,COMPLETED,INTERVENTIONAL,['NA']
15484,NCT00945659,Glycated Hemoglobin (HbA1c),Hypoglycemia Fear Survey-Parent,,2009-08,COMPLETED,INTERVENTIONAL,['NA']
15485,NCT01207349,%HbA1c,anthropometry,,2002-08,COMPLETED,OBSERVATIONAL,['NA']
15486,NCT01526720,Genetic basis of beta cell function,Genetic basis of insulin sensitivity,,2003-10,UNKNOWN,OBSERVATIONAL,['NA']
15487,NCT06145542,Continuous glucose monitoring at follow-up,Ambulatory Blood Pressure at follow-up,,2023-12-11,RECRUITING,INTERVENTIONAL,['NA']
15488,NCT00097877,HbA1c,other glycemic variables,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE3']
15489,NCT05691712,Mean Change from Baseline in HbA1c (Tirzepatide 10 or 15 milligram [mg]),"Percentage of Participants with HbA1c ≤6.5%, Without Weight Gain <0.1 kg and Without Hypoglycemia (Blood glucose <3.9 mmol/L [70 mg/dL] or Severe Hypoglycemia)",,2023-02-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
15490,NCT03474731,Hemoglobin A1c,Total cholesterol,,2018-04-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
15491,NCT02077179,Metabolic Syndrome Z Score,Adherence to the HIP Program; Percent of Dietary Logs Completed,,2014-09,TERMINATED,INTERVENTIONAL,['NA']
15492,NCT02601989,insulin sensitivity,"Endothelial function in peripheral arteries measured with EndoPAT, measured as difference in reactive hyperemia",,2015-11,COMPLETED,INTERVENTIONAL,['PHASE2']
15493,NCT02564926,Adjusted Mean Changes From Baseline in Percentage of Total Body Fat Assessed by DXA Scan,Adjusted Mean Change in High Sensitivity C-Reactive Protein (hsCRP) at Week 52,,2016-01-05,COMPLETED,INTERVENTIONAL,['PHASE4']
15494,NCT03660683,CD 34+ Cell Migratory Function,Arterial Stiffness - Augmentation Pressure,Serum Glucose,2018-10-22,TERMINATED,INTERVENTIONAL,['PHASE4']
15495,NCT03506230,Differences in HbA1c after six months,Whether or not HbA1c test was performed at 3 months,Differences in the number of GP visits,2018-11-25,UNKNOWN,INTERVENTIONAL,['NA']
15496,NCT03261895,Self-management,,,2017-05-04,COMPLETED,INTERVENTIONAL,['NA']
15497,NCT04090307,Effects of TLC group prenatal care on infant skinfold thickness,Determine the effect of TLC on psychosocial stress and depression using the Munich Chronotype Questionnaire (MCTQ),,2019-11-26,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
15498,NCT00589134,osmotic regulation of AVP,temperature responses,,2006-01,COMPLETED,INTERVENTIONAL,['NA']
15499,NCT04920253,Wound Closure,Healed Proportion,AWC Failure,2021-11-29,RECRUITING,INTERVENTIONAL,['NA']
15500,NCT02031081,Change In Cumulative Meal-related Symptoms,Gastric Emptying Rate,,2014-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
15501,NCT01373476,Ocular fundus,Optic coherence tomography (OCT),,2011-03,COMPLETED,INTERVENTIONAL,['PHASE2']
15502,NCT01269502,Recurrency of diabetic foot ulcer,,,2009-06,COMPLETED,INTERVENTIONAL,['NA']
15503,NCT02936843,Skin Biopsy - Intraepidermal Nerve Fiber Density (IENFD) - Distal Thigh,,,2016-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
15504,NCT00476151,Placebo vs. Active Comparison of the Change From Average Pain at Baseline to Average Pain at 4 Weeks.,,,2007-07,COMPLETED,INTERVENTIONAL,['PHASE2']
15505,NCT03509324,fasting plasma glucose after insulin therapy,,,2015-03-01,COMPLETED,INTERVENTIONAL,['PHASE4']
15506,NCT03034226,Insulin sensitivity,Symptoms during hypoglycemia,,2017-02-23,COMPLETED,INTERVENTIONAL,['NA']
15507,NCT03887936,Finite element analysis of bone to measure bone strength,Osteoblast and osteoclast progenitor cells which are cells found in bone,,2019-10-01,RECRUITING,INTERVENTIONAL,['PHASE4']
15508,NCT02183324,"Number of patients with clinically relevant changes in clinical laboratory tests (haematology, clinical chemistry, and urinalysis)",DPP-IV activity at different time points,,2007-02,COMPLETED,INTERVENTIONAL,['PHASE2']
15509,NCT01086319,"Hospitalizations with any hypersensitivity reaction, including anaphylaxis, angioedema, generalized urticaria, SJS, TEN, and other severe skin reactions (i.e., acute generalized exanthematous pustulosis and drug rash with eosinophilia/systemic symptoms)",Hospitalized for for toxic epidermal necrolysis (TEN),,2009-08,COMPLETED,OBSERVATIONAL,['NA']
15510,NCT01136785,Change in Mean Serum Insulin Derived From 24 Hour Blood Sampling,Change in 24-h Mean Level of Plasma Norepinephrine,,2009-11,COMPLETED,INTERVENTIONAL,['NA']
15511,NCT05569772,type 2 diabetes,diabetes remission,,2023-09-14,RECRUITING,INTERVENTIONAL,['PHASE3']
15512,NCT01357109,Peripheral endothelial function,Myocardial perfusion,,2007-11,COMPLETED,INTERVENTIONAL,['PHASE2']
15513,NCT00377676,Subjects Experiencing Serious Adverse Events,Change in HbA1c From Baseline to Week 24 for Subjects With a Baseline HbA1c of ≥ 7.5% Who Were Taking at Least One Oral Hypoglycemia Agent (OHA) at Baseline.,,2004-07,COMPLETED,INTERVENTIONAL,['PHASE3']
15514,NCT02138097,Subsequent Insulin Initiation for MarketScan Patients,Persistence at 12 Months for MarketScan Patients,,2014-05,COMPLETED,OBSERVATIONAL,['NA']
15515,NCT01939522,Pneumococcal serotype-specific (SpVS) antibody concentrations at 3 months following a single dose of 13-valent pneumococcal conjugate vaccine (PCV13),Blood glucose control in the week preceding and the week following immunisation with PCV13,,2013-08,COMPLETED,INTERVENTIONAL,['PHASE4']
15516,NCT01817569,Adverse event incidence.,Mean change in lipid metabolism.,,2011-02-13,COMPLETED,OBSERVATIONAL,['NA']
15517,NCT01643811,Proportion of patients who quit previous medication for hypertension because of improved disease,"difference of serum levels of c-peptide, Ghrelin, GIP, GLP-1, glucagon, insulin between before and after operation",,2012-04,COMPLETED,OBSERVATIONAL,['NA']
15518,NCT02726217,Acceptability of the intervention protocol will be evaluated using a satisfaction survey.,,,2016-03-01,COMPLETED,INTERVENTIONAL,['NA']
15519,NCT00511875,Change in Early Treatment Diabetic Retinopathy Study (ETDRS),Change in Arteriovenous Ratio Diameter,,2008-07,COMPLETED,INTERVENTIONAL,['PHASE2']
15520,NCT04820270,Immunization,PRA level,,2018-08-20,UNKNOWN,INTERVENTIONAL,['NA']
15521,NCT05739214,percent of wound size measurement methods,percent of wounds complete closure,,2022-08-01,COMPLETED,INTERVENTIONAL,['NA']
15522,NCT00717457,Change in HbA1c,Beta cell function (proinsulin/insulin ratio),,2008-07,COMPLETED,INTERVENTIONAL,['PHASE3']
15523,NCT05282641,Chronic glucose metabolism,Cerebral blood flow (CBF),Exploratory objective micro-albuminuria and kidney function,2021-05-26,COMPLETED,INTERVENTIONAL,['NA']
15524,NCT02624817,Metabolic control,Insulin secretory response to a glucagon test,,2015-12,COMPLETED,INTERVENTIONAL,['PHASE4']
15525,NCT05291026,Primary outcome measure,Secondary outcome measure II,,2018-12-15,COMPLETED,INTERVENTIONAL,['NA']
15526,NCT06098729,Accuracy,Interview themes,,2023-11-02,RECRUITING,INTERVENTIONAL,['NA']
15527,NCT01715090,Mean change in HbA1c,Detection of important factors for patient compliance to internet-based self-care interventions,,2012-12,COMPLETED,INTERVENTIONAL,['NA']
15528,NCT05094986,Rate of use of services,Outliers registries,,2020-11-01,COMPLETED,INTERVENTIONAL,['NA']
15529,NCT01603121,Safety and Tolerability of Study Drug,Evaluation of Early Efficacy of Study Drug,,2012-02,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
15530,NCT05466643,Changes from Baseline HbA1c,,,2022-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
15531,NCT01630980,Metabolic syndrome measures,,,2012-05,COMPLETED,OBSERVATIONAL,['NA']
15532,NCT02088034,Body Weight,,,2013-09,COMPLETED,INTERVENTIONAL,['PHASE4']
15533,NCT05429359,CGM outcomes during and after morning exercise,Change in growth hormone concentration in venous blood during and after morning exercise test,,2022-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
15534,NCT01703221,Percentage of Participants Who Discontinued From the Study Due to an Adverse Event During the Overall Study,Change From Baseline for Fasting Plasma Glucose (FPG) at Week 24,,2012-10-24,COMPLETED,INTERVENTIONAL,['PHASE3']
15535,NCT05763303,assessment of change in measurements of glycated hemoglobin (HbA1c),assessment of change in measurement of body mass index (BMI),,2023-10-25,RECRUITING,INTERVENTIONAL,['NA']
15536,NCT02442024,Change from baseline fructosamine after 1 and 2 months of diet,Change from baseline lipid profile after 1 and 2 months of diet,,2014-01,UNKNOWN,INTERVENTIONAL,['NA']
15537,NCT00775216,The primary outcome will be assessed by the short version of the International Physical Activity Questionnaire and the 6-minute Walk Test.,"Questions regarding readiness to change, self-efficacy, knowledge of and access to physical activity centers, basic demographics, height/weight, and blood pressure will be assessed.",,2008-10,TERMINATED,INTERVENTIONAL,['NA']
15538,NCT02015780,Change from Baseline in Glycosylated Hemoglobin (HbA1c) at Week 16,Change from Baseline in Total Daily Dose of Insulin at Week 52,,2013-12,WITHDRAWN,INTERVENTIONAL,['PHASE3']
15539,NCT06227650,Percentage of time spent in the target,Microangiopathic events,,2024-02-06,RECRUITING,OBSERVATIONAL,['NA']
15540,NCT01492218,Change in Diabetes Treatment Satisfaction Questionnaire (DTSQ) score,Technical complaints of NovoLet® device,,2004-03-15,COMPLETED,OBSERVATIONAL,['NA']
15541,NCT02273258,Area under the body weight standardized glucose infusion rate (GIR) versus time curve from 0 to 12 hours post administration (GIR-AUC0-12),"Number of patients with AEs, SAEs, laboratory, vital signs and electrocardiographic abnormalities , injections site reaction assessment (ISR), and if any, hypoglycemia",,2013-03,COMPLETED,INTERVENTIONAL,['PHASE1']
15542,NCT05756361,Change in Weight for parent and child,"In parents, change in medication dosing",,2023-04-26,RECRUITING,INTERVENTIONAL,['NA']
15543,NCT02229383,Change in HbA1c From Baseline to Week 28,Change in Seated Systolic Blood Pressure From Baseline to Week 28,,2014-09-06,COMPLETED,INTERVENTIONAL,['PHASE3']
15544,NCT00015626,,,,na,COMPLETED,INTERVENTIONAL,['PHASE2']
15545,NCT01679210,Dietary Intake,,,2013-01,COMPLETED,INTERVENTIONAL,['NA']
15546,NCT03380325,Capillary recruitment,Continous cardiovascular monitoring,,2016-05-11,COMPLETED,INTERVENTIONAL,['NA']
15547,NCT00986349,Change in Anti-diabetes Medications,Total Weight Change (kg) at Week 52 Compared to Baseline Weight,Fasting Plasma Glucose Over Time for All Subjects,2010-06,COMPLETED,INTERVENTIONAL,['NA']
15548,NCT02600845,Treatment Satisfaction: Diabetes Treatment Satisfaction Questionnaire (DTSQc) Score at Week 24,Percentage of Blood Glucose Tagged Data,,2015-12-30,COMPLETED,INTERVENTIONAL,['NA']
15549,NCT03997656,body weight,health-related quality of life,,2019-09-01,UNKNOWN,INTERVENTIONAL,['NA']
15550,NCT00103857,Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24,Change From Baseline in 2-Hour PMG (Post-Meal Glucose) at Week 104,,2005-03-17,COMPLETED,INTERVENTIONAL,['PHASE3']
15551,NCT03994289,Postprandial glucose AUC,,,2019-02-20,COMPLETED,INTERVENTIONAL,['NA']
15552,NCT01831154,The Effect of Intraoperative Tight Glycemic Control on Postoperative C-Reactive Protein Plasma Levels in Patients Undergoing Open Heart Surgery,Intraoperative Glycemic Stability in Patients Undergoing Open Heart Surgery Compared Between Three Glycemic Protocols.,,2010-05,COMPLETED,INTERVENTIONAL,['NA']
15553,NCT01368328,Insulin Sensitivity as assessed with homeostatic model assessment (HOMA),urea and creatinine,,2010-03,UNKNOWN,INTERVENTIONAL,['PHASE3']
15554,NCT04324229,Incidence of type 2 diabetes,,,2020-02-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
15555,NCT01850134,Hunger,Prospective Consumption,,2013-06,WITHDRAWN,INTERVENTIONAL,['NA']
15556,NCT01854463,glycemic control,arterial stiffenss,non-alcoholic fatty liver diseases and bone turnover marker,2011-12,COMPLETED,INTERVENTIONAL,['PHASE4']
15557,NCT00806338,"Safety and Tolerance of multiple intravenous doses of trodusquemine (MSI-1436) in obese or overweight type 2 diabetics. Safety will be evaluated by physical exams, vital signs assessments, 12-lead ECGs, clinical lab tests and adverse event profile.",Effect on exploratory biomarkers,,2008-11,COMPLETED,INTERVENTIONAL,['PHASE1']
15558,NCT00725257,Hemoglobin A1c,Time to introduction of an oral hypoglycemic agent,,2004-06,COMPLETED,INTERVENTIONAL,['NA']
15559,NCT05170984,Rate of wound closure,Changes in the Pain Visual Analogic Scale,,2022-02-10,RECRUITING,INTERVENTIONAL,['NA']
15560,NCT00573781,"Changes in glucose metabolism, changes in transcriptomic and metabolomic profiles",Interaction between the diet and genetic factors within treatment groups,,2007-09,COMPLETED,INTERVENTIONAL,['PHASE2']
15561,NCT01503112,Glycaemic response (HbA1c change post treatment),Weight change over 6 months treatment,,2011-05,COMPLETED,OBSERVATIONAL,['NA']
15562,NCT02723110,Calculated Incretin Effect,PAM enzyme activity assay,,2015-06,UNKNOWN,OBSERVATIONAL,['NA']
15563,NCT05166382,Prescription rates of cardioprotective medications in the informed group vs uniformed group at Month 6,Standard of care risk assessment: Atherosclerotic Cardiovascular Disease risk calculator (ASCVD) at 6 months,,2022-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
15564,NCT00006438,,,,1997-01,COMPLETED,INTERVENTIONAL,['NA']
15565,NCT00288236,Absolute change in HbA1C from baseline to Week 48,"Fasting glucose, total daily insulin dose, body weight, waist circumference, HDL-cholesterol, triglycerides, safety (physical examination, vital signs, laboratory tests, adverse events).",,2006-01,COMPLETED,INTERVENTIONAL,['PHASE3']
15566,NCT00147758,To assess the additional lowering of HbA1c achieved by addition of colesevelam hydrochloride to current antidiabetic therapy,To assess the safety and tolerability of colesevelam hydrochloride as add-on therapy,,2004-06,COMPLETED,INTERVENTIONAL,['PHASE3']
15567,NCT03808376,Safety Endpoint - Incidence of device-related or sensor insertion/removal procedure-related serious adverse,,,2018-12-27,COMPLETED,INTERVENTIONAL,['NA']
15568,NCT00097786,Percentage of Patients Reaching the Endpoint: Core Cardiovascular Morbidity and Mortality Event - Nateglinide Versus Non-nateglinide,,,2002-01,COMPLETED,INTERVENTIONAL,['PHASE3']
15569,NCT03549754,6. Provide real world data on renal outcomes and other microvascular complications in patients with type 2 diabetes and Heart Failure,,,2018-02-17,RECRUITING,OBSERVATIONAL,['NA']
15570,NCT03656887,Number of hypoglycemic events (<70 mg/dl) detected by capillary blood glucose measurement or clinical signs suggestive of hypoglycemia.,,,2019-01-08,COMPLETED,OBSERVATIONAL,['NA']
15571,NCT04136067,Number of treatment-emergent adverse events (AEs),Maximum observed serum NNC0268-0965 concentration after the last dose,,2019-10-29,COMPLETED,INTERVENTIONAL,['PHASE1']
15572,NCT00707447,Waist Circumference,Emotional Well-being/ Depression (CES-D),,2004-04,COMPLETED,INTERVENTIONAL,['PHASE4']
15573,NCT00603291,Co-primary Endpoint- Percentage of Participants Achieving Greater Than or Equal to 5% Weight Loss From Baseline to Week 52,Percent Change in Body Weight From Baseline to Week 52,,2007-12,COMPLETED,INTERVENTIONAL,['PHASE3']
15574,NCT01849731,Glycosylated Haemoglobin levels,,,2011-02,COMPLETED,INTERVENTIONAL,['NA']
15575,NCT00350779,Change From Baseline in HbA1c (Hemoglobin A1C) at Week 18,Change From Baseline in 2-hour PMG (Post-meal Glucose) at Week 54,,2006-06-12,COMPLETED,INTERVENTIONAL,['PHASE3']
15576,NCT01103622,"evaluate the pharmacokinetics of digoxin after a single dose when administered alone and in combination with AZD1656 at steady state, by assessment of AUC and Cmax of digoxin",describe the pharmacokinetics of digoxin when administered alone or in combination with AZD1656 by assessment of tmax and t1/2.,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE1']
15577,NCT01574820,"major cardiovascular events, including myocardial infarction, overt heart failure, and surgery or coronary intervention for CAD",Biomarkers measurements,,2006-11,COMPLETED,INTERVENTIONAL,['PHASE3']
15578,NCT01509157,Parental fear of hypoglycemia,Hypoglycemic events-number and severity of episodes,,2012-01,COMPLETED,INTERVENTIONAL,['PHASE1']
15579,NCT02863328,Change in HbA1c,Change in CoEQ: Scores From the 4 Domains and the 19 Items,,2016-08-10,COMPLETED,INTERVENTIONAL,['PHASE3']
15580,NCT04935554,Change in HbA1c from baseline until week 12,Change in mental health by questionnaire SCL-90r until week 12,,2020-08-17,COMPLETED,INTERVENTIONAL,['NA']
15581,NCT00291772,Area under the curve for glucose,glucagon and gastric emptying,,2006-01,COMPLETED,INTERVENTIONAL,['PHASE4']
15582,NCT03060694,controlled attenuation parameter; liver stiffness measure,,,2016-09,COMPLETED,OBSERVATIONAL,['NA']
15583,NCT03593694,Change from Baseline Hemoglobin A1c (HbA1c) at 3 and 6 months,,,2017-11-06,TERMINATED,INTERVENTIONAL,['NA']
15584,NCT01810952,Average Daily Glucose Levels on Days 1-5 After the Initiation of the Treatment Protocol.,Glucose Values <70 mg/dL.,,2010-09,COMPLETED,INTERVENTIONAL,['PHASE4']
15585,NCT05589467,height in centimeters,,,2020-01-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
15586,NCT06010004,Number of Participants with Treatment Emergent Adverse Events (TEAEs),Change from Baseline in Daily Average 7-Point Self-Monitored Blood Glucose (SMBG),,2023-09-28,RECRUITING,INTERVENTIONAL,['PHASE3']
15587,NCT02143765,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12,Diabetes Treatment Satisfaction,,2014-05,COMPLETED,INTERVENTIONAL,['PHASE4']
15588,NCT00574782,,,,2003-09,COMPLETED,OBSERVATIONAL,['NA']
15589,NCT01898923,Number of Participants With Complete Ulcer Closure,Incidence of Infection of the Target Ulcer,,2012-11-23,COMPLETED,INTERVENTIONAL,['PHASE3']
15590,NCT03955289,Improved healing rate to time to healing,"Decreased complications in diabetic foot ulcers, i.e. infection, hospital admission, amputation",,2019-01-15,COMPLETED,OBSERVATIONAL,['NA']
15591,NCT01302028,Effect of grade of renal impairment on the pharmacokinetics of ASP1941,"Assessment of safety through evaluation of adverse events, physical examination, vital sins, lab-tests and 12-lead ECG",,2010-01-22,COMPLETED,INTERVENTIONAL,['PHASE1']
15592,NCT02092051,Difference in HbA1c between week 26 and week 69,Difference in the mean number of severe hypoglycaemic events between weeks 1-26 and weeks 43-69 defined as unconsciousness due to hypoglycaemia or need of assistance from another person to resolve the hypoglycaemia,,2014-01,COMPLETED,INTERVENTIONAL,['NA']
15593,NCT03490747,Change in cardiorespiratory fitness,Change in patient health care utilisation costs,Exercise referral practitioner (ERP) interviews (intervention group only),2018-03-12,COMPLETED,INTERVENTIONAL,['NA']
15594,NCT00741923,"body weight, waist circumference, blood glucose, satiety hormones, and blood lipids, inflammation factor, and glycated haemoglobin",,,2007-11,COMPLETED,INTERVENTIONAL,['NA']
15595,NCT03211832,Partnerships to Support EBDM,Inter-agency Connectedness,,2017-07-05,COMPLETED,INTERVENTIONAL,['NA']
15596,NCT00928889,Change From Baseline in Postprandial Glucose Excursion (PPGE) at the End of the Study (Week 4),Change From Baseline in Glycosylated Serum Albumin (GSA) at the End of the Study (Week 4),,2009-07,COMPLETED,INTERVENTIONAL,['PHASE4']
15597,NCT00655044,HbA1C,Safety,,2007-05,COMPLETED,OBSERVATIONAL,['NA']
15598,NCT01157403,C peptide release test,,,2010-07,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
15599,NCT06285487,Changes in Glycemic Control,,,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
15600,NCT02184455,Percentage of Wound Area Reduction Compared to Baseline,Percent Change in Wound Area From Baseline,,2016-07-01,COMPLETED,INTERVENTIONAL,['PHASE1']
15601,NCT05979987,Opening link within SMS Text message,Completion rate of one screening/test,,2023-07-27,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
15602,NCT02929355,Rate of vascular events between day one and the last day of follow-up reviewed by patient examination,Rate of carotid atherosclerosis progression measured by duplex ultrasonography in percentage of stenosis,,2012-01,COMPLETED,OBSERVATIONAL,['NA']
15603,NCT01247896,"The single dose PK of PF-05190457 will be described by estimating parameters of AUC(0-infinity), AUC(0-last), AUC(0-24), Cmax, Tmax, CL/F, Vz/F and half-life (t1/2), as the data permit","Gastric half-emptying time (GET½), the duration of the lag phase (Tlag), gastric emptying coefficient (GEC)",,2010-12,COMPLETED,INTERVENTIONAL,['PHASE1']
15604,NCT05921461,PedCheck parameters that demonstrate correlation between HOVR and Ankle Brachial Index (ABI) and Toe Brachial Index (TBI).,Evaluation of usability based on collected data using standard pain scoring questionnaires.,,2022-05-01,COMPLETED,OBSERVATIONAL,['NA']
15605,NCT01559181,Pubertal development,PCOS,,2012-04,COMPLETED,OBSERVATIONAL,['NA']
15606,NCT03520855,Diapason questionnaire (Aide aux Jeunes Diabètes),Evaluation of well-being with DQOLY,,2019-04-03,RECRUITING,INTERVENTIONAL,['NA']
15607,NCT03202277,Fasting glucose,Dietary quality measured by the NCI dietary factor screener,,2017-09-17,COMPLETED,INTERVENTIONAL,['NA']
15608,NCT01390610,Derive optimum Self Monitored Blood Glucose (SMBG) testing patterns from CGM data. CGM data will be graphically and statistically represented by an Ambulatory Glucose Profile (AGP).,,,2011-06,COMPLETED,OBSERVATIONAL,['NA']
15609,NCT05660941,Time in range,Time above and below significant sensor glucose levels,,2023-07-21,RECRUITING,INTERVENTIONAL,['NA']
15610,NCT01177163,The number of patients with symptomatic hypoglycemia and severe hypoglycemia,Change in urine glucose excretion (pharmacodynamics parameter),,2008-05,COMPLETED,INTERVENTIONAL,['PHASE1']
15611,NCT05127538,Dynamic Balance,,,2021-12-10,COMPLETED,INTERVENTIONAL,['NA']
15612,NCT01996228,Autoimmune control,Metabolic control,,2013-11,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
15613,NCT01467674,HbA1c,Clinical Periodontal Status,,2008-01,COMPLETED,OBSERVATIONAL,['NA']
15614,NCT01086280,"Major cardiovascular events defined as a composite of acute MI, stroke or death due to acute MI, stroke, CHF, dysrhythmia, sudden death, or coronary revascularization. Alternative outcomes include DVT, PE, and arterial vascular disease",All-cause death,,2010-01,COMPLETED,OBSERVATIONAL,['NA']
15615,NCT03926806,Glycemic control,Change of GLP-1 response,,2016-11-25,COMPLETED,INTERVENTIONAL,['NA']
15616,NCT02806960,PD: Baseline-Adjusted Glucose Maximum Concentration (BGmax),,,2014-06,TERMINATED,INTERVENTIONAL,['PHASE1']
15617,NCT01422590,AUC of DPP-4 activity,,,2010-05,COMPLETED,INTERVENTIONAL,['PHASE1']
15618,NCT01831752,blood glucose correlation coefficient,,,2013-02,COMPLETED,OBSERVATIONAL,['NA']
15619,NCT02980627,Metabolic Control (Change in HbA1c),Decrease in Overall Eating Disorder symptomatology,,2016-03,COMPLETED,INTERVENTIONAL,['NA']
15620,NCT00727779,euglycemic clamp steady state glucose infusion rate (clamp GIR),GLUT4 content of muscle,,2008-01,COMPLETED,INTERVENTIONAL,['NA']
15621,NCT01677546,HbA1c (Glycated hemoglobin),Frequency of bolus calculator using,Body mass index- standard deviation (BMI- sds),2011-01,COMPLETED,INTERVENTIONAL,['NA']
15622,NCT05132335,To evaluate the repeatability of the ratio of subcutaneous adipose tissue (SAT) to skeletal muscle fatty acid uptake rates,,,2021-03-29,COMPLETED,INTERVENTIONAL,['NA']
15623,NCT04714762,Change in fasting glucose,Costs,,2021-03-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
15624,NCT03128320,Change in transcutaneous oxygen pressure (TcPO2),Number of subjects with TEAEs in different severity,,2017-05-25,COMPLETED,INTERVENTIONAL,['PHASE2']
15625,NCT06246851,Intradermal (in type 2 diabetics) vs intradermal (in non-type 2 diabetics),Intradermal or aerosol BCG re-vaccination safety in healthy volunteers,Examination of immunological and microbiological markers,2024-02,RECRUITING,INTERVENTIONAL,['NA']
15626,NCT03311724,Change From Baseline in Haemoglobin A1c (HbA1c),Pharmacokinetics (PK): Average Trough Concentration (Conctrough) of Tirzepatide,,2017-10-19,COMPLETED,INTERVENTIONAL,['PHASE2']
15627,NCT06005519,change in body fat percentage in long time period,,,2018-12-01,COMPLETED,INTERVENTIONAL,['NA']
15628,NCT03362528,Generation and validation of predictive algorithms for determining blood glucose levels,,,2017-09-25,COMPLETED,INTERVENTIONAL,['NA']
15629,NCT01137474,Adjusted Mean Change From Baseline in Hemoglobin (HbA1c) at Week 12,Adjusted Mean Change From Baseline in Serum Uric Acid Levels at Week 12,,2010-07,COMPLETED,INTERVENTIONAL,['PHASE3']
15630,NCT02502253,"Evaluate BDPP effect on cognition with measures of memory, executive function, and attention measures (composite)",,,2015-06,COMPLETED,INTERVENTIONAL,['PHASE1']
15631,NCT01396330,Mean and maximum change from baseline in glucose level (mmol/l),,,2011-09,COMPLETED,INTERVENTIONAL,['NA']
15632,NCT05140694,Changes of CAP score,Changes of inflammation biomarker,Changes of gut microbiota,2023-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
15633,NCT01261494,HbA1c,Insulin resistance Index [fasting insulin and homeostasis model assessment of insulin resistance (HOMA-IR)],,2010-12,COMPLETED,INTERVENTIONAL,['PHASE2']
15634,NCT00409461,,,,na,TERMINATED,INTERVENTIONAL,['NA']
15635,NCT00675311,"The primary study measures for this study include glycemic control and LDL levels, satisfaction with diabetes care, and adherence to diabetes medications and self-monitoring recommendations",Secondary measures include diabetes-related health-care utilization and physiologic data.,,2008-03,COMPLETED,INTERVENTIONAL,['NA']
15636,NCT01371318,Lower extremity amputation secondary to diabetic foot ulcer,,,2011-07,COMPLETED,INTERVENTIONAL,['NA']
15637,NCT00774904,"GFR, HbA1c and the adiponectin concentration",,,2007-04,COMPLETED,INTERVENTIONAL,['NA']
15638,NCT01406262,QTc interval,Number of participants with adverse events,,2011-07-06,COMPLETED,INTERVENTIONAL,['PHASE1']
15639,NCT03539133,Rehospitalization due to heart failure,Restenosis rate,,2017-10-18,RECRUITING,OBSERVATIONAL,['NA']
15640,NCT06288412,"Time below range, glucose less than (<) 3.0 millimoles per liter (mmol/L) (54 milligrams per deciliter [mg/dL]) within 24 hours after start of exercise (TBR3.0mmol/L,exe)","Number of hypoglycaemic episodes for 18 hours in reference week (26 to 44 hours after dosing) (Hypo18h,ref)",,2024-02-26,RECRUITING,INTERVENTIONAL,['PHASE1']
15641,NCT00332488,Difference in Change From Baseline for HbA1c Between TI+ Metformin and Metformin+Secretagogue,Change in HbA1c From Baseline to Week 24 (Subjects Who Stayed on Original Treatment),,2004-12,COMPLETED,INTERVENTIONAL,['PHASE3']
15642,NCT04833413,Change in HbA1c,Impact on body weight,,2021-04-15,RECRUITING,OBSERVATIONAL,['NA']
15643,NCT01974674,restoration of normal glycemic control without insulin,degenerative complications of diabetes,,2013-07,UNKNOWN,INTERVENTIONAL,['PHASE2']
15644,NCT01274052,,,,2007-03,COMPLETED,OBSERVATIONAL,['NA']
15645,NCT03721848,Health Behavior-Amount of Red Meat Intake (Assessing Change),Primary Care PTSD (Assessing Change),,2017-04-30,COMPLETED,INTERVENTIONAL,['NA']
15646,NCT00362765,Endogenous Glucose Production (EGP) and Glucose Disposal Rate (GDR) by two-step hyperinsulinemic euglycemic clamp (HEC),"Gluconeogenesis, Glycogenolysis, Skeletal muscle and liver fat content, Abdominal fat content, Body energy expenditure and respiratory quotient, Lipids and glycemic parameters",,2006-10,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
15647,NCT04791826,Frequency of prescription of SGLT-2i medication at outpatient clinic visits,Adherence of prescription of SGLT-2i medication at outpatient clinic visit,Frequency of incident HF,2021-03-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
15648,NCT00869076,Hgb A1c change,Percent of patients with a 1 point decrease in A1c by ethnicity,,2006-05,COMPLETED,INTERVENTIONAL,['PHASE4']
15649,NCT02536950,Mean glucose,% time < 60 mg/dl,,2015-08,COMPLETED,INTERVENTIONAL,['NA']
15650,NCT06018844,Moderate to Vigorous Physical Activity (MVPA) levels,Change in participant HbA1c,,2024-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
15651,NCT02877355,Area under the semaglutide plasma concentration-time curve,Maximum observed SNAC plasma concentration,,2016-08-22,COMPLETED,INTERVENTIONAL,['PHASE1']
15652,NCT04531462,Change in HbA1c From Baseline After 52 Weeks of Treatment,Change of Time in the 5-time Chair Stand Test From Baseline to Week 52,,2020-10-05,COMPLETED,INTERVENTIONAL,['PHASE4']
15653,NCT04076800,Insulin daily doses,HbA1c,,2019-08-01,RECRUITING,INTERVENTIONAL,['NA']
15654,NCT00375388,"To investigate the quality of the metabolic control of diabetes and related variables (daily dose of insulin, body weight).",To perform a socio-economic evaluation.,,1998-01,COMPLETED,INTERVENTIONAL,['PHASE3']
15655,NCT01761318,Left ventricular filling pressure (= early peak filling rate / peak mitral annulus longitudinal motion),Myocardial T1 - mapping,Hypoglycaemic episodes,2013-11,COMPLETED,INTERVENTIONAL,['PHASE4']
15656,NCT05261776,Blood glucose level,,,2021-03-15,COMPLETED,INTERVENTIONAL,['NA']
15657,NCT00812487,Hospital Readmission,Mean Glucose,,2009-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
15658,NCT01276106,Change in HbA1c From Baseline,,,2011-01,COMPLETED,INTERVENTIONAL,['PHASE2']
15659,NCT01786707,Number of Participants With a Reduction of HbA1c of >0.5%,The Number of Subjects With a Reduction of >1% in HbA1c,,2009-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
15660,NCT03658980,Number of Participants Who Had Successful Referrals,Increase in Knowledge About Diabetic Retinopathy,,2018-12-15,COMPLETED,INTERVENTIONAL,['NA']
15661,NCT01309698,Pharmacokinetics of vildagliptin,"Pharmacodynamic parameters (dipeptidyl peptidase IV (DPP-4) activity, glucagon-like peptide-1(GLP-1), glucose, insulin, glucagon)",,2011-02,COMPLETED,INTERVENTIONAL,['PHASE4']
15662,NCT06200519,Persistence of diastolic function changes into infancy,,,2024-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
15663,NCT03766308,HbA1c,Change in Waist circumference,,2017-11-01,COMPLETED,INTERVENTIONAL,['NA']
15664,NCT03659383,Rate of reaching target of glucose,Time of reaching target of glucose,,2018-09-20,UNKNOWN,INTERVENTIONAL,['PHASE4']
15665,NCT00933062,To assess the plasma pharmacokinetic profile of SRT2104 following administration of single and multiple oral doses (once a day for seven days) at a single dose level (2.0 g/day) to healthy male volunteers in the fed state.,To assess the safety and tolerability of SRT2104 following administration of single and multiple oral doses (once a day for seven days) at a single dose level (2.0 g/day) to healthy male volunteers in the fed state.,,2009-03-23,COMPLETED,INTERVENTIONAL,['PHASE1']
15666,NCT05200819,"Risk-marker signatures for severe COVID-19 disease, longer-term complications in patients surviving COVID-19.",,,2020-12-02,COMPLETED,OBSERVATIONAL,['NA']
15667,NCT02693964,Difference in carotid intima media thickness between postmenopausal women with type 1 diabetes and controls,Correlation between biomarkers with cardiovascular risk measures (carotid intima media thickness),,2016-03,COMPLETED,OBSERVATIONAL,['NA']
15668,NCT05613556,Frequency and location of high-pressure plantar areas,,,2022-04-01,COMPLETED,OBSERVATIONAL,['NA']
15669,NCT00130208,Number of Subjects With Greater Than 50% Reduction in Microalbuminuria,Change in Serum Albumin From Baseline to End of 26 Weeks,,2005-08,COMPLETED,INTERVENTIONAL,['PHASE3']
15670,NCT00879970,Number of Participants With the Indicated Components of the Composite Outcome for Vitamin D,"Mean Score on Montreal Cognitive Assessment (MoCA) Test, as an Assessment of Cognitive Function (CF)",,2009-05,TERMINATED,INTERVENTIONAL,['PHASE4']
15671,NCT01515202,"Safety and tolerability, as measured by the number, frequency and intensity of adverse events, vital sign measurements, ECGs, physical examinations, and clinical laboratory tests","Pharmacodynamics, as measured by Serum concentration of cortisol and cortisone after an oral dose of cortisone and biomarkers for HPA axis activity (urinary free cortisol and cortisone, salivary cortisol, ACTH, DHEA-S and 4-androstenedione)",,2012-03,COMPLETED,INTERVENTIONAL,['PHASE1']
15672,NCT00715624,Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24,Percentage of Patients Requiring Rescue Therapy During Main 24-Week Period,Number of Patients With Symptomatic Hypoglycemia and Severe Symptomatic Hypoglycemia,2008-07,COMPLETED,INTERVENTIONAL,['PHASE3']
15673,NCT05163002,Differences between baseline A1c (%) and 90 days after the last educational session.,Difference in mean glycaemia (mg /dL) between baseline and 90 days following the last educational session,,2021-05-10,UNKNOWN,INTERVENTIONAL,['NA']
15674,NCT04412200,Cytokine secretion,AUC of stimulated C peptide,,2020-06-01,RECRUITING,INTERVENTIONAL,['NA']
15675,NCT03367663,Serum atherogenicity,,,2018-01-17,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
15676,NCT03017287,Correlation between GlucoMe and HCT recommendations,Target HbA1C/glucose achievement,,2017-01,TERMINATED,INTERVENTIONAL,['NA']
15677,NCT03502174,FreeStyle Libre Flash Glucose Monitoring System Related adverse device effects,,,2018-04-05,COMPLETED,OBSERVATIONAL,['NA']
15678,NCT06293664,Difference in the total or incremental area under the curve of glucose and insulin concentration at an OGTT during saline vs. α-MSH infusion,"Difference in the total or incremental area under the curve of the concentration of metabolites (C-peptide, Glucagon, Gut hormones, α-MSH) during OGTT with saline or α-MSH infusion.",Adverse events (including flushing),2024-03-04,RECRUITING,INTERVENTIONAL,['NA']
15679,NCT00331604,Treatment difference in HbA1c,Hypoglycaemia,,2006-08-31,TERMINATED,INTERVENTIONAL,['PHASE3']
15680,NCT00759720,Change from Baseline in Glycosylated hemoglobin level.,"Low-density lipoprotein fractionation [L-DL particles (total), intermediate-density lipoprotein, large L-DL, small L-DL (total), medium-small L-DL, very-small L-DL, mean L-DL size].",,2003-11,TERMINATED,INTERVENTIONAL,['PHASE3']
15681,NCT05041621,Comparison of 5 hours postprandial percentage of time below 3.9 mmol/L (for high-fat meals and/or postprandial exercise) of the last month algorithm recommendations with the first month recommendations,Mobile app usability questionnaire: score is the average of 16 items and each item scores ranges 0-6 (average of higher scores means higher usability),,2021-07-07,COMPLETED,INTERVENTIONAL,['NA']
15682,NCT02350478,Changes in Endothelial Function (FMD - Flow Mediated Dilatation) From Baseline to 12 Weeks,Changes in Biochemical Markers (svCAM-1),,2013-07,COMPLETED,INTERVENTIONAL,['PHASE4']
15683,NCT01882036,Measure homeostasis model assessment i.e. estimated change in insulin resistance (HOMA-IR) index,,,2011-11,COMPLETED,INTERVENTIONAL,['NA']
15684,NCT02361437,Rate of healing of diabetic ulcers measured by ulcer size,lower extremity skin oxygenation measured by trancutaneous oximetry,,2015-02,TERMINATED,INTERVENTIONAL,['NA']
15685,NCT02947555,Association of lens autofluorescence with atherosclerotic vascular events,Association of lens autofluorescence with antropoetric parameters,,2016-05-01,UNKNOWN,OBSERVATIONAL,['NA']
15686,NCT04548232,Hepatic steatosis,Fertility,,2017-01-01,COMPLETED,OBSERVATIONAL,['NA']
15687,NCT01364129,Proportion of Participants that Receive Annual Eye Exam,,,2006-08,COMPLETED,INTERVENTIONAL,['NA']
15688,NCT04926623,HbA1c (%) changes at 24 weeks compared to baseline,,,2021-06-17,COMPLETED,INTERVENTIONAL,['NA']
15689,NCT01493895,To assess the efficacy of b-cure laser in patients with diabetes mellitus induced lower leg skin ulcers,safety,,na,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
15690,NCT01007097,Change from Baseline in Glycosylated Hemoglobin at Week 12.,Incidence of Hypoglycemia During Double-Blind Treatment Period.,,2009-12,COMPLETED,INTERVENTIONAL,['PHASE2']
15691,NCT01960062,Change in Hemoglobin A1c,Office visit time,,2011-10,WITHDRAWN,INTERVENTIONAL,['NA']
15692,NCT03073343,Change in alanine aminotransferase (ALT) level in all study participants,Compare changes in alanine aminotransferase (ALT) level in both cohorts,,2013-11-12,UNKNOWN,INTERVENTIONAL,['NA']
15693,NCT05413005,Clinically important hypoglycemic episodes,Serum IgM levels,,2022-09-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
15694,NCT01063374,plaque volume,retinal photography,,2010-03,COMPLETED,INTERVENTIONAL,['PHASE2']
15695,NCT01709201,Percent days abstinent,Medical complications,Medical complications 90 days post baseline,2013-07,WITHDRAWN,INTERVENTIONAL,['NA']
15696,NCT02634528,"PK: Cins.max, maximum observed insulin concentration",Changes in Electrocardiogram recordings,,2016-11-16,COMPLETED,INTERVENTIONAL,['PHASE1']
15697,NCT02247271,Patient Activation Measure (PAM),Self-reported healthcare utilization,,2014-09-01,COMPLETED,INTERVENTIONAL,['NA']
15698,NCT00279240,Reduction in conversion of IGT to diabetes,Benefits of the drug on anthropometric variables and biochemical parameters,,2001-03,COMPLETED,INTERVENTIONAL,['PHASE1']
15699,NCT00435981,To evaluate the efficacy of Diamyd® 20ug versus placebo with respect to preserving residual insulin secretion as measured by C-peptide levels. The effect of intervention will be evaluated at month 15 (main study period) and at month 30 (Extension phase).,To evaluate the safety of Diamyd® 20ug.,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE2']
15700,NCT05716607,glycemic variability,immunoglobulins,,2023-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
15701,NCT03932721,Difference in the percentage change in flow mediated dilation (FMD),Difference in the percentage change in FMD reserve,Difference in Plasma C-Reactive Protein Change in mg/dL from randomization to 16 weeks of treatment.,2018-10-01,COMPLETED,INTERVENTIONAL,['PHASE4']
15702,NCT04347252,hepatic glucose production,Change in Beta-hydroxybutyrate concentrations,,2019-09-24,COMPLETED,INTERVENTIONAL,['PHASE1']
15703,NCT01818674,Temporally investigate the causal induction of cascading changes in body weight between follow-ups on subsequent weight changes in other participants.,Relative changes in blood pressure between individual trial arms,,2012-01,COMPLETED,INTERVENTIONAL,['NA']
15704,NCT05148897,Evaluate general knowledge of women about different aspects of Gestational Diabetes: Questionnaire,,,2021-10-01,UNKNOWN,OBSERVATIONAL,['NA']
15705,NCT04126291,Change in knowledge,Change in practice related to pediatric weight management,,2019-10-01,COMPLETED,INTERVENTIONAL,['NA']
15706,NCT03185689,Proportion of T2D patients with controlled BGL as measured by a change in HbA1c,Proportion of T2D patients with a recommended level of diabetes self-care behavior as measured by summary of diabetes self-care activities (SDSCA) questionnaire,Change in the level of depressive symptoms as measured by patient health questionnaire depression scale (PHQ-9),2016-04-04,COMPLETED,INTERVENTIONAL,['NA']
15707,NCT03591939,rate of patients with positive T-regulatory cells in blood,,,2018-08-01,UNKNOWN,OBSERVATIONAL,['NA']
15708,NCT05587348,Odds of attending 1 DSMES class,Change in Diabetes Self-Efficacy from baseline to 6 months,,2023-09-12,RECRUITING,INTERVENTIONAL,['NA']
15709,NCT05540132,Time to completion of distance bike challenge,Glycemic variability in the 12 hours following the exercise test,,2023-07-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
15710,NCT02804698,Framingham cardiovascular disease risk,,,2016-08,COMPLETED,INTERVENTIONAL,['NA']
15711,NCT03230175,Number of Subjects With Complete Wound Healing,Percent Change in Wound Surface Area,,2017-10-04,COMPLETED,INTERVENTIONAL,['PHASE2']
15712,NCT02455011,"Number of treatment emergent adverse events per subject, including changes in vital signs, physical and neurological examinations, laboratory safety tests and ECGs","Geometric mean ratio to baseline over time of AST, ALT, ALP and total bilirubin.",,2015-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
15713,NCT03478306,"Progression of diabetic retinopathy, oscillary potential",Retinal structure,,2018-03-27,COMPLETED,INTERVENTIONAL,['PHASE3']
15714,NCT03602950,changes in wound healing,morbidly wound healing,,2018-08-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
15715,NCT06291766,Adverse Pregnancy Outcome,Week of delivery,,2024-01-01,RECRUITING,INTERVENTIONAL,['NA']
15716,NCT00891995,C-peptide Average Area Under the Curve (AUC) in Response to a Mixed Meal at 1 Year Following Enrollment.,BMI Percentile,,2010-09,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
15717,NCT01978704,mean plasma glucose concentrations,postprandial plasma glucose concentrations,,2013-02,COMPLETED,INTERVENTIONAL,['NA']
15718,NCT02951260,Overall aerobic work performed during an exercise bout with self-selected intensity,Physical fitness (VO2max),Oxidative phosphorylation in skeletal muscle fibers,2016-10,COMPLETED,INTERVENTIONAL,['NA']
15719,NCT01645995,Changes in body weight and body composition,"Changes in cardiovascular risk factors (blood pressure, inflammatory markers)",,2012-03,COMPLETED,INTERVENTIONAL,['NA']
15720,NCT02917226,fasting blood glucose,,,na,UNKNOWN,INTERVENTIONAL,['NA']
15721,NCT03359629,Percentage of Measurements With < 15% Error,,,2017-09-27,COMPLETED,OBSERVATIONAL,['NA']
15722,NCT01135394,Change in Insulin Resistance,Number of Genes Determined to be Correlated With Change in Insulin Sensitivity,,2009-03,COMPLETED,INTERVENTIONAL,['NA']
15723,NCT00321321,Insulin Secretion,,,2006-05,COMPLETED,INTERVENTIONAL,['PHASE2']
15724,NCT01780051,AUCt and Cmax of repaglinide and metformin,"AUC∞, Tmax, t1/2, CL/F and Vd/F of repaglinide and metformin",,2013-03,COMPLETED,INTERVENTIONAL,['PHASE1']
15725,NCT05802121,Side effects and tolerability,Bone health: Vitamin K2,,2023-06,NOT_YET_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
15726,NCT02998008,echocardiography,,,2017-01-02,TERMINATED,INTERVENTIONAL,['NA']
15727,NCT03282136,"all cause mortality, and cardiac cause mortality.",hospital admissions for HF,,2017-09-01,COMPLETED,INTERVENTIONAL,['PHASE4']
15728,NCT05935839,Visualization of tissue changes in diabetic patients using MSOT.,,,2023-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
15729,NCT01899274,Changes in Hemoglobin A1C levels,bant Component Usage,,2013-07,COMPLETED,INTERVENTIONAL,['NA']
15730,NCT01830569,Pre- to post-implementation change in HbA1c.,Pre- to post-implementation change in a composite process score.,Actual use of the EBMeDS system,2017-03-29,COMPLETED,INTERVENTIONAL,['NA']
15731,NCT04585581,Plasma glucose concentration,Infant bone mass,Infant bone mass,2020-11-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
15732,NCT03662984,Myocardial insulin sensitivity,Cholesterol profile,,2018-11-01,COMPLETED,INTERVENTIONAL,['PHASE3']
15733,NCT00546728,Change in Reactive Hyperemic Index Over the 3-month Treatment Period,,,2007-10,COMPLETED,INTERVENTIONAL,['PHASE4']
15734,NCT05290233,Lean mass,processing speed,,2023-07-01,RECRUITING,INTERVENTIONAL,['NA']
15735,NCT02115932,Change in EQ5D HUI from baseline at 2 and 6 months,Cost-utility of intervention measured by cost per Quality-Adjusted Life Year (QALY) gained,Change in gait from baseline at 2 and 6 months,2014-07-30,COMPLETED,INTERVENTIONAL,['NA']
15736,NCT00308139,Sub-study Relative Bioavailability of Exenatide When Administered Using the Exenatide Once Weekly Dual Chambered Pen and the Exenatide Once Weekly Single Dose Tray (Single Dose Tray-11 Weekly Doses Switch to Dual Chamber Pen-11 Weekly Dose),Assessment on Event Rate of Treatment-emergent Hypoglycemic Events With Non-SU Use at Screening,,2006-04,COMPLETED,INTERVENTIONAL,['PHASE3']
15737,NCT05181631,Echographic cardiomyopathy,,,2022-01-15,UNKNOWN,INTERVENTIONAL,['NA']
15738,NCT01285518,Number of Participants With Abnormal Cardiac Rhythms Recorded by Telemetry,Volume of Distribution at Steady State (Vss) of PF-05231023,,2011-02,COMPLETED,INTERVENTIONAL,['PHASE1']
15739,NCT00639964,fetal weight corrected by gestational age,erythrocytary and plasmatic fatty acid distribution,,2008-01,COMPLETED,INTERVENTIONAL,['NA']
15740,NCT01030796,Caffeine abstinence,HbA1c,,2009-12,COMPLETED,INTERVENTIONAL,['PHASE1']
15741,NCT04832464,Berg Balance Scale,Michigan Neuropathy Screening Instrument,,2021-03-30,UNKNOWN,INTERVENTIONAL,['NA']
15742,NCT00848705,Self-management behaviors,Self-management Problem solving,,2007-10,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
15743,NCT04698720,Immune cells,Representations regarding the DFU,Heart rate,2019-02-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
15744,NCT02675855,Complete closure of index wound,Number of patients with worsening of wound by ≥50% increase in size,,2016-01,COMPLETED,INTERVENTIONAL,['PHASE4']
15745,NCT01327404,,,,2009-10,UNKNOWN,OBSERVATIONAL,['NA']
15746,NCT01820715,Number of Subjects or Incidence with Adverse Events including Adverse Drug Event and Serious Adverse Event,overnight pain score,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE1']
15747,NCT05483777,Wound Observation and Evaluation Form,,,2023-02-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
15748,NCT03512665,Homeostasis Model Assessment - Insulin Resistance (HOMA-IR),Change in plasma FGF-21,,2018-04-07,COMPLETED,INTERVENTIONAL,['NA']
15749,NCT03602378,"Stress in parents of children with developmental disability and chronic disease, and healthy children.","Advanced glycation end products in parents of children with developmental disability, chronic disease and parents of healthy children.",,2018-04-02,UNKNOWN,OBSERVATIONAL,['NA']
15750,NCT00376870,In-Segment Late Loss,Stent thrombosis,,2008-07,UNKNOWN,INTERVENTIONAL,['PHASE3']
15751,NCT01976923,Visual acuity change,Proportion of eyes gaining at least 15 letters of BCVA,Molecules in the vitreous humor and epiretinal membranes,2013-11,COMPLETED,INTERVENTIONAL,['PHASE3']
15752,NCT05587413,Change of HbA1C between the control group and interventional group.,,,2022-11-02,RECRUITING,INTERVENTIONAL,['NA']
15753,NCT05841225,diet adherence,,,2023-06-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
15754,NCT06333977,"Incidence, severity of adverse events",Renal Clearance (CLR) in urine,HbA1c,2022-03-25,COMPLETED,INTERVENTIONAL,['PHASE1']
15755,NCT02842554,Pain Assessment Training,Predicted Response to Training,,2013-08,COMPLETED,INTERVENTIONAL,['PHASE4']
15756,NCT02344082,Change in hemoglobin A1c,Telemedicine Adherence (Percent of telephone encounters completed in intervention arm),,2015-01,COMPLETED,INTERVENTIONAL,['NA']
15757,NCT04829903,Adverse effects,,,2020-01-02,COMPLETED,INTERVENTIONAL,['NA']
15758,NCT04953221,The change in the average weekly NRS score of pain from baseline,The change from baseline in the SF-36 Quality of Life Scale score,,2021-07-01,UNKNOWN,OBSERVATIONAL,['NA']
15759,NCT01973400,"Total Symptoms Score (TSS) (pain, paresthesia, burning, and numbness)of patients with diabetes type 1 and 2 neuropathy.",Neuropathy Impairment Score (NIS) of patients with diabetes type 1 and 2 neuropathy,"Mini Mental State Examination (MMSE) score, Montreal Cognitive Assessment (MoCA) test.",2011-06,COMPLETED,INTERVENTIONAL,['PHASE3']
15760,NCT03489083,Heat Shock Response Change.,Visceral Adipose Tissue Change.,,2016-02-01,COMPLETED,INTERVENTIONAL,['NA']
15761,NCT04647617,5-time chair stand test,WHOQOL-BREF World Health Organization Quality of Life Taiwan version,,2020-08-24,COMPLETED,INTERVENTIONAL,['NA']
15762,NCT04537637,Change in Glycated haemoglobin (HbA1c ),"Diabetes Treatment Satisfaction Questionnaire, status (DTSQs), change in absolute treatment satisfaction",,2020-08-28,COMPLETED,OBSERVATIONAL,['NA']
15763,NCT01554020,Fasting glucose,Blood pressure,,2012-06,WITHDRAWN,INTERVENTIONAL,['PHASE2']
15764,NCT05921344,Consensus Error Grid (CEG) for venous plasma glucose and glucose values measured by mμSORS at each time point of OGTT.,Incidence of Treatment-Emergent Adverse Events,,2023-06-20,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
15765,NCT00754624,Annual Rate of Change in FEV1 From Baseline to End of Study,High Resolution Computerized Tomography Scans of the Chest,,2004-05,COMPLETED,INTERVENTIONAL,['PHASE2']
15766,NCT02617693,Difference in waist circumference,"Change in stress levels, as measured by the Depression Anxiety and Stress Scale 21-items (DASS-21) used in National Health Surveys in Malaysia",,2015-11-23,COMPLETED,INTERVENTIONAL,['PHASE4']
15767,NCT00289705,BMI development,"Medical risk factors, incidence of diseases (such as diabetes, hypertension etc), quality of life, socioeconomic development, eating pattern.",,2006-02,UNKNOWN,INTERVENTIONAL,['PHASE3']
15768,NCT01623934,Diagnosis of gestational diabetes mellitus,,,2010-01,UNKNOWN,OBSERVATIONAL,['NA']
15769,NCT01490112,Change in weight,Adverse events: Serious and non-serious,,2005-01,COMPLETED,OBSERVATIONAL,['NA']
15770,NCT04593173,Analysis of Value of 2D and 3D Left Ventricular Strains in Echocardiography in Type 2 of diabetic Patients,,,2020-10-01,UNKNOWN,OBSERVATIONAL,['NA']
15771,NCT00333723,Efficacy of rosiglitazone combined with glyburide to glyburide monotherapy in reducing glycosylated hemoglobin (HbA1c).,"Efficacy of rosiglitazone combined with glyburide to glyburide monotherapy upon FPG, c-peptide, HOMA and responder rates.",,2000-07-28,COMPLETED,INTERVENTIONAL,['PHASE4']
15772,NCT01770639,Treatment failure within the first year after surgery,Foot angles,,2013-01,COMPLETED,OBSERVATIONAL,['NA']
15773,NCT05581966,Data Collection,,,2023-03-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
15774,NCT04141761,Effect of Multistrain Probiotic on Immune System Inflammation as measured by plasma transcription analysis,System-wide Effects as measured by systemic microbial antigen (a marker of intestinal permeability) as measured by plasma analysis,,2019-04-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
15775,NCT03283774,Cost analysis,,,2015-01,COMPLETED,OBSERVATIONAL,['NA']
15776,NCT06086912,"After a single subcutaneous injection of HR17031, the PK parameters of plasma Noiiglutide and serum INS068: Maximum Concentration (Cmax)",Immunogenicity indicators: anti-INS068 antibodies,,2023-11-07,COMPLETED,INTERVENTIONAL,['PHASE1']
15777,NCT04805970,Measure and characterize organ volume change in patients with and without diabetes through use of summary statistics.,,,2021-03-24,RECRUITING,OBSERVATIONAL,['NA']
15778,NCT03088566,Patients reported experience measure (PREM),Patients reported outcome measure (PROM),,2017-08-15,COMPLETED,INTERVENTIONAL,['NA']
15779,NCT01556984,The changes of endothelial function,,,2012-10,COMPLETED,OBSERVATIONAL,['NA']
15780,NCT05952739,Diabetes mellitus complicating pregnancy,,,2023-08-01,RECRUITING,OBSERVATIONAL,['NA']
15781,NCT00329862,"Reduction and or elimination of co-morbidities @ 6, 12, 18, 24, 30, 36, 42, 48, 54, 60 weeks",,,2006-05,TERMINATED,INTERVENTIONAL,['NA']
15782,NCT02377388,changes on platelet aggregability.,platelet aggregability differences by two point-of-care methods.,"measure of safety, Number of participants with adverse effects by analysis on changes of serum level",2017-02-07,COMPLETED,INTERVENTIONAL,['PHASE3']
15783,NCT00849316,Incidence of major hypoglycaemic episodes,Number of all minor (daytime and nocturnal) hypoglycaemic events,,2009-02,WITHDRAWN,OBSERVATIONAL,['NA']
15784,NCT01704612,the duration of sensory block in hours,the duration of motor sciatic block,"occurrence of neurological omplications, yes/no",2011-07,COMPLETED,INTERVENTIONAL,['PHASE4']
15785,NCT01037582,Number and severity of adverse events (AEs) recorded,The uptake in blood of oral NN9924 compared to i.v. and s.c. administration of the same compound,,2009-12-17,COMPLETED,INTERVENTIONAL,['PHASE1']
15786,NCT01183715,Single dose pharmacokinetics of PF-05161704 and its metabolite PF-05200145,Preliminary pharmacodynamics of PF-05161704,,2010-07,COMPLETED,INTERVENTIONAL,['PHASE1']
15787,NCT03269084,Clinical diagnosis of type 1 diabetes,,,1994-11-07,RECRUITING,OBSERVATIONAL,['NA']
15788,NCT03341793,Changes in myokine (muscle secretome) secretion induced by bariatric surgery,,,2017-11-14,UNKNOWN,INTERVENTIONAL,['NA']
15789,NCT04057261,Changes in the metabolomics profile (fold changes) between Liraglutide treatment group and placebo group after 1 and 3 months,Differences in circulation inflammatory cell composition by flow cytometry analyses (FACS) between Liraglutide treatment group and placebo group,,2020-11,WITHDRAWN,INTERVENTIONAL,['PHASE3']
15790,NCT06147414,% of inconclusive results,Estimated delay for result in standard care diagnosis condition,,2024-04,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
15791,NCT01191866,,,,2009-09,UNKNOWN,OBSERVATIONAL,['NA']
15792,NCT04029402,Renal function change,,,2019-07-01,RECRUITING,OBSERVATIONAL,['NA']
15793,NCT01839344,Glucose tolerance following a maltose tolerance test,Area under the Glucose Curve (AUC),Reactive Hyperemia Index (RHI),2013-05,COMPLETED,INTERVENTIONAL,['PHASE2']
15794,NCT00560417,Change From Baseline in Hemoglobin A1C (HbA1c) at Endpoint (Last Observation Carried Forward [LOCF]),Total Daily Insulin Dose at Endpoint (LOCF),,2007-11,COMPLETED,INTERVENTIONAL,['PHASE3']
15795,NCT00743808,Systolic blood pressure,Measure changes in action taken related to improving blood pressure management as percent of providers reporting changing (initiating or adjusting) blood pressure medication,,2006-12,COMPLETED,OBSERVATIONAL,['NA']
15796,NCT01002521,Genetic Phenotyping (Haptoglobin and TRAPS),Quality of Life,,2009-12,UNKNOWN,OBSERVATIONAL,['NA']
15797,NCT00642174,Inhibition of Platelet Aggregation (IPA) 4 Hours After Loading Dose Assessed by Accumetrics VerifyNow™ P2Y12 Assay,Inhibition of Platelet Function as Measured by Thromboelastography (TEG)-Platelet Mapping Maximum Amplitude - Adenosine Diphosphate,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE2']
15798,NCT03961854,Adverse Event and/or Serious Adverse Event,,,2019-10-10,RECRUITING,INTERVENTIONAL,['PHASE2']
15799,NCT02065310,Percentage of quality controls that fall within 15% of the nominal value for a analytical run of the CEdG assay.,Correlation of Hemoglobin A1c and CEdG levels,,2014-10,COMPLETED,INTERVENTIONAL,['NA']
15800,NCT00823849,"Primary Efficacy Evaluation: Comparing with the basic line information, the change value of arteriosclerosis related biomarker in 4 groups after 12 weeks of treatment.",,,2008-10,COMPLETED,INTERVENTIONAL,['PHASE4']
15801,NCT05887999,Pharmacodynamics (PD): Area under the concentration versus time curve from time 60 to 120 minutes (AUC60-120min) of plasma glucagon during the insulin-induced hypoglycemia,Change from Baseline in Glucagon Concentration at Fasting and Post meal during sMMTT,,2023-06-12,COMPLETED,INTERVENTIONAL,['PHASE1']
15802,NCT03077360,Percent Change in Body Weight Compared to Baseline Measurement,,,2017-02-01,COMPLETED,INTERVENTIONAL,['NA']
15803,NCT06111586,Change from baseline to W52 in mean 2h mixed meal tolerance test (MMTT) stimulated C-peptide concentration,Change from baseline to W52 and W104 in DTSQs Total and item scores (caregivers of all participants 12-17 y.o.),,2023-12-11,RECRUITING,INTERVENTIONAL,['PHASE2']
15804,NCT05292833,The percentage of patients adhering to the Mediterranean Diet,Describe the difficulties/barriers to the initiation of the Mediterranean Diet,,2023-07-06,RECRUITING,OBSERVATIONAL,['NA']
15805,NCT01617434,Change in Glycosylated Haemoglobin (HbA1c) From Baseline to Week 26,Number of Severe Hypoglycaemic Episodes During The Randomised Treatment Period,,2012-09,COMPLETED,INTERVENTIONAL,['PHASE3']
15806,NCT01935167,log ACR,Cystatin C,,2013-10,COMPLETED,INTERVENTIONAL,['PHASE2']
15807,NCT00627484,Change in Insulin Sensitivity,Change in Resting Energy Expenditure,,2005-03-01,COMPLETED,OBSERVATIONAL,['NA']
15808,NCT03254524,Emergency Deparrtment (ED) visit by a patient,Hospital Selection,,2014-08-20,COMPLETED,OBSERVATIONAL,['NA']
15809,NCT06132334,Physical activity level,Upper extremity functional exercise capacity (percentage of the expected value (%)),,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
15810,NCT05434559,Time in range,Body mass index,Glycemic consensus targets,2022-02-20,COMPLETED,OBSERVATIONAL,['NA']
15811,NCT03279107,Change in plasma blood insulin from fasting baseline value (Time Frame: Up to 180 minutes).,Change in subjective appetite ratings from fasting baseline value (Time Frame: Up to 180 minutes).,,2017-08-25,COMPLETED,INTERVENTIONAL,['NA']
15812,NCT02028195,Functional capacity,,Health economy assessment,2013-05,UNKNOWN,INTERVENTIONAL,['NA']
15813,NCT03865381,Mean Change in Hemoglobin A1c,Mean Change in A1c,,2019-02-08,COMPLETED,INTERVENTIONAL,['NA']
15814,NCT00683735,To assess the effect of co-administration of sitagliptin and metformin compared to placebo on the incretin effect (based on the comparison of the insulin secretory response to oral glucose load and an 'isoglycaemic' intravenous glucose load),To assess the effect of sitagliptin compared with placebo on the incretin effect (based on the comparison of the insulin secretory response to oral glucose load and an 'isoglycaemic' intravenous glucose load),,2009-02,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
15815,NCT02226640,Perform 'deep' clinical and molecular phenotyping of 360 adults- Diabetic and Non-Diabetic,,,2010-11,COMPLETED,OBSERVATIONAL,['NA']
15816,NCT06064669,healthy live birth,Cumulative live birth,,2023-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
15817,NCT03607435,Calibration of the KBS-1 Test Article using the POC Control data for comparison.,Calibration of the RBA-1 Test Article using the hospital lab test Control data and POC blood glucose monitor Control data for comparison.,,2018-08-02,UNKNOWN,INTERVENTIONAL,['NA']
15818,NCT04428645,Mean Change in the Percent of Time With Sensed Glucose Between 70 - 180 mg/dl,Change in Coefficient of Variation of Sensor Glucose Based on the Dexcom G6 CGM Data.,,2020-07-21,COMPLETED,INTERVENTIONAL,['NA']
15819,NCT01088451,Differences in mean blood glucose concentrations and the pattern of fluctuation on control and study days; and changes in the glycated hemoglobin A1c after the study period. Occurrence of side effects especially hypoglycemic episodes.,"The difference in postprandial areas under the curve when comparing conventional therapy and experimental combined prandial insulin therapy in the 5 to 6 hours following meal ingestion, taking into account the glycemic index profile of the meal.",,2009-12,UNKNOWN,INTERVENTIONAL,['NA']
15820,NCT04105608,Changes in serum GLP-1 concentration,Hunger-satiety scores (millimeters),,2017-11-01,COMPLETED,INTERVENTIONAL,['NA']
15821,NCT03987438,The risk of diabetes mellitus (DM) in patients with impaired glucose tolerance,Changes in glycosylated hemoglobin levels.,,2019-08-03,UNKNOWN,INTERVENTIONAL,['NA']
15822,NCT03033849,Acceptance criteria defined by ISO 15197:2013 (E) will be applied,,,2017-01,COMPLETED,INTERVENTIONAL,['NA']
15823,NCT03661177,Lipid panel,Cultural identity change,,2020-01-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
15824,NCT00893425,Flow mediated dilatation,ADMA CD95,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE4']
15825,NCT03602638,coronary calcification score,,,2018-10-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
15826,NCT00767884,Changes in optic nerve head topography before and after panretinal photocoagulation,,,2008-10-29,TERMINATED,OBSERVATIONAL,['NA']
15827,NCT00879710,Changes in LDL Cholesterol,Changes in Cholesterol Absorption or Synthesis Rates From the Baseline,,2008-08,COMPLETED,INTERVENTIONAL,['NA']
15828,NCT05622630,Vibration sensation test,,,2019-08-13,COMPLETED,INTERVENTIONAL,['NA']
15829,NCT06273124,Primary Outcome,,,2024-03-07,RECRUITING,INTERVENTIONAL,['NA']
15830,NCT03487029,muscle oxigeneration,Physical activity level,,2018-03-02,COMPLETED,INTERVENTIONAL,['NA']
15831,NCT01895712,Target Vessel Failure (TVF),Target lesion revascularization (TLR),,2013-08,COMPLETED,OBSERVATIONAL,['NA']
15832,NCT03910205,Interleukin-18 level,Tnf-alpha level,,2019-04-08,COMPLETED,OBSERVATIONAL,['NA']
15833,NCT03699189,HbA1c,The quality of life,,2011-11,COMPLETED,INTERVENTIONAL,['NA']
15834,NCT05373199,AUCGIR 6-24h,Local tolerability,,2022-05-12,COMPLETED,INTERVENTIONAL,['PHASE1']
15835,NCT00645424,Percentage of subjects with low-density lipoprotein cholesterol (LDL-C) levels of <100 mg/dL (LDL-C responders) at Week 12,"Percentage of subjects with total cholesterol (TC) levels of <160 mg/dL (TC responders) at Weeks 4, 8, and 12",,2003-12,COMPLETED,INTERVENTIONAL,['PHASE4']
15836,NCT02040571,Continuous glucose monitoring (CGM) time spent in target glycaemic range (4.0-8.0 mmol/L) from 2000h-0800h in clinical trial centre (phase 1 of the study).,Cognitive Assessment: CogState assessment battery outcome measures will be generated. Each battery test point will record participant response times and accuracy rates for all tasks performed.,,2014-01,COMPLETED,INTERVENTIONAL,['NA']
15837,NCT05348499,Diabetes Distress Score-T1 score in people with type 1 diabetes,Thematic analysis of semi-structured interviews to explore the impact of HCL systems on different aspects of life and daily functioning of people with type 1 diabetes and their partners.,,2021-11-14,RECRUITING,OBSERVATIONAL,['NA']
15838,NCT05317455,PDH flux in the frontal lobe,,,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
15839,NCT01377155,Days to reach the titration target,The frequency of reported and documented (<70 mg/dl) hypoglycemic events per 24 hour period,,2011-06,COMPLETED,INTERVENTIONAL,['NA']
15840,NCT05517863,percent of wounds complete closure,percent of days needed for surface area reduction,,2022-03-01,COMPLETED,INTERVENTIONAL,['NA']
15841,NCT00798161,HbA1c Change From Baseline at Week 24,Use of Rescue Therapy,,2008-12,COMPLETED,INTERVENTIONAL,['PHASE3']
15842,NCT04795531,Change in HbA1c (glycated haemoglobin),Mean weekly insulin dose,,2021-03-24,COMPLETED,INTERVENTIONAL,['PHASE3']
15843,NCT00148304,diabetes self-care/attitudes,,,2005-09,COMPLETED,OBSERVATIONAL,['NA']
15844,NCT02569060,Change from Baseline HbA1c at 6 Months,Change from Baseline Food stability,Change from Baseline Diabetes Self-Care,2015-10,COMPLETED,INTERVENTIONAL,['NA']
15845,NCT01616433,Glucose,,,2012-03,COMPLETED,INTERVENTIONAL,['PHASE2']
15846,NCT06192121,Diabetes Self-Care Activities,,,2023-09-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
15847,NCT00857870,Area under the curve (AUC) after a testmeal measured CGM.,"HbA1C, glycemic variability, glycemic load, insulin secretion after testmeal, free fatty acids, biomarkers of low grade inflammation, endothelial dysfunction.",,2009-03,COMPLETED,INTERVENTIONAL,['PHASE4']
15848,NCT05782881,"Composite cardiovascular disease (cardiovascular death, non fatal myocardial infarction, non fatal stroke, hospitalization for heart failure, and readmission for acute coronary syndrome)",Blood pressure( both diastolic and systolic will be measured),,2023-01-15,RECRUITING,INTERVENTIONAL,['NA']
15849,NCT00005905,,,,2000-06,COMPLETED,INTERVENTIONAL,['PHASE2']
15850,NCT03222245,Change in quality of life,Change in HbA1c,,2017-06-30,COMPLETED,OBSERVATIONAL,['NA']
15851,NCT03398902,Change in % time glucose is ≥ 140mg/dL,,,2020-09-01,UNKNOWN,INTERVENTIONAL,['NA']
15852,NCT01617824,M1/M2 polarization balance,Endothelial progenitor cell levels,,2012-09,COMPLETED,INTERVENTIONAL,['PHASE4']
15853,NCT02397447,Insulin Sensitivity (Matsuda Index) After 90 Days,AUC-insulin After 90 Days,,2013-03,COMPLETED,INTERVENTIONAL,['PHASE2']
15854,NCT00471926,,,,2007-04,UNKNOWN,OBSERVATIONAL,['NA']
15855,NCT00348725,Quotation by Visual Numeric Rating Scale before and after 4-week treatment,Assessment of safety by reporting of Adverse Events,,2005-04,COMPLETED,INTERVENTIONAL,['PHASE3']
15856,NCT03353376,change in in Hba1c levels,change in non HDL Cholesterol,change in number in hospital admission,2010-09-13,COMPLETED,INTERVENTIONAL,['NA']
15857,NCT03591081,"The proportion of patients who self-refer for recurrence of diabetic foot-ulcer over a twelve-month period, compared with the current National diabetes foot audit average of 33.3%",Changes in cardiovascular markers,,2018-06-22,COMPLETED,INTERVENTIONAL,['NA']
15858,NCT05365529,Glycemic regulation assessed by HbA1c,Quality of life Assessment via Short Form-36 Questionnaire (SF-36),Long term TRE adherence,2022-05-16,RECRUITING,INTERVENTIONAL,['NA']
15859,NCT03024944,Amount of Tau Accumulation by Measuring Standardized Uptake Value Ratio (SUVR),,,2017-12,WITHDRAWN,INTERVENTIONAL,['PHASE2']
15860,NCT00743002,"To evaluate the safety and tolerability of TT223 as a treatment for Type 2 diabetes at 1 mg, 2 mg and 3 mg.",To determine the pharmacokinetic (PK) parameter profile of TT223 in a subset of patients.,,2008-08,COMPLETED,INTERVENTIONAL,['PHASE2']
15861,NCT01906359,6-hour postprandial changes from fasting in glucose-dependent insulinotropic polypeptide (GIP),6-hour changes from fasting hunger rating using visual analogue scale (VAS),,2012-09,COMPLETED,INTERVENTIONAL,['NA']
15862,NCT04167761,Rate of isoproterenol-stimulated lipolysis to measure metabolic flexibility in epicardial adipose tissue samples.,Distribution of adipose cell size in epicardial tissue.,,2020-07-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
15863,NCT02518945,Absolute Change After 12 Weeks From Baseline in Mean HbA1c With Addition of Dapagliflozin Compared to Placebo.,Change in Blood Ketone Bodies,,2015-08,COMPLETED,INTERVENTIONAL,['PHASE3']
15864,NCT01212913,Change in hemoglobin A1c level (HbA1c),Continuous Glucose Monitoring System (CGMS) data,,2010-08,COMPLETED,INTERVENTIONAL,['PHASE4']
15865,NCT05599893,Glycemic level,Health related quality of life,,2021-01-01,COMPLETED,INTERVENTIONAL,['NA']
15866,NCT02144441,Trial feasibility metric: reasons for disenrollment,Hypoglycemia,,2014-06,WITHDRAWN,INTERVENTIONAL,['NA']
15867,NCT01847144,Change in fasting glucose,Additional changes in biochemical results,,2013-04,COMPLETED,INTERVENTIONAL,['PHASE4']
15868,NCT01963130,"This study investigated the effect of the used type 2 DM drug, vildagliptin, a DPP-4 inhibitor, on portal hemodynamics.","This study investigated the effect of the used type 2 DM drug, vildagliptin, a DPP-4 inhibitor, on hepatosteatosis.",,2012-07,COMPLETED,OBSERVATIONAL,['NA']
15869,NCT01827735,The primary endpoint is based upon the percentage of CD4+T regulatory (defined as CD3+CD4+CD25highCD127low) cells within the CD3+CD4+T cell gate following treatment with IL-2.,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,,2013-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
15870,NCT05041673,Change in steatosis as measured using CAP score (fibroscan) and MRI,Changes in fibrosis grade,,2021-02-23,UNKNOWN,INTERVENTIONAL,['NA']
15871,NCT05256615,Sleep (minutes per night),Infant Apgar Scores,,2020-01-01,RECRUITING,INTERVENTIONAL,['NA']
15872,NCT02382159,Variation of the Lipid parameter pattern patients who are treated by lipid-lowering drug.,Variation for lipid parameter when the patients who are treated for 3±1 months by lipid-lowering drug.,Setting the sub-group by the result of lipid parameter,2010-10,COMPLETED,OBSERVATIONAL,['NA']
15873,NCT01762644,Insulin Independence and Hemoglobin A1c (A1C) < 6.5%,Average daily insulin requirement per week,,2015-08,WITHDRAWN,INTERVENTIONAL,['PHASE3']
15874,NCT04418908,Change in quantitative immunuofluorescence of endothelial cell proteins,,,2010-11-24,COMPLETED,INTERVENTIONAL,['NA']
15875,NCT01649219,Glucose and lipid metabolism,Changes in muscle metabolism,,2010-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
15876,NCT03767699,Gestational Weight Gain,,,2013-11,COMPLETED,OBSERVATIONAL,['NA']
15877,NCT03155594,Changes in care,Accuracy of device,,2017-05-09,UNKNOWN,INTERVENTIONAL,['NA']
15878,NCT04900636,Impact on quality of life,Metabolic control,,2021-05-01,COMPLETED,INTERVENTIONAL,['NA']
15879,NCT02464800,Visual acuity,Retinal reattachment,,2007-04,COMPLETED,OBSERVATIONAL,['NA']
15880,NCT01461499,Reduction in Albuminuria,Change in the Serum Insulin Level,,2011-10,COMPLETED,INTERVENTIONAL,['PHASE4']
15881,NCT04466501,"Evaluate the performance agreement of the ACR |LAB compared to the comparator device, tested by professional users.",,,2019-06-30,COMPLETED,INTERVENTIONAL,['NA']
15882,NCT05216172,peripheral regulatory T cells,incidence of treatment emergent adverse events (with particular reference to episodes of infection),regulatory T cells: functional assay,2020-01-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
15883,NCT02167243,To assess if the intervention reduces A1c,,,2014-07,COMPLETED,INTERVENTIONAL,['NA']
15884,NCT01637727,Long term effects of gestational diabetes mellitus in a population of parous women,Long term effects of gestational diabetes mellitus in a population of parous women,,2012-09,UNKNOWN,OBSERVATIONAL,['NA']
15885,NCT00659282,Incidence of major hypoglycaemic events reported as serious adverse drug reactions,,,2006-09-11,COMPLETED,OBSERVATIONAL,['NA']
15886,NCT05857085,evaluation of arterial stiffness with peak wave velocity ( PWV),evaluation of endothelial progenitor cells EPC count,changes of glycemia endpoints glucovariability/time in range,2021-12-15,COMPLETED,INTERVENTIONAL,['PHASE4']
15887,NCT01869790,Area under the curve (AUC),,,2013-06,COMPLETED,INTERVENTIONAL,['NA']
15888,NCT01547403,Primary Endpoint for CUSTOM Trial,,,2012-08,WITHDRAWN,OBSERVATIONAL,['NA']
15889,NCT00241124,Change from baseline in systolic 24 hour blood pressure after 12 weeks,"Adverse events, serious adverse events, laboratory values, physical examinations, vital signs for up to 26 weeks",,2004-04,COMPLETED,INTERVENTIONAL,['PHASE4']
15890,NCT02302508,"Pharmacokinetics (AUC0-t metabolites and parent drug) of clopidogrel, prasugrel and ticagrelor.",Platelet function activities,,2019-09-01,WITHDRAWN,INTERVENTIONAL,['PHASE4']
15891,NCT01084369,Improvement in endothelial dependent and endothelial-independent vasodilatation,Markers of endothelial function,,2013-10-11,TERMINATED,INTERVENTIONAL,['PHASE4']
15892,NCT05392166,pancreatic enzymes elevation in diabetic children .,,,2022-05-13,RECRUITING,INTERVENTIONAL,['NA']
15893,NCT01333514,Probability of Hypoglycemia,Probability of Hyperglycemia,,2011-04,TERMINATED,INTERVENTIONAL,['PHASE4']
15894,NCT05540405,Glycated hemoglobin (HbA1c),Skeletal muscle mass,,2023-01-24,COMPLETED,INTERVENTIONAL,['NA']
15895,NCT05613920,Changes in blood glucose levels over time,pregnancy outcomes,Apgar score of newborn,2022-11-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
15896,NCT01146314,Improvement of health status of overweight children,Improvement of health behaviors and psychosocial adjustment,,2006-09,COMPLETED,INTERVENTIONAL,['NA']
15897,NCT03854656,Change in body weight (kg),Satisfaction with the intervention (qualitative methods),,2019-02-25,COMPLETED,INTERVENTIONAL,['NA']
15898,NCT00838344,medication adherence,medication adherence challenges,,2008-04,UNKNOWN,INTERVENTIONAL,['NA']
15899,NCT05195567,Analysis of system accuracy based on DIN EN ISO 15197,,,2022-02-17,COMPLETED,INTERVENTIONAL,['NA']
15900,NCT00236639,The percent change in body weight from the baseline (randomization) to Week 60 (after one year of maintenance therapy).,"Changes from either baseline to Week 60 and/or Week 112, or enrollment to Week 60 and/or Week 112 in absolute body weight, Body Mass Index (BMI), body measurements, fasting lipid profile.",,2000-07,COMPLETED,INTERVENTIONAL,['PHASE3']
15901,NCT05449782,Macrovascular endothelial function,Leg perfusion pressure,Photoplethysmography (PPG) blood flow,2021-05-17,COMPLETED,INTERVENTIONAL,['NA']
15902,NCT04698200,Change of systolic and diastolic blood pressure,Skin and body temperature,,2021-01-01,UNKNOWN,INTERVENTIONAL,['NA']
15903,NCT03610412,The effect of cinnamomum cassia on body weight,The effect of cinnamomum cassia potentiates the IGF1 insulin response on body fat%.,,2019-08-01,COMPLETED,INTERVENTIONAL,['PHASE3']
15904,NCT05515744,Incidence of neonatal intensive care unit (NICU) > 1 day (24 hours) stay,Duration of maternal hospital stay,,2023-01-20,RECRUITING,INTERVENTIONAL,['NA']
15905,NCT02152852,Improvement in HbA1c,Physical and mental functioning,,2011-11,COMPLETED,INTERVENTIONAL,['NA']
15906,NCT01268488,Numbers of Fingerstick Blood Glucose (BG) Results Within +/- 5 to 15mg/dL (<75 mg/dL) or Within +/- 5% to 20% (>=75 mg/dL) of Laboratory Glucose Method,Numbers of Forearm Blood Glucose (BG) Results Within +/- 5 to 15 mg/dL (<75 mg/dL) or Within +/- 5% to 20% (>=75 mg/dL) of Laboratory Glucose Method,,2010-12,COMPLETED,INTERVENTIONAL,['NA']
15907,NCT02832739,Level of and potential changes in technology acceptance in participants,Level of and potential changes in eHealth Literacy in participants,,2016-11,UNKNOWN,INTERVENTIONAL,['NA']
15908,NCT01510509,Major adverse cardiac events,Late luminal loss,,2009-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
15909,NCT05911256,Change in participant HbA1c values,Change in Glycemic variability from baseline,,2024-07,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
15910,NCT00564668,Safety,HbA1c,,2004-06-19,COMPLETED,INTERVENTIONAL,['PHASE3']
15911,NCT00270985,HbA1c,Il-6,,2006-01,COMPLETED,INTERVENTIONAL,['PHASE1']
15912,NCT05372445,Gut microbiota metabolic pathways changes,Gut microbiota diversity changes,,2022-05-30,RECRUITING,INTERVENTIONAL,['NA']
15913,NCT00282451,HbA1c,Postprandial glucose concentration increments (calculated based on 7-point blood glucose profiles),,2006-02,COMPLETED,INTERVENTIONAL,['PHASE4']
15914,NCT01832311,level of vascular endothelial growth factor in aqueous humor,degree of corneal edema,,2009-01,COMPLETED,INTERVENTIONAL,['PHASE4']
15915,NCT03136939,the rate of positive reactivation against the IGRP epitopes,,,2017-01-01,COMPLETED,OBSERVATIONAL,['NA']
15916,NCT01307917,"compare endothelial function by studying reactive hyperemia, nitric oxide, and proinflammatory factors in adolescents (12-21 years old) with diabetes vs. healthy sex- and age-matched control subjects.","examine the effects of flavonoids on vascular function, urine nitric oxide, and proinflammatory factors in patients with diabetes mellitus",,2009-07,WITHDRAWN,INTERVENTIONAL,['NA']
15917,NCT01290575,"Adverse events, physical examinations, clinical laboratory determinations, electrocardiograms (ECG), and vital sign assessments.",AUC(0-24 h) and postprandial AUC(0-4h) for biomarkers of glucose homeostasis,,2011-02,COMPLETED,INTERVENTIONAL,['PHASE1']
15918,NCT03085550,Degree of wound healing,Patient reported outcome measures,,2018-02-01,COMPLETED,INTERVENTIONAL,['NA']
15919,NCT02073474,Incidence rates of adverse events.,Number of MS patients discontinuing medications for MS symptoms other than anti-spasticity medications.,,2011-02,COMPLETED,OBSERVATIONAL,['NA']
15920,NCT01437592,Area under the serum insulin degludec concentration-time curve,Time to maximum observed serum insulin degludec concentration,,2011-09-06,COMPLETED,INTERVENTIONAL,['PHASE1']
15921,NCT01072708,Describe the natural history of the glucose tolerance in cystic fibrosis patients and to identify the predictive factors of the reversibility or the aggravation in the disorders of the glucidic metabolism.,"Estimate the probability of arisen the complications associated to the disorders of the glucidic metabolism : - deterioration of the respiratory function, - lung exacerbations - alteration of the nutritional state",,2009-04,COMPLETED,INTERVENTIONAL,['NA']
15922,NCT00105898,Change in HbA1c at 12 months,"Change in blood pressure, lipid profile and diabetes-related stress (self-report) at 12 months; cost-effectiveness analysis of the interventions.",,2005-02,COMPLETED,INTERVENTIONAL,['NA']
15923,NCT05295329,IMR improvementcompared with baseline.,,,2022-04-01,UNKNOWN,INTERVENTIONAL,['NA']
15924,NCT00770445,Change from Baseline in Matrix Metallo Proteinase 9.,Change from Baseline in Circadian (7 point) Blood Glucose Profile (Week 12).,,2008-05,COMPLETED,INTERVENTIONAL,['PHASE4']
15925,NCT02387749,Change of Nerve Conduction Amplitude of Nerves Affected Measured by Nerve Conduction Study.,Change of Levels of Glycated Haemoglobin( HA1C) After Stem Cells Transfusion Measured in Percent %,,2014-05,COMPLETED,INTERVENTIONAL,['NA']
15926,NCT03668808,Continuous Glucose Monitoring - Time in Range (70-140 mg/dl),Sleep Efficiency Measured by ActiGraph,,2018-11-16,COMPLETED,INTERVENTIONAL,['PHASE4']
15927,NCT04867785,Change From Baseline in Hemoglobin A1c (HbA1c),"Population PK: Average Steady-State Plasma Concentration (Cav,ss) of LY3437943",,2021-05-13,COMPLETED,INTERVENTIONAL,['PHASE2']
15928,NCT01585818,Average mean glucose levels and variability,Glucose and Insulin Levels,,2011-08,UNKNOWN,INTERVENTIONAL,['PHASE2']
15929,NCT01094054,Disposition Index,Gastric emptying and intestinal transit,,2010-10,COMPLETED,INTERVENTIONAL,['PHASE4']
15930,NCT02402985,Variance of glucose metabolism after different diet intervention,Variance of intestinal hormones,,2013-09,COMPLETED,INTERVENTIONAL,['NA']
15931,NCT00511108,Percent Change From Baseline in Index of Static Beta-cell Sensitivity to Glucose After 12 Weeks of Treatment,Change From Baseline in Glucose 5-hour Total AUC After 12 Weeks of Treatment,,2007-07-11,COMPLETED,INTERVENTIONAL,['PHASE1']
15932,NCT05880810,Mean daily glucose,Percentage of subjects to continue use of continuous glucose monitor,,2024-04-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
15933,NCT03289494,"Mean postprandial incremental Area Under the Curve (iAUC), measured by CGMS",Charaterisation of acceptability to H-SDS diet in free living conditions,,2017-08-30,COMPLETED,INTERVENTIONAL,['NA']
15934,NCT03672409,Change in knowledge measurements in diabetes by questionnaire,,,2018-09-05,UNKNOWN,INTERVENTIONAL,['NA']
15935,NCT03436212,Relationships between glucose levels and insulin doses,,,2017-09-05,UNKNOWN,INTERVENTIONAL,['NA']
15936,NCT05673668,Changes of islet secretory function (HOMA-β),Change of sympathetic nervous system activity,,2022-12-27,RECRUITING,INTERVENTIONAL,['NA']
15937,NCT01508858,AUC of levonorgestrel,Adverse events,,2006-11,COMPLETED,INTERVENTIONAL,['PHASE1']
15938,NCT06209411,Number of participants who completed OGTT during the first year postpartum,"Number of women with abnormal OGTT who get tests including hemoglobin, lipid profile, creatinine.",,2024-03-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
15939,NCT00337337,"Changes in glycemic parameters including fasting plasma glucose, postprandial plasma glucose, insulin sensitivity and lipid profile",Acceptabiliy and tolerability,,2005-04,UNKNOWN,INTERVENTIONAL,['PHASE4']
15940,NCT04025801,Confocal microscopy exam of sub-basal corneal nerve fibre tortuosity (NFT) by using the CCMetrics software,,,2019-07-31,UNKNOWN,OBSERVATIONAL,['NA']
15941,NCT04796779,Time in Range,CGM-measured Percent Below 54 mg/dL,"CGM-measured % >300 mg/dL During the Four Hours Following the Announced Meal, or Until the Next Meal Bolus is Given, for the Missed Meal Bolus Challenge",2021-04-21,COMPLETED,INTERVENTIONAL,['NA']
15942,NCT00263939,"Health related quality of life (HRQoL) at 2wks and 4wks during the intervention, immediately post intervention and at 6 months and 1 year post intervention","self-care self-efficacy at 2wks and 4wks during the intervention, immediately post intervention and at 6 months and 1 year post intervention",,2004-07,COMPLETED,INTERVENTIONAL,['NA']
15943,NCT03553680,Change in Diabetes Distress,Change in Diabetes Self-Care,,2017-10-20,COMPLETED,INTERVENTIONAL,['NA']
15944,NCT05631444,Efficacy profile: Quality of life,,,2019-01-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
15945,NCT03733743,Day-night rhythm in skeletal muscle mitochondrial respiration,Change in energy status of the heart between morning and evening,,2018-07-09,COMPLETED,INTERVENTIONAL,['NA']
15946,NCT01727661,exercise testing with near-infrared spectroscopy,quality of life,,2012-02,COMPLETED,OBSERVATIONAL,['NA']
15947,NCT02970656,Glycosylated Hemoglobin (HbA1c),DNA Methylation,,2017-02-08,COMPLETED,INTERVENTIONAL,['NA']
15948,NCT00598663,HbA1c at 6 Month,Diabetic Ketoacidosis Events,,2008-01,COMPLETED,INTERVENTIONAL,['NA']
15949,NCT00526552,,,,2007-06,COMPLETED,OBSERVATIONAL,['NA']
15950,NCT02876744,Detection and measure of ischemic territories in central and peripheral retina,,,2017-04-04,COMPLETED,OBSERVATIONAL,['NA']
15951,NCT00855010,Bone Turnover Marker - Plasma 25-hydroxyvitamin D,Disposition Index,,2009-02,COMPLETED,INTERVENTIONAL,['NA']
15952,NCT03334318,iGFR at the end of the PERL trial,HBGI (High blood glucose index),,2017-10-01,COMPLETED,OBSERVATIONAL,['NA']
15953,NCT00668109,Sexual encounter profile question 3 observed within 15 minutes to 4 hours for vardenafil and 22 to 26 hours for the tadalafil group,Safety and tolerability,,2003-12,COMPLETED,INTERVENTIONAL,['PHASE3']
15954,NCT02114554,Prognostic factors for poor outcome,,,2014-01,UNKNOWN,OBSERVATIONAL,['NA']
15955,NCT00931879,Efficacy Measures Examining Increased Vascular Response to Ischemic Block and to Local Warming at the Dorsum of the Foot.,,,2009-10,COMPLETED,INTERVENTIONAL,['PHASE4']
15956,NCT04779645,Change in Cardiovascular Disease (CVD) Risk Markers.,,,2021-07-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
15957,NCT00038727,"Major Adverse Cardiovascular Events (MACE): Myocardial Infarction (MI), Stroke, or Cardiovascular Death (CVD)",Mortality,,2002-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
15958,NCT03371940,Change in depression status - Diagnosis of Major Depressive Disorder,Cost effectiveness analyses,,2012-01-01,COMPLETED,INTERVENTIONAL,['NA']
15959,NCT02955875,Medications knowledge at 9 months,Cost-effectiveness of pharmaceutical care at 9 months,,2015-01,COMPLETED,INTERVENTIONAL,['NA']
15960,NCT01555164,Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24,Change From Baseline in 2-hour Postprandial Serum Glucose at Week 24,,2012-06,COMPLETED,INTERVENTIONAL,['PHASE3']
15961,NCT02060201,Area under the concentration-time curve from time zero extrapolated to infinite time [(AUC(INF)] for Saxagliptin and Dapagliflozin,"Safety measured by the occurrence of deaths, adverse events (AEs), serious adverse events (SAEs), results of clinical laboratory tests, vital sign measurements, physical examination findings, and 12-lead electrocardiogram (ECG) results",,2014-02,COMPLETED,INTERVENTIONAL,['PHASE1']
15962,NCT00069602,Accuracy of the GlucoWatch G2 Biographer and CGMS sensors,,,2002-08,COMPLETED,INTERVENTIONAL,['PHASE4']
15963,NCT01608425,Surgical procedures,Ulcer healing,,2011-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
15964,NCT03089333,Change in Systolic Blood Pressure,Change in microalbuminuria,,2016-07,COMPLETED,INTERVENTIONAL,['PHASE4']
15965,NCT00259701,,,,2005-06,COMPLETED,OBSERVATIONAL,['NA']
15966,NCT02079870,Ad libitum energy intake during a lunch meal (following a standardised breakfast meal),Incidence of adverse events,,2014-03-06,COMPLETED,INTERVENTIONAL,['PHASE1']
15967,NCT02883751,Wound closure,Cost-benefit ratio of ulcer treatment following minor amputations,,2017-01,WITHDRAWN,INTERVENTIONAL,['NA']
15968,NCT00888238,Insulin Secretion Rate (ISR) During 190 - 340 Minutes Post-dose,Glucose Infusion Rate (GIR) During 190 - 340 Minutes Post-dose,,2009-05-12,COMPLETED,INTERVENTIONAL,['PHASE1']
15969,NCT03647306,MI-IS,,,2018-02-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
15970,NCT00231660,The percent change in body weight and change in HbA1c from baseline (Week 0) to one year after maintenance therapy (Week 60).,"Changes from baseline or from enrollment to Week 60 in BMI and HRQOL measures; safety evaluations, such as adverse events and vital signs throughout study.",,2000-10,COMPLETED,INTERVENTIONAL,['PHASE3']
15971,NCT05516576,"Remission of diabetes after endoscopic gastroplasty with endomina, in patients with type-2 diabetes and class I obesity",,,2023-09-29,RECRUITING,INTERVENTIONAL,['NA']
15972,NCT01856907,Normalization of Glucose Levels,Waist-to-Height Ratio,Liver Enzymes as Safety Measure,2013-09-28,COMPLETED,INTERVENTIONAL,['PHASE4']
15973,NCT05711108,Biochemical hypoglycemia,Symptoms of hypoglycemia reported to the staff by the resident in between or at the time of fingerstick glucose monitoring (information derived from nursing notes),,2022-01-19,RECRUITING,OBSERVATIONAL,['NA']
15974,NCT01787214,Within-day glucose variability,Net glycemia at 4 hours,,2013-06,TERMINATED,INTERVENTIONAL,['NA']
15975,NCT03179657,Nonalcoholic fatty liver disease (NAFLD),Cognitive function,,2008-07-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
15976,NCT00097071,HbA1c,"Measurements of glycaemic control, safety parameters including frequency of hypoglycaemia, laboratory tests, clinical evaluations and adverse events",,2004-10,COMPLETED,INTERVENTIONAL,['PHASE3']
15977,NCT02458131,Change in BMI,"Change in knowledge, attitudes, beliefs and behaviors related to diabetes and weight loss",,2016-11-11,COMPLETED,INTERVENTIONAL,['NA']
15978,NCT03068273,CGM patient acceptability questionnaire - patient-reported outcome,Hyperglycemia (>250 mg/dL): rate comparison (type 2 diabetes),,2015-05,COMPLETED,INTERVENTIONAL,['NA']
15979,NCT00653302,% of responders with HbA1c<7% and/or a final decrease of HbA1c>15% compare to the basal value (HbA1c final - HbA1c basal).,AE/SAE evaluation,,2003-04,COMPLETED,INTERVENTIONAL,['PHASE4']
15980,NCT00269646,insulin sensitivity,Flow-mediated dilation,,2004-11,UNKNOWN,INTERVENTIONAL,['NA']
15981,NCT05132179,Time to healing,"Change of diabetic foot ulcer´s, DFU´s, depth",,2022-02-01,RECRUITING,INTERVENTIONAL,['NA']
15982,NCT01332370,medical resource utilization,,,2009-12,COMPLETED,OBSERVATIONAL,['NA']
15983,NCT04209075,Gastrointestinal (GI) Tolerability Score,Stool Short Chain Fatty Acids (SCFA),,2020-03-10,COMPLETED,INTERVENTIONAL,['PHASE2']
15984,NCT05872269,Frequency and severity of treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs),Change in BMI,,2023-07-20,RECRUITING,INTERVENTIONAL,['PHASE4']
15985,NCT00762684,Change from baseline in glycosylated hemoglobin.,Change from baseline in urinary albumin to creatinine ratio.,,2004-11,TERMINATED,INTERVENTIONAL,['PHASE3']
15986,NCT03877783,retention rate,Memory function,,2020-10-19,UNKNOWN,INTERVENTIONAL,['NA']
15987,NCT02528695,Glucose uptake in adipose tissue measured by uptake of 18F-FDG on PET images,,,2014-11,COMPLETED,INTERVENTIONAL,['NA']
15988,NCT03482869,Maximal walking distance,,,2018-03-30,UNKNOWN,INTERVENTIONAL,['NA']
15989,NCT02513875,fasting glucose (mg/dL),TC (mg/dL),,2013-02,COMPLETED,INTERVENTIONAL,['NA']
15990,NCT01783275,Splanchnic glucose uptake,Endogenous glucose production,,2013-02,COMPLETED,INTERVENTIONAL,['NA']
15991,NCT05745441,24-hour total fat oxidation,14-hour post-dinner cumulative dietary fat oxidation,,2023-07-05,RECRUITING,INTERVENTIONAL,['NA']
15992,NCT03993366,Time in hyperglycemia,,Gastrointestinal symptoms,2019-03-01,COMPLETED,INTERVENTIONAL,['NA']
15993,NCT03199638,"HbA1c, Glycated Hemoglobin",Insulin Sensitivity Score (ISS),,2016-04-01,COMPLETED,INTERVENTIONAL,['NA']
15994,NCT03703869,Change in HbA1c at month 6,Body weight,,2018-03-06,COMPLETED,OBSERVATIONAL,['NA']
15995,NCT01587599,drug-drug-interactions,improved overall health status,,2010-06,UNKNOWN,INTERVENTIONAL,['PHASE4']
15996,NCT03204799,Metagenomic profile change,blood glucose change,,2016-12-17,UNKNOWN,OBSERVATIONAL,['NA']
15997,NCT02889510,Changes From Baseline on Measurements of Respiratory Function Defined by Forced Expiratory Volume in 1 Second (FEV1),Changes From Baseline on Measurements of Respiratory Function Defined by Residual Functional Capacity (RFC),,2016-10-04,COMPLETED,INTERVENTIONAL,['PHASE3']
15998,NCT03268941,Number of Participants With Markedly Abnormal Electrocardiogram (ECG) Values,Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-906 in Part 1,,2017-09-26,COMPLETED,INTERVENTIONAL,['PHASE2']
15999,NCT00703612,"Lowering of blood glucose be it fasting, random or post prandial",Lowering of glycosylated hemoglobin (HbA1C).,,2007-11,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
16000,NCT03312179,MACE,,,2017-01-01,COMPLETED,OBSERVATIONAL,['NA']
16001,NCT05310916,"Evaluation of the study biomarkers, IL-6, and VEGF",Occurrence of adverse events,,2022-06-06,RECRUITING,INTERVENTIONAL,['PHASE3']
16002,NCT02813343,Glucose control (HbA1c levels),Standardized PROMs/PREMs,,2016-04,COMPLETED,INTERVENTIONAL,['NA']
16003,NCT05236660,Foot ulcer recurrence during the 12-months follow-up (as the primary clinical outcome),Quality-adjusted life years,,2022-03-02,RECRUITING,INTERVENTIONAL,['NA']
16004,NCT05418699,HbA1c level,Coefficient of variation,,2022-09-26,RECRUITING,OBSERVATIONAL,['NA']
16005,NCT05195944,Change in HbA1c level (%),Number of treatment-emergent adverse events,Change in alanine aminotransferase (ALT) level,2022-10-26,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE4']
16006,NCT02197520,Pharmacodynamics (PD): Average Glucose Infusion Rate From Euglycemic 2-step Hyperinsulinemic Clamp (M-value),Pharmacokinetics (PK): Area Under the Concentration Curve (AUC) for Insulin Lispro During Clamp,,2014-07,COMPLETED,INTERVENTIONAL,['PHASE1']
16007,NCT01877603,The relation between plasma irisin and endothelium-dependent vasodilation,,,2013-07,COMPLETED,OBSERVATIONAL,['NA']
16008,NCT01031108,To examine the effects of SRT2104 (2.0 g administered once daily for 28 days) on reversing vasomotor and fibrinolytic dysfunction in both type 2 diabetes mellitus patients and otherwise healthy smokers in a fed state.,"To explore the effects of SRT2104 on potential biomarkers of activity for glucose control (HbA1c, glycated albumin and fructosamine) and/or Sirt1 activation.",,2010-05-28,COMPLETED,INTERVENTIONAL,['PHASE1']
16009,NCT01065948,"monitor safety and performance of FAS response in two different body sites (abdomen, forearm)","assess comfort level during FAS insertion, when worn during normal activities, and during FAS removal",,2009-11,COMPLETED,INTERVENTIONAL,['PHASE1']
16010,NCT06253351,HbA1c after HCL,nephropathy,,2024-03-13,RECRUITING,OBSERVATIONAL,['NA']
16011,NCT01614613,MAD Mean Absolute Value of the Difference Between Blood Glucose Meter (BGMS) Results and Corresponding YSI Blood Glucose (BG) Results in the Low BG Range(<70 mg/dL),Number of Subject Responses 'Strongly Agree' 'Agree' or 'Neutral' With Questionnaire Statements,,2012-05,COMPLETED,INTERVENTIONAL,['NA']
16012,NCT02582736,Hospitalization for a hyperglycemic emergency,,,2012-04,COMPLETED,OBSERVATIONAL,['NA']
16013,NCT05262387,Change From Baseline in Plasma Glucose (PG) From the Start to the End of Exercise for Each Treatment Arm,Change From Baseline in Postprandial Plasma Glucose (PPG) Excursion During Mixed-Meal Tolerance Test (MMTT) for Each Treatment Arm,,2022-02-14,COMPLETED,INTERVENTIONAL,['PHASE1']
16014,NCT04025762,Time spent in the target sensor glucose range,"Total, basal and bolus insulin dose",Sleep quality assessment,2019-09-01,COMPLETED,INTERVENTIONAL,['NA']
16015,NCT04698018,"AUCIAsp,0-30min, area under the serum insulin aspart concentration-time curve from 0 to 30 minutes",Number of treatment emergent hypoglycaemic episodes,,2021-04-20,COMPLETED,INTERVENTIONAL,['PHASE1']
16016,NCT05790681,"Time to maximum observed serum insulin icodec concentration after a single dose (tmax,Ico,SD)","Model-based area under the serum insulin icodec concentration-time curve during one dosing interval at steady state (AUC,Ico,τ,SS,model)",,2023-04-25,RECRUITING,INTERVENTIONAL,['PHASE1']
16017,NCT05691985,The association of fibrinogen to albumin ratio (FAR) with DKD type 2.,,,2024-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
16018,NCT04096989,Health-related quality of life of short form 36 (SF-36),Body mass index (BMI),,2020-02-17,COMPLETED,INTERVENTIONAL,['NA']
16019,NCT04279613,Adverse Events,Change in the area under the plasma C-peptide concentration-time curve,,2020-11-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
16020,NCT01987258,Glycemic control,Excess post-exercise oxygen consumption (EPOC),,2013-06,COMPLETED,INTERVENTIONAL,['NA']
16021,NCT05714059,Primary Effectiveness Endpoint for Age 7-17 - Percent of Time in Range (TIR 70-180 mg/dL),Secondary Effectiveness Endpoint 2 for Age 7-17 - Percent of Time in Range (TIR 70-180 mg/dL),,2023-02-28,COMPLETED,INTERVENTIONAL,['NA']
16022,NCT01609582,Time to First Occurrence of Any Component of Primary Major Adverse Cardiovascular Event (MACE) Composite,Time to First Occurrence of Any Component of Secondary Major Adverse Cardiovascular Event (MACE) Composite,,2012-06,TERMINATED,INTERVENTIONAL,['PHASE3']
16023,NCT04342845,Problem Areas in Diabetes Questionnaire,Stages of Change score,,2016-05-01,COMPLETED,INTERVENTIONAL,['NA']
16024,NCT03122041,The main outcome was change in HOMA-β index (Homeostasis model assessment for beta cell function index).,The secondary outcome was change in plasma glucose level at 120 minutes (G120) after glucose load in oral glucose tolerant test (OGTT).,,2016-08,COMPLETED,INTERVENTIONAL,['PHASE4']
16025,NCT04388280,Major adverse cardiovascular events (MACE),Differences in the outcome between functional and angiographic imaging in imaging arm,,2021-01-28,UNKNOWN,INTERVENTIONAL,['NA']
16026,NCT03771066,Change in rate of glucose appearance,Change in concentration of clostridia,,2019-01-01,UNKNOWN,INTERVENTIONAL,['NA']
16027,NCT04939753,Nephrogenic Diabetes Insipidus prevalence,Timing of symptoms of NDI,,2021-05-26,COMPLETED,OBSERVATIONAL,['NA']
16028,NCT03869411,maximum rate of oxygen consumption,blood cholesterol,,2019-08-15,COMPLETED,INTERVENTIONAL,['NA']
16029,NCT05716503,Patient satisfaction of aesthetic outcome,,,2023-02-01,RECRUITING,INTERVENTIONAL,['NA']
16030,NCT05247840,diagnostic accuracy of peripheral nerve conduction test 3.6,clinical symptoms of diabetic patients will be measured and compared to healthy children. 8.6,,2022-09-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
16031,NCT03008239,Adverse Events reporting,Blood maltose concentrations,,2017-11-14,UNKNOWN,INTERVENTIONAL,['NA']
16032,NCT00660764,"Effects of starting treatment with rosuvastatin were assessed, on low-density lipoprotein cholesterol (LDL-C) goal achievement, in patients with a dissimilar high-risk profile who hadn't been treated with cholesterol lowering drugs in the past 3 months.",Also set-up costs of rosuvastatin treatment and proportional changes in LDL-C and high-density lipoprotein cholesterol (HDL-C) were studied.,,2003-05,COMPLETED,OBSERVATIONAL,['NA']
16033,NCT01537120,24 Hour Weighted Mean Glucose (WMG) At 2 Weeks,HbA1C At 12 Weeks,,2011-12,COMPLETED,INTERVENTIONAL,['PHASE1']
16034,NCT02132676,Change in Glycemic Control,Endocrinology Visits,,2016-04-25,COMPLETED,OBSERVATIONAL,['NA']
16035,NCT03740919,Change From Baseline in Hemoglobin A1c (HbA1c) Efficacy Estimand at Week 26,Change From Baseline in 7-Point Self-Monitored Blood Glucose (SMBG) Values at Week 26,,2019-04-07,COMPLETED,INTERVENTIONAL,['PHASE3']
16036,NCT01493050,glucose metabolism,serum phosphate level,,2012-02,COMPLETED,INTERVENTIONAL,['PHASE2']
16037,NCT01247558,All-Cause Health Plan Costs,Demographics of Patients Taking Metanx®,,2010-11,COMPLETED,OBSERVATIONAL,['NA']
16038,NCT00898534,Hemoglobin A1c,Number of phone and/or email contacts between practitioner and patient,,2003-11,COMPLETED,INTERVENTIONAL,['PHASE4']
16039,NCT00171119,Change from baseline in urine albumin excretion rate after 24 weeks,Percent of patients returning to normal urine albumin excretion rate after 24 weeks,,2004-01,TERMINATED,INTERVENTIONAL,['PHASE4']
16040,NCT03757910,Brain Tau SUVR,White Matter Hyper Intensity Volume,,2019-10-01,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1']
16041,NCT01333176,Does the HbA1c identify the same individuals as fasting and 2-hr pc glucose tests to identify diabetes and pre-diabetes in a First Nation community,"To identify the response rate of ""gold standard"" diabetes testing in a First nation community",,2011-04,UNKNOWN,INTERVENTIONAL,['NA']
16042,NCT01812694,Gestational weight gain,Gestational Diabetes,,2013-03-28,COMPLETED,INTERVENTIONAL,['PHASE3']
16043,NCT00992797,"Insulin sensitivity measured with euglycemic, hyperinsulinemic clamp",Metabolomics analyses.,,2009-09,UNKNOWN,INTERVENTIONAL,['PHASE2']
16044,NCT00419562,Rate of Type 1 Diabetes Per Year Among Individuals in the Primary Stratum When Treated With Oral Inulin Versus Placebo,Rate of Type 1 Diabetes in Secondary Stratum (Stratum 3+4) When Treated With Oral Insulin Versus Placebo,,2007-02,COMPLETED,INTERVENTIONAL,['PHASE3']
16045,NCT00851903,HbA1c Response Rate: Percentage of Patients Achieving Glycosylated Haemoglobin A1c (HbA1c) < 7% at Study Endpoint (End of Treatment Period),Change in Body Weight From Baseline to Study Endpoint,,2009-06,COMPLETED,INTERVENTIONAL,['PHASE3']
16046,NCT02242825,Change from Baseline in diastolic blood pressure (DBP),Number of patients with adverse events,,2006-01,COMPLETED,OBSERVATIONAL,['NA']
16047,NCT06012799,Rate of NODAT,,,2021-05-15,RECRUITING,OBSERVATIONAL,['NA']
16048,NCT03555734,Cardiovascular disease (CVD),Obesity,,2017-11-21,UNKNOWN,OBSERVATIONAL,['NA']
16049,NCT03215953,Severe adverse events related to use of offloading device,Lifestyle limitation,,2019-02-01,UNKNOWN,INTERVENTIONAL,['NA']
16050,NCT03783598,Canada activity performance measure (COPM),Demographic questionnaire,,2015-12-02,COMPLETED,INTERVENTIONAL,['NA']
16051,NCT05957055,The frequency of adverse events - lisdexamphetamine arm,"Percentage of trial participants achieving an improvement in ADHD symptom severity on the basis of Conners 3 ""hyperactivity/impulsivity"" scale",,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
16052,NCT02429232,Change from baseline in bone turnover markers,Change from baseline in urine biomarkers,,2015-10,UNKNOWN,INTERVENTIONAL,['PHASE4']
16053,NCT05282602,Timed Up and Go Test,,,2022-02-20,COMPLETED,INTERVENTIONAL,['NA']
16054,NCT04354090,Incidence of adverse events and serious adverse events related to JY09,Immunogenicity,,2018-04-26,COMPLETED,INTERVENTIONAL,['PHASE1']
16055,NCT02276196,"Changes from baseline following 8-week treatment with a glucagon-like peptide(GLP)-1 receptor agonist versus insulin glulisine on renal hemodynamics, measured as glomerular filtration rate (GFR) / effective renal plasma flow (ERPF)",Blood Pressure,Arterial stiffness,2014-09,COMPLETED,INTERVENTIONAL,['PHASE4']
16056,NCT05029115,recurrence rate of AF within a year in ablated participants,Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT) score,,2021-10-05,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
16057,NCT00374270,difference in change in systolic BP between the intervention and usual care groups,proportion of patients that are prescribed an ACE inhibitor or angiotensin receptor antagonist between groups,,2005-05,COMPLETED,INTERVENTIONAL,['PHASE4']
16058,NCT02472236,Composite measure the plasma concentrations of Digoxin.,Incidence of adverse events and serious adverse events,,2015-06-08,COMPLETED,INTERVENTIONAL,['PHASE1']
16059,NCT00005124,,,,1969-07,COMPLETED,OBSERVATIONAL,['NA']
16060,NCT00699790,Change in HbA1c,"Other glycemic, atherosclerosis, lipid and mechanism-based biomarkers will be measured",,2009-02,COMPLETED,INTERVENTIONAL,['PHASE2']
16061,NCT01656850,Plasma Vitamin E Level at the Baseline and at the End of 3-month Dietary Intervention,,,2011-11,COMPLETED,INTERVENTIONAL,['NA']
16062,NCT02318706,Change in the Average Daily Pain Score (ADPS) From Baseline to Week 14 Following Administration of DS-5565 in Participants With Diabetic Peripheral Neuropathic Pain,Change in Visual Analog Scale From Baseline (Week 14) to Week 66 Following Administration of DS-5565 in Participants With Diabetic Peripheral Neuropathic Pain,,2015-01,COMPLETED,INTERVENTIONAL,['PHASE3']
16063,NCT04782128,"The proportion of subjects who have improved by ≥2 steps from baseline in DRSS score at week 24, 52",Safety of RC28-E injection,,2021-05-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
16064,NCT01812811,Fraction of missed pulse wave analysis,Reproducibility of pulse wave analysis parameters,"Diurnal variation of brachial blood pressure, central blood pressure and pulse wave velocity",2012-09,COMPLETED,OBSERVATIONAL,['NA']
16065,NCT02954601,Change in Glucose Levels Between Pre-treatment and End of Treatment as Measured by 24-hour Continuous Glucose Monitoring (CGM),Calculate the Difference Between Values of Pre-treatment and End-of-treatment Mean Daytime CGM Glucose,,2016-10,COMPLETED,INTERVENTIONAL,['PHASE2']
16066,NCT02498002,ACADM Gene Expression in Subcutaneous Adipose Tissue,Post-Prandial Protein Oxidation,,2015-05,COMPLETED,INTERVENTIONAL,['NA']
16067,NCT04446026,Hb1Ac,Fasting glucose,,2020-07-08,COMPLETED,INTERVENTIONAL,['PHASE4']
16068,NCT01133600,Pharmaco-economic,Quality of Life/patient satisfaction,,2010-08,TERMINATED,INTERVENTIONAL,['PHASE4']
16069,NCT03150654,Change macular pigment optical density from baseline at 6 months,Correlation analysis between macular pigment optical density and panretinal laser photocoagulation parameters during 6 months,,2015-10-01,COMPLETED,INTERVENTIONAL,['NA']
16070,NCT04141787,Clinical cure rate of deep-seated methicillin sensitive Staphylococcal infections,Adverse event rate,Duration of therapy,2019-07-11,UNKNOWN,INTERVENTIONAL,['PHASE4']
16071,NCT05478525,Number of participants with adverse events [safety and tolerability of GLY-200],Change from baseline in 3-hours postprandial plasma insulin profile,,2022-08-03,COMPLETED,INTERVENTIONAL,['PHASE2']
16072,NCT00547183,Effectiveness measured by IIEF score of questions 1-5 and 15 plus the percentages of positive responses to questions 2 and 3 in the SEP diary,"Change in the GAQ, SEP, IIEF, SEAR, and RSE scores.",,2004-10,COMPLETED,INTERVENTIONAL,['PHASE3']
16073,NCT00537498,"Number of patients being alive, having no major amputation and healed ulceration","Each of overall survival, major amputation rate, survival free of major amputation rate, rate of ulcer healing, and safety",,2002-02,COMPLETED,INTERVENTIONAL,['PHASE2']
16074,NCT02519309,Change from Baseline Body Weight,Change from Baseline Body Weight,,2015-08,COMPLETED,INTERVENTIONAL,['NA']
16075,NCT02373319,Pre-post changes in blood lipid levels,Pre-post changes in body mass index,,2016-03,COMPLETED,INTERVENTIONAL,['NA']
16076,NCT03378765,BMI,,,2018-01-02,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
16077,NCT00403741,"Score on Treatment Self-Regulation Questionnaire(TSRQ)at Treatment Self-Regulation Questionnaire (TSRQ) at 3 months, 9 months and 15 months after assesment's day of the education period.","HbA1c et lipid profile at 3 months, 9 months and 15 months after assesment's day of the education period.",,2007-01,COMPLETED,INTERVENTIONAL,['NA']
16078,NCT04600167,First diagnosis of TB,"Occurrence of possible, probable, or definite TB, or death",,2022-06-17,RECRUITING,INTERVENTIONAL,['PHASE3']
16079,NCT03839511,Peak Epinephrine Levels,CGM Glucose,,2018-11-28,COMPLETED,OBSERVATIONAL,['NA']
16080,NCT00185601,HbA1c,Health care utilization,,2006-02,COMPLETED,INTERVENTIONAL,['NA']
16081,NCT05237076,Chemosensitivity of carotid bodies during baseline and euglycemic clamp,HRV during baseline and euglycemic clamp,,2021-12-01,COMPLETED,INTERVENTIONAL,['NA']
16082,NCT03627182,Change from baseline in Glycosylated Hemoglobin (HbA1c),Evaluate safety of CKD-501 from number of participants with adverse events,,2018-04-26,UNKNOWN,INTERVENTIONAL,['PHASE3']
16083,NCT01542060,HbA1c (glycosylated haemoglobin),Incidence of hypoglycaemic episodes,,2004-01,COMPLETED,OBSERVATIONAL,['NA']
16084,NCT01257373,Cumulative major adverse cardiovascular events（MACE）,Stroke,,2010-04,UNKNOWN,OBSERVATIONAL,['NA']
16085,NCT04567225,Time to Anion Gap Closure,Incidence of Hypoglycemia,,2020-10-01,TERMINATED,INTERVENTIONAL,['PHASE4']
16086,NCT06003634,Number of Participants with Change in A1c,Social Network Scale,,2023-11-20,RECRUITING,OBSERVATIONAL,['NA']
16087,NCT04445168,Moderate to vigorous physical activity (MVPA),Health-related quality of life,,2020-08-31,UNKNOWN,INTERVENTIONAL,['NA']
16088,NCT03909555,Difference in the proportions of chronic complications,Difference of quality of life,New biomarkers which may indicate the occurrence of chronic complications of diabetes,2019-06-01,UNKNOWN,OBSERVATIONAL,['NA']
16089,NCT02378493,Antibiogram results,The capacity of the S. aureus strains isolated to create biofilms in the presence of antibiotics,Perception threshold for vibrations at the ankle (Hz),2015-12-16,COMPLETED,OBSERVATIONAL,['NA']
16090,NCT00484068,nutritional status,,,2003-01,COMPLETED,INTERVENTIONAL,['NA']
16091,NCT05782192,HbA1c change from baseline at week 24,Pancreatic β-cell function change (calculated by HOMA-β ) from baseline at week 24 and week 52,,2019-06-13,COMPLETED,INTERVENTIONAL,['PHASE3']
16092,NCT00237250,Change in area under the 0-2 hour prandial glucose curve at 12 weeks,Change in fasting proinsulin/insulin ratio at 12 weeks,,2005-10,COMPLETED,INTERVENTIONAL,['PHASE3']
16093,NCT00469287,,,,2007-06,COMPLETED,OBSERVATIONAL,['NA']
16094,NCT05956106,Blood pressure will be assessed before and after the trial.,,,2023-08-01,RECRUITING,INTERVENTIONAL,['NA']
16095,NCT04531111,Impact of COVID-19 pandemic and lockdown on glycemic control among a sample of Egyptian children and adolescents with type 1 diabetes,Impact of COVID-19 pandemic and lockdown on insulin dosage among a sample of Egyptian children and adolescents with type 1 diabetes,,2020-07-07,UNKNOWN,OBSERVATIONAL,['NA']
16096,NCT03064321,Average Glucose Control for Last 3 Months Assessed by A!C level,Sleep Quality,Insomnia Severity,2017-11-01,COMPLETED,INTERVENTIONAL,['NA']
16097,NCT03847129,Static two-point discrimination (S2PD) test,,,2015-08-20,COMPLETED,INTERVENTIONAL,['NA']
16098,NCT04726657,Fructosamine,time below 70,,2016-01-18,COMPLETED,INTERVENTIONAL,['NA']
16099,NCT01525992,Hemoglobin A1c,Blood pressure,,2012-03,COMPLETED,INTERVENTIONAL,['NA']
16100,NCT00198900,,,,2000-01,COMPLETED,OBSERVATIONAL,['NA']
16101,NCT02367131,Percentage of Patients With Adverse Drug Reactions (ADRs),Change From Baseline in Fasting Plasma Glucose at the Last Observation During the Observation Period,,2015-02-24,COMPLETED,OBSERVATIONAL,['NA']
16102,NCT02547519,The activation of an antibody response against insulin.,GAD and IA-2 autoantibodies,Adverse events,2015-08,COMPLETED,INTERVENTIONAL,['PHASE2']
16103,NCT00123435,Weight loss,Quality of life and participant satisfaction,,2005-07,COMPLETED,INTERVENTIONAL,['NA']
16104,NCT03476460,Incidence of contrast nephropathy during the first 48 hours after contrast administration,Determination of biomarkers of contrast nephropathy during the first 48 hours after contrast administration,,2014-03-01,COMPLETED,INTERVENTIONAL,['PHASE2']
16105,NCT06137222,Incidence of adverse events (AEs) and serious adverse events (SAEs). Primary safety endpoint,Wound size (area in cm2) reduction from baseline/treatment initiation,,2023-12-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
16106,NCT05888259,pressure-time integrals,,,2021-09-17,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
16107,NCT00509223,HbA1c Change,,,2007-07,COMPLETED,INTERVENTIONAL,['NA']
16108,NCT05141929,Change from Self Rated Abilities for Health Practices levels in pregnant women with GDM,Rate of maternal-fetal-neonatal complications in pregnant women with GDM,,2020-06-01,COMPLETED,INTERVENTIONAL,['NA']
16109,NCT02023320,Change in HbA1c from baseline,Change in serum C-peptide from baseline,,2013-11,COMPLETED,INTERVENTIONAL,['NA']
16110,NCT01897688,To demonstrate the safety and efficacy of islet transplantation under alemtuzumab induction for treatment of Type-1 Diabetes (T1D) in subjects with hypoglycemia unawareness and a history of severe hypoglycemic episodes.,To relate clinical transplant outcomes based upon islet quantity/quality to organ donor characteristics.,,2012-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
16111,NCT05684406,evaluate the potential of peripheral blood mtDNA-CN as biomarker in type 2 diabetic patients,evaluate the potential of leukocyte telomere length as biomarker in type 2 diabetic patients,,2023-01,RECRUITING,OBSERVATIONAL,['NA']
16112,NCT02796950,Levels of GLP-1 in plasma,Insulin sensitivity by measuring blood glucose after an OGTT,"Secretion of the hormones ghrelin, leptin and GIP (gastric inhibitory polypeptide) by measuring hormone levels in plasma",2016-06,COMPLETED,INTERVENTIONAL,['NA']
16113,NCT00992537,Area under the glucose infusion rate curve,Maximum observed insulin aspart concentration,,2009-10,COMPLETED,INTERVENTIONAL,['PHASE1']
16114,NCT03363594,To evaluate total body fat content across various BMI categories in the study population,To correlate HbA1C level with various BMI categories,,2017-12-11,COMPLETED,OBSERVATIONAL,['NA']
16115,NCT00381342,Change in HbA1c (glycosylated hemoglobin) from Baseline to Week 24,"Changes in fasting and 30, 60, 120 and 180-minute glucose measurements",,2006-09,COMPLETED,INTERVENTIONAL,['PHASE3']
16116,NCT02833415,Change in Glycerol Enrichment,,,2016-03,COMPLETED,INTERVENTIONAL,['PHASE4']
16117,NCT05680207,improvement in The Diabetes Empowerment Scale scores,improvement in triglyceride,,2019-03-01,COMPLETED,INTERVENTIONAL,['NA']
16118,NCT00992043,glycated hemoglobin,,,2009-10,COMPLETED,INTERVENTIONAL,['NA']
16119,NCT05375656,Glycemic variability during Inuit diet,Glycemic variability during habitual diet,Fecal proteomics.,2022-01-08,COMPLETED,INTERVENTIONAL,['NA']
16120,NCT04432090,Incremental AUC for glucagon during hypoglycemia (above baseline levels during euglycemia),,,2021-04-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
16121,NCT04762719,Uptake of 11C-ER 176 in the Stomach Muscle,Percentage of Immune Cells With CD45 Expression,,2021-05-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
16122,NCT02643251,Change From Baseline to Day 84 (Week 12) in Numeric Pain Rating Scale Score,Mean Daily Worst Pain Intensity Numeric Pain Rating Scale Scores,,2015-12,COMPLETED,INTERVENTIONAL,['PHASE2']
16123,NCT00068094,,,,2005-07,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
16124,NCT05322551,Changes in lipid related biochemical parameters,Dietary Intake changes,,2022-06-24,RECRUITING,OBSERVATIONAL,['NA']
16125,NCT05977465,Change in HbA1c %,,,2022-01-20,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
16126,NCT05293808,Effects of different doses of aspirin on platelet aggregation,Valuation of RAC1 levels in platelets,,2014-05-01,COMPLETED,INTERVENTIONAL,['PHASE4']
16127,NCT03779139,Clarke score,,,2019-08-01,RECRUITING,INTERVENTIONAL,['NA']
16128,NCT05203575,HbA1c after Cycle 2,Sleep quality after Cycle 2,,2022-03-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
16129,NCT02509624,PK Parameter: Cmax of Selonsertib and Its Metabolite GS-607509,Percentage of Participants Experiencing Any Treatment-Emergent and Grade ≥ 3 Laboratory Abnormalities,,2015-08-18,COMPLETED,INTERVENTIONAL,['PHASE1']
16130,NCT05544825,75-g Oral Glucose Tolerance Test (120 minute glucose),High-density lipoprotein cholesterol,,2022-07-01,COMPLETED,INTERVENTIONAL,['NA']
16131,NCT00894322,Time to Maximum Concentration (Tmax) of 2 mg Exenatide (Cohort 2) in Participants With Diabetes in Pharmacokinetic Evaluable Population,Mean Change From Baseline at Week 12 in Fasting Plasma Glucose in Participants With Diabetes (Cohort 2) for the ITT Population,,2009-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
16132,NCT01700075,full recovery from atherosclerotic diseases,normalised laboratory and instrumental data,,2009-01,COMPLETED,INTERVENTIONAL,['PHASE4']
16133,NCT02087826,Response to the Mixed Meal Tolerance Test,Response to Metformin,Response to a Mixed Meal Tolerance Test after Metformin,2014-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
16134,NCT01973374,Compliance with Obstetric and Diabetes Care,Neonatal Outcomes,,2013-01,COMPLETED,INTERVENTIONAL,['NA']
16135,NCT03048227,Time spent with glucose,Score of Quality of Life questionnaire (IDSRQ),,2017-04-21,TERMINATED,INTERVENTIONAL,['NA']
16136,NCT03295578,Wellbeing,Qualitative user experiences,BMI,2017-10-02,COMPLETED,INTERVENTIONAL,['NA']
16137,NCT01726491,DNA methylation of genes in insulin resistance,mRNA expression of genes,,2012-08,COMPLETED,OBSERVATIONAL,['NA']
16138,NCT03778580,Bone formation in serum by P1NP,Advanced glycation endproducts,,2018-03-01,COMPLETED,INTERVENTIONAL,['NA']
16139,NCT01337141,Optimise metabolic control,Treatment adherence,,2011-05,COMPLETED,INTERVENTIONAL,['NA']
16140,NCT06141811,Evaluation of incidence of adverse events,,,2023-04-25,RECRUITING,OBSERVATIONAL,['NA']
16141,NCT04120844,Problem Areas in Diabetic (PAID) Questionnaire,Stages of Change score,,2016-05-01,COMPLETED,INTERVENTIONAL,['NA']
16142,NCT00407771,"The magnitude of platelet aggregation inhibition before randomization, 10 minutes (t=0) and 8 hours (t=8) post tirofiban administration using the Ultegra RPFA assay.",Major adverse cardiac events (MACE) at 24 hours and 30 days post PCI.,,2007-11,UNKNOWN,INTERVENTIONAL,['PHASE4']
16143,NCT01921192,homocysteine,folic acid,vitamin B12,2012-09,UNKNOWN,INTERVENTIONAL,['PHASE4']
16144,NCT01454024,Number of adverse events and technical complaints,HbA1c (haemoglobin A1c),,2011-11,COMPLETED,OBSERVATIONAL,['NA']
16145,NCT05791929,Area Under ROC curve generated by the statistical model able to discriminate between healing and not healing ulcers,The AUC of the models estimated according to different sites of ulcers.,,2023-04-13,WITHDRAWN,OBSERVATIONAL,['NA']
16146,NCT06060743,insulin information sheet,Insulin Injection Skill Observation Form,,2022-11-01,COMPLETED,INTERVENTIONAL,['NA']
16147,NCT05900505,"To compare participant satisfaction with NSRCH (social navigator) vs. standard care (social worker), as measured by the Client Satisfaction Questionnaire (CSQ).","To compare change in Quality of Life (QOL) of participants (pre/post intervention) referred to NSRCH (social navigator) vs standard care (social worker), as measured by the WHOQOL-BREF.",To compare the resource cost of the social navigator compared to the social worker.,2023-06-26,RECRUITING,INTERVENTIONAL,['NA']
16148,NCT00997282,Changes in HbA1C from baseline,Changes in 3 hour PPG AUC from baseline,,2009-09,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
16149,NCT03565809,Diabetes control,hospitalization for falls and femoral fracture,,2017-05-02,COMPLETED,OBSERVATIONAL,['NA']
16150,NCT06317584,Diabetes Empowerment scale,Albumin to Creatinine Ratio (ACR),,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
16151,NCT02941874,Normal values of IRAP concentration will be calculated by making the average of the three dosages of IRAP measured at base line.,Temporal reproducibility of the concentration of IRAP,kinetic profile of the concentration of IRAP during OGTT,2017-04-07,COMPLETED,OBSERVATIONAL,['NA']
16152,NCT02425410,Delay between viral events and T1D diagnosis,Age at T1D diagnosis as a quantitative trait,,2010-03,UNKNOWN,OBSERVATIONAL,['NA']
16153,NCT03022682,Complete recruitment of IDEO cohort participants to spur novel and creative interactions between investigators that have transformative potential in obesity research.,Adipose tissue inflammation and fibrosis,,2015-02,RECRUITING,OBSERVATIONAL,['NA']
16154,NCT03936062,"Relative hazard of composite outcome of ACS/unstable angina, Stroke, MI, and Mortality",,,2017-09-22,COMPLETED,OBSERVATIONAL,['NA']
16155,NCT03645382,Change from baseline fat mass at 12-week.,Change from baseline visceral/subcutaneous fat area ratio of L1 and L4 at 12-week.,Change from baseline blood pressure (BP; mmHg) at 12-week.,2017-02-21,COMPLETED,INTERVENTIONAL,['NA']
16156,NCT04328207,Percentage of participants that adhere to referral appointment,,,2020-11-18,RECRUITING,INTERVENTIONAL,['NA']
16157,NCT01353066,Measurement of the progression carotid intima media thickness (CIMT) at 24 months after entry into the trial relative to baseline,,,na,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
16158,NCT06003153,Insulin response to oral semaglutide treatment,Baseline incretin level,,2024-03-12,RECRUITING,INTERVENTIONAL,['PHASE4']
16159,NCT04025489,Investigation of gene polymorphism and other markers in 500 subjects,Effect of vitamin d supplementation on raging and other metabolic measures.,,2020-03-01,RECRUITING,INTERVENTIONAL,['NA']
16160,NCT01847092,Changes in Urine Albumin to Creatinine Ratio (UACR),Change in Estimated Glomerular Filtration Rate (mL/Min/1.73 m2) From Baseline to Week 12 Endpoint,,2013-05,COMPLETED,INTERVENTIONAL,['PHASE2']
16161,NCT05071898,Rate of glucose disappearance,Weight loss,Glucose effectiveness (Sg),2022-04-11,RECRUITING,INTERVENTIONAL,['PHASE1']
16162,NCT02824510,Subcutaneous glucose evolution,,,2014-08,COMPLETED,INTERVENTIONAL,['NA']
16163,NCT01552005,Retention rate of Saxagliptin and to describe discontinuation rate and reasons,Saxagliptin utilization according to patient's profile and disease characteristics,,2012-05,COMPLETED,OBSERVATIONAL,['NA']
16164,NCT05624970,insulin sensitivity,A body shape index (ABSI),,2022-11-09,RECRUITING,INTERVENTIONAL,['NA']
16165,NCT05722873,Trabecular bone microarchitecture,Insulin sensitivity,,2023-10-25,RECRUITING,INTERVENTIONAL,['NA']
16166,NCT03259321,Type 2 diabetes,Fish and polyunsaturated fatty acids intake,,1989-01-01,COMPLETED,OBSERVATIONAL,['NA']
16167,NCT05651724,Predictive power of non-invasive tests for detection of high-risk patients,Patient Reported Outcomes: Disease-specific health-related Quality of Life (HR-QoL),Assess if implementation of the patient care pathway as proposed in this study increases awareness and knowledge of NAFLD and NASH management among participating physicians and clinicians,2023-01-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
16168,NCT01507337,Area under the liraglutide plasma concentration time curve (AUC 0-t),Adverse events,,2004-04,COMPLETED,INTERVENTIONAL,['PHASE1']
16169,NCT05802862,Change From Baseline in Hemoglobin A1c (HbA1c),Number of Treatment-emergent Adverse Events (TEAE) and Serious Adverse Events(SAE),,2023-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
16170,NCT04507347,Primary composite endpoint consisting of incidence of cardiac mortality and/or number of worsening of heart failure and/or change from baseline to week 48 in functional capacity,,,2021-06,WITHDRAWN,INTERVENTIONAL,['PHASE3']
16171,NCT01713764,Hemoglobin A1c,Hemoglobin A1c,,2012-10,COMPLETED,INTERVENTIONAL,['PHASE2']
16172,NCT00935805,Blood pressure,Fasting blood glucose,,2006-07,UNKNOWN,OBSERVATIONAL,['NA']
16173,NCT02556840,Birth weight for gestational age,Anxiety score (short form of the Spielberger State - Trait Anxiety Inventory,,2016-04-25,COMPLETED,INTERVENTIONAL,['NA']
16174,NCT04924504,Association between insulin sensitivity Versus structural and functional changes in the placenta,Changes from baseline in the central aortic pressure waveform,,2021-05-01,RECRUITING,OBSERVATIONAL,['NA']
16175,NCT01357603,Pharmacokinetic Parameters: Maximum concentration (Cmax),Pharmacodynamic parameter: GIR max and tGIR max,,2011-06,COMPLETED,INTERVENTIONAL,['PHASE1']
16176,NCT05151770,Algorithm efficacy,Influence of the insulin administration on algorithm results,,2021-12-30,COMPLETED,OBSERVATIONAL,['NA']
16177,NCT04643171,superoxide dismutase,lipid hydroperoxidase,,2020-11-19,UNKNOWN,INTERVENTIONAL,['NA']
16178,NCT01014884,Determine the impact of multidisciplinary team interventions in reducing the rate of non-elective hospitalizations over a 12 month period compared to usual care,Determine the impact of multidisciplinary team interventions versus usual care on the length of stay (LOS) of each non-elective hospitalization,,2009-11,TERMINATED,INTERVENTIONAL,['NA']
16179,NCT02562313,Pharmacokinetics: AUClis 0-30min,Local tolerability,,2015-09,COMPLETED,INTERVENTIONAL,['PHASE1']
16180,NCT05307172,the rate of annual decline in glomerular filtration rate (GFR year n+1 - GFR year n) measured by iohexol clearance,The occurrence of severe liver damage,,2022-05-03,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
16181,NCT00920764,Mean change from baseline to each post-baseline observation on UACR over the course of treatment period versus standard of care,Change from baseline to each weekly measurement in NGAL,,2009-06,COMPLETED,INTERVENTIONAL,['PHASE2']
16182,NCT04219462,the Five-Version of International Index of Erectile function,,,2019-12-02,UNKNOWN,INTERVENTIONAL,['NA']
16183,NCT03231709,Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period,Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (A-T Administered Group),,2017-08-18,COMPLETED,INTERVENTIONAL,['PHASE4']
16184,NCT03928899,caesarean section rate,rate of labor pain,,2019-07-15,UNKNOWN,INTERVENTIONAL,['NA']
16185,NCT05362474,Change in Albuminuria at 3 months,,,2022-07-01,TERMINATED,INTERVENTIONAL,['PHASE3']
16186,NCT01513473,Change From Baseline in HbA1c (Glycosylated Haemoglobin) (%) at 26 Weeks (Analysed by Central Laboratory),"Insulin Antibodies (Insulin Degludec Specific, Insulin Detemir Specific, Insulin Aspart Specific and Antibodies Cross-reacting to Human Insulin)",,2012-01-16,COMPLETED,INTERVENTIONAL,['PHASE3']
16187,NCT03138174,To meet the requirements of ISO 15197:2015,,,2017-03-23,COMPLETED,OBSERVATIONAL,['NA']
16188,NCT04626453,Oxyhemoglobin differences,blood glucose level in mg/dL,,2020-10-29,COMPLETED,INTERVENTIONAL,['NA']
16189,NCT05854069,Gaps in CGM use,CGM satisfaction during the intervention period,Satisfaction with data-sharing relationships,2023-04-30,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
16190,NCT04441216,Between-group differences in glycemic excursion during 75g OGTT as indicated by area under the curve (AUC) plasma glucose concentration during 12-week on-treatment and 12-week off treatment period,Prevalence of euglycaemic chinese subject after 12-week on-treatment and 12-week off treatment period,,2020-08-02,RECRUITING,INTERVENTIONAL,['NA']
16191,NCT00545857,C-peptide response to a Sustacal meal,Hemoglobin A1c,,2002-06,COMPLETED,INTERVENTIONAL,['PHASE1']
16192,NCT04902378,Glycemic control as reflected by percent glucose time-in-range,Proportion of participants who experience device-related adverse events,,2021-06-15,RECRUITING,INTERVENTIONAL,['NA']
16193,NCT02591576,Long term excess mortality,,,2003-01,COMPLETED,OBSERVATIONAL,['NA']
16194,NCT02923089,Postprandial plasma insulin,,,2017-01,COMPLETED,INTERVENTIONAL,['NA']
16195,NCT05762783,Daytime time-in-range (TIR),,,2023-03-27,RECRUITING,OBSERVATIONAL,['NA']
16196,NCT01818557,Neonatal weight,Macrosomia,,2013-05,COMPLETED,INTERVENTIONAL,['NA']
16197,NCT02412852,Reporting of Adverse Events During 12 Week Study Period,Assessment of Blood Oxygenation. (Pulse Oximetry),,2015-04-28,COMPLETED,INTERVENTIONAL,['PHASE2']
16198,NCT01486381,"Standard safety parameters: Haematology, biochemistry and vital signs",BMI (Body Mass Index),,2002-03-20,COMPLETED,INTERVENTIONAL,['PHASE3']
16199,NCT04079413,Immunogenicity,Achievement of Glycated Hemoglobin < 7%,,2019-06-03,COMPLETED,INTERVENTIONAL,['PHASE3']
16200,NCT04812392,Change in glycemic control during a reduced physical activity state,,,2021-04-01,COMPLETED,INTERVENTIONAL,['NA']
16201,NCT00593476,Changes in weight at 12 weeks.,"Changes in HbA1c, lipids, inflammatory markers (hs-CRP), fasting glucose, blood pressure, waist circumference and survey measures at 12 weeks.",,2007-03,COMPLETED,INTERVENTIONAL,['NA']
16202,NCT06198881,Number of vaginal deliveries among the population studied,,,2023-10-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
16203,NCT02202668,Transcutaneous Raman spectra of subcutaneous deep wound soft tissue and underlying bone,Wound temperature post-Transcutaneous Raman Spectroscope,,2014-09,TERMINATED,INTERVENTIONAL,['NA']
16204,NCT03479242,Functional skin closure in DFU in relation to biofilm infection,,,2019-01-25,TERMINATED,OBSERVATIONAL,['NA']
16205,NCT01982253,Change From Baseline in HbA1c at Week 12.,Change From Baseline in Fasting Plasma Glucose (FPG) at Week 12,,2013-10,TERMINATED,INTERVENTIONAL,['PHASE2']
16206,NCT00046501,to measure change in glycemic control as measured by hemoglobin A1c (A1c).,"Clinical values: physical examination, vital signs, change in age-adjusted body mass index (BMI)",,2002-11,COMPLETED,INTERVENTIONAL,['PHASE3']
16207,NCT05354947,Number of Hepatic Adverse Events - Elevation of liver transaminases AST / ALT.,Number of Metabolism and nutrition disorders - Hypoglycemia,,2022-11-01,RECRUITING,INTERVENTIONAL,['NA']
16208,NCT03338803,Change in Glycosylated Hemoglobin (HbA1c) Across Renal Function Categories,Percentage of Adults With T2DM Who Achieve HbA1c < 7.0% Across Renal Function Categories,,2017-11-21,COMPLETED,OBSERVATIONAL,['NA']
16209,NCT01933256,The safety and tolerability of repeat doses of HIP2B in subjects with type 2 diabetes mellitus.,Glucose-stimulated insulin secretion.,Pharmacodynamic (PD) effects of repeat doses of HIP2B on measures of glycemic control and β-cell function,2013-08,COMPLETED,INTERVENTIONAL,['PHASE1']
16210,NCT03781102,Change in Body Mass Index (BMI) Percentile,Change in demographic and social and environmental risk factors for T2D,,2019-07-01,SUSPENDED,INTERVENTIONAL,['NA']
16211,NCT05479435,Hearth Rate,Body Mass Index (BMI),,2021-09-01,RECRUITING,INTERVENTIONAL,['NA']
16212,NCT05290246,Change in glycemic measures- HbA1c (12w),Intervention burden (24w),,2022-05-27,RECRUITING,INTERVENTIONAL,['NA']
16213,NCT00223782,Plantar Pressure,,,2004-05,COMPLETED,INTERVENTIONAL,['NA']
16214,NCT01948986,Change From Baseline in 24 Hour Fluid Balance,Urinary Glucose Excretion Over 24 Hours (UGE0-24hr) for Ertugliflozin,,2013-10-01,COMPLETED,INTERVENTIONAL,['PHASE1']
16215,NCT00067886,,,,2003-03,COMPLETED,OBSERVATIONAL,['NA']
16216,NCT00060918,Change from baseline in HbA1c at 5 months,"Blood pressure at 3 and 5 months. Body weight at 3 and 5 months. Lab values (glucose, insulin, triglycerides, cholesterol, and albumin:creatinine ratio) at 3 and 5 months.",,2001-06,COMPLETED,INTERVENTIONAL,['PHASE4']
16217,NCT00619983,Visual Analog Scale for Pain,,,2008-02,TERMINATED,INTERVENTIONAL,['PHASE4']
16218,NCT05245110,Changes from baseline Health-related quality of life at 12 weeks,,,2018-04-01,UNKNOWN,INTERVENTIONAL,['NA']
16219,NCT04463277,Serum Lipid Profile.,,,2020-09-01,COMPLETED,INTERVENTIONAL,['NA']
16220,NCT04005261,Correlations of fasting C-peptide concentrations with patients characteristics and biochemical findings,,,2018-11-01,COMPLETED,OBSERVATIONAL,['NA']
16221,NCT03127852,Quality of Life as Measured by SF-36,Self-efficacy as Measured by the SEMCD6.,,2016-08-23,COMPLETED,INTERVENTIONAL,['NA']
16222,NCT04041492,Insulin,HOMA Index,,2017-02-14,COMPLETED,INTERVENTIONAL,['NA']
16223,NCT00775541,"MRI, mRS, urine and blood samples",7 day food and DHQ food questionnaire,,2007-10,TERMINATED,INTERVENTIONAL,['NA']
16224,NCT04797208,Time in range,Level 2 hypoglycaemia,Usability,2023-01-09,RECRUITING,INTERVENTIONAL,['NA']
16225,NCT05503303,"Total cholesterol, HDL cholesterol, LDL cholesterol, and triacylglycerols",,,2021-08-01,COMPLETED,OBSERVATIONAL,['NA']
16226,NCT05288452,Primary Outcome for the HIV Cohort: Change in HbA1c level between baseline and 6 months,,,2023-01-01,RECRUITING,INTERVENTIONAL,['NA']
16227,NCT01040806,HbA1c level,LDL cholesterol level,,2009-08,COMPLETED,INTERVENTIONAL,['NA']
16228,NCT02089152,Culture-confirmed melioidosis,Overall melioidosis,,2014-04-01,COMPLETED,INTERVENTIONAL,['NA']
16229,NCT02302963,Change in Hypoglycemia During Closed Loop Control (Assessed by Low Blood Glucose Index [LBGI]),,,2015-06,COMPLETED,INTERVENTIONAL,['NA']
16230,NCT04190277,Difference in percentage of time spent in hypoglycemia (<70mg/dL) during 12 weeks between closed-loop and open-loop,"Questionnaire of usability (for 50 subjects from Arm 1, including 15 adolescents and 35 adults)",,2020-01-07,TERMINATED,INTERVENTIONAL,['NA']
16231,NCT04878419,Recruitment Rate,Correlation of outcome expectation on degree of change in participants Time in Range after the educational intervention.,Correlation of childhood opportunity index (COI) with degree of change in participants' Time In Range after the educational intervention.,2021-06-17,COMPLETED,INTERVENTIONAL,['NA']
16232,NCT00013208,,,,na,COMPLETED,INTERVENTIONAL,['NA']
16233,NCT04333823,Measured Glomerular Filtration Rate (mGFR),Total Daily Insulin Dose (TDID),Exercise Session - Blood Glucose Variability,2020-12-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
16234,NCT01863147,Left ventricular mass and left ventricular volume,Endothelial function and augmentation index (AIx),,2013-07,COMPLETED,INTERVENTIONAL,['PHASE4']
16235,NCT04831385,"The primary outcome measure will be changes in glycemic control, as measured by HbA1c, from baseline.",,,2022-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
16236,NCT05570162,Adherence to Flash 1,Percentage of patients attaining the the International Consensus on Time in Range (ICTR),,2022-11-01,COMPLETED,INTERVENTIONAL,['NA']
16237,NCT00765817,Change in Glycosylated Hemoglobin (HbA1c),Percentage of Subjects Experiencing Minor Hypoglycemia,,2008-10,COMPLETED,INTERVENTIONAL,['PHASE3']
16238,NCT00703027,,,,2002-10,COMPLETED,OBSERVATIONAL,['NA']
16239,NCT00550979,endothelial function,,,2007-09,UNKNOWN,OBSERVATIONAL,['NA']
16240,NCT04420728,Effect of Auto vs. Manual Mode of MiniMed 670G on Time in Target Range Assessed via CGM,"Assess Feasibility of Auto-mode MiniMed 670G via study recruitment, retention and completion rates.",Impact of Weaning on Total Daily Insulin Requirement Assessed by Child Food and Liquid Intake Questionnaire,2020-07-15,COMPLETED,INTERVENTIONAL,['NA']
16241,NCT01722643,HbA1c at 12 Months,Daily Frequency of Self Monitoring of Blood Glucose Checks 12 Months Following Enrollment,,2014-01,COMPLETED,INTERVENTIONAL,['NA']
16242,NCT04080960,hemoglobin A1C,,,2019-05-01,COMPLETED,OBSERVATIONAL,['NA']
16243,NCT03547960,Gestational diabetes,Insulin secretion,,2018-05-30,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
16244,NCT04889859,diabetes remission rate (%),changes in gut microbiota,,2019-05-01,COMPLETED,INTERVENTIONAL,['NA']
16245,NCT03817099,Rate of participants completed the study,Efficacy potential on body mass index,,2019-04-01,UNKNOWN,INTERVENTIONAL,['NA']
16246,NCT00318786,Hemoglobin A1C (HbA1C),"HbA1C, after 28 weeks of treatment; Plasma glucose levels",,2006-04,COMPLETED,INTERVENTIONAL,['PHASE3']
16247,NCT03163511,Change in C-peptide for Cohort 2 subjects,,,2017-07-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
16248,NCT00639808,12-lead ECG data,Scintigraphy to measure rate of gastric emptying after ingestion of a radio-labeled meal,,2006-08,COMPLETED,INTERVENTIONAL,['PHASE1']
16249,NCT03362580,Educational level,,,2017-12-12,COMPLETED,OBSERVATIONAL,['NA']
16250,NCT01291719,glucose control in target range,hypoglycemia,,2008-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
16251,NCT00780559,Change in 6-Minute-Walk Test Measured in Feet Between Baseline and 12 Months,Intraepidermal Nerve Fiber Density (IENFD) at the Proximal Thigh,Change in Physical Activity (PA) at 12 Months as Measured by the CHAMPS (Community Health Activities Model Program for Seniors) Activity Scale,2009-11-01,COMPLETED,INTERVENTIONAL,['NA']
16252,NCT01045447,Change in Glycosylated Haemoglobin (HbA1c),Mean of 9-point Self Measured Plasma Glucose Profile (SMPG),,2010-01,COMPLETED,INTERVENTIONAL,['PHASE3']
16253,NCT02885428,diagnostic of the silent myocardial ischemia,,,2015-04-15,TERMINATED,OBSERVATIONAL,['NA']
16254,NCT01576887,Number of Adverse Events,Area under the curve,,2012-07-31,WITHDRAWN,INTERVENTIONAL,['PHASE2']
16255,NCT04106440,Connected Health Survey,Hemoglobin A1c values,,2019-10-18,COMPLETED,INTERVENTIONAL,['NA']
16256,NCT04838743,Change in local laboratory measured HbA1c (Glycated haemoglobin ),Change in daily dose of Xultophy®,,2021-04-23,COMPLETED,OBSERVATIONAL,['NA']
16257,NCT01667003,Target Lesion Failure (TLF),Clinical Procedural Success,,2012-08,COMPLETED,OBSERVATIONAL,['NA']
16258,NCT03196687,percentage of Frequency of asymptomatic left ventricular diastolic dysfunction in diabetes mellitus type 2,,,2017-07-01,UNKNOWN,OBSERVATIONAL,['NA']
16259,NCT00968708,Percentage of Participants With Primary Major Adverse Cardiac Events (MACE),Percentage of Participants With Secondary Major Adverse Cardiac Events (MACE),,2009-09,COMPLETED,INTERVENTIONAL,['PHASE3']
16260,NCT02366481,Change in beta-cell function,Change in endothelial function (FMD),,2015-02,UNKNOWN,INTERVENTIONAL,['NA']
16261,NCT03498534,Development of active TB,,,2012-09,WITHDRAWN,INTERVENTIONAL,['PHASE4']
16262,NCT03392961,Glucose concentration (Tmin) will be assessed. (Cohort 3),Number of Participants With Adverse Events as a Measure of Safety and Tolerability,,2014-03-27,COMPLETED,INTERVENTIONAL,['PHASE1']
16263,NCT03930758,Bone-specific alkaline phosphatase,Novel Pedar,,2009-10-08,COMPLETED,INTERVENTIONAL,['NA']
16264,NCT02399332,Change in HbA1C from baseline at one year,Change in medication adherence from baseline at one year,,2016-03,COMPLETED,INTERVENTIONAL,['NA']
16265,NCT02213159,Total dose of morphine consumed in Post Anesthesia Care Unit (PACU),overall satisfaction at one month,,2014-07,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
16266,NCT03887403,Assess the effectiveness of the intervention to increase adherence to OAD treatment.,,,2016-03,COMPLETED,INTERVENTIONAL,['NA']
16267,NCT00154414,HbA1c,Safety and tolerability,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE2']
16268,NCT05628311,HbA1c change from baseline at week 24,To assess changes in PD parameters fasting C-peptide at different time points before and after administration.,,2023-01-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
16269,NCT06067022,Temporomandibular Dysfunction,Pain assessment,,2023-01-05,COMPLETED,OBSERVATIONAL,['NA']
16270,NCT05011032,Erythrocyte sedimentation rate (ESR),,,2021-08-12,WITHDRAWN,INTERVENTIONAL,['NA']
16271,NCT03057444,Change of short chain fatty acid concentration in the gut,Change from baseline in anthropometry at four weeks and eight weeks after consumption resistant starch type III,Change from baseline in GLP-1 (Glucagon-like peptide-1) at four weeks and eight weeks after consumption resistant starch type III,2017-02-10,COMPLETED,INTERVENTIONAL,['NA']
16272,NCT00171743,,,,2004-04,COMPLETED,INTERVENTIONAL,['PHASE4']
16273,NCT03703999,HbA1c,insulin use,,2018-06-01,COMPLETED,OBSERVATIONAL,['NA']
16274,NCT01076634,"Area under the glucose infusion rate curve during one dosing interval at steady-date""",Area under the serum Insulin Degludec concentration-time curve,,2010-02,COMPLETED,INTERVENTIONAL,['PHASE1']
16275,NCT04623086,Mean Change in Percent Time in Range,Correction Boluses,,2020-02-14,COMPLETED,INTERVENTIONAL,['PHASE4']
16276,NCT01328561,,,,2011-03-17,TERMINATED,OBSERVATIONAL,['NA']
16277,NCT02351466,Changes in total and regional gray and white matter volumes and white matter microstructure.,Changes in Neurocognitive metrics including IQ as well as executive and visual-spatial memory.,,2015-03,COMPLETED,OBSERVATIONAL,['NA']
16278,NCT01430143,Change from baseline in insulin sensitivity at 12 weeks,Diameter of t-tubuli in skeletal muscle,,2009-09,COMPLETED,INTERVENTIONAL,['NA']
16279,NCT02690883,the percentage change of 24h-UAER(urinary albumin excretion rates) from baseline at Week 24,Change in Blood pressure,,2016-04-08,COMPLETED,INTERVENTIONAL,['PHASE4']
16280,NCT01273675,,,,2010-09,UNKNOWN,OBSERVATIONAL,['NA']
16281,NCT04650646,Hypoglycaemia and QTc interval prolongation,"Type 1 diabetes, healthy controls and coagulability",,2020-09-01,COMPLETED,INTERVENTIONAL,['NA']
16282,NCT01573897,Transcutaneous oxygen tension (PtcO2),,,2012-06-04,TERMINATED,OBSERVATIONAL,['NA']
16283,NCT01707134,Number of hypoglycaemic events,HbA1c (glycosylated haemoglobin),,1997-09,COMPLETED,INTERVENTIONAL,['PHASE3']
16284,NCT04793165,To evaluate the effectiveness and safety of AP treatment without CHO counting in an outpatient setting.,"To determine, as a safety parameter, the percentage of time with glycemic levels less than 70 mg/dl.",,2021-03-08,COMPLETED,INTERVENTIONAL,['NA']
16285,NCT01155206,Triglyceride-rich lipoprotein production rate,,,2009-06,COMPLETED,INTERVENTIONAL,['PHASE4']
16286,NCT00894270,Assess the safety and effectiveness of 5 mm needles using either thigh or abdomen and either a pinched or unpinched skin fold.,Examine pain/discomfort of injections using the different techniques and the different injection sites.,,2008-11,COMPLETED,INTERVENTIONAL,['PHASE4']
16287,NCT02305914,Change in the Levels of fecal elastase-1,outpatient clinic and phone questionnaire,,2014-11,UNKNOWN,OBSERVATIONAL,['NA']
16288,NCT01500850,Fasting Intact Proinsulin,Hypoglycemic events.,,2011-10,UNKNOWN,INTERVENTIONAL,['PHASE4']
16289,NCT02258932,Eating behaviours of adult patients with Type 1 diabetes using continuous subcutaneous insulin infusion therapy measured using food diaries and food surveys.,Cardiometabolic risks of adult patients with Type 1 diabetes who are using insulin pump therapy.,,2013-12,COMPLETED,OBSERVATIONAL,['NA']
16290,NCT05611541,Postprandial 2 hour blood glucose value,Level of compliance with the weekly diet,,2018-10-01,COMPLETED,INTERVENTIONAL,['NA']
16291,NCT03096392,"The amount of time, in minutes, glucose levels are within range (70-180 mg/dL)",Total doses of insulin used (in number of units of insulin injected) during the study,,2017-04-18,COMPLETED,INTERVENTIONAL,['PHASE2']
16292,NCT00915772,Clinical Relevant Drug-related Abnormal Findings in Physical Examination and ECG as Reported as AE,Change in HbA1c From Baseline Over Time,,2009-06,COMPLETED,INTERVENTIONAL,['PHASE3']
16293,NCT01315977,Activation of Antioxidant Response Element After Consumption of Green Tea,,,2011-02,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
16294,NCT02199834,Change of HbA1c,Change in depressive symptom,,2013-02,COMPLETED,INTERVENTIONAL,['NA']
16295,NCT00799435,"Change in Aortic Stiffness, as Measured by the Change in the Mean Aortic Pulse Wave Velocity","Changes in Left Ventricular Diastolic Stiffness, Serum Levels of Advanced Glycation End Products, Serum Biomarkers of Collagen Synthesis, and Serum Levels of Brain Natriuretic Peptide",,2009-07,TERMINATED,INTERVENTIONAL,['PHASE4']
16296,NCT05347862,Change from Baseline Glycated Hemoglobin at 3 and 6 months,Short Form Health Survey (SF-36),Handgrip strength,2022-12-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
16297,NCT02688218,Mean Change in Sensor Glucose in Subjects With Type 1 Diabetes,,,2016-02,COMPLETED,INTERVENTIONAL,['NA']
16298,NCT01296100,The proportion of patients who reach normal levels of all glycaemic parameters.,Difference in reduction of 10 year-estimated cardiovascular risk score of 10% between the standard therapy control group and the lifestyle intervention groups (WHO CVD prediction chart).,,2011-02,COMPLETED,INTERVENTIONAL,['NA']
16299,NCT02358668,Change in Serum Fructosamine in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo,Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in Percent Coefficient of Variation of Blood Glucose Over 24 Hours on Continuous Glucose Monitoring System Repeated Measures Analysis,Changes in Complete Blood Count in Subjects Treated With High Dose and Low Dose BTI320 Compared to Placebo,2015-03-30,COMPLETED,INTERVENTIONAL,['PHASE2']
16300,NCT00133809,The Number of Insulin-Independent Subjects at One Year Following Islet Cell Transplantation,The Number of Subjects Exhibiting Fasting C-peptide Levels ≥ 0.5 ng/mL,,2002-07,COMPLETED,INTERVENTIONAL,['PHASE2']
16301,NCT04558710,Coefficient of variation,Time Above Range,,2018-06-01,COMPLETED,OBSERVATIONAL,['NA']
16302,NCT02821871,Cumulative percentage drainage of SP2086 in fecal,The number of volunteers with adverse events as a measure of safety and tolerability,,2016-03,UNKNOWN,INTERVENTIONAL,['PHASE1']
16303,NCT01057628,change from baseline in HbA1c,"safety as reflected by adverse events, routine safety laboratories, vital signs, physical examinations and 12-lead electrocardiograms (ECGs)",,2010-01-13,COMPLETED,INTERVENTIONAL,['PHASE3']
16304,NCT03232983,Pharmacokinetics: Insulin Lispro Area Under the Concentration Versus Time Curve (AUC) Following LY900014 Administration,Total Amount of Glucose Infused (Gtot) Over Duration of the Clamp Procedure,,2017-08-14,COMPLETED,INTERVENTIONAL,['PHASE1']
16305,NCT03088410,Homeo-static Model Assessment-Insulin Resistance (HOMA-IR),,,2016-08-22,COMPLETED,INTERVENTIONAL,['PHASE4']
16306,NCT03226457,The Effect of Empagliflozin Versus Placebo on the Change in Urine Output.,"The Effect of Empagliflozin Versus Placebo on the Change to the Renal Biomarker, Cystatin C.",,2017-12-11,COMPLETED,INTERVENTIONAL,['PHASE4']
16307,NCT00771069,Attainment rate to the target blood pressure.,Treatment pattern and factors that affect BP control,,2008-11,COMPLETED,OBSERVATIONAL,['NA']
16308,NCT00605189,Compare Energy Charge Between Wound Treatment Therapies,,,2007-07,TERMINATED,INTERVENTIONAL,['NA']
16309,NCT06297603,Change from Baseline in Hemoglobin A1c (HbA1c) (%),Change from Baseline in Systolic Blood Pressure (SBP),,2024-04-12,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
16310,NCT00349986,HgbA1c measurement,,,2006-09,TERMINATED,INTERVENTIONAL,['PHASE4']
16311,NCT03592784,Feasibility of the Food Order Intervention,Birthweight,,2018-06-18,TERMINATED,INTERVENTIONAL,['NA']
16312,NCT04067440,Characterization of microbiome,,,2019-10-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
16313,NCT06208618,Diabetes management self-efficacy,Belief in a healthy lifestyle,,2024-01-15,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
16314,NCT02117518,"Identification, isolation, propagation and targeting of autoreactive T cells from T1D patients",,,2014-05,UNKNOWN,OBSERVATIONAL,['NA']
16315,NCT01251016,Patient Selection,,,2010-07,UNKNOWN,OBSERVATIONAL,['NA']
16316,NCT05264376,"Change over time in Perceived Well-Being as assessed by the World Health Organization Well-Being Index (WHO-5; deWit et al., 2007).",,,2022-03-21,COMPLETED,INTERVENTIONAL,['NA']
16317,NCT01459809,Change in HbA1c,Frequence and incidence of hypoglycemia,,2012-02,COMPLETED,INTERVENTIONAL,['PHASE3']
16318,NCT04734132,Glycated hemoglobin (HbA1C),Conversion rate from prediabetes to normal,Microbiota composition,2019-01-22,COMPLETED,INTERVENTIONAL,['NA']
16319,NCT03670225,Determine if Invia Motion Endure supports acceptable progress towards the goal of therapy for DFU and PI/PU wounds,Evaluation of ease of use and satisfaction,Adequate management of the exudate,2018-10-16,COMPLETED,INTERVENTIONAL,['NA']
16320,NCT03415256,Skin blood flow,balance,,2018-11,WITHDRAWN,INTERVENTIONAL,['NA']
16321,NCT01134224,Area under the glucose infusion rate curve (only for IDegAsp),Area under the insulin aspart concentration-time curve (only for BIAsp 30),,2010-05,COMPLETED,INTERVENTIONAL,['PHASE1']
16322,NCT02164279,Identify predictive non-invasive urinary biomarkers,Relation of urinary markers with patient characteristics,,2013-06,COMPLETED,OBSERVATIONAL,['NA']
16323,NCT03730662,Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg),Rate of Hypoglycemia With Blood Glucose <54 Milligram/Deciliter (mg/dL) [<3.0 (Millimole/Liter (mmol/L))] or Severe Hypoglycemia,,2018-11-20,COMPLETED,INTERVENTIONAL,['PHASE3']
16324,NCT00478127,,,,na,COMPLETED,OBSERVATIONAL,['NA']
16325,NCT04236895,PD endpoint,Safety endpoints,,2018-07-10,COMPLETED,INTERVENTIONAL,['PHASE1']
16326,NCT03239457,Proportion of patients with 100% of the lesion area covered by granulation tissue.,Adverse events,,2015-12,COMPLETED,OBSERVATIONAL,['NA']
16327,NCT04428723,Analysis of hormonal responses during mixed meal testing.,Relationship between hormonal responses and microbiome.,Safety outcome- hyperglycemia and hypoglycemia during the study,2020-08-11,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
16328,NCT03748420,Mean Change in A1c,Clinic-based Medical Care Costs,,2020-08-19,COMPLETED,INTERVENTIONAL,['NA']
16329,NCT02798172,"The primary endpoints were changes from baseline to week 26 in pulmonary function parameters [VC%, FVC%, FEV1%, PEF%, MVV%, TLC%, FEV1/FVC%, DLCO%, and DLCO/VA%] between pretherapy and posttreatment.","In addition, safety endpoints were assessed (AEs, clinical laboratory tests, vital signs, and electrocardiographic readings)",The changes of BMI from baseline to week 26 in intervention group (n=44) and control group (n=37).,2014-05,COMPLETED,INTERVENTIONAL,['NA']
16330,NCT00101478,,,,2004-09,COMPLETED,OBSERVATIONAL,['NA']
16331,NCT01523041,Area under the insulin aspart curve in the interval from 0-24 hours,"tmin, time to minimum concentration",,1999-11-03,COMPLETED,INTERVENTIONAL,['PHASE1']
16332,NCT02762708,Changes in the Gut Microbiome Following RYGB or Caloric Restriction,,,2016-03,COMPLETED,INTERVENTIONAL,['PHASE2']
16333,NCT04714216,Percentage of time sensor glucose is within target glucose range,Patient Survey,,2021-06-29,COMPLETED,INTERVENTIONAL,['NA']
16334,NCT04069234,Coronary Flow Velocity Reserve (CFR),Coronary flow parameter-LAD resting mean diastolic flow velocity,,2019-09-15,WITHDRAWN,INTERVENTIONAL,['PHASE3']
16335,NCT02742701,Predictive performance of glycosuria measured on urine collected between 10 am and 16 am on the blood glucose level at 6 pm,"Type, frequency and intensity of symptoms in relation to the blood glucose level",,2016-04,UNKNOWN,OBSERVATIONAL,['NA']
16336,NCT01083043,Serum levels of endothelial dysfunction biomarkers and glycemic variability,Metabolic parameters and glycemic variability,,2006-12,COMPLETED,OBSERVATIONAL,['NA']
16337,NCT05890950,Proportion of participants who discontinued study medication due to an AE,t1/2 of plasma K-833,,2023-03-13,COMPLETED,INTERVENTIONAL,['PHASE1']
16338,NCT06014879,Demographic and Medical Information Questionnaire,,,2023-08-07,RECRUITING,INTERVENTIONAL,['NA']
16339,NCT00878813,Major disability or death,"severe cerebrovascular re-event (i.e. new TIA, and stroke)",,2009-03,COMPLETED,OBSERVATIONAL,['NA']
16340,NCT01618214,Change From Baseline in HbA1c (Glycosylated Haemoglobin),"Incidence of Hypoglycaemic Episodes (All, Major, Minor and Symptoms Only)",,2012-06,COMPLETED,INTERVENTIONAL,['PHASE4']
16341,NCT04468152,We hypothesize that neck circumference correlated significantly with DME.,We hypothesize that the sRAGE levels were higher in the DME group.,,2018-07-07,COMPLETED,INTERVENTIONAL,['NA']
16342,NCT02656212,Change from baseline in major safety endpoints: Hepatic Function,Change from baseline: C-Peptide,,2015-09,COMPLETED,INTERVENTIONAL,['PHASE1']
16343,NCT00579371,Incidence of insulin independence with a single islet transplant,Metabolic functional assessments of the islet graft,,2004-03-17,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
16344,NCT04997512,Mortality at 2 years,Scores from GOLD score,,2021-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
16345,NCT01614262,change in glycosylated hemoglobin using intensive periodic CGM monitoring vs traditional monitoring,quality of life data evaluation,,2012-06,COMPLETED,INTERVENTIONAL,['NA']
16346,NCT01555008,Change from baseline in postprandial glucose,Area Under Curve (AUC),,2012-03,COMPLETED,INTERVENTIONAL,['PHASE1']
16347,NCT06268821,HbA1c,Frequency of hypoglycaemia events,,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
16348,NCT04421001,Total insulin daily dose per kg per day,"treatment satisfaction, scale up to 10, higher is better",,2020-10,UNKNOWN,INTERVENTIONAL,['NA']
16349,NCT00833846,,,,2009-01-27,COMPLETED,OBSERVATIONAL,['NA']
16350,NCT03620890,Number of Neonates With Composite Adverse Neonatal Outcome,Number of Neonates Who Had Jaundice Requiring Therapy,,2018-09-04,COMPLETED,INTERVENTIONAL,['PHASE4']
16351,NCT06087679,change in resting PPS,Problem Areas In Diabetes (PAID-20),Kidney function measured as creatinine,2022-07-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
16352,NCT03857802,Change of glycated hemoglobin levels.,Change in sleep quality: Pittsburgh Sleep Quality Index,,2017-09-01,COMPLETED,INTERVENTIONAL,['NA']
16353,NCT02652026,Change from baseline in Glycosylated Hemoglobin (HbA1c),,,2013-06,COMPLETED,INTERVENTIONAL,['NA']
16354,NCT00399204,,,,2006-01,WITHDRAWN,INTERVENTIONAL,['PHASE4']
16355,NCT03625752,Changes in pain as measured by the Visual Analog Scale (VAS),Adverse events,,2019-06-06,RECRUITING,INTERVENTIONAL,['NA']
16356,NCT04639414,Histological resolution of NASH without worsening of fibrosis,Hepatic steatosis grade,,2021-03-26,RECRUITING,INTERVENTIONAL,['PHASE4']
16357,NCT00847262,"Metabolic profiles, including lipid profile and blood glucose",Incidents of side effects between groups,,2008-06,COMPLETED,INTERVENTIONAL,['PHASE4']
16358,NCT06096935,exom,exome variations,,2024-02-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
16359,NCT03674866,Change in Glycated Haemoglobin (HbA1c),Reason(s) for discontinuing insulin degludec,,2018-10-29,COMPLETED,OBSERVATIONAL,['NA']
16360,NCT04881110,Peripheral transcutaneous oxygen pressure,Female sexual function,,2021-04-28,UNKNOWN,INTERVENTIONAL,['PHASE4']
16361,NCT01157923,Time spent in the normal range,Number and type of changes in any pump setting per iteration,,2010-07,COMPLETED,INTERVENTIONAL,['NA']
16362,NCT02650050,Number of intra-vitreal anti-VEGF injections,Time to reduction of the macular thickness,,2016-01-19,TERMINATED,INTERVENTIONAL,['NA']
16363,NCT02463097,Change in A1C,Number of Diabetic Ketoacidosis (DKA) Events,,2015-06,COMPLETED,INTERVENTIONAL,['NA']
16364,NCT05218395,To assess the risk of Persistent organic pollutant exposure to type 2 diabetes,To assess the risk of Persistent organic pollutant exposure to thyroid cancer,,2021-12-20,RECRUITING,OBSERVATIONAL,['NA']
16365,NCT04233801,Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) at Week 24,Number of Participants With Adjudicated Diabetic Ketoacidosis (DKA) Events,,2020-04-15,COMPLETED,INTERVENTIONAL,['PHASE3']
16366,NCT01549444,Renin and Aldosterone levels corelated to BP measurements,Blood pressure measurements,,2012-03,COMPLETED,OBSERVATIONAL,['NA']
16367,NCT00108225,"IGF-1, GH, Body Composition",,,2004-07,COMPLETED,INTERVENTIONAL,['NA']
16368,NCT02699307,Change in physical activity: Community Healthy Activities Model Program for Seniors (CHAMPS) survey,Change in social participation:validated questionnaires from the Patient-Reported Outcomes Measurement Information System (PROMIS) assessment center,,2016-06,COMPLETED,INTERVENTIONAL,['NA']
16369,NCT03013985,Mean Daily Blood Glucose Concentration After Hospital Discharge,Hospital Mortality,,2017-05-17,COMPLETED,INTERVENTIONAL,['PHASE4']
16370,NCT04834518,Frequency of Diabetic Ketoacidosis on the clinical presentation of Type 1 Diabetes,The rate of progression from pre-symptomatic T1D to clinical diabetes,,2021-04-01,RECRUITING,OBSERVATIONAL,['NA']
16371,NCT01606397,Number of participants with one or more drug related adverse events (AEs) or any serious AEs,Change in fasting glucagon-like peptide-1 (GLP-1) level,,2008-03,COMPLETED,INTERVENTIONAL,['PHASE1']
16372,NCT01170039,"Efficacy, Measured by the Average Number of Spontaneous Bowel Movements (SBMs) Per Week",Change in Scores on the Patient Assessment of Constipation Quality of Life (PAC-QOL) Questionnaire,,2010-09,COMPLETED,INTERVENTIONAL,['PHASE4']
16373,NCT02456922,Harmony 1 Sensor accuracy,,,2018-07,WITHDRAWN,INTERVENTIONAL,['NA']
16374,NCT05144360,Systolic blood pressure (SBP),Adverse events,,2022-08,WITHDRAWN,INTERVENTIONAL,['PHASE3']
16375,NCT03690778,Cmax of Metformin and rosuvastatin,,,2018-10-04,COMPLETED,INTERVENTIONAL,['PHASE1']
16376,NCT02409017,Mean maternal glucose,,,2015-04,TERMINATED,INTERVENTIONAL,['NA']
16377,NCT01795833,Number of Participants With Progression to Type 2 Diabetes,Total Physical Activity,,2013-06-03,COMPLETED,INTERVENTIONAL,['NA']
16378,NCT02049359,Change From Baseline A1C,"Change in A1C Based on Age, Gender, Race, Type and Duration of Diabetes",,2014-01,COMPLETED,INTERVENTIONAL,['NA']
16379,NCT04830969,Change in Probing Pocket Depth at the 6-month Post-SRP Completed at Baseline,Change in Distance to the Healthy Plane Based on the Subgingival Plaque Microbiome at 6 Months,,2016-11-08,COMPLETED,INTERVENTIONAL,['PHASE2']
16380,NCT01471275,Glycosylated hemoglobin,Adverse events recorded,,2011-11,UNKNOWN,INTERVENTIONAL,['NA']
16381,NCT06197906,accuracy,,,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
16382,NCT01595750,Endotelial function,"Serum endothelial dysfunction markers:TWEAKs, FasL, ADMA",,2012-05,UNKNOWN,INTERVENTIONAL,['PHASE4']
16383,NCT05607160,Proportion of participants achieving the HbA1c target value,"Absolute change in HbA1c (%), from baseline to month 3 and 6",,2022-10-05,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
16384,NCT00994955,best-corrected visual acuity,"change of retinal thickness, presence of hard exudates and leakage in FFA, specificity and sensitivity of optoacoustic measurements",,2006-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
16385,NCT01513369,reduction in HBA1c-levels,Change in used insulin dosage during study,,2012-08,COMPLETED,INTERVENTIONAL,['PHASE3']
16386,NCT01168076,,,,2001-12,COMPLETED,OBSERVATIONAL,['NA']
16387,NCT00986375,physical activity fruit & vegetable consumption,intervention engagement,,2009-10,COMPLETED,INTERVENTIONAL,['NA']
16388,NCT06113588,Diabetes-related distress (patient and family member),Patient medical outcomes,,2023-06-09,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
16389,NCT02411578,Number of Hypoglycemic Events ≥50 mg/dl 15 Minutes AND ≥ 70 mg/dl 30 Minutes After Initial Treatment,CGM Coefficient of Variation,,2015-09,COMPLETED,INTERVENTIONAL,['PHASE2']
16390,NCT02637622,The importance of medication cost from patient perspective,,Self-reported difficulty in understanding and answering the survey questions,2013-07,UNKNOWN,OBSERVATIONAL,['NA']
16391,NCT03940183,HbA1c,Body Mass Index,,2019-07-08,COMPLETED,INTERVENTIONAL,['PHASE3']
16392,NCT02035371,Area under the serum insulin aspart concentration-time curve,Maximum observed serum insulin aspart concentration,,2014-01-13,COMPLETED,INTERVENTIONAL,['PHASE1']
16393,NCT01626053,Changes in A1c levels for pretest and post test (Preset baseline and post-test 2 years,,,2009-03,COMPLETED,INTERVENTIONAL,['NA']
16394,NCT06057623,Change of the isometric force,Change of Rate of Perceived Exertion,,2023-06-15,RECRUITING,OBSERVATIONAL,['NA']
16395,NCT00389896,HDL-C raising effects after 6 weeks,Effect on other lipids and lipoproteins at 6 weeks,,2001-07-26,COMPLETED,INTERVENTIONAL,['PHASE3']
16396,NCT02846857,Percentage of time of glucose levels below 3.9 mmol/L,Percentage of time when the closed-loop was automatically switched to insulin pump therapy,,na,WITHDRAWN,INTERVENTIONAL,['PHASE2']
16397,NCT04442698,Delta Hemoglobin A1c Levels (HbA1c),,,2008-01-01,COMPLETED,OBSERVATIONAL,['NA']
16398,NCT00502138,Fasting and postprandial pramlintide pharmacokinetics,Hemoglobin A1c,,2007-07,COMPLETED,INTERVENTIONAL,['PHASE4']
16399,NCT03931434,Progression rates of low attenuation plaque under influence of Aged Garlic Extract (AGE) as compared to placebo.,Rate of change in endothelial function,,2016-02-23,COMPLETED,INTERVENTIONAL,['NA']
16400,NCT02037321,Non-alcoholic fatty liver disease (NAFLD) analysis,,,2013-05,UNKNOWN,OBSERVATIONAL,['NA']
16401,NCT04455633,Change from Baseline in Average Daily Pain Score (ADPS),Safety: # of AEs reported,,2020-07-07,COMPLETED,INTERVENTIONAL,['PHASE2']
16402,NCT04207619,Percent 13C enrichment of bicarbonate measured via carbon-13 magnetic resonance spectroscopy (13C-MRS),Change in serum epinephrine levels,,2020-02-19,RECRUITING,INTERVENTIONAL,['NA']
16403,NCT03385135,Endothelium-dependent vasodilation,Major adverse cardiac events (MACE),,2017-12,UNKNOWN,INTERVENTIONAL,['NA']
16404,NCT04378114,Bias (mg/dL) Between the Guardian™ Sensor (3) Values and Yellow Springs Instrument™ (YSI™) Plasma Glucose,Percentage of Guardian™ Sensor (3) Values That Were Within 20% of YSI™ Plasma Glucose Values,,2020-05-18,COMPLETED,INTERVENTIONAL,['NA']
16405,NCT01025856,postprandial lipids metabolism,adipose tissue lipolytic activities,,2009-09,COMPLETED,INTERVENTIONAL,['NA']
16406,NCT00993304,"AUC0-8h (triglyceride), the area under the triglyceride-concentration-time curve in the interval 0-8 hours following a meal with a high fat content","Glucose, insulin, C-peptide and glucagon: AUC0-8 hours after meal with a high fat content",,2009-10,COMPLETED,INTERVENTIONAL,['PHASE1']
16407,NCT00634543,Change From Baseline in Pain Intensity Score at Day 43,Change From Baseline in Short Form-36 (SF-36) Score at Day 43,,2006-12,COMPLETED,INTERVENTIONAL,['PHASE4']
16408,NCT04062890,Blood Pressure,,,2019-12-15,UNKNOWN,INTERVENTIONAL,['PHASE2']
16409,NCT01245166,The changes from baseline in HbA1c to the end of treatment period,"the change from baseline to the end of treatment in FBG, PBG, lipid profiles, and body weight. The safety evaluation will include: 1) Adverse events; 2) Laboratory data; 3) Physical examination; 4) Vital signs; 5) 12- lead ECG",,2010-11,UNKNOWN,INTERVENTIONAL,['PHASE3']
16410,NCT00446264,Composite Criteria: Insulin Independence and Glycosylated Hemoglobin (HbA1c) Under 6.5% at One Year,Number of Adverse Events,,2003-05,COMPLETED,INTERVENTIONAL,['PHASE2']
16411,NCT05887544,Concentration of Indole-3-lactic acid in blood,Concentration of 3-Phenyllactic acid in urine,Exploratory analyses,2023-06-01,RECRUITING,OBSERVATIONAL,['NA']
16412,NCT01708902,The Change From Baseline in HbA1c After 12 Weeks of Treatment in APG,The Frequency of Patients With Use of Rescue Therapy During 12 Week Treatment Period in APG,,2012-10,COMPLETED,INTERVENTIONAL,['PHASE3']
16413,NCT00628524,"Parameters of triglyceride tolerance and glucose tolerance in correlation to cardiovascular events, cardiovascular mortality, total mortality.","Waist-to-Hip ratio, nutrition protocol, physical activity, non-invasive endothelial function, body fat composition, other biomarkers of lipid and glucose metabolism.",,2008-02,COMPLETED,OBSERVATIONAL,['NA']
16414,NCT02779413,Number of Adverse Events (AE),Weight gain,,2016-06-02,COMPLETED,OBSERVATIONAL,['NA']
16415,NCT03076528,Balance change from Baseline to 4 weeks quantified by body sway,Change of Incidents of foot problems,,2016-11-06,COMPLETED,INTERVENTIONAL,['PHASE2']
16416,NCT00396071,Change in C-peptide IAUC (0-4hr),Change in postprandial GLP-1,,2006-10,COMPLETED,INTERVENTIONAL,['PHASE3']
16417,NCT01498276,Intergenerational transfer of diet-related behaviors,Efficacy of utilizing mothers to educate family members of disease risk and motivate healthy behaviors.,,2012-01-03,COMPLETED,OBSERVATIONAL,['NA']
16418,NCT03263494,Change in HbA1c from baseline to 26 weeks adjusted for baseline,Pittsburgh Sleep Quality Index,,2018-01-25,COMPLETED,INTERVENTIONAL,['PHASE3']
16419,NCT05501223,Number of medications used at baseline compared to number of medications used at follow-up. Resulting in a rate of medications used at baseline compared to follow-up i.e. no. medication at follow-up/no. at baseline.,EQ5D index score. (a Euro Quality of Life 5-dimension 5-level (EQ-5D-5L) scale). The score is retrieved by using the validated EQ5D questionnaire which translates to a corresponding EQ5D index score using country specific value sets.,,2020-11-01,RECRUITING,INTERVENTIONAL,['NA']
16420,NCT01042977,Proportion of Responders Meeting All Criteria of a 3-item Endpoint of Clinical Benefit,Adjusted Mean Change in Seated Systolic Blood Pressure (SBP) at Week 8 (LOCF) in Participants With Baseline SBP>=130 mmHg,,2010-03,COMPLETED,INTERVENTIONAL,['PHASE3']
16421,NCT05553184,"Change in Brown Adipose Tissue thermogenesis (formoterol induced, cold-induced and effect of nicotinic acid)",Protein expression of subcutaneous abdominal white adipose tissue,,2022-07-05,COMPLETED,INTERVENTIONAL,['NA']
16422,NCT04602754,Percentual reduction of LDL-c levels measured between the first visit and the last visit.,Incidence and severity of adverse events recorded during the study.,,2023-12-01,RECRUITING,INTERVENTIONAL,['PHASE3']
16423,NCT01859793,Brachial Artery Flow Mediated Dilation,Circulating Inflammatory Markers VCAM-1,,2013-06,COMPLETED,INTERVENTIONAL,['PHASE4']
16424,NCT01217307,Improvement in Left Ventricular Ejection Fraction,"Cardiac MRI After 4 Months, Per Protocol Analysis",,2011-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
16425,NCT01386541,Assessment of the safety/tolerability of multiple dosing of BYK324677 given once daily (SID) or twice daily (BID) in healthy volunteers.,Exploratory assessment of the pharmacodynamics (PD) of multiple dosing of BYK324677 (SID or BID) under steady state conditions in healthy volunteers.,,2011-06,COMPLETED,INTERVENTIONAL,['PHASE1']
16426,NCT03968952,Number of home visits completed by Community Health Worker,Mean postpartum Diastolic Blood Pressure,,2019-10-01,COMPLETED,INTERVENTIONAL,['NA']
16427,NCT02523131,Time spent in the target glucose range from 3.9 to 10.0 mmol/l (70 to 180mg/dl) based on CGM glucose levels,Change of body weight from screening to end of study,Amount of CGM use,2016-05,COMPLETED,INTERVENTIONAL,['NA']
16428,NCT01453751,Number of adverse events reported,reduction in requirement of insulin dosage compared to baseline,,2014-03,WITHDRAWN,INTERVENTIONAL,['NA']
16429,NCT02660476,"Diabetes Complications (Nephropathy, Neuropathy, Retinopathy)",Physical activity,,2014-10,TERMINATED,OBSERVATIONAL,['NA']
16430,NCT05902650,OCTA data,,,2021-01-01,RECRUITING,OBSERVATIONAL,['NA']
16431,NCT04531163,Systolic blood pressure,,,2019-10-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
16432,NCT04389775,Number of treatment emergent adverse events (TEAEs),Trough plasma XW003 concentrations before next dosing (Day 1 to last dosing),,2020-03-29,COMPLETED,INTERVENTIONAL,['PHASE1']
16433,NCT03366168,"To demonstrate that in humans, epithelial stem cells isolated from the base of human taste buds can be propagated.",To investigate if differentiation capability of the stem cells changes as a factor of age.,,2017-12-18,RECRUITING,OBSERVATIONAL,['NA']
16434,NCT03502109,Quality of Life (QoL) by visual analog scale (VAS),ACR (albumin-creatinine ratio),,2018-01-05,COMPLETED,INTERVENTIONAL,['NA']
16435,NCT02823678,Percent resected volume of pancreas and diabetes development,Blood glucose control,,2013-10,UNKNOWN,OBSERVATIONAL,['NA']
16436,NCT01839370,Percent of Glucose Measurements within Target Range,,,2013-07,COMPLETED,INTERVENTIONAL,['NA']
16437,NCT00879801,The rate of conversion to diabetes of IGR subjects carrier of type 2 diabetes susceptibility genes,,,2003-01,COMPLETED,OBSERVATIONAL,['NA']
16438,NCT00099892,Change from baseline in HbA1c after 24 weeks,Change from baseline in fasting lipids at 24 weeks,,2004-05,COMPLETED,INTERVENTIONAL,['PHASE3']
16439,NCT02459535,"change in combined blood levels of glucose and insulin, expressed in calculated indices for insulin sensitivity",,,2015-03,COMPLETED,INTERVENTIONAL,['NA']
16440,NCT03686722,Maximum excretion rate (Urate max),Maximum Glucose concentration(Gmax),,2017-09-09,COMPLETED,INTERVENTIONAL,['PHASE1']
16441,NCT04245826,Total mortality,,,2019-05-16,UNKNOWN,OBSERVATIONAL,['NA']
16442,NCT00967629,serum AGE levels,inflammatory markers,,2009-06,COMPLETED,INTERVENTIONAL,['PHASE1']
16443,NCT04158921,The mean change in blood glucose.,The change in the number of hypoglycemic episodes.,,2019-11-07,TERMINATED,INTERVENTIONAL,['NA']
16444,NCT00856986,Mean Change From Randomisation in Glycosylated Haemoglobin A1c (HbA1c) at Week 26.,Hypoglycaemic Episodes Weeks 0-52,,2009-03,COMPLETED,INTERVENTIONAL,['PHASE3']
16445,NCT01797601,Insulin effect on regional brain activity assessed by fMRI,,,2013-02,COMPLETED,INTERVENTIONAL,['NA']
16446,NCT03445065,Cohort 2: Percentage of Time Spent in Hypoglycemia (<54 mg/dL) From Day 90 to Day 120,Change From Baseline in the Partner Diabetes Distress Scale (Partner-DDS) Questionnaire Total and Subscale Scores at Day 60 and Day 180,,2018-02-28,COMPLETED,INTERVENTIONAL,['NA']
16447,NCT05102851,CCU admission,,,2021-08-01,COMPLETED,OBSERVATIONAL,['NA']
16448,NCT01170403,Cardiovascular event,,,2006-01,COMPLETED,OBSERVATIONAL,['NA']
16449,NCT02317211,Glycemic Control,Blood lipids,,2014-02,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
16450,NCT04189510,Efficacy of Artificial Pancreas system,,,2021-04-01,WITHDRAWN,INTERVENTIONAL,['NA']
16451,NCT00130806,The difference in daily dose requirements of insulin after 24 weeks,"(a) HbA1C; (b) FPG; (c) Percent of patients with HbA1C <7.0%; (d) TG, HDL-C, non-HDL-C and apolipoprotein B; (e) Free Fatty Acids (FFA); (f) the incidence of hypoglycemic events at 24 weeks",,2005-09,TERMINATED,INTERVENTIONAL,['PHASE3']
16452,NCT05776420,Hemoglobin A1c,Carotenoid level,,2023-03-21,RECRUITING,INTERVENTIONAL,['PHASE3']
16453,NCT02367066,Change From Baseline to Endpoint GGI AUC(1-2h) for Plasma C-Peptide,"Apparent Oral Plasma AZD1981 at Steady-State, CL_ss/F",,2015-03,COMPLETED,INTERVENTIONAL,['PHASE1']
16454,NCT00482729,Change From Baseline in Hemoglobin A1c (A1C) at Week 18,Change From Baseline in Fasting Plasma Glucose (FPG) at Week 18,Number of Patients With A1C < 7.0% at Week 44,2007-06-19,COMPLETED,INTERVENTIONAL,['PHASE3']
16455,NCT03746392,Documentation of goals of care,,,2018-07-01,COMPLETED,INTERVENTIONAL,['NA']
16456,NCT01763567,Device Performance: Accuracy of HGMS,,Functionality of HGMS: Alerts and Alarms - % of Hyper False Alert,2012-03,COMPLETED,OBSERVATIONAL,['NA']
16457,NCT01972477,Percent change in HDL-cholesterol level,Adverse event,,2016-07,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
16458,NCT01342874,altered OGTT,delivery and neonatal outcomes,,2010-08,COMPLETED,OBSERVATIONAL,['NA']
16459,NCT01449747,"Change in AUC of Active GLP-1, Total GLP-1 and Total GIP Between Before and After Sitagliptin Treatment",Differences of DPP-4 Activity After Sitagliptin Treatment Between Responder and Non-responder Groups,,2011-12,COMPLETED,INTERVENTIONAL,['PHASE4']
16460,NCT01629862,Absolute Change in Brachial Artery Flow-mediated Dilation (FMD).,,,2012-04,COMPLETED,INTERVENTIONAL,['PHASE2']
16461,NCT02115555,Glycemic Control using HBA1C,Treatment Adherence Behaviors,Satisfaction,2014-05,COMPLETED,INTERVENTIONAL,['NA']
16462,NCT01404078,Tolerability of a Double Dose of Half Strength Polycap,Blood Pressure Reduction and Lipid Lowering in Type 2 Diabetics,,2010-04,COMPLETED,INTERVENTIONAL,['NA']
16463,NCT01941238,Incidence of hypoglycemia,Rate of acute complications,,2013-07,COMPLETED,OBSERVATIONAL,['NA']
16464,NCT00341237,Disease,,,2010-05-26,RECRUITING,OBSERVATIONAL,['NA']
16465,NCT05390892,"Total (first and recurrent) cardiovascular, kidney, and death events",,,2022-09-26,RECRUITING,INTERVENTIONAL,['PHASE4']
16466,NCT06057246,Post-prandial glucose response,Sleep duration,,2023-05-15,RECRUITING,INTERVENTIONAL,['NA']
